ID   A8K6P0_HUMAN            Unreviewed;       773 AA.
AC   A8K6P0;
DT   04-DEC-2007, integrated into UniProtKB/TrEMBL.
DT   04-DEC-2007, sequence version 1.
DT   31-JAN-2018, entry version 80.
DE   SubName: Full=cDNA FLJ75039, highly similar to Homo sapiens aryl hydrocarbon receptor nuclear translocator (ARNT), transcript variant 3, mRNA {ECO:0000313|EMBL:BAF84394.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAF84394.1};
RN   [1] {ECO:0000313|EMBL:BAF84394.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Placenta {ECO:0000313|EMBL:BAF84394.1};
RA   Wakamatsu A., Yamamoto J., Kimura K., Ishii S., Watanabe K.,
RA   Sugiyama A., Murakawa K., Kaida T., Tsuchiya K., Fukuzumi Y.,
RA   Kumagai A., Oishi Y., Yamamoto S., Ono Y., Komori Y., Yamazaki M.,
RA   Kisu Y., Nishikawa T., Sugano S., Nomura N., Isogai T.;
RT   "NEDO human cDNA sequencing project.";
RL   Submitted (OCT-2007) to the EMBL/GenBank/DDBJ databases.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000256|SAAS:SAAS00895706}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK291705; BAF84394.1; -; mRNA.
DR   RefSeq; NP_001184254.1; NM_001197325.1.
DR   UniGene; Hs.632446; -.
DR   PeptideAtlas; A8K6P0; -.
DR   PRIDE; A8K6P0; -.
DR   DNASU; 405; -.
DR   GeneID; 405; -.
DR   CTD; 405; -.
DR   eggNOG; ENOG410IQ5T; Eukaryota.
DR   eggNOG; ENOG410XVHF; LUCA.
DR   HOVERGEN; HBG000164; -.
DR   GenomeRNAi; 405; -.
DR   Genevisible; A8K6P0; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:InterPro.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005667; C:transcription factor complex; IEA:InterPro.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0046983; F:protein dimerization activity; IEA:InterPro.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   CDD; cd00083; HLH; 1.
DR   CDD; cd00130; PAS; 2.
DR   Gene3D; 4.10.280.10; -; 1.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR036638; HLH_DNA-bd_sf.
DR   InterPro; IPR001067; Nuc_translocat.
DR   InterPro; IPR001610; PAC.
DR   InterPro; IPR000014; PAS.
DR   InterPro; IPR035965; PAS-like_dom_sf.
DR   InterPro; IPR013767; PAS_fold.
DR   Pfam; PF00010; HLH; 1.
DR   Pfam; PF00989; PAS; 1.
DR   PRINTS; PR00785; NCTRNSLOCATR.
DR   SMART; SM00353; HLH; 1.
DR   SMART; SM00086; PAC; 1.
DR   SMART; SM00091; PAS; 2.
DR   SUPFAM; SSF47459; SSF47459; 1.
DR   SUPFAM; SSF55785; SSF55785; 4.
DR   TIGRFAMs; TIGR00229; sensory_box; 1.
DR   PROSITE; PS50888; BHLH; 1.
DR   PROSITE; PS50112; PAS; 2.
PE   2: Evidence at transcript level;
KW   DNA-binding {ECO:0000256|SAAS:SAAS00929448};
KW   Nucleus {ECO:0000256|SAAS:SAAS00896251};
KW   Receptor {ECO:0000313|EMBL:BAF84394.1};
KW   Repeat {ECO:0000256|SAAS:SAAS00895860};
KW   Transcription {ECO:0000256|SAAS:SAAS00896243};
KW   Transcription regulation {ECO:0000256|SAAS:SAAS00896243}.
FT   DOMAIN       74    127       BHLH. {ECO:0000259|PROSITE:PS50888}.
FT   DOMAIN      146    220       PAS. {ECO:0000259|PROSITE:PS50112}.
FT   DOMAIN      353    404       PAS. {ECO:0000259|PROSITE:PS50112}.
SQ   SEQUENCE   773 AA;  84721 MW;  37743C0A0AD918FA CRC64;
     MAATTANPEM TSDVPSLGPA IASGNSGPGI QGGGAIVQRA IKRRPGLDFD DDGEGNSKFL
     RCDDDQMSND KERFARENHS EIERRRRNKM TAYITELSDM VPTCSALARK PDKLTILRMA
     VSHMKSLRGT GNTSTDGSYK PSFLTDQELK HLILEAADGF LFIVSCETGR VVYVSDSVTP
     VLNQPQSEWF GSTLYDQVHP DDVDKLREQL STSENALTGR ILDLKTGTVK KEGQQSSMRM
     CMGSRRSFIC RMRCGSSSVD PVSVNRLSFV RNRCRNGLGS VKDGEPHFVV VHCTGYIKAW
     PPAGVSLPDD DPEAGQGSKF CLVAIGRLQV TSSPNCTDMS NVCQPTEFIS RHNIEGIFTF
     VDHRCVATVG YQPQELLGKN IVEFCHPEDQ QLLRDSFQQV VKLKGQVLSV MFRFRSKNQE
     WLWMRTSSFT FQNPYSDEIE YIICTNTNVK NSSQEPRPTL SNTIQRPQLG PTANLPLEMG
     SGQLAPGQQQ QQTELDMVPG RDGLASYNHS QVVQPVTTTG PEHSKPLEKS DGLFAQDRDP
     RFSEIYHNIN ADQSKGISSS TVPATQQLFS QGNTFPPTPR PAENFRNSGL APPVTIVQPS
     ASAGQMLAQI SRHSNPTQGA TPTWTPTTRS GFSAQVATQA TAKTRTSQFG VGSFQTPSSF
     SSMSLPGAPT ASPGAAAYPS LTNRGSNFAP ETGQTAGQFQ TRTAEGVGVW PQWQGQQPHH
     RSSSSEQHVQ QPPAQQPGQP EVFQEMLSML GDQSNSYNNE EFPDLTMFPP FSE
//
ID   B0AZM1_HUMAN            Unreviewed;       774 AA.
AC   B0AZM1;
DT   26-FEB-2008, integrated into UniProtKB/TrEMBL.
DT   26-FEB-2008, sequence version 1.
DT   28-FEB-2018, entry version 80.
DE   SubName: Full=cDNA, FLJ79461, highly similar to Aryl hydrocarbon receptor nuclear translocator {ECO:0000313|EMBL:BAF98703.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAF98703.1};
RN   [1] {ECO:0000313|EMBL:BAF98703.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Brain {ECO:0000313|EMBL:BAF98703.1};
RA   Wakamatsu A., Yamamoto J., Kimura K., Ishii S., Watanabe K.,
RA   Sugiyama A., Murakawa K., Kaida T., Tsuchiya K., Fukuzumi Y.,
RA   Kumagai A., Oishi Y., Yamamoto S., Ono Y., Komori Y., Yamazaki M.,
RA   Kisu Y., Nishikawa T., Sugano S., Nomura N., Isogai T.;
RT   "NEDO human cDNA sequencing project.";
RL   Submitted (JAN-2008) to the EMBL/GenBank/DDBJ databases.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000256|SAAS:SAAS00895706}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK315812; BAF98703.1; -; mRNA.
DR   RefSeq; NP_848514.1; NM_178427.2.
DR   UniGene; Hs.632446; -.
DR   IntAct; B0AZM1; 1.
DR   MINT; B0AZM1; -.
DR   PeptideAtlas; B0AZM1; -.
DR   PRIDE; B0AZM1; -.
DR   DNASU; 405; -.
DR   GeneID; 405; -.
DR   CTD; 405; -.
DR   eggNOG; ENOG410IQ5T; Eukaryota.
DR   eggNOG; ENOG410XVHF; LUCA.
DR   HOGENOM; HOG000234380; -.
DR   HOVERGEN; HBG000164; -.
DR   GenomeRNAi; 405; -.
DR   Genevisible; B0AZM1; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:InterPro.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005667; C:transcription factor complex; IEA:InterPro.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0046983; F:protein dimerization activity; IEA:InterPro.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   CDD; cd00083; HLH; 1.
DR   CDD; cd00130; PAS; 2.
DR   Gene3D; 4.10.280.10; -; 1.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR036638; HLH_DNA-bd_sf.
DR   InterPro; IPR001067; Nuc_translocat.
DR   InterPro; IPR001610; PAC.
DR   InterPro; IPR000014; PAS.
DR   InterPro; IPR035965; PAS-like_dom_sf.
DR   InterPro; IPR013767; PAS_fold.
DR   Pfam; PF00010; HLH; 1.
DR   Pfam; PF00989; PAS; 1.
DR   PRINTS; PR00785; NCTRNSLOCATR.
DR   SMART; SM00353; HLH; 1.
DR   SMART; SM00086; PAC; 1.
DR   SMART; SM00091; PAS; 2.
DR   SUPFAM; SSF47459; SSF47459; 1.
DR   SUPFAM; SSF55785; SSF55785; 4.
DR   TIGRFAMs; TIGR00229; sensory_box; 1.
DR   PROSITE; PS50888; BHLH; 1.
DR   PROSITE; PS50112; PAS; 2.
PE   2: Evidence at transcript level;
KW   DNA-binding {ECO:0000256|SAAS:SAAS00929448};
KW   Nucleus {ECO:0000256|SAAS:SAAS00896251};
KW   Receptor {ECO:0000313|EMBL:BAF98703.1};
KW   Repeat {ECO:0000256|SAAS:SAAS00895860};
KW   Transcription {ECO:0000256|SAAS:SAAS00896243};
KW   Transcription regulation {ECO:0000256|SAAS:SAAS00896243}.
FT   DOMAIN       74    127       BHLH. {ECO:0000259|PROSITE:PS50888}.
FT   DOMAIN      146    220       PAS. {ECO:0000259|PROSITE:PS50112}.
FT   DOMAIN      353    404       PAS. {ECO:0000259|PROSITE:PS50112}.
SQ   SEQUENCE   774 AA;  84994 MW;  7DB22949B18F149C CRC64;
     MAATTANPEM TSDVPSLGPA IASGNSGPGI QGGGAIVQRA IKRRPGLDFD DDGEGNSKFL
     RCDDDQMSND KERYARENHS EIERRRRNKM TAYITELSDM VPTCSALARK PDKLTILRMA
     VSHMKSLRGT GNTSTDGSYK PSFLTDQELK HLILEATDGF LFIVSCETGR VVYVSDSVTP
     VLNQPQSEWF GSTLYDQVHP DDVDKLREQL STSENALTGR ILDLKTGTVK KEGQQSSMRM
     CMGSRRSFIC RMRCGSSSVD PVSVNRLSFV RNRCRNGLGS VKDGEPHFVV VHCTGYIKAW
     PPAGVSLPDD DPEAGQGSKF CLVAIGRLQV TSSPNCTDMS NVCQPTEFIS RHNIEGIFTF
     VDHRCVATVG YQPQELLGKN IVEFCHPEDQ QLLRDSFQQV VKLKGQVLSV MFRFRSKNQE
     WLWMRTSSFT FQNPYSDEIE YIICTNTNVK NSSQEPRPTL SNTIQRPQLG PTANLPLEMG
     SGQLAPRQQQ QQTELDMVPG RDGLASYNHS QVVQPVTTTG PEHSKPLEKS DGLFAQDRDP
     RFSEIYHNIN ADQSKGISSS TVPATQQLFS QGNTFPPTPR PAENFRNSGL APPVTIVQPS
     ASAGQMLAQI SRHSNPTQGA TPTWTPTTRS GFSAQQVATQ ATAKTRTSQF GVGSFQTPSS
     FSSMSLPGAP TASPGAAAYP SLTNRGSNFA PETGQTAGQF QTRTAEGVGV WPQWQGQQPH
     HRSSSSEQHV QQPPAQQPGQ PEVFQEMLSM LGDQSNSYNN EEFPDLTMFP PFSE
//
ID   ARNT_HUMAN              Reviewed;         789 AA.
AC   P27540; B2R9H1; C4AMA1; F8WAP6; Q59ED4; Q5QP39; Q8NDC7;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1992, sequence version 1.
DT   28-FEB-2018, entry version 197.
DE   RecName: Full=Aryl hydrocarbon receptor nuclear translocator;
DE            Short=ARNT protein;
DE   AltName: Full=Class E basic helix-loop-helix protein 2;
DE            Short=bHLHe2;
DE   AltName: Full=Dioxin receptor, nuclear translocator;
DE   AltName: Full=Hypoxia-inducible factor 1-beta;
DE            Short=HIF-1-beta;
DE            Short=HIF1-beta;
GN   Name=ARNT; Synonyms=BHLHE2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=1852076; DOI=10.1126/science.1852076;
RA   Hoffman E.C., Reyes H., Chu F.-F., Sander F., Conley L.H.,
RA   Brooks B.A., Hankinson O.;
RT   "Cloning of a factor required for activity of the Ah (dioxin)
RT   receptor.";
RL   Science 252:954-958(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Scheel J.;
RL   Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis, Thalamus, and Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Aortic endothelium;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RT   "Homo sapiens protein coding cDNA.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=11230166; DOI=10.1101/gr.GR1547R;
RA   Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S.,
RA   Ansorge W., Boecher M., Bloecker H., Bauersachs S., Blum H.,
RA   Lauber J., Duesterhoeft A., Beyer A., Koehrer K., Strack N.,
RA   Mewes H.-W., Ottenwaelder B., Obermaier B., Tampe J., Heubner D.,
RA   Wambutt R., Korn B., Klein M., Poustka A.;
RT   "Towards a catalog of human genes and proteins: sequencing and
RT   analysis of 500 novel complete protein coding human cDNAs.";
RL   Genome Res. 11:422-435(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLU-517.
RG   NIEHS SNPs program;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   PROTEIN SEQUENCE OF 186-203 AND 662-694.
RX   PubMed=7539918; DOI=10.1073/pnas.92.12.5510;
RA   Wang G.L., Jiang B.-H., Rue E.A., Semenza G.L.;
RT   "Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS
RT   heterodimer regulated by cellular O2 tension.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:5510-5514(1995).
RN   [10]
RP   CHARACTERIZATION.
RX   PubMed=1317062; DOI=10.1126/science.256.5060.1193;
RA   Reyes H., Reisz-Porszasz S., Hankinson O.;
RT   "Identification of the Ah receptor nuclear translocator protein (Arnt)
RT   as a component of the DNA binding form of the Ah receptor.";
RL   Science 256:1193-1195(1992).
RN   [11]
RP   DNA-BINDING, AND MUTAGENESIS OF ARG-91; ASN-93; HIS-94; GLU-98;
RP   ARG-99; ARG-101 AND ARG-102.
RX   PubMed=8621524; DOI=10.1074/jbc.271.15.8843;
RA   Bacsi S.G., Hankinson O.;
RT   "Functional characterization of DNA-binding domains of the subunits of
RT   the heterodimeric aryl hydrocarbon receptor complex imputing novel and
RT   canonical basic helix-loop-helix protein-DNA interactions.";
RL   J. Biol. Chem. 271:8843-8850(1996).
RN   [12]
RP   INTERACTION WITH NOCA7.
RX   PubMed=10395741; DOI=10.1006/abbi.1999.1282;
RA   Nguyen T.A., Hoivik D., Lee J.-E., Safe S.;
RT   "Interactions of nuclear receptor coactivator/corepressor proteins
RT   with the aryl hydrocarbon receptor complex.";
RL   Arch. Biochem. Biophys. 367:250-257(1999).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-77, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   INTERACTION WITH HIF1A.
RX   PubMed=20699359; DOI=10.1242/jcs.068122;
RA   Kalousi A., Mylonis I., Politou A.S., Chachami G., Paraskeva E.,
RA   Simos G.;
RT   "Casein kinase 1 regulates human hypoxia-inducible factor HIF-1.";
RL   J. Cell Sci. 123:2976-2986(2010).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-77, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-58, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-
RT   modification with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   -!- FUNCTION: Required for activity of the Ah (dioxin) receptor. This
CC       protein is required for the ligand-binding subunit to translocate
CC       from the cytosol to the nucleus after ligand binding. The complex
CC       then initiates transcription of genes involved in the activation
CC       of PAH procarcinogens. The heterodimer with HIF1A or EPAS1/HIF2A
CC       functions as a transcriptional regulator of the adaptive response
CC       to hypoxia.
CC   -!- SUBUNIT: Efficient DNA binding requires dimerization with another
CC       bHLH protein. Forms a heterodimer with AHR, AHRR, HIF1A and
CC       EPAS1/HIF2A as well as with other bHLH proteins. Interacts with
CC       TACC3 (By similarity). Interacts with NOCA7. Heterodimer with
CC       HIF1A. {ECO:0000250, ECO:0000269|PubMed:10395741,
CC       ECO:0000269|PubMed:20699359}.
CC   -!- INTERACTION:
CC       P35869:AHR; NbExp=5; IntAct=EBI-80809, EBI-80780;
CC       Q99814:EPAS1; NbExp=6; IntAct=EBI-80809, EBI-447470;
CC       Q16665:HIF1A; NbExp=10; IntAct=EBI-80809, EBI-447269;
CC       Q8NI08:NCOA7; NbExp=2; IntAct=EBI-80809, EBI-80799;
CC       Q9Y618:NCOR2; NbExp=2; IntAct=EBI-80809, EBI-80830;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=Long;
CC         IsoId=P27540-1; Sequence=Displayed;
CC       Name=2; Synonyms=Short;
CC         IsoId=P27540-2; Sequence=VSP_002092;
CC       Name=3;
CC         IsoId=P27540-3; Sequence=VSP_036532, VSP_036533;
CC         Note=No experimental confirmation available.;
CC       Name=4;
CC         IsoId=P27540-4; Sequence=VSP_055030;
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD93114.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=CAD38953.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ARNTID223ch1q21.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/arnt/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M69238; AAA51777.1; -; mRNA.
DR   EMBL; Y18859; CAC21446.1; -; Genomic_DNA.
DR   EMBL; AJ251863; CAC21446.1; JOINED; Genomic_DNA.
DR   EMBL; AJ404851; CAC21446.1; JOINED; Genomic_DNA.
DR   EMBL; AJ404852; CAC21446.1; JOINED; Genomic_DNA.
DR   EMBL; AJ404853; CAC21446.1; JOINED; Genomic_DNA.
DR   EMBL; AJ404854; CAC21446.1; JOINED; Genomic_DNA.
DR   EMBL; AK290177; BAF82866.1; -; mRNA.
DR   EMBL; AK293027; BAF85716.1; -; mRNA.
DR   EMBL; AK313780; BAG36518.1; -; mRNA.
DR   EMBL; AB209877; BAD93114.1; ALT_INIT; mRNA.
DR   EMBL; AL834279; CAD38953.1; ALT_INIT; mRNA.
DR   EMBL; AY430083; AAQ96598.1; -; Genomic_DNA.
DR   EMBL; AL355860; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471121; EAW53510.1; -; Genomic_DNA.
DR   EMBL; CH471121; EAW53513.1; -; Genomic_DNA.
DR   CCDS; CCDS65641.1; -. [P27540-3]
DR   CCDS; CCDS65642.1; -. [P27540-4]
DR   CCDS; CCDS970.1; -. [P27540-1]
DR   CCDS; CCDS971.1; -. [P27540-2]
DR   PIR; I59550; I59550.
DR   RefSeq; NP_001184254.1; NM_001197325.1.
DR   RefSeq; NP_001272964.1; NM_001286035.1. [P27540-3]
DR   RefSeq; NP_001272965.1; NM_001286036.1. [P27540-4]
DR   RefSeq; NP_001659.1; NM_001668.3. [P27540-1]
DR   RefSeq; NP_848514.1; NM_178427.2. [P27540-2]
DR   RefSeq; XP_016856778.1; XM_017001289.1. [P27540-3]
DR   UniGene; Hs.632446; -.
DR   PDB; 1D7G; Model; -; C=87-145.
DR   PDB; 1X0O; NMR; -; A=356-470.
DR   PDB; 2A24; NMR; -; B=358-465.
DR   PDB; 2ARN; Model; -; A=335-462.
DR   PDB; 2B02; X-ray; 1.50 A; A=354-470.
DR   PDB; 2HV1; NMR; -; A/B=356-470.
DR   PDB; 2K7S; NMR; -; A=356-470.
DR   PDB; 3F1N; X-ray; 1.48 A; B=356-470.
DR   PDB; 3F1O; X-ray; 1.60 A; B=356-470.
DR   PDB; 3F1P; X-ray; 1.17 A; B=356-470.
DR   PDB; 3H7W; X-ray; 1.65 A; B=356-470.
DR   PDB; 3H82; X-ray; 1.50 A; B=356-470.
DR   PDB; 4EQ1; X-ray; 1.60 A; A/B=357-464.
DR   PDB; 4GHI; X-ray; 1.50 A; B=356-470.
DR   PDB; 4GS9; X-ray; 1.72 A; B=356-470.
DR   PDB; 4H6J; X-ray; 1.52 A; B=357-470.
DR   PDB; 4LPZ; X-ray; 3.15 A; A/B=356-470.
DR   PDB; 4PKY; X-ray; 3.20 A; A/D=356-470.
DR   PDB; 4XT2; X-ray; 1.70 A; B/D=356-470.
DR   PDB; 5NJ8; X-ray; 3.30 A; B/D=84-345.
DR   PDB; 5TBM; X-ray; 1.85 A; B=356-467.
DR   PDB; 5UFP; X-ray; 1.90 A; B=356-467.
DR   PDB; 5V0L; X-ray; 4.00 A; A=70-346.
DR   PDBsum; 1D7G; -.
DR   PDBsum; 1X0O; -.
DR   PDBsum; 2A24; -.
DR   PDBsum; 2ARN; -.
DR   PDBsum; 2B02; -.
DR   PDBsum; 2HV1; -.
DR   PDBsum; 2K7S; -.
DR   PDBsum; 3F1N; -.
DR   PDBsum; 3F1O; -.
DR   PDBsum; 3F1P; -.
DR   PDBsum; 3H7W; -.
DR   PDBsum; 3H82; -.
DR   PDBsum; 4EQ1; -.
DR   PDBsum; 4GHI; -.
DR   PDBsum; 4GS9; -.
DR   PDBsum; 4H6J; -.
DR   PDBsum; 4LPZ; -.
DR   PDBsum; 4PKY; -.
DR   PDBsum; 4XT2; -.
DR   PDBsum; 5NJ8; -.
DR   PDBsum; 5TBM; -.
DR   PDBsum; 5UFP; -.
DR   PDBsum; 5V0L; -.
DR   ProteinModelPortal; P27540; -.
DR   SMR; P27540; -.
DR   BioGrid; 106898; 59.
DR   CORUM; P27540; -.
DR   DIP; DIP-30886N; -.
DR   ELM; P27540; -.
DR   IntAct; P27540; 28.
DR   MINT; P27540; -.
DR   STRING; 9606.ENSP00000351407; -.
DR   ChEMBL; CHEMBL5618; -.
DR   iPTMnet; P27540; -.
DR   PhosphoSitePlus; P27540; -.
DR   BioMuta; ARNT; -.
DR   DMDM; 114163; -.
DR   EPD; P27540; -.
DR   MaxQB; P27540; -.
DR   PaxDb; P27540; -.
DR   PeptideAtlas; P27540; -.
DR   PRIDE; P27540; -.
DR   DNASU; 405; -.
DR   Ensembl; ENST00000354396; ENSP00000346372; ENSG00000143437. [P27540-4]
DR   Ensembl; ENST00000358595; ENSP00000351407; ENSG00000143437. [P27540-1]
DR   Ensembl; ENST00000505755; ENSP00000427571; ENSG00000143437. [P27540-2]
DR   Ensembl; ENST00000515192; ENSP00000423851; ENSG00000143437. [P27540-3]
DR   GeneID; 405; -.
DR   KEGG; hsa:405; -.
DR   UCSC; uc001evr.2; human. [P27540-1]
DR   CTD; 405; -.
DR   DisGeNET; 405; -.
DR   EuPathDB; HostDB:ENSG00000143437.20; -.
DR   GeneCards; ARNT; -.
DR   HGNC; HGNC:700; ARNT.
DR   HPA; CAB004318; -.
DR   HPA; HPA001759; -.
DR   MIM; 126110; gene.
DR   neXtProt; NX_P27540; -.
DR   OpenTargets; ENSG00000143437; -.
DR   PharmGKB; PA24994; -.
DR   eggNOG; ENOG410IQ5T; Eukaryota.
DR   eggNOG; ENOG410XVHF; LUCA.
DR   GeneTree; ENSGT00760000118788; -.
DR   HOGENOM; HOG000234380; -.
DR   HOVERGEN; HBG000164; -.
DR   InParanoid; P27540; -.
DR   KO; K09097; -.
DR   OMA; IVEFCHP; -.
DR   OrthoDB; EOG091G03AI; -.
DR   PhylomeDB; P27540; -.
DR   TreeFam; TF319983; -.
DR   Reactome; R-HSA-1234158; Regulation of gene expression by Hypoxia-inducible Factor.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-211945; Phase I - Functionalization of compounds.
DR   Reactome; R-HSA-211976; Endogenous sterols.
DR   Reactome; R-HSA-211981; Xenobiotics.
DR   Reactome; R-HSA-8937144; Aryl hydrocarbon receptor signalling.
DR   SignaLink; P27540; -.
DR   SIGNOR; P27540; -.
DR   ChiTaRS; ARNT; human.
DR   EvolutionaryTrace; P27540; -.
DR   GeneWiki; Aryl_hydrocarbon_receptor_nuclear_translocator; -.
DR   GenomeRNAi; 405; -.
DR   PRO; PR:P27540; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000143437; -.
DR   CleanEx; HS_ARNT; -.
DR   ExpressionAtlas; P27540; baseline and differential.
DR   Genevisible; P27540; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0090575; C:RNA polymerase II transcription factor complex; IDA:BHF-UCL.
DR   GO; GO:0004874; F:aryl hydrocarbon receptor activity; IEA:Ensembl.
DR   GO; GO:0017162; F:aryl hydrocarbon receptor binding; IPI:BHF-UCL.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; TAS:ProtInc.
DR   GO; GO:0035326; F:enhancer binding; IDA:MGI.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0003713; F:transcription coactivator activity; TAS:ProtInc.
DR   GO; GO:0008134; F:transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0030154; P:cell differentiation; IEA:Ensembl.
DR   GO; GO:0001892; P:embryonic placenta development; IEA:Ensembl.
DR   GO; GO:0042789; P:mRNA transcription from RNA polymerase II promoter; IC:BHF-UCL.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IC:BHF-UCL.
DR   GO; GO:0045648; P:positive regulation of erythrocyte differentiation; IC:BHF-UCL.
DR   GO; GO:0045821; P:positive regulation of glycolytic process; IC:BHF-UCL.
DR   GO; GO:0046886; P:positive regulation of hormone biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0033235; P:positive regulation of protein sumoylation; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:BHF-UCL.
DR   GO; GO:0010575; P:positive regulation of vascular endothelial growth factor production; IDA:BHF-UCL.
DR   GO; GO:0030949; P:positive regulation of vascular endothelial growth factor receptor signaling pathway; IC:BHF-UCL.
DR   GO; GO:0061418; P:regulation of transcription from RNA polymerase II promoter in response to hypoxia; TAS:Reactome.
DR   GO; GO:0043619; P:regulation of transcription from RNA polymerase II promoter in response to oxidative stress; IDA:BHF-UCL.
DR   GO; GO:0001666; P:response to hypoxia; IDA:BHF-UCL.
DR   GO; GO:0006351; P:transcription, DNA-templated; TAS:ProtInc.
DR   GO; GO:0006805; P:xenobiotic metabolic process; TAS:Reactome.
DR   CDD; cd00083; HLH; 1.
DR   CDD; cd00130; PAS; 2.
DR   Gene3D; 4.10.280.10; -; 1.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR036638; HLH_DNA-bd_sf.
DR   InterPro; IPR001067; Nuc_translocat.
DR   InterPro; IPR001610; PAC.
DR   InterPro; IPR000014; PAS.
DR   InterPro; IPR035965; PAS-like_dom_sf.
DR   InterPro; IPR013767; PAS_fold.
DR   Pfam; PF00010; HLH; 1.
DR   Pfam; PF00989; PAS; 1.
DR   PRINTS; PR00785; NCTRNSLOCATR.
DR   SMART; SM00353; HLH; 1.
DR   SMART; SM00086; PAC; 1.
DR   SMART; SM00091; PAS; 2.
DR   SUPFAM; SSF47459; SSF47459; 1.
DR   SUPFAM; SSF55785; SSF55785; 4.
DR   TIGRFAMs; TIGR00229; sensory_box; 1.
DR   PROSITE; PS50888; BHLH; 1.
DR   PROSITE; PS50112; PAS; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing;
KW   Complete proteome; Direct protein sequencing; DNA-binding;
KW   Isopeptide bond; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Transcription; Transcription regulation;
KW   Ubl conjugation.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:22814378}.
FT   CHAIN         2    789       Aryl hydrocarbon receptor nuclear
FT                                translocator.
FT                                /FTId=PRO_0000127118.
FT   DOMAIN       89    142       bHLH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00981}.
FT   DOMAIN      161    235       PAS 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00140}.
FT   DOMAIN      349    419       PAS 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00140}.
FT   DOMAIN      424    467       PAC.
FT   COMPBIAS     99    102       Poly-Arg.
FT   COMPBIAS    503    507       Poly-Gln.
FT   COMPBIAS    710    769       Gln-rich.
FT   COMPBIAS    738    741       Poly-Ser.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:22814378}.
FT   MOD_RES      77     77       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   CROSSLNK     58     58       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   VAR_SEQ       1      9       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:11230166}.
FT                                /FTId=VSP_036532.
FT   VAR_SEQ      77     91       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:1852076}.
FT                                /FTId=VSP_002092.
FT   VAR_SEQ     319    323       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:11230166}.
FT                                /FTId=VSP_036533.
FT   VAR_SEQ     601    602       Missing (in isoform 4).
FT                                {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_055030.
FT   VARIANT     430    430       R -> Q (in dbSNP:rs2229175).
FT                                /FTId=VAR_024280.
FT   VARIANT     511    511       D -> N (in dbSNP:rs1805133).
FT                                /FTId=VAR_014819.
FT   VARIANT     517    517       D -> E (in dbSNP:rs10305741).
FT                                {ECO:0000269|Ref.6}.
FT                                /FTId=VAR_018906.
FT   VARIANT     706    706       P -> L (in dbSNP:rs2275237).
FT                                /FTId=VAR_020189.
FT   MUTAGEN      91     91       R->A: Diminishes DNA interaction.
FT                                {ECO:0000269|PubMed:8621524}.
FT   MUTAGEN      93     93       N->A: Diminishes DNA interaction.
FT                                {ECO:0000269|PubMed:8621524}.
FT   MUTAGEN      94     94       H->A: Severely diminishes DNA
FT                                interaction.
FT                                {ECO:0000269|PubMed:8621524}.
FT   MUTAGEN      98     98       E->A: Severely diminishes DNA
FT                                interaction.
FT                                {ECO:0000269|PubMed:8621524}.
FT   MUTAGEN      99     99       R->A: Diminishes DNA interaction.
FT                                {ECO:0000269|PubMed:8621524}.
FT   MUTAGEN     101    101       R->A: Severely diminishes DNA
FT                                interaction.
FT                                {ECO:0000269|PubMed:8621524}.
FT   MUTAGEN     102    102       R->A: Severely diminishes DNA
FT                                interaction.
FT                                {ECO:0000269|PubMed:8621524}.
FT   CONFLICT    627    627       R -> H (in Ref. 3; BAG36518).
FT                                {ECO:0000305}.
FT   HELIX        87    112       {ECO:0000244|PDB:5NJ8}.
FT   STRAND      115    117       {ECO:0000244|PDB:5NJ8}.
FT   HELIX       128    142       {ECO:0000244|PDB:5NJ8}.
FT   HELIX       161    171       {ECO:0000244|PDB:5NJ8}.
FT   STRAND      174    183       {ECO:0000244|PDB:5NJ8}.
FT   STRAND      186    189       {ECO:0000244|PDB:5NJ8}.
FT   HELIX       191    193       {ECO:0000244|PDB:5NJ8}.
FT   STRAND      196    199       {ECO:0000244|PDB:5NJ8}.
FT   TURN        203    205       {ECO:0000244|PDB:5NJ8}.
FT   HELIX       209    212       {ECO:0000244|PDB:5NJ8}.
FT   HELIX       215    217       {ECO:0000244|PDB:5NJ8}.
FT   HELIX       218    222       {ECO:0000244|PDB:5NJ8}.
FT   TURN        223    225       {ECO:0000244|PDB:5NJ8}.
FT   STRAND      260    268       {ECO:0000244|PDB:5NJ8}.
FT   STRAND      303    314       {ECO:0000244|PDB:5NJ8}.
FT   STRAND      335    343       {ECO:0000244|PDB:5NJ8}.
FT   STRAND      356    358       {ECO:0000244|PDB:2K7S}.
FT   STRAND      362    367       {ECO:0000244|PDB:3F1P}.
FT   STRAND      371    376       {ECO:0000244|PDB:3F1P}.
FT   HELIX       380    384       {ECO:0000244|PDB:3F1P}.
FT   HELIX       388    390       {ECO:0000244|PDB:3F1P}.
FT   TURN        391    393       {ECO:0000244|PDB:3F1P}.
FT   HELIX       396    399       {ECO:0000244|PDB:3F1P}.
FT   TURN        402    404       {ECO:0000244|PDB:3F1P}.
FT   HELIX       405    415       {ECO:0000244|PDB:3F1P}.
FT   TURN        416    420       {ECO:0000244|PDB:3F1N}.
FT   STRAND      423    430       {ECO:0000244|PDB:3F1P}.
FT   STRAND      436    446       {ECO:0000244|PDB:3F1P}.
FT   TURN        449    451       {ECO:0000244|PDB:2B02}.
FT   STRAND      456    463       {ECO:0000244|PDB:3F1P}.
SQ   SEQUENCE   789 AA;  86636 MW;  2E278F8E62BFBF6D CRC64;
     MAATTANPEM TSDVPSLGPA IASGNSGPGI QGGGAIVQRA IKRRPGLDFD DDGEGNSKFL
     RCDDDQMSND KERFARSDDE QSSADKERLA RENHSEIERR RRNKMTAYIT ELSDMVPTCS
     ALARKPDKLT ILRMAVSHMK SLRGTGNTST DGSYKPSFLT DQELKHLILE AADGFLFIVS
     CETGRVVYVS DSVTPVLNQP QSEWFGSTLY DQVHPDDVDK LREQLSTSEN ALTGRILDLK
     TGTVKKEGQQ SSMRMCMGSR RSFICRMRCG SSSVDPVSVN RLSFVRNRCR NGLGSVKDGE
     PHFVVVHCTG YIKAWPPAGV SLPDDDPEAG QGSKFCLVAI GRLQVTSSPN CTDMSNVCQP
     TEFISRHNIE GIFTFVDHRC VATVGYQPQE LLGKNIVEFC HPEDQQLLRD SFQQVVKLKG
     QVLSVMFRFR SKNQEWLWMR TSSFTFQNPY SDEIEYIICT NTNVKNSSQE PRPTLSNTIQ
     RPQLGPTANL PLEMGSGQLA PRQQQQQTEL DMVPGRDGLA SYNHSQVVQP VTTTGPEHSK
     PLEKSDGLFA QDRDPRFSEI YHNINADQSK GISSSTVPAT QQLFSQGNTF PPTPRPAENF
     RNSGLAPPVT IVQPSASAGQ MLAQISRHSN PTQGATPTWT PTTRSGFSAQ QVATQATAKT
     RTSQFGVGSF QTPSSFSSMS LPGAPTASPG AAAYPSLTNR GSNFAPETGQ TAGQFQTRTA
     EGVGVWPQWQ GQQPHHRSSS SEQHVQQPPA QQPGQPEVFQ EMLSMLGDQS NSYNNEEFPD
     LTMFPPFSE
//
ID   Q53F30_HUMAN            Unreviewed;       315 AA.
AC   Q53F30;
DT   24-MAY-2005, integrated into UniProtKB/TrEMBL.
DT   24-MAY-2005, sequence version 1.
DT   31-JAN-2018, entry version 89.
DE   SubName: Full=Aryl hydrocarbon receptor nuclear translocator isoform 2 variant {ECO:0000313|EMBL:BAD97179.1};
DE   Flags: Fragment;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAD97179.1};
RN   [1] {ECO:0000313|EMBL:BAD97179.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Kidney {ECO:0000313|EMBL:BAD97179.1};
RX   PubMed=8125298; DOI=10.1016/0378-1119(94)90802-8;
RA   Maruyama K., Sugano S.;
RT   "Oligo-capping: a simple method to replace the cap structure of
RT   eukaryotic mRNAs with oligoribonucleotides.";
RL   Gene 138:171-174(1994).
RN   [2] {ECO:0000313|EMBL:BAD97179.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Kidney {ECO:0000313|EMBL:BAD97179.1};
RX   PubMed=9373149; DOI=10.1016/S0378-1119(97)00411-3;
RA   Suzuki Y., Yoshitomo K., Maruyama K., Suyama A., Sugano S.;
RT   "Construction and characterization of a full length-enriched and a 5'-
RT   end-enriched cDNA library.";
RL   Gene 200:149-156(1997).
RN   [3] {ECO:0000313|EMBL:BAD97179.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Kidney {ECO:0000313|EMBL:BAD97179.1};
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000256|SAAS:SAAS00895706}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK223459; BAD97179.1; -; mRNA.
DR   RefSeq; NP_001272964.1; NM_001286035.1.
DR   RefSeq; NP_001272965.1; NM_001286036.1.
DR   UniGene; Hs.632446; -.
DR   SMR; Q53F30; -.
DR   PeptideAtlas; Q53F30; -.
DR   GeneID; 405; -.
DR   CTD; 405; -.
DR   eggNOG; ENOG410IQ5T; Eukaryota.
DR   eggNOG; ENOG410XVHF; LUCA.
DR   HOVERGEN; HBG000164; -.
DR   GenomeRNAi; 405; -.
DR   GO; GO:0005737; C:cytoplasm; IEA:InterPro.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005667; C:transcription factor complex; IEA:InterPro.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0046983; F:protein dimerization activity; IEA:InterPro.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   CDD; cd00083; HLH; 1.
DR   CDD; cd00130; PAS; 1.
DR   Gene3D; 4.10.280.10; -; 1.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR036638; HLH_DNA-bd_sf.
DR   InterPro; IPR001067; Nuc_translocat.
DR   InterPro; IPR000014; PAS.
DR   InterPro; IPR035965; PAS-like_dom_sf.
DR   InterPro; IPR013767; PAS_fold.
DR   Pfam; PF00010; HLH; 1.
DR   Pfam; PF00989; PAS; 1.
DR   PRINTS; PR00785; NCTRNSLOCATR.
DR   SMART; SM00353; HLH; 1.
DR   SMART; SM00091; PAS; 1.
DR   SUPFAM; SSF47459; SSF47459; 1.
DR   SUPFAM; SSF55785; SSF55785; 3.
DR   PROSITE; PS50888; BHLH; 1.
DR   PROSITE; PS50112; PAS; 1.
PE   2: Evidence at transcript level;
KW   Nucleus {ECO:0000256|SAAS:SAAS00896251};
KW   Receptor {ECO:0000313|EMBL:BAD97179.1};
KW   Transcription {ECO:0000256|SAAS:SAAS00896243};
KW   Transcription regulation {ECO:0000256|SAAS:SAAS00896243}.
FT   DOMAIN       89    142       BHLH. {ECO:0000259|PROSITE:PS50888}.
FT   DOMAIN      161    235       PAS. {ECO:0000259|PROSITE:PS50112}.
FT   NON_TER       1      1       {ECO:0000313|EMBL:BAD97179.1}.
FT   NON_TER     315    315       {ECO:0000313|EMBL:BAD97179.1}.
SQ   SEQUENCE   315 AA;  34822 MW;  40F79278697E6EB8 CRC64;
     MAATTANPEM TSDVPSLVPA IASGNSGPGI QGGGAIVQRA IKRRPGLDFD DDGEGNSKFL
     RCDDDQMSND KERFARSDDE QSSADKERLA RENHSEIERR RRNKMTAYIT ELSDMVPTCS
     ALARKPDKLT ILRMAVSHMK SLRGTGNTST DGSYKPSFLT DQELKHLILE AADGFLFIVS
     CETGRVVYVS DSVTPVLNQP QSEWFGSTLY DQVHPDDVDK LREQLSTSEN ALTGRILDLK
     TGTVKKEGQQ SSMRMCMGSR RSFICRMRCG SSSVDPVSVN RLSFVRNRCR NGLGSVKDGE
     PHFVVVHCTG YIKAW
//
ID   L8B567_HUMAN            Unreviewed;       823 AA.
AC   L8B567;
DT   03-APR-2013, integrated into UniProtKB/TrEMBL.
DT   03-APR-2013, sequence version 1.
DT   28-FEB-2018, entry version 41.
DE   SubName: Full=ATL1-gamma zinc finger protein {ECO:0000313|EMBL:BAM78284.1};
DE   SubName: Full=B-cell CLL/lymphoma 11B (Zinc finger protein), isoform CRA_a {ECO:0000313|EMBL:EAW81662.1};
GN   Name=ATL1-gamma {ECO:0000313|EMBL:BAM78284.1};
GN   Synonyms=BCL11B {ECO:0000313|EMBL:EAW81662.1};
GN   ORFNames=hCG_1657560 {ECO:0000313|EMBL:EAW81662.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAM78284.1};
RN   [1] {ECO:0000313|EMBL:EAW81662.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D.,
RA   Amanatides P., Ballew R.M., Huson D.H., Wortman J.R., Zhang Q.,
RA   Kodira C.D., Zheng X.H., Chen L., Skupski M., Subramanian G.,
RA   Thomas P.D., Zhang J., Gabor Miklos G.L., Nelson C., Broder S.,
RA   Clark A.G., Nadeau J., McKusick V.A., Zinder N., Levine A.J.,
RA   Roberts R.J., Simon M., Slayman C., Hunkapiller M., Bolanos R.,
RA   Delcher A., Dew I., Fasulo D., Flanigan M., Florea L., Halpern A.,
RA   Hannenhalli S., Kravitz S., Levy S., Mobarry C., Reinert K.,
RA   Remington K., Abu-Threideh J., Beasley E., Biddick K., Bonazzi V.,
RA   Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z.,
RA   Guan P., Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A.,
RA   Lai Z., Lei Y., Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V.,
RA   Milshina N., Moore H.M., Naik A.K., Narayan V.A., Neelam B.,
RA   Nusskern D., Rusch D.B., Salzberg S., Shao W., Shue B., Sun J.,
RA   Wang Z., Wang A., Wang X., Wang J., Wei M., Wides R., Xiao C., Yan C.,
RA   Yao A., Ye J., Zhan M., Zhang W., Zhang H., Zhao Q., Zheng L.,
RA   Zhong F., Zhong W., Zhu S., Zhao S., Gilbert D., Baumhueter S.,
RA   Spier G., Carter C., Cravchik A., Woodage T., Ali F., An H., Awe A.,
RA   Baldwin D., Baden H., Barnstead M., Barrow I., Beeson K., Busam D.,
RA   Carver A., Center A., Cheng M.L., Curry L., Danaher S., Davenport L.,
RA   Desilets R., Dietz S., Dodson K., Doup L., Ferriera S., Garg N.,
RA   Gluecksmann A., Hart B., Haynes J., Haynes C., Heiner C., Hladun S.,
RA   Hostin D., Houck J., Howland T., Ibegwam C., Johnson J., Kalush F.,
RA   Kline L., Koduru S., Love A., Mann F., May D., McCawley S.,
RA   McIntosh T., McMullen I., Moy M., Moy L., Murphy B., Nelson K.,
RA   Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N.,
RA   Tse S., Vech C., Wang G., Wetter J., Williams S., Williams M.,
RA   Windsor S., Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F.,
RA   Guigo R., Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A.,
RA   Mi H., Lazareva B., Hatton T., Narechania A., Diemer K.,
RA   Muruganujan A., Guo N., Sato S., Bafna V., Istrail S., Lippert R.,
RA   Schwartz R., Walenz B., Yooseph S., Allen D., Basu A., Baxendale J.,
RA   Blick L., Caminha M., Carnes-Stine J., Caulk P., Chiang Y.H.,
RA   Coyne M., Dahlke C., Mays A., Dombroski M., Donnelly M., Ely D.,
RA   Esparham S., Fosler C., Gire H., Glanowski S., Glasser K., Glodek A.,
RA   Gorokhov M., Graham K., Gropman B., Harris M., Heil J., Henderson S.,
RA   Hoover J., Jennings D., Jordan C., Jordan J., Kasha J., Kagan L.,
RA   Kraft C., Levitsky A., Lewis M., Liu X., Lopez J., Ma D., Majoros W.,
RA   McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N., Nodell M.,
RA   Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|EMBL:BAM78284.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Thymus {ECO:0000313|EMBL:BAM78284.1};
RA   Isobe M., Ozawa T.;
RT   "Identification of the human candidate tumor suppressor gene (ATL1)
RT   encoding novel Zinc finger protein.";
RL   Submitted (MAR-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3] {ECO:0000313|EMBL:EAW81662.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB057669; BAM78284.1; -; mRNA.
DR   EMBL; CH471061; EAW81662.1; -; Genomic_DNA.
DR   RefSeq; NP_075049.1; NM_022898.2.
DR   UniGene; Hs.709690; -.
DR   SMR; L8B567; -.
DR   GeneID; 64919; -.
DR   CTD; 64919; -.
DR   EuPathDB; HostDB:ENSG00000127152.17; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   eggNOG; COG5048; LUCA.
DR   ChiTaRS; BCL11B; human.
DR   GenomeRNAi; 64919; -.
DR   Bgee; ENSG00000127152; -.
DR   GO; GO:0003676; F:nucleic acid binding; IEA:InterPro.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   SMART; SM00355; ZnF_C2H2; 6.
DR   SUPFAM; SSF57667; SSF57667; 3.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 6.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 6.
PE   2: Evidence at transcript level;
KW   Metal-binding {ECO:0000256|PROSITE-ProRule:PRU00042};
KW   Zinc {ECO:0000256|PROSITE-ProRule:PRU00042};
KW   Zinc-finger {ECO:0000256|PROSITE-ProRule:PRU00042}.
FT   DOMAIN      150    173       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
FT   DOMAIN      356    383       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
FT   DOMAIN      384    411       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
FT   DOMAIN      725    752       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
FT   DOMAIN      753    775       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
FT   DOMAIN      783    806       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
SQ   SEQUENCE   823 AA;  88476 MW;  589266E55A4C367E CRC64;
     MSRRKQGNPQ HLSQRELITP EADHVEAAIL EEDEGLEIEE PSGLGLMVGG PDPDLLTCGQ
     CQMNFPLGDI LVFIEHKRKQ CGGSLGACYD KALDKDSPPP SSRSELRKVS EPVEIGIQVT
     PDEDDHLLSP TKGICPKQEN IAGKDEPSSY ICTTCKQPFN SAWFLLQHAQ NTHGFRIYLE
     PGPASSSLTP RLTIPPPLGP EAVAQSPLMN FLGDSNPFNL LRMTGPILRD HPGFGEGRLP
     GTPPLFSPPP RHHLDPHRLS AEEMGLVAQH PSAFDRVMRL NPMAIDSPAM DFSRRLRELA
     GNSSTPPPVS PGRGNPMHRL LNPFQPSPKS PFLSTPPLPP MPPGGTPPPQ PPAKSKSCEF
     CGKTFKFQSN LIVHRRSHTG EKPYKCQLCD HACSQASKLK RHMKTHMHKA GSLAGRSDDG
     LSAASSPEPG TSELAGEGLK AADGDFRHHE SDPSLGHEPE EEDEEEEEEE EELLLENESR
     PESSFSMDSE LSRNRENGGG GVPGVPGAGG GAAKALADEK ALVLGKVMEN VGLGALPQYG
     ELLADKQKRG AFLKRAAGGG DAGDDDDAGG CGDAGAGGAV NGRGGGFAPG TEPFPGLFPR
     KPAPLPSPGL NSAAKRIKVE KDLELPPAAL IPSENVYSQW LVGYAASRHF MKDPFLGFTD
     ARQSPFATSS EHSSENGSLR FSTPPGDLLD GGLSGRSGTA SGGSTPHLGG PGPGRPSSKE
     GRRSDTCEYC GKVFKNCSNL TVHRRSHTGE RPYKCELCNY ACAQSSKLTR HMKTHGQIGK
     EVYRCDICQM PFSVYSTLEK HMKKWHGEHL LTNDVKIEQA ERS
//
ID   L8B7P7_HUMAN            Unreviewed;       894 AA.
AC   L8B7P7;
DT   03-APR-2013, integrated into UniProtKB/TrEMBL.
DT   03-APR-2013, sequence version 1.
DT   28-FEB-2018, entry version 51.
DE   SubName: Full=ATL1-alpha zinc finger protein {ECO:0000313|EMBL:BAM78282.1};
DE   SubName: Full=B-cell CLL/lymphoma 11B (Zinc finger protein), isoform CRA_b {ECO:0000313|EMBL:EAW81663.1};
GN   Name=ATL1-alpha {ECO:0000313|EMBL:BAM78282.1};
GN   Synonyms=BCL11B {ECO:0000313|EMBL:EAW81663.1};
GN   ORFNames=hCG_1657560 {ECO:0000313|EMBL:EAW81663.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAM78282.1};
RN   [1] {ECO:0000313|EMBL:BAM78282.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Thymus {ECO:0000313|EMBL:BAM78282.1};
RA   Isobe M., Ozawa T.;
RT   "Identification of the human candidate tumor suppressor gene (ATL1-
RT   alpha) encoding novel Zinc finger protein.";
RL   Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [2] {ECO:0000313|EMBL:EAW81663.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D.,
RA   Amanatides P., Ballew R.M., Huson D.H., Wortman J.R., Zhang Q.,
RA   Kodira C.D., Zheng X.H., Chen L., Skupski M., Subramanian G.,
RA   Thomas P.D., Zhang J., Gabor Miklos G.L., Nelson C., Broder S.,
RA   Clark A.G., Nadeau J., McKusick V.A., Zinder N., Levine A.J.,
RA   Roberts R.J., Simon M., Slayman C., Hunkapiller M., Bolanos R.,
RA   Delcher A., Dew I., Fasulo D., Flanigan M., Florea L., Halpern A.,
RA   Hannenhalli S., Kravitz S., Levy S., Mobarry C., Reinert K.,
RA   Remington K., Abu-Threideh J., Beasley E., Biddick K., Bonazzi V.,
RA   Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z.,
RA   Guan P., Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A.,
RA   Lai Z., Lei Y., Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V.,
RA   Milshina N., Moore H.M., Naik A.K., Narayan V.A., Neelam B.,
RA   Nusskern D., Rusch D.B., Salzberg S., Shao W., Shue B., Sun J.,
RA   Wang Z., Wang A., Wang X., Wang J., Wei M., Wides R., Xiao C., Yan C.,
RA   Yao A., Ye J., Zhan M., Zhang W., Zhang H., Zhao Q., Zheng L.,
RA   Zhong F., Zhong W., Zhu S., Zhao S., Gilbert D., Baumhueter S.,
RA   Spier G., Carter C., Cravchik A., Woodage T., Ali F., An H., Awe A.,
RA   Baldwin D., Baden H., Barnstead M., Barrow I., Beeson K., Busam D.,
RA   Carver A., Center A., Cheng M.L., Curry L., Danaher S., Davenport L.,
RA   Desilets R., Dietz S., Dodson K., Doup L., Ferriera S., Garg N.,
RA   Gluecksmann A., Hart B., Haynes J., Haynes C., Heiner C., Hladun S.,
RA   Hostin D., Houck J., Howland T., Ibegwam C., Johnson J., Kalush F.,
RA   Kline L., Koduru S., Love A., Mann F., May D., McCawley S.,
RA   McIntosh T., McMullen I., Moy M., Moy L., Murphy B., Nelson K.,
RA   Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N.,
RA   Tse S., Vech C., Wang G., Wetter J., Williams S., Williams M.,
RA   Windsor S., Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F.,
RA   Guigo R., Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A.,
RA   Mi H., Lazareva B., Hatton T., Narechania A., Diemer K.,
RA   Muruganujan A., Guo N., Sato S., Bafna V., Istrail S., Lippert R.,
RA   Schwartz R., Walenz B., Yooseph S., Allen D., Basu A., Baxendale J.,
RA   Blick L., Caminha M., Carnes-Stine J., Caulk P., Chiang Y.H.,
RA   Coyne M., Dahlke C., Mays A., Dombroski M., Donnelly M., Ely D.,
RA   Esparham S., Fosler C., Gire H., Glanowski S., Glasser K., Glodek A.,
RA   Gorokhov M., Graham K., Gropman B., Harris M., Heil J., Henderson S.,
RA   Hoover J., Jennings D., Jordan C., Jordan J., Kasha J., Kagan L.,
RA   Kraft C., Levitsky A., Lewis M., Liu X., Lopez J., Ma D., Majoros W.,
RA   McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N., Nodell M.,
RA   Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [3] {ECO:0000313|EMBL:EAW81663.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB041218; BAM78282.1; -; mRNA.
DR   EMBL; CH471061; EAW81663.1; -; Genomic_DNA.
DR   RefSeq; NP_612808.1; NM_138576.3.
DR   UniGene; Hs.709690; -.
DR   SMR; L8B7P7; -.
DR   GeneID; 64919; -.
DR   KEGG; hsa:64919; -.
DR   CTD; 64919; -.
DR   EuPathDB; HostDB:ENSG00000127152.17; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   eggNOG; COG5048; LUCA.
DR   KO; K22046; -.
DR   OMA; DDAGGCG; -.
DR   OrthoDB; EOG091G160N; -.
DR   ChiTaRS; BCL11B; human.
DR   GenomeRNAi; 64919; -.
DR   Bgee; ENSG00000127152; -.
DR   GO; GO:0043005; C:neuron projection; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0000978; F:RNA polymerase II proximal promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0001077; F:transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0046632; P:alpha-beta T cell differentiation; IEA:Ensembl.
DR   GO; GO:0021902; P:commitment of neuronal cell to specific neuron type in forebrain; IEA:Ensembl.
DR   GO; GO:0003382; P:epithelial cell morphogenesis; IEA:Ensembl.
DR   GO; GO:0003334; P:keratinocyte development; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0071678; P:olfactory bulb axon guidance; IEA:Ensembl.
DR   GO; GO:0043368; P:positive T cell selection; IEA:Ensembl.
DR   GO; GO:0031077; P:post-embryonic camera-type eye development; IEA:Ensembl.
DR   GO; GO:0010837; P:regulation of keratinocyte proliferation; IEA:Ensembl.
DR   GO; GO:0019216; P:regulation of lipid metabolic process; IEA:Ensembl.
DR   GO; GO:0045664; P:regulation of neuron differentiation; IEA:Ensembl.
DR   GO; GO:0021773; P:striatal medium spiny neuron differentiation; IEA:Ensembl.
DR   GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl.
DR   GO; GO:0033153; P:T cell receptor V(D)J recombination; IEA:Ensembl.
DR   GO; GO:0048538; P:thymus development; IEA:Ensembl.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   SMART; SM00355; ZnF_C2H2; 6.
DR   SUPFAM; SSF57667; SSF57667; 3.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 6.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 6.
PE   2: Evidence at transcript level;
KW   Metal-binding {ECO:0000256|PROSITE-ProRule:PRU00042};
KW   Zinc {ECO:0000256|PROSITE-ProRule:PRU00042};
KW   Zinc-finger {ECO:0000256|PROSITE-ProRule:PRU00042}.
FT   DOMAIN      221    244       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
FT   DOMAIN      427    454       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
FT   DOMAIN      455    482       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
FT   DOMAIN      796    823       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
FT   DOMAIN      824    846       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
FT   DOMAIN      854    877       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
SQ   SEQUENCE   894 AA;  95519 MW;  DF6C467AE2EEC122 CRC64;
     MSRRKQGNPQ HLSQRELITP EADHVEAAIL EEDEGLEIEE PSGLGLMVGG PDPDLLTCGQ
     CQMNFPLGDI LVFIEHKRKQ CGGSLGACYD KALDKDSPPP SSRSELRKVS EPVEIGIQVT
     PDEDDHLLSP TKGICPKQEN IAGPCRPAQL PAVAPIAASS HPHSSVITSP LRALGALPPC
     LPLPCCSARP VSGDGTQGEG QTEAPFGCQC QLSGKDEPSS YICTTCKQPF NSAWFLLQHA
     QNTHGFRIYL EPGPASSSLT PRLTIPPPLG PEAVAQSPLM NFLGDSNPFN LLRMTGPILR
     DHPGFGEGRL PGTPPLFSPP PRHHLDPHRL SAEEMGLVAQ HPSAFDRVMR LNPMAIDSPA
     MDFSRRLREL AGNSSTPPPV SPGRGNPMHR LLNPFQPSPK SPFLSTPPLP PMPPGGTPPP
     QPPAKSKSCE FCGKTFKFQS NLIVHRRSHT GEKPYKCQLC DHACSQASKL KRHMKTHMHK
     AGSLAGRSDD GLSAASSPEP GTSELAGEGL KAADGDFRHH ESDPSLGHEP EEEDEEEEEE
     EEELLLENES RPESSFSMDS ELSRNRENGG GGVPGVPGAG GGAAKALADE KALVLGKVME
     NVGLGALPQY GELLADKQKR GAFLKRAAGG GDAGDDDDAG GCGDAGAGGA VNGRGGGFAP
     GTEPFPGLFP RKPAPLPSPG LNSAAKRIKV EKDLELPPAA LIPSENVYSQ WLVGYAASRH
     FMKDPFLGFT DARQSPFATS SEHSSENGSL RFSTPPGDLL DGGLSGRSGT ASGGSTPHLG
     GPGPGRPSSK EGRRSDTCEY CGKVFKNCSN LTVHRRSHTG ERPYKCELCN YACAQSSKLT
     RHMKTHGQIG KEVYRCDICQ MPFSVYSTLE KHMKKWHGEH LLTNDVKIEQ AERS
//
ID   L8B862_HUMAN            Unreviewed;       822 AA.
AC   L8B862;
DT   03-APR-2013, integrated into UniProtKB/TrEMBL.
DT   03-APR-2013, sequence version 1.
DT   31-JAN-2018, entry version 21.
DE   SubName: Full=ATL1-delta zinc finger protein {ECO:0000313|EMBL:BAM78285.1};
GN   Name=ATL1-delta {ECO:0000313|EMBL:BAM78285.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAM78285.1};
RN   [1] {ECO:0000313|EMBL:BAM78285.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Thymus {ECO:0000313|EMBL:BAM78285.1};
RA   Isobe M., Ozawa T.;
RT   "Identification of the human candidate tumor suppressor gene (ATL1)
RT   encoding novel Zinc finger protein.";
RL   Submitted (MAR-2001) to the EMBL/GenBank/DDBJ databases.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB057670; BAM78285.1; -; mRNA.
DR   RefSeq; NP_001269167.1; NM_001282238.1.
DR   UniGene; Hs.709690; -.
DR   ProteinModelPortal; L8B862; -.
DR   PeptideAtlas; L8B862; -.
DR   PRIDE; L8B862; -.
DR   GeneID; 64919; -.
DR   CTD; 64919; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   eggNOG; COG5048; LUCA.
DR   ChiTaRS; BCL11B; human.
DR   GenomeRNAi; 64919; -.
DR   GO; GO:0003676; F:nucleic acid binding; IEA:InterPro.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   SMART; SM00355; ZnF_C2H2; 6.
DR   SUPFAM; SSF57667; SSF57667; 3.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 6.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 6.
PE   2: Evidence at transcript level;
KW   Metal-binding {ECO:0000256|PROSITE-ProRule:PRU00042};
KW   Zinc {ECO:0000256|PROSITE-ProRule:PRU00042};
KW   Zinc-finger {ECO:0000256|PROSITE-ProRule:PRU00042}.
FT   DOMAIN      149    172       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
FT   DOMAIN      355    382       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
FT   DOMAIN      383    410       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
FT   DOMAIN      724    751       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
FT   DOMAIN      752    774       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
FT   DOMAIN      782    805       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
SQ   SEQUENCE   822 AA;  88378 MW;  7E91064476C479E3 CRC64;
     MSRRKQGNPQ HLSQRELITQ ADHVEAAILE EDEGLEIEEP SGLGLMVGGP DPDLLTCGQC
     QMNFPLGDIL VFIEHKRKQC GGSLGACYDK ALDKDSPPPS SRSELRKVSE PVEIGIQVTP
     DEDDHLLSPT KGICPKQENI AGKDEPSSYI CTTCKQPFNS AWFLLQHAQN THGFRIYLEP
     GPASSSLTPR LTIPPPLGPE AVAQSPLMNF LGDSNPFNLL RMTGPILRDH PGFGEGRLPG
     TPPLFSPPPR HHLDPHRLSA EEMGLVAQHP SAFDRVMRLN PMAIDSPAMD FSRRLRELAG
     NSSTPPPVSP GRGNPMHRLL NPFQPSPKSP FLSTPPLPPM PPGGTPPPQP PAKSKSCEFC
     GKTFKFQSNL IVHRRSHTGE KPYKCQLCDH ACSQASKLKR HMKTHMHKAG SLAGRSDDGL
     SAASSPEPGT SELAGEGLKA ADGDFRHHES DPSLGHEPEE EDEEEEEEEE ELLLENESRP
     ESSFSMDSEL SRNRENGGGG VPGVPGAGGG AAKALADEKA LVLGKVMENV GLGALPQYGE
     LLADKQKRGA FLKRAAGGGD AGDDDDAGGC GDAGAGGAVN GRGGGFAPGT EPFPGLFPRK
     PAPLPSPGLN SAAKRIKVEK DLELPPAALI PSENVYSQWL VGYAASRHFM KDPFLGFTDA
     RQSPFATSSE HSSENGSLRF STPPGDLLDG GLSGRSGTAS GGSTPHLGGP GPGRPSSKEG
     RRSDTCEYCG KVFKNCSNLT VHRRSHTGER PYKCELCNYA CAQSSKLTRH MKTHGQIGKE
     VYRCDICQMP FSVYSTLEKH MKKWHGEHLL TNDVKIEQAE RS
//
ID   L8B8F6_HUMAN            Unreviewed;       893 AA.
AC   L8B8F6;
DT   03-APR-2013, integrated into UniProtKB/TrEMBL.
DT   03-APR-2013, sequence version 1.
DT   28-FEB-2018, entry version 24.
DE   SubName: Full=ATL1 zinc finger protein {ECO:0000313|EMBL:BAM78533.1};
DE   SubName: Full=ATL1-beta zinc finger protein {ECO:0000313|EMBL:BAM78283.1};
GN   Name=ATL1 {ECO:0000313|EMBL:BAM78533.1};
GN   Synonyms=ATL1-beta {ECO:0000313|EMBL:BAM78283.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAM78533.1};
RN   [1] {ECO:0000313|EMBL:BAM78533.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Isobe M., Ozawa T.;
RT   "Identification of the human candidate tumor suppressor gene (ATL1)
RT   encoding novel Zinc finger protein.";
RL   Submitted (APR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [2] {ECO:0000313|EMBL:BAM78283.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Thymus {ECO:0000313|EMBL:BAM78283.1};
RA   Isobe M., Ozawa T.;
RT   "Identification of the human candidate tumor suppressor gene (ATL1)
RT   encoding novel Zinc finger protein.";
RL   Submitted (MAR-2001) to the EMBL/GenBank/DDBJ databases.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB057668; BAM78283.1; -; mRNA.
DR   EMBL; AB041222; BAM78533.1; -; Genomic_DNA.
DR   RefSeq; NP_001269166.1; NM_001282237.1.
DR   UniGene; Hs.709690; -.
DR   SMR; L8B8F6; -.
DR   PeptideAtlas; L8B8F6; -.
DR   GeneID; 64919; -.
DR   CTD; 64919; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   eggNOG; COG5048; LUCA.
DR   ChiTaRS; ATL1; human.
DR   GenomeRNAi; 64919; -.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003676; F:nucleic acid binding; IEA:InterPro.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   SMART; SM00355; ZnF_C2H2; 6.
DR   SUPFAM; SSF57667; SSF57667; 3.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 6.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 6.
PE   2: Evidence at transcript level;
KW   Metal-binding {ECO:0000256|PROSITE-ProRule:PRU00042};
KW   Zinc {ECO:0000256|PROSITE-ProRule:PRU00042};
KW   Zinc-finger {ECO:0000256|PROSITE-ProRule:PRU00042}.
FT   DOMAIN      220    243       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
FT   DOMAIN      426    453       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
FT   DOMAIN      454    481       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
FT   DOMAIN      795    822       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
FT   DOMAIN      823    845       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
FT   DOMAIN      853    876       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
SQ   SEQUENCE   893 AA;  95421 MW;  36BAB220D2FB1FB5 CRC64;
     MSRRKQGNPQ HLSQRELITQ ADHVEAAILE EDEGLEIEEP SGLGLMVGGP DPDLLTCGQC
     QMNFPLGDIL VFIEHKRKQC GGSLGACYDK ALDKDSPPPS SRSELRKVSE PVEIGIQVTP
     DEDDHLLSPT KGICPKQENI AGPCRPAQLP AVAPIAASSH PHSSVITSPL RALGALPPCL
     PLPCCSARPV SGDGTQGEGQ TEAPFGCQCQ LSGKDEPSSY ICTTCKQPFN SAWFLLQHAQ
     NTHGFRIYLE PGPASSSLTP RLTIPPPLGP EAVAQSPLMN FLGDSNPFNL LRMTGPILRD
     HPGFGEGRLP GTPPLFSPPP RHHLDPHRLS AEEMGLVAQH PSAFDRVMRL NPMAIDSPAM
     DFSRRLRELA GNSSTPPPVS PGRGNPMHRL LNPFQPSPKS PFLSTPPLPP MPPGGTPPPQ
     PPAKSKSCEF CGKTFKFQSN LIVHRRSHTG EKPYKCQLCD HACSQASKLK RHMKTHMHKA
     GSLAGRSDDG LSAASSPEPG TSELAGEGLK AADGDFRHHE SDPSLGHEPE EEDEEEEEEE
     EELLLENESR PESSFSMDSE LSRNRENGGG GVPGVPGAGG GAAKALADEK ALVLGKVMEN
     VGLGALPQYG ELLADKQKRG AFLKRAAGGG DAGDDDDAGG CGDAGAGGAV NGRGGGFAPG
     TEPFPGLFPR KPAPLPSPGL NSAAKRIKVE KDLELPPAAL IPSENVYSQW LVGYAASRHF
     MKDPFLGFTD ARQSPFATSS EHSSENGSLR FSTPPGDLLD GGLSGRSGTA SGGSTPHLGG
     PGPGRPSSKE GRRSDTCEYC GKVFKNCSNL TVHRRSHTGE RPYKCELCNY ACAQSSKLTR
     HMKTHGQIGK EVYRCDICQM PFSVYSTLEK HMKKWHGEHL LTNDVKIEQA ERS
//
ID   BC11B_HUMAN             Reviewed;         894 AA.
AC   Q9C0K0; Q9H162;
DT   01-MAR-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2001, sequence version 1.
DT   28-FEB-2018, entry version 143.
DE   RecName: Full=B-cell lymphoma/leukemia 11B;
DE            Short=BCL-11B;
DE   AltName: Full=B-cell CLL/lymphoma 11B;
DE   AltName: Full=COUP-TF-interacting protein 2;
DE   AltName: Full=Radiation-induced tumor suppressor gene 1 protein;
DE            Short=hRit1;
GN   Name=BCL11B; Synonyms=CTIP2, RIT1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=11719382; DOI=10.1182/blood.V98.12.3413;
RA   Satterwhite E., Sonoki T., Willis T.G., Harder L., Nowak R.,
RA   Arriola E.L., Liu H., Price H.P., Gesk S., Steinemann D.,
RA   Schlegelberger B., Oscier D.G., Siebert R., Tucker P.W., Dyer M.J.;
RT   "The BCL11 gene family: involvement of BCL11A in lymphoid
RT   malignancies.";
RL   Blood 98:3413-3420(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Thymus;
RX   PubMed=12565905; DOI=10.1016/S0006-291X(02)03069-3;
RA   Wakabayashi Y., Inoue J., Takahashi Y., Matsuki A., Kosugi-Okano H.,
RA   Shinbo T., Mishima Y., Niwa O., Kominami R.;
RT   "Homozygous deletions and point mutations of the Rit1/Bcl11b gene in
RT   gamma-ray induced mouse thymic lymphomas.";
RL   Biochem. Biophys. Res. Commun. 301:598-603(2003).
RN   [3]
RP   FUNCTION, AND INTERACTION WITH EP300.
RX   PubMed=16809611; DOI=10.1182/blood-2006-05-021790;
RA   Cismasiu V.B., Ghanta S., Duque J., Albu D.I., Chen H.M., Kasturi R.,
RA   Avram D.;
RT   "BCL11B participates in the activation of IL2 gene expression in CD4+
RT   T lymphocytes.";
RL   Blood 108:2695-2702(2006).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-97; THR-120; SER-256;
RP   THR-260; SER-277; SER-358; THR-376; SER-381; SER-398; THR-417;
RP   SER-483; SER-488; SER-496; SER-497; SER-678 AND SER-765, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [5]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-851, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-381, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [7]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-591 AND LYS-887, SUMOYLATION
RP   [LARGE SCALE ANALYSIS] AT LYS-137 (ISOFORM 2), AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.O114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to
RT   replication stress reveals novel small ubiquitin-like modified target
RT   proteins and acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [8]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-137; LYS-591; LYS-617;
RP   LYS-686; LYS-723 AND LYS-887, SUMOYLATION [LARGE SCALE ANALYSIS] AT
RP   LYS-137 (ISOFORM 2), AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-
RT   modification with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [9]
RP   VARIANT [LARGE SCALE ANALYSIS] PRO-331.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [10]
RP   VARIANTS VAL-32 AND SER-229.
RX   PubMed=21220648; DOI=10.1001/archneurol.2010.351;
RA   Daoud H., Valdmanis P.N., Gros-Louis F., Belzil V., Spiegelman D.,
RA   Henrion E., Diallo O., Desjarlais A., Gauthier J., Camu W., Dion P.A.,
RA   Rouleau G.A.;
RT   "Resequencing of 29 candidate genes in patients with familial and
RT   sporadic amyotrophic lateral sclerosis.";
RL   Arch. Neurol. 68:587-593(2011).
RN   [11]
RP   FUNCTION, INTERACTION WITH EP300, INVOLVEMENT IN IMD49, VARIANT IMD49
RP   LYS-441, AND CHARACTERIZATION OF VARIANT IMD49 LYS-441.
RX   PubMed=27959755; DOI=10.1056/NEJMoa1509164;
RA   Punwani D., Zhang Y., Yu J., Cowan M.J., Rana S., Kwan A.,
RA   Adhikari A.N., Lizama C.O., Mendelsohn B.A., Fahl S.P., Chellappan A.,
RA   Srinivasan R., Brenner S.E., Wiest D.L., Puck J.M.;
RT   "Multisystem anomalies in severe combined immunodeficiency with mutant
RT   BCL11B.";
RL   N. Engl. J. Med. 375:2165-2176(2016).
CC   -!- FUNCTION: Key regulator of both differentiation and survival of T-
CC       lymphocytes during thymocyte development in mammals. Essential in
CC       controlling the responsiveness of hematopoietic stem cells to
CC       chemotactic signals by modulating the expression of the receptors
CC       CCR7 and CCR9, which direct the movement of progenitor cells from
CC       the bone marrow to the thymus (PubMed:27959755). Is a regulator of
CC       IL2 promoter and enhances IL2 expression in activated CD4(+) T-
CC       lymphocytes (PubMed:16809611). Tumor-suppressor that represses
CC       transcription through direct, TFCOUP2-independent binding to a GC-
CC       rich response element (By similarity). May also function in the
CC       P53-signaling pathway (By similarity).
CC       {ECO:0000250|UniProtKB:Q99PV8, ECO:0000269|PubMed:16809611,
CC       ECO:0000269|PubMed:27959755}.
CC   -!- SUBUNIT: Interacts with TFCOUP1, SIRT1, ARP1 and EAR2 (By
CC       similarity). Interacts with EP300; the interaction is detected in
CC       activated T-lymphocytes, but not under resting conditions
CC       (PubMed:27959755). {ECO:0000250|UniProtKB:Q99PV8,
CC       ECO:0000269|PubMed:27959755}.
CC   -!- INTERACTION:
CC       Q13547:HDAC1; NbExp=3; IntAct=EBI-6597578, EBI-301834;
CC       Q92769:HDAC2; NbExp=3; IntAct=EBI-6597578, EBI-301821;
CC       O43463:SUV39H1; NbExp=3; IntAct=EBI-6597578, EBI-349968;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=Alpha;
CC         IsoId=Q9C0K0-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9C0K0-2; Sequence=VSP_009565;
CC         Note=May be due to exon skipping. Contains a glycyl lysine
CC         isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2) at
CC         position 137. {ECO:0000244|PubMed:25755297,
CC         ECO:0000244|PubMed:28112733};
CC   -!- TISSUE SPECIFICITY: Highly expressed in brain and in malignant T-
CC       cell lines derived from patients with adult T-cell
CC       leukemia/lymphoma.
CC   -!- PTM: Sumoylated with SUMO1. {ECO:0000250}.
CC   -!- DISEASE: Immunodeficiency 49 (IMD49) [MIM:617237]: A form of
CC       severe combined immunodeficiency characterized by severe T-cell
CC       lymphopenia, no detectable T-cell receptor excision circles, no
CC       naive helper CD4+ T-cells, and impaired T-cell proliferative
CC       response. In addition to primary immunodeficiency, affected
CC       individuals manifest multiple abnormal systemic features,
CC       including severe delayed psychomotor development, intellectual
CC       disability, spastic quadriplegia, and craniofacial abnormalities.
CC       {ECO:0000269|PubMed:27959755}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/BCL11BID392.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ404614; CAC17726.1; -; mRNA.
DR   EMBL; AB043584; BAB32731.1; -; mRNA.
DR   CCDS; CCDS9949.1; -. [Q9C0K0-2]
DR   CCDS; CCDS9950.1; -. [Q9C0K0-1]
DR   RefSeq; NP_001269166.1; NM_001282237.1.
DR   RefSeq; NP_001269167.1; NM_001282238.1.
DR   RefSeq; NP_075049.1; NM_022898.2. [Q9C0K0-2]
DR   RefSeq; NP_612808.1; NM_138576.3. [Q9C0K0-1]
DR   UniGene; Hs.709690; -.
DR   ProteinModelPortal; Q9C0K0; -.
DR   SMR; Q9C0K0; -.
DR   BioGrid; 122343; 18.
DR   DIP; DIP-44025N; -.
DR   IntAct; Q9C0K0; 8.
DR   MINT; Q9C0K0; -.
DR   STRING; 9606.ENSP00000349723; -.
DR   iPTMnet; Q9C0K0; -.
DR   PhosphoSitePlus; Q9C0K0; -.
DR   BioMuta; BCL11B; -.
DR   DMDM; 44887723; -.
DR   MaxQB; Q9C0K0; -.
DR   PaxDb; Q9C0K0; -.
DR   PeptideAtlas; Q9C0K0; -.
DR   PRIDE; Q9C0K0; -.
DR   Ensembl; ENST00000345514; ENSP00000280435; ENSG00000127152. [Q9C0K0-2]
DR   Ensembl; ENST00000357195; ENSP00000349723; ENSG00000127152. [Q9C0K0-1]
DR   GeneID; 64919; -.
DR   KEGG; hsa:64919; -.
DR   UCSC; uc001yga.5; human. [Q9C0K0-1]
DR   CTD; 64919; -.
DR   DisGeNET; 64919; -.
DR   EuPathDB; HostDB:ENSG00000127152.17; -.
DR   GeneCards; BCL11B; -.
DR   HGNC; HGNC:13222; BCL11B.
DR   HPA; HPA049117; -.
DR   MalaCards; BCL11B; -.
DR   MIM; 606558; gene.
DR   MIM; 617237; phenotype.
DR   neXtProt; NX_Q9C0K0; -.
DR   OpenTargets; ENSG00000127152; -.
DR   PharmGKB; PA25301; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   eggNOG; COG5048; LUCA.
DR   GeneTree; ENSGT00530000063542; -.
DR   HOGENOM; HOG000015256; -.
DR   HOVERGEN; HBG050673; -.
DR   InParanoid; Q9C0K0; -.
DR   KO; K22046; -.
DR   OMA; DDAGGCG; -.
DR   OrthoDB; EOG091G160N; -.
DR   PhylomeDB; Q9C0K0; -.
DR   TreeFam; TF318131; -.
DR   SIGNOR; Q9C0K0; -.
DR   ChiTaRS; BCL11B; human.
DR   GeneWiki; BCL11B; -.
DR   GenomeRNAi; 64919; -.
DR   PRO; PR:Q9C0K0; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   Bgee; ENSG00000127152; -.
DR   CleanEx; HS_BCL11B; -.
DR   CleanEx; HS_RIT1; -.
DR   ExpressionAtlas; Q9C0K0; baseline and differential.
DR   Genevisible; Q9C0K0; HS.
DR   GO; GO:0043005; C:neuron projection; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0000978; F:RNA polymerase II proximal promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IBA:GO_Central.
DR   GO; GO:0001077; F:transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0046632; P:alpha-beta T cell differentiation; IEA:Ensembl.
DR   GO; GO:0021902; P:commitment of neuronal cell to specific neuron type in forebrain; IEA:Ensembl.
DR   GO; GO:0003382; P:epithelial cell morphogenesis; IEA:Ensembl.
DR   GO; GO:0035701; P:hematopoietic stem cell migration; IMP:UniProtKB.
DR   GO; GO:0003334; P:keratinocyte development; IEA:Ensembl.
DR   GO; GO:0097535; P:lymphoid lineage cell migration into thymus; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0022008; P:neurogenesis; IBA:GO_Central.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0071678; P:olfactory bulb axon guidance; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IMP:MGI.
DR   GO; GO:0043368; P:positive T cell selection; IEA:Ensembl.
DR   GO; GO:0031077; P:post-embryonic camera-type eye development; IEA:Ensembl.
DR   GO; GO:0010837; P:regulation of keratinocyte proliferation; IEA:Ensembl.
DR   GO; GO:0019216; P:regulation of lipid metabolic process; IEA:Ensembl.
DR   GO; GO:0045664; P:regulation of neuron differentiation; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; IBA:GO_Central.
DR   GO; GO:0021773; P:striatal medium spiny neuron differentiation; IEA:Ensembl.
DR   GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl.
DR   GO; GO:0033153; P:T cell receptor V(D)J recombination; IEA:Ensembl.
DR   GO; GO:0048538; P:thymus development; IEA:Ensembl.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   SMART; SM00355; ZnF_C2H2; 6.
DR   SUPFAM; SSF57667; SSF57667; 3.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 6.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 6.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Complete proteome;
KW   Disease mutation; Isopeptide bond; Mental retardation; Metal-binding;
KW   Methylation; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Repressor; SCID; Transcription;
KW   Transcription regulation; Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN         1    894       B-cell lymphoma/leukemia 11B.
FT                                /FTId=PRO_0000047104.
FT   ZN_FING     221    251       C2H2-type 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00042}.
FT   ZN_FING     427    454       C2H2-type 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00042}.
FT   ZN_FING     455    482       C2H2-type 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00042}.
FT   ZN_FING     796    823       C2H2-type 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00042}.
FT   ZN_FING     824    853       C2H2-type 5. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00042}.
FT   ZN_FING     854    884       C2H2-type 6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00042}.
FT   COMPBIAS    529    553       Glu-rich.
FT   COMPBIAS    569    661       Gly-rich.
FT   MOD_RES      97     97       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     110    110       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q99PV8}.
FT   MOD_RES     120    120       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     129    129       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q99PV8}.
FT   MOD_RES     256    256       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     260    260       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     277    277       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     293    293       Omega-N-methylarginine.
FT                                {ECO:0000250|UniProtKB:Q99PV8}.
FT   MOD_RES     322    322       Asymmetric dimethylarginine.
FT                                {ECO:0000250|UniProtKB:Q99PV8}.
FT   MOD_RES     358    358       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     376    376       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     381    381       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     398    398       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     401    401       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q99PV8}.
FT   MOD_RES     406    406       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q99PV8}.
FT   MOD_RES     417    417       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     483    483       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     488    488       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     496    496       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     497    497       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     678    678       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     754    754       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q99PV8}.
FT   MOD_RES     765    765       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     772    772       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q99PV8}.
FT   MOD_RES     851    851       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   CROSSLNK    137    137       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    591    591       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25755297,
FT                                ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    617    617       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    686    686       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    723    723       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    887    887       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25755297,
FT                                ECO:0000244|PubMed:28112733}.
FT   VAR_SEQ     143    213       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:11719382}.
FT                                /FTId=VSP_009565.
FT   VARIANT      32     32       E -> V (in a patient with amyotrophic
FT                                lateral sclerosis).
FT                                {ECO:0000269|PubMed:21220648}.
FT                                /FTId=VAR_065741.
FT   VARIANT     229    229       P -> S (in a patient with amyotrophic
FT                                lateral sclerosis; dbSNP:rs749837100).
FT                                {ECO:0000269|PubMed:21220648}.
FT                                /FTId=VAR_065742.
FT   VARIANT     331    331       S -> P (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035554.
FT   VARIANT     441    441       N -> K (in IMD49; loss of stimulation of
FT                                T-lymphocyte development; dominant
FT                                negative loss of activation of IL2
FT                                expression; results in reduced binding to
FT                                known canonical promoters and abnormal
FT                                binding to novel DNA sites not recognized
FT                                by the wild-type protein; no effect on
FT                                interaction with EP300;
FT                                dbSNP:rs750610248).
FT                                {ECO:0000269|PubMed:27959755}.
FT                                /FTId=VAR_078423.
SQ   SEQUENCE   894 AA;  95519 MW;  DF6C467AE2EEC122 CRC64;
     MSRRKQGNPQ HLSQRELITP EADHVEAAIL EEDEGLEIEE PSGLGLMVGG PDPDLLTCGQ
     CQMNFPLGDI LVFIEHKRKQ CGGSLGACYD KALDKDSPPP SSRSELRKVS EPVEIGIQVT
     PDEDDHLLSP TKGICPKQEN IAGPCRPAQL PAVAPIAASS HPHSSVITSP LRALGALPPC
     LPLPCCSARP VSGDGTQGEG QTEAPFGCQC QLSGKDEPSS YICTTCKQPF NSAWFLLQHA
     QNTHGFRIYL EPGPASSSLT PRLTIPPPLG PEAVAQSPLM NFLGDSNPFN LLRMTGPILR
     DHPGFGEGRL PGTPPLFSPP PRHHLDPHRL SAEEMGLVAQ HPSAFDRVMR LNPMAIDSPA
     MDFSRRLREL AGNSSTPPPV SPGRGNPMHR LLNPFQPSPK SPFLSTPPLP PMPPGGTPPP
     QPPAKSKSCE FCGKTFKFQS NLIVHRRSHT GEKPYKCQLC DHACSQASKL KRHMKTHMHK
     AGSLAGRSDD GLSAASSPEP GTSELAGEGL KAADGDFRHH ESDPSLGHEP EEEDEEEEEE
     EEELLLENES RPESSFSMDS ELSRNRENGG GGVPGVPGAG GGAAKALADE KALVLGKVME
     NVGLGALPQY GELLADKQKR GAFLKRAAGG GDAGDDDDAG GCGDAGAGGA VNGRGGGFAP
     GTEPFPGLFP RKPAPLPSPG LNSAAKRIKV EKDLELPPAA LIPSENVYSQ WLVGYAASRH
     FMKDPFLGFT DARQSPFATS SEHSSENGSL RFSTPPGDLL DGGLSGRSGT ASGGSTPHLG
     GPGPGRPSSK EGRRSDTCEY CGKVFKNCSN LTVHRRSHTG ERPYKCELCN YACAQSSKLT
     RHMKTHGQIG KEVYRCDICQ MPFSVYSTLE KHMKKWHGEH LLTNDVKIEQ AERS
//
ID   BIRC3_HUMAN             Reviewed;         604 AA.
AC   Q13489; Q16628; Q9HC27; Q9UP46;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 2.
DT   28-FEB-2018, entry version 187.
DE   RecName: Full=Baculoviral IAP repeat-containing protein 3;
DE            EC=2.3.2.27 {ECO:0000269|PubMed:21931591, ECO:0000269|PubMed:23453969};
DE   AltName: Full=Apoptosis inhibitor 2;
DE            Short=API2;
DE   AltName: Full=Cellular inhibitor of apoptosis 2;
DE            Short=C-IAP2 {ECO:0000303|PubMed:8548810};
DE   AltName: Full=IAP homolog C;
DE   AltName: Full=Inhibitor of apoptosis protein 1;
DE            Short=hIAP-1;
DE            Short=hIAP1;
DE   AltName: Full=RING finger protein 49;
DE   AltName: Full=RING-type E3 ubiquitin transferase BIRC3 {ECO:0000305};
DE   AltName: Full=TNFR2-TRAF-signaling complex protein 1;
GN   Name=BIRC3; Synonyms=API2, MIHC, RNF49;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8548810; DOI=10.1016/0092-8674(95)90149-3;
RA   Rothe M., Pan M.-G., Henzel W.J., Ayres T.M., Goeddel D.V.;
RT   "The TNFR2-TRAF signaling complex contains two novel proteins related
RT   to baculoviral inhibitor of apoptosis proteins.";
RL   Cell 83:1243-1252(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=8552191; DOI=10.1038/379349a0;
RA   Liston P., Roy N., Tamai K., Lefebvre C., Baird S., Cherton-Horvat G.,
RA   Farahani R., McLean M., Ikeda J., Mackenzie A., Korneluk R.G.;
RT   "Suppression of apoptosis in mammalian cells by NAIP and a related
RT   family of IAP genes.";
RL   Nature 379:349-353(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Fetal liver;
RX   PubMed=8643514; DOI=10.1073/pnas.93.10.4974;
RA   Uren A.G., Pakusch M., Hawkins C.J., Puls K.L., Vaux D.L.;
RT   "Cloning and expression of apoptosis inhibitory protein homologs that
RT   function to inhibit apoptosis and/or bind tumor necrosis factor
RT   receptor-associated factors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:4974-4978(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=10233894;
RA   Horrevoets A.J.G., Fontijn R.D., van Zonneveld A.J., de Vries C.J.M.,
RA   ten Cate J.W., Pannekoek H.;
RT   "Vascular endothelial genes that are responsive to tumor necrosis
RT   factor-alpha in vitro are expressed in atherosclerotic lesions,
RT   including inhibitor of apoptosis protein-1, stannin, and two novel
RT   genes.";
RL   Blood 93:3418-3431(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-260 AND LYS-401.
RG   NIEHS SNPs program;
RL   Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 362-441.
RX   PubMed=11066071;
RX   DOI=10.1002/1098-2264(2000)9999:9999<::AID-GCC1036>3.0.CO;2-I;
RA   Baens M., Steyls A., Dierlamm J., De Wolf-Peeters C., Marynen P.;
RT   "Structure of the MLT gene and molecular characterization of the
RT   genomic breakpoint junctions in the t(11;18)(q21;q21) of marginal zone
RT   B-cell lymphomas of MALT type.";
RL   Genes Chromosomes Cancer 29:281-291(2000).
RN   [8]
RP   SUBCELLULAR LOCATION.
RX   PubMed=15665297;
RA   Samuel T., Okada K., Hyer M., Welsh K., Zapata J.M., Reed J.C.;
RT   "cIAP1 Localizes to the nuclear compartment and modulates the cell
RT   cycle.";
RL   Cancer Res. 65:210-218(2005).
RN   [9]
RP   REVIEW ON FUNCTION.
RX   PubMed=18414036; DOI=10.4161/cc.7.8.5783;
RA   Dubrez-Daloz L., Dupoux A., Cartier J.;
RT   "IAPs: more than just inhibitors of apoptosis proteins.";
RL   Cell Cycle 7:1036-1046(2008).
RN   [10]
RP   REVIEW ON FUNCTION.
RX   PubMed=20888210; DOI=10.1016/j.ceb.2010.08.025;
RA   Lopez J., Meier P.;
RT   "To fight or die - inhibitor of apoptosis proteins at the crossroad of
RT   innate immunity and death.";
RL   Curr. Opin. Cell Biol. 22:872-881(2010).
RN   [11]
RP   REVIEW ON FUNCTION.
RX   PubMed=20651737; DOI=10.1038/nrc2889;
RA   Gyrd-Hansen M., Meier P.;
RT   "IAPs: from caspase inhibitors to modulators of NF-kappaB,
RT   inflammation and cancer.";
RL   Nat. Rev. Cancer 10:561-574(2010).
RN   [12]
RP   REVIEW ON FUNCTION.
RX   PubMed=21447281;
RA   Damgaard R.B., Gyrd-Hansen M.;
RT   "Inhibitor of apoptosis (IAP) proteins in regulation of inflammation
RT   and innate immunity.";
RL   Discov. Med. 11:221-231(2011).
RN   [13]
RP   ENZYME REGULATION, AND INTERACTION WITH USP19.
RX   PubMed=21849505; DOI=10.1074/jbc.M111.282020;
RA   Mei Y., Hahn A.A., Hu S., Yang X.;
RT   "The USP19 deubiquitinase regulates the stability of c-IAP1 and c-
RT   IAP2.";
RL   J. Biol. Chem. 286:35380-35387(2011).
RN   [14]
RP   FUNCTION IN THE UBIQUITINATION OF RIPK1; RIPK2; RIPK3 AND RIPK4,
RP   INTERACTION WITH RIPK1; RIPK2; RIPK3 AND RIPK4, AND CATALYTIC
RP   ACTIVITY.
RX   PubMed=21931591; DOI=10.1371/journal.pone.0022356;
RA   Bertrand M.J., Lippens S., Staes A., Gilbert B., Roelandt R.,
RA   De Medts J., Gevaert K., Declercq W., Vandenabeele P.;
RT   "cIAP1/2 are direct E3 ligases conjugating diverse types of ubiquitin
RT   chains to receptor interacting proteins kinases 1 to 4 (RIP1-4).";
RL   PLoS ONE 6:E22356-E22356(2011).
RN   [15]
RP   REVIEW ON FUNCTION.
RX   PubMed=22095281; DOI=10.1038/cdd.2011.163;
RA   Darding M., Meier P.;
RT   "IAPs: guardians of RIPK1.";
RL   Cell Death Differ. 19:58-66(2012).
RN   [16]
RP   FUNCTION IN IKBKE UBIQUITINATION, AND CATALYTIC ACTIVITY.
RX   PubMed=23453969; DOI=10.1016/j.celrep.2013.01.031;
RA   Zhou A.Y., Shen R.R., Kim E., Lock Y.J., Xu M., Chen Z.J., Hahn W.C.;
RT   "IKKepsilon-mediated tumorigenesis requires K63-linked
RT   polyubiquitination by a cIAP1/cIAP2/TRAF2 E3 ubiquitin ligase
RT   complex.";
RL   Cell Rep. 3:724-733(2013).
CC   -!- FUNCTION: Multi-functional protein which regulates not only
CC       caspases and apoptosis, but also modulates inflammatory signaling
CC       and immunity, mitogenic kinase signaling and cell proliferation,
CC       as well as cell invasion and metastasis. Acts as an E3 ubiquitin-
CC       protein ligase regulating NF-kappa-B signaling and regulates both
CC       canonical and non-canonical NF-kappa-B signaling by acting in
CC       opposite directions: acts as a positive regulator of the canonical
CC       pathway and suppresses constitutive activation of non-canonical
CC       NF-kappa-B signaling. The target proteins for its E3 ubiquitin-
CC       protein ligase activity include: RIPK1, RIPK2, RIPK3, RIPK4,
CC       CASP3, CASP7, CASP8, IKBKE, TRAF1, and BCL10. Acts as an important
CC       regulator of innate immune signaling via regulation of Toll-like
CC       receptors (TLRs), Nodlike receptors (NLRs) and RIG-I like
CC       receptors (RLRs), collectively referred to as pattern recognition
CC       receptors (PRRs). Protects cells from spontaneous formation of the
CC       ripoptosome, a large multi-protein complex that has the capability
CC       to kill cancer cells in a caspase-dependent and caspase-
CC       independent manner. Suppresses ripoptosome formation by
CC       ubiquitinating RIPK1 and CASP8. {ECO:0000269|PubMed:21931591,
CC       ECO:0000269|PubMed:23453969}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine. {ECO:0000269|PubMed:21931591,
CC       ECO:0000269|PubMed:23453969}.
CC   -!- ENZYME REGULATION: USP19 regulates the stability of BIRC3/c-IAP2
CC       by preventing its ubiquitination. {ECO:0000269|PubMed:21849505}.
CC   -!- SUBUNIT: Interacts with DIABLO/SMAC and with PRSS25; these
CC       interactions inhibit apoptotic suppressor activity. The BIR motifs
CC       region interacts with TNF receptor associated factors 1 and 2
CC       (TRAF1 and TRAF2) to form a heteromeric complex, which is then
CC       recruited to the tumor necrosis factor receptor 2 (TNFR2).
CC       Interaction with TRAF2 is required for ubiquitination of IKBKE,
CC       degradation of NFKBIA and activation of NF-kappa-B. Interacts with
CC       RIP1, RIP2, RIP3, RIP4 and USP19. {ECO:0000269|PubMed:21849505,
CC       ECO:0000269|PubMed:21931591}.
CC   -!- INTERACTION:
CC       P55211:CASP9; NbExp=2; IntAct=EBI-517709, EBI-516799;
CC       Q13546:RIPK1; NbExp=3; IntAct=EBI-517709, EBI-358507;
CC       O43353:RIPK2; NbExp=3; IntAct=EBI-517709, EBI-358522;
CC       Q9Y572:RIPK3; NbExp=3; IntAct=EBI-517709, EBI-298250;
CC       P57078:RIPK4; NbExp=3; IntAct=EBI-517709, EBI-4422308;
CC       Q13077:TRAF1; NbExp=2; IntAct=EBI-517709, EBI-359224;
CC       Q12933:TRAF2; NbExp=7; IntAct=EBI-517709, EBI-355744;
CC       P62837:UBE2D2; NbExp=2; IntAct=EBI-517709, EBI-347677;
CC       P61088:UBE2N; NbExp=2; IntAct=EBI-517709, EBI-1052908;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15665297}.
CC       Nucleus {ECO:0000269|PubMed:15665297}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in fetal lung, and kidney. In
CC       the adult, expression is mainly seen in lymphoid tissues,
CC       including spleen, thymus and peripheral blood lymphocytes.
CC   -!- PTM: Auto-ubiquitinated and degraded by the proteasome in
CC       apoptotic cells.
CC   -!- DISEASE: Note=A chromosomal aberration involving BIRC3 is
CC       recurrent in low-grade mucosa-associated lymphoid tissue (MALT
CC       lymphoma). Translocation t(11;18)(q21;q21) with MALT1. This
CC       translocation is found in approximately 50% of cytogenetically
CC       abnormal low-grade MALT lymphoma.
CC   -!- SIMILARITY: Belongs to the IAP family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/BIRC3ID239.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/birc3/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L49432; AAC41943.1; -; mRNA.
DR   EMBL; U45878; AAC50371.1; -; mRNA.
DR   EMBL; U37546; AAC50507.1; -; mRNA.
DR   EMBL; AF070674; AAC83232.1; -; mRNA.
DR   EMBL; AY764389; AAU88144.1; -; Genomic_DNA.
DR   EMBL; BC037420; AAH37420.1; -; mRNA.
DR   EMBL; AF178945; AAG09369.1; -; Genomic_DNA.
DR   CCDS; CCDS8315.1; -.
DR   PIR; S68449; S68449.
DR   RefSeq; NP_001156.1; NM_001165.4.
DR   RefSeq; NP_892007.1; NM_182962.2.
DR   RefSeq; XP_016873132.1; XM_017017643.1.
DR   UniGene; Hs.127799; -.
DR   PDB; 2UVL; X-ray; 1.91 A; A/B=244-337.
DR   PDB; 3EB5; X-ray; 2.00 A; A=536-604.
DR   PDB; 3EB6; X-ray; 3.40 A; A=536-604.
DR   PDB; 3M0A; X-ray; 2.61 A; D=26-99.
DR   PDB; 3M0D; X-ray; 2.80 A; D=26-99.
DR   PDBsum; 2UVL; -.
DR   PDBsum; 3EB5; -.
DR   PDBsum; 3EB6; -.
DR   PDBsum; 3M0A; -.
DR   PDBsum; 3M0D; -.
DR   ProteinModelPortal; Q13489; -.
DR   SMR; Q13489; -.
DR   BioGrid; 106827; 79.
DR   CORUM; Q13489; -.
DR   DIP; DIP-33720N; -.
DR   IntAct; Q13489; 40.
DR   MINT; Q13489; -.
DR   STRING; 9606.ENSP00000263464; -.
DR   BindingDB; Q13489; -.
DR   ChEMBL; CHEMBL5335; -.
DR   GuidetoPHARMACOLOGY; 2792; -.
DR   MEROPS; I32.007; -.
DR   iPTMnet; Q13489; -.
DR   PhosphoSitePlus; Q13489; -.
DR   BioMuta; BIRC3; -.
DR   DMDM; 2497236; -.
DR   EPD; Q13489; -.
DR   MaxQB; Q13489; -.
DR   PaxDb; Q13489; -.
DR   PeptideAtlas; Q13489; -.
DR   PRIDE; Q13489; -.
DR   Ensembl; ENST00000263464; ENSP00000263464; ENSG00000023445.
DR   Ensembl; ENST00000532808; ENSP00000432907; ENSG00000023445.
DR   Ensembl; ENST00000615299; ENSP00000481903; ENSG00000023445.
DR   GeneID; 330; -.
DR   KEGG; hsa:330; -.
DR   UCSC; uc001pgx.5; human.
DR   CTD; 330; -.
DR   DisGeNET; 330; -.
DR   EuPathDB; HostDB:ENSG00000023445.13; -.
DR   GeneCards; BIRC3; -.
DR   HGNC; HGNC:591; BIRC3.
DR   HPA; HPA002317; -.
DR   MalaCards; BIRC3; -.
DR   MIM; 601721; gene.
DR   neXtProt; NX_Q13489; -.
DR   OpenTargets; ENSG00000023445; -.
DR   Orphanet; 52417; MALT lymphoma.
DR   PharmGKB; PA25360; -.
DR   eggNOG; KOG1101; Eukaryota.
DR   eggNOG; ENOG410YPNM; LUCA.
DR   GeneTree; ENSGT00500000044782; -.
DR   HOGENOM; HOG000232059; -.
DR   HOVERGEN; HBG004848; -.
DR   InParanoid; Q13489; -.
DR   KO; K16060; -.
DR   OMA; CAMNTEK; -.
DR   OrthoDB; EOG091G0CXH; -.
DR   PhylomeDB; Q13489; -.
DR   TreeFam; TF105356; -.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-168927; TICAM1, RIP1-mediated IKK complex recruitment.
DR   Reactome; R-HSA-5213460; RIPK1-mediated regulated necrosis.
DR   Reactome; R-HSA-5357905; Regulation of TNFR1 signaling.
DR   Reactome; R-HSA-5357956; TNFR1-induced NFkappaB signaling pathway.
DR   Reactome; R-HSA-5668541; TNFR2 non-canonical NF-kB pathway.
DR   Reactome; R-HSA-5675482; Regulation of necroptotic cell death.
DR   Reactome; R-HSA-5676594; TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-937041; IKK complex recruitment mediated by RIP1.
DR   SignaLink; Q13489; -.
DR   SIGNOR; Q13489; -.
DR   ChiTaRS; BIRC3; human.
DR   EvolutionaryTrace; Q13489; -.
DR   GeneWiki; Baculoviral_IAP_repeat-containing_protein_3; -.
DR   GenomeRNAi; 330; -.
DR   PMAP-CutDB; Q13489; -.
DR   PRO; PR:Q13489; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000023445; -.
DR   CleanEx; HS_BIRC3; -.
DR   ExpressionAtlas; Q13489; baseline and differential.
DR   Genevisible; Q13489; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0045121; C:membrane raft; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0043234; C:protein complex; IEA:Ensembl.
DR   GO; GO:0043027; F:cysteine-type endopeptidase inhibitor activity involved in apoptotic process; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0016740; F:transferase activity; EXP:Reactome.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; TAS:Reactome.
DR   GO; GO:1990001; P:inhibition of cysteine-type endopeptidase activity involved in apoptotic process; IBA:GO_Central.
DR   GO; GO:0002756; P:MyD88-independent toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:ProtInc.
DR   GO; GO:0060546; P:negative regulation of necroptotic process; IBA:GO_Central.
DR   GO; GO:0038061; P:NIK/NF-kappaB signaling; TAS:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; TAS:UniProtKB.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0051291; P:protein heterooligomerization; IEA:Ensembl.
DR   GO; GO:0042981; P:regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:2000116; P:regulation of cysteine-type endopeptidase activity; TAS:UniProtKB.
DR   GO; GO:0050727; P:regulation of inflammatory response; TAS:UniProtKB.
DR   GO; GO:0045088; P:regulation of innate immune response; TAS:UniProtKB.
DR   GO; GO:0060544; P:regulation of necroptotic process; IMP:UniProtKB.
DR   GO; GO:0070424; P:regulation of nucleotide-binding oligomerization domain containing signaling pathway; TAS:UniProtKB.
DR   GO; GO:0039535; P:regulation of RIG-I signaling pathway; TAS:UniProtKB.
DR   GO; GO:0034121; P:regulation of toll-like receptor signaling pathway; TAS:UniProtKB.
DR   GO; GO:0010803; P:regulation of tumor necrosis factor-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0035666; P:TRIF-dependent toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; TAS:Reactome.
DR   CDD; cd00022; BIR; 3.
DR   InterPro; IPR001370; BIR_rpt.
DR   InterPro; IPR001315; CARD.
DR   InterPro; IPR011029; DEATH-like_dom_sf.
DR   InterPro; IPR001841; Znf_RING.
DR   Pfam; PF00653; BIR; 3.
DR   Pfam; PF00619; CARD; 1.
DR   SMART; SM00238; BIR; 3.
DR   SMART; SM00114; CARD; 1.
DR   SMART; SM00184; RING; 1.
DR   SUPFAM; SSF47986; SSF47986; 1.
DR   PROSITE; PS01282; BIR_REPEAT_1; 3.
DR   PROSITE; PS50143; BIR_REPEAT_2; 3.
DR   PROSITE; PS50209; CARD; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Apoptosis; Chromosomal rearrangement; Complete proteome;
KW   Cytoplasm; Metal-binding; Nucleus; Polymorphism; Reference proteome;
KW   Repeat; Transferase; Ubl conjugation; Ubl conjugation pathway; Zinc;
KW   Zinc-finger.
FT   CHAIN         1    604       Baculoviral IAP repeat-containing protein
FT                                3.
FT                                /FTId=PRO_0000122349.
FT   REPEAT       29     96       BIR 1.
FT   REPEAT      169    235       BIR 2.
FT   REPEAT      255    322       BIR 3.
FT   DOMAIN      439    529       CARD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00046}.
FT   ZN_FING     557    592       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   METAL       292    292       Zinc. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00029}.
FT   METAL       295    295       Zinc. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00029}.
FT   METAL       312    312       Zinc. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00029}.
FT   METAL       319    319       Zinc. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00029}.
FT   SITE        442    443       Breakpoint for translocation to form
FT                                BIRC3-MALT1.
FT   VARIANT     260    260       K -> R (in dbSNP:rs2276113).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_021069.
FT   VARIANT     386    386       V -> M (in dbSNP:rs12222256).
FT                                /FTId=VAR_049536.
FT   VARIANT     401    401       R -> K (in dbSNP:rs17881197).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_021070.
FT   CONFLICT     18     18       N -> Y (in Ref. 4; AAC83232).
FT                                {ECO:0000305}.
FT   CONFLICT    119    119       N -> H (in Ref. 2; AAC50371).
FT                                {ECO:0000305}.
FT   CONFLICT    153    153       D -> E (in Ref. 2; AAC50371).
FT                                {ECO:0000305}.
FT   CONFLICT    163    163       H -> P (in Ref. 2; AAC50371).
FT                                {ECO:0000305}.
FT   CONFLICT    165    165       A -> P (in Ref. 2; AAC50371).
FT                                {ECO:0000305}.
FT   CONFLICT    191    191       K -> R (in Ref. 2; AAC50371).
FT                                {ECO:0000305}.
FT   CONFLICT    364    364       F -> L (in Ref. 2; AAC50371).
FT                                {ECO:0000305}.
FT   CONFLICT    552    552       Q -> P (in Ref. 2; AAC50371).
FT                                {ECO:0000305}.
FT   HELIX        28     34       {ECO:0000244|PDB:3M0A}.
FT   HELIX        35     38       {ECO:0000244|PDB:3M0A}.
FT   HELIX        47     52       {ECO:0000244|PDB:3M0A}.
FT   STRAND       55     57       {ECO:0000244|PDB:3M0A}.
FT   STRAND       64     66       {ECO:0000244|PDB:3M0A}.
FT   TURN         67     69       {ECO:0000244|PDB:3M0A}.
FT   HELIX        82     89       {ECO:0000244|PDB:3M0A}.
FT   TURN         94     97       {ECO:0000244|PDB:3M0A}.
FT   HELIX       250    252       {ECO:0000244|PDB:2UVL}.
FT   HELIX       255    260       {ECO:0000244|PDB:2UVL}.
FT   HELIX       261    264       {ECO:0000244|PDB:2UVL}.
FT   HELIX       273    278       {ECO:0000244|PDB:2UVL}.
FT   STRAND      281    285       {ECO:0000244|PDB:2UVL}.
FT   TURN        286    288       {ECO:0000244|PDB:2UVL}.
FT   STRAND      289    292       {ECO:0000244|PDB:2UVL}.
FT   TURN        293    295       {ECO:0000244|PDB:2UVL}.
FT   STRAND      298    301       {ECO:0000244|PDB:2UVL}.
FT   HELIX       308    315       {ECO:0000244|PDB:2UVL}.
FT   HELIX       320    334       {ECO:0000244|PDB:2UVL}.
FT   HELIX       544    555       {ECO:0000244|PDB:3EB5}.
FT   TURN        558    560       {ECO:0000244|PDB:3EB5}.
FT   STRAND      561    564       {ECO:0000244|PDB:3EB5}.
FT   STRAND      567    570       {ECO:0000244|PDB:3EB5}.
FT   STRAND      575    577       {ECO:0000244|PDB:3EB5}.
FT   TURN        579    581       {ECO:0000244|PDB:3EB5}.
FT   HELIX       582    584       {ECO:0000244|PDB:3EB5}.
FT   STRAND      589    591       {ECO:0000244|PDB:3EB5}.
FT   STRAND      597    600       {ECO:0000244|PDB:3EB5}.
SQ   SEQUENCE   604 AA;  68372 MW;  8581A00BA9AAB4A7 CRC64;
     MNIVENSIFL SNLMKSANTF ELKYDLSCEL YRMSTYSTFP AGVPVSERSL ARAGFYYTGV
     NDKVKCFCCG LMLDNWKRGD SPTEKHKKLY PSCRFVQSLN SVNNLEATSQ PTFPSSVTNS
     THSLLPGTEN SGYFRGSYSN SPSNPVNSRA NQDFSALMRS SYHCAMNNEN ARLLTFQTWP
     LTFLSPTDLA KAGFYYIGPG DRVACFACGG KLSNWEPKDN AMSEHLRHFP KCPFIENQLQ
     DTSRYTVSNL SMQTHAARFK TFFNWPSSVL VNPEQLASAG FYYVGNSDDV KCFCCDGGLR
     CWESGDDPWV QHAKWFPRCE YLIRIKGQEF IRQVQASYPH LLEQLLSTSD SPGDENAESS
     IIHFEPGEDH SEDAIMMNTP VINAAVEMGF SRSLVKQTVQ RKILATGENY RLVNDLVLDL
     LNAEDEIREE ERERATEEKE SNDLLLIRKN RMALFQHLTC VIPILDSLLT AGIINEQEHD
     VIKQKTQTSL QARELIDTIL VKGNIAATVF RNSLQEAEAV LYEHLFVQQD IKYIPTEDVS
     DLPVEEQLRR LQEERTCKVC MDKEVSIVFI PCGHLVVCKD CAPSLRKCPI CRSTIKGTVR
     TFLS
//
ID   CBL_HUMAN               Reviewed;         906 AA.
AC   P22681; A3KMP8;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   07-JUL-2009, sequence version 2.
DT   28-FEB-2018, entry version 217.
DE   RecName: Full=E3 ubiquitin-protein ligase CBL;
DE            EC=2.3.2.27 {ECO:0000269|PubMed:10514377, ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:17509076};
DE   AltName: Full=Casitas B-lineage lymphoma proto-oncogene;
DE   AltName: Full=Proto-oncogene c-Cbl;
DE   AltName: Full=RING finger protein 55;
DE   AltName: Full=RING-type E3 ubiquitin transferase CBL {ECO:0000305};
DE   AltName: Full=Signal transduction protein CBL;
GN   Name=CBL; Synonyms=CBL2, RNF55;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2030914;
RA   Blake T.J., Shapiro M., Morse H.C. III, Langdon W.Y.;
RT   "The sequences of the human and mouse c-cbl proto-oncogenes show v-cbl
RT   was generated by a large truncation encompassing a proline-rich domain
RT   and a leucine zipper-like motif.";
RL   Oncogene 6:653-657(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PHOSPHORYLATION BY HCK, AND INTERACTION WITH HCK.
RX   PubMed=10092522; DOI=10.1006/bbrc.1999.0427;
RA   Howlett C.J., Bisson S.A., Resek M.E., Tigley A.W., Robbins S.M.;
RT   "The proto-oncogene p120(Cbl) is a downstream substrate of the Hck
RT   protein-tyrosine kinase.";
RL   Biochem. Biophys. Res. Commun. 257:129-138(1999).
RN   [5]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=10514377; DOI=10.1126/science.286.5438.309;
RA   Joazeiro C.A., Wing S.S., Huang H.-K., Leverson J.D., Hunter T.,
RA   Liu Y.-C.;
RT   "The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-
RT   dependent ubiquitin-protein ligase.";
RL   Science 286:309-312(1999).
RN   [6]
RP   INTERACTION WITH BLK.
RX   PubMed=8083187;
RA   Donovan J.A., Wange R.L., Langdon W.Y., Samelson L.E.;
RT   "The protein product of the c-cbl protooncogene is the 120-kDa
RT   tyrosine-phosphorylated protein in Jurkat cells activated via the T
RT   cell antigen receptor.";
RL   J. Biol. Chem. 269:22921-22924(1994).
RN   [7]
RP   PHOSPHORYLATION BY EGFR, AND INTERACTION WITH EGFR.
RX   PubMed=7657591; DOI=10.1074/jbc.270.35.20242;
RA   Galisteo M.L., Dikic I., Batzer A.G., Langdon W.Y., Schlessinger J.;
RT   "Tyrosine phosphorylation of the c-cbl proto-oncogene protein product
RT   and association with epidermal growth factor (EGF) receptor upon EGF
RT   stimulation.";
RL   J. Biol. Chem. 270:20242-20245(1995).
RN   [8]
RP   INTERACTION WITH ZAP70.
RX   PubMed=9407100; DOI=10.1074/jbc.272.52.33140;
RA   Lupher M.L. Jr., Songyang Z., Shoelson S.E., Cantley L.C., Band H.;
RT   "The Cbl phosphotyrosine-binding domain selects a D(N/D)XpY motif and
RT   binds to the Tyr292 negative regulatory phosphorylation site of ZAP-
RT   70.";
RL   J. Biol. Chem. 272:33140-33144(1997).
RN   [9]
RP   PHOSPHORYLATION BY SYK AND FYN.
RX   PubMed=9535867; DOI=10.1074/jbc.273.15.8867;
RA   Deckert M., Elly C., Altman A., Liu Y.C.;
RT   "Coordinated regulation of the tyrosine phosphorylation of Cbl by Fyn
RT   and Syk tyrosine kinases.";
RL   J. Biol. Chem. 273:8867-8874(1998).
RN   [10]
RP   INTERACTION WITH LAT2.
RX   PubMed=12486104; DOI=10.1084/jem.20021405;
RA   Brdicka T., Imrich M., Angelisova P., Brdickova N., Horvath O.,
RA   Spicka J., Hilgert I., Luskova P., Draber P., Novak P., Engels N.,
RA   Wienands J., Simeoni L., Oesterreicher J., Aguado E., Malissen M.,
RA   Schraven B., Horejsi V.;
RT   "Non-T cell activation linker (NTAL): a transmembrane adaptor protein
RT   involved in immunoreceptor signaling.";
RL   J. Exp. Med. 196:1617-1626(2002).
RN   [11]
RP   INTERACTION WITH CSF1R, AND PHOSPHORYLATION.
RX   PubMed=11850825; DOI=10.1038/sj.onc.1205166;
RA   Wilhelmsen K., Burkhalter S., van der Geer P.;
RT   "C-Cbl binds the CSF-1 receptor at tyrosine 973, a novel
RT   phosphorylation site in the receptor's carboxy-terminus.";
RL   Oncogene 21:1079-1089(2002).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, UBIQUITINATION, MUTAGENESIS OF
RP   CYS-381, AND INTERACTION WITH HCK.
RX   PubMed=11896602; DOI=10.1038/sj.onc.1205228;
RA   Howlett C.J., Robbins S.M.;
RT   "Membrane-anchored Cbl suppresses Hck protein-tyrosine kinase mediated
RT   cellular transformation.";
RL   Oncogene 21:1707-1716(2002).
RN   [13]
RP   INTERACTION WITH FGR, AND PHOSPHORYLATION BY FGR.
RX   PubMed=12435267; DOI=10.1042/BJ20021201;
RA   Melander F., Andersson T., Dib K.;
RT   "Fgr but not Syk tyrosine kinase is a target for beta 2 integrin-
RT   induced c-Cbl-mediated ubiquitination in adherent human neutrophils.";
RL   Biochem. J. 370:687-694(2003).
RN   [14]
RP   INTERACTION WITH SH2B2.
RX   PubMed=10374881; DOI=10.1038/sj/leu/2401397;
RA   Wakioka T., Sasaki A., Mitsui K., Yokouchi M., Inoue A., Komiya S.,
RA   Yoshimura A.;
RT   "APS, an adaptor protein containing pleckstrin homology (PH) and Src
RT   homology-2 (SH2) domains inhibits the JAK-STAT pathway in
RT   collaboration with c-Cbl.";
RL   Leukemia 13:760-767(1999).
RN   [15]
RP   INTERACTION WITH SH2B2.
RX   PubMed=9989826; DOI=10.1038/sj.onc.1202326;
RA   Yokouchi M., Wakioka T., Sakamoto H., Yasukawa H., Ohtsuka S.,
RA   Sasaki A., Ohtsubo M., Valius M., Inoue A., Komiya S., Yoshimura A.;
RT   "APS, an adaptor protein containing PH and SH2 domains, is associated
RT   with the PDGF receptor and c-Cbl and inhibits PDGF-induced
RT   mitogenesis.";
RL   Oncogene 18:759-767(1999).
RN   [16]
RP   INTERACTION WITH SLA AND ZAP70, AND MUTAGENESIS OF GLY-306.
RX   PubMed=10449770; DOI=10.1073/pnas.96.17.9775;
RA   Tang J., Sawasdikosol S., Chang J.-H., Burakoff S.J.;
RT   "SLAP, a dimeric adapter protein, plays a functional role in T cell
RT   receptor signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:9775-9780(1999).
RN   [17]
RP   INTERACTION WITH SLA2.
RX   PubMed=11696592; DOI=10.1084/jem.194.9.1263;
RA   Holland S.J., Liao X.C., Mendenhall M.K., Zhou X., Pardo J., Chu P.,
RA   Spencer C., Fu A.C., Sheng N., Yu P., Pali E., Nagin A., Shen M.,
RA   Yu S., Chan E., Wu X., Li C., Woisetschlager M., Aversa G.,
RA   Kolbinger F., Bennett M.K., Molineaux S., Luo Y., Payan D.G.,
RA   Mancebo H.S.Y., Wu J.;
RT   "Functional cloning of Src-like adapter protein-2 (SLAP-2), a novel
RT   inhibitor of antigen receptor signaling.";
RL   J. Exp. Med. 194:1263-1276(2001).
RN   [18]
RP   INTERACTION WITH CD2AP.
RX   PubMed=11067845; DOI=10.1074/jbc.M005784200;
RA   Kirsch K.H., Georgescu M.M., Shishido T., Langdon W.Y., Birge R.B.,
RA   Hanafusa H.;
RT   "The adapter type protein CMS/CD2AP binds to the proto-oncogenic
RT   protein c-Cbl through a tyrosine phosphorylation-regulated Src
RT   homology 3 domain interaction.";
RL   J. Biol. Chem. 276:4957-4963(2001).
RN   [19]
RP   INTERACTION WITH SH2B2, MUTAGENESIS OF TYR-371; TYR-700; TYR-731 AND
RP   TYR-774, AND PHOSPHORYLATION AT TYR-371; TYR-700 AND TYR-774.
RX   PubMed=11997497; DOI=10.1128/MCB.22.11.3599-3609.2002;
RA   Liu J., Kimura A., Baumann C.A., Saltiel A.R.;
RT   "APS facilitates c-Cbl tyrosine phosphorylation and GLUT4
RT   translocation in response to insulin in 3T3-L1 adipocytes.";
RL   Mol. Cell. Biol. 22:3599-3609(2002).
RN   [20]
RP   INTERACTION WITH INPPL1.
RX   PubMed=12504111; DOI=10.1016/S0006-291X(02)02894-2;
RA   Vandenbroere I., Paternotte N., Dumont J.E., Erneux C., Pirson I.;
RT   "The c-Cbl-associated protein and c-Cbl are two new partners of the
RT   SH2-containing inositol polyphosphate 5-phosphatase SHIP2.";
RL   Biochem. Biophys. Res. Commun. 300:494-500(2003).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=12522270; DOI=10.1073/pnas.2436191100;
RA   Salomon A.R., Ficarro S.B., Brill L.M., Brinker A., Phung Q.T.,
RA   Ericson C., Sauer K., Brock A., Horn D.M., Schultz P.G., Peters E.C.;
RT   "Profiling of tyrosine phosphorylation pathways in human cells using
RT   mass spectrometry.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:443-448(2003).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites
RT   from human T cells using immobilized metal affinity chromatography and
RT   tandem mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [23]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=14661060; DOI=10.1038/sj.onc.1207298;
RA   Kim M., Tezuka T., Tanaka K., Yamamoto T.;
RT   "Cbl-c suppresses v-Src-induced transformation through ubiquitin-
RT   dependent protein degradation.";
RL   Oncogene 23:1645-1655(2004).
RN   [24]
RP   REVIEW ON ROLE IN KIT SIGNALING AND KIT DEGRADATION.
RX   PubMed=15526160; DOI=10.1007/s00018-004-4189-6;
RA   Ronnstrand L.;
RT   "Signal transduction via the stem cell factor receptor/c-Kit.";
RL   Cell. Mol. Life Sci. 61:2535-2548(2004).
RN   [25]
RP   PHOSPHORYLATION AT TYR-700.
RX   PubMed=15556646; DOI=10.1016/j.febslet.2004.10.054;
RA   Grossmann A.H., Kolibaba K.S., Willis S.G., Corbin A.S., Langdon W.S.,
RA   Deininger M.W., Druker B.J.;
RT   "Catalytic domains of tyrosine kinases determine the phosphorylation
RT   sites within c-Cbl.";
RL   FEBS Lett. 577:555-562(2004).
RN   [26]
RP   FUNCTION, PHOSPHORYLATION AT TYR-731, AND MUTAGENESIS OF TYR-731.
RX   PubMed=14739300; DOI=10.1074/jbc.M311032200;
RA   Miyazaki T., Sanjay A., Neff L., Tanaka S., Horne W.C., Baron R.;
RT   "Src kinase activity is essential for osteoclast function.";
RL   J. Biol. Chem. 279:17660-17666(2004).
RN   [27]
RP   FUNCTION, PHOSPHORYLATION, AND INTERACTION WITH FGFR2; LYN AND FYN.
RX   PubMed=15190072; DOI=10.1074/jbc.M402469200;
RA   Kaabeche K., Lemonnier J., Le Mee S., Caverzasio J., Marie P.J.;
RT   "Cbl-mediated degradation of Lyn and Fyn induced by constitutive
RT   fibroblast growth factor receptor-2 activation supports osteoblast
RT   differentiation.";
RL   J. Biol. Chem. 279:36259-36267(2004).
RN   [28]
RP   INTERACTION WITH ALK, AND PHOSPHORYLATION BY ALK.
RX   PubMed=15226403; DOI=10.1242/jcs.01183;
RA   Motegi A., Fujimoto J., Kotani M., Sakuraba H., Yamamoto T.;
RT   "ALK receptor tyrosine kinase promotes cell growth and neurite
RT   outgrowth.";
RL   J. Cell Sci. 117:3319-3329(2004).
RN   [29]
RP   INTERACTION WITH AXL.
RX   PubMed=15958209; DOI=10.1016/j.bbrc.2005.05.086;
RA   Valverde P.;
RT   "Effects of Gas6 and hydrogen peroxide in Axl ubiquitination and
RT   downregulation.";
RL   Biochem. Biophys. Res. Commun. 333:180-185(2005).
RN   [30]
RP   REVIEW ON ROLE IN KIT SIGNALING AND KIT DEGRADATION.
RX   PubMed=16129412; DOI=10.1016/j.bbrc.2005.08.055;
RA   Roskoski R. Jr.;
RT   "Signaling by Kit protein-tyrosine kinase--the stem cell factor
RT   receptor.";
RL   Biochem. Biophys. Res. Commun. 337:1-13(2005).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-900, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [33]
RP   FUNCTION, CATALYTIC ACTIVITY, AND PHOSPHORYLATION.
RX   PubMed=17509076; DOI=10.1111/j.1742-4658.2007.05835.x;
RA   Bonaventure J., Horne W.C., Baron R.;
RT   "The localization of FGFR3 mutations causing thanatophoric dysplasia
RT   type I differentially affects phosphorylation, processing and
RT   ubiquitylation of the receptor.";
RL   FEBS J. 274:3078-3093(2007).
RN   [34]
RP   INTERACTION WITH PDGFRB.
RX   PubMed=17620338; DOI=10.1074/jbc.M701797200;
RA   Reddi A.L., Ying G., Duan L., Chen G., Dimri M., Douillard P.,
RA   Druker B.J., Naramura M., Band V., Band H.;
RT   "Binding of Cbl to a phospholipase Cgamma1-docking site on platelet-
RT   derived growth factor receptor beta provides a dual mechanism of
RT   negative regulation.";
RL   J. Biol. Chem. 282:29336-29347(2007).
RN   [35]
RP   INTERACTION WITH LYN.
RX   PubMed=18235045; DOI=10.1182/blood-2007-08-109330;
RA   Wu J., Meng F., Lu H., Kong L., Bornmann W., Peng Z., Talpaz M.,
RA   Donato N.J.;
RT   "Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl
RT   protein stability in imatinib-resistant chronic myelogenous leukemia
RT   cells.";
RL   Blood 111:3821-3829(2008).
RN   [36]
RP   FUNCTION, INTERACTION WITH FGFR2, AND SUBCELLULAR LOCATION.
RX   PubMed=18374639; DOI=10.1016/j.bone.2008.02.009;
RA   Dufour C., Guenou H., Kaabeche K., Bouvard D., Sanjay A., Marie P.J.;
RT   "FGFR2-Cbl interaction in lipid rafts triggers attenuation of PI3K/Akt
RT   signaling and osteoblast survival.";
RL   Bone 42:1032-1039(2008).
RN   [37]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [38]
RP   INTERACTION WITH EPHB1, AND PHOSPHORYLATION.
RX   PubMed=18034775; DOI=10.1111/j.1600-0854.2007.00679.x;
RA   Fasen K., Cerretti D.P., Huynh-Do U.;
RT   "Ligand binding induces Cbl-dependent EphB1 receptor degradation
RT   through the lysosomal pathway.";
RL   Traffic 9:251-266(2008).
RN   [39]
RP   INTERACTION WITH TEK/TIE2, AND FUNCTION.
RX   PubMed=19689429; DOI=10.1042/BJ20091010;
RA   Wehrle C., Van Slyke P., Dumont D.J.;
RT   "Angiopoietin-1-induced ubiquitylation of Tie2 by c-Cbl is required
RT   for internalization and degradation.";
RL   Biochem. J. 423:375-380(2009).
RN   [40]
RP   INTERACTION WITH EGFR.
RX   PubMed=19836242; DOI=10.1016/j.cub.2009.09.048;
RA   Tarcic G., Boguslavsky S.K., Wakim J., Kiuchi T., Liu A., Reinitz F.,
RA   Nathanson D., Takahashi T., Mischel P.S., Ng T., Yarden Y.;
RT   "An unbiased screen identifies DEP-1 tumor suppressor as a phosphatase
RT   controlling EGFR endocytosis.";
RL   Curr. Biol. 19:1788-1798(2009).
RN   [41]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-452, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [42]
RP   INTERACTION WITH PDGFRB, AND PHOSPHORYLATION.
RX   PubMed=20494825; DOI=10.1016/j.cellsig.2010.05.004;
RA   Wardega P., Heldin C.H., Lennartsson J.;
RT   "Mutation of tyrosine residue 857 in the PDGF beta-receptor affects
RT   cell proliferation but not migration.";
RL   Cell. Signal. 22:1363-1368(2010).
RN   [43]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [44]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [45]
RP   FUNCTION, AND INTERACTION WITH FGFR2.
RX   PubMed=21596750; DOI=10.1074/jbc.M110.197525;
RA   Severe N., Miraoui H., Marie P.J.;
RT   "The Casitas B lineage lymphoma (Cbl) mutant G306E enhances osteogenic
RT   differentiation in human mesenchymal stromal cells in part by
RT   decreased Cbl-mediated platelet-derived growth factor receptor alpha
RT   and fibroblast growth factor receptor 2 ubiquitination.";
RL   J. Biol. Chem. 286:24443-24450(2011).
RN   [46]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-439; SER-483 AND
RP   SER-669, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [47]
RP   CHARACTERIZATION OF VARIANTS NSLL GLU-382; TYR-390 AND GLN-420.
RX   PubMed=25178484; DOI=10.1002/humu.22682;
RA   Brand K., Kentsch H., Glashoff C., Rosenberger G.;
RT   "RASopathy-associated CBL germline mutations cause aberrant
RT   ubiquitylation and trafficking of EGFR.";
RL   Hum. Mutat. 35:1372-1381(2014).
RN   [48]
RP   REVIEW ON FUNCTION IN FGF SIGNALING, AND UBIQUITINATION OF FGFR1.
RX   PubMed=20094046; DOI=10.1038/nrc2780;
RA   Turner N., Grose R.;
RT   "Fibroblast growth factor signalling: from development to cancer.";
RL   Nat. Rev. Cancer 10:116-129(2010).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 47-350 IN COMPLEX WITH ZAP70
RP   PEPTIDE AND CALCIUM IONS, CALCIUM-BINDING SITE, AND MUTAGENESIS OF
RP   SER-80; PRO-82; ASP-229; GLU-240; ARG-294 AND GLY-306.
RX   PubMed=10078535; DOI=10.1038/18050;
RA   Meng W., Sawasdikosol S., Burakoff S.J., Eck M.J.;
RT   "Structure of the amino-terminal domain of Cbl complexed to its
RT   binding site on ZAP-70 kinase.";
RL   Nature 398:84-90(1999).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 47-434 IN COMPLEX WITH ZAP70
RP   AND UBE2L3.
RX   PubMed=10966114; DOI=10.1016/S0092-8674(00)00057-X;
RA   Zheng N., Wang P., Jeffrey P.D., Pavletich N.P.;
RT   "Structure of a c-Cbl-UbcH7 complex: RING domain function in
RT   ubiquitin-protein ligases.";
RL   Cell 102:533-539(2000).
RN   [51]
RP   VARIANTS NSLL PRO-367; GLU-382; TYR-390 AND GLN-420, AND
RP   CHARACTERIZATION OF VARIANTS NSLL TYR-390 AND GLN-420.
RX   PubMed=20619386; DOI=10.1016/j.ajhg.2010.06.015;
RA   Martinelli S., De Luca A., Stellacci E., Rossi C., Checquolo S.,
RA   Lepri F., Caputo V., Silvano M., Buscherini F., Consoli F.,
RA   Ferrara G., Digilio M.C., Cavaliere M.L., van Hagen J.M., Zampino G.,
RA   van der Burgt I., Ferrero G.B., Mazzanti L., Screpanti I.,
RA   Yntema H.G., Nillesen W.M., Savarirayan R., Zenker M.,
RA   Dallapiccola B., Gelb B.D., Tartaglia M.;
RT   "Heterozygous germline mutations in the CBL tumor-suppressor gene
RT   cause a Noonan syndrome-like phenotype.";
RL   Am. J. Hum. Genet. 87:250-257(2010).
RN   [52]
RP   VARIANTS ARG-287; SER-LYS-365 INS; HIS-371 AND LEU-499,
RP   CHARACTERIZATION OF VARIANTS SER-LYS-365 INS AND HIS-371, AND
RP   PHOSPHORYLATION AT TYR-674; TYR-700 AND TYR-774.
RX   PubMed=20622007; DOI=10.1074/jbc.M110.106161;
RA   Fernandes M.S., Reddy M.M., Croteau N.J., Walz C., Weisbach H.,
RA   Podar K., Band H., Carroll M., Reiter A., Larson R.A., Salgia R.,
RA   Griffin J.D., Sattler M.;
RT   "Novel oncogenic mutations of CBL in human acute myeloid leukemia that
RT   activate growth and survival pathways depend on increased
RT   metabolism.";
RL   J. Biol. Chem. 285:32596-32605(2010).
CC   -!- FUNCTION: Adapter protein that functions as a negative regulator
CC       of many signaling pathways that are triggered by activation of
CC       cell surface receptors. Acts as an E3 ubiquitin-protein ligase,
CC       which accepts ubiquitin from specific E2 ubiquitin-conjugating
CC       enzymes, and then transfers it to substrates promoting their
CC       degradation by the proteasome. Recognizes activated receptor
CC       tyrosine kinases, including KIT, FLT1, FGFR1, FGFR2, PDGFRA,
CC       PDGFRB, EGFR, CSF1R, EPHA8 and KDR and terminates signaling.
CC       Recognizes membrane-bound HCK, SRC and other kinases of the SRC
CC       family and mediates their ubiquitination and degradation.
CC       Participates in signal transduction in hematopoietic cells. Plays
CC       an important role in the regulation of osteoblast differentiation
CC       and apoptosis. Essential for osteoclastic bone resorption. The
CC       'Tyr-731' phosphorylated form induces the activation and
CC       recruitment of phosphatidylinositol 3-kinase to the cell membrane
CC       in a signaling pathway that is critical for osteoclast function.
CC       May be functionally coupled with the E2 ubiquitin-protein ligase
CC       UB2D3. {ECO:0000269|PubMed:10514377, ECO:0000269|PubMed:11896602,
CC       ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:14739300,
CC       ECO:0000269|PubMed:15190072, ECO:0000269|PubMed:17509076,
CC       ECO:0000269|PubMed:18374639, ECO:0000269|PubMed:19689429,
CC       ECO:0000269|PubMed:21596750}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine. {ECO:0000269|PubMed:10514377,
CC       ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:17509076}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts (phosphorylated at Tyr-731) with PIK3R1.
CC       Associates with NCK via its SH3 domain. The phosphorylated C-
CC       terminus interacts with CD2AP via its second SH3 domain. Binds to
CC       UBE2L3. Interacts with adapters SLA, SLA2 and with the
CC       phosphorylated C-terminus of SH2B2. Interacts with EGFR, SYK and
CC       ZAP70 via the highly conserved Cbl-N region. Also interacts with
CC       SORBS1 and INPPL1/SHIP2. Interacts with phosphorylated LAT2. May
CC       interact with CBLB (By similarity). Interacts with ALK, AXL, BLK,
CC       FGR and FGFR2. Interacts with CSF1R, EPHB1, FLT1, KDR, PDGFRA and
CC       PDGFRB; regulates receptor degradation through ubiquitination.
CC       Interacts with HCK and LYN. Interacts with TEK/TIE2 (tyrosine
CC       phosphorylated). Interacts with SH3KBP1 and this interaction is
CC       inhibited in the presence of SHKBP1 (By similarity). Interacts
CC       with SIGLEC10 (By similarity). {ECO:0000250|UniProtKB:P22682,
CC       ECO:0000269|PubMed:10078535, ECO:0000269|PubMed:10092522,
CC       ECO:0000269|PubMed:10374881, ECO:0000269|PubMed:10449770,
CC       ECO:0000269|PubMed:10966114, ECO:0000269|PubMed:11067845,
CC       ECO:0000269|PubMed:11696592, ECO:0000269|PubMed:11850825,
CC       ECO:0000269|PubMed:11896602, ECO:0000269|PubMed:11997497,
CC       ECO:0000269|PubMed:12435267, ECO:0000269|PubMed:12486104,
CC       ECO:0000269|PubMed:12504111, ECO:0000269|PubMed:15190072,
CC       ECO:0000269|PubMed:15226403, ECO:0000269|PubMed:15958209,
CC       ECO:0000269|PubMed:17620338, ECO:0000269|PubMed:18034775,
CC       ECO:0000269|PubMed:18235045, ECO:0000269|PubMed:18374639,
CC       ECO:0000269|PubMed:19689429, ECO:0000269|PubMed:19836242,
CC       ECO:0000269|PubMed:20494825, ECO:0000269|PubMed:21596750,
CC       ECO:0000269|PubMed:7657591, ECO:0000269|PubMed:8083187,
CC       ECO:0000269|PubMed:9407100, ECO:0000269|PubMed:9989826}.
CC   -!- INTERACTION:
CC       Q8IZP0-2:ABI1; NbExp=3; IntAct=EBI-518228, EBI-7358775;
CC       Q14155:ARHGEF7; NbExp=9; IntAct=EBI-518228, EBI-717515;
CC       Q9Y5K6:CD2AP; NbExp=4; IntAct=EBI-518228, EBI-298152;
CC       P46108:CRK; NbExp=8; IntAct=EBI-518228, EBI-886;
CC       P46109:CRKL; NbExp=3; IntAct=EBI-518228, EBI-910;
CC       P00533:EGFR; NbExp=22; IntAct=EBI-518228, EBI-297353;
CC       P55085:F2RL1; NbExp=3; IntAct=EBI-518228, EBI-4303189;
CC       P17948:FLT1; NbExp=2; IntAct=EBI-518228, EBI-1026718;
CC       P39688:Fyn (xeno); NbExp=3; IntAct=EBI-518228, EBI-524514;
CC       P62993:GRB2; NbExp=10; IntAct=EBI-518228, EBI-401755;
CC       P08631-2:HCK; NbExp=2; IntAct=EBI-518228, EBI-9834454;
CC       Q15811:ITSN1; NbExp=12; IntAct=EBI-518228, EBI-602041;
CC       P45983:MAPK8; NbExp=2; IntAct=EBI-518228, EBI-286483;
CC       P08581:MET; NbExp=15; IntAct=EBI-518228, EBI-1039152;
CC       P04629:NTRK1; NbExp=2; IntAct=EBI-518228, EBI-1028226;
CC       P27986:PIK3R1; NbExp=5; IntAct=EBI-518228, EBI-79464;
CC       O00459:PIK3R2; NbExp=4; IntAct=EBI-518228, EBI-346930;
CC       Q92569:PIK3R3; NbExp=4; IntAct=EBI-518228, EBI-79893;
CC       F1SDV6:PLCG1 (xeno); NbExp=2; IntAct=EBI-518228, EBI-15628084;
CC       P08487:PLCG1 (xeno); NbExp=3; IntAct=EBI-518228, EBI-8013886;
CC       O14492:SH2B2; NbExp=7; IntAct=EBI-518228, EBI-7507432;
CC       Q96B97:SH3KBP1; NbExp=18; IntAct=EBI-518228, EBI-346595;
CC       O43597:SPRY2; NbExp=17; IntAct=EBI-518228, EBI-742487;
CC       Q9C004:SPRY4; NbExp=9; IntAct=EBI-518228, EBI-354861;
CC       P12931:SRC; NbExp=8; IntAct=EBI-518228, EBI-621482;
CC       P43405:SYK; NbExp=2; IntAct=EBI-518228, EBI-78302;
CC       P62837:UBE2D2; NbExp=4; IntAct=EBI-518228, EBI-347677;
CC       P31946:YWHAB; NbExp=3; IntAct=EBI-518228, EBI-359815;
CC       P27348:YWHAQ; NbExp=6; IntAct=EBI-518228, EBI-359854;
CC       P43403:ZAP70; NbExp=3; IntAct=EBI-518228, EBI-1211276;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cell membrane. Note=Colocalizes
CC       with FGFR2 in lipid rafts at the cell membrane.
CC   -!- DOMAIN: The RING-type zinc finger domain mediates binding to an E2
CC       ubiquitin-conjugating enzyme.
CC   -!- DOMAIN: The N-terminus is composed of the phosphotyrosine binding
CC       (PTB) domain, a short linker region and the RING-type zinc finger.
CC       The PTB domain, which is also called TKB (tyrosine kinase binding)
CC       domain, is composed of three different subdomains: a four-helix
CC       bundle (4H), a calcium-binding EF hand and a divergent SH2 domain.
CC   -!- PTM: Phosphorylated on tyrosine residues by ALK, EGFR, SYK, FYN
CC       and ZAP70 (By similarity). Phosphorylated on tyrosine residues in
CC       response to FLT1 and KIT signaling. Phosphorylated on tyrosine
CC       residues by INSR and FGR. Phosphorylated on several tyrosine
CC       residues by constitutively activated FGFR3. Not phosphorylated at
CC       Tyr-731 by FGFR3. Phosphorylated on tyrosine residues by activated
CC       CSF1R, PDGFRA and PDGFRB. Phosphorylated on tyrosine residues by
CC       HCK. {ECO:0000250, ECO:0000269|PubMed:10092522,
CC       ECO:0000269|PubMed:11850825, ECO:0000269|PubMed:11997497,
CC       ECO:0000269|PubMed:12435267, ECO:0000269|PubMed:14739300,
CC       ECO:0000269|PubMed:15190072, ECO:0000269|PubMed:15226403,
CC       ECO:0000269|PubMed:15556646, ECO:0000269|PubMed:17509076,
CC       ECO:0000269|PubMed:18034775, ECO:0000269|PubMed:20494825,
CC       ECO:0000269|PubMed:20622007, ECO:0000269|PubMed:7657591,
CC       ECO:0000269|PubMed:9535867}.
CC   -!- PTM: Ubiquitinated, leading to its degradation via the proteasome.
CC       {ECO:0000269|PubMed:11896602, ECO:0000269|PubMed:20094046}.
CC   -!- DISEASE: Noonan syndrome-like disorder with or without juvenile
CC       myelomonocytic leukemia (NSLL) [MIM:613563]: A syndrome
CC       characterized by a phenotype reminiscent of Noonan syndrome.
CC       Clinical features are highly variable, including facial
CC       dysmorphism, short neck, developmental delay, hyperextensible
CC       joints and thorax abnormalities with widely spaced nipples. The
CC       facial features consist of triangular face with hypertelorism,
CC       large low-set ears, ptosis, and flat nasal bridge. Some patients
CC       manifest cardiac defects. Some have an increased risk for certain
CC       malignancies, particularly juvenile myelomonocytic leukemia.
CC       {ECO:0000269|PubMed:20619386, ECO:0000269|PubMed:25178484}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- MISCELLANEOUS: This protein has one functional calcium-binding
CC       site.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CBLID171.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X57110; CAA40393.1; -; mRNA.
DR   EMBL; AP002956; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC132733; AAI32734.1; -; mRNA.
DR   EMBL; BC136463; AAI36464.1; -; mRNA.
DR   CCDS; CCDS8418.1; -.
DR   PIR; A43817; A43817.
DR   RefSeq; NP_005179.2; NM_005188.3.
DR   UniGene; Hs.504096; -.
DR   PDB; 1B47; X-ray; 2.20 A; A/B/C=47-350.
DR   PDB; 1FBV; X-ray; 2.90 A; A=47-434.
DR   PDB; 1YVH; X-ray; 2.05 A; A=25-351.
DR   PDB; 2CBL; X-ray; 2.10 A; A=47-351.
DR   PDB; 2JUJ; NMR; -; A=851-906.
DR   PDB; 2K4D; NMR; -; A=358-437.
DR   PDB; 2OO9; X-ray; 2.10 A; A/B/C=856-895.
DR   PDB; 2Y1M; X-ray; 2.67 A; A/B/C/D/E/F=47-435.
DR   PDB; 2Y1N; X-ray; 2.00 A; A/C=47-435.
DR   PDB; 3BUM; X-ray; 2.00 A; B=25-351.
DR   PDB; 3BUN; X-ray; 2.00 A; B=25-351.
DR   PDB; 3BUO; X-ray; 2.60 A; B/D=25-351.
DR   PDB; 3BUW; X-ray; 1.45 A; B/D=25-351.
DR   PDB; 3BUX; X-ray; 1.35 A; B/D=25-351.
DR   PDB; 3OB1; X-ray; 2.20 A; B=25-351.
DR   PDB; 3OB2; X-ray; 2.10 A; B=25-351.
DR   PDB; 3PLF; X-ray; 1.92 A; B/D=25-351.
DR   PDB; 4A49; X-ray; 2.21 A; A=354-435.
DR   PDB; 4A4B; X-ray; 2.79 A; A=47-435.
DR   PDB; 4A4C; X-ray; 2.70 A; A=47-435.
DR   PDB; 4GPL; X-ray; 3.00 A; B=47-351.
DR   PDB; 5HKW; X-ray; 2.25 A; A/B/C=47-351.
DR   PDB; 5HKX; X-ray; 1.85 A; A=47-435.
DR   PDB; 5HKY; X-ray; 1.80 A; A=47-351.
DR   PDB; 5HKZ; X-ray; 1.80 A; A=47-351.
DR   PDB; 5HL0; X-ray; 2.20 A; A=47-351.
DR   PDB; 5J3X; X-ray; 2.82 A; A/B/C/D/E/F=47-435.
DR   PDB; 5O76; X-ray; 2.47 A; A/C=47-435.
DR   PDBsum; 1B47; -.
DR   PDBsum; 1FBV; -.
DR   PDBsum; 1YVH; -.
DR   PDBsum; 2CBL; -.
DR   PDBsum; 2JUJ; -.
DR   PDBsum; 2K4D; -.
DR   PDBsum; 2OO9; -.
DR   PDBsum; 2Y1M; -.
DR   PDBsum; 2Y1N; -.
DR   PDBsum; 3BUM; -.
DR   PDBsum; 3BUN; -.
DR   PDBsum; 3BUO; -.
DR   PDBsum; 3BUW; -.
DR   PDBsum; 3BUX; -.
DR   PDBsum; 3OB1; -.
DR   PDBsum; 3OB2; -.
DR   PDBsum; 3PLF; -.
DR   PDBsum; 4A49; -.
DR   PDBsum; 4A4B; -.
DR   PDBsum; 4A4C; -.
DR   PDBsum; 4GPL; -.
DR   PDBsum; 5HKW; -.
DR   PDBsum; 5HKX; -.
DR   PDBsum; 5HKY; -.
DR   PDBsum; 5HKZ; -.
DR   PDBsum; 5HL0; -.
DR   PDBsum; 5J3X; -.
DR   PDBsum; 5O76; -.
DR   ProteinModelPortal; P22681; -.
DR   SMR; P22681; -.
DR   BioGrid; 107315; 250.
DR   CORUM; P22681; -.
DR   DIP; DIP-189N; -.
DR   IntAct; P22681; 93.
DR   MINT; P22681; -.
DR   STRING; 9606.ENSP00000264033; -.
DR   iPTMnet; P22681; -.
DR   PhosphoSitePlus; P22681; -.
DR   BioMuta; CBL; -.
DR   DMDM; 251757253; -.
DR   EPD; P22681; -.
DR   MaxQB; P22681; -.
DR   PaxDb; P22681; -.
DR   PeptideAtlas; P22681; -.
DR   PRIDE; P22681; -.
DR   Ensembl; ENST00000264033; ENSP00000264033; ENSG00000110395.
DR   GeneID; 867; -.
DR   KEGG; hsa:867; -.
DR   UCSC; uc001pwe.5; human.
DR   CTD; 867; -.
DR   DisGeNET; 867; -.
DR   EuPathDB; HostDB:ENSG00000110395.5; -.
DR   GeneCards; CBL; -.
DR   HGNC; HGNC:1541; CBL.
DR   HPA; CAB004350; -.
DR   HPA; HPA027956; -.
DR   MalaCards; CBL; -.
DR   MIM; 165360; gene.
DR   MIM; 613563; phenotype.
DR   neXtProt; NX_P22681; -.
DR   OpenTargets; ENSG00000110395; -.
DR   Orphanet; 86834; Juvenile myelomonocytic leukemia.
DR   Orphanet; 363972; Noonan syndrome-like disorder with juvenile myelomonocytic leukemia.
DR   PharmGKB; PA26115; -.
DR   eggNOG; KOG1785; Eukaryota.
DR   eggNOG; ENOG410YDNH; LUCA.
DR   GeneTree; ENSGT00390000011617; -.
DR   HOGENOM; HOG000294176; -.
DR   HOVERGEN; HBG005255; -.
DR   InParanoid; P22681; -.
DR   KO; K04707; -.
DR   OMA; CEHPKIK; -.
DR   OrthoDB; EOG091G0GPE; -.
DR   PhylomeDB; P22681; -.
DR   TreeFam; TF314210; -.
DR   BRENDA; 2.3.2.B10; 2681.
DR   Reactome; R-HSA-1059683; Interleukin-6 signaling.
DR   Reactome; R-HSA-1236382; Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants.
DR   Reactome; R-HSA-1295596; Spry regulation of FGF signaling.
DR   Reactome; R-HSA-1433559; Regulation of KIT signaling.
DR   Reactome; R-HSA-182971; EGFR downregulation.
DR   Reactome; R-HSA-2173789; TGF-beta receptor signaling activates SMADs.
DR   Reactome; R-HSA-5637810; Constitutive Signaling by EGFRvIII.
DR   Reactome; R-HSA-5654726; Negative regulation of FGFR1 signaling.
DR   Reactome; R-HSA-5654727; Negative regulation of FGFR2 signaling.
DR   Reactome; R-HSA-5654732; Negative regulation of FGFR3 signaling.
DR   Reactome; R-HSA-5654733; Negative regulation of FGFR4 signaling.
DR   Reactome; R-HSA-6807004; Negative regulation of MET activity.
DR   Reactome; R-HSA-8849469; PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1.
DR   Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis.
DR   Reactome; R-HSA-8856828; Clathrin-mediated endocytosis.
DR   Reactome; R-HSA-8875360; InlB-mediated entry of Listeria monocytogenes into host cell.
DR   Reactome; R-HSA-912631; Regulation of signaling by CBL.
DR   Reactome; R-HSA-983695; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
DR   SignaLink; P22681; -.
DR   SIGNOR; P22681; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; CBL; human.
DR   EvolutionaryTrace; P22681; -.
DR   GeneWiki; CBL_(gene); -.
DR   GenomeRNAi; 867; -.
DR   PMAP-CutDB; P22681; -.
DR   PRO; PR:P22681; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000110395; -.
DR   CleanEx; HS_CBL; -.
DR   ExpressionAtlas; P22681; baseline and differential.
DR   Genevisible; P22681; HS.
DR   GO; GO:0030424; C:axon; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0016600; C:flotillin complex; IEA:Ensembl.
DR   GO; GO:0005925; C:focal adhesion; IEA:Ensembl.
DR   GO; GO:0030426; C:growth cone; IEA:Ensembl.
DR   GO; GO:0042629; C:mast cell granule; IEA:GOC.
DR   GO; GO:0045121; C:membrane raft; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; IEA:InterPro.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:HGNC.
DR   GO; GO:0045296; F:cadherin binding; IDA:BHF-UCL.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; TAS:ProtInc.
DR   GO; GO:0046875; F:ephrin receptor binding; IPI:UniProtKB.
DR   GO; GO:0005154; F:epidermal growth factor receptor binding; IEA:Ensembl.
DR   GO; GO:0036312; F:phosphatidylinositol 3-kinase regulatory subunit binding; IEA:Ensembl.
DR   GO; GO:0001784; F:phosphotyrosine residue binding; IEA:InterPro.
DR   GO; GO:0030971; F:receptor tyrosine kinase binding; IBA:GO_Central.
DR   GO; GO:0017124; F:SH3 domain binding; IPI:BHF-UCL.
DR   GO; GO:0004871; F:signal transducer activity; IEA:InterPro.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IBA:GO_Central.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; TAS:HGNC.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:HGNC.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IEA:Ensembl.
DR   GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IEA:Ensembl.
DR   GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0090650; P:cellular response to oxygen-glucose deprivation; IEA:Ensembl.
DR   GO; GO:0036120; P:cellular response to platelet-derived growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0035635; P:entry of bacterium into host cell; TAS:Reactome.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:HGNC.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0070102; P:interleukin-6-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0008584; P:male gonad development; IEA:Ensembl.
DR   GO; GO:0043303; P:mast cell degranulation; IEA:Ensembl.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0042059; P:negative regulation of epidermal growth factor receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0007175; P:negative regulation of epidermal growth factor-activated receptor activity; IBA:GO_Central.
DR   GO; GO:1901215; P:negative regulation of neuron death; IEA:Ensembl.
DR   GO; GO:0070997; P:neuron death; IEA:Ensembl.
DR   GO; GO:0045742; P:positive regulation of epidermal growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IMP:BHF-UCL.
DR   GO; GO:0048260; P:positive regulation of receptor-mediated endocytosis; IMP:UniProtKB.
DR   GO; GO:0006513; P:protein monoubiquitination; IEA:Ensembl.
DR   GO; GO:0000209; P:protein polyubiquitination; IEA:Ensembl.
DR   GO; GO:0016567; P:protein ubiquitination; TAS:HGNC.
DR   GO; GO:0042787; P:protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0046677; P:response to antibiotic; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0010332; P:response to gamma radiation; IEA:Ensembl.
DR   GO; GO:0042594; P:response to starvation; IEA:Ensembl.
DR   GO; GO:0033574; P:response to testosterone; IEA:Ensembl.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; TAS:Reactome.
DR   CDD; cd09920; SH2_Cbl-b_TKB; 1.
DR   Gene3D; 1.20.930.20; -; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR024162; Adaptor_Cbl.
DR   InterPro; IPR014741; Adaptor_Cbl_EF_hand-like.
DR   InterPro; IPR036537; Adaptor_Cbl_N_dom_sf.
DR   InterPro; IPR003153; Adaptor_Cbl_N_hlx.
DR   InterPro; IPR014742; Adaptor_Cbl_SH2-like.
DR   InterPro; IPR024159; Cbl_PTB.
DR   InterPro; IPR011992; EF-hand-dom_pair.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR015940; UBA.
DR   InterPro; IPR009060; UBA-like_sf.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   PANTHER; PTHR23007; PTHR23007; 1.
DR   Pfam; PF02262; Cbl_N; 1.
DR   Pfam; PF02761; Cbl_N2; 1.
DR   Pfam; PF02762; Cbl_N3; 1.
DR   Pfam; PF00627; UBA; 1.
DR   SMART; SM00184; RING; 1.
DR   SMART; SM00165; UBA; 1.
DR   SUPFAM; SSF46934; SSF46934; 1.
DR   SUPFAM; SSF47473; SSF47473; 1.
DR   SUPFAM; SSF47668; SSF47668; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   PROSITE; PS51506; CBL_PTB; 1.
DR   PROSITE; PS50030; UBA; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Cell membrane; Complete proteome; Cytoplasm;
KW   Disease mutation; Membrane; Metal-binding; Phosphoprotein;
KW   Polymorphism; Proto-oncogene; Reference proteome; Repeat; Transferase;
KW   Ubl conjugation; Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN         1    906       E3 ubiquitin-protein ligase CBL.
FT                                /FTId=PRO_0000055858.
FT   DOMAIN       47    351       Cbl-PTB. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00839}.
FT   DOMAIN      856    895       UBA. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00212}.
FT   CA_BIND     227    240
FT   ZN_FING     381    420       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   REGION        1    357       Sufficient for interaction with EPHB1.
FT                                {ECO:0000269|PubMed:18034775}.
FT   REGION       47    175       4H.
FT   REGION      176    248       EF-hand-like.
FT   REGION      249    351       SH2-like.
FT   REGION      352    380       Linker.
FT   REGION      648    906       Interaction with CD2AP.
FT                                {ECO:0000269|PubMed:11067845}.
FT   COMPBIAS    357    476       Asp/Glu-rich (acidic).
FT   COMPBIAS    477    688       Pro-rich.
FT   COMPBIAS    689    834       Asp/Glu-rich (acidic).
FT   BINDING     294    294       Phosphotyrosine. {ECO:0000250}.
FT   MOD_RES     371    371       Phosphotyrosine; by INSR.
FT                                {ECO:0000269|PubMed:11997497}.
FT   MOD_RES     439    439       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     452    452       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     483    483       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     619    619       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P22682}.
FT   MOD_RES     642    642       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P22682}.
FT   MOD_RES     668    668       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P22682}.
FT   MOD_RES     669    669       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     674    674       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:20622007}.
FT   MOD_RES     700    700       Phosphotyrosine; by ABL1.
FT                                {ECO:0000269|PubMed:11997497,
FT                                ECO:0000269|PubMed:15556646,
FT                                ECO:0000269|PubMed:20622007}.
FT   MOD_RES     731    731       Phosphotyrosine; by SRC.
FT                                {ECO:0000269|PubMed:14739300}.
FT   MOD_RES     774    774       Phosphotyrosine.
FT                                {ECO:0000269|PubMed:11997497,
FT                                ECO:0000269|PubMed:20622007}.
FT   MOD_RES     900    900       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243}.
FT   VARIANT     287    287       K -> R (found in patients with acute
FT                                myeloid leukemia; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20622007}.
FT                                /FTId=VAR_071040.
FT   VARIANT     365    365       Q -> QSK (found in patients with acute
FT                                myeloid leukemia; unknown pathological
FT                                significance; loss of the ability to
FT                                negatively regulate signaling pathways;
FT                                promotes cell cycle progression;
FT                                decreases apoptosis).
FT                                /FTId=VAR_071041.
FT   VARIANT     367    367       Q -> P (in NSLL; dbSNP:rs267606704).
FT                                {ECO:0000269|PubMed:20619386}.
FT                                /FTId=VAR_064332.
FT   VARIANT     371    371       Y -> H (found in patients with acute
FT                                myeloid leukemia; unknown pathological
FT                                significance; loss of the ability to
FT                                negatively regulate signaling pathways;
FT                                promotes cell cycle progression;
FT                                decreases apoptosis; dbSNP:rs267606706).
FT                                {ECO:0000269|PubMed:20622007}.
FT                                /FTId=VAR_071042.
FT   VARIANT     382    382       K -> E (in NSLL; dominant-negative;
FT                                impairs CBL-mediated ubiquitination,
FT                                internalization and degradation of the
FT                                EGF receptor/EGFR; decreases the ability
FT                                to negatively regulate EGFR signaling;
FT                                dbSNP:rs267606705).
FT                                {ECO:0000269|PubMed:25178484}.
FT                                /FTId=VAR_064333.
FT   VARIANT     390    390       D -> Y (in NSLL; dominant-negative;
FT                                impairs CBL-mediated ubiquitination,
FT                                internalization and degradation of the
FT                                EGF receptor/EGFR; decreases the ability
FT                                to negatively regulate EGFR signaling;
FT                                dbSNP:rs267606707).
FT                                {ECO:0000269|PubMed:20619386,
FT                                ECO:0000269|PubMed:25178484}.
FT                                /FTId=VAR_064334.
FT   VARIANT     420    420       R -> Q (in NSLL; dominant-negative;
FT                                impairs CBL-mediated ubiquitination,
FT                                internalization and degradation of the
FT                                EGF receptor/EGFR; decreases the ability
FT                                to negatively regulate EGFR signaling;
FT                                dbSNP:rs267606708).
FT                                {ECO:0000269|PubMed:20619386,
FT                                ECO:0000269|PubMed:25178484}.
FT                                /FTId=VAR_064335.
FT   VARIANT     499    499       R -> L (found in patients with acute
FT                                myeloid leukemia; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:20622007}.
FT                                /FTId=VAR_071043.
FT   VARIANT     620    620       L -> F (in dbSNP:rs2227988).
FT                                /FTId=VAR_057211.
FT   VARIANT     782    782       P -> L (in dbSNP:rs2229073).
FT                                /FTId=VAR_057212.
FT   VARIANT     904    904       V -> I (in dbSNP:rs17122769).
FT                                /FTId=VAR_057213.
FT   MUTAGEN      80     80       S->D: Abolishes interaction with ZAP70.
FT                                {ECO:0000269|PubMed:10078535}.
FT   MUTAGEN      82     82       P->A: Abolishes interaction with ZAP70.
FT                                {ECO:0000269|PubMed:10078535}.
FT   MUTAGEN     229    229       D->Q: Abolishes interaction with ZAP70.
FT                                {ECO:0000269|PubMed:10078535}.
FT   MUTAGEN     240    240       E->S: Abolishes interaction with ZAP70.
FT                                {ECO:0000269|PubMed:10078535}.
FT   MUTAGEN     294    294       R->K: Abolishes interaction with ZAP70.
FT                                {ECO:0000269|PubMed:10078535}.
FT   MUTAGEN     306    306       G->E: Abolishes interaction with ZAP70
FT                                and EPHB1, but does not affect
FT                                interaction with SLA.
FT                                {ECO:0000269|PubMed:10078535,
FT                                ECO:0000269|PubMed:10449770}.
FT   MUTAGEN     371    371       Y->F: Strongly reduces tyrosine
FT                                phosphorylation by INSR; when associated
FT                                with F-700 and F-774.
FT                                {ECO:0000269|PubMed:11997497}.
FT   MUTAGEN     381    381       C->A: Loss of ubiquitin ligase activity.
FT                                {ECO:0000269|PubMed:11896602}.
FT   MUTAGEN     700    700       Y->F: Strongly reduces tyrosine
FT                                phosphorylation by INSR; when associated
FT                                with F-371 and F-774.
FT                                {ECO:0000269|PubMed:11997497}.
FT   MUTAGEN     731    731       Y->F: No effect on tyrosine
FT                                phosphorylation by INSR. Loss of
FT                                phosphorylation by SRC. Inhibition of
FT                                bone resorption. Abolishes interaction
FT                                with PIK3R1.
FT                                {ECO:0000269|PubMed:11997497,
FT                                ECO:0000269|PubMed:14739300}.
FT   MUTAGEN     774    774       Y->F: Strongly reduces tyrosine
FT                                phosphorylation by INSR; when associated
FT                                with F-371 and F-700.
FT                                {ECO:0000269|PubMed:11997497}.
FT   CONFLICT     15     15       S -> T (in Ref. 1; CAA40393).
FT                                {ECO:0000305}.
FT   HELIX        53     70       {ECO:0000244|PDB:3BUX}.
FT   HELIX        73     75       {ECO:0000244|PDB:3BUX}.
FT   STRAND       80     82       {ECO:0000244|PDB:5HKY}.
FT   HELIX        84    101       {ECO:0000244|PDB:3BUX}.
FT   TURN        102    104       {ECO:0000244|PDB:5HKY}.
FT   HELIX       106    111       {ECO:0000244|PDB:3BUX}.
FT   HELIX       113    136       {ECO:0000244|PDB:3BUX}.
FT   HELIX       137    141       {ECO:0000244|PDB:3BUX}.
FT   HELIX       146    168       {ECO:0000244|PDB:3BUX}.
FT   HELIX       170    172       {ECO:0000244|PDB:3BUX}.
FT   HELIX       176    178       {ECO:0000244|PDB:3BUX}.
FT   HELIX       184    194       {ECO:0000244|PDB:3BUX}.
FT   STRAND      198    201       {ECO:0000244|PDB:3BUX}.
FT   HELIX       202    212       {ECO:0000244|PDB:3BUX}.
FT   HELIX       218    228       {ECO:0000244|PDB:3BUX}.
FT   STRAND      233    237       {ECO:0000244|PDB:3BUX}.
FT   HELIX       238    247       {ECO:0000244|PDB:3BUX}.
FT   HELIX       251    253       {ECO:0000244|PDB:3BUX}.
FT   HELIX       254    261       {ECO:0000244|PDB:3BUX}.
FT   TURN        262    264       {ECO:0000244|PDB:2Y1M}.
FT   STRAND      268    271       {ECO:0000244|PDB:5HKX}.
FT   HELIX       274    281       {ECO:0000244|PDB:3BUX}.
FT   HELIX       282    284       {ECO:0000244|PDB:3BUX}.
FT   STRAND      290    295       {ECO:0000244|PDB:3BUX}.
FT   STRAND      297    299       {ECO:0000244|PDB:3BUX}.
FT   STRAND      302    308       {ECO:0000244|PDB:3BUX}.
FT   TURN        310    312       {ECO:0000244|PDB:3BUO}.
FT   STRAND      314    317       {ECO:0000244|PDB:3BUX}.
FT   STRAND      320    322       {ECO:0000244|PDB:3BUW}.
FT   HELIX       324    333       {ECO:0000244|PDB:3BUX}.
FT   HELIX       350    352       {ECO:0000244|PDB:5HKX}.
FT   STRAND      354    356       {ECO:0000244|PDB:1FBV}.
FT   STRAND      360    362       {ECO:0000244|PDB:4A49}.
FT   HELIX       365    378       {ECO:0000244|PDB:5HKX}.
FT   TURN        382    384       {ECO:0000244|PDB:5HKX}.
FT   STRAND      385    388       {ECO:0000244|PDB:5HKX}.
FT   STRAND      391    394       {ECO:0000244|PDB:5HKX}.
FT   STRAND      398    400       {ECO:0000244|PDB:2K4D}.
FT   HELIX       402    410       {ECO:0000244|PDB:5HKX}.
FT   TURN        417    419       {ECO:0000244|PDB:5HKX}.
FT   STRAND      425    428       {ECO:0000244|PDB:5HKX}.
FT   STRAND      430    432       {ECO:0000244|PDB:4A49}.
FT   HELIX       856    866       {ECO:0000244|PDB:2OO9}.
FT   HELIX       871    880       {ECO:0000244|PDB:2OO9}.
FT   TURN        881    883       {ECO:0000244|PDB:2OO9}.
FT   HELIX       885    895       {ECO:0000244|PDB:2OO9}.
SQ   SEQUENCE   906 AA;  99633 MW;  1AA6BF67377322CA CRC64;
     MAGNVKKSSG AGGGSGSGGS GSGGLIGLMK DAFQPHHHHH HHLSPHPPGT VDKKMVEKCW
     KLMDKVVRLC QNPKLALKNS PPYILDLLPD TYQHLRTILS RYEGKMETLG ENEYFRVFME
     NLMKKTKQTI SLFKEGKERM YEENSQPRRN LTKLSLIFSH MLAELKGIFP SGLFQGDTFR
     ITKADAAEFW RKAFGEKTIV PWKSFRQALH EVHPISSGLE AMALKSTIDL TCNDYISVFE
     FDIFTRLFQP WSSLLRNWNS LAVTHPGYMA FLTYDEVKAR LQKFIHKPGS YIFRLSCTRL
     GQWAIGYVTA DGNILQTIPH NKPLFQALID GFREGFYLFP DGRNQNPDLT GLCEPTPQDH
     IKVTQEQYEL YCEMGSTFQL CKICAENDKD VKIEPCGHLM CTSCLTSWQE SEGQGCPFCR
     CEIKGTEPIV VDPFDPRGSG SLLRQGAEGA PSPNYDDDDD ERADDTLFMM KELAGAKVER
     PPSPFSMAPQ ASLPPVPPRL DLLPQRVCVP SSASALGTAS KAASGSLHKD KPLPVPPTLR
     DLPPPPPPDR PYSVGAESRP QRRPLPCTPG DCPSRDKLPP VPSSRLGDSW LPRPIPKVPV
     SAPSSSDPWT GRELTNRHSL PFSLPSQMEP RPDVPRLGST FSLDTSMSMN SSPLVGPECD
     HPKIKPSSSA NAIYSLAARP LPVPKLPPGE QCEGEEDTEY MTPSSRPLRP LDTSQSSRAC
     DCDQQIDSCT YEAMYNIQSQ APSITESSTF GEGNLAAAHA NTGPEESENE DDGYDVPKPP
     VPAVLARRTL SDISNASSSF GWLSLDGDPT TNVTEGSQVP ERPPKPFPRR INSERKAGSC
     QQGSGPAASA ATASPQLSSE IENLMSQGYS YQDIQKALVI AQNNIEMAKN ILREFVSISS
     PAHVAT
//
ID   A0A0A0MQR4_HUMAN        Unreviewed;      1606 AA.
AC   A0A0A0MQR4;
DT   07-JAN-2015, integrated into UniProtKB/TrEMBL.
DT   07-JAN-2015, sequence version 1.
DT   28-FEB-2018, entry version 31.
DE   SubName: Full=Protein capicua homolog {ECO:0000313|Ensembl:ENSP00000160740};
GN   Name=CIC {ECO:0000313|Ensembl:ENSP00000160740};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000160740, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Ensembl:ENSP00000160740, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [2] {ECO:0000213|PubMed:17081983}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [3] {ECO:0000213|PubMed:18220336}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.D., Yates J.R.;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [4] {ECO:0000213|PubMed:18669648}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [5] {ECO:0000213|PubMed:19690332}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:ra46-RA46(2009).
RN   [6] {ECO:0000213|PubMed:20068231}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:ra3-RA3(2010).
RN   [7] {ECO:0000213|PubMed:21406692}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:rs3-RS3(2011).
RN   [8] {ECO:0000213|PubMed:23186163}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=23186163;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [9] {ECO:0000213|PubMed:24275569}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [10] {ECO:0000213|PubMed:24129315}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=24129315;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V.,
RA   Aguiar M., Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C.,
RA   Vemulapalli V., Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [11] {ECO:0000313|Ensembl:ENSP00000160740}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (NOV-2014) to UniProtKB.
CC   -!- CAUTION: The sequence shown here is derived from an Ensembl
CC       automatic analysis pipeline and should be considered as
CC       preliminary data. {ECO:0000313|Ensembl:ENSP00000160740}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AC006486; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; XP_005258730.1; XM_005258673.2.
DR   UniGene; Hs.388236; -.
DR   ProteinModelPortal; A0A0A0MQR4; -.
DR   EPD; A0A0A0MQR4; -.
DR   PeptideAtlas; A0A0A0MQR4; -.
DR   PRIDE; A0A0A0MQR4; -.
DR   Ensembl; ENST00000160740; ENSP00000160740; ENSG00000079432.
DR   GeneID; 23152; -.
DR   UCSC; uc060zgk.1; human.
DR   CTD; 23152; -.
DR   EuPathDB; HostDB:ENSG00000079432.7; -.
DR   HGNC; HGNC:14214; CIC.
DR   OpenTargets; ENSG00000079432; -.
DR   eggNOG; ENOG410ITBG; Eukaryota.
DR   eggNOG; ENOG4111S7E; LUCA.
DR   GeneTree; ENSGT00530000063757; -.
DR   ChiTaRS; CIC; human.
DR   GenomeRNAi; 23152; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000079432; -.
DR   ExpressionAtlas; A0A0A0MQR4; baseline and differential.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-UniRule.
DR   Gene3D; 1.10.30.10; -; 1.
DR   InterPro; IPR009071; HMG_box_dom.
DR   InterPro; IPR036910; HMG_box_dom_sf.
DR   Pfam; PF00505; HMG_box; 1.
DR   SMART; SM00398; HMG; 1.
DR   SUPFAM; SSF47095; SSF47095; 1.
DR   PROSITE; PS50118; HMG_BOX_2; 1.
PE   1: Evidence at protein level;
KW   Complete proteome {ECO:0000313|Proteomes:UP000005640};
KW   DNA-binding {ECO:0000256|PROSITE-ProRule:PRU00267,
KW   ECO:0000256|SAAS:SAAS00879239};
KW   Nucleus {ECO:0000256|PROSITE-ProRule:PRU00267};
KW   Proteomics identification {ECO:0000213|EPD:A0A0A0MQR4,
KW   ECO:0000213|MaxQB:A0A0A0MQR4, ECO:0000213|PeptideAtlas:A0A0A0MQR4};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640}.
FT   DOMAIN      200    268       HMG box. {ECO:0000259|PROSITE:PS50118}.
FT   DNA_BIND    200    268       HMG box. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00267}.
SQ   SEQUENCE   1606 AA;  163678 MW;  05017395BCD6FE5F CRC64;
     MYSAHRPLMP ASSAASRGLG MFVWTNVEPR SVAVFPWHSL VPFLAPSQPD PSVQPSEAQQ
     PASHPVASNQ SKEPAESAAV AHERPPGGTG SADPERPPGA TCPESPGPGP PHPLGVVESG
     KGPPPTTEEE ASGPPGEPRL DSETESDHDD AFLSIMSPEI QLPLPPGKRR TQSLSALPKE
     RDSSSEKDGR SPNKREKDHI RRPMNAFMIF SKRHRALVHQ RHPNQDNRTV SKILGEWWYA
     LGPKEKQKYH DLAFQVKEAH FKAHPDWKWC NKDRKKSSSE AKPTSLGLAG GHKETRERSM
     SETGTAAAPG VSSELLSVAA QTLLSSDTKA PGSSSCGAER LHTVGGPGSA RPRAFSHSGV
     HSLDGGEVDS QALQELTQMV SGPASYSGPK PSTQYGAPGP FAAPGEGGAL AATGRPPLLP
     TRASRSQRAA SEDMTSDEER MVICEEEGDD DVIADDGFGT TDIDLKCKER VTDSESGDSS
     GEDPEGNKGF GRKVFSPVIR SSFTHCRPPL DPEPPGPPDP PVAFGKGYGS APSSSASSPA
     SSSASAATSF SLGSGTFKAQ ESGQGSTAGP LRPPPPGAGG PATPSKATRF LPMDPATFRR
     KRPESVGGLE PPGPSVIAAP PSGGGNILQT LVLPPNKEEQ EGGGARVPSA PAPSLAYGAP
     AAPLSRPAAT MVTNVVRPVS STPVPIASKP FPTSGRAEAS PNDTAGARTE MGTGSRVPGG
     SPLGVSLVYS DKKSAAATSP APHLVAGPLL GTVGKAPATV TNLLVGTPGY GAPAPPAVQF
     IAQGAPGGGT TAGSGAGAGS GPNGPVPLGI LQPGALGKAG GITQVQYILP TLPQQLQVAP
     APAPAPGTKA AAPSGPAPTT SIRFTLPPGT STNGKVLAAT APTPGIPILQ SVPSAPPPKA
     QSVSPVQAPP PGGSAQLLPG KVLVPLAAPS MSVRGGGAGQ PLPLVSPPFS VPVQNGAQPP
     SKIIQLTPVP VSTPSGLVPP LSPATLPGPT SQPQKVLLPS STRITYVQSA GGHALPLGTS
     PASSQAGTVT SYGPTSSVAL GFTSLGPSGP AFVQPLLSGQ APLLAPGQVG VSPVPSPQLP
     PACAAPGGPV ITAFYSGSPA PTSSAPLAQP SQAPPSLVYT VATSTTPPAA TILPKGPPAP
     ATATPAPTSP FPSATGSMTY SLVAPKAQRP SPKAPQKVKA AIASIPVGSF EAGASGRPGP
     APRQPLEPGP VREPTAPESE LEGQPTPPAP PPLPETWTPT ARSSPPLPPP AEERTSAKGP
     ETMASKFPSS SSDWRVPGQG LENRGEPPTP PSPAPAPAVA PGGSSESSSG RAAGDTPERK
     EAAGTGKKVK VRPPPLKKTF DSVDNRVLSE VDFEERFAEL PEFRPEEVLP SPTLQSLATS
     PRAILGSYRK KRKNSTDLDS APEDPTSPKR KMRRRSSCSS EPNTPKSAKC EGDIFTFDRT
     GTEAEDVLGE LEYDKVPYSS LRRTLDQRRA LVMQLFQDHG FFPSAQATAA FQARYADIFP
     SKVCLQLKIR EVRQKIMQAA TPTEQPPGAE APLPVPPPTG TAAAPAPTPS PAGGPDPTSP
     SSDSGTAQAA PPLPPPPESG PGQPGWEGAP QPSPPPPGPS TAATGR
//
ID   CIC_HUMAN               Reviewed;        1608 AA.
AC   Q96RK0; Q7LGI1; Q9UEG5; Q9Y6T1;
DT   27-SEP-2005, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   28-FEB-2018, entry version 148.
DE   RecName: Full=Protein capicua homolog;
GN   Name=CIC; Synonyms=KIAA0306;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], POSSIBLE FUNCTION, AND VARIANT GLY-982.
RX   PubMed=12393275; DOI=10.1016/S0169-328X(02)00439-4;
RA   Lee C.-J., Chan W.-I., Cheung M., Cheng Y.-C., Appleby V.J.,
RA   Orme A.T., Scotting P.J.;
RT   "CIC, a member of a novel subfamily of the HMG-box superfamily, is
RT   transiently expressed in developing granule neurons.";
RL   Brain Res. Mol. Brain Res. 106:151-156(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 158-1608, AND VARIANT
RP   GLY-982.
RC   TISSUE=Brain;
RX   PubMed=9205841; DOI=10.1093/dnares/4.2.141;
RA   Nagase T., Ishikawa K., Nakajima D., Ohira M., Seki N., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. VII.
RT   The complete sequences of 100 new cDNA clones from brain which can
RT   code for large proteins in vitro.";
RL   DNA Res. 4:141-150(1997).
RN   [4]
RP   TISSUE SPECIFICITY, AND EXPRESSION IN MEDULLOBLASTOMA.
RX   PubMed=15981098; DOI=10.1007/s11060-004-4598-2;
RA   Lee C.-J., Chan W.-I., Scotting P.J.;
RT   "CIC, a gene involved in cerebellar development and ErbB signaling, is
RT   significantly expressed in medulloblastomas.";
RL   J. Neurooncol. 73:101-108(2005).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1378, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-173; SER-721; SER-1373
RP   AND SER-1382, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-721; SER-1373; SER-1382;
RP   SER-1397; SER-1402 AND SER-1409, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-721 AND SER-1373, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1402, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-173; SER-277; SER-721;
RP   SER-739; SER-1294; SER-1351; SER-1373; SER-1389; SER-1397 AND
RP   SER-1409, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-173; SER-362; SER-700;
RP   SER-1397; THR-1398; SER-1409 AND SER-1595, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-863, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.O113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V.,
RA   Aguiar M., Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C.,
RA   Vemulapalli V., Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [14]
RP   VARIANTS [LARGE SCALE ANALYSIS] LYS-104 AND THR-652.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [15]
RP   VARIANT MRD45 TRP-492.
RX   PubMed=21076407; DOI=10.1038/ng.712;
RA   Vissers L.E., de Ligt J., Gilissen C., Janssen I., Steehouwer M.,
RA   de Vries P., van Lier B., Arts P., Wieskamp N., del Rosario M.,
RA   van Bon B.W., Hoischen A., de Vries B.B., Brunner H.G., Veltman J.A.;
RT   "A de novo paradigm for mental retardation.";
RL   Nat. Genet. 42:1109-1112(2010).
RN   [16]
RP   VARIANTS MRD45 353-ARG--ARG-1608 DEL AND 992-GLN--ARG-1608 DEL, AND
RP   CHARACTERIZATION OF VARIANT MRD45 353-ARG--ARG-1608 DEL.
RX   PubMed=28288114; DOI=10.1038/ng.3808;
RA   Lu H.C., Tan Q., Rousseaux M.W., Wang W., Kim J.Y., Richman R.,
RA   Wan Y.W., Yeh S.Y., Patel J.M., Liu X., Lin T., Lee Y., Fryer J.D.,
RA   Han J., Chahrour M., Finnell R.H., Lei Y., Zurita-Jimenez M.E.,
RA   Ahimaz P., Anyane-Yeboa K., Van Maldergem L., Lehalle D.,
RA   Jean-Marcais N., Mosca-Boidron A.L., Thevenon J., Cousin M.A.,
RA   Bro D.E., Lanpher B.C., Klee E.W., Alexander N., Bainbridge M.N.,
RA   Orr H.T., Sillitoe R.V., Ljungberg M.C., Liu Z., Schaaf C.P.,
RA   Zoghbi H.Y.;
RT   "Disruption of the ATXN1-CIC complex causes a spectrum of
RT   neurobehavioral phenotypes in mice and humans.";
RL   Nat. Genet. 49:527-536(2017).
CC   -!- FUNCTION: Transcriptional repressor which plays a role in
CC       development of the central nervous system (CNS). In concert with
CC       ATXN1 and ATXN1L, involved in brain development.
CC       {ECO:0000250|UniProtKB:Q924A2}.
CC   -!- SUBUNIT: Interacts with ATXN1 and ATXN1L. Found in a complex with
CC       ATXN1 and ATXN1L. {ECO:0000250|UniProtKB:Q924A2}.
CC   -!- INTERACTION:
CC       P54253:ATXN1; NbExp=6; IntAct=EBI-945857, EBI-930964;
CC       Q9HC77:CENPJ; NbExp=2; IntAct=EBI-945857, EBI-946194;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-
CC       ProRule:PRU00267}.
CC   -!- TISSUE SPECIFICITY: Expressed in fetal brain.
CC       {ECO:0000269|PubMed:15981098}.
CC   -!- DISEASE: Mental retardation, autosomal dominant 45 (MRD45)
CC       [MIM:617600]: A form of mental retardation, a disorder
CC       characterized by significantly below average general intellectual
CC       functioning associated with impairments in adaptive behavior and
CC       manifested during the developmental period. MRD45 patients
CC       manifest developmental delay, variable intellectual disability,
CC       and behavioral disorders, including autistic features, attention
CC       deficit, and hyperactivity. {ECO:0000269|PubMed:21076407,
CC       ECO:0000269|PubMed:28288114}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Expressed in medulloblastoma, a pediatric brain
CC       tumor which may arise from the granule cell lineage.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD11988.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF363689; AAK73515.1; -; mRNA.
DR   EMBL; AC006486; AAD11988.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AB002304; BAA20765.1; -; mRNA.
DR   CCDS; CCDS12601.1; -.
DR   RefSeq; NP_001291744.1; NM_001304815.1.
DR   RefSeq; NP_055940.3; NM_015125.4.
DR   UniGene; Hs.388236; -.
DR   PDB; 2M41; NMR; -; A=34-48.
DR   PDB; 4J2J; X-ray; 2.50 A; D/E/F=28-48.
DR   PDB; 4J2L; X-ray; 3.15 A; C/D=21-48.
DR   PDBsum; 2M41; -.
DR   PDBsum; 4J2J; -.
DR   PDBsum; 4J2L; -.
DR   ProteinModelPortal; Q96RK0; -.
DR   SMR; Q96RK0; -.
DR   BioGrid; 116767; 20.
DR   DIP; DIP-49964N; -.
DR   IntAct; Q96RK0; 18.
DR   MINT; Q96RK0; -.
DR   STRING; 9606.ENSP00000160740; -.
DR   iPTMnet; Q96RK0; -.
DR   PhosphoSitePlus; Q96RK0; -.
DR   BioMuta; CIC; -.
DR   DMDM; 116241300; -.
DR   EPD; Q96RK0; -.
DR   MaxQB; Q96RK0; -.
DR   PaxDb; Q96RK0; -.
DR   PeptideAtlas; Q96RK0; -.
DR   PRIDE; Q96RK0; -.
DR   DNASU; 23152; -.
DR   Ensembl; ENST00000575354; ENSP00000458663; ENSG00000079432.
DR   GeneID; 23152; -.
DR   KEGG; hsa:23152; -.
DR   UCSC; uc002otf.1; human.
DR   CTD; 23152; -.
DR   DisGeNET; 23152; -.
DR   EuPathDB; HostDB:ENSG00000079432.7; -.
DR   GeneCards; CIC; -.
DR   H-InvDB; HIX0015175; -.
DR   H-InvDB; HIX0137483; -.
DR   HGNC; HGNC:14214; CIC.
DR   HPA; CAB026388; -.
DR   HPA; HPA044341; -.
DR   HPA; HPA064725; -.
DR   MIM; 612082; gene.
DR   MIM; 617600; phenotype.
DR   neXtProt; NX_Q96RK0; -.
DR   OpenTargets; ENSG00000079432; -.
DR   PharmGKB; PA26513; -.
DR   eggNOG; ENOG410ITBG; Eukaryota.
DR   eggNOG; ENOG4111S7E; LUCA.
DR   GeneTree; ENSGT00530000063757; -.
DR   HOVERGEN; HBG081174; -.
DR   InParanoid; Q96RK0; -.
DR   KO; K20225; -.
DR   PhylomeDB; Q96RK0; -.
DR   TreeFam; TF323412; -.
DR   SignaLink; Q96RK0; -.
DR   SIGNOR; Q96RK0; -.
DR   ChiTaRS; CIC; human.
DR   GeneWiki; CIC_(gene); -.
DR   GenomeRNAi; 23152; -.
DR   PRO; PR:Q96RK0; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000079432; -.
DR   CleanEx; HS_CIC; -.
DR   ExpressionAtlas; Q96RK0; baseline and differential.
DR   Genevisible; Q96RK0; HS.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0043234; C:protein complex; IEA:Ensembl.
DR   GO; GO:0003682; F:chromatin binding; IEA:Ensembl.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0007420; P:brain development; ISS:UniProtKB.
DR   GO; GO:0007612; P:learning; ISS:UniProtKB.
DR   GO; GO:0048286; P:lung alveolus development; IEA:Ensembl.
DR   GO; GO:0007613; P:memory; ISS:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IBA:GO_Central.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0035176; P:social behavior; ISS:UniProtKB.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   Gene3D; 1.10.30.10; -; 1.
DR   InterPro; IPR009071; HMG_box_dom.
DR   InterPro; IPR036910; HMG_box_dom_sf.
DR   Pfam; PF00505; HMG_box; 1.
DR   SMART; SM00398; HMG; 1.
DR   SUPFAM; SSF47095; SSF47095; 1.
DR   PROSITE; PS50118; HMG_BOX_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Complete proteome; Disease mutation;
KW   DNA-binding; Mental retardation; Methylation; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repressor; Transcription;
KW   Transcription regulation.
FT   CHAIN         1   1608       Protein capicua homolog.
FT                                /FTId=PRO_0000048598.
FT   DNA_BIND    200    268       HMG box. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00267}.
FT   REGION       28     46       Interaction with ATXN1. {ECO:0000250}.
FT   COMPBIAS     42    138       Pro-rich.
FT   COMPBIAS    508   1303       Pro-rich.
FT   COMPBIAS   1524   1601       Pro-rich.
FT   MOD_RES     146    146       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q924A2}.
FT   MOD_RES     173    173       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     190    190       Omega-N-methylarginine.
FT                                {ECO:0000250|UniProtKB:Q924A2}.
FT   MOD_RES     277    277       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     362    362       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     431    431       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q924A2}.
FT   MOD_RES     436    436       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q924A2}.
FT   MOD_RES     496    496       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q924A2}.
FT   MOD_RES     700    700       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     721    721       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     739    739       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     863    863       Asymmetric dimethylarginine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES     934    934       Omega-N-methylarginine.
FT                                {ECO:0000250|UniProtKB:Q924A2}.
FT   MOD_RES    1268   1268       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q924A2}.
FT   MOD_RES    1291   1291       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q924A2}.
FT   MOD_RES    1294   1294       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1351   1351       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1373   1373       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1378   1378       Phosphoserine.
FT                                {ECO:0000244|PubMed:18220336}.
FT   MOD_RES    1382   1382       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332}.
FT   MOD_RES    1389   1389       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1397   1397       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1398   1398       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1402   1402       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692}.
FT   MOD_RES    1409   1409       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1595   1595       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   VARIANT     104    104       E -> K (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035936.
FT   VARIANT     353   1608       Missing (in MRD45; decreased protein
FT                                expression).
FT                                {ECO:0000269|PubMed:28288114}.
FT                                /FTId=VAR_079294.
FT   VARIANT     492    492       R -> W (in MRD45; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:21076407}.
FT                                /FTId=VAR_065090.
FT   VARIANT     652    652       A -> T (in a breast cancer sample;
FT                                somatic mutation; dbSNP:rs770323488).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035937.
FT   VARIANT     982    982       S -> G (in dbSNP:rs17339472).
FT                                {ECO:0000269|PubMed:12393275,
FT                                ECO:0000269|PubMed:9205841}.
FT                                /FTId=VAR_028302.
FT   VARIANT     992   1608       Missing (in MRD45).
FT                                {ECO:0000269|PubMed:28288114}.
FT                                /FTId=VAR_079295.
FT   STRAND       31     33       {ECO:0000244|PDB:4J2J}.
FT   HELIX        37     39       {ECO:0000244|PDB:4J2J}.
FT   STRAND       44     46       {ECO:0000244|PDB:2M41}.
SQ   SEQUENCE   1608 AA;  163820 MW;  355603C8BD67244E CRC64;
     MYSAHRPLMP ASSAASRGLG MFVWTNVEPR SVAVFPWHSL VPFLAPSQPD PSVQPSEAQQ
     PASHPVASNQ SKEPAESAAV AHERPPGGTG SADPERPPGA TCPESPGPGP PHPLGVVESG
     KGPPPTTEEE ASGPPGEPRL DSETESDHDD AFLSIMSPEI QLPLPPGKRR TQSLSALPKE
     RDSSSEKDGR SPNKREKDHI RRPMNAFMIF SKRHRALVHQ RHPNQDNRTV SKILGEWWYA
     LGPKEKQKYH DLAFQVKEAH FKAHPDWKWC NKDRKKSSSE AKPTSLGLAG GHKETRERSM
     SETGTAAAPG VSSELLSVAA QTLLSSDTKA PGSSSCGAER LHTVGGPGSA RPRAFSHSGV
     HSLDGGEVDS QALQELTQMV SGPASYSGPK PSTQYGAPGP FAAPGEGGAL AATGRPPLLP
     TRASRSQRAA SEDMTSDEER MVICEEEGDD DVIADDGFGT TDIDLKCKER VTDSESGDSS
     GEDPEGNKGF GRKVFSPVIR SSFTHCRPPL DPEPPGPPDP PVAFGKGYGS APSSSASSPA
     SSSASAATSF SLGSGTFKAQ ESGQGSTAGP LRPPPPGAGG PATPSKATRF LPMDPATFRR
     KRPESVGGLE PPGPSVIAAP PSGGGNILQT LVLPPNKEEQ EGGGARVPSA PAPSLAYGAP
     AAPLSRPAAT MVTNVVRPVS STPVPIASKP FPTSGRAEAS PNDTAGARTE MGTGSRVPGG
     SPLGVSLVYS DKKSAAATSP APHLVAGPLL GTVGKAPATV TNLLVGTPGY GAPAPPAVQF
     IAQGAPGGGT TAGSGAGAGS GPNGPVPLGI LQPGALGKAG GITQVQYILP TLPQQLQVAP
     APAPAPGTKA AAPSGPAPTT SIRFTLPPGT STNGKVLAAT APTPGIPILQ SVPSAPPPKA
     QSVSPVQAPP PGGSAQLLPG KVLVPLAAPS MSVRGGGAGQ PLPLVSPPFS VPVQNGAQPP
     SKIIQLTPVP VSTPSGLVPP LSPATLPGPT SQPQKVLLPS STRITYVQSA GGHALPLGTS
     PASSQAGTVT SYGPTSSVAL GFTSLGPSGP AFVQPLLSAG QAPLLAPGQV GVSPVPSPQL
     PPACAAPGGP VITAFYSGSP APTSSAPLAQ PSQAPPSLVY TVATSTTPPA ATILPKGPPA
     PATATPAPTS PFPSATAGSM TYSLVAPKAQ RPSPKAPQKV KAAIASIPVG SFEAGASGRP
     GPAPRQPLEP GPVREPTAPE SELEGQPTPP APPPLPETWT PTARSSPPLP PPAEERTSAK
     GPETMASKFP SSSSDWRVPG QGLENRGEPP TPPSPAPAPA VAPGGSSESS SGRAAGDTPE
     RKEAAGTGKK VKVRPPPLKK TFDSVDNRVL SEVDFEERFA ELPEFRPEEV LPSPTLQSLA
     TSPRAILGSY RKKRKNSTDL DSAPEDPTSP KRKMRRRSSC SSEPNTPKSA KCEGDIFTFD
     RTGTEAEDVL GELEYDKVPY SSLRRTLDQR RALVMQLFQD HGFFPSAQAT AAFQARYADI
     FPSKVCLQLK IREVRQKIMQ AATPTEQPPG AEAPLPVPPP TGTAAAPAPT PSPAGGPDPT
     SPSSDSGTAQ AAPPLPPPPE SGPGQPGWEG APQPSPPPPG PSTAATGR
//
ID   CBP_HUMAN               Reviewed;        2442 AA.
AC   Q92793; D3DUC9; O00147; Q16376; Q4LE28;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 3.
DT   28-FEB-2018, entry version 220.
DE   RecName: Full=CREB-binding protein;
DE            EC=2.3.1.48 {ECO:0000269|PubMed:24616510};
GN   Name=CREBBP; Synonyms=CBP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9238046; DOI=10.1073/pnas.94.16.8732;
RA   Sobulo O.M., Borrow J., Tomek R., Reshimi S., Harden A.,
RA   Schlegelberger B., Housman D., Doggett N.A., Rowley J.D.,
RA   Zeleznik-Le N.J.;
RT   "MLL is fused to CBP, a histone acetyltransferase, in therapy-related
RT   acute myeloid leukemia with a t(11;16)(q23;p13.3).";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:8732-8737(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9177780; DOI=10.1006/geno.1997.4699;
RA   Giles R.H., Petrij F., Dauwerse H.G., den Hollander A.I.,
RA   Lushnikova T., van Ommen G.J.B., Goodman R.H., Deaven L.L.,
RA   Doggett N.A., Peters D.J.M., Breuning M.H.;
RT   "Construction of a 1.2-Mb contig surrounding, and molecular analysis
RT   of, the human CREB-binding protein (CBP/CREBBP) gene on chromosome
RT   16p13.3.";
RL   Genomics 42:96-114(1997).
RN   [3]
RP   SEQUENCE REVISION TO 1724-1725; 1789 AND 1812.
RA   Petrij F., den Hollander A.I., Chrivia J.C.;
RL   Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RA   Nakajima D., Saito K., Yamakawa H., Kikuno R.F., Nakayama M.,
RA   Ohara R., Okazaki N., Koga H., Nagase T., Ohara O.;
RT   "Preparation of a set of expression-ready clones of mammalian long
RT   cDNAs encoding large proteins by the ORF trap cloning method.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-405, AND CHROMOSOMAL TRANSLOCATION
RP   WITH KAT6A.
RX   PubMed=8782817; DOI=10.1038/ng0996-33;
RA   Borrow J., Stanton V.P. Jr., Andresen J.M., Becher R., Behm F.G.,
RA   Chaganti R.S.K., Civin C.I., Disteche C., Dube I., Frischauf A.M.,
RA   Horsman D., Mitelman F., Volinia S., Watmore A.E., Housman D.E.;
RT   "The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a
RT   putative acetyltransferase to the CREB-binding protein.";
RL   Nat. Genet. 14:33-41(1996).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-83, AND CHROMOSOMAL TRANSLOCATION WITH
RP   KAT6B.
RX   PubMed=11157802; DOI=10.1093/hmg/10.4.395;
RA   Panagopoulos I., Fioretos T., Isaksson M., Samuelsson U.,
RA   Billstroem R., Stroembeck B., Mitelman F., Johansson B.;
RT   "Fusion of the MORF and CBP genes in acute myeloid leukemia with the
RT   t(10;16)(q22;p13).";
RL   Hum. Mol. Genet. 10:395-404(2001).
RN   [8]
RP   INTERACTION WITH PCAF.
RX   PubMed=8684459; DOI=10.1038/382319a0;
RA   Yang X.-J., Ogryzko V.V., Nishikawa J., Howard B.H., Nakatani Y.;
RT   "A p300/CBP-associated factor that competes with the adenoviral
RT   oncoprotein E1A.";
RL   Nature 382:319-324(1996).
RN   [9]
RP   INTERACTION WITH HIF1A AND EP300.
RX   PubMed=8917528; DOI=10.1073/pnas.93.23.12969;
RA   Arany Z., Huang L.E., Eckner R., Bhattacharya S., Jiang C.,
RA   Goldberg M.A., Bunn H.F., Livingston D.M.;
RT   "An essential role for p300/CBP in the cellular response to hypoxia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:12969-12973(1996).
RN   [10]
RP   INTERACTION WITH DHX9.
RX   PubMed=9323138; DOI=10.1016/S0092-8674(00)80376-1;
RA   Nakajima T., Uchida C., Anderson S.F., Lee C.-G., Hurwitz J.,
RA   Parvin J.D., Montminy M.;
RT   "RNA helicase A mediates association of CBP with RNA polymerase II.";
RL   Cell 90:1107-1112(1997).
RN   [11]
RP   INTERACTION WITH HTLV-1 TAX.
RX   PubMed=9528808; DOI=10.1128/MCB.18.4.2392;
RA   Bex F., Yin M.-J., Burny A., Gaynor R.B.;
RT   "Differential transcriptional activation by human T-cell leukemia
RT   virus type 1 Tax mutants is mediated by distinct interactions with
RT   CREB binding protein and p300.";
RL   Mol. Cell. Biol. 18:2392-2405(1998).
RN   [12]
RP   INTERACTION WITH KLF1, AND FUNCTION.
RX   PubMed=9707565; DOI=10.1073/pnas.95.17.9855;
RA   Zhang W., Bieker J.J.;
RT   "Acetylation and modulation of erythroid Krueppel-like factor (EKLF)
RT   activity by interaction with histone acetyltransferases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:9855-9860(1998).
RN   [13]
RP   INTERACTION WITH SRCAP.
RX   PubMed=10347196; DOI=10.1074/jbc.274.23.16370;
RA   Johnston H., Kneer J., Chackalaparampil I., Yaciuk P., Chrivia J.;
RT   "Identification of a novel SNF2/SWI2 protein family member, SRCAP,
RT   which interacts with CREB-binding protein.";
RL   J. Biol. Chem. 274:16370-16376(1999).
RN   [14]
RP   INTERACTION WITH PML.
RX   PubMed=10077561; DOI=10.1073/pnas.96.6.2627;
RA   Doucas V., Tini M., Egan D.A., Evans R.M.;
RT   "Modulation of CREB binding protein function by the promyelocytic
RT   (PML) oncoprotein suggests a role for nuclear bodies in hormone
RT   signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:2627-2632(1999).
RN   [15]
RP   ACETYLATION OF NCOA3.
RX   PubMed=10490106; DOI=10.1016/S0092-8674(00)80054-9;
RA   Chen H., Lin R.J., Xie W., Wilpitz D., Evans R.M.;
RT   "Regulation of hormone-induced histone hyperacetylation and gene
RT   activation via acetylation of an acetylase.";
RL   Cell 98:675-686(1999).
RN   [16]
RP   INTERACTION WITH CITED1.
RX   PubMed=10722728; DOI=10.1074/jbc.275.12.8825;
RA   Yahata T., de Caestecker M.P., Lechleider R.J., Andriole S.,
RA   Roberts A.B., Isselbacher K.J., Shioda T.;
RT   "The MSG1 non-DNA-binding transactivator binds to the p300/CBP
RT   coactivators, enhancing their functional link to the Smad
RT   transcription factors.";
RL   J. Biol. Chem. 275:8825-8834(2000).
RN   [17]
RP   INTERACTION WITH NCOA6.
RX   PubMed=10866662; DOI=10.1128/MCB.20.14.5048-5063.2000;
RA   Mahajan M.A., Samuels H.H.;
RT   "A new family of nuclear receptor coregulators that integrates nuclear
RT   receptor signaling through CBP.";
RL   Mol. Cell. Biol. 20:5048-5063(2000).
RN   [18]
RP   INTERACTION WITH MAFG, AND FUNCTION IN ACETYLATION OF MAFG.
RX   PubMed=11154691; DOI=10.1074/jbc.M007846200;
RA   Hung H.-L., Kim A.Y., Hong W., Rakowski C., Blobel G.A.;
RT   "Stimulation of NF-E2 DNA binding by CREB-binding protein (CBP)-
RT   mediated acetylation.";
RL   J. Biol. Chem. 276:10715-10721(2001).
RN   [19]
RP   INTERACTION WITH NFATC4.
RX   PubMed=11514544; DOI=10.1074/jbc.M102961200;
RA   Yang T.T.C., Davis R.J., Chow C.-W.;
RT   "Requirement of two NFATc4 transactivation domains for CBP
RT   potentiation.";
RL   J. Biol. Chem. 276:39569-39576(2001).
RN   [20]
RP   INTERACTION WITH MECOM.
RX   PubMed=11568182; DOI=10.1074/jbc.M106733200;
RA   Chakraborty S., Senyuk V., Sitailo S., Chi Y., Nucifora G.;
RT   "Interaction of EVI1 with cAMP-responsive element-binding protein-
RT   binding protein (CBP) and p300/CBP-associated factor (P/CAF) results
RT   in reversible acetylation of EVI1 and in co-localization in nuclear
RT   speckles.";
RL   J. Biol. Chem. 276:44936-44943(2001).
RN   [21]
RP   INTERACTION WITH HTLV-1 TAX.
RX   PubMed=11463834; DOI=10.1128/MCB.21.16.5520-5530.2001;
RA   Scoggin K.E.S., Ulloa A., Nyborg J.K.;
RT   "The oncoprotein Tax binds the SRC-1-interacting domain of CBP/p300 to
RT   mediate transcriptional activation.";
RL   Mol. Cell. Biol. 21:5520-5530(2001).
RN   [22]
RP   INTERACTION WITH HTLV-1 ACCESSORY PROTEIN P30II.
RX   PubMed=11559821; DOI=10.1128/JVI.75.20.9885-9895.2001;
RA   Zhang W., Nisbet J.W., Albrecht B., Ding W., Kashanchi F.,
RA   Bartoe J.T., Lairmore M.D.;
RT   "Human T-lymphotropic virus type 1 p30(II) regulates gene
RT   transcription by binding CREB binding protein/p300.";
RL   J. Virol. 75:9885-9895(2001).
RN   [23]
RP   INTERACTION WITH TRERF1.
RX   PubMed=11349124; DOI=10.1074/jbc.M100113200;
RA   Gizard F., Lavallee B., DeWitte F., Hum D.W.;
RT   "A novel zinc finger protein TReP-132 interacts with CBP/p300 to
RT   regulate human CYP11A1 gene expression.";
RL   J. Biol. Chem. 276:33881-33892(2001).
RN   [24]
RP   INTERACTION WITH PELP1.
RX   PubMed=11481323; DOI=10.1074/jbc.M103783200;
RA   Vadlamudi R.K., Wang R.-A., Mazumdar A., Kim Y.-S., Shin J., Sahin A.,
RA   Kumar R.;
RT   "Molecular cloning and characterization of PELP1, a novel human
RT   coregulator of estrogen receptor alpha.";
RL   J. Biol. Chem. 276:38272-38279(2001).
RN   [25]
RP   INTERACTION WITH HHV-8 PROTEIN VIRF1.
RX   PubMed=11314014; DOI=10.1038/sj.onc.1204163;
RA   Lin R., Genin P., Mamane Y., Sgarbanti M., Battistini A.,
RA   Harrington W.J. Jr., Barber G.N., Hiscott J.;
RT   "HHV-8 encoded vIRF-1 represses the interferon antiviral response by
RT   blocking IRF-3 recruitment of the CBP/p300 coactivators.";
RL   Oncogene 20:800-811(2001).
RN   [26]
RP   INTERACTION WITH SPIB.
RX   PubMed=11864910;
RA   Yamamoto H., Kihara-Negishi F., Yamada T., Suzuki M., Nakano T.,
RA   Oikawa T.;
RT   "Interaction between the hematopoietic Ets transcription factor Spi-B
RT   and the coactivator CREB-binding protein associated with negative
RT   cross-talk with c-Myb.";
RL   Cell Growth Differ. 13:69-75(2002).
RN   [27]
RP   INTERACTION WITH CITED4.
RX   PubMed=11744733; DOI=10.1074/jbc.M110850200;
RA   Braganca J., Swingler T., Marques F.I.R., Jones T., Eloranta J.J.,
RA   Hurst H.C., Shioda T., Bhattacharya S.;
RT   "Human CREB-binding protein/p300-interacting transactivator with ED-
RT   rich tail (CITED) 4, a new member of the CITED family, functions as a
RT   co-activator for transcription factor AP-2.";
RL   J. Biol. Chem. 277:8559-8565(2002).
RN   [28]
RP   IDENTIFICATION IN A COMPLEX WITH NCOA2; NCOA3; IKKA; IKKB AND IKBKG.
RX   PubMed=11971985; DOI=10.1128/MCB.22.10.3549-3561.2002;
RA   Wu R.-C., Qin J., Hashimoto Y., Wong J., Xu J., Tsai S.Y., Tsai M.-J.,
RA   O'Malley B.W.;
RT   "Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) coactivator
RT   activity by I kappa B kinase.";
RL   Mol. Cell. Biol. 22:3549-3561(2002).
RN   [29]
RP   INTERACTION WITH IRF2, AND FUNCTION IN ACETYLATION OF IRF2.
RX   PubMed=12738767; DOI=10.1074/jbc.M213037200;
RA   Masumi A., Yamakawa Y., Fukazawa H., Ozato K., Komuro K.;
RT   "Interferon regulatory factor-2 regulates cell growth through its
RT   acetylation.";
RL   J. Biol. Chem. 278:25401-25407(2003).
RN   [30]
RP   INTERACTION WITH N4BP2.
RX   PubMed=12730195; DOI=10.1074/jbc.M303518200;
RA   Watanabe N., Wachi S., Fujita T.;
RT   "Identification and characterization of BCL-3-binding protein:
RT   implications for transcription and DNA repair or recombination.";
RL   J. Biol. Chem. 278:26102-26110(2003).
RN   [31]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12929931; DOI=10.1359/jbmr.2003.18.8.1419;
RA   Iioka T., Furukawa K., Yamaguchi A., Shindo H., Yamashita S.,
RA   Tsukazaki T.;
RT   "P300/CBP acts as a coactivator to cartilage homeoprotein-1 (Cart1),
RT   paired-like homeoprotein, through acetylation of the conserved lysine
RT   residue adjacent to the homeodomain.";
RL   J. Bone Miner. Res. 18:1419-1429(2003).
RN   [32]
RP   FUNCTION, AND INTERACTION WITH NPAS2 AND CLOCK.
RX   PubMed=14645221; DOI=10.1074/jbc.M311973200;
RA   Curtis A.M., Seo S.B., Westgate E.J., Rudic R.D., Smyth E.M.,
RA   Chakravarti D., FitzGerald G.A., McNamara P.;
RT   "Histone acetyltransferase-dependent chromatin remodeling and the
RT   vascular clock.";
RL   J. Biol. Chem. 279:7091-7097(2004).
RN   [33]
RP   INTERACTION WITH ELF3.
RX   PubMed=15075319; DOI=10.1074/jbc.M401356200;
RA   Wang H., Fang R., Cho J.-Y., Libermann T.A., Oettgen P.;
RT   "Positive and negative modulation of the transcriptional activity of
RT   the ETS factor ESE-1 through interaction with p300, CREB-binding
RT   protein, and Ku 70/86.";
RL   J. Biol. Chem. 279:25241-25250(2004).
RN   [34]
RP   INTERACTION WITH MLLT7.
RX   PubMed=15126506; DOI=10.1074/jbc.M401138200;
RA   van der Horst A., Tertoolen L.G.J., de Vries-Smits L.M.M., Frye R.A.,
RA   Medema R.H., Burgering B.M.T.;
RT   "FOXO4 is acetylated upon peroxide stress and deacetylated by the
RT   longevity protein hSir2(SIRT1).";
RL   J. Biol. Chem. 279:28873-28879(2004).
RN   [35]
RP   SUBCELLULAR LOCATION.
RX   PubMed=15488321; DOI=10.1016/j.neulet.2004.08.062;
RA   Pradhan A., Liu Y.;
RT   "The calcium-responsive transactivator recruits CREB binding protein
RT   to nuclear bodies.";
RL   Neurosci. Lett. 370:191-195(2004).
RN   [36]
RP   INTERACTION WITH FOXO1.
RX   PubMed=15220471; DOI=10.1073/pnas.0400593101;
RA   Daitoku H., Hatta M., Matsuzaki H., Aratani S., Ohshima T.,
RA   Miyagishi M., Nakajima T., Fukamizu A.;
RT   "Silent information regulator 2 potentiates Foxo1-mediated
RT   transcription through its deacetylase activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:10042-10047(2004).
RN   [37]
RP   INTERACTION WITH SS18L1/CREST.
RX   PubMed=14716005; DOI=10.1126/science.1089845;
RA   Aizawa H., Hu S.-C., Bobb K., Balakrishnan K., Ince G., Gurevich I.,
RA   Cowan M., Ghosh A.;
RT   "Dendrite development regulated by CREST, a calcium-regulated
RT   transcriptional activator.";
RL   Science 303:197-202(2004).
RN   [38]
RP   PHOSPHORYLATION AT SER-1382 AND SER-1386 BY CHUK/IKKA.
RX   PubMed=17434128; DOI=10.1016/j.molcel.2007.02.019;
RA   Huang W.C., Ju T.K., Hung M.C., Chen C.C.;
RT   "Phosphorylation of CBP by IKKalpha promotes cell growth by switching
RT   the binding preference of CBP from p53 to NF-kappaB.";
RL   Mol. Cell 26:75-87(2007).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1030, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [40]
RP   INTERACTION WITH MTDH.
RX   PubMed=18316612; DOI=10.1158/0008-5472.CAN-07-6164;
RA   Sarkar D., Park E.S., Emdad L., Lee S.-G., Su Z.-Z., Fisher P.B.;
RT   "Molecular basis of nuclear factor-kappaB activation by astrocyte
RT   elevated gene-1.";
RL   Cancer Res. 68:1478-1484(2008).
RN   [41]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-121; SER-2063; SER-2076
RP   AND SER-2079, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [42]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [43]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2063, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [44]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-1014; LYS-1216; LYS-1583;
RP   LYS-1591; LYS-1592; LYS-1595; LYS-1597; LYS-1741 AND LYS-1744, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [45]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-121, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [46]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [47]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [48]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1076; SER-1763 AND
RP   SER-2063, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [49]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [50]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-220, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.O113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V.,
RA   Aguiar M., Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C.,
RA   Vemulapalli V., Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [51]
RP   FUNCTION AS ACETYLTRANSFERASE OF PCNA, AND INTERACTION WITH PCNA.
RX   PubMed=24939902; DOI=10.1093/nar/gku533;
RA   Cazzalini O., Sommatis S., Tillhon M., Dutto I., Bachi A., Rapp A.,
RA   Nardo T., Scovassi A.I., Necchi D., Cardoso M.C., Stivala L.A.,
RA   Prosperi E.;
RT   "CBP and p300 acetylate PCNA to link its degradation with nucleotide
RT   excision repair synthesis.";
RL   Nucleic Acids Res. 42:8433-8448(2014).
RN   [52]
RP   STRUCTURE BY NMR OF 345-439 IN COMPLEX WITH 776-826 OF HIF1A.
RX   PubMed=11959977; DOI=10.1073/pnas.082121399;
RA   Dames S.A., Martinez-Yamout M., De Guzman R.N., Dyson H.J.,
RA   Wright P.E.;
RT   "Structural basis for Hif-1 alpha /CBP recognition in the cellular
RT   hypoxic response.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:5271-5276(2002).
RN   [53]
RP   CHROMOSOMAL TRANSLOCATION WITH KAT6A.
RX   PubMed=11742995; DOI=10.1093/emboj/20.24.7184;
RA   Kitabayashi I., Aikawa Y., Nguyen L.A., Yokoyama A., Ohki M.;
RT   "Activation of AML1-mediated transcription by MOZ and inhibition by
RT   the MOZ-CBP fusion protein.";
RL   EMBO J. 20:7184-7196(2001).
RN   [54]
RP   STRUCTURE BY NMR OF 589-679 IN COMPLEX WITH HIV-1 TAT.
RX   PubMed=14744133; DOI=10.1021/bi035612l;
RA   Vendel A.C., Lumb K.J.;
RT   "NMR mapping of the HIV-1 Tat interaction surface of the KIX domain of
RT   the human coactivator CBP.";
RL   Biochemistry 43:904-908(2004).
RN   [55]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 1081-1197.
RX   PubMed=22464331; DOI=10.1016/j.cell.2012.02.013;
RA   Filippakopoulos P., Picaud S., Mangos M., Keates T., Lambert J.P.,
RA   Barsyte-Lovejoy D., Felletar I., Volkmer R., Muller S., Pawson T.,
RA   Gingras A.C., Arrowsmith C.H., Knapp S.;
RT   "Histone recognition and large-scale structural analysis of the human
RT   bromodomain family.";
RL   Cell 149:214-231(2012).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (1.40 ANGSTROMS) OF 1082-1197, FUNCTION,
RP   INTERACTION WITH ASF1A; ASF1B; ACETYLATED HISTONES AND TP53,
RP   MUTAGENESIS OF ASP-1116; PHE-1126; ASN-1162; TRP-1165; SER-1179;
RP   LYS-1180 AND GLU-1183, CHARACTERIZATION OF VARIANT RSTS1 CYS-1175,
RP   CATALYTIC ACTIVITY, AND AUTOACETYLATION.
RX   PubMed=24616510; DOI=10.1073/pnas.1319122111;
RA   Das C., Roy S., Namjoshi S., Malarkey C.S., Jones D.N.,
RA   Kutateladze T.G., Churchill M.E., Tyler J.K.;
RT   "Binding of the histone chaperone ASF1 to the CBP bromodomain promotes
RT   histone acetylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:E1072-E1081(2014).
RN   [57]
RP   X-RAY CRYSTALLOGRAPHY (1.83 ANGSTROMS) OF 1080-1316 IN COMPLEX WITH
RP   ZINC.
RX   PubMed=24361270; DOI=10.1016/j.str.2013.10.021;
RA   Plotnikov A.N., Yang S., Zhou T.J., Rusinova E., Frasca A., Zhou M.M.;
RT   "Structural insights into acetylated-histone H4 recognition by the
RT   bromodomain-PHD finger module of human transcriptional coactivator
RT   CBP.";
RL   Structure 22:353-360(2014).
RN   [58]
RP   VARIANT RSTS1 PRO-1378.
RX   PubMed=11331617; DOI=10.1093/hmg/10.10.1071;
RA   Murata T., Kurokawa R., Krones A., Tatsumi K., Ishii M., Taki T.,
RA   Masuno M., Ohashi H., Yanagisawa M., Rosenfeld M.G., Glass C.K.,
RA   Hayashi Y.;
RT   "Defect of histone acetyltransferase activity of the nuclear
RT   transcriptional coactivator CBP in Rubinstein-Taybi syndrome.";
RL   Hum. Mol. Genet. 10:1071-1076(2001).
RN   [59]
RP   VARIANT RSTS1 CYS-1175.
RX   PubMed=12114483; DOI=10.1136/jmg.39.7.496;
RA   Bartsch O., Locher K., Meinecke P., Kress W., Seemanova E., Wagner A.,
RA   Ostermann K., Roedel G.;
RT   "Molecular studies in 10 cases of Rubinstein-Taybi syndrome, including
RT   a mild variant showing a missense mutation in codon 1175 of CREBBP.";
RL   J. Med. Genet. 39:496-501(2002).
RN   [60]
RP   VARIANTS RSTS1 LYS-1278 AND HIS-1664, AND CHARACTERIZATION OF VARIANTS
RP   RSTS1 LYS-1278 AND HIS-1664.
RX   PubMed=12566391; DOI=10.1093/hmg/ddg039;
RA   Kalkhoven E., Roelfsema J.H., Teunissen H., den Boer A., Ariyuerek Y.,
RA   Zantema A., Breuning M.H., Hennekam R.C.M., Peters D.J.M.;
RT   "Loss of CBP acetyltransferase activity by PHD finger mutations in
RT   Rubinstein-Taybi syndrome.";
RL   Hum. Mol. Genet. 12:441-450(2003).
RN   [61]
RP   VARIANTS RSTS1 LYS-1278; ILE-1447; HIS-1450; ARG-1470 AND HIS-1664.
RX   PubMed=15706485; DOI=10.1086/429130;
RA   Roelfsema J.H., White S.J., Ariyuerek Y., Bartholdi D., Niedrist D.,
RA   Papadia F., Bacino C.A., den Dunnen J.T., van Ommen G.-J.B.,
RA   Breuning M.H., Hennekam R.C., Peters D.J.M.;
RT   "Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both
RT   the CBP and EP300 genes cause disease.";
RL   Am. J. Hum. Genet. 76:572-580(2005).
RN   [62]
RP   VARIANT RSTS1 ALA-910.
RX   PubMed=20684013; DOI=10.1002/ajmg.a.33598;
RA   Bartsch O., Kress W., Kempf O., Lechno S., Haaf T., Zechner U.;
RT   "Inheritance and variable expression in Rubinstein-Taybi syndrome.";
RL   Am. J. Med. Genet. A 152A:2254-2261(2010).
RN   [63]
RP   VARIANTS HIS-503; THR-532 AND ASN-546, AND VARIANTS RSTS1 PHE-650;
RP   THR-789; CYS-1175; ALA-1278; PRO-1378; TYR-1406; PRO-1415; THR-1475;
RP   PHE-1503; PRO-1507 AND ASN-1543.
RX   PubMed=25388907; DOI=10.1111/cge.12537;
RA   Spena S., Milani D., Rusconi D., Negri G., Colapietro P., Elcioglu N.,
RA   Bedeschi F., Pilotta A., Spaccini L., Ficcadenti A., Magnani C.,
RA   Scarano G., Selicorni A., Larizza L., Gervasini C.;
RT   "Insights into genotype-phenotype correlations from CREBBP point
RT   mutation screening in a cohort of 46 Rubinstein-Taybi syndrome
RT   patients.";
RL   Clin. Genet. 88:431-440(2015).
RN   [64]
RP   INVOLVEMENT IN RUBINSTEIN-TAYBI-LIKE SYNDROME, AND VARIANTS ARG-1710;
RP   ARG-1747; PRO-1786; PHE-1819; TRP-1826; TYR-1838; GLN-1867; TRP-1867;
RP   TRP-1868 AND VAL-1872.
RX   PubMed=27311832; DOI=10.1002/ajmg.a.37800;
RG   DDD Study;
RA   Menke L.A., van Belzen M.J., Alders M., Cristofoli F., Ehmke N.,
RA   Fergelot P., Foster A., Gerkes E.H., Hoffer M.J., Horn D., Kant S.G.,
RA   Lacombe D., Leon E., Maas S.M., Melis D., Muto V., Park S.M.,
RA   Peeters H., Peters D.J., Pfundt R., van Ravenswaaij-Arts C.M.,
RA   Tartaglia M., Hennekam R.C.;
RT   "CREBBP mutations in individuals without Rubinstein-Taybi syndrome
RT   phenotype.";
RL   Am. J. Med. Genet. A 170:2681-2693(2016).
CC   -!- FUNCTION: Acetylates histones, giving a specific tag for
CC       transcriptional activation. Also acetylates non-histone proteins,
CC       like NCOA3 and FOXO1. Binds specifically to phosphorylated CREB
CC       and enhances its transcriptional activity toward cAMP-responsive
CC       genes. Acts as a coactivator of ALX1. Acts as a circadian
CC       transcriptional coactivator which enhances the activity of the
CC       circadian transcriptional activators: NPAS2-ARNTL/BMAL1 and CLOCK-
CC       ARNTL/BMAL1 heterodimers. Acetylates PCNA; acetylation promotes
CC       removal of chromatin-bound PCNA and its degradation during
CC       nucleotide excision repair (NER) (PubMed:24939902).
CC       {ECO:0000269|PubMed:11154691, ECO:0000269|PubMed:12738767,
CC       ECO:0000269|PubMed:12929931, ECO:0000269|PubMed:14645221,
CC       ECO:0000269|PubMed:24939902, ECO:0000269|PubMed:9707565}.
CC   -!- CATALYTIC ACTIVITY: Acetyl-CoA + [protein]-L-lysine = CoA +
CC       [protein]-N(6)-acetyl-L-lysine. {ECO:0000269|PubMed:24616510}.
CC   -!- SUBUNIT: Found in a complex containing NCOA2; NCOA3; IKKA; IKKB
CC       and IKBKG. Probably part of a complex with HIF1A and EP300.
CC       Interacts with GATA1; the interaction results in acetylation and
CC       enhancement of transcriptional activity of GATA1. Interacts with
CC       MAF AND ZCCHC12. Interacts with DAXX; the interaction is dependent
CC       on CBP sumoylation and results in suppression of the
CC       transcriptional activity via recruitment of HDAC2 to DAXX (By
CC       similarity). Interacts with phosphorylated CREB1. Interacts with
CC       CITED4 (C-terminal region). Interacts (via the TAZ-type 1 domain)
CC       with HIF1A. Interacts with SRCAP, CARM1, ELF3, MLLT7/FOXO4, N4BP2,
CC       NCOA1, NCOA3, NCOA6, PCAF, DDX5, DDX17, PELP1, PML, SMAD1, SMAD2,
CC       SMAD3, SPIB and TRERF1. Interacts with HTLV-1 Tax and p30II.
CC       Interacts with HIV-1 Tat. Interacts with KLF1; the interaction
CC       results in acetylation of KLF1 and enhancement of its
CC       transcriptional activity. Interacts with MTDH. Interacts with
CC       NFATC4. Interacts with MAFG; the interaction acetylates MAFG in
CC       the basic region and stimulates NFE2 transcriptional activity
CC       through increasing its DNA-binding activity. Interacts with IRF2;
CC       the interaction acetylates IRF2 and regulates its activity on the
CC       H4 promoter. Interacts (via N-terminus) with SS18L1/CREST (via C-
CC       terminus). Interacts with MECOM. Interacts with CITED1 (via C-
CC       terminus). Interacts with FOXO1; the interaction acetylates FOXO1
CC       and inhibits its transcriptional activity. Interacts with human
CC       herpes virus 8/HHV-8 protein vIRF-1; this interaction inhibits
CC       CREBBP binding to IRF3. Interacts with NPAS2, CLOCK and
CC       ARNTL/BMAL1. Interacts with ASF1A and ASF1B; this promotes histone
CC       acetylation. Interacts with acetylated TP53/p53 and with the
CC       acetylated histones H3 and H4. Interacts (via transactivation
CC       domain and C-terminus) with PCNA; the interaction occurs on
CC       chromatin in UV-irradiated damaged cells (PubMed:24939902).
CC       Interacts with DHX9 (via N-terminus); this interaction mediates
CC       association with RNA polymerase II holoenzyme and stimulates CREB-
CC       dependent transcriptional activation (PubMed:9323138).
CC       {ECO:0000250, ECO:0000269|PubMed:10077561,
CC       ECO:0000269|PubMed:10347196, ECO:0000269|PubMed:10722728,
CC       ECO:0000269|PubMed:10866662, ECO:0000269|PubMed:11154691,
CC       ECO:0000269|PubMed:11314014, ECO:0000269|PubMed:11349124,
CC       ECO:0000269|PubMed:11463834, ECO:0000269|PubMed:11481323,
CC       ECO:0000269|PubMed:11514544, ECO:0000269|PubMed:11559821,
CC       ECO:0000269|PubMed:11568182, ECO:0000269|PubMed:11744733,
CC       ECO:0000269|PubMed:11864910, ECO:0000269|PubMed:11959977,
CC       ECO:0000269|PubMed:11971985, ECO:0000269|PubMed:12730195,
CC       ECO:0000269|PubMed:12738767, ECO:0000269|PubMed:14645221,
CC       ECO:0000269|PubMed:14716005, ECO:0000269|PubMed:14744133,
CC       ECO:0000269|PubMed:15075319, ECO:0000269|PubMed:15126506,
CC       ECO:0000269|PubMed:15220471, ECO:0000269|PubMed:18316612,
CC       ECO:0000269|PubMed:24616510, ECO:0000269|PubMed:24939902,
CC       ECO:0000269|PubMed:8684459, ECO:0000269|PubMed:8917528,
CC       ECO:0000269|PubMed:9323138, ECO:0000269|PubMed:9528808,
CC       ECO:0000269|PubMed:9707565}.
CC   -!- INTERACTION:
CC       P03070:- (xeno); NbExp=2; IntAct=EBI-81215, EBI-617698;
CC       P03255:- (xeno); NbExp=3; IntAct=EBI-81215, EBI-2603114;
CC       P03259:- (xeno); NbExp=5; IntAct=EBI-81215, EBI-6947456;
CC       P03259-2:- (xeno); NbExp=3; IntAct=EBI-81215, EBI-7225021;
CC       P31749:AKT1; NbExp=3; IntAct=EBI-81215, EBI-296087;
CC       P10275:AR; NbExp=2; IntAct=EBI-81215, EBI-608057;
CC       P61201:COPS2; NbExp=3; IntAct=EBI-81215, EBI-1050386;
CC       P16220:CREB1; NbExp=3; IntAct=EBI-81215, EBI-711855;
CC       P35222:CTNNB1; NbExp=2; IntAct=EBI-81215, EBI-491549;
CC       Q9UER7:DAXX; NbExp=2; IntAct=EBI-81215, EBI-77321;
CC       Q12778:FOXO1; NbExp=3; IntAct=EBI-81215, EBI-1108782;
CC       O43524:FOXO3; NbExp=3; IntAct=EBI-81215, EBI-1644164;
CC       Q16665:HIF1A; NbExp=2; IntAct=EBI-81215, EBI-447269;
CC       P62805:HIST2H4B; NbExp=6; IntAct=EBI-81215, EBI-302023;
CC       P42858:HTT; NbExp=2; IntAct=EBI-81215, EBI-466029;
CC       P48551:IFNAR2; NbExp=4; IntAct=EBI-81215, EBI-958408;
CC       O14920:IKBKB; NbExp=2; IntAct=EBI-81215, EBI-81266;
CC       Q14653:IRF3; NbExp=10; IntAct=EBI-81215, EBI-2650369;
CC       Q13568:IRF5; NbExp=3; IntAct=EBI-81215, EBI-3931258;
CC       Q92831:KAT2B; NbExp=4; IntAct=EBI-81215, EBI-477430;
CC       Q13351:KLF1; NbExp=2; IntAct=EBI-81215, EBI-8284732;
CC       Q86UE4:MTDH; NbExp=2; IntAct=EBI-81215, EBI-1046588;
CC       P55209:NAP1L1; NbExp=3; IntAct=EBI-81215, EBI-356392;
CC       Q14686:NCOA6; NbExp=2; IntAct=EBI-81215, EBI-78670;
CC       Q04206:RELA; NbExp=5; IntAct=EBI-81215, EBI-73886;
CC       O95863:SNAI1; NbExp=9; IntAct=EBI-81215, EBI-1045459;
CC       P36956-1:SREBF1; NbExp=3; IntAct=EBI-81215, EBI-948328;
CC       P36956-3:SREBF1; NbExp=2; IntAct=EBI-81215, EBI-948338;
CC       Q12772:SREBF2; NbExp=2; IntAct=EBI-81215, EBI-465059;
CC       P04608:tat (xeno); NbExp=2; IntAct=EBI-81215, EBI-6164389;
CC       Q9UL17:TBX21; NbExp=4; IntAct=EBI-81215, EBI-3922312;
CC       P04637:TP53; NbExp=11; IntAct=EBI-81215, EBI-366083;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Recruited to
CC       nuclear bodies by SS18L1/CREST. In the presence of ALX1
CC       relocalizes from the cytoplasm to the nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q92793-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q92793-2; Sequence=VSP_045700;
CC         Note=No experimental confirmation available.;
CC   -!- DOMAIN: The KIX domain mediates binding to HIV-1 Tat.
CC   -!- PTM: Methylation of the KIX domain by CARM1 blocks association
CC       with CREB. This results in the blockade of CREB signaling, and in
CC       activation of apoptotic response (By similarity). {ECO:0000250}.
CC   -!- PTM: Phosphorylated by CHUK/IKKA at Ser-1382 and Ser-1386; these
CC       phosphorylations promote cell growth by switching the binding
CC       preference of CREBBP from TP53 to NF-kappa-B.
CC       {ECO:0000269|PubMed:17434128}.
CC   -!- PTM: Sumoylation negatively regulates transcriptional activity via
CC       the recruitment of DAAX. {ECO:0000250}.
CC   -!- PTM: Autoacetylation is required for binding to protein
CC       substrates, such as acetylated histones and acetylated TP53/p53.
CC       {ECO:0000269|PubMed:24616510}.
CC   -!- DISEASE: Note=Chromosomal aberrations involving CREBBP may be a
CC       cause of acute myeloid leukemias. Translocation t(8;16)(p11;p13)
CC       with KAT6A; translocation t(11;16)(q23;p13.3) with KMT2A/MLL1;
CC       translocation t(10;16)(q22;p13) with KAT6B. KAT6A-CREBBP may
CC       induce leukemia by inhibiting RUNX1-mediated transcription.
CC   -!- DISEASE: Rubinstein-Taybi syndrome 1 (RSTS1) [MIM:180849]: A
CC       disorder characterized by craniofacial abnormalities, postnatal
CC       growth deficiency, broad thumbs, broad big toes, mental
CC       retardation and a propensity for development of malignancies.
CC       {ECO:0000269|PubMed:11331617, ECO:0000269|PubMed:12114483,
CC       ECO:0000269|PubMed:12566391, ECO:0000269|PubMed:15706485,
CC       ECO:0000269|PubMed:20684013, ECO:0000269|PubMed:24616510,
CC       ECO:0000269|PubMed:25388907}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=De novo missense mutations in the last part of exon
CC       30 or beginning of exon 31 are associated with growth retardation,
CC       craniofacial dysmorphism and additional Rubinstein-Taybi-like
CC       features. No patients have broad thumbs. Patients have
CC       intellectual disability of variable severity, a marked speech
CC       delay, short stature and microcephaly. Main facial characteristics
CC       include short palpebral fissures, telecanthi, depressed nasal
CC       ridge, short nose, anteverted nares, short columella and long
CC       philtrum. {ECO:0000269|PubMed:27311832}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAE06125.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CBPID42.html";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=P300/CBP entry;
CC       URL="https://en.wikipedia.org/wiki/P300/CBP";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U85962; AAC51331.2; -; mRNA.
DR   EMBL; U89354; AAC51339.1; -; mRNA.
DR   EMBL; U89355; AAC51340.1; -; mRNA.
DR   EMBL; U47741; AAC51770.1; -; mRNA.
DR   EMBL; AB210043; BAE06125.1; ALT_INIT; mRNA.
DR   EMBL; CH471112; EAW85335.1; -; Genomic_DNA.
DR   EMBL; CH471112; EAW85336.1; -; Genomic_DNA.
DR   EMBL; CH471112; EAW85337.1; -; Genomic_DNA.
DR   CCDS; CCDS10509.1; -. [Q92793-1]
DR   CCDS; CCDS45399.1; -. [Q92793-2]
DR   PIR; S39162; S39162.
DR   RefSeq; NP_001073315.1; NM_001079846.1. [Q92793-2]
DR   RefSeq; NP_004371.2; NM_004380.2. [Q92793-1]
DR   UniGene; Hs.459759; -.
DR   PDB; 1JSP; NMR; -; B=1081-1197.
DR   PDB; 1LIQ; NMR; -; A=376-402.
DR   PDB; 1RDT; X-ray; 2.40 A; E=58-80.
DR   PDB; 1WO3; NMR; -; A=387-398.
DR   PDB; 1WO4; NMR; -; A=387-398.
DR   PDB; 1WO5; NMR; -; A=387-398.
DR   PDB; 1WO6; NMR; -; A=376-400.
DR   PDB; 1WO7; NMR; -; A=376-400.
DR   PDB; 1ZOQ; X-ray; 2.37 A; C/D=2065-2111.
DR   PDB; 2D82; NMR; -; A=1081-1197.
DR   PDB; 2KJE; NMR; -; A=1763-1854.
DR   PDB; 2KWF; NMR; -; A=587-673.
DR   PDB; 2L84; NMR; -; A=1081-1197.
DR   PDB; 2L85; NMR; -; A=1081-1197.
DR   PDB; 2LXS; NMR; -; A=587-673.
DR   PDB; 2LXT; NMR; -; A=587-673.
DR   PDB; 2N1A; NMR; -; B=1699-1751.
DR   PDB; 2RNY; NMR; -; A=1081-1197.
DR   PDB; 3DWY; X-ray; 1.98 A; A/B=1081-1197.
DR   PDB; 3P1C; X-ray; 1.82 A; A/B=1081-1197.
DR   PDB; 3P1D; X-ray; 1.86 A; A/B=1081-1197.
DR   PDB; 3P1E; X-ray; 1.80 A; A/B=1081-1197.
DR   PDB; 3P1F; X-ray; 1.63 A; A/B=1081-1197.
DR   PDB; 3SVH; X-ray; 1.80 A; A/B=1081-1197.
DR   PDB; 4A9K; X-ray; 1.81 A; A/B=1081-1197.
DR   PDB; 4N3W; X-ray; 1.90 A; A=1080-1316.
DR   PDB; 4N4F; X-ray; 1.83 A; A=1080-1316.
DR   PDB; 4NR4; X-ray; 1.69 A; A/B=1081-1197.
DR   PDB; 4NR5; X-ray; 1.66 A; A=1081-1197.
DR   PDB; 4NR6; X-ray; 1.66 A; A=1081-1197.
DR   PDB; 4NR7; X-ray; 1.20 A; A=1081-1197.
DR   PDB; 4NYV; X-ray; 1.83 A; A/B/C/D=1081-1197.
DR   PDB; 4NYW; X-ray; 1.43 A; A=1081-1197.
DR   PDB; 4NYX; X-ray; 1.10 A; A=1081-1197.
DR   PDB; 4OUF; X-ray; 1.40 A; A/B=1082-1197.
DR   PDB; 4TQN; X-ray; 1.70 A; A=1081-1197.
DR   PDB; 4TS8; X-ray; 2.00 A; A=1081-1197.
DR   PDB; 4WHU; X-ray; 2.11 A; A=1081-1197.
DR   PDB; 4YK0; X-ray; 1.65 A; A/B/C/D=1083-1196.
DR   PDB; 5CGP; X-ray; 1.96 A; A=1081-1197.
DR   PDB; 5DBM; X-ray; 1.86 A; A/B/C=1082-1197.
DR   PDB; 5EIC; X-ray; 1.50 A; A/B=1081-1197.
DR   PDB; 5ENG; X-ray; 1.30 A; A=1081-1197.
DR   PDB; 5EP7; X-ray; 1.20 A; A=1081-1197.
DR   PDB; 5GH9; X-ray; 1.45 A; A=1081-1196.
DR   PDB; 5H85; X-ray; 1.70 A; A=1081-1197.
DR   PDB; 5I83; X-ray; 1.35 A; A=1082-1197.
DR   PDB; 5I86; X-ray; 1.05 A; A/B=1082-1197.
DR   PDB; 5I89; X-ray; 1.07 A; A=1082-1197.
DR   PDB; 5I8B; X-ray; 1.52 A; A=1081-1312.
DR   PDB; 5I8G; X-ray; 1.41 A; A=1081-1312.
DR   PDB; 5J0D; X-ray; 1.05 A; A=1081-1197.
DR   PDB; 5JEM; X-ray; 2.50 A; C/D/F/H=2065-2111.
DR   PDB; 5KTU; X-ray; 1.38 A; A/B=1082-1197.
DR   PDB; 5KTW; X-ray; 1.09 A; A/B/C=1085-1194.
DR   PDB; 5KTX; X-ray; 1.27 A; A=1085-1194.
DR   PDB; 5LPJ; X-ray; 1.65 A; A=1081-1197.
DR   PDB; 5LPL; X-ray; 1.65 A; A=1081-1197.
DR   PDB; 5MME; X-ray; 1.35 A; A/B=1081-1197.
DR   PDB; 5MMG; X-ray; 1.23 A; A=1081-1197.
DR   PDB; 5MPK; X-ray; 1.90 A; A/B=1081-1197.
DR   PDB; 5MPN; X-ray; 1.23 A; A=1081-1197.
DR   PDB; 5MPZ; X-ray; 1.40 A; A=1081-1197.
DR   PDB; 5MQE; X-ray; 1.65 A; A/B=1081-1197.
DR   PDB; 5MQG; X-ray; 1.35 A; A/B=1081-1197.
DR   PDB; 5MQK; X-ray; 1.53 A; A/B=1081-1197.
DR   PDB; 5NRW; X-ray; 1.70 A; A=1081-1197.
DR   PDB; 5NU3; X-ray; 1.75 A; A=1081-1197.
DR   PDB; 5TB6; X-ray; 1.79 A; A=1081-1197.
DR   PDBsum; 1JSP; -.
DR   PDBsum; 1LIQ; -.
DR   PDBsum; 1RDT; -.
DR   PDBsum; 1WO3; -.
DR   PDBsum; 1WO4; -.
DR   PDBsum; 1WO5; -.
DR   PDBsum; 1WO6; -.
DR   PDBsum; 1WO7; -.
DR   PDBsum; 1ZOQ; -.
DR   PDBsum; 2D82; -.
DR   PDBsum; 2KJE; -.
DR   PDBsum; 2KWF; -.
DR   PDBsum; 2L84; -.
DR   PDBsum; 2L85; -.
DR   PDBsum; 2LXS; -.
DR   PDBsum; 2LXT; -.
DR   PDBsum; 2N1A; -.
DR   PDBsum; 2RNY; -.
DR   PDBsum; 3DWY; -.
DR   PDBsum; 3P1C; -.
DR   PDBsum; 3P1D; -.
DR   PDBsum; 3P1E; -.
DR   PDBsum; 3P1F; -.
DR   PDBsum; 3SVH; -.
DR   PDBsum; 4A9K; -.
DR   PDBsum; 4N3W; -.
DR   PDBsum; 4N4F; -.
DR   PDBsum; 4NR4; -.
DR   PDBsum; 4NR5; -.
DR   PDBsum; 4NR6; -.
DR   PDBsum; 4NR7; -.
DR   PDBsum; 4NYV; -.
DR   PDBsum; 4NYW; -.
DR   PDBsum; 4NYX; -.
DR   PDBsum; 4OUF; -.
DR   PDBsum; 4TQN; -.
DR   PDBsum; 4TS8; -.
DR   PDBsum; 4WHU; -.
DR   PDBsum; 4YK0; -.
DR   PDBsum; 5CGP; -.
DR   PDBsum; 5DBM; -.
DR   PDBsum; 5EIC; -.
DR   PDBsum; 5ENG; -.
DR   PDBsum; 5EP7; -.
DR   PDBsum; 5GH9; -.
DR   PDBsum; 5H85; -.
DR   PDBsum; 5I83; -.
DR   PDBsum; 5I86; -.
DR   PDBsum; 5I89; -.
DR   PDBsum; 5I8B; -.
DR   PDBsum; 5I8G; -.
DR   PDBsum; 5J0D; -.
DR   PDBsum; 5JEM; -.
DR   PDBsum; 5KTU; -.
DR   PDBsum; 5KTW; -.
DR   PDBsum; 5KTX; -.
DR   PDBsum; 5LPJ; -.
DR   PDBsum; 5LPL; -.
DR   PDBsum; 5MME; -.
DR   PDBsum; 5MMG; -.
DR   PDBsum; 5MPK; -.
DR   PDBsum; 5MPN; -.
DR   PDBsum; 5MPZ; -.
DR   PDBsum; 5MQE; -.
DR   PDBsum; 5MQG; -.
DR   PDBsum; 5MQK; -.
DR   PDBsum; 5NRW; -.
DR   PDBsum; 5NU3; -.
DR   PDBsum; 5TB6; -.
DR   ProteinModelPortal; Q92793; -.
DR   SMR; Q92793; -.
DR   BioGrid; 107777; 326.
DR   CORUM; Q92793; -.
DR   DIP; DIP-952N; -.
DR   ELM; Q92793; -.
DR   IntAct; Q92793; 84.
DR   MINT; Q92793; -.
DR   STRING; 9606.ENSP00000262367; -.
DR   BindingDB; Q92793; -.
DR   ChEMBL; CHEMBL5747; -.
DR   GuidetoPHARMACOLOGY; 2734; -.
DR   iPTMnet; Q92793; -.
DR   PhosphoSitePlus; Q92793; -.
DR   BioMuta; CREBBP; -.
DR   DMDM; 116241283; -.
DR   EPD; Q92793; -.
DR   MaxQB; Q92793; -.
DR   PaxDb; Q92793; -.
DR   PeptideAtlas; Q92793; -.
DR   PRIDE; Q92793; -.
DR   Ensembl; ENST00000262367; ENSP00000262367; ENSG00000005339. [Q92793-1]
DR   Ensembl; ENST00000382070; ENSP00000371502; ENSG00000005339. [Q92793-2]
DR   GeneID; 1387; -.
DR   KEGG; hsa:1387; -.
DR   UCSC; uc002cvv.4; human. [Q92793-1]
DR   CTD; 1387; -.
DR   DisGeNET; 1387; -.
DR   EuPathDB; HostDB:ENSG00000005339.13; -.
DR   GeneCards; CREBBP; -.
DR   GeneReviews; CREBBP; -.
DR   HGNC; HGNC:2348; CREBBP.
DR   HPA; CAB004212; -.
DR   HPA; HPA055861; -.
DR   MalaCards; CREBBP; -.
DR   MIM; 180849; phenotype.
DR   MIM; 600140; gene.
DR   neXtProt; NX_Q92793; -.
DR   OpenTargets; ENSG00000005339; -.
DR   Orphanet; 370026; Acute myeloid leukemia with t(8;16)(p11;p13) translocation.
DR   Orphanet; 353281; Rubinstein-Taybi syndrome due to 16p13.3 microdeletion.
DR   Orphanet; 353277; Rubinstein-Taybi syndrome due to CREBBP mutations.
DR   PharmGKB; PA26866; -.
DR   eggNOG; KOG1778; Eukaryota.
DR   eggNOG; COG5076; LUCA.
DR   GeneTree; ENSGT00760000119206; -.
DR   HOGENOM; HOG000111353; -.
DR   HOVERGEN; HBG000185; -.
DR   InParanoid; Q92793; -.
DR   KO; K04498; -.
DR   OMA; SGHSLMN; -.
DR   OrthoDB; EOG091G0L04; -.
DR   PhylomeDB; Q92793; -.
DR   TreeFam; TF101097; -.
DR   Reactome; R-HSA-1234158; Regulation of gene expression by Hypoxia-inducible Factor.
DR   Reactome; R-HSA-1368082; RORA activates gene expression.
DR   Reactome; R-HSA-1368108; BMAL1:CLOCK,NPAS2 activates circadian gene expression.
DR   Reactome; R-HSA-1912408; Pre-NOTCH Transcription and Translation.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-201722; Formation of the beta-catenin:TCF transactivating complex.
DR   Reactome; R-HSA-2032785; YAP1- and WWTR1 (TAZ)-stimulated gene expression.
DR   Reactome; R-HSA-2122947; NOTCH1 Intracellular Domain Regulates Transcription.
DR   Reactome; R-HSA-2151201; Transcriptional activation of mitochondrial biogenesis.
DR   Reactome; R-HSA-2426168; Activation of gene expression by SREBF (SREBP).
DR   Reactome; R-HSA-2644606; Constitutive Signaling by NOTCH1 PEST Domain Mutants.
DR   Reactome; R-HSA-2894862; Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants.
DR   Reactome; R-HSA-3134973; LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production.
DR   Reactome; R-HSA-3214847; HATs acetylate histones.
DR   Reactome; R-HSA-3371568; Attenuation phase.
DR   Reactome; R-HSA-350054; Notch-HLH transcription pathway.
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   Reactome; R-HSA-400206; Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha).
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   Reactome; R-HSA-5617472; Activation of anterior HOX genes in hindbrain development during early embryogenesis.
DR   Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling.
DR   Reactome; R-HSA-6803204; TP53 Regulates Transcription of Genes Involved in Cytochrome C Release.
DR   Reactome; R-HSA-8866907; Activation of the TFAP2 (AP-2) family of transcription factors.
DR   Reactome; R-HSA-8939246; RUNX1 regulates transcription of genes involved in differentiation of myeloid cells.
DR   Reactome; R-HSA-8941856; RUNX3 regulates NOTCH signaling.
DR   Reactome; R-HSA-8951671; RUNX3 regulates YAP1-mediated transcription.
DR   Reactome; R-HSA-9013508; NOTCH3 Intracellular Domain Regulates Transcription.
DR   Reactome; R-HSA-918233; TRAF3-dependent IRF activation pathway.
DR   Reactome; R-HSA-933541; TRAF6 mediated IRF7 activation.
DR   Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production.
DR   SignaLink; Q92793; -.
DR   SIGNOR; Q92793; -.
DR   ChiTaRS; CREBBP; human.
DR   EvolutionaryTrace; Q92793; -.
DR   GeneWiki; CREB-binding_protein; -.
DR   GenomeRNAi; 1387; -.
DR   PRO; PR:Q92793; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000005339; -.
DR   CleanEx; HS_CREBBP; -.
DR   ExpressionAtlas; Q92793; baseline and differential.
DR   Genevisible; Q92793; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0000123; C:histone acetyltransferase complex; IEA:InterPro.
DR   GO; GO:0016604; C:nuclear body; IDA:UniProtKB.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016407; F:acetyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; IDA:UniProtKB.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; TAS:ProtInc.
DR   GO; GO:0004402; F:histone acetyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0043426; F:MRF binding; IDA:UniProtKB.
DR   GO; GO:0002039; F:p53 binding; IPI:UniProtKB.
DR   GO; GO:0034212; F:peptide N-acetyltransferase activity; TAS:Reactome.
DR   GO; GO:0000987; F:proximal promoter sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0001102; F:RNA polymerase II activating transcription factor binding; TAS:BHF-UCL.
DR   GO; GO:0001105; F:RNA polymerase II transcription coactivator activity; TAS:BHF-UCL.
DR   GO; GO:0001085; F:RNA polymerase II transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0004871; F:signal transducer activity; TAS:ProtInc.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0001078; F:transcriptional repressor activity, RNA polymerase II proximal promoter sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0001191; F:transcriptional repressor activity, RNA polymerase II transcription factor binding; IDA:BHF-UCL.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:1904837; P:beta-catenin-TCF complex assembly; TAS:Reactome.
DR   GO; GO:0034644; P:cellular response to UV; IDA:UniProtKB.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; TAS:BHF-UCL.
DR   GO; GO:0016573; P:histone acetylation; IDA:UniProtKB.
DR   GO; GO:0042592; P:homeostatic process; NAS:UniProtKB.
DR   GO; GO:0018076; P:N-terminal peptidyl-lysine acetylation; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0007219; P:Notch signaling pathway; TAS:Reactome.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; TAS:Reactome.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0007221; P:positive regulation of transcription of Notch receptor target; TAS:Reactome.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0032481; P:positive regulation of type I interferon production; TAS:Reactome.
DR   GO; GO:0006473; P:protein acetylation; IDA:UniProtKB.
DR   GO; GO:0006461; P:protein complex assembly; TAS:ProtInc.
DR   GO; GO:0031648; P:protein destabilization; IMP:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; TAS:Reactome.
DR   GO; GO:1900034; P:regulation of cellular response to heat; TAS:Reactome.
DR   GO; GO:0019216; P:regulation of lipid metabolic process; TAS:Reactome.
DR   GO; GO:0045637; P:regulation of myeloid cell differentiation; TAS:Reactome.
DR   GO; GO:0008589; P:regulation of smoothened signaling pathway; TAS:BHF-UCL.
DR   GO; GO:0061418; P:regulation of transcription from RNA polymerase II promoter in response to hypoxia; TAS:Reactome.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:HGNC.
DR   GO; GO:0001666; P:response to hypoxia; TAS:UniProtKB.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0002223; P:stimulatory C-type lectin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006367; P:transcription initiation from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   CDD; cd15802; RING_CBP-p300; 1.
DR   Gene3D; 1.10.1630.10; -; 1.
DR   Gene3D; 1.20.1020.10; -; 2.
DR   Gene3D; 1.20.920.10; -; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR001487; Bromodomain.
DR   InterPro; IPR036427; Bromodomain-like_sf.
DR   InterPro; IPR018359; Bromodomain_CS.
DR   InterPro; IPR031162; CBP_P300_HAT.
DR   InterPro; IPR013178; Histone_AcTrfase_Rtt109/CBP.
DR   InterPro; IPR003101; KIX_dom.
DR   InterPro; IPR036529; KIX_dom_sf.
DR   InterPro; IPR009110; Nuc_rcpt_coact.
DR   InterPro; IPR014744; Nuc_rcpt_coact_CREBbp.
DR   InterPro; IPR037073; Nuc_rcpt_coact_CREBbp_sf.
DR   InterPro; IPR010303; RING_CBP-p300.
DR   InterPro; IPR035898; TAZ_dom_sf.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR000197; Znf_TAZ.
DR   InterPro; IPR000433; Znf_ZZ.
DR   Pfam; PF00439; Bromodomain; 1.
DR   Pfam; PF09030; Creb_binding; 1.
DR   Pfam; PF06001; DUF902; 1.
DR   Pfam; PF08214; HAT_KAT11; 1.
DR   Pfam; PF02172; KIX; 1.
DR   Pfam; PF02135; zf-TAZ; 2.
DR   Pfam; PF00569; ZZ; 1.
DR   PRINTS; PR00503; BROMODOMAIN.
DR   SMART; SM00297; BROMO; 1.
DR   SMART; SM01250; KAT11; 1.
DR   SMART; SM00551; ZnF_TAZ; 2.
DR   SMART; SM00291; ZnF_ZZ; 1.
DR   SUPFAM; SSF47040; SSF47040; 1.
DR   SUPFAM; SSF47370; SSF47370; 1.
DR   SUPFAM; SSF57933; SSF57933; 2.
DR   SUPFAM; SSF69125; SSF69125; 1.
DR   PROSITE; PS00633; BROMODOMAIN_1; 1.
DR   PROSITE; PS50014; BROMODOMAIN_2; 1.
DR   PROSITE; PS51727; CBP_P300_HAT; 1.
DR   PROSITE; PS50952; KIX; 1.
DR   PROSITE; PS50134; ZF_TAZ; 2.
DR   PROSITE; PS01357; ZF_ZZ_1; 1.
DR   PROSITE; PS50135; ZF_ZZ_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Acyltransferase;
KW   Alternative splicing; Biological rhythms; Bromodomain;
KW   Chromosomal rearrangement; Complete proteome; Cytoplasm;
KW   Disease mutation; Host-virus interaction; Isopeptide bond;
KW   Metal-binding; Methylation; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Transcription; Transcription regulation;
KW   Transferase; Ubl conjugation; Zinc; Zinc-finger.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22814378}.
FT   CHAIN         2   2442       CREB-binding protein.
FT                                /FTId=PRO_0000211190.
FT   DOMAIN      587    666       KIX. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00311}.
FT   DOMAIN     1103   1175       Bromo. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00035}.
FT   DOMAIN     1323   1700       CBP/p300-type HAT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01065}.
FT   ZN_FING     347    433       TAZ-type 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00203}.
FT   ZN_FING    1701   1744       ZZ-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00228}.
FT   ZN_FING    1765   1846       TAZ-type 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00203}.
FT   REGION      227    410       Interaction with SRCAP.
FT                                {ECO:0000269|PubMed:10347196}.
FT   REGION     1124   1170       Interaction with histone.
FT                                {ECO:0000269|PubMed:24361270}.
FT   REGION     1162   1180       Interaction with ASF1A.
FT                                {ECO:0000269|PubMed:24616510}.
FT   REGION     1433   1435       Interaction with histone.
FT                                {ECO:0000250|UniProtKB:Q09472}.
FT   REGION     1434   1436       Acetyl-CoA binding.
FT                                {ECO:0000250|UniProtKB:Q09472}.
FT   REGION     1446   1447       Acetyl-CoA binding.
FT                                {ECO:0000250|UniProtKB:Q09472}.
FT   REGION     1460   1891       Interaction with TRERF1.
FT                                {ECO:0000269|PubMed:11349124}.
FT   COMPBIAS   1061   1064       Poly-Glu.
FT   COMPBIAS   1199   1487       Cys/His-rich.
FT   COMPBIAS   1555   1562       Poly-Glu.
FT   COMPBIAS   1943   1948       Poly-Pro.
FT   COMPBIAS   1967   1970       Poly-Gln.
FT   COMPBIAS   2081   2085       Poly-Gln.
FT   COMPBIAS   2199   2216       Poly-Gln.
FT   COMPBIAS   2245   2248       Poly-Gln.
FT   COMPBIAS   2297   2300       Poly-Gln.
FT   METAL       363    363       Zinc 1. {ECO:0000250}.
FT   METAL       367    367       Zinc 1. {ECO:0000250}.
FT   METAL       380    380       Zinc 1. {ECO:0000250}.
FT   METAL       385    385       Zinc 1. {ECO:0000250}.
FT   METAL       394    394       Zinc 2. {ECO:0000250}.
FT   METAL       398    398       Zinc 2. {ECO:0000250}.
FT   METAL       404    404       Zinc 2. {ECO:0000250}.
FT   METAL       409    409       Zinc 2. {ECO:0000250}.
FT   METAL       418    418       Zinc 3. {ECO:0000250}.
FT   METAL       422    422       Zinc 3. {ECO:0000250}.
FT   METAL       427    427       Zinc 3. {ECO:0000250}.
FT   METAL       430    430       Zinc 3. {ECO:0000250}.
FT   BINDING    1493   1493       Acetyl-CoA; via carbonyl oxygen.
FT                                {ECO:0000250|UniProtKB:Q09472}.
FT   BINDING    1498   1498       Acetyl-CoA.
FT                                {ECO:0000250|UniProtKB:Q09472}.
FT   BINDING    1502   1502       Acetyl-CoA.
FT                                {ECO:0000250|UniProtKB:Q09472}.
FT   SITE         29     30       Breakpoint for translocation to form
FT                                KAT6B-CREBBP.
FT   SITE        266    267       Breakpoint for translocation to form
FT                                KAT6A-CREBBP.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22814378}.
FT   MOD_RES     121    121       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231}.
FT   MOD_RES     220    220       Omega-N-methylarginine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES     601    601       Omega-N-methylated arginine.
FT                                {ECO:0000250}.
FT   MOD_RES     625    625       Omega-N-methylated arginine.
FT                                {ECO:0000250}.
FT   MOD_RES     657    657       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P45481}.
FT   MOD_RES    1014   1014       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1030   1030       Phosphoserine.
FT                                {ECO:0000244|PubMed:17525332}.
FT   MOD_RES    1076   1076       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1216   1216       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1382   1382       Phosphoserine; by IKKA.
FT                                {ECO:0000269|PubMed:17434128}.
FT   MOD_RES    1386   1386       Phosphoserine; by IKKA.
FT                                {ECO:0000269|PubMed:17434128}.
FT   MOD_RES    1583   1583       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1591   1591       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1592   1592       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1595   1595       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1597   1597       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1741   1741       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1744   1744       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1763   1763       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2063   2063       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2076   2076       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES    2079   2079       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES    2351   2351       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P45481}.
FT   CROSSLNK    998    998       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO1).
FT                                {ECO:0000250|UniProtKB:P45481}.
FT   CROSSLNK   1033   1033       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO1).
FT                                {ECO:0000250|UniProtKB:P45481}.
FT   CROSSLNK   1056   1056       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO1).
FT                                {ECO:0000250|UniProtKB:P45481}.
FT   VAR_SEQ     406    444       VAHCASSRQIISHWKNCTRHDCPVCLPLKNASDKRNQQT
FT                                -> A (in isoform 2). {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_045700.
FT   VARIANT     503    503       Q -> H (in dbSNP:rs748447855).
FT                                {ECO:0000269|PubMed:25388907}.
FT                                /FTId=VAR_072912.
FT   VARIANT     532    532       P -> T (in dbSNP:rs902901184).
FT                                {ECO:0000269|PubMed:25388907}.
FT                                /FTId=VAR_072913.
FT   VARIANT     546    546       I -> N. {ECO:0000269|PubMed:25388907}.
FT                                /FTId=VAR_072914.
FT   VARIANT     650    650       Y -> F (in RSTS1).
FT                                {ECO:0000269|PubMed:25388907}.
FT                                /FTId=VAR_072915.
FT   VARIANT     789    789       A -> T (in RSTS1; dbSNP:rs746728741).
FT                                {ECO:0000269|PubMed:25388907}.
FT                                /FTId=VAR_072916.
FT   VARIANT     910    910       T -> A (in RSTS1; incomplete;
FT                                dbSNP:rs143247685).
FT                                {ECO:0000269|PubMed:20684013}.
FT                                /FTId=VAR_072917.
FT   VARIANT    1175   1175       Y -> C (in RSTS1; mild form; impairs
FT                                binding to ASF1A and acetylated histone
FT                                H3; dbSNP:rs28937315).
FT                                {ECO:0000269|PubMed:12114483,
FT                                ECO:0000269|PubMed:24616510,
FT                                ECO:0000269|PubMed:25388907}.
FT                                /FTId=VAR_037305.
FT   VARIANT    1278   1278       E -> A (in RSTS1).
FT                                {ECO:0000269|PubMed:25388907}.
FT                                /FTId=VAR_072918.
FT   VARIANT    1278   1278       E -> K (in RSTS1; abolishes
FT                                acetyltransferase activity;
FT                                dbSNP:rs267606752).
FT                                {ECO:0000269|PubMed:12566391,
FT                                ECO:0000269|PubMed:15706485}.
FT                                /FTId=VAR_035080.
FT   VARIANT    1378   1378       R -> P (in RSTS1; abolishes
FT                                acetyltransferase activity and the
FT                                ability of transactivate CREB;
FT                                dbSNP:rs121434626).
FT                                {ECO:0000269|PubMed:11331617,
FT                                ECO:0000269|PubMed:25388907}.
FT                                /FTId=VAR_015578.
FT   VARIANT    1406   1406       D -> Y (in RSTS1).
FT                                {ECO:0000269|PubMed:25388907}.
FT                                /FTId=VAR_072919.
FT   VARIANT    1414   1414       V -> I (in dbSNP:rs130015).
FT                                /FTId=VAR_027953.
FT   VARIANT    1415   1415       Q -> P (in RSTS1).
FT                                {ECO:0000269|PubMed:25388907}.
FT                                /FTId=VAR_072920.
FT   VARIANT    1447   1447       T -> I (in RSTS1).
FT                                {ECO:0000269|PubMed:15706485}.
FT                                /FTId=VAR_035081.
FT   VARIANT    1450   1450       Y -> H (in RSTS1).
FT                                {ECO:0000269|PubMed:15706485}.
FT                                /FTId=VAR_035082.
FT   VARIANT    1470   1470       H -> R (in RSTS1; dbSNP:rs797044860).
FT                                {ECO:0000269|PubMed:15706485}.
FT                                /FTId=VAR_035083.
FT   VARIANT    1475   1475       P -> T (in RSTS1).
FT                                {ECO:0000269|PubMed:25388907}.
FT                                /FTId=VAR_072921.
FT   VARIANT    1503   1503       Y -> F (in RSTS1).
FT                                {ECO:0000269|PubMed:25388907}.
FT                                /FTId=VAR_072922.
FT   VARIANT    1507   1507       L -> P (in RSTS1).
FT                                {ECO:0000269|PubMed:25388907}.
FT                                /FTId=VAR_072923.
FT   VARIANT    1543   1543       D -> N (in RSTS1).
FT                                {ECO:0000269|PubMed:25388907}.
FT                                /FTId=VAR_072924.
FT   VARIANT    1664   1664       R -> H (in RSTS1; abolishes
FT                                acetyltransferase activity).
FT                                {ECO:0000269|PubMed:12566391,
FT                                ECO:0000269|PubMed:15706485}.
FT                                /FTId=VAR_035084.
FT   VARIANT    1710   1710       C -> R (probable disease-associated
FT                                mutation found in patient with growth
FT                                retardation, craniofacial dysmorphism and
FT                                additional Rubinstein-Taybi-like
FT                                features; de novo mutation).
FT                                {ECO:0000269|PubMed:27311832}.
FT                                /FTId=VAR_078557.
FT   VARIANT    1747   1747       L -> R (probable disease-associated
FT                                mutation found in patient with growth
FT                                retardation, craniofacial dysmorphism and
FT                                additional Rubinstein-Taybi-like
FT                                features; de novo mutation).
FT                                {ECO:0000269|PubMed:27311832}.
FT                                /FTId=VAR_078558.
FT   VARIANT    1786   1786       R -> P (probable disease-associated
FT                                mutation found in patient with growth
FT                                retardation, craniofacial dysmorphism and
FT                                additional Rubinstein-Taybi-like
FT                                features; de novo mutation).
FT                                {ECO:0000269|PubMed:27311832}.
FT                                /FTId=VAR_078559.
FT   VARIANT    1819   1819       C -> F (probable disease-associated
FT                                mutation found in patient with growth
FT                                retardation, craniofacial dysmorphism and
FT                                additional Rubinstein-Taybi-like
FT                                features; de novo mutation).
FT                                {ECO:0000269|PubMed:27311832}.
FT                                /FTId=VAR_078560.
FT   VARIANT    1826   1826       C -> W (probable disease-associated
FT                                mutation found in patient with growth
FT                                retardation, craniofacial dysmorphism and
FT                                additional Rubinstein-Taybi-like
FT                                features; de novo mutation).
FT                                {ECO:0000269|PubMed:27311832}.
FT                                /FTId=VAR_078561.
FT   VARIANT    1838   1838       C -> Y (probable disease-associated
FT                                mutation found in patient with growth
FT                                retardation, craniofacial dysmorphism and
FT                                additional Rubinstein-Taybi-like
FT                                features; de novo mutation).
FT                                {ECO:0000269|PubMed:27311832}.
FT                                /FTId=VAR_078562.
FT   VARIANT    1867   1867       R -> Q (probable disease-associated
FT                                mutation found in patient with growth
FT                                retardation, craniofacial dysmorphism and
FT                                additional Rubinstein-Taybi-like
FT                                features; de novo mutation).
FT                                {ECO:0000269|PubMed:27311832}.
FT                                /FTId=VAR_078563.
FT   VARIANT    1867   1867       R -> W (probable disease-associated
FT                                mutation found in patient with growth
FT                                retardation, craniofacial dysmorphism and
FT                                additional Rubinstein-Taybi-like
FT                                features; de novo mutation).
FT                                {ECO:0000269|PubMed:27311832}.
FT                                /FTId=VAR_078564.
FT   VARIANT    1868   1868       R -> W (probable disease-associated
FT                                mutation found in patient with growth
FT                                retardation, craniofacial dysmorphism and
FT                                additional Rubinstein-Taybi-like
FT                                features; de novo mutation;
FT                                dbSNP:rs886039491).
FT                                {ECO:0000269|PubMed:27311832}.
FT                                /FTId=VAR_078565.
FT   VARIANT    1872   1872       M -> V (probable disease-associated
FT                                mutation found in patient with growth
FT                                retardation, craniofacial dysmorphism and
FT                                additional Rubinstein-Taybi-like
FT                                features; de novo mutation;
FT                                dbSNP:rs797045037).
FT                                {ECO:0000269|PubMed:27311832}.
FT                                /FTId=VAR_078566.
FT   MUTAGEN    1116   1116       D->R: Impairs binding to acetylated
FT                                histones. {ECO:0000269|PubMed:24616510}.
FT   MUTAGEN    1126   1126       F->A: Impairs binding to acetylated
FT                                histones. {ECO:0000269|PubMed:24616510}.
FT   MUTAGEN    1162   1162       N->E,R: Abolishes interaction with ASF1A.
FT                                {ECO:0000269|PubMed:24616510}.
FT   MUTAGEN    1165   1165       W->A: Abolishes interaction with ASF1A.
FT                                {ECO:0000269|PubMed:24616510}.
FT   MUTAGEN    1170   1170       K->E: Impairs binding to acetylated
FT                                histones. {ECO:0000269|PubMed:24616510}.
FT   MUTAGEN    1179   1179       S->I: Impairs interaction with ASF1A.
FT                                {ECO:0000269|PubMed:24616510}.
FT   MUTAGEN    1180   1180       K->E: Abolishes interaction with ASF1A.
FT                                {ECO:0000269|PubMed:24616510}.
FT   MUTAGEN    1183   1183       E->R: Abolishes interaction with ASF1A.
FT                                {ECO:0000269|PubMed:24616510}.
FT   CONFLICT   1511   1513       FAE -> NSG (in Ref. 2; AAC51340).
FT                                {ECO:0000305}.
FT   CONFLICT   1724   1725       ED -> VV (in Ref. 2; AAC51340).
FT                                {ECO:0000305}.
FT   CONFLICT   1770   1770       L -> V (in Ref. 1; AAC51770).
FT                                {ECO:0000305}.
FT   CONFLICT   1789   1789       N -> F (in Ref. 2; AAC51340).
FT                                {ECO:0000305}.
FT   CONFLICT   1812   1812       T -> P (in Ref. 2; AAC51340).
FT                                {ECO:0000305}.
FT   HELIX        69     73       {ECO:0000244|PDB:1RDT}.
FT   HELIX       377    379       {ECO:0000244|PDB:1LIQ}.
FT   TURN        383    388       {ECO:0000244|PDB:1LIQ}.
FT   HELIX       391    395       {ECO:0000244|PDB:1LIQ}.
FT   TURN        593    596       {ECO:0000244|PDB:2KWF}.
FT   HELIX       598    612       {ECO:0000244|PDB:2KWF}.
FT   TURN        618    622       {ECO:0000244|PDB:2KWF}.
FT   HELIX       624    642       {ECO:0000244|PDB:2KWF}.
FT   HELIX       647    669       {ECO:0000244|PDB:2KWF}.
FT   TURN        670    672       {ECO:0000244|PDB:2KWF}.
FT   HELIX      1087   1102       {ECO:0000244|PDB:5I86}.
FT   TURN       1105   1108       {ECO:0000244|PDB:5I86}.
FT   HELIX      1109   1111       {ECO:0000244|PDB:5I86}.
FT   HELIX      1117   1120       {ECO:0000244|PDB:5I86}.
FT   HELIX      1125   1128       {ECO:0000244|PDB:5I86}.
FT   HELIX      1135   1143       {ECO:0000244|PDB:5I86}.
FT   STRAND     1146   1149       {ECO:0000244|PDB:2L85}.
FT   HELIX      1150   1167       {ECO:0000244|PDB:5I86}.
FT   TURN       1169   1171       {ECO:0000244|PDB:1JSP}.
FT   HELIX      1173   1195       {ECO:0000244|PDB:5I86}.
FT   STRAND     1214   1218       {ECO:0000244|PDB:5I8G}.
FT   STRAND     1226   1230       {ECO:0000244|PDB:5I8G}.
FT   TURN       1231   1233       {ECO:0000244|PDB:5I8G}.
FT   STRAND     1234   1237       {ECO:0000244|PDB:5I8G}.
FT   TURN       1238   1240       {ECO:0000244|PDB:5I8G}.
FT   STRAND     1266   1272       {ECO:0000244|PDB:5I8G}.
FT   STRAND     1280   1282       {ECO:0000244|PDB:5I8G}.
FT   TURN       1284   1286       {ECO:0000244|PDB:5I8G}.
FT   STRAND     1289   1291       {ECO:0000244|PDB:5I8G}.
FT   HELIX      1292   1295       {ECO:0000244|PDB:5I8G}.
FT   TURN       1309   1311       {ECO:0000244|PDB:5I8G}.
FT   TURN       1708   1710       {ECO:0000244|PDB:2N1A}.
FT   STRAND     1718   1721       {ECO:0000244|PDB:2N1A}.
FT   STRAND     1725   1728       {ECO:0000244|PDB:2N1A}.
FT   HELIX      1730   1736       {ECO:0000244|PDB:2N1A}.
FT   STRAND     1742   1744       {ECO:0000244|PDB:2N1A}.
FT   HELIX      1765   1784       {ECO:0000244|PDB:2KJE}.
FT   HELIX      1793   1805       {ECO:0000244|PDB:2KJE}.
FT   TURN       1811   1815       {ECO:0000244|PDB:2KJE}.
FT   HELIX      1817   1832       {ECO:0000244|PDB:2KJE}.
FT   HELIX      1841   1853       {ECO:0000244|PDB:2KJE}.
FT   HELIX      2066   2072       {ECO:0000244|PDB:1ZOQ}.
FT   HELIX      2080   2091       {ECO:0000244|PDB:1ZOQ}.
FT   HELIX      2094   2103       {ECO:0000244|PDB:1ZOQ}.
FT   TURN       2104   2106       {ECO:0000244|PDB:1ZOQ}.
SQ   SEQUENCE   2442 AA;  265351 MW;  3BEA9B8558BA1A5E CRC64;
     MAENLLDGPP NPKRAKLSSP GFSANDSTDF GSLFDLENDL PDELIPNGGE LGLLNSGNLV
     PDAASKHKQL SELLRGGSGS SINPGIGNVS ASSPVQQGLG GQAQGQPNSA NMASLSAMGK
     SPLSQGDSSA PSLPKQAAST SGPTPAASQA LNPQAQKQVG LATSSPATSQ TGPGICMNAN
     FNQTHPGLLN SNSGHSLINQ ASQGQAQVMN GSLGAAGRGR GAGMPYPTPA MQGASSSVLA
     ETLTQVSPQM TGHAGLNTAQ AGGMAKMGIT GNTSPFGQPF SQAGGQPMGA TGVNPQLASK
     QSMVNSLPTF PTDIKNTSVT NVPNMSQMQT SVGIVPTQAI ATGPTADPEK RKLIQQQLVL
     LLHAHKCQRR EQANGEVRAC SLPHCRTMKN VLNHMTHCQA GKACQVAHCA SSRQIISHWK
     NCTRHDCPVC LPLKNASDKR NQQTILGSPA SGIQNTIGSV GTGQQNATSL SNPNPIDPSS
     MQRAYAALGL PYMNQPQTQL QPQVPGQQPA QPQTHQQMRT LNPLGNNPMN IPAGGITTDQ
     QPPNLISESA LPTSLGATNP LMNDGSNSGN IGTLSTIPTA APPSSTGVRK GWHEHVTQDL
     RSHLVHKLVQ AIFPTPDPAA LKDRRMENLV AYAKKVEGDM YESANSRDEY YHLLAEKIYK
     IQKELEEKRR SRLHKQGILG NQPALPAPGA QPPVIPQAQP VRPPNGPLSL PVNRMQVSQG
     MNSFNPMSLG NVQLPQAPMG PRAASPMNHS VQMNSMGSVP GMAISPSRMP QPPNMMGAHT
     NNMMAQAPAQ SQFLPQNQFP SSSGAMSVGM GQPPAQTGVS QGQVPGAALP NPLNMLGPQA
     SQLPCPPVTQ SPLHPTPPPA STAAGMPSLQ HTTPPGMTPP QPAAPTQPST PVSSSGQTPT
     PTPGSVPSAT QTQSTPTVQA AAQAQVTPQP QTPVQPPSVA TPQSSQQQPT PVHAQPPGTP
     LSQAAASIDN RVPTPSSVAS AETNSQQPGP DVPVLEMKTE TQAEDTEPDP GESKGEPRSE
     MMEEDLQGAS QVKEETDIAE QKSEPMEVDE KKPEVKVEVK EEEESSSNGT ASQSTSPSQP
     RKKIFKPEEL RQALMPTLEA LYRQDPESLP FRQPVDPQLL GIPDYFDIVK NPMDLSTIKR
     KLDTGQYQEP WQYVDDVWLM FNNAWLYNRK TSRVYKFCSK LAEVFEQEID PVMQSLGYCC
     GRKYEFSPQT LCCYGKQLCT IPRDAAYYSY QNRYHFCEKC FTEIQGENVT LGDDPSQPQT
     TISKDQFEKK KNDTLDPEPF VDCKECGRKM HQICVLHYDI IWPSGFVCDN CLKKTGRPRK
     ENKFSAKRLQ TTRLGNHLED RVNKFLRRQN HPEAGEVFVR VVASSDKTVE VKPGMKSRFV
     DSGEMSESFP YRTKALFAFE EIDGVDVCFF GMHVQEYGSD CPPPNTRRVY ISYLDSIHFF
     RPRCLRTAVY HEILIGYLEY VKKLGYVTGH IWACPPSEGD DYIFHCHPPD QKIPKPKRLQ
     EWYKKMLDKA FAERIIHDYK DIFKQATEDR LTSAKELPYF EGDFWPNVLE ESIKELEQEE
     EERKKEESTA ASETTEGSQG DSKNAKKKNN KKTNKNKSSI SRANKKKPSM PNVSNDLSQK
     LYATMEKHKE VFFVIHLHAG PVINTLPPIV DPDPLLSCDL MDGRDAFLTL ARDKHWEFSS
     LRRSKWSTLC MLVELHTQGQ DRFVYTCNEC KHHVETRWHC TVCEDYDLCI NCYNTKSHAH
     KMVKWGLGLD DEGSSQGEPQ SKSPQESRRL SIQRCIQSLV HACQCRNANC SLPSCQKMKR
     VVQHTKGCKR KTNGGCPVCK QLIALCCYHA KHCQENKCPV PFCLNIKHKL RQQQIQHRLQ
     QAQLMRRRMA TMNTRNVPQQ SLPSPTSAPP GTPTQQPSTP QTPQPPAQPQ PSPVSMSPAG
     FPSVARTQPP TTVSTGKPTS QVPAPPPPAQ PPPAAVEAAR QIEREAQQQQ HLYRVNINNS
     MPPGRTGMGT PGSQMAPVSL NVPRPNQVSG PVMPSMPPGQ WQQAPLPQQQ PMPGLPRPVI
     SMQAQAAVAG PRMPSVQPPR SISPSALQDL LRTLKSPSSP QQQQQVLNIL KSNPQLMAAF
     IKQRTAKYVA NQPGMQPQPG LQSQPGMQPQ PGMHQQPSLQ NLNAMQAGVP RPGVPPQQQA
     MGGLNPQGQA LNIMNPGHNP NMASMNPQYR EMLRRQLLQQ QQQQQQQQQQ QQQQQQGSAG
     MAGGMAGHGQ FQQPQGPGGY PPAMQQQQRM QQHLPLQGSS MGQMAAQMGQ LGQMGQPGLG
     ADSTPNIQQA LQQRILQQQQ MKQQIGSPGQ PNPMSPQQHM LSGQPQASHL PGQQIATSLS
     NQVRSPAPVQ SPRPQSQPPH SSPSPRIQPQ PSPHHVSPQT GSPHPGLAVT MASSIDQGHL
     GNPEQSAMLP QLNTPSRSAL SSELSLVGDT TGDTLEKFVE GL
//
ID   ELF4_HUMAN              Reviewed;         663 AA.
AC   Q99607; D3DTG1; O60435;
DT   21-JUN-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1997, sequence version 1.
DT   31-JAN-2018, entry version 153.
DE   RecName: Full=ETS-related transcription factor Elf-4;
DE   AltName: Full=E74-like factor 4;
DE   AltName: Full=Myeloid Elf-1-like factor;
GN   Name=ELF4 {ECO:0000312|EMBL:CAI42882.1};
GN   Synonyms=ELFR {ECO:0000312|EMBL:AAC17452.1},
GN   MEF {ECO:0000312|EMBL:AAB53693.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:AAB53693.1}
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Promyelocytic leukemia {ECO:0000269|PubMed:8895518};
RX   PubMed=8895518;
RA   Miyazaki Y., Sun X., Uchida H., Zhang J., Nimer S.;
RT   "MEF, a novel transcription factor with an Elf-1 like DNA binding
RT   domain but distinct transcriptional activating properties.";
RL   Oncogene 13:1721-1729(1996).
RN   [2] {ECO:0000305, ECO:0000312|EMBL:AAC17452.1}
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Ewing sarcoma {ECO:0000269|PubMed:9524226};
RX   PubMed=9524226; DOI=10.1016/S0378-1119(98)00022-5;
RA   Aryee D.N.T., Petermann R., Kos K., Henn T., Haas O.A., Kovar H.;
RT   "Cloning of a novel human ELF-1-related ETS transcription factor,
RT   ELFR, its characterization and chromosomal assignment relative to ELF-
RT   1.";
RL   Gene 210:71-78(1998).
RN   [3] {ECO:0000305, ECO:0000312|EMBL:CAI42882.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5] {ECO:0000312|EMBL:AAH17194.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta {ECO:0000312|EMBL:AAH17194.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6] {ECO:0000305}
RP   FUNCTION, AND INTERACTION WITH RUNX1.
RX   PubMed=10207087; DOI=10.1128/MCB.19.5.3635;
RA   Mao S., Frank R.C., Zhang J., Miyazaki Y., Nimer S.D.;
RT   "Functional and physical interactions between AML1 proteins and an ETS
RT   protein, MEF: implications for the pathogenesis of t(8;21)-positive
RT   leukemias.";
RL   Mol. Cell. Biol. 19:3635-3644(1999).
RN   [7] {ECO:0000305}
RP   FUNCTION, AND INDUCTION.
RX   PubMed=14625302; DOI=10.1074/jbc.M307524200;
RA   Hedvat C.V., Yao J., Sokolic R.A., Nimer S.D.;
RT   "Myeloid ELF1-like factor is a potent activator of interleukin-8
RT   expression in hematopoietic cells.";
RL   J. Biol. Chem. 279:6395-6400(2004).
RN   [8] {ECO:0000305}
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PML.
RX   PubMed=14976184; DOI=10.1074/jbc.M312439200;
RA   Suico M.A., Yoshida H., Seki Y., Uchikawa T., Lu Z., Shuto T.,
RA   Matsuzaki K., Nakao M., Li J.-D., Kai H.;
RT   "Myeloid Elf-1-like factor, an ETS transcription factor, up-regulates
RT   lysozyme transcription in epithelial cells through interaction with
RT   promyelocytic leukemia protein.";
RL   J. Biol. Chem. 279:19091-19098(2004).
RN   [9]
RP   CHROMOSOMAL TRANSLOCATION WITH ERG.
RX   PubMed=16303180; DOI=10.1016/j.leukres.2005.10.014;
RA   Moore S.D., Offor O., Ferry J.A., Amrein P.C., Morton C.C.,
RA   Dal Cin P.;
RT   "ELF4 is fused to ERG in a case of acute myeloid leukemia with a
RT   t(X;21)(q25-26;q22).";
RL   Leuk. Res. 30:1037-1042(2006).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-151 AND SER-648, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   FUNCTION.
RX   PubMed=19380490; DOI=10.1128/MCB.01551-08;
RA   Sashida G., Liu Y., Elf S., Miyata Y., Ohyashiki K., Izumi M.,
RA   Menendez S., Nimer S.D.;
RT   "ELF4/MEF activates MDM2 expression and blocks oncogene-induced p16
RT   activation to promote transformation.";
RL   Mol. Cell. Biol. 29:3687-3699(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-648, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-648, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-151; SER-188 AND
RP   SER-641, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
CC   -!- FUNCTION: Transcriptional activator that binds to DNA sequences
CC       containing the consensus 5'-WGGA-3'. Transactivates promoters of
CC       the hematopoietic growth factor genes CSF2, IL3, IL8, and of the
CC       bovine lysozyme gene. Acts synergistically with RUNX1 to
CC       transactivate the IL3 promoter (By similarity). Also
CC       transactivates the PRF1 promoter in natural killer (NK) cells.
CC       Plays a role in the development and function of NK and NK T-cells
CC       and in innate immunity. Controls the proliferation and homing of
CC       CD8+ T-cells via the Kruppel-like factors KLF4 and KLF2 (By
CC       similarity). Controls cell senescence in a p53-dependent manner.
CC       Can also promote cellular transformation through inhibition of the
CC       p16 pathway. {ECO:0000250, ECO:0000269|PubMed:10207087,
CC       ECO:0000269|PubMed:14625302, ECO:0000269|PubMed:14976184,
CC       ECO:0000269|PubMed:19380490, ECO:0000269|PubMed:8895518,
CC       ECO:0000269|PubMed:9524226}.
CC   -!- SUBUNIT: Interacts with RUNX1 (via the Runt domain); the
CC       interaction transactivates the IL3 promoter. Interacts (via its C-
CC       terminus) with PML; the interaction translocates ELF4 to PML
CC       nuclear bodies and enhances transactivation of LYZ.
CC       {ECO:0000269|PubMed:10207087, ECO:0000269|PubMed:14976184}.
CC   -!- SUBCELLULAR LOCATION: Nucleus, PML body
CC       {ECO:0000269|PubMed:14976184}. Note=Accumulation into PML nuclear
CC       bodies is mediated by PML.
CC   -!- TISSUE SPECIFICITY: Abundantly expressed in the placenta and in a
CC       variety of myeloid leukemia cell lines. Moderate levels of
CC       expression in heart, lung, spleen, thymus, peripheral blood
CC       lymphocytes, ovary and colon. Lower levels of expression in Jurkat
CC       T-cells and other T-cell lines and no expression in brain.
CC       {ECO:0000269|PubMed:8895518, ECO:0000269|PubMed:9524226}.
CC   -!- INDUCTION: By ponisterone A in erythroleukemia cells.
CC       {ECO:0000269|PubMed:14625302}.
CC   -!- DISEASE: Note=A chromosomal aberration involving ELF4 has been
CC       found in a case of acute myeloid leukemia (AML). Translocation
CC       t(X;21)(q25-26;q22) with ERG. {ECO:0000269|PubMed:16303180}.
CC   -!- SIMILARITY: Belongs to the ETS family. {ECO:0000255}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC17452.1; Type=Frameshift; Positions=334, 412; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U32645; AAB53693.1; -; mRNA.
DR   EMBL; AF000670; AAC17452.1; ALT_FRAME; mRNA.
DR   EMBL; AL136450; CAI42882.1; -; Genomic_DNA.
DR   EMBL; Z81363; CAI42882.1; JOINED; Genomic_DNA.
DR   EMBL; Z81363; CAI42371.1; -; Genomic_DNA.
DR   EMBL; AL136450; CAI42371.1; JOINED; Genomic_DNA.
DR   EMBL; CH471107; EAX11813.1; -; Genomic_DNA.
DR   EMBL; CH471107; EAX11814.1; -; Genomic_DNA.
DR   EMBL; BC017194; AAH17194.1; -; mRNA.
DR   CCDS; CCDS14617.1; -.
DR   RefSeq; NP_001120669.1; NM_001127197.1.
DR   RefSeq; NP_001412.1; NM_001421.3.
DR   RefSeq; XP_005262446.1; XM_005262389.3.
DR   UniGene; Hs.271940; -.
DR   ProteinModelPortal; Q99607; -.
DR   SMR; Q99607; -.
DR   BioGrid; 108315; 8.
DR   IntAct; Q99607; 4.
DR   STRING; 9606.ENSP00000311280; -.
DR   iPTMnet; Q99607; -.
DR   PhosphoSitePlus; Q99607; -.
DR   BioMuta; ELF4; -.
DR   DMDM; 68052244; -.
DR   EPD; Q99607; -.
DR   MaxQB; Q99607; -.
DR   PaxDb; Q99607; -.
DR   PeptideAtlas; Q99607; -.
DR   PRIDE; Q99607; -.
DR   DNASU; 2000; -.
DR   Ensembl; ENST00000308167; ENSP00000311280; ENSG00000102034.
DR   Ensembl; ENST00000335997; ENSP00000338608; ENSG00000102034.
DR   GeneID; 2000; -.
DR   KEGG; hsa:2000; -.
DR   UCSC; uc004evd.5; human.
DR   CTD; 2000; -.
DR   DisGeNET; 2000; -.
DR   EuPathDB; HostDB:ENSG00000102034.16; -.
DR   GeneCards; ELF4; -.
DR   HGNC; HGNC:3319; ELF4.
DR   HPA; HPA058595; -.
DR   HPA; HPA060277; -.
DR   MalaCards; ELF4; -.
DR   MIM; 300775; gene.
DR   neXtProt; NX_Q99607; -.
DR   OpenTargets; ENSG00000102034; -.
DR   Orphanet; 632; Short stature due to isolated growth hormone deficiency with X-linked hypogammaglobulinemia.
DR   PharmGKB; PA27747; -.
DR   eggNOG; KOG3804; Eukaryota.
DR   eggNOG; ENOG4111K4J; LUCA.
DR   GeneTree; ENSGT00760000118996; -.
DR   HOGENOM; HOG000049253; -.
DR   HOVERGEN; HBG007183; -.
DR   InParanoid; Q99607; -.
DR   KO; K09428; -.
DR   OMA; PTSLIKM; -.
DR   OrthoDB; EOG091G0B4I; -.
DR   PhylomeDB; Q99607; -.
DR   TreeFam; TF318679; -.
DR   SIGNOR; Q99607; -.
DR   ChiTaRS; ELF4; human.
DR   GeneWiki; ELF4; -.
DR   GenomeRNAi; 2000; -.
DR   PRO; PR:Q99607; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000102034; -.
DR   CleanEx; HS_ELF4; -.
DR   ExpressionAtlas; Q99607; baseline and differential.
DR   Genevisible; Q99607; HS.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0016605; C:PML body; IDA:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II proximal promoter sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0001077; F:transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0045087; P:innate immune response; IEA:InterPro.
DR   GO; GO:0001787; P:natural killer cell proliferation; ISS:UniProtKB.
DR   GO; GO:0001866; P:NK T cell proliferation; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   Gene3D; 1.10.10.10; -; 1.
DR   InterPro; IPR033070; Elf4.
DR   InterPro; IPR000418; Ets_dom.
DR   InterPro; IPR022084; TF_Elf_N.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   PANTHER; PTHR11849:SF170; PTHR11849:SF170; 1.
DR   Pfam; PF12310; Elf-1_N; 1.
DR   Pfam; PF00178; Ets; 1.
DR   PRINTS; PR00454; ETSDOMAIN.
DR   SMART; SM00413; ETS; 1.
DR   SUPFAM; SSF46785; SSF46785; 1.
DR   PROSITE; PS00345; ETS_DOMAIN_1; 1.
DR   PROSITE; PS00346; ETS_DOMAIN_2; 1.
DR   PROSITE; PS50061; ETS_DOMAIN_3; 1.
PE   1: Evidence at protein level;
KW   Activator; Chromosomal rearrangement; Complete proteome; DNA-binding;
KW   Nucleus; Phosphoprotein; Proto-oncogene; Reference proteome;
KW   Transcription; Transcription regulation.
FT   CHAIN         1    663       ETS-related transcription factor Elf-4.
FT                                /FTId=PRO_0000204089.
FT   DNA_BIND    209    291       ETS. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00237}.
FT   REGION       87    206       RUNX1-binding.
FT                                {ECO:0000269|PubMed:10207087}.
FT   SITE         25     26       Breakpoint for translocation to form
FT                                ELF4-ERG oncogene.
FT   MOD_RES     151    151       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     188    188       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     641    641       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     648    648       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231}.
FT   CONFLICT    293    294       MP -> IA (in Ref. 2; AAC17452).
FT                                {ECO:0000305}.
FT   CONFLICT    499    499       P -> L (in Ref. 2; AAC17452).
FT                                {ECO:0000305}.
SQ   SEQUENCE   663 AA;  70730 MW;  1696085D31B09BC5 CRC64;
     MAITLQPSDL IFEFASNGMD DDIHQLEDPS VFPAVIVEQV PYPDLLHLYS GLELDDVHNG
     IITDGTLCMT QDQILEGSFL LTDDNEATSH TMSTAEVLLN MESPSDILDE KQIFSTSEML
     PDSDPAPAVT LPNYLFPASE PDALNRAGDT SDQEGHSLEE KASREESAKK TGKSKKRIRK
     TKGNRSTSPV TDPSIPIRKK SKDGKGSTIY LWEFLLALLQ DRNTCPKYIK WTQREKGIFK
     LVDSKAVSKL WGKQKNKPDM NYETMGRALR YYYQRGILAK VEGQRLVYQF KEMPKDLVVI
     EDEDESSEAT AAPPQASTAS VASASTTRRT SSRVSSRSAP QGKGSSSWEK PKIQHVGLQP
     SASLELGPSL DEEIPTTSTM LVSPAEGQVK LTKAVSASSV PSNIHLGVAP VGSGSALTLQ
     TIPLTTVLTN GPPASTTAPT QLVLQSVPAA STFKDTFTLQ ASFPLNASFQ DSQVAAPGAP
     LILSGLPQLL AGANRPTNPA PPTVTGAGPA GPSSQPPGTV IAAFIRTSGT TAAPRVKEGP
     LRSSSYVQGM VTGAPMEGLL VPEETLRELL RDQAHLQPLP TQVVSRGSHN PSLLGNQTLS
     PPSRPTVGLT PVAELELSSG SGSLLMAEPS VTTSGSLLTR SPTPAPFSPF NPTSLIKMEP
     HDI
//
ID   A0A125SXW3_HUMAN        Unreviewed;       483 AA.
AC   A0A125SXW3;
DT   13-APR-2016, integrated into UniProtKB/TrEMBL.
DT   13-APR-2016, sequence version 1.
DT   28-FEB-2018, entry version 17.
DE   SubName: Full=Estrogen receptor alpha splice variant, ERalphai67 {ECO:0000313|EMBL:BAU46553.1};
GN   Name=ESR1 {ECO:0000313|EMBL:BAU46553.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAU46553.1};
RN   [1] {ECO:0000313|EMBL:BAU46553.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Uterus {ECO:0000313|EMBL:BAU46553.1};
RX   PubMed=26835991; DOI=10.1016/j.mce.2016.01.026;
RA   Hattori Y., Ishii H., Munetomo A., Watanabe H., Morita A., Sakuma Y.,
RA   Ozawa H.;
RT   "Human C-terminally truncated ER? variants resulting from the use of
RT   alternative exons in the ligand-binding domain.";
RL   Mol. Cell. Endocrinol. 425:111-122(2016).
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000256|PIRNR:PIRNR002527,
CC       ECO:0000256|SAAS:SAAS00982927}.
CC   -!- SIMILARITY: Belongs to the nuclear hormone receptor family. NR3
CC       subfamily. {ECO:0000256|PIRNR:PIRNR002527}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; LC120330; BAU46553.1; -; mRNA.
DR   RefSeq; XP_011533849.1; XM_011535547.2.
DR   UniGene; Hs.208124; -.
DR   UniGene; Hs.744830; -.
DR   PeptideAtlas; A0A125SXW3; -.
DR   GeneID; 2099; -.
DR   CTD; 2099; -.
DR   ChiTaRS; ESR1; human.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0030284; F:estrogen receptor activity; IEA:InterPro.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IEA:InterPro.
DR   GO; GO:0005496; F:steroid binding; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-UniRule.
DR   Gene3D; 3.30.50.10; -; 1.
DR   InterPro; IPR035500; NHR_like_dom_sf.
DR   InterPro; IPR000536; Nucl_hrmn_rcpt_lig-bd.
DR   InterPro; IPR001723; Nuclear_hrmn_rcpt.
DR   InterPro; IPR024178; Oest_rcpt/oest-rel_rcp.
DR   InterPro; IPR001292; Oestr_rcpt.
DR   InterPro; IPR001628; Znf_hrmn_rcpt.
DR   InterPro; IPR013088; Znf_NHR/GATA.
DR   Pfam; PF00104; Hormone_recep; 1.
DR   Pfam; PF02159; Oest_recep; 1.
DR   Pfam; PF00105; zf-C4; 1.
DR   PIRSF; PIRSF002527; ER-like_NR; 1.
DR   PRINTS; PR00543; OESTROGENR.
DR   PRINTS; PR00398; STRDHORMONER.
DR   PRINTS; PR00047; STROIDFINGER.
DR   SMART; SM00430; HOLI; 1.
DR   SMART; SM00399; ZnF_C4; 1.
DR   SUPFAM; SSF48508; SSF48508; 2.
DR   PROSITE; PS00031; NUCLEAR_REC_DBD_1; 1.
DR   PROSITE; PS51030; NUCLEAR_REC_DBD_2; 1.
PE   2: Evidence at transcript level;
KW   DNA-binding {ECO:0000256|PROSITE-ProRule:PRU00407,
KW   ECO:0000256|SAAS:SAAS00517091};
KW   Metal-binding {ECO:0000256|PROSITE-ProRule:PRU00407,
KW   ECO:0000256|SAAS:SAAS00517125};
KW   Nucleus {ECO:0000256|PIRNR:PIRNR002527,
KW   ECO:0000256|SAAS:SAAS00983050};
KW   Receptor {ECO:0000256|PIRNR:PIRNR002527,
KW   ECO:0000256|SAAS:SAAS00982657, ECO:0000313|EMBL:BAU46553.1};
KW   Transcription {ECO:0000256|PIRNR:PIRNR002527,
KW   ECO:0000256|SAAS:SAAS00982829};
KW   Transcription regulation {ECO:0000256|PIRNR:PIRNR002527,
KW   ECO:0000256|SAAS:SAAS00982829};
KW   Zinc {ECO:0000256|PROSITE-ProRule:PRU00407,
KW   ECO:0000256|SAAS:SAAS00517125};
KW   Zinc-finger {ECO:0000256|PROSITE-ProRule:PRU00407,
KW   ECO:0000256|SAAS:SAAS00517125}.
FT   DOMAIN      182    257       Nuclear receptor.
FT                                {ECO:0000259|PROSITE:PS51030}.
FT   DNA_BIND    182    257       Nuclear receptor. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00407}.
SQ   SEQUENCE   483 AA;  53748 MW;  2BD7CE2C94A8D1B9 CRC64;
     MTMTLHTKAS GMALLHQIQG NELEPLNRPQ LKIPLERPLG EVYLDSSKPA VYNYPEGAAY
     EFNAAAAANA QVYGQTGLPY GPGSEAAAFG SNGLGGFPPL NSVSPSPLML LHPPPQLSPF
     LQPHGQQVPY YLENEPSGYT VREAGPPAFY RPNSDNRRQG GRERLASTND KGSMAMESAK
     ETRYCAVCND YASGYHYGVW SCEGCKAFFK RSIQGHNDYM CPATNQCTID KNRRKSCQAC
     RLRKCYEVGM MKGGIRKDRR GGRMLKHKRQ RDDGEGRGEV GSAGDMRAAN LWPSPLMIKR
     SKKNSLALSL TADQMVSALL DAEPPILYSE YDPTRPFSEA SMMGLLTNLA DRELVHMINW
     AKRVPGFVDL TLHDQVHLLE CAWLEILMIG LVWRSMEHPG KLLFAPNLLL DRNQGKCVEG
     MVEIFDMLLA TSSRFRMMNL QGEEFVCLKS IILLNSVLTT GRPGDTLPCL AQWVTRPWRL
     AHC
//
ID   A8KAF4_HUMAN            Unreviewed;       594 AA.
AC   A8KAF4;
DT   04-DEC-2007, integrated into UniProtKB/TrEMBL.
DT   04-DEC-2007, sequence version 1.
DT   28-FEB-2018, entry version 77.
DE   RecName: Full=Estrogen receptor {ECO:0000256|PIRNR:PIRNR002527};
DE            Short=ER {ECO:0000256|PIRNR:PIRNR002527};
DE   AltName: Full=ER-alpha {ECO:0000256|PIRNR:PIRNR002527};
DE   AltName: Full=Estradiol receptor {ECO:0000256|PIRNR:PIRNR002527};
DE   AltName: Full=Nuclear receptor subfamily 3 group A member 1 {ECO:0000256|PIRNR:PIRNR002527};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAF85708.1};
RN   [1] {ECO:0000313|EMBL:BAF85708.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Uterus {ECO:0000313|EMBL:BAF85708.1};
RA   Wakamatsu A., Yamamoto J., Kimura K., Ishii S., Watanabe K.,
RA   Sugiyama A., Murakawa K., Kaida T., Tsuchiya K., Fukuzumi Y.,
RA   Kumagai A., Oishi Y., Yamamoto S., Ono Y., Komori Y., Yamazaki M.,
RA   Kisu Y., Nishikawa T., Sugano S., Nomura N., Isogai T.;
RT   "NEDO human cDNA sequencing project.";
RL   Submitted (OCT-2007) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: The steroid hormones and their receptors are involved in
CC       the regulation of eukaryotic gene expression and affect cellular
CC       proliferation and differentiation in target tissues.
CC       {ECO:0000256|PIRNR:PIRNR002527}.
CC   -!- SUBUNIT: Binds DNA as a homodimer.
CC       {ECO:0000256|PIRNR:PIRNR002527}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000256|PIRNR:PIRNR002527,
CC       ECO:0000256|SAAS:SAAS00982927}.
CC   -!- SIMILARITY: Belongs to the nuclear hormone receptor family. NR3
CC       subfamily. {ECO:0000256|PIRNR:PIRNR002527}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK293019; BAF85708.1; -; mRNA.
DR   RefSeq; NP_001278170.1; NM_001291241.1.
DR   UniGene; Hs.208124; -.
DR   UniGene; Hs.744830; -.
DR   PeptideAtlas; A8KAF4; -.
DR   PRIDE; A8KAF4; -.
DR   GeneID; 2099; -.
DR   CTD; 2099; -.
DR   eggNOG; KOG3575; Eukaryota.
DR   eggNOG; ENOG410XRZC; LUCA.
DR   HOVERGEN; HBG108344; -.
DR   GenomeRNAi; 2099; -.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0030284; F:estrogen receptor activity; IEA:InterPro.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IEA:InterPro.
DR   GO; GO:0005496; F:steroid binding; IEA:UniProtKB-KW.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-UniRule.
DR   Gene3D; 3.30.50.10; -; 1.
DR   InterPro; IPR035500; NHR_like_dom_sf.
DR   InterPro; IPR000536; Nucl_hrmn_rcpt_lig-bd.
DR   InterPro; IPR001723; Nuclear_hrmn_rcpt.
DR   InterPro; IPR024178; Oest_rcpt/oest-rel_rcp.
DR   InterPro; IPR001292; Oestr_rcpt.
DR   InterPro; IPR024736; Oestrogen-typ_rcpt_final_C_dom.
DR   InterPro; IPR001628; Znf_hrmn_rcpt.
DR   InterPro; IPR013088; Znf_NHR/GATA.
DR   Pfam; PF12743; ESR1_C; 1.
DR   Pfam; PF00104; Hormone_recep; 1.
DR   Pfam; PF02159; Oest_recep; 1.
DR   Pfam; PF00105; zf-C4; 1.
DR   PIRSF; PIRSF500101; ER-a; 1.
DR   PIRSF; PIRSF002527; ER-like_NR; 1.
DR   PRINTS; PR00543; OESTROGENR.
DR   PRINTS; PR00398; STRDHORMONER.
DR   PRINTS; PR00047; STROIDFINGER.
DR   SMART; SM00430; HOLI; 1.
DR   SMART; SM00399; ZnF_C4; 1.
DR   SUPFAM; SSF48508; SSF48508; 1.
DR   PROSITE; PS00031; NUCLEAR_REC_DBD_1; 1.
DR   PROSITE; PS51030; NUCLEAR_REC_DBD_2; 1.
PE   2: Evidence at transcript level;
KW   DNA-binding {ECO:0000256|PIRNR:PIRNR002527,
KW   ECO:0000256|SAAS:SAAS00517091};
KW   Lipid-binding {ECO:0000256|PIRNR:PIRNR002527};
KW   Metal-binding {ECO:0000256|PROSITE-ProRule:PRU00407,
KW   ECO:0000256|SAAS:SAAS00517125};
KW   Nucleus {ECO:0000256|PIRNR:PIRNR002527,
KW   ECO:0000256|SAAS:SAAS00983050};
KW   Receptor {ECO:0000256|PIRNR:PIRNR002527,
KW   ECO:0000256|SAAS:SAAS00982657, ECO:0000313|EMBL:BAF85708.1};
KW   Steroid-binding {ECO:0000256|PIRNR:PIRNR002527};
KW   Transcription {ECO:0000256|PIRNR:PIRNR002527,
KW   ECO:0000256|SAAS:SAAS00982829};
KW   Transcription regulation {ECO:0000256|PIRNR:PIRNR002527,
KW   ECO:0000256|SAAS:SAAS00982829};
KW   Zinc {ECO:0000256|PROSITE-ProRule:PRU00407,
KW   ECO:0000256|SAAS:SAAS00517125};
KW   Zinc-finger {ECO:0000256|PROSITE-ProRule:PRU00407,
KW   ECO:0000256|SAAS:SAAS00517125}.
FT   DOMAIN      182    257       Nuclear receptor.
FT                                {ECO:0000259|PROSITE:PS51030}.
FT   DNA_BIND    182    257       Nuclear receptor. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00407}.
SQ   SEQUENCE   594 AA;  66169 MW;  48F6B6D48709786B CRC64;
     MTMTLHTKAS GMALLHQIQG NELEPLNRPQ LKIPLERPLG EVYLDSSKPA VYNYPEGAAY
     EFNAAAAANA QVYGQTGLPY GPGSEAAAFG SNGLGGFPPL NSVSPSPLML LHPPPQLSPF
     LQPHGQQVPY YLENEPSGYT VREAGPPAFY RPNSDNRRQG GRERLASTND KGSMAMESAK
     ETRYCAVCND YASGYHYGVW SCEGCKAFFK RSIQGHNDYM CPATNQCTID KNRRKSCQAC
     RLRKCYEVGM MKGIRKDRRG GRMLKHKRQR DDGEGRGEVG SAGDMRAANL WPSPLMIKRS
     KKNSLALSLT ADQMVSALLD AEPPILYPEY DPTRPFSEAS MMGLLTNLAD RELVHMINWA
     KRVPGFVDLT LHDQVHLLEC AWLEILMIGL VWRSMEHPGK LLFAPNLLLD RNQGKCVEGM
     VEIFDMLLAT SSRFRMMNLQ GEEFVCLKSI ILLNSGVYTF LSSTLKSLEE KDHIHRVLDK
     ITDTLIHLMA KAGLTLQQQH QRLAQLLLIL SHIRHMSNKG MEHLYSMKCK NVVPLYDLLL
     EMLDAHRLHA PTSRGGASVE ETDQSHLATA GSTSSHSLQK YYITGEAEGF PATV
//
ID   G4XH65_HUMAN            Unreviewed;       595 AA.
AC   G4XH65;
DT   14-DEC-2011, integrated into UniProtKB/TrEMBL.
DT   14-DEC-2011, sequence version 1.
DT   28-FEB-2018, entry version 59.
DE   RecName: Full=Estrogen receptor {ECO:0000256|PIRNR:PIRNR002527};
DE            Short=ER {ECO:0000256|PIRNR:PIRNR002527};
DE   AltName: Full=ER-alpha {ECO:0000256|PIRNR:PIRNR002527};
DE   AltName: Full=Estradiol receptor {ECO:0000256|PIRNR:PIRNR002527};
DE   AltName: Full=Nuclear receptor subfamily 3 group A member 1 {ECO:0000256|PIRNR:PIRNR002527};
GN   Name=ESR1 {ECO:0000313|EMBL:AEP43755.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AEP43755.1};
RN   [1] {ECO:0000313|EMBL:AEP43755.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Kidney {ECO:0000313|EMBL:AEP43755.1};
RA   Kaighin V.A., Martin A.L., Aronstam R.S.;
RL   Submitted (APR-2011) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: The steroid hormones and their receptors are involved in
CC       the regulation of eukaryotic gene expression and affect cellular
CC       proliferation and differentiation in target tissues.
CC       {ECO:0000256|PIRNR:PIRNR002527}.
CC   -!- SUBUNIT: Binds DNA as a homodimer.
CC       {ECO:0000256|PIRNR:PIRNR002527}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000256|PIRNR:PIRNR002527,
CC       ECO:0000256|SAAS:SAAS00982927}.
CC   -!- SIMILARITY: Belongs to the nuclear hormone receptor family. NR3
CC       subfamily. {ECO:0000256|PIRNR:PIRNR002527}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; JF810888; AEP43755.1; -; mRNA.
DR   RefSeq; NP_000116.2; NM_000125.3.
DR   RefSeq; NP_001116212.1; NM_001122740.1.
DR   RefSeq; NP_001116213.1; NM_001122741.1.
DR   RefSeq; NP_001116214.1; NM_001122742.1.
DR   RefSeq; XP_011533845.1; XM_011535543.2.
DR   RefSeq; XP_011533846.1; XM_011535544.2.
DR   RefSeq; XP_011533847.1; XM_011535545.2.
DR   RefSeq; XP_016865865.1; XM_017010376.1.
DR   RefSeq; XP_016865866.1; XM_017010377.1.
DR   RefSeq; XP_016865867.1; XM_017010378.1.
DR   RefSeq; XP_016865868.1; XM_017010379.1.
DR   RefSeq; XP_016865869.1; XM_017010380.1.
DR   RefSeq; XP_016865870.1; XM_017010381.1.
DR   UniGene; Hs.208124; -.
DR   UniGene; Hs.744830; -.
DR   ProteinModelPortal; G4XH65; -.
DR   SMR; G4XH65; -.
DR   PRIDE; G4XH65; -.
DR   GeneID; 2099; -.
DR   KEGG; hsa:2099; -.
DR   CTD; 2099; -.
DR   EuPathDB; HostDB:ENSG00000091831.21; -.
DR   eggNOG; KOG3575; Eukaryota.
DR   eggNOG; ENOG410XRZC; LUCA.
DR   KO; K08550; -.
DR   OMA; EAGPPAF; -.
DR   OrthoDB; EOG091G03V4; -.
DR   PhylomeDB; G4XH65; -.
DR   ChiTaRS; ESR1; human.
DR   GenomeRNAi; 2099; -.
DR   Bgee; ENSG00000091831; -.
DR   ExpressionAtlas; G4XH65; baseline and differential.
DR   Genevisible; G4XH65; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0003682; F:chromatin binding; IEA:Ensembl.
DR   GO; GO:0030284; F:estrogen receptor activity; IEA:InterPro.
DR   GO; GO:0004879; F:nuclear receptor activity; IEA:Ensembl.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0005496; F:steroid binding; IEA:UniProtKB-KW.
DR   GO; GO:0008134; F:transcription factor binding; IEA:Ensembl.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0008209; P:androgen metabolic process; IEA:Ensembl.
DR   GO; GO:0001547; P:antral ovarian follicle growth; IEA:Ensembl.
DR   GO; GO:0071392; P:cellular response to estradiol stimulus; IEA:Ensembl.
DR   GO; GO:0071391; P:cellular response to estrogen stimulus; IEA:Ensembl.
DR   GO; GO:0002064; P:epithelial cell development; IEA:Ensembl.
DR   GO; GO:0060750; P:epithelial cell proliferation involved in mammary gland duct elongation; IEA:Ensembl.
DR   GO; GO:0008584; P:male gonad development; IEA:Ensembl.
DR   GO; GO:0060749; P:mammary gland alveolus development; IEA:Ensembl.
DR   GO; GO:0060745; P:mammary gland branching involved in pregnancy; IEA:Ensembl.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0060527; P:prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis; IEA:Ensembl.
DR   GO; GO:0060523; P:prostate epithelial cord elongation; IEA:Ensembl.
DR   GO; GO:0042981; P:regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0060687; P:regulation of branching involved in prostate gland morphogenesis; IEA:Ensembl.
DR   GO; GO:0050727; P:regulation of inflammatory response; IEA:Ensembl.
DR   GO; GO:0034121; P:regulation of toll-like receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0048863; P:stem cell differentiation; IEA:Ensembl.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-UniRule.
DR   GO; GO:0060065; P:uterus development; IEA:Ensembl.
DR   GO; GO:0060068; P:vagina development; IEA:Ensembl.
DR   Gene3D; 3.30.50.10; -; 1.
DR   InterPro; IPR035500; NHR_like_dom_sf.
DR   InterPro; IPR000536; Nucl_hrmn_rcpt_lig-bd.
DR   InterPro; IPR001723; Nuclear_hrmn_rcpt.
DR   InterPro; IPR024178; Oest_rcpt/oest-rel_rcp.
DR   InterPro; IPR001292; Oestr_rcpt.
DR   InterPro; IPR024736; Oestrogen-typ_rcpt_final_C_dom.
DR   InterPro; IPR001628; Znf_hrmn_rcpt.
DR   InterPro; IPR013088; Znf_NHR/GATA.
DR   Pfam; PF12743; ESR1_C; 1.
DR   Pfam; PF00104; Hormone_recep; 1.
DR   Pfam; PF02159; Oest_recep; 1.
DR   Pfam; PF00105; zf-C4; 1.
DR   PIRSF; PIRSF500101; ER-a; 1.
DR   PIRSF; PIRSF002527; ER-like_NR; 1.
DR   PRINTS; PR00543; OESTROGENR.
DR   PRINTS; PR00398; STRDHORMONER.
DR   PRINTS; PR00047; STROIDFINGER.
DR   SMART; SM00430; HOLI; 1.
DR   SMART; SM00399; ZnF_C4; 1.
DR   SUPFAM; SSF48508; SSF48508; 1.
DR   PROSITE; PS00031; NUCLEAR_REC_DBD_1; 1.
DR   PROSITE; PS51030; NUCLEAR_REC_DBD_2; 1.
PE   2: Evidence at transcript level;
KW   DNA-binding {ECO:0000256|PIRNR:PIRNR002527,
KW   ECO:0000256|SAAS:SAAS00517091};
KW   Lipid-binding {ECO:0000256|PIRNR:PIRNR002527};
KW   Metal-binding {ECO:0000256|PROSITE-ProRule:PRU00407,
KW   ECO:0000256|SAAS:SAAS00517125};
KW   Nucleus {ECO:0000256|PIRNR:PIRNR002527,
KW   ECO:0000256|SAAS:SAAS00983050};
KW   Receptor {ECO:0000256|PIRNR:PIRNR002527,
KW   ECO:0000256|SAAS:SAAS00982657, ECO:0000313|EMBL:AEP43755.1};
KW   Steroid-binding {ECO:0000256|PIRNR:PIRNR002527};
KW   Transcription {ECO:0000256|PIRNR:PIRNR002527,
KW   ECO:0000256|SAAS:SAAS00982829};
KW   Transcription regulation {ECO:0000256|PIRNR:PIRNR002527,
KW   ECO:0000256|SAAS:SAAS00982829};
KW   Zinc {ECO:0000256|PROSITE-ProRule:PRU00407,
KW   ECO:0000256|SAAS:SAAS00517125};
KW   Zinc-finger {ECO:0000256|PROSITE-ProRule:PRU00407,
KW   ECO:0000256|SAAS:SAAS00517125}.
FT   DOMAIN      182    257       Nuclear receptor.
FT                                {ECO:0000259|PROSITE:PS51030}.
FT   DNA_BIND    182    257       Nuclear receptor. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00407}.
SQ   SEQUENCE   595 AA;  66216 MW;  5455C57AB0CCCAA7 CRC64;
     MTMTLHTKAS GMALLHQIQG NELEPLNRPQ LKIPLERPLG EVYLDSSKPA VYNYPEGAAY
     EFNAAAAANA QVYGQTGLPY GPGSEAAAFG SNGLGGFPPL NSVSPSPLML LHPPPQLSPF
     LQPHGQQVPY YLENEPSGYT VREAGPPAFY RPNSDNRRQG GRERLASTND KGSMAMESAK
     ETRYCAVCND YASGYHYGVW SCEGCKAFFK RSIQGHNDYM CPATNQCTID KNRRKSCQAC
     RLRKCYEVGM MKGGIRKDRR GGRMLKHKRQ RDDGEGRGEV GSAGDMRAAN LWPSPLMIKR
     SKKNSLALSL TADQMVSALL DAEPPILYSE YDPTRPFSEA SMMGLLTNLA DRELVHMINW
     AKRVPGFVDL TLHDQVHLLE CAWLEILMIG LVWRSMEHPG KLLFAPNLLL DRNQGKCVEG
     MVEIFDMLLA TSSRFRMMNL QGEEFVCLKS IILLNSGVYT FLSSTLKSLE EKDHIHRVLD
     KITDTLIHLM AKAGLTLQQQ HQRLAQLLLI LSHIRHMSNK GMEHLYSMKC KNVVPLYDLL
     LEMLDAHRLH APTSRGGASV EETDQSHLAT AGSTSSHSLQ KYYITGEAEG FPATV
//
ID   H0Y4W6_HUMAN            Unreviewed;       310 AA.
AC   H0Y4W6;
DT   22-FEB-2012, integrated into UniProtKB/TrEMBL.
DT   19-FEB-2014, sequence version 2.
DT   28-FEB-2018, entry version 52.
DE   SubName: Full=Estrogen receptor {ECO:0000313|Ensembl:ENSP00000394721};
GN   Name=ESR1 {ECO:0000313|Ensembl:ENSP00000394721};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000394721, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [2] {ECO:0000313|Ensembl:ENSP00000394721}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [3] {ECO:0000313|Ensembl:ENSP00000394721}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (JAN-2012) to UniProtKB.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000256|PROSITE-
CC       ProRule:PRU00407, ECO:0000256|SAAS:SAAS00982927}.
CC   -!- SIMILARITY: Belongs to the nuclear hormone receptor family.
CC       {ECO:0000256|SAAS:SAAS00983249}.
CC   -!- CAUTION: The sequence shown here is derived from an Ensembl
CC       automatic analysis pipeline and should be considered as
CC       preliminary data. {ECO:0000313|Ensembl:ENSP00000394721}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AL035695; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL049821; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL356311; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL590993; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF454881; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF458326; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF458327; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_001315029.1; NM_001328100.1.
DR   UniGene; Hs.208124; -.
DR   UniGene; Hs.744830; -.
DR   ProteinModelPortal; H0Y4W6; -.
DR   SMR; H0Y4W6; -.
DR   PeptideAtlas; H0Y4W6; -.
DR   PRIDE; H0Y4W6; -.
DR   Ensembl; ENST00000427531; ENSP00000394721; ENSG00000091831.
DR   GeneID; 2099; -.
DR   UCSC; uc063shm.1; human.
DR   CTD; 2099; -.
DR   EuPathDB; HostDB:ENSG00000091831.21; -.
DR   HGNC; HGNC:3467; ESR1.
DR   OpenTargets; ENSG00000091831; -.
DR   eggNOG; KOG3575; Eukaryota.
DR   eggNOG; ENOG410XRZC; LUCA.
DR   GeneTree; ENSGT00760000118887; -.
DR   ChiTaRS; ESR1; human.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000091831; -.
DR   ExpressionAtlas; H0Y4W6; baseline and differential.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IEA:InterPro.
DR   GO; GO:0005496; F:steroid binding; IEA:InterPro.
DR   GO; GO:0003707; F:steroid hormone receptor activity; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-UniRule.
DR   Gene3D; 3.30.50.10; -; 1.
DR   InterPro; IPR035500; NHR_like_dom_sf.
DR   InterPro; IPR000536; Nucl_hrmn_rcpt_lig-bd.
DR   InterPro; IPR001723; Nuclear_hrmn_rcpt.
DR   InterPro; IPR024178; Oest_rcpt/oest-rel_rcp.
DR   InterPro; IPR001628; Znf_hrmn_rcpt.
DR   InterPro; IPR013088; Znf_NHR/GATA.
DR   Pfam; PF00104; Hormone_recep; 1.
DR   Pfam; PF00105; zf-C4; 1.
DR   PIRSF; PIRSF002527; ER-like_NR; 1.
DR   PRINTS; PR00398; STRDHORMONER.
DR   PRINTS; PR00047; STROIDFINGER.
DR   SMART; SM00430; HOLI; 1.
DR   SMART; SM00399; ZnF_C4; 1.
DR   SUPFAM; SSF48508; SSF48508; 2.
DR   PROSITE; PS00031; NUCLEAR_REC_DBD_1; 1.
DR   PROSITE; PS51030; NUCLEAR_REC_DBD_2; 1.
PE   1: Evidence at protein level;
KW   Complete proteome {ECO:0000313|Proteomes:UP000005640};
KW   DNA-binding {ECO:0000256|PROSITE-ProRule:PRU00407,
KW   ECO:0000256|SAAS:SAAS00517091};
KW   Metal-binding {ECO:0000256|PROSITE-ProRule:PRU00407,
KW   ECO:0000256|SAAS:SAAS00517125};
KW   Nucleus {ECO:0000256|PROSITE-ProRule:PRU00407,
KW   ECO:0000256|SAAS:SAAS00983050};
KW   Proteomics identification {ECO:0000213|EPD:H0Y4W6,
KW   ECO:0000213|MaxQB:H0Y4W6, ECO:0000213|PeptideAtlas:H0Y4W6};
KW   Receptor {ECO:0000256|SAAS:SAAS00982657};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640};
KW   Transcription {ECO:0000256|PROSITE-ProRule:PRU00407,
KW   ECO:0000256|SAAS:SAAS00982829};
KW   Transcription regulation {ECO:0000256|PROSITE-ProRule:PRU00407,
KW   ECO:0000256|SAAS:SAAS00982829};
KW   Zinc {ECO:0000256|PROSITE-ProRule:PRU00407,
KW   ECO:0000256|SAAS:SAAS00517125};
KW   Zinc-finger {ECO:0000256|PROSITE-ProRule:PRU00407,
KW   ECO:0000256|SAAS:SAAS00517125}.
FT   DOMAIN        9     84       Nuclear receptor.
FT                                {ECO:0000259|PROSITE:PS51030}.
FT   DNA_BIND      9     84       Nuclear receptor. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00407}.
SQ   SEQUENCE   310 AA;  35298 MW;  051CA0996E56C356 CRC64;
     MAMESAKETR YCAVCNDYAS GYHYGVWSCE GCKAFFKRSI QGHNDYMCPA TNQCTIDKNR
     RKSCQACRLR KCYEVGMMKG GIRKDRRGGR MLKHKRQRDD GEGRGEVGSA GDMRAANLWP
     SPLMIKRSKK NSLALSLTAD QMVSALLDAE PPILYSEYDP TRPFSEASMM GLLTNLADRE
     LVHMINWAKR VPGFVDLTLH DQVHLLECAW LEILMIGLVW RSMEHPGKLL FAPNLLLDRN
     QGKCVEGMVE IFDMLLATSS RFRMMNLQGE EFVCLKSIIL LNSGISHVEA KKRILNLHPK
     IFGNKWFPRV
//
ID   ESR1_HUMAN              Reviewed;         595 AA.
AC   P03372; Q13511; Q14276; Q5T5H7; Q6MZQ9; Q9NU51; Q9UDZ7; Q9UIS7;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 2.
DT   28-FEB-2018, entry version 249.
DE   RecName: Full=Estrogen receptor;
DE            Short=ER;
DE   AltName: Full=ER-alpha;
DE   AltName: Full=Estradiol receptor;
DE   AltName: Full=Nuclear receptor subfamily 3 group A member 1;
GN   Name=ESR1; Synonyms=ESR, NR3A1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT VAL-400.
RX   PubMed=3754034; DOI=10.1038/320134a0;
RA   Green S., Walter P., Kumar V., Krust A., Bornert J.-M., Argos P.,
RA   Chambon P.;
RT   "Human oestrogen receptor cDNA: sequence, expression and homology to
RT   v-erb-A.";
RL   Nature 320:134-139(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT VAL-400.
RX   PubMed=3753802; DOI=10.1126/science.3753802;
RA   Greene G.L., Gilna P., Waterfield M., Baker A., Hort Y., Shine J.;
RT   "Sequence and expression of human estrogen receptor complementary
RT   DNA.";
RL   Science 231:1150-1154(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Mammary gland;
RX   PubMed=8600466; DOI=10.1093/nar/24.5.962;
RA   Pink J.J., Wu S.Q., Wolf D.M., Bilimoria M.M., Jordan V.C.;
RT   "A novel 80 kDa human estrogen receptor containing a duplication of
RT   exons 6 and 7.";
RL   Nucleic Acids Res. 24:962-969(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), ALTERNATIVE PROMOTER USAGE,
RP   AND SUBCELLULAR LOCATION.
RC   TISSUE=Placenta;
RX   PubMed=16165085; DOI=10.1016/j.bbrc.2005.08.226;
RA   Wang Z., Zhang X., Shen P., Loggie B.W., Chang Y., Deuel T.F.;
RT   "Identification, cloning, and expression of human estrogen receptor-
RT   alpha36, a novel variant of human estrogen receptor-alpha66.";
RL   Biochem. Biophys. Res. Commun. 336:1023-1027(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PROTEIN SEQUENCE OF 110-117, PHOSPHORYLATION, AND MUTAGENESIS.
RX   PubMed=7476978; DOI=10.1210/mend.9.8.7476978;
RA   Joel P.B., Traish A.M., Lannigan D.A.;
RT   "Estradiol and phorbol ester cause phosphorylation of serine 118 in
RT   the human estrogen receptor.";
RL   Mol. Endocrinol. 9:1041-1052(1995).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 152-595 (ISOFORM 1).
RX   PubMed=10619354; DOI=10.1016/S0960-0760(99)00126-0;
RA   Schubert E.L., Lee M.K., Newman B., King M.C.;
RT   "Single nucleotide polymorphisms (SNPs) in the estrogen receptor gene
RT   and breast cancer susceptibility.";
RL   J. Steroid Biochem. Mol. Biol. 71:21-27(1999).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 216-434 (ISOFORM 2).
RC   TISSUE=Mammary carcinoma;
RX   PubMed=7916651;
RA   Pfeffer U., Fecarotta E., Castagnetta L., Vidali G.;
RT   "Estrogen receptor variant messenger RNA lacking exon 4 in estrogen-
RT   responsive human breast cancer cell lines.";
RL   Cancer Res. 53:741-743(1993).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 354-548.
RC   TISSUE=Mammary carcinoma;
RA   Naundorf H., Becker M., Fiebig C., Buettner B., Fichtner I.;
RT   "Mechanisms of acquired tamoxifen resistance in a xenotransplanted
RT   human breast carcinoma.";
RL   Submitted (AUG-1996) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   PROTEIN SEQUENCE OF 532-542, AND PHOSPHORYLATION AT TYR-537.
RX   PubMed=7539106; DOI=10.1210/mend.9.1.7539106;
RA   Arnold S.F., Obourn J.D., Jaffe H., Notides A.C.;
RT   "Phosphorylation of the human estrogen receptor on tyrosine 537 in
RT   vivo and by src family tyrosine kinases in vitro.";
RL   Mol. Endocrinol. 9:24-33(1995).
RN   [15]
RP   MUTAGENESIS OF CYS-447.
RX   PubMed=1577818;
RA   Reese J.C., Katzenellenbogen B.S.;
RT   "Characterization of a temperature-sensitive mutation in the hormone
RT   binding domain of the human estrogen receptor. Studies in cell
RT   extracts and intact cells and their implications for hormone-dependent
RT   transcriptional activation.";
RL   J. Biol. Chem. 267:9868-9873(1992).
RN   [16]
RP   PHOSPHORYLATION AT SER-167 BY CK2.
RX   PubMed=7838153; DOI=10.1210/mend.8.9.7838153;
RA   Arnold S.F., Obourn J.D., Jaffe H., Notides A.C.;
RT   "Serine 167 is the major estradiol-induced phosphorylation site on the
RT   human estrogen receptor.";
RL   Mol. Endocrinol. 8:1208-1214(1994).
RN   [17]
RP   FUNCTION IN TRANSREPRESSION OF NF-KAPPA-B.
RX   PubMed=7651415; DOI=10.1128/MCB.15.9.4971;
RA   Stein B., Yang M.X.;
RT   "Repression of the interleukin-6 promoter by estrogen receptor is
RT   mediated by NF-kappa B and C/EBP beta.";
RL   Mol. Cell. Biol. 15:4971-4979(1995).
RN   [18]
RP   MUTAGENESIS OF VAL-364.
RX   PubMed=8961262; DOI=10.1210/mend.10.12.8961262;
RA   McInerney E.M., Ince B.A., Shapiro D.J., Katzenellenbogen B.S.;
RT   "A transcriptionally active estrogen receptor mutant is a novel type
RT   of dominant negative inhibitor of estrogen action.";
RL   Mol. Endocrinol. 10:1519-1526(1996).
RN   [19]
RP   INTERACTION WITH DDX5, AND MUTAGENESIS OF SER-118.
RX   PubMed=10409727; DOI=10.1128/MCB.19.8.5363;
RA   Endoh H., Maruyama K., Masuhiro Y., Kobayashi Y., Goto M., Tai H.,
RA   Yanagisawa J., Metzger D., Hashimoto S., Kato S.;
RT   "Purification and identification of p68 RNA helicase acting as a
RT   transcriptional coactivator specific for the activation function 1 of
RT   human estrogen receptor alpha.";
RL   Mol. Cell. Biol. 19:5363-5372(1999).
RN   [20]
RP   FUNCTION (ISOFORM 3), TISSUE SPECIFICITY, ALTERNATIVE PROMOTER USAGE
RP   (ISOFORM 3), AND SUBUNIT.
RX   PubMed=10970861; DOI=10.1093/emboj/19.17.4688;
RA   Flouriot G., Brand H., Denger S., Metivier R., Kos M., Reid G.,
RA   Sonntag-Buck V., Gannon F.;
RT   "Identification of a new isoform of the human estrogen receptor-alpha
RT   (hER-alpha) that is encoded by distinct transcripts and that is able
RT   to repress hER-alpha activation function 1.";
RL   EMBO J. 19:4688-4700(2000).
RN   [21]
RP   MUTAGENESIS OF LEU-39 AND TYR-43.
RX   PubMed=11075817; DOI=10.1210/mend.14.11.0546;
RA   Metivier R., Petit F.G., Valotaire Y., Pakdel F.;
RT   "Function of N-terminal transactivation domain of the estrogen
RT   receptor requires a potential alpha-helical structure and is
RT   negatively regulated by the A domain.";
RL   Mol. Endocrinol. 14:1849-1871(2000).
RN   [22]
RP   INTERACTION WITH NCOA1; NCOA2 AND NCOA3, SUBUNIT, AND MUTAGENESIS OF
RP   LEU-539.
RX   PubMed=12554772; DOI=10.1210/me.2002-0351;
RA   Bai Y., Giguere V.;
RT   "Isoform-selective interactions between estrogen receptors and steroid
RT   receptor coactivators promoted by estradiol and ErbB-2 signaling in
RT   living cells.";
RL   Mol. Endocrinol. 17:589-599(2003).
RN   [23]
RP   SUBCELLULAR LOCATION (ISOFORMS 1 AND 3), AND PALMITOYLATION (ISOFORM
RP   3).
RX   PubMed=12682286; DOI=10.1073/pnas.0831079100;
RA   Li L., Haynes M.P., Bender J.R.;
RT   "Plasma membrane localization and function of the estrogen receptor
RT   alpha variant (ER46) in human endothelial cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:4807-4812(2003).
RN   [24]
RP   GLYCOSYLATION.
RX   PubMed=8999954;
RA   Jiang M.S., Hart G.W.;
RT   "A subpopulation of estrogen receptors are modified by O-linked N-
RT   acetylglucosamine.";
RL   J. Biol. Chem. 272:2421-2428(1997).
RN   [25]
RP   FUNCTION, AND INTERACTION WITH SP1.
RX   PubMed=9328340; DOI=10.1210/mend.11.11.9916;
RA   Porter W., Saville B., Hoivik D., Safe S.;
RT   "Functional synergy between the transcription factor Sp1 and the
RT   estrogen receptor.";
RL   Mol. Endocrinol. 11:1569-1580(1997).
RN   [26]
RP   INTERACTION WITH AKAP13.
RX   PubMed=9627117; DOI=10.1038/sj.onc.1201783;
RA   Rubino D., Driggers P., Arbit D., Kemp L., Miller B., Coso O.,
RA   Pagliai K., Gray K., Gutkind S., Segars J.;
RT   "Characterization of Brx, a novel Dbl family member that modulates
RT   estrogen receptor action.";
RL   Oncogene 16:2513-2526(1998).
RN   [27]
RP   PHOSPHORYLATION AT SER-104 AND SER-106, AND MUTAGENESIS.
RX   PubMed=10428798; DOI=10.1074/jbc.274.32.22296;
RA   Rogatsky I., Trowbridge J.M., Garabedian M.J.;
RT   "Potentiation of human estrogen receptor alpha transcriptional
RT   activation through phosphorylation of serines 104 and 106 by the
RT   cyclin A-CDK2 complex.";
RL   J. Biol. Chem. 274:22296-22302(1999).
RN   [28]
RP   INTERACTION WITH NCOA6.
RX   PubMed=10567404; DOI=10.1074/jbc.274.48.34283;
RA   Lee S.-K., Anzick S.L., Choi J.-E., Bubendorf L., Guan X.-Y.,
RA   Jung Y.-K., Kallioniemi O.-P., Kononen J., Trent J.M., Azorsa D.,
RA   Jhun B.-H., Cheong J.H., Lee Y.C., Meltzer P.S., Lee J.W.;
RT   "A nuclear factor ASC-2, as a cancer-amplified transcriptional
RT   coactivator essential for ligand-dependent transactivation by nuclear
RT   receptors in vivo.";
RL   J. Biol. Chem. 274:34283-34293(1999).
RN   [29]
RP   INTERACTION WITH PHB2.
RX   PubMed=10359819; DOI=10.1073/pnas.96.12.6947;
RA   Montano M.M., Ekena K., Delage-Mourroux R., Chang W., Martini P.,
RA   Katzenellenbogen B.S.;
RT   "An estrogen receptor-selective coregulator that potentiates the
RT   effectiveness of antiestrogens and represses the activity of
RT   estrogens.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:6947-6952(1999).
RN   [30]
RP   INTERACTION WITH NCOA2.
RX   PubMed=11265755; DOI=10.1093/embo-reports/kvd028;
RA   Benecke A., Chambon P., Gronemeyer H.;
RT   "Synergy between estrogen receptor alpha activation functions AF1 and
RT   AF2 mediated by transcription intermediary factor TIF2.";
RL   EMBO Rep. 1:151-157(2000).
RN   [31]
RP   FUNCTION, AND INTERACTION WITH SP1.
RX   PubMed=10681512; DOI=10.1074/jbc.275.8.5379;
RA   Saville B., Wormke M., Wang F., Nguyen T., Enmark E., Kuiper G.,
RA   Gustafsson J.A., Safe S.;
RT   "Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent
RT   activation at GC-rich (Sp1) promoter elements.";
RL   J. Biol. Chem. 275:5379-5387(2000).
RN   [32]
RP   FUNCTION, AND INTERACTION WITH SP3.
RX   PubMed=10816575; DOI=10.1074/jbc.M002188200;
RA   Stoner M., Wang F., Wormke M., Nguyen T., Samudio I., Vyhlidal C.,
RA   Marme D., Finkenzeller G., Safe S.;
RT   "Inhibition of vascular endothelial growth factor expression in HEC1A
RT   endometrial cancer cells through interactions of estrogen receptor
RT   alpha and Sp3 proteins.";
RL   J. Biol. Chem. 275:22769-22779(2000).
RN   [33]
RP   INTERACTION WITH CITED1 AND EP300.
RX   PubMed=11581164; DOI=10.1101/gad.906301;
RA   Yahata T., Shao W., Endoh H., Hur J., Coser K.R., Sun H., Ueda Y.,
RA   Kato S., Isselbacher K.J., Brown M., Shioda T.;
RT   "Selective coactivation of estrogen-dependent transcription by CITED1
RT   CBP/p300-binding protein.";
RL   Genes Dev. 15:2598-2612(2001).
RN   [34]
RP   FUNCTION, AND INTERACTION WITH JUN; JUNB AND JUND.
RX   PubMed=11477071; DOI=10.1074/jbc.M101806200;
RA   Teyssier C., Belguise K., Galtier F., Chalbos D.;
RT   "Characterization of the physical interaction between estrogen
RT   receptor alpha and JUN proteins.";
RL   J. Biol. Chem. 276:36361-36369(2001).
RN   [35]
RP   INTERACTION WITH KDM5A.
RX   PubMed=11358960; DOI=10.1074/jbc.M100313200;
RA   Chan S.W., Hong W.;
RT   "Retinoblastoma-binding protein 2 (Rbp2) potentiates nuclear hormone
RT   receptor-mediated transcription.";
RL   J. Biol. Chem. 276:28402-28412(2001).
RN   [36]
RP   INTERACTION WITH NCOA5.
RX   PubMed=11113208; DOI=10.1128/MCB.21.1.343-353.2001;
RA   Sauve F., McBroom L.D.B., Gallant J., Moraitis A.N., Labrie F.,
RA   Giguere V.;
RT   "CIA, a novel estrogen receptor coactivator with a bifunctional
RT   nuclear receptor interacting determinant.";
RL   Mol. Cell. Biol. 21:343-353(2001).
RN   [37]
RP   FUNCTION, AND INTERACTION WITH NCOA1 AND DDX5.
RX   PubMed=11682626; DOI=10.1210/mend.15.11.0727;
RA   Metivier R., Penot G., Flouriot G., Pakdel F.;
RT   "Synergism between ERalpha transactivation function 1 (AF-1) and AF-2
RT   mediated by steroid receptor coactivator protein-1: requirement for
RT   the AF-1 alpha-helical core and for a direct interaction between the
RT   N- and C-terminal domains.";
RL   Mol. Endocrinol. 15:1953-1970(2001).
RN   [38]
RP   INTERACTION WITH PRMT2.
RX   PubMed=12039952; DOI=10.1074/jbc.M201053200;
RA   Qi C., Chang J., Zhu Y., Yeldandi A.V., Rao S.M., Zhu Y.-J.;
RT   "Identification of protein arginine methyltransferase 2 as a
RT   coactivator for estrogen receptor alpha.";
RL   J. Biol. Chem. 277:28624-28630(2002).
RN   [39]
RP   INTERACTION WITH NR2C1.
RX   PubMed=12093804; DOI=10.1074/jbc.M203531200;
RA   Hu Y.C., Shyr C.R., Che W., Mu X.M., Kim E., Chang C.;
RT   "Suppression of estrogen receptor-mediated transcription and cell
RT   growth by interaction with TR2 orphan receptor.";
RL   J. Biol. Chem. 277:33571-33579(2002).
RN   [40]
RP   INTERACTION WITH NCOA7.
RX   PubMed=11971969; DOI=10.1128/MCB.22.10.3358-3372.2002;
RA   Shao W., Halachmi S., Brown M.;
RT   "ERAP140, a conserved tissue-specific nuclear receptor coactivator.";
RL   Mol. Cell. Biol. 22:3358-3372(2002).
RN   [41]
RP   INTERACTION WITH RBFOX2.
RX   PubMed=11875103; DOI=10.1210/mend.16.3.0787;
RA   Norris J.D., Fan D., Sherk A., McDonnell D.P.;
RT   "A negative coregulator for the human ER.";
RL   Mol. Endocrinol. 16:459-468(2002).
RN   [42]
RP   INTERACTION WITH PELP1.
RX   PubMed=12415108; DOI=10.1073/pnas.192569699;
RA   Wong C.-W., McNally C., Nickbarg E., Komm B.S., Cheskis B.J.;
RT   "Estrogen receptor-interacting protein that modulates its nongenomic
RT   activity-crosstalk with Src/Erk phosphorylation cascade.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:14783-14788(2002).
RN   [43]
RP   INTERACTION WITH SMARD1.
RX   PubMed=12917342; DOI=10.1128/MCB.23.17.6210-6220.2003;
RA   Hsiao P.W., Fryer C.J., Trotter K.W., Wang W., Archer T.K.;
RT   "BAF60a mediates critical interactions between nuclear receptors and
RT   the BRG1 chromatin-remodeling complex for transactivation.";
RL   Mol. Cell. Biol. 23:6210-6220(2003).
RN   [44]
RP   INTERACTION WITH DNTTIP2.
RX   PubMed=15047147; DOI=10.1016/j.bbrc.2004.02.179;
RA   Bu H., Kashireddy P., Chang J., Zhu Y.T., Zhang Z., Zheng W.,
RA   Rao S.M., Zhu Y.-J.;
RT   "ERBP, a novel estrogen receptor binding protein enhancing the
RT   activity of estrogen receptor.";
RL   Biochem. Biophys. Res. Commun. 317:54-59(2004).
RN   [45]
RP   FUNCTION.
RX   PubMed=15078875; DOI=10.1074/jbc.M402148200;
RA   Merot Y., Metivier R., Penot G., Manu D., Saligaut C., Gannon F.,
RA   Pakdel F., Kah O., Flouriot G.;
RT   "The relative contribution exerted by AF-1 and AF-2 transactivation
RT   functions in estrogen receptor alpha transcriptional activity depends
RT   upon the differentiation stage of the cell.";
RL   J. Biol. Chem. 279:26184-26191(2004).
RN   [46]
RP   INTERACTION WITH TXNRD1.
RX   PubMed=15199063; DOI=10.1074/jbc.M402753200;
RA   Damdimopoulos A.E., Miranda-Vizuete A., Treuter E., Gustafsson J.-A.,
RA   Spyrou G.;
RT   "An alternative splicing variant of the selenoprotein thioredoxin
RT   reductase is a modulator of estrogen signaling.";
RL   J. Biol. Chem. 279:38721-38729(2004).
RN   [47]
RP   FUNCTION, PHOSPHORYLATION AT SER-118, DEPHOSPHORYLATION AT SER-118 BY
RP   PPP5C, AND MUTAGENESIS OF SER-118.
RX   PubMed=14764652; DOI=10.1210/me.2003-0308;
RA   Ikeda K., Ogawa S., Tsukui T., Horie-Inoue K., Ouchi Y., Kato S.,
RA   Muramatsu M., Inoue S.;
RT   "Protein phosphatase 5 is a negative regulator of estrogen receptor-
RT   mediated transcription.";
RL   Mol. Endocrinol. 18:1131-1143(2004).
RN   [48]
RP   FUNCTION IN NF-KAPPA-B TRANSREPRESSION.
RX   PubMed=16043358; DOI=10.1016/j.cyto.2004.12.008;
RA   Liu H., Liu K., Bodenner D.L.;
RT   "Estrogen receptor inhibits interleukin-6 gene expression by
RT   disruption of nuclear factor kappaB transactivation.";
RL   Cytokine 31:251-257(2005).
RN   [49]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH DYNLL1.
RX   PubMed=15891768; DOI=10.1038/sj.embor.7400417;
RA   Rayala S.K., den Hollander P., Balasenthil S., Yang Z., Broaddus R.R.,
RA   Kumar R.;
RT   "Functional regulation of oestrogen receptor pathway by the dynein
RT   light chain 1.";
RL   EMBO Rep. 6:538-544(2005).
RN   [50]
RP   ERRATUM.
RA   Rayala S.K., den Hollander P., Balasenthil S., Yang Z., Broaddus R.R.,
RA   Kumar R.;
RL   EMBO Rep. 6:1101-1101(2005).
RN   [51]
RP   INTERACTION WITH HEXIM1.
RX   PubMed=15940264; DOI=10.1038/sj.onc.1208728;
RA   Wittmann B.M., Fujinaga K., Deng H., Ogba N., Montano M.M.;
RT   "The breast cell growth inhibitor, estrogen down regulated gene 1,
RT   modulates a novel functional interaction between estrogen receptor
RT   alpha and transcriptional elongation factor cyclin T1.";
RL   Oncogene 24:5576-5588(2005).
RN   [52]
RP   INTERACTION WITH KMT2D.
RX   PubMed=16603732; DOI=10.1074/jbc.M513245200;
RA   Mo R., Rao S.M., Zhu Y.-J.;
RT   "Identification of the MLL2 complex as a coactivator for estrogen
RT   receptor alpha.";
RL   J. Biol. Chem. 281:15714-15720(2006).
RN   [53]
RP   FUNCTION.
RX   PubMed=16684779; DOI=10.1074/jbc.M600021200;
RA   Rayala S.K., den Hollander P., Manavathi B., Talukder A.H., Song C.,
RA   Peng S., Barnekow A., Kremerskothen J., Kumar R.;
RT   "Essential role of KIBRA in co-activator function of dynein light
RT   chain 1 in mammalian cells.";
RL   J. Biol. Chem. 281:19092-19099(2006).
RN   [54]
RP   INTERACTION WITH MUC1.
RX   PubMed=16427018; DOI=10.1016/j.molcel.2005.11.030;
RA   Wei X., Xu H., Kufe D.;
RT   "MUC1 oncoprotein stabilizes and activates estrogen receptor alpha.";
RL   Mol. Cell 21:295-305(2006).
RN   [55]
RP   INTERACTION WITH UBE3A AND WBP2.
RX   PubMed=16772533; DOI=10.1210/me.2005-0533;
RA   Dhananjayan S.C., Ramamoorthy S., Khan O.Y., Ismail A., Sun J.,
RA   Slingerland J., O'Malley B.W., Nawaz Z.;
RT   "WW domain binding protein-2, an E6-associated protein interacting
RT   protein, acts as a coactivator of estrogen and progesterone
RT   receptors.";
RL   Mol. Endocrinol. 20:2343-2354(2006).
RN   [56]
RP   INTERACTION WITH ZNF366.
RX   PubMed=17085477; DOI=10.1093/nar/gkl875;
RA   Lopez-Garcia J., Periyasamy M., Thomas R.S., Christian M., Leao M.,
RA   Jat P., Kindle K.B., Heery D.M., Parker M.G., Buluwela L.,
RA   Kamalati T., Ali S.;
RT   "ZNF366 is an estrogen receptor corepressor that acts through CtBP and
RT   histone deacetylases.";
RL   Nucleic Acids Res. 34:6126-6136(2006).
RN   [57]
RP   FUNCTION.
RX   PubMed=16617102; DOI=10.1073/pnas.0601989103;
RA   Gururaj A.E., Singh R.R., Rayala S.K., Holm C., den Hollander P.,
RA   Zhang H., Balasenthil S., Talukder A.H., Landberg G., Kumar R.;
RT   "MTA1, a transcriptional activator of breast cancer amplified sequence
RT   3.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:6670-6675(2006).
RN   [58]
RP   ERRATUM.
RA   Gururaj A.E., Singh R.R., Rayala S.K., Holm C., den Hollander P.,
RA   Zhang H., Balasenthil S., Talukder A.H., Landberg G., Kumar R.;
RL   Proc. Natl. Acad. Sci. U.S.A. 110:4147-4148(2013).
RN   [59]
RP   INTERACTION WITH PBXIP1.
RX   PubMed=17043237; DOI=10.1073/pnas.0607445103;
RA   Manavathi B., Acconcia F., Rayala S.K., Kumar R.;
RT   "An inherent role of microtubule network in the action of nuclear
RT   receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:15981-15986(2006).
RN   [60]
RP   INTERACTION WITH MAP1S.
RX   PubMed=17658481; DOI=10.1016/j.bbrc.2007.06.179;
RA   Eriksson M., Samuelsson H., Samuelsson E.-B., Liu L., McKeehan W.L.,
RA   Benedikz E., Sundstroem E.;
RT   "The NMDAR subunit NR3A interacts with microtubule-associated protein
RT   1S in the brain.";
RL   Biochem. Biophys. Res. Commun. 361:127-132(2007).
RN   [61]
RP   INTERACTION WITH CUEDC2.
RX   PubMed=17347654; DOI=10.1038/sj.emboj.7601602;
RA   Zhang P.-J., Zhao J., Li H.-Y., Man J.-H., He K., Zhou T., Pan X.,
RA   Li A.-L., Gong W.-L., Jin B.-F., Xia Q., Yu M., Shen B.-F.,
RA   Zhang X.-M.;
RT   "CUE domain containing 2 regulates degradation of progesterone
RT   receptor by ubiquitin-proteasome.";
RL   EMBO J. 26:1831-1842(2007).
RN   [62]
RP   INTERACTION WITH MACROD1.
RX   PubMed=17914104; DOI=10.1677/ERC-06-0082;
RA   Han W.-D., Zhao Y.-L., Meng Y.G., Zang L., Wu Z.-Q., Li Q., Si Y.-L.,
RA   Huang K., Ba J.-M., Morinaga H., Nomura M., Mu Y.-M.;
RT   "Estrogenically regulated LRP16 interacts with estrogen receptor alpha
RT   and enhances the receptor's transcriptional activity.";
RL   Endocr. Relat. Cancer 14:741-753(2007).
RN   [63]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH KIF18A.
RX   PubMed=17006958; DOI=10.1002/jcb.21000;
RA   Luboshits G., Benayahu D.;
RT   "MS-KIF18A, a kinesin, is associated with estrogen receptor.";
RL   J. Cell. Biochem. 100:693-702(2007).
RN   [64]
RP   INTERACTION WITH PRMT2.
RX   PubMed=17587566; DOI=10.1016/j.jsbmb.2007.05.006;
RA   Meyer R., Wolf S.S., Obendorf M.;
RT   "PRMT2, a member of the protein arginine methyltransferase family, is
RT   a coactivator of the androgen receptor.";
RL   J. Steroid Biochem. Mol. Biol. 107:1-14(2007).
RN   [65]
RP   INTERACTION WITH BCAS3.
RX   PubMed=17505058; DOI=10.1210/me.2006-0514;
RA   Gururaj A.E., Peng S., Vadlamudi R.K., Kumar R.;
RT   "Estrogen induces expression of BCAS3, a novel estrogen receptor-alpha
RT   coactivator, through proline-, glutamic acid-, and leucine-rich
RT   protein-1 (PELP1).";
RL   Mol. Endocrinol. 21:1847-1860(2007).
RN   [66]
RP   INTERACTION WITH UIMC1.
RX   PubMed=17311814; DOI=10.1093/nar/gkl1112;
RA   Yan J., Kim Y.S., Yang X.-P., Albers M., Koegl M., Jetten A.M.;
RT   "Ubiquitin-interaction motifs of RAP80 are critical in its regulation
RT   of estrogen receptor alpha.";
RL   Nucleic Acids Res. 35:1673-1686(2007).
RN   [67]
RP   INTERACTION WITH ATAD2.
RX   PubMed=17998543; DOI=10.1073/pnas.0705814104;
RA   Zou J.X., Revenko A.S., Li L.B., Gemo A.T., Chen H.-W.;
RT   "ANCCA, an estrogen-regulated AAA+ ATPase coactivator for ERalpha, is
RT   required for coregulator occupancy and chromatin modification.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:18067-18072(2007).
RN   [68]
RP   FUNCTION IN ASSOCIATION WITH AP-1.
RX   PubMed=18247370; DOI=10.1002/jcp.21379;
RA   Lambertini E., Tavanti E., Torreggiani E., Penolazzi L., Gambari R.,
RA   Piva R.;
RT   "ERalpha and AP-1 interact in vivo with a specific sequence of the F
RT   promoter of the human ERalpha gene in osteoblasts.";
RL   J. Cell. Physiol. 216:101-110(2008).
RN   [69]
RP   METHYLATION AT ARG-260 BY PRMT1, MUTAGENESIS OF ARG-260, SUBCELLULAR
RP   LOCATION, AND INTERACTION WITH PI3KR1/2; SRC AND PTK2/FAK1.
RX   PubMed=18657504; DOI=10.1016/j.molcel.2008.05.025;
RA   Le Romancer M., Treilleux I., Leconte N., Robin-Lespinasse Y.,
RA   Sentis S., Bouchekioua-Bouzaghou K., Goddard S., Gobert-Gosse S.,
RA   Corbo L.;
RT   "Regulation of estrogen rapid signaling through arginine methylation
RT   by PRMT1.";
RL   Mol. Cell 31:212-221(2008).
RN   [70]
RP   FUNCTION IN NF-KAPPA-B TRANSREPRESSION, AND INTERACTION WITH RELA.
RX   PubMed=17932106; DOI=10.1210/me.2007-0324;
RA   Nettles K.W., Gil G., Nowak J., Metivier R., Sharma V.B., Greene G.L.;
RT   "CBP Is a dosage-dependent regulator of nuclear factor-kappaB
RT   suppression by the estrogen receptor.";
RL   Mol. Endocrinol. 22:263-272(2008).
RN   [71]
RP   FUNCTION.
RX   PubMed=17922032; DOI=10.1038/sj.onc.1210839;
RA   Molli P.R., Singh R.R., Lee S.W., Kumar R.;
RT   "MTA1-mediated transcriptional repression of BRCA1 tumor suppressor
RT   gene.";
RL   Oncogene 27:1971-1980(2008).
RN   [72]
RP   INTERACTION WITH CCDC62.
RX   PubMed=18563714; DOI=10.1002/pros.20774;
RA   Chen M., Ni J., Zhang Y., Muyan M., Yeh S.;
RT   "ERAP75 functions as a coactivator to enhance estrogen receptor alpha
RT   transactivation in prostate stromal cells.";
RL   Prostate 68:1273-1282(2008).
RN   [73]
RP   INTERACTION WITH SH2D4A AND PLCG.
RX   PubMed=19712589; DOI=10.5483/BMBRep.2009.42.8.516;
RA   Li T., Li W., Lu J., Liu H., Li Y., Zhao Y.;
RT   "SH2D4A regulates cell proliferation via the ERalpha/PLC-gamma/PKC
RT   pathway.";
RL   BMB Rep. 42:516-522(2009).
RN   [74]
RP   INTERACTION WITH LDB1 AND RLIM.
RX   PubMed=19117995; DOI=10.1158/0008-5472.CAN-08-1630;
RA   Johnsen S.A., Guengoer C., Prenzel T., Riethdorf S., Riethdorf L.,
RA   Taniguchi-Ishigaki N., Rau T., Tursun B., Furlow J.D., Sauter G.,
RA   Scheffner M., Pantel K., Gannon F., Bach I.;
RT   "Regulation of estrogen-dependent transcription by the LIM cofactors
RT   CLIM and RLIM in breast cancer.";
RL   Cancer Res. 69:128-136(2009).
RN   [75]
RP   INTERACTION WITH DNAAF4.
RX   PubMed=19423554; DOI=10.1093/hmg/ddp215;
RA   Massinen S., Tammimies K., Tapia-Paez I., Matsson H., Hokkanen M.E.,
RA   Soederberg O., Landegren U., Castren E., Gustafsson J.A., Treuter E.,
RA   Kere J.;
RT   "Functional interaction of DYX1C1 with estrogen receptors suggests
RT   involvement of hormonal pathways in dyslexia.";
RL   Hum. Mol. Genet. 18:2802-2812(2009).
RN   [76]
RP   FUNCTION IN MUTUAL TRANSREPRESSION WITH NF-KAPPA-B, AND INTERACTION
RP   WITH NFKB1 AND RELA.
RX   PubMed=19350539; DOI=10.1002/jcb.22141;
RA   Gionet N., Jansson D., Mader S., Pratt M.A.;
RT   "NF-kappaB and estrogen receptor alpha interactions: Differential
RT   function in estrogen receptor-negative and -positive hormone-
RT   independent breast cancer cells.";
RL   J. Cell. Biochem. 107:448-459(2009).
RN   [77]
RP   UBIQUITINATION, AND INTERACTION WITH OTUB1.
RX   PubMed=19383985; DOI=10.1074/jbc.M109.007484;
RA   Stanisic V., Malovannaya A., Qin J., Lonard D.M., O'Malley B.W.;
RT   "OTU Domain-containing ubiquitin aldehyde-binding protein 1 (OTUB1)
RT   deubiquitinates estrogen receptor (ER) alpha and affects ERalpha
RT   transcriptional activity.";
RL   J. Biol. Chem. 284:16135-16145(2009).
RN   [78]
RP   PHOSPHORYLATION BY CSNK1D/CK1, AND INTERACTION WITH CSNK1D.
RX   PubMed=19339517; DOI=10.1093/nar/gkp136;
RA   Giamas G., Castellano L., Feng Q., Knippschild U., Jacob J.,
RA   Thomas R.S., Coombes R.C., Smith C.L., Jiao L.R., Stebbing J.;
RT   "CK1delta modulates the transcriptional activity of ERalpha via AIB1
RT   in an estrogen-dependent manner and regulates ERalpha-AIB1
RT   interactions.";
RL   Nucleic Acids Res. 37:3110-3123(2009).
RN   [79]
RP   INTERACTION WITH DDX17.
RX   PubMed=19718048; DOI=10.1038/onc.2009.261;
RA   Wortham N.C., Ahamed E., Nicol S.M., Thomas R.S., Periyasamy M.,
RA   Jiang J., Ochocka A.M., Shousha S., Huson L., Bray S.E., Coombes R.C.,
RA   Ali S., Fuller-Pace F.V.;
RT   "The DEAD-box protein p72 regulates ERalpha-/oestrogen-dependent
RT   transcription and cell growth, and is associated with improved
RT   survival in ERalpha-positive breast cancer.";
RL   Oncogene 28:4053-4064(2009).
RN   [80]
RP   INTERACTION WITH KIF18A.
RX   PubMed=19636373; DOI=10.1371/journal.pone.0006407;
RA   Zusev M., Benayahu D.;
RT   "The regulation of MS-KIF18A expression and cross talk with estrogen
RT   receptor.";
RL   PLoS ONE 4:E6407-E6407(2009).
RN   [81]
RP   FUNCTION, INTERACTION WITH CCAR2, AND SUBCELLULAR LOCATION.
RX   PubMed=20074560; DOI=10.1016/j.bbrc.2010.01.025;
RA   Koyama S., Wada-Hiraike O., Nakagawa S., Tanikawa M., Hiraike H.,
RA   Miyamoto Y., Sone K., Oda K., Fukuhara H., Nakagawa K., Kato S.,
RA   Yano T., Taketani Y.;
RT   "Repression of estrogen receptor beta function by putative tumor
RT   suppressor DBC1.";
RL   Biochem. Biophys. Res. Commun. 392:357-362(2010).
RN   [82]
RP   FUNCTION IN SYNERGISM WITH NF-KAPPA-B.
RX   PubMed=20705611; DOI=10.1074/jbc.M110.155309;
RA   Pradhan M., Bembinster L.A., Baumgarten S.C., Frasor J.;
RT   "Proinflammatory cytokines enhance estrogen-dependent expression of
RT   the multidrug transporter gene ABCG2 through estrogen receptor and
RT   NF{kappa}B cooperativity at adjacent response elements.";
RL   J. Biol. Chem. 285:31100-31106(2010).
RN   [83]
RP   INTERACTION WITH ZFHX3.
RX   PubMed=20720010; DOI=10.1074/jbc.M110.128330;
RA   Dong X.Y., Sun X., Guo P., Li Q., Sasahara M., Ishii Y., Dong J.T.;
RT   "ATBF1 inhibits estrogen receptor (ER) function by selectively
RT   competing with AIB1 for binding to the ER in ER-positive breast cancer
RT   cells.";
RL   J. Biol. Chem. 285:32801-32809(2010).
RN   [84]
RP   INTERACTION WITH ESRRB.
RX   PubMed=19755138; DOI=10.1016/j.mce.2009.09.007;
RA   Bombail V., Collins F., Brown P., Saunders P.T.;
RT   "Modulation of ER alpha transcriptional activity by the orphan nuclear
RT   receptor ERR beta and evidence for differential effects of long- and
RT   short-form splice variants.";
RL   Mol. Cell. Endocrinol. 314:53-61(2010).
RN   [85]
RP   INTERACTION WITH SAV1 AND STK3/MST2.
RX   PubMed=21104395; DOI=10.1007/s00109-010-0698-y;
RA   Park Y., Park J., Lee Y., Lim W., Oh B.C., Shin C., Kim W., Lee Y.;
RT   "Mammalian MST2 kinase and human Salvador activate and reduce estrogen
RT   receptor alpha in the absence of ligand.";
RL   J. Mol. Med. 89:181-191(2011).
RN   [86]
RP   FUNCTION (ISOFORM 3), SUBCELLULAR LOCATION (ISOFORM 3), TOPOLOGY
RP   (ISOFORM 3), AND MUTAGENESIS OF ILE-386.
RX   PubMed=21937726; DOI=10.1091/mbc.E11-05-0416;
RA   Kim K.H., Toomre D., Bender J.R.;
RT   "Splice isoform estrogen receptors as integral transmembrane
RT   proteins.";
RL   Mol. Biol. Cell 22:4415-4423(2011).
RN   [87]
RP   FUNCTION IN ERE-INDEPENDENT SIGNALING.
RX   PubMed=21330404; DOI=10.1210/me.2010-0425;
RA   Heldring N., Isaacs G.D., Diehl A.G., Sun M., Cheung E., Ranish J.A.,
RA   Kraus W.L.;
RT   "Multiple sequence-specific DNA-binding proteins mediate estrogen
RT   receptor signaling through a tethering pathway.";
RL   Mol. Endocrinol. 25:564-574(2011).
RN   [88]
RP   INTERACTION WITH LMTK3, PHOSPHORYLATION, AND UBIQUITINATION.
RX   PubMed=21602804; DOI=10.1038/nm.2351;
RA   Giamas G., Filipovic A., Jacob J., Messier W., Zhang H., Yang D.,
RA   Zhang W., Shifa B.A., Photiou A., Tralau-Stewart C., Castellano L.,
RA   Green A.R., Coombes R.C., Ellis I.O., Ali S., Lenz H.J., Stebbing J.;
RT   "Kinome screening for regulators of the estrogen receptor identifies
RT   LMTK3 as a new therapeutic target in breast cancer.";
RL   Nat. Med. 17:715-719(2011).
RN   [89]
RP   SUBCELLULAR LOCATION, AND PALMITOYLATION.
RX   PubMed=22031296; DOI=10.1091/mbc.E11-07-0638;
RA   Pedram A., Razandi M., Deschenes R.J., Levin E.R.;
RT   "DHHC-7 and -21 are palmitoylacyltransferases for sex steroid
RT   receptors.";
RL   Mol. Biol. Cell 23:188-199(2012).
RN   [90]
RP   FUNCTION IN SYNERGISM WITH NF-KAPPA-B.
RX   PubMed=22083956; DOI=10.1128/MCB.05869-11;
RA   Pradhan M., Baumgarten S.C., Bembinster L.A., Frasor J.;
RT   "CBP mediates NF-kappaB-dependent histone acetylation and estrogen
RT   receptor recruitment to an estrogen response element in the BIRC3
RT   promoter.";
RL   Mol. Cell. Biol. 32:569-575(2012).
RN   [91]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH CLOCK.
RX   PubMed=23160374; DOI=10.1038/onc.2012.518;
RA   Li S., Wang M., Ao X., Chang A.K., Yang C., Zhao F., Bi H., Liu Y.,
RA   Xiao L., Wu H.;
RT   "CLOCK is a substrate of SUMO and sumoylation of CLOCK upregulates the
RT   transcriptional activity of estrogen receptor-alpha.";
RL   Oncogene 32:4883-4891(2013).
RN   [92]
RP   INTERACTION WITH SFR1.
RX   PubMed=23874500; DOI=10.1371/journal.pone.0068075;
RA   Feng Y., Singleton D., Guo C., Gardner A., Pakala S., Kumar R.,
RA   Jensen E., Zhang J., Khan S.;
RT   "DNA homologous recombination factor SFR1 physically and functionally
RT   interacts with estrogen receptor alpha.";
RL   PLoS ONE 8:E68075-E68075(2013).
RN   [93]
RP   INTERACTION WITH TRIP4.
RX   PubMed=25219498; DOI=10.1016/j.molcel.2014.08.007;
RA   Yoo H.M., Kang S.H., Kim J.Y., Lee J.E., Seong M.W., Lee S.W.,
RA   Ka S.H., Sou Y.S., Komatsu M., Tanaka K., Lee S.T., Noh D.Y.,
RA   Baek S.H., Jeon Y.J., Chung C.H.;
RT   "Modification of ASC1 by UFM1 is crucial for ERalpha transactivation
RT   and breast cancer development.";
RL   Mol. Cell 56:261-274(2014).
RN   [94]
RP   INTERACTION WITH DCAF13; LATS1 AND DCAF1, AND UBIQUITINATION.
RX   PubMed=28068668; DOI=10.1038/nature20829;
RA   Britschgi A., Duss S., Kim S., Couto J.P., Brinkhaus H., Koren S.,
RA   De Silva D., Mertz K.D., Kaup D., Varga Z., Voshol H., Vissieres A.,
RA   Leroy C., Roloff T., Stadler M.B., Scheel C.H., Miraglia L.J.,
RA   Orth A.P., Bonamy G.M., Reddy V.A., Bentires-Alj M.;
RT   "The Hippo kinases LATS1 and 2 control human breast cell fate via
RT   crosstalk with ERalpha.";
RL   Nature 541:541-545(2017).
RN   [95]
RP   STRUCTURE BY NMR OF 180-262.
RX   PubMed=2247153; DOI=10.1038/348458a0;
RA   Schwabe J.W.E., Neuhaus D., Rhodes D.;
RT   "Solution structure of the DNA-binding domain of the oestrogen
RT   receptor.";
RL   Nature 348:458-461(1990).
RN   [96]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 180-262.
RX   PubMed=8221895; DOI=10.1016/0092-8674(93)90390-C;
RA   Schwabe J.W.E., Chapman L., Finch J.T., Rhodes D.;
RT   "The crystal structure of the estrogen receptor DNA-binding domain
RT   bound to DNA: how receptors discriminate between their response
RT   elements.";
RL   Cell 75:567-578(1993).
RN   [97]
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 305-548.
RX   PubMed=9338790; DOI=10.1038/39645;
RA   Brzozowski A.M., Pike A.C.W., Dauter Z., Hubbard R.E., Bonn T.,
RA   Engstroem O., Oehman L., Greene G.L., Gustafsson J.-A., Carlquist M.;
RT   "Molecular basis of agonism and antagonism in the oestrogen
RT   receptor.";
RL   Nature 389:753-758(1997).
RN   [98]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 306-544.
RX   PubMed=9600906; DOI=10.1073/pnas.95.11.5998;
RA   Tanenbaum D.M., Wang Y., Williams S.P., Sigler P.B.;
RT   "Crystallographic comparison of the estrogen and progesterone
RT   receptor's ligand binding domains.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:5998-6003(1998).
RN   [99]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 294-554.
RX   PubMed=9875847; DOI=10.1016/S0092-8674(00)81717-1;
RA   Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J.,
RA   Agard D.A., Greene G.L.;
RT   "The structural basis of estrogen receptor/coactivator recognition and
RT   the antagonism of this interaction by tamoxifen.";
RL   Cell 95:927-937(1998).
RN   [100]
RP   3D-STRUCTURE MODELING OF 311-547.
RX   PubMed=9619507; DOI=10.1080/07391102.1998.10508206;
RA   Maalouf G.J., Xu W., Smith T., Mohr S.C.;
RT   "Homology model for the ligand-binding domain of the human estrogen
RT   receptor.";
RL   J. Biomol. Struct. Dyn. 15:841-850(1998).
RN   [101]
RP   VARIANT VAL-400.
RX   PubMed=2792078;
RA   Tora L., Mullick A., Metzger D., Ponglikitmongkol M., Park I.,
RA   Chambon P.;
RT   "The cloned human oestrogen receptor contains a mutation which alters
RT   its hormone binding properties.";
RL   EMBO J. 8:1981-1986(1989).
RN   [102]
RP   VARIANT CYS-160.
RX   PubMed=9195227;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:6<531::AID-HUMU6>3.3.CO;2-J;
RA   Anderson T.I., Wooster R., Laake K., Collins N., Warren W., Skrede M.,
RA   Eeles R., Tveit K.M., Johnston S.R.D., Dowsett M., Olsen A.O.,
RA   Moeller P., Stratton M.R., Boerresen-Dale A.-L.;
RT   "Screening for ESR mutations in breast and ovarian cancer patients.";
RL   Hum. Mutat. 9:531-536(1997).
RN   [103]
RP   INVOLVEMENT IN BMD.
RX   PubMed=10942433; DOI=10.1093/hmg/9.13.2043;
RA   Becherini L., Gennari L., Masi L., Mansani R., Massart F., Morelli A.,
RA   Falchetti A., Gonnelli S., Fiorelli G., Tanini A., Brandi M.L.;
RT   "Evidence of a linkage disequilibrium between polymorphisms in the
RT   human estrogen receptor alpha gene and their relationship to bone mass
RT   variation in postmenopausal Italian women.";
RL   Hum. Mol. Genet. 9:2043-2050(2000).
RN   [104]
RP   INTERACTION WITH GPER1.
RX   PubMed=19749156; DOI=10.1210/me.2009-0120;
RA   Vivacqua A., Lappano R., De Marco P., Sisci D., Aquila S.,
RA   De Amicis F., Fuqua S.A., Ando S., Maggiolini M.;
RT   "G protein-coupled receptor 30 expression is up-regulated by EGF and
RT   TGF alpha in estrogen receptor alpha-positive cancer cells.";
RL   Mol. Endocrinol. 23:1815-1826(2009).
RN   [105]
RP   VARIANTS TYR-6 AND ILE-264.
RX   PubMed=17224074; DOI=10.1186/bcr1637;
RA   Chanock S.J., Burdett L., Yeager M., Llaca V., Langeroed A.,
RA   Presswalla S., Kaaresen R., Strausberg R.L., Gerhard D.S.,
RA   Kristensen V., Perou C.M., Boerresen-Dale A.-L.;
RT   "Somatic sequence alterations in twenty-one genes selected by
RT   expression profile analysis of breast carcinomas.";
RL   Breast Cancer Res. 9:R5-R5(2007).
RN   [106]
RP   VARIANT ESTRR HIS-375, AND CHARACTERIZATION OF VARIANT ESTRR HIS-375.
RX   PubMed=23841731; DOI=10.1056/NEJMoa1303611;
RA   Quaynor S.D., Stradtman E.W. Jr., Kim H.G., Shen Y., Chorich L.P.,
RA   Schreihofer D.A., Layman L.C.;
RT   "Delayed puberty and estrogen resistance in a woman with estrogen
RT   receptor alpha variant.";
RL   N. Engl. J. Med. 369:164-171(2013).
RN   [107]
RP   VARIANT ESTRR HIS-394, AND CHARACTERIZATION OF VARIANT ESTRR HIS-394.
RX   PubMed=27754803; DOI=10.1210/jc.2016-2749;
RA   Bernard V., Kherra S., Francou B., Fagart J., Viengchareun S.,
RA   Guechot J., Ladjouze A., Guiochon-Mantel A., Korach K.S., Binart N.,
RA   Lombes M., Christin-Maitre S.;
RT   "Familial multiplicity of estrogen insensitivity associated with a
RT   loss-of-function ESR1 mutation.";
RL   J. Clin. Endocrinol. Metab. 102:93-99(2017).
CC   -!- FUNCTION: Nuclear hormone receptor. The steroid hormones and their
CC       receptors are involved in the regulation of eukaryotic gene
CC       expression and affect cellular proliferation and differentiation
CC       in target tissues. Ligand-dependent nuclear transactivation
CC       involves either direct homodimer binding to a palindromic estrogen
CC       response element (ERE) sequence or association with other DNA-
CC       binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2,
CC       Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding
CC       induces a conformational change allowing subsequent or
CC       combinatorial association with multiprotein coactivator complexes
CC       through LXXLL motifs of their respective components. Mutual
CC       transrepression occurs between the estrogen receptor (ER) and NF-
CC       kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-
CC       binding activity and inhibits NF-kappa-B-mediated transcription
CC       from the IL6 promoter and displace RELA/p65 and associated
CC       coregulators from the promoter. Recruited to the NF-kappa-B
CC       response element of the CCL2 and IL8 promoters and can displace
CC       CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50
CC       on ERE sequences. Can also act synergistically with NF-kappa-B to
CC       activate transcription involving respective recruitment adjacent
CC       response elements; the function involves CREBBP. Can activate the
CC       transcriptional activity of TFF1. Also mediates membrane-initiated
CC       estrogen signaling involving various kinase cascades. Isoform 3 is
CC       involved in activation of NOS3 and endothelial nitric oxide
CC       production. Isoforms lacking one or several functional domains are
CC       thought to modulate transcriptional activity by competitive ligand
CC       or DNA binding and/or heterodimerization with the full-length
CC       receptor. Essential for MTA1-mediated transcriptional regulation
CC       of BRCA1 and BCAS3. Isoform 3 can bind to ERE and inhibit isoform
CC       1. {ECO:0000269|PubMed:10681512, ECO:0000269|PubMed:10816575,
CC       ECO:0000269|PubMed:11477071, ECO:0000269|PubMed:11682626,
CC       ECO:0000269|PubMed:14764652, ECO:0000269|PubMed:15078875,
CC       ECO:0000269|PubMed:15891768, ECO:0000269|PubMed:16043358,
CC       ECO:0000269|PubMed:16617102, ECO:0000269|PubMed:16684779,
CC       ECO:0000269|PubMed:17922032, ECO:0000269|PubMed:17932106,
CC       ECO:0000269|PubMed:18247370, ECO:0000269|PubMed:19350539,
CC       ECO:0000269|PubMed:20074560, ECO:0000269|PubMed:20705611,
CC       ECO:0000269|PubMed:21330404, ECO:0000269|PubMed:22083956,
CC       ECO:0000269|PubMed:7651415, ECO:0000269|PubMed:9328340}.
CC   -!- SUBUNIT: Binds DNA as a homodimer. Can form a heterodimer with
CC       ESR2. Isoform 3 can probably homodimerize or heterodimerize with
CC       isoform 1 and ESR2. Interacts with FOXC2, MAP1S, SLC30A9, UBE1C
CC       and NCOA3 coactivator (By similarity). Interacts with EP300; the
CC       interaction is estrogen-dependent and enhanced by CITED1.
CC       Interacts with CITED1; the interaction is estrogen-dependent.
CC       Interacts with NCOA5 and NCOA6 coactivators. Interacts with NCOA7;
CC       the interaction is a ligand-inducible. Interacts with PHB2, PELP1
CC       and UBE1C. Interacts with AKAP13. Interacts with CUEDC2. Interacts
CC       with KDM5A. Interacts with SMARD1. Interacts with HEXIM1.
CC       Interacts with PBXIP1. Interaction with MUC1 is stimulated by 7
CC       beta-estradiol (E2) and enhances ERS1-mediated transcription.
CC       Interacts with DNTTIP2, FAM120B and UIMC1. Interacts with isoform
CC       4 of TXNRD1. Interacts with KMT2D/MLL2. Interacts with ATAD2 and
CC       this interaction is enhanced by estradiol. Interacts with KIF18A
CC       and LDB1. Interacts with RLIM (via C-terminus). Interacts with
CC       MACROD1. Interacts with SH2D4A and PLCG. Interaction with SH2D4A
CC       blocks binding to PLCG and inhibits estrogen-induced cell
CC       proliferation. Interacts with DYNLL1. Interacts with CCDC62 in the
CC       presence of estradiol/E2; this interaction seems to enhance the
CC       transcription of target genes. Interacts with NR2C1; the
CC       interaction prevents homodimerization of ESR1 and suppresses its
CC       transcriptional activity and cell growth. Interacts with DNAAF4.
CC       Interacts with PRMT2. Interacts with PI3KR1 or PI3KR2, SRC and
CC       PTK2/FAK1. Interacts with RBFOX2. Interacts with STK3/MST2 only in
CC       the presence of SAV1 and vice-versa. Binds to CSNK1D. Interacts
CC       with NCOA2; NCOA2 can interact with ESR1 AF-1 and AF-2 domains
CC       simultaneously and mediate their transcriptional synergy.
CC       Interacts with DDX5. Interacts with NCOA1; the interaction seems
CC       to require a self-association of N-terminal and C-terminal
CC       regions. Interacts with ZNF366, DDX17, NFKB1, RELA, SP1 and SP3.
CC       Interacts with NRIP1 (By similarity). Interacts with GPER1; the
CC       interaction occurs in an estrogen-dependent manner. Interacts with
CC       CLOCK and the interaction is stimulated by estrogen. Interacts
CC       with BCAS3. Interacts with TRIP4 (ufmylated); estrogen dependent.
CC       Interacts with LMTK3; the interaction phosphorylates ESR1 (in
CC       vitro) and protects it against proteasomal degradation. Interacts
CC       with CCAR2 (via N-terminus) in a ligand-independent manner.
CC       Interacts with ZFHX3. Interacts with SFR1 in a ligand-dependent
CC       and -independent manner (PubMed:23874500). Interacts with DCAF13,
CC       LATS1 and DCAF1; regulates ESR1 ubiquitination and ubiquitin-
CC       mediated proteasomal degradation (PubMed:28068668). Interacts (via
CC       DNA-binding domain) with POU4F2 (C-terminus); this interaction
CC       increases the estrogen receptor ESR1 transcriptional activity in a
CC       DNA- and ligand 17-beta-estradiol-independent manner (By
CC       similarity). Interacts with ESRRB isoform 1 (PubMed:19755138).
CC       Interacts with UBE3A nad WBP2 (PubMed:16772533). {ECO:0000250,
CC       ECO:0000250|UniProtKB:P19785, ECO:0000269|PubMed:10359819,
CC       ECO:0000269|PubMed:10409727, ECO:0000269|PubMed:10567404,
CC       ECO:0000269|PubMed:10681512, ECO:0000269|PubMed:10816575,
CC       ECO:0000269|PubMed:10970861, ECO:0000269|PubMed:11113208,
CC       ECO:0000269|PubMed:11265755, ECO:0000269|PubMed:11358960,
CC       ECO:0000269|PubMed:11477071, ECO:0000269|PubMed:11581164,
CC       ECO:0000269|PubMed:11682626, ECO:0000269|PubMed:11875103,
CC       ECO:0000269|PubMed:11971969, ECO:0000269|PubMed:12039952,
CC       ECO:0000269|PubMed:12093804, ECO:0000269|PubMed:12415108,
CC       ECO:0000269|PubMed:12554772, ECO:0000269|PubMed:12917342,
CC       ECO:0000269|PubMed:15047147, ECO:0000269|PubMed:15199063,
CC       ECO:0000269|PubMed:15891768, ECO:0000269|PubMed:15940264,
CC       ECO:0000269|PubMed:16427018, ECO:0000269|PubMed:16603732,
CC       ECO:0000269|PubMed:16772533, ECO:0000269|PubMed:17006958,
CC       ECO:0000269|PubMed:17043237, ECO:0000269|PubMed:17085477,
CC       ECO:0000269|PubMed:17311814, ECO:0000269|PubMed:17347654,
CC       ECO:0000269|PubMed:17505058, ECO:0000269|PubMed:17587566,
CC       ECO:0000269|PubMed:17658481, ECO:0000269|PubMed:17914104,
CC       ECO:0000269|PubMed:17932106, ECO:0000269|PubMed:17998543,
CC       ECO:0000269|PubMed:18563714, ECO:0000269|PubMed:18657504,
CC       ECO:0000269|PubMed:19117995, ECO:0000269|PubMed:19339517,
CC       ECO:0000269|PubMed:19350539, ECO:0000269|PubMed:19383985,
CC       ECO:0000269|PubMed:19423554, ECO:0000269|PubMed:19636373,
CC       ECO:0000269|PubMed:19712589, ECO:0000269|PubMed:19718048,
CC       ECO:0000269|PubMed:19749156, ECO:0000269|PubMed:19755138,
CC       ECO:0000269|PubMed:20074560, ECO:0000269|PubMed:20720010,
CC       ECO:0000269|PubMed:21104395, ECO:0000269|PubMed:21602804,
CC       ECO:0000269|PubMed:23160374, ECO:0000269|PubMed:23874500,
CC       ECO:0000269|PubMed:25219498, ECO:0000269|PubMed:28068668,
CC       ECO:0000269|PubMed:9328340, ECO:0000269|PubMed:9627117}.
CC   -!- INTERACTION:
CC       Self; NbExp=9; IntAct=EBI-78473, EBI-78473;
CC       Q12802:AKAP13; NbExp=3; IntAct=EBI-78473, EBI-1373806;
CC       Q03989:ARID5A; NbExp=9; IntAct=EBI-78473, EBI-948603;
CC       Q9Y294:ASF1A; NbExp=2; IntAct=EBI-78473, EBI-749553;
CC       Q8IXJ9:ASXL1; NbExp=2; IntAct=EBI-78473, EBI-1646500;
CC       P59598:Asxl1 (xeno); NbExp=2; IntAct=EBI-78473, EBI-5743705;
CC       Q6PL18:ATAD2; NbExp=3; IntAct=EBI-78473, EBI-6598454;
CC       P62952:BLCAP; NbExp=2; IntAct=EBI-78473, EBI-3895726;
CC       P38398:BRCA1; NbExp=12; IntAct=EBI-78473, EBI-349905;
CC       P20290-2:BTF3; NbExp=5; IntAct=EBI-78473, EBI-1054703;
CC       Q86Y37:CACUL1; NbExp=5; IntAct=EBI-78473, EBI-8168227;
CC       Q99966:CITED1; NbExp=3; IntAct=EBI-78473, EBI-2624951;
CC       Q9H467:CUEDC2; NbExp=2; IntAct=EBI-78473, EBI-1248228;
CC       O00429:DNM1L; NbExp=2; IntAct=EBI-78473, EBI-724571;
CC       P00533:EGFR; NbExp=4; IntAct=EBI-4309277, EBI-297353;
CC       Q09472:EP300; NbExp=2; IntAct=EBI-78473, EBI-447295;
CC       Q92731:ESR2; NbExp=5; IntAct=EBI-15606245, EBI-78505;
CC       Q12778:FOXO1; NbExp=2; IntAct=EBI-78473, EBI-1108782;
CC       Q9Y3R0:GRIP1; NbExp=2; IntAct=EBI-78473, EBI-5349621;
CC       O00165:HAX1; NbExp=2; IntAct=EBI-78473, EBI-357001;
CC       P05627:Jun (xeno); NbExp=6; IntAct=EBI-78473, EBI-764369;
CC       Q92993:KAT5; NbExp=3; IntAct=EBI-15606245, EBI-399080;
CC       O15054:KDM6B; NbExp=2; IntAct=EBI-78473, EBI-2831260;
CC       O14686:KMT2D; NbExp=3; IntAct=EBI-78473, EBI-996065;
CC       Q9BQ69:MACROD1; NbExp=4; IntAct=EBI-78473, EBI-5324932;
CC       Q00987:MDM2; NbExp=2; IntAct=EBI-78473, EBI-389668;
CC       P60660:MYL6; NbExp=3; IntAct=EBI-78473, EBI-300817;
CC       Q15788:NCOA1; NbExp=7; IntAct=EBI-78473, EBI-455189;
CC       Q15596:NCOA2; NbExp=5; IntAct=EBI-78473, EBI-81236;
CC       Q9Y6Q9:NCOA3; NbExp=4; IntAct=EBI-78473, EBI-81196;
CC       Q9JLI4:Ncoa6 (xeno); NbExp=2; IntAct=EBI-78473, EBI-286271;
CC       Q9UN36:NDRG2; NbExp=2; IntAct=EBI-78473, EBI-3895741;
CC       P19838:NFKB1; NbExp=3; IntAct=EBI-78473, EBI-697771;
CC       Q96RI1-3:NR1H4; NbExp=2; IntAct=EBI-78473, EBI-10921781;
CC       Q9BTK6:PAGR1; NbExp=5; IntAct=EBI-78473, EBI-2372223;
CC       Q96AQ6-1:PBXIP1; NbExp=5; IntAct=EBI-15606245, EBI-15606280;
CC       P62962:Pfn1 (xeno); NbExp=3; IntAct=EBI-78473, EBI-647096;
CC       P06401:PGR; NbExp=20; IntAct=EBI-78473, EBI-78539;
CC       P06401-1:PGR; NbExp=4; IntAct=EBI-78473, EBI-12590474;
CC       Q99623:PHB2; NbExp=4; IntAct=EBI-78473, EBI-358348;
CC       P27986:PIK3R1; NbExp=7; IntAct=EBI-78473, EBI-79464;
CC       P53041:PPP5C; NbExp=4; IntAct=EBI-78473, EBI-716663;
CC       P55345:PRMT2; NbExp=9; IntAct=EBI-78473, EBI-78458;
CC       P60763:RAC3; NbExp=5; IntAct=EBI-78473, EBI-767084;
CC       O43251:RBFOX2; NbExp=4; IntAct=EBI-78473, EBI-746056;
CC       Q04206:RELA; NbExp=7; IntAct=EBI-78473, EBI-73886;
CC       Q14151:SAFB2; NbExp=2; IntAct=EBI-78473, EBI-352869;
CC       Q96HI0:SENP5; NbExp=2; IntAct=EBI-78473, EBI-3895753;
CC       P29353:SHC1; NbExp=2; IntAct=EBI-4309277, EBI-78835;
CC       P08047:SP1; NbExp=2; IntAct=EBI-78473, EBI-298336;
CC       Q02447:SP3; NbExp=2; IntAct=EBI-78473, EBI-348158;
CC       P00523:SRC (xeno); NbExp=2; IntAct=EBI-78473, EBI-848039;
CC       P12931:SRC; NbExp=11; IntAct=EBI-78473, EBI-621482;
CC       O15164:TRIM24; NbExp=3; IntAct=EBI-78473, EBI-2130378;
CC       Q16881-4:TXNRD1; NbExp=4; IntAct=EBI-78473, EBI-9080335;
CC       Q9UBK9:UXT; NbExp=2; IntAct=EBI-78473, EBI-357355;
CC       Q8N895:ZNF366; NbExp=6; IntAct=EBI-78473, EBI-2813661;
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Nucleus {ECO:0000255|PROSITE-
CC       ProRule:PRU00407, ECO:0000269|PubMed:12682286,
CC       ECO:0000269|PubMed:20074560}. Cytoplasm
CC       {ECO:0000269|PubMed:12682286}. Cell membrane
CC       {ECO:0000269|PubMed:12682286}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:12682286}; Cytoplasmic side
CC       {ECO:0000269|PubMed:12682286}. Note=A minor fraction is associated
CC       with the inner membrane.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Nucleus. Cytoplasm. Cell
CC       membrane; Peripheral membrane protein; Cytoplasmic side. Cell
CC       membrane; Single-pass type I membrane protein. Note=Associated
CC       with the inner membrane via palmitoylation (Probable). At least a
CC       subset exists as a transmembrane protein with a N-terminal
CC       extracellular domain. {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Nucleus. Golgi apparatus. Cell membrane.
CC       Note=Colocalizes with ZDHHC7 and ZDHHC21 in the Golgi apparatus
CC       where most probably palmitoylation occurs. Associated with the
CC       plasma membrane when palmitoylated.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=Long, hER-alpha66, ER66;
CC         IsoId=P03372-1; Sequence=Displayed;
CC       Name=2; Synonyms=Short;
CC         IsoId=P03372-2; Sequence=VSP_003680;
CC         Note=No experimental confirmation available.;
CC       Name=3; Synonyms=hER-alpha46, ER46;
CC         IsoId=P03372-3; Sequence=VSP_042460;
CC         Note=Produced by alternative promoter usage.;
CC       Name=4; Synonyms=hER-alpha36, ER36;
CC         IsoId=P03372-4; Sequence=VSP_042460, VSP_042461;
CC         Note=Produced by alternative splicing of isoform 3.;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Isoform 3 is not expressed
CC       in the pituitary gland. {ECO:0000269|PubMed:10970861}.
CC   -!- DOMAIN: Composed of three domains: a modulating N-terminal domain,
CC       a DNA-binding domain and a C-terminal ligand-binding domain. The
CC       modulating domain, also known as A/B or AF-1 domain has a ligand-
CC       independent transactivation function. The C-terminus contains a
CC       ligand-dependent transactivation domain, also known as E/F or AF-2
CC       domain which overlaps with the ligand binding domain. AF-1 and AF-
CC       2 activate transcription independently and synergistically and act
CC       in a promoter- and cell-specific manner. AF-1 seems to provide the
CC       major transactivation function in differentiated cells.
CC   -!- PTM: Phosphorylated by cyclin A/CDK2 and CK1. Phosphorylation
CC       probably enhances transcriptional activity. Self-association
CC       induces phosphorylation. Dephosphorylation at Ser-118 by PPP5C
CC       inhibits its transactivation activity. Phosphorylated by LMTK3 in
CC       vitro. {ECO:0000269|PubMed:10428798, ECO:0000269|PubMed:14764652,
CC       ECO:0000269|PubMed:19339517, ECO:0000269|PubMed:21602804,
CC       ECO:0000269|PubMed:7476978, ECO:0000269|PubMed:7539106,
CC       ECO:0000269|PubMed:7838153}.
CC   -!- PTM: Glycosylated; contains N-acetylglucosamine, probably O-
CC       linked. {ECO:0000269|PubMed:8999954}.
CC   -!- PTM: Ubiquitinated; regulated by LATS1 via DCAF1 it leads to ESR1
CC       proteasomal degradation (PubMed:21602804, PubMed:28068668).
CC       Deubiquitinated by OTUB1 (PubMed:19383985).
CC       {ECO:0000269|PubMed:19383985, ECO:0000269|PubMed:21602804,
CC       ECO:0000269|PubMed:28068668}.
CC   -!- PTM: Dimethylated by PRMT1 at Arg-260. The methylation may favor
CC       cytoplasmic localization. {ECO:0000269|PubMed:18657504}.
CC   -!- PTM: Palmitoylated (isoform 3). Not biotinylated (isoform 3).
CC       {ECO:0000269|PubMed:22031296}.
CC   -!- PTM: Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is
CC       required for plasma membrane targeting and for rapid intracellular
CC       signaling via ERK and AKT kinases and cAMP generation, but not for
CC       signaling mediated by the nuclear hormone receptor.
CC       {ECO:0000269|PubMed:22031296}.
CC   -!- POLYMORPHISM: Genetic variations in ESR1 are correlated with bone
CC       mineral density (BMD). Low BMD is a risk factor for osteoporotic
CC       fracture. Osteoporosis is characterized by reduced bone mineral
CC       density, disruption of bone microarchitecture, and the alteration
CC       of the amount and variety of non-collagenous proteins in bone.
CC       Osteoporotic bones are more at risk of fracture.
CC       {ECO:0000269|PubMed:10942433}.
CC   -!- DISEASE: Estrogen resistance (ESTRR) [MIM:615363]: A disorder
CC       characterized by partial or complete resistance to estrogens, in
CC       the presence of elevated estrogen serum levels. Clinical features
CC       include absence of the pubertal growth spurt, delayed bone
CC       maturation, unfused epiphyses, reduced bone mineral density,
CC       osteoporosis, continued growth into adulthood and very tall adult
CC       stature. Glucose intolerance, hyperinsulinemia and lipid
CC       abnormalities may also be present. {ECO:0000269|PubMed:23841731,
CC       ECO:0000269|PubMed:27754803}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Selective estrogen receptor modulators (SERMs),
CC       such as tamoxifen, raloxifene, toremifene, lasofoxifene,
CC       clomifene, femarelle and ormeloxifene, have tissue selective
CC       agonistic and antagonistic effects on the estrogen receptor (ER).
CC       They interfere with the ER association with coactivators or
CC       corepressors, mainly involving the AF-2 domain.
CC   -!- SIMILARITY: Belongs to the nuclear hormone receptor family. NR3
CC       subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB00115.1; Type=Miscellaneous discrepancy; Note=contains an in-frame duplication of exons 6 and 7.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/esr1/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Estrogen receptor entry;
CC       URL="https://en.wikipedia.org/wiki/Estrogen_receptor";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X03635; CAA27284.1; -; mRNA.
DR   EMBL; M12674; AAA52399.1; -; mRNA.
DR   EMBL; U47678; AAB00115.1; ALT_SEQ; mRNA.
DR   EMBL; AY425004; AAQ91815.1; -; Genomic_DNA.
DR   EMBL; BX640939; CAE45969.1; -; mRNA.
DR   EMBL; AL049821; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL078582; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL356311; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL590993; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471051; EAW47740.1; -; Genomic_DNA.
DR   EMBL; BC128573; AAI28574.1; -; mRNA.
DR   EMBL; BC128574; AAI28575.1; -; mRNA.
DR   EMBL; AH008151; AAD52984.1; -; Genomic_DNA.
DR   EMBL; X73067; CAA51528.1; -; mRNA.
DR   EMBL; Z75126; CAA99436.1; -; mRNA.
DR   CCDS; CCDS5234.1; -. [P03372-1]
DR   PIR; S64737; S64737.
DR   RefSeq; NP_000116.2; NM_000125.3. [P03372-1]
DR   RefSeq; NP_001116212.1; NM_001122740.1. [P03372-1]
DR   RefSeq; NP_001116213.1; NM_001122741.1. [P03372-1]
DR   RefSeq; NP_001116214.1; NM_001122742.1. [P03372-1]
DR   RefSeq; NP_001278159.1; NM_001291230.1.
DR   RefSeq; NP_001278170.1; NM_001291241.1.
DR   RefSeq; NP_001315029.1; NM_001328100.1.
DR   RefSeq; XP_006715438.1; XM_006715375.3. [P03372-3]
DR   RefSeq; XP_011533845.1; XM_011535543.2. [P03372-1]
DR   RefSeq; XP_011533846.1; XM_011535544.2. [P03372-1]
DR   RefSeq; XP_011533847.1; XM_011535545.2. [P03372-1]
DR   RefSeq; XP_016865865.1; XM_017010376.1. [P03372-1]
DR   RefSeq; XP_016865866.1; XM_017010377.1. [P03372-1]
DR   RefSeq; XP_016865867.1; XM_017010378.1. [P03372-1]
DR   RefSeq; XP_016865868.1; XM_017010379.1. [P03372-1]
DR   RefSeq; XP_016865869.1; XM_017010380.1. [P03372-1]
DR   RefSeq; XP_016865870.1; XM_017010381.1. [P03372-1]
DR   UniGene; Hs.208124; -.
DR   UniGene; Hs.744830; -.
DR   PDB; 1A52; X-ray; 2.80 A; A/B=297-554.
DR   PDB; 1AKF; Model; -; A=309-547.
DR   PDB; 1ERE; X-ray; 3.10 A; A/B/C/D/E/F=301-553.
DR   PDB; 1ERR; X-ray; 2.60 A; A/B=301-553.
DR   PDB; 1G50; X-ray; 2.90 A; A/B/C=304-550.
DR   PDB; 1GWQ; X-ray; 2.45 A; A/B=301-548.
DR   PDB; 1GWR; X-ray; 2.40 A; A/B=305-549.
DR   PDB; 1HCP; NMR; -; A=180-254.
DR   PDB; 1HCQ; X-ray; 2.40 A; A/B/E/F=180-262.
DR   PDB; 1L2I; X-ray; 1.95 A; A/B=297-554.
DR   PDB; 1PCG; X-ray; 2.70 A; A/B=304-547.
DR   PDB; 1QKT; X-ray; 2.20 A; A=304-551.
DR   PDB; 1QKU; X-ray; 3.20 A; A/B/C=301-550.
DR   PDB; 1R5K; X-ray; 2.70 A; A/B/C=297-554.
DR   PDB; 1SJ0; X-ray; 1.90 A; A=307-554.
DR   PDB; 1UOM; X-ray; 2.28 A; A=301-553.
DR   PDB; 1X7E; X-ray; 2.80 A; A/B=305-549.
DR   PDB; 1X7R; X-ray; 2.00 A; A=305-549.
DR   PDB; 1XP1; X-ray; 1.80 A; A=307-554.
DR   PDB; 1XP6; X-ray; 1.70 A; A=307-554.
DR   PDB; 1XP9; X-ray; 1.80 A; A=307-554.
DR   PDB; 1XPC; X-ray; 1.60 A; A=307-554.
DR   PDB; 1XQC; X-ray; 2.05 A; A/B/C/D=301-553.
DR   PDB; 1YIM; X-ray; 1.90 A; A=307-554.
DR   PDB; 1YIN; X-ray; 2.20 A; A=307-554.
DR   PDB; 1ZKY; X-ray; 2.25 A; A/B=298-554.
DR   PDB; 2AYR; X-ray; 1.90 A; A=304-551.
DR   PDB; 2B1V; X-ray; 1.80 A; A/B=298-554.
DR   PDB; 2B1Z; X-ray; 1.78 A; A/B=298-554.
DR   PDB; 2B23; X-ray; 2.10 A; A/B=298-554.
DR   PDB; 2BJ4; X-ray; 2.00 A; A/B=305-533.
DR   PDB; 2FAI; X-ray; 2.10 A; A/B=298-554.
DR   PDB; 2G44; X-ray; 2.65 A; A/B=298-554.
DR   PDB; 2G5O; X-ray; 2.30 A; A/B=298-554.
DR   PDB; 2I0J; X-ray; 2.90 A; A/B/C/D=304-547.
DR   PDB; 2IOG; X-ray; 1.60 A; A=309-554.
DR   PDB; 2IOK; X-ray; 2.40 A; A/B=301-554.
DR   PDB; 2JF9; X-ray; 2.10 A; A/B/C=304-533.
DR   PDB; 2JFA; X-ray; 2.55 A; A/B=304-533.
DR   PDB; 2LLO; NMR; -; B=287-305.
DR   PDB; 2LLQ; NMR; -; B=287-305.
DR   PDB; 2OCF; X-ray; 2.95 A; A=298-595.
DR   PDB; 2OUZ; X-ray; 2.00 A; A=301-553.
DR   PDB; 2P15; X-ray; 1.94 A; A/B=298-554.
DR   PDB; 2POG; X-ray; 1.84 A; A/B=304-551.
DR   PDB; 2Q6J; X-ray; 2.70 A; A/B=298-554.
DR   PDB; 2Q70; X-ray; 1.95 A; A/B=304-551.
DR   PDB; 2QA6; X-ray; 2.60 A; A/B=298-554.
DR   PDB; 2QA8; X-ray; 1.85 A; A/B=298-554.
DR   PDB; 2QAB; X-ray; 1.89 A; A/B=298-554.
DR   PDB; 2QE4; X-ray; 2.40 A; A/B=304-551.
DR   PDB; 2QGT; X-ray; 2.15 A; A/B=298-554.
DR   PDB; 2QGW; X-ray; 2.39 A; A/B=298-554.
DR   PDB; 2QH6; X-ray; 2.70 A; A/B=298-554.
DR   PDB; 2QR9; X-ray; 2.00 A; A/B=298-554.
DR   PDB; 2QSE; X-ray; 1.85 A; A/B=298-554.
DR   PDB; 2QXM; X-ray; 2.30 A; A/B=298-554.
DR   PDB; 2QXS; X-ray; 1.70 A; A/B=298-554.
DR   PDB; 2QZO; X-ray; 1.72 A; A/B=298-554.
DR   PDB; 2R6W; X-ray; 2.00 A; A/B=304-551.
DR   PDB; 2R6Y; X-ray; 2.00 A; A/B=304-551.
DR   PDB; 2YAT; X-ray; 2.60 A; A=301-551.
DR   PDB; 2YJA; X-ray; 1.82 A; B=299-551.
DR   PDB; 3CBM; X-ray; 1.69 A; B=298-307.
DR   PDB; 3CBO; X-ray; 1.65 A; B=298-307.
DR   PDB; 3CBP; X-ray; 1.42 A; B=298-307.
DR   PDB; 3DT3; X-ray; 2.40 A; A/B=299-551.
DR   PDB; 3ERD; X-ray; 2.03 A; A/B=297-554.
DR   PDB; 3ERT; X-ray; 1.90 A; A=297-554.
DR   PDB; 3HLV; X-ray; 3.00 A; A/B=298-550.
DR   PDB; 3HM1; X-ray; 2.33 A; A/B=298-550.
DR   PDB; 3L03; X-ray; 1.90 A; A/B=298-550.
DR   PDB; 3OS8; X-ray; 2.03 A; A/B/C/D=299-553.
DR   PDB; 3OS9; X-ray; 2.30 A; A/B/C/D=299-553.
DR   PDB; 3OSA; X-ray; 2.30 A; A/B/C/D=299-553.
DR   PDB; 3Q95; X-ray; 2.05 A; A/B=298-554.
DR   PDB; 3UU7; X-ray; 2.20 A; A/B=302-552.
DR   PDB; 3UUA; X-ray; 2.05 A; A/B=302-552.
DR   PDB; 3UUC; X-ray; 2.10 A; A/B/C/D=302-552.
DR   PDB; 3UUD; X-ray; 1.60 A; A/B=302-552.
DR   PDB; 4AA6; X-ray; 2.60 A; A/B/E/F=182-252.
DR   PDB; 4DMA; X-ray; 2.30 A; A/B=303-549.
DR   PDB; 4IU7; X-ray; 2.29 A; A/B=303-549.
DR   PDB; 4IUI; X-ray; 2.30 A; A/B=303-549.
DR   PDB; 4IV2; X-ray; 2.14 A; A/B=303-549.
DR   PDB; 4IV4; X-ray; 2.30 A; A/B=303-549.
DR   PDB; 4IVW; X-ray; 2.06 A; A/B=303-549.
DR   PDB; 4IVY; X-ray; 1.95 A; A/B=303-549.
DR   PDB; 4IW6; X-ray; 1.98 A; A/B=303-549.
DR   PDB; 4IW8; X-ray; 2.04 A; A/B=303-549.
DR   PDB; 4IWC; X-ray; 2.24 A; A/B=303-549.
DR   PDB; 4IWF; X-ray; 1.93 A; A/B=303-549.
DR   PDB; 4JC3; X-ray; 2.05 A; B=585-595.
DR   PDB; 4JDD; X-ray; 2.10 A; B=585-595.
DR   PDB; 4MG5; X-ray; 2.05 A; A/B=302-552.
DR   PDB; 4MG6; X-ray; 2.10 A; A/B=302-552.
DR   PDB; 4MG7; X-ray; 2.15 A; A/B=302-552.
DR   PDB; 4MG8; X-ray; 1.85 A; A/B=302-552.
DR   PDB; 4MG9; X-ray; 2.00 A; A/B=302-552.
DR   PDB; 4MGA; X-ray; 1.80 A; A/B=302-552.
DR   PDB; 4MGB; X-ray; 1.85 A; A/B=302-552.
DR   PDB; 4MGC; X-ray; 2.15 A; A/B=302-552.
DR   PDB; 4MGD; X-ray; 1.90 A; A/B=302-552.
DR   PDB; 4O6F; X-ray; 2.82 A; B=261-271.
DR   PDB; 4PP6; X-ray; 2.20 A; A/B=305-548.
DR   PDB; 4PPP; X-ray; 2.69 A; A/B=305-548.
DR   PDB; 4PPS; X-ray; 1.93 A; A/B=305-548.
DR   PDB; 4PXM; X-ray; 1.90 A; A/B=299-554.
DR   PDB; 4Q13; X-ray; 2.24 A; A/B=299-554.
DR   PDB; 4Q50; X-ray; 3.07 A; A/B/C/D/E/F/G/H=299-554.
DR   PDB; 4TUZ; X-ray; 1.90 A; A/B=302-552.
DR   PDB; 4TV1; X-ray; 1.85 A; A/B=302-552.
DR   PDB; 4XI3; X-ray; 2.49 A; A/B/C/D=306-548.
DR   PDB; 4ZN7; X-ray; 1.93 A; A/B=301-559.
DR   PDB; 4ZN9; X-ray; 2.21 A; A/B=301-559.
DR   PDB; 4ZNH; X-ray; 1.93 A; A/B=301-559.
DR   PDB; 4ZNS; X-ray; 1.86 A; A/B=301-559.
DR   PDB; 4ZNT; X-ray; 1.90 A; A/B=301-559.
DR   PDB; 4ZNU; X-ray; 2.40 A; A/B=301-559.
DR   PDB; 4ZNV; X-ray; 1.77 A; A/B=301-559.
DR   PDB; 4ZNW; X-ray; 2.31 A; A/B=301-559.
DR   PDB; 5AAU; X-ray; 1.90 A; A/B=307-554.
DR   PDB; 5AAV; X-ray; 1.95 A; A=307-554, B=306-554.
DR   PDB; 5ACC; X-ray; 1.88 A; A=307-554.
DR   PDB; 5AK2; X-ray; 2.19 A; A/B=307-554.
DR   PDB; 5DI7; X-ray; 2.24 A; A/B=298-554.
DR   PDB; 5DID; X-ray; 2.24 A; A/B=298-554.
DR   PDB; 5DIE; X-ray; 2.24 A; A/B=298-554.
DR   PDB; 5DIG; X-ray; 2.24 A; A/B=298-554.
DR   PDB; 5DK9; X-ray; 2.28 A; A/B=298-554.
DR   PDB; 5DKB; X-ray; 2.40 A; A/B=298-554.
DR   PDB; 5DKE; X-ray; 2.60 A; A/B=298-554.
DR   PDB; 5DKG; X-ray; 2.15 A; A/B=298-554.
DR   PDB; 5DKS; X-ray; 2.60 A; A/B=298-554.
DR   PDB; 5DL4; X-ray; 2.10 A; A/B=298-554.
DR   PDB; 5DLR; X-ray; 2.26 A; A/B=298-554.
DR   PDB; 5DMC; X-ray; 2.40 A; A/B=298-554.
DR   PDB; 5DMF; X-ray; 2.40 A; A/B=298-554.
DR   PDB; 5DP0; X-ray; 2.38 A; A/B=298-554.
DR   PDB; 5DRJ; X-ray; 2.07 A; A/B=298-554.
DR   PDB; 5DRM; X-ray; 2.24 A; A/B=298-554.
DR   PDB; 5DTV; X-ray; 2.29 A; A/B=298-554.
DR   PDB; 5DU5; X-ray; 2.19 A; A/B=298-554.
DR   PDB; 5DUE; X-ray; 2.09 A; A/B=298-554.
DR   PDB; 5DUG; X-ray; 2.25 A; A/B=298-554.
DR   PDB; 5DUH; X-ray; 2.24 A; A/B=298-554.
DR   PDB; 5DVS; X-ray; 2.28 A; A/B=298-554.
DR   PDB; 5DVV; X-ray; 2.50 A; A/B=298-554.
DR   PDB; 5DWE; X-ray; 1.92 A; A/B=298-554.
DR   PDB; 5DWG; X-ray; 2.30 A; A/B=298-554.
DR   PDB; 5DWI; X-ray; 2.43 A; A/B=298-554.
DR   PDB; 5DWJ; X-ray; 2.00 A; A/B=298-554.
DR   PDB; 5DX3; X-ray; 2.09 A; A/B=297-554.
DR   PDB; 5DXB; X-ray; 2.08 A; A/B=297-554.
DR   PDB; 5DXE; X-ray; 1.50 A; A/B=297-554.
DR   PDB; 5DXG; X-ray; 1.86 A; A/B=297-554.
DR   PDB; 5DXK; X-ray; 2.23 A; A/B=298-554.
DR   PDB; 5DXM; X-ray; 2.37 A; A/B=298-554.
DR   PDB; 5DXP; X-ray; 2.20 A; A/B=298-554.
DR   PDB; 5DXQ; X-ray; 2.40 A; A/B=298-554.
DR   PDB; 5DXR; X-ray; 2.28 A; A/B=298-554.
DR   PDB; 5DY8; X-ray; 2.03 A; A/B=298-554.
DR   PDB; 5DYB; X-ray; 2.27 A; A/B=298-554.
DR   PDB; 5DYD; X-ray; 2.48 A; A/B=298-554.
DR   PDB; 5DZ0; X-ray; 2.24 A; A/B=298-554.
DR   PDB; 5DZ1; X-ray; 2.20 A; A/B=298-554.
DR   PDB; 5DZ3; X-ray; 2.15 A; A/B=298-554.
DR   PDB; 5DZH; X-ray; 2.11 A; A/B=298-554.
DR   PDB; 5DZI; X-ray; 1.90 A; A/B=298-554.
DR   PDB; 5E0W; X-ray; 2.00 A; A/B=298-554.
DR   PDB; 5E0X; X-ray; 2.01 A; A/B=298-554.
DR   PDB; 5E14; X-ray; 2.22 A; A/B=298-554.
DR   PDB; 5E15; X-ray; 2.10 A; A/B=298-554.
DR   PDB; 5E19; X-ray; 2.24 A; A/B=298-554.
DR   PDB; 5E1C; X-ray; 1.98 A; A/B=298-554.
DR   PDB; 5EGV; X-ray; 2.86 A; A/B=298-554.
DR   PDB; 5EHJ; X-ray; 2.50 A; A/B=298-554.
DR   PDB; 5EI1; X-ray; 2.40 A; A/B=298-554.
DR   PDB; 5EIT; X-ray; 2.68 A; A/B=298-554.
DR   PDB; 5FQP; X-ray; 1.88 A; A=307-554.
DR   PDB; 5FQR; X-ray; 1.88 A; A=307-554.
DR   PDB; 5FQS; X-ray; 1.94 A; A=307-554.
DR   PDB; 5FQT; X-ray; 1.99 A; A=307-554.
DR   PDB; 5FQV; X-ray; 1.74 A; A=307-554.
DR   PDB; 5GS4; X-ray; 2.40 A; A=305-547.
DR   PDB; 5GTR; X-ray; 2.80 A; A=305-547.
DR   PDB; 5HYR; X-ray; 2.27 A; A/B=302-559.
DR   PDB; 5JMM; X-ray; 2.10 A; A/B=302-552.
DR   PDB; 5KCC; X-ray; 2.39 A; A/B=298-554, A/B=304-549.
DR   PDB; 5KCD; X-ray; 1.82 A; A/B=298-554, A/B=305-549.
DR   PDB; 5KCE; X-ray; 1.85 A; A/B=298-554, A/B=303-549.
DR   PDB; 5KCF; X-ray; 2.07 A; A/B=298-554, A/B=303-549.
DR   PDB; 5KCT; X-ray; 1.60 A; A/B=298-554, A/B=303-548.
DR   PDB; 5KCU; X-ray; 2.03 A; A/B=298-554, A/B=303-548.
DR   PDB; 5KCW; X-ray; 1.91 A; A/B=303-549, A/B=298-554.
DR   PDB; 5KD9; X-ray; 1.78 A; A/B=298-554, A/B=303-549.
DR   PDB; 5KR9; X-ray; 2.25 A; A/B=298-554.
DR   PDB; 5KRA; X-ray; 2.40 A; A/B/E/F=298-554.
DR   PDB; 5KRC; X-ray; 2.40 A; A/B=298-554.
DR   PDB; 5KRF; X-ray; 2.19 A; A/B=298-554.
DR   PDB; 5KRH; X-ray; 2.24 A; A/B=298-554.
DR   PDB; 5KRI; X-ray; 2.25 A; A/B=298-554.
DR   PDB; 5KRJ; X-ray; 2.70 A; A/B=298-554.
DR   PDB; 5KRK; X-ray; 2.39 A; A/B=298-554.
DR   PDB; 5KRL; X-ray; 2.40 A; A/B=298-554.
DR   PDB; 5KRM; X-ray; 2.24 A; A/B=298-554.
DR   PDB; 5KRO; X-ray; 2.10 A; A/B=298-554.
DR   PDB; 5N10; X-ray; 1.60 A; C/D/F=584-595.
DR   PDB; 5T0X; NMR; -; B/C=287-305.
DR   PDB; 5T1Z; X-ray; 2.10 A; A/B=298-554.
DR   PDB; 5T92; X-ray; 2.22 A; A/B=301-553.
DR   PDB; 5T97; X-ray; 3.00 A; A/B=301-553.
DR   PDB; 5TLD; X-ray; 2.38 A; A/B=298-554.
DR   PDB; 5TLF; X-ray; 2.20 A; A/B=298-554.
DR   PDB; 5TLG; X-ray; 2.23 A; A/B=298-554.
DR   PDB; 5TLL; X-ray; 2.42 A; A/B=298-554.
DR   PDB; 5TLM; X-ray; 2.50 A; A/B=298-554.
DR   PDB; 5TLO; X-ray; 2.28 A; A/B=298-554.
DR   PDB; 5TLP; X-ray; 2.08 A; A/B=298-554.
DR   PDB; 5TLT; X-ray; 1.90 A; A/B=298-554.
DR   PDB; 5TLU; X-ray; 2.22 A; A/B=298-554.
DR   PDB; 5TLV; X-ray; 2.32 A; A/B=298-554.
DR   PDB; 5TLX; X-ray; 2.10 A; A/B=298-554.
DR   PDB; 5TLY; X-ray; 2.14 A; A/B=298-554.
DR   PDB; 5TM1; X-ray; 2.23 A; A/B=298-554.
DR   PDB; 5TM2; X-ray; 2.60 A; A/B=298-554.
DR   PDB; 5TM3; X-ray; 2.19 A; A/B=298-554.
DR   PDB; 5TM4; X-ray; 2.25 A; A/B=298-554.
DR   PDB; 5TM5; X-ray; 2.24 A; A/B=298-554.
DR   PDB; 5TM6; X-ray; 2.54 A; A/B=298-554.
DR   PDB; 5TM7; X-ray; 2.40 A; A/B=298-554.
DR   PDB; 5TM8; X-ray; 1.99 A; A/B=298-554.
DR   PDB; 5TM9; X-ray; 2.50 A; A/B=298-554.
DR   PDB; 5TML; X-ray; 2.25 A; A/B=298-554.
DR   PDB; 5TMM; X-ray; 2.20 A; A/B=298-554.
DR   PDB; 5TMO; X-ray; 2.17 A; A/B=298-554.
DR   PDB; 5TMQ; X-ray; 2.24 A; A/B=298-554.
DR   PDB; 5TMR; X-ray; 2.30 A; A/B=298-554.
DR   PDB; 5TMS; X-ray; 2.24 A; A/B=298-554.
DR   PDB; 5TMT; X-ray; 2.05 A; A/B=298-554.
DR   PDB; 5TMU; X-ray; 2.43 A; A/B=298-554.
DR   PDB; 5TMV; X-ray; 2.38 A; A/B=298-554.
DR   PDB; 5TMW; X-ray; 2.29 A; A/B=298-554.
DR   PDB; 5TMZ; X-ray; 2.21 A; A/B=298-554.
DR   PDB; 5TN1; X-ray; 2.06 A; A/B=298-554.
DR   PDB; 5TN3; X-ray; 2.54 A; A/B=298-554.
DR   PDB; 5TN4; X-ray; 1.86 A; A/B=298-554.
DR   PDB; 5TN5; X-ray; 1.89 A; A/B=298-554.
DR   PDB; 5TN6; X-ray; 2.09 A; A/B=298-554.
DR   PDB; 5TN7; X-ray; 2.24 A; A/B=298-554.
DR   PDB; 5TN8; X-ray; 2.65 A; A/B=298-554.
DR   PDB; 5TN9; X-ray; 2.25 A; A/B/C/D=298-554.
DR   PDB; 5TNB; X-ray; 2.08 A; A/B/C/D=298-554.
DR   PDB; 5U2B; X-ray; 2.22 A; A/B/C/D/E/F=298-554.
DR   PDB; 5U2D; X-ray; 1.86 A; A/B=298-554.
DR   PDB; 5UF9; X-ray; 2.00 A; A/B=307-554.
DR   PDB; 5UFW; X-ray; 1.58 A; A/B=306-554.
DR   PDB; 5UFX; X-ray; 1.55 A; A/B=306-554.
DR   PDB; 5W9D; X-ray; 1.65 A; A/B=306-554.
DR   PDBsum; 1A52; -.
DR   PDBsum; 1AKF; -.
DR   PDBsum; 1ERE; -.
DR   PDBsum; 1ERR; -.
DR   PDBsum; 1G50; -.
DR   PDBsum; 1GWQ; -.
DR   PDBsum; 1GWR; -.
DR   PDBsum; 1HCP; -.
DR   PDBsum; 1HCQ; -.
DR   PDBsum; 1L2I; -.
DR   PDBsum; 1PCG; -.
DR   PDBsum; 1QKT; -.
DR   PDBsum; 1QKU; -.
DR   PDBsum; 1R5K; -.
DR   PDBsum; 1SJ0; -.
DR   PDBsum; 1UOM; -.
DR   PDBsum; 1X7E; -.
DR   PDBsum; 1X7R; -.
DR   PDBsum; 1XP1; -.
DR   PDBsum; 1XP6; -.
DR   PDBsum; 1XP9; -.
DR   PDBsum; 1XPC; -.
DR   PDBsum; 1XQC; -.
DR   PDBsum; 1YIM; -.
DR   PDBsum; 1YIN; -.
DR   PDBsum; 1ZKY; -.
DR   PDBsum; 2AYR; -.
DR   PDBsum; 2B1V; -.
DR   PDBsum; 2B1Z; -.
DR   PDBsum; 2B23; -.
DR   PDBsum; 2BJ4; -.
DR   PDBsum; 2FAI; -.
DR   PDBsum; 2G44; -.
DR   PDBsum; 2G5O; -.
DR   PDBsum; 2I0J; -.
DR   PDBsum; 2IOG; -.
DR   PDBsum; 2IOK; -.
DR   PDBsum; 2JF9; -.
DR   PDBsum; 2JFA; -.
DR   PDBsum; 2LLO; -.
DR   PDBsum; 2LLQ; -.
DR   PDBsum; 2OCF; -.
DR   PDBsum; 2OUZ; -.
DR   PDBsum; 2P15; -.
DR   PDBsum; 2POG; -.
DR   PDBsum; 2Q6J; -.
DR   PDBsum; 2Q70; -.
DR   PDBsum; 2QA6; -.
DR   PDBsum; 2QA8; -.
DR   PDBsum; 2QAB; -.
DR   PDBsum; 2QE4; -.
DR   PDBsum; 2QGT; -.
DR   PDBsum; 2QGW; -.
DR   PDBsum; 2QH6; -.
DR   PDBsum; 2QR9; -.
DR   PDBsum; 2QSE; -.
DR   PDBsum; 2QXM; -.
DR   PDBsum; 2QXS; -.
DR   PDBsum; 2QZO; -.
DR   PDBsum; 2R6W; -.
DR   PDBsum; 2R6Y; -.
DR   PDBsum; 2YAT; -.
DR   PDBsum; 2YJA; -.
DR   PDBsum; 3CBM; -.
DR   PDBsum; 3CBO; -.
DR   PDBsum; 3CBP; -.
DR   PDBsum; 3DT3; -.
DR   PDBsum; 3ERD; -.
DR   PDBsum; 3ERT; -.
DR   PDBsum; 3HLV; -.
DR   PDBsum; 3HM1; -.
DR   PDBsum; 3L03; -.
DR   PDBsum; 3OS8; -.
DR   PDBsum; 3OS9; -.
DR   PDBsum; 3OSA; -.
DR   PDBsum; 3Q95; -.
DR   PDBsum; 3UU7; -.
DR   PDBsum; 3UUA; -.
DR   PDBsum; 3UUC; -.
DR   PDBsum; 3UUD; -.
DR   PDBsum; 4AA6; -.
DR   PDBsum; 4DMA; -.
DR   PDBsum; 4IU7; -.
DR   PDBsum; 4IUI; -.
DR   PDBsum; 4IV2; -.
DR   PDBsum; 4IV4; -.
DR   PDBsum; 4IVW; -.
DR   PDBsum; 4IVY; -.
DR   PDBsum; 4IW6; -.
DR   PDBsum; 4IW8; -.
DR   PDBsum; 4IWC; -.
DR   PDBsum; 4IWF; -.
DR   PDBsum; 4JC3; -.
DR   PDBsum; 4JDD; -.
DR   PDBsum; 4MG5; -.
DR   PDBsum; 4MG6; -.
DR   PDBsum; 4MG7; -.
DR   PDBsum; 4MG8; -.
DR   PDBsum; 4MG9; -.
DR   PDBsum; 4MGA; -.
DR   PDBsum; 4MGB; -.
DR   PDBsum; 4MGC; -.
DR   PDBsum; 4MGD; -.
DR   PDBsum; 4O6F; -.
DR   PDBsum; 4PP6; -.
DR   PDBsum; 4PPP; -.
DR   PDBsum; 4PPS; -.
DR   PDBsum; 4PXM; -.
DR   PDBsum; 4Q13; -.
DR   PDBsum; 4Q50; -.
DR   PDBsum; 4TUZ; -.
DR   PDBsum; 4TV1; -.
DR   PDBsum; 4XI3; -.
DR   PDBsum; 4ZN7; -.
DR   PDBsum; 4ZN9; -.
DR   PDBsum; 4ZNH; -.
DR   PDBsum; 4ZNS; -.
DR   PDBsum; 4ZNT; -.
DR   PDBsum; 4ZNU; -.
DR   PDBsum; 4ZNV; -.
DR   PDBsum; 4ZNW; -.
DR   PDBsum; 5AAU; -.
DR   PDBsum; 5AAV; -.
DR   PDBsum; 5ACC; -.
DR   PDBsum; 5AK2; -.
DR   PDBsum; 5DI7; -.
DR   PDBsum; 5DID; -.
DR   PDBsum; 5DIE; -.
DR   PDBsum; 5DIG; -.
DR   PDBsum; 5DK9; -.
DR   PDBsum; 5DKB; -.
DR   PDBsum; 5DKE; -.
DR   PDBsum; 5DKG; -.
DR   PDBsum; 5DKS; -.
DR   PDBsum; 5DL4; -.
DR   PDBsum; 5DLR; -.
DR   PDBsum; 5DMC; -.
DR   PDBsum; 5DMF; -.
DR   PDBsum; 5DP0; -.
DR   PDBsum; 5DRJ; -.
DR   PDBsum; 5DRM; -.
DR   PDBsum; 5DTV; -.
DR   PDBsum; 5DU5; -.
DR   PDBsum; 5DUE; -.
DR   PDBsum; 5DUG; -.
DR   PDBsum; 5DUH; -.
DR   PDBsum; 5DVS; -.
DR   PDBsum; 5DVV; -.
DR   PDBsum; 5DWE; -.
DR   PDBsum; 5DWG; -.
DR   PDBsum; 5DWI; -.
DR   PDBsum; 5DWJ; -.
DR   PDBsum; 5DX3; -.
DR   PDBsum; 5DXB; -.
DR   PDBsum; 5DXE; -.
DR   PDBsum; 5DXG; -.
DR   PDBsum; 5DXK; -.
DR   PDBsum; 5DXM; -.
DR   PDBsum; 5DXP; -.
DR   PDBsum; 5DXQ; -.
DR   PDBsum; 5DXR; -.
DR   PDBsum; 5DY8; -.
DR   PDBsum; 5DYB; -.
DR   PDBsum; 5DYD; -.
DR   PDBsum; 5DZ0; -.
DR   PDBsum; 5DZ1; -.
DR   PDBsum; 5DZ3; -.
DR   PDBsum; 5DZH; -.
DR   PDBsum; 5DZI; -.
DR   PDBsum; 5E0W; -.
DR   PDBsum; 5E0X; -.
DR   PDBsum; 5E14; -.
DR   PDBsum; 5E15; -.
DR   PDBsum; 5E19; -.
DR   PDBsum; 5E1C; -.
DR   PDBsum; 5EGV; -.
DR   PDBsum; 5EHJ; -.
DR   PDBsum; 5EI1; -.
DR   PDBsum; 5EIT; -.
DR   PDBsum; 5FQP; -.
DR   PDBsum; 5FQR; -.
DR   PDBsum; 5FQS; -.
DR   PDBsum; 5FQT; -.
DR   PDBsum; 5FQV; -.
DR   PDBsum; 5GS4; -.
DR   PDBsum; 5GTR; -.
DR   PDBsum; 5HYR; -.
DR   PDBsum; 5JMM; -.
DR   PDBsum; 5KCC; -.
DR   PDBsum; 5KCD; -.
DR   PDBsum; 5KCE; -.
DR   PDBsum; 5KCF; -.
DR   PDBsum; 5KCT; -.
DR   PDBsum; 5KCU; -.
DR   PDBsum; 5KCW; -.
DR   PDBsum; 5KD9; -.
DR   PDBsum; 5KR9; -.
DR   PDBsum; 5KRA; -.
DR   PDBsum; 5KRC; -.
DR   PDBsum; 5KRF; -.
DR   PDBsum; 5KRH; -.
DR   PDBsum; 5KRI; -.
DR   PDBsum; 5KRJ; -.
DR   PDBsum; 5KRK; -.
DR   PDBsum; 5KRL; -.
DR   PDBsum; 5KRM; -.
DR   PDBsum; 5KRO; -.
DR   PDBsum; 5N10; -.
DR   PDBsum; 5T0X; -.
DR   PDBsum; 5T1Z; -.
DR   PDBsum; 5T92; -.
DR   PDBsum; 5T97; -.
DR   PDBsum; 5TLD; -.
DR   PDBsum; 5TLF; -.
DR   PDBsum; 5TLG; -.
DR   PDBsum; 5TLL; -.
DR   PDBsum; 5TLM; -.
DR   PDBsum; 5TLO; -.
DR   PDBsum; 5TLP; -.
DR   PDBsum; 5TLT; -.
DR   PDBsum; 5TLU; -.
DR   PDBsum; 5TLV; -.
DR   PDBsum; 5TLX; -.
DR   PDBsum; 5TLY; -.
DR   PDBsum; 5TM1; -.
DR   PDBsum; 5TM2; -.
DR   PDBsum; 5TM3; -.
DR   PDBsum; 5TM4; -.
DR   PDBsum; 5TM5; -.
DR   PDBsum; 5TM6; -.
DR   PDBsum; 5TM7; -.
DR   PDBsum; 5TM8; -.
DR   PDBsum; 5TM9; -.
DR   PDBsum; 5TML; -.
DR   PDBsum; 5TMM; -.
DR   PDBsum; 5TMO; -.
DR   PDBsum; 5TMQ; -.
DR   PDBsum; 5TMR; -.
DR   PDBsum; 5TMS; -.
DR   PDBsum; 5TMT; -.
DR   PDBsum; 5TMU; -.
DR   PDBsum; 5TMV; -.
DR   PDBsum; 5TMW; -.
DR   PDBsum; 5TMZ; -.
DR   PDBsum; 5TN1; -.
DR   PDBsum; 5TN3; -.
DR   PDBsum; 5TN4; -.
DR   PDBsum; 5TN5; -.
DR   PDBsum; 5TN6; -.
DR   PDBsum; 5TN7; -.
DR   PDBsum; 5TN8; -.
DR   PDBsum; 5TN9; -.
DR   PDBsum; 5TNB; -.
DR   PDBsum; 5U2B; -.
DR   PDBsum; 5U2D; -.
DR   PDBsum; 5UF9; -.
DR   PDBsum; 5UFW; -.
DR   PDBsum; 5UFX; -.
DR   PDBsum; 5W9D; -.
DR   DisProt; DP00074; -.
DR   ProteinModelPortal; P03372; -.
DR   SMR; P03372; -.
DR   BioGrid; 108403; 708.
DR   CORUM; P03372; -.
DR   DIP; DIP-5965N; -.
DR   ELM; P03372; -.
DR   IntAct; P03372; 472.
DR   MINT; P03372; -.
DR   STRING; 9606.ENSP00000206249; -.
DR   BindingDB; P03372; -.
DR   ChEMBL; CHEMBL206; -.
DR   DrugBank; DB06871; 17-METHYL-17-ALPHA-DIHYDROEQUILENIN.
DR   DrugBank; DB07708; 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL.
DR   DrugBank; DB07712; 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL.
DR   DrugBank; DB06927; [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE.
DR   DrugBank; DB04468; Afimoxifene.
DR   DrugBank; DB01431; Allylestrenol.
DR   DrugBank; DB05233; AP1081.
DR   DrugBank; DB05338; atamestane-plus-toremifene.
DR   DrugBank; DB06401; Bazedoxifene.
DR   DrugBank; DB05487; CC-8490.
DR   DrugBank; DB05882; CHF 4227.
DR   DrugBank; DB00269; Chlorotrianisene.
DR   DrugBank; DB00882; Clomifene.
DR   DrugBank; DB02715; Compound 18.
DR   DrugBank; DB02615; Compound 19.
DR   DrugBank; DB03742; Compound 4-D.
DR   DrugBank; DB00286; Conjugated Equine Estrogens.
DR   DrugBank; DB01406; Danazol.
DR   DrugBank; DB00304; Desogestrel.
DR   DrugBank; DB00890; Dienestrol.
DR   DrugBank; DB00255; Diethylstilbestrol.
DR   DrugBank; DB00783; Estradiol.
DR   DrugBank; DB01196; Estramustine.
DR   DrugBank; DB04573; Estriol.
DR   DrugBank; DB00655; Estrone.
DR   DrugBank; DB04574; Estrone sulfate.
DR   DrugBank; DB00977; Ethinyl Estradiol.
DR   DrugBank; DB00823; Ethynodiol diacetate.
DR   DrugBank; DB00294; Etonogestrel.
DR   DrugBank; DB01185; Fluoxymesterone.
DR   DrugBank; DB00947; Fulvestrant.
DR   DrugBank; DB01645; Genistein.
DR   DrugBank; DB06202; Lasofoxifene.
DR   DrugBank; DB00367; Levonorgestrel.
DR   DrugBank; DB00603; Medroxyprogesterone acetate.
DR   DrugBank; DB01065; Melatonin.
DR   DrugBank; DB01357; Mestranol.
DR   DrugBank; DB07991; N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE.
DR   DrugBank; DB01183; Naloxone.
DR   DrugBank; DB00957; Norgestimate.
DR   DrugBank; DB05662; NP-50301.
DR   DrugBank; DB04938; Ospemifene.
DR   DrugBank; DB01708; Prasterone.
DR   DrugBank; DB00396; Progesterone.
DR   DrugBank; DB04575; Quinestrol.
DR   DrugBank; DB00481; Raloxifene.
DR   DrugBank; DB08773; RALOXIFENE CORE.
DR   DrugBank; DB00675; Tamoxifen.
DR   DrugBank; DB09070; Tibolone.
DR   DrugBank; DB00539; Toremifene.
DR   DrugBank; DB01108; Trilostane.
DR   GuidetoPHARMACOLOGY; 620; -.
DR   SwissLipids; SLP:000001568; -.
DR   iPTMnet; P03372; -.
DR   PhosphoSitePlus; P03372; -.
DR   SwissPalm; P03372; -.
DR   UniCarbKB; P03372; -.
DR   BioMuta; ESR1; -.
DR   DMDM; 544257; -.
DR   EPD; P03372; -.
DR   PaxDb; P03372; -.
DR   PeptideAtlas; P03372; -.
DR   PRIDE; P03372; -.
DR   DNASU; 2099; -.
DR   Ensembl; ENST00000206249; ENSP00000206249; ENSG00000091831. [P03372-1]
DR   Ensembl; ENST00000338799; ENSP00000342630; ENSG00000091831. [P03372-1]
DR   Ensembl; ENST00000440973; ENSP00000405330; ENSG00000091831. [P03372-1]
DR   Ensembl; ENST00000443427; ENSP00000387500; ENSG00000091831. [P03372-1]
DR   GeneID; 2099; -.
DR   KEGG; hsa:2099; -.
DR   UCSC; uc003qom.5; human. [P03372-1]
DR   CTD; 2099; -.
DR   DisGeNET; 2099; -.
DR   EuPathDB; HostDB:ENSG00000091831.21; -.
DR   GeneCards; ESR1; -.
DR   HGNC; HGNC:3467; ESR1.
DR   HPA; CAB000037; -.
DR   HPA; CAB055099; -.
DR   HPA; CAB072858; -.
DR   HPA; HPA000449; -.
DR   HPA; HPA000450; -.
DR   MalaCards; ESR1; -.
DR   MIM; 133430; gene.
DR   MIM; 615363; phenotype.
DR   neXtProt; NX_P03372; -.
DR   OpenTargets; ENSG00000091831; -.
DR   Orphanet; 785; Estrogen resistance syndrome.
DR   PharmGKB; PA156; -.
DR   eggNOG; KOG3575; Eukaryota.
DR   eggNOG; ENOG410XRZC; LUCA.
DR   GeneTree; ENSGT00760000118887; -.
DR   HOVERGEN; HBG108344; -.
DR   InParanoid; P03372; -.
DR   KO; K08550; -.
DR   OMA; EAGPPAF; -.
DR   OrthoDB; EOG091G03V4; -.
DR   PhylomeDB; P03372; -.
DR   TreeFam; TF323751; -.
DR   Reactome; R-HSA-1251985; Nuclear signaling by ERBB4.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-383280; Nuclear Receptor transcription pathway.
DR   Reactome; R-HSA-5689896; Ovarian tumor domain proteases.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-8866910; TFAP2 (AP-2) family regulates transcription of growth factors and their receptors.
DR   Reactome; R-HSA-8931987; RUNX1 regulates estrogen receptor mediated transcription.
DR   Reactome; R-HSA-8939256; RUNX1 regulates transcription of genes involved in WNT signaling.
DR   Reactome; R-HSA-8939902; Regulation of RUNX2 expression and activity.
DR   SignaLink; P03372; -.
DR   SIGNOR; P03372; -.
DR   ChiTaRS; ESR1; human.
DR   EvolutionaryTrace; P03372; -.
DR   GeneWiki; Estrogen_receptor_alpha; -.
DR   GenomeRNAi; 2099; -.
DR   PRO; PR:P03372; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000091831; -.
DR   CleanEx; HS_ESR1; -.
DR   ExpressionAtlas; P03372; baseline and differential.
DR   Genevisible; P03372; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016020; C:membrane; NAS:UniProtKB.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043234; C:protein complex; IMP:CAFA.
DR   GO; GO:0097550; C:transcriptional preinitiation complex; IDA:CAFA.
DR   GO; GO:0035327; C:transcriptionally active chromatin; IDA:UniProtKB.
DR   GO; GO:0051117; F:ATPase binding; IDA:MGI.
DR   GO; GO:0008013; F:beta-catenin binding; IPI:BHF-UCL.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0001046; F:core promoter sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; NAS:BHF-UCL.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0030284; F:estrogen receptor activity; IDA:CAFA.
DR   GO; GO:0030331; F:estrogen receptor binding; IPI:CAFA.
DR   GO; GO:0034056; F:estrogen response element binding; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0030235; F:nitric-oxide synthase regulator activity; NAS:UniProtKB.
DR   GO; GO:0046934; F:phosphatidylinositol-4,5-bisphosphate 3-kinase activity; TAS:Reactome.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II proximal promoter sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0038052; F:RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0005496; F:steroid binding; ISS:UniProtKB.
DR   GO; GO:0003707; F:steroid hormone receptor activity; TAS:ProtInc.
DR   GO; GO:0017025; F:TBP-class protein binding; IPI:CAFA.
DR   GO; GO:0001093; F:TFIIB-class transcription factor binding; IPI:CAFA.
DR   GO; GO:0001223; F:transcription coactivator binding; IPI:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0001077; F:transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0008209; P:androgen metabolic process; IEA:Ensembl.
DR   GO; GO:0001547; P:antral ovarian follicle growth; IEA:Ensembl.
DR   GO; GO:0071392; P:cellular response to estradiol stimulus; IDA:BHF-UCL.
DR   GO; GO:0071391; P:cellular response to estrogen stimulus; IEA:Ensembl.
DR   GO; GO:0006338; P:chromatin remodeling; NAS:UniProtKB.
DR   GO; GO:0002064; P:epithelial cell development; IEA:Ensembl.
DR   GO; GO:0060750; P:epithelial cell proliferation involved in mammary gland duct elongation; IEA:Ensembl.
DR   GO; GO:0030520; P:intracellular estrogen receptor signaling pathway; IDA:CAFA.
DR   GO; GO:0030518; P:intracellular steroid hormone receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0008584; P:male gonad development; IEA:Ensembl.
DR   GO; GO:0060749; P:mammary gland alveolus development; IEA:Ensembl.
DR   GO; GO:0060745; P:mammary gland branching involved in pregnancy; IEA:Ensembl.
DR   GO; GO:0043433; P:negative regulation of DNA binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0043124; P:negative regulation of I-kappaB kinase/NF-kappaB signaling; IDA:UniProtKB.
DR   GO; GO:1903799; P:negative regulation of production of miRNAs involved in gene silencing by miRNA; IMP:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0007200; P:phospholipase C-activating G-protein coupled receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; ISS:UniProtKB.
DR   GO; GO:0051091; P:positive regulation of DNA binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IEA:Ensembl.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0051000; P:positive regulation of nitric-oxide synthase activity; IDA:UniProtKB.
DR   GO; GO:0010863; P:positive regulation of phospholipase C activity; ISS:UniProtKB.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; TAS:Reactome.
DR   GO; GO:0045899; P:positive regulation of RNA polymerase II transcriptional preinitiation complex assembly; IDA:CAFA.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0060527; P:prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis; IEA:Ensembl.
DR   GO; GO:0060523; P:prostate epithelial cord elongation; IEA:Ensembl.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0071168; P:protein localization to chromatin; IMP:BHF-UCL.
DR   GO; GO:0042981; P:regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0060687; P:regulation of branching involved in prostate gland morphogenesis; IEA:Ensembl.
DR   GO; GO:0050727; P:regulation of inflammatory response; IEA:Ensembl.
DR   GO; GO:0033146; P:regulation of intracellular estrogen receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0034121; P:regulation of toll-like receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; NAS:UniProtKB.
DR   GO; GO:0030111; P:regulation of Wnt signaling pathway; TAS:Reactome.
DR   GO; GO:0032355; P:response to estradiol; IDA:BHF-UCL.
DR   GO; GO:0043627; P:response to estrogen; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0048863; P:stem cell differentiation; IEA:Ensembl.
DR   GO; GO:0006366; P:transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0006367; P:transcription initiation from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0006351; P:transcription, DNA-templated; TAS:ProtInc.
DR   GO; GO:0060065; P:uterus development; IEA:Ensembl.
DR   GO; GO:0060068; P:vagina development; IEA:Ensembl.
DR   Gene3D; 3.30.50.10; -; 1.
DR   InterPro; IPR035500; NHR_like_dom_sf.
DR   InterPro; IPR000536; Nucl_hrmn_rcpt_lig-bd.
DR   InterPro; IPR001723; Nuclear_hrmn_rcpt.
DR   InterPro; IPR024178; Oest_rcpt/oest-rel_rcp.
DR   InterPro; IPR001292; Oestr_rcpt.
DR   InterPro; IPR024736; Oestrogen-typ_rcpt_final_C_dom.
DR   InterPro; IPR001628; Znf_hrmn_rcpt.
DR   InterPro; IPR013088; Znf_NHR/GATA.
DR   Pfam; PF12743; ESR1_C; 1.
DR   Pfam; PF00104; Hormone_recep; 1.
DR   Pfam; PF02159; Oest_recep; 1.
DR   Pfam; PF00105; zf-C4; 1.
DR   PIRSF; PIRSF500101; ER-a; 1.
DR   PIRSF; PIRSF002527; ER-like_NR; 1.
DR   PRINTS; PR00543; OESTROGENR.
DR   PRINTS; PR00398; STRDHORMONER.
DR   PRINTS; PR00047; STROIDFINGER.
DR   SMART; SM00430; HOLI; 1.
DR   SMART; SM00399; ZnF_C4; 1.
DR   SUPFAM; SSF48508; SSF48508; 1.
DR   PROSITE; PS51843; NR_LBD; 1.
DR   PROSITE; PS00031; NUCLEAR_REC_DBD_1; 1.
DR   PROSITE; PS51030; NUCLEAR_REC_DBD_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative promoter usage;
KW   Alternative splicing; Cell membrane; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Disease mutation; DNA-binding;
KW   Glycoprotein; Golgi apparatus; Lipid-binding; Lipoprotein; Membrane;
KW   Metal-binding; Methylation; Nucleus; Palmitate; Phosphoprotein;
KW   Polymorphism; Receptor; Reference proteome; Steroid-binding;
KW   Transcription; Transcription regulation; Transmembrane;
KW   Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN         1    595       Estrogen receptor.
FT                                /FTId=PRO_0000053618.
FT   DOMAIN      311    547       NR LBD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01189}.
FT   DNA_BIND    185    250       Nuclear receptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00407}.
FT   ZN_FING     185    205       NR C4-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00407}.
FT   ZN_FING     221    245       NR C4-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00407}.
FT   REGION        1    184       Modulating (transactivation AF-1);
FT                                mediates interaction with MACROD1.
FT                                {ECO:0000269|PubMed:17914104}.
FT   REGION       35    174       Interaction with DDX5; self-association.
FT   REGION       35     47       Required for interaction with NCOA1.
FT   REGION      185    310       Mediates interaction with DNTTIP2.
FT                                {ECO:0000269|PubMed:15047147}.
FT   REGION      251    310       Hinge.
FT   REGION      262    595       Interaction with AKAP13.
FT                                {ECO:0000269|PubMed:9627117}.
FT   REGION      264    595       Self-association.
FT   REGION      311    595       Transactivation AF-2.
FT   MOD_RES     104    104       Phosphoserine; by CDK2.
FT                                {ECO:0000269|PubMed:10428798}.
FT   MOD_RES     106    106       Phosphoserine; by CDK2.
FT                                {ECO:0000269|PubMed:10428798}.
FT   MOD_RES     118    118       Phosphoserine.
FT                                {ECO:0000269|PubMed:14764652}.
FT   MOD_RES     167    167       Phosphoserine; by CK2.
FT                                {ECO:0000269|PubMed:7838153}.
FT   MOD_RES     260    260       Asymmetric dimethylarginine; by PRMT1.
FT                                {ECO:0000269|PubMed:18657504}.
FT   MOD_RES     537    537       Phosphotyrosine; by Tyr-kinases.
FT                                {ECO:0000269|PubMed:7539106}.
FT   LIPID       447    447       S-palmitoyl cysteine. {ECO:0000250}.
FT   CARBOHYD     10     10       O-linked (GlcNAc) serine. {ECO:0000250}.
FT   VAR_SEQ       1    173       Missing (in isoform 3 and isoform 4).
FT                                {ECO:0000303|PubMed:16165085,
FT                                ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_042460.
FT   VAR_SEQ     255    366       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:3753802}.
FT                                /FTId=VSP_003680.
FT   VAR_SEQ     458    595       VYTFLSSTLKSLEEKDHIHRVLDKITDTLIHLMAKAGLTLQ
FT                                QQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKNVVPLYDL
FT                                LLEMLDAHRLHAPTSRGGASVEETDQSHLATAGSTSSHSLQ
FT                                KYYITGEAEGFPATV -> FTISHVEAKKRILNLHPKIFGN
FT                                KWFPRV (in isoform 4).
FT                                {ECO:0000303|PubMed:16165085,
FT                                ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_042461.
FT   VARIANT       6      6       H -> Y (in a breast cancer sample;
FT                                somatic mutation; dbSNP:rs139960913).
FT                                {ECO:0000269|PubMed:17224074}.
FT                                /FTId=VAR_033028.
FT   VARIANT      77     77       G -> S (in dbSNP:rs9340773).
FT                                /FTId=VAR_018905.
FT   VARIANT     160    160       G -> C (in dbSNP:rs149308960).
FT                                {ECO:0000269|PubMed:9195227}.
FT                                /FTId=VAR_004671.
FT   VARIANT     264    264       M -> I (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17224074}.
FT                                /FTId=VAR_033029.
FT   VARIANT     375    375       Q -> H (in ESTRR; results in highly
FT                                reduced activity; dbSNP:rs397509428).
FT                                {ECO:0000269|PubMed:23841731}.
FT                                /FTId=VAR_070072.
FT   VARIANT     394    394       R -> H (in ESTRR; highly decreased
FT                                estrogen receptor activity).
FT                                {ECO:0000269|PubMed:27754803}.
FT                                /FTId=VAR_078516.
FT   VARIANT     400    400       G -> V (destabilizes the receptor and
FT                                decreases its affinity for estradiol at
FT                                25 degrees Celsius, but not at 4 degrees
FT                                Celsius). {ECO:0000269|PubMed:2792078,
FT                                ECO:0000269|PubMed:3753802,
FT                                ECO:0000269|PubMed:3754034}.
FT                                /FTId=VAR_004673.
FT   VARIANT     411    411       D -> RNQGKCVEGMVEIFDMLLATSSRFRMMNLQGEEFVC
FT                                LKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLDKITDTLIH
FT                                LMAKAGLTLQQQHQRLAQLLLILSHIRHM (in a 80
FT                                kDa form found in a breast cancer line;
FT                                contains an in-frame duplication of exons
FT                                6 and 7).
FT                                /FTId=VAR_010143.
FT   MUTAGEN      39     39       L->P: Impairs AF-1 transactivation.
FT                                {ECO:0000269|PubMed:11075817}.
FT   MUTAGEN      43     43       Y->P: Impairs AF-1 transactivation.
FT                                {ECO:0000269|PubMed:11075817}.
FT   MUTAGEN     104    104       S->A: Loss of cyclin A-dependent
FT                                induction of transcriptional activation.
FT   MUTAGEN     106    106       S->A: Loss of cyclin A-dependent
FT                                induction of transcriptional activation.
FT   MUTAGEN     118    118       S->A: Decreases phosphorylation and
FT                                transactivation activity. Abolishes AF-1
FT                                transactivation. Insensitive to PPP5C
FT                                inhibition of transactivation activity.
FT                                {ECO:0000269|PubMed:10409727,
FT                                ECO:0000269|PubMed:14764652}.
FT   MUTAGEN     118    118       S->E: Enhances transactivation activity.
FT                                Enhances interaction with DDX5.
FT                                Insensitive to PPP5C inhibition of
FT                                transactivation activity.
FT                                {ECO:0000269|PubMed:10409727,
FT                                ECO:0000269|PubMed:14764652}.
FT   MUTAGEN     260    260       R->A,K: Loss of methylation.
FT                                {ECO:0000269|PubMed:18657504}.
FT   MUTAGEN     364    364       V->E: Has higher transcriptional activity
FT                                in the absence of wild type ER. Inhibits
FT                                transcriptional activity when coexpressed
FT                                with the wild type receptor.
FT                                {ECO:0000269|PubMed:8961262}.
FT   MUTAGEN     386    386       I->C: Loss of transmembrane localization,
FT                                no effect on peripheral membrane
FT                                localization. Impairs activation of
FT                                estrogen-induced activation of NOS3 and
FT                                production of nitric oxide. No effect on
FT                                binding to ERES.
FT                                {ECO:0000269|PubMed:21937726}.
FT   MUTAGEN     447    447       C->A: Loss of hormone binding capacity
FT                                and temperature-sensitive loss in DNA-
FT                                binding. {ECO:0000269|PubMed:1577818}.
FT   MUTAGEN     539    539       L->A: Abolishes interaction with NCOA1,
FT                                NCOA2 and NCOA3.
FT                                {ECO:0000269|PubMed:12554772}.
FT   CONFLICT    452    452       I -> L (in Ref. 5; CAE45969).
FT                                {ECO:0000305}.
FT   TURN        186    188       {ECO:0000244|PDB:1HCQ}.
FT   STRAND      189    191       {ECO:0000244|PDB:1HCP}.
FT   STRAND      194    196       {ECO:0000244|PDB:1HCQ}.
FT   STRAND      199    201       {ECO:0000244|PDB:1HCQ}.
FT   HELIX       203    213       {ECO:0000244|PDB:1HCQ}.
FT   STRAND      222    225       {ECO:0000244|PDB:1HCQ}.
FT   TURN        231    236       {ECO:0000244|PDB:1HCQ}.
FT   HELIX       238    248       {ECO:0000244|PDB:1HCQ}.
FT   HELIX       288    291       {ECO:0000244|PDB:2LLO}.
FT   HELIX       302    304       {ECO:0000244|PDB:3Q95}.
FT   HELIX       307    309       {ECO:0000244|PDB:3UUD}.
FT   HELIX       312    322       {ECO:0000244|PDB:5DXE}.
FT   STRAND      330    332       {ECO:0000244|PDB:2YJA}.
FT   STRAND      334    336       {ECO:0000244|PDB:2QZO}.
FT   HELIX       339    361       {ECO:0000244|PDB:5DXE}.
FT   HELIX       367    369       {ECO:0000244|PDB:5DXE}.
FT   HELIX       372    394       {ECO:0000244|PDB:5DXE}.
FT   TURN        395    397       {ECO:0000244|PDB:5DXE}.
FT   STRAND      402    405       {ECO:0000244|PDB:5DXE}.
FT   STRAND      408    410       {ECO:0000244|PDB:5DXE}.
FT   HELIX       412    415       {ECO:0000244|PDB:5DXE}.
FT   STRAND      418    420       {ECO:0000244|PDB:5KCW}.
FT   HELIX       421    438       {ECO:0000244|PDB:5DXE}.
FT   HELIX       442    455       {ECO:0000244|PDB:5DXE}.
FT   HELIX       458    460       {ECO:0000244|PDB:5DXE}.
FT   TURN        464    466       {ECO:0000244|PDB:2B1V}.
FT   HELIX       467    469       {ECO:0000244|PDB:3UUD}.
FT   HELIX       473    492       {ECO:0000244|PDB:5DXE}.
FT   HELIX       497    530       {ECO:0000244|PDB:5DXE}.
FT   STRAND      531    533       {ECO:0000244|PDB:2OUZ}.
FT   HELIX       538    545       {ECO:0000244|PDB:5DXE}.
FT   HELIX       547    549       {ECO:0000244|PDB:5AAU}.
FT   HELIX       588    590       {ECO:0000244|PDB:5N10}.
SQ   SEQUENCE   595 AA;  66216 MW;  5455C57AB0CCCAA7 CRC64;
     MTMTLHTKAS GMALLHQIQG NELEPLNRPQ LKIPLERPLG EVYLDSSKPA VYNYPEGAAY
     EFNAAAAANA QVYGQTGLPY GPGSEAAAFG SNGLGGFPPL NSVSPSPLML LHPPPQLSPF
     LQPHGQQVPY YLENEPSGYT VREAGPPAFY RPNSDNRRQG GRERLASTND KGSMAMESAK
     ETRYCAVCND YASGYHYGVW SCEGCKAFFK RSIQGHNDYM CPATNQCTID KNRRKSCQAC
     RLRKCYEVGM MKGGIRKDRR GGRMLKHKRQ RDDGEGRGEV GSAGDMRAAN LWPSPLMIKR
     SKKNSLALSL TADQMVSALL DAEPPILYSE YDPTRPFSEA SMMGLLTNLA DRELVHMINW
     AKRVPGFVDL TLHDQVHLLE CAWLEILMIG LVWRSMEHPG KLLFAPNLLL DRNQGKCVEG
     MVEIFDMLLA TSSRFRMMNL QGEEFVCLKS IILLNSGVYT FLSSTLKSLE EKDHIHRVLD
     KITDTLIHLM AKAGLTLQQQ HQRLAQLLLI LSHIRHMSNK GMEHLYSMKC KNVVPLYDLL
     LEMLDAHRLH APTSRGGASV EETDQSHLAT AGSTSSHSLQ KYYITGEAEG FPATV
//
ID   Q9UBT1_HUMAN            Unreviewed;        23 AA.
AC   Q9UBT1;
DT   01-MAY-2000, integrated into UniProtKB/TrEMBL.
DT   01-MAY-2000, sequence version 1.
DT   30-AUG-2017, entry version 89.
DE   SubName: Full=Estrogen receptor {ECO:0000313|EMBL:AAC51875.1};
DE   Flags: Fragment;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AAC51875.1};
RN   [1] {ECO:0000313|EMBL:AAC51875.1}
RP   NUCLEOTIDE SEQUENCE OF 1-17.
RC   TISSUE=Breast adenocarcinoma {ECO:0000313|EMBL:AAC51875.1};
RX   PubMed=3754034; DOI=10.1038/320134a0;
RA   Green S., Walter P., Kumar V., Krust A., Bornert J.M., Argos P.,
RA   Chambon P.;
RT   "Human oestrogen receptor cDNA: sequence, expression and homology to
RT   v-erb-A.";
RL   Nature 320:134-139(1986).
RN   [2] {ECO:0000313|EMBL:AAC51875.1}
RP   NUCLEOTIDE SEQUENCE OF 1-17.
RC   TISSUE=Breast adenocarcinoma {ECO:0000313|EMBL:AAC51875.1};
RX   PubMed=3753802; DOI=10.1126/science.3753802;
RA   Greene G.L., Gilna P., Waterfield M., Baker A., Hort Y., Shine J.;
RT   "Sequence and expression of human estrogen receptor complementary
RT   DNA.";
RL   Science 231:1150-1154(1986).
RN   [3] {ECO:0000313|EMBL:AAC51875.1}
RP   NUCLEOTIDE SEQUENCE OF 1-17.
RC   TISSUE=Breast adenocarcinoma {ECO:0000313|EMBL:AAC51875.1};
RX   PubMed=2015052;
RA   Keaveney M., Klug J., Dawson M.T., Nestor P.V., Neilan J.G.,
RA   Forde R.C., Gannon F.;
RT   "Evidence for a previously unidentified upstream exon in the human
RT   oestrogen receptor gene.";
RL   J. Mol. Endocrinol. 6:111-115(1991).
RN   [4] {ECO:0000313|EMBL:AAC51875.1}
RP   NUCLEOTIDE SEQUENCE OF 1-17.
RC   TISSUE=Breast adenocarcinoma {ECO:0000313|EMBL:AAC51875.1};
RX   PubMed=1567414; DOI=10.1016/S0006-291X(05)80289-X;
RA   Piva R., Gambari R., Zorzato F., Kumar L., del Senno L.;
RT   "Analysis of upstream sequences of the human estrogen receptor gene.";
RL   Biochem. Biophys. Res. Commun. 183:996-1002(1992).
RN   [5] {ECO:0000313|EMBL:AAC51875.1}
RP   NUCLEOTIDE SEQUENCE OF 1-17.
RC   TISSUE=Breast adenocarcinoma {ECO:0000313|EMBL:AAC51875.1};
RX   PubMed=1476547;
RA   Keaveney M., Klug J., Gannon F.;
RT   "Sequence analysis of the 5' flanking region of the human estrogen
RT   receptor gene.";
RL   DNA Seq. 2:347-358(1992).
RN   [6] {ECO:0000313|EMBL:AAC51875.1}
RP   NUCLEOTIDE SEQUENCE OF 1-17.
RC   TISSUE=Breast adenocarcinoma {ECO:0000313|EMBL:AAC51875.1};
RX   PubMed=8240974; DOI=10.1016/0960-0760(93)90179-Z;
RA   Piva R., Bianchi N., Aguiari G.L., Gambari R., del Senno L.;
RT   "Sequencing of an RNA transcript of the human estrogen receptor gene:
RT   evidence for a new transcriptional event.";
RL   J. Steroid Biochem. Mol. Biol. 46:531-538(1993).
RN   [7] {ECO:0000313|EMBL:AAC51875.1}
RP   NUCLEOTIDE SEQUENCE OF 1-17.
RC   TISSUE=Breast adenocarcinoma {ECO:0000313|EMBL:AAC51875.1};
RX   PubMed=8647321; DOI=10.1016/0303-7207(95)03716-0;
RA   Grandien K.;
RT   "Determination of transcription start sites in the human estrogen
RT   receptor gene and identification of a novel, tissue-specific, estrogen
RT   receptor-mRNA isoform.";
RL   Mol. Cell. Endocrinol. 116:207-212(1996).
RN   [8] {ECO:0000313|EMBL:AAC51875.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Breast adenocarcinoma {ECO:0000313|EMBL:AAC51875.1};
RX   PubMed=9393949; DOI=10.1016/S0960-0760(97)00029-0;
RA   Thompson D.A., McPherson L.A., Carmeci C., deConinck E.C.,
RA   Weigel R.J.;
RT   "Identification of two estrogen receptor transcripts with novel 5'
RT   exons isolated from a MCF7 cDNA library.";
RL   J. Steroid Biochem. Mol. Biol. 62:143-153(1997).
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U68067; AAC51874.1; -; mRNA.
DR   EMBL; U68068; AAC51875.1; -; mRNA.
DR   RefSeq; NP_001116212.1; NM_001122740.1.
DR   UniGene; Hs.208124; -.
DR   UniGene; Hs.744830; -.
DR   DNASU; 2099; -.
DR   GeneID; 2099; -.
DR   CTD; 2099; -.
DR   PharmGKB; PA156; -.
DR   eggNOG; KOG3575; Eukaryota.
DR   eggNOG; ENOG410XRZC; LUCA.
DR   GenomeRNAi; 2099; -.
PE   2: Evidence at transcript level;
KW   Receptor {ECO:0000313|EMBL:AAC51875.1}.
FT   NON_TER      23     23       {ECO:0000313|EMBL:AAC51875.1}.
SQ   SEQUENCE   23 AA;  2526 MW;  4A678094301081FD CRC64;
     MTMTLHTKAS GMALLHQIQG NEL
//
ID   FOXO1_HUMAN             Reviewed;         655 AA.
AC   Q12778; O43523; Q5VYC7; Q6NSK6;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   28-FEB-2018, entry version 192.
DE   RecName: Full=Forkhead box protein O1;
DE   AltName: Full=Forkhead box protein O1A;
DE   AltName: Full=Forkhead in rhabdomyosarcoma;
GN   Name=FOXO1; Synonyms=FKHR, FOXO1A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND CHROMOSOMAL TRANSLOCATION WITH PAX3.
RX   PubMed=8275086; DOI=10.1038/ng1193-230;
RA   Galili N., Davis R.J., Fredericks W.J., Mukhopadhyay S.,
RA   Rauscher F.J. III, Emanuel B.S., Rovera G., Barr F.G.;
RT   "Fusion of a fork head domain gene to PAX3 in the solid tumour
RT   alveolar rhabdomyosarcoma.";
RL   Nat. Genet. 5:230-235(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Rhabdomyosarcoma;
RX   PubMed=9479491; DOI=10.1006/geno.1997.5122;
RA   Anderson M.J., Viars C.S., Czekay S., Cavenee W.K., Arden K.C.;
RT   "Cloning and characterization of three human forkhead genes that
RT   comprise an FKHR-like gene subfamily.";
RL   Genomics 47:187-199(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E.,
RA   Griffiths-Jones S., Jones M.C., Keenan S.J., Oliver K., Scott C.E.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Andrews D.T.,
RA   Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J., Bannerjee R.,
RA   Barlow K.F., Bates K., Beasley H., Bird C.P., Bray-Allen S.,
RA   Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M.,
RA   Clegg S.C., Cobley V., Collins J.E., Corby N., Coville G.J.,
RA   Deloukas P., Dhami P., Dunham I., Dunn M., Earthrowl M.E.,
RA   Ellington A.G., Faulkner L., Frankish A.G., Frankland J., French L.,
RA   Garner P., Garnett J., Gilbert J.G.R., Gilson C.J., Ghori J.,
RA   Grafham D.V., Gribble S.M., Griffiths C., Hall R.E., Hammond S.,
RA   Harley J.L., Hart E.A., Heath P.D., Howden P.J., Huckle E.J.,
RA   Hunt P.J., Hunt A.R., Johnson C., Johnson D., Kay M., Kimberley A.M.,
RA   King A., Laird G.K., Langford C.J., Lawlor S., Leongamornlert D.A.,
RA   Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., Martin S.,
RA   Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K.M., Rice C.M., Searle S.,
RA   Sehra H.K., Shownkeen R., Skuce C.D., Smith M., Steward C.A.,
RA   Sycamore N., Tester J., Thomas D.W., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., Whitehead S.L., Willey D.L.,
RA   Wilming L., Wray P.W., Wright M.W., Young L., Coulson A., Durbin R.M.,
RA   Hubbard T., Sulston J.E., Beck S., Bentley D.R., Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lymph, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   CHROMOSOMAL TRANSLOCATION WITH PAX7.
RX   PubMed=8187070;
RA   Davis R.J., D'Cruz C.M., Lovell M.A., Biegel J.A., Barr F.G.;
RT   "Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation
RT   in alveolar rhabdomyosarcoma.";
RL   Cancer Res. 54:2869-2872(1994).
RN   [7]
RP   PHOSPHORYLATION AT THR-24; SER-256 AND SER-319.
RX   PubMed=10358075; DOI=10.1074/jbc.274.24.17179;
RA   Rena G., Guo S., Cichy S.C., Unterman T.G., Cohen P.;
RT   "Phosphorylation of the transcription factor forkhead family member
RT   FKHR by protein kinase B.";
RL   J. Biol. Chem. 274:17179-17183(1999).
RN   [8]
RP   DNA-BINDING, PHOSPHORYLATION AT SER-256, AND FUNCTION.
RX   PubMed=10358076; DOI=10.1074/jbc.274.24.17184;
RA   Guo S., Rena G., Cichy S., He X., Cohen P., Unterman T.;
RT   "Phosphorylation of serine 256 by protein kinase B disrupts
RT   transactivation by FKHR and mediates effects of insulin on insulin-
RT   like growth factor-binding protein-1 promoter activity through a
RT   conserved insulin response sequence.";
RL   J. Biol. Chem. 274:17184-17192(1999).
RN   [9]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION AT SER-329, AND MUTAGENESIS OF
RP   SER-329.
RX   PubMed=11311120;
RA   Woods Y.L., Rena G., Morrice N., Barthel A., Becker W., Guo S.,
RA   Unterman T.G., Cohen P.;
RT   "The kinase DYRK1A phosphorylates the transcription factor FKHR at
RT   Ser329 in vitro, a novel in vivo phosphorylation site.";
RL   Biochem. J. 355:597-607(2001).
RN   [10]
RP   INTERACTION WITH YWHAG AND YWHAZ, PHOSPHORYLATION AT THR-24; SER-256
RP   AND SER-319, SUBCELLULAR LOCATION, AND MUTAGENESIS OF THR-24; SER-256
RP   AND SER-319.
RX   PubMed=11237865; DOI=10.1042/0264-6021:3540605;
RA   Rena G., Prescott A.R., Guo S., Cohen P., Unterman T.G.;
RT   "Roles of the forkhead in rhabdomyosarcoma (FKHR) phosphorylation
RT   sites in regulating 14-3-3 binding, transactivation and nuclear
RT   targetting.";
RL   Biochem. J. 354:605-612(2001).
RN   [11]
RP   PHOSPHORYLATION AT THR-24; SER-256; SER-319; SER-322; SER-325 AND
RP   SER-329.
RX   PubMed=11980723; DOI=10.1093/emboj/21.9.2263;
RA   Rena G., Woods Y.L., Prescott A.R., Peggie M., Unterman T.G.,
RA   Williams M.R., Cohen P.;
RT   "Two novel phosphorylation sites on FKHR that are critical for its
RT   nuclear exclusion.";
RL   EMBO J. 21:2263-2271(2002).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF THR-24; SER-256 AND
RP   SER-319.
RX   PubMed=12228231; DOI=10.1074/jbc.M208063200;
RA   Zhang X., Gan L., Pan H., Guo S., He X., Olson S.T., Mesecar A.,
RA   Adam S., Unterman T.G.;
RT   "Phosphorylation of serine 256 suppresses transactivation by FKHR
RT   (FOXO1) by multiple mechanisms. Direct and indirect effects on
RT   nuclear/cytoplasmic shuttling and DNA binding.";
RL   J. Biol. Chem. 277:45276-45284(2002).
RN   [13]
RP   INTERACTION WITH CREBBP AND SIRT1, ACETYLATION, DEACETYLATION, AND
RP   FUNCTION.
RX   PubMed=15220471; DOI=10.1073/pnas.0400593101;
RA   Daitoku H., Hatta M., Matsuzaki H., Aratani S., Ohshima T.,
RA   Miyagishi M., Nakajima T., Fukamizu A.;
RT   "Silent information regulator 2 potentiates Foxo1-mediated
RT   transcription through its deacetylase activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:10042-10047(2004).
RN   [14]
RP   INTERACTION WITH EP300, ACETYLATION, SUBCELLULAR LOCATION,
RP   PHOSPHORYLATION, AND FUNCTION.
RX   PubMed=15890677; DOI=10.1210/me.2004-0292;
RA   Perrot V., Rechler M.M.;
RT   "The coactivator p300 directly acetylates the forkhead transcription
RT   factor Foxo1 and stimulates Foxo1-induced transcription.";
RL   Mol. Endocrinol. 19:2283-2298(2005).
RN   [15]
RP   INTERACTION WITH SKP2, UBIQUITINATION, AND MUTAGENESIS OF SER-256.
RX   PubMed=15668399; DOI=10.1073/pnas.0406789102;
RA   Huang H., Regan K.M., Wang F., Wang D., Smith D.I., van Deursen J.M.,
RA   Tindall D.J.;
RT   "Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated
RT   degradation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:1649-1654(2005).
RN   [16]
RP   INTERACTION WITH PRMT1.
RX   PubMed=18951090; DOI=10.1016/j.molcel.2008.09.013;
RA   Yamagata K., Daitoku H., Takahashi Y., Namiki K., Hisatake K.,
RA   Kako K., Mukai H., Kasuya Y., Fukamizu A.;
RT   "Arginine methylation of FOXO transcription factors inhibits their
RT   phosphorylation by Akt.";
RL   Mol. Cell 32:221-231(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   FUNCTION, PHOSPHORYLATION AT SER-249 BY CDK1, INTERACTION WITH CDK1
RP   AND 14-3-3 PROTEINS, AND MUTAGENESIS OF SER-249.
RX   PubMed=18356527; DOI=10.1126/science.1152337;
RA   Yuan Z., Becker E.B.E., Merlo P., Yamada T., DiBacco S., Konishi Y.,
RA   Schaefer E.M., Bonni A.;
RT   "Activation of FOXO1 by Cdk1 in cycling cells and postmitotic
RT   neurons.";
RL   Science 319:1665-1668(2008).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [20]
RP   PHOSPHORYLATION AT SER-212, SUBCELLULAR LOCATION, FUNCTION, AND
RP   MUTAGENESIS OF SER-212.
RX   PubMed=19221179; DOI=10.1074/jbc.M900461200;
RA   Yuan Z., Lehtinen M.K., Merlo P., Villen J., Gygi S., Bonni A.;
RT   "Regulation of neuronal cell death by MST1-FOXO1 signaling.";
RL   J. Biol. Chem. 284:11285-11292(2009).
RN   [21]
RP   ACETYLATION AT LYS-262; LYS-265 AND LYS-274, DEACETYLATION BY SIRT2,
RP   FUNCTION IN AUTOPHAGY, AND INTERACTION WITH SIRT2 AND ATG7.
RX   PubMed=20543840; DOI=10.1038/ncb2069;
RA   Zhao Y., Yang J., Liao W., Liu X., Zhang H., Wang S., Wang D.,
RA   Feng J., Yu L., Zhu W.G.;
RT   "Cytosolic FoxO1 is essential for the induction of autophagy and
RT   tumour suppressor activity.";
RL   Nat. Cell Biol. 12:665-675(2010).
RN   [22]
RP   INDUCTION.
RX   PubMed=20668652; DOI=10.1371/journal.pone.0011786;
RA   Goitre L., Balzac F., Degani S., Degan P., Marchi S., Pinton P.,
RA   Retta S.F.;
RT   "KRIT1 regulates the homeostasis of intracellular reactive oxygen
RT   species.";
RL   PLoS ONE 5:E11786-E11786(2010).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [24]
RP   FUNCTION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT SER-212.
RX   PubMed=21245099; DOI=10.1158/0008-5472.CAN-10-2203;
RA   Valis K., Prochazka L., Boura E., Chladova J., Obsil T., Rohlena J.,
RA   Truksa J., Dong L.F., Ralph S.J., Neuzil J.;
RT   "Hippo/Mst1 stimulates transcription of the proapoptotic mediator NOXA
RT   in a FoxO1-dependent manner.";
RL   Cancer Res. 71:946-954(2011).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-287, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 151-266, DNA-BINDING,
RP   PHOSPHORYLATION AT SER-212; SER-218; SER-234 AND SER-235, ACETYLATION,
RP   IDENTIFICATION BY MASS SPECTROMETRY, AND MUTAGENESIS OF SER-249.
RX   PubMed=18786403; DOI=10.1016/j.str.2008.06.013;
RA   Brent M.M., Anand R., Marmorstein R.;
RT   "Structural basis for DNA recognition by FoxO1 and its regulation by
RT   posttranslational modification.";
RL   Structure 16:1407-1416(2008).
CC   -!- FUNCTION: Transcription factor that is the main target of insulin
CC       signaling and regulates metabolic homeostasis in response to
CC       oxidative stress. Binds to the insulin response element (IRE) with
CC       consensus sequence 5'-TT[G/A]TTTTG-3' and the related Daf-16
CC       family binding element (DBE) with consensus sequence 5'-
CC       TT[G/A]TTTAC-3'. Activity suppressed by insulin. Main regulator of
CC       redox balance and osteoblast numbers and controls bone mass.
CC       Orchestrates the endocrine function of the skeleton in regulating
CC       glucose metabolism. Acts synergistically with ATF4 to suppress
CC       osteocalcin/BGLAP activity, increasing glucose levels and
CC       triggering glucose intolerance and insulin insensitivity. Also
CC       suppresses the transcriptional activity of RUNX2, an upstream
CC       activator of osteocalcin/BGLAP. In hepatocytes, promotes
CC       gluconeogenesis by acting together with PPARGC1A and CEBPA to
CC       activate the expression of genes such as IGFBP1, G6PC and PCK1.
CC       Important regulator of cell death acting downstream of CDK1,
CC       PKB/AKT1 and SKT4/MST1. Promotes neural cell death. Mediates
CC       insulin action on adipose tissue. Regulates the expression of
CC       adipogenic genes such as PPARG during preadipocyte differentiation
CC       and, adipocyte size and adipose tissue-specific gene expression in
CC       response to excessive calorie intake. Regulates the
CC       transcriptional activity of GADD45A and repair of nitric oxide-
CC       damaged DNA in beta-cells. Required for the autophagic cell death
CC       induction in response to starvation or oxidative stress in a
CC       transcription-independent manner. Mediates the function of MLIP in
CC       cardiomyocytes hypertrophy and cardiac remodeling (By similarity).
CC       {ECO:0000250|UniProtKB:G3V7R4, ECO:0000250|UniProtKB:Q9R1E0,
CC       ECO:0000269|PubMed:10358076, ECO:0000269|PubMed:12228231,
CC       ECO:0000269|PubMed:15220471, ECO:0000269|PubMed:15890677,
CC       ECO:0000269|PubMed:18356527, ECO:0000269|PubMed:19221179,
CC       ECO:0000269|PubMed:20543840, ECO:0000269|PubMed:21245099}.
CC   -!- SUBUNIT: Interacts with LRPPRC. Interacts with RUNX2; the
CC       interaction inhibits RUNX2 transcriptional activity and mediates
CC       the IGF1/insulin-dependent BGLAP expression in osteoblasts
CC       Interacts with PPP2R1A; the interaction regulates the
CC       dephosphorylation of FOXO1 at Thr-24 and Ser-256 leading to its
CC       nuclear import. Interacts (acetylated form) with PPARG. Interacts
CC       with XBP1 isoform 2; this interaction is direct and leads to FOXO1
CC       ubiquitination and degradation via the proteasome pathway (By
CC       similarity). Interacts with NLK. Interacts with SIRT1; the
CC       interaction results in the deacetylation of FOXO1 leading to
CC       activation of FOXO1-mediated transcription of genes involved in
CC       DNA repair and stress resistance. Binds to CDK1. Interacts with
CC       the 14-3-3 proteins, YWHAG and YWHAZ; the interactions require
CC       insulin-stimulated phosphorylation on Thr-24, promote nuclear exit
CC       and loss of transcriptional activity. Interacts with SKP2; the
CC       interaction ubiquitinates FOXO1 leading to its proteosomal
CC       degradation. The interaction requires the presence of KRIT1.
CC       Interacts (via the C-terminal half) with ATF4 (via its DNA-binding
CC       domain); the interaction occurs in osteoblasts, regulates glucose
CC       homeostasis via suppression of beta-cell proliferation and
CC       subsequent decrease in insulin production. Interacts with PRMT1;
CC       the interaction methylates FOXO1, prevents PKB/AKT1
CC       phosphorylation and retains FOXO1 in the nucleus. Interacts with
CC       EP300 and CREBBP; the interactions acetylate FOXO1. Interacts with
CC       SIRT2; the interaction is disrupted in response to oxidative
CC       stress or serum deprivation, leading to increased level of
CC       acetylated FOXO1, which promotes stress-induced autophagy by
CC       stimulating E1-like activating enzyme ATG7. Interacts (acetylated
CC       form) with ATG7; the interaction is increased in response to
CC       oxidative stress or serum deprivation and promotes the autophagic
CC       process leading to cell death. Interacts (via the Fork-head
CC       domain) with CEBPA; the interaction increases when FOXO1 is
CC       deacetylated. Interacts with WDFY2. Forms a complex with WDFY2 and
CC       AKT1 (By similarity). {ECO:0000250|UniProtKB:Q9R1E0,
CC       ECO:0000269|PubMed:11237865, ECO:0000269|PubMed:15220471,
CC       ECO:0000269|PubMed:15668399, ECO:0000269|PubMed:15890677,
CC       ECO:0000269|PubMed:18356527, ECO:0000269|PubMed:18951090,
CC       ECO:0000269|PubMed:20543840}.
CC   -!- INTERACTION:
CC       P31749:AKT1; NbExp=2; IntAct=EBI-1108782, EBI-296087;
CC       P14635:CCNB1; NbExp=2; IntAct=EBI-1108782, EBI-495332;
CC       P06493:CDK1; NbExp=5; IntAct=EBI-1108782, EBI-444308;
CC       Q92793:CREBBP; NbExp=3; IntAct=EBI-1108782, EBI-81215;
CC       P03372:ESR1; NbExp=2; IntAct=EBI-1108782, EBI-78473;
CC       Q14192:FHL2; NbExp=8; IntAct=EBI-1108782, EBI-701903;
CC       Q01105:SET; NbExp=5; IntAct=EBI-1108782, EBI-1053182;
CC       Q96EB6:SIRT1; NbExp=4; IntAct=EBI-1108782, EBI-1802965;
CC       Q923E4:Sirt1 (xeno); NbExp=2; IntAct=EBI-1108782, EBI-1802585;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q9R1E0}.
CC       Nucleus {ECO:0000250|UniProtKB:Q9R1E0}. Note=Shuttles between the
CC       cytoplasm and nucleus. Largely nuclear in unstimulated cells. In
CC       osteoblasts, colocalizes with ATF4 and RUNX2 in the nucleus (By
CC       similarity). Insulin-induced phosphorylation at Ser-256 by
CC       PKB/AKT1 leads, via stimulation of Thr-24 phosphorylation, to
CC       binding of 14-3-3 proteins and nuclear export to the cytoplasm
CC       where it is degraded by the ubiquitin-proteosomal pathway.
CC       Phosphorylation at Ser-249 by CDK1 disrupts binding of 14-3-3
CC       proteins and promotes nuclear accumulation. Phosphorylation by NLK
CC       results in nuclear export. Translocates to the nucleus upon
CC       oxidative stress-induced phosphorylation at Ser-212 by STK4/MST1.
CC       SGK1-mediated phosphorylation also results in nuclear
CC       translocation. Retained in the nucleus under stress stimuli
CC       including oxidative stress, nutrient deprivation or nitric oxide.
CC       Retained in the nucleus on methylation. {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Ubiquitous. {ECO:0000269|PubMed:9479491}.
CC   -!- INDUCTION: Expression is regulated by KRIT1. Levels of expression
CC       also regulated by FOXC1 which binds to a conserved element in the
CC       FOXO1 promoter. {ECO:0000269|PubMed:20668652}.
CC   -!- PTM: Phosphorylation by NLK promotes nuclear export and inhibits
CC       the transcriptional activity. In response to growth factors,
CC       phosphorylation on Thr-24, Ser-256 and Ser-322 by PKB/AKT1
CC       promotes nuclear export and inactivation of transactivational
CC       activity. Phosphorylation on Thr-24 is required for binding 14-3-3
CC       proteins. Phosphorylation of Ser-256 decreases DNA-binding
CC       activity and promotes the phosphorylation of Thr-24 and Ser-319,
CC       permitting phosphorylation of Ser-322 and Ser-325, probably by
CC       CDK1, leading to nuclear exclusion and loss of function. Stress
CC       signals, such as response to oxygen or nitric oxide, attenuate the
CC       PKB/AKT1-mediated phosphorylation leading to nuclear retention.
CC       Phosphorylation of Ser-329 is independent of IGF1 and leads to
CC       reduced function. Dephosphorylated on Thr-24 and Ser-256 by PP2A
CC       in beta-cells under oxidative stress leading to nuclear retention
CC       (By similarity). Phosphorylation of Ser-249 by CDK1 disrupts
CC       binding of 14-3-3 proteins leading to nuclear accumulation and has
CC       no effect on DNA-binding nor transcriptional activity.
CC       Phosphorylation by STK4/MST1 on Ser-212, upon oxidative stress,
CC       inhibits binding to 14-3-3 proteins and nuclear export.
CC       {ECO:0000250, ECO:0000269|PubMed:10358075,
CC       ECO:0000269|PubMed:10358076, ECO:0000269|PubMed:11237865,
CC       ECO:0000269|PubMed:11311120, ECO:0000269|PubMed:11980723,
CC       ECO:0000269|PubMed:18356527, ECO:0000269|PubMed:18786403,
CC       ECO:0000269|PubMed:19221179, ECO:0000269|PubMed:21245099}.
CC   -!- PTM: Acetylated. Acetylation at Lys-262, Lys-265 and Lys-274 are
CC       necessary for autophagic cell death induction. Deacetylated by
CC       SIRT2 in response to oxidative stress or serum deprivation,
CC       thereby negatively regulating FOXO1-mediated autophagic cell
CC       death. {ECO:0000269|PubMed:20543840}.
CC   -!- PTM: Ubiquitinated by SRT2. Ubiquitination leads to proteasomal
CC       degradation. {ECO:0000269|PubMed:15668399}.
CC   -!- PTM: Methylation inhibits AKT1-mediated phosphorylation at Ser-256
CC       and is increased by oxidative stress. {ECO:0000250}.
CC   -!- PTM: Once in the nucleus, acetylated by CREBBP/EP300. Acetylation
CC       diminishes the interaction with target DNA and attenuates the
CC       transcriptional activity. It increases the phosphorylation at Ser-
CC       256. Deacetylation by SIRT1 results in reactivation of the
CC       transcriptional activity. Oxidative stress by hydrogen peroxide
CC       treatment appears to promote deacetylation and uncoupling of
CC       insulin-induced phosphorylation. By contrast, resveratrol acts
CC       independently of acetylation. {ECO:0000269|PubMed:10358075,
CC       ECO:0000269|PubMed:10358076, ECO:0000269|PubMed:11237865,
CC       ECO:0000269|PubMed:11980723}.
CC   -!- DISEASE: Rhabdomyosarcoma 2 (RMS2) [MIM:268220]: A form of
CC       rhabdomyosarcoma, a highly malignant tumor of striated muscle
CC       derived from primitive mesenchymal cells and exhibiting
CC       differentiation along rhabdomyoblastic lines. Rhabdomyosarcoma is
CC       one of the most frequently occurring soft tissue sarcomas and the
CC       most common in children. It occurs in four forms: alveolar,
CC       pleomorphic, embryonal and botryoidal rhabdomyosarcomas. Note=The
CC       gene represented in this entry may be involved in disease
CC       pathogenesis. Chromosomal aberrations involving FOXO1 are found in
CC       rhabdomyosarcoma. Translocation (2;13)(q35;q14) with PAX3 and
CC       translocation t(1;13)(p36;q14) with PAX7. The resulting protein is
CC       a transcriptional activator.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/FOXO1ID83ch13q14.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U02310; AAA03629.1; -; mRNA.
DR   EMBL; AF032885; AAC39591.1; -; mRNA.
DR   EMBL; BT007455; AAP36123.1; -; mRNA.
DR   EMBL; AL355132; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL133318; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC021981; AAH21981.1; -; mRNA.
DR   EMBL; BC070065; AAH70065.3; -; mRNA.
DR   CCDS; CCDS9371.1; -.
DR   PIR; S40521; S40521.
DR   RefSeq; NP_002006.2; NM_002015.3.
DR   UniGene; Hs.370666; -.
DR   PDB; 3CO6; X-ray; 2.10 A; C=151-249.
DR   PDB; 3CO7; X-ray; 2.91 A; C/F=151-266.
DR   PDB; 3COA; X-ray; 2.20 A; C/F=151-266.
DR   PDB; 4LG0; X-ray; 2.19 A; A=143-270.
DR   PDB; 5DUI; X-ray; 2.31 A; A/B=151-259.
DR   PDBsum; 3CO6; -.
DR   PDBsum; 3CO7; -.
DR   PDBsum; 3COA; -.
DR   PDBsum; 4LG0; -.
DR   PDBsum; 5DUI; -.
DR   ProteinModelPortal; Q12778; -.
DR   SMR; Q12778; -.
DR   BioGrid; 108597; 58.
DR   CORUM; Q12778; -.
DR   DIP; DIP-35654N; -.
DR   IntAct; Q12778; 31.
DR   MINT; Q12778; -.
DR   STRING; 9606.ENSP00000368880; -.
DR   BindingDB; Q12778; -.
DR   ChEMBL; CHEMBL5294; -.
DR   iPTMnet; Q12778; -.
DR   PhosphoSitePlus; Q12778; -.
DR   BioMuta; FOXO1; -.
DR   DMDM; 116241368; -.
DR   EPD; Q12778; -.
DR   MaxQB; Q12778; -.
DR   PaxDb; Q12778; -.
DR   PeptideAtlas; Q12778; -.
DR   PRIDE; Q12778; -.
DR   DNASU; 2308; -.
DR   Ensembl; ENST00000379561; ENSP00000368880; ENSG00000150907.
DR   GeneID; 2308; -.
DR   KEGG; hsa:2308; -.
DR   UCSC; uc001uxl.5; human.
DR   CTD; 2308; -.
DR   DisGeNET; 2308; -.
DR   EuPathDB; HostDB:ENSG00000150907.6; -.
DR   GeneCards; FOXO1; -.
DR   HGNC; HGNC:3819; FOXO1.
DR   HPA; CAB022326; -.
DR   HPA; HPA001252; -.
DR   MalaCards; FOXO1; -.
DR   MIM; 136533; gene.
DR   MIM; 268220; phenotype.
DR   neXtProt; NX_Q12778; -.
DR   OpenTargets; ENSG00000150907; -.
DR   Orphanet; 99756; Alveolar rhabdomyosarcoma.
DR   PharmGKB; PA28237; -.
DR   eggNOG; KOG2294; Eukaryota.
DR   eggNOG; COG5025; LUCA.
DR   GeneTree; ENSGT00910000144016; -.
DR   HOGENOM; HOG000251635; -.
DR   HOVERGEN; HBG057789; -.
DR   InParanoid; Q12778; -.
DR   KO; K07201; -.
DR   OMA; KWPGSPN; -.
DR   OrthoDB; EOG091G06K3; -.
DR   PhylomeDB; Q12778; -.
DR   TreeFam; TF315583; -.
DR   Reactome; R-HSA-198693; AKT phosphorylates targets in the nucleus.
DR   Reactome; R-HSA-210745; Regulation of gene expression in beta cells.
DR   Reactome; R-HSA-211163; AKT-mediated inactivation of FOXO1A.
DR   Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer.
DR   Reactome; R-HSA-5687128; MAPK6/MAPK4 signaling.
DR   Reactome; R-HSA-6785807; Interleukin-4 and 13 signaling.
DR   SignaLink; Q12778; -.
DR   SIGNOR; Q12778; -.
DR   ChiTaRS; FOXO1; human.
DR   EvolutionaryTrace; Q12778; -.
DR   GeneWiki; FOXO1; -.
DR   GenomeRNAi; 2308; -.
DR   PRO; PR:Q12778; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   Bgee; ENSG00000150907; -.
DR   CleanEx; HS_FOXO1; -.
DR   Genevisible; Q12778; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; ISS:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; ISS:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0008013; F:beta-catenin binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0003682; F:chromatin binding; ISS:UniProtKB.
DR   GO; GO:0051721; F:protein phosphatase 2A binding; ISS:UniProtKB.
DR   GO; GO:0000981; F:RNA polymerase II transcription factor activity, sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0001223; F:transcription coactivator binding; IEA:Ensembl.
DR   GO; GO:0000989; F:transcription factor activity, transcription factor binding; IEA:Ensembl.
DR   GO; GO:0001078; F:transcriptional repressor activity, RNA polymerase II proximal promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0009653; P:anatomical structure morphogenesis; IBA:GO_Central.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0001568; P:blood vessel development; IEA:Ensembl.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0001678; P:cellular glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0070417; P:cellular response to cold; ISS:UniProtKB.
DR   GO; GO:0071549; P:cellular response to dexamethasone stimulus; IEA:Ensembl.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; ISS:UniProtKB.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0071455; P:cellular response to hyperoxia; IDA:UniProtKB.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; ISS:UniProtKB.
DR   GO; GO:0071732; P:cellular response to nitric oxide; ISS:UniProtKB.
DR   GO; GO:0034599; P:cellular response to oxidative stress; ISS:UniProtKB.
DR   GO; GO:0009267; P:cellular response to starvation; IDA:UniProtKB.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0070166; P:enamel mineralization; IEA:Ensembl.
DR   GO; GO:0031018; P:endocrine pancreas development; TAS:Reactome.
DR   GO; GO:0045444; P:fat cell differentiation; ISS:UniProtKB.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:1903243; P:negative regulation of cardiac muscle hypertrophy in response to stress; ISS:UniProtKB.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; ISS:UniProtKB.
DR   GO; GO:0032873; P:negative regulation of stress-activated MAPK cascade; IDA:BHF-UCL.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0097150; P:neuronal stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0010508; P:positive regulation of autophagy; IMP:UniProtKB.
DR   GO; GO:0045722; P:positive regulation of gluconeogenesis; IEA:Ensembl.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0006473; P:protein acetylation; ISS:UniProtKB.
DR   GO; GO:0043491; P:protein kinase B signaling; TAS:Reactome.
DR   GO; GO:2000505; P:regulation of energy homeostasis; ISS:UniProtKB.
DR   GO; GO:0035947; P:regulation of gluconeogenesis by regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:2000177; P:regulation of neural precursor cell proliferation; IEA:Ensembl.
DR   GO; GO:2000377; P:regulation of reactive oxygen species metabolic process; IEA:Ensembl.
DR   GO; GO:1902617; P:response to fluoride; IEA:Ensembl.
DR   GO; GO:0001659; P:temperature homeostasis; ISS:UniProtKB.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   CDD; cd00059; FH; 1.
DR   Gene3D; 1.10.10.10; -; 1.
DR   InterPro; IPR001766; Fork_head_dom.
DR   InterPro; IPR032067; FOXO-TAD.
DR   InterPro; IPR032068; FOXO_KIX-bd.
DR   InterPro; IPR030456; TF_fork_head_CS_2.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   Pfam; PF00250; Forkhead; 1.
DR   Pfam; PF16676; FOXO-TAD; 1.
DR   Pfam; PF16675; FOXO_KIX_bdg; 1.
DR   PRINTS; PR00053; FORKHEAD.
DR   SMART; SM00339; FH; 1.
DR   SUPFAM; SSF46785; SSF46785; 1.
DR   PROSITE; PS00658; FORK_HEAD_2; 1.
DR   PROSITE; PS50039; FORK_HEAD_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Apoptosis; Autophagy;
KW   Chromosomal rearrangement; Complete proteome; Cytoplasm;
KW   Differentiation; DNA-binding; Methylation; Nucleus; Phosphoprotein;
KW   Proto-oncogene; Reference proteome; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN         1    655       Forkhead box protein O1.
FT                                /FTId=PRO_0000091872.
FT   DNA_BIND    159    235       Fork-head. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00089}.
FT   REGION      211    218       DNA-binding.
FT   REGION      234    237       DNA-binding.
FT   REGION      283    563       Sufficient for interaction with NLK.
FT                                {ECO:0000250}.
FT   REGION      363    459       Required for interaction with RUNX2.
FT                                {ECO:0000250}.
FT   MOTIF       251    253       Nuclear localization signal.
FT   MOTIF       462    466       Required for interaction with SIRT1.
FT                                {ECO:0000250}.
FT   COMPBIAS     91    102       Poly-Ala.
FT   COMPBIAS    120    130       Poly-Pro.
FT   COMPBIAS    152    155       Poly-Ser.
FT   SITE        158    158       DNA-binding.
FT   SITE        165    165       DNA-binding.
FT   SITE        225    225       DNA-binding.
FT   MOD_RES      24     24       Phosphothreonine; by PKB/AKT1 or PKB/AKT2
FT                                and SGK1. {ECO:0000269|PubMed:10358075,
FT                                ECO:0000269|PubMed:11237865,
FT                                ECO:0000269|PubMed:11980723}.
FT   MOD_RES     212    212       Phosphoserine; by STK4/MST1.
FT                                {ECO:0000269|PubMed:18786403,
FT                                ECO:0000269|PubMed:19221179,
FT                                ECO:0000269|PubMed:21245099}.
FT   MOD_RES     218    218       Phosphoserine; by STK4/MST1.
FT                                {ECO:0000269|PubMed:18786403}.
FT   MOD_RES     234    234       Phosphoserine; by STK4/MST1.
FT                                {ECO:0000269|PubMed:18786403}.
FT   MOD_RES     235    235       Phosphoserine; by STK4/MST1.
FT                                {ECO:0000269|PubMed:18786403}.
FT   MOD_RES     245    245       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q9R1E0}.
FT   MOD_RES     248    248       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q9R1E0}.
FT   MOD_RES     249    249       Phosphoserine; by CDK1.
FT                                {ECO:0000269|PubMed:18356527}.
FT   MOD_RES     251    251       Omega-N-methylarginine; by PRMT1.
FT                                {ECO:0000250|UniProtKB:Q9R1E0}.
FT   MOD_RES     253    253       Omega-N-methylarginine; by PRMT1.
FT                                {ECO:0000250|UniProtKB:Q9R1E0}.
FT   MOD_RES     256    256       Phosphoserine; by PKB/AKT1 and SGK1.
FT                                {ECO:0000269|PubMed:10358075,
FT                                ECO:0000269|PubMed:10358076,
FT                                ECO:0000269|PubMed:11237865,
FT                                ECO:0000269|PubMed:11980723}.
FT   MOD_RES     262    262       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:20543840}.
FT   MOD_RES     265    265       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:20543840}.
FT   MOD_RES     274    274       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:20543840}.
FT   MOD_RES     287    287       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692}.
FT   MOD_RES     298    298       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9R1E0}.
FT   MOD_RES     319    319       Phosphoserine; by PKB/AKT1.
FT                                {ECO:0000269|PubMed:10358075,
FT                                ECO:0000269|PubMed:11237865,
FT                                ECO:0000269|PubMed:11980723}.
FT   MOD_RES     322    322       Phosphoserine; by CK1 and SGK1.
FT                                {ECO:0000269|PubMed:11980723}.
FT   MOD_RES     325    325       Phosphoserine; by CK1.
FT                                {ECO:0000269|PubMed:11980723}.
FT   MOD_RES     329    329       Phosphoserine; by DYRK1A.
FT                                {ECO:0000269|PubMed:11311120,
FT                                ECO:0000269|PubMed:11980723}.
FT   MOD_RES     333    333       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q9R1E0}.
FT   MUTAGEN      24     24       T->A: Abolishes PKB/AKT1-mediated
FT                                phosphorylation but does not prevent
FT                                phosphorylation of Ser-256 or Ser-319.
FT                                Also inhibits binding of 14-3-3 proteins.
FT                                Nuclear in unstimulated cells, and little
FT                                export to cytoplasm on IGF1 stimulation.
FT                                Inhibits the PKB/AKT1-mediated activity
FT                                towards other substrates but does not
FT                                block the IGF1-activated 'T-308' of
FT                                phosphorylation of PKB/AKT1; when
FT                                associated with A-256 and A-319. Targeted
FT                                to the nucleus and enhances
FT                                transactivation; when associated with A-
FT                                319. {ECO:0000269|PubMed:11237865,
FT                                ECO:0000269|PubMed:12228231}.
FT   MUTAGEN     212    212       S->A: Abolishes STK4/MST1-mediated
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:19221179}.
FT   MUTAGEN     245    245       K->A: Disrupts DNA-binding; when
FT                                associated with A-248.
FT   MUTAGEN     248    248       K->A: Disrupts DNA-binding; when
FT                                associated with A-245.
FT   MUTAGEN     249    249       S->A: Impaired phosphorylation by CDK1.
FT                                {ECO:0000269|PubMed:18356527,
FT                                ECO:0000269|PubMed:18786403}.
FT   MUTAGEN     249    249       S->E: No effect on DNA-binding.
FT                                {ECO:0000269|PubMed:18356527,
FT                                ECO:0000269|PubMed:18786403}.
FT   MUTAGEN     251    253       RRR->SAS: No targeting to the nucleus and
FT                                disruption of DNA-binding.
FT   MUTAGEN     256    256       S->A: Completely abolishes PKB/AKT1-
FT                                mediated phosphorylation at all three
FT                                sites, and inhibits binding of 14-3-3
FT                                proteins. Inhibits the PKB/AKT1-mediated
FT                                activity towards other substrates but
FT                                does not block the IGF1-activated 'T-308'
FT                                of phosphorylation of PKB/AKT1; when
FT                                associated with or without A-24 and A-
FT                                319. Nuclear in unstimulated cells, and
FT                                little export to cytoplasm on IGF1
FT                                stimulation. Abolishes the ability of
FT                                IGF1 to suppress transactivation.
FT                                Prevents T-24 and S-319 phosphorylation.
FT                                Enhances transactivation; when associated
FT                                with A-24 and A-319.
FT                                {ECO:0000269|PubMed:11237865,
FT                                ECO:0000269|PubMed:12228231,
FT                                ECO:0000269|PubMed:15668399}.
FT   MUTAGEN     256    256       S->D: Reduces DNA binding, promotes
FT                                nuclear exclusion and partially promotes
FT                                T-24 and S-319 phosphorylation. Reduces
FT                                DNA binding, does not promote nuclear
FT                                exclusion but reduces transactivation;
FT                                when associated with A-24 and A-319.
FT                                {ECO:0000269|PubMed:11237865,
FT                                ECO:0000269|PubMed:12228231,
FT                                ECO:0000269|PubMed:15668399}.
FT   MUTAGEN     262    262       K->R: Inhibits interaction with ATG7 and
FT                                FOXO1-acetylation-induced autophagic cell
FT                                death; when associated with R-265 and R-
FT                                274.
FT   MUTAGEN     265    265       K->R: Inhibits interaction with ATG7 and
FT                                FOXO1-acetylation-induced autophagic cell
FT                                death; when associated with R-262 and R-
FT                                274.
FT   MUTAGEN     274    274       K->R: Inhibits interaction with ATG7 and
FT                                FOXO1-acetylation-induced autophagic cell
FT                                death; when associated with R-262 and R-
FT                                265.
FT   MUTAGEN     319    319       S->A: Abolishes PKB/AKT1-mediated
FT                                phosphorylation but does not prevent
FT                                phosphorylation of Ser-24 or Ser-256.
FT                                Inhibits the PKB/AKT1-mediated activity
FT                                towards other substrates but does not
FT                                block the IGF1-activated 'T-308' of
FT                                phosphorylation of PKB/AKT1; when
FT                                associated with A-24 and A-256. Targeted
FT                                to the nucleus and enhances
FT                                transactivation; when associated with A-
FT                                24. {ECO:0000269|PubMed:11237865,
FT                                ECO:0000269|PubMed:12228231}.
FT   MUTAGEN     329    329       S->A: Targeted to the nucleus and
FT                                enhances transactivation.
FT                                {ECO:0000269|PubMed:11311120}.
FT   CONFLICT    131    131       L -> V (in Ref. 1; AAA03629).
FT                                {ECO:0000305}.
FT   CONFLICT    343    343       V -> M (in Ref. 5; AAH70065).
FT                                {ECO:0000305}.
FT   STRAND      156    158       {ECO:0000244|PDB:3CO6}.
FT   HELIX       165    175       {ECO:0000244|PDB:3CO6}.
FT   STRAND      176    181       {ECO:0000244|PDB:5DUI}.
FT   HELIX       183    193       {ECO:0000244|PDB:3CO6}.
FT   HELIX       195    197       {ECO:0000244|PDB:3CO6}.
FT   HELIX       203    219       {ECO:0000244|PDB:3CO6}.
FT   STRAND      223    226       {ECO:0000244|PDB:3CO6}.
FT   TURN        230    232       {ECO:0000244|PDB:3CO6}.
FT   STRAND      236    239       {ECO:0000244|PDB:3CO6}.
SQ   SEQUENCE   655 AA;  69662 MW;  6DEF6C994BDFDBAB CRC64;
     MAEAPQVVEI DPDFEPLPRP RSCTWPLPRP EFSQSNSATS SPAPSGSAAA NPDAAAGLPS
     ASAAAVSADF MSNLSLLEES EDFPQAPGSV AAAVAAAAAA AATGGLCGDF QGPEAGCLHP
     APPQPPPPGP LSQHPPVPPA AAGPLAGQPR KSSSSRRNAW GNLSYADLIT KAIESSAEKR
     LTLSQIYEWM VKSVPYFKDK GDSNSSAGWK NSIRHNLSLH SKFIRVQNEG TGKSSWWMLN
     PEGGKSGKSP RRRAASMDNN SKFAKSRSRA AKKKASLQSG QEGAGDSPGS QFSKWPASPG
     SHSNDDFDNW STFRPRTSSN ASTISGRLSP IMTEQDDLGE GDVHSMVYPP SAAKMASTLP
     SLSEISNPEN MENLLDNLNL LSSPTSLTVS TQSSPGTMMQ QTPCYSFAPP NTSLNSPSPN
     YQKYTYGQSS MSPLPQMPIQ TLQDNKSSYG GMSQYNCAPG LLKELLTSDS PPHNDIMTPV
     DPGVAQPNSR VLGQNVMMGP NSVMSTYGSQ ASHNKMMNPS SHTHPGHAQQ TSAVNGRPLP
     HTVSTMPHTS GMNRLTQVKT PVQVPLPHPM QMSALGGYSS VSSCNGYGRM GLLHQEKLPS
     DLDGMFIERL DCDMESIIRN DLMDGDTLDF NFDNVLPNQS FPHSVKTTTH SWVSG
//
ID   FOXO3_HUMAN             Reviewed;         673 AA.
AC   O43524; B4DVZ6; E1P5E6; O15171; Q5T2I7; Q9BZ04;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1998, sequence version 1.
DT   28-FEB-2018, entry version 196.
DE   RecName: Full=Forkhead box protein O3 {ECO:0000305};
DE   AltName: Full=AF6q21 protein {ECO:0000303|PubMed:9345057};
DE   AltName: Full=Forkhead in rhabdomyosarcoma-like 1 {ECO:0000303|PubMed:9479491};
GN   Name=FOXO3 {ECO:0000312|HGNC:HGNC:3821};
GN   Synonyms=FKHRL1 {ECO:0000303|PubMed:9479491},
GN   FOXO3A {ECO:0000303|PubMed:11154281};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Rhabdomyosarcoma;
RX   PubMed=9479491; DOI=10.1006/geno.1997.5122;
RA   Anderson M.J., Viars C.S., Czekay S., Cavenee W.K., Arden K.C.;
RT   "Cloning and characterization of three human forkhead genes that
RT   comprise an FKHR-like gene subfamily.";
RL   Genomics 47:187-199(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Stomach;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Muscle, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 1-383 (ISOFORM 1), AND
RP   INVOLVEMENT IN SECONDARY ACUTE LEUKEMIAS.
RX   PubMed=9345057;
RA   Hillion J., Le Coniat M., Jonveaux P., Berger R., Bernard O.A.;
RT   "AF6q21, a novel partner of the MLL gene in t(6;11)(q21;q23), defines
RT   a forkhead transcriptional factor subfamily.";
RL   Blood 90:3714-3719(1997).
RN   [7]
RP   FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION AT THR-32; SER-253 AND
RP   SER-315, AND MUTAGENESIS OF THR-32; SER-253 AND SER-315.
RX   PubMed=10102273; DOI=10.1016/S0092-8674(00)80595-4;
RA   Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S.,
RA   Anderson M.J., Arden K.C., Blenis J., Greenberg M.E.;
RT   "Akt promotes cell survival by phosphorylating and inhibiting a
RT   Forkhead transcription factor.";
RL   Cell 96:857-868(1999).
RN   [8]
RP   PHOSPHORYLATION AT SER-315.
RX   PubMed=11154281; DOI=10.1128/MCB.21.3.952-965.2001;
RA   Brunet A., Park J., Tran H., Hu L.S., Hemmings B.A., Greenberg M.E.;
RT   "Protein kinase SGK mediates survival signals by phosphorylating the
RT   forkhead transcription factor FKHRL1 (FOXO3a).";
RL   Mol. Cell. Biol. 21:952-965(2001).
RN   [9]
RP   INTERACTION WITH CHUK AND IKBKB, REGION, SUBCELLULAR LOCATION,
RP   PHOSPHORYLATION AT SER-644, AND MUTAGENESIS OF SER-644.
RX   PubMed=15084260; DOI=10.1016/S0092-8674(04)00302-2;
RA   Hu M.C., Lee D.F., Xia W., Golfman L.S., Ou-Yang F., Yang J.Y.,
RA   Zou Y., Bao S., Hanada N., Saso H., Kobayashi R., Hung M.C.;
RT   "IkappaB kinase promotes tumorigenesis through inhibition of forkhead
RT   FOXO3a.";
RL   Cell 117:225-237(2004).
RN   [10]
RP   FUNCTION, PHOSPHORYLATION AT SER-209, INTERACTION WITH STK4/MST1 AND
RP   YWHAB, SUBCELLULAR LOCATION, AND MUTAGENESIS OF SER-209.
RX   PubMed=16751106; DOI=10.1016/j.cell.2006.03.046;
RA   Lehtinen M.K., Yuan Z., Boag P.R., Yang Y., Villen J., Becker E.B.E.,
RA   DiBacco S., de la Iglesia N., Gygi S.P., Blackwell T.K., Bonni A.;
RT   "A conserved MST-FOXO signaling pathway mediates oxidative-stress
RT   responses and extends life span.";
RL   Cell 125:987-1001(2006).
RN   [11]
RP   PHOSPHORYLATION AT THR-179; SER-399; SER-413; SER-555; SER-588 AND
RP   SER-626, MUTAGENESIS OF THR-179; SER-399; SER-413; SER-555; SER-588
RP   AND SER-626, AND SUBCELLULAR LOCATION.
RX   PubMed=17711846; DOI=10.1074/jbc.M705325200;
RA   Greer E.L., Oskoui P.R., Banko M.R., Maniar J.M., Gygi M.P.,
RA   Gygi S.P., Brunet A.;
RT   "The energy sensor AMP-activated protein kinase directly regulates the
RT   mammalian FOXO3 transcription factor.";
RL   J. Biol. Chem. 282:30107-30119(2007).
RN   [12]
RP   INTERACTION WITH PIM1, AND PHOSPHORYLATION.
RX   PubMed=18593906; DOI=10.1158/0008-5472.CAN-08-0634;
RA   Morishita D., Katayama R., Sekimizu K., Tsuruo T., Fujita N.;
RT   "Pim kinases promote cell cycle progression by phosphorylating and
RT   down-regulating p27Kip1 at the transcriptional and posttranscriptional
RT   levels.";
RL   Cancer Res. 68:5076-5085(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-421, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-280 AND SER-284, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-280, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   FUNCTION, SUBCELLULAR LOCATION, DNA-BINDING, AND PHOSPHORYLATION AT
RP   SER-215; SER-253; SER-551 AND SER-555.
RX   PubMed=21329882; DOI=10.1016/j.molcel.2011.01.023;
RA   Kress T.R., Cannell I.G., Brenkman A.B., Samans B., Gaestel M.,
RA   Roepman P., Burgering B.M., Bushell M., Rosenwald A., Eilers M.;
RT   "The MK5/PRAK kinase and Myc form a negative feedback loop that is
RT   disrupted during colorectal tumorigenesis.";
RL   Mol. Cell 41:445-457(2011).
RN   [19]
RP   METHYLATION AT LYS-46; LYS-149; LYS-230; LYS-262; LYS-271; LYS-290 AND
RP   LYS-419, AND MUTAGENESIS OF LYS-269; LYS-270 AND LYS-271.
RX   PubMed=22820736;
RA   Calnan D.R., Webb A.E., White J.L., Stowe T.R., Goswami T., Shi X.,
RA   Espejo A., Bedford M.T., Gozani O., Gygi S.P., Brunet A.;
RT   "Methylation by Set9 modulates FoxO3 stability and transcriptional
RT   activity.";
RL   Aging (Albany NY) 4:462-479(2012).
RN   [20]
RP   INTERACTION WITH IKBKB, AND SUBCELLULAR LOCATION.
RX   PubMed=22313691; DOI=10.1016/j.cellsig.2012.01.012;
RA   Tezil T., Bodur C., Kutuk O., Basaga H.;
RT   "IKK-beta mediates chemoresistance by sequestering FOXO3; a critical
RT   factor for cell survival and death.";
RL   Cell. Signal. 24:1361-1368(2012).
RN   [21]
RP   ACETYLATION, DEACETYLATION BY SIRT2, INTERACTION WITH SKP2,
RP   UBIQUITINATION BY SKP2, AND MUTAGENESIS OF LYS-242; LYS-259; LYS-290
RP   AND LYS-569.
RX   PubMed=21841822; DOI=10.1038/onc.2011.347;
RA   Wang F., Chan C.H., Chen K., Guan X., Lin H.K., Tong Q.;
RT   "Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to Skp2-mediated FOXO3
RT   ubiquitination and degradation.";
RL   Oncogene 31:1546-1557(2012).
RN   [22]
RP   INTERACTION WITH DDIT3, AND SUBCELLULAR LOCATION.
RX   PubMed=22761832; DOI=10.1371/journal.pone.0039586;
RA   Ghosh A.P., Klocke B.J., Ballestas M.E., Roth K.A.;
RT   "CHOP potentially co-operates with FOXO3a in neuronal cells to
RT   regulate PUMA and BIM expression in response to ER stress.";
RL   PLoS ONE 7:E39586-E39586(2012).
RN   [23]
RP   PHOSPHORYLATION AT SER-299, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=23805378; DOI=10.7554/eLife.00518;
RA   Tao L., Xie Q., Ding Y.H., Li S.T., Peng S., Zhang Y.P., Tan D.,
RA   Yuan Z., Dong M.Q.;
RT   "CAMKII and Calcineurin regulate the lifespan of Caenorhabditis
RT   elegans through the FOXO transcription factor DAF-16.";
RL   Elife 2:E00518-E00518(2013).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-280; SER-284; SER-299;
RP   SER-311; SER-413 AND SER-551, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 158-253 IN COMPLEX WITH DNA,
RP   MUTAGENESIS OF LYS-242 AND LYS-245, AND NUCLEAR LOCALIZATION SIGNAL.
RX   PubMed=17940099; DOI=10.1093/nar/gkm703;
RA   Tsai K.-L., Sun Y.-J., Huang C.-Y., Yang J.-Y., Hung M.-C.,
RA   Hsiao C.-D.;
RT   "Crystal structure of the human FOXO3a-DBD/DNA complex suggests the
RT   effects of post-translational modification.";
RL   Nucleic Acids Res. 35:6984-6994(2007).
CC   -!- FUNCTION: Transcriptional activator which triggers apoptosis in
CC       the absence of survival factors, including neuronal cell death
CC       upon oxidative stress. Recognizes and binds to the DNA sequence
CC       5'-[AG]TAAA[TC]A-3'. Participates in post-transcriptional
CC       regulation of MYC: following phosphorylation by MAPKAPK5, promotes
CC       induction of miR-34b and miR-34c expression, 2 post-
CC       transcriptional regulators of MYC that bind to the 3'UTR of MYC
CC       transcript and prevent its translation.
CC       {ECO:0000269|PubMed:10102273, ECO:0000269|PubMed:16751106,
CC       ECO:0000269|PubMed:21329882}.
CC   -!- SUBUNIT: Interacts with SIRT2; the interaction occurs
CC       independently of SIRT2 deacetylase activity (By similarity).
CC       Interacts with YWHAB/14-3-3-beta and YWHAZ/14-3-3-zeta, which are
CC       required for cytosolic sequestration (PubMed:16751106). Upon
CC       oxidative stress, interacts with STK4/MST1, which disrupts
CC       interaction with YWHAB/14-3-3-beta and leads to nuclear
CC       translocation (PubMed:16751106). Interacts with PIM1
CC       (PubMed:18593906). Interacts with DDIT3/CHOP (PubMed:22761832).
CC       Interacts (deacetylated form) with SKP2 (PubMed:21841822).
CC       Interacts with CHUK and IKBKB (PubMed:15084260, PubMed:22313691).
CC       Interacts with CAMK2A, CAMK2B and calcineurin A (By similarity).
CC       {ECO:0000250|UniProtKB:Q9WVH4, ECO:0000269|PubMed:15084260,
CC       ECO:0000269|PubMed:16751106, ECO:0000269|PubMed:18593906,
CC       ECO:0000269|PubMed:21841822, ECO:0000269|PubMed:22313691,
CC       ECO:0000269|PubMed:22761832}.
CC   -!- INTERACTION:
CC       P31749:AKT1; NbExp=3; IntAct=EBI-1644164, EBI-296087;
CC       Q92974:ARHGEF2; NbExp=2; IntAct=EBI-1644164, EBI-302405;
CC       P30260:CDC27; NbExp=2; IntAct=EBI-1644164, EBI-994813;
CC       Q92793:CREBBP; NbExp=3; IntAct=EBI-1644164, EBI-81215;
CC       Q60987:Foxg1 (xeno); NbExp=5; IntAct=EBI-1644164, EBI-11166131;
CC       P85037:FOXK1; NbExp=2; IntAct=EBI-1644164, EBI-2509974;
CC       Q08050:FOXM1; NbExp=2; IntAct=EBI-1644164, EBI-866480;
CC       P51610:HCFC1; NbExp=2; IntAct=EBI-1644164, EBI-396176;
CC       P01106:MYC; NbExp=3; IntAct=EBI-1644164, EBI-447544;
CC       P11309:PIM1; NbExp=2; IntAct=EBI-1644164, EBI-696621;
CC       Q96T60:PNKP; NbExp=2; IntAct=EBI-1644164, EBI-1045072;
CC       P06400:RB1; NbExp=2; IntAct=EBI-1644164, EBI-491274;
CC       P28749:RBL1; NbExp=3; IntAct=EBI-1644164, EBI-971402;
CC       Q96EB6:SIRT1; NbExp=5; IntAct=EBI-1644164, EBI-1802965;
CC       P84022:SMAD3; NbExp=5; IntAct=EBI-1644164, EBI-347161;
CC       Q13485:SMAD4; NbExp=9; IntAct=EBI-1644164, EBI-347263;
CC       O75529:TAF5L; NbExp=2; IntAct=EBI-1644164, EBI-1785876;
CC       P04637:TP53; NbExp=2; IntAct=EBI-1644164, EBI-366083;
CC       P63104:YWHAZ; NbExp=2; IntAct=EBI-1644164, EBI-347088;
CC       P63101:Ywhaz (xeno); NbExp=2; IntAct=EBI-1644164, EBI-354751;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol
CC       {ECO:0000269|PubMed:10102273, ECO:0000269|PubMed:15084260,
CC       ECO:0000269|PubMed:16751106, ECO:0000269|PubMed:17711846,
CC       ECO:0000269|PubMed:21329882, ECO:0000269|PubMed:22313691,
CC       ECO:0000269|PubMed:22761832}. Nucleus
CC       {ECO:0000269|PubMed:10102273, ECO:0000269|PubMed:15084260,
CC       ECO:0000269|PubMed:16751106, ECO:0000269|PubMed:17711846,
CC       ECO:0000269|PubMed:21329882, ECO:0000269|PubMed:22313691,
CC       ECO:0000269|PubMed:22761832}. Note=Retention in the cytoplasm
CC       contributes to its inactivation. Translocates to the nucleus upon
CC       oxidative stress and in the absence of survival factors.
CC       {ECO:0000269|PubMed:10102273, ECO:0000269|PubMed:15084260,
CC       ECO:0000269|PubMed:16751106}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O43524-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O43524-2; Sequence=VSP_056225;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. {ECO:0000269|PubMed:9479491}.
CC   -!- PTM: In the presence of survival factors such as IGF-1,
CC       phosphorylated on Thr-32 and Ser-253 by AKT1/PKB. This
CC       phosphorylated form then interacts with 14-3-3 proteins and is
CC       retained in the cytoplasm. Survival factor withdrawal induces
CC       dephosphorylation and promotes translocation to the nucleus where
CC       the dephosphorylated protein induces transcription of target genes
CC       and triggers apoptosis. Although AKT1/PKB doesn't appear to
CC       phosphorylate Ser-315 directly, it may activate other kinases that
CC       trigger phosphorylation at this residue. Phosphorylated by
CC       STK4/MST1 on Ser-209 upon oxidative stress, which leads to
CC       dissociation from YWHAB/14-3-3-beta and nuclear translocation.
CC       Phosphorylated by PIM1. Phosphorylation by AMPK leads to the
CC       activation of transcriptional activity without affecting
CC       subcellular localization. Phosphorylation by MAPKAPK5 promotes
CC       nuclear localization and DNA-binding, leading to induction of miR-
CC       34b and miR-34c expression, 2 post-transcriptional regulators of
CC       MYC that bind to the 3'UTR of MYC transcript and prevent its
CC       translation (PubMed:10102273, PubMed:11154281, PubMed:16751106,
CC       PubMed:17711846, PubMed:18593906, PubMed:21329882). Phosphorylated
CC       by CHUK/IKKA and IKBKB/IKKB. TNF-induced inactivation of FOXO3
CC       requires its phosphorylation at Ser-644 by IKBKB/IKKB which
CC       promotes FOXO3 retention in the cytoplasm, polyubiquitination and
CC       ubiquitin-mediated proteasomal degradation (PubMed:15084260). May
CC       be dephosphorylated by calcineurin A on Ser-299 which abolishes
CC       FOXO3 transcriptional activity (By similarity).
CC       {ECO:0000250|UniProtKB:Q9WVH4, ECO:0000269|PubMed:10102273,
CC       ECO:0000269|PubMed:11154281, ECO:0000269|PubMed:15084260,
CC       ECO:0000269|PubMed:16751106, ECO:0000269|PubMed:17711846,
CC       ECO:0000269|PubMed:18593906, ECO:0000269|PubMed:21329882}.
CC   -!- PTM: Deacetylation by SIRT1 or SIRT2 stimulates interaction of
CC       FOXO3 with SKP2 and facilitates SCF(SKP2)-mediated FOXO3
CC       ubiquitination and proteasomal degradation (PubMed:21841822).
CC       Deacetylation by SIRT2 stimulates FOXO3-mediated transcriptional
CC       activity in response to oxidative stress (By similarity).
CC       {ECO:0000250|UniProtKB:Q9WVH4, ECO:0000269|PubMed:21841822}.
CC   -!- PTM: Heavily methylated by SET9 which decreases stability, while
CC       moderately increasing transcriptional activity. The main
CC       methylation site is Lys-271. Methylation doesn't affect
CC       subcellular location. {ECO:0000269|PubMed:22820736}.
CC   -!- PTM: Polyubiquitinated. Ubiquitinated by a SCF complex containing
CC       SKP2, leading to proteasomal degradation.
CC       {ECO:0000269|PubMed:21841822}.
CC   -!- DISEASE: Note=A chromosomal aberration involving FOXO3 is found in
CC       secondary acute leukemias. Translocation t(6;11)(q21;q23) with
CC       KMT2A/MLL1.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/AF6q21ID125.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF032886; AAC39592.1; -; mRNA.
DR   EMBL; AK301304; BAG62858.1; -; mRNA.
DR   EMBL; AL096818; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL391646; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL365509; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471051; EAW48373.1; -; Genomic_DNA.
DR   EMBL; CH471051; EAW48374.1; -; Genomic_DNA.
DR   EMBL; BC020227; AAH20227.1; -; mRNA.
DR   EMBL; BC021224; AAH21224.1; -; mRNA.
DR   EMBL; BC068552; AAH68552.1; -; mRNA.
DR   EMBL; AJ001589; CAA04860.1; -; mRNA.
DR   EMBL; AJ001590; CAA04861.1; -; Genomic_DNA.
DR   CCDS; CCDS5068.1; -. [O43524-1]
DR   RefSeq; NP_001446.1; NM_001455.3. [O43524-1]
DR   RefSeq; NP_963853.1; NM_201559.2. [O43524-1]
DR   RefSeq; XP_005266925.1; XM_005266868.3. [O43524-2]
DR   RefSeq; XP_011533930.1; XM_011535628.2. [O43524-2]
DR   RefSeq; XP_011533931.1; XM_011535629.2. [O43524-2]
DR   RefSeq; XP_016866075.1; XM_017010586.1. [O43524-2]
DR   UniGene; Hs.220950; -.
DR   PDB; 2K86; NMR; -; A=151-251.
DR   PDB; 2LQH; NMR; -; B=461-635.
DR   PDB; 2LQI; NMR; -; B=461-635.
DR   PDB; 2UZK; X-ray; 2.70 A; A/C=158-253.
DR   PDBsum; 2K86; -.
DR   PDBsum; 2LQH; -.
DR   PDBsum; 2LQI; -.
DR   PDBsum; 2UZK; -.
DR   ProteinModelPortal; O43524; -.
DR   SMR; O43524; -.
DR   BioGrid; 108598; 65.
DR   CORUM; O43524; -.
DR   DIP; DIP-29723N; -.
DR   IntAct; O43524; 43.
DR   MINT; O43524; -.
DR   STRING; 9606.ENSP00000339527; -.
DR   BindingDB; O43524; -.
DR   ChEMBL; CHEMBL5778; -.
DR   iPTMnet; O43524; -.
DR   PhosphoSitePlus; O43524; -.
DR   BioMuta; FOXO3; -.
DR   EPD; O43524; -.
DR   MaxQB; O43524; -.
DR   PaxDb; O43524; -.
DR   PeptideAtlas; O43524; -.
DR   PRIDE; O43524; -.
DR   DNASU; 2309; -.
DR   Ensembl; ENST00000343882; ENSP00000339527; ENSG00000118689. [O43524-1]
DR   Ensembl; ENST00000406360; ENSP00000385824; ENSG00000118689. [O43524-1]
DR   Ensembl; ENST00000540898; ENSP00000446316; ENSG00000118689. [O43524-2]
DR   GeneID; 2309; -.
DR   KEGG; hsa:2309; -.
DR   UCSC; uc003psk.3; human. [O43524-1]
DR   CTD; 2309; -.
DR   DisGeNET; 2309; -.
DR   EuPathDB; HostDB:ENSG00000118689.14; -.
DR   GeneCards; FOXO3; -.
DR   HGNC; HGNC:3821; FOXO3.
DR   HPA; CAB004074; -.
DR   HPA; HPA063104; -.
DR   MIM; 602681; gene.
DR   neXtProt; NX_O43524; -.
DR   OpenTargets; ENSG00000118689; -.
DR   PharmGKB; PA28239; -.
DR   eggNOG; KOG2294; Eukaryota.
DR   eggNOG; COG5025; LUCA.
DR   GeneTree; ENSGT00910000144016; -.
DR   HOGENOM; HOG000251635; -.
DR   HOVERGEN; HBG057789; -.
DR   InParanoid; O43524; -.
DR   KO; K09408; -.
DR   OMA; PSVSKPC; -.
DR   OrthoDB; EOG091G06K3; -.
DR   PhylomeDB; O43524; -.
DR   TreeFam; TF315583; -.
DR   Reactome; R-HSA-1181150; Signaling by NODAL.
DR   Reactome; R-HSA-198693; AKT phosphorylates targets in the nucleus.
DR   Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer.
DR   Reactome; R-HSA-5687128; MAPK6/MAPK4 signaling.
DR   Reactome; R-HSA-6785807; Interleukin-4 and 13 signaling.
DR   Reactome; R-HSA-8862803; Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models.
DR   Reactome; R-HSA-8950505; Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation.
DR   Reactome; R-HSA-8952158; RUNX3 regulates BCL2L11 (BIM) transcription.
DR   SignaLink; O43524; -.
DR   SIGNOR; O43524; -.
DR   ChiTaRS; FOXO3; human.
DR   EvolutionaryTrace; O43524; -.
DR   GeneWiki; FOXO3; -.
DR   GenomeRNAi; 2309; -.
DR   PRO; PR:O43524; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000118689; -.
DR   CleanEx; HS_FOXO3; -.
DR   Genevisible; O43524; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:FlyBase.
DR   GO; GO:0016020; C:membrane; IEA:Ensembl.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0008013; F:beta-catenin binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0031490; F:chromatin DNA binding; ISS:UniProtKB.
DR   GO; GO:0001047; F:core promoter binding; ISS:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IDA:MGI.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0001221; F:transcription cofactor binding; IEA:Ensembl.
DR   GO; GO:0001228; F:transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0001227; F:transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0009653; P:anatomical structure morphogenesis; IBA:GO_Central.
DR   GO; GO:0001547; P:antral ovarian follicle growth; IEA:Ensembl.
DR   GO; GO:0048854; P:brain morphogenesis; IEA:Ensembl.
DR   GO; GO:1904646; P:cellular response to amyloid-beta; IEA:Ensembl.
DR   GO; GO:0071386; P:cellular response to corticosterone stimulus; IEA:Ensembl.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0034599; P:cellular response to oxidative stress; ISS:UniProtKB.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; IEA:Ensembl.
DR   GO; GO:0097192; P:extrinsic apoptotic signaling pathway in absence of ligand; IEA:Ensembl.
DR   GO; GO:0001544; P:initiation of primordial ovarian follicle growth; IEA:Ensembl.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0045665; P:negative regulation of neuron differentiation; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0097150; P:neuronal stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0001556; P:oocyte maturation; IEA:Ensembl.
DR   GO; GO:0001542; P:ovulation from ovarian follicle; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:BHF-UCL.
DR   GO; GO:2000353; P:positive regulation of endothelial cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0045648; P:positive regulation of erythrocyte differentiation; IDA:MGI.
DR   GO; GO:1901300; P:positive regulation of hydrogen peroxide-mediated programmed cell death; IEA:Ensembl.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IMP:UniProtKB.
DR   GO; GO:1903428; P:positive regulation of reactive oxygen species biosynthetic process; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0043491; P:protein kinase B signaling; TAS:Reactome.
DR   GO; GO:2000177; P:regulation of neural precursor cell proliferation; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0006417; P:regulation of translation; IDA:UniProtKB.
DR   GO; GO:0071548; P:response to dexamethasone; IEA:Ensembl.
DR   GO; GO:0031667; P:response to nutrient levels; IEA:Ensembl.
DR   GO; GO:1990785; P:response to water-immersion restraint stress; IEA:Ensembl.
DR   GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IMP:UniProtKB.
DR   CDD; cd00059; FH; 1.
DR   Gene3D; 1.10.10.10; -; 1.
DR   InterPro; IPR001766; Fork_head_dom.
DR   InterPro; IPR032067; FOXO-TAD.
DR   InterPro; IPR032068; FOXO_KIX-bd.
DR   InterPro; IPR030456; TF_fork_head_CS_2.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   Pfam; PF00250; Forkhead; 1.
DR   Pfam; PF16676; FOXO-TAD; 1.
DR   Pfam; PF16675; FOXO_KIX_bdg; 1.
DR   PRINTS; PR00053; FORKHEAD.
DR   SMART; SM00339; FH; 1.
DR   SUPFAM; SSF46785; SSF46785; 1.
DR   PROSITE; PS00658; FORK_HEAD_2; 1.
DR   PROSITE; PS50039; FORK_HEAD_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing; Apoptosis;
KW   Chromosomal rearrangement; Complete proteome; Cytoplasm; DNA-binding;
KW   Methylation; Nucleus; Phosphoprotein; Proto-oncogene;
KW   Reference proteome; Transcription; Transcription regulation;
KW   Ubl conjugation.
FT   CHAIN         1    673       Forkhead box protein O3.
FT                                /FTId=PRO_0000091874.
FT   DNA_BIND    157    251       Fork-head. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00089}.
FT   REGION      300    673       Mediates interaction with CHUK/IKKA and
FT                                IKBKB/IKKB.
FT                                {ECO:0000269|PubMed:15084260}.
FT   MOTIF       242    259       Nuclear localization signal.
FT                                {ECO:0000269|PubMed:17940099}.
FT   MOD_RES      32     32       Phosphothreonine; by PKB/AKT1.
FT                                {ECO:0000269|PubMed:10102273}.
FT   MOD_RES      46     46       N6-methyllysine.
FT                                {ECO:0000269|PubMed:22820736}.
FT   MOD_RES     149    149       N6-methyllysine.
FT                                {ECO:0000269|PubMed:22820736}.
FT   MOD_RES     179    179       Phosphothreonine; by AMPK.
FT                                {ECO:0000269|PubMed:17711846}.
FT   MOD_RES     209    209       Phosphoserine; by STK4/MST1.
FT                                {ECO:0000269|PubMed:16751106}.
FT   MOD_RES     215    215       Phosphoserine; by MAPKAPK5.
FT                                {ECO:0000269|PubMed:21329882}.
FT   MOD_RES     230    230       N6-methyllysine.
FT                                {ECO:0000269|PubMed:22820736}.
FT   MOD_RES     242    242       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q9WVH4}.
FT   MOD_RES     253    253       Phosphoserine; by PKB/AKT1 and MAPKAPK5.
FT                                {ECO:0000269|PubMed:10102273,
FT                                ECO:0000269|PubMed:21329882}.
FT   MOD_RES     262    262       N6-methyllysine.
FT                                {ECO:0000269|PubMed:22820736}.
FT   MOD_RES     271    271       N6-methyllysine.
FT                                {ECO:0000269|PubMed:22820736}.
FT   MOD_RES     280    280       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     284    284       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     290    290       N6-methyllysine.
FT                                {ECO:0000269|PubMed:22820736}.
FT   MOD_RES     294    294       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9WVH4}.
FT   MOD_RES     299    299       Phosphoserine; by CaMK2A.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:23805378}.
FT   MOD_RES     311    311       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     315    315       Phosphoserine; by SGK1.
FT                                {ECO:0000269|PubMed:10102273,
FT                                ECO:0000269|PubMed:11154281}.
FT   MOD_RES     399    399       Phosphoserine; by AMPK.
FT                                {ECO:0000269|PubMed:17711846}.
FT   MOD_RES     413    413       Phosphoserine; by AMPK.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:17711846}.
FT   MOD_RES     419    419       N6-methyllysine.
FT                                {ECO:0000269|PubMed:22820736}.
FT   MOD_RES     421    421       Phosphoserine.
FT                                {ECO:0000244|PubMed:18220336}.
FT   MOD_RES     551    551       Phosphoserine; by MAPKAPK5.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:21329882}.
FT   MOD_RES     555    555       Phosphoserine; by AMPK and MAPKAPK5.
FT                                {ECO:0000269|PubMed:17711846,
FT                                ECO:0000269|PubMed:21329882}.
FT   MOD_RES     588    588       Phosphoserine; by AMPK.
FT                                {ECO:0000269|PubMed:17711846}.
FT   MOD_RES     626    626       Phosphoserine; by AMPK.
FT                                {ECO:0000269|PubMed:17711846}.
FT   MOD_RES     644    644       Phosphoserine; by IKKB.
FT                                {ECO:0000269|PubMed:15084260}.
FT   VAR_SEQ       1    220       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_056225.
FT   MUTAGEN      32     32       T->A: Abolishes YWHAZ-binding; when
FT                                associated with A-253. Exclusively
FT                                nuclear, induces transcription and
FT                                promotes apoptosis; when associated with
FT                                A-253 and A-315.
FT                                {ECO:0000269|PubMed:10102273}.
FT   MUTAGEN     179    179       T->A: Decreased phosphorylation by AMPK
FT                                and impaired ability to transactivate a
FT                                reporter gene; when associated with A-
FT                                399; A-413; A-555; A-588 and A-626.
FT                                {ECO:0000269|PubMed:17711846}.
FT   MUTAGEN     209    209       S->A: Impairs nuclear translocation upon
FT                                oxidative stress.
FT                                {ECO:0000269|PubMed:16751106}.
FT   MUTAGEN     242    242       K->A: Slightly decreases DNA affinity.
FT                                {ECO:0000269|PubMed:17940099,
FT                                ECO:0000269|PubMed:21841822}.
FT   MUTAGEN     242    242       K->R: Reduces acetylation, increases
FT                                interaction with SKP2 and inhibits FOXO3
FT                                ubiquitination and degradation; when
FT                                associated with R-259; R-290 and R-569.
FT                                {ECO:0000269|PubMed:17940099,
FT                                ECO:0000269|PubMed:21841822}.
FT   MUTAGEN     245    245       K->A: Decreases DNA affinity.
FT                                {ECO:0000269|PubMed:17940099}.
FT   MUTAGEN     253    253       S->A: Abolishes YWHAZ-binding; when
FT                                associated with A-32. Exclusively
FT                                nuclear, induces transcription and
FT                                promotes apoptosis; when associated with
FT                                A-32 and A-315.
FT                                {ECO:0000269|PubMed:10102273}.
FT   MUTAGEN     259    259       K->R: Reduces acetylation, increases
FT                                interaction with SKP2 and inhibits FOXO3
FT                                ubiquitination and degradation; when
FT                                associated with R-242; R-290 and R-569.
FT                                {ECO:0000269|PubMed:21841822}.
FT   MUTAGEN     269    269       K->R: Methylation levels similar to wild-
FT                                type; when associated with ARG-270.
FT                                {ECO:0000269|PubMed:22820736}.
FT   MUTAGEN     270    270       K->R: Methylation levels similar to wild-
FT                                type; when associated with ARG-269.
FT                                {ECO:0000269|PubMed:22820736}.
FT   MUTAGEN     271    271       K->R: Methylation levels strongly
FT                                reduced. {ECO:0000269|PubMed:22820736}.
FT   MUTAGEN     290    290       K->R: Reduces acetylation, increases
FT                                interaction with SKP2 and inhibits FOXO3
FT                                ubiquitination and degradation; when
FT                                associated with R-242; R-259 and R-569.
FT                                {ECO:0000269|PubMed:21841822}.
FT   MUTAGEN     315    315       S->A: No effect on YWHAZ-binding.
FT                                Promotes nuclear translocation.
FT                                Exclusively nuclear, induces
FT                                transcription and promotes apoptosis;
FT                                when associated with A-32 and A-253.
FT                                {ECO:0000269|PubMed:10102273}.
FT   MUTAGEN     399    399       S->A: Decreased phosphorylation by AMPK
FT                                and impaired ability to transactivate a
FT                                reporter gene; when associated with A-
FT                                179; A-413; A-555; A-588 and A-626.
FT                                {ECO:0000269|PubMed:17711846}.
FT   MUTAGEN     413    413       S->A: Decreased phosphorylation by AMPK
FT                                and impaired ability to transactivate a
FT                                reporter gene; when associated with A-
FT                                179; A-399; A-555; A-588 and A-626.
FT                                {ECO:0000269|PubMed:17711846}.
FT   MUTAGEN     555    555       S->A: Decreased phosphorylation by AMPK
FT                                and impaired ability to transactivate a
FT                                reporter gene; when associated with A-
FT                                179; A-399; A-413; A-588 and A-626.
FT                                {ECO:0000269|PubMed:17711846}.
FT   MUTAGEN     569    569       K->R: Reduces acetylation, increases
FT                                interaction with SKP2 and inhibits FOXO3
FT                                ubiquitination and degradation; when
FT                                associated with R-242; R-259 and R-290.
FT                                {ECO:0000269|PubMed:21841822}.
FT   MUTAGEN     588    588       S->A: Decreased phosphorylation by AMPK
FT                                and impaired ability to transactivate a
FT                                reporter gene; when associated with A-
FT                                179; A-399; A-413; A-555 and A-626.
FT                                {ECO:0000269|PubMed:17711846}.
FT   MUTAGEN     626    626       S->A: Decreased phosphorylation by AMPK
FT                                and impaired ability to transactivate a
FT                                reporter gene; when associated with A-
FT                                179; A-399; A-413; A-555 and A-588.
FT                                {ECO:0000269|PubMed:17711846}.
FT   MUTAGEN     644    644       S->A: Loss of phosphorylation by IKKB.
FT                                {ECO:0000269|PubMed:15084260}.
FT   CONFLICT    156    163       AWGNLSYA -> WGKPVYS (in Ref. 6;
FT                                CAA04860). {ECO:0000305}.
FT   CONFLICT    238    246       PDGGKSGKA -> LMGEERKT (in Ref. 6;
FT                                CAA04860). {ECO:0000305}.
FT   CONFLICT    253    253       S -> T (in Ref. 6; CAA04860).
FT                                {ECO:0000305}.
FT   CONFLICT    271    271       Missing (in Ref. 6; CAA04860).
FT                                {ECO:0000305}.
FT   CONFLICT    292    330       PGSPTSRSSDELDAWTDFRSRTNSNASTVSGRLSPIMAS
FT                                -> AWQPHVNAAVMSWMRGRTSVHAPILTPAQSVAACRPSW
FT                                QV (in Ref. 6; CAA04860). {ECO:0000305}.
FT   CONFLICT    345    361       PMLYSSSASLSPSVSKP -> AHALQHVSQPVTFSKQA
FT                                (in Ref. 6; CAA04860). {ECO:0000305}.
FT   CONFLICT    367    367       P -> R (in Ref. 6; CAA04860).
FT                                {ECO:0000305}.
FT   CONFLICT    371    371       D -> E (in Ref. 6; CAA04860).
FT                                {ECO:0000305}.
FT   CONFLICT    382    383       LT -> AD (in Ref. 6; CAA04860).
FT                                {ECO:0000305}.
FT   TURN        156    158       {ECO:0000244|PDB:2K86}.
FT   HELIX       162    169       {ECO:0000244|PDB:2UZK}.
FT   STRAND      172    176       {ECO:0000244|PDB:2UZK}.
FT   HELIX       180    189       {ECO:0000244|PDB:2UZK}.
FT   STRAND      198    200       {ECO:0000244|PDB:2UZK}.
FT   HELIX       206    216       {ECO:0000244|PDB:2UZK}.
FT   STRAND      217    229       {ECO:0000244|PDB:2UZK}.
FT   STRAND      233    236       {ECO:0000244|PDB:2UZK}.
FT   STRAND      238    240       {ECO:0000244|PDB:2K86}.
FT   STRAND      463    465       {ECO:0000244|PDB:2LQH}.
FT   HELIX       468    477       {ECO:0000244|PDB:2LQH}.
FT   TURN        478    480       {ECO:0000244|PDB:2LQH}.
FT   HELIX       621    623       {ECO:0000244|PDB:2LQI}.
FT   HELIX       624    633       {ECO:0000244|PDB:2LQH}.
SQ   SEQUENCE   673 AA;  71277 MW;  E5B4E830665A9982 CRC64;
     MAEAPASPAP LSPLEVELDP EFEPQSRPRS CTWPLQRPEL QASPAKPSGE TAADSMIPEE
     EDDEDDEDGG GRAGSAMAIG GGGGSGTLGS GLLLEDSARV LAPGGQDPGS GPATAAGGLS
     GGTQALLQPQ QPLPPPQPGA AGGSGQPRKC SSRRNAWGNL SYADLITRAI ESSPDKRLTL
     SQIYEWMVRC VPYFKDKGDS NSSAGWKNSI RHNLSLHSRF MRVQNEGTGK SSWWIINPDG
     GKSGKAPRRR AVSMDNSNKY TKSRGRAAKK KAALQTAPES ADDSPSQLSK WPGSPTSRSS
     DELDAWTDFR SRTNSNASTV SGRLSPIMAS TELDEVQDDD APLSPMLYSS SASLSPSVSK
     PCTVELPRLT DMAGTMNLND GLTENLMDDL LDNITLPPSQ PSPTGGLMQR SSSFPYTTKG
     SGLGSPTSSF NSTVFGPSSL NSLRQSPMQT IQENKPATFS SMSHYGNQTL QDLLTSDSLS
     HSDVMMTQSD PLMSQASTAV SAQNSRRNVM LRNDPMMSFA AQPNQGSLVN QNLLHHQHQT
     QGALGGSRAL SNSVSNMGLS ESSSLGSAKH QQQSPVSQSM QTLSDSLSGS SLYSTSANLP
     VMGHEKFPSD LDLDMFNGSL ECDMESIIRS ELMDADGLDF NFDSLISTQN VVGLNVGNFT
     GAKQASSQSW VPG
//
ID   FOXO4_HUMAN             Reviewed;         505 AA.
AC   P98177; B7WPJ7; O43821; Q13720; Q3KPF1; Q8TDK9;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   25-JUL-2006, sequence version 5.
DT   28-FEB-2018, entry version 183.
DE   RecName: Full=Forkhead box protein O4;
DE   AltName: Full=Fork head domain transcription factor AFX1;
GN   Name=FOXO4; Synonyms=AFX, AFX1, MLLT7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Blood;
RX   PubMed=9341872; DOI=10.1007/s004390050553;
RA   Peters U., Haberhausen G., Kostrzewa M., Nolte D., Mueller U.;
RT   "AFX1 and p54nrb: fine mapping, genomic structure, and exclusion as
RT   candidate genes of X-linked dystonia parkinsonism.";
RL   Hum. Genet. 100:569-572(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9010221; DOI=10.1038/sj.onc.1200814;
RA   Borkhardt A., Repp R., Haas O.A., Leis T., Harbott J., Kreuder J.,
RA   Hammermann J., Henn T., Lampert F.;
RT   "Cloning and characterization of AFX, the gene that fuses to MLL in
RT   acute leukemias with a t(X;11)(q13;q23).";
RL   Oncogene 14:195-202(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ZETA).
RX   PubMed=11779849; DOI=10.1074/jbc.M106091200;
RA   Yang Z., Whelan J., Babb R., Bowen B.R.;
RT   "An mRNA splice variant of the AFX gene with altered transcriptional
RT   activity.";
RL   J. Biol. Chem. 277:8068-8075(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   CHROMOSOMAL TRANSLOCATION.
RC   TISSUE=Bone marrow;
RX   PubMed=7529552; DOI=10.1002/gcc.2870110203;
RA   Parry P., Wei Y., Evans G.;
RT   "Cloning and characterization of the t(X;11) breakpoint from a
RT   leukemic cell line identify a new member of the forkhead gene
RT   family.";
RL   Genes Chromosomes Cancer 11:79-84(1994).
RN   [8]
RP   FUNCTION, PHOSPHORYLATION AT SER-197 AND SER-262, AND MUTAGENESIS OF
RP   SER-197 AND SER-262.
RX   PubMed=10217147; DOI=10.1038/19328;
RA   Kops G.J.P.L., de Ruiter N.D., De Vries-Smits A.M.M., Powell D.R.,
RA   Bos J.L., Burgering B.M.T.;
RT   "Direct control of the forkhead transcription factor AFX by protein
RT   kinase B.";
RL   Nature 398:630-634(1999).
RN   [9]
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION AT SER-197 AND SER-262, AND
RP   MUTAGENESIS OF THR-32; SER-197 AND SER-262.
RX   PubMed=10518537; DOI=10.1073/pnas.96.21.11836;
RA   Takaishi H., Konishi H., Matsuzaki H., Ono Y., Shirai Y., Saito N.,
RA   Kitamura T., Ogawa W., Kasuga M., Kikkawa U., Nishizuka Y.;
RT   "Regulation of nuclear translocation of forkhead transcription factor
RT   AFX by protein kinase B.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:11836-11841(1999).
RN   [10]
RP   FUNCTION.
RX   PubMed=10783894; DOI=10.1038/35008115;
RA   Medema R.H., Kops G.J.P.L., Bos J.L., Burgering B.M.T.;
RT   "AFX-like forkhead transcription factors mediate cell-cycle regulation
RT   by Ras and PKB through p27kip1.";
RL   Nature 404:782-787(2000).
RN   [11]
RP   FUNCTION.
RX   PubMed=12761217; DOI=10.1074/jbc.M302042200;
RA   Tang T.T.-L., Lasky L.A.;
RT   "The forkhead transcription factor FOXO4 induces the down-regulation
RT   of hypoxia-inducible factor 1 alpha by a von Hippel-Lindau protein-
RT   independent mechanism.";
RL   J. Biol. Chem. 278:30125-30135(2003).
RN   [12]
RP   FUNCTION, INTERACTION WITH CREBBP AND SIRT1, AND ACETYLATION.
RX   PubMed=15126506; DOI=10.1074/jbc.M401138200;
RA   van der Horst A., Tertoolen L.G.J., de Vries-Smits L.M.M., Frye R.A.,
RA   Medema R.H., Burgering B.M.T.;
RT   "FOXO4 is acetylated upon peroxide stress and deacetylated by the
RT   longevity protein hSir2(SIRT1).";
RL   J. Biol. Chem. 279:28873-28879(2004).
RN   [13]
RP   INTERACTION WITH YWHAZ, AND SUBCELLULAR LOCATION.
RX   PubMed=16114898; DOI=10.1021/bi050618r;
RA   Obsilova V., Vecer J., Herman P., Pabianova A., Sulc M., Teisinger J.,
RA   Boura E., Obsil T.;
RT   "14-3-3 protein interacts with nuclear localization sequence of
RT   forkhead transcription factor FoxO4.";
RL   Biochemistry 44:11608-11617(2005).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH MYOCD AND SRF.
RX   PubMed=16054032; DOI=10.1016/j.devcel.2005.05.017;
RA   Liu Z.-P., Wang Z., Yanagisawa H., Olson E.N.;
RT   "Phenotypic modulation of smooth muscle cells through interaction of
RT   Foxo4 and myocardin.";
RL   Dev. Cell 9:261-270(2005).
RN   [15]
RP   PHOSPHORYLATION AT THR-32; SER-197 AND SER-262, AND MUTAGENESIS OF
RP   THR-32; SER-197 AND SER-262.
RX   PubMed=16272144; DOI=10.1093/jb/mvi146;
RA   Matsuzaki H., Ichino A., Hayashi T., Yamamoto T., Kikkawa U.;
RT   "Regulation of intracellular localization and transcriptional activity
RT   of FOXO4 by protein kinase B through phosphorylation at the motif
RT   sites conserved among the FOXO family.";
RL   J. Biochem. 138:485-491(2005).
RN   [16]
RP   PHARMACEUTICAL USE.
RX   PubMed=15688030; DOI=10.1038/sj.onc.1208352;
RA   Yang H., Zhao R., Yang H.-Y., Lee M.-H.;
RT   "Constitutively active FOXO4 inhibits Akt activity, regulates p27 Kip1
RT   stability, and suppresses HER2-mediated tumorigenicity.";
RL   Oncogene 24:1924-1935(2005).
RN   [17]
RP   FUNCTION, INTERACTION WITH USP7, UBIQUITINATION, DEUBIQUITINATION BY
RP   USP7, AND SUBCELLULAR LOCATION.
RX   PubMed=16964248; DOI=10.1038/ncb1469;
RA   van der Horst A., de Vries-Smits A.M., Brenkman A.B., van Triest M.H.,
RA   van den Broek N., Colland F., Maurice M.M., Burgering B.M.;
RT   "FOXO4 transcriptional activity is regulated by monoubiquitination and
RT   USP7/HAUSP.";
RL   Nat. Cell Biol. 8:1064-1073(2006).
RN   [18]
RP   FUNCTION, AND INTERACTION WITH NLK; CTNNB1 AND CREBBP.
RX   PubMed=20874444; DOI=10.1089/ars.2010.3243;
RA   Szypowska A.A., de Ruiter H., Meijer L.A.T., Smits L.M.M.,
RA   Burgering B.M.T.;
RT   "Oxidative stress-dependent regulation of Forkhead box O4 activity by
RT   nemo-like kinase.";
RL   Antioxid. Redox Signal. 14:563-578(2011).
RN   [19]
RP   FUNCTION, AND MUTAGENESIS OF THR-32; SER-197 AND SER-262.
RX   PubMed=22972301; DOI=10.1038/nature11468;
RA   Vilchez D., Boyer L., Morantte I., Lutz M., Merkwirth C., Joyce D.,
RA   Spencer B., Page L., Masliah E., Berggren W.T., Gage F.H., Dillin A.;
RT   "Increased proteasome activity in human embryonic stem cells is
RT   regulated by PSMD11.";
RL   Nature 489:304-308(2012).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [21]
RP   STRUCTURE BY NMR OF 86-211.
RX   PubMed=10921784; DOI=10.1023/A:1008358816478;
RA   Weigelt J., Climent I., Dahlman-Wright K., Wikstrom M.;
RT   "1H, 13C and 15N resonance assignments of the DNA binding domain of
RT   the human forkhead transcription factor AFX.";
RL   J. Biomol. NMR 17:181-182(2000).
RN   [22]
RP   STRUCTURE BY NMR OF 86-211.
RX   PubMed=11352721; DOI=10.1021/bi001663w;
RA   Weigelt J., Climent I., Dahlman-Wright K., Wikstrom M.;
RT   "Solution structure of the DNA binding domain of the human forkhead
RT   transcription factor AFX (FOXO4).";
RL   Biochemistry 40:5861-5869(2001).
CC   -!- FUNCTION: Transcription factor involved in the regulation of the
CC       insulin signaling pathway. Binds to insulin-response elements
CC       (IREs) and can activate transcription of IGFBP1. Down-regulates
CC       expression of HIF1A and suppresses hypoxia-induced transcriptional
CC       activation of HIF1A-modulated genes. Also involved in negative
CC       regulation of the cell cycle. Involved in increased proteasome
CC       activity in embryonic stem cells (ESCs) by activating expression
CC       of PSMD11 in ESCs, leading to enhanced assembly of the 26S
CC       proteasome, followed by higher proteasome activity.
CC       {ECO:0000269|PubMed:10217147, ECO:0000269|PubMed:10783894,
CC       ECO:0000269|PubMed:12761217, ECO:0000269|PubMed:15126506,
CC       ECO:0000269|PubMed:16054032, ECO:0000269|PubMed:16964248,
CC       ECO:0000269|PubMed:20874444, ECO:0000269|PubMed:22972301}.
CC   -!- SUBUNIT: Interacts with CREBBP/CBP, CTNNB1, MYOCD, SIRT1, SRF and
CC       YWHAZ. Acetylated by CREBBP/CBP and deacetylated by SIRT1. Binding
CC       of YWHAZ inhibits DNA-binding. Interacts with USP7; the
CC       interaction is enhanced in presence of hydrogen peroxide and
CC       occurs independently of TP53. Interacts with NLK, and this
CC       inhibits monoubiquitination and transcriptional activity.
CC       Interacts with FOXK1; the interaction inhibits MEF2C
CC       transactivation activity (By similarity).
CC       {ECO:0000250|UniProtKB:Q9WVH3, ECO:0000269|PubMed:15126506,
CC       ECO:0000269|PubMed:16054032, ECO:0000269|PubMed:16114898,
CC       ECO:0000269|PubMed:16964248, ECO:0000269|PubMed:20874444}.
CC   -!- INTERACTION:
CC       Self; NbExp=2; IntAct=EBI-4481939, EBI-4481939;
CC       Q04864:REL; NbExp=3; IntAct=EBI-4481939, EBI-307352;
CC       P31947:SFN; NbExp=3; IntAct=EBI-4481939, EBI-476295;
CC       Q96EB6:SIRT1; NbExp=3; IntAct=EBI-4481939, EBI-1802965;
CC       Q13485:SMAD4; NbExp=2; IntAct=EBI-4481939, EBI-347263;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=When
CC       phosphorylated, translocated from nucleus to cytoplasm.
CC       Dephosphorylation triggers nuclear translocation.
CC       Monoubiquitination increases nuclear localization. When
CC       deubiquitinated, translocated from nucleus to cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=FOXO4a;
CC         IsoId=P98177-1; Sequence=Displayed;
CC       Name=Zeta; Synonyms=AFXzeta, FOXO4b;
CC         IsoId=P98177-2; Sequence=VSP_001552;
CC   -!- TISSUE SPECIFICITY: Heart, brain, placenta, lung, liver, skeletal
CC       muscle, kidney and pancreas. Isoform zeta is most abundant in the
CC       liver, kidney, and pancreas.
CC   -!- PTM: Acetylation by CREBBP/CBP, which is induced by peroxidase
CC       stress, inhibits transcriptional activity. Deacetylation by SIRT1
CC       is NAD-dependent and stimulates transcriptional activity.
CC       {ECO:0000269|PubMed:15126506}.
CC   -!- PTM: Phosphorylation by PKB/AKT1 inhibits transcriptional activity
CC       and is responsible for cytoplasmic localization. May be
CC       phosphorylated at multiple sites by NLK.
CC       {ECO:0000269|PubMed:10217147, ECO:0000269|PubMed:10518537,
CC       ECO:0000269|PubMed:16272144}.
CC   -!- PTM: Monoubiquitinated; monoubiquitination is induced by oxidative
CC       stress and reduced by deacetylase inhibitors; results in its
CC       relocalization to the nucleus and its increased transcriptional
CC       activity. Deubiquitinated by USP7; deubiquitination is induced by
CC       oxidative stress; enhances its interaction with USP7 and
CC       consequently, deubiquitination; increases its translocation to the
CC       cytoplasm and inhibits its transcriptional activity. Hydrogene-
CC       peroxide-induced ubiquitination and USP7-mediated deubiquitination
CC       have no major effect on its protein stability.
CC       {ECO:0000269|PubMed:16964248}.
CC   -!- DISEASE: Note=A chromosomal aberration involving FOXO4 is found in
CC       acute leukemias. Translocation t(X;11)(q13;q23) with KMT2A/MLL1.
CC       The result is a rogue activator protein.
CC   -!- PHARMACEUTICAL: A constitutively active FOXO4 mutant where
CC       phosphorylation sites Thr-32, Ser-197 and Ser-262 have been
CC       mutated to alanine may have therapeutic potential in ERBB2/HER2-
CC       overexpressing cancers as it inhibits ERBB2-mediated cell
CC       survival, transformation and tumorigenicity.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/AFX1ID57.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y11284; CAA72156.1; -; Genomic_DNA.
DR   EMBL; Y11285; CAA72156.1; JOINED; Genomic_DNA.
DR   EMBL; Y11286; CAA72156.1; JOINED; Genomic_DNA.
DR   EMBL; X93996; CAA63819.1; -; mRNA.
DR   EMBL; AF384029; AAL85197.1; -; mRNA.
DR   EMBL; AL590764; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471132; EAX05321.1; -; Genomic_DNA.
DR   EMBL; BC106761; AAI06762.1; -; mRNA.
DR   EMBL; U10072; AAA82171.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS43969.1; -. [P98177-1]
DR   CCDS; CCDS55440.1; -. [P98177-2]
DR   PIR; I38654; I38654.
DR   RefSeq; NP_001164402.1; NM_001170931.1. [P98177-2]
DR   RefSeq; NP_005929.2; NM_005938.3. [P98177-1]
DR   UniGene; Hs.584654; -.
DR   PDB; 1E17; NMR; -; A=86-211.
DR   PDB; 3L2C; X-ray; 1.87 A; A=86-187.
DR   PDBsum; 1E17; -.
DR   PDBsum; 3L2C; -.
DR   ProteinModelPortal; P98177; -.
DR   SMR; P98177; -.
DR   BioGrid; 110449; 20.
DR   CORUM; P98177; -.
DR   IntAct; P98177; 12.
DR   MINT; P98177; -.
DR   STRING; 9606.ENSP00000363377; -.
DR   iPTMnet; P98177; -.
DR   PhosphoSitePlus; P98177; -.
DR   BioMuta; FOXO4; -.
DR   DMDM; 110825720; -.
DR   EPD; P98177; -.
DR   MaxQB; P98177; -.
DR   PaxDb; P98177; -.
DR   PeptideAtlas; P98177; -.
DR   PRIDE; P98177; -.
DR   Ensembl; ENST00000341558; ENSP00000342209; ENSG00000184481. [P98177-2]
DR   Ensembl; ENST00000374259; ENSP00000363377; ENSG00000184481. [P98177-1]
DR   GeneID; 4303; -.
DR   KEGG; hsa:4303; -.
DR   UCSC; uc004dys.3; human. [P98177-1]
DR   CTD; 4303; -.
DR   DisGeNET; 4303; -.
DR   EuPathDB; HostDB:ENSG00000184481.16; -.
DR   GeneCards; FOXO4; -.
DR   HGNC; HGNC:7139; FOXO4.
DR   HPA; HPA039560; -.
DR   HPA; HPA040232; -.
DR   MIM; 300033; gene.
DR   neXtProt; NX_P98177; -.
DR   OpenTargets; ENSG00000184481; -.
DR   PharmGKB; PA162388882; -.
DR   eggNOG; KOG2294; Eukaryota.
DR   eggNOG; COG5025; LUCA.
DR   GeneTree; ENSGT00910000144016; -.
DR   HOGENOM; HOG000251635; -.
DR   HOVERGEN; HBG057789; -.
DR   InParanoid; P98177; -.
DR   KO; K12358; -.
DR   OMA; ENLECDM; -.
DR   OrthoDB; EOG091G06K3; -.
DR   PhylomeDB; P98177; -.
DR   TreeFam; TF315583; -.
DR   Reactome; R-HSA-198693; AKT phosphorylates targets in the nucleus.
DR   Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   SignaLink; P98177; -.
DR   SIGNOR; P98177; -.
DR   ChiTaRS; FOXO4; human.
DR   EvolutionaryTrace; P98177; -.
DR   GeneWiki; FOXO4; -.
DR   GenomeRNAi; 4303; -.
DR   PRO; PR:P98177; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000184481; -.
DR   CleanEx; HS_FOXO4; -.
DR   Genevisible; P98177; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0008013; F:beta-catenin binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:1990841; F:promoter-specific chromatin binding; IEA:Ensembl.
DR   GO; GO:0000981; F:RNA polymerase II transcription factor activity, sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0001228; F:transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding; IC:NTNU_SB.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0007050; P:cell cycle arrest; IDA:UniProtKB.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007095; P:mitotic G2 DNA damage checkpoint; IEA:Ensembl.
DR   GO; GO:0007517; P:muscle organ development; IEA:UniProtKB-KW.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IDA:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:0070317; P:negative regulation of G0 to G1 transition; IDA:UniProtKB.
DR   GO; GO:0051151; P:negative regulation of smooth muscle cell differentiation; IDA:UniProtKB.
DR   GO; GO:0071158; P:positive regulation of cell cycle arrest; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0014911; P:positive regulation of smooth muscle cell migration; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:NTNU_SB.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0043491; P:protein kinase B signaling; TAS:Reactome.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0031667; P:response to nutrient levels; IEA:Ensembl.
DR   GO; GO:1990785; P:response to water-immersion restraint stress; IEA:Ensembl.
DR   GO; GO:0048863; P:stem cell differentiation; IMP:UniProtKB.
DR   GO; GO:0006366; P:transcription from RNA polymerase II promoter; TAS:ProtInc.
DR   CDD; cd00059; FH; 1.
DR   Gene3D; 1.10.10.10; -; 1.
DR   InterPro; IPR001766; Fork_head_dom.
DR   InterPro; IPR032067; FOXO-TAD.
DR   InterPro; IPR030456; TF_fork_head_CS_2.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   Pfam; PF00250; Forkhead; 1.
DR   Pfam; PF16676; FOXO-TAD; 1.
DR   PRINTS; PR00053; FORKHEAD.
DR   SMART; SM00339; FH; 1.
DR   SUPFAM; SSF46785; SSF46785; 1.
DR   PROSITE; PS00658; FORK_HEAD_2; 1.
DR   PROSITE; PS50039; FORK_HEAD_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing;
KW   Cell cycle; Chromosomal rearrangement; Complete proteome; Cytoplasm;
KW   Developmental protein; Differentiation; DNA-binding; Myogenesis;
KW   Nucleus; Pharmaceutical; Phosphoprotein; Proto-oncogene;
KW   Reference proteome; Transcription; Transcription regulation;
KW   Ubl conjugation.
FT   CHAIN         1    505       Forkhead box protein O4.
FT                                /FTId=PRO_0000091875.
FT   DNA_BIND    100    188       Fork-head. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00089}.
FT   MOD_RES      32     32       Phosphothreonine; by PKB/AKT1.
FT                                {ECO:0000269|PubMed:16272144}.
FT   MOD_RES     197    197       Phosphoserine; by PKB/AKT1.
FT                                {ECO:0000269|PubMed:10217147,
FT                                ECO:0000269|PubMed:10518537,
FT                                ECO:0000269|PubMed:16272144}.
FT   MOD_RES     262    262       Phosphoserine; by PKB/AKT1.
FT                                {ECO:0000269|PubMed:10217147,
FT                                ECO:0000269|PubMed:10518537,
FT                                ECO:0000269|PubMed:16272144}.
FT   VAR_SEQ      58    112       Missing (in isoform Zeta).
FT                                {ECO:0000303|PubMed:11779849}.
FT                                /FTId=VSP_001552.
FT   MUTAGEN      32     32       T->A: Abolishes phosphorylation. Protein
FT                                is located mainly in nucleus and shows
FT                                increased transcriptional activity.
FT                                Increased transcriptional and proteasome
FT                                activities in embryonic stem cells; when
FT                                associated with A-197 and A-262.
FT                                {ECO:0000269|PubMed:10518537,
FT                                ECO:0000269|PubMed:16272144,
FT                                ECO:0000269|PubMed:22972301}.
FT   MUTAGEN     197    197       S->A: Abolishes phosphorylation. Protein
FT                                is located mainly in nucleus and shows
FT                                increased transcriptional activity.
FT                                Increased transcriptional and proteasome
FT                                activities in embryonic stem cells; when
FT                                associated with A-32 and A-262.
FT                                {ECO:0000269|PubMed:10217147,
FT                                ECO:0000269|PubMed:10518537,
FT                                ECO:0000269|PubMed:16272144,
FT                                ECO:0000269|PubMed:22972301}.
FT   MUTAGEN     262    262       S->A: Abolishes phosphorylation. No
FT                                effect on cellular location or
FT                                transcriptional activity. Increased
FT                                transcriptional and proteasome activities
FT                                in embryonic stem cells; when associated
FT                                with A-32 and A-197.
FT                                {ECO:0000269|PubMed:10217147,
FT                                ECO:0000269|PubMed:10518537,
FT                                ECO:0000269|PubMed:16272144,
FT                                ECO:0000269|PubMed:22972301}.
FT   CONFLICT      1     11       MDPGNENSATE -> MRIQPQK (in Ref. 2;
FT                                CAA63819). {ECO:0000305}.
FT   CONFLICT     25     34       QSRPRSCTWP -> RAVPLLHLA (in Ref. 1;
FT                                CAA72156). {ECO:0000305}.
FT   CONFLICT     74     74       P -> S (in Ref. 2; CAA63819).
FT                                {ECO:0000305}.
FT   CONFLICT     79     79       G -> A (in Ref. 1; CAA72156).
FT                                {ECO:0000305}.
FT   CONFLICT    109    109       L -> F (in Ref. 2; CAA63819).
FT                                {ECO:0000305}.
FT   CONFLICT    422    422       P -> R (in Ref. 2; CAA63819 and 3;
FT                                AAL85197). {ECO:0000305}.
FT   HELIX       106    116       {ECO:0000244|PDB:3L2C}.
FT   STRAND      117    119       {ECO:0000244|PDB:1E17}.
FT   HELIX       124    134       {ECO:0000244|PDB:3L2C}.
FT   HELIX       136    138       {ECO:0000244|PDB:3L2C}.
FT   HELIX       139    142       {ECO:0000244|PDB:1E17}.
FT   HELIX       149    160       {ECO:0000244|PDB:3L2C}.
FT   STRAND      164    167       {ECO:0000244|PDB:3L2C}.
FT   TURN        170    172       {ECO:0000244|PDB:1E17}.
FT   STRAND      173    175       {ECO:0000244|PDB:1E17}.
FT   STRAND      177    180       {ECO:0000244|PDB:3L2C}.
SQ   SEQUENCE   505 AA;  53684 MW;  0C71C8E2167CEE68 CRC64;
     MDPGNENSAT EAAAIIDLDP DFEPQSRPRS CTWPLPRPEI ANQPSEPPEV EPDLGEKVHT
     EGRSEPILLP SRLPEPAGGP QPGILGAVTG PRKGGSRRNA WGNQSYAELI SQAIESAPEK
     RLTLAQIYEW MVRTVPYFKD KGDSNSSAGW KNSIRHNLSL HSKFIKVHNE ATGKSSWWML
     NPEGGKSGKA PRRRAASMDS SSKLLRGRSK APKKKPSVLP APPEGATPTS PVGHFAKWSG
     SPCSRNREEA DMWTTFRPRS SSNASSVSTR LSPLRPESEV LAEEIPASVS SYAGGVPPTL
     NEGLELLDGL NLTSSHSLLS RSGLSGFSLQ HPGVTGPLHT YSSSLFSPAE GPLSAGEGCF
     SSSQALEALL TSDTPPPPAD VLMTQVDPIL SQAPTLLLLG GLPSSSKLAT GVGLCPKPLE
     APGPSSLVPT LSMIAPPPVM ASAPIPKALG TPVLTPPTEA ASQDRMPQDL DLDMYMENLE
     CDMDNIISDL MDEGEGLDFN FEPDP
//
ID   HXA11_HUMAN             Reviewed;         313 AA.
AC   P31270; A4D190;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   21-FEB-2001, sequence version 2.
DT   28-FEB-2018, entry version 171.
DE   RecName: Full=Homeobox protein Hox-A11;
DE   AltName: Full=Homeobox protein Hox-1I;
GN   Name=HOXA11; Synonyms=HOX1I;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9745033; DOI=10.1007/s003359900870;
RA   Potter S.S., Branford W.W.;
RT   "Evolutionary conservation and tissue-specific processing of hoxa 11
RT   antisense transcripts.";
RL   Mamm. Genome 9:799-806(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Mi X., Winters J.L., Stevens D.B., Fleischman R.A.;
RL   Submitted (DEC-1997) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S.,
RA   Kwasnicka D., Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z.,
RA   Lu F., Zeesman S., Nowaczyk M.J., Teshima I., Chitayat D., Shuman C.,
RA   Weksberg R., Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J.,
RA   Rahman N., Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F.,
RA   Belloni E., Shaffer L.G., Pober B., Morton C.C., Gusella J.F.,
RA   Bruns G.A.P., Korf B.R., Quade B.J., Ligon A.H., Ferguson H.,
RA   Higgins A.W., Leach N.T., Herrick S.R., Lemyre E., Farra C.G.,
RA   Kim H.-G., Summers A.M., Gripp K.W., Roberts W., Szatmari P.,
RA   Winsor E.J.T., Grzeschik K.-H., Teebi A., Minassian B.A., Kere J.,
RA   Armengol L., Pujana M.A., Estivill X., Wilson M.D., Koop B.F.,
RA   Tosi S., Moore G.E., Boright A.P., Zlotorynski E., Kerem B.,
RA   Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W.,
RA   Mural R.J., Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE OF 241-306.
RX   PubMed=2574852; DOI=10.1093/nar/17.24.10385;
RA   Acampora D., D'Esposito M., Faiella A., Pannese M., Migliaccio E.,
RA   Morelli F., Stornaiuolo A., Nigro V., Simeone A., Boncinelli E.;
RT   "The human HOX gene family.";
RL   Nucleic Acids Res. 17:10385-10402(1989).
RN   [8]
RP   INVOLVEMENT IN RUSAT1.
RX   PubMed=11101832; DOI=10.1038/82511;
RA   Thompson A.A., Nguyen L.T.;
RT   "Amegakaryocytic thrombocytopenia and radio-ulnar synostosis are
RT   associated with HOXA11 mutation.";
RL   Nat. Genet. 26:397-398(2000).
CC   -!- FUNCTION: Sequence-specific transcription factor which is part of
CC       a developmental regulatory system that provides cells with
CC       specific positional identities on the anterior-posterior axis.
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- DISEASE: Radioulnar synostosis with amegakaryocytic
CC       thrombocytopenia 1 (RUSAT1) [MIM:605432]: The syndrome consists of
CC       an unusual association of bone marrow failure and skeletal
CC       defects. Patients have the same skeletal defects, the proximal
CC       fusion of the radius and ulna, resulting in extremely limited
CC       pronation and supination of the forearm. Some patients have also
CC       symptomatic thrombocytopenia, with bruising and bleeding problems
CC       since birth, necessitating correction by bone marrow or umbilical-
CC       cord stem-cell transplantation. {ECO:0000269|PubMed:11101832}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the Abd-B homeobox family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/HOXA11ID40847ch7p15.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF071164; AAC80455.1; -; Genomic_DNA.
DR   EMBL; AF039307; AAB94761.1; -; Genomic_DNA.
DR   EMBL; AC004080; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH236948; EAL24220.1; -; Genomic_DNA.
DR   EMBL; CH471073; EAW93888.1; -; Genomic_DNA.
DR   EMBL; BC040948; AAH40948.1; -; mRNA.
DR   CCDS; CCDS5411.1; -.
DR   PIR; S14931; S14931.
DR   RefSeq; NP_005514.1; NM_005523.5.
DR   UniGene; Hs.249171; -.
DR   ProteinModelPortal; P31270; -.
DR   SMR; P31270; -.
DR   BioGrid; 109447; 5.
DR   IntAct; P31270; 1.
DR   STRING; 9606.ENSP00000006015; -.
DR   iPTMnet; P31270; -.
DR   PhosphoSitePlus; P31270; -.
DR   BioMuta; HOXA11; -.
DR   DMDM; 13124744; -.
DR   MaxQB; P31270; -.
DR   PaxDb; P31270; -.
DR   PeptideAtlas; P31270; -.
DR   PRIDE; P31270; -.
DR   DNASU; 3207; -.
DR   Ensembl; ENST00000006015; ENSP00000006015; ENSG00000005073.
DR   GeneID; 3207; -.
DR   KEGG; hsa:3207; -.
DR   UCSC; uc003syx.4; human.
DR   CTD; 3207; -.
DR   DisGeNET; 3207; -.
DR   EuPathDB; HostDB:ENSG00000005073.5; -.
DR   GeneCards; HOXA11; -.
DR   HGNC; HGNC:5101; HOXA11.
DR   HPA; HPA006770; -.
DR   HPA; HPA035623; -.
DR   MalaCards; HOXA11; -.
DR   MIM; 142958; gene.
DR   MIM; 605432; phenotype.
DR   neXtProt; NX_P31270; -.
DR   OpenTargets; ENSG00000005073; -.
DR   Orphanet; 71289; Radio-ulnar synostosis - amegakaryocytic thrombocytopenia.
DR   PharmGKB; PA29378; -.
DR   eggNOG; KOG0487; Eukaryota.
DR   eggNOG; ENOG4111FJP; LUCA.
DR   GeneTree; ENSGT00910000143984; -.
DR   HOGENOM; HOG000231898; -.
DR   HOVERGEN; HBG052048; -.
DR   InParanoid; P31270; -.
DR   KO; K21951; -.
DR   OMA; FGKNTAN; -.
DR   OrthoDB; EOG091G0DZB; -.
DR   PhylomeDB; P31270; -.
DR   TreeFam; TF350668; -.
DR   SignaLink; P31270; -.
DR   SIGNOR; P31270; -.
DR   GeneWiki; HOXA11; -.
DR   GenomeRNAi; 3207; -.
DR   PRO; PR:P31270; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; ENSG00000005073; -.
DR   CleanEx; HS_HOXA11; -.
DR   ExpressionAtlas; P31270; baseline and differential.
DR   Genevisible; P31270; HS.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0043234; C:protein complex; ISS:UniProtKB.
DR   GO; GO:0032993; C:protein-DNA complex; ISS:UniProtKB.
DR   GO; GO:0005667; C:transcription factor complex; ISS:UniProtKB.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IEA:InterPro.
DR   GO; GO:0009653; P:anatomical structure morphogenesis; TAS:ProtInc.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; IEA:Ensembl.
DR   GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; ISS:UniProtKB.
DR   GO; GO:0060351; P:cartilage development involved in endochondral bone morphogenesis; ISS:UniProtKB.
DR   GO; GO:0048589; P:developmental growth; ISS:UniProtKB.
DR   GO; GO:0009953; P:dorsal/ventral pattern formation; ISS:UniProtKB.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; IEA:Ensembl.
DR   GO; GO:0035115; P:embryonic forelimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0030326; P:embryonic limb morphogenesis; ISS:UniProtKB.
DR   GO; GO:0060272; P:embryonic skeletal joint morphogenesis; IEA:Ensembl.
DR   GO; GO:0008584; P:male gonad development; IEA:Ensembl.
DR   GO; GO:0007501; P:mesodermal cell fate specification; ISS:UniProtKB.
DR   GO; GO:0001656; P:metanephros development; IEA:Ensembl.
DR   GO; GO:0007275; P:multicellular organism development; ISS:UniProtKB.
DR   GO; GO:0001759; P:organ induction; IEA:Ensembl.
DR   GO; GO:0010720; P:positive regulation of cell development; ISS:UniProtKB.
DR   GO; GO:0032332; P:positive regulation of chondrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0009954; P:proximal/distal pattern formation; IEA:Ensembl.
DR   GO; GO:0007338; P:single fertilization; IEA:Ensembl.
DR   GO; GO:0001501; P:skeletal system development; ISS:UniProtKB.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0060065; P:uterus development; IEA:Ensembl.
DR   CDD; cd00086; homeodomain; 1.
DR   InterPro; IPR021918; DUF3528.
DR   InterPro; IPR009057; Homeobox-like_sf.
DR   InterPro; IPR017970; Homeobox_CS.
DR   InterPro; IPR001356; Homeobox_dom.
DR   InterPro; IPR020479; Homeobox_metazoa.
DR   Pfam; PF12045; DUF3528; 1.
DR   Pfam; PF00046; Homeobox; 1.
DR   PRINTS; PR00024; HOMEOBOX.
DR   SMART; SM00389; HOX; 1.
DR   SUPFAM; SSF46689; SSF46689; 1.
DR   PROSITE; PS00027; HOMEOBOX_1; 1.
DR   PROSITE; PS50071; HOMEOBOX_2; 1.
PE   2: Evidence at transcript level;
KW   Complete proteome; Developmental protein; DNA-binding; Homeobox;
KW   Nucleus; Reference proteome; Transcription; Transcription regulation.
FT   CHAIN         1    313       Homeobox protein Hox-A11.
FT                                /FTId=PRO_0000200095.
FT   DNA_BIND    241    300       Homeobox. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00108}.
FT   COMPBIAS    177    183       Poly-Ala.
FT   COMPBIAS    195    199       Poly-Gly.
FT   COMPBIAS    204    207       Poly-Ala.
FT   COMPBIAS    212    215       Poly-Arg.
FT   COMPBIAS    218    221       Poly-Ser.
SQ   SEQUENCE   313 AA;  34486 MW;  B345B987816AB9FB CRC64;
     MDFDERGPCS SNMYLPSCTY YVSGPDFSSL PSFLPQTPSS RPMTYSYSSN LPQVQPVREV
     TFREYAIEPA TKWHPRGNLA HCYSAEELVH RDCLQAPSAA GVPGDVLAKS SANVYHHPTP
     AVSSNFYSTV GRNGVLPQAF DQFFETAYGT PENLASSDYP GDKSAEKGPP AATATSAAAA
     AAATGAPATS SSDSGGGGGC RETAAAAEEK ERRRRPESSS SPESSSGHTE DKAGGSSGQR
     TRKKRCPYTK YQIRELEREF FFSVYINKEK RLQLSRMLNL TDRQVKIWFQ NRRMKEKKIN
     RDRLQYYSAN PLL
//
ID   HXA9_HUMAN              Reviewed;         272 AA.
AC   P31269; O43369; O43429; Q99820;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1999, sequence version 4.
DT   28-FEB-2018, entry version 181.
DE   RecName: Full=Homeobox protein Hox-A9;
DE   AltName: Full=Homeobox protein Hox-1G;
GN   Name=HOXA9; Synonyms=HOX1G;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Bone marrow;
RA   Rozenfeld S., Sauvageau G., Largman C.;
RL   Submitted (DEC-1996) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9880515; DOI=10.1074/jbc.274.3.1415;
RA   Patel C.V., Sharangpani R., Bandyopadhyay S., DiCorleto P.E.;
RT   "Endothelial cells express a novel, tumor necrosis factor-alpha-
RT   regulated variant of HOXA9.";
RL   J. Biol. Chem. 274:1415-1422(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 195-272, AND CHROMOSOMAL TRANSLOCATION
RP   WITH NUP98.
RX   PubMed=8563754; DOI=10.1038/ng0296-159;
RA   Borrow J., Shearman A.M., Stanton V.P., Becher R., Collins T.,
RA   Williams A.J., Dube I., Katz F., Kwong Y.L., Morris C., Ohyashiki K.,
RA   Toyama K., Rowley J., Housman D.E.;
RT   "The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses
RT   the genes for nucleoporin NUP98 and class I homeoprotein HOXA9.";
RL   Nat. Genet. 12:159-167(1996).
RN   [7]
RP   NUCLEOTIDE SEQUENCE OF 206-271.
RX   PubMed=2574852; DOI=10.1093/nar/17.24.10385;
RA   Acampora D., D'Esposito M., Faiella A., Pannese M., Migliaccio E.,
RA   Morelli F., Stornaiuolo A., Nigro V., Simeone A., Boncinelli E.;
RT   "The human HOX gene family.";
RL   Nucleic Acids Res. 17:10385-10402(1989).
RN   [8]
RP   CHROMOSOMAL TRANSLOCATION WITH MSI2.
RX   PubMed=12649177;
RA   Barbouti A., Hoeglund M., Johansson B., Lassen C., Nilsson P.-G.,
RA   Hagemeijer A., Mitelman F., Fioretos T.;
RT   "A novel gene, MSI2, encoding a putative RNA-binding protein is
RT   recurrently rearranged at disease progression of chronic myeloid
RT   leukemia and forms a fusion gene with HOXA9 as a result of the cryptic
RT   t(7;17)(p15;q23).";
RL   Cancer Res. 63:1202-1206(2003).
RN   [9]
RP   FUNCTION, INTERACTION WITH PRMT5, METHYLATION AT ARG-140, MUTAGENESIS
RP   OF ARG-140, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=22269951; DOI=10.1128/MCB.05977-11;
RA   Bandyopadhyay S., Harris D.P., Adams G.N., Lause G.E., McHugh A.,
RA   Tillmaand E.G., Money A., Willard B., Fox P.L., Dicorleto P.E.;
RT   "HOXA9 methylation by PRMT5 is essential for endothelial cell
RT   expression of leukocyte adhesion molecules.";
RL   Mol. Cell. Biol. 32:1202-1213(2012).
CC   -!- FUNCTION: Sequence-specific transcription factor which is part of
CC       a developmental regulatory system that provides cells with
CC       specific positional identities on the anterior-posterior axis.
CC       Required for induction of E-selectin and VCAM-1, on the
CC       endothelial cells surface at sites of inflammation.
CC       {ECO:0000269|PubMed:22269951}.
CC   -!- SUBUNIT: Transiently interacts with PRMT5 in TNF-alpha stimulated
CC       endothelial cells. {ECO:0000269|PubMed:22269951}.
CC   -!- INTERACTION:
CC       O14744:PRMT5; NbExp=4; IntAct=EBI-742314, EBI-351098;
CC       Q15654:TRIP6; NbExp=4; IntAct=EBI-742314, EBI-742327;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- PTM: Methylated on Arg-140 by PRMT5; methylation is critical for
CC       E-selectin induction. {ECO:0000269|PubMed:22269951}.
CC   -!- DISEASE: Note=A chromosomal aberration involving HOXA9 is found in
CC       a form of acute myeloid leukemia. Translocation t(7;11)(p15;p15)
CC       with NUP98.
CC   -!- DISEASE: Note=A chromosomal aberration involving HOXA9 may
CC       contribute to disease progression in chronic myeloid leukemia.
CC       Translocation t(7;17)(p15;q23) with MSI2.
CC   -!- SIMILARITY: Belongs to the Abd-B homeobox family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC50364.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/HOXA9ID61.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U82759; AAB40867.1; -; mRNA.
DR   EMBL; AF010258; AAD08713.1; -; Genomic_DNA.
DR   EMBL; BT006990; AAP35636.1; -; mRNA.
DR   EMBL; AC004080; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC006537; AAH06537.1; -; mRNA.
DR   EMBL; BC010023; AAH10023.1; -; mRNA.
DR   EMBL; U41813; AAC50364.1; ALT_INIT; mRNA.
DR   CCDS; CCDS5409.1; -.
DR   PIR; S14929; S14929.
DR   RefSeq; NP_689952.1; NM_152739.3.
DR   UniGene; Hs.659350; -.
DR   ProteinModelPortal; P31269; -.
DR   SMR; P31269; -.
DR   BioGrid; 109445; 16.
DR   CORUM; P31269; -.
DR   IntAct; P31269; 8.
DR   MINT; P31269; -.
DR   STRING; 9606.ENSP00000343619; -.
DR   iPTMnet; P31269; -.
DR   PhosphoSitePlus; P31269; -.
DR   BioMuta; HOXA9; -.
DR   DMDM; 6166219; -.
DR   EPD; P31269; -.
DR   MaxQB; P31269; -.
DR   PaxDb; P31269; -.
DR   PeptideAtlas; P31269; -.
DR   PRIDE; P31269; -.
DR   DNASU; 3205; -.
DR   Ensembl; ENST00000343483; ENSP00000343619; ENSG00000078399.
DR   GeneID; 3205; -.
DR   KEGG; hsa:3205; -.
DR   UCSC; uc003syt.4; human.
DR   CTD; 3205; -.
DR   DisGeNET; 3205; -.
DR   EuPathDB; HostDB:ENSG00000078399.15; -.
DR   GeneCards; HOXA9; -.
DR   HGNC; HGNC:5109; HOXA9.
DR   HPA; HPA061982; -.
DR   MIM; 142956; gene.
DR   neXtProt; NX_P31269; -.
DR   OpenTargets; ENSG00000078399; -.
DR   PharmGKB; PA29386; -.
DR   eggNOG; KOG0487; Eukaryota.
DR   eggNOG; ENOG4111FJP; LUCA.
DR   GeneTree; ENSGT00910000143984; -.
DR   HOGENOM; HOG000231180; -.
DR   HOVERGEN; HBG016849; -.
DR   InParanoid; P31269; -.
DR   KO; K21950; -.
DR   OMA; WSHVPAQ; -.
DR   OrthoDB; EOG091G0IP5; -.
DR   PhylomeDB; P31269; -.
DR   TreeFam; TF317819; -.
DR   SignaLink; P31269; -.
DR   SIGNOR; P31269; -.
DR   ChiTaRS; HOXA9; human.
DR   GeneWiki; HOXA9; -.
DR   GenomeRNAi; 3205; -.
DR   PRO; PR:P31269; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; ENSG00000078399; -.
DR   CleanEx; HS_HOXA9; -.
DR   ExpressionAtlas; P31269; baseline and differential.
DR   Genevisible; P31269; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IDA:LIFEdb.
DR   GO; GO:0005667; C:transcription factor complex; IEA:Ensembl.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II proximal promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; IEA:Ensembl.
DR   GO; GO:0060216; P:definitive hemopoiesis; IEA:Ensembl.
DR   GO; GO:0035115; P:embryonic forelimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0048706; P:embryonic skeletal system development; IEA:Ensembl.
DR   GO; GO:0042118; P:endothelial cell activation; IMP:UniProtKB.
DR   GO; GO:0008584; P:male gonad development; IEA:Ensembl.
DR   GO; GO:0030879; P:mammary gland development; IEA:Ensembl.
DR   GO; GO:0007275; P:multicellular organism development; TAS:ProtInc.
DR   GO; GO:0045638; P:negative regulation of myeloid cell differentiation; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0009954; P:proximal/distal pattern formation; IEA:Ensembl.
DR   GO; GO:0007338; P:single fertilization; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0060065; P:uterus development; IEA:Ensembl.
DR   CDD; cd00086; homeodomain; 1.
DR   InterPro; IPR009057; Homeobox-like_sf.
DR   InterPro; IPR017970; Homeobox_CS.
DR   InterPro; IPR001356; Homeobox_dom.
DR   InterPro; IPR020479; Homeobox_metazoa.
DR   InterPro; IPR006711; Hox9_activation_N.
DR   InterPro; IPR017112; HXA9/HXB9/HXC9.
DR   Pfam; PF00046; Homeobox; 1.
DR   Pfam; PF04617; Hox9_act; 1.
DR   PIRSF; PIRSF037109; Homeobox_Hox9; 1.
DR   PRINTS; PR00024; HOMEOBOX.
DR   SMART; SM00389; HOX; 1.
DR   SUPFAM; SSF46689; SSF46689; 1.
DR   PROSITE; PS00027; HOMEOBOX_1; 1.
DR   PROSITE; PS50071; HOMEOBOX_2; 1.
PE   1: Evidence at protein level;
KW   Chromosomal rearrangement; Complete proteome; Developmental protein;
KW   DNA-binding; Homeobox; Methylation; Nucleus; Proto-oncogene;
KW   Reference proteome; Transcription; Transcription regulation.
FT   CHAIN         1    272       Homeobox protein Hox-A9.
FT                                /FTId=PRO_0000200081.
FT   DNA_BIND    206    265       Homeobox. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00108}.
FT   SITE        163    164       Breakpoint for translocation to form
FT                                MSI2/HOXA9 fusion protein.
FT   MOD_RES     140    140       Symmetric dimethylarginine.
FT                                {ECO:0000269|PubMed:22269951}.
FT   MUTAGEN     140    140       R->A: Results in loss of methylation.
FT                                {ECO:0000269|PubMed:22269951}.
FT   CONFLICT     64     64       G -> V (in Ref. 1; AAB40867).
FT                                {ECO:0000305}.
FT   CONFLICT     67     67       W -> R (in Ref. 2; AAD08713).
FT                                {ECO:0000305}.
FT   CONFLICT     80     80       Missing (in Ref. 1; AAB40867).
FT                                {ECO:0000305}.
FT   CONFLICT    243    243       L -> F (in Ref. 1; AAB40867).
FT                                {ECO:0000305}.
SQ   SEQUENCE   272 AA;  30172 MW;  823A1A22BB07A881 CRC64;
     MATTGALGNY YVDSFLLGAD AADELSVGRY APGTLGQPPR QAATLAEHPD FSPCSFQSKA
     TVFGASWNPV HAAGANAVPA AVYHHHHHHP YVHPQAPVAA AAPDGRYMRS WLEPTPGALS
     FAGLPSSRPY GIKPEPLSAR RGDCPTLDTH TLSLTDYACG SPPVDREKQP SEGAFSENNA
     ENESGGDKPP IDPNNPAANW LHARSTRKKR CPYTKHQTLE LEKEFLFNMY LTRDRRYEVA
     RLLNLTERQV KIWFQNRRMK MKKINKDRAK DE
//
ID   IRF4_HUMAN              Reviewed;         451 AA.
AC   Q15306; Q5VUI7; Q99660;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 1.
DT   28-FEB-2018, entry version 182.
DE   RecName: Full=Interferon regulatory factor 4;
DE            Short=IRF-4;
DE   AltName: Full=Lymphocyte-specific interferon regulatory factor;
DE            Short=LSIRF;
DE   AltName: Full=Multiple myeloma oncogene 1;
DE   AltName: Full=NF-EM5;
GN   Name=IRF4; Synonyms=MUM1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Spleen;
RX   PubMed=8921401; DOI=10.1006/geno.1996.0547;
RA   Grossman A., Mittrucker H.W., Nicholl J., Suzuki A., Chung S.,
RA   Antonio L., Sugga S., Sutherland G.R., Siderovski D.P., Mak T.W.;
RT   "Cloning of human lymphocyte-specific interferon regulatory factor
RT   (hLSIRF/hIRF4) and mapping of the gene to 6p23-p25.";
RL   Genomics 37:229-233(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INVOLVEMENT IN MULTIPLE
RP   MYELOMA.
RC   TISSUE=Spleen;
RX   PubMed=9326949; DOI=10.1038/ng1097-226;
RA   Iida S., Rao P.H., Butler M., Corradini P., Boccadoro M., Klein B.,
RA   Chaganti R.S.K., Dalla-Favera R.;
RT   "Deregulation of MUM1/IRF4 by chromosomal translocation in multiple
RT   myeloma.";
RL   Nat. Genet. 17:226-230(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INTERACTION WITH SPIB.
RX   PubMed=10196196; DOI=10.1074/jbc.274.16.11115;
RA   Rao S., Matsumura A., Yoon J., Simon M.C.;
RT   "SPI-B activates transcription via a unique proline, serine, and
RT   threonine domain and exhibits DNA binding affinity differences from
RT   PU.1.";
RL   J. Biol. Chem. 274:11115-11124(1999).
RN   [6]
RP   INTERACTION WITH DEF6.
RC   TISSUE=Lymph node;
RX   PubMed=12651066; DOI=10.1016/S0198-8859(03)00024-7;
RA   Gupta S., Lee A.E., Hu C., Fanzo J.C., Goldberg I., Cattoretti G.,
RA   Pernis A.B.;
RT   "Molecular cloning of IBP, a SWAP-70 homologous GEF, which is highly
RT   expressed in the immune system.";
RL   Hum. Immunol. 64:389-401(2003).
RN   [7]
RP   POLYMORPHISM.
RX   PubMed=18483556; DOI=10.1371/journal.pgen.1000074;
RA   Han J., Kraft P., Nan H., Guo Q., Chen C., Qureshi A., Hankinson S.E.,
RA   Hu F.B., Duffy D.L., Zhao Z.Z., Martin N.G., Montgomery G.W.,
RA   Hayward N.K., Thomas G., Hoover R.N., Chanock S., Hunter D.J.;
RT   "A genome-wide association study identifies novel alleles associated
RT   with hair color and skin pigmentation.";
RL   PLoS Genet. 4:E1000074-E1000074(2008).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [9]
RP   POLYMORPHISM.
RX   PubMed=24267888; DOI=10.1016/j.cell.2013.10.022;
RA   Praetorius C., Grill C., Stacey S.N., Metcalf A.M., Gorkin D.U.,
RA   Robinson K.C., Van Otterloo E., Kim R.S., Bergsteinsdottir K.,
RA   Ogmundsdottir M.H., Magnusdottir E., Mishra P.J., Davis S.R., Guo T.,
RA   Zaidi M.R., Helgason A.S., Sigurdsson M.I., Meltzer P.S., Merlino G.,
RA   Petit V., Larue L., Loftus S.K., Adams D.R., Sobhiafshar U.,
RA   Emre N.C., Pavan W.J., Cornell R., Smith A.G., McCallion A.S.,
RA   Fisher D.E., Stefansson K., Sturm R.A., Steingrimsson E.;
RT   "A polymorphism in IRF4 affects human pigmentation through a
RT   tyrosinase-dependent MITF/TFAP2A pathway.";
RL   Cell 155:1022-1033(2013).
RN   [10]
RP   STRUCTURE BY NMR OF 22-130.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the IRF domain of human interferon regulator
RT   factor 4.";
RL   Submitted (OCT-2006) to the PDB data bank.
CC   -!- FUNCTION: Transcriptional activator. Binds to the interferon-
CC       stimulated response element (ISRE) of the MHC class I promoter.
CC       Binds the immunoglobulin lambda light chain enhancer, together
CC       with PU.1. Probably plays a role in ISRE-targeted signal
CC       transduction mechanisms specific to lymphoid cells. Involved in
CC       CD8(+) dendritic cell differentiation by forming a complex with
CC       the BATF-JUNB heterodimer in immune cells, leading to recognition
CC       of AICE sequence (5'-TGAnTCA/GAAA-3'), an immune-specific
CC       regulatory element, followed by cooperative binding of BATF and
CC       IRF4 and activation of genes (By similarity).
CC       {ECO:0000250|UniProtKB:Q64287}.
CC   -!- SUBUNIT: Interacts with the BATF-JUNB heterodimer. Interacts with
CC       BATF (via bZIP domain); the interaction is direct (By similarity).
CC       Interacts with SPIB and DEF6. Directly interacts with NLRP3 in the
CC       nucleus of Th2 cells; this interaction enhances IRF4 ability to
CC       bind to the IL4 promoter and is required for optimal IRF4-
CC       dependent IL4 transcription (By similarity). {ECO:0000250,
CC       ECO:0000250|UniProtKB:Q64287, ECO:0000269|PubMed:10196196,
CC       ECO:0000269|PubMed:12651066}.
CC   -!- INTERACTION:
CC       O95163:ELP1; NbExp=2; IntAct=EBI-751345, EBI-347559;
CC       P51617:IRAK1; NbExp=2; IntAct=EBI-751345, EBI-358664;
CC       Q86UE8:TLK2; NbExp=2; IntAct=EBI-751345, EBI-1047967;
CC       Q9H6S0:YTHDC2; NbExp=2; IntAct=EBI-751345, EBI-1057466;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q15306-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q15306-2; Sequence=VSP_002755;
CC   -!- TISSUE SPECIFICITY: Lymphoid cells.
CC   -!- INDUCTION: Not induced by interferons.
CC   -!- PTM: Phosphorylation by ROCK2 regulates IL-17 and IL-21
CC       production. {ECO:0000250}.
CC   -!- POLYMORPHISM: Genetic variants in IRF4 define the skin/hair/eye
CC       pigmentation variation locus 8 (SHEP8) [MIM:611724]. Hair, eye and
CC       skin pigmentation are among the most visible examples of human
CC       phenotypic variation, with a broad normal range that is subject to
CC       substantial geographic stratification. In the case of skin,
CC       individuals tend to have lighter pigmentation with increasing
CC       distance from the equator. By contrast, the majority of variation
CC       in human eye and hair color is found among individuals of European
CC       ancestry, with most other human populations fixed for brown eyes
CC       and black hair. {ECO:0000269|PubMed:18483556,
CC       ECO:0000269|PubMed:24267888}.
CC   -!- DISEASE: Multiple myeloma (MM) [MIM:254500]: A malignant tumor of
CC       plasma cells usually arising in the bone marrow and characterized
CC       by diffuse involvement of the skeletal system, hyperglobulinemia,
CC       Bence-Jones proteinuria and anemia. Complications of multiple
CC       myeloma are bone pain, hypercalcemia, renal failure and spinal
CC       cord compression. The aberrant antibodies that are produced lead
CC       to impaired humoral immunity and patients have a high prevalence
CC       of infection. Amyloidosis may develop in some patients. Multiple
CC       myeloma is part of a spectrum of diseases ranging from monoclonal
CC       gammopathy of unknown significance (MGUS) to plasma cell leukemia.
CC       {ECO:0000269|PubMed:9326949}. Note=The gene represented in this
CC       entry may be involved in disease pathogenesis. A chromosomal
CC       aberration involving IRF4 has been found in multiple myeloma.
CC       Translocation t(6;14)(p25;q32) with the IgH locus.
CC   -!- SIMILARITY: Belongs to the IRF family. {ECO:0000255|PROSITE-
CC       ProRule:PRU00840}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/IRF4ID231ch6p25.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U52682; AAC50779.1; -; mRNA.
DR   EMBL; U63738; AAB37258.1; -; mRNA.
DR   EMBL; AL589962; CAH71554.1; -; Genomic_DNA.
DR   EMBL; AL365272; CAH71554.1; JOINED; Genomic_DNA.
DR   EMBL; AL365272; CAH72537.1; -; Genomic_DNA.
DR   EMBL; AL589962; CAH72537.1; JOINED; Genomic_DNA.
DR   EMBL; BC015752; AAH15752.1; -; mRNA.
DR   CCDS; CCDS4469.1; -. [Q15306-1]
DR   RefSeq; NP_001182215.1; NM_001195286.1. [Q15306-2]
DR   RefSeq; NP_002451.2; NM_002460.3. [Q15306-1]
DR   UniGene; Hs.401013; -.
DR   PDB; 2DLL; NMR; -; A=23-130.
DR   PDBsum; 2DLL; -.
DR   ProteinModelPortal; Q15306; -.
DR   SMR; Q15306; -.
DR   BioGrid; 109870; 24.
DR   IntAct; Q15306; 11.
DR   STRING; 9606.ENSP00000370343; -.
DR   iPTMnet; Q15306; -.
DR   PhosphoSitePlus; Q15306; -.
DR   BioMuta; IRF4; -.
DR   DMDM; 2497445; -.
DR   MaxQB; Q15306; -.
DR   PaxDb; Q15306; -.
DR   PeptideAtlas; Q15306; -.
DR   PRIDE; Q15306; -.
DR   DNASU; 3662; -.
DR   Ensembl; ENST00000380956; ENSP00000370343; ENSG00000137265. [Q15306-1]
DR   GeneID; 3662; -.
DR   KEGG; hsa:3662; -.
DR   UCSC; uc003msz.5; human. [Q15306-1]
DR   CTD; 3662; -.
DR   DisGeNET; 3662; -.
DR   EuPathDB; HostDB:ENSG00000137265.14; -.
DR   GeneCards; IRF4; -.
DR   HGNC; HGNC:6119; IRF4.
DR   HPA; CAB013508; -.
DR   HPA; HPA002038; -.
DR   HPA; HPA002698; -.
DR   MIM; 254500; phenotype.
DR   MIM; 601900; gene.
DR   MIM; 611724; phenotype.
DR   neXtProt; NX_Q15306; -.
DR   OpenTargets; ENSG00000137265; -.
DR   PharmGKB; PA29918; -.
DR   eggNOG; ENOG410IES5; Eukaryota.
DR   eggNOG; ENOG411023V; LUCA.
DR   GeneTree; ENSGT00760000119093; -.
DR   HOGENOM; HOG000010107; -.
DR   HOVERGEN; HBG003072; -.
DR   InParanoid; Q15306; -.
DR   KO; K09445; -.
DR   OMA; SDCRLHI; -.
DR   OrthoDB; EOG091G067P; -.
DR   PhylomeDB; Q15306; -.
DR   TreeFam; TF328512; -.
DR   Reactome; R-HSA-6785807; Interleukin-4 and 13 signaling.
DR   Reactome; R-HSA-877300; Interferon gamma signaling.
DR   Reactome; R-HSA-909733; Interferon alpha/beta signaling.
DR   SIGNOR; Q15306; -.
DR   ChiTaRS; IRF4; human.
DR   EvolutionaryTrace; Q15306; -.
DR   GeneWiki; IRF4; -.
DR   GenomeRNAi; 3662; -.
DR   PRO; PR:Q15306; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000137265; -.
DR   CleanEx; HS_IRF4; -.
DR   CleanEx; HS_MUM1; -.
DR   ExpressionAtlas; Q15306; baseline and differential.
DR   Genevisible; Q15306; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0000788; C:nuclear nucleosome; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IC:UniProtKB.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; ISS:UniProtKB.
DR   GO; GO:0016279; F:protein-lysine N-methyltransferase activity; IEA:Ensembl.
DR   GO; GO:0000978; F:RNA polymerase II proximal promoter sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0043565; F:sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; NAS:UniProtKB.
DR   GO; GO:0001077; F:transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0042832; P:defense response to protozoan; ISS:UniProtKB.
DR   GO; GO:0043966; P:histone H3 acetylation; IEA:Ensembl.
DR   GO; GO:0043967; P:histone H4 acetylation; IEA:Ensembl.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0043011; P:myeloid dendritic cell differentiation; IEA:Ensembl.
DR   GO; GO:0034122; P:negative regulation of toll-like receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0043388; P:positive regulation of DNA binding; IEA:Ensembl.
DR   GO; GO:0045082; P:positive regulation of interleukin-10 biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0045368; P:positive regulation of interleukin-13 biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0045086; P:positive regulation of interleukin-2 biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0045404; P:positive regulation of interleukin-4 biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:NTNU_SB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0045622; P:regulation of T-helper cell differentiation; NAS:UniProtKB.
DR   GO; GO:0042110; P:T cell activation; NAS:UniProtKB.
DR   GO; GO:0072540; P:T-helper 17 cell lineage commitment; ISS:UniProtKB.
DR   GO; GO:0060337; P:type I interferon signaling pathway; TAS:Reactome.
DR   CDD; cd00103; IRF; 1.
DR   Gene3D; 1.10.10.10; -; 1.
DR   Gene3D; 2.60.200.10; -; 1.
DR   InterPro; IPR019817; Interferon_reg_fac_CS.
DR   InterPro; IPR001346; Interferon_reg_fact_DNA-bd_dom.
DR   InterPro; IPR019471; Interferon_reg_factor-3.
DR   InterPro; IPR017855; SMAD-like_dom_sf.
DR   InterPro; IPR008984; SMAD_FHA_dom_sf.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   PANTHER; PTHR11949; PTHR11949; 1.
DR   Pfam; PF00605; IRF; 1.
DR   Pfam; PF10401; IRF-3; 1.
DR   PRINTS; PR00267; INTFRNREGFCT.
DR   SMART; SM00348; IRF; 1.
DR   SMART; SM01243; IRF-3; 1.
DR   SUPFAM; SSF46785; SSF46785; 1.
DR   SUPFAM; SSF49879; SSF49879; 1.
DR   PROSITE; PS00601; IRF_1; 1.
DR   PROSITE; PS51507; IRF_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing;
KW   Chromosomal rearrangement; Complete proteome; DNA-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Transcription;
KW   Transcription regulation.
FT   CHAIN         1    451       Interferon regulatory factor 4.
FT                                /FTId=PRO_0000154556.
FT   DNA_BIND     21    129       IRF tryptophan pentad repeat.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00840}.
FT   MOD_RES     447    447       Phosphoserine; by ROCK2.
FT                                {ECO:0000250|UniProtKB:Q64287}.
FT   MOD_RES     448    448       Phosphoserine; by ROCK2.
FT                                {ECO:0000250|UniProtKB:Q64287}.
FT   VAR_SEQ     165    165       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:8921401}.
FT                                /FTId=VSP_002755.
FT   CONFLICT    300    300       Q -> H (in Ref. 2; AAB37258).
FT                                {ECO:0000305}.
FT   CONFLICT    306    306       K -> N (in Ref. 2; AAB37258).
FT                                {ECO:0000305}.
FT   CONFLICT    333    333       R -> T (in Ref. 2; AAB37258).
FT                                {ECO:0000305}.
FT   HELIX        24     34       {ECO:0000244|PDB:2DLL}.
FT   STRAND       37     39       {ECO:0000244|PDB:2DLL}.
FT   STRAND       41     47       {ECO:0000244|PDB:2DLL}.
FT   STRAND       49     53       {ECO:0000244|PDB:2DLL}.
FT   STRAND       60     62       {ECO:0000244|PDB:2DLL}.
FT   HELIX        64     67       {ECO:0000244|PDB:2DLL}.
FT   HELIX        69     78       {ECO:0000244|PDB:2DLL}.
FT   HELIX        90    103       {ECO:0000244|PDB:2DLL}.
FT   STRAND      107    109       {ECO:0000244|PDB:2DLL}.
FT   TURN        111    113       {ECO:0000244|PDB:2DLL}.
FT   STRAND      115    120       {ECO:0000244|PDB:2DLL}.
FT   STRAND      122    127       {ECO:0000244|PDB:2DLL}.
SQ   SEQUENCE   451 AA;  51772 MW;  17CD1327C6F5BFFA CRC64;
     MNLEGGGRGG EFGMSAVSCG NGKLRQWLID QIDSGKYPGL VWENEEKSIF RIPWKHAGKQ
     DYNREEDAAL FKAWALFKGK FREGIDKPDP PTWKTRLRCA LNKSNDFEEL VERSQLDISD
     PYKVYRIVPE GAKKGAKQLT LEDPQMSMSH PYTMTTPYPS LPAQQVHNYM MPPLDRSWRD
     YVPDQPHPEI PYQCPMTFGP RGHHWQGPAC ENGCQVTGTF YACAPPESQA PGVPTEPSIR
     SAEALAFSDC RLHICLYYRE ILVKELTTSS PEGCRISHGH TYDASNLDQV LFPYPEDNGQ
     RKNIEKLLSH LERGVVLWMA PDGLYAKRLC QSRIYWDGPL ALCNDRPNKL ERDQTCKLFD
     TQQFLSELQA FAHHGRSLPR FQVTLCFGEE FPDPQRQRKL ITAHVEPLLA RQLYYFAQQN
     SGHFLRGYDL PEHISNPEDY HRSIRHSSIQ E
//
ID   A4FUJ8_HUMAN            Unreviewed;       798 AA.
AC   A4FUJ8;
DT   17-APR-2007, integrated into UniProtKB/TrEMBL.
DT   17-APR-2007, sequence version 1.
DT   28-FEB-2018, entry version 67.
DE   SubName: Full=MKL1 protein {ECO:0000313|EMBL:AAI15040.1};
GN   Name=MKL1 {ECO:0000313|EMBL:AAI15040.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AAI15040.1};
RN   [1] {ECO:0000313|EMBL:AAI15040.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lymph {ECO:0000313|EMBL:AAI15040.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RA   Gerhard D.S., Wagner L., Feingold E.A., Shenmen C.M., Grouse L.H.,
RA   Schuler G., Klein S.L., Old S., Rasooly R., Good P., Guyer M.,
RA   Peck A.M., Derge J.G., Lipman D., Collins F.S., Jang W., Sherry S.,
RA   Feolo M., Misquitta L., Lee E., Rotmistrovsky K., Greenhut S.F.,
RA   Schaefer C.F., Buetow K., Bonner T.I., Haussler D., Kent J.,
RA   Kiekhaus M., Furey T., Brent M., Prange C., Schreiber K., Shapiro N.,
RA   Bhat N.K., Hopkins R.F., Hsie F., Driscoll T., Soares M.B.,
RA   Casavant T.L., Scheetz T.E., Brown-stein M.J., Usdin T.B.,
RA   Toshiyuki S., Carninci P., Piao Y., Dudekula D.B., Ko M.S.,
RA   Kawakami K., Suzuki Y., Sugano S., Gruber C.E., Smith M.R.,
RA   Simmons B., Moore T., Waterman R., Johnson S.L., Ruan Y., Wei C.L.,
RA   Mathavan S., Gunaratne P.H., Wu J., Garcia A.M., Hulyk S.W., Fuh E.,
RA   Yuan Y., Sneed A., Kowis C., Hodgson A., Muzny D.M., McPherson J.,
RA   Gibbs R.A., Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S.,
RA   Sanchez A., Whiting M., Madari A., Young A.C., Wetherby K.D.,
RA   Granite S.J., Kwong P.N., Brinkley C.P., Pearson R.L., Bouffard G.G.,
RA   Blakesly R.W., Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J.,
RA   Schmutz J., Myers R.M., Butterfield Y.S., Griffith M., Griffith O.L.,
RA   Krzywinski M.I., Liao N., Morin R., Morrin R., Palmquist D.,
RA   Petrescu A.S., Skalska U., Smailus D.E., Stott J.M., Schnerch A.,
RA   Schein J.E., Jones S.J., Holt R.A., Baross A., Marra M.A., Clifton S.,
RA   Makowski K.A., Bosak S., Malek J.;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; BC115039; AAI15040.1; -; mRNA.
DR   RefSeq; NP_001269589.1; NM_001282660.1.
DR   RefSeq; NP_001269590.1; NM_001282661.1.
DR   RefSeq; NP_001269591.1; NM_001282662.1.
DR   RefSeq; NP_001305068.1; NM_001318139.1.
DR   RefSeq; NP_065882.1; NM_020831.4.
DR   UniGene; Hs.654688; -.
DR   ProteinModelPortal; A4FUJ8; -.
DR   MaxQB; A4FUJ8; -.
DR   PeptideAtlas; A4FUJ8; -.
DR   PRIDE; A4FUJ8; -.
DR   GeneID; 57591; -.
DR   KEGG; hsa:57591; -.
DR   CTD; 57591; -.
DR   eggNOG; ENOG410IFJX; Eukaryota.
DR   eggNOG; ENOG41101AM; LUCA.
DR   HOVERGEN; HBG036493; -.
DR   ChiTaRS; MKL1; human.
DR   GenomeRNAi; 57591; -.
DR   GO; GO:0005737; C:cytoplasm; IEA:InterPro.
DR   GO; GO:0005634; C:nucleus; IEA:InterPro.
DR   GO; GO:0003785; F:actin monomer binding; IEA:InterPro.
DR   GO; GO:0003713; F:transcription coactivator activity; IEA:InterPro.
DR   GO; GO:0010735; P:positive regulation of transcription via serum response element binding; IEA:InterPro.
DR   Gene3D; 1.10.720.30; -; 1.
DR   InterPro; IPR029992; MRTF-A.
DR   InterPro; IPR004018; RPEL_repeat.
DR   InterPro; IPR003034; SAP_dom.
DR   InterPro; IPR036361; SAP_dom_sf.
DR   PANTHER; PTHR22793:SF6; PTHR22793:SF6; 2.
DR   Pfam; PF02755; RPEL; 2.
DR   Pfam; PF02037; SAP; 1.
DR   SMART; SM00707; RPEL; 2.
DR   SMART; SM00513; SAP; 1.
DR   SUPFAM; SSF68906; SSF68906; 1.
DR   PROSITE; PS51073; RPEL; 2.
DR   PROSITE; PS50800; SAP; 1.
PE   2: Evidence at transcript level;
KW   Coiled coil {ECO:0000256|SAM:Coils}.
FT   REPEAT       24     49       RPEL. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00401}.
FT   REPEAT       68     93       RPEL. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00401}.
FT   DOMAIN      347    381       SAP. {ECO:0000259|PROSITE:PS50800}.
FT   COILED       56     76       {ECO:0000256|SAM:Coils}.
FT   COILED      527    561       {ECO:0000256|SAM:Coils}.
SQ   SEQUENCE   798 AA;  85046 MW;  55B8CF6F845F873C CRC64;
     MPPLKSPAAF HEQRRSLERA RTEDYLKRKI RSRPERSELV RMHILEETSA EPSLQAKQLK
     LKRARLADDL NEKIAQRPGP MELVEKNILP VESSLKEAII VGQVNYPKVA DSSSFDEDSS
     DALSPEQPAS HESQGSVPSP LEARVSEPLL SATSASPTQV VSQLPMGRDS REMLFLAEQP
     PLPPPPLLPP SLTNGTTIPT AKSTPTLIKQ SQPKSASEKS QRSKKAKELK PKVKKLKYHQ
     YIPPDQKQDR GAPPMDSSYA KILQQQQLFL QLQILNQQQQ QHHNYQAILP APPKSAGEAL
     GSSGTPPVRS LSTTNSSSSS GAPGPCGLAR QNSTSLTGKP GALPANLDDM KVAELKQELK
     LRSLPVSGTK TELIERLRAY QDQISPVPGA PKAPAATSIL HKAGEVVVAF PAARLSTGPA
     LVAAGLAPAE VVVATVASSG VVKFGSTGST PPVSPTPSER SLLSTGDENS TPGDTFGEMV
     TSPLTQLTLQ ASPLQILVKE EGPRAGSCCL SPGGRAELEG RDKDQMLQEK DKQIEALTRM
     LRQKQQLVER LKLQLEQEKR AQQPAPAPAP LGTPVKQENS FSSCQLSQQP LGPAHPFNPS
     LAAPATNHID PCAVAPGPPS VVVKQEALQP EPEPVPAPQL LLGPQGPGLI KGVAPPTLIT
     DSTGTHLVLT VTNKNADSPG LSSGSPQQPS SQPGSPAPAP SAQMDLEHPL QPLFGTPTSL
     LKKEPPGYEE AMSQQPKQQE NGSSSQQMDD LFDILIQSGG NPRNFSRFQG AAIPAREGEA
     IPEDSLWVPP GSTAITFC
//
ID   B0QY83_HUMAN            Unreviewed;       881 AA.
AC   B0QY83;
DT   08-APR-2008, integrated into UniProtKB/TrEMBL.
DT   08-APR-2008, sequence version 1.
DT   28-FEB-2018, entry version 80.
DE   SubName: Full=MKL/myocardin-like protein 1 {ECO:0000313|Ensembl:ENSP00000385584};
GN   Name=MKL1 {ECO:0000313|Ensembl:ENSP00000385584};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000385584, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Ensembl:ENSP00000385584, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [2] {ECO:0000213|PubMed:17081983}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [3] {ECO:0000213|PubMed:18669648}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [4] {ECO:0000213|PubMed:19413330}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [5] {ECO:0000213|PubMed:20068231}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:ra3-RA3(2010).
RN   [6] {ECO:0000213|PubMed:21406692}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:rs3-RS3(2011).
RN   [7] {ECO:0000313|Ensembl:ENSP00000385584}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (FEB-2012) to UniProtKB.
RN   [8] {ECO:0000213|PubMed:23186163}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=23186163;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [9] {ECO:0000213|PubMed:24275569}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- CAUTION: The sequence shown here is derived from an Ensembl
CC       automatic analysis pipeline and should be considered as
CC       preliminary data. {ECO:0000313|Ensembl:ENSP00000385584}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AL022238; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL031594; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF457470; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z86090; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_001269590.1; NM_001282661.1.
DR   UniGene; Hs.654688; -.
DR   ProteinModelPortal; B0QY83; -.
DR   MaxQB; B0QY83; -.
DR   PeptideAtlas; B0QY83; -.
DR   PRIDE; B0QY83; -.
DR   Ensembl; ENST00000402042; ENSP00000385584; ENSG00000196588.
DR   GeneID; 57591; -.
DR   UCSC; uc010gyf.3; human.
DR   CTD; 57591; -.
DR   EuPathDB; HostDB:ENSG00000196588.14; -.
DR   HGNC; HGNC:14334; MKL1.
DR   OpenTargets; ENSG00000196588; -.
DR   GeneTree; ENSGT00530000063195; -.
DR   HOGENOM; HOG000038001; -.
DR   HOVERGEN; HBG036493; -.
DR   ChiTaRS; MKL1; human.
DR   GenomeRNAi; 57591; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   Bgee; ENSG00000196588; -.
DR   ExpressionAtlas; B0QY83; baseline and differential.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003785; F:actin monomer binding; IEA:InterPro.
DR   GO; GO:0003713; F:transcription coactivator activity; IEA:InterPro.
DR   GO; GO:0010735; P:positive regulation of transcription via serum response element binding; IEA:InterPro.
DR   Gene3D; 1.10.720.30; -; 1.
DR   InterPro; IPR029992; MRTF-A.
DR   InterPro; IPR004018; RPEL_repeat.
DR   InterPro; IPR003034; SAP_dom.
DR   InterPro; IPR036361; SAP_dom_sf.
DR   PANTHER; PTHR22793:SF6; PTHR22793:SF6; 2.
DR   Pfam; PF02755; RPEL; 2.
DR   Pfam; PF02037; SAP; 1.
DR   SMART; SM00707; RPEL; 2.
DR   SMART; SM00513; SAP; 1.
DR   SUPFAM; SSF68906; SSF68906; 1.
DR   PROSITE; PS51073; RPEL; 2.
DR   PROSITE; PS50800; SAP; 1.
PE   1: Evidence at protein level;
KW   Coiled coil {ECO:0000256|SAM:Coils};
KW   Complete proteome {ECO:0000313|Proteomes:UP000005640};
KW   Proteomics identification {ECO:0000213|EPD:B0QY83,
KW   ECO:0000213|MaxQB:B0QY83, ECO:0000213|PeptideAtlas:B0QY83};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640}.
FT   REPEAT       24     49       RPEL. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00401}.
FT   REPEAT       68     93       RPEL. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00401}.
FT   DOMAIN      297    331       SAP. {ECO:0000259|PROSITE:PS50800}.
FT   COILED       56     76       {ECO:0000256|SAM:Coils}.
FT   COILED      477    511       {ECO:0000256|SAM:Coils}.
SQ   SEQUENCE   881 AA;  93588 MW;  86844F800009AC00 CRC64;
     MPPLKSPAAF HEQRRSLERA RTEDYLKRKI RSRPERSELV RMHILEETSA EPSLQAKQLK
     LKRARLADDL NEKIAQRPGP MELVEKNILP VESSLKEAII VGQVNYPKVA DSSSFDEDSS
     DALSPEQPAS HESQGSVPSP LEARVSEPLL SATSASPTQQ SQPKSASEKS QRSKKAKELK
     PKVKKLKYHQ YIPPDQKQDR GAPPMDSSYA KILQQQQLFL QLQILNQQQQ QHHNYQAILP
     APPKSAGEAL GSSGTPPVRS LSTTNSSSSS GAPGPCGLAR QNSTSLTGKP GALPANLDDM
     KVAELKQELK LRSLPVSGTK TELIERLRAY QDQISPVPGA PKAPAATSIL HKAGEVVVAF
     PAARLSTGPA LVAAGLAPAE VVVATVASSG VVKFGSTGST PPVSPTPSER SLLSTGDENS
     TPGDTFGEMV TSPLTQLTLQ ASPLQILVKE EGPRAGSCCL SPGGRAELEG RDKDQMLQEK
     DKQIEALTRM LRQKQQLVER LKLQLEQEKR AQQPAPAPAP LGTPVKQENS FSSCQLSQQP
     LGPAHPFNPS LAAPATNHID PCAVAPGPPS VVVKQEALQP EPEPVPAPQL LLGPQGPSLI
     KGVAPPTLIT DSTGTHLVLT VTNKNADSPG LSSGSPQQPS SQPGSPAPAP SAQMDLEHPL
     QPLFGTPTSL LKKEPPGYEE AMSQQPKQQE NGSSSQQMDD LFDILIQSGE ISADFKEPPS
     LPGKEKPSPK TVCGSPLAAQ PSPSAELPQA APPPPGSPSL PGRLEDFLES STGLPLLTSG
     HDGPEPLSLI DDLHSQMLSS TAILDHPPSP MDTSELHFVP EPSSTMGLDL ADGHLDSMDW
     LELSSGGPVL SLAPLSTTAP SLFSTDFLDG HDLQLHWDSC L
//
ID   E7ER32_HUMAN            Unreviewed;       798 AA.
AC   E7ER32;
DT   08-MAR-2011, integrated into UniProtKB/TrEMBL.
DT   28-JUN-2011, sequence version 2.
DT   28-FEB-2018, entry version 58.
DE   SubName: Full=MKL/myocardin-like protein 1 {ECO:0000313|Ensembl:ENSP00000379861};
GN   Name=MKL1 {ECO:0000313|Ensembl:ENSP00000379861};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000379861, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Ensembl:ENSP00000379861, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [2] {ECO:0000213|PubMed:17081983}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [3] {ECO:0000213|PubMed:18669648}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [4] {ECO:0000213|PubMed:19413330}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [5] {ECO:0000213|PubMed:19690332}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:ra46-RA46(2009).
RN   [6] {ECO:0000213|PubMed:20068231}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:ra3-RA3(2010).
RN   [7] {ECO:0000213|PubMed:21406692}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:rs3-RS3(2011).
RN   [8] {ECO:0000313|Ensembl:ENSP00000379861}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (JUL-2011) to UniProtKB.
RN   [9] {ECO:0000213|PubMed:23186163}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=23186163;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [10] {ECO:0000213|PubMed:24275569}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- CAUTION: The sequence shown here is derived from an Ensembl
CC       automatic analysis pipeline and should be considered as
CC       preliminary data. {ECO:0000313|Ensembl:ENSP00000379861}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AL022238; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL031594; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF457470; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z86090; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_001269591.1; NM_001282662.1.
DR   UniGene; Hs.654688; -.
DR   ProteinModelPortal; E7ER32; -.
DR   MaxQB; E7ER32; -.
DR   PeptideAtlas; E7ER32; -.
DR   Ensembl; ENST00000396617; ENSP00000379861; ENSG00000196588.
DR   GeneID; 57591; -.
DR   UCSC; uc010gye.3; human.
DR   CTD; 57591; -.
DR   EuPathDB; HostDB:ENSG00000196588.14; -.
DR   HGNC; HGNC:14334; MKL1.
DR   OpenTargets; ENSG00000196588; -.
DR   eggNOG; ENOG410IFJX; Eukaryota.
DR   eggNOG; ENOG41101AM; LUCA.
DR   GeneTree; ENSGT00530000063195; -.
DR   ChiTaRS; MKL1; human.
DR   GenomeRNAi; 57591; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   Bgee; ENSG00000196588; -.
DR   ExpressionAtlas; E7ER32; baseline and differential.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003785; F:actin monomer binding; IEA:InterPro.
DR   GO; GO:0003713; F:transcription coactivator activity; IEA:InterPro.
DR   GO; GO:0010735; P:positive regulation of transcription via serum response element binding; IEA:InterPro.
DR   Gene3D; 1.10.720.30; -; 1.
DR   InterPro; IPR029992; MRTF-A.
DR   InterPro; IPR004018; RPEL_repeat.
DR   InterPro; IPR003034; SAP_dom.
DR   InterPro; IPR036361; SAP_dom_sf.
DR   PANTHER; PTHR22793:SF6; PTHR22793:SF6; 2.
DR   Pfam; PF02755; RPEL; 2.
DR   Pfam; PF02037; SAP; 1.
DR   SMART; SM00707; RPEL; 2.
DR   SMART; SM00513; SAP; 1.
DR   SUPFAM; SSF68906; SSF68906; 1.
DR   PROSITE; PS51073; RPEL; 2.
DR   PROSITE; PS50800; SAP; 1.
PE   1: Evidence at protein level;
KW   Coiled coil {ECO:0000256|SAM:Coils};
KW   Complete proteome {ECO:0000313|Proteomes:UP000005640};
KW   Proteomics identification {ECO:0000213|EPD:E7ER32,
KW   ECO:0000213|MaxQB:E7ER32, ECO:0000213|PeptideAtlas:E7ER32};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640}.
FT   REPEAT       24     49       RPEL. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00401}.
FT   REPEAT       68     93       RPEL. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00401}.
FT   DOMAIN      347    381       SAP. {ECO:0000259|PROSITE:PS50800}.
FT   COILED       56     76       {ECO:0000256|SAM:Coils}.
FT   COILED      527    561       {ECO:0000256|SAM:Coils}.
SQ   SEQUENCE   798 AA;  85077 MW;  85399B6F911EDCA7 CRC64;
     MPPLKSPAAF HEQRRSLERA RTEDYLKRKI RSRPERSELV RMHILEETSA EPSLQAKQLK
     LKRARLADDL NEKIAQRPGP MELVEKNILP VESSLKEAII VGQVNYPKVA DSSSFDEDSS
     DALSPEQPAS HESQGSVPSP LEARVSEPLL SATSASPTQV VSQLPMGRDS REMLFLAEQP
     PLPPPPLLPP SLTNGTTIPT AKSTPTLIKQ SQPKSASEKS QRSKKAKELK PKVKKLKYHQ
     YIPPDQKQDR GAPPMDSSYA KILQQQQLFL QLQILNQQQQ QHHNYQAILP APPKSAGEAL
     GSSGTPPVRS LSTTNSSSSS GAPGPCGLAR QNSTSLTGKP GALPANLDDM KVAELKQELK
     LRSLPVSGTK TELIERLRAY QDQISPVPGA PKAPAATSIL HKAGEVVVAF PAARLSTGPA
     LVAAGLAPAE VVVATVASSG VVKFGSTGST PPVSPTPSER SLLSTGDENS TPGDTFGEMV
     TSPLTQLTLQ ASPLQILVKE EGPRAGSCCL SPGGRAELEG RDKDQMLQEK DKQIEALTRM
     LRQKQQLVER LKLQLEQEKR AQQPAPAPAP LGTPVKQENS FSSCQLSQQP LGPAHPFNPS
     LAAPATNHID PCAVAPGPPS VVVKQEALQP EPEPVPAPQL LLGPQGPSLI KGVAPPTLIT
     DSTGTHLVLT VTNKNADSPG LSSGSPQQPS SQPGSPAPAP SAQMDLEHPL QPLFGTPTSL
     LKKEPPGYEE AMSQQPKQQE NGSSSQQMDD LFDILIQSGG NPRNFSRFQG AAIPAREGEA
     IPEDSLWVPP GSTAITFC
//
ID   MKL1_HUMAN              Reviewed;         931 AA.
AC   Q969V6; Q8TCL1; Q96SC5; Q96SC6; Q9P2B0;
DT   27-JUN-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   28-FEB-2018, entry version 160.
DE   RecName: Full=MKL/myocardin-like protein 1;
DE   AltName: Full=Megakaryoblastic leukemia 1 protein;
DE   AltName: Full=Megakaryocytic acute leukemia protein;
DE   AltName: Full=Myocardin-related transcription factor A;
DE            Short=MRTF-A;
GN   Name=MKL1; Synonyms=KIAA1438, MAL;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND CHROMOSOMAL TRANSLOCATION WITH RBM15.
RX   PubMed=11431691; DOI=10.1038/90054;
RA   Ma Z., Morris S.W., Valentine V., Li M., Herbrick J.-A., Cui X.,
RA   Bouman D., Li Y., Mehta P.K., Nizetic D., Kaneko Y., Chan G.C.F.,
RA   Chan L.C., Squire J., Scherer S.W., Hitzler J.K.;
RT   "Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of
RT   acute megakaryoblastic leukemia.";
RL   Nat. Genet. 28:220-221(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND CHROMOSOMAL TRANSLOCATION WITH RBM15.
RC   TISSUE=Blood;
RX   PubMed=11344311; DOI=10.1073/pnas.101001498;
RA   Mercher T., Coniat M.B.-L., Monni R., Mauchauffe M., Khac F.N.,
RA   Gressin L., Mugneret F., Leblanc T., Dastugue N., Berger R.,
RA   Bernard O.A.;
RT   "Involvement of a human gene related to the Drosophila spen gene in
RT   the recurrent t(1;22) translocation of acute megakaryocytic
RT   leukemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:5776-5779(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=10718198; DOI=10.1093/dnares/7.1.65;
RA   Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XVI.
RT   The complete sequences of 150 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 7:65-73(2000).
RN   [4]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT GLY-648.
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 195-931, AND VARIANT
RP   GLY-648.
RC   TISSUE=Testis;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-6, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-305 AND THR-450, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [11]
RP   INTERACTION WITH SCAI AND SRF, AND SUBCELLULAR LOCATION.
RX   PubMed=19350017; DOI=10.1038/ncb1862;
RA   Brandt D.T., Baarlink C., Kitzing T.M., Kremmer E., Ivaska J.,
RA   Nollau P., Grosse R.;
RT   "SCAI acts as a suppressor of cancer cell invasion through the
RT   transcriptional control of beta1-integrin.";
RL   Nat. Cell Biol. 11:557-568(2009).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-450 AND SER-454, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-6; THR-450 AND SER-454,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-156; SER-333; SER-385
RP   AND THR-450, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   SUBCELLULAR LOCATION.
RX   PubMed=24440334; DOI=10.1016/j.cell.2013.12.035;
RA   Lundquist M.R., Storaska A.J., Liu T.C., Larsen S.D., Evans T.,
RA   Neubig R.R., Jaffrey S.R.;
RT   "Redox modification of nuclear actin by MICAL-2 regulates SRF
RT   signaling.";
RL   Cell 156:563-576(2014).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-385, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   STRUCTURE BY NMR OF 336-396.
RG   Northeast structural genomics consortium (NESG);
RT   "Northeast structural genomics consortium target HR4547E.";
RL   Submitted (JUN-2010) to the PDB data bank.
CC   -!- FUNCTION: Transcriptional coactivator of serum response factor
CC       (SRF) with the potential to modulate SRF target genes. Suppresses
CC       TNF-induced cell death by inhibiting activation of caspases; its
CC       transcriptional activity is indispensable for the antiapoptotic
CC       function. It may up-regulate antiapoptotic molecules, which in
CC       turn inhibit caspase activation (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Forms with SCAI and SRF a nuclear ternary complex which
CC       binds the CArG consensus motif (CArG box) on DNA via SRF.
CC       Interacts with ACTB; interaction with ACTB prevents interaction
CC       with SCAI. Interacts with MKL2 (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       P11831:SRF; NbExp=2; IntAct=EBI-493122, EBI-493034;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:19350017,
CC       ECO:0000269|PubMed:24440334}. Cytoplasm {ECO:0000250}.
CC       Note=Binding to globular actin is required to maintain cytoplasmic
CC       localization. Nuclear localization is regulated by MICAL2, which
CC       mediates depolymerization of nuclear globular actin, promoting
CC       retention of MKL1 in the nucleus and subsequent formation of an
CC       active complex with SRF (PubMed:24440334).
CC       {ECO:0000269|PubMed:24440334}.
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed, has been detected in
CC       lung, placenta, small intestine, liver, kidney, spleen, thymus,
CC       colon, muscle, heart and brain.
CC   -!- DOMAIN: The N-terminal region is required for nuclear localization
CC       and the C-terminal region mediates transcriptional activity.
CC       {ECO:0000250}.
CC   -!- DOMAIN: The RPEL repeats mediate binding to globular actin.
CC       {ECO:0000250}.
CC   -!- DISEASE: Note=A chromosomal aberration involving MKL1 may be a
CC       cause of acute megakaryoblastic leukemia. Translocation
CC       t(1;22)(p13;q13) with RBM15. Although both reciprocal fusion
CC       transcripts are detected in acute megakaryoblastic leukemia (AMKL,
CC       FAB-M7), the RBM15-MKL1 chimeric protein has all the putative
CC       functional domains encoded by each gene and is the candidate
CC       oncogene.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAK56920.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=BAA92676.2; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=CAC38828.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=CAC38829.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MALID352.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ297257; CAC38826.1; -; mRNA.
DR   EMBL; AF364035; AAK56920.1; ALT_INIT; mRNA.
DR   EMBL; CR456522; CAG30408.1; -; mRNA.
DR   EMBL; AJ297258; CAC38827.1; -; mRNA.
DR   EMBL; AF368061; AAK54721.1; -; mRNA.
DR   EMBL; AJ303089; CAC38828.1; ALT_INIT; mRNA.
DR   EMBL; AJ303090; CAC38829.1; ALT_INIT; mRNA.
DR   EMBL; AB037859; BAA92676.2; ALT_INIT; mRNA.
DR   EMBL; AL022238; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL713710; CAD28507.2; -; mRNA.
DR   CCDS; CCDS14003.1; -.
DR   RefSeq; NP_001269589.1; NM_001282660.1.
DR   RefSeq; NP_001269590.1; NM_001282661.1.
DR   RefSeq; NP_065882.1; NM_020831.4.
DR   RefSeq; XP_005261751.1; XM_005261694.1.
DR   UniGene; Hs.654688; -.
DR   PDB; 2KVU; NMR; -; A=336-396.
DR   PDB; 2KW9; NMR; -; A=336-396.
DR   PDBsum; 2KVU; -.
DR   PDBsum; 2KW9; -.
DR   ProteinModelPortal; Q969V6; -.
DR   SMR; Q969V6; -.
DR   BioGrid; 121642; 23.
DR   IntAct; Q969V6; 12.
DR   MINT; Q969V6; -.
DR   STRING; 9606.ENSP00000347847; -.
DR   DrugBank; DB08080; LATRUNCULIN B.
DR   iPTMnet; Q969V6; -.
DR   PhosphoSitePlus; Q969V6; -.
DR   BioMuta; MKL1; -.
DR   DMDM; 32363202; -.
DR   EPD; Q969V6; -.
DR   MaxQB; Q969V6; -.
DR   PaxDb; Q969V6; -.
DR   PeptideAtlas; Q969V6; -.
DR   PRIDE; Q969V6; -.
DR   DNASU; 57591; -.
DR   Ensembl; ENST00000355630; ENSP00000347847; ENSG00000196588.
DR   Ensembl; ENST00000407029; ENSP00000385835; ENSG00000196588.
DR   GeneID; 57591; -.
DR   KEGG; hsa:57591; -.
DR   UCSC; uc003ayv.3; human.
DR   CTD; 57591; -.
DR   DisGeNET; 57591; -.
DR   EuPathDB; HostDB:ENSG00000196588.14; -.
DR   GeneCards; MKL1; -.
DR   HGNC; HGNC:14334; MKL1.
DR   HPA; HPA030782; -.
DR   MalaCards; MKL1; -.
DR   MIM; 606078; gene.
DR   neXtProt; NX_Q969V6; -.
DR   OpenTargets; ENSG00000196588; -.
DR   Orphanet; 402023; 'Megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13)'.
DR   PharmGKB; PA30827; -.
DR   eggNOG; ENOG410IFJX; Eukaryota.
DR   eggNOG; ENOG41101AM; LUCA.
DR   GeneTree; ENSGT00530000063195; -.
DR   HOGENOM; HOG000038001; -.
DR   HOVERGEN; HBG036493; -.
DR   InParanoid; Q969V6; -.
DR   PhylomeDB; Q969V6; -.
DR   TreeFam; TF326024; -.
DR   Reactome; R-HSA-5663220; RHO GTPases Activate Formins.
DR   SIGNOR; Q969V6; -.
DR   ChiTaRS; MKL1; human.
DR   EvolutionaryTrace; Q969V6; -.
DR   GeneWiki; MKL1; -.
DR   GenomeRNAi; 57591; -.
DR   PRO; PR:Q969V6; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   Bgee; ENSG00000196588; -.
DR   CleanEx; HS_MAL; -.
DR   CleanEx; HS_MKL1; -.
DR   ExpressionAtlas; Q969V6; baseline and differential.
DR   Genevisible; Q969V6; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0003779; F:actin binding; IDA:UniProtKB.
DR   GO; GO:0003785; F:actin monomer binding; ISS:UniProtKB.
DR   GO; GO:0043522; F:leucine zipper domain binding; IPI:BHF-UCL.
DR   GO; GO:0001105; F:RNA polymerase II transcription coactivator activity; IBA:GO_Central.
DR   GO; GO:0003713; F:transcription coactivator activity; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0010735; P:positive regulation of transcription via serum response element binding; IDA:UniProtKB.
DR   GO; GO:0051145; P:smooth muscle cell differentiation; IMP:BHF-UCL.
DR   Gene3D; 1.10.720.30; -; 1.
DR   InterPro; IPR029992; MRTF-A.
DR   InterPro; IPR004018; RPEL_repeat.
DR   InterPro; IPR003034; SAP_dom.
DR   InterPro; IPR036361; SAP_dom_sf.
DR   PANTHER; PTHR22793:SF6; PTHR22793:SF6; 2.
DR   Pfam; PF02755; RPEL; 2.
DR   Pfam; PF02037; SAP; 1.
DR   SMART; SM00707; RPEL; 2.
DR   SMART; SM00513; SAP; 1.
DR   SUPFAM; SSF68906; SSF68906; 1.
DR   PROSITE; PS51073; RPEL; 2.
DR   PROSITE; PS50800; SAP; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Actin-binding; Chromosomal rearrangement; Coiled coil;
KW   Complete proteome; Cytoplasm; Nucleus; Phosphoprotein; Polymorphism;
KW   Proto-oncogene; Reference proteome; Repeat; Transcription;
KW   Transcription regulation.
FT   CHAIN         1    931       MKL/myocardin-like protein 1.
FT                                /FTId=PRO_0000126625.
FT   REPEAT       24     49       RPEL 1.
FT   REPEAT       68     93       RPEL 2.
FT   DOMAIN      347    381       SAP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00186}.
FT   REGION        1    256       Mediates interaction with SCAI and ACTB.
FT                                {ECO:0000250}.
FT   COILED      515    563       {ECO:0000255}.
FT   COMPBIAS    264    286       Gln-rich.
FT   COMPBIAS    564    811       Pro-rich.
FT   SITE          3      4       Breakpoint for translocation to form
FT                                RBM15-MKL1.
FT   MOD_RES       6      6       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:21406692}.
FT   MOD_RES     156    156       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     305    305       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     333    333       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     385    385       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     450    450       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     454    454       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692}.
FT   VARIANT     648    648       S -> G (in dbSNP:rs878756).
FT                                {ECO:0000269|PubMed:15461802,
FT                                ECO:0000269|PubMed:17974005}.
FT                                /FTId=VAR_021409.
FT   TURN        345    349       {ECO:0000244|PDB:2KVU}.
FT   HELIX       352    361       {ECO:0000244|PDB:2KVU}.
FT   HELIX       370    382       {ECO:0000244|PDB:2KVU}.
FT   STRAND      388    390       {ECO:0000244|PDB:2KVU}.
FT   STRAND      392    394       {ECO:0000244|PDB:2KW9}.
SQ   SEQUENCE   931 AA;  98919 MW;  6EDE5E2C56D89609 CRC64;
     MPPLKSPAAF HEQRRSLERA RTEDYLKRKI RSRPERSELV RMHILEETSA EPSLQAKQLK
     LKRARLADDL NEKIAQRPGP MELVEKNILP VESSLKEAII VGQVNYPKVA DSSSFDEDSS
     DALSPEQPAS HESQGSVPSP LEARVSEPLL SATSASPTQV VSQLPMGRDS REMLFLAEQP
     PLPPPPLLPP SLTNGTTIPT AKSTPTLIKQ SQPKSASEKS QRSKKAKELK PKVKKLKYHQ
     YIPPDQKQDR GAPPMDSSYA KILQQQQLFL QLQILNQQQQ QHHNYQAILP APPKSAGEAL
     GSSGTPPVRS LSTTNSSSSS GAPGPCGLAR QNSTSLTGKP GALPANLDDM KVAELKQELK
     LRSLPVSGTK TELIERLRAY QDQISPVPGA PKAPAATSIL HKAGEVVVAF PAARLSTGPA
     LVAAGLAPAE VVVATVASSG VVKFGSTGST PPVSPTPSER SLLSTGDENS TPGDTFGEMV
     TSPLTQLTLQ ASPLQILVKE EGPRAGSCCL SPGGRAELEG RDKDQMLQEK DKQIEALTRM
     LRQKQQLVER LKLQLEQEKR AQQPAPAPAP LGTPVKQENS FSSCQLSQQP LGPAHPFNPS
     LAAPATNHID PCAVAPGPPS VVVKQEALQP EPEPVPAPQL LLGPQGPSLI KGVAPPTLIT
     DSTGTHLVLT VTNKNADSPG LSSGSPQQPS SQPGSPAPAP SAQMDLEHPL QPLFGTPTSL
     LKKEPPGYEE AMSQQPKQQE NGSSSQQMDD LFDILIQSGE ISADFKEPPS LPGKEKPSPK
     TVCGSPLAAQ PSPSAELPQA APPPPGSPSL PGRLEDFLES STGLPLLTSG HDGPEPLSLI
     DDLHSQMLSS TAILDHPPSP MDTSELHFVP EPSSTMGLDL ADGHLDSMDW LELSSGGPVL
     SLAPLSTTAP SLFSTDFLDG HDLQLHWDSC L
//
ID   W0Z7M9_HUMAN            Unreviewed;       966 AA.
AC   W0Z7M9;
DT   19-MAR-2014, integrated into UniProtKB/TrEMBL.
DT   19-MAR-2014, sequence version 1.
DT   28-FEB-2018, entry version 39.
DE   SubName: Full=MKL/myocardin-like protein 1 {ECO:0000313|Ensembl:ENSP00000479510};
DE   SubName: Full=Mkl1 variant 1 Mkl1_S {ECO:0000313|EMBL:CDJ79779.1};
GN   Name=MKL1 {ECO:0000313|Ensembl:ENSP00000479510};
GN   Synonyms=mkl1 {ECO:0000313|EMBL:CDJ79779.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:CDJ79779.1};
RN   [1] {ECO:0000313|Ensembl:ENSP00000479510, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10591208; DOI=10.1038/990031;
RA   Dunham I., Hunt A.R., Collins J.E., Bruskiewich R., Beare D.M.,
RA   Clamp M., Smink L.J., Ainscough R., Almeida J.P., Babbage A.K.,
RA   Bagguley C., Bailey J., Barlow K.F., Bates K.N., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Buck D., Burgess J.,
RA   Burrill W.D., Burton J., Carder C., Carter N.P., Chen Y., Clark G.,
RA   Clegg S.M., Cobley V.E., Cole C.G., Collier R.E., Connor R.,
RA   Conroy D., Corby N.R., Coville G.J., Cox A.V., Davis J., Dawson E.,
RA   Dhami P.D., Dockree C., Dodsworth S.J., Durbin R.M., Ellington A.G.,
RA   Evans K.L., Fey J.M., Fleming K., French L., Garner A.A.,
RA   Gilbert J.G.R., Goward M.E., Grafham D.V., Griffiths M.N.D., Hall C.,
RA   Hall R.E., Hall-Tamlyn G., Heathcott R.W., Ho S., Holmes S.,
RA   Hunt S.E., Jones M.C., Kershaw J., Kimberley A.M., King A.,
RA   Laird G.K., Langford C.F., Leversha M.A., Lloyd C., Lloyd D.M.,
RA   Martyn I.D., Mashreghi-Mohammadi M., Matthews L.H., Mccann O.T.,
RA   Mcclay J., Mclaren S., McMurray A.A., Milne S.A., Mortimore B.J.,
RA   Odell C.N., Pavitt R., Pearce A.V., Pearson D., Phillimore B.J.C.T.,
RA   Phillips S.H., Plumb R.W., Ramsay H., Ramsey Y., Rogers L., Ross M.T.,
RA   Scott C.E., Sehra H.K., Skuce C.D., Smalley S., Smith M.L.,
RA   Soderlund C., Spragon L., Steward C.A., Sulston J.E., Swann R.M.,
RA   Vaudin M., Wall M., Wallis J.M., Whiteley M.N., Willey D.L.,
RA   Williams L., Williams S.A., Williamson H., Wilmer T.E., Wilming L.,
RA   Wright C.L., Hubbard T., Bentley D.R., Beck S., Rogers J., Shimizu N.,
RA   Minoshima S., Kawasaki K., Sasaki T., Asakawa S., Kudoh J.,
RA   Shintani A., Shibuya K., Yoshizaki Y., Aoki N., Mitsuyama S.,
RA   Roe B.A., Chen F., Chu L., Crabtree J., Deschamps S., Do A., Do T.,
RA   Dorman A., Fang F., Fu Y., Hu P., Hua A., Kenton S., Lai H., Lao H.I.,
RA   Lewis J., Lewis S., Lin S.-P., Loh P., Malaj E., Nguyen T., Pan H.,
RA   Phan S., Qi S., Qian Y., Ray L., Ren Q., Shaull S., Sloan D., Song L.,
RA   Wang Q., Wang Y., Wang Z., White J., Willingham D., Wu H., Yao Z.,
RA   Zhan M., Zhang G., Chissoe S., Murray J., Miller N., Minx P.,
RA   Fulton R., Johnson D., Bemis G., Bentley D., Bradshaw H., Bourne S.,
RA   Cordes M., Du Z., Fulton L., Goela D., Graves T., Hawkins J.,
RA   Hinds K., Kemp K., Latreille P., Layman D., Ozersky P., Rohlfing T.,
RA   Scheet P., Walker C., Wamsley A., Wohldmann P., Pepin K., Nelson J.,
RA   Korf I., Bedell J.A., Hillier L.W., Mardis E., Waterston R.,
RA   Wilson R., Emanuel B.S., Shaikh T., Kurahashi H., Saitta S.,
RA   Budarf M.L., McDermid H.E., Johnson A., Wong A.C.C., Morrow B.E.,
RA   Edelmann L., Kim U.J., Shizuya H., Simon M.I., Dumanski J.P.,
RA   Peyrard M., Kedra D., Seroussi E., Fransson I., Tapia I., Bruder C.E.,
RA   O'Brien K.P., Wilkinson P., Bodenteich A., Hartman K., Hu X.,
RA   Khan A.S., Lane L., Tilahun Y., Wright H.;
RT   "The DNA sequence of human chromosome 22.";
RL   Nature 402:489-495(1999).
RN   [2] {ECO:0000213|PubMed:17081983}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [3] {ECO:0000213|PubMed:18669648}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [4] {ECO:0000213|PubMed:19413330}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [5] {ECO:0000213|PubMed:19690332}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:ra46-RA46(2009).
RN   [6] {ECO:0000213|PubMed:20068231}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:ra3-RA3(2010).
RN   [7] {ECO:0000213|PubMed:21406692}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:rs3-RS3(2011).
RN   [8] {ECO:0000213|PubMed:23186163}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=23186163;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [9] {ECO:0000313|EMBL:CDJ79779.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Brain {ECO:0000313|EMBL:CDJ79779.1};
RA   Scharenberg M.A., Pippenger B.E., Sack R., Zingg D., Schenk S.,
RA   Ferralli J., Martin I., Chiquet-Ehrismann R.;
RT   "TGF-beta-induced differentiation into myofibroblasts involves
RT   specific regulation of two MKL1 isoforms.";
RL   Submitted (OCT-2013) to the EMBL/GenBank/DDBJ databases.
RN   [10] {ECO:0000213|PubMed:24275569}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [11] {ECO:0000313|Ensembl:ENSP00000479510}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (SEP-2014) to UniProtKB.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AL022238; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL031594; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF457470; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; Z86090; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; HG764171; CDJ79779.1; -; mRNA.
DR   RefSeq; NP_001305068.1; NM_001318139.1.
DR   UniGene; Hs.654688; -.
DR   PeptideAtlas; W0Z7M9; -.
DR   Ensembl; ENST00000618196; ENSP00000479510; ENSG00000196588.
DR   GeneID; 57591; -.
DR   UCSC; uc032qph.2; human.
DR   CTD; 57591; -.
DR   EuPathDB; HostDB:ENSG00000196588.14; -.
DR   HGNC; HGNC:14334; MKL1.
DR   OpenTargets; ENSG00000196588; -.
DR   eggNOG; ENOG410IFJX; Eukaryota.
DR   eggNOG; ENOG41101AM; LUCA.
DR   GeneTree; ENSGT00530000063195; -.
DR   OMA; AQMDLEH; -.
DR   OrthoDB; EOG091G01ZY; -.
DR   ChiTaRS; MKL1; human.
DR   GenomeRNAi; 57591; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   Bgee; ENSG00000196588; -.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003785; F:actin monomer binding; IEA:Ensembl.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IEA:Ensembl.
DR   GO; GO:0003713; F:transcription coactivator activity; IEA:Ensembl.
DR   GO; GO:0000976; F:transcription regulatory region sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0030036; P:actin cytoskeleton organization; IEA:Ensembl.
DR   GO; GO:0030900; P:forebrain development; IEA:Ensembl.
DR   GO; GO:2001234; P:negative regulation of apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IEA:Ensembl.
DR   GO; GO:0001764; P:neuron migration; IEA:Ensembl.
DR   GO; GO:0031175; P:neuron projection development; IEA:Ensembl.
DR   GO; GO:0010735; P:positive regulation of transcription via serum response element binding; IEA:InterPro.
DR   Gene3D; 1.10.720.30; -; 1.
DR   InterPro; IPR029992; MRTF-A.
DR   InterPro; IPR004018; RPEL_repeat.
DR   InterPro; IPR003034; SAP_dom.
DR   InterPro; IPR036361; SAP_dom_sf.
DR   PANTHER; PTHR22793:SF6; PTHR22793:SF6; 2.
DR   Pfam; PF02755; RPEL; 3.
DR   Pfam; PF02037; SAP; 1.
DR   SMART; SM00707; RPEL; 3.
DR   SMART; SM00513; SAP; 1.
DR   SUPFAM; SSF68906; SSF68906; 1.
DR   PROSITE; PS51073; RPEL; 3.
DR   PROSITE; PS50800; SAP; 1.
PE   1: Evidence at protein level;
KW   Coiled coil {ECO:0000256|SAM:Coils};
KW   Complete proteome {ECO:0000313|Proteomes:UP000005640};
KW   Proteomics identification {ECO:0000213|EPD:W0Z7M9,
KW   ECO:0000213|MaxQB:W0Z7M9, ECO:0000213|PeptideAtlas:W0Z7M9};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640}.
FT   REPEAT       15     40       RPEL. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00401}.
FT   REPEAT       59     84       RPEL. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00401}.
FT   REPEAT      103    128       RPEL. {ECO:0000256|PROSITE-
FT                                ProRule:PRU00401}.
FT   DOMAIN      382    416       SAP. {ECO:0000259|PROSITE:PS50800}.
FT   COILED       91    111       {ECO:0000256|SAM:Coils}.
FT   COILED      562    596       {ECO:0000256|SAM:Coils}.
SQ   SEQUENCE   966 AA;  103002 MW;  375B00BFFC7536B4 CRC64;
     MTLLEPEMLM MAVQSVLQLK LQQRRTREEL VSQGIMPPLK SPAAFHEQRR SLERARTEDY
     LKRKIRSRPE RSELVRMHIL EETSAEPSLQ AKQLKLKRAR LADDLNEKIA QRPGPMELVE
     KNILPVESSL KEAIIVGQVN YPKVADSSSF DEDSSDALSP EQPASHESQG SVPSPLEARV
     SEPLLSATSA SPTQVVSQLP MGRDSREMLF LAEQPPLPPP PLLPPSLTNG TTIPTAKSTP
     TLIKQSQPKS ASEKSQRSKK AKELKPKVKK LKYHQYIPPD QKQDRGAPPM DSSYAKILQQ
     QQLFLQLQIL NQQQQQHHNY QAILPAPPKS AGEALGSSGT PPVRSLSTTN SSSSSGAPGP
     CGLARQNSTS LTGKPGALPA NLDDMKVAEL KQELKLRSLP VSGTKTELIE RLRAYQDQIS
     PVPGAPKAPA ATSILHKAGE VVVAFPAARL STGPALVAAG LAPAEVVVAT VASSGVVKFG
     STGSTPPVSP TPSERSLLST GDENSTPGDT FGEMVTSPLT QLTLQASPLQ ILVKEEGPRA
     GSCCLSPGGR AELEGRDKDQ MLQEKDKQIE ALTRMLRQKQ QLVERLKLQL EQEKRAQQPA
     PAPAPLGTPV KQENSFSSCQ LSQQPLGPAH PFNPSLAAPA TNHIDPCAVA PGPPSVVVKQ
     EALQPEPEPV PAPQLLLGPQ GPSLIKGVAP PTLITDSTGT HLVLTVTNKN ADSPGLSSGS
     PQQPSSQPGS PAPAPSAQMD LEHPLQPLFG TPTSLLKKEP PGYEEAMSQQ PKQQENGSSS
     QQMDDLFDIL IQSGEISADF KEPPSLPGKE KPSPKTVCGS PLAAQPSPSA ELPQAAPPPP
     GSPSLPGRLE DFLESSTGLP LLTSGHDGPE PLSLIDDLHS QMLSSTAILD HPPSPMDTSE
     LHFVPEPSST MGLDLADGHL DSMDWLELSS GGPVLSLAPL STTAPSLFST DFLDGHDLQL
     HWDSCL
//
ID   NFKB2_HUMAN             Reviewed;         900 AA.
AC   Q00653; A8K9D9; D3DR83; Q04860; Q9BU75; Q9H471; Q9H472;
DT   01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 4.
DT   28-FEB-2018, entry version 220.
DE   RecName: Full=Nuclear factor NF-kappa-B p100 subunit;
DE   AltName: Full=DNA-binding factor KBF2;
DE   AltName: Full=H2TF1;
DE   AltName: Full=Lymphocyte translocation chromosome 10 protein;
DE   AltName: Full=Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2;
DE   AltName: Full=Oncogene Lyt-10;
DE            Short=Lyt10;
DE   Contains:
DE     RecName: Full=Nuclear factor NF-kappa-B p52 subunit;
GN   Name=NFKB2; Synonyms=LYT10;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 4).
RC   TISSUE=Leukemia;
RX   PubMed=1876189; DOI=10.1038/352733a0;
RA   Schmid R.M., Perkins N.D., Duckett C.S., Andrews P.C., Nabel G.J.;
RT   "Cloning of an NF-kappa B subunit which stimulates HIV transcription
RT   in synergy with p65.";
RL   Nature 352:733-736(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1531086; DOI=10.1128/MCB.12.2.685;
RA   Bours V., Burd P.R., Brown K., Villalobos J., Park S., Ryseck R.P.,
RA   Bravo R., Kelly K., Siebenlist U.;
RT   "A novel mitogen-inducible gene product related to p50/p105-NF-kappa B
RT   participates in transactivation through a kappa B site.";
RL   Mol. Cell. Biol. 12:685-695(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], CHROMOSOMAL TRANSLOCATION, AND P80HT
RP   GENERATION.
RX   PubMed=8036016;
RA   Thakur S., Lin H.C., Tseng W.T., Kumar S., Bravo R., Foss F.,
RA   Gelinas C., Rabson A.B.;
RT   "Rearrangement and altered expression of the NFKB-2 gene in human
RT   cutaneous T-lymphoma cells.";
RL   Oncogene 9:2335-2344(1994).
RN   [4]
RP   SEQUENCE REVISION.
RA   Rabson A.B.;
RL   Submitted (FEB-2006) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LYS-14; ARG-351 AND
RP   ARG-452.
RG   NIEHS SNPs program;
RL   Submitted (DEC-2004) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-220.
RX   PubMed=7969113; DOI=10.1128/MCB.14.12.7695;
RA   Liptay S., Schmid R.M., Nabel E.G., Nabel G.J.;
RT   "Transcriptional regulation of NF-kappa B2: evidence for kappa B-
RT   mediated positive and negative autoregulation.";
RL   Mol. Cell. Biol. 14:7695-7703(1994).
RN   [12]
RP   PROTEIN SEQUENCE OF 459-470; 580-597 AND 636-647 (ISOFORM 1).
RX   PubMed=8360178;
RA   Potter D.A., Larson C.J., Eckes P., Schmid R.M., Nabel G.J.,
RA   Verdine G.L., Sharp P.A.;
RT   "Purification of the major histocompatibility complex class I
RT   transcription factor H2TF1. The full-length product of the nfkb2
RT   gene.";
RL   J. Biol. Chem. 268:18882-18890(1993).
RN   [13]
RP   IDENTIFICATION IN A COMPLEX WITH BCL3.
RX   PubMed=8453667; DOI=10.1016/0092-8674(93)90401-B;
RA   Bours V., Franzoso G., Azarenko V., Park S., Kanno T., Brown K.,
RA   Siebenlist U.;
RT   "The oncoprotein Bcl-3 directly transactivates through kappa B motifs
RT   via association with DNA-binding p50B homodimers.";
RL   Cell 72:729-739(1993).
RN   [14]
RP   FUNCTION, AND IDENTIFICATION IN THE NF-KAPPA-B RELB-P52 COMPLEX.
RX   PubMed=7925301;
RA   Dobrzanski P., Ryseck R.P., Bravo R.;
RT   "Differential interactions of Rel-NF-kappa B complexes with I kappa B
RT   alpha determine pools of constitutive and inducible NF-kappa B
RT   activity.";
RL   EMBO J. 13:4608-4616(1994).
RN   [15]
RP   IDENTIFICATION IN THE NF-KAPPA-B P52-C-REL COMPLEX, AND IDENTIFICATION
RP   IN THE NF-KAPPA-B P65-P52 COMPLEX.
RX   PubMed=8152812;
RA   Beg A.A., Baldwin A.S. Jr.;
RT   "Activation of multiple NF-kappa B/Rel DNA-binding complexes by tumor
RT   necrosis factor.";
RL   Oncogene 9:1487-1492(1994).
RN   [16]
RP   INTERACTION WITH NFKBIE.
RX   PubMed=9315679; DOI=10.1128/MCB.17.10.6184;
RA   Li Z., Nabel G.J.;
RT   "A new member of the IkappaB protein family, IkappaB epsilon, inhibits
RT   RelA (p65)-mediated NF-kappaB transcription.";
RL   Mol. Cell. Biol. 17:6184-6190(1997).
RN   [17]
RP   COTRANSLATIONAL FOLDING/PROCESSING OF P100, AND GENERATION OF
RP   P52/P100.
RX   PubMed=10597218; DOI=10.1038/sj.onc.1203022;
RA   Heusch M., Lin L., Geleziunas R., Greene W.C.;
RT   "The generation of nfkb2 p52: mechanism and efficiency.";
RL   Oncogene 18:6201-6208(1999).
RN   [18]
RP   PHOSPHORYLATION AT SER-713; SER-715 AND SER-717, MUTAGENESIS,
RP   DIMERIZATION, AND PROTEOLYTIC PROCESSING OF P100.
RX   PubMed=8887665; DOI=10.1128/MCB.16.11.6363;
RA   Betts J.C., Nabel G.J.;
RT   "Differential regulation of NF-kappaB2(p100) processing and control by
RT   amino-terminal sequences.";
RL   Mol. Cell. Biol. 16:6363-6371(1996).
RN   [19]
RP   PHOSPHORYLATION AT SER-866 AND SER-870, MUTAGENESIS OF SER-866 AND
RP   SER-870, AND PROTEOLYTIC PROCESSING OF P100.
RX   PubMed=11239468; DOI=10.1016/S1097-2765(01)00187-3;
RA   Xiao G., Harhaj E.W., Sun S.-C.;
RT   "NF-kappaB-inducing kinase regulates the processing of NF-kappaB2
RT   p100.";
RL   Mol. Cell 7:401-409(2001).
RN   [20]
RP   CHROMOSOMAL TRANSLOCATION WITH IGHA1.
RX   PubMed=1760839; DOI=10.1016/0092-8674(91)90285-7;
RA   Neri A., Chang C.C., Lombardi L., Salina M., Corradini P.,
RA   Maiolo A.T., Chaganti R.S., Dalla-Favera R.;
RT   "B cell lymphoma-associated chromosomal translocation involves
RT   candidate oncogene lyt-10, homologous to NF-kappa B p50.";
RL   Cell 67:1075-1087(1991).
RN   [21]
RP   CHROMOSOMAL ABERRATIONS, AND GENERATION OF LB40 AND EB308.
RX   PubMed=7949142;
RA   Migliazza A., Lombardi L., Rocchi M., Trecca D., Chang C.-C.,
RA   Antonacci R., Fracchiolla N.S., Ciana P., Maiolo A.T., Neri A.;
RT   "Heterogeneous chromosomal aberrations generate 3' truncations of the
RT   NFKB2/lyt-10 gene in lymphoid malignancies.";
RL   Blood 84:3850-3860(1994).
RN   [22]
RP   CHARACTERIZATION OF THE TWO PROMOTER REGIONS.
RX   PubMed=7541912; DOI=10.1093/nar/23.12.2328;
RA   Lombardi L., Ciana P., Cappellini C., Trecca D., Guerrini L.,
RA   Migliazza A., Maiolo A.T., Neri A.;
RT   "Structural and functional characterization of the promoter regions of
RT   the NFKB2 gene.";
RL   Nucleic Acids Res. 23:2328-2336(1995).
RN   [23]
RP   INTERACTION WITH MEN1.
RX   PubMed=11526476; DOI=10.1038/sj.onc.1204529;
RA   Heppner C., Bilimoria K.Y., Agarwal S.K., Kester M., Whitty L.J.,
RA   Guru S.C., Chandrasekharappa S.C., Collins F.S., Spiegel A.M.,
RA   Marx S.J., Burns A.L.;
RT   "The tumor suppressor protein menin interacts with NF-kappaB proteins
RT   and inhibits NF-kappaB-mediated transactivation.";
RL   Oncogene 20:4917-4925(2001).
RN   [24]
RP   UBIQUITINATION AT LYS-855.
RX   PubMed=14676825; DOI=10.1038/sj.onc.1207366;
RA   Amir R.E., Haecker H., Karin M., Ciechanover A.;
RT   "Mechanism of processing of the NF-kappa B2 p100 precursor:
RT   identification of the specific polyubiquitin chain-anchoring lysine
RT   residue and analysis of the role of NEDD8-modification on the
RT   SCF(beta-TrCP) ubiquitin ligase.";
RL   Oncogene 23:2540-2547(2004).
RN   [25]
RP   IDENTIFICATION IN THE NF-KAPPA-B P65-P52 COMPLEX.
RX   PubMed=16477006; DOI=10.1073/pnas.0511096103;
RA   Song Y.J., Jen K.Y., Soni V., Kieff E., Cahir-McFarland E.;
RT   "IL-1 receptor-associated kinase 1 is critical for latent membrane
RT   protein 1-induced p65/RelA serine 536 phosphorylation and NF-kappaB
RT   activation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:2689-2694(2006).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-429, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-23; SER-161 AND SER-812,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [30]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 37-327.
RX   PubMed=9384586; DOI=10.1093/emboj/16.23.7078;
RA   Cramer P., Larson C.J., Verdine G.L., Mueller C.W.;
RT   "Structure of the human NF-kappaB p52 homodimer-DNA complex at 2.1-A
RT   resolution.";
RL   EMBO J. 16:7078-7090(1997).
RN   [32]
RP   STRUCTURE BY NMR OF 764-859.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the death domain of nuclear factor NF-kappa-B
RT   p100.";
RL   Submitted (DEC-2006) to the PDB data bank.
RN   [33]
RP   INVOLVEMENT IN CVID10.
RX   PubMed=24140114; DOI=10.1016/j.ajhg.2013.09.009;
RA   Chen K., Coonrod E.M., Kumanovics A., Franks Z.F., Durtschi J.D.,
RA   Margraf R.L., Wu W., Heikal N.M., Augustine N.H., Ridge P.G.,
RA   Hill H.R., Jorde L.B., Weyrich A.S., Zimmerman G.A., Gundlapalli A.V.,
RA   Bohnsack J.F., Voelkerding K.V.;
RT   "Germline mutations in NFKB2 implicate the noncanonical NF-kappaB
RT   pathway in the pathogenesis of common variable immunodeficiency.";
RL   Am. J. Hum. Genet. 93:812-824(2013).
RN   [34]
RP   VARIANTS CVID10 GLY-865 AND VAL-867.
RX   PubMed=25524009; DOI=10.1186/s12881-014-0139-9;
RA   Brue T., Quentien M.H., Khetchoumian K., Bensa M., Capo-Chichi J.M.,
RA   Delemer B., Balsalobre A., Nassif C., Papadimitriou D.T., Pagnier A.,
RA   Hasselmann C., Patry L., Schwartzentruber J., Souchon P.F.,
RA   Takayasu S., Enjalbert A., Van Vliet G., Majewski J., Drouin J.,
RA   Samuels M.E.;
RT   "Mutations in NFKB2 and potential genetic heterogeneity in patients
RT   with DAVID syndrome, having variable endocrine and immune
RT   deficiencies.";
RL   BMC Med. Genet. 15:139-139(2014).
CC   -!- FUNCTION: NF-kappa-B is a pleiotropic transcription factor present
CC       in almost all cell types and is the endpoint of a series of signal
CC       transduction events that are initiated by a vast array of stimuli
CC       related to many biological processes such as inflammation,
CC       immunity, differentiation, cell growth, tumorigenesis and
CC       apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed
CC       by the Rel-like domain-containing proteins RELA/p65, RELB,
CC       NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at
CC       kappa-B sites in the DNA of their target genes and the individual
CC       dimers have distinct preferences for different kappa-B sites that
CC       they can bind with distinguishable affinity and specificity.
CC       Different dimer combinations act as transcriptional activators or
CC       repressors, respectively. NF-kappa-B is controlled by various
CC       mechanisms of post-translational modification and subcellular
CC       compartmentalization as well as by interactions with other
CC       cofactors or corepressors. NF-kappa-B complexes are held in the
CC       cytoplasm in an inactive state complexed with members of the NF-
CC       kappa-B inhibitor (I-kappa-B) family. In a conventional activation
CC       pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs)
CC       in response to different activators, subsequently degraded thus
CC       liberating the active NF-kappa-B complex which translocates to the
CC       nucleus. In a non-canonical activation pathway, the MAP3K14-
CC       activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated
CC       with RelB, inducing its proteolytic processing to NFKB2/p52 and
CC       the formation of NF-kappa-B RelB-p52 complexes. The NF-kappa-B
CC       heterodimeric RelB-p52 complex is a transcriptional activator. The
CC       NF-kappa-B p52-p52 homodimer is a transcriptional repressor. NFKB2
CC       appears to have dual functions such as cytoplasmic retention of
CC       attached NF-kappa-B proteins by p100 and generation of p52 by a
CC       cotranslational processing. The proteasome-mediated process
CC       ensures the production of both p52 and p100 and preserves their
CC       independent function. p52 binds to the kappa-B consensus sequence
CC       5'-GGRNNYYCC-3', located in the enhancer region of genes involved
CC       in immune response and acute phase reactions. p52 and p100 are
CC       respectively the minor and major form; the processing of p100
CC       being relatively poor. Isoform p49 is a subunit of the NF-kappa-B
CC       protein complex, which stimulates the HIV enhancer in synergy with
CC       p65. In concert with RELB, regulates the circadian clock by
CC       repressing the transcriptional activator activity of the CLOCK-
CC       ARNTL/BMAL1 heterodimer. {ECO:0000269|PubMed:7925301}.
CC   -!- SUBUNIT: Component of the NF-kappa-B RelB-p52 complex. Homodimer;
CC       component of the NF-kappa-B p52-p52 complex. Component of the NF-
CC       kappa-B p65-p52 complex. Component of the NF-kappa-B p52-c-Rel
CC       complex. NFKB2/p52 interacts with NFKBIE. Component of a complex
CC       consisting of the NF-kappa-B p50-p50 homodimer and BCL3. Directly
CC       interacts with MEN1. {ECO:0000269|PubMed:11526476,
CC       ECO:0000269|PubMed:16477006, ECO:0000269|PubMed:7925301,
CC       ECO:0000269|PubMed:8152812, ECO:0000269|PubMed:8453667,
CC       ECO:0000269|PubMed:9315679}.
CC   -!- INTERACTION:
CC       P41279:MAP3K8; NbExp=2; IntAct=EBI-307326, EBI-354900;
CC       O00255-2:MEN1; NbExp=3; IntAct=EBI-9869360, EBI-9869387;
CC       P19838:NFKB1; NbExp=6; IntAct=EBI-307326, EBI-300010;
CC       P63165:SUMO1; NbExp=2; IntAct=EBI-307326, EBI-80140;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasm. Note=Nuclear, but also
CC       found in the cytoplasm in an inactive form complexed to an
CC       inhibitor (I-kappa-B).
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=p100;
CC         IsoId=Q00653-1; Sequence=Displayed;
CC       Name=3; Synonyms=p49;
CC         IsoId=Q00653-3; Sequence=VSP_040082, VSP_040083;
CC         Note=Ref.1 (CAA43716.1) sequence(s) differ(s) from that shown
CC         due to frameshifts in positions 407, 414.;
CC       Name=4;
CC         IsoId=Q00653-4; Sequence=VSP_040084;
CC   -!- DOMAIN: The C-terminus of p100 might be involved in cytoplasmic
CC       retention, inhibition of DNA-binding by p52 homodimers, and/or
CC       transcription activation. {ECO:0000250}.
CC   -!- DOMAIN: The glycine-rich region (GRR) appears to be a critical
CC       element in the generation of p52.
CC   -!- PTM: While translation occurs, the particular unfolded structure
CC       after the GRR repeat promotes the generation of p52 making it an
CC       acceptable substrate for the proteasome. This process is known as
CC       cotranslational processing. The processed form is active and the
CC       unprocessed form acts as an inhibitor (I kappa B-like), being able
CC       to form cytosolic complexes with NF-kappa B, trapping it in the
CC       cytoplasm. Complete folding of the region downstream of the GRR
CC       repeat precludes processing.
CC   -!- PTM: Subsequent to MAP3K14-dependent serine phosphorylation, p100
CC       polyubiquitination occurs then triggering its proteasome-dependent
CC       processing. {ECO:0000269|PubMed:11239468,
CC       ECO:0000269|PubMed:14676825, ECO:0000269|PubMed:8887665}.
CC   -!- PTM: Constitutive processing is tightly suppressed by its C-
CC       terminal processing inhibitory domain, named PID, which contains
CC       the death domain.
CC   -!- DISEASE: Note=A chromosomal aberration involving NFKB2 is found in
CC       a case of B-cell non Hodgkin lymphoma (B-NHL). Translocation
CC       t(10;14)(q24;q32) with IGHA1. The resulting oncogene is also
CC       called Lyt-10C alpha variant.
CC   -!- DISEASE: Note=A chromosomal aberration involving NFKB2 is found in
CC       a cutaneous T-cell leukemia (C-TCL) cell line. This rearrangement
CC       produces the p80HT gene which codes for a truncated 80 kDa protein
CC       (p80HT).
CC   -!- DISEASE: Note=In B-cell leukemia (B-CLL) cell line, LB40 and
CC       EB308, can be found after heterogeneous chromosomal aberrations,
CC       such as internal deletions.
CC   -!- DISEASE: Immunodeficiency, common variable, 10 (CVID10)
CC       [MIM:615577]: A primary immunodeficiency characterized by
CC       childhood-onset of recurrent infections, hypogammaglobulinemia,
CC       and decreased numbers of memory and marginal zone B-cells. Some
CC       patients may develop autoimmune features and have circulating
CC       autoantibodies. An unusual feature is central adrenal
CC       insufficiency. {ECO:0000269|PubMed:24140114,
CC       ECO:0000269|PubMed:25524009}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA43715.1; Type=Frameshift; Positions=456, 458, 470, 900; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/NFKB2ID362.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/nfkb2/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X61498; CAA43715.1; ALT_FRAME; mRNA.
DR   EMBL; X61499; CAA43716.1; ALT_FRAME; mRNA.
DR   EMBL; S76638; AAB21124.1; -; mRNA.
DR   EMBL; U09609; AAA21462.2; -; mRNA.
DR   EMBL; BT009769; AAP88771.1; -; mRNA.
DR   EMBL; AK292654; BAF85343.1; -; mRNA.
DR   EMBL; AY865619; AAW56071.1; -; Genomic_DNA.
DR   EMBL; AL121928; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471066; EAW49700.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49701.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49702.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49704.1; -; Genomic_DNA.
DR   EMBL; CH471066; EAW49706.1; -; Genomic_DNA.
DR   EMBL; BC002844; AAH02844.1; -; mRNA.
DR   EMBL; U20816; AAA68171.1; -; Genomic_DNA.
DR   CCDS; CCDS41564.1; -. [Q00653-1]
DR   CCDS; CCDS41565.1; -. [Q00653-4]
DR   PIR; A42024; A42024.
DR   PIR; A57034; A57034.
DR   PIR; I38609; I38609.
DR   PIR; S17233; S17233.
DR   RefSeq; NP_001070962.1; NM_001077494.3. [Q00653-1]
DR   RefSeq; NP_001248332.1; NM_001261403.2. [Q00653-4]
DR   RefSeq; NP_001275653.1; NM_001288724.1. [Q00653-4]
DR   RefSeq; NP_001309863.1; NM_001322934.1. [Q00653-1]
DR   RefSeq; NP_001309864.1; NM_001322935.1.
DR   RefSeq; NP_002493.3; NM_002502.5. [Q00653-4]
DR   UniGene; Hs.73090; -.
DR   PDB; 1A3Q; X-ray; 2.10 A; A/B=37-327.
DR   PDB; 2D96; NMR; -; A=766-859.
DR   PDB; 3DO7; X-ray; 3.05 A; B=37-329.
DR   PDB; 4OT9; X-ray; 3.35 A; A=407-765.
DR   PDBsum; 1A3Q; -.
DR   PDBsum; 2D96; -.
DR   PDBsum; 3DO7; -.
DR   PDBsum; 4OT9; -.
DR   ProteinModelPortal; Q00653; -.
DR   SMR; Q00653; -.
DR   BioGrid; 110858; 53.
DR   CORUM; Q00653; -.
DR   DIP; DIP-24239N; -.
DR   DIP; DIP-27535N; -.
DR   IntAct; Q00653; 36.
DR   MINT; Q00653; -.
DR   STRING; 9606.ENSP00000358983; -.
DR   ChEMBL; CHEMBL3003; -.
DR   DrugBank; DB00945; Acetylsalicylic acid.
DR   DrugBank; DB05487; CC-8490.
DR   DrugBank; DB01296; Glucosamine.
DR   DrugBank; DB05212; HE3286.
DR   DrugBank; DB05767; HMPL-004.
DR   DrugBank; DB05464; NOX-700.
DR   DrugBank; DB05451; P54.
DR   DrugBank; DB05471; SGN-30.
DR   CarbonylDB; Q00653; -.
DR   iPTMnet; Q00653; -.
DR   PhosphoSitePlus; Q00653; -.
DR   SwissPalm; Q00653; -.
DR   DMDM; 116242678; -.
DR   EPD; Q00653; -.
DR   MaxQB; Q00653; -.
DR   PaxDb; Q00653; -.
DR   PeptideAtlas; Q00653; -.
DR   PRIDE; Q00653; -.
DR   DNASU; 4791; -.
DR   Ensembl; ENST00000189444; ENSP00000189444; ENSG00000077150. [Q00653-4]
DR   Ensembl; ENST00000369966; ENSP00000358983; ENSG00000077150. [Q00653-1]
DR   Ensembl; ENST00000428099; ENSP00000410256; ENSG00000077150. [Q00653-4]
DR   GeneID; 4791; -.
DR   KEGG; hsa:4791; -.
DR   UCSC; uc001kva.4; human. [Q00653-1]
DR   CTD; 4791; -.
DR   DisGeNET; 4791; -.
DR   EuPathDB; HostDB:ENSG00000077150.17; -.
DR   GeneCards; NFKB2; -.
DR   HGNC; HGNC:7795; NFKB2.
DR   HPA; CAB022098; -.
DR   HPA; HPA008422; -.
DR   HPA; HPA023900; -.
DR   MalaCards; NFKB2; -.
DR   MIM; 164012; gene.
DR   MIM; 615577; phenotype.
DR   neXtProt; NX_Q00653; -.
DR   OpenTargets; ENSG00000077150; -.
DR   Orphanet; 1572; Common variable immunodeficiency.
DR   PharmGKB; PA31600; -.
DR   eggNOG; KOG0504; Eukaryota.
DR   eggNOG; COG0666; LUCA.
DR   GeneTree; ENSGT00500000044765; -.
DR   HOGENOM; HOG000004822; -.
DR   HOVERGEN; HBG052613; -.
DR   InParanoid; Q00653; -.
DR   KO; K04469; -.
DR   OMA; FRGHTPL; -.
DR   OrthoDB; EOG091G03PF; -.
DR   PhylomeDB; Q00653; -.
DR   TreeFam; TF325632; -.
DR   Reactome; R-HSA-1810476; RIP-mediated NFkB activation via ZBP1.
DR   Reactome; R-HSA-3134963; DEx/H-box helicases activate type I IFN and inflammatory cytokines production.
DR   Reactome; R-HSA-3214841; PKMTs methylate histone lysines.
DR   Reactome; R-HSA-445989; TAK1 activates NFkB by phosphorylation and activation of IKKs complex.
DR   Reactome; R-HSA-448706; Interleukin-1 processing.
DR   Reactome; R-HSA-5603027; IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR).
DR   Reactome; R-HSA-5603029; IkBA variant leads to EDA-ID.
DR   Reactome; R-HSA-5607761; Dectin-1 mediated noncanonical NF-kB signaling.
DR   Reactome; R-HSA-5676590; NIK-->noncanonical NF-kB signaling.
DR   Reactome; R-HSA-933542; TRAF6 mediated NF-kB activation.
DR   SIGNOR; Q00653; -.
DR   ChiTaRS; NFKB2; human.
DR   EvolutionaryTrace; Q00653; -.
DR   GeneWiki; NFKB2; -.
DR   GenomeRNAi; 4791; -.
DR   PMAP-CutDB; Q00653; -.
DR   PRO; PR:Q00653; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000077150; -.
DR   CleanEx; HS_NFKB2; -.
DR   ExpressionAtlas; Q00653; baseline and differential.
DR   Genevisible; Q00653; HS.
DR   GO; GO:0033257; C:Bcl3/NF-kappaB2 complex; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IBA:GO_Central.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; TAS:ProtInc.
DR   GO; GO:0000978; F:RNA polymerase II proximal promoter sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0003713; F:transcription coactivator activity; TAS:ProtInc.
DR   GO; GO:0001077; F:transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0030198; P:extracellular matrix organization; IEA:Ensembl.
DR   GO; GO:0002268; P:follicular dendritic cell differentiation; IEA:Ensembl.
DR   GO; GO:0002467; P:germinal center formation; IEA:Ensembl.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; IBA:GO_Central.
DR   GO; GO:0006954; P:inflammatory response; IBA:GO_Central.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IBA:GO_Central.
DR   GO; GO:0038061; P:NIK/NF-kappaB signaling; IBA:GO_Central.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; TAS:Reactome.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:NTNU_SB.
DR   GO; GO:0032481; P:positive regulation of type I interferon production; TAS:Reactome.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0034097; P:response to cytokine; IBA:GO_Central.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0048536; P:spleen development; IEA:Ensembl.
DR   CDD; cd00204; ANK; 2.
DR   CDD; cd01177; IPT_NFkappaB; 1.
DR   Gene3D; 1.25.40.20; -; 1.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 2.60.40.340; -; 1.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR020683; Ankyrin_rpt-contain_dom.
DR   InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR   InterPro; IPR011029; DEATH-like_dom_sf.
DR   InterPro; IPR000488; Death_domain.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR014756; Ig_E-set.
DR   InterPro; IPR002909; IPT_dom.
DR   InterPro; IPR033926; IPT_NFkappaB.
DR   InterPro; IPR000451; NFkB/Dor.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR030492; RHD_CS.
DR   InterPro; IPR032397; RHD_dimer.
DR   InterPro; IPR011539; RHD_DNA_bind_dom.
DR   InterPro; IPR037059; RHD_DNA_bind_dom_sf.
DR   PANTHER; PTHR24169; PTHR24169; 1.
DR   Pfam; PF12796; Ank_2; 2.
DR   Pfam; PF00531; Death; 1.
DR   Pfam; PF16179; RHD_dimer; 1.
DR   Pfam; PF00554; RHD_DNA_bind; 1.
DR   PRINTS; PR01415; ANKYRIN.
DR   PRINTS; PR00057; NFKBTNSCPFCT.
DR   SMART; SM00248; ANK; 6.
DR   SMART; SM00005; DEATH; 1.
DR   SMART; SM00429; IPT; 1.
DR   SUPFAM; SSF47986; SSF47986; 1.
DR   SUPFAM; SSF48403; SSF48403; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   SUPFAM; SSF81296; SSF81296; 1.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 5.
DR   PROSITE; PS01204; REL_1; 1.
DR   PROSITE; PS50254; REL_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; ANK repeat;
KW   Biological rhythms; Chromosomal rearrangement; Complete proteome;
KW   Cytoplasm; Direct protein sequencing; Disease mutation; DNA-binding;
KW   Isopeptide bond; Nucleus; Phosphoprotein; Polymorphism;
KW   Proto-oncogene; Reference proteome; Repeat; Repressor; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN         1    900       Nuclear factor NF-kappa-B p100 subunit.
FT                                /FTId=PRO_0000030321.
FT   CHAIN         1    454       Nuclear factor NF-kappa-B p52 subunit.
FT                                /FTId=PRO_0000030322.
FT   DOMAIN       38    343       RHD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00265}.
FT   REPEAT      487    519       ANK 1.
FT   REPEAT      526    555       ANK 2.
FT   REPEAT      559    591       ANK 3.
FT   REPEAT      599    628       ANK 4.
FT   REPEAT      633    663       ANK 5.
FT   REPEAT      667    696       ANK 6.
FT   REPEAT      729    758       ANK 7.
FT   DOMAIN      764    851       Death.
FT   REGION      346    377       GRR.
FT   MOTIF       337    341       Nuclear localization signal.
FT                                {ECO:0000255}.
FT   COMPBIAS    350    400       Gly-rich.
FT   SITE        454    455       Cleavage (when cotranslationally
FT                                processed).
FT   SITE        490    491       Breakpoint for translocation to form
FT                                NFKB2-IGHA1 oncogene.
FT   MOD_RES      23     23       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     161    161       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     429    429       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     713    713       Phosphoserine.
FT                                {ECO:0000269|PubMed:8887665}.
FT   MOD_RES     715    715       Phosphoserine.
FT                                {ECO:0000269|PubMed:8887665}.
FT   MOD_RES     717    717       Phosphoserine.
FT                                {ECO:0000269|PubMed:8887665}.
FT   MOD_RES     812    812       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     866    866       Phosphoserine; by MAP3K14.
FT                                {ECO:0000269|PubMed:11239468}.
FT   MOD_RES     870    870       Phosphoserine; by MAP3K14.
FT                                {ECO:0000269|PubMed:11239468}.
FT   CROSSLNK    855    855       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:14676825}.
FT   VAR_SEQ     374    428       GSLGFFPSSLAYSPYQSGAGPMGCYPGGGGGAQMAATVPSR
FT                                DSGEEAAEPSAPSR -> EGVLMEGGVKVREAVEEKNLGEA
FT                                GRGLHACNPALWEAKAGRLPEIRSSRPAWPTA (in
FT                                isoform 3). {ECO:0000303|PubMed:1876189}.
FT                                /FTId=VSP_040082.
FT   VAR_SEQ     429    900       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:1876189}.
FT                                /FTId=VSP_040083.
FT   VAR_SEQ     860    860       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:1876189,
FT                                ECO:0000303|Ref.5}.
FT                                /FTId=VSP_040084.
FT   VARIANT      14     14       E -> K (in dbSNP:rs45581936).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_022223.
FT   VARIANT     351    351       G -> R (in dbSNP:rs45580031).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_022224.
FT   VARIANT     392    392       A -> G (in dbSNP:rs11574848).
FT                                /FTId=VAR_051781.
FT   VARIANT     452    452       G -> R (in dbSNP:rs45471103).
FT                                {ECO:0000269|Ref.7}.
FT                                /FTId=VAR_022225.
FT   VARIANT     618    900       Missing (in truncated form EB308).
FT                                /FTId=VAR_018452.
FT   VARIANT     667    669       AGN -> SAS (in truncated form p80HT).
FT                                /FTId=VAR_006909.
FT   VARIANT     670    900       Missing (in truncated form p80HT).
FT                                /FTId=VAR_006910.
FT   VARIANT     703    900       Missing (in truncated form LB40).
FT                                /FTId=VAR_018453.
FT   VARIANT     865    865       D -> G (in CVID10; unknown pathological
FT                                significance; de novo mutation;
FT                                dbSNP:rs727502787).
FT                                {ECO:0000269|PubMed:25524009}.
FT                                /FTId=VAR_074035.
FT   VARIANT     867    867       A -> V (in CVID10; unknown pathological
FT                                significance; de novo mutation;
FT                                dbSNP:rs727502788).
FT                                {ECO:0000269|PubMed:25524009}.
FT                                /FTId=VAR_074036.
FT   MUTAGEN     247    249       YLL->AAA: Two-fold reduction in
FT                                heterodimerization with RelA.
FT                                {ECO:0000269|PubMed:8887665}.
FT   MUTAGEN     399    399       P->A: No change in cleavage rate or
FT                                products. {ECO:0000269|PubMed:8887665}.
FT   MUTAGEN     404    404       G->A: No change in cleavage rate or
FT                                products. {ECO:0000269|PubMed:8887665}.
FT   MUTAGEN     405    405       A->P: No change in cleavage rate or
FT                                products. {ECO:0000269|PubMed:8887665}.
FT   MUTAGEN     406    406       Q->N: No change in cleavage rate or
FT                                products. {ECO:0000269|PubMed:8887665}.
FT   MUTAGEN     713    713       S->G: Loss of phosphorylation; when
FT                                associated with A-715 and A-717.
FT                                {ECO:0000269|PubMed:8887665}.
FT   MUTAGEN     715    715       S->A: Loss of phosphorylation; when
FT                                associated with G-713 and A-717.
FT                                {ECO:0000269|PubMed:8887665}.
FT   MUTAGEN     717    717       S->A: Loss of phosphorylation; when
FT                                associated with G-713 and A-715.
FT                                {ECO:0000269|PubMed:8887665}.
FT   MUTAGEN     866    866       S->A: Decrease in MAP3K14-induced
FT                                phosphorylation; no inducible processing
FT                                occurs; when associated with A-869.
FT                                {ECO:0000269|PubMed:11239468}.
FT   MUTAGEN     870    870       S->A: Decrease in MAP3K14-induced
FT                                phosphorylation; no inducible processing
FT                                occurs; when associated with A-865.
FT                                {ECO:0000269|PubMed:11239468}.
FT   CONFLICT    144    144       K -> E (in Ref. 2; AAB21124).
FT                                {ECO:0000305}.
FT   CONFLICT    213    213       I -> T (in Ref. 1; CAA43715/CAA43716 and
FT                                11; AAA68171). {ECO:0000305}.
FT   CONFLICT    396    396       G -> R (in Ref. 1; CAA43715).
FT                                {ECO:0000305}.
FT   CONFLICT    433    434       EP -> DA (in Ref. 2; AAB21124).
FT                                {ECO:0000305}.
FT   CONFLICT    459    459       R -> K (in Ref. 12; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    465    465       G -> C (in Ref. 1; CAA43715).
FT                                {ECO:0000305}.
FT   CONFLICT    470    470       A -> R (in Ref. 1; CAA43715 and 2;
FT                                AAB21124). {ECO:0000305}.
FT   CONFLICT    741    741       K -> L (in Ref. 1; CAA43715).
FT                                {ECO:0000305}.
FT   CONFLICT    860    860       A -> T (in Ref. 2; AAB21124).
FT                                {ECO:0000305}.
FT   CONFLICT    876    876       E -> K (in Ref. 2; AAB21124).
FT                                {ECO:0000305}.
FT   CONFLICT    891    891       C -> S (in Ref. 1; CAA43715).
FT                                {ECO:0000305}.
FT   STRAND       39     44       {ECO:0000244|PDB:1A3Q}.
FT   STRAND       48     51       {ECO:0000244|PDB:1A3Q}.
FT   TURN         56     58       {ECO:0000244|PDB:1A3Q}.
FT   STRAND       79     83       {ECO:0000244|PDB:1A3Q}.
FT   STRAND       87     96       {ECO:0000244|PDB:1A3Q}.
FT   STRAND       98    101       {ECO:0000244|PDB:1A3Q}.
FT   STRAND      106    111       {ECO:0000244|PDB:1A3Q}.
FT   STRAND      116    118       {ECO:0000244|PDB:3DO7}.
FT   STRAND      120    124       {ECO:0000244|PDB:1A3Q}.
FT   STRAND      130    132       {ECO:0000244|PDB:1A3Q}.
FT   STRAND      136    140       {ECO:0000244|PDB:1A3Q}.
FT   TURN        143    145       {ECO:0000244|PDB:1A3Q}.
FT   HELIX       146    158       {ECO:0000244|PDB:1A3Q}.
FT   TURN        159    161       {ECO:0000244|PDB:1A3Q}.
FT   HELIX       168    182       {ECO:0000244|PDB:1A3Q}.
FT   STRAND      189    198       {ECO:0000244|PDB:1A3Q}.
FT   STRAND      205    207       {ECO:0000244|PDB:3DO7}.
FT   STRAND      217    219       {ECO:0000244|PDB:1A3Q}.
FT   STRAND      220    222       {ECO:0000244|PDB:3DO7}.
FT   TURN        223    225       {ECO:0000244|PDB:1A3Q}.
FT   STRAND      230    234       {ECO:0000244|PDB:1A3Q}.
FT   STRAND      236    239       {ECO:0000244|PDB:1A3Q}.
FT   STRAND      240    242       {ECO:0000244|PDB:3DO7}.
FT   STRAND      245    252       {ECO:0000244|PDB:1A3Q}.
FT   TURN        255    257       {ECO:0000244|PDB:1A3Q}.
FT   STRAND      258    264       {ECO:0000244|PDB:1A3Q}.
FT   STRAND      266    268       {ECO:0000244|PDB:1A3Q}.
FT   STRAND      270    273       {ECO:0000244|PDB:1A3Q}.
FT   HELIX       278    280       {ECO:0000244|PDB:1A3Q}.
FT   TURN        283    285       {ECO:0000244|PDB:1A3Q}.
FT   STRAND      286    290       {ECO:0000244|PDB:1A3Q}.
FT   STRAND      303    311       {ECO:0000244|PDB:1A3Q}.
FT   TURN        312    314       {ECO:0000244|PDB:1A3Q}.
FT   STRAND      321    326       {ECO:0000244|PDB:1A3Q}.
FT   HELIX       439    467       {ECO:0000244|PDB:4OT9}.
FT   HELIX       470    475       {ECO:0000244|PDB:4OT9}.
FT   HELIX       476    480       {ECO:0000244|PDB:4OT9}.
FT   HELIX       491    497       {ECO:0000244|PDB:4OT9}.
FT   HELIX       501    512       {ECO:0000244|PDB:4OT9}.
FT   TURN        513    515       {ECO:0000244|PDB:4OT9}.
FT   HELIX       519    521       {ECO:0000244|PDB:4OT9}.
FT   HELIX       530    536       {ECO:0000244|PDB:4OT9}.
FT   HELIX       540    548       {ECO:0000244|PDB:4OT9}.
FT   HELIX       563    567       {ECO:0000244|PDB:4OT9}.
FT   HELIX       575    582       {ECO:0000244|PDB:4OT9}.
FT   HELIX       586    588       {ECO:0000244|PDB:4OT9}.
FT   TURN        589    593       {ECO:0000244|PDB:4OT9}.
FT   TURN        597    599       {ECO:0000244|PDB:4OT9}.
FT   HELIX       603    609       {ECO:0000244|PDB:4OT9}.
FT   HELIX       613    621       {ECO:0000244|PDB:4OT9}.
FT   TURN        631    633       {ECO:0000244|PDB:4OT9}.
FT   HELIX       637    643       {ECO:0000244|PDB:4OT9}.
FT   HELIX       647    654       {ECO:0000244|PDB:4OT9}.
FT   TURN        655    657       {ECO:0000244|PDB:4OT9}.
FT   HELIX       671    678       {ECO:0000244|PDB:4OT9}.
FT   HELIX       681    689       {ECO:0000244|PDB:4OT9}.
FT   TURN        733    735       {ECO:0000244|PDB:4OT9}.
FT   HELIX       740    751       {ECO:0000244|PDB:4OT9}.
FT   STRAND      752    754       {ECO:0000244|PDB:4OT9}.
FT   HELIX       772    782       {ECO:0000244|PDB:2D96}.
FT   STRAND      783    786       {ECO:0000244|PDB:2D96}.
FT   HELIX       791    798       {ECO:0000244|PDB:2D96}.
FT   HELIX       801    808       {ECO:0000244|PDB:2D96}.
FT   HELIX       813    823       {ECO:0000244|PDB:2D96}.
FT   HELIX       828    838       {ECO:0000244|PDB:2D96}.
FT   HELIX       841    848       {ECO:0000244|PDB:2D96}.
SQ   SEQUENCE   900 AA;  96749 MW;  6BAD7038834783CA CRC64;
     MESCYNPGLD GIIEYDDFKL NSSIVEPKEP APETADGPYL VIVEQPKQRG FRFRYGCEGP
     SHGGLPGASS EKGRKTYPTV KICNYEGPAK IEVDLVTHSD PPRAHAHSLV GKQCSELGIC
     AVSVGPKDMT AQFNNLGVLH VTKKNMMGTM IQKLQRQRLR SRPQGLTEAE QRELEQEAKE
     LKKVMDLSIV RLRFSAFLRA SDGSFSLPLK PVISQPIHDS KSPGASNLKI SRMDKTAGSV
     RGGDEVYLLC DKVQKDDIEV RFYEDDENGW QAFGDFSPTD VHKQYAIVFR TPPYHKMKIE
     RPVTVFLQLK RKRGGDVSDS KQFTYYPLVE DKEEVQRKRR KALPTFSQPF GGGSHMGGGS
     GGAAGGYGGA GGGGSLGFFP SSLAYSPYQS GAGPMGCYPG GGGGAQMAAT VPSRDSGEEA
     AEPSAPSRTP QCEPQAPEML QRAREYNARL FGLAQRSARA LLDYGVTADA RALLAGQRHL
     LTAQDENGDT PLHLAIIHGQ TSVIEQIVYV IHHAQDLGVV NLTNHLHQTP LHLAVITGQT
     SVVSFLLRVG ADPALLDRHG DSAMHLALRA GAGAPELLRA LLQSGAPAVP QLLHMPDFEG
     LYPVHLAVRA RSPECLDLLV DSGAEVEATE RQGGRTALHL ATEMEELGLV THLVTKLRAN
     VNARTFAGNT PLHLAAGLGY PTLTRLLLKA GADIHAENEE PLCPLPSPPT SDSDSDSEGP
     EKDTRSSFRG HTPLDLTCST KVKTLLLNAA QNTMEPPLTP PSPAGPGLSL GDTALQNLEQ
     LLDGPEAQGS WAELAERLGL RSLVDTYRQT TSPSGSLLRS YELAGGDLAG LLEALSDMGL
     EEGVRLLRGP ETRDKLPSTA EVKEDSAYGS QSVEQEAEKL GPPPEPPGGL CHGHPQPQVH
//
ID   NOTC1_HUMAN             Reviewed;        2555 AA.
AC   P46531; Q59ED8; Q5SXM3;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   23-SEP-2008, sequence version 4.
DT   28-FEB-2018, entry version 217.
DE   RecName: Full=Neurogenic locus notch homolog protein 1;
DE            Short=Notch 1;
DE            Short=hN1;
DE   AltName: Full=Translocation-associated notch protein TAN-1;
DE   Contains:
DE     RecName: Full=Notch 1 extracellular truncation;
DE              Short=NEXT;
DE   Contains:
DE     RecName: Full=Notch 1 intracellular domain;
DE              Short=NICD;
DE   Flags: Precursor;
GN   Name=NOTCH1; Synonyms=TAN1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RA   Mann R.S., Blaumueller C.M., Zagouras P.;
RT   "Complete human notch 1 (hN1) cDNA sequence.";
RL   Submitted (SEP-2000) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-2443.
RX   PubMed=1831692; DOI=10.1016/0092-8674(91)90111-B;
RA   Ellisen L.W., Bird J., West D.C., Soreng A.L., Reynolds T.C.,
RA   Smith S.D., Sklar J.;
RT   "TAN-1, the human homolog of the Drosophila notch gene, is broken by
RT   chromosomal translocations in T lymphoblastic neoplasms.";
RL   Cell 66:649-661(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 489-2555.
RC   TISSUE=Aortic endothelium;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   PROTEIN SEQUENCE OF 1947-1962, INTERACTION WITH HIF1AN, HYDROXYLATION
RP   AT ASN-1955, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=17573339; DOI=10.1074/jbc.M704102200;
RA   Coleman M.L., McDonough M.A., Hewitson K.S., Coles C., Mecinovic J.,
RA   Edelmann M., Cook K.M., Cockman M.E., Lancaster D.E., Kessler B.M.,
RA   Oldham N.J., Ratcliffe P.J., Schofield C.J.;
RT   "Asparaginyl hydroxylation of the Notch ankyrin repeat domain by
RT   factor inhibiting hypoxia-inducible factor.";
RL   J. Biol. Chem. 282:24027-24038(2007).
RN   [6]
RP   IDENTIFICATION OF LIGANDS.
RX   PubMed=10079256; DOI=10.1016/S0002-9440(10)65325-4;
RA   Gray G.E., Mann R.S., Mitsiadis E., Henrique D., Carcangiu M.-L.,
RA   Banks A., Leiman J., Ward D., Ish-Horowitz D., Artavanis-Tsakonas S.;
RT   "Human ligands of the Notch receptor.";
RL   Am. J. Pathol. 154:785-794(1999).
RN   [7]
RP   INTERACTION WITH DTX1.
RX   PubMed=9590294; DOI=10.1038/ng0598-74;
RA   Matsuno K., Eastman D., Mitsiades T., Quinn A.M., Carcanciu M.L.,
RA   Ordentlich P., Kadesch T., Artavanis-Tsakonas S.;
RT   "Human deltex is a conserved regulator of Notch signalling.";
RL   Nat. Genet. 19:74-78(1998).
RN   [8]
RP   INTERACTION WITH SNW1.
RX   PubMed=10713164; DOI=10.1128/MCB.20.7.2400-2410.2000;
RA   Zhou S., Fujimuro M., Hsieh J.J., Chen L., Miyamoto A., Weinmaster G.,
RA   Hayward S.D.;
RT   "SKIP, a CBF1-associated protein, interacts with the ankyrin repeat
RT   domain of NotchIC To facilitate NotchIC function.";
RL   Mol. Cell. Biol. 20:2400-2410(2000).
RN   [9]
RP   INTERACTION WITH MAML1.
RX   PubMed=11101851; DOI=10.1038/82644;
RA   Wu L., Aster J.C., Blacklow S.C., Lake R., Artavanis-Tsakonas S.,
RA   Griffin J.D.;
RT   "MAML1, a human homologue of Drosophila mastermind, is a
RT   transcriptional co-activator for NOTCH receptors.";
RL   Nat. Genet. 26:484-489(2000).
RN   [10]
RP   INTERACTION WITH MAML2 AND MAML3.
RX   PubMed=12370315; DOI=10.1128/MCB.22.21.7688-7700.2002;
RA   Wu L., Sun T., Kobayashi K., Gao P., Griffin J.D.;
RT   "Identification of a family of mastermind-like transcriptional
RT   coactivators for mammalian notch receptors.";
RL   Mol. Cell. Biol. 22:7688-7700(2002).
RN   [11]
RP   INTERACTION WITH NOV.
RX   PubMed=12050162; DOI=10.1074/jbc.M203727200;
RA   Sakamoto K., Yamaguchi S., Ando R., Miyawaki A., Kabasawa Y.,
RA   Takagi M., Li C.L., Perbal B., Katsube K.;
RT   "The nephroblastoma overexpressed gene (NOV/ccn3) protein associates
RT   with Notch1 extracellular domain and inhibits myoblast differentiation
RT   via Notch signaling pathway.";
RL   J. Biol. Chem. 277:29399-29405(2002).
RN   [12]
RP   UBIQUITINATION BY ITCH.
RX   PubMed=18628966; DOI=10.1371/journal.pone.0002735;
RA   Chastagner P., Israel A., Brou C.;
RT   "AIP4/Itch regulates Notch receptor degradation in the absence of
RT   ligand.";
RL   PLoS ONE 3:E2735-E2735(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   FUNCTION.
RX   PubMed=20616313; DOI=10.1161/CIRCRESAHA.110.217257;
RA   Brutsch R., Liebler S.S., Wustehube J., Bartol A., Herberich S.E.,
RA   Adam M.G., Telzerow A., Augustin H.G., Fischer A.;
RT   "Integrin cytoplasmic domain-associated protein-1 attenuates sprouting
RT   angiogenesis.";
RL   Circ. Res. 107:592-601(2010).
RN   [15]
RP   INTERACTION WITH SNAI1 AND MDM2A.
RX   PubMed=22128911; DOI=10.1186/1741-7007-9-83;
RA   Lim S.O., Kim H.S., Quan X., Ahn S.M., Kim H., Hsieh D., Seong J.K.,
RA   Jung G.;
RT   "Notch1 binds and induces degradation of Snail in hepatocellular
RT   carcinoma.";
RL   BMC Biol. 9:83-83(2011).
RN   [16]
RP   INTERACTION WITH AAK1.
RX   PubMed=21464124; DOI=10.1074/jbc.M110.190769;
RA   Gupta-Rossi N., Ortica S., Meas-Yedid V., Heuss S., Moretti J.,
RA   Olivo-Marin J.C., Israel A.;
RT   "The adaptor-associated kinase 1, AAK1, is a positive regulator of the
RT   Notch pathway.";
RL   J. Biol. Chem. 286:18720-18730(2011).
RN   [17]
RP   INTERACTION WITH SGK1 AND FBXW7.
RX   PubMed=21147854; DOI=10.1242/jcs.073924;
RA   Mo J.S., Ann E.J., Yoon J.H., Jung J., Choi Y.H., Kim H.Y., Ahn J.S.,
RA   Kim S.M., Kim M.Y., Hong J.A., Seo M.S., Lang F., Choi E.J.,
RA   Park H.S.;
RT   "Serum- and glucocorticoid-inducible kinase 1 (SGK1) controls Notch1
RT   signaling by downregulation of protein stability through Fbw7
RT   ubiquitin ligase.";
RL   J. Cell Sci. 124:100-112(2011).
RN   [18]
RP   INTERACTION WITH SNW1.
RX   PubMed=21245387; DOI=10.1128/MCB.00360-10;
RA   Vasquez-Del Carpio R., Kaplan F.M., Weaver K.L., VanWye J.D.,
RA   Alves-Guerra M.C., Robbins D.J., Capobianco A.J.;
RT   "Assembly of a Notch transcriptional activation complex requires
RT   multimerization.";
RL   Mol. Cell. Biol. 31:1396-1408(2011).
RN   [19]
RP   GLYCOSYLATION AT THR-232; THR-1402 AND THR-1725, AND PROTEOLYTIC
RP   PROCESSING.
RX   PubMed=24226769; DOI=10.1038/nature12723;
RA   Boskovski M.T., Yuan S., Pedersen N.B., Goth C.K., Makova S.,
RA   Clausen H., Brueckner M., Khokha M.K.;
RT   "The heterotaxy gene GALNT11 glycosylates Notch to orchestrate cilia
RT   type and laterality.";
RL   Nature 504:456-459(2013).
RN   [20]
RP   ANKYRIN REPEATS.
RX   PubMed=25547411; DOI=10.1186/s12859-014-0440-9;
RA   Chakrabarty B., Parekh N.;
RT   "Identifying tandem Ankyrin repeats in protein structures.";
RL   BMC Bioinformatics 15:6599-6599(2014).
RN   [21]
RP   INTERACTION WITH ZMIZ1.
RX   PubMed=26522984; DOI=10.1016/j.immuni.2015.10.007;
RA   Pinnell N., Yan R., Cho H.J., Keeley T., Murai M.J., Liu Y.,
RA   Alarcon A.S., Qin J., Wang Q., Kuick R., Elenitoba-Johnson K.S.,
RA   Maillard I., Samuelson L.C., Cierpicki T., Chiang M.Y.;
RT   "The PIAS-like coactivator Zmiz1 is a direct and selective cofactor of
RT   Notch1 in T cell development and leukemia.";
RL   Immunity 43:870-883(2015).
RN   [22]
RP   STRUCTURE BY NMR OF 1446-1480 IN COMPLEX WITH CALCIUM IONS, AND
RP   DISULFIDE BONDS.
RX   PubMed=12795601; DOI=10.1021/bi034156y;
RA   Vardar D., North C.L., Sanchez-Irizarry C., Aster J.C., Blacklow S.C.;
RT   "Nuclear magnetic resonance structure of a prototype Lin12-Notch
RT   repeat module from human Notch1.";
RL   Biochemistry 42:7061-7067(2003).
RN   [23]
RP   STRUCTURE BY NMR OF 411-526.
RX   PubMed=15576031; DOI=10.1016/j.str.2004.09.012;
RA   Hambleton S., Valeyev N.V., Muranyi A., Knott V., Werner J.M.,
RA   McMichael A.J., Handford P.A., Downing A.K.;
RT   "Structural and functional properties of the human notch-1 ligand
RT   binding region.";
RL   Structure 12:2173-2183(2004).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 1872-2114.
RX   PubMed=16011479; DOI=10.1042/BJ20050515;
RA   Ehebauer M.T., Chirgadze D.Y., Hayward P., Martinez Arias A.,
RA   Blundell T.L.;
RT   "High-resolution crystal structure of the human Notch 1 ankyrin
RT   domain.";
RL   Biochem. J. 392:13-20(2005).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (3.25 ANGSTROMS) OF 1872-2126 IN COMPLEX WITH
RP   RBPSUH AND MAML1.
RX   PubMed=16530044; DOI=10.1016/j.cell.2005.12.037;
RA   Nam Y., Sliz P., Song L., Aster J.C., Blacklow S.C.;
RT   "Structural basis for cooperativity in recruitment of MAML
RT   coactivators to Notch transcription complexes.";
RL   Cell 124:973-983(2006).
RN   [26]
RP   INVOLVEMENT IN AOVD1.
RX   PubMed=16025100; DOI=10.1038/nature03940;
RA   Garg V., Muth A.N., Ransom J.F., Schluterman M.K., Barnes R.,
RA   King I.N., Grossfeld P.D., Srivastava D.;
RT   "Mutations in NOTCH1 cause aortic valve disease.";
RL   Nature 437:270-274(2005).
RN   [27]
RP   UBIQUITINATION BY ITCH.
RX   PubMed=23886940; DOI=10.1242/jcs.130500;
RA   Puca L., Chastagner P., Meas-Yedid V., Israel A., Brou C.;
RT   "Alpha-arrestin 1 (ARRDC1) and beta-arrestins cooperate to mediate
RT   Notch degradation in mammals.";
RL   J. Cell Sci. 126:4457-4468(2013).
RN   [28]
RP   INVOLVEMENT IN AOS5, AND VARIANTS AOS5 ARG-429; TYR-1496 AND ASN-1989.
RX   PubMed=25132448; DOI=10.1016/j.ajhg.2014.07.011;
RA   Stittrich A.B., Lehman A., Bodian D.L., Ashworth J., Zong Z., Li H.,
RA   Lam P., Khromykh A., Iyer R.K., Vockley J.G., Baveja R., Silva E.S.,
RA   Dixon J., Leon E.L., Solomon B.D., Glusman G., Niederhuber J.E.,
RA   Roach J.C., Patel M.S.;
RT   "Mutations in NOTCH1 cause Adams-Oliver syndrome.";
RL   Am. J. Hum. Genet. 95:275-284(2014).
CC   -!- FUNCTION: Functions as a receptor for membrane-bound ligands
CC       Jagged1, Jagged2 and Delta1 to regulate cell-fate determination.
CC       Upon ligand activation through the released notch intracellular
CC       domain (NICD) it forms a transcriptional activator complex with
CC       RBPJ/RBPSUH and activates genes of the enhancer of split locus.
CC       Affects the implementation of differentiation, proliferation and
CC       apoptotic programs. Involved in angiogenesis; negatively regulates
CC       endothelial cell proliferation and migration and angiogenic
CC       sprouting. Involved in the maturation of both CD4+ and CD8+ cells
CC       in the thymus. Important for follicular differentiation and
CC       possibly cell fate selection within the follicle. During
CC       cerebellar development, functions as a receptor for neuronal DNER
CC       and is involved in the differentiation of Bergmann glia. Represses
CC       neuronal and myogenic differentiation. May play an essential role
CC       in postimplantation development, probably in some aspect of cell
CC       specification and/or differentiation. May be involved in mesoderm
CC       development, somite formation and neurogenesis. May enhance HIF1A
CC       function by sequestering HIF1AN away from HIF1A. Required for the
CC       THBS4 function in regulating protective astrogenesis from the
CC       subventricular zone (SVZ) niche after injury. Involved in
CC       determination of left/right symmetry by modulating the balance
CC       between motile and immotile (sensory) cilia at the left-right
CC       organiser (LRO). {ECO:0000269|PubMed:20616313}.
CC   -!- SUBUNIT: Heterodimer of a C-terminal fragment N(TM) and an N-
CC       terminal fragment N(EC) which are probably linked by disulfide
CC       bonds. Interacts with DNER, DTX1, DTX2 and RBPJ/RBPSUH. Also
CC       interacts with MAML1, MAML2 and MAML3 which act as transcriptional
CC       coactivators for NOTCH1 (PubMed:11101851, PubMed:12370315). Notch
CC       1 intracellular domain interacts with SNW1; the interaction
CC       involves multimerized NOTCH1 NICD and is implicated in a formation
CC       of an intermediate preactivation complex which associates with
CC       DNA-bound CBF-1/RBPJ (PubMed:10713164). The activated membrane-
CC       bound form interacts with AAK1 which promotes NOTCH1
CC       stabilization. Forms a trimeric complex with FBXW7 and SGK1.
CC       Interacts with HIF1AN. HIF1AN negatively regulates the function of
CC       notch intracellular domain (NICD), accelerating myogenic
CC       differentiation (PubMed:17573339). Interacts (via NICD) with SNAI1
CC       (via zinc fingers); the interaction induces SNAI1 degradation via
CC       MDM2-mediated ubiquitination and inhibits SNAI1-induced cell
CC       invasion. Interacts (via NICD) with MDM2A. Interacts (via NICD)
CC       with BCL6; the interaction decreases MAML1 recruitment by NOTCH1
CC       NICD on target genes DNA and inhibits NOTCH1 transcractivation
CC       activity. Interacts with THBS4 (By similarity). Interacts (via the
CC       EGF-like repeat region) with NOV (via CTCK domain)
CC       (PubMed:12050162). Interacts (via EGF-like domains) with DLL4 (via
CC       N-terminal DSL and MNNL domains) (By similarity). Interacts with
CC       ZMIZ1. Interacts (via NICD domain) with MEGF10 (via the
CC       cytoplasmic domain). Interacts with DLL1 and JAG1 (By similarity).
CC       {ECO:0000250|UniProtKB:Q01705, ECO:0000250|UniProtKB:Q07008,
CC       ECO:0000269|PubMed:10713164, ECO:0000269|PubMed:11101851,
CC       ECO:0000269|PubMed:12050162, ECO:0000269|PubMed:12370315,
CC       ECO:0000269|PubMed:17573339, ECO:0000269|PubMed:26522984,
CC       ECO:0000269|PubMed:9590294}.
CC   -!- INTERACTION:
CC       Q13315:ATM; NbExp=8; IntAct=EBI-636374, EBI-495465;
CC       Q969H0:FBXW7; NbExp=10; IntAct=EBI-636374, EBI-359574;
CC       Q16665:HIF1A; NbExp=2; IntAct=EBI-636374, EBI-447269;
CC       P78504:JAG1; NbExp=6; IntAct=EBI-636374, EBI-2847071;
CC       O60341:KDM1A; NbExp=8; IntAct=EBI-636374, EBI-710124;
CC       Q8N423:LILRB2; NbExp=8; IntAct=EBI-636374, EBI-2816428;
CC       Q92585:MAML1; NbExp=14; IntAct=EBI-636374, EBI-908250;
CC       P19838:NFKB1; NbExp=2; IntAct=EBI-636374, EBI-300010;
CC       Q13526:PIN1; NbExp=9; IntAct=EBI-636374, EBI-714158;
CC       Q06330:RBPJ; NbExp=12; IntAct=EBI-636374, EBI-632552;
CC       Q06330-6:RBPJ; NbExp=6; IntAct=EBI-636374, EBI-12599287;
CC       Q13573:SNW1; NbExp=3; IntAct=EBI-636374, EBI-632715;
CC       P98170:XIAP; NbExp=4; IntAct=EBI-636374, EBI-517127;
CC   -!- SUBCELLULAR LOCATION: Cell membrane
CC       {ECO:0000250|UniProtKB:Q01705}; Single-pass type I membrane
CC       protein {ECO:0000250|UniProtKB:Q01705}.
CC   -!- SUBCELLULAR LOCATION: Notch 1 intracellular domain: Nucleus
CC       {ECO:0000250|UniProtKB:Q01705}. Note=Following proteolytical
CC       processing NICD is translocated to the nucleus. Nuclear location
CC       may require MEGF10. {ECO:0000250|UniProtKB:Q01705}.
CC   -!- TISSUE SPECIFICITY: In fetal tissues most abundant in spleen,
CC       brain stem and lung. Also present in most adult tissues where it
CC       is found mainly in lymphoid tissues.
CC   -!- PTM: Synthesized in the endoplasmic reticulum as an inactive form
CC       which is proteolytically cleaved by a furin-like convertase in the
CC       trans-Golgi network before it reaches the plasma membrane to yield
CC       an active, ligand-accessible form. Cleavage results in a C-
CC       terminal fragment N(TM) and a N-terminal fragment N(EC). Following
CC       ligand binding, it is cleaved by ADAM17 to yield a membrane-
CC       associated intermediate fragment called notch extracellular
CC       truncation (NEXT). Following endocytosis, this fragment is then
CC       cleaved by presenilin dependent gamma-secretase to release a
CC       notch-derived peptide containing the intracellular domain (NICD)
CC       from the membrane. {ECO:0000250|UniProtKB:Q01705}.
CC   -!- PTM: Phosphorylated. {ECO:0000250}.
CC   -!- PTM: O-glycosylated on the EGF-like domains (PubMed:24226769).
CC       Contains both O-linked fucose and O-linked glucose in the EGF-like
CC       domains 11, 12 and 13, which are interacting with the residues on
CC       DLL4 (By similarity). O-linked glycosylation by GALNT11 is
CC       involved in determination of left/right symmetry: glycosylation
CC       promotes activation of NOTCH1, possibly by promoting cleavage by
CC       ADAM17, modulating the balance between motile and immotile
CC       (sensory) cilia at the left-right organiser (LRO)
CC       (PubMed:24226769). MFNG-, RFNG- and LFNG-mediated modification of
CC       O-fucose residues at specific EGF-like domains results in
CC       inhibition of its activation by JAG1 and enhancement of its
CC       activation by DLL1 via an increased binding to DLL1 (By
CC       similarity). {ECO:0000250|UniProtKB:Q01705,
CC       ECO:0000250|UniProtKB:Q07008, ECO:0000269|PubMed:24226769}.
CC   -!- PTM: Ubiquitinated. Undergoes 'Lys-29'-linked polyubiquitination
CC       by ITCH; promotes the lysosomal degradation of non-activated
CC       internalized NOTCH1 (PubMed:18628966, PubMed:23886940).
CC       Monoubiquitination at Lys-1759 is required for activation by
CC       gamma-secretase cleavage, it promotes interaction with AAK1, which
CC       stabilizes it. Deubiquitination by EIF3F is necessary for nuclear
CC       import of activated Notch (PubMed:24226769).
CC       {ECO:0000269|PubMed:18628966, ECO:0000269|PubMed:23886940,
CC       ECO:0000269|PubMed:24226769}.
CC   -!- PTM: Hydroxylated at Asn-1955 by HIF1AN. Hydroxylated at Asn-2022
CC       by HIF1AN (By similarity). Hydroxylation reduces affinity for
CC       HI1AN and may thus indirectly modulate negative regulation of NICD
CC       (By similarity). {ECO:0000250}.
CC   -!- DISEASE: Aortic valve disease 1 (AOVD1) [MIM:109730]: A common
CC       defect in the aortic valve in which two rather than three leaflets
CC       are present. It is often associated with aortic valve
CC       calcification, stenosis and insufficiency. In extreme cases, the
CC       blood flow may be so restricted that the left ventricle fails to
CC       grow, resulting in hypoplastic left heart syndrome.
CC       {ECO:0000269|PubMed:16025100}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Adams-Oliver syndrome 5 (AOS5) [MIM:616028]: A form of
CC       Adams-Oliver syndrome, a disorder characterized by the congenital
CC       absence of skin (aplasia cutis congenita) in combination with
CC       transverse limb defects. Aplasia cutis congenita can be located
CC       anywhere on the body, but in the vast majority of the cases, it is
CC       present on the posterior parietal region where it is often
CC       associated with an underlying defect of the parietal bones. Limb
CC       abnormalities are typically limb truncation defects affecting the
CC       distal phalanges or entire digits (true ectrodactyly). Only
CC       rarely, metatarsals/metacarpals or more proximal limb structures
CC       are also affected. Apart from transverse limb defects, syndactyly,
CC       most commonly of second and third toes, can also be observed. The
CC       clinical features are highly variable and can also include
CC       cardiovascular malformations, brain abnormalities and vascular
CC       defects such as cutis marmorata and dilated scalp veins.
CC       {ECO:0000269|PubMed:25132448}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the NOTCH family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/NOTCH1ID30ch9q34.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF308602; AAG33848.1; -; mRNA.
DR   EMBL; AL592301; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL354671; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; M73980; AAA60614.1; -; mRNA.
DR   EMBL; AB209873; BAD93110.1; -; mRNA.
DR   CCDS; CCDS43905.1; -.
DR   PIR; A40043; A40043.
DR   RefSeq; NP_060087.3; NM_017617.4.
DR   UniGene; Hs.495473; -.
DR   PDB; 1PB5; NMR; -; A=1446-1480.
DR   PDB; 1TOZ; NMR; -; A=411-526.
DR   PDB; 1YYH; X-ray; 1.90 A; A/B=1872-2114.
DR   PDB; 2F8X; X-ray; 3.25 A; K=1872-2126.
DR   PDB; 2F8Y; X-ray; 1.55 A; A/B=1905-2126.
DR   PDB; 2HE0; X-ray; 1.90 A; A/B=1872-2114.
DR   PDB; 2VJ3; X-ray; 2.60 A; A=411-526.
DR   PDB; 3ETO; X-ray; 2.00 A; A/B=1446-1733.
DR   PDB; 3I08; X-ray; 3.20 A; A/C=1446-1664, B/D=1665-1733.
DR   PDB; 3L95; X-ray; 2.19 A; X/Y=1448-1728.
DR   PDB; 3NBN; X-ray; 3.45 A; B/E=1872-2126.
DR   PDB; 3V79; X-ray; 3.85 A; K=1872-2126, R=1759-1777.
DR   PDB; 4CUD; X-ray; 1.85 A; A=411-526.
DR   PDB; 4CUE; X-ray; 3.00 A; A=411-526.
DR   PDB; 4CUF; X-ray; 2.29 A; A=411-526.
DR   PDB; 4D0E; X-ray; 1.61 A; A=411-526.
DR   PDB; 4D0F; X-ray; 2.80 A; A=411-526.
DR   PDB; 5FM9; X-ray; 2.92 A; A=140-294.
DR   PDB; 5FMA; X-ray; 2.46 A; A/B=142-294.
DR   PDB; 5KZO; NMR; -; A=1721-1771.
DR   PDB; 5L0R; X-ray; 1.50 A; B=452-491.
DR   PDB; 5UB5; X-ray; 2.09 A; B=452-491.
DR   PDBsum; 1PB5; -.
DR   PDBsum; 1TOZ; -.
DR   PDBsum; 1YYH; -.
DR   PDBsum; 2F8X; -.
DR   PDBsum; 2F8Y; -.
DR   PDBsum; 2HE0; -.
DR   PDBsum; 2VJ3; -.
DR   PDBsum; 3ETO; -.
DR   PDBsum; 3I08; -.
DR   PDBsum; 3L95; -.
DR   PDBsum; 3NBN; -.
DR   PDBsum; 3V79; -.
DR   PDBsum; 4CUD; -.
DR   PDBsum; 4CUE; -.
DR   PDBsum; 4CUF; -.
DR   PDBsum; 4D0E; -.
DR   PDBsum; 4D0F; -.
DR   PDBsum; 5FM9; -.
DR   PDBsum; 5FMA; -.
DR   PDBsum; 5KZO; -.
DR   PDBsum; 5L0R; -.
DR   PDBsum; 5UB5; -.
DR   DisProt; DP01104; -.
DR   ProteinModelPortal; P46531; -.
DR   SMR; P46531; -.
DR   BioGrid; 110913; 201.
DR   CORUM; P46531; -.
DR   DIP; DIP-29919N; -.
DR   IntAct; P46531; 153.
DR   MINT; P46531; -.
DR   STRING; 9606.ENSP00000277541; -.
DR   BindingDB; P46531; -.
DR   ChEMBL; CHEMBL2146346; -.
DR   TCDB; 9.B.87.1.12; the selenoprotein p receptor (selp-receptor) family.
DR   iPTMnet; P46531; -.
DR   PhosphoSitePlus; P46531; -.
DR   BioMuta; NOTCH1; -.
DR   DMDM; 206729936; -.
DR   EPD; P46531; -.
DR   MaxQB; P46531; -.
DR   PaxDb; P46531; -.
DR   PeptideAtlas; P46531; -.
DR   PRIDE; P46531; -.
DR   Ensembl; ENST00000277541; ENSP00000277541; ENSG00000148400.
DR   GeneID; 4851; -.
DR   KEGG; hsa:4851; -.
DR   UCSC; uc004chz.4; human.
DR   CTD; 4851; -.
DR   DisGeNET; 4851; -.
DR   EuPathDB; HostDB:ENSG00000148400.9; -.
DR   GeneCards; NOTCH1; -.
DR   H-InvDB; HIX0008549; -.
DR   HGNC; HGNC:7881; NOTCH1.
DR   HPA; CAB008112; -.
DR   HPA; CAB022466; -.
DR   HPA; HPA067168; -.
DR   MalaCards; NOTCH1; -.
DR   MIM; 109730; phenotype.
DR   MIM; 190198; gene.
DR   MIM; 616028; phenotype.
DR   neXtProt; NX_P46531; -.
DR   OpenTargets; ENSG00000148400; -.
DR   Orphanet; 974; Adams-Oliver syndrome.
DR   Orphanet; 402075; Familial bicuspid aortic valve.
DR   PharmGKB; PA31683; -.
DR   eggNOG; ENOG410IR7G; Eukaryota.
DR   eggNOG; COG0666; LUCA.
DR   GeneTree; ENSGT00810000125346; -.
DR   HOGENOM; HOG000234369; -.
DR   HOVERGEN; HBG052650; -.
DR   InParanoid; P46531; -.
DR   KO; K02599; -.
DR   OMA; QYVNSYT; -.
DR   OrthoDB; EOG091G01NU; -.
DR   PhylomeDB; P46531; -.
DR   TreeFam; TF351641; -.
DR   Reactome; R-HSA-1912399; Pre-NOTCH Processing in the Endoplasmic Reticulum.
DR   Reactome; R-HSA-1912408; Pre-NOTCH Transcription and Translation.
DR   Reactome; R-HSA-1912420; Pre-NOTCH Processing in Golgi.
DR   Reactome; R-HSA-210744; Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells.
DR   Reactome; R-HSA-2122947; NOTCH1 Intracellular Domain Regulates Transcription.
DR   Reactome; R-HSA-2122948; Activated NOTCH1 Transmits Signal to the Nucleus.
DR   Reactome; R-HSA-2644606; Constitutive Signaling by NOTCH1 PEST Domain Mutants.
DR   Reactome; R-HSA-2644607; Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling.
DR   Reactome; R-HSA-2660826; Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant.
DR   Reactome; R-HSA-2691232; Constitutive Signaling by NOTCH1 HD Domain Mutants.
DR   Reactome; R-HSA-2894862; Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants.
DR   Reactome; R-HSA-350054; Notch-HLH transcription pathway.
DR   Reactome; R-HSA-5083630; Defective LFNG causes SCDO3.
DR   Reactome; R-HSA-8941856; RUNX3 regulates NOTCH signaling.
DR   Reactome; R-HSA-9013508; NOTCH3 Intracellular Domain Regulates Transcription.
DR   SignaLink; P46531; -.
DR   SIGNOR; P46531; -.
DR   ChiTaRS; NOTCH1; human.
DR   EvolutionaryTrace; P46531; -.
DR   GeneWiki; Notch-1; -.
DR   GenomeRNAi; 4851; -.
DR   PRO; PR:P46531; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000148400; -.
DR   CleanEx; HS_NOTCH1; -.
DR   Genevisible; P46531; HS.
DR   GO; GO:0001669; C:acrosomal vesicle; IEA:Ensembl.
DR   GO; GO:0005912; C:adherens junction; ISS:UniProtKB.
DR   GO; GO:0016324; C:apical plasma membrane; ISS:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0002193; C:MAML1-RBP-Jkappa- ICN1 complex; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0031490; F:chromatin DNA binding; IEA:Ensembl.
DR   GO; GO:0001047; F:core promoter binding; ISS:UniProtKB.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IEA:Ensembl.
DR   GO; GO:0019899; F:enzyme binding; ISS:UniProtKB.
DR   GO; GO:0004857; F:enzyme inhibitor activity; ISS:UniProtKB.
DR   GO; GO:0005112; F:Notch binding; IEA:Ensembl.
DR   GO; GO:0046982; F:protein heterodimerization activity; IEA:Ensembl.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0001190; F:transcriptional activator activity, RNA polymerase II transcription factor binding; ISS:BHF-UCL.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; IEA:Ensembl.
DR   GO; GO:0031100; P:animal organ regeneration; IEA:Ensembl.
DR   GO; GO:0003180; P:aortic valve morphogenesis; IMP:BHF-UCL.
DR   GO; GO:1902263; P:apoptotic process involved in embryonic digit morphogenesis; IEA:Ensembl.
DR   GO; GO:0060842; P:arterial endothelial cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0048708; P:astrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0003162; P:atrioventricular node development; IEA:Ensembl.
DR   GO; GO:0003181; P:atrioventricular valve morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0009912; P:auditory receptor cell fate commitment; IEA:Ensembl.
DR   GO; GO:0007409; P:axonogenesis; IEA:Ensembl.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; IEA:Ensembl.
DR   GO; GO:0003209; P:cardiac atrium morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003207; P:cardiac chamber formation; ISS:BHF-UCL.
DR   GO; GO:0060317; P:cardiac epithelial to mesenchymal transition; ISS:BHF-UCL.
DR   GO; GO:0003214; P:cardiac left ventricle morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0060038; P:cardiac muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0055008; P:cardiac muscle tissue morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003213; P:cardiac right atrium morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003219; P:cardiac right ventricle formation; IEA:Ensembl.
DR   GO; GO:0060411; P:cardiac septum morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0060948; P:cardiac vascular smooth muscle cell development; ISS:BHF-UCL.
DR   GO; GO:0003208; P:cardiac ventricle morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0007050; P:cell cycle arrest; IDA:UniProtKB.
DR   GO; GO:0021515; P:cell differentiation in spinal cord; IEA:Ensembl.
DR   GO; GO:0001708; P:cell fate specification; IEA:Ensembl.
DR   GO; GO:0003273; P:cell migration involved in endocardial cushion formation; ISS:BHF-UCL.
DR   GO; GO:0071372; P:cellular response to follicle-stimulating hormone stimulus; IDA:BHF-UCL.
DR   GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IDA:UniProtKB.
DR   GO; GO:0060271; P:cilium assembly; ISS:UniProtKB.
DR   GO; GO:0072044; P:collecting duct development; IEA:Ensembl.
DR   GO; GO:0007386; P:compartment pattern specification; IEA:Ensembl.
DR   GO; GO:0060982; P:coronary artery morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003169; P:coronary vein morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0007368; P:determination of left/right symmetry; ISS:BHF-UCL.
DR   GO; GO:0072017; P:distal tubule development; IEA:Ensembl.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0060956; P:endocardial cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0003203; P:endocardial cushion morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0003157; P:endocardium development; ISS:BHF-UCL.
DR   GO; GO:0003160; P:endocardium morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0007492; P:endoderm development; IEA:Ensembl.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; ISS:BHF-UCL.
DR   GO; GO:0003198; P:epithelial to mesenchymal transition involved in endocardial cushion formation; ISS:BHF-UCL.
DR   GO; GO:0030900; P:forebrain development; IEA:Ensembl.
DR   GO; GO:0007440; P:foregut morphogenesis; IEA:Ensembl.
DR   GO; GO:0072144; P:glomerular mesangial cell development; IEA:Ensembl.
DR   GO; GO:0003241; P:growth involved in heart morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0031069; P:hair follicle morphogenesis; IEA:Ensembl.
DR   GO; GO:0007507; P:heart development; IMP:DFLAT.
DR   GO; GO:0001947; P:heart looping; ISS:BHF-UCL.
DR   GO; GO:0061384; P:heart trabecula morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0006959; P:humoral immune response; IEA:Ensembl.
DR   GO; GO:0006955; P:immune response; NAS:UniProtKB.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0002437; P:inflammatory response to antigenic stimulus; IEA:Ensembl.
DR   GO; GO:0072602; P:interleukin-4 secretion; IEA:Ensembl.
DR   GO; GO:0030216; P:keratinocyte differentiation; IEA:Ensembl.
DR   GO; GO:0070986; P:left/right axis specification; IEA:Ensembl.
DR   GO; GO:0001889; P:liver development; IEA:Ensembl.
DR   GO; GO:0030324; P:lung development; IEA:Ensembl.
DR   GO; GO:0014031; P:mesenchymal cell development; ISS:BHF-UCL.
DR   GO; GO:0003192; P:mitral valve formation; IMP:BHF-UCL.
DR   GO; GO:2000811; P:negative regulation of anoikis; IMP:BHF-UCL.
DR   GO; GO:0030514; P:negative regulation of BMP signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0045955; P:negative regulation of calcium ion-dependent exocytosis; IEA:Ensembl.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0043086; P:negative regulation of catalytic activity; ISS:UniProtKB.
DR   GO; GO:0090051; P:negative regulation of cell migration involved in sprouting angiogenesis; IDA:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:0010812; P:negative regulation of cell-substrate adhesion; IDA:BHF-UCL.
DR   GO; GO:2001027; P:negative regulation of endothelial cell chemotaxis; IDA:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0060253; P:negative regulation of glial cell proliferation; ISS:UniProtKB.
DR   GO; GO:0045967; P:negative regulation of growth rate; IDA:UniProtKB.
DR   GO; GO:0045608; P:negative regulation of inner ear auditory receptor cell differentiation; IEA:Ensembl.
DR   GO; GO:0045662; P:negative regulation of myoblast differentiation; IMP:UniProtKB.
DR   GO; GO:0010832; P:negative regulation of myotube differentiation; ISS:UniProtKB.
DR   GO; GO:0050768; P:negative regulation of neurogenesis; ISS:UniProtKB.
DR   GO; GO:0048715; P:negative regulation of oligodendrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0030279; P:negative regulation of ossification; ISS:BHF-UCL.
DR   GO; GO:0045668; P:negative regulation of osteoblast differentiation; ISS:BHF-UCL.
DR   GO; GO:0046533; P:negative regulation of photoreceptor cell differentiation; IEA:Ensembl.
DR   GO; GO:2000974; P:negative regulation of pro-B cell differentiation; ISS:UniProtKB.
DR   GO; GO:2000737; P:negative regulation of stem cell differentiation; IMP:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:BHF-UCL.
DR   GO; GO:0021915; P:neural tube development; IEA:Ensembl.
DR   GO; GO:0097150; P:neuronal stem cell population maintenance; IEP:UniProtKB.
DR   GO; GO:0061314; P:Notch signaling involved in heart development; IMP:BHF-UCL.
DR   GO; GO:0007219; P:Notch signaling pathway; IDA:UniProtKB.
DR   GO; GO:0003270; P:Notch signaling pathway involved in regulation of secondary heart field cardioblast proliferation; IEA:Ensembl.
DR   GO; GO:0048709; P:oligodendrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0003344; P:pericardium morphogenesis; ISS:BHF-UCL.
DR   GO; GO:1903849; P:positive regulation of aorta morphogenesis; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0048711; P:positive regulation of astrocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0030513; P:positive regulation of BMP signaling pathway; ISS:UniProtKB.
DR   GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; ISS:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; ISS:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:0045603; P:positive regulation of endothelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IMP:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0046427; P:positive regulation of JAK-STAT cascade; ISS:UniProtKB.
DR   GO; GO:0045618; P:positive regulation of keratinocyte differentiation; IEA:Ensembl.
DR   GO; GO:0002052; P:positive regulation of neuroblast proliferation; IEA:Ensembl.
DR   GO; GO:0045747; P:positive regulation of Notch signaling pathway; TAS:Reactome.
DR   GO; GO:0046579; P:positive regulation of Ras protein signal transduction; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0061419; P:positive regulation of transcription from RNA polymerase II promoter in response to hypoxia; ISS:UniProtKB.
DR   GO; GO:0007221; P:positive regulation of transcription of Notch receptor target; ISS:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0045070; P:positive regulation of viral genome replication; IEA:Ensembl.
DR   GO; GO:0060740; P:prostate gland epithelium morphogenesis; IEA:Ensembl.
DR   GO; GO:0003184; P:pulmonary valve morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0060768; P:regulation of epithelial cell proliferation involved in prostate gland development; IEA:Ensembl.
DR   GO; GO:1901201; P:regulation of extracellular matrix assembly; ISS:BHF-UCL.
DR   GO; GO:0014807; P:regulation of somitogenesis; IEA:Ensembl.
DR   GO; GO:0003256; P:regulation of transcription from RNA polymerase II promoter involved in myocardial precursor cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; TAS:UniProtKB.
DR   GO; GO:0031960; P:response to corticosteroid; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0032495; P:response to muramyl dipeptide; IEA:Ensembl.
DR   GO; GO:0060528; P:secretory columnal luminar epithelial cell differentiation involved in prostate glandular acinus development; IEA:Ensembl.
DR   GO; GO:0035914; P:skeletal muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0048103; P:somatic stem cell division; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0002040; P:sprouting angiogenesis; IEA:Ensembl.
DR   GO; GO:0042246; P:tissue regeneration; IEA:Ensembl.
DR   GO; GO:0006367; P:transcription initiation from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0035148; P:tube formation; IMP:UniProtKB.
DR   GO; GO:0060979; P:vasculogenesis involved in coronary vascular morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0060843; P:venous endothelial cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0060412; P:ventricular septum morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0003222; P:ventricular trabecula myocardium morphogenesis; ISS:BHF-UCL.
DR   CDD; cd00204; ANK; 2.
DR   Gene3D; 1.25.40.20; -; 1.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR020683; Ankyrin_rpt-contain_dom.
DR   InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR   InterPro; IPR024600; DUF3454_notch.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   InterPro; IPR008297; Notch.
DR   InterPro; IPR035993; Notch-like_dom_sf.
DR   InterPro; IPR022362; Notch_1.
DR   InterPro; IPR000800; Notch_dom.
DR   InterPro; IPR010660; Notch_NOD_dom.
DR   InterPro; IPR011656; Notch_NODP_dom.
DR   Pfam; PF12796; Ank_2; 2.
DR   Pfam; PF11936; DUF3454; 1.
DR   Pfam; PF00008; EGF; 25.
DR   Pfam; PF07645; EGF_CA; 4.
DR   Pfam; PF12661; hEGF; 2.
DR   Pfam; PF06816; NOD; 1.
DR   Pfam; PF07684; NODP; 1.
DR   Pfam; PF00066; Notch; 3.
DR   PIRSF; PIRSF002279; Notch; 1.
DR   PRINTS; PR01452; LNOTCHREPEAT.
DR   PRINTS; PR01984; NOTCH1.
DR   SMART; SM00248; ANK; 6.
DR   SMART; SM01334; DUF3454; 1.
DR   SMART; SM00181; EGF; 36.
DR   SMART; SM00179; EGF_CA; 33.
DR   SMART; SM00004; NL; 3.
DR   SMART; SM01338; NOD; 1.
DR   SMART; SM01339; NODP; 1.
DR   SUPFAM; SSF48403; SSF48403; 1.
DR   SUPFAM; SSF57184; SSF57184; 6.
DR   SUPFAM; SSF90193; SSF90193; 3.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 4.
DR   PROSITE; PS00010; ASX_HYDROXYL; 22.
DR   PROSITE; PS00022; EGF_1; 35.
DR   PROSITE; PS01186; EGF_2; 27.
DR   PROSITE; PS50026; EGF_3; 36.
DR   PROSITE; PS01187; EGF_CA; 20.
DR   PROSITE; PS50258; LNR; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Angiogenesis; ANK repeat; Calcium;
KW   Cell membrane; Complete proteome; Developmental protein;
KW   Differentiation; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; EGF-like domain; Glycoprotein; Hydroxylation;
KW   Isopeptide bond; Membrane; Metal-binding; Notch signaling pathway;
KW   Nucleus; Phosphoprotein; Polymorphism; Receptor; Reference proteome;
KW   Repeat; Signal; Transcription; Transcription regulation;
KW   Transmembrane; Transmembrane helix; Ubl conjugation.
FT   SIGNAL        1     18       {ECO:0000255}.
FT   CHAIN        19   2555       Neurogenic locus notch homolog protein 1.
FT                                /FTId=PRO_0000007674.
FT   CHAIN      1721   2555       Notch 1 extracellular truncation.
FT                                {ECO:0000250}.
FT                                /FTId=PRO_0000007675.
FT   CHAIN      1754   2555       Notch 1 intracellular domain.
FT                                {ECO:0000250}.
FT                                /FTId=PRO_0000007676.
FT   TOPO_DOM     19   1735       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1736   1756       Helical. {ECO:0000255}.
FT   TOPO_DOM   1757   2555       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       20     58       EGF-like 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN       59     99       EGF-like 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      102    139       EGF-like 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      140    176       EGF-like 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      178    216       EGF-like 5; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      218    255       EGF-like 6. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      257    293       EGF-like 7; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      295    333       EGF-like 8; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      335    371       EGF-like 9; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      372    410       EGF-like 10. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      412    450       EGF-like 11; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      452    488       EGF-like 12; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      490    526       EGF-like 13; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      528    564       EGF-like 14; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      566    601       EGF-like 15; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      603    639       EGF-like 16; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      641    676       EGF-like 17; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      678    714       EGF-like 18; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      716    751       EGF-like 19; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      753    789       EGF-like 20. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      791    827       EGF-like 21; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      829    867       EGF-like 22. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      869    905       EGF-like 23; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      907    943       EGF-like 24. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN      945    981       EGF-like 25; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN      983   1019       EGF-like 26. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1021   1057       EGF-like 27. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1059   1095       EGF-like 28. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1097   1143       EGF-like 29. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1145   1181       EGF-like 30. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1183   1219       EGF-like 31; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1221   1265       EGF-like 32; calcium-binding.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00076}.
FT   DOMAIN     1267   1305       EGF-like 33. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1307   1346       EGF-like 34. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1348   1384       EGF-like 35. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   DOMAIN     1387   1426       EGF-like 36. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00076}.
FT   REPEAT     1449   1489       LNR 1.
FT   REPEAT     1490   1531       LNR 2.
FT   REPEAT     1532   1571       LNR 3.
FT   REPEAT     1928   1960       ANK 1.
FT   REPEAT     1961   1994       ANK 2.
FT   REPEAT     1995   2027       ANK 3.
FT   REPEAT     2028   2060       ANK 4.
FT   REPEAT     2061   2094       ANK 5.
FT   REPEAT     2095   2122       ANK 6.
FT   REGION      420    421       Interaction with DLL4.
FT                                {ECO:0000250|UniProtKB:Q07008}.
FT   REGION      448    452       Interaction with DLL4.
FT                                {ECO:0000250|UniProtKB:Q07008}.
FT   REGION     1947   1955       HIF1AN-binding. {ECO:0000250}.
FT   REGION     2014   2022       HIF1AN-binding. {ECO:0000250}.
FT   COMPBIAS   1575   1578       Poly-Val.
FT   COMPBIAS   1661   1664       Poly-Arg.
FT   COMPBIAS   1728   1731       Poly-Pro.
FT   COMPBIAS   1740   1743       Poly-Ala.
FT   COMPBIAS   1901   1904       Poly-Glu.
FT   COMPBIAS   2259   2262       Poly-Gly.
FT   COMPBIAS   2403   2406       Poly-Gln.
FT   COMPBIAS   2410   2417       Poly-Pro.
FT   COMPBIAS   2521   2524       Poly-Ser.
FT   METAL       432    432       Calcium 1; via carbonyl oxygen.
FT                                {ECO:0000250|UniProtKB:Q07008}.
FT   METAL       435    435       Calcium 1; via amide nitrogen.
FT                                {ECO:0000250|UniProtKB:Q07008}.
FT   METAL       452    452       Calcium 2.
FT                                {ECO:0000250|UniProtKB:Q07008}.
FT   METAL       453    453       Calcium 2; via carbonyl oxygen.
FT                                {ECO:0000250|UniProtKB:Q07008}.
FT   METAL       455    455       Calcium 2.
FT                                {ECO:0000250|UniProtKB:Q07008}.
FT   METAL       469    469       Calcium 2.
FT                                {ECO:0000250|UniProtKB:Q07008}.
FT   METAL       470    470       Calcium 2; via carbonyl oxygen.
FT                                {ECO:0000250|UniProtKB:Q07008}.
FT   METAL       490    490       Calcium 3.
FT                                {ECO:0000250|UniProtKB:Q07008}.
FT   METAL       491    491       Calcium 3; via carbonyl oxygen.
FT                                {ECO:0000250|UniProtKB:Q07008}.
FT   METAL       493    493       Calcium 3.
FT                                {ECO:0000250|UniProtKB:Q07008}.
FT   METAL       507    507       Calcium 3.
FT                                {ECO:0000250|UniProtKB:Q07008}.
FT   METAL       508    508       Calcium 3; via carbonyl oxygen.
FT                                {ECO:0000250|UniProtKB:Q07008}.
FT   METAL      1457   1457       Calcium 4; via carbonyl oxygen.
FT   METAL      1460   1460       Calcium 4.
FT   METAL      1475   1475       Calcium 4.
FT   METAL      1478   1478       Calcium 4.
FT   SITE        469    469       Interaction with DLL4.
FT                                {ECO:0000250|UniProtKB:Q07008}.
FT   SITE       1664   1665       Cleavage; by furin-like protease.
FT                                {ECO:0000250}.
FT   SITE       1710   1711       Cleavage; by ADAM17. {ECO:0000250}.
FT   SITE       1720   1721       Cleavage; by ADAM17.
FT   MOD_RES    1861   1861       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   MOD_RES    1955   1955       (3S)-3-hydroxyasparagine; by HIF1AN;
FT                                partial. {ECO:0000269|PubMed:17573339}.
FT   MOD_RES    2022   2022       (3S)-3-hydroxyasparagine; by HIF1AN.
FT                                {ECO:0000250}.
FT   CARBOHYD     41     41       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD     65     65       O-linked (Glc...) serine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD     73     73       O-linked (Fuc...) threonine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD    116    116       O-linked (Fuc...) threonine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD    146    146       O-linked (Glc...) serine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD    194    194       O-linked (Fuc...) threonine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD    232    232       O-linked (Fuc...) threonine; alternate.
FT                                {ECO:0000269|PubMed:24226769}.
FT   CARBOHYD    232    232       O-linked (GalNAc...) threonine;
FT                                alternate. {ECO:0000269|PubMed:24226769}.
FT   CARBOHYD    311    311       O-linked (Fuc...) threonine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD    341    341       O-linked (Glc...) serine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD    349    349       O-linked (Fuc...) threonine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD    378    378       O-linked (Glc...) serine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD    435    435       O-linked (Glc...) serine.
FT                                {ECO:0000250|UniProtKB:Q07008}.
FT   CARBOHYD    458    458       O-linked (Glc...) serine.
FT                                {ECO:0000250|UniProtKB:Q07008}.
FT   CARBOHYD    466    466       O-linked (Fuc...) threonine.
FT                                {ECO:0000250|UniProtKB:Q07008}.
FT   CARBOHYD    496    496       O-linked (Glc...) serine.
FT                                {ECO:0000250|UniProtKB:Q07008}.
FT   CARBOHYD    534    534       O-linked (Glc...) serine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD    609    609       O-linked (Glc...) serine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD    617    617       O-linked (Fuc...) threonine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD    647    647       O-linked (Glc...) serine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD    692    692       O-linked (Fuc...) threonine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD    722    722       O-linked (Glc...) serine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD    759    759       O-linked (Glc...) serine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD    767    767       O-linked (Fuc...) threonine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD    784    784       O-linked (GlcNAc) serine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD    797    797       O-linked (Glc...) serine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD    805    805       O-linked (Fuc...) threonine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD    921    921       O-linked (Fuc) serine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD    951    951       O-linked (Glc...) serine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD    959    959       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    997    997       O-linked (Fuc...) threonine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD   1027   1027       O-linked (Glc...) serine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD   1035   1035       O-linked (Fuc...) threonine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD   1065   1065       O-linked (Glc...) serine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD   1159   1159       O-linked (Fuc...) threonine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD   1179   1179       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   1189   1189       O-linked (Glc...) serine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD   1197   1197       O-linked (Fuc...) threonine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD   1241   1241       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   1273   1273       O-linked (Glc...) serine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD   1362   1362       O-linked (Fuc...) threonine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD   1379   1379       O-linked (GlcNAc...) threonine.
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   CARBOHYD   1402   1402       O-linked (Fuc...) threonine; alternate.
FT                                {ECO:0000269|PubMed:24226769}.
FT   CARBOHYD   1402   1402       O-linked (GalNAc...) threonine;
FT                                alternate. {ECO:0000269|PubMed:24226769}.
FT   CARBOHYD   1489   1489       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   1587   1587       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD   1725   1725       O-linked (GalNAc...) threonine.
FT                                {ECO:0000269|PubMed:24226769}.
FT   DISULFID     24     37       {ECO:0000250}.
FT   DISULFID     31     46       {ECO:0000250}.
FT   DISULFID     48     57       {ECO:0000250}.
FT   DISULFID     63     74       {ECO:0000250}.
FT   DISULFID     68     87       {ECO:0000250}.
FT   DISULFID     89     98       {ECO:0000250}.
FT   DISULFID    106    117       {ECO:0000250}.
FT   DISULFID    111    127       {ECO:0000250}.
FT   DISULFID    129    138       {ECO:0000250}.
FT   DISULFID    144    155       {ECO:0000250}.
FT   DISULFID    149    164       {ECO:0000250}.
FT   DISULFID    166    175       {ECO:0000250}.
FT   DISULFID    182    195       {ECO:0000250}.
FT   DISULFID    189    204       {ECO:0000250}.
FT   DISULFID    206    215       {ECO:0000250}.
FT   DISULFID    222    233       {ECO:0000250}.
FT   DISULFID    227    243       {ECO:0000250}.
FT   DISULFID    245    254       {ECO:0000250}.
FT   DISULFID    261    272       {ECO:0000250}.
FT   DISULFID    266    281       {ECO:0000250}.
FT   DISULFID    283    292       {ECO:0000250}.
FT   DISULFID    299    312       {ECO:0000250}.
FT   DISULFID    306    321       {ECO:0000250}.
FT   DISULFID    323    332       {ECO:0000250}.
FT   DISULFID    339    350       {ECO:0000250}.
FT   DISULFID    344    359       {ECO:0000250}.
FT   DISULFID    361    370       {ECO:0000250}.
FT   DISULFID    376    387       {ECO:0000250}.
FT   DISULFID    381    398       {ECO:0000250}.
FT   DISULFID    400    409       {ECO:0000250}.
FT   DISULFID    416    429       {ECO:0000250|UniProtKB:Q07008}.
FT   DISULFID    423    438       {ECO:0000250|UniProtKB:Q07008}.
FT   DISULFID    440    449       {ECO:0000250|UniProtKB:Q07008}.
FT   DISULFID    456    467       {ECO:0000250|UniProtKB:Q07008}.
FT   DISULFID    461    476       {ECO:0000250|UniProtKB:Q07008}.
FT   DISULFID    478    487       {ECO:0000250|UniProtKB:Q07008}.
FT   DISULFID    494    505       {ECO:0000250|UniProtKB:Q07008}.
FT   DISULFID    499    514       {ECO:0000250|UniProtKB:Q07008}.
FT   DISULFID    516    525       {ECO:0000250|UniProtKB:Q07008}.
FT   DISULFID    532    543       {ECO:0000250}.
FT   DISULFID    537    552       {ECO:0000250}.
FT   DISULFID    554    563       {ECO:0000250}.
FT   DISULFID    570    580       {ECO:0000250}.
FT   DISULFID    575    589       {ECO:0000250}.
FT   DISULFID    591    600       {ECO:0000250}.
FT   DISULFID    607    618       {ECO:0000250}.
FT   DISULFID    612    627       {ECO:0000250}.
FT   DISULFID    629    638       {ECO:0000250}.
FT   DISULFID    645    655       {ECO:0000250}.
FT   DISULFID    650    664       {ECO:0000250}.
FT   DISULFID    666    675       {ECO:0000250}.
FT   DISULFID    682    693       {ECO:0000250}.
FT   DISULFID    687    702       {ECO:0000250}.
FT   DISULFID    704    713       {ECO:0000250}.
FT   DISULFID    720    730       {ECO:0000250}.
FT   DISULFID    725    739       {ECO:0000250}.
FT   DISULFID    741    750       {ECO:0000250}.
FT   DISULFID    757    768       {ECO:0000250}.
FT   DISULFID    762    777       {ECO:0000250}.
FT   DISULFID    779    788       {ECO:0000250}.
FT   DISULFID    795    806       {ECO:0000250}.
FT   DISULFID    800    815       {ECO:0000250}.
FT   DISULFID    817    826       {ECO:0000250}.
FT   DISULFID    833    844       {ECO:0000250}.
FT   DISULFID    838    855       {ECO:0000250}.
FT   DISULFID    857    866       {ECO:0000250}.
FT   DISULFID    873    884       {ECO:0000250}.
FT   DISULFID    878    893       {ECO:0000250}.
FT   DISULFID    895    904       {ECO:0000250}.
FT   DISULFID    911    922       {ECO:0000250}.
FT   DISULFID    916    931       {ECO:0000250}.
FT   DISULFID    933    942       {ECO:0000250}.
FT   DISULFID    949    960       {ECO:0000250}.
FT   DISULFID    954    969       {ECO:0000250}.
FT   DISULFID    971    980       {ECO:0000250}.
FT   DISULFID    987    998       {ECO:0000250}.
FT   DISULFID    992   1007       {ECO:0000250}.
FT   DISULFID   1009   1018       {ECO:0000250}.
FT   DISULFID   1025   1036       {ECO:0000250}.
FT   DISULFID   1030   1045       {ECO:0000250}.
FT   DISULFID   1047   1056       {ECO:0000250}.
FT   DISULFID   1063   1074       {ECO:0000250}.
FT   DISULFID   1068   1083       {ECO:0000250}.
FT   DISULFID   1085   1094       {ECO:0000250}.
FT   DISULFID   1101   1122       {ECO:0000250}.
FT   DISULFID   1116   1131       {ECO:0000250}.
FT   DISULFID   1133   1142       {ECO:0000250}.
FT   DISULFID   1149   1160       {ECO:0000250}.
FT   DISULFID   1154   1169       {ECO:0000250}.
FT   DISULFID   1171   1180       {ECO:0000250}.
FT   DISULFID   1187   1198       {ECO:0000250}.
FT   DISULFID   1192   1207       {ECO:0000250}.
FT   DISULFID   1209   1218       {ECO:0000250}.
FT   DISULFID   1225   1244       {ECO:0000250}.
FT   DISULFID   1238   1253       {ECO:0000250}.
FT   DISULFID   1255   1264       {ECO:0000250}.
FT   DISULFID   1271   1284       {ECO:0000250}.
FT   DISULFID   1276   1293       {ECO:0000250}.
FT   DISULFID   1295   1304       {ECO:0000250}.
FT   DISULFID   1311   1322       {ECO:0000250}.
FT   DISULFID   1316   1334       {ECO:0000250}.
FT   DISULFID   1336   1345       {ECO:0000250}.
FT   DISULFID   1352   1363       {ECO:0000250}.
FT   DISULFID   1357   1372       {ECO:0000250}.
FT   DISULFID   1374   1383       {ECO:0000250}.
FT   DISULFID   1391   1403       {ECO:0000250}.
FT   DISULFID   1397   1414       {ECO:0000250}.
FT   DISULFID   1416   1425       {ECO:0000250}.
FT   DISULFID   1449   1472       {ECO:0000269|PubMed:12795601}.
FT   DISULFID   1454   1467       {ECO:0000269|PubMed:12795601}.
FT   DISULFID   1463   1479       {ECO:0000269|PubMed:12795601}.
FT   DISULFID   1490   1514       {ECO:0000250}.
FT   DISULFID   1496   1509       {ECO:0000250}.
FT   DISULFID   1505   1521       {ECO:0000250}.
FT   DISULFID   1536   1549       {ECO:0000250}.
FT   DISULFID   1545   1561       {ECO:0000250}.
FT   CROSSLNK   1759   1759       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:Q01705}.
FT   VARIANT     300    300       Q -> R (in dbSNP:rs11574885).
FT                                /FTId=VAR_034898.
FT   VARIANT     429    429       C -> R (in AOS5; dbSNP:rs587777736).
FT                                {ECO:0000269|PubMed:25132448}.
FT                                /FTId=VAR_071960.
FT   VARIANT     879    879       R -> W (in dbSNP:rs11574895).
FT                                /FTId=VAR_048990.
FT   VARIANT    1496   1496       C -> Y (in AOS5; dbSNP:rs587781259).
FT                                {ECO:0000269|PubMed:25132448}.
FT                                /FTId=VAR_071961.
FT   VARIANT    1671   1671       V -> I (in dbSNP:rs2229968).
FT                                /FTId=VAR_046618.
FT   VARIANT    1989   1989       D -> N (in AOS5; dbSNP:rs587777734).
FT                                {ECO:0000269|PubMed:25132448}.
FT                                /FTId=VAR_071962.
FT   CONFLICT    187    187       G -> R (in Ref. 1; AAG33848 and 3;
FT                                AAA60614). {ECO:0000305}.
FT   CONFLICT    282    282       R -> P (in Ref. 1; AAG33848 and 3;
FT                                AAA60614). {ECO:0000305}.
FT   CONFLICT    477    477       I -> M (in Ref. 1; AAG33848 and 3;
FT                                AAA60614). {ECO:0000305}.
FT   CONFLICT    614    615       HG -> LR (in Ref. 1; AAG33848 and 3;
FT                                AAA60614). {ECO:0000305}.
FT   CONFLICT    621    621       R -> P (in Ref. 1; AAG33848 and 3;
FT                                AAA60614). {ECO:0000305}.
FT   CONFLICT    677    677       I -> S (in Ref. 1; AAG33848 and 3;
FT                                AAA60614). {ECO:0000305}.
FT   CONFLICT    775    775       Y -> I (in Ref. 1; AAG33848 and 3;
FT                                AAA60614). {ECO:0000305}.
FT   CONFLICT    803    803       Q -> K (in Ref. 1; AAG33848 and 3;
FT                                AAA60614). {ECO:0000305}.
FT   CONFLICT    860    862       GWQ -> AGAK (in Ref. 1; AAG33848 and 3;
FT                                AAA60614). {ECO:0000305}.
FT   CONFLICT   1021   1021       D -> V (in Ref. 1; AAG33848 and 3;
FT                                AAA60614). {ECO:0000305}.
FT   CONFLICT   1028   1028       Q -> R (in Ref. 1; AAG33848 and 3;
FT                                AAA60614). {ECO:0000305}.
FT   CONFLICT   1032   1032       H -> L (in Ref. 1; AAG33848 and 3;
FT                                AAA60614). {ECO:0000305}.
FT   CONFLICT   1040   1043       CGSY -> RGLH (in Ref. 1; AAG33848 and 3;
FT                                AAA60614). {ECO:0000305}.
FT   HELIX       143    146       {ECO:0000244|PDB:5FMA}.
FT   STRAND      154    157       {ECO:0000244|PDB:5FMA}.
FT   STRAND      162    165       {ECO:0000244|PDB:5FMA}.
FT   STRAND      170    175       {ECO:0000244|PDB:5FMA}.
FT   HELIX       181    184       {ECO:0000244|PDB:5FMA}.
FT   TURN        190    192       {ECO:0000244|PDB:5FMA}.
FT   STRAND      194    198       {ECO:0000244|PDB:5FMA}.
FT   STRAND      201    205       {ECO:0000244|PDB:5FMA}.
FT   STRAND      210    212       {ECO:0000244|PDB:5FMA}.
FT   STRAND      232    235       {ECO:0000244|PDB:5FMA}.
FT   STRAND      237    239       {ECO:0000244|PDB:5FMA}.
FT   STRAND      241    244       {ECO:0000244|PDB:5FMA}.
FT   STRAND      249    254       {ECO:0000244|PDB:5FMA}.
FT   STRAND      271    274       {ECO:0000244|PDB:5FMA}.
FT   STRAND      279    282       {ECO:0000244|PDB:5FMA}.
FT   STRAND      289    292       {ECO:0000244|PDB:5FMA}.
FT   HELIX       415    417       {ECO:0000244|PDB:4D0E}.
FT   STRAND      418    420       {ECO:0000244|PDB:4D0E}.
FT   STRAND      422    424       {ECO:0000244|PDB:4D0E}.
FT   STRAND      428    432       {ECO:0000244|PDB:4D0E}.
FT   STRAND      435    439       {ECO:0000244|PDB:4D0E}.
FT   STRAND      444    446       {ECO:0000244|PDB:4D0E}.
FT   HELIX       455    458       {ECO:0000244|PDB:5L0R}.
FT   STRAND      466    470       {ECO:0000244|PDB:5L0R}.
FT   STRAND      473    477       {ECO:0000244|PDB:5L0R}.
FT   STRAND      482    484       {ECO:0000244|PDB:5L0R}.
FT   TURN        493    496       {ECO:0000244|PDB:4D0E}.
FT   TURN        500    502       {ECO:0000244|PDB:2VJ3}.
FT   STRAND      504    507       {ECO:0000244|PDB:4D0E}.
FT   STRAND      512    515       {ECO:0000244|PDB:4D0E}.
FT   STRAND      520    522       {ECO:0000244|PDB:4D0E}.
FT   HELIX      1452   1457       {ECO:0000244|PDB:3ETO}.
FT   STRAND     1460   1462       {ECO:0000244|PDB:3ETO}.
FT   HELIX      1465   1467       {ECO:0000244|PDB:3ETO}.
FT   HELIX      1470   1472       {ECO:0000244|PDB:3ETO}.
FT   HELIX      1473   1476       {ECO:0000244|PDB:3ETO}.
FT   TURN       1477   1482       {ECO:0000244|PDB:3ETO}.
FT   TURN       1486   1489       {ECO:0000244|PDB:3ETO}.
FT   HELIX      1492   1494       {ECO:0000244|PDB:3ETO}.
FT   HELIX      1496   1498       {ECO:0000244|PDB:3ETO}.
FT   TURN       1499   1501       {ECO:0000244|PDB:3ETO}.
FT   STRAND     1502   1504       {ECO:0000244|PDB:3ETO}.
FT   HELIX      1507   1509       {ECO:0000244|PDB:3ETO}.
FT   HELIX      1512   1519       {ECO:0000244|PDB:3ETO}.
FT   TURN       1530   1532       {ECO:0000244|PDB:3ETO}.
FT   HELIX      1533   1539       {ECO:0000244|PDB:3ETO}.
FT   STRAND     1542   1544       {ECO:0000244|PDB:3ETO}.
FT   HELIX      1547   1549       {ECO:0000244|PDB:3ETO}.
FT   HELIX      1552   1559       {ECO:0000244|PDB:3ETO}.
FT   STRAND     1571   1580       {ECO:0000244|PDB:3ETO}.
FT   HELIX      1582   1587       {ECO:0000244|PDB:3ETO}.
FT   HELIX      1589   1600       {ECO:0000244|PDB:3ETO}.
FT   STRAND     1602   1606       {ECO:0000244|PDB:3ETO}.
FT   STRAND     1616   1620       {ECO:0000244|PDB:3ETO}.
FT   STRAND     1672   1681       {ECO:0000244|PDB:3ETO}.
FT   HELIX      1685   1688       {ECO:0000244|PDB:3ETO}.
FT   HELIX      1696   1708       {ECO:0000244|PDB:3ETO}.
FT   STRAND     1714   1716       {ECO:0000244|PDB:3ETO}.
FT   STRAND     1718   1724       {ECO:0000244|PDB:3ETO}.
FT   HELIX      1732   1756       {ECO:0000244|PDB:5KZO}.
FT   STRAND     1767   1769       {ECO:0000244|PDB:5KZO}.
FT   HELIX      1884   1890       {ECO:0000244|PDB:2F8X}.
FT   HELIX      1909   1914       {ECO:0000244|PDB:2F8X}.
FT   TURN       1925   1927       {ECO:0000244|PDB:2F8Y}.
FT   HELIX      1931   1937       {ECO:0000244|PDB:2F8Y}.
FT   HELIX      1941   1949       {ECO:0000244|PDB:2F8Y}.
FT   HELIX      1964   1970       {ECO:0000244|PDB:2F8Y}.
FT   HELIX      1974   1982       {ECO:0000244|PDB:2F8Y}.
FT   STRAND     1983   1985       {ECO:0000244|PDB:2F8X}.
FT   HELIX      1998   2005       {ECO:0000244|PDB:2F8Y}.
FT   HELIX      2008   2016       {ECO:0000244|PDB:2F8Y}.
FT   HELIX      2031   2037       {ECO:0000244|PDB:2F8Y}.
FT   HELIX      2041   2049       {ECO:0000244|PDB:2F8Y}.
FT   HELIX      2064   2071       {ECO:0000244|PDB:2F8Y}.
FT   HELIX      2074   2082       {ECO:0000244|PDB:2F8Y}.
FT   HELIX      2097   2103       {ECO:0000244|PDB:2F8Y}.
FT   HELIX      2107   2115       {ECO:0000244|PDB:2F8Y}.
SQ   SEQUENCE   2555 AA;  272505 MW;  E173C872D195F028 CRC64;
     MPPLLAPLLC LALLPALAAR GPRCSQPGET CLNGGKCEAA NGTEACVCGG AFVGPRCQDP
     NPCLSTPCKN AGTCHVVDRR GVADYACSCA LGFSGPLCLT PLDNACLTNP CRNGGTCDLL
     TLTEYKCRCP PGWSGKSCQQ ADPCASNPCA NGGQCLPFEA SYICHCPPSF HGPTCRQDVN
     ECGQKPGLCR HGGTCHNEVG SYRCVCRATH TGPNCERPYV PCSPSPCQNG GTCRPTGDVT
     HECACLPGFT GQNCEENIDD CPGNNCKNGG ACVDGVNTYN CRCPPEWTGQ YCTEDVDECQ
     LMPNACQNGG TCHNTHGGYN CVCVNGWTGE DCSENIDDCA SAACFHGATC HDRVASFYCE
     CPHGRTGLLC HLNDACISNP CNEGSNCDTN PVNGKAICTC PSGYTGPACS QDVDECSLGA
     NPCEHAGKCI NTLGSFECQC LQGYTGPRCE IDVNECVSNP CQNDATCLDQ IGEFQCICMP
     GYEGVHCEVN TDECASSPCL HNGRCLDKIN EFQCECPTGF TGHLCQYDVD ECASTPCKNG
     AKCLDGPNTY TCVCTEGYTG THCEVDIDEC DPDPCHYGSC KDGVATFTCL CRPGYTGHHC
     ETNINECSSQ PCRHGGTCQD RDNAYLCFCL KGTTGPNCEI NLDDCASSPC DSGTCLDKID
     GYECACEPGY TGSMCNINID ECAGNPCHNG GTCEDGINGF TCRCPEGYHD PTCLSEVNEC
     NSNPCVHGAC RDSLNGYKCD CDPGWSGTNC DINNNECESN PCVNGGTCKD MTSGYVCTCR
     EGFSGPNCQT NINECASNPC LNQGTCIDDV AGYKCNCLLP YTGATCEVVL APCAPSPCRN
     GGECRQSEDY ESFSCVCPTG WQGQTCEVDI NECVLSPCRH GASCQNTHGG YRCHCQAGYS
     GRNCETDIDD CRPNPCHNGG SCTDGINTAF CDCLPGFRGT FCEEDINECA SDPCRNGANC
     TDCVDSYTCT CPAGFSGIHC ENNTPDCTES SCFNGGTCVD GINSFTCLCP PGFTGSYCQH
     DVNECDSQPC LHGGTCQDGC GSYRCTCPQG YTGPNCQNLV HWCDSSPCKN GGKCWQTHTQ
     YRCECPSGWT GLYCDVPSVS CEVAAQRQGV DVARLCQHGG LCVDAGNTHH CRCQAGYTGS
     YCEDLVDECS PSPCQNGATC TDYLGGYSCK CVAGYHGVNC SEEIDECLSH PCQNGGTCLD
     LPNTYKCSCP RGTQGVHCEI NVDDCNPPVD PVSRSPKCFN NGTCVDQVGG YSCTCPPGFV
     GERCEGDVNE CLSNPCDARG TQNCVQRVND FHCECRAGHT GRRCESVING CKGKPCKNGG
     TCAVASNTAR GFICKCPAGF EGATCENDAR TCGSLRCLNG GTCISGPRSP TCLCLGPFTG
     PECQFPASSP CLGGNPCYNQ GTCEPTSESP FYRCLCPAKF NGLLCHILDY SFGGGAGRDI
     PPPLIEEACE LPECQEDAGN KVCSLQCNNH ACGWDGGDCS LNFNDPWKNC TQSLQCWKYF
     SDGHCDSQCN SAGCLFDGFD CQRAEGQCNP LYDQYCKDHF SDGHCDQGCN SAECEWDGLD
     CAEHVPERLA AGTLVVVVLM PPEQLRNSSF HFLRELSRVL HTNVVFKRDA HGQQMIFPYY
     GREEELRKHP IKRAAEGWAA PDALLGQVKA SLLPGGSEGG RRRRELDPMD VRGSIVYLEI
     DNRQCVQASS QCFQSATDVA AFLGALASLG SLNIPYKIEA VQSETVEPPP PAQLHFMYVA
     AAAFVLLFFV GCGVLLSRKR RRQHGQLWFP EGFKVSEASK KKRREPLGED SVGLKPLKNA
     SDGALMDDNQ NEWGDEDLET KKFRFEEPVV LPDLDDQTDH RQWTQQHLDA ADLRMSAMAP
     TPPQGEVDAD CMDVNVRGPD GFTPLMIASC SGGGLETGNS EEEEDAPAVI SDFIYQGASL
     HNQTDRTGET ALHLAARYSR SDAAKRLLEA SADANIQDNM GRTPLHAAVS ADAQGVFQIL
     IRNRATDLDA RMHDGTTPLI LAARLAVEGM LEDLINSHAD VNAVDDLGKS ALHWAAAVNN
     VDAAVVLLKN GANKDMQNNR EETPLFLAAR EGSYETAKVL LDHFANRDIT DHMDRLPRDI
     AQERMHHDIV RLLDEYNLVR SPQLHGAPLG GTPTLSPPLC SPNGYLGSLK PGVQGKKVRK
     PSSKGLACGS KEAKDLKARR KKSQDGKGCL LDSSGMLSPV DSLESPHGYL SDVASPPLLP
     SPFQQSPSVP LNHLPGMPDT HLGIGHLNVA AKPEMAALGG GGRLAFETGP PRLSHLPVAS
     GTSTVLGSSS GGALNFTVGG STSLNGQCEW LSRLQSGMVP NQYNPLRGSV APGPLSTQAP
     SLQHGMVGPL HSSLAASALS QMMSYQGLPS TRLATQPHLV QTQQVQPQNL QMQQQNLQPA
     NIQQQQSLQP PPPPPQPHLG VSSAASGHLG RSFLSGEPSQ ADVQPLGPSS LAVHTILPQE
     SPALPTSLPS SLVPPVTAAQ FLTPPSQHSY SSPVDNTPSH QLQVPEHPFL TPSPESPDQW
     SSSSPHSNVS DWSEGVSSPP TSMQSQIARI PEAFK
//
ID   NTRK1_HUMAN             Reviewed;         796 AA.
AC   P04629; B2R6T5; B7ZM34; P08119; Q15655; Q15656; Q5D056; Q5VZS2;
AC   Q7Z5C3; Q9UIU7;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   02-MAY-2006, sequence version 4.
DT   28-FEB-2018, entry version 231.
DE   RecName: Full=High affinity nerve growth factor receptor;
DE            EC=2.7.10.1 {ECO:0000269|PubMed:1281417, ECO:0000269|PubMed:2927393};
DE   AltName: Full=Neurotrophic tyrosine kinase receptor type 1;
DE   AltName: Full=TRK1-transforming tyrosine kinase protein;
DE   AltName: Full=Tropomyosin-related kinase A;
DE   AltName: Full=Tyrosine kinase receptor;
DE   AltName: Full=Tyrosine kinase receptor A;
DE            Short=Trk-A;
DE   AltName: Full=gp140trk {ECO:0000303|PubMed:2927393};
DE   AltName: Full=p140-TrkA;
DE   Flags: Precursor;
GN   Name=NTRK1;
GN   Synonyms=MTC, TRK {ECO:0000303|PubMed:2927393},
GN   TRKA {ECO:0000303|PubMed:9290260};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM TRKA-I), CATALYTIC ACTIVITY,
RP   PHOSPHORYLATION, GLYCOSYLATION, AND SUBCELLULAR LOCATION.
RC   TISSUE=Colon;
RX   PubMed=2927393; DOI=10.1128/MCB.9.1.24;
RA   Martin-Zanca D., Oskam R., Mitra G., Copeland T.D., Barbacid M.;
RT   "Molecular and biochemical characterization of the human trk proto-
RT   oncogene.";
RL   Mol. Cell. Biol. 9:24-33(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=7823156;
RA   Shelton D.L., Sutherland J., Gripp J., Camerato T., Armanini M.P.,
RA   Phillips H.S., Carroll K., Spencer S.D., Levinson A.D.;
RT   "Human trks: molecular cloning, tissue distribution, and expression of
RT   extracellular domain immunoadhesins.";
RL   J. Neurosci. 15:477-491(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9290260; DOI=10.1007/BF02766957;
RA   Indo Y., Mardy S., Tsuruta M., Karim M.A., Matsuda I.;
RT   "Structure and organization of the human TRKA gene encoding a high
RT   affinity receptor for nerve growth factor.";
RL   Jpn. J. Hum. Genet. 42:343-351(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM TRKA-II), AND
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-175 (ISOFORM 3).
RC   TISSUE=Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS TRKA-I AND TRKA-II).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-71.
RX   PubMed=15870692; DOI=10.1038/sj.onc.1208697;
RA   Fujimoto M., Kitazawa R., Maeda S., Kitazawa S.;
RT   "Methylation adjacent to negatively regulating AP-1 site reactivates
RT   TrkA gene expression during cancer progression.";
RL   Oncogene 24:5108-5118(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 399-796, AND CHROMOSOMAL TRANSLOCATION
RP   WITH TPM3.
RX   PubMed=2869410; DOI=10.1038/319743a0;
RA   Martin-Zanca D., Hughes S.H., Barbacid M.;
RT   "A human oncogene formed by the fusion of truncated tropomyosin and
RT   protein tyrosine kinase sequences.";
RL   Nature 319:743-748(1986).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 399-796.
RX   PubMed=2966065;
RA   Kozma S.C., Redmond S.M.S., Saurer S.M., Groner B., Hynes N.E.;
RT   "Activation of the receptor kinase domain of the trk oncogene by
RT   recombination with two different cellular sequences.";
RL   EMBO J. 7:147-154(1988).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 399-796, AND CHROMOSOMAL TRANSLOCATION
RP   WITH TFG.
RX   PubMed=7565764; DOI=10.1128/MCB.15.11.6118;
RA   Greco A., Mariani C., Miranda C., Lupas A., Pagliardini S., Pomati M.,
RA   Pierotti M.A.;
RT   "The DNA rearrangement that generates the TRK-T3 oncogene involves a
RT   novel gene on chromosome 3 whose product has a potential coiled-coil
RT   domain.";
RL   Mol. Cell. Biol. 15:6118-6127(1995).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 486-796, AND CHROMOSOMAL REARRANGEMENT
RP   WITH TPR.
RX   PubMed=1532241;
RA   Greco A., Pierotti M.A., Bongarzone I., Pagliardini S., Lanzi C.,
RA   Della Porta G.;
RT   "TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes
RT   in human papillary thyroid carcinomas.";
RL   Oncogene 7:237-242(1992).
RN   [12]
RP   FUNCTION AS RECEPTOR FOR NGF.
RX   PubMed=1850821; DOI=10.1038/350678a0;
RA   Hempstead B.L., Martin-Zanca D., Kaplan D.R., Parada L.F., Chao M.V.;
RT   "High-affinity NGF binding requires coexpression of the trk proto-
RT   oncogene and the low-affinity NGF receptor.";
RL   Nature 350:678-683(1991).
RN   [13]
RP   FUNCTION IN NGF SIGNALING, AND IDENTIFICATION AS THE HIGH AFFINITY NGF
RP   RECEPTOR.
RX   PubMed=1849459; DOI=10.1016/0092-8674(91)90419-Y;
RA   Klein R., Jing S., Nanduri V., O'Rourke E., Barbacid M.;
RT   "The trk proto-oncogene encodes a receptor for nerve growth factor.";
RL   Cell 65:189-197(1991).
RN   [14]
RP   FUNCTION, SUBUNIT, CATALYTIC ACTIVITY, PHOSPHORYLATION, SUBCELLULAR
RP   LOCATION, AND MUTAGENESIS OF LYS-544.
RX   PubMed=1281417; DOI=10.1016/0896-6273(92)90066-M;
RA   Jing S., Tapley P., Barbacid M.;
RT   "Nerve growth factor mediates signal transduction through trk
RT   homodimer receptors.";
RL   Neuron 9:1067-1079(1992).
RN   [15]
RP   ALTERNATIVE SPLICING (ISOFORMS TRKA-I AND TRKA-II), FUNCTION IN CELL
RP   SURVIVAL, NGF-BINDING, PHOSPHORYLATION, AND TISSUE SPECIFICITY.
RX   PubMed=8325889;
RA   Barker P.A., Lomen-Hoerth C., Gensch E.M., Meakin S.O., Glass D.J.,
RA   Shooter E.M.;
RT   "Tissue-specific alternative splicing generates two isoforms of the
RT   trkA receptor.";
RL   J. Biol. Chem. 268:15150-15157(1993).
RN   [16]
RP   PHOSPHORYLATION AT TYR-791, INTERACTION WITH PLCG1, AND MUTAGENESIS OF
RP   TYR-791.
RX   PubMed=7510697;
RA   Loeb D.M., Stephens R.M., Copeland T.D., Kaplan D.R., Greene L.A.;
RT   "A Trk nerve growth factor (NGF) receptor point mutation affecting
RT   interaction with phospholipase C-gamma 1 abolishes NGF-promoted
RT   peripherin induction but not neurite outgrowth.";
RL   J. Biol. Chem. 269:8901-8910(1994).
RN   [17]
RP   FUNCTION IN NEURONAL DIFFERENTIATION, FUNCTION IN PHOSPHORYLATION OF
RP   SHC1 AND PLCG1, INTERACTION WITH SHC1, MUTAGENESIS OF TYR-496; LYS-544
RP   AND TYR-791, AND PHOSPHORYLATION AT TYR-496 AND TYR-791.
RX   PubMed=8155326; DOI=10.1016/0896-6273(94)90223-2;
RA   Stephens R.M., Loeb D.M., Copeland T.D., Pawson T., Greene L.A.,
RA   Kaplan D.R.;
RT   "Trk receptors use redundant signal transduction pathways involving
RT   SHC and PLC-gamma 1 to mediate NGF responses.";
RL   Neuron 12:691-705(1994).
RN   [18]
RP   FUNCTION IN NF-KAPPA-B ACTIVATION, AND INTERACTION WITH SQSTM1.
RX   PubMed=11244088; DOI=10.1074/jbc.C000869200;
RA   Wooten M.W., Seibenhener M.L., Mamidipudi V., Diaz-Meco M.T.,
RA   Barker P.A., Moscat J.;
RT   "The atypical protein kinase C-interacting protein p62 is a scaffold
RT   for NF-kappaB activation by nerve growth factor.";
RL   J. Biol. Chem. 276:7709-7712(2001).
RN   [19]
RP   FUNCTION IN NEURONAL CELL PROLIFERATION AND DIFFERENTIATION, FUNCTION
RP   IN SIGNALING CASCADE ACTIVATION, NGF-BINDING, SUBCELLULAR LOCATION,
RP   ALTERNATIVE SPLICING (ISOFORM TRKA-III), CHARACTERIZATION OF ISOFORM
RP   TRKA-III, PHOSPHORYLATION AT TYR-496; TYR-680; TYR-681 AND TYR-791,
RP   INTERACTION WITH FRS2; GRB2; PIK3R1; PLCG1; SHC1, GLYCOSYLATION,
RP   TISSUE SPECIFICITY, AND INDUCTION BY HYPOXIA.
RX   PubMed=15488758; DOI=10.1016/j.ccr.2004.09.011;
RA   Tacconelli A., Farina A.R., Cappabianca L., Desantis G., Tessitore A.,
RA   Vetuschi A., Sferra R., Rucci N., Argenti B., Screpanti I., Gulino A.,
RA   Mackay A.R.;
RT   "TrkA alternative splicing: a regulated tumor-promoting switch in
RT   human neuroblastoma.";
RL   Cancer Cell 6:347-360(2004).
RN   [20]
RP   INTERACTION WITH SORT1, AND ENZYME REGULATION.
RX   PubMed=21102451; DOI=10.1038/nn.2689;
RA   Vaegter C.B., Jansen P., Fjorback A.W., Glerup S., Skeldal S.,
RA   Kjolby M., Richner M., Erdmann B., Nyengaard J.R., Tessarollo L.,
RA   Lewin G.R., Willnow T.E., Chao M.V., Nykjaer A.;
RT   "Sortilin associates with Trk receptors to enhance anterograde
RT   transport and neurotrophin signaling.";
RL   Nat. Neurosci. 14:54-61(2011).
RN   [21]
RP   PHOSPHORYLATION, VARIANTS CIPA 235-SER--GLY-796 DEL; ASN-596 AND
RP   TYR-674, AND CHARACTERIZATION OF VARIANTS CIPA 235-SER--GLY-796 DEL
RP   AND ASN-596.
RX   PubMed=28177573; DOI=10.1111/jns.12205;
RA   Nam T.S., Li W., Yoon S., Eom G.H., Kim M.K., Jung S.T., Choi S.Y.;
RT   "Novel NTRK1 mutations associated with congenital insensitivity to
RT   pain with anhidrosis verified by functional studies.";
RL   J. Peripher. Nerv. Syst. 22:92-99(2017).
RN   [22]
RP   STRUCTURE BY NMR OF 489-500.
RX   PubMed=8524391; DOI=10.1038/378584a0;
RA   Zhou M.-M., Ravichandran K.S., Olejniczak E.F., Petros A.M.,
RA   Meadows R.P., Sattler M., Harlan J.E., Wade W.S., Burakoff S.J.,
RA   Fesik S.W.;
RT   "Structure and ligand recognition of the phosphotyrosine binding
RT   domain of Shc.";
RL   Nature 378:584-592(1995).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 278-386, AND DISULFIDE
RP   BONDS.
RX   PubMed=10388563; DOI=10.1006/jmbi.1999.2816;
RA   Ultsch M.H., Wiesmann C., Simmons L.C., Henrich J., Yang M.,
RA   Reilly D., Bass S.H., de Vos A.M.;
RT   "Crystal structures of the neurotrophin-binding domain of TrkA, TrkB
RT   and TrkC.";
RL   J. Mol. Biol. 290:149-159(1999).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 282-382 IN COMPLEX WITH NGF,
RP   SUBUNIT, AND DISULFIDE BONDS.
RX   PubMed=10490030; DOI=10.1038/43705;
RA   Wiesmann C., Ultsch M.H., Bass S.H., de Vos A.M.;
RT   "Crystal structure of nerve growth factor in complex with the ligand-
RT   binding domain of the TrkA receptor.";
RL   Nature 401:184-188(1999).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (3.4 ANGSTROMS) OF 36-382 IN COMPLEX WITH NGF,
RP   HOMODIMERIZATION, SUBUNIT, SUBCELLULAR LOCATION, DISULFIDE BONDS, AND
RP   GLYCOSYLATION AT ASN-95; ASN-121; ASN-188; ASN-262; ASN-281 AND
RP   ASN-358.
RX   PubMed=17196528; DOI=10.1016/j.neuron.2006.09.034;
RA   Wehrman T., He X., Raab B., Dukipatti A., Blau H., Garcia K.C.;
RT   "Structural and mechanistic insights into nerve growth factor
RT   interactions with the TrkA and p75 receptors.";
RL   Neuron 53:25-38(2007).
RN   [26]
RP   VARIANT CIPA ARG-577.
RX   PubMed=8696348; DOI=10.1038/ng0896-485;
RA   Indo Y., Tsuruta M., Hayashida Y., Karim M.A., Ohta K., Kawano T.,
RA   Mitsubuchi H., Tonoki H., Awaya Y., Matsuda I.;
RT   "Mutations in the TRKA/NGF receptor gene in patients with congenital
RT   insensitivity to pain with anhidrosis.";
RL   Nat. Genet. 13:485-488(1996).
RN   [27]
RP   VARIANT CIPA PRO-780.
RX   PubMed=10090906; DOI=10.1086/302319;
RA   Greco A., Villa R., Tubino B., Romano L., Penso D., Pierotti M.A.;
RT   "A novel NTRK1 mutation associated with congenital insensitivity to
RT   pain with anhidrosis.";
RL   Am. J. Hum. Genet. 64:1207-1210(1999).
RN   [28]
RP   VARIANTS CIPA PRO-213; TRP-649 AND SER-714, AND VARIANTS SER-85;
RP   TYR-604 AND VAL-613.
RX   PubMed=10330344; DOI=10.1086/302422;
RA   Mardy S., Miura Y., Endo F., Matsuda I., Sztriha L., Frossard P.,
RA   Moosa A., Ismail E.A.R., Macaya A., Andria G., Toscano E., Gibson W.,
RA   Graham G.E., Indo Y.;
RT   "Congenital insensitivity to pain with anhidrosis: novel mutations in
RT   the TRKA (NTRK1) gene encoding a high-affinity receptor for nerve
RT   growth factor.";
RL   Am. J. Hum. Genet. 64:1570-1579(1999).
RN   [29]
RP   VARIANTS TYR-604; VAL-613 AND GLN-780.
RX   PubMed=10443680; DOI=10.1210/jcem.84.8.5901;
RA   Gimm O., Greco A., Hoang-Vu C., Dralle H., Pierotti M.A., Eng C.;
RT   "Mutation analysis reveals novel sequence variants in NTRK1 in
RT   sporadic human medullary thyroid carcinoma.";
RL   J. Clin. Endocrinol. Metab. 84:2784-2787(1999).
RN   [30]
RP   VARIANT CIPA VAL-587.
RX   PubMed=10233776; DOI=10.1046/j.1523-1747.1999.00569.x;
RA   Yotsumoto S., Setoyama M., Hozumi H., Mizoguchi S., Fukumaru S.,
RA   Kobayashi K., Saheki T., Kanzaki T.;
RT   "A novel point mutation affecting the tyrosine kinase domain of the
RT   TRKA gene in a family with congenital insensitivity to pain with
RT   anhidrosis.";
RL   J. Invest. Dermatol. 112:810-814(1999).
RN   [31]
RP   VARIANTS TYR-604 AND VAL-613.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions
RT   of human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [32]
RP   ERRATUM.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [33]
RP   VARIANT CIPA LEU-695, AND VARIANT VAL-613.
RC   TISSUE=Peripheral blood;
RX   PubMed=10861667;
RX   DOI=10.1002/1096-8628(20000619)92:5<353::AID-AJMG12>3.0.CO;2-C;
RA   Shatzky S., Moses S., Levy J., Pinsk V., Hershkovitz E., Herzog L.,
RA   Shorer Z., Luder A., Parvari R.;
RT   "Congenital insensitivity to pain with anhidrosis (CIPA) in Israeli-
RT   Bedouins: genetic heterogeneity, novel mutations in the TRKA/NGF
RT   receptor gene, clinical findings, and results of nerve conduction
RT   studies.";
RL   Am. J. Med. Genet. 92:353-360(2000).
RN   [34]
RP   VARIANTS CIPA PRO-93; ARG-522; ARG-577; CYS-654 AND TYR-674.
RX   PubMed=10982191; DOI=10.1007/s004390051018;
RA   Miura Y., Mardy S., Awaya Y., Nihei K., Endo F., Matsuda I., Indo Y.;
RT   "Mutation and polymorphism analysis of the TRKA (NTRK1) gene encoding
RT   a high-affinity receptor for nerve growth factor in congenital
RT   insensitivity to pain with anhidrosis (CIPA) families.";
RL   Hum. Genet. 106:116-124(2000).
RN   [35]
RP   VARIANT CIPA ARG-577.
RX   PubMed=10567924;
RX   DOI=10.1002/(SICI)1097-4652(200001)182:1<127::AID-JCP14>3.0.CO;2-0;
RA   Greco A., Villa R., Fusetti L., Orlandi R., Pierotti M.A.;
RT   "The Gly571Arg mutation, associated with the autonomic and sensory
RT   disorder congenital insensitivity to pain with anhidrosis, causes the
RT   inactivation of the NTRK1/nerve growth factor receptor.";
RL   J. Cell. Physiol. 182:127-133(2000).
RN   [36]
RP   VARIANT CIPA CYS-359, AND VARIANTS TYR-604 AND VAL-613.
RX   PubMed=11310631; DOI=10.1002/ana.103;
RA   Houlden H., King R.H., Hashemi-Nejad A., Wood N.W., Mathias C.J.,
RA   Reilly M., Thomas P.K.;
RT   "A novel TRK A (NTRK1) mutation associated with hereditary sensory and
RT   autonomic neuropathy type V.";
RL   Ann. Neurol. 49:521-525(2001).
RN   [37]
RP   CHARACTERIZATION OF VARIANTS CIPA PRO-93; PRO-213; ARG-522; ARG-577;
RP   TRP-649; CYS-654 AND SER-714, AND CHARACTERIZATION OF VARIANTS SER-85;
RP   TYR-604; VAL-613 AND TYR-674.
RX   PubMed=11159935; DOI=10.1093/hmg/10.3.179;
RA   Mardy S., Miura Y., Endo F., Matsuda I., Indo Y.;
RT   "Congenital insensitivity to pain with anhidrosis (CIPA): effect of
RT   TRKA (NTRK1) missense mutations on autophosphorylation of the receptor
RT   tyrosine kinase for nerve growth factor.";
RL   Hum. Mol. Genet. 10:179-188(2001).
RN   [38]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-80; VAL-107; MET-237; GLY-238;
RP   GLY-260; GLN-444; CYS-452; THR-566; TYR-604; VAL-613; GLN-780 AND
RP   ILE-790.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [39]
RP   VARIANTS CIPA SER-572 AND ARG-717.
RX   PubMed=18077166; DOI=10.1016/j.nmd.2007.10.005;
RA   Huehne K., Zweier C., Raab K., Odent S., Bonnaure-Mallet M.,
RA   Sixou J.L., Landrieu P., Goizet C., Sarlangue J., Baumann M.,
RA   Eggermann T., Rauch A., Ruppert S., Stettner G.M., Rautenstrauss B.;
RT   "Novel missense, insertion and deletion mutations in the neurotrophic
RT   tyrosine kinase receptor type 1 gene (NTRK1) associated with
RT   congenital insensitivity to pain with anhidrosis.";
RL   Neuromuscul. Disord. 18:159-166(2008).
RN   [40]
RP   VARIANTS CIPA LYS-492 AND CYS-654, AND VARIANT TRP-6.
RX   PubMed=22302274; DOI=10.1007/s00415-011-6397-y;
RA   Davidson G.L., Murphy S.M., Polke J.M., Laura M., Salih M.A.,
RA   Muntoni F., Blake J., Brandner S., Davies N., Horvath R., Price S.,
RA   Donaghy M., Roberts M., Foulds N., Ramdharry G., Soler D., Lunn M.P.,
RA   Manji H., Davis M.B., Houlden H., Reilly M.M.;
RT   "Frequency of mutations in the genes associated with hereditary
RT   sensory and autonomic neuropathy in a UK cohort.";
RL   J. Neurol. 259:1673-1685(2012).
RN   [41]
RP   VARIANTS CIPA ASP-110; 146-SER--GLY-796 DEL; 176-GLN--GLY-796 DEL;
RP   476-LEU--GLY-796 DEL; GLN-649 AND PRO-700.
RX   PubMed=28328124; DOI=10.1002/ajmg.a.38120;
RA   Altassan R., Saud H.A., Masoodi T.A., Dosssari H.A., Khalifa O.,
RA   Al-Zaidan H., Sakati N., Rhabeeni Z., Al-Hassnan Z., Binamer Y.,
RA   Alhashemi N., Wade W., Al-Zayed Z., Al-Sayed M., Al-Muhaizea M.A.,
RA   Meyer B., Al-Owain M., Wakil S.M.;
RT   "Exome sequencing identifies novel NTRK1 mutations in patients with
RT   HSAN-IV phenotype.";
RL   Am. J. Med. Genet. A 173:1009-1016(2017).
RN   [42]
RP   VARIANTS CIPA GLU-517; GLU-522; PRO-657; THR-699; SER-752; SER-763 AND
RP   CYS-771, CHARACTERIZATION OF VARIANTS CIPA GLU-517; GLU-522; PRO-657;
RP   THR-699; SER-752; SER-763 AND CYS-771, GLYCOSYLATION, SUBCELLULAR
RP   LOCATION, AUTOPHOSPHORYLATION AFTER NGF STIMULATION, AND FUNCTION.
RX   PubMed=27676246; DOI=10.1002/humu.23123;
RA   Shaikh S.S., Chen Y.C., Halsall S.A., Nahorski M.S., Omoto K.,
RA   Young G.T., Phelan A., Woods C.G.;
RT   "A comprehensive functional analysis of NTRK1 missense mutations
RT   causing hereditary sensory and autonomic neuropathy type IV (HSAN
RT   IV).";
RL   Hum. Mutat. 38:55-63(2017).
CC   -!- FUNCTION: Receptor tyrosine kinase involved in the development and
CC       the maturation of the central and peripheral nervous systems
CC       through regulation of proliferation, differentiation and survival
CC       of sympathetic and nervous neurons. High affinity receptor for NGF
CC       which is its primary ligand (PubMed:1850821, PubMed:1849459,
CC       PubMed:1281417, PubMed:8325889, PubMed:15488758, PubMed:17196528).
CC       Can also bind and be activated by NTF3/neurotrophin-3. However,
CC       NTF3 only supports axonal extension through NTRK1 but has no
CC       effect on neuron survival (By similarity). Upon dimeric NGF
CC       ligand-binding, undergoes homodimerization, autophosphorylation
CC       and activation (PubMed:1281417). Recruits, phosphorylates and/or
CC       activates several downstream effectors including SHC1, FRS2,
CC       SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping
CC       signaling cascades driving cell survival and differentiation.
CC       Through SHC1 and FRS2 activates a GRB2-Ras-MAPK cascade that
CC       regulates cell differentiation and survival. Through PLCG1
CC       controls NF-Kappa-B activation and the transcription of genes
CC       involved in cell survival. Through SHC1 and SH2B1 controls a Ras-
CC       PI3 kinase-AKT1 signaling cascade that is also regulating
CC       survival. In absence of ligand and activation, may promote cell
CC       death, making the survival of neurons dependent on trophic
CC       factors. {ECO:0000250|UniProtKB:P35739,
CC       ECO:0000250|UniProtKB:Q3UFB7, ECO:0000269|PubMed:11244088,
CC       ECO:0000269|PubMed:1281417, ECO:0000269|PubMed:15488758,
CC       ECO:0000269|PubMed:17196528, ECO:0000269|PubMed:1849459,
CC       ECO:0000269|PubMed:1850821, ECO:0000269|PubMed:27676246,
CC       ECO:0000269|PubMed:8155326, ECO:0000269|PubMed:8325889}.
CC   -!- FUNCTION: Isoform TrkA-III: Resistant to NGF, it constitutively
CC       activates AKT1 and NF-kappa-B and is unable to activate the Ras-
CC       MAPK signaling cascade. Antagonizes the anti-proliferative NGF-
CC       NTRK1 signaling that promotes neuronal precursors differentiation.
CC       Isoform TrkA-III promotes angiogenesis and has oncogenic activity
CC       when overexpressed. {ECO:0000269|PubMed:15488758}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:1281417,
CC       ECO:0000269|PubMed:2927393}.
CC   -!- ENZYME REGULATION: The pro-survival signaling effect of NTRK1 in
CC       neurons requires its endocytosis into signaling early endosomes
CC       and its retrograde axonal transport. This is regulated by
CC       different proteins including CFL1, RAC1 and SORT1. NTF3 is unable
CC       to induce this signaling probably due to the lability of the NTF3-
CC       NTRK1 complex in endosomes. SH2D1A inhibits the
CC       autophosphorylation of the receptor, and alters the recruitment
CC       and activation of downstream effectors and signaling cascades (By
CC       similarity). Regulated by NGFR (By similarity). {ECO:0000250,
CC       ECO:0000250|UniProtKB:Q3UFB7}.
CC   -!- SUBUNIT: Exists in a dynamic equilibrium between monomeric (low
CC       affinity) and dimeric (high affinity) structures. Homodimerization
CC       is induced by binding of a NGF dimer (PubMed:1281417,
CC       PubMed:10490030, PubMed:17196528). Interacts with SQSTM1; bridges
CC       NTRK1 to NGFR (PubMed:11244088). Forms a ternary complex with NGFR
CC       and KIDINS220; this complex is affected by the expression levels
CC       of KIDINS220 and an increase in KIDINS220 expression leads to a
CC       decreased association of NGFR and NTRK1 (By similarity). Interacts
CC       with SH2D1A; regulates NTRK1 (By similarity). Interacts
CC       (phosphorylated upon activation by NGF) with SHC1; mediates SHC1
CC       phosphorylation and activation (PubMed:8155326, PubMed:15488758).
CC       Interacts (phosphorylated upon activation by NGF) with PLCG1;
CC       mediates PLCG1 phosphorylation and activation (PubMed:7510697,
CC       PubMed:15488758). Interacts (phosphorylated) with SH2B1 and SH2B2
CC       (By similarity). Interacts with GRB2 (PubMed:15488758). Interacts
CC       with PIK3R1 (PubMed:15488758). Interacts with FRS2
CC       (PubMed:15488758). Interacts with SORT1; may regulate NTRK1
CC       anterograde axonal transport (PubMed:21102451). Interacts with
CC       RAB7A (By similarity). Found in a complex, at least composed of
CC       KIDINS220, MAGI2, NTRK1 and RAPGEF2; the complex is mainly formed
CC       at late endosomes in a nerve growth factor (NGF)-dependent manner
CC       (By similarity). Interacts with RAPGEF2; the interaction is
CC       strengthened after NGF stimulation (By similarity). Interacts with
CC       PTPRS (By similarity). {ECO:0000250, ECO:0000250|UniProtKB:P35739,
CC       ECO:0000269|PubMed:10490030, ECO:0000269|PubMed:11244088,
CC       ECO:0000269|PubMed:1281417, ECO:0000269|PubMed:15488758,
CC       ECO:0000269|PubMed:17196528, ECO:0000269|PubMed:21102451,
CC       ECO:0000269|PubMed:7510697, ECO:0000269|PubMed:8155326,
CC       ECO:0000269|PubMed:8325889}.
CC   -!- INTERACTION:
CC       P22681:CBL; NbExp=2; IntAct=EBI-1028226, EBI-518228;
CC       P01138:NGF; NbExp=3; IntAct=EBI-1028226, EBI-1028250;
CC       Q8K4V6:Pirb (xeno); NbExp=2; IntAct=EBI-1028226, EBI-8602514;
CC       P18031:PTPN1; NbExp=2; IntAct=EBI-1028226, EBI-968788;
CC       Q99523:SORT1; NbExp=3; IntAct=EBI-1028226, EBI-1057058;
CC       Q13501:SQSTM1; NbExp=2; IntAct=EBI-1028226, EBI-307104;
CC       O75385:ULK1; NbExp=2; IntAct=EBI-1028226, EBI-908831;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:1281417,
CC       ECO:0000269|PubMed:15488758, ECO:0000269|PubMed:17196528,
CC       ECO:0000269|PubMed:27676246, ECO:0000269|PubMed:2927393}; Single-
CC       pass type I membrane protein {ECO:0000269|PubMed:1281417,
CC       ECO:0000269|PubMed:15488758}. Early endosome membrane
CC       {ECO:0000250|UniProtKB:P35739}; Single-pass type I membrane
CC       protein {ECO:0000250|UniProtKB:P35739}. Late endosome membrane
CC       {ECO:0000250|UniProtKB:P35739}; Single-pass type I membrane
CC       protein {ECO:0000250|UniProtKB:P35739}. Note=Rapidly internalized
CC       after NGF binding (PubMed:1281417). Internalized to endosomes upon
CC       binding of NGF or NTF3 and further transported to the cell body
CC       via a retrograde axonal transport. Localized at cell membrane and
CC       early endosomes before nerve growth factor (NGF) stimulation.
CC       Recruited to late endosomes after NGF stimulation. Colocalized
CC       with RAPGEF2 at late endosomes. {ECO:0000250|UniProtKB:P35739,
CC       ECO:0000269|PubMed:1281417}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC         Comment=TrkA-I and TrkA-II isoforms have similar biological
CC         properties but are differentially expressed.;
CC       Name=TrkA-II; Synonyms=TrkAII;
CC         IsoId=P04629-1; Sequence=Displayed;
CC         Note=Major isoform.;
CC       Name=TrkA-I; Synonyms=TrkAI;
CC         IsoId=P04629-2; Sequence=VSP_002899;
CC         Note=Has enhanced responsiveness to NTF3 neurotrophin.;
CC       Name=3;
CC         IsoId=P04629-3; Sequence=VSP_041905, VSP_002899;
CC       Name=TrkA-III; Synonyms=TrkAIII;
CC         IsoId=P04629-4; Sequence=VSP_042152, VSP_002899;
CC         Note=Constitutively active. Does not bind NGF and does not
CC         interact with GRB2 and FRS2.;
CC   -!- TISSUE SPECIFICITY: Isoform TrkA-I is found in most non-neuronal
CC       tissues. Isoform TrkA-II is primarily expressed in neuronal cells.
CC       TrkA-III is specifically expressed by pluripotent neural stem and
CC       neural crest progenitors. {ECO:0000269|PubMed:15488758,
CC       ECO:0000269|PubMed:8325889}.
CC   -!- INDUCTION: Isoform TrkA-III is up-regulated upon hypoxia in cells
CC       normally expressing it. {ECO:0000269|PubMed:15488758}.
CC   -!- DOMAIN: The transmembrane domain mediates interaction with
CC       KIDINS220. {ECO:0000250}.
CC   -!- DOMAIN: The extracellular domain mediates interaction with NGFR.
CC       {ECO:0000250}.
CC   -!- PTM: Ligand-mediated autophosphorylation (PubMed:2927393,
CC       PubMed:1281417, PubMed:15488758, PubMed:7510697, PubMed:8155326,
CC       PubMed:8325889, PubMed:27676246, PubMed:28177573). Interaction
CC       with SQSTM1 is phosphotyrosine-dependent. Autophosphorylation at
CC       Tyr-496 mediates interaction and phosphorylation of SHC1
CC       (PubMed:15488758, PubMed:7510697, PubMed:8155326, PubMed:8325889).
CC       {ECO:0000269|PubMed:1281417, ECO:0000269|PubMed:15488758,
CC       ECO:0000269|PubMed:27676246, ECO:0000269|PubMed:28177573,
CC       ECO:0000269|PubMed:2927393, ECO:0000269|PubMed:7510697,
CC       ECO:0000269|PubMed:8155326, ECO:0000269|PubMed:8325889}.
CC   -!- PTM: N-glycosylated (PubMed:2927393). Isoform TrkA-I and isoform
CC       TrkA-II are N-glycosylated. {ECO:0000269|PubMed:15488758,
CC       ECO:0000269|PubMed:17196528, ECO:0000269|PubMed:27676246,
CC       ECO:0000269|PubMed:2927393}.
CC   -!- PTM: Ubiquitinated. Undergoes polyubiquitination upon activation;
CC       regulated by NGFR. Ubiquitination regulates the internalization of
CC       the receptor. {ECO:0000250|UniProtKB:Q3UFB7}.
CC   -!- DISEASE: Congenital insensitivity to pain with anhidrosis (CIPA)
CC       [MIM:256800]: Characterized by a congenital insensitivity to pain,
CC       anhidrosis (absence of sweating), absence of reaction to noxious
CC       stimuli, self-mutilating behavior, and mental retardation. This
CC       rare autosomal recessive disorder is also known as congenital
CC       sensory neuropathy with anhidrosis or hereditary sensory and
CC       autonomic neuropathy type IV or familial dysautonomia type II.
CC       {ECO:0000269|PubMed:10090906, ECO:0000269|PubMed:10233776,
CC       ECO:0000269|PubMed:10330344, ECO:0000269|PubMed:10567924,
CC       ECO:0000269|PubMed:10861667, ECO:0000269|PubMed:10982191,
CC       ECO:0000269|PubMed:11159935, ECO:0000269|PubMed:11310631,
CC       ECO:0000269|PubMed:18077166, ECO:0000269|PubMed:22302274,
CC       ECO:0000269|PubMed:27676246, ECO:0000269|PubMed:28177573,
CC       ECO:0000269|PubMed:28328124, ECO:0000269|PubMed:8696348}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Note=Chromosomal aberrations involving NTRK1 are found in
CC       papillary thyroid carcinomas (PTCs) (PubMed:2869410,
CC       PubMed:7565764, PubMed:1532241). Translocation t(1;3)(q21;q11)
CC       with TFG generates the TRKT3 (TRK-T3) transcript by fusing TFG to
CC       the 3'-end of NTRK1 (PubMed:7565764). A rearrangement with TPM3
CC       generates the TRK transcript by fusing TPM3 to the 3'-end of NTRK1
CC       (PubMed:2869410). An intrachromosomal rearrangement that links the
CC       protein kinase domain of NTRK1 to the 5'-end of the TPR gene forms
CC       the fusion protein TRK-T1. TRK-T1 is a 55 kDa protein reacting
CC       with antibodies against the C-terminus of the NTRK1 protein
CC       (PubMed:1532241). {ECO:0000269|PubMed:1532241,
CC       ECO:0000269|PubMed:2869410, ECO:0000269|PubMed:7565764}.
CC   -!- MISCELLANEOUS: Trk also stands for tropomyosin-related kinase
CC       since it was first isolated as an oncogenic protein which was the
CC       result of a fusion between the tropomyosin gene TPM3 and NTRK1.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA27243.1; Type=Erroneous termination; Positions=786; Note=Translated as Gln.; Evidence={ECO:0000305};
CC       Sequence=CAA27243.1; Type=Frameshift; Positions=769; Evidence={ECO:0000305};
CC       Sequence=CAA27243.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC       Sequence=CAA29888.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC       Sequence=CAA44719.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC       Sequence=CAA59936.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M23102; AAA36770.1; -; mRNA.
DR   EMBL; AB019488; BAA34355.1; -; Genomic_DNA.
DR   EMBL; AK312704; BAG35582.1; -; mRNA.
DR   EMBL; DB265639; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AL158169; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC062580; AAH62580.1; -; mRNA.
DR   EMBL; BC136554; AAI36555.1; -; mRNA.
DR   EMBL; BC144239; AAI44240.1; -; mRNA.
DR   EMBL; AY321513; AAP88292.1; -; Genomic_DNA.
DR   EMBL; X03541; CAA27243.1; ALT_SEQ; mRNA.
DR   EMBL; X06704; CAA29888.1; ALT_SEQ; mRNA.
DR   EMBL; X85960; CAA59936.1; ALT_SEQ; mRNA.
DR   EMBL; X62947; CAA44719.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS1161.1; -. [P04629-1]
DR   CCDS; CCDS30890.1; -. [P04629-3]
DR   CCDS; CCDS30891.1; -. [P04629-2]
DR   PIR; A30124; TVHUTT.
DR   PIR; S23741; S23741.
DR   RefSeq; NP_001007793.1; NM_001007792.1. [P04629-3]
DR   RefSeq; NP_001012331.1; NM_001012331.1. [P04629-2]
DR   RefSeq; NP_002520.2; NM_002529.3. [P04629-1]
DR   UniGene; Hs.406293; -.
DR   PDB; 1HE7; X-ray; 2.00 A; A=285-413.
DR   PDB; 1SHC; NMR; -; B=489-500.
DR   PDB; 1WWA; X-ray; 2.50 A; X/Y=278-386.
DR   PDB; 1WWW; X-ray; 2.20 A; X/Y=282-382.
DR   PDB; 2IFG; X-ray; 3.40 A; A/B=36-382.
DR   PDB; 2N90; NMR; -; A/B=410-447.
DR   PDB; 4AOJ; X-ray; 2.75 A; A/B/C=473-796.
DR   PDB; 4CRP; NMR; -; A=282-383.
DR   PDB; 4F0I; X-ray; 2.30 A; A/B=498-796.
DR   PDB; 4GT5; X-ray; 2.40 A; A=498-796.
DR   PDB; 4PMM; X-ray; 2.00 A; A=501-787.
DR   PDB; 4PMP; X-ray; 1.80 A; A=501-787.
DR   PDB; 4PMS; X-ray; 2.80 A; A=501-787.
DR   PDB; 4PMT; X-ray; 2.10 A; A=501-787.
DR   PDB; 4YNE; X-ray; 2.02 A; A=502-796.
DR   PDB; 4YPS; X-ray; 2.10 A; A=502-796.
DR   PDB; 5H3Q; X-ray; 2.10 A; A=473-796.
DR   PDB; 5I8A; X-ray; 2.33 A; A=498-787.
DR   PDB; 5JFS; X-ray; 2.07 A; A=502-796.
DR   PDB; 5JFV; X-ray; 1.59 A; A=502-796.
DR   PDB; 5JFW; X-ray; 1.52 A; A=502-796.
DR   PDB; 5JFX; X-ray; 1.63 A; A=502-796.
DR   PDB; 5KMI; X-ray; 1.87 A; A=474-796.
DR   PDB; 5KMJ; X-ray; 2.04 A; A=474-796.
DR   PDB; 5KMK; X-ray; 2.24 A; A=474-796.
DR   PDB; 5KML; X-ray; 2.01 A; A=474-796.
DR   PDB; 5KMM; X-ray; 2.12 A; A=474-796.
DR   PDB; 5KMN; X-ray; 2.14 A; A=474-796.
DR   PDB; 5KMO; X-ray; 2.67 A; A=474-796.
DR   PDB; 5KVT; X-ray; 2.45 A; A=501-787.
DR   PDB; 5WR7; X-ray; 2.76 A; A=489-792.
DR   PDBsum; 1HE7; -.
DR   PDBsum; 1SHC; -.
DR   PDBsum; 1WWA; -.
DR   PDBsum; 1WWW; -.
DR   PDBsum; 2IFG; -.
DR   PDBsum; 2N90; -.
DR   PDBsum; 4AOJ; -.
DR   PDBsum; 4CRP; -.
DR   PDBsum; 4F0I; -.
DR   PDBsum; 4GT5; -.
DR   PDBsum; 4PMM; -.
DR   PDBsum; 4PMP; -.
DR   PDBsum; 4PMS; -.
DR   PDBsum; 4PMT; -.
DR   PDBsum; 4YNE; -.
DR   PDBsum; 4YPS; -.
DR   PDBsum; 5H3Q; -.
DR   PDBsum; 5I8A; -.
DR   PDBsum; 5JFS; -.
DR   PDBsum; 5JFV; -.
DR   PDBsum; 5JFW; -.
DR   PDBsum; 5JFX; -.
DR   PDBsum; 5KMI; -.
DR   PDBsum; 5KMJ; -.
DR   PDBsum; 5KMK; -.
DR   PDBsum; 5KML; -.
DR   PDBsum; 5KMM; -.
DR   PDBsum; 5KMN; -.
DR   PDBsum; 5KMO; -.
DR   PDBsum; 5KVT; -.
DR   PDBsum; 5WR7; -.
DR   ProteinModelPortal; P04629; -.
DR   SMR; P04629; -.
DR   BioGrid; 110969; 1943.
DR   CORUM; P04629; -.
DR   DIP; DIP-5714N; -.
DR   ELM; P04629; -.
DR   IntAct; P04629; 19.
DR   MINT; P04629; -.
DR   STRING; 9606.ENSP00000431418; -.
DR   BindingDB; P04629; -.
DR   ChEMBL; CHEMBL2815; -.
DR   DrugBank; DB00321; Amitriptyline.
DR   DrugBank; DB00619; Imatinib.
DR   DrugBank; DB08896; Regorafenib.
DR   GuidetoPHARMACOLOGY; 1817; -.
DR   iPTMnet; P04629; -.
DR   PhosphoSitePlus; P04629; -.
DR   BioMuta; NTRK1; -.
DR   DMDM; 94730402; -.
DR   PaxDb; P04629; -.
DR   PeptideAtlas; P04629; -.
DR   PRIDE; P04629; -.
DR   Ensembl; ENST00000368196; ENSP00000357179; ENSG00000198400. [P04629-2]
DR   Ensembl; ENST00000392302; ENSP00000376120; ENSG00000198400. [P04629-3]
DR   Ensembl; ENST00000524377; ENSP00000431418; ENSG00000198400. [P04629-1]
DR   GeneID; 4914; -.
DR   KEGG; hsa:4914; -.
DR   UCSC; uc001fqf.2; human. [P04629-1]
DR   CTD; 4914; -.
DR   DisGeNET; 4914; -.
DR   EuPathDB; HostDB:ENSG00000198400.11; -.
DR   GeneCards; NTRK1; -.
DR   GeneReviews; NTRK1; -.
DR   HGNC; HGNC:8031; NTRK1.
DR   HPA; CAB004606; -.
DR   HPA; HPA035799; -.
DR   HPA; HPA076570; -.
DR   MalaCards; NTRK1; -.
DR   MIM; 164970; gene.
DR   MIM; 191315; gene.
DR   MIM; 256800; phenotype.
DR   neXtProt; NX_P04629; -.
DR   OpenTargets; ENSG00000198400; -.
DR   Orphanet; 99361; Familial medullary thyroid carcinoma.
DR   Orphanet; 642; Hereditary sensory and autonomic neuropathy type 4.
DR   Orphanet; 64752; Hereditary sensory and autonomic neuropathy type 5.
DR   Orphanet; 146; Papillary or follicular thyroid carcinoma.
DR   PharmGKB; PA31817; -.
DR   eggNOG; ENOG410IMMI; Eukaryota.
DR   eggNOG; ENOG410XTGG; LUCA.
DR   GeneTree; ENSGT00760000118818; -.
DR   HOVERGEN; HBG056735; -.
DR   InParanoid; P04629; -.
DR   KO; K03176; -.
DR   OMA; PEVYAIM; -.
DR   OrthoDB; EOG091G01JY; -.
DR   PhylomeDB; P04629; -.
DR   TreeFam; TF106465; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-167021; PLC-gamma1 signalling.
DR   Reactome; R-HSA-167044; Signalling to RAS.
DR   Reactome; R-HSA-170968; Frs2-mediated activation.
DR   Reactome; R-HSA-170984; ARMS-mediated activation.
DR   Reactome; R-HSA-177504; Retrograde neurotrophin signalling.
DR   Reactome; R-HSA-187024; NGF-independant TRKA activation.
DR   Reactome; R-HSA-187042; TRKA activation by NGF.
DR   Reactome; R-HSA-187706; Signalling to p38 via RIT and RIN.
DR   Reactome; R-HSA-198203; PI3K/AKT activation.
DR   Reactome; R-HSA-198745; Signalling to STAT3.
DR   SignaLink; P04629; -.
DR   SIGNOR; P04629; -.
DR   ChiTaRS; NTRK1; human.
DR   EvolutionaryTrace; P04629; -.
DR   GenomeRNAi; 4914; -.
DR   PRO; PR:P04629; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000198400; -.
DR   ExpressionAtlas; P04629; baseline and differential.
DR   Genevisible; P04629; HS.
DR   GO; GO:0030424; C:axon; IEA:Ensembl.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0005769; C:early endosome; ISS:UniProtKB.
DR   GO; GO:0031901; C:early endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005768; C:endosome; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005770; C:late endosome; ISS:UniProtKB.
DR   GO; GO:0031902; C:late endosome membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0043234; C:protein complex; ISS:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005004; F:GPI-linked ephrin receptor activity; IEA:Ensembl.
DR   GO; GO:0019900; F:kinase binding; IEA:Ensembl.
DR   GO; GO:0048406; F:nerve growth factor binding; IDA:UniProtKB.
DR   GO; GO:0010465; F:nerve growth factor receptor activity; IDA:UniProtKB.
DR   GO; GO:0043121; F:neurotrophin binding; TAS:ProtInc.
DR   GO; GO:0005166; F:neurotrophin p75 receptor binding; IEA:Ensembl.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0000186; P:activation of MAPKK activity; TAS:Reactome.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; IEA:Ensembl.
DR   GO; GO:0060385; P:axonogenesis involved in innervation; ISS:UniProtKB.
DR   GO; GO:0030183; P:B cell differentiation; IEA:Ensembl.
DR   GO; GO:0061368; P:behavioral response to formalin induced pain; IEA:Ensembl.
DR   GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IMP:UniProtKB.
DR   GO; GO:0071316; P:cellular response to nicotine; IEA:Ensembl.
DR   GO; GO:0007623; P:circadian rhythm; IEA:Ensembl.
DR   GO; GO:0050966; P:detection of mechanical stimulus involved in sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0050965; P:detection of temperature stimulus involved in sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0007611; P:learning or memory; IEA:Ensembl.
DR   GO; GO:0042490; P:mechanoreceptor differentiation; IEA:Ensembl.
DR   GO; GO:0007018; P:microtubule-based movement; TAS:Reactome.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:ARUK-UCL.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISS:UniProtKB.
DR   GO; GO:0038180; P:nerve growth factor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0021553; P:olfactory nerve development; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IMP:UniProtKB.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IDA:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IDA:UniProtKB.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IDA:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0043068; P:positive regulation of programmed cell death; ISS:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; TAS:BHF-UCL.
DR   GO; GO:0046579; P:positive regulation of Ras protein signal transduction; IDA:UniProtKB.
DR   GO; GO:0051965; P:positive regulation of synapse assembly; IEA:Ensembl.
DR   GO; GO:0051968; P:positive regulation of synaptic transmission, glutamatergic; IEA:Ensembl.
DR   GO; GO:0010623; P:programmed cell death involved in cell development; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0048678; P:response to axon injury; IEA:Ensembl.
DR   GO; GO:0051602; P:response to electrical stimulus; IEA:Ensembl.
DR   GO; GO:0051599; P:response to hydrostatic pressure; IEA:Ensembl.
DR   GO; GO:0031667; P:response to nutrient levels; IEA:Ensembl.
DR   GO; GO:0009314; P:response to radiation; IEA:Ensembl.
DR   GO; GO:0060009; P:Sertoli cell development; IEA:Ensembl.
DR   GO; GO:0048485; P:sympathetic nervous system development; ISS:UniProtKB.
DR   Gene3D; 2.60.40.10; -; 2.
DR   Gene3D; 3.80.10.10; -; 1.
DR   InterPro; IPR000483; Cys-rich_flank_reg_C.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR032675; LRR_dom_sf.
DR   InterPro; IPR031635; NTRK_C2.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR020461; Tyr_kinase_neurotrophic_rcpt_1.
DR   InterPro; IPR020777; Tyr_kinase_NGF_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF13855; LRR_8; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF16920; TPKR_C2; 1.
DR   PRINTS; PR01939; NTKRECEPTOR.
DR   PRINTS; PR01940; NTKRECEPTOR1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00082; LRRCT; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Chromosomal rearrangement; Complete proteome; Developmental protein;
KW   Differentiation; Disease mutation; Disulfide bond; Endosome;
KW   Glycoprotein; Immunoglobulin domain; Kinase; Leucine-rich repeat;
KW   Membrane; Neurogenesis; Nucleotide-binding; Phosphoprotein;
KW   Polymorphism; Proto-oncogene; Receptor; Reference proteome; Repeat;
KW   Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     32       {ECO:0000255}.
FT   CHAIN        33    796       High affinity nerve growth factor
FT                                receptor.
FT                                /FTId=PRO_0000016724.
FT   TOPO_DOM     33    423       Extracellular. {ECO:0000255}.
FT   TRANSMEM    424    439       Helical. {ECO:0000255}.
FT   TOPO_DOM    440    796       Cytoplasmic. {ECO:0000255}.
FT   REPEAT       90    113       LRR 1.
FT   REPEAT      116    137       LRR 2.
FT   DOMAIN      148    193       LRRCT.
FT   DOMAIN      194    283       Ig-like C2-type 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00114}.
FT   DOMAIN      299    365       Ig-like C2-type 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00114}.
FT   DOMAIN      510    781       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     516    524       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      469    490       Interaction with SQSTM1. {ECO:0000250}.
FT   ACT_SITE    650    650       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     544    544       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE        398    399       Breakpoint for translocation to form TRK
FT                                and TRK-T3.
FT   SITE        486    486       Breakpoint for translocation to form TRK-
FT                                T1.
FT   SITE        496    496       Interaction with SHC1.
FT   SITE        791    791       Interaction with PLCG1.
FT   MOD_RES     496    496       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15488758,
FT                                ECO:0000269|PubMed:27676246,
FT                                ECO:0000269|PubMed:8155326}.
FT   MOD_RES     676    676       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000305|PubMed:8325889}.
FT   MOD_RES     680    680       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15488758}.
FT   MOD_RES     681    681       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15488758}.
FT   MOD_RES     791    791       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:15488758,
FT                                ECO:0000269|PubMed:7510697,
FT                                ECO:0000269|PubMed:8155326}.
FT   CARBOHYD     67     67       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD     95     95       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:17196528}.
FT   CARBOHYD    121    121       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:17196528}.
FT   CARBOHYD    188    188       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:2IFG,
FT                                ECO:0000269|PubMed:17196528}.
FT   CARBOHYD    202    202       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    253    253       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    262    262       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:2IFG,
FT                                ECO:0000269|PubMed:17196528}.
FT   CARBOHYD    281    281       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:2IFG,
FT                                ECO:0000269|PubMed:17196528}.
FT   CARBOHYD    318    318       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    323    323       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    338    338       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    358    358       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000244|PDB:2IFG,
FT                                ECO:0000269|PubMed:17196528}.
FT   CARBOHYD    401    401       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     36     41       {ECO:0000244|PDB:2IFG}.
FT   DISULFID     40     50       {ECO:0000244|PDB:2IFG}.
FT   DISULFID    154    191       {ECO:0000244|PDB:2IFG,
FT                                ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:17196528}.
FT   DISULFID    215    265       {ECO:0000244|PDB:2IFG,
FT                                ECO:0000255|PROSITE-ProRule:PRU00114,
FT                                ECO:0000269|PubMed:17196528}.
FT   DISULFID    300    345       {ECO:0000244|PDB:1HE7,
FT                                ECO:0000244|PDB:1WWA,
FT                                ECO:0000244|PDB:1WWW,
FT                                ECO:0000244|PDB:2IFG,
FT                                ECO:0000244|PDB:4CRP}.
FT   VAR_SEQ       1     71       MLRGGRRGQLGWHSWAAGPGSLLAWLILASAGAAPCPDACC
FT                                PHGSSGLRCTRDGALDSLHHLPGAENLTEL -> MKEAALI
FT                                CLAPSVPPILTVKSWDTMQLRAARSRCTNLLAAS (in
FT                                isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_041905.
FT   VAR_SEQ     192    284       GVPTLKVQVPNASVDVGDDVLLRCQVEGRGLEQAGWILTEL
FT                                EQSATVMKSGGLPSLGLTLANVTSDLNRKNVTCWAENDVGR
FT                                AEVSVQVNVSF -> V (in isoform TrkA-III).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_042152.
FT   VAR_SEQ     393    398       Missing (in isoform TrkA-I, isoform 3 and
FT                                isoform TrkA-III).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:2927393}.
FT                                /FTId=VSP_002899.
FT   VARIANT       6      6       R -> W (in dbSNP:rs201472270).
FT                                {ECO:0000269|PubMed:22302274}.
FT                                /FTId=VAR_068480.
FT   VARIANT      18     18       G -> E (in dbSNP:rs1007211).
FT                                /FTId=VAR_049714.
FT   VARIANT      80     80       Q -> R (in dbSNP:rs55891455).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041461.
FT   VARIANT      85     85       R -> S (in dbSNP:rs543320028).
FT                                {ECO:0000269|PubMed:10330344,
FT                                ECO:0000269|PubMed:11159935}.
FT                                /FTId=VAR_009623.
FT   VARIANT      93     93       L -> P (in CIPA; aberrantly processed;
FT                                shows diminished autophosphorylation in
FT                                neuronal cells).
FT                                {ECO:0000269|PubMed:10982191,
FT                                ECO:0000269|PubMed:11159935}.
FT                                /FTId=VAR_009624.
FT   VARIANT     107    107       A -> V (in an ovarian serous carcinoma
FT                                sample; somatic mutation;
FT                                dbSNP:rs540521894).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041462.
FT   VARIANT     110    110       A -> D (in CIPA).
FT                                {ECO:0000269|PubMed:28328124}.
FT                                /FTId=VAR_079399.
FT   VARIANT     146    796       Missing (in CIPA).
FT                                {ECO:0000269|PubMed:28328124}.
FT                                /FTId=VAR_079400.
FT   VARIANT     176    796       Missing (in CIPA).
FT                                {ECO:0000269|PubMed:28328124}.
FT                                /FTId=VAR_079401.
FT   VARIANT     213    213       L -> P (in CIPA; aberrantly processed;
FT                                shows diminished autophosphorylation in
FT                                neuronal cells; dbSNP:rs747711259).
FT                                {ECO:0000269|PubMed:10330344,
FT                                ECO:0000269|PubMed:11159935}.
FT                                /FTId=VAR_009625.
FT   VARIANT     235    796       Missing (in CIPA; loss of protein).
FT                                {ECO:0000269|PubMed:28177573}.
FT                                /FTId=VAR_079402.
FT   VARIANT     237    237       T -> M (in dbSNP:rs55909005).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041463.
FT   VARIANT     238    238       V -> G (in dbSNP:rs56000394).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041464.
FT   VARIANT     260    260       R -> G (in dbSNP:rs35116695).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041465.
FT   VARIANT     359    359       Y -> C (in CIPA; dbSNP:rs121964869).
FT                                {ECO:0000269|PubMed:11310631}.
FT                                /FTId=VAR_068481.
FT   VARIANT     444    444       R -> Q (in dbSNP:rs56320207).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041466.
FT   VARIANT     452    452       R -> C (in dbSNP:rs34900547).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041467.
FT   VARIANT     476    796       Missing (in CIPA).
FT                                {ECO:0000269|PubMed:28328124}.
FT                                /FTId=VAR_079403.
FT   VARIANT     492    492       E -> K (in CIPA; dbSNP:rs144901788).
FT                                {ECO:0000269|PubMed:22302274}.
FT                                /FTId=VAR_068482.
FT   VARIANT     517    517       G -> E (in CIPA; following transfection
FT                                in neuroblastoma cells and NGF treatment,
FT                                small decrease in the percentage of cells
FT                                differentiated into neuronal phenotype,
FT                                but in differentiated cells, the average
FT                                neurite length is comparable to wild-
FT                                type; no effect on N-glycosylation,
FT                                subcellular location, nor on basal and
FT                                NGF-induced autophosphorylation; loss of
FT                                NGF-stimulated calcium flux;
FT                                dbSNP:rs606231467).
FT                                {ECO:0000269|PubMed:27676246}.
FT                                /FTId=VAR_077472.
FT   VARIANT     522    522       G -> E (in CIPA; no effect on N-
FT                                glycosylation, nor on subcellular
FT                                location; reduced basal
FT                                autophosphorylation and complete loss of
FT                                NGF-induced autophosphorylation; loss of
FT                                NGF-stimulated calcium flux).
FT                                {ECO:0000269|PubMed:27676246}.
FT                                /FTId=VAR_077473.
FT   VARIANT     522    522       G -> R (in CIPA; processed as wild-type
FT                                but shows significantly diminished
FT                                autophosphorylation in both neuronal and
FT                                non-neuronal cells).
FT                                {ECO:0000269|PubMed:10982191,
FT                                ECO:0000269|PubMed:11159935}.
FT                                /FTId=VAR_009626.
FT   VARIANT     566    566       M -> T (in dbSNP:rs55892037).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041468.
FT   VARIANT     572    572       I -> S (in CIPA).
FT                                {ECO:0000269|PubMed:18077166}.
FT                                /FTId=VAR_077474.
FT   VARIANT     577    577       G -> R (in CIPA; loss of function;
FT                                processed as wild-type but shows
FT                                significantly diminished
FT                                autophosphorylation in both neuronal and
FT                                non-neuronal cells; dbSNP:rs121964866).
FT                                {ECO:0000269|PubMed:10567924,
FT                                ECO:0000269|PubMed:10982191,
FT                                ECO:0000269|PubMed:11159935,
FT                                ECO:0000269|PubMed:8696348}.
FT                                /FTId=VAR_004103.
FT   VARIANT     587    587       M -> V (in CIPA; dbSNP:rs121964870).
FT                                {ECO:0000269|PubMed:10233776}.
FT                                /FTId=VAR_009627.
FT   VARIANT     596    596       D -> N (in CIPA; abolishes
FT                                autophosphorylation).
FT                                {ECO:0000269|PubMed:28177573}.
FT                                /FTId=VAR_079404.
FT   VARIANT     604    604       H -> Y (in dbSNP:rs6336).
FT                                {ECO:0000269|PubMed:10330344,
FT                                ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:10443680,
FT                                ECO:0000269|PubMed:11159935,
FT                                ECO:0000269|PubMed:11310631,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_009628.
FT   VARIANT     613    613       G -> V (in dbSNP:rs6339).
FT                                {ECO:0000269|PubMed:10330344,
FT                                ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:10443680,
FT                                ECO:0000269|PubMed:10861667,
FT                                ECO:0000269|PubMed:11159935,
FT                                ECO:0000269|PubMed:11310631,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_009629.
FT   VARIANT     649    649       R -> Q (in CIPA; dbSNP:rs786205449).
FT                                {ECO:0000269|PubMed:28328124}.
FT                                /FTId=VAR_079405.
FT   VARIANT     649    649       R -> W (in CIPA; processed as wild-type
FT                                but shows significantly diminished
FT                                autophosphorylation in both neuronal and
FT                                non-neuronal cells; dbSNP:rs369353892).
FT                                {ECO:0000269|PubMed:10330344,
FT                                ECO:0000269|PubMed:11159935}.
FT                                /FTId=VAR_009630.
FT   VARIANT     654    654       R -> C (in CIPA; processed as wild-type
FT                                but shows significantly diminished
FT                                autophosphorylation in both neuronal and
FT                                non-neuronal cells; dbSNP:rs764992664).
FT                                {ECO:0000269|PubMed:10982191,
FT                                ECO:0000269|PubMed:11159935,
FT                                ECO:0000269|PubMed:22302274}.
FT                                /FTId=VAR_009631.
FT   VARIANT     657    657       L -> P (in CIPA; following transfection
FT                                in neuroblastoma cells and NGF treatment,
FT                                loss of differentiation into neuronal
FT                                phenotype; partially decreased N-
FT                                glycosylation; reduced expression at the
FT                                plasma membrane; reduced basal
FT                                autophosphorylation and complete loss of
FT                                NGF-induced autophosphorylation; loss of
FT                                NGF-stimulated calcium flux).
FT                                {ECO:0000269|PubMed:27676246}.
FT                                /FTId=VAR_077475.
FT   VARIANT     674    674       D -> Y (in CIPA; might impair the
FT                                function of the enzyme without
FT                                compromising autophosphorylation;
FT                                dbSNP:rs80356677).
FT                                {ECO:0000269|PubMed:10982191,
FT                                ECO:0000269|PubMed:11159935,
FT                                ECO:0000269|PubMed:28177573}.
FT                                /FTId=VAR_009632.
FT   VARIANT     695    695       P -> L (in CIPA; dbSNP:rs121964868).
FT                                {ECO:0000269|PubMed:10861667}.
FT                                /FTId=VAR_009633.
FT   VARIANT     699    699       I -> T (in CIPA; partially decreased N-
FT                                glycosylation; reduced expression at the
FT                                plasma membrane; reduced basal
FT                                autophosphorylation and complete loss of
FT                                NGF-induced autophosphorylation; loss of
FT                                NGF-stimulated calcium flux).
FT                                {ECO:0000269|PubMed:27676246}.
FT                                /FTId=VAR_077476.
FT   VARIANT     700    700       L -> P (in CIPA).
FT                                {ECO:0000269|PubMed:28328124}.
FT                                /FTId=VAR_079406.
FT   VARIANT     714    714       G -> S (in CIPA; processed as wild-type
FT                                but shows significantly diminished
FT                                autophosphorylation in both neuronal and
FT                                non-neuronal cells; dbSNP:rs770727871).
FT                                {ECO:0000269|PubMed:10330344,
FT                                ECO:0000269|PubMed:11159935}.
FT                                /FTId=VAR_009634.
FT   VARIANT     717    717       L -> R (in CIPA; found in a compound
FT                                heterozygote also carrying an premature
FT                                stop codon at position 558).
FT                                {ECO:0000269|PubMed:18077166}.
FT                                /FTId=VAR_077477.
FT   VARIANT     752    752       C -> S (in CIPA; unknown pathological
FT                                significance; following transfection in
FT                                neuroblastoma cells and NGF treatment, no
FT                                effect on neurite outgrowth, nor neurite
FT                                length; no effect on N-glycosylation,
FT                                subcellular location, basal and NGF-
FT                                induced autophosphorylation, nor on NGF-
FT                                stimulated calcium flux).
FT                                {ECO:0000269|PubMed:27676246}.
FT                                /FTId=VAR_077478.
FT   VARIANT     763    763       C -> S (in CIPA; following transfection
FT                                in neuroblastoma cells and NGF treatment,
FT                                decreased percentage of cells
FT                                differentiated into neuronal phenotype
FT                                and reduced neurite length compared with
FT                                wild-type; slightly decreased N-
FT                                glycosylation; reduced expression at the
FT                                plasma membrane; reduced basal and NGF-
FT                                induced autophosphorylation; small
FT                                reduction in NGF-stimulated calcium
FT                                flux). {ECO:0000269|PubMed:27676246}.
FT                                /FTId=VAR_077479.
FT   VARIANT     771    771       R -> C (in CIPA; partially decreased N-
FT                                glycosylation; reduced expression at the
FT                                plasma membrane; reduced basal
FT                                autophosphorylation and complete loss of
FT                                NGF-induced autophosphorylation; loss of
FT                                NGF-stimulated calcium flux).
FT                                {ECO:0000269|PubMed:27676246}.
FT                                /FTId=VAR_077480.
FT   VARIANT     780    780       R -> P (in CIPA; loss of function;
FT                                dbSNP:rs35669708).
FT                                {ECO:0000269|PubMed:10090906}.
FT                                /FTId=VAR_009635.
FT   VARIANT     780    780       R -> Q (in dbSNP:rs35669708).
FT                                {ECO:0000269|PubMed:10443680,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_009636.
FT   VARIANT     790    790       V -> I (in dbSNP:rs55948542).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041469.
FT   MUTAGEN     496    496       Y->F: Loss of interaction with SHC1 and
FT                                altered phosphorylation of SHC1. Altered
FT                                neurite outgrowth and altered activation
FT                                of the MAPK pathway; when associated with
FT                                F-791. {ECO:0000269|PubMed:8155326}.
FT   MUTAGEN     544    544       K->N: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:1281417,
FT                                ECO:0000269|PubMed:8155326}.
FT   MUTAGEN     791    791       Y->F: Loss of interaction with PLCG1 and
FT                                altered phosphorylation of PLCG1. Altered
FT                                neurite outgrowth and altered activation
FT                                of the MAPK pathway; when associated with
FT                                F-496. {ECO:0000269|PubMed:7510697,
FT                                ECO:0000269|PubMed:8155326}.
FT   CONFLICT    263    263       V -> L (in Ref. 1; AAA36770).
FT                                {ECO:0000305}.
FT   CONFLICT    300    300       C -> S (in Ref. 1; AAA36770).
FT                                {ECO:0000305}.
FT   CONFLICT    529    529       C -> S (in Ref. 10; CAA59936).
FT                                {ECO:0000305}.
FT   STRAND       38     40       {ECO:0000244|PDB:2IFG}.
FT   STRAND       43     46       {ECO:0000244|PDB:2IFG}.
FT   TURN         57     61       {ECO:0000244|PDB:2IFG}.
FT   STRAND       69     72       {ECO:0000244|PDB:2IFG}.
FT   HELIX        84     86       {ECO:0000244|PDB:2IFG}.
FT   STRAND       94     97       {ECO:0000244|PDB:2IFG}.
FT   HELIX       110    112       {ECO:0000244|PDB:2IFG}.
FT   STRAND      119    121       {ECO:0000244|PDB:2IFG}.
FT   TURN        133    135       {ECO:0000244|PDB:2IFG}.
FT   STRAND      142    144       {ECO:0000244|PDB:2IFG}.
FT   HELIX       154    156       {ECO:0000244|PDB:2IFG}.
FT   HELIX       157    164       {ECO:0000244|PDB:2IFG}.
FT   HELIX       171    173       {ECO:0000244|PDB:2IFG}.
FT   STRAND      178    181       {ECO:0000244|PDB:2IFG}.
FT   STRAND      195    199       {ECO:0000244|PDB:2IFG}.
FT   STRAND      211    218       {ECO:0000244|PDB:2IFG}.
FT   STRAND      227    230       {ECO:0000244|PDB:2IFG}.
FT   STRAND      234    238       {ECO:0000244|PDB:2IFG}.
FT   STRAND      244    253       {ECO:0000244|PDB:2IFG}.
FT   TURN        257    260       {ECO:0000244|PDB:2IFG}.
FT   STRAND      263    265       {ECO:0000244|PDB:2IFG}.
FT   STRAND      276    278       {ECO:0000244|PDB:2IFG}.
FT   STRAND      284    290       {ECO:0000244|PDB:1WWW}.
FT   STRAND      298    305       {ECO:0000244|PDB:1HE7}.
FT   STRAND      312    317       {ECO:0000244|PDB:1HE7}.
FT   STRAND      326    333       {ECO:0000244|PDB:1HE7}.
FT   STRAND      342    350       {ECO:0000244|PDB:1HE7}.
FT   HELIX       353    355       {ECO:0000244|PDB:1HE7}.
FT   STRAND      357    365       {ECO:0000244|PDB:1HE7}.
FT   STRAND      368    376       {ECO:0000244|PDB:1HE7}.
FT   HELIX       418    441       {ECO:0000244|PDB:2N90}.
FT   STRAND      476    478       {ECO:0000244|PDB:5KML}.
FT   HELIX       490    492       {ECO:0000244|PDB:5KMI}.
FT   TURN        494    496       {ECO:0000244|PDB:1SHC}.
FT   HELIX       507    509       {ECO:0000244|PDB:5JFW}.
FT   STRAND      510    517       {ECO:0000244|PDB:5JFW}.
FT   STRAND      520    522       {ECO:0000244|PDB:5JFW}.
FT   STRAND      524    533       {ECO:0000244|PDB:5JFW}.
FT   TURN        534    536       {ECO:0000244|PDB:5KMI}.
FT   STRAND      537    545       {ECO:0000244|PDB:5JFW}.
FT   HELIX       552    566       {ECO:0000244|PDB:5JFW}.
FT   STRAND      575    579       {ECO:0000244|PDB:5JFW}.
FT   STRAND      581    584       {ECO:0000244|PDB:5JFW}.
FT   STRAND      586    590       {ECO:0000244|PDB:5JFW}.
FT   HELIX       597    603       {ECO:0000244|PDB:5JFW}.
FT   STRAND      605    607       {ECO:0000244|PDB:4F0I}.
FT   HELIX       608    611       {ECO:0000244|PDB:4PMP}.
FT   STRAND      615    617       {ECO:0000244|PDB:4YNE}.
FT   STRAND      619    621       {ECO:0000244|PDB:5KMI}.
FT   HELIX       624    643       {ECO:0000244|PDB:5JFW}.
FT   STRAND      646    648       {ECO:0000244|PDB:5KML}.
FT   HELIX       653    655       {ECO:0000244|PDB:5JFW}.
FT   STRAND      656    659       {ECO:0000244|PDB:5JFW}.
FT   HELIX       660    662       {ECO:0000244|PDB:5JFW}.
FT   STRAND      663    666       {ECO:0000244|PDB:5JFW}.
FT   HELIX       672    675       {ECO:0000244|PDB:5KMI}.
FT   HELIX       677    679       {ECO:0000244|PDB:4PMP}.
FT   STRAND      680    683       {ECO:0000244|PDB:5KMI}.
FT   TURN        684    686       {ECO:0000244|PDB:5KMI}.
FT   STRAND      687    689       {ECO:0000244|PDB:5KMI}.
FT   HELIX       691    693       {ECO:0000244|PDB:5JFW}.
FT   HELIX       696    701       {ECO:0000244|PDB:5JFW}.
FT   HELIX       706    721       {ECO:0000244|PDB:5JFW}.
FT   TURN        722    724       {ECO:0000244|PDB:5JFV}.
FT   TURN        727    730       {ECO:0000244|PDB:5JFW}.
FT   HELIX       733    742       {ECO:0000244|PDB:5JFW}.
FT   HELIX       754    763       {ECO:0000244|PDB:5JFW}.
FT   HELIX       768    770       {ECO:0000244|PDB:5JFW}.
FT   HELIX       774    786       {ECO:0000244|PDB:5JFW}.
FT   HELIX       789    793       {ECO:0000244|PDB:5KMI}.
SQ   SEQUENCE   796 AA;  87497 MW;  6C15C721E336B601 CRC64;
     MLRGGRRGQL GWHSWAAGPG SLLAWLILAS AGAAPCPDAC CPHGSSGLRC TRDGALDSLH
     HLPGAENLTE LYIENQQHLQ HLELRDLRGL GELRNLTIVK SGLRFVAPDA FHFTPRLSRL
     NLSFNALESL SWKTVQGLSL QELVLSGNPL HCSCALRWLQ RWEEEGLGGV PEQKLQCHGQ
     GPLAHMPNAS CGVPTLKVQV PNASVDVGDD VLLRCQVEGR GLEQAGWILT ELEQSATVMK
     SGGLPSLGLT LANVTSDLNR KNVTCWAEND VGRAEVSVQV NVSFPASVQL HTAVEMHHWC
     IPFSVDGQPA PSLRWLFNGS VLNETSFIFT EFLEPAANET VRHGCLRLNQ PTHVNNGNYT
     LLAANPFGQA SASIMAAFMD NPFEFNPEDP IPVSFSPVDT NSTSGDPVEK KDETPFGVSV
     AVGLAVFACL FLSTLLLVLN KCGRRNKFGI NRPAVLAPED GLAMSLHFMT LGGSSLSPTE
     GKGSGLQGHI IENPQYFSDA CVHHIKRRDI VLKWELGEGA FGKVFLAECH NLLPEQDKML
     VAVKALKEAS ESARQDFQRE AELLTMLQHQ HIVRFFGVCT EGRPLLMVFE YMRHGDLNRF
     LRSHGPDAKL LAGGEDVAPG PLGLGQLLAV ASQVAAGMVY LAGLHFVHRD LATRNCLVGQ
     GLVVKIGDFG MSRDIYSTDY YRVGGRTMLP IRWMPPESIL YRKFTTESDV WSFGVVLWEI
     FTYGKQPWYQ LSNTEAIDCI TQGRELERPR ACPPEVYAIM RGCWQREPQQ RHSIKDVHAR
     LQALAQAPPV YLDVLG
//
ID   X5DR71_HUMAN            Unreviewed;       790 AA.
AC   X5DR71;
DT   11-JUN-2014, integrated into UniProtKB/TrEMBL.
DT   11-JUN-2014, sequence version 1.
DT   28-FEB-2018, entry version 34.
DE   RecName: Full=Tyrosine-protein kinase receptor {ECO:0000256|RuleBase:RU000312};
DE            EC=2.7.10.1 {ECO:0000256|RuleBase:RU000312};
DE   Flags: Fragment;
GN   Name=NTRK1 {ECO:0000313|EMBL:AHW56542.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AHW56542.1};
RN   [1] {ECO:0000313|EMBL:AHW56542.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Adult whole brain {ECO:0000313|EMBL:AHW56542.1};
RX   PubMed=24722188;
RA   Corominas R., Yang X., Lin G.N., Kang S., Shen Y., Ghamsari L.,
RA   Broly M., Rodriguez M., Tam S., Wanamaker S.A., Fan C., Yi S.,
RA   Tasan M., Lemmens I., Kuang X., Zhao N., Malhotra D., Michaelson J.J.,
RA   Vacic V., Calderwood M.A., Roth F.P., Tavernier J., Horvath S.,
RA   Salehi-Ashtiani K., Korkin D., Sebat J., Hill D.E., Hao T., Vidal M.,
RA   Iakoucheva L.M.;
RT   "Protein interaction network of alternatively spliced isoforms from
RT   brain links genetic risk factors for autism.";
RL   Nat. Commun. 5:3650-3650(2014).
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000256|RuleBase:RU000312}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily.
CC       {ECO:0000256|RuleBase:RU000312}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; KJ534902; AHW56542.1; -; mRNA.
DR   RefSeq; NP_001012331.1; NM_001012331.1.
DR   UniGene; Hs.406293; -.
DR   ProteinModelPortal; X5DR71; -.
DR   SMR; X5DR71; -.
DR   GeneID; 4914; -.
DR   UCSC; uc001fqi.2; human.
DR   CTD; 4914; -.
DR   EuPathDB; HostDB:ENSG00000198400.11; -.
DR   eggNOG; ENOG410IMMI; Eukaryota.
DR   eggNOG; ENOG410XTGG; LUCA.
DR   ChiTaRS; NTRK1; human.
DR   GenomeRNAi; 4914; -.
DR   Bgee; ENSG00000198400; -.
DR   ExpressionAtlas; X5DR71; baseline and differential.
DR   GO; GO:0005887; C:integral component of plasma membrane; IEA:InterPro.
DR   GO; GO:0005524; F:ATP binding; IEA:InterPro.
DR   GO; GO:0005030; F:neurotrophin receptor activity; IEA:InterPro.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IEA:InterPro.
DR   Gene3D; 2.60.40.10; -; 2.
DR   Gene3D; 3.80.10.10; -; 1.
DR   InterPro; IPR000483; Cys-rich_flank_reg_C.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR032675; LRR_dom_sf.
DR   InterPro; IPR031635; NTRK_C2.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR020461; Tyr_kinase_neurotrophic_rcpt_1.
DR   InterPro; IPR020777; Tyr_kinase_NGF_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF13855; LRR_8; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF16920; TPKR_C2; 1.
DR   PRINTS; PR01939; NTKRECEPTOR.
DR   PRINTS; PR01940; NTKRECEPTOR1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00082; LRRCT; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   2: Evidence at transcript level;
KW   Disulfide bond {ECO:0000256|SAAS:SAAS01010727};
KW   Immunoglobulin domain {ECO:0000256|SAAS:SAAS00941986};
KW   Kinase {ECO:0000313|EMBL:AHW56542.1};
KW   Leucine-rich repeat {ECO:0000256|SAAS:SAAS00488662};
KW   Membrane {ECO:0000256|SAAS:SAAS00602683, ECO:0000256|SAM:Phobius};
KW   Phosphoprotein {ECO:0000256|RuleBase:RU000312};
KW   Receptor {ECO:0000256|RuleBase:RU000312,
KW   ECO:0000256|SAAS:SAAS00600436, ECO:0000313|EMBL:AHW56542.1};
KW   Signal {ECO:0000256|SAM:SignalP};
KW   Transferase {ECO:0000313|EMBL:AHW56542.1};
KW   Transmembrane {ECO:0000256|SAAS:SAAS00602683,
KW   ECO:0000256|SAM:Phobius};
KW   Transmembrane helix {ECO:0000256|SAAS:SAAS00602683,
KW   ECO:0000256|SAM:Phobius}.
FT   SIGNAL        1     33       {ECO:0000256|SAM:SignalP}.
FT   CHAIN        34    790       Tyrosine-protein kinase receptor.
FT                                {ECO:0000256|SAM:SignalP}.
FT                                /FTId=PRO_5004955970.
FT   TRANSMEM    410    433       Helical. {ECO:0000256|SAM:Phobius}.
FT   DOMAIN      194    283       Ig-like. {ECO:0000259|PROSITE:PS50835}.
FT   DOMAIN      504    775       Protein kinase.
FT                                {ECO:0000259|PROSITE:PS50011}.
FT   NON_TER     790    790       {ECO:0000313|EMBL:AHW56542.1}.
SQ   SEQUENCE   790 AA;  86880 MW;  25F05BADA8A2A50C CRC64;
     MLRGGRRGQL GWHSWAAGPG SLLAWLILAS AGAAPCPDAC CPHGSSGLRC TRDGALDSLH
     HLPGAENLTE LYIENQQHLQ HLELRDLRGL GELRNLTIVK SGLRFVAPDA FHFTPRLSRL
     NLSFNALESL SWKTVQGLSL QELVLSGNPL HCSCALRWLQ RWEEEGLGGV PEQKLQCHGQ
     GPLAHMPNAS CGVPTLKVQV PNASVDVGDD VLLRCQVEGR GLEQAGWILT ELEQSATVMK
     SGGLPSLGLT LANVTSDLNR KNVTCWAEND VGRAEVSVQV NVSFPASVQL HTAVEMHHWC
     IPFSVDGQPA PSLRWLFNGS VLNETSFIFT EFLEPAANET VRHGCLRLNQ PTHVNNGNYT
     LLAANPFGQA SASIMAAFMD NPFEFNPEDP IPDTNSTSGD PVEKKDETPF GVSVAVGLAV
     FACLFLSTLL LVLNKCGRRN KFGINRPAVL APEDGLAMSL HFMTLGGSSL SPTEGKGSGL
     QGHIIENPQY FSDACVHHIK RRDIVLKWEL GEGAFGKVFL AECHNLLPEQ DKMLVAVKAL
     KEASESARQD FQREAELLTM LQHQHIVRFF GVCTEGRPLL MVFEYMRHGD LNRFLRSHGP
     DAKLLAGGED VAPGPLGLGQ LLAVASQVAA GMVYLAGLHF VHRDLATRNC LVGQGLVVKI
     GDFGMSRDIY STDYYRVGGR TMLPIRWMPP ESILYRKFTT ESDVWSFGVV LWEIFTYGKQ
     PWYQLSNTEA IDCITQGREL ERPRACPPEV YAIMRGCWQR EPQQRHSIKD VHARLQALAQ
     APPVYLDVLG
//
ID   C0KTE5_HUMAN            Unreviewed;       136 AA.
AC   C0KTE5;
DT   05-MAY-2009, integrated into UniProtKB/TrEMBL.
DT   05-MAY-2009, sequence version 1.
DT   31-JAN-2018, entry version 44.
DE   SubName: Full=B cell specific activator protein variant delta 8/9 {ECO:0000313|EMBL:ACM91593.1};
DE   Flags: Fragment;
GN   Name=PAX5 {ECO:0000313|EMBL:ACM91593.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:ACM91593.1};
RN   [1] {ECO:0000313|EMBL:ACM91593.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=19725825; DOI=10.1111/j.1365-2141.2009.07859.x;
RA   Arseneau J.R., Laflamme M., Lewis S.M., Maicas E., Ouellette R.J.;
RT   "Multiple isoforms of PAX5 are expressed in both lymphomas and normal
RT   B-cells.";
RL   Br. J. Haematol. 147:328-338(2009).
RN   [2] {ECO:0000313|EMBL:ACM91593.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Arseneau J.-R., Laflamme M., Lewis S.M., Maicas E., Ouellette R.J.;
RL   Submitted (JAN-2009) to the EMBL/GenBank/DDBJ databases.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; FJ626410; ACM91593.1; -; mRNA.
DR   RefSeq; NP_001267480.1; NM_001280551.1.
DR   UniGene; Hs.654464; -.
DR   PeptideAtlas; C0KTE5; -.
DR   GeneID; 5079; -.
DR   CTD; 5079; -.
DR   eggNOG; KOG3862; Eukaryota.
DR   eggNOG; ENOG410ZT0S; LUCA.
DR   HOGENOM; HOG000230939; -.
DR   ChiTaRS; PAX5; human.
DR   GenomeRNAi; 5079; -.
PE   2: Evidence at transcript level;
FT   NON_TER       1      1       {ECO:0000313|EMBL:ACM91593.1}.
SQ   SEQUENCE   136 AA;  14857 MW;  1429D7ED040BFD00 CRC64;
     DTNKRKRDEG IQESPVPNGH SLPGRDFLRK QMRGDLFTQQ QLEVLDRVFE RQHYSDIFTT
     TEPIKPEQTT EYSAMASLAG GLDDMKANLA SPTPADIGSS VPGPQSYPIV TGSPYYYSAA
     ARGAAPPAAA TAYDRH
//
ID   C0KTF5_HUMAN            Unreviewed;        26 AA.
AC   C0KTF5;
DT   05-MAY-2009, integrated into UniProtKB/TrEMBL.
DT   05-MAY-2009, sequence version 1.
DT   07-JUN-2017, entry version 17.
DE   SubName: Full=B cell specific activator protein variant A delta 2/8/9 {ECO:0000313|EMBL:ACM91603.1};
GN   Name=PAX5 {ECO:0000313|EMBL:ACM91603.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:ACM91603.1};
RN   [1] {ECO:0000313|EMBL:ACM91603.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=19725825; DOI=10.1111/j.1365-2141.2009.07859.x;
RA   Arseneau J.R., Laflamme M., Lewis S.M., Maicas E., Ouellette R.J.;
RT   "Multiple isoforms of PAX5 are expressed in both lymphomas and normal
RT   B-cells.";
RL   Br. J. Haematol. 147:328-338(2009).
RN   [2] {ECO:0000313|EMBL:ACM91603.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Arseneau J.-R., Laflamme M., Lewis S.M., Maicas E., Ouellette R.J.;
RL   Submitted (JAN-2009) to the EMBL/GenBank/DDBJ databases.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; FJ626420; ACM91603.1; -; mRNA.
DR   RefSeq; NP_001267480.1; NM_001280551.1.
DR   UniGene; Hs.654464; -.
DR   PeptideAtlas; C0KTF5; -.
DR   GeneID; 5079; -.
DR   CTD; 5079; -.
DR   ChiTaRS; PAX5; human.
DR   GenomeRNAi; 5079; -.
PE   2: Evidence at transcript level;
SQ   SEQUENCE   26 AA;  2939 MW;  2A72F22CE9512382 CRC64;
     MDLEKNYPTP RTSRTGIMRQ EASSLG
//
ID   E7EQT0_HUMAN            Unreviewed;       324 AA.
AC   E7EQT0;
DT   08-MAR-2011, integrated into UniProtKB/TrEMBL.
DT   08-MAR-2011, sequence version 1.
DT   28-FEB-2018, entry version 62.
DE   SubName: Full=Paired box protein Pax-5 {ECO:0000313|Ensembl:ENSP00000429637};
GN   Name=PAX5 {ECO:0000313|Ensembl:ENSP00000429637};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000429637, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [2] {ECO:0000313|Ensembl:ENSP00000429637}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [3] {ECO:0000313|Ensembl:ENSP00000429637}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (JUL-2011) to UniProtKB.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000256|PROSITE-
CC       ProRule:PRU00381, ECO:0000256|SAAS:SAAS00117811}.
CC   -!- CAUTION: The sequence shown here is derived from an Ensembl
CC       automatic analysis pipeline and should be considered as
CC       preliminary data. {ECO:0000313|Ensembl:ENSP00000429637}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AL161781; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL450267; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_001267478.1; NM_001280549.1.
DR   UniGene; Hs.654464; -.
DR   ProteinModelPortal; E7EQT0; -.
DR   SMR; E7EQT0; -.
DR   MaxQB; E7EQT0; -.
DR   PeptideAtlas; E7EQT0; -.
DR   Ensembl; ENST00000523241; ENSP00000429637; ENSG00000196092.
DR   GeneID; 5079; -.
DR   UCSC; uc010mlr.3; human.
DR   CTD; 5079; -.
DR   EuPathDB; HostDB:ENSG00000196092.12; -.
DR   HGNC; HGNC:8619; PAX5.
DR   OpenTargets; ENSG00000196092; -.
DR   eggNOG; KOG3862; Eukaryota.
DR   eggNOG; ENOG410ZT0S; LUCA.
DR   GeneTree; ENSGT00680000099553; -.
DR   ChiTaRS; PAX5; human.
DR   GenomeRNAi; 5079; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000196092; -.
DR   ExpressionAtlas; E7EQT0; baseline and differential.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0001650; C:fibrillar center; IDA:HPA.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0007275; P:multicellular organism development; IEA:UniProtKB-KW.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:UniProtKB-UniRule.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-UniRule.
DR   CDD; cd00131; PAX; 1.
DR   Gene3D; 1.10.10.10; -; 2.
DR   InterPro; IPR009057; Homeobox-like_sf.
DR   InterPro; IPR001523; Paired_dom.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   Pfam; PF00292; PAX; 1.
DR   PRINTS; PR00027; PAIREDBOX.
DR   SMART; SM00351; PAX; 1.
DR   SUPFAM; SSF46689; SSF46689; 1.
DR   PROSITE; PS00034; PAIRED_1; 1.
DR   PROSITE; PS51057; PAIRED_2; 1.
PE   1: Evidence at protein level;
KW   Complete proteome {ECO:0000313|Proteomes:UP000005640};
KW   Developmental protein {ECO:0000256|SAAS:SAAS00117810};
KW   DNA-binding {ECO:0000256|PROSITE-ProRule:PRU00381,
KW   ECO:0000256|SAAS:SAAS00117818};
KW   Nucleus {ECO:0000256|PROSITE-ProRule:PRU00381,
KW   ECO:0000256|SAAS:SAAS00117821};
KW   Paired box {ECO:0000256|PROSITE-ProRule:PRU00381,
KW   ECO:0000256|SAAS:SAAS00117809};
KW   Proteomics identification {ECO:0000213|MaxQB:E7EQT0,
KW   ECO:0000213|PeptideAtlas:E7EQT0};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640};
KW   Transcription {ECO:0000256|PROSITE-ProRule:PRU00381,
KW   ECO:0000256|SAAS:SAAS00117816};
KW   Transcription regulation {ECO:0000256|PROSITE-ProRule:PRU00381,
KW   ECO:0000256|SAAS:SAAS00117816}.
FT   DOMAIN       16    142       Paired. {ECO:0000259|PROSITE:PS51057}.
SQ   SEQUENCE   324 AA;  35269 MW;  58AE4FF245B8B979 CRC64;
     MDLEKNYPTP RTSRTGHGGV NQLGGVFVNG RPLPDVVRQR IVELAHQGVR PCDISRQLRV
     SHGCVSKILG RYYETGSIKP GVIGGSKPKV ATPKVVEKIA EYKRQNPTMF AWEIRDRLLA
     ERVCDNDTVP SVSSINRIIR TKVQQPPNQP VPASSHSIVS TGSVTQVSSV STDSAGSSYS
     ISGILGITSP SADTNKRKRD EGIQESPVPN GHSLPGRDFL RKQMRGDLFT QQQLEVLDRV
     FERQHYSDIF TTTEPIKPEQ GVSFPGVPTA TLSIPRTTTP GGSPTRGCLA PPTIIALPPE
     EPPHLQPPLP MTVTDPWSQA GTKH
//
ID   E7ERK2_HUMAN            Unreviewed;       283 AA.
AC   E7ERK2;
DT   08-MAR-2011, integrated into UniProtKB/TrEMBL.
DT   08-MAR-2011, sequence version 1.
DT   31-JAN-2018, entry version 59.
DE   SubName: Full=Paired box protein Pax-5 {ECO:0000313|Ensembl:ENSP00000429359};
GN   Name=PAX5 {ECO:0000313|Ensembl:ENSP00000429359};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000429359, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [2] {ECO:0000313|Ensembl:ENSP00000429359}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [3] {ECO:0000313|Ensembl:ENSP00000429359}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (JUL-2011) to UniProtKB.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000256|PROSITE-
CC       ProRule:PRU00381}.
CC   -!- CAUTION: The sequence shown here is derived from an Ensembl
CC       automatic analysis pipeline and should be considered as
CC       preliminary data. {ECO:0000313|Ensembl:ENSP00000429359}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AL161781; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL450267; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_001267485.1; NM_001280556.1.
DR   UniGene; Hs.654464; -.
DR   ProteinModelPortal; E7ERK2; -.
DR   MaxQB; E7ERK2; -.
DR   PeptideAtlas; E7ERK2; -.
DR   Ensembl; ENST00000522003; ENSP00000429359; ENSG00000196092.
DR   GeneID; 5079; -.
DR   UCSC; uc011lqa.3; human.
DR   CTD; 5079; -.
DR   EuPathDB; HostDB:ENSG00000196092.12; -.
DR   HGNC; HGNC:8619; PAX5.
DR   OpenTargets; ENSG00000196092; -.
DR   eggNOG; KOG3862; Eukaryota.
DR   eggNOG; ENOG410ZT0S; LUCA.
DR   GeneTree; ENSGT00680000099553; -.
DR   ChiTaRS; PAX5; human.
DR   GenomeRNAi; 5079; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000196092; -.
DR   ExpressionAtlas; E7ERK2; baseline and differential.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0001650; C:fibrillar center; IDA:HPA.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:UniProtKB-UniRule.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-UniRule.
DR   Gene3D; 1.10.10.10; -; 1.
DR   InterPro; IPR009057; Homeobox-like_sf.
DR   InterPro; IPR001523; Paired_dom.
DR   InterPro; IPR022130; Pax2_C.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   Pfam; PF00292; PAX; 1.
DR   Pfam; PF12403; Pax2_C; 1.
DR   SUPFAM; SSF46689; SSF46689; 1.
DR   PROSITE; PS51057; PAIRED_2; 1.
PE   1: Evidence at protein level;
KW   Complete proteome {ECO:0000313|Proteomes:UP000005640};
KW   DNA-binding {ECO:0000256|PROSITE-ProRule:PRU00381};
KW   Nucleus {ECO:0000256|PROSITE-ProRule:PRU00381};
KW   Paired box {ECO:0000256|PROSITE-ProRule:PRU00381};
KW   Proteomics identification {ECO:0000213|MaxQB:E7ERK2,
KW   ECO:0000213|PeptideAtlas:E7ERK2};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640};
KW   Transcription {ECO:0000256|PROSITE-ProRule:PRU00381};
KW   Transcription regulation {ECO:0000256|PROSITE-ProRule:PRU00381}.
FT   DOMAIN        1     34       Paired. {ECO:0000259|PROSITE:PS51057}.
SQ   SEQUENCE   283 AA;  30321 MW;  20828150572E66D5 CRC64;
     MFAWEIRDRL LAERVCDNDT VPSVSSINRI IRTKVQQPPN QPVPASSHSI VSTGSVTQVS
     SVSTDSAGSS YSISGILGIT SPSADTNKRK RDEGIQESPV PNGHSLPGRD FLRKQMRGDL
     FTQQQLEVLD RVFERQHYSD IFTTTEPIKP EQTTEYSAMA SLAGGLDDMK ANLASPTPAD
     IGSSVPGPQS YPIVTGRDLA STTLPGYPPH VPPAGQGSYS APTLTGMVPG SEFSGSPYSH
     PQYSSYNDSW RFPNPGLLGS PYYYSAAARG AAPPAAATAY DRH
//
ID   E7ERW5_HUMAN            Unreviewed;       295 AA.
AC   E7ERW5;
DT   08-MAR-2011, integrated into UniProtKB/TrEMBL.
DT   08-MAR-2011, sequence version 1.
DT   28-FEB-2018, entry version 60.
DE   SubName: Full=Paired box protein Pax-5 {ECO:0000313|Ensembl:ENSP00000429291};
GN   Name=PAX5 {ECO:0000313|Ensembl:ENSP00000429291};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000429291, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [2] {ECO:0000313|Ensembl:ENSP00000429291}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [3] {ECO:0000313|Ensembl:ENSP00000429291}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (JUL-2011) to UniProtKB.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000256|PROSITE-
CC       ProRule:PRU00381, ECO:0000256|SAAS:SAAS00117811}.
CC   -!- CAUTION: The sequence shown here is derived from an Ensembl
CC       automatic analysis pipeline and should be considered as
CC       preliminary data. {ECO:0000313|Ensembl:ENSP00000429291}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AL161781; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL450267; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_001267479.1; NM_001280550.1.
DR   UniGene; Hs.654464; -.
DR   ProteinModelPortal; E7ERW5; -.
DR   MaxQB; E7ERW5; -.
DR   PeptideAtlas; E7ERW5; -.
DR   Ensembl; ENST00000520154; ENSP00000429291; ENSG00000196092.
DR   GeneID; 5079; -.
DR   UCSC; uc010mls.3; human.
DR   CTD; 5079; -.
DR   EuPathDB; HostDB:ENSG00000196092.12; -.
DR   HGNC; HGNC:8619; PAX5.
DR   OpenTargets; ENSG00000196092; -.
DR   eggNOG; KOG3862; Eukaryota.
DR   eggNOG; ENOG410ZT0S; LUCA.
DR   GeneTree; ENSGT00680000099553; -.
DR   ChiTaRS; PAX5; human.
DR   GenomeRNAi; 5079; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000196092; -.
DR   ExpressionAtlas; E7ERW5; baseline and differential.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0001650; C:fibrillar center; IDA:HPA.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0007275; P:multicellular organism development; IEA:UniProtKB-KW.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:UniProtKB-UniRule.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-UniRule.
DR   CDD; cd00131; PAX; 1.
DR   Gene3D; 1.10.10.10; -; 2.
DR   InterPro; IPR009057; Homeobox-like_sf.
DR   InterPro; IPR001523; Paired_dom.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   Pfam; PF00292; PAX; 1.
DR   PRINTS; PR00027; PAIREDBOX.
DR   SMART; SM00351; PAX; 1.
DR   SUPFAM; SSF46689; SSF46689; 1.
DR   PROSITE; PS00034; PAIRED_1; 1.
DR   PROSITE; PS51057; PAIRED_2; 1.
PE   1: Evidence at protein level;
KW   Complete proteome {ECO:0000313|Proteomes:UP000005640};
KW   Developmental protein {ECO:0000256|SAAS:SAAS00117810};
KW   DNA-binding {ECO:0000256|PROSITE-ProRule:PRU00381,
KW   ECO:0000256|SAAS:SAAS00117818};
KW   Nucleus {ECO:0000256|PROSITE-ProRule:PRU00381,
KW   ECO:0000256|SAAS:SAAS00117821};
KW   Paired box {ECO:0000256|PROSITE-ProRule:PRU00381,
KW   ECO:0000256|SAAS:SAAS00117809};
KW   Proteomics identification {ECO:0000213|MaxQB:E7ERW5,
KW   ECO:0000213|PeptideAtlas:E7ERW5};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640};
KW   Transcription {ECO:0000256|PROSITE-ProRule:PRU00381,
KW   ECO:0000256|SAAS:SAAS00117816};
KW   Transcription regulation {ECO:0000256|PROSITE-ProRule:PRU00381,
KW   ECO:0000256|SAAS:SAAS00117816}.
FT   DOMAIN       16    142       Paired. {ECO:0000259|PROSITE:PS51057}.
SQ   SEQUENCE   295 AA;  32459 MW;  7BE055066EE14208 CRC64;
     MDLEKNYPTP RTSRTGHGGV NQLGGVFVNG RPLPDVVRQR IVELAHQGVR PCDISRQLRV
     SHGCVSKILG RYYETGSIKP GVIGGSKPKV ATPKVVEKIA EYKRQNPTMF AWEIRDRLLA
     ERVCDNDTVP SVSSINRIIR TKVQQPPNQP VPASSHSIVS TGSVTQVSSV STDSAGSSYS
     ISGILGITSP SADTNKRKRD EGIQESPVPN GHSLPGRDFL RKQMRGDLFT QQQLEVLDRV
     FERQHYSDIF TTTEPIKPEQ APPTIIALPP EEPPHLQPPL PMTVTDPWSQ AGTKH
//
ID   E7ES87_HUMAN            Unreviewed;       220 AA.
AC   E7ES87;
DT   08-MAR-2011, integrated into UniProtKB/TrEMBL.
DT   08-MAR-2011, sequence version 1.
DT   31-JAN-2018, entry version 60.
DE   SubName: Full=Paired box protein Pax-5 {ECO:0000313|Ensembl:ENSP00000429197};
GN   Name=PAX5 {ECO:0000313|Ensembl:ENSP00000429197};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000429197, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [2] {ECO:0000313|Ensembl:ENSP00000429197}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [3] {ECO:0000313|Ensembl:ENSP00000429197}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (JUL-2011) to UniProtKB.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000256|PROSITE-
CC       ProRule:PRU00381}.
CC   -!- CAUTION: The sequence shown here is derived from an Ensembl
CC       automatic analysis pipeline and should be considered as
CC       preliminary data. {ECO:0000313|Ensembl:ENSP00000429197}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AL161781; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL450267; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_001267480.1; NM_001280551.1.
DR   UniGene; Hs.654464; -.
DR   ProteinModelPortal; E7ES87; -.
DR   SMR; E7ES87; -.
DR   MaxQB; E7ES87; -.
DR   PeptideAtlas; E7ES87; -.
DR   Ensembl; ENST00000523145; ENSP00000429197; ENSG00000196092.
DR   GeneID; 5079; -.
DR   UCSC; uc011lpy.3; human.
DR   CTD; 5079; -.
DR   EuPathDB; HostDB:ENSG00000196092.12; -.
DR   HGNC; HGNC:8619; PAX5.
DR   OpenTargets; ENSG00000196092; -.
DR   eggNOG; KOG3862; Eukaryota.
DR   eggNOG; ENOG410ZT0S; LUCA.
DR   GeneTree; ENSGT00680000099553; -.
DR   ChiTaRS; PAX5; human.
DR   GenomeRNAi; 5079; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000196092; -.
DR   ExpressionAtlas; E7ES87; baseline and differential.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0001650; C:fibrillar center; IDA:HPA.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:UniProtKB-UniRule.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-UniRule.
DR   Gene3D; 1.10.10.10; -; 1.
DR   InterPro; IPR009057; Homeobox-like_sf.
DR   InterPro; IPR001523; Paired_dom.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   Pfam; PF00292; PAX; 1.
DR   SUPFAM; SSF46689; SSF46689; 1.
DR   PROSITE; PS51057; PAIRED_2; 1.
PE   1: Evidence at protein level;
KW   Complete proteome {ECO:0000313|Proteomes:UP000005640};
KW   DNA-binding {ECO:0000256|PROSITE-ProRule:PRU00381};
KW   Nucleus {ECO:0000256|PROSITE-ProRule:PRU00381};
KW   Paired box {ECO:0000256|PROSITE-ProRule:PRU00381};
KW   Proteomics identification {ECO:0000213|MaxQB:E7ES87,
KW   ECO:0000213|PeptideAtlas:E7ES87};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640};
KW   Transcription {ECO:0000256|PROSITE-ProRule:PRU00381};
KW   Transcription regulation {ECO:0000256|PROSITE-ProRule:PRU00381}.
FT   DOMAIN        1     34       Paired. {ECO:0000259|PROSITE:PS51057}.
SQ   SEQUENCE   220 AA;  23685 MW;  74A33883A0719337 CRC64;
     MFAWEIRDRL LAERVCDNDT VPSVSSINRI IRTKVQQPPN QPVPASSHSI VSTGSVTQVS
     SVSTDSAGSS YSISGILGIT SPSADTNKRK RDEGIQESPV PNGHSLPGRD FLRKQMRGDL
     FTQQQLEVLD RVFERQHYSD IFTTTEPIKP EQTTEYSAMA SLAGGLDDMK ANLASPTPAD
     IGSSVPGPQS YPIVTGSPYY YSAAARGAAP PAAATAYDRH
//
ID   PAX5_HUMAN              Reviewed;         391 AA.
AC   Q02548; A3QVP6; A3QVP7; A3QVP8; C0KTF6; C0KTF7; C0KTF8; C0KTF9;
AC   C0KTG0; O75933; Q5SFM2; Q6S728; Q6S729; Q6S730; Q6S731; Q6S732;
DT   01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1993, sequence version 1.
DT   31-JAN-2018, entry version 170.
DE   RecName: Full=Paired box protein Pax-5;
DE   AltName: Full=B-cell-specific transcription factor;
DE            Short=BSAP;
GN   Name=PAX5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1516825; DOI=10.1101/gad.6.9.1589;
RA   Adams B., Doerfler P., Aguzzi A., Kozmik Z., Urbanek P.,
RA   Maurer-Fogy I., Busslinger M.;
RT   "Pax-5 encodes the transcription factor BSAP and is expressed in B
RT   lymphocytes, the developing CNS, and adult testis.";
RL   Genes Dev. 6:1589-1607(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 4; 5 AND 6), AND
RP   ALTERNATIVE SPLICING.
RX   PubMed=15385562; DOI=10.1074/jbc.M407171200;
RA   Robichaud G.A., Nardini M., Laflamme M., Cuperlovic-Culf M.,
RA   Ouellette R.J.;
RT   "Human Pax-5 C-terminal isoforms possess distinct transactivation
RT   properties and are differentially modulated in normal and malignant B
RT   cells.";
RL   J. Biol. Chem. 279:49956-49963(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 7; 8; 9; 10 AND 11).
RX   PubMed=19725825; DOI=10.1111/j.1365-2141.2009.07859.x;
RA   Arseneau J.R., Laflamme M., Lewis S.M., Maicas E., Ouellette R.J.;
RT   "Multiple isoforms of PAX5 are expressed in both lymphomas and normal
RT   B-cells.";
RL   Br. J. Haematol. 147:328-338(2009).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Livingston R.J., Shaffer T., McFarland I., Nguyen C.P., Stanaway I.B.,
RA   Rajkumar N., Johnson E.J., da Ponte S.H., Willa H., Ahearn M.O.,
RA   Bertucci C., Acklestad J., Carroll A., Swanson J., Gildersleeve H.I.,
RA   Nickerson D.A.;
RL   Submitted (OCT-2006) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-333 (ISOFORM 1), CHROMOSOMAL
RP   TRANSLOCATION WITH ZNF521, CHROMOSOMAL TRANSLOCATION WITH FOXP1, AND
RP   CHROMOSOMAL TRANSLOCATION WITH ETV6.
RX   PubMed=17344859; DOI=10.1038/nature05690;
RA   Mullighan C.G., Goorha S., Radtke I., Miller C.B., Coustan-Smith E.,
RA   Dalton J.D., Girtman K., Mathew S., Ma J., Pounds S.B., Su X.,
RA   Pui C.-H., Relling M.V., Evans W.E., Shurtleff S.A., Downing J.R.;
RT   "Genome-wide analysis of genetic alterations in acute lymphoblastic
RT   leukaemia.";
RL   Nature 446:758-764(2007).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 62-197.
RX   PubMed=9742255; DOI=10.1093/nar/26.19.4497;
RA   Verkoczy L.K., Berinstein N.L.;
RT   "Isolation of genes negatively or positively co-expressed with human
RT   recombination activating gene 1 (RAG1) by differential display PCR (DD
RT   RT-PCR).";
RL   Nucleic Acids Res. 26:4497-4507(1998).
RN   [9]
RP   INTERACTION WITH TLE4.
RX   PubMed=10811620; DOI=10.1093/emboj/19.10.2292;
RA   Eberhard D., Jimenez G., Heavey B., Busslinger M.;
RT   "Transcriptional repression by Pax5 (BSAP) through interaction with
RT   corepressors of the Groucho family.";
RL   EMBO J. 19:2292-2303(2000).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 1-149 IN COMPLEX WITH MOUSE
RP   ETS1 AND DNA.
RX   PubMed=11779502; DOI=10.1016/S1097-2765(01)00410-5;
RA   Garvie C.W., Hagman J., Wolberger C.;
RT   "Structural studies of Ets-1/Pax5 complex formation on DNA.";
RL   Mol. Cell 8:1267-1276(2001).
RN   [11]
RP   VARIANT ALL3 SER-183, VARIANTS ARG-24; GLY-26; GLN-34; VAL-53; GLY-59;
RP   ASN-66; ARG-75; ARG-80; THR-139; ILE-151; VAL-183; LEU-213; THR-301
RP   AND VAL-338, AND CHARACTERIZATION OF VARIANT ALL3 SER-183.
RX   PubMed=24013638; DOI=10.1038/ng.2754;
RA   Shah S., Schrader K.A., Waanders E., Timms A.E., Vijai J.,
RA   Miething C., Wechsler J., Yang J., Hayes J., Klein R.J., Zhang J.,
RA   Wei L., Wu G., Rusch M., Nagahawatte P., Ma J., Chen S.C., Song G.,
RA   Cheng J., Meyers P., Bhojwani D., Jhanwar S., Maslak P., Fleisher M.,
RA   Littman J., Offit L., Rau-Murthy R., Fleischut M.H., Corines M.,
RA   Murali R., Gao X., Manschreck C., Kitzing T., Murty V.V.,
RA   Raimondi S.C., Kuiper R.P., Simons A., Schiffman J.D., Onel K.,
RA   Plon S.E., Wheeler D.A., Ritter D., Ziegler D.S., Tucker K.,
RA   Sutton R., Chenevix-Trench G., Li J., Huntsman D.G., Hansford S.,
RA   Senz J., Walsh T., Lee M., Hahn C.N., Roberts K.G., King M.C.,
RA   Lo S.M., Levine R.L., Viale A., Socci N.D., Nathanson K.L.,
RA   Scott H.S., Daly M., Lipkin S.M., Lowe S.W., Downing J.R.,
RA   Altshuler D., Sandlund J.T., Horwitz M.S., Mullighan C.G., Offit K.;
RT   "A recurrent germline PAX5 mutation confers susceptibility to pre-B
RT   cell acute lymphoblastic leukemia.";
RL   Nat. Genet. 45:1226-1231(2013).
CC   -!- FUNCTION: May play an important role in B-cell differentiation as
CC       well as neural development and spermatogenesis. Involved in the
CC       regulation of the CD19 gene, a B-lymphoid-specific target gene.
CC   -!- SUBUNIT: Interacts with DAXX (By similarity). Binds DNA as a
CC       monomer. Binds TLE4. Interacts with ETS1, altering its DNA-binding
CC       properties. {ECO:0000250, ECO:0000269|PubMed:10811620,
CC       ECO:0000269|PubMed:11779502}.
CC   -!- INTERACTION:
CC       Q9NX04:C1orf109; NbExp=4; IntAct=EBI-296331, EBI-8643161;
CC       Q03164:KMT2A; NbExp=2; IntAct=EBI-296331, EBI-2610266;
CC       Q13952-2:NFYC; NbExp=4; IntAct=EBI-296331, EBI-11956831;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=11;
CC       Name=1;
CC         IsoId=Q02548-1; Sequence=Displayed;
CC       Name=2; Synonyms=delta9;
CC         IsoId=Q02548-2; Sequence=VSP_044121;
CC       Name=3; Synonyms=delta78;
CC         IsoId=Q02548-3; Sequence=VSP_044117, VSP_044118, VSP_044120;
CC       Name=4; Synonyms=delta789;
CC         IsoId=Q02548-4; Sequence=VSP_044116, VSP_044120;
CC       Name=5; Synonyms=delta8;
CC         IsoId=Q02548-5; Sequence=VSP_044115;
CC       Name=6; Synonyms=delta7;
CC         IsoId=Q02548-6; Sequence=VSP_044119;
CC       Name=7;
CC         IsoId=Q02548-7; Sequence=VSP_047830;
CC       Name=8;
CC         IsoId=Q02548-8; Sequence=VSP_047828;
CC       Name=9;
CC         IsoId=Q02548-9; Sequence=VSP_047828, VSP_044121;
CC       Name=10;
CC         IsoId=Q02548-10; Sequence=VSP_047827, VSP_047831;
CC       Name=11;
CC         IsoId=Q02548-11; Sequence=VSP_047829, VSP_047832;
CC   -!- DEVELOPMENTAL STAGE: Expressed at early B-cell differentiation, in
CC       the developing CNS and in adult testis.
CC   -!- PTM: O-glycosylated. {ECO:0000305}.
CC   -!- DISEASE: Note=A chromosomal aberration involving PAX5 is a cause
CC       of acute lymphoblastic leukemia. Translocation t(9;18)(p13;q11.2)
CC       with ZNF521. Translocation t(9;3)(p13;p14.1) with FOXP1.
CC       Translocation t(9;12)(p13;p13) with ETV6.
CC       {ECO:0000269|PubMed:17344859}.
CC   -!- DISEASE: Leukemia, acute lymphoblastic, 3 (ALL3) [MIM:613065]: A
CC       subtype of acute leukemia, a cancer of the white blood cells.
CC       Acute lymphoblastic anemia is a malignant disease of bone marrow
CC       and the most common malignancy diagnosed in children. The
CC       malignant cells are lymphoid precursor cells (lymphoblasts) that
CC       are arrested in an early stage of development. The lymphoblasts
CC       replace the normal marrow elements, resulting in a marked decrease
CC       in the production of normal blood cells. Consequently, anemia,
CC       thrombocytopenia, and neutropenia occur to varying degrees. The
CC       lymphoblasts also proliferate in organs other than the marrow,
CC       particularly the liver, spleen, and lymphnodes.
CC       {ECO:0000269|PubMed:24013638}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PAX5ID62.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M96944; AAA58397.1; -; mRNA.
DR   EMBL; AY463952; AAR27590.1; -; mRNA.
DR   EMBL; AY463953; AAR27591.1; -; mRNA.
DR   EMBL; AY463954; AAR27592.1; -; mRNA.
DR   EMBL; AY463955; AAR27593.1; -; mRNA.
DR   EMBL; AY463956; AAR27594.1; -; mRNA.
DR   EMBL; AY463957; AAR27595.1; -; mRNA.
DR   EMBL; FJ626421; ACM91604.1; -; mRNA.
DR   EMBL; FJ626422; ACM91605.1; -; mRNA.
DR   EMBL; FJ626423; ACM91606.1; -; mRNA.
DR   EMBL; FJ626424; ACM91607.1; -; mRNA.
DR   EMBL; FJ626425; ACM91608.1; -; mRNA.
DR   EMBL; EF064717; ABK41900.1; -; Genomic_DNA.
DR   EMBL; AL161781; CAH72137.1; -; Genomic_DNA.
DR   EMBL; AL450267; CAH72137.1; JOINED; Genomic_DNA.
DR   EMBL; AL450267; CAH72740.1; -; Genomic_DNA.
DR   EMBL; AL161781; CAH72740.1; JOINED; Genomic_DNA.
DR   EMBL; CH471071; EAW58294.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58295.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58296.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58297.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58298.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58299.1; -; Genomic_DNA.
DR   EMBL; DQ841178; ABI30005.1; ALT_TERM; mRNA.
DR   EMBL; DQ845345; ABI33104.1; ALT_TERM; mRNA.
DR   EMBL; DQ845346; ABI33105.1; ALT_TERM; mRNA.
DR   EMBL; AF080573; AAC35286.1; -; mRNA.
DR   CCDS; CCDS65041.1; -. [Q02548-10]
DR   CCDS; CCDS65042.1; -. [Q02548-9]
DR   CCDS; CCDS65043.1; -. [Q02548-8]
DR   CCDS; CCDS65044.1; -. [Q02548-4]
DR   CCDS; CCDS65045.1; -. [Q02548-3]
DR   CCDS; CCDS65046.1; -. [Q02548-7]
DR   CCDS; CCDS65047.1; -. [Q02548-6]
DR   CCDS; CCDS65048.1; -. [Q02548-2]
DR   CCDS; CCDS6607.1; -. [Q02548-1]
DR   PIR; A44063; A44063.
DR   RefSeq; NP_001267476.1; NM_001280547.1. [Q02548-6]
DR   RefSeq; NP_001267477.1; NM_001280548.1. [Q02548-2]
DR   RefSeq; NP_001267478.1; NM_001280549.1.
DR   RefSeq; NP_001267479.1; NM_001280550.1.
DR   RefSeq; NP_001267481.1; NM_001280552.1. [Q02548-7]
DR   RefSeq; NP_001267482.1; NM_001280553.1. [Q02548-9]
DR   RefSeq; NP_001267483.1; NM_001280554.1. [Q02548-8]
DR   RefSeq; NP_001267484.1; NM_001280555.1. [Q02548-10]
DR   RefSeq; NP_001267485.1; NM_001280556.1.
DR   RefSeq; NP_057953.1; NM_016734.2. [Q02548-1]
DR   UniGene; Hs.654464; -.
DR   PDB; 1K78; X-ray; 2.25 A; A/E/I=1-149.
DR   PDB; 1MDM; X-ray; 2.80 A; A=1-149.
DR   PDBsum; 1K78; -.
DR   PDBsum; 1MDM; -.
DR   DisProt; DP00969; -.
DR   ProteinModelPortal; Q02548; -.
DR   SMR; Q02548; -.
DR   BioGrid; 111113; 9.
DR   ELM; Q02548; -.
DR   IntAct; Q02548; 41.
DR   STRING; 9606.ENSP00000350844; -.
DR   iPTMnet; Q02548; -.
DR   PhosphoSitePlus; Q02548; -.
DR   BioMuta; PAX5; -.
DR   DMDM; 417449; -.
DR   PaxDb; Q02548; -.
DR   PeptideAtlas; Q02548; -.
DR   PRIDE; Q02548; -.
DR   DNASU; 5079; -.
DR   Ensembl; ENST00000358127; ENSP00000350844; ENSG00000196092. [Q02548-1]
DR   Ensembl; ENST00000377840; ENSP00000367071; ENSG00000196092. [Q02548-5]
DR   Ensembl; ENST00000377847; ENSP00000367078; ENSG00000196092. [Q02548-7]
DR   Ensembl; ENST00000377852; ENSP00000367083; ENSG00000196092. [Q02548-6]
DR   Ensembl; ENST00000377853; ENSP00000367084; ENSG00000196092. [Q02548-2]
DR   Ensembl; ENST00000414447; ENSP00000412188; ENSG00000196092. [Q02548-8]
DR   Ensembl; ENST00000446742; ENSP00000404687; ENSG00000196092. [Q02548-10]
DR   Ensembl; ENST00000520281; ENSP00000430773; ENSG00000196092. [Q02548-9]
DR   Ensembl; ENST00000523493; ENSP00000431038; ENSG00000196092. [Q02548-11]
DR   GeneID; 5079; -.
DR   KEGG; hsa:5079; -.
DR   UCSC; uc003zzo.3; human. [Q02548-1]
DR   CTD; 5079; -.
DR   DisGeNET; 5079; -.
DR   EuPathDB; HostDB:ENSG00000196092.12; -.
DR   GeneCards; PAX5; -.
DR   HGNC; HGNC:8619; PAX5.
DR   HPA; CAB026269; -.
DR   HPA; CAB026869; -.
DR   HPA; HPA056394; -.
DR   HPA; HPA068498; -.
DR   MalaCards; PAX5; -.
DR   MIM; 167414; gene.
DR   MIM; 613065; phenotype.
DR   neXtProt; NX_Q02548; -.
DR   OpenTargets; ENSG00000196092; -.
DR   Orphanet; 99860; Precursor B-cell acute lymphoblastic leukemia.
DR   PharmGKB; PA32959; -.
DR   eggNOG; KOG3862; Eukaryota.
DR   eggNOG; ENOG410ZT0S; LUCA.
DR   GeneTree; ENSGT00680000099553; -.
DR   HOGENOM; HOG000230939; -.
DR   HOVERGEN; HBG009115; -.
DR   InParanoid; Q02548; -.
DR   KO; K09383; -.
DR   OMA; YSTYNDS; -.
DR   OrthoDB; EOG091G0S4E; -.
DR   PhylomeDB; Q02548; -.
DR   TreeFam; TF315397; -.
DR   Reactome; R-HSA-8939245; RUNX1 regulates transcription of genes involved in BCR signaling.
DR   SignaLink; Q02548; -.
DR   SIGNOR; Q02548; -.
DR   ChiTaRS; PAX5; human.
DR   EvolutionaryTrace; Q02548; -.
DR   GeneWiki; PAX5; -.
DR   GenomeRNAi; 5079; -.
DR   PRO; PR:Q02548; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000196092; -.
DR   CleanEx; HS_PAX5; -.
DR   ExpressionAtlas; Q02548; baseline and differential.
DR   Genevisible; Q02548; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0001650; C:fibrillar center; IDA:HPA.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0000978; F:RNA polymerase II proximal promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0001077; F:transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0030534; P:adult behavior; IEA:Ensembl.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0009887; P:animal organ morphogenesis; TAS:ProtInc.
DR   GO; GO:0021987; P:cerebral cortex development; IEA:Ensembl.
DR   GO; GO:0048701; P:embryonic cranial skeleton morphogenesis; IEA:Ensembl.
DR   GO; GO:0006959; P:humoral immune response; TAS:ProtInc.
DR   GO; GO:0021670; P:lateral ventricle development; IEA:Ensembl.
DR   GO; GO:0007275; P:multicellular organism development; TAS:ProtInc.
DR   GO; GO:0051573; P:negative regulation of histone H3-K9 methylation; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0050855; P:regulation of B cell receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0035914; P:skeletal muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0006366; P:transcription from RNA polymerase II promoter; TAS:ProtInc.
DR   CDD; cd00131; PAX; 1.
DR   Gene3D; 1.10.10.10; -; 2.
DR   InterPro; IPR009057; Homeobox-like_sf.
DR   InterPro; IPR001523; Paired_dom.
DR   InterPro; IPR022130; Pax2_C.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   Pfam; PF00292; PAX; 1.
DR   Pfam; PF12403; Pax2_C; 1.
DR   PRINTS; PR00027; PAIREDBOX.
DR   SMART; SM00351; PAX; 1.
DR   SUPFAM; SSF46689; SSF46689; 1.
DR   PROSITE; PS00034; PAIRED_1; 1.
DR   PROSITE; PS51057; PAIRED_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Chromosomal rearrangement;
KW   Complete proteome; Developmental protein; Differentiation;
KW   Disease mutation; DNA-binding; Glycoprotein; Neurogenesis; Nucleus;
KW   Paired box; Polymorphism; Proto-oncogene; Reference proteome;
KW   Spermatogenesis; Transcription; Transcription regulation.
FT   CHAIN         1    391       Paired box protein Pax-5.
FT                                /FTId=PRO_0000050183.
FT   DOMAIN       16    142       Paired. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00381}.
FT   SITE        158    159       Breakpoint for translocation to form
FT                                PAX5-ETV6.
FT   SITE        260    261       Breakpoint for translocation to form
FT                                PAX5-FOXP1.
FT   SITE        303    304       Breakpoint for translocation to form
FT                                PAX5-ZNF521.
FT   VAR_SEQ      71    136       Missing (in isoform 10).
FT                                {ECO:0000303|PubMed:19725825}.
FT                                /FTId=VSP_047827.
FT   VAR_SEQ     159    201       Missing (in isoform 8 and isoform 9).
FT                                {ECO:0000303|PubMed:19725825}.
FT                                /FTId=VSP_047828.
FT   VAR_SEQ     261    391       TTEYSAMASLAGGLDDMKANLASPTPADIGSSVPGPQSYPI
FT                                VTGRDLASTTLPGYPPHVPPAGQGSYSAPTLTGMVPGSEFS
FT                                GSPYSHPQYSSYNDSWRFPNPGLLGSPYYYSAAARGAAPPA
FT                                AATAYDRH -> AVTWRARPSPGTLHTSPPLDRAATQHRR
FT                                (in isoform 5).
FT                                {ECO:0000303|PubMed:15385562}.
FT                                /FTId=VSP_044115.
FT   VAR_SEQ     261    315       TTEYSAMASLAGGLDDMKANLASPTPADIGSSVPGPQSYPI
FT                                VTGRDLASTTLPGY -> APPIIIALPPEE (in
FT                                isoform 4).
FT                                {ECO:0000303|PubMed:15385562}.
FT                                /FTId=VSP_044116.
FT   VAR_SEQ     261    307       TTEYSAMASLAGGLDDMKANLASPTPADIGSSVPGPQSYPI
FT                                VTGRDL -> WCPVLMRQYLVQPQAVLFQAVTWRARPSPGT
FT                                LHTSPPLDRAATQHRR (in isoform 11).
FT                                {ECO:0000303|PubMed:19725825}.
FT                                /FTId=VSP_047829.
FT   VAR_SEQ     261    282       TTEYSAMASLAGGLDDMKANLA -> GVSFPGVPTATLSIP
FT                                RTTTPGG (in isoform 3).
FT                                {ECO:0000303|PubMed:15385562}.
FT                                /FTId=VSP_044117.
FT   VAR_SEQ     286    315       PADIGSSVPGPQSYPIVTGRDLASTTLPGY -> RGCLAPP
FT                                IIIALPPEE (in isoform 3).
FT                                {ECO:0000303|PubMed:15385562}.
FT                                /FTId=VSP_044118.
FT   VAR_SEQ     304    366       Missing (in isoform 7).
FT                                {ECO:0000303|PubMed:19725825}.
FT                                /FTId=VSP_047830.
FT   VAR_SEQ     304    337       Missing (in isoform 10).
FT                                {ECO:0000303|PubMed:19725825}.
FT                                /FTId=VSP_047831.
FT   VAR_SEQ     305    349       RDLASTTLPGYPPHVPPAGQGSYSAPTLTGMVPGSEFSGSP
FT                                YSHP -> SEFSGSPYSHP (in isoform 6).
FT                                {ECO:0000303|PubMed:15385562}.
FT                                /FTId=VSP_044119.
FT   VAR_SEQ     308    391       Missing (in isoform 11).
FT                                {ECO:0000303|PubMed:19725825}.
FT                                /FTId=VSP_047832.
FT   VAR_SEQ     319    391       VPPAGQGSYSAPTLTGMVPGSEFSGSPYSHPQYSSYNDSWR
FT                                FPNPGLLGSPYYYSAAARGAAPPAAATAYDRH -> LQPPL
FT                                PMTVTDPWSQAGTKH (in isoform 3 and isoform
FT                                4). {ECO:0000303|PubMed:15385562}.
FT                                /FTId=VSP_044120.
FT   VAR_SEQ     338    366       Missing (in isoform 2 and isoform 9).
FT                                {ECO:0000303|PubMed:15385562,
FT                                ECO:0000303|PubMed:19725825}.
FT                                /FTId=VSP_044121.
FT   VARIANT      24     24       G -> R (in dbSNP:rs868494257).
FT                                {ECO:0000269|PubMed:24013638}.
FT                                /FTId=VAR_070672.
FT   VARIANT      26     26       V -> G (in dbSNP:rs926053251).
FT                                {ECO:0000269|PubMed:24013638}.
FT                                /FTId=VAR_070673.
FT   VARIANT      34     34       P -> Q. {ECO:0000269|PubMed:24013638}.
FT                                /FTId=VAR_070674.
FT   VARIANT      53     53       D -> V. {ECO:0000269|PubMed:24013638}.
FT                                /FTId=VAR_070675.
FT   VARIANT      59     59       R -> G. {ECO:0000269|PubMed:24013638}.
FT                                /FTId=VAR_070676.
FT   VARIANT      66     66       S -> N. {ECO:0000269|PubMed:24013638}.
FT                                /FTId=VAR_070677.
FT   VARIANT      75     75       T -> R. {ECO:0000269|PubMed:24013638}.
FT                                /FTId=VAR_070678.
FT   VARIANT      80     80       P -> R. {ECO:0000269|PubMed:24013638}.
FT                                /FTId=VAR_070679.
FT   VARIANT     139    139       I -> T. {ECO:0000269|PubMed:24013638}.
FT                                /FTId=VAR_070680.
FT   VARIANT     151    151       V -> I (in dbSNP:rs115889954).
FT                                {ECO:0000269|PubMed:24013638}.
FT                                /FTId=VAR_070681.
FT   VARIANT     183    183       G -> S (in ALL3; confers susceptibility
FT                                to ALL3; reduced transcription factor
FT                                activity; dbSNP:rs398123063).
FT                                {ECO:0000269|PubMed:24013638}.
FT                                /FTId=VAR_070682.
FT   VARIANT     183    183       G -> V. {ECO:0000269|PubMed:24013638}.
FT                                /FTId=VAR_070683.
FT   VARIANT     213    213       S -> L (in dbSNP:rs137870876).
FT                                {ECO:0000269|PubMed:24013638}.
FT                                /FTId=VAR_070684.
FT   VARIANT     301    301       I -> T (in dbSNP:rs372989600).
FT                                {ECO:0000269|PubMed:24013638}.
FT                                /FTId=VAR_070685.
FT   VARIANT     322    322       A -> T (in dbSNP:rs34810717).
FT                                /FTId=VAR_034370.
FT   VARIANT     338    338       G -> V. {ECO:0000269|PubMed:24013638}.
FT                                /FTId=VAR_070686.
FT   CONFLICT     99     99       I -> F (in Ref. 8; AAC35286).
FT                                {ECO:0000305}.
FT   CONFLICT    141    143       TKV -> PKL (in Ref. 8; AAC35286).
FT                                {ECO:0000305}.
FT   HELIX        35     46       {ECO:0000244|PDB:1K78}.
FT   HELIX        51     58       {ECO:0000244|PDB:1K78}.
FT   HELIX        62     75       {ECO:0000244|PDB:1K78}.
FT   STRAND       89     91       {ECO:0000244|PDB:1K78}.
FT   HELIX        93    105       {ECO:0000244|PDB:1K78}.
FT   HELIX       111    120       {ECO:0000244|PDB:1K78}.
FT   TURN        126    128       {ECO:0000244|PDB:1K78}.
FT   HELIX       132    140       {ECO:0000244|PDB:1K78}.
SQ   SEQUENCE   391 AA;  42149 MW;  DB37E6EACD9F993A CRC64;
     MDLEKNYPTP RTSRTGHGGV NQLGGVFVNG RPLPDVVRQR IVELAHQGVR PCDISRQLRV
     SHGCVSKILG RYYETGSIKP GVIGGSKPKV ATPKVVEKIA EYKRQNPTMF AWEIRDRLLA
     ERVCDNDTVP SVSSINRIIR TKVQQPPNQP VPASSHSIVS TGSVTQVSSV STDSAGSSYS
     ISGILGITSP SADTNKRKRD EGIQESPVPN GHSLPGRDFL RKQMRGDLFT QQQLEVLDRV
     FERQHYSDIF TTTEPIKPEQ TTEYSAMASL AGGLDDMKAN LASPTPADIG SSVPGPQSYP
     IVTGRDLAST TLPGYPPHVP PAGQGSYSAP TLTGMVPGSE FSGSPYSHPQ YSSYNDSWRF
     PNPGLLGSPY YYSAAARGAA PPAAATAYDR H
//
ID   B2R5T5_HUMAN            Unreviewed;       381 AA.
AC   B2R5T5;
DT   01-JUL-2008, integrated into UniProtKB/TrEMBL.
DT   01-JUL-2008, sequence version 1.
DT   28-FEB-2018, entry version 93.
DE   SubName: Full=Protein kinase, cAMP-dependent, regulatory, type I, alpha (Tissue specific extinguisher 1), isoform CRA_a {ECO:0000313|EMBL:EAW89060.1};
DE   SubName: Full=cDNA FLJ40261 fis, clone TESTI2025609, highly similar to cAMP-dependent protein kinase type I-alpha regulatory subunit {ECO:0000313|EMBL:BAG53489.1};
DE   SubName: Full=cDNA, FLJ92612, Homo sapiens protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific extinguisher 1) (PRKAR1A), mRNA {ECO:0000313|EMBL:BAG35232.1};
GN   Name=PRKAR1A {ECO:0000313|EMBL:EAW89060.1};
GN   ORFNames=hCG_28462 {ECO:0000313|EMBL:EAW89060.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAG35232.1};
RN   [1] {ECO:0000313|EMBL:EAW89060.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D.,
RA   Amanatides P., Ballew R.M., Huson D.H., Wortman J.R., Zhang Q.,
RA   Kodira C.D., Zheng X.H., Chen L., Skupski M., Subramanian G.,
RA   Thomas P.D., Zhang J., Gabor Miklos G.L., Nelson C., Broder S.,
RA   Clark A.G., Nadeau J., McKusick V.A., Zinder N., Levine A.J.,
RA   Roberts R.J., Simon M., Slayman C., Hunkapiller M., Bolanos R.,
RA   Delcher A., Dew I., Fasulo D., Flanigan M., Florea L., Halpern A.,
RA   Hannenhalli S., Kravitz S., Levy S., Mobarry C., Reinert K.,
RA   Remington K., Abu-Threideh J., Beasley E., Biddick K., Bonazzi V.,
RA   Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z.,
RA   Guan P., Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A.,
RA   Lai Z., Lei Y., Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V.,
RA   Milshina N., Moore H.M., Naik A.K., Narayan V.A., Neelam B.,
RA   Nusskern D., Rusch D.B., Salzberg S., Shao W., Shue B., Sun J.,
RA   Wang Z., Wang A., Wang X., Wang J., Wei M., Wides R., Xiao C., Yan C.,
RA   Yao A., Ye J., Zhan M., Zhang W., Zhang H., Zhao Q., Zheng L.,
RA   Zhong F., Zhong W., Zhu S., Zhao S., Gilbert D., Baumhueter S.,
RA   Spier G., Carter C., Cravchik A., Woodage T., Ali F., An H., Awe A.,
RA   Baldwin D., Baden H., Barnstead M., Barrow I., Beeson K., Busam D.,
RA   Carver A., Center A., Cheng M.L., Curry L., Danaher S., Davenport L.,
RA   Desilets R., Dietz S., Dodson K., Doup L., Ferriera S., Garg N.,
RA   Gluecksmann A., Hart B., Haynes J., Haynes C., Heiner C., Hladun S.,
RA   Hostin D., Houck J., Howland T., Ibegwam C., Johnson J., Kalush F.,
RA   Kline L., Koduru S., Love A., Mann F., May D., McCawley S.,
RA   McIntosh T., McMullen I., Moy M., Moy L., Murphy B., Nelson K.,
RA   Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N.,
RA   Tse S., Vech C., Wang G., Wetter J., Williams S., Williams M.,
RA   Windsor S., Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F.,
RA   Guigo R., Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A.,
RA   Mi H., Lazareva B., Hatton T., Narechania A., Diemer K.,
RA   Muruganujan A., Guo N., Sato S., Bafna V., Istrail S., Lippert R.,
RA   Schwartz R., Walenz B., Yooseph S., Allen D., Basu A., Baxendale J.,
RA   Blick L., Caminha M., Carnes-Stine J., Caulk P., Chiang Y.H.,
RA   Coyne M., Dahlke C., Mays A., Dombroski M., Donnelly M., Ely D.,
RA   Esparham S., Fosler C., Gire H., Glanowski S., Glasser K., Glodek A.,
RA   Gorokhov M., Graham K., Gropman B., Harris M., Heil J., Henderson S.,
RA   Hoover J., Jennings D., Jordan C., Jordan J., Kasha J., Kagan L.,
RA   Kraft C., Levitsky A., Lewis M., Liu X., Lopez J., Ma D., Majoros W.,
RA   McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N., Nodell M.,
RA   Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|EMBL:BAG53489.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Testis {ECO:0000313|EMBL:BAG53489.1};
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3] {ECO:0000313|EMBL:EAW89060.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4] {ECO:0000313|EMBL:BAG35232.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Cerebellum {ECO:0000313|EMBL:BAG35232.1};
RA   Wakamatsu A., Yamamoto J., Kimura K., Kaida T., Tsuchiya K., Iida Y.,
RA   Takayama Y., Murakawa K., Kanehori K., Andoh T., Kagawa N., Sato R.,
RA   Kawamura Y., Tanaka S., Kisu Y., Sugano S., Goshima N., Nomura N.,
RA   Isogai T.;
RT   "NEDO functional analysis of protein and research application
RT   project.";
RL   Submitted (JAN-2008) to the EMBL/GenBank/DDBJ databases.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK312307; BAG35232.1; -; mRNA.
DR   EMBL; AK097580; BAG53489.1; -; mRNA.
DR   EMBL; CH471099; EAW89060.1; -; Genomic_DNA.
DR   EMBL; CH471099; EAW89061.1; -; Genomic_DNA.
DR   EMBL; CH471099; EAW89062.1; -; Genomic_DNA.
DR   EMBL; CH471099; EAW89063.1; -; Genomic_DNA.
DR   EMBL; CH471099; EAW89065.1; -; Genomic_DNA.
DR   RefSeq; NP_001263218.1; NM_001276289.1.
DR   RefSeq; NP_001265362.1; NM_001278433.1.
DR   RefSeq; NP_002725.1; NM_002734.4.
DR   RefSeq; NP_997636.1; NM_212471.2.
DR   RefSeq; NP_997637.1; NM_212472.2.
DR   RefSeq; XP_011523285.1; XM_011524983.2.
DR   RefSeq; XP_011523286.1; XM_011524984.2.
DR   RefSeq; XP_011523287.1; XM_011524985.2.
DR   UniGene; Hs.280342; -.
DR   UniGene; Hs.745160; -.
DR   SMR; B2R5T5; -.
DR   DNASU; 5573; -.
DR   GeneID; 5573; -.
DR   KEGG; hsa:5573; -.
DR   CTD; 5573; -.
DR   EuPathDB; HostDB:ENSG00000108946.14; -.
DR   PharmGKB; PA33754; -.
DR   eggNOG; KOG1113; Eukaryota.
DR   eggNOG; COG0664; LUCA.
DR   HOVERGEN; HBG002025; -.
DR   KO; K04739; -.
DR   OMA; VQLCTVR; -.
DR   OrthoDB; EOG091G0F1K; -.
DR   ChiTaRS; PRKAR1A; human.
DR   GenomeRNAi; 5573; -.
DR   Bgee; ENSG00000108946; -.
DR   GO; GO:0005952; C:cAMP-dependent protein kinase complex; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0031594; C:neuromuscular junction; IEA:Ensembl.
DR   GO; GO:0030552; F:cAMP binding; IEA:UniProtKB-KW.
DR   GO; GO:0008603; F:cAMP-dependent protein kinase regulator activity; IEA:Ensembl.
DR   GO; GO:0016301; F:kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0060038; P:cardiac muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0007143; P:female meiotic nuclear division; IEA:Ensembl.
DR   GO; GO:0001707; P:mesoderm formation; IEA:Ensembl.
DR   GO; GO:0045835; P:negative regulation of meiotic nuclear division; IEA:Ensembl.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; IEA:Ensembl.
DR   GO; GO:0045214; P:sarcomere organization; IEA:Ensembl.
DR   CDD; cd00038; CAP_ED; 2.
DR   Gene3D; 1.20.890.10; -; 1.
DR   Gene3D; 2.60.120.10; -; 2.
DR   InterPro; IPR012198; cAMP_dep_PK_reg_su.
DR   InterPro; IPR003117; cAMP_dep_PK_reg_su_I/II_a/b.
DR   InterPro; IPR036536; cAMP_dep_PK_reg_su_sf.
DR   InterPro; IPR018490; cNMP-bd-like.
DR   InterPro; IPR018488; cNMP-bd_CS.
DR   InterPro; IPR000595; cNMP-bd_dom.
DR   InterPro; IPR014710; RmlC-like_jellyroll.
DR   Pfam; PF00027; cNMP_binding; 2.
DR   Pfam; PF02197; RIIa; 1.
DR   PIRSF; PIRSF000548; PK_regulatory; 1.
DR   SMART; SM00100; cNMP; 2.
DR   SMART; SM00394; RIIa; 1.
DR   SUPFAM; SSF47391; SSF47391; 1.
DR   SUPFAM; SSF51206; SSF51206; 2.
DR   PROSITE; PS00888; CNMP_BINDING_1; 2.
DR   PROSITE; PS00889; CNMP_BINDING_2; 2.
DR   PROSITE; PS50042; CNMP_BINDING_3; 2.
PE   2: Evidence at transcript level;
KW   cAMP {ECO:0000256|PIRSR:PIRSR000548-1};
KW   cAMP-binding {ECO:0000256|PIRSR:PIRSR000548-1};
KW   Kinase {ECO:0000313|EMBL:BAG35232.1};
KW   Nucleotide-binding {ECO:0000256|PIRSR:PIRSR000548-1};
KW   Transferase {ECO:0000313|EMBL:BAG35232.1}.
FT   DOMAIN      137    252       Cyclic nucleotide-binding.
FT                                {ECO:0000259|PROSITE:PS50042}.
FT   DOMAIN      255    376       Cyclic nucleotide-binding.
FT                                {ECO:0000259|PROSITE:PS50042}.
FT   BINDING     202    202       cAMP 1. {ECO:0000256|PIRSR:PIRSR000548-
FT                                1}.
FT   BINDING     211    211       cAMP 1. {ECO:0000256|PIRSR:PIRSR000548-
FT                                1}.
FT   BINDING     326    326       cAMP 2. {ECO:0000256|PIRSR:PIRSR000548-
FT                                1}.
FT   BINDING     335    335       cAMP 2. {ECO:0000256|PIRSR:PIRSR000548-
FT                                1}.
SQ   SEQUENCE   381 AA;  42982 MW;  2D04F08CE8857A6D CRC64;
     MESGSTAASE EARSLRECEL YVQKHNIQAL LKDSIVQLCT ARPERPMAFL REYFERLEKE
     EAKQIQNLQK AGTRTDSRED EISPPPPNPV VKGRRRRGAI SAEVYTEEDA ASYVRKVIPK
     DYKTMAALAK AIEKNVLFSH LDDNERSDIF DAMFSVSFIA GETVIQQGDE GDNFYVIDQG
     ETDVYVNNEW ATSVGEGGSF GELALIYGTP RAATVKAKTN VKLWGIDRDS YRRILMGSTL
     RKRKMYEEFL SKVSILESLD KWERLTVADA LEPVQFEDGQ KIVVQGEPGD EFFIILEGSA
     AVLQRRSENE EFVEVGRLGP SDYFGEIALL MNRPRAATVV ARGPLKCVKL DRPRFERVLG
     PCSDILKRNI QQYNSFVSLS V
//
ID   KAP0_HUMAN              Reviewed;         381 AA.
AC   P10644; K7ER48; Q567S7;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 1.
DT   28-FEB-2018, entry version 209.
DE   RecName: Full=cAMP-dependent protein kinase type I-alpha regulatory subunit;
DE   AltName: Full=Tissue-specific extinguisher 1;
DE            Short=TSE1;
GN   Name=PRKAR1A; Synonyms=PKR1, PRKAR1, TSE1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=3426618; DOI=10.1016/0006-291X(87)90499-2;
RA   Sandberg M., Tasken K., Oeyen O., Hansson V., Jahnsen T.;
RT   "Molecular cloning, cDNA structure and deduced amino acid sequence for
RT   a type I regulatory subunit of cAMP-dependent protein kinase from
RT   human testis.";
RL   Biochem. Biophys. Res. Commun. 149:939-945(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=2310396; DOI=10.1016/0006-291X(90)91768-N;
RA   Sandberg M., Skalhegg B., Jahnsen T.;
RT   "The two mRNA forms for the type I alpha regulatory subunit of cAMP-
RT   dependent protein kinase from human testis are due to the use of
RT   different polyadenylation site signals.";
RL   Biochem. Biophys. Res. Commun. 167:323-330(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1889088; DOI=10.1016/0092-8674(91)90433-Y;
RA   Jones K.W., Shapero M.H., Chevrette M., Fournier R.E.;
RT   "Subtractive hybridization cloning of a tissue-specific extinguisher:
RT   TSE1 encodes a regulatory subunit of protein kinase A.";
RL   Cell 66:861-872(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=8977401; DOI=10.1210/endo.138.1.4864;
RA   Solberg R., Sandberg M., Natarajan V., Torjesen P.A., Hansson V.,
RA   Jahnsen T., Tasken K.;
RT   "The human gene for the regulatory subunit RI alpha of cyclic
RT   adenosine 3', 5'-monophosphate-dependent protein kinase: two distinct
RT   promoters provide differential regulation of alternately spliced
RT   messenger ribonucleic acids.";
RL   Endocrinology 138:169-181(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lymph, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 1-13, AND ACETYLATION AT MET-1.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [8]
RP   INVOLVEMENT IN PPNAD1.
RX   PubMed=12213893; DOI=10.1210/jc.2002-020592;
RA   Groussin L., Jullian E., Perlemoine K., Louvel A., Leheup B.,
RA   Luton J.P., Bertagna X., Bertherat J.;
RT   "Mutations of the PRKAR1A gene in Cushing's syndrome due to sporadic
RT   primary pigmented nodular adrenocortical disease.";
RL   J. Clin. Endocrinol. Metab. 87:4324-4329(2002).
RN   [9]
RP   INTERACTION WITH RFC2.
RX   PubMed=15655353;
RA   Gupte R.S., Weng Y., Liu L., Lee M.Y.;
RT   "The second subunit of the replication factor C complex (RFC40) and
RT   the regulatory subunit (RIalpha) of protein kinase A form a protein
RT   complex promoting cell survival.";
RL   Cell Cycle 4:323-329(2005).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [11]
RP   FUNCTION, AND INTERACTION WITH PRKX.
RX   PubMed=16491121; DOI=10.1038/sj.onc.1209436;
RA   Glesne D., Huberman E.;
RT   "Smad6 is a protein kinase X phosphorylation substrate and is required
RT   for HL-60 cell differentiation.";
RL   Oncogene 25:4086-4098(2006).
RN   [12]
RP   INTERACTION WITH AICDA.
RX   PubMed=16387847; DOI=10.1073/pnas.0509969103;
RA   Pasqualucci L., Kitaura Y., Gu H., Dalla-Favera R.;
RT   "PKA-mediated phosphorylation regulates the function of activation-
RT   induced deaminase (AID) in B cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:395-400(2006).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=T-cell;
RX   PubMed=19367720; DOI=10.1021/pr800500r;
RA   Carrascal M., Ovelleiro D., Casas V., Gay M., Abian J.;
RT   "Phosphorylation analysis of primary human T lymphocytes using
RT   sequential IMAC and titanium oxide enrichment.";
RL   J. Proteome Res. 7:5167-5176(2008).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=18318008; DOI=10.1002/pmic.200700884;
RA   Han G., Ye M., Zhou H., Jiang X., Feng S., Jiang X., Tian R., Wan D.,
RA   Zou H., Gu J.;
RT   "Large-scale phosphoproteome analysis of human liver tissue by
RT   enrichment and fractionation of phosphopeptides with strong anion
RT   exchange chromatography.";
RL   Proteomics 8:1346-1361(2008).
RN   [18]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [21]
RP   INTERACTION WITH RARA, AND FUNCTION.
RX   PubMed=20215566; DOI=10.1210/en.2009-1338;
RA   Santos N.C., Kim K.H.;
RT   "Activity of retinoic acid receptor-alpha is directly regulated at its
RT   protein kinase A sites in response to follicle-stimulating hormone
RT   signaling.";
RL   Endocrinology 151:2361-2372(2010).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [24]
RP   INVOLVEMENT IN ACRDYS1, AND MUTAGENESIS OF TYR-373.
RX   PubMed=21651393; DOI=10.1056/NEJMoa1012717;
RA   Linglart A., Menguy C., Couvineau A., Auzan C., Gunes Y., Cancel M.,
RA   Motte E., Pinto G., Chanson P., Bougneres P., Clauser E., Silve C.;
RT   "Recurrent PRKAR1A mutation in acrodysostosis with hormone
RT   resistance.";
RL   N. Engl. J. Med. 364:2218-2226(2011).
RN   [25]
RP   INTERACTION WITH PJA2.
RX   PubMed=21423175; DOI=10.1038/ncb2209;
RA   Lignitto L., Carlucci A., Sepe M., Stefan E., Cuomo O., Nistico R.,
RA   Scorziello A., Savoia C., Garbi C., Annunziato L., Feliciello A.;
RT   "Control of PKA stability and signalling by the RING ligase praja2.";
RL   Nat. Cell Biol. 13:412-422(2011).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [27]
RP   INVOLVEMENT IN CNC1.
RX   PubMed=22785148; DOI=10.1507/endocrj.EJ12-0040;
RA   Tung S.C., Hwang D.Y., Yang J.W., Chen W.J., Lee C.T.;
RT   "An unusual presentation of Carney complex with diffuse primary
RT   pigmented nodular adrenocortical disease on one adrenal gland and a
RT   nonpigmented adrenocortical adenoma and focal primary pigmented
RT   nodular adrenocortical disease on the other.";
RL   Endocr. J. 59:823-830(2012).
RN   [28]
RP   INTERACTION WITH C2ORF88/SMAKAP, AND SUBCELLULAR LOCATION.
RX   PubMed=23115245; DOI=10.1074/jbc.M112.395970;
RA   Burgers P.P., Ma Y., Margarucci L., Mackey M., van der Heyden M.A.,
RA   Ellisman M., Scholten A., Taylor S.S., Heck A.J.;
RT   "A small novel A-kinase anchoring protein (AKAP) that localizes
RT   specifically protein kinase A-regulatory subunit I (PKA-RI) to the
RT   plasma membrane.";
RL   J. Biol. Chem. 287:43789-43797(2012).
RN   [29]
RP   INVOLVEMENT IN CNC1.
RX   PubMed=23323113; DOI=10.4132/KoreanJPathol.2012.46.6.595;
RA   Park K.U., Kim H.S., Lee S.K., Jung W.W., Park Y.K.;
RT   "Novel Mutation in PRKAR1A in Carney Complex.";
RL   Korean J. Pathol. 46:595-600(2012).
RN   [30]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [31]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-83, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-75; SER-77 AND SER-83,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [34]
RP   VARIANT CNC1 CYS-74.
RX   PubMed=15371594; DOI=10.1073/pnas.0405535101;
RA   Veugelers M., Wilkes D., Burton K., McDermott D.A., Song Y.,
RA   Goldstein M.M., La Perle K., Vaughan C.J., O'Hagan A., Bennett K.R.,
RA   Meyer B.J., Legius E., Karttunen M., Norio R., Kaariainen H.,
RA   Lavyne M., Neau J.-P., Richter G., Kirali K., Farnsworth A.,
RA   Stapleton K., Morelli P., Takanashi Y., Bamforth J.-S.,
RA   Eitelberger F., Noszian I., Manfroi W., Powers J., Mochizuki Y.,
RA   Imai T., Ko G.T.C., Driscoll D.A., Goldmuntz E., Edelberg J.M.,
RA   Collins A., Eccles D., Irvine A.D., McKnight G.S., Basson C.T.;
RT   "Comparative PRKAR1A genotype-phenotype analyses in humans with Carney
RT   complex and prkar1a haploinsufficient mice.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:14222-14227(2004).
RN   [35]
RP   VARIANTS CNC1 ASN-9; SER-146; TYR-183; ASP-213 AND TRP-289, AND
RP   CHARACTERIZATION OF VARIANTS CNC1 ASN-9; CYS-74; SER-146; TYR-183;
RP   ASP-213 AND TRP-289.
RX   PubMed=18241045; DOI=10.1002/humu.20688;
RA   Greene E.L., Horvath A.D., Nesterova M., Giatzakis C., Bossis I.,
RA   Stratakis C.A.;
RT   "In vitro functional studies of naturally occurring pathogenic PRKAR1A
RT   mutations that are not subject to nonsense mRNA decay.";
RL   Hum. Mutat. 29:633-639(2008).
RN   [36]
RP   VARIANT ACRDYS1 HIS-373.
RX   PubMed=22464250; DOI=10.1016/j.ajhg.2012.03.003;
RA   Michot C., Le Goff C., Goldenberg A., Abhyankar A., Klein C.,
RA   Kinning E., Guerrot A.M., Flahaut P., Duncombe A., Baujat G.,
RA   Lyonnet S., Thalassinos C., Nitschke P., Casanova J.L., Le Merrer M.,
RA   Munnich A., Cormier-Daire V.;
RT   "Exome sequencing identifies PDE4D mutations as another cause of
RT   acrodysostosis.";
RL   Am. J. Hum. Genet. 90:740-745(2012).
RN   [37]
RP   VARIANTS ACRDYS1 THR-327 AND PRO-335.
RX   PubMed=22464252; DOI=10.1016/j.ajhg.2012.03.004;
RA   Lee H., Graham J.M. Jr., Rimoin D.L., Lachman R.S., Krejci P.,
RA   Tompson S.W., Nelson S.F., Krakow D., Cohn D.H.;
RT   "Exome sequencing identifies PDE4D mutations in acrodysostosis.";
RL   Am. J. Hum. Genet. 90:746-751(2012).
RN   [38]
RP   VARIANTS ACRDYS1 ARG-285; GLU-289; VAL-328 AND LEU-335.
RX   PubMed=23043190; DOI=10.1210/jc.2012-2326;
RA   Linglart A., Fryssira H., Hiort O., Holterhus P.M.,
RA   Perez de Nanclares G., Argente J., Heinrichs C., Kuechler A.,
RA   Mantovani G., Leheup B., Wicart P., Chassot V., Schmidt D.,
RA   Rubio-Cabezas O., Richter-Unruh A., Berrade S., Pereda A., Boros E.,
RA   Munoz-Calvo M.T., Castori M., Gunes Y., Bertrand G., Bougneres P.,
RA   Clauser E., Silve C.;
RT   "PRKAR1A and PDE4D mutations cause acrodysostosis but two distinct
RT   syndromes with or without GPCR-signaling hormone resistance.";
RL   J. Clin. Endocrinol. Metab. 97:E2328-E2338(2012).
RN   [39]
RP   VARIANT ACRDYS1 ALA-239, AND CHARACTERIZATION OF VARIANT ACRDYS1
RP   ALA-239.
RX   PubMed=22723333; DOI=10.1210/jc.2012-1369;
RA   Nagasaki K., Iida T., Sato H., Ogawa Y., Kikuchi T., Saitoh A.,
RA   Ogata T., Fukami M.;
RT   "PRKAR1A mutation affecting cAMP-mediated G protein-coupled receptor
RT   signaling in a patient with acrodysostosis and hormone resistance.";
RL   J. Clin. Endocrinol. Metab. 97:E1808-E1813(2012).
RN   [40]
RP   VARIANTS ACRDYS1 THR-213 AND CYS-373, AND VARIANT ASN-227.
RX   PubMed=23425300; DOI=10.1111/cge.12106;
RA   Muhn F., Klopocki E., Graul-Neumann L., Uhrig S., Colley A.,
RA   Castori M., Lankes E., Henn W., Gruber-Sedlmayr U., Seifert W.,
RA   Horn D.;
RT   "Novel mutations of the PRKAR1A gene in patients with
RT   acrodysostosis.";
RL   Clin. Genet. 84:531-538(2013).
RN   [41]
RP   VARIANT ACRDYS1 CYS-175, CHARACTERIZATION OF VARIANTS ACRDYS1 CYS-175;
RP   THR-213; ARG-285; GLU-289; VAL-328 AND LEU-335, CHARACTERIZATION OF
RP   VARIANTS CNC1 ASP-213 AND TRP-289, AND FUNCTION.
RX   PubMed=26405036; DOI=10.1074/jbc.M115.656553;
RA   Rhayem Y., Le Stunff C., Abdel Khalek W., Auzan C., Bertherat J.,
RA   Linglart A., Couvineau A., Silve C., Clauser E.;
RT   "Functional characterization of PRKAR1A mutations reveals a unique
RT   molecular mechanism causing acrodysostosis but multiple mechanisms
RT   causing carney complex.";
RL   J. Biol. Chem. 290:27816-27828(2015).
CC   -!- FUNCTION: Regulatory subunit of the cAMP-dependent protein kinases
CC       involved in cAMP signaling in cells. {ECO:0000269|PubMed:16491121,
CC       ECO:0000269|PubMed:20215566, ECO:0000269|PubMed:26405036}.
CC   -!- SUBUNIT: The inactive holoenzyme is composed of two regulatory
CC       chains and two catalytic chains. Activation by cAMP releases the
CC       two active catalytic monomers and the regulatory dimer. PRKAR1A
CC       also interacts with RFC2; the complex may be involved in cell
CC       survival. Interacts with AKAP4. Interacts with RARA; the
CC       interaction occurs in the presence of cAMP or FSH and regulates
CC       RARA transcriptional activity. Interacts with the phosphorylated
CC       form of PJA2. Interacts with CBFA2T3 (By similarity). Interacts
CC       with PRKX; regulates this cAMP-dependent protein kinase. Interacts
CC       with C2orf88/smAKAP; this interaction may target PRKAR1A to the
CC       plasma membrane. Interacts with AICDA. {ECO:0000250,
CC       ECO:0000269|PubMed:15655353, ECO:0000269|PubMed:16387847,
CC       ECO:0000269|PubMed:16491121, ECO:0000269|PubMed:20215566,
CC       ECO:0000269|PubMed:21423175, ECO:0000269|PubMed:23115245}.
CC   -!- INTERACTION:
CC       P03259-2:- (xeno); NbExp=5; IntAct=EBI-476431, EBI-7225021;
CC       Q9GZX7:AICDA; NbExp=5; IntAct=EBI-476431, EBI-3834328;
CC       O43687-2:AKAP7; NbExp=4; IntAct=EBI-476431, EBI-10185182;
CC       Q9BSF0:C2orf88; NbExp=5; IntAct=EBI-476431, EBI-744298;
CC       Q9H0R8:GABARAPL1; NbExp=2; IntAct=EBI-476431, EBI-746969;
CC       Q9H8W4:PLEKHF2; NbExp=3; IntAct=EBI-476431, EBI-742388;
CC       P17612:PRKACA; NbExp=8; IntAct=EBI-476431, EBI-476586;
CC       P51817:PRKX; NbExp=2; IntAct=EBI-476431, EBI-4302903;
CC       P35250:RFC2; NbExp=7; IntAct=EBI-476431, EBI-476409;
CC       Q01105:SET; NbExp=2; IntAct=EBI-476431, EBI-1053182;
CC       P0DO92:T-ENOL; NbExp=4; IntAct=EBI-476431, EBI-13044706;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:23115245}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P10644-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P10644-2; Sequence=VSP_054833, VSP_054834;
CC         Note=No experimental confirmation available. Gene prediction
CC         based on EST data.;
CC   -!- TISSUE SPECIFICITY: Four types of regulatory chains are found: I-
CC       alpha, I-beta, II-alpha, and II-beta. Their expression varies
CC       among tissues and is in some cases constitutive and in others
CC       inducible.
CC   -!- PTM: The pseudophosphorylation site binds to the substrate-binding
CC       region of the catalytic chain, resulting in the inhibition of its
CC       activity.
CC   -!- DISEASE: Carney complex 1 (CNC1) [MIM:160980]: CNC is a multiple
CC       neoplasia syndrome characterized by spotty skin pigmentation,
CC       cardiac and other myxomas, endocrine tumors, and psammomatous
CC       melanotic schwannomas. {ECO:0000269|PubMed:15371594,
CC       ECO:0000269|PubMed:18241045, ECO:0000269|PubMed:22785148,
CC       ECO:0000269|PubMed:23323113, ECO:0000269|PubMed:26405036}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Intracardiac myxoma (INTMYX) [MIM:255960]: Inheritance is
CC       autosomal recessive. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Primary pigmented nodular adrenocortical disease 1
CC       (PPNAD1) [MIM:610489]: A rare bilateral adrenal defect causing
CC       ACTH-independent Cushing syndrome. Macroscopic appearance of the
CC       adrenals is characteristic with small pigmented micronodules
CC       observed in the cortex. Clinical manifestations of Cushing
CC       syndrome include facial and truncal obesity, abdominal striae,
CC       muscular weakness, osteoporosis, arterial hypertension, diabetes.
CC       PPNAD1 is most often diagnosed in patients with Carney complex, a
CC       multiple neoplasia syndrome. However it can also be observed in
CC       patients without other manifestations.
CC       {ECO:0000269|PubMed:12213893}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Acrodysostosis 1, with or without hormone resistance
CC       (ACRDYS1) [MIM:101800]: A form of skeletal dysplasia characterized
CC       by short stature, severe brachydactyly, facial dysostosis, and
CC       nasal hypoplasia. Affected individuals often have advanced bone
CC       age and obesity. Laboratory studies show resistance to multiple
CC       hormones, including parathyroid, thyrotropin, calcitonin, growth
CC       hormone-releasing hormone, and gonadotropin. However, not all
CC       patients show endocrine abnormalities.
CC       {ECO:0000269|PubMed:21651393, ECO:0000269|PubMed:22464250,
CC       ECO:0000269|PubMed:22464252, ECO:0000269|PubMed:22723333,
CC       ECO:0000269|PubMed:23043190, ECO:0000269|PubMed:23425300,
CC       ECO:0000269|PubMed:26405036}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the cAMP-dependent kinase regulatory chain
CC       family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PRKAR1AID387.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M18468; AAB50922.1; -; mRNA.
DR   EMBL; M33336; AAB50921.1; -; mRNA.
DR   EMBL; S54705; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; S54707; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; S54709; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; S54711; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; Y07642; CAA68925.1; -; mRNA.
DR   EMBL; AC079210; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC036285; AAH36285.1; -; mRNA.
DR   EMBL; BC093042; AAH93042.1; -; mRNA.
DR   CCDS; CCDS11678.1; -. [P10644-1]
DR   CCDS; CCDS62307.1; -. [P10644-2]
DR   PIR; A34627; OKHU1R.
DR   RefSeq; NP_001263218.1; NM_001276289.1. [P10644-1]
DR   RefSeq; NP_001263219.1; NM_001276290.1. [P10644-2]
DR   RefSeq; NP_001265362.1; NM_001278433.1. [P10644-1]
DR   RefSeq; NP_002725.1; NM_002734.4. [P10644-1]
DR   RefSeq; NP_997636.1; NM_212471.2. [P10644-1]
DR   RefSeq; NP_997637.1; NM_212472.2. [P10644-1]
DR   RefSeq; XP_011523285.1; XM_011524983.2. [P10644-1]
DR   RefSeq; XP_011523286.1; XM_011524984.2. [P10644-1]
DR   RefSeq; XP_011523287.1; XM_011524985.2. [P10644-1]
DR   UniGene; Hs.280342; -.
DR   UniGene; Hs.745160; -.
DR   PDB; 5KJX; X-ray; 1.90 A; A=234-381.
DR   PDB; 5KJY; X-ray; 2.00 A; A=234-381.
DR   PDB; 5KJZ; X-ray; 1.35 A; A=234-381.
DR   PDBsum; 5KJX; -.
DR   PDBsum; 5KJY; -.
DR   PDBsum; 5KJZ; -.
DR   ProteinModelPortal; P10644; -.
DR   SMR; P10644; -.
DR   BioGrid; 111559; 88.
DR   DIP; DIP-34368N; -.
DR   IntAct; P10644; 85.
DR   MINT; P10644; -.
DR   STRING; 9606.ENSP00000351410; -.
DR   BindingDB; P10644; -.
DR   DrugBank; DB02527; Cyclic Adenosine Monophosphate.
DR   DrugBank; DB02315; Cyclic Guanosine Monophosphate.
DR   DrugBank; DB05798; GEM-231.
DR   GuidetoPHARMACOLOGY; 1472; -.
DR   iPTMnet; P10644; -.
DR   PhosphoSitePlus; P10644; -.
DR   SwissPalm; P10644; -.
DR   DMDM; 125193; -.
DR   OGP; P10644; -.
DR   REPRODUCTION-2DPAGE; IPI00021831; -.
DR   EPD; P10644; -.
DR   MaxQB; P10644; -.
DR   PaxDb; P10644; -.
DR   PeptideAtlas; P10644; -.
DR   PRIDE; P10644; -.
DR   DNASU; 5573; -.
DR   Ensembl; ENST00000358598; ENSP00000351410; ENSG00000108946. [P10644-1]
DR   Ensembl; ENST00000392711; ENSP00000376475; ENSG00000108946. [P10644-1]
DR   Ensembl; ENST00000536854; ENSP00000445625; ENSG00000108946. [P10644-1]
DR   Ensembl; ENST00000586397; ENSP00000466459; ENSG00000108946. [P10644-1]
DR   Ensembl; ENST00000588188; ENSP00000468106; ENSG00000108946. [P10644-2]
DR   Ensembl; ENST00000589228; ENSP00000464977; ENSG00000108946. [P10644-1]
DR   GeneID; 5573; -.
DR   KEGG; hsa:5573; -.
DR   UCSC; uc002jhg.5; human. [P10644-1]
DR   CTD; 5573; -.
DR   DisGeNET; 5573; -.
DR   EuPathDB; HostDB:ENSG00000108946.14; -.
DR   GeneCards; PRKAR1A; -.
DR   GeneReviews; PRKAR1A; -.
DR   HGNC; HGNC:9388; PRKAR1A.
DR   HPA; CAB019378; -.
DR   HPA; HPA049979; -.
DR   MalaCards; PRKAR1A; -.
DR   MIM; 101800; phenotype.
DR   MIM; 160980; phenotype.
DR   MIM; 188830; gene.
DR   MIM; 255960; phenotype.
DR   MIM; 610489; phenotype.
DR   neXtProt; NX_P10644; -.
DR   OpenTargets; ENSG00000108946; -.
DR   Orphanet; 950; Acrodysostosis.
DR   Orphanet; 280651; Acrodysostosis with multiple hormone resistance.
DR   Orphanet; 520; Acute promyelocytic leukemia.
DR   Orphanet; 1359; Carney complex.
DR   Orphanet; 615; Familial atrial myxoma.
DR   Orphanet; 189439; Primary pigmented nodular adrenocortical disease.
DR   PharmGKB; PA33754; -.
DR   eggNOG; KOG1113; Eukaryota.
DR   eggNOG; COG0664; LUCA.
DR   GeneTree; ENSGT00530000062947; -.
DR   HOGENOM; HOG000196669; -.
DR   HOVERGEN; HBG002025; -.
DR   InParanoid; P10644; -.
DR   KO; K04739; -.
DR   OMA; VQLCTVR; -.
DR   OrthoDB; EOG091G0F1K; -.
DR   PhylomeDB; P10644; -.
DR   TreeFam; TF314920; -.
DR   Reactome; R-HSA-163615; PKA activation.
DR   Reactome; R-HSA-164378; PKA activation in glucagon signalling.
DR   Reactome; R-HSA-180024; DARPP-32 events.
DR   Reactome; R-HSA-381676; Glucagon-like Peptide-1 (GLP1) regulates insulin secretion.
DR   Reactome; R-HSA-432040; Vasopressin regulates renal water homeostasis via Aquaporins.
DR   Reactome; R-HSA-5610787; Hedgehog 'off' state.
DR   Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production.
DR   SignaLink; P10644; -.
DR   SIGNOR; P10644; -.
DR   ChiTaRS; PRKAR1A; human.
DR   GenomeRNAi; 5573; -.
DR   PRO; PR:P10644; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000108946; -.
DR   CleanEx; HS_PRKAR1A; -.
DR   ExpressionAtlas; P10644; baseline and differential.
DR   Genevisible; P10644; HS.
DR   GO; GO:0005952; C:cAMP-dependent protein kinase complex; IEA:Ensembl.
DR   GO; GO:0097546; C:ciliary base; TAS:Reactome.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0031594; C:neuromuscular junction; IEA:Ensembl.
DR   GO; GO:0031588; C:nucleotide-activated protein kinase complex; IDA:BHF-UCL.
DR   GO; GO:0044853; C:plasma membrane raft; IDA:UniProtKB.
DR   GO; GO:0043234; C:protein complex; IDA:UniProtKB.
DR   GO; GO:0030552; F:cAMP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004862; F:cAMP-dependent protein kinase inhibitor activity; IDA:BHF-UCL.
DR   GO; GO:0008603; F:cAMP-dependent protein kinase regulator activity; IDA:BHF-UCL.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:UniProtKB.
DR   GO; GO:0034236; F:protein kinase A catalytic subunit binding; IPI:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IDA:UniProtKB.
DR   GO; GO:0034199; P:activation of protein kinase A activity; TAS:Reactome.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0060038; P:cardiac muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0071377; P:cellular response to glucagon stimulus; TAS:Reactome.
DR   GO; GO:0007143; P:female meiotic nuclear division; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; TAS:ProtInc.
DR   GO; GO:0001707; P:mesoderm formation; IEA:Ensembl.
DR   GO; GO:0046007; P:negative regulation of activated T cell proliferation; IMP:UniProtKB.
DR   GO; GO:2000480; P:negative regulation of cAMP-dependent protein kinase activity; IDA:BHF-UCL.
DR   GO; GO:0045835; P:negative regulation of meiotic nuclear division; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; TAS:ProtInc.
DR   GO; GO:0003091; P:renal water homeostasis; TAS:Reactome.
DR   GO; GO:0045214; P:sarcomere organization; IEA:Ensembl.
DR   CDD; cd00038; CAP_ED; 2.
DR   Gene3D; 1.20.890.10; -; 1.
DR   Gene3D; 2.60.120.10; -; 2.
DR   InterPro; IPR012198; cAMP_dep_PK_reg_su.
DR   InterPro; IPR003117; cAMP_dep_PK_reg_su_I/II_a/b.
DR   InterPro; IPR036536; cAMP_dep_PK_reg_su_sf.
DR   InterPro; IPR018490; cNMP-bd-like.
DR   InterPro; IPR018488; cNMP-bd_CS.
DR   InterPro; IPR000595; cNMP-bd_dom.
DR   InterPro; IPR014710; RmlC-like_jellyroll.
DR   Pfam; PF00027; cNMP_binding; 2.
DR   Pfam; PF02197; RIIa; 1.
DR   PIRSF; PIRSF000548; PK_regulatory; 1.
DR   SMART; SM00100; cNMP; 2.
DR   SMART; SM00394; RIIa; 1.
DR   SUPFAM; SSF47391; SSF47391; 1.
DR   SUPFAM; SSF51206; SSF51206; 2.
DR   PROSITE; PS00888; CNMP_BINDING_1; 2.
DR   PROSITE; PS00889; CNMP_BINDING_2; 2.
DR   PROSITE; PS50042; CNMP_BINDING_3; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; cAMP; cAMP-binding;
KW   Cell membrane; Complete proteome; Cushing syndrome;
KW   Direct protein sequencing; Disease mutation; Disulfide bond; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome; Repeat.
FT   CHAIN         1    381       cAMP-dependent protein kinase type I-
FT                                alpha regulatory subunit.
FT                                /FTId=PRO_0000205377.
FT   NP_BIND     137    254       cAMP 1.
FT   NP_BIND     255    381       cAMP 2.
FT   REGION        1    136       Dimerization and phosphorylation.
FT   MOTIF        96    100       Pseudophosphorylation motif.
FT   BINDING     202    202       cAMP 1.
FT   BINDING     211    211       cAMP 1.
FT   BINDING     326    326       cAMP 2.
FT   BINDING     335    335       cAMP 2.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378,
FT                                ECO:0000269|PubMed:12665801}.
FT   MOD_RES       3      3       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P09456}.
FT   MOD_RES      75     75       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES      77     77       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES      83     83       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18318008,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19367720,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     101    101       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9DBC7}.
FT   MOD_RES     258    258       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P09456}.
FT   DISULFID     18     18       Interchain (with C-39). {ECO:0000250}.
FT   DISULFID     39     39       Interchain (with C-18). {ECO:0000250}.
FT   VAR_SEQ     326    337       EIALLMNRPRAA -> HLIISRRSIPLG (in isoform
FT                                2). {ECO:0000305}.
FT                                /FTId=VSP_054833.
FT   VAR_SEQ     338    381       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_054834.
FT   VARIANT       9      9       S -> N (in CNC1; exhibits increased PKA
FT                                activity which is attributed to decreased
FT                                binding to cAMP and/or the catalytic
FT                                subunit). {ECO:0000269|PubMed:18241045}.
FT                                /FTId=VAR_046894.
FT   VARIANT      74     74       R -> C (in CNC1; exhibits increased PKA
FT                                activity which is attributed to decreased
FT                                binding to cAMP and/or the catalytic
FT                                subunit; dbSNP:rs137853303).
FT                                {ECO:0000269|PubMed:15371594,
FT                                ECO:0000269|PubMed:18241045}.
FT                                /FTId=VAR_046895.
FT   VARIANT     146    146       R -> S (in CNC1; exhibits increased PKA
FT                                activity which is attributed to decreased
FT                                binding to cAMP and/or the catalytic
FT                                subunit). {ECO:0000269|PubMed:18241045}.
FT                                /FTId=VAR_046896.
FT   VARIANT     175    175       Y -> C (in ACRDYS1; reduces PKA activity;
FT                                decreases cAMP binding).
FT                                {ECO:0000269|PubMed:26405036}.
FT                                /FTId=VAR_075533.
FT   VARIANT     183    183       D -> Y (in CNC1; exhibits increased PKA
FT                                activity which is attributed to decreased
FT                                binding to cAMP and/or the catalytic
FT                                subunit). {ECO:0000269|PubMed:18241045}.
FT                                /FTId=VAR_046897.
FT   VARIANT     213    213       A -> D (in CNC1; exhibits increased PKA
FT                                activity which is attributed to decreased
FT                                binding to cAMP and/or the catalytic
FT                                subunit; reduces protein degradation;
FT                                dbSNP:rs281864786).
FT                                {ECO:0000269|PubMed:18241045,
FT                                ECO:0000269|PubMed:26405036}.
FT                                /FTId=VAR_046898.
FT   VARIANT     213    213       A -> T (in ACRDYS1; reduces PKA activity;
FT                                decreases cAMP binding; reduces protein
FT                                degradation).
FT                                {ECO:0000269|PubMed:23425300,
FT                                ECO:0000269|PubMed:26405036}.
FT                                /FTId=VAR_069456.
FT   VARIANT     227    227       D -> N. {ECO:0000269|PubMed:23425300}.
FT                                /FTId=VAR_069457.
FT   VARIANT     239    239       T -> A (in ACRDYS1; impairs response of
FT                                PKA to c-AMP).
FT                                {ECO:0000269|PubMed:22723333}.
FT                                /FTId=VAR_069458.
FT   VARIANT     285    285       Q -> R (in ACRDYS1; reduces PKA activity;
FT                                decreases cAMP binding).
FT                                {ECO:0000269|PubMed:23043190,
FT                                ECO:0000269|PubMed:26405036}.
FT                                /FTId=VAR_069459.
FT   VARIANT     289    289       G -> E (in ACRDYS1; reduces PKA activity;
FT                                decreases cAMP binding; reduces protein
FT                                degradation).
FT                                {ECO:0000269|PubMed:23043190,
FT                                ECO:0000269|PubMed:26405036}.
FT                                /FTId=VAR_069460.
FT   VARIANT     289    289       G -> W (in CNC1; exhibits increased PKA
FT                                activity which is attributed to decreased
FT                                binding to cAMP and/or the catalytic
FT                                subunit; accelerates protein
FT                                degradation).
FT                                {ECO:0000269|PubMed:18241045,
FT                                ECO:0000269|PubMed:26405036}.
FT                                /FTId=VAR_046899.
FT   VARIANT     327    327       I -> T (in ACRDYS1; dbSNP:rs387906695).
FT                                {ECO:0000269|PubMed:22464252}.
FT                                /FTId=VAR_069461.
FT   VARIANT     328    328       A -> V (in ACRDYS1; disrupts cAMP
FT                                binding). {ECO:0000269|PubMed:23043190,
FT                                ECO:0000269|PubMed:26405036}.
FT                                /FTId=VAR_069462.
FT   VARIANT     335    335       R -> L (in ACRDYS1; disrupts cAMP
FT                                binding). {ECO:0000269|PubMed:23043190,
FT                                ECO:0000269|PubMed:26405036}.
FT                                /FTId=VAR_069464.
FT   VARIANT     335    335       R -> P (in ACRDYS1; dbSNP:rs387906694).
FT                                {ECO:0000269|PubMed:22464252}.
FT                                /FTId=VAR_069463.
FT   VARIANT     373    373       Y -> C (in ACRDYS1).
FT                                {ECO:0000269|PubMed:23425300}.
FT                                /FTId=VAR_069465.
FT   VARIANT     373    373       Y -> H (in ACRDYS1; dbSNP:rs387906693).
FT                                {ECO:0000269|PubMed:22464250}.
FT                                /FTId=VAR_068241.
FT   MUTAGEN     373    373       Y->A: Impairs response of PKA to c-AMP.
FT                                {ECO:0000269|PubMed:21651393}.
FT   HELIX       237    250       {ECO:0000244|PDB:5KJZ}.
FT   HELIX       254    256       {ECO:0000244|PDB:5KJZ}.
FT   HELIX       261    270       {ECO:0000244|PDB:5KJZ}.
FT   STRAND      272    276       {ECO:0000244|PDB:5KJZ}.
FT   STRAND      281    283       {ECO:0000244|PDB:5KJZ}.
FT   STRAND      291    304       {ECO:0000244|PDB:5KJZ}.
FT   STRAND      313    318       {ECO:0000244|PDB:5KJZ}.
FT   HELIX       326    330       {ECO:0000244|PDB:5KJZ}.
FT   STRAND      336    351       {ECO:0000244|PDB:5KJZ}.
FT   HELIX       352    358       {ECO:0000244|PDB:5KJZ}.
FT   HELIX       360    362       {ECO:0000244|PDB:5KJZ}.
FT   HELIX       363    370       {ECO:0000244|PDB:5KJZ}.
FT   TURN        371    376       {ECO:0000244|PDB:5KJZ}.
SQ   SEQUENCE   381 AA;  42982 MW;  2D04F08CE8857A6D CRC64;
     MESGSTAASE EARSLRECEL YVQKHNIQAL LKDSIVQLCT ARPERPMAFL REYFERLEKE
     EAKQIQNLQK AGTRTDSRED EISPPPPNPV VKGRRRRGAI SAEVYTEEDA ASYVRKVIPK
     DYKTMAALAK AIEKNVLFSH LDDNERSDIF DAMFSVSFIA GETVIQQGDE GDNFYVIDQG
     ETDVYVNNEW ATSVGEGGSF GELALIYGTP RAATVKAKTN VKLWGIDRDS YRRILMGSTL
     RKRKMYEEFL SKVSILESLD KWERLTVADA LEPVQFEDGQ KIVVQGEPGD EFFIILEGSA
     AVLQRRSENE EFVEVGRLGP SDYFGEIALL MNRPRAATVV ARGPLKCVKL DRPRFERVLG
     PCSDILKRNI QQYNSFVSLS V
//
ID   RUNX1_HUMAN             Reviewed;         453 AA.
AC   Q01196; A8MV94; B2RMS4; D3DSG1; O60472; O60473; O76047; O76089;
AC   Q13081; Q13755; Q13756; Q13757; Q13758; Q13759; Q15341; Q15343;
AC   Q16122; Q16284; Q16285; Q16286; Q16346; Q16347; Q92479;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2008, sequence version 3.
DT   28-FEB-2018, entry version 219.
DE   RecName: Full=Runt-related transcription factor 1;
DE   AltName: Full=Acute myeloid leukemia 1 protein;
DE   AltName: Full=Core-binding factor subunit alpha-2;
DE            Short=CBF-alpha-2;
DE   AltName: Full=Oncogene AML-1;
DE   AltName: Full=Polyomavirus enhancer-binding protein 2 alpha B subunit;
DE            Short=PEA2-alpha B;
DE            Short=PEBP2-alpha B;
DE   AltName: Full=SL3-3 enhancer factor 1 alpha B subunit;
DE   AltName: Full=SL3/AKV core-binding factor alpha B subunit;
GN   Name=RUNX1; Synonyms=AML1, CBFA2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Ahn M.-Y., Bae S.C., Zhang Y.W., Shigesada K., Ito Y.;
RL   Submitted (SEP-1994) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM AML-1C).
RC   TISSUE=Leukocyte;
RX   PubMed=1720541; DOI=10.1073/pnas.88.23.10431;
RA   Miyoshi H., Shimizu K., Kozu T., Maseki N., Kaneko Y., Ohki M.;
RT   "t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are
RT   clustered within a limited region of a single gene, AML1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:10431-10434(1991).
RN   [3]
RP   ALTERNATIVE PRODUCTS, AND CHROMOSOMAL TRANSLOCATION WITH EAP.
RX   PubMed=7533526; DOI=10.1002/gcc.2870110405;
RA   Sacchi N., Nisson P.E., Watkins P.C., Faustinella F., Wijsman J.,
RA   Hagemeijer A.;
RT   "AML1 fusion transcripts in t(3;21) positive leukemia: evidence of
RT   molecular heterogeneity and usage of splicing sites frequently
RT   involved in the generation of normal AML1 transcripts.";
RL   Genes Chromosomes Cancer 11:226-236(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM AML-1E), AND CHROMOSOMAL
RP   TRANSLOCATION WITH ETO.
RX   PubMed=8490181;
RA   Nucifora G., Birn D.J., Espinosa R. III, Erickson P., Lebeau M.M.,
RA   Roulston D., McKeithan T.W., Drabkin H., Rowley J.D.;
RT   "Involvement of the AML1 gene in the t(3;21) in therapy-related
RT   leukemia and in chronic myeloid leukemia in blast crisis.";
RL   Blood 81:2728-2734(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM AML-1A).
RC   TISSUE=Monocyte;
RX   PubMed=7835892; DOI=10.1006/geno.1994.1519;
RA   Levanon D., Negreanu V., Bernstein Y., Bar-Am I., Avivi L., Groner Y.;
RT   "AML1, AML2, and AML3, the human members of the runt domain gene-
RT   family: cDNA structure, expression, and chromosomal localization.";
RL   Genomics 23:425-432(1994).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS AML-1B; AML-1A; AML-1G AND
RP   AML-1L).
RX   PubMed=7651838; DOI=10.1093/nar/23.14.2762;
RA   Miyoshi H., Ohira M., Shimizu K., Mitani K., Hirai H., Imai T.,
RA   Yokoyama K., Soeda E., Ohki M.;
RT   "Alternative splicing and genomic structure of the AML1 gene involved
RT   in acute myeloid leukemia.";
RL   Nucleic Acids Res. 23:2762-2769(1995).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM AML-1G).
RC   TISSUE=B-cell;
RX   PubMed=7891692; DOI=10.1128/MCB.15.4.1974;
RA   Meyers S., Lenny N., Hiebert S.W.;
RT   "The t(8;21) fusion protein interferes with AML-1B-dependent
RT   transcriptional activation.";
RL   Mol. Cell. Biol. 15:1974-1982(1995).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM AML-1L).
RX   PubMed=9199349; DOI=10.1128/MCB.17.7.4133;
RA   Zhang Y.-W., Bae S.-C., Huang G., Fu Y.-X., Lu J., Ahn M.-Y.,
RA   Kanno Y., Kanno T., Ito Y.;
RT   "A novel transcript encoding an N-terminally truncated AML1/PEBP2
RT   alphaB protein interferes with transactivation and blocks granulocytic
RT   differentiation of 32Dcl3 myeloid cells.";
RL   Mol. Cell. Biol. 17:4133-4145(1997).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10830953; DOI=10.1038/35012518;
RA   Hattori M., Fujiyama A., Taylor T.D., Watanabe H., Yada T.,
RA   Park H.-S., Toyoda A., Ishii K., Totoki Y., Choi D.-K., Groner Y.,
RA   Soeda E., Ohki M., Takagi T., Sakaki Y., Taudien S., Blechschmidt K.,
RA   Polley A., Menzel U., Delabar J., Kumpf K., Lehmann R., Patterson D.,
RA   Reichwald K., Rump A., Schillhabel M., Schudy A., Zimmermann W.,
RA   Rosenthal A., Kudoh J., Shibuya K., Kawasaki K., Asakawa S.,
RA   Shintani A., Sasaki T., Nagamine K., Mitsuyama S., Antonarakis S.E.,
RA   Minoshima S., Shimizu N., Nordsiek G., Hornischer K., Brandt P.,
RA   Scharfe M., Schoen O., Desario A., Reichelt J., Kauer G., Bloecker H.,
RA   Ramser J., Beck A., Klages S., Hennig S., Riesselmann L., Dagand E.,
RA   Wehrmeyer S., Borzym K., Gardiner K., Nizetic D., Francis F.,
RA   Lehrach H., Reinhardt R., Yaspo M.-L.;
RT   "The DNA sequence of human chromosome 21.";
RL   Nature 405:311-319(2000).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM AML-1G).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-177, AND CHROMOSOMAL TRANSLOCATION
RP   WITH MECOM IN CHRONIC MYELOCYTIC LEUKEMIA.
RX   PubMed=8313895;
RA   Mitani K., Ogawa S., Tanaka T., Miyoshi H., Kurokawa M., Mano H.,
RA   Yazaki Y., Ohki M., Hirai H.;
RT   "Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22)
RT   causes blastic crisis in chronic myelocytic leukemia.";
RL   EMBO J. 13:504-510(1994).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-90 (ISOFORMS AML-1H AND
RP   AML-1I).
RX   PubMed=8700862; DOI=10.1073/pnas.93.5.1935;
RA   Ghozi M.C., Bernstein Y., Negreanu V., Levanon D., Groner Y.;
RT   "Expression of the human acute myeloid leukemia gene AML1 is regulated
RT   by two promoter regions.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:1935-1940(1996).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 440-453, AND ALTERNATIVE
RP   SPLICING.
RC   TISSUE=Monocyte;
RX   PubMed=8634147; DOI=10.1089/dna.1996.15.175;
RA   Levanon D., Bernstein Y., Negreanu V., Ghozi M.C., Bar-Am I.,
RA   Aloya R., Goldenberg D., Lotem J., Groner Y.;
RT   "A large variety of alternatively spliced and differentially expressed
RT   mRNAs are encoded by the human acute myeloid leukemia gene AML1.";
RL   DNA Cell Biol. 15:175-185(1996).
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-19, AND ALTERNATIVE SPLICING
RP   (ISOFORM AML-1G).
RA   Blechschmidt K., Rump A., Nordsiek G., Drescher B., Weber J.,
RA   Rosenthal A.;
RT   "Sequencing and analysis of 960 kb between AML1 and CBR1 on chromosome
RT   21q22.2.";
RL   Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases.
RN   [16]
RP   SIMILARITY TO RUNT.
RX   PubMed=1560822; DOI=10.1038/356484b0;
RA   Daga A., Tighe J.E., Calabi F.;
RT   "Leukaemia/Drosophila homology.";
RL   Nature 356:484-484(1992).
RN   [17]
RP   ENHANCER CORE BINDING SEQUENCE.
RX   PubMed=8413232; DOI=10.1128/MCB.13.10.6336;
RA   Meyers S., Downing J.R., Hiebert S.W.;
RT   "Identification of AML-1 and the (8;21) translocation protein (AML-
RT   1/ETO) as sequence-specific DNA-binding proteins: the runt homology
RT   domain is required for DNA binding and protein-protein interactions.";
RL   Mol. Cell. Biol. 13:6336-6345(1993).
RN   [18]
RP   INTERACTION WITH ALYREF/THOC4.
RX   PubMed=9119228; DOI=10.1101/gad.11.5.640;
RA   Bruhn L., Munnerlyn A., Grosschedl R.;
RT   "ALY, a context-dependent coactivator of LEF-1 and AML-1, is required
RT   for TCRalpha enhancer function.";
RL   Genes Dev. 11:640-653(1997).
RN   [19]
RP   CHROMOSOMAL TRANSLOCATION WITH CBFA2T3.
RX   PubMed=9596646;
RA   Gamou T., Kitamura E., Hosoda F., Shimuzu K., Hayashi Y., Nagase T.,
RA   Yokoyama Y., Ohki M.;
RT   "The partner gene of AML1 in t(16;21) myeloid malignancies is a novel
RT   member of the MTG8(ETO) family.";
RL   Blood 91:4028-4037(1998).
RN   [20]
RP   INTERACTION WITH TLE1.
RX   PubMed=9751710; DOI=10.1073/pnas.95.20.11590;
RA   Levanon D., Goldstein R.E., Bernstein Y., Tang H., Goldenberg D.,
RA   Stifani S., Paroush Z., Groner Y.;
RT   "Transcriptional repression by AML1 and LEF-1 is mediated by the
RT   TLE/Groucho corepressors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:11590-11595(1998).
RN   [21]
RP   FUNCTION, AND INTERACTION WITH ELF1; ELF2; ELF4 AND SPI1.
RX   PubMed=10207087; DOI=10.1128/MCB.19.5.3635;
RA   Mao S., Frank R.C., Zhang J., Miyazaki Y., Nimer S.D.;
RT   "Functional and physical interactions between AML1 proteins and an ETS
RT   protein, MEF: implications for the pathogenesis of t(8;21)-positive
RT   leukemias.";
RL   Mol. Cell. Biol. 19:3635-3644(1999).
RN   [22]
RP   INTERACTION WITH KAT6A, AND PHOSPHORYLATION.
RX   PubMed=11742995; DOI=10.1093/emboj/20.24.7184;
RA   Kitabayashi I., Aikawa Y., Nguyen L.A., Yokoyama A., Ohki M.;
RT   "Activation of AML1-mediated transcription by MOZ and inhibition by
RT   the MOZ-CBP fusion protein.";
RL   EMBO J. 20:7184-7196(2001).
RN   [23]
RP   INTERACTION WITH KAT6B, AND FUNCTION.
RX   PubMed=11965546; DOI=10.1038/sj.onc.1205367;
RA   Pelletier N., Champagne N., Stifani S., Yang X.-J.;
RT   "MOZ and MORF histone acetyltransferases interact with the Runt-domain
RT   transcription factor Runx2.";
RL   Oncogene 21:2729-2740(2002).
RN   [24]
RP   INTERACTION WITH SUV39H1, AND METHYLATION.
RX   PubMed=12917624; DOI=10.1038/sj.onc.1206600;
RA   Chakraborty S., Sinha K.K., Senyuk V., Nucifora G.;
RT   "SUV39H1 interacts with AML1 and abrogates AML1 transactivity. AML1 is
RT   methylated in vivo.";
RL   Oncogene 22:5229-5237(2003).
RN   [25]
RP   FUNCTION, AND INTERACTION WITH ELF2.
RX   PubMed=14970218; DOI=10.1074/jbc.M309074200;
RA   Cho J.-Y., Akbarali Y., Zerbini L.F., Gu X., Boltax J., Wang Y.,
RA   Oettgen P., Zhang D.-E., Libermann T.A.;
RT   "Isoforms of the Ets transcription factor NERF/ELF-2 physically
RT   interact with AML1 and mediate opposing effects on AML1-mediated
RT   transcription of the B cell-specific blk gene.";
RL   J. Biol. Chem. 279:19512-19522(2004).
RN   [26]
RP   INTERACTION WITH SUV39H1.
RX   PubMed=16652147; DOI=10.1038/sj.onc.1209591;
RA   Reed-Inderbitzin E., Moreno-Miralles I., Vanden-Eynden S.K., Xie J.,
RA   Lutterbach B., Durst-Goodwin K.L., Luce K.S., Irvin B.J., Cleary M.L.,
RA   Brandt S.J., Hiebert S.W.;
RT   "RUNX1 associates with histone deacetylases and SUV39H1 to repress
RT   transcription.";
RL   Oncogene 25:5777-5786(2006).
RN   [27]
RP   FUNCTION IN MYELOID DIFFERENTIATION, AND INTERACTION WITH CDK6.
RX   PubMed=17431401; DOI=10.1038/sj.emboj.7601675;
RA   Fujimoto T., Anderson K., Jacobsen S.E., Nishikawa S.I., Nerlov C.;
RT   "Cdk6 blocks myeloid differentiation by interfering with Runx1 DNA
RT   binding and Runx1-C/EBPalpha interaction.";
RL   EMBO J. 26:2361-2370(2007).
RN   [28]
RP   CHROMOSOMAL TRANSLOCATION WITH MACROD1.
RX   PubMed=17532767; DOI=10.1111/j.1600-0609.2007.00858.x;
RA   Imagama S., Abe A., Suzuki M., Hayakawa F., Katsumi A., Emi N.,
RA   Kiyoi H., Naoe T.;
RT   "LRP16 is fused to RUNX1 in monocytic leukemia cell line with
RT   t(11;21)(q13;q22).";
RL   Eur. J. Haematol. 79:25-31(2007).
RN   [29]
RP   FUNCTION, AND INTERACTION WITH FOXP3.
RX   PubMed=17377532; DOI=10.1038/nature05673;
RA   Ono M., Yaguchi H., Ohkura N., Kitabayashi I., Nagamura Y., Nomura T.,
RA   Miyachi Y., Tsukada T., Sakaguchi S.;
RT   "Foxp3 controls regulatory T-cell function by interacting with
RT   AML1/Runx1.";
RL   Nature 446:685-689(2007).
RN   [30]
RP   PHOSPHORYLATION AT SER-249; THR-273 AND SER-276 BY HIPK2, VARIANT
RP   GLN-174, AND MUTAGENESIS OF SER-67; LYS-83; GLY-108; SER-249; THR-273
RP   AND SER-276.
RX   PubMed=18695000; DOI=10.1182/blood-2008-01-134122;
RA   Wee H.-J., Voon D.C.-C., Bae S.-C., Ito Y.;
RT   "PEBP2-beta/CBF-beta-dependent phosphorylation of RUNX1 and p300 by
RT   HIPK2: implications for leukemogenesis.";
RL   Blood 112:3777-3787(2008).
RN   [31]
RP   INTERACTION WITH YAP1.
RX   PubMed=18280240; DOI=10.1016/j.molcel.2007.12.022;
RA   Levy D., Adamovich Y., Reuven N., Shaul Y.;
RT   "Yap1 phosphorylation by c-Abl is a critical step in selective
RT   activation of proapoptotic genes in response to DNA damage.";
RL   Mol. Cell 29:350-361(2008).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-14 AND SER-21, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [33]
RP   INTERACTION WITH CBFB, AND MUTAGENESIS OF MET-106; ALA-107 AND
RP   SER-140.
RX   PubMed=19202074; DOI=10.1073/pnas.0810558106;
RA   Kwok C., Zeisig B.B., Qiu J., Dong S., So C.W.;
RT   "Transforming activity of AML1-ETO is independent of CBFbeta and ETO
RT   interaction but requires formation of homo-oligomeric complexes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:2853-2858(2009).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-14; SER-249; SER-266;
RP   SER-268 AND SER-276, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [35]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-24 AND LYS-43, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [36]
RP   CHROMOSOMAL TRANSLOCATION WITH CBFA2T2.
RX   PubMed=20520637; DOI=10.1038/leu.2010.106;
RA   Guastadisegni M.C., Lonoce A., Impera L., Di Terlizzi F., Fugazza G.,
RA   Aliano S., Grasso R., Cluzeau T., Raynaud S., Rocchi M.,
RA   Storlazzi C.T.;
RT   "CBFA2T2 and C20orf112: two novel fusion partners of RUNX1 in acute
RT   myeloid leukemia.";
RL   Leukemia 24:1516-1519(2010).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-14; SER-21; SER-193;
RP   SER-212 AND THR-296, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-212 AND SER-435, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 59-173 IN COMPLEX WITH CBFB.
RX   PubMed=10856244; DOI=10.1093/emboj/19.12.3004;
RA   Warren A.J., Bravo J., Williams R.L., Rabbitts T.H.;
RT   "Structural basis for the heterodimeric interaction between the acute
RT   leukaemia-associated transcription factors AML1 and CBFbeta.";
RL   EMBO J. 19:3004-3015(2000).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 54-243 IN COMPLEX WITH CBFB
RP   AND DNA, AND MUTAGENESIS OF ARG-80; LYS-83; THR-84; ARG-135; ARG-139;
RP   ARG-142; LYS-167; THR-169; ASP-171; ARG-174 AND ARG-177.
RX   PubMed=11276260; DOI=10.1038/86264;
RA   Bravo J., Li Z., Speck N.A., Warren A.J.;
RT   "The leukemia-associated AML1 (Runx1) -- CBF beta complex functions as
RT   a DNA-induced molecular clamp.";
RL   Nat. Struct. Biol. 8:371-378(2001).
RN   [41]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 61-174 IN COMPLEX WITH DNA.
RX   PubMed=12377125; DOI=10.1016/S0969-2126(02)00853-5;
RA   Bartfeld D., Shimon L., Couture G.C., Rabinovich D., Frolow F.,
RA   Levanon D., Groner Y., Shakked Z.;
RT   "DNA recognition by the RUNX1 transcription factor is mediated by an
RT   allosteric transition in the RUNT domain and by DNA bending.";
RL   Structure 10:1395-1407(2002).
RN   [42]
RP   STRUCTURE BY NMR OF 53-178, AND MUTAGENESIS OF ALA-107 AND GLY-108.
RX   PubMed=10404214; DOI=10.1038/10658;
RA   Nagata T., Gupta V., Sorce D., Kim W.-Y., Sali A., Chait B.T.,
RA   Shigesada K., Ito Y., Werner M.H.;
RT   "Immunoglobulin motif DNA recognition and heterodimerization of the
RT   PEBP2/CBF Runt domain.";
RL   Nat. Struct. Biol. 6:615-619(1999).
RN   [43]
RP   STRUCTURE BY NMR OF 61-175 IN COMPLEX WITH DNA.
RX   PubMed=10545320; DOI=10.1016/S0969-2126(00)80058-1;
RA   Berardi M.J., Sun C., Zehr M., Abildgaard F., Peng J., Speck N.A.,
RA   Bushweller J.H.;
RT   "The Ig fold of the core binding factor alpha Runt domain is a member
RT   of a family of structurally and functionally related Ig-fold DNA-
RT   binding domains.";
RL   Structure 7:1247-1256(1999).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (1.25 ANGSTROMS) OF 46-185, AND
RP   CHLORIDE-BINDING.
RX   PubMed=12217689; DOI=10.1016/S0022-2836(02)00702-7;
RA   Baeckstroem S., Wolf-Watz M., Grundstroem C., Haerd T.,
RA   Grundstroem T., Sauer U.H.;
RT   "The RUNX1 Runt domain at 1.25A resolution: a structural switch and
RT   specifically bound chloride ions modulate DNA binding.";
RL   J. Mol. Biol. 322:259-272(2002).
RN   [45]
RP   REVIEW ON AML1 TRANSLOCATIONS.
RX   PubMed=7795214;
RA   Nucifora G., Rowley J.D.;
RT   "AML1 and the 8;21 and 3;21 translocations in acute and chronic
RT   myeloid leukemia.";
RL   Blood 86:1-14(1995).
RN   [46]
RP   CHROMOSOMAL TRANSLOCATION WITH MTG8/ETO IN AML-M2.
RX   PubMed=1423235; DOI=10.1016/0165-4608(92)90384-K;
RA   Nisson P.E., Watkins P.C., Sacchi N.;
RT   "Transcriptionally active chimeric gene derived from the fusion of the
RT   AML1 gene and a novel gene on chromosome 8 in t(8;21) leukemic
RT   cells.";
RL   Cancer Genet. Cytogenet. 63:81-88(1992).
RN   [47]
RP   CHROMOSOMAL TRANSLOCATION WITH MTG8/ETO IN AML-M2.
RX   PubMed=8353289;
RA   Kozu T., Miyoshi H., Shimizu K., Maseki N., Kaneko Y., Asou H.,
RA   Kamada N., Ohki M.;
RT   "Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute
RT   myeloid leukemia detected by reverse transcription polymerase chain
RT   reaction.";
RL   Blood 82:1270-1276(1993).
RN   [48]
RP   CHROMOSOMAL TRANSLOCATION WITH MTG8/ETO IN AML-M2.
RX   PubMed=8334990;
RA   Miyoshi H., Kozu T., Shimizu K., Enomoto K., Maseki N., Kaneko Y.,
RA   Kamada N., Ohki M.;
RT   "The t(8;21) translocation in acute myeloid leukemia results in
RT   production of an AML1-MTG8 fusion transcript.";
RL   EMBO J. 12:2715-2721(1993).
RN   [49]
RP   CHROMOSOMAL TRANSLOCATION WITH EAP IN MYELODYSPLASIA.
RC   TISSUE=Peripheral blood;
RX   PubMed=8395054; DOI=10.1073/pnas.90.16.7784;
RA   Nucifora G., Begy C.R., Erickson P., Drabkin H.A., Rowley J.D.;
RT   "The 3;21 translocation in myelodysplasia results in a fusion
RT   transcript between the AML1 gene and the gene for EAP, a highly
RT   conserved protein associated with the Epstein-Barr virus small RNA
RT   EBER 1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:7784-7788(1993).
RN   [50]
RP   CHROMOSOMAL TRANSLOCATION WITH MTG8/ETO IN AML-M2.
RX   PubMed=7919324;
RA   Tighe J.E., Calabi F.;
RT   "Alternative, out-of-frame runt/MTG8 transcripts are encoded by the
RT   derivative (8) chromosome in the t(8;21) of acute myeloid leukemia
RT   M2.";
RL   Blood 84:2115-2121(1994).
RN   [51]
RP   CHROMOSOMAL TRANSLOCATION WITH TEL IN ACUTE LYMPHOBLASTIC LEUKEMIA
RP   (ALL).
RX   PubMed=7780150;
RA   Romana S.P., Mauchauffe M., le Coniat M., Chumakov I., le Paslier D.,
RA   Berger R., Bernard O.A.;
RT   "The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1
RT   gene fusion.";
RL   Blood 85:3662-3670(1995).
RN   [52]
RP   CHROMOSOMAL TRANSLOCATION WITH MTG8/ETO IN AML-M2.
RX   PubMed=7541640; DOI=10.1002/gcc.2870130105;
RA   Era T., Asou N., Kunisada T., Yamasaki H., Asou H., Kamada N.,
RA   Nishikawa S., Yamaguchi K., Takatsuki K.;
RT   "Identification of two transcripts of AML1/ETO-fused gene in t(8;21)
RT   leukemic cells and expression of wild-type ETO gene in hematopoietic
RT   cells.";
RL   Genes Chromosomes Cancer 13:25-33(1995).
RN   [53]
RP   CHROMOSOMAL TRANSLOCATION WITH TEL IN ACUTE LYMPHOBLASTIC LEUKEMIA
RP   (ALL).
RX   PubMed=7761424; DOI=10.1073/pnas.92.11.4917;
RA   Golub T.R., Barker G.F., Bohlander S.K., Hiebert S.W., Ward D.C.,
RA   Bray-Ward P., Morgan E., Raimondi S.C., Rowley J.D., Gilliland D.G.;
RT   "Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute
RT   lymphoblastic leukemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:4917-4921(1995).
RN   [54]
RP   VARIANTS FPDMM GLN-139 AND GLN-174.
RX   PubMed=10508512; DOI=10.1038/13793;
RA   Song W.-J., Sullivan M.G., Legare R.D., Hutchings S., Tan X.,
RA   Kufrin D., Ratajczak J., Resende I.C., Haworth C., Hock R., Loh M.,
RA   Felix C., Roy D.-C., Busque L., Kurnit D., Willman C., Gewirtz A.M.,
RA   Speck N.A., Bushweller J.H., Li F.P., Gardiner K., Poncz M.,
RA   Maris J.M., Gilliland D.G.;
RT   "Haploinsufficiency of CBFA2 causes familial thrombocytopenia with
RT   propensity to develop acute myelogenous leukaemia.";
RL   Nat. Genet. 23:166-175(1999).
RN   [55]
RP   CHROMOSOMAL REARRANGEMENT.
RX   PubMed=18925961; DOI=10.1186/1471-2407-8-299;
RA   Gelsi-Boyer V., Trouplin V., Adelaide J., Aceto N., Remy V.,
RA   Pinson S., Houdayer C., Arnoulet C., Sainty D., Bentires-Alj M.,
RA   Olschwang S., Vey N., Mozziconacci M.-J., Birnbaum D., Chaffanet M.;
RT   "Genome profiling of chronic myelomonocytic leukemia: frequent
RT   alterations of RAS and RUNX1 genes.";
RL   BMC Cancer 8:299-299(2008).
CC   -!- FUNCTION: CBF binds to the core site, 5'-PYGPYGGT-3', of a number
CC       of enhancers and promoters, including murine leukemia virus,
CC       polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and
CC       GM-CSF promoters. The alpha subunit binds DNA and appears to have
CC       a role in the development of normal hematopoiesis. Isoform AML-1L
CC       interferes with the transactivation activity of RUNX1. Acts
CC       synergistically with ELF4 to transactivate the IL-3 promoter and
CC       with ELF2 to transactivate the mouse BLK promoter. Inhibits KAT6B-
CC       dependent transcriptional activation. Controls the anergy and
CC       suppressive function of regulatory T-cells (Treg) by associating
CC       with FOXP3. Activates the expression of IL2 and IFNG and down-
CC       regulates the expression of TNFRSF18, IL2RA and CTLA4, in
CC       conventional T-cells (PubMed:17377532). Positively regulates the
CC       expression of RORC in T-helper 17 cells (By similarity).
CC       {ECO:0000250|UniProtKB:Q03347, ECO:0000269|PubMed:10207087,
CC       ECO:0000269|PubMed:11965546, ECO:0000269|PubMed:14970218,
CC       ECO:0000269|PubMed:17377532, ECO:0000269|PubMed:17431401}.
CC   -!- SUBUNIT: Heterodimer with CBFB. RUNX1 binds DNA as a monomer and
CC       through the Runt domain. DNA-binding is increased by
CC       heterodimerization. Isoform AML-1L can neither bind DNA nor
CC       heterodimerize. Interacts with TLE1 and ALYREF/THOC4. Interacts
CC       with ELF1, ELF2 and SPI1. Interacts via its Runt domain with the
CC       ELF4 N-terminal region. Interaction with ELF2 isoform 2 (NERF-1a)
CC       may act to repress RUNX1-mediated transactivation. Interacts with
CC       KAT6A and KAT6B. Interacts with SUV39H1, leading to abrogation of
CC       transactivating and DNA-binding properties of RUNX1. Interacts
CC       with YAP1. Interacts with HIPK2 (By similarity). Interaction with
CC       CDK6 prevents myeloid differentiation, reducing its transcription
CC       transactivation activity. Found in a complex with PRMT5, RUNX1 AND
CC       CBFB. Interacts with FOXP3. Interacts with TBX21 (By similarity).
CC       {ECO:0000250|UniProtKB:Q03347, ECO:0000269|PubMed:10207087,
CC       ECO:0000269|PubMed:10545320, ECO:0000269|PubMed:10856244,
CC       ECO:0000269|PubMed:11276260, ECO:0000269|PubMed:11742995,
CC       ECO:0000269|PubMed:11965546, ECO:0000269|PubMed:12377125,
CC       ECO:0000269|PubMed:12917624, ECO:0000269|PubMed:14970218,
CC       ECO:0000269|PubMed:16652147, ECO:0000269|PubMed:17377532,
CC       ECO:0000269|PubMed:17431401, ECO:0000269|PubMed:18280240,
CC       ECO:0000269|PubMed:9119228, ECO:0000269|PubMed:9751710}.
CC   -!- INTERACTION:
CC       Q13951:CBFB; NbExp=3; IntAct=EBI-925904, EBI-718750;
CC       Q00534:CDK6; NbExp=5; IntAct=EBI-925904, EBI-295663;
CC       Q15723:ELF2; NbExp=2; IntAct=EBI-925904, EBI-956941;
CC       P16371:gro (xeno); NbExp=4; IntAct=EBI-925940, EBI-153866;
CC       Q9H2X6:HIPK2; NbExp=4; IntAct=EBI-925904, EBI-348345;
CC       P17542:TAL1; NbExp=3; IntAct=EBI-925904, EBI-1753878;
CC       Q04724:TLE1; NbExp=4; IntAct=EBI-925940, EBI-711424;
CC       P46937:YAP1; NbExp=3; IntAct=EBI-925904, EBI-1044059;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=11;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=AML-1B;
CC         IsoId=Q01196-1; Sequence=Displayed;
CC       Name=AML-1A;
CC         IsoId=Q01196-2; Sequence=VSP_005929;
CC       Name=AML-1C;
CC         IsoId=Q01196-3; Sequence=VSP_005926, VSP_005927;
CC       Name=AML-1E;
CC         IsoId=Q01196-4; Sequence=VSP_005928;
CC       Name=AML-1FA;
CC         IsoId=Q01196-5; Sequence=VSP_005923, VSP_005924;
CC       Name=AML-1FB;
CC         IsoId=Q01196-6; Sequence=VSP_005921, VSP_005922;
CC       Name=AML-1FC;
CC         IsoId=Q01196-7; Sequence=VSP_005920, VSP_005925;
CC       Name=AML-1G;
CC         IsoId=Q01196-8; Sequence=VSP_005917;
CC       Name=AML-1H;
CC         IsoId=Q01196-9; Sequence=VSP_005916;
CC       Name=AML-1I;
CC         IsoId=Q01196-10; Sequence=VSP_005918;
CC       Name=AML-1L; Synonyms=AML1-delta N;
CC         IsoId=Q01196-11; Sequence=VSP_005919;
CC   -!- TISSUE SPECIFICITY: Expressed in all tissues examined except brain
CC       and heart. Highest levels in thymus, bone marrow and peripheral
CC       blood.
CC   -!- DOMAIN: A proline/serine/threonine rich region at the C-terminus
CC       is necessary for transcriptional activation of target genes.
CC   -!- PTM: Phosphorylated in its C-terminus upon IL-6 treatment.
CC       Phosphorylation enhances interaction with KAT6A.
CC   -!- PTM: Methylated. {ECO:0000269|PubMed:12917624}.
CC   -!- PTM: Phosphorylated in Ser-249 Thr-273 and Ser-276 by HIPK2 when
CC       associated with CBFB and DNA. This phosphorylation promotes
CC       subsequent EP300 phosphorylation. {ECO:0000269|PubMed:18695000}.
CC   -!- DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a
CC       cause of M2 type acute myeloid leukemia (AML-M2). Translocation
CC       t(8;21)(q22;q22) with RUNX1T1.
CC   -!- DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a
CC       cause of therapy-related myelodysplastic syndrome (T-MDS).
CC       Translocation t(3;21)(q26;q22) with EAP or MECOM.
CC   -!- DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a
CC       cause of chronic myelogenous leukemia (CML). Translocation
CC       t(3;21)(q26;q22) with EAP or MECOM.
CC   -!- DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is
CC       found in childhood acute lymphoblastic leukemia (ALL).
CC       Translocation t(12;21)(p13;q22) with TEL. The translocation fuses
CC       the 3'-end of TEL to the alternate 5'-exon of AML-1H.
CC   -!- DISEASE: Note=A chromosomal aberration involving RUNX1 is found in
CC       acute leukemia. Translocation t(11,21)(q13;q22) that forms a
CC       MACROD1-RUNX1 fusion protein.
CC   -!- DISEASE: Familial platelet disorder with associated myeloid
CC       malignancy (FPDMM) [MIM:601399]: Autosomal dominant disease
CC       characterized by qualitative and quantitative platelet defects,
CC       and propensity to develop acute myelogenous leukemia.
CC       {ECO:0000269|PubMed:10508512}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is
CC       found in therapy-related myeloid malignancies. Translocation
CC       t(16;21)(q24;q22) that forms a RUNX1-CBFA2T3 fusion protein.
CC   -!- DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is a
CC       cause of chronic myelomonocytic leukemia. Inversion
CC       inv(21)(q21;q22) with USP16.
CC   -!- DISEASE: Note=A chromosomal aberration involving RUNX1/AML1 is
CC       found in acute myeloid leukemia. Translocation t(20;21)(q11;q22)
CC       with CBFA2T2. {ECO:0000269|PubMed:20520637}.
CC   -!- CAUTION: The fusion of AML1 with EAP in T-MDS induces a change of
CC       reading frame in the latter resulting in 17 AA unrelated to those
CC       of EAP. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC05246.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=AAC05247.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/AML1ID52.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L34598; AAA51720.1; -; mRNA.
DR   EMBL; D43967; BAA07902.1; -; mRNA.
DR   EMBL; D10570; BAA01426.1; -; mRNA.
DR   EMBL; S76345; AAB33729.1; -; mRNA.
DR   EMBL; S76346; AAB33730.1; -; mRNA.
DR   EMBL; S76350; AAB33731.1; -; mRNA.
DR   EMBL; S60998; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; X79549; CAA56092.1; -; mRNA.
DR   EMBL; D43968; BAA07903.1; -; mRNA.
DR   EMBL; D43969; BAA07904.1; -; mRNA.
DR   EMBL; U19601; AAB51691.1; -; mRNA.
DR   EMBL; L21756; AAA03086.1; ALT_TERM; mRNA.
DR   EMBL; S69002; AAB29907.1; ALT_TERM; mRNA.
DR   EMBL; D13979; BAA03089.1; -; mRNA.
DR   EMBL; D14822; BAA03559.1; ALT_TERM; mRNA.
DR   EMBL; D14823; BAA03560.1; ALT_TERM; mRNA.
DR   EMBL; S78158; AAB34819.2; ALT_TERM; mRNA.
DR   EMBL; S78159; AAB34820.2; ALT_TERM; mRNA.
DR   EMBL; S50186; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; S78496; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; S74092; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; X90979; CAA62466.1; -; mRNA.
DR   EMBL; X90976; CAA62464.1; -; mRNA.
DR   EMBL; D89790; BAA14022.1; -; mRNA.
DR   EMBL; D89788; BAA14020.1; -; mRNA.
DR   EMBL; D89789; BAA14021.1; -; mRNA.
DR   EMBL; AP000330; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP000331; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP000332; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP000333; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP000334; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF015262; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471079; EAX09769.1; -; Genomic_DNA.
DR   EMBL; CH471079; EAX09770.1; -; Genomic_DNA.
DR   EMBL; BC136380; AAI36381.1; -; mRNA.
DR   EMBL; BC136381; AAI36382.1; -; mRNA.
DR   EMBL; BC144053; AAI44054.1; -; mRNA.
DR   EMBL; AF025841; AAC05246.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AF025841; AAC05247.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AJ229043; CAA13070.1; -; Genomic_DNA.
DR   CCDS; CCDS13639.1; -. [Q01196-8]
DR   CCDS; CCDS42922.1; -. [Q01196-1]
DR   CCDS; CCDS46646.1; -. [Q01196-3]
DR   PIR; I39443; I39443.
DR   PIR; S57842; S57842.
DR   RefSeq; NP_001001890.1; NM_001001890.2. [Q01196-1]
DR   RefSeq; NP_001116079.1; NM_001122607.1. [Q01196-3]
DR   RefSeq; NP_001745.2; NM_001754.4. [Q01196-8]
DR   RefSeq; XP_005261125.1; XM_005261068.3. [Q01196-10]
DR   RefSeq; XP_011528068.1; XM_011529766.2. [Q01196-8]
DR   UniGene; Hs.149261; -.
DR   UniGene; Hs.612648; -.
DR   UniGene; Hs.705364; -.
DR   PDB; 1CMO; NMR; -; A=52-178.
DR   PDB; 1CO1; NMR; -; A=61-175.
DR   PDB; 1E50; X-ray; 2.60 A; A/C/E/G/Q/R=50-183.
DR   PDB; 1H9D; X-ray; 2.60 A; A/C=50-183.
DR   PDB; 1LJM; X-ray; 2.50 A; A/B=51-181.
DR   PDBsum; 1CMO; -.
DR   PDBsum; 1CO1; -.
DR   PDBsum; 1E50; -.
DR   PDBsum; 1H9D; -.
DR   PDBsum; 1LJM; -.
DR   ProteinModelPortal; Q01196; -.
DR   SMR; Q01196; -.
DR   BioGrid; 107309; 81.
DR   CORUM; Q01196; -.
DR   DIP; DIP-36773N; -.
DR   ELM; Q01196; -.
DR   IntAct; Q01196; 34.
DR   MINT; Q01196; -.
DR   STRING; 9606.ENSP00000300305; -.
DR   BindingDB; Q01196; -.
DR   iPTMnet; Q01196; -.
DR   PhosphoSitePlus; Q01196; -.
DR   BioMuta; RUNX1; -.
DR   DMDM; 215274205; -.
DR   EPD; Q01196; -.
DR   MaxQB; Q01196; -.
DR   PaxDb; Q01196; -.
DR   PeptideAtlas; Q01196; -.
DR   PRIDE; Q01196; -.
DR   Ensembl; ENST00000300305; ENSP00000300305; ENSG00000159216. [Q01196-8]
DR   Ensembl; ENST00000344691; ENSP00000340690; ENSG00000159216. [Q01196-1]
DR   Ensembl; ENST00000358356; ENSP00000351123; ENSG00000159216. [Q01196-3]
DR   Ensembl; ENST00000437180; ENSP00000409227; ENSG00000159216. [Q01196-8]
DR   GeneID; 861; -.
DR   KEGG; hsa:861; -.
DR   UCSC; uc002yuh.3; human. [Q01196-1]
DR   CTD; 861; -.
DR   DisGeNET; 861; -.
DR   EuPathDB; HostDB:ENSG00000159216.18; -.
DR   GeneCards; RUNX1; -.
DR   HGNC; HGNC:10471; RUNX1.
DR   HPA; HPA004176; -.
DR   HPA; HPA037912; -.
DR   MalaCards; RUNX1; -.
DR   MIM; 151385; gene.
DR   MIM; 601399; phenotype.
DR   neXtProt; NX_Q01196; -.
DR   OpenTargets; ENSG00000159216; -.
DR   Orphanet; 102724; 'Acute myeloid leukemia with t(8;21)(q22;q22) translocation'.
DR   Orphanet; 521; Chronic myeloid leukemia.
DR   Orphanet; 71290; Familial platelet syndrome with predisposition to acute myelogenous leukemia.
DR   Orphanet; 248340; Isolated delta-storage pool disease.
DR   Orphanet; 99860; Precursor B-cell acute lymphoblastic leukemia.
DR   PharmGKB; PA34884; -.
DR   eggNOG; KOG3982; Eukaryota.
DR   eggNOG; ENOG4111J4Y; LUCA.
DR   GeneTree; ENSGT00390000016964; -.
DR   HOVERGEN; HBG060268; -.
DR   InParanoid; Q01196; -.
DR   KO; K08367; -.
DR   OMA; QSYPYLG; -.
DR   OrthoDB; EOG091G0CXB; -.
DR   PhylomeDB; Q01196; -.
DR   TreeFam; TF321496; -.
DR   Reactome; R-HSA-549127; Organic cation transport.
DR   Reactome; R-HSA-8877330; RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs).
DR   Reactome; R-HSA-8931987; RUNX1 regulates estrogen receptor mediated transcription.
DR   Reactome; R-HSA-8934593; Regulation of RUNX1 Expression and Activity.
DR   Reactome; R-HSA-8935964; RUNX1 regulates expression of components of tight junctions.
DR   Reactome; R-HSA-8936459; RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function.
DR   Reactome; R-HSA-8939236; RUNX1 regulates transcription of genes involved in differentiation of HSCs.
DR   Reactome; R-HSA-8939242; RUNX1 regulates transcription of genes involved in differentiation of keratinocytes.
DR   Reactome; R-HSA-8939243; RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known.
DR   Reactome; R-HSA-8939245; RUNX1 regulates transcription of genes involved in BCR signaling.
DR   Reactome; R-HSA-8939246; RUNX1 regulates transcription of genes involved in differentiation of myeloid cells.
DR   Reactome; R-HSA-8939247; RUNX1 regulates transcription of genes involved in interleukin signaling.
DR   Reactome; R-HSA-8939256; RUNX1 regulates transcription of genes involved in WNT signaling.
DR   Reactome; R-HSA-8941333; RUNX2 regulates genes involved in differentiation of myeloid cells.
DR   Reactome; R-HSA-8951936; RUNX3 regulates p14-ARF.
DR   SignaLink; Q01196; -.
DR   SIGNOR; Q01196; -.
DR   ChiTaRS; RUNX1; human.
DR   EvolutionaryTrace; Q01196; -.
DR   GeneWiki; RUNX1; -.
DR   GenomeRNAi; 861; -.
DR   PRO; PR:Q01196; -.
DR   Proteomes; UP000005640; Chromosome 21.
DR   Bgee; ENSG00000159216; -.
DR   ExpressionAtlas; Q01196; baseline and differential.
DR   Genevisible; Q01196; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:InterPro.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0001047; F:core promoter binding; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0000977; F:RNA polymerase II regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0008134; F:transcription factor binding; IDA:UniProtKB.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IDA:UniProtKB.
DR   GO; GO:0001228; F:transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0002062; P:chondrocyte differentiation; IBA:GO_Central.
DR   GO; GO:0071425; P:hematopoietic stem cell proliferation; TAS:UniProtKB.
DR   GO; GO:0030097; P:hemopoiesis; IDA:UniProtKB.
DR   GO; GO:0030099; P:myeloid cell differentiation; IDA:UniProtKB.
DR   GO; GO:0030853; P:negative regulation of granulocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0001503; P:ossification; IBA:GO_Central.
DR   GO; GO:0048935; P:peripheral nervous system neuron development; TAS:BHF-UCL.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; ISS:UniProtKB.
DR   GO; GO:0030854; P:positive regulation of granulocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0032743; P:positive regulation of interleukin-2 production; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0050855; P:regulation of B cell receptor signaling pathway; TAS:Reactome.
DR   GO; GO:2000810; P:regulation of bicellular tight junction assembly; TAS:Reactome.
DR   GO; GO:0001959; P:regulation of cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:1902036; P:regulation of hematopoietic stem cell differentiation; TAS:Reactome.
DR   GO; GO:0033146; P:regulation of intracellular estrogen receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0045616; P:regulation of keratinocyte differentiation; TAS:Reactome.
DR   GO; GO:0045652; P:regulation of megakaryocyte differentiation; TAS:Reactome.
DR   GO; GO:0045637; P:regulation of myeloid cell differentiation; TAS:Reactome.
DR   GO; GO:0045589; P:regulation of regulatory T cell differentiation; TAS:Reactome.
DR   GO; GO:0030111; P:regulation of Wnt signaling pathway; TAS:Reactome.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.770.10; -; 1.
DR   InterPro; IPR000040; AML1_Runt.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR013524; Runt_dom.
DR   InterPro; IPR027384; Runx_central_dom_sf.
DR   InterPro; IPR013711; RunxI_C_dom.
DR   InterPro; IPR016554; TF_Runt-rel_RUNX.
DR   PANTHER; PTHR11950; PTHR11950; 1.
DR   Pfam; PF00853; Runt; 1.
DR   Pfam; PF08504; RunxI; 1.
DR   PIRSF; PIRSF009374; TF_Runt-rel_RUNX; 1.
DR   PRINTS; PR00967; ONCOGENEAML1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS51062; RUNT; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing; Chloride;
KW   Chromosomal rearrangement; Complete proteome; Disease mutation;
KW   DNA-binding; Methylation; Nucleus; Phosphoprotein; Polymorphism;
KW   Proto-oncogene; Reference proteome; Repressor; Transcription;
KW   Transcription regulation.
FT   CHAIN         1    453       Runt-related transcription factor 1.
FT                                /FTId=PRO_0000174655.
FT   DOMAIN       50    178       Runt. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00399}.
FT   REGION       80     84       Interaction with DNA.
FT   REGION      135    143       Interaction with DNA.
FT   REGION      168    177       Interaction with DNA.
FT   REGION      291    371       Interaction with KAT6A.
FT                                {ECO:0000269|PubMed:11742995}.
FT   REGION      307    400       Interaction with KAT6B. {ECO:0000250}.
FT   REGION      362    402       Interaction with FOXP3.
FT                                {ECO:0000269|PubMed:17377532}.
FT   COMPBIAS    187    453       Pro/Ser/Thr-rich.
FT   BINDING     112    112       Chloride 1.
FT   BINDING     116    116       Chloride 1; via amide nitrogen.
FT   BINDING     139    139       Chloride 2.
FT   BINDING     170    170       Chloride 2; via amide nitrogen.
FT   SITE        177    178       Breakpoint for translocation to form
FT                                AML1-EMV-1 (or AML1-EAP) in CML and T-
FT                                MDS, to form AML1-MTG8 (ETO) in AML-M2,
FT                                to form AML1-CBFA2T3 in therapy-related
FT                                myeloid malignancies, to form AML1-MECOM
FT                                in CML and to form type I MACROD1-RUNX1
FT                                fusion protein.
FT   SITE        241    242       Breakpoint for translocation to form
FT                                AML1-EAP in T-MDS and CML, to form type
FT                                II MACROD1-RUNX1 fusion protein and to
FT                                form RUNX1-CBFA2T2 in acute myeloid
FT                                leukemia. {ECO:0000269|PubMed:20520637}.
FT   MOD_RES      14     14       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      21     21       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      24     24       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES      43     43       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     193    193       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     212    212       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     249    249       Phosphoserine; by HIPK2.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000269|PubMed:18695000}.
FT   MOD_RES     266    266       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     268    268       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     273    273       Phosphothreonine; by HIPK2.
FT                                {ECO:0000269|PubMed:18695000}.
FT   MOD_RES     276    276       Phosphoserine; by HIPK2.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000269|PubMed:18695000}.
FT   MOD_RES     296    296       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     435    435       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   VAR_SEQ       1    105       Missing (in isoform AML-1L).
FT                                {ECO:0000303|PubMed:7651838,
FT                                ECO:0000303|PubMed:9199349}.
FT                                /FTId=VSP_005919.
FT   VAR_SEQ       1      5       MRIPV -> MASDSIFESFPSYPQCFMRECILGMNPSRDVH
FT                                (in isoform AML-1G).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:7651838,
FT                                ECO:0000303|PubMed:7891692}.
FT                                /FTId=VSP_005917.
FT   VAR_SEQ       1      5       MRIPV -> MNPSRDVH (in isoform AML-1H).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_005916.
FT   VAR_SEQ       1      5       MRIPV -> MPAAPRGPAQGEAAARTRSR (in isoform
FT                                AML-1I). {ECO:0000305}.
FT                                /FTId=VSP_005918.
FT   VAR_SEQ     137    242       VGRSGRGKSFTLTITVFTNPPQVATYHRAIKITVDGPREPR
FT                                RHRQKLDDQTKPGSLSFSERLSELEQLRRTAMRVSPHHPAP
FT                                TPNPRASLNHSTAFNPQPQSQMQD -> VDGPREPRRHRQK
FT                                LDDQTKPGSLSFSERLSELEQLRRTAMRVSPHHPAPTPNPR
FT                                ASLNHSTAFNPQPQSQMQDTRQIQPSPPWSYDQSYQYLGSI
FT                                ASPSVHPATPI (in isoform AML-1FC).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_005920.
FT   VAR_SEQ     178    224       RHRQKLDDQTKPGSLSFSERLSELEQLRRTAMRVSPHHPAP
FT                                TPNPRA -> SKCIHLGLVHPPGWYTLQAGILRDHVSDSLG
FT                                STFPPGGWQAPVKPKS (in isoform AML-1FA).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_005923.
FT   VAR_SEQ     178    188       RHRQKLDDQTK -> NSLTWPRYPHI (in isoform
FT                                AML-1FB). {ECO:0000305}.
FT                                /FTId=VSP_005921.
FT   VAR_SEQ     189    453       Missing (in isoform AML-1FB).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_005922.
FT   VAR_SEQ     225    453       Missing (in isoform AML-1FA).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_005924.
FT   VAR_SEQ     242    250       DTRQIQPSP -> EEDTAPWRC (in isoform AML-
FT                                1C). {ECO:0000303|PubMed:1720541}.
FT                                /FTId=VSP_005926.
FT   VAR_SEQ     243    453       Missing (in isoform AML-1FC).
FT                                {ECO:0000305}.
FT                                /FTId=VSP_005925.
FT   VAR_SEQ     251    453       Missing (in isoform AML-1C).
FT                                {ECO:0000303|PubMed:1720541}.
FT                                /FTId=VSP_005927.
FT   VAR_SEQ     258    453       Missing (in isoform AML-1E).
FT                                {ECO:0000303|PubMed:8490181}.
FT                                /FTId=VSP_005928.
FT   VAR_SEQ     440    453       APSARLEEAVWRPY -> GGASCSRQARRDPGPWARTPSWG
FT                                RGRPTDRISL (in isoform AML-1A).
FT                                {ECO:0000303|PubMed:7651838,
FT                                ECO:0000303|PubMed:7835892}.
FT                                /FTId=VSP_005929.
FT   VARIANT     139    139       R -> Q (in FPDMM).
FT                                {ECO:0000269|PubMed:10508512}.
FT                                /FTId=VAR_012128.
FT   VARIANT     174    174       R -> Q (in FPDMM; impaired
FT                                phosphorylation; dbSNP:rs74315450).
FT                                {ECO:0000269|PubMed:10508512,
FT                                ECO:0000269|PubMed:18695000}.
FT                                /FTId=VAR_012129.
FT   VARIANT     431    431       S -> R (in dbSNP:rs1055308).
FT                                /FTId=VAR_013177.
FT   VARIANT     433    433       S -> R (in dbSNP:rs1055309).
FT                                /FTId=VAR_013178.
FT   MUTAGEN      67     67       S->R: Loss of heterodimerization and
FT                                reduced EP300 phosphorylation induction.
FT                                {ECO:0000269|PubMed:18695000}.
FT   MUTAGEN      80     80       R->A: Strongly reduces DNA-binding.
FT                                {ECO:0000269|PubMed:11276260}.
FT   MUTAGEN      83     83       K->A: Strongly reduces DNA-binding.
FT                                {ECO:0000269|PubMed:11276260,
FT                                ECO:0000269|PubMed:18695000}.
FT   MUTAGEN      83     83       K->E: Strongly reduces DNA-binding,
FT                                impaired phosphorylation and reduced
FT                                EP300 phosphorylation induction.
FT                                {ECO:0000269|PubMed:11276260,
FT                                ECO:0000269|PubMed:18695000}.
FT   MUTAGEN      84     84       T->A: No effect on DNA binding.
FT                                {ECO:0000269|PubMed:11276260}.
FT   MUTAGEN     106    106       M->V: Disrupts interaction of AML1-
FT                                MTG8/ETO with CBFB, no effect on AML1-
FT                                MTG8/ETO-mediated transformation
FT                                activity. {ECO:0000269|PubMed:19202074}.
FT   MUTAGEN     107    107       A->T: Loss of heterodimerization.
FT                                Disrupts interactionof AML1-MTG8/ETO with
FT                                CBFB, no effect on AML1-MTG8/ETO-mediated
FT                                transformation activity.
FT                                {ECO:0000269|PubMed:10404214,
FT                                ECO:0000269|PubMed:19202074}.
FT   MUTAGEN     108    108       G->R: Loss of heterodimerization and
FT                                impaired phosphorylation.
FT                                {ECO:0000269|PubMed:10404214,
FT                                ECO:0000269|PubMed:18695000}.
FT   MUTAGEN     135    135       R->A: Strongly reduces DNA-binding.
FT                                {ECO:0000269|PubMed:11276260}.
FT   MUTAGEN     139    139       R->A: Strongly reduces DNA-binding.
FT                                {ECO:0000269|PubMed:11276260}.
FT   MUTAGEN     140    140       S->G: Disrupts AML1-MTG8/ETO DNA-binding,
FT                                decreases AML1-MTG8/ETO transforming
FT                                activity. {ECO:0000269|PubMed:19202074}.
FT   MUTAGEN     142    142       R->A: Strongly reduces DNA-binding.
FT                                {ECO:0000269|PubMed:11276260}.
FT   MUTAGEN     145    453       Missing: No DNA-binding.
FT   MUTAGEN     167    167       K->A: Reduces DNA-binding.
FT                                {ECO:0000269|PubMed:11276260}.
FT   MUTAGEN     169    169       T->A: Strongly reduces DNA-binding.
FT                                {ECO:0000269|PubMed:11276260}.
FT   MUTAGEN     171    171       D->A: Strongly reduces DNA-binding.
FT                                {ECO:0000269|PubMed:11276260}.
FT   MUTAGEN     174    174       R->A: Strongly reduces DNA-binding.
FT                                {ECO:0000269|PubMed:11276260}.
FT   MUTAGEN     177    177       R->A: Strongly reduces DNA-binding.
FT                                {ECO:0000269|PubMed:11276260}.
FT   MUTAGEN     249    249       S->A: Reduced phosphorylation.
FT                                {ECO:0000269|PubMed:18695000}.
FT   MUTAGEN     273    273       T->A: Reduced phosphorylation; when
FT                                associated with A-276.
FT                                {ECO:0000269|PubMed:18695000}.
FT   MUTAGEN     276    276       S->A: Reduced phosphorylation; when
FT                                associated with A-273.
FT                                {ECO:0000269|PubMed:18695000}.
FT   CONFLICT    412    412       S -> F (in Ref. 1; AAA51720).
FT                                {ECO:0000305}.
FT   HELIX        54     57       {ECO:0000244|PDB:1CMO}.
FT   STRAND       62     64       {ECO:0000244|PDB:1LJM}.
FT   STRAND       70     73       {ECO:0000244|PDB:1LJM}.
FT   STRAND       77     80       {ECO:0000244|PDB:1LJM}.
FT   STRAND       82     84       {ECO:0000244|PDB:1CMO}.
FT   STRAND       90     93       {ECO:0000244|PDB:1LJM}.
FT   STRAND      102    108       {ECO:0000244|PDB:1LJM}.
FT   STRAND      110    114       {ECO:0000244|PDB:1H9D}.
FT   STRAND      117    119       {ECO:0000244|PDB:1LJM}.
FT   STRAND      121    123       {ECO:0000244|PDB:1LJM}.
FT   STRAND      128    130       {ECO:0000244|PDB:1LJM}.
FT   STRAND      146    152       {ECO:0000244|PDB:1LJM}.
FT   STRAND      154    156       {ECO:0000244|PDB:1E50}.
FT   STRAND      158    161       {ECO:0000244|PDB:1LJM}.
FT   STRAND      166    171       {ECO:0000244|PDB:1LJM}.
FT   HELIX       175    177       {ECO:0000244|PDB:1CMO}.
SQ   SEQUENCE   453 AA;  48737 MW;  4F1F193A7CADDBAB CRC64;
     MRIPVDASTS RRFTPPSTAL SPGKMSEALP LGAPDAGAAL AGKLRSGDRS MVEVLADHPG
     ELVRTDSPNF LCSVLPTHWR CNKTLPIAFK VVALGDVPDG TLVTVMAGND ENYSAELRNA
     TAAMKNQVAR FNDLRFVGRS GRGKSFTLTI TVFTNPPQVA TYHRAIKITV DGPREPRRHR
     QKLDDQTKPG SLSFSERLSE LEQLRRTAMR VSPHHPAPTP NPRASLNHST AFNPQPQSQM
     QDTRQIQPSP PWSYDQSYQY LGSIASPSVH PATPISPGRA SGMTTLSAEL SSRLSTAPDL
     TAFSDPRQFP ALPSISDPRM HYPGAFTYSP TPVTSGIGIG MSAMGSATRY HTYLPPPYPG
     SSQAQGGPFQ ASSPSYHLYY GASAGSYQFS MVGGERSPPR ILPPCTNAST GSALLNPSLP
     NQSDVVEAEG SHSNSPTNMA PSARLEEAVW RPY
//
ID   A0A087WWT6_HUMAN        Unreviewed;       584 AA.
AC   A0A087WWT6;
DT   29-OCT-2014, integrated into UniProtKB/TrEMBL.
DT   29-OCT-2014, sequence version 1.
DT   28-FEB-2018, entry version 36.
DE   SubName: Full=Protein CBFA2T1 {ECO:0000313|Ensembl:ENSP00000480500};
DE   SubName: Full=Runt-related transcription factor 1 translocated to, 1 (Cyclin D-related), isoform CRA_c {ECO:0000313|EMBL:EAW91683.1};
GN   Name=RUNX1T1 {ECO:0000313|EMBL:EAW91683.1,
GN   ECO:0000313|Ensembl:ENSP00000480500};
GN   ORFNames=hCG_20715 {ECO:0000313|EMBL:EAW91683.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000480500, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|EMBL:EAW91683.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D.,
RA   Amanatides P., Ballew R.M., Huson D.H., Wortman J.R., Zhang Q.,
RA   Kodira C.D., Zheng X.H., Chen L., Skupski M., Subramanian G.,
RA   Thomas P.D., Zhang J., Gabor Miklos G.L., Nelson C., Broder S.,
RA   Clark A.G., Nadeau J., McKusick V.A., Zinder N., Levine A.J.,
RA   Roberts R.J., Simon M., Slayman C., Hunkapiller M., Bolanos R.,
RA   Delcher A., Dew I., Fasulo D., Flanigan M., Florea L., Halpern A.,
RA   Hannenhalli S., Kravitz S., Levy S., Mobarry C., Reinert K.,
RA   Remington K., Abu-Threideh J., Beasley E., Biddick K., Bonazzi V.,
RA   Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z.,
RA   Guan P., Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A.,
RA   Lai Z., Lei Y., Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V.,
RA   Milshina N., Moore H.M., Naik A.K., Narayan V.A., Neelam B.,
RA   Nusskern D., Rusch D.B., Salzberg S., Shao W., Shue B., Sun J.,
RA   Wang Z., Wang A., Wang X., Wang J., Wei M., Wides R., Xiao C., Yan C.,
RA   Yao A., Ye J., Zhan M., Zhang W., Zhang H., Zhao Q., Zheng L.,
RA   Zhong F., Zhong W., Zhu S., Zhao S., Gilbert D., Baumhueter S.,
RA   Spier G., Carter C., Cravchik A., Woodage T., Ali F., An H., Awe A.,
RA   Baldwin D., Baden H., Barnstead M., Barrow I., Beeson K., Busam D.,
RA   Carver A., Center A., Cheng M.L., Curry L., Danaher S., Davenport L.,
RA   Desilets R., Dietz S., Dodson K., Doup L., Ferriera S., Garg N.,
RA   Gluecksmann A., Hart B., Haynes J., Haynes C., Heiner C., Hladun S.,
RA   Hostin D., Houck J., Howland T., Ibegwam C., Johnson J., Kalush F.,
RA   Kline L., Koduru S., Love A., Mann F., May D., McCawley S.,
RA   McIntosh T., McMullen I., Moy M., Moy L., Murphy B., Nelson K.,
RA   Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N.,
RA   Tse S., Vech C., Wang G., Wetter J., Williams S., Williams M.,
RA   Windsor S., Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F.,
RA   Guigo R., Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A.,
RA   Mi H., Lazareva B., Hatton T., Narechania A., Diemer K.,
RA   Muruganujan A., Guo N., Sato S., Bafna V., Istrail S., Lippert R.,
RA   Schwartz R., Walenz B., Yooseph S., Allen D., Basu A., Baxendale J.,
RA   Blick L., Caminha M., Carnes-Stine J., Caulk P., Chiang Y.H.,
RA   Coyne M., Dahlke C., Mays A., Dombroski M., Donnelly M., Ely D.,
RA   Esparham S., Fosler C., Gire H., Glanowski S., Glasser K., Glodek A.,
RA   Gorokhov M., Graham K., Gropman B., Harris M., Heil J., Henderson S.,
RA   Hoover J., Jennings D., Jordan C., Jordan J., Kasha J., Kagan L.,
RA   Kraft C., Levitsky A., Lewis M., Liu X., Lopez J., Ma D., Majoros W.,
RA   McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N., Nodell M.,
RA   Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|Ensembl:ENSP00000480500}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [3] {ECO:0000313|EMBL:EAW91683.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4] {ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S.,
RA   Garber M., Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A.,
RA   Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Allen N.R., Anderson S., Asakawa T., Blechschmidt K., Bloom T.,
RA   Borowsky M.L., Butler J., Cook A., Corum B., DeArellano K.,
RA   DeCaprio D., Dooley K.T., Dorris L. III, Engels R., Glockner G.,
RA   Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., Jaffe D.B.,
RA   Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C.,
RA   O'Leary S.B., O'Neill K., Parker S.C., Polley A., Raymond C.K.,
RA   Reichwald K., Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R.,
RA   Smith C.L., Sneddon T.P., Talamas J.A., Tenzin P., Topham K.,
RA   Venkataraman V., Wen G., Yamazaki S., Young S.K., Zeng Q.,
RA   Zimmer A.R., Rosenthal A., Birren B.W., Platzer M., Shimizu N.,
RA   Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [5] {ECO:0000213|PubMed:19413330}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [6] {ECO:0000213|PubMed:21406692}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:rs3-RS3(2011).
RN   [7] {ECO:0000313|Ensembl:ENSP00000480500}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (SEP-2014) to UniProtKB.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AC103680; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC104339; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF181450; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF458797; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471060; EAW91683.1; -; Genomic_DNA.
DR   RefSeq; NP_001185562.1; NM_001198633.1.
DR   UniGene; Hs.368431; -.
DR   UniGene; Hs.739194; -.
DR   Ensembl; ENST00000615601; ENSP00000480500; ENSG00000079102.
DR   GeneID; 862; -.
DR   UCSC; uc022axu.1; human.
DR   CTD; 862; -.
DR   EuPathDB; HostDB:ENSG00000079102.16; -.
DR   HGNC; HGNC:1535; RUNX1T1.
DR   OpenTargets; ENSG00000079102; -.
DR   eggNOG; ENOG410IG1Z; Eukaryota.
DR   eggNOG; ENOG410XR30; LUCA.
DR   GeneTree; ENSGT00390000013479; -.
DR   ChiTaRS; RUNX1T1; human.
DR   GenomeRNAi; 862; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000079102; -.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0003714; F:transcription corepressor activity; IEA:InterPro.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IEA:InterPro.
DR   InterPro; IPR013290; CBFA2T1.
DR   InterPro; IPR013289; CBFA2T1/2/3.
DR   InterPro; IPR014896; NHR2.
DR   InterPro; IPR037249; TAFH/NHR1_dom_sf.
DR   InterPro; IPR003894; TAFH_NHR1.
DR   InterPro; IPR002893; Znf_MYND.
DR   PANTHER; PTHR10379; PTHR10379; 1.
DR   PANTHER; PTHR10379:SF5; PTHR10379:SF5; 1.
DR   Pfam; PF08788; NHR2; 1.
DR   Pfam; PF07531; TAFH; 1.
DR   Pfam; PF01753; zf-MYND; 1.
DR   PRINTS; PR01875; ETOFAMILY.
DR   PRINTS; PR01876; MTG8PROTEIN.
DR   SMART; SM00549; TAFH; 1.
DR   SUPFAM; SSF158553; SSF158553; 1.
DR   PROSITE; PS51119; TAFH; 1.
DR   PROSITE; PS01360; ZF_MYND_1; 1.
DR   PROSITE; PS50865; ZF_MYND_2; 1.
PE   1: Evidence at protein level;
KW   Coiled coil {ECO:0000256|SAM:Coils};
KW   Complete proteome {ECO:0000313|Proteomes:UP000005640};
KW   Metal-binding {ECO:0000256|PROSITE-ProRule:PRU00134,
KW   ECO:0000256|SAAS:SAAS00513840};
KW   Proteomics identification {ECO:0000213|PeptideAtlas:A0A087WWT6};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640};
KW   Zinc {ECO:0000256|PROSITE-ProRule:PRU00134,
KW   ECO:0000256|SAAS:SAAS00513840};
KW   Zinc-finger {ECO:0000256|PROSITE-ProRule:PRU00134,
KW   ECO:0000256|SAAS:SAAS00513840}.
FT   DOMAIN      100    195       TAFH. {ECO:0000259|PROSITE:PS51119}.
FT   DOMAIN      495    531       MYND-type. {ECO:0000259|PROSITE:PS50865}.
FT   COILED      434    476       {ECO:0000256|SAM:Coils}.
SQ   SEQUENCE   584 AA;  65085 MW;  581085B1DF3AB0BA CRC64;
     MVGLSGPVQY RTEKHSTMPD SPVDVKTQSR LTPPTMPPPP TTQGAPRTSS FTPTTLTNGT
     SHSPTALNGA PSPPNGFSNG PSSSSSSSLA NQQLPPACGA RQLSKLKRFL TTLQQFGNDI
     SPEIGERVRT LVLGLVNSTL TIEEFHSKLQ EATNFPLRPF VIPFLKANLP LLQRELLHCA
     RLAKQNPAQY LAQHEQLLLD ASTTSPVDSS ELLLDVNENG KRRTPDRTKE NGFDREPLHS
     EHPSKRPCTI SPGQRYSPNN GLSYQPNGLP HPTPPPPQHY RLDDMAIAHH YRDSYRHPSH
     RDLRDRNRPM GLHGTRQEEM IDHRLTDREW AEEWKHLDHL LNCIMDMVEK TRRSLTVLRR
     CQEADREELN YWIRRYSDAE DLKKGGGSSS SHSRQQSPVN PDPVALDAHR EFLHRPASGY
     VPEEIWKKAE EAVNEVKRQA MTELQKAVSE AERKAHDMIT TERAKMERTV AEAKRQAAED
     ALAVINQQED SSESCWNCGR KASETCSGCN TARYCGSFCQ HKDWEKHHHI CGQTLQAQQQ
     GDTPAVSSSV TPNSGAGSPM DTPPAATPRS TTPGTPSTIE TTPR
//
ID   A0A0A0MSU1_HUMAN        Unreviewed;       663 AA.
AC   A0A0A0MSU1;
DT   07-JAN-2015, integrated into UniProtKB/TrEMBL.
DT   07-JAN-2015, sequence version 1.
DT   28-FEB-2018, entry version 33.
DE   SubName: Full=Protein CBFA2T1 {ECO:0000313|Ensembl:ENSP00000402257};
GN   Name=RUNX1T1 {ECO:0000313|Ensembl:ENSP00000402257};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000402257, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Ensembl:ENSP00000402257}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [2] {ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S.,
RA   Garber M., Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A.,
RA   Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Allen N.R., Anderson S., Asakawa T., Blechschmidt K., Bloom T.,
RA   Borowsky M.L., Butler J., Cook A., Corum B., DeArellano K.,
RA   DeCaprio D., Dooley K.T., Dorris L. III, Engels R., Glockner G.,
RA   Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., Jaffe D.B.,
RA   Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C.,
RA   O'Leary S.B., O'Neill K., Parker S.C., Polley A., Raymond C.K.,
RA   Reichwald K., Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R.,
RA   Smith C.L., Sneddon T.P., Talamas J.A., Tenzin P., Topham K.,
RA   Venkataraman V., Wen G., Yamazaki S., Young S.K., Zeng Q.,
RA   Zimmer A.R., Rosenthal A., Birren B.W., Platzer M., Shimizu N.,
RA   Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [3] {ECO:0000213|PubMed:19413330}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [4] {ECO:0000213|PubMed:21406692}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:rs3-RS3(2011).
RN   [5] {ECO:0000313|Ensembl:ENSP00000402257}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (NOV-2014) to UniProtKB.
CC   -!- CAUTION: The sequence shown here is derived from an Ensembl
CC       automatic analysis pipeline and should be considered as
CC       preliminary data. {ECO:0000313|Ensembl:ENSP00000402257}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AC103680; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC104339; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF181450; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF458797; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_001185608.1; NM_001198679.1.
DR   UniGene; Hs.368431; -.
DR   UniGene; Hs.739194; -.
DR   ProteinModelPortal; A0A0A0MSU1; -.
DR   EPD; A0A0A0MSU1; -.
DR   PRIDE; A0A0A0MSU1; -.
DR   Ensembl; ENST00000436581; ENSP00000402257; ENSG00000079102.
DR   GeneID; 862; -.
DR   UCSC; uc022axs.1; human.
DR   CTD; 862; -.
DR   EuPathDB; HostDB:ENSG00000079102.16; -.
DR   HGNC; HGNC:1535; RUNX1T1.
DR   OpenTargets; ENSG00000079102; -.
DR   GeneTree; ENSGT00390000013479; -.
DR   OMA; MQRDERD; -.
DR   OrthoDB; EOG091G0EIC; -.
DR   ChiTaRS; RUNX1T1; human.
DR   GenomeRNAi; 862; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000079102; -.
DR   ExpressionAtlas; A0A0A0MSU1; baseline and differential.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0003714; F:transcription corepressor activity; IEA:InterPro.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IEA:InterPro.
DR   InterPro; IPR013290; CBFA2T1.
DR   InterPro; IPR013289; CBFA2T1/2/3.
DR   InterPro; IPR014896; NHR2.
DR   InterPro; IPR037249; TAFH/NHR1_dom_sf.
DR   InterPro; IPR003894; TAFH_NHR1.
DR   InterPro; IPR002893; Znf_MYND.
DR   PANTHER; PTHR10379; PTHR10379; 1.
DR   PANTHER; PTHR10379:SF5; PTHR10379:SF5; 1.
DR   Pfam; PF08788; NHR2; 1.
DR   Pfam; PF07531; TAFH; 1.
DR   Pfam; PF01753; zf-MYND; 1.
DR   PRINTS; PR01875; ETOFAMILY.
DR   PRINTS; PR01876; MTG8PROTEIN.
DR   SMART; SM00549; TAFH; 1.
DR   SUPFAM; SSF158553; SSF158553; 1.
DR   PROSITE; PS51119; TAFH; 1.
DR   PROSITE; PS01360; ZF_MYND_1; 1.
DR   PROSITE; PS50865; ZF_MYND_2; 1.
PE   1: Evidence at protein level;
KW   Coiled coil {ECO:0000256|SAM:Coils};
KW   Complete proteome {ECO:0000313|Proteomes:UP000005640};
KW   Metal-binding {ECO:0000256|PROSITE-ProRule:PRU00134,
KW   ECO:0000256|SAAS:SAAS00513840};
KW   Proteomics identification {ECO:0000213|PeptideAtlas:A0A0A0MSU1};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640};
KW   Zinc {ECO:0000256|PROSITE-ProRule:PRU00134,
KW   ECO:0000256|SAAS:SAAS00513840};
KW   Zinc-finger {ECO:0000256|PROSITE-ProRule:PRU00134,
KW   ECO:0000256|SAAS:SAAS00513840}.
FT   DOMAIN      179    274       TAFH. {ECO:0000259|PROSITE:PS51119}.
FT   DOMAIN      574    610       MYND-type. {ECO:0000259|PROSITE:PS50865}.
FT   COILED      513    555       {ECO:0000256|SAM:Coils}.
SQ   SEQUENCE   663 AA;  74192 MW;  E6D792FD9B56D7C9 CRC64;
     MCHPDKAFTS DKLQCVFNEY KAAVWVPPRP RPLSRAPLPE AGGENLHLKI SRVRKRNLPF
     VVWGEEEAST PGLDAISHHL CYPDRTHRDR TEKHSTMPDS PVDVKTQSRL TPPTMPPPPT
     TQGAPRTSSF TPTTLTNGTS HSPTALNGAP SPPNGFSNGP SSSSSSSLAN QQLPPACGAR
     QLSKLKRFLT TLQQFGNDIS PEIGERVRTL VLGLVNSTLT IEEFHSKLQE ATNFPLRPFV
     IPFLKANLPL LQRELLHCAR LAKQNPAQYL AQHEQLLLDA STTSPVDSSE LLLDVNENGK
     RRTPDRTKEN GFDREPLHSE HPSKRPCTIS PGQRYSPNNG LSYQPNGLPH PTPPPPQHYR
     LDDMAIAHHY RDSYRHPSHR DLRDRNRPMG LHGTRQEEMI DHRLTDREWA EEWKHLDHLL
     NCIMDMVEKT RRSLTVLRRC QEADREELNY WIRRYSDAED LKKGGGSSSS HSRQQSPVNP
     DPVALDAHRE FLHRPASGYV PEEIWKKAEE AVNEVKRQAM TELQKAVSEA ERKAHDMITT
     ERAKMERTVA EAKRQAAEDA LAVINQQEDS SESCWNCGRK ASETCSGCNT ARYCGSFCQH
     KDWEKHHHIC GQTLQAQQQG DTPAVSSSVT PNSGAGSPMD TPPAATPRST TPGTPSTIET
     TPR
//
ID   B2R6I9_HUMAN            Unreviewed;       577 AA.
AC   B2R6I9;
DT   01-JUL-2008, integrated into UniProtKB/TrEMBL.
DT   01-JUL-2008, sequence version 1.
DT   28-FEB-2018, entry version 63.
DE   SubName: Full=cDNA, FLJ92968, highly similar to Homo sapiens runt-related transcription factor 1; translocated to, 1 (cyclin D-related) (RUNX1T1), transcript variant 1, mRNA {ECO:0000313|EMBL:BAG35486.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAG35486.1};
RN   [1] {ECO:0000313|EMBL:BAG35486.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Brain {ECO:0000313|EMBL:BAG35486.1};
RA   Wakamatsu A., Yamamoto J., Kimura K., Kaida T., Tsuchiya K., Iida Y.,
RA   Takayama Y., Murakawa K., Kanehori K., Andoh T., Kagawa N., Sato R.,
RA   Kawamura Y., Tanaka S., Kisu Y., Sugano S., Goshima N., Nomura N.,
RA   Isogai T.;
RT   "NEDO functional analysis of protein and research application
RT   project.";
RL   Submitted (JAN-2008) to the EMBL/GenBank/DDBJ databases.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK312592; BAG35486.1; -; mRNA.
DR   RefSeq; NP_001185554.1; NM_001198625.1.
DR   UniGene; Hs.368431; -.
DR   UniGene; Hs.739194; -.
DR   PeptideAtlas; B2R6I9; -.
DR   PRIDE; B2R6I9; -.
DR   DNASU; 862; -.
DR   GeneID; 862; -.
DR   CTD; 862; -.
DR   eggNOG; ENOG410IG1Z; Eukaryota.
DR   eggNOG; ENOG410XR30; LUCA.
DR   HOGENOM; HOG000049245; -.
DR   HOVERGEN; HBG000169; -.
DR   GenomeRNAi; 862; -.
DR   Genevisible; B2R6I9; HS.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0003714; F:transcription corepressor activity; IEA:InterPro.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IEA:InterPro.
DR   InterPro; IPR013290; CBFA2T1.
DR   InterPro; IPR013289; CBFA2T1/2/3.
DR   InterPro; IPR014896; NHR2.
DR   InterPro; IPR037249; TAFH/NHR1_dom_sf.
DR   InterPro; IPR003894; TAFH_NHR1.
DR   InterPro; IPR002893; Znf_MYND.
DR   PANTHER; PTHR10379; PTHR10379; 1.
DR   PANTHER; PTHR10379:SF5; PTHR10379:SF5; 1.
DR   Pfam; PF08788; NHR2; 1.
DR   Pfam; PF07531; TAFH; 1.
DR   Pfam; PF01753; zf-MYND; 1.
DR   PRINTS; PR01875; ETOFAMILY.
DR   PRINTS; PR01876; MTG8PROTEIN.
DR   SMART; SM00549; TAFH; 1.
DR   SUPFAM; SSF158553; SSF158553; 1.
DR   PROSITE; PS51119; TAFH; 1.
DR   PROSITE; PS01360; ZF_MYND_1; 1.
DR   PROSITE; PS50865; ZF_MYND_2; 1.
PE   2: Evidence at transcript level;
KW   Coiled coil {ECO:0000256|SAM:Coils};
KW   Metal-binding {ECO:0000256|PROSITE-ProRule:PRU00134,
KW   ECO:0000256|SAAS:SAAS00513840};
KW   Zinc {ECO:0000256|PROSITE-ProRule:PRU00134,
KW   ECO:0000256|SAAS:SAAS00513840};
KW   Zinc-finger {ECO:0000256|PROSITE-ProRule:PRU00134,
KW   ECO:0000256|SAAS:SAAS00513840}.
FT   DOMAIN       93    188       TAFH. {ECO:0000259|PROSITE:PS51119}.
FT   DOMAIN      488    524       MYND-type. {ECO:0000259|PROSITE:PS50865}.
FT   COILED      427    469       {ECO:0000256|SAM:Coils}.
SQ   SEQUENCE   577 AA;  64369 MW;  E2AAB735120EDC07 CRC64;
     MPDRTEKHST MPDSPVDVKT QSRLTPPTMP PPPTTQGAPR TSSFTPTTLT NGTSHSPTAL
     NGAPSPPNGF SNGPSSSSSS SLANQQLPPA CGARQLSKLK RFLTTLQQFG NDISPEIGER
     VRTLVLGLVN STLTIEEFHS KLQEATNFPL RPFVIPFLKA NLPLLQRELL HCARLAKQSP
     AQYLAQHEQL LLDASTTSPV DSSELLLDVN ENGKRRTPDR TKENGFDREP LHSEHPSKRP
     CTISPGQRYS PNNGLSYQPN GLPHPTPPPP QHYRLDDMAI AHHYRDSYRH PSHRDLRDRN
     RPMGLHGTRQ EEMIDHRLTD REWAEEWKHL DHLLNCIMDM VEKTRRSLTV LRRCQEADRE
     ELNYWIRRYS DAEDLKKGGG SSSSHSRQQS PVNPDPVALD AHREFLHRPA SGYVPEEIWK
     KAEEAVNEVK RQAMTELQKA VSEAERKAHD MITTERAKME RTVAEAKRQA AEDALAVINQ
     QEDSSESCWN CGRKASETCS GCNTARYCGS FCQHKDWEKH HHICGQTLQA QQQGDTPAVS
     SSVTPNSGAG SPMDTPPAAT PRSTTPGTPS TIETTPR
//
ID   MTG8_HUMAN              Reviewed;         604 AA.
AC   Q06455; B7Z4P4; E7EPN4; O14784; Q06456; Q14873; Q16239; Q16346;
AC   Q16347; Q6IBL1; Q6NXH1; Q7Z4J5; Q92479; Q9BRZ0;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 2.
DT   28-FEB-2018, entry version 186.
DE   RecName: Full=Protein CBFA2T1;
DE   AltName: Full=Cyclin-D-related protein;
DE   AltName: Full=Eight twenty one protein;
DE   AltName: Full=Protein ETO;
DE   AltName: Full=Protein MTG8;
DE   AltName: Full=Zinc finger MYND domain-containing protein 2;
GN   Name=RUNX1T1; Synonyms=AML1T1, CBFA2T1, CDR, ETO, MTG8, ZMYND2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM MTG8B), AND VARIANT AML1-MTG8/ETO
RP   FUSION IN AML-M2.
RC   TISSUE=Fetal brain;
RX   PubMed=8334990;
RA   Miyoshi H., Kozu T., Shimizu K., Enomoto K., Maseki N., Kaneko Y.,
RA   Kamada N., Ohki M.;
RT   "The t(8;21) translocation in acute myeloid leukemia results in
RT   production of an AML1-MTG8 fusion transcript.";
RL   EMBO J. 12:2715-2721(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM MTG8B), AND
RP   ALTERNATIVE SPLICING (ISOFORMS MTG8A-2 AND MTG8B-2).
RX   PubMed=9661669; DOI=10.1016/S0378-1119(98)00141-3;
RA   Wolford J.K., Prochazka M.;
RT   "Structure and expression of the human MTG8/ETO gene.";
RL   Gene 212:103-109(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM MTG8A).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S.,
RA   Garber M., Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A.,
RA   Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Allen N.R., Anderson S., Asakawa T., Blechschmidt K., Bloom T.,
RA   Borowsky M.L., Butler J., Cook A., Corum B., DeArellano K.,
RA   DeCaprio D., Dooley K.T., Dorris L. III, Engels R., Gloeckner G.,
RA   Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., Jaffe D.B.,
RA   Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C.,
RA   O'Leary S.B., O'Neill K., Parker S.C.J., Polley A., Raymond C.K.,
RA   Reichwald K., Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R.,
RA   Smith C.L., Sneddon T.P., Talamas J.A., Tenzin P., Topham K.,
RA   Venkataraman V., Wen G., Yamazaki S., Young S.K., Zeng Q.,
RA   Zimmer A.R., Rosenthal A., Birren B.W., Platzer M., Shimizu N.,
RA   Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 31-604.
RX   PubMed=8137293;
RA   Erickson P.F., Robinson M., Owens G., Drabkin H.A.;
RT   "The ETO portion of acute myeloid leukemia t(8;21) fusion transcript
RT   encodes a highly evolutionarily conserved putative transcription
RT   factor.";
RL   Cancer Res. 54:1782-1786(1994).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 334-432, AND VARIANT
RP   AML1-MTG8/ETO FUSION.
RX   PubMed=7919324;
RA   Tighe J.E., Calabi F.;
RT   "Alternative, out-of-frame runt/MTG8 transcripts are encoded by the
RT   derivative (8) chromosome in the t(8;21) of acute myeloid leukemia
RT   M2.";
RL   Blood 84:2115-2121(1994).
RN   [11]
RP   INTERACTION WITH ATN1, SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=10973986; DOI=10.1083/jcb.150.5.939;
RA   Wood J.D., Nucifora F.C. Jr., Duan K., Zhang C., Wang J., Kim Y.,
RA   Schilling G., Sacchi N., Liu J.M., Ross C.A.;
RT   "Atrophin-1, the dentato-rubral and pallido-luysian atrophy gene
RT   product, interacts with ETO/MTG8 in the nuclear matrix and represses
RT   transcription.";
RL   J. Cell Biol. 150:939-948(2000).
RN   [12]
RP   INTERACTION WITH CBFA2T3.
RX   PubMed=12242670; DOI=10.1038/sj.onc.1205882;
RA   Hoogeveen A.T., Rossetti S., Stoyanova V., Schonkeren J., Fenaroli A.,
RA   Schiaffonati L., van Unen L., Sacchi N.;
RT   "The transcriptional corepressor MTG16a contains a novel nucleolar
RT   targeting sequence deranged in t(16; 21)-positive myeloid
RT   malignancies.";
RL   Oncogene 21:6703-6712(2002).
RN   [13]
RP   REVIEW.
RX   PubMed=12559562; DOI=10.1016/S0378-1119(02)01172-1;
RA   Davis J.N., McGhee L., Meyers S.;
RT   "The ETO (MTG8) gene family.";
RL   Gene 303:1-10(2003).
RN   [14]
RP   REVIEW.
RX   PubMed=15203199; DOI=10.1016/j.ygeno.2004.02.011;
RA   Rossetti S., Hoogeveen A.T., Sacchi N.;
RT   "The MTG proteins: chromatin repression players with a passion for
RT   networking.";
RL   Genomics 84:1-9(2004).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [16]
RP   SUBUNIT.
RX   PubMed=19202074; DOI=10.1073/pnas.0810558106;
RA   Kwok C., Zeisig B.B., Qiu J., Dong S., So C.W.;
RT   "Transforming activity of AML1-ETO is independent of CBFbeta and ETO
RT   interaction but requires formation of homo-oligomeric complexes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:2853-2858(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-41 AND SER-417, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [18]
RP   FUNCTION.
RX   PubMed=23251453; DOI=10.1371/journal.pone.0051205;
RA   Barrett C.W., Smith J.J., Lu L.C., Markham N., Stengel K.R.,
RA   Short S.P., Zhang B., Hunt A.A., Fingleton B.M., Carnahan R.H.,
RA   Engel M.E., Chen X., Beauchamp R.D., Wilson K.T., Hiebert S.W.,
RA   Reynolds A.B., Williams C.S.;
RT   "Kaiso directs the transcriptional corepressor MTG16 to the Kaiso
RT   binding site in target promoters.";
RL   PLoS ONE 7:E51205-E51205(2012).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 335-403, SUBUNIT, NRH2
RP   DOMAIN, INTERACTION WITH HDAC1; HDAC2; HDAC3; TCF12; NCOR1; NCOR2;
RP   SIN3A; CBFA2T2 AND CBFA2T3, AND MUTAGENESIS OF LEU-345; LEU-357;
RP   LEU-360; LEU-361; LEU-375; LEU-378 AND LEU-389.
RX   PubMed=16616331; DOI=10.1016/j.ccr.2006.03.012;
RA   Liu Y., Cheney M.D., Gaudet J.J., Chruszcz M., Lukasik S.M.,
RA   Sugiyama D., Lary J., Cole J., Dauter Z., Minor W., Speck N.A.,
RA   Bushweller J.H.;
RT   "The tetramer structure of the Nervy homology two domain, NHR2, is
RT   critical for AML1/ETO's activity.";
RL   Cancer Cell 9:249-260(2006).
RN   [20]
RP   STRUCTURE BY NMR OF 120-222, INTERACTION WITH TCF12, FUNCTION, AND
RP   MUTAGENESIS OF LYS-125; LEU-126; ARG-128; PHE-129; ARG-178 AND
RP   PHE-184.
RX   PubMed=16803958; DOI=10.1073/pnas.0603463103;
RA   Plevin M.J., Zhang J., Guo C., Roeder R.G., Ikura M.;
RT   "The acute myeloid leukemia fusion protein AML1-ETO targets E proteins
RT   via a paired amphipathic helix-like TBP-associated factor homology
RT   domain.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:10242-10247(2006).
RN   [21]
RP   STRUCTURE BY NMR OF 510-559 IN COMPLEX WITH ZINC IONS AND NCOR2,
RP   MUTAGENESIS OF HIS-547, AND INTERACTION WITH NCOR1 AND NCOR2.
RX   PubMed=17560331; DOI=10.1016/j.ccr.2007.04.010;
RA   Liu Y., Chen W., Gaudet J., Cheney M.D., Roudaia L., Cierpicki T.,
RA   Klet R.C., Hartman K., Laue T.M., Speck N.A., Bushweller J.H.;
RT   "Structural basis for recognition of SMRT/N-CoR by the MYND domain and
RT   its contribution to AML1/ETO's activity.";
RL   Cancer Cell 11:483-497(2007).
RN   [22]
RP   STRUCTURE BY NMR OF 119-225, INTERACTION WITH NCOR1 AND TCF12,
RP   MUTAGENESIS OF PHE-129; PHE-136; GLN-170; THR-173; PHE-175 AND
RP   LEU-177, AND DOMAIN.
RX   PubMed=17572682; DOI=10.1038/nsmb1258;
RA   Wei Y., Liu S., Lausen J., Woodrell C., Cho S., Biris N.,
RA   Kobayashi N., Wei Y., Yokoyama S., Werner M.H.;
RT   "A TAF4-homology domain from the corepressor ETO is a docking platform
RT   for positive and negative regulators of transcription.";
RL   Nat. Struct. Mol. Biol. 14:653-661(2007).
RN   [23]
RP   STRUCTURE BY NMR OF 505-551.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of ZF-MYND domain of protein CBFA2TI (protein
RT   MTG8).";
RL   Submitted (OCT-2006) to the PDB data bank.
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.91 ANGSTROMS) OF 338-400 IN COMPLEX WITH
RP   TCF12, FUNCTION, SUBUNIT, AND MUTAGENESIS OF LEU-345; 352-GLU-GLU-353;
RP   LEU-357; LEU-360; LEU-361; LEU-375; LEU-378; 379-ARG--CYS-381 AND
RP   LEU-389.
RX   PubMed=23812588; DOI=10.1038/nature12287;
RA   Sun X.J., Wang Z., Wang L., Jiang Y., Kost N., Soong T.D., Chen W.Y.,
RA   Tang Z., Nakadai T., Elemento O., Fischle W., Melnick A., Patel D.J.,
RA   Nimer S.D., Roeder R.G.;
RT   "A stable transcription factor complex nucleated by oligomeric AML1-
RT   ETO controls leukaemogenesis.";
RL   Nature 500:93-97(2013).
RN   [25]
RP   VARIANT AML1-MTG8/ETO FUSION IN AML-M2.
RX   PubMed=7541640; DOI=10.1002/gcc.2870130105;
RA   Era T., Asou N., Kunisada T., Yamasaki H., Asou H., Kamada N.,
RA   Nishikawa S., Yamaguchi K., Takatsuki K.;
RT   "Identification of two transcripts of AML1/ETO-fused gene in t(8;21)
RT   leukemic cells and expression of wild-type ETO gene in hematopoietic
RT   cells.";
RL   Genes Chromosomes Cancer 13:25-33(1995).
RN   [26]
RP   VARIANT AML1-MTG8/ETO FUSION IN AML-M2.
RX   PubMed=8353289;
RA   Kozu T., Miyoshi H., Shimizu K., Maseki N., Kaneko Y., Asou H.,
RA   Kamada N., Ohki M.;
RT   "Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute
RT   myeloid leukemia detected by reverse transcription polymerase chain
RT   reaction.";
RL   Blood 82:1270-1276(1993).
RN   [27]
RP   VARIANT AML1-MTG8/ETO FUSION IN AML-M2.
RX   PubMed=1423235; DOI=10.1016/0165-4608(92)90384-K;
RA   Nisson P.E., Watkins P.C., Sacchi N.;
RT   "Transcriptionally active chimeric gene derived from the fusion of the
RT   AML1 gene and a novel gene on chromosome 8 in t(8;21) leukemic
RT   cells.";
RL   Cancer Genet. Cytogenet. 63:81-88(1992).
RN   [28]
RP   VARIANTS [LARGE SCALE ANALYSIS] TRP-386; TRP-395 AND VAL-471.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Transcriptional corepressor which facilitates
CC       transcriptional repression via its association with DNA-binding
CC       transcription factors and recruitment of other corepressors and
CC       histone-modifying enzymes (PubMed:12559562, PubMed:15203199). Can
CC       repress the expression of MMP7 in a ZBTB33-dependent manner
CC       (PubMed:23251453). Can repress transactivation mediated by TCF12
CC       (PubMed:16803958). Acts as a negative regulator of adipogenesis
CC       (By similarity). The AML1-MTG8/ETO fusion protein frequently found
CC       in leukemic cells is involved in leukemogenesis and contributes to
CC       hematopoietic stem/progenitor cell self-renewal (PubMed:23812588).
CC       {ECO:0000250|UniProtKB:Q61909, ECO:0000269|PubMed:10973986,
CC       ECO:0000269|PubMed:16803958, ECO:0000269|PubMed:23251453,
CC       ECO:0000269|PubMed:23812588, ECO:0000303|PubMed:12559562,
CC       ECO:0000303|PubMed:15203199}.
CC   -!- SUBUNIT: Homooligomer. Homotetramerization is mediated by nervy
CC       homology region 2 (NRH2). Can interact with CBFA2T2 and CBFA2T3;
CC       heterotetramerization between members of the CBFA2T family is
CC       proposed. Interacts with TCF12, SIN3A, HDAC1, HDAC2, HDAC3, NCOR1,
CC       NCOR2. Interacts with ATN1 (via its N-terminus); the interaction
CC       enhances the transcriptional repression. AML1-MTG8/ETO fusion
CC       protein interacts with CBFB. AML1-MTG8/ETO is part of a stable
CC       transcription factor complex AETFC in leukemic cells; AETFC
CC       formation seems to be involved in recruitment of EP300. AML1-
CC       MTG8/ETO nervy homology region 2-mediated oligomerization is
CC       proposed to be homotypic, required for AML1-MTG8/ETO-mediated
CC       tranformation of primary hematopoietic cells and is required for
CC       AML1-MTG8/ETO interaction with TCF12.
CC       {ECO:0000269|PubMed:10973986, ECO:0000269|PubMed:12242670,
CC       ECO:0000269|PubMed:16616331, ECO:0000269|PubMed:16803958,
CC       ECO:0000269|PubMed:17560331, ECO:0000269|PubMed:17572682,
CC       ECO:0000269|PubMed:19202074, ECO:0000269|PubMed:23812588}.
CC   -!- INTERACTION:
CC       G2XKQ0:-; NbExp=4; IntAct=EBI-11984663, EBI-10175576;
CC       Q9P2A4:ABI3; NbExp=3; IntAct=EBI-10224192, EBI-742038;
CC       Q0VDD7:C19orf57; NbExp=3; IntAct=EBI-10224192, EBI-741210;
CC       Q8IYA8:CCDC36; NbExp=3; IntAct=EBI-10224192, EBI-8638439;
CC       Q8N684:CPSF7; NbExp=3; IntAct=EBI-10224192, EBI-746909;
CC       Q96BA8:CREB3L1; NbExp=3; IntAct=EBI-10224192, EBI-6942903;
CC       Q5JST6:EFHC2; NbExp=3; IntAct=EBI-10224192, EBI-2349927;
CC       Q12929:EPS8; NbExp=3; IntAct=EBI-10224192, EBI-375576;
CC       Q14687:GSE1; NbExp=3; IntAct=EBI-10224192, EBI-372619;
CC       Q9NSC5:HOMER3; NbExp=3; IntAct=EBI-10224192, EBI-748420;
CC       O60711:LPXN; NbExp=3; IntAct=EBI-10224192, EBI-744222;
CC       Q9BRK4:LZTS2; NbExp=3; IntAct=EBI-10224192, EBI-741037;
CC       P50222:MEOX2; NbExp=3; IntAct=EBI-10224192, EBI-748397;
CC       Q9UJV3-2:MID2; NbExp=3; IntAct=EBI-10224192, EBI-10172526;
CC       O75376:NCOR1; NbExp=5; IntAct=EBI-743342, EBI-347233;
CC       Q7Z6G3-2:NECAB2; NbExp=3; IntAct=EBI-10224192, EBI-10172876;
CC       Q9GZV8:PRDM14; NbExp=3; IntAct=EBI-10224192, EBI-3957793;
CC       Q9Y4B4:RAD54L2; NbExp=4; IntAct=EBI-11984663, EBI-948156;
CC       Q9QX47:Son (xeno); NbExp=4; IntAct=EBI-743342, EBI-643037;
CC       P08047:SP1; NbExp=2; IntAct=EBI-743342, EBI-298336;
CC       Q8NA61:SPERT; NbExp=3; IntAct=EBI-10224192, EBI-741724;
CC       O43597:SPRY2; NbExp=3; IntAct=EBI-10224192, EBI-742487;
CC       O75558:STX11; NbExp=3; IntAct=EBI-10224192, EBI-714135;
CC       Q99081-3:TCF12; NbExp=2; IntAct=EBI-10224192, EBI-11952764;
CC       Q8IWZ5:TRIM42; NbExp=3; IntAct=EBI-10224192, EBI-5235829;
CC       Q5VZL5:ZMYM4; NbExp=3; IntAct=EBI-10224192, EBI-2514659;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-
CC       ProRule:PRU00440, ECO:0000269|PubMed:10973986}. Note=Colocalizes
CC       with ATN1 in discrete nuclear dots.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=MTG8B;
CC         IsoId=Q06455-1; Sequence=Displayed;
CC       Name=MTG8A;
CC         IsoId=Q06455-2; Sequence=VSP_003327;
CC       Name=3;
CC         IsoId=Q06455-3; Sequence=VSP_044558;
CC       Name=4;
CC         IsoId=Q06455-4; Sequence=VSP_045442;
CC       Name=MTG8B-2;
CC         IsoId=Q06455-5; Sequence=VSP_058512, VSP_058513;
CC       Name=MTG8A-2;
CC         IsoId=Q06455-6; Sequence=VSP_003327, VSP_058512, VSP_058513;
CC   -!- TISSUE SPECIFICITY: Most abundantly expressed in brain. Lower
CC       levels in lung, heart, testis and ovary.
CC   -!- DOMAIN: The TAFH domain mediates interaction with transcription
CC       regulators. {ECO:0000269|PubMed:17572682}.
CC   -!- DOMAIN: Nervy homology region 2 (NHR2) mediates homo- and possibly
CC       heterotypic oligomerization by forming a four-helix bundle
CC       tetrameric structure. {ECO:0000269|PubMed:16616331}.
CC   -!- DISEASE: Note=A chromosomal aberration involving RUNX1T1 is a
CC       cause of acute myeloid leukemia (AML-M2). Translocation
CC       t(8;21)(q22;q22) with RUNX1/AML1. {ECO:0000269|PubMed:1423235,
CC       ECO:0000269|PubMed:7541640, ECO:0000269|PubMed:8334990,
CC       ECO:0000269|PubMed:8353289}.
CC   -!- SIMILARITY: Belongs to the CBFA2T family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH05850.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BAA03247.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ETOID26.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D14821; BAA03558.1; -; mRNA.
DR   EMBL; D13979; BAA03089.1; ALT_SEQ; mRNA.
DR   EMBL; D14289; BAA03247.1; ALT_INIT; mRNA.
DR   EMBL; AF018282; AAC28932.1; -; Genomic_DNA.
DR   EMBL; AF018271; AAC28932.1; JOINED; Genomic_DNA.
DR   EMBL; AF018272; AAC28932.1; JOINED; Genomic_DNA.
DR   EMBL; AF018273; AAC28932.1; JOINED; Genomic_DNA.
DR   EMBL; AF018274; AAC28932.1; JOINED; Genomic_DNA.
DR   EMBL; AF018275; AAC28932.1; JOINED; Genomic_DNA.
DR   EMBL; AF018276; AAC28932.1; JOINED; Genomic_DNA.
DR   EMBL; AF018277; AAC28932.1; JOINED; Genomic_DNA.
DR   EMBL; AF018278; AAC28932.1; JOINED; Genomic_DNA.
DR   EMBL; AF018279; AAC28932.1; JOINED; Genomic_DNA.
DR   EMBL; AF018281; AAC28932.1; JOINED; Genomic_DNA.
DR   EMBL; AF018282; AAC28931.1; -; Genomic_DNA.
DR   EMBL; AF018270; AAC28931.1; JOINED; Genomic_DNA.
DR   EMBL; AF018272; AAC28931.1; JOINED; Genomic_DNA.
DR   EMBL; AF018273; AAC28931.1; JOINED; Genomic_DNA.
DR   EMBL; AF018274; AAC28931.1; JOINED; Genomic_DNA.
DR   EMBL; AF018275; AAC28931.1; JOINED; Genomic_DNA.
DR   EMBL; AF018276; AAC28931.1; JOINED; Genomic_DNA.
DR   EMBL; AF018277; AAC28931.1; JOINED; Genomic_DNA.
DR   EMBL; AF018278; AAC28931.1; JOINED; Genomic_DNA.
DR   EMBL; AF018279; AAC28931.1; JOINED; Genomic_DNA.
DR   EMBL; AF018281; AAC28931.1; JOINED; Genomic_DNA.
DR   EMBL; AF018283; AAC26143.1; -; mRNA.
DR   EMBL; AK297616; BAH12630.1; -; mRNA.
DR   EMBL; BT009871; AAP88873.1; -; mRNA.
DR   EMBL; CR456792; CAG33073.1; -; mRNA.
DR   EMBL; AC103680; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC104339; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471060; EAW91685.1; -; Genomic_DNA.
DR   EMBL; BC005850; AAH05850.1; ALT_INIT; mRNA.
DR   EMBL; BC067078; AAH67078.2; -; mRNA.
DR   EMBL; AF181450; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; D43638; BAA07755.1; -; mRNA.
DR   EMBL; X79990; CAA56311.1; -; mRNA.
DR   EMBL; S74096; AAB32126.1; -; Genomic_DNA.
DR   EMBL; S74092; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; S78158; AAB34819.2; ALT_SEQ; mRNA.
DR   EMBL; S78159; AAB34820.2; ALT_SEQ; mRNA.
DR   EMBL; D14822; BAA03559.1; ALT_SEQ; mRNA.
DR   EMBL; D14823; BAA03560.1; ALT_SEQ; mRNA.
DR   EMBL; S50186; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS47891.1; -. [Q06455-2]
DR   CCDS; CCDS56544.1; -. [Q06455-3]
DR   CCDS; CCDS6256.1; -. [Q06455-1]
DR   CCDS; CCDS6257.1; -. [Q06455-4]
DR   PIR; A57784; A57784.
DR   PIR; C57784; C57784.
DR   RefSeq; NP_001185554.1; NM_001198625.1. [Q06455-2]
DR   RefSeq; NP_001185555.1; NM_001198626.1. [Q06455-1]
DR   RefSeq; NP_001185556.1; NM_001198627.1. [Q06455-1]
DR   RefSeq; NP_001185557.1; NM_001198628.1. [Q06455-1]
DR   RefSeq; NP_001185558.1; NM_001198629.1. [Q06455-1]
DR   RefSeq; NP_001185559.1; NM_001198630.1. [Q06455-1]
DR   RefSeq; NP_001185560.1; NM_001198631.1. [Q06455-1]
DR   RefSeq; NP_001185561.1; NM_001198632.1. [Q06455-2]
DR   RefSeq; NP_001185562.1; NM_001198633.1.
DR   RefSeq; NP_001185563.1; NM_001198634.1. [Q06455-3]
DR   RefSeq; NP_001185608.1; NM_001198679.1.
DR   RefSeq; NP_004340.1; NM_004349.3. [Q06455-2]
DR   RefSeq; NP_783552.1; NM_175634.2. [Q06455-1]
DR   RefSeq; NP_783553.1; NM_175635.2. [Q06455-4]
DR   RefSeq; NP_783554.1; NM_175636.2. [Q06455-4]
DR   RefSeq; XP_006716739.1; XM_006716676.3. [Q06455-4]
DR   RefSeq; XP_011515653.1; XM_011517351.2. [Q06455-1]
DR   RefSeq; XP_011515654.1; XM_011517352.2. [Q06455-2]
DR   RefSeq; XP_011515655.1; XM_011517353.2. [Q06455-4]
DR   RefSeq; XP_016869420.1; XM_017013931.1. [Q06455-1]
DR   RefSeq; XP_016869421.1; XM_017013932.1. [Q06455-2]
DR   RefSeq; XP_016869422.1; XM_017013933.1. [Q06455-2]
DR   RefSeq; XP_016869423.1; XM_017013934.1. [Q06455-4]
DR   RefSeq; XP_016869424.1; XM_017013935.1. [Q06455-4]
DR   RefSeq; XP_016869425.1; XM_017013936.1. [Q06455-4]
DR   RefSeq; XP_016869426.1; XM_017013937.1. [Q06455-4]
DR   UniGene; Hs.368431; -.
DR   UniGene; Hs.739194; -.
DR   PDB; 1WQ6; X-ray; 2.00 A; A/B=335-403.
DR   PDB; 2DJ8; NMR; -; A=505-551.
DR   PDB; 2H7B; NMR; -; A=120-222.
DR   PDB; 2KNH; NMR; -; A=119-216.
DR   PDB; 2KYG; NMR; -; C=437-467.
DR   PDB; 2OD1; NMR; -; A=510-559.
DR   PDB; 2ODD; NMR; -; A=510-559.
DR   PDB; 2PP4; NMR; -; A=119-225.
DR   PDB; 4JOL; X-ray; 2.91 A; A/B/C/D=338-400.
DR   PDBsum; 1WQ6; -.
DR   PDBsum; 2DJ8; -.
DR   PDBsum; 2H7B; -.
DR   PDBsum; 2KNH; -.
DR   PDBsum; 2KYG; -.
DR   PDBsum; 2OD1; -.
DR   PDBsum; 2ODD; -.
DR   PDBsum; 2PP4; -.
DR   PDBsum; 4JOL; -.
DR   ProteinModelPortal; Q06455; -.
DR   SMR; Q06455; -.
DR   BioGrid; 107310; 61.
DR   DIP; DIP-29401N; -.
DR   ELM; Q06455; -.
DR   IntAct; Q06455; 72.
DR   MINT; Q06455; -.
DR   STRING; 9606.ENSP00000402257; -.
DR   iPTMnet; Q06455; -.
DR   PhosphoSitePlus; Q06455; -.
DR   BioMuta; RUNX1T1; -.
DR   DMDM; 2498595; -.
DR   MaxQB; Q06455; -.
DR   PaxDb; Q06455; -.
DR   PeptideAtlas; Q06455; -.
DR   PRIDE; Q06455; -.
DR   DNASU; 862; -.
DR   Ensembl; ENST00000265814; ENSP00000265814; ENSG00000079102. [Q06455-1]
DR   Ensembl; ENST00000360348; ENSP00000353504; ENSG00000079102. [Q06455-4]
DR   Ensembl; ENST00000396218; ENSP00000379520; ENSG00000079102. [Q06455-2]
DR   Ensembl; ENST00000422361; ENSP00000390137; ENSG00000079102. [Q06455-4]
DR   Ensembl; ENST00000518844; ENSP00000430728; ENSG00000079102. [Q06455-2]
DR   Ensembl; ENST00000520724; ENSP00000428742; ENSG00000079102. [Q06455-3]
DR   Ensembl; ENST00000523629; ENSP00000428543; ENSG00000079102. [Q06455-1]
DR   Ensembl; ENST00000613302; ENSP00000481799; ENSG00000079102. [Q06455-1]
DR   Ensembl; ENST00000613886; ENSP00000478331; ENSG00000079102. [Q06455-2]
DR   Ensembl; ENST00000614812; ENSP00000481315; ENSG00000079102. [Q06455-1]
DR   Ensembl; ENST00000617740; ENSP00000481112; ENSG00000079102. [Q06455-1]
DR   GeneID; 862; -.
DR   KEGG; hsa:862; -.
DR   UCSC; uc003yfc.3; human. [Q06455-1]
DR   CTD; 862; -.
DR   DisGeNET; 862; -.
DR   EuPathDB; HostDB:ENSG00000079102.16; -.
DR   GeneCards; RUNX1T1; -.
DR   HGNC; HGNC:1535; RUNX1T1.
DR   HPA; HPA049852; -.
DR   HPA; HPA070951; -.
DR   MalaCards; RUNX1T1; -.
DR   MIM; 133435; gene.
DR   neXtProt; NX_Q06455; -.
DR   OpenTargets; ENSG00000079102; -.
DR   Orphanet; 102724; 'Acute myeloid leukemia with t(8;21)(q22;q22) translocation'.
DR   PharmGKB; PA26111; -.
DR   eggNOG; ENOG410IG1Z; Eukaryota.
DR   eggNOG; ENOG410XR30; LUCA.
DR   GeneTree; ENSGT00390000013479; -.
DR   HOGENOM; HOG000049245; -.
DR   HOVERGEN; HBG000169; -.
DR   InParanoid; Q06455; -.
DR   KO; K10053; -.
DR   PhylomeDB; Q06455; -.
DR   TreeFam; TF106303; -.
DR   SIGNOR; Q06455; -.
DR   ChiTaRS; RUNX1T1; human.
DR   EvolutionaryTrace; Q06455; -.
DR   GeneWiki; RUNX1T1; -.
DR   GenomeRNAi; 862; -.
DR   PRO; PR:Q06455; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000079102; -.
DR   ExpressionAtlas; Q06455; baseline and differential.
DR   Genevisible; Q06455; HS.
DR   GO; GO:0016363; C:nuclear matrix; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; TAS:ProtInc.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003714; F:transcription corepressor activity; TAS:UniProtKB.
DR   GO; GO:0006091; P:generation of precursor metabolites and energy; TAS:ProtInc.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; ISS:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   InterPro; IPR013290; CBFA2T1.
DR   InterPro; IPR013289; CBFA2T1/2/3.
DR   InterPro; IPR014896; NHR2.
DR   InterPro; IPR037249; TAFH/NHR1_dom_sf.
DR   InterPro; IPR003894; TAFH_NHR1.
DR   InterPro; IPR002893; Znf_MYND.
DR   PANTHER; PTHR10379; PTHR10379; 1.
DR   PANTHER; PTHR10379:SF5; PTHR10379:SF5; 1.
DR   Pfam; PF08788; NHR2; 1.
DR   Pfam; PF07531; TAFH; 1.
DR   Pfam; PF01753; zf-MYND; 1.
DR   PRINTS; PR01875; ETOFAMILY.
DR   PRINTS; PR01876; MTG8PROTEIN.
DR   SMART; SM00549; TAFH; 1.
DR   SUPFAM; SSF158553; SSF158553; 1.
DR   PROSITE; PS51119; TAFH; 1.
DR   PROSITE; PS01360; ZF_MYND_1; 1.
DR   PROSITE; PS50865; ZF_MYND_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Chromosomal rearrangement;
KW   Complete proteome; DNA-binding; Metal-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Proto-oncogene; Reference proteome;
KW   Repressor; Transcription; Transcription regulation; Zinc; Zinc-finger.
FT   CHAIN         1    604       Protein CBFA2T1.
FT                                /FTId=PRO_0000218299.
FT   DOMAIN      120    215       TAFH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00440}.
FT   ZN_FING     515    551       MYND-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00134}.
FT   REGION      337    383       Important for oligomerization.
FT   REGION      337    383       Nervy homology region 2 (NHR2).
FT                                {ECO:0000303|PubMed:12559562}.
FT   REGION      443    492       Nervy homology region 3 (NHR3).
FT                                {ECO:0000303|PubMed:12559562}.
FT   COMPBIAS     57     60       Poly-Pro.
FT   COMPBIAS    102    108       Poly-Ser.
FT   COMPBIAS    290    297       Poly-Pro.
FT   COMPBIAS    408    413       Poly-Ser.
FT   SITE         30     31       Breakpoint for translocation to form
FT                                AML1-MTG8 in AML-M2.
FT                                {ECO:0000269|PubMed:8334990}.
FT   MOD_RES      41     41       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES     417    417       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   VAR_SEQ       1     37       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|Ref.4}.
FT                                /FTId=VSP_045442.
FT   VAR_SEQ       1     29       MISVKRNTWRALSLVIGDCRKKGNFEYCQ -> MCHPDKAF
FT                                TSDKLQCVFNEYKAAVWVPPRPRPLSRAPLPE (in
FT                                isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_044558.
FT   VAR_SEQ       1     29       MISVKRNTWRALSLVIGDCRKKGNFEYCQ -> MP (in
FT                                isoform MTG8A and isoform MTG8A-2).
FT                                {ECO:0000303|Ref.5}.
FT                                /FTId=VSP_003327.
FT   VAR_SEQ     427    427       D -> G (in isoform MTG8B-2 and isoform
FT                                MTG8A-2). {ECO:0000303|PubMed:9661669}.
FT                                /FTId=VSP_058512.
FT   VAR_SEQ     428    604       Missing (in isoform MTG8B-2 and isoform
FT                                MTG8A-2). {ECO:0000303|PubMed:9661669}.
FT                                /FTId=VSP_058513.
FT   VARIANT     386    386       R -> W (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036321.
FT   VARIANT     395    395       R -> W (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036322.
FT   VARIANT     471    471       A -> V (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036323.
FT   MUTAGEN     125    125       K->A,D: Loss of interaction with TCF12.
FT                                {ECO:0000269|PubMed:16803958}.
FT   MUTAGEN     126    126       L->A: Loss of interaction with TCF12.
FT                                {ECO:0000269|PubMed:16803958}.
FT   MUTAGEN     128    128       R->D: Loss of interaction with TCF12.
FT                                {ECO:0000269|PubMed:16803958}.
FT   MUTAGEN     129    129       F->A: Loss of interaction with TCF12.
FT                                {ECO:0000269|PubMed:16803958,
FT                                ECO:0000269|PubMed:17572682}.
FT   MUTAGEN     129    129       F->K: Abolishes interaction with
FT                                corepressor.
FT                                {ECO:0000269|PubMed:16803958,
FT                                ECO:0000269|PubMed:17572682}.
FT   MUTAGEN     136    136       F->A: Abolishes interaction with
FT                                corepressor.
FT                                {ECO:0000269|PubMed:17572682}.
FT   MUTAGEN     170    170       Q->A: Abolishes interaction with
FT                                corepressor.
FT                                {ECO:0000269|PubMed:17572682}.
FT   MUTAGEN     173    173       T->Q: Abolishes interaction with
FT                                corepressor.
FT                                {ECO:0000269|PubMed:17572682}.
FT   MUTAGEN     175    175       F->A: Abolishes interaction with
FT                                corepressor.
FT                                {ECO:0000269|PubMed:17572682}.
FT   MUTAGEN     177    177       L->A: Abolishes interaction with
FT                                corepressor.
FT                                {ECO:0000269|PubMed:17572682}.
FT   MUTAGEN     178    178       R->A,D: Loss of interaction with TCF12.
FT                                {ECO:0000269|PubMed:16803958}.
FT   MUTAGEN     184    184       F->A: Loss of interaction with TCF12.
FT                                {ECO:0000269|PubMed:16803958}.
FT   MUTAGEN     345    345       L->E: Disrupts tetramerization, disrupts
FT                                AML1-MTG8/ETO interaction with TCF12,
FT                                decreases AML1-MTG8/ETO interaction with
FT                                RUNX1T1, CBFA2T3 and CBFA2T2; when
FT                                associated with R-357; R-360; E-361; E-
FT                                375; R-378 and R-389.
FT                                {ECO:0000269|PubMed:16616331,
FT                                ECO:0000269|PubMed:23812588}.
FT   MUTAGEN     352    353       EE->AA: Decreases interaction with TCF12,
FT                                no effect on oligomerization. Impairs
FT                                AML1-MTG8/ETO activity in hematopoietic
FT                                stem/progenitor cell self-renewal but no
FT                                effect in inhibiting differentiation;
FT                                when associated with 379-A--A-381.
FT                                {ECO:0000269|PubMed:23812588}.
FT   MUTAGEN     357    357       L->R: Disrupts tetramerization, disrupts
FT                                AML1-MTG8/ETO interaction with TCF12,
FT                                decreases AML1-MTG8/ETO interaction with
FT                                RUNX1T1, CBFA2T3 and CBFA2T2; when
FT                                associated with E-345; R-360; E- 61; E-
FT                                375; R-378 and R-389.
FT                                {ECO:0000269|PubMed:16616331,
FT                                ECO:0000269|PubMed:23812588}.
FT   MUTAGEN     360    360       L->R: Disrupts tetramerization, disrupts
FT                                AML1-MTG8/ETO interaction with TCF12,
FT                                decreases AML1-MTG8/ETO interaction with
FT                                RUNX1T1, CBFA2T3 and CBFA2T2; when
FT                                associated with E-345; R-357; E-361; E-
FT                                375; R-378 and R-389.
FT                                {ECO:0000269|PubMed:16616331,
FT                                ECO:0000269|PubMed:23812588}.
FT   MUTAGEN     361    361       L->E: Disrupts tetramerization, disrupts
FT                                AML1-MTG8/ETO interaction with TCF12,
FT                                decreases AML1-MTG8/ETO interaction with
FT                                RUNX1T1, CBFA2T3 and CBFA2T2; when
FT                                associated with E-345; R-357; R-360; E-
FT                                375; R-378 and R-389.
FT                                {ECO:0000269|PubMed:16616331,
FT                                ECO:0000269|PubMed:23812588}.
FT   MUTAGEN     375    375       L->E: Disrupts tetramerization, disrupts
FT                                AML1-MTG8/ETO interaction with TCF12,
FT                                decreases AML1-MTG8/ETO interaction with
FT                                RUNX1T1, CBFA2T3 and CBFA2T2; when
FT                                associated with E-345; R-357; R-360; E-
FT                                361; R-378 and R-389.
FT                                {ECO:0000269|PubMed:16616331,
FT                                ECO:0000269|PubMed:23812588}.
FT   MUTAGEN     378    378       L->R: Disrupts tetramerization, disrupts
FT                                AML1-MTG8/ETO interaction with TCF12,
FT                                decreases AML1-MTG8/ETO interaction with
FT                                RUNX1T1, CBFA2T3 and CBFA2T2 when
FT                                associated with E-345; R-357; R-360; E-
FT                                361; E-375 and R-389.
FT                                {ECO:0000269|PubMed:16616331,
FT                                ECO:0000269|PubMed:23812588}.
FT   MUTAGEN     379    381       RRC->AAA: Disrupts interaction with
FT                                TCF12, no effect on oligomerization.
FT                                Impairs AML1-MTG8/ETO activity in
FT                                hematopoietic stem/progenitor cell self-
FT                                renewal but no effect in inhibiting
FT                                differentiation; when associated with
FT                                352-E-E-353.
FT                                {ECO:0000269|PubMed:23812588}.
FT   MUTAGEN     389    389       L->R: Disrupts tetramerization, disrupts
FT                                AML1-MTG8/ETO interaction with TCF12,
FT                                decreases AML1-MTG8/ETO interaction with
FT                                RUNX1T1, CBFA2T3 and CBFA2T2; when
FT                                associated with E-345; R-357; R-360; E-
FT                                361; E-375 and R-378.
FT                                {ECO:0000269|PubMed:16616331,
FT                                ECO:0000269|PubMed:23812588}.
FT   MUTAGEN     547    547       H->A: Causes unfolding of the MYND-type
FT                                zinc finger domain.
FT                                {ECO:0000269|PubMed:17560331}.
FT   CONFLICT    455    455       E -> G (in Ref. 3; BAH12630).
FT                                {ECO:0000305}.
FT   CONFLICT    506    506       N -> S (in Ref. 3; BAH12630).
FT                                {ECO:0000305}.
FT   HELIX       121    123       {ECO:0000244|PDB:2H7B}.
FT   HELIX       125    135       {ECO:0000244|PDB:2H7B}.
FT   HELIX       137    140       {ECO:0000244|PDB:2H7B}.
FT   HELIX       142    156       {ECO:0000244|PDB:2H7B}.
FT   HELIX       162    172       {ECO:0000244|PDB:2H7B}.
FT   STRAND      173    176       {ECO:0000244|PDB:2H7B}.
FT   STRAND      179    181       {ECO:0000244|PDB:2H7B}.
FT   HELIX       182    186       {ECO:0000244|PDB:2H7B}.
FT   HELIX       189    199       {ECO:0000244|PDB:2H7B}.
FT   HELIX       200    202       {ECO:0000244|PDB:2H7B}.
FT   HELIX       209    212       {ECO:0000244|PDB:2H7B}.
FT   HELIX       347    399       {ECO:0000244|PDB:1WQ6}.
FT   HELIX       444    465       {ECO:0000244|PDB:2KYG}.
FT   STRAND      512    514       {ECO:0000244|PDB:2ODD}.
FT   STRAND      516    518       {ECO:0000244|PDB:2DJ8}.
FT   STRAND      524    526       {ECO:0000244|PDB:2ODD}.
FT   TURN        527    529       {ECO:0000244|PDB:2DJ8}.
FT   STRAND      533    536       {ECO:0000244|PDB:2DJ8}.
FT   HELIX       537    542       {ECO:0000244|PDB:2DJ8}.
FT   HELIX       544    547       {ECO:0000244|PDB:2DJ8}.
FT   TURN        548    550       {ECO:0000244|PDB:2DJ8}.
SQ   SEQUENCE   604 AA;  67566 MW;  C3D2452F96E65679 CRC64;
     MISVKRNTWR ALSLVIGDCR KKGNFEYCQD RTEKHSTMPD SPVDVKTQSR LTPPTMPPPP
     TTQGAPRTSS FTPTTLTNGT SHSPTALNGA PSPPNGFSNG PSSSSSSSLA NQQLPPACGA
     RQLSKLKRFL TTLQQFGNDI SPEIGERVRT LVLGLVNSTL TIEEFHSKLQ EATNFPLRPF
     VIPFLKANLP LLQRELLHCA RLAKQNPAQY LAQHEQLLLD ASTTSPVDSS ELLLDVNENG
     KRRTPDRTKE NGFDREPLHS EHPSKRPCTI SPGQRYSPNN GLSYQPNGLP HPTPPPPQHY
     RLDDMAIAHH YRDSYRHPSH RDLRDRNRPM GLHGTRQEEM IDHRLTDREW AEEWKHLDHL
     LNCIMDMVEK TRRSLTVLRR CQEADREELN YWIRRYSDAE DLKKGGGSSS SHSRQQSPVN
     PDPVALDAHR EFLHRPASGY VPEEIWKKAE EAVNEVKRQA MTELQKAVSE AERKAHDMIT
     TERAKMERTV AEAKRQAAED ALAVINQQED SSESCWNCGR KASETCSGCN TARYCGSFCQ
     HKDWEKHHHI CGQTLQAQQQ GDTPAVSSSV TPNSGAGSPM DTPPAATPRS TTPGTPSTIE
     TTPR
//
ID   W8FW32_HUMAN            Unreviewed;       567 AA.
AC   W8FW32;
DT   14-MAY-2014, integrated into UniProtKB/TrEMBL.
DT   14-MAY-2014, sequence version 1.
DT   28-FEB-2018, entry version 39.
DE   SubName: Full=CBFA2T1 isoform r1t1-7d56 {ECO:0000313|EMBL:AHK05730.1};
DE   SubName: Full=CBFA2T1 isoform r1t1-8a60 {ECO:0000313|EMBL:AHK05734.1};
GN   Name=RUNX1T1 {ECO:0000313|EMBL:AHK05730.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AHK05730.1};
RN   [1] {ECO:0000313|EMBL:AHK05730.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Migas A.A., Mishkova O.A., Ramanouskaya T.V., Ilyushonak I.M.,
RA   Aleinikova O.V., Grinev V.V.;
RT   "RUNX1T1/MTG8/ETO Gene Expression Status in Human t(8;21)(q22;q22)-
RT   Positive Acute Myeloid Leukemia Cells.";
RL   Submitted (NOV-2013) to the EMBL/GenBank/DDBJ databases.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; KF946514; AHK05730.1; -; mRNA.
DR   EMBL; KF946518; AHK05734.1; -; mRNA.
DR   RefSeq; NP_783553.1; NM_175635.2.
DR   RefSeq; NP_783554.1; NM_175636.2.
DR   RefSeq; XP_006716739.1; XM_006716676.3.
DR   RefSeq; XP_011515655.1; XM_011517353.2.
DR   RefSeq; XP_016869423.1; XM_017013934.1.
DR   RefSeq; XP_016869424.1; XM_017013935.1.
DR   RefSeq; XP_016869425.1; XM_017013936.1.
DR   RefSeq; XP_016869426.1; XM_017013937.1.
DR   UniGene; Hs.368431; -.
DR   UniGene; Hs.739194; -.
DR   SMR; W8FW32; -.
DR   MaxQB; W8FW32; -.
DR   GeneID; 862; -.
DR   UCSC; uc003yfb.3; human.
DR   CTD; 862; -.
DR   EuPathDB; HostDB:ENSG00000079102.16; -.
DR   eggNOG; ENOG410IG1Z; Eukaryota.
DR   eggNOG; ENOG410XR30; LUCA.
DR   ChiTaRS; RUNX1T1; human.
DR   GenomeRNAi; 862; -.
DR   Bgee; ENSG00000079102; -.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0003714; F:transcription corepressor activity; IEA:InterPro.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IEA:InterPro.
DR   InterPro; IPR013290; CBFA2T1.
DR   InterPro; IPR013289; CBFA2T1/2/3.
DR   InterPro; IPR014896; NHR2.
DR   InterPro; IPR037249; TAFH/NHR1_dom_sf.
DR   InterPro; IPR003894; TAFH_NHR1.
DR   InterPro; IPR002893; Znf_MYND.
DR   PANTHER; PTHR10379; PTHR10379; 1.
DR   PANTHER; PTHR10379:SF5; PTHR10379:SF5; 1.
DR   Pfam; PF08788; NHR2; 1.
DR   Pfam; PF07531; TAFH; 1.
DR   Pfam; PF01753; zf-MYND; 1.
DR   PRINTS; PR01875; ETOFAMILY.
DR   PRINTS; PR01876; MTG8PROTEIN.
DR   SMART; SM00549; TAFH; 1.
DR   SUPFAM; SSF158553; SSF158553; 1.
DR   PROSITE; PS51119; TAFH; 1.
DR   PROSITE; PS01360; ZF_MYND_1; 1.
DR   PROSITE; PS50865; ZF_MYND_2; 1.
PE   2: Evidence at transcript level;
KW   Coiled coil {ECO:0000256|SAM:Coils};
KW   Metal-binding {ECO:0000256|PROSITE-ProRule:PRU00134,
KW   ECO:0000256|SAAS:SAAS00513840};
KW   Zinc {ECO:0000256|PROSITE-ProRule:PRU00134,
KW   ECO:0000256|SAAS:SAAS00513840};
KW   Zinc-finger {ECO:0000256|PROSITE-ProRule:PRU00134,
KW   ECO:0000256|SAAS:SAAS00513840}.
FT   DOMAIN       83    178       TAFH. {ECO:0000259|PROSITE:PS51119}.
FT   DOMAIN      478    514       MYND-type. {ECO:0000259|PROSITE:PS50865}.
FT   COILED      417    459       {ECO:0000256|SAM:Coils}.
SQ   SEQUENCE   567 AA;  63212 MW;  44AADF2EC7032050 CRC64;
     MPDSPVDVKT QSRLTPPTMP PPPTTQGAPR TSSFTPTTLT NGTSHSPTAL NGAPSPPNGF
     SNGPSSSSSS SLANQQLPPA CGARQLSKLK RFLTTLQQFG NDISPEIGER VRTLVLGLVN
     STLTIEEFHS KLQEATNFPL RPFVIPFLKA NLPLLQRELL HCARLAKQNP AQYLAQHEQL
     LLDASTTSPV DSSELLLDVN ENGKRRTPDR TKENGFDREP LHSEHPSKRP CTISPGQRYS
     PNNGLSYQPN GLPHPTPPPP QHYRLDDMAI AHHYRDSYRH PSHRDLRDRN RPMGLHGTRQ
     EEMIDHRLTD REWAEEWKHL DHLLNCIMDM VEKTRRSLTV LRRCQEADRE ELNYWIRRYS
     DAEDLKKGGG SSSSHSRQQS PVNPDPVALD AHREFLHRPA SGYVPEEIWK KAEEAVNEVK
     RQAMTELQKA VSEAERKAHD MITTERAKME RTVAEAKRQA AEDALAVINQ QEDSSESCWN
     CGRKASETCS GCNTARYCGS FCQHKDWEKH HHICGQTLQA QQQGDTPAVS SSVTPNSGAG
     SPMDTPPAAT PRSTTPGTPS TIETTPR
//
ID   STA5B_HUMAN             Reviewed;         787 AA.
AC   P51692; Q8WWS8;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   16-JAN-2004, sequence version 2.
DT   28-FEB-2018, entry version 184.
DE   RecName: Full=Signal transducer and activator of transcription 5B;
GN   Name=STAT5B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RX   PubMed=8732682; DOI=10.1210/mend.10.5.8732682;
RA   Silva C.M., Lu H., Day R.N.;
RT   "Characterization and cloning of STAT5 from IM-9 cells and its
RT   activation by growth hormone.";
RL   Mol. Endocrinol. 10:508-518(1996).
RN   [2]
RP   SEQUENCE REVISION TO 628; 717 AND 720.
RA   Silva C.M., Lu H.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8631883; DOI=10.1074/jbc.271.18.10690;
RA   Lin J.-X., Mietz J., Modi W.S., John S., Leonard W.J.;
RT   "Cloning of human Stat5B. Reconstitution of interleukin-2-induced
RT   Stat5A and Stat5B DNA binding activity in COS-7 cells.";
RL   J. Biol. Chem. 271:10738-10744(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=12039059; DOI=10.1016/S0378-1119(02)00421-3;
RA   Ambrosio R., Fimiani G., Monfregola J., Sanzari E., De Felice N.,
RA   Salerno M.C., Pignata C., D'Urso M., Ursini M.V.;
RT   "The structure of human STAT5A and B genes reveals two regions of
RT   nearly identical sequence and an alternative tissue specific STAT5B
RT   promoter.";
RL   Gene 285:311-318(2002).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PHOSPHORYLATION BY INSR, INTERACTION WITH INSR, AND MUTAGENESIS OF
RP   THR-684.
RX   PubMed=9428692; DOI=10.1111/j.1432-1033.1997.0411a.x;
RA   Sawka-Verhelle D., Filloux C., Tartare-Deckert S., Mothe I.,
RA   Van Obberghen E.;
RT   "Identification of Stat 5B as a substrate of the insulin receptor.";
RL   Eur. J. Biochem. 250:411-417(1997).
RN   [7]
RP   INTERACTION WITH NMI.
RX   PubMed=9989503; DOI=10.1016/S0092-8674(00)80965-4;
RA   Zhu M.-H., John S., Berg M., Leonard W.J.;
RT   "Functional association of Nmi with Stat5 and Stat1 in IL-2- and
RT   IFNgamma-mediated signaling.";
RL   Cell 96:121-130(1999).
RN   [8]
RP   PHOSPHORYLATION AT TYR-699, AND MUTAGENESIS OF TYR-699.
RX   PubMed=12411494; DOI=10.1093/emboj/cdf562;
RA   Klejman A., Schreiner S.J., Nieborowska-Skorska M., Slupianek A.,
RA   Wilson M., Smithgall T.E., Skorski T.;
RT   "The Src family kinase Hck couples BCR/ABL to STAT5 activation in
RT   myeloid leukemia cells.";
RL   EMBO J. 21:5766-5774(2002).
RN   [9]
RP   CAUTION.
RX   PubMed=11773439; DOI=10.1210/mend.16.1.0761;
RA   Aoki N., Matsuda T.;
RT   "A nuclear protein tyrosine phosphatase TC-PTP is a potential negative
RT   regulator of the PRL-mediated signaling pathway: dephosphorylation and
RT   deactivation of signal transducer and activator of transcription 5a
RT   and 5b by TC-PTP in nucleus.";
RL   Mol. Endocrinol. 16:58-69(2002).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-193, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-193, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-128, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-193, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-90; SER-128 AND SER-193,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   RETRACTION, AND CAUTION.
RX   PubMed=24319783; DOI=10.1210/me.2013-1264;
RA   Aoki N., Matsuda T.;
RT   "Retraction.";
RL   Mol. Endocrinol. 27:1982-1982(2013).
RN   [18]
RP   INTERACTION WITH NCOA1.
RX   PubMed=12954634; DOI=10.1074/jbc.M303644200;
RA   Litterst C.M., Kliem S., Marilley D., Pfitzner E.;
RT   "NCoA-1/SRC-1 is an essential coactivator of STAT5 that binds to the
RT   FDL motif in the alpha-helical region of the STAT5 transactivation
RT   domain.";
RL   J. Biol. Chem. 278:45340-45351(2003).
RN   [19]
RP   PHOSPHORYLATION IN RESPONSE TO FLT3 SIGNALING.
RX   PubMed=14504097; DOI=10.1182/blood-2003-02-0418;
RA   Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R.,
RA   Tsuchida M., Sugita K., Ida K., Hayashi Y.;
RT   "FLT3 mutations in the activation loop of tyrosine kinase domain are
RT   frequently found in infant ALL with MLL rearrangements and pediatric
RT   ALL with hyperdiploidy.";
RL   Blood 103:1085-1088(2004).
RN   [20]
RP   REVIEW ON ROLE IN KIT SIGNALING.
RX   PubMed=15526160; DOI=10.1007/s00018-004-4189-6;
RA   Ronnstrand L.;
RT   "Signal transduction via the stem cell factor receptor/c-Kit.";
RL   Cell. Mol. Life Sci. 61:2535-2548(2004).
RN   [21]
RP   PHOSPHORYLATION BY JAK2.
RX   PubMed=15121872; DOI=10.1128/MCB.24.10.4557-4570.2004;
RA   Kurzer J.H., Argetsinger L.S., Zhou Y.J., Kouadio J.L., O'Shea J.J.,
RA   Carter-Su C.;
RT   "Tyrosine 813 is a site of JAK2 autophosphorylation critical for
RT   activation of JAK2 by SH2-B beta.";
RL   Mol. Cell. Biol. 24:4557-4570(2004).
RN   [22]
RP   INTERACTION WITH SOCS7.
RX   PubMed=15677474; DOI=10.1074/jbc.M411596200;
RA   Martens N., Uzan G., Wery M., Hooghe R., Hooghe-Peters E.L.,
RA   Gertler A.;
RT   "Suppressor of cytokine signaling 7 inhibits prolactin, growth
RT   hormone, and leptin signaling by interacting with STAT5 or STAT3 and
RT   attenuating their nuclear translocation.";
RL   J. Biol. Chem. 280:13817-13823(2005).
RN   [23]
RP   INVOLVEMENT IN GHII.
RX   PubMed=15827093; DOI=10.1210/jc.2005-0515;
RA   Hwa V., Little B., Adiyaman P., Kofoed E.M., Pratt K.L., Ocal G.,
RA   Berberoglu M., Rosenfeld R.G.;
RT   "Severe growth hormone insensitivity resulting from total absence of
RT   signal transducer and activator of transcription 5b.";
RL   J. Clin. Endocrinol. Metab. 90:4260-4266(2005).
RN   [24]
RP   PHOSPHORYLATION AT TYR-699 BY PTK6.
RX   PubMed=17997837; DOI=10.1186/bcr1794;
RA   Weaver A.M., Silva C.M.;
RT   "Signal transducer and activator of transcription 5b: a new target of
RT   breast tumor kinase/protein tyrosine kinase 6.";
RL   Breast Cancer Res. 9:R79-R79(2007).
RN   [25]
RP   FUNCTION.
RX   PubMed=20702587; DOI=10.1091/mbc.E10-01-0040;
RA   Vignudelli T., Selmi T., Martello A., Parenti S., Grande A.,
RA   Gemelli C., Zanocco-Marani T., Ferrari S.;
RT   "ZFP36L1 negatively regulates erythroid differentiation of CD34+
RT   hematopoietic stem cells by interfering with the Stat5b pathway.";
RL   Mol. Biol. Cell 21:3340-3351(2010).
RN   [26]
RP   INTERACTION WITH CPEB3.
RX   PubMed=20639532; DOI=10.1093/nar/gkq634;
RA   Peng S.C., Lai Y.T., Huang H.Y., Huang H.D., Huang Y.S.;
RT   "A novel role of CPEB3 in regulating EGFR gene transcription via
RT   association with Stat5b in neurons.";
RL   Nucleic Acids Res. 38:7446-7457(2010).
RN   [27]
RP   PHOSPHORYLATION IN RESPONSE TO KIT SIGNALING.
RX   PubMed=21135090; DOI=10.1074/jbc.M110.182642;
RA   Chaix A., Lopez S., Voisset E., Gros L., Dubreuil P., De Sepulveda P.;
RT   "Mechanisms of STAT protein activation by oncogenic KIT mutants in
RT   neoplastic mast cells.";
RL   J. Biol. Chem. 286:5956-5966(2011).
RN   [28]
RP   VARIANT GHII PRO-630.
RX   PubMed=13679528; DOI=10.1056/NEJMoa022926;
RA   Kofoed E.M., Hwa V., Little B., Woods K.A., Buckway C.K., Tsubaki J.,
RA   Pratt K.L., Bezrodnik L., Jasper H., Tepper A., Heinrich J.J.,
RA   Rosenfeld R.G.;
RT   "Growth hormone insensitivity associated with a STAT5b mutation.";
RL   N. Engl. J. Med. 349:1139-1147(2003).
RN   [29]
RP   VARIANT GHII SER-646, AND CHARACTERIZATION OF VARIANT GHII SER-646.
RX   PubMed=22419735; DOI=10.1210/jc.2011-2554;
RA   Scaglia P.A., Martinez A.S., Feigerlova E., Bezrodnik L.,
RA   Gaillard M.I., Di Giovanni D., Ballerini M.G., Jasper H.G.,
RA   Heinrich J.J., Fang P., Domene H.M., Rosenfeld R.G., Hwa V.;
RT   "A Novel Missense Mutation in the SH2 Domain of the STAT5B Gene
RT   Results in a transcriptionally inactive STAT5b associated with severe
RT   IGF-I deficiency, immune dysfunction, and lack of pulmonary disease.";
RL   J. Clin. Endocrinol. Metab. 97:E830-839(2012).
CC   -!- FUNCTION: Carries out a dual function: signal transduction and
CC       activation of transcription. Mediates cellular responses to the
CC       cytokine KITLG/SCF and other growth factors. Binds to the GAS
CC       element and activates PRL-induced transcription. Positively
CC       regulates hematopoietic/erythroid differentiation.
CC       {ECO:0000269|PubMed:20702587, ECO:0000269|PubMed:8732682}.
CC   -!- SUBUNIT: Forms a homodimer or a heterodimer with a related family
CC       member. Binds NR3C1 (By similarity). Interacts with NCOA1
CC       (PubMed:12954634). Interacts with NMI (PubMed:9989503). Interacts
CC       with SOCS7 (PubMed:15677474). Interacts (via SH2 domain) with INSR
CC       (PubMed:9428692). Interacts with CPEB3; this inhibits STAT5B-
CC       mediated transcriptional activation (PubMed:20639532).
CC       {ECO:0000250|UniProtKB:P42232, ECO:0000269|PubMed:12954634,
CC       ECO:0000269|PubMed:15677474, ECO:0000269|PubMed:20639532,
CC       ECO:0000269|PubMed:9428692, ECO:0000269|PubMed:9989503}.
CC   -!- INTERACTION:
CC       Q96EY1:DNAJA3; NbExp=2; IntAct=EBI-1186119, EBI-356767;
CC       Q13287:NMI; NbExp=7; IntAct=EBI-1186119, EBI-372942;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:P42232}.
CC       Nucleus {ECO:0000250|UniProtKB:P42232}. Note=Translocated into the
CC       nucleus in response to phosphorylation. {ECO:0000250}.
CC   -!- PTM: Tyrosine phosphorylated in response to signaling via
CC       activated KIT, resulting in translocation to the nucleus. Tyrosine
CC       phosphorylated in response to signaling via activated FLT3; wild-
CC       type FLT3 results in much weaker phosphorylation than
CC       constitutively activated mutant FLT3. Alternatively, can be
CC       phosphorylated by JAK2. Phosphorylation at Tyr-699 by PTK6 or HCK
CC       leads to an increase of its transcriptional activity.
CC       {ECO:0000269|PubMed:12411494, ECO:0000269|PubMed:14504097,
CC       ECO:0000269|PubMed:15121872, ECO:0000269|PubMed:17997837,
CC       ECO:0000269|PubMed:21135090, ECO:0000269|PubMed:9428692}.
CC   -!- DISEASE: Growth hormone insensitivity with immunodeficiency (GHII)
CC       [MIM:245590]: A disease characterized by short stature, growth
CC       hormone deficiency in the presence of normal to elevated
CC       circulating concentrations of growth hormone, resistance to
CC       hexogeneous growth hormone therapy, and recurrent infections.
CC       {ECO:0000269|PubMed:13679528, ECO:0000269|PubMed:15827093,
CC       ECO:0000269|PubMed:22419735}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the transcription factor STAT family.
CC       {ECO:0000305}.
CC   -!- CAUTION: It was reported that dephosphorylation on tyrosine
CC       residues by PTPN2 would negatively regulate prolactin signaling
CC       pathway (PubMed:11773439). However, the corresponding article has
CC       been retracted (PubMed:24319783). {ECO:0000269|PubMed:11773439,
CC       ECO:0000303|PubMed:24319783}.
CC   -!- WEB RESOURCE: Name=STAT5Bbase; Note=STAT5B mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/STAT5Bbase/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=STAT5 entry;
CC       URL="https://en.wikipedia.org/wiki/STAT5";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/STAT5BID217ch17q21.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U48730; AAC50485.2; -; mRNA.
DR   EMBL; U47686; AAC50491.1; -; mRNA.
DR   EMBL; AJ412888; CAD19638.1; -; Genomic_DNA.
DR   EMBL; AJ412889; CAD19638.1; JOINED; Genomic_DNA.
DR   EMBL; AJ412890; CAD19638.1; JOINED; Genomic_DNA.
DR   EMBL; AJ412891; CAD19638.1; JOINED; Genomic_DNA.
DR   EMBL; AJ412892; CAD19638.1; JOINED; Genomic_DNA.
DR   EMBL; AJ412893; CAD19638.1; JOINED; Genomic_DNA.
DR   EMBL; AJ412894; CAD19638.1; JOINED; Genomic_DNA.
DR   EMBL; AJ412895; CAD19638.1; JOINED; Genomic_DNA.
DR   EMBL; AJ412896; CAD19638.1; JOINED; Genomic_DNA.
DR   EMBL; AJ412897; CAD19638.1; JOINED; Genomic_DNA.
DR   EMBL; AJ412898; CAD19638.1; JOINED; Genomic_DNA.
DR   EMBL; AJ412899; CAD19638.1; JOINED; Genomic_DNA.
DR   EMBL; BC065227; AAH65227.1; -; mRNA.
DR   CCDS; CCDS11423.1; -.
DR   RefSeq; NP_036580.2; NM_012448.3.
DR   UniGene; Hs.595276; -.
DR   ProteinModelPortal; P51692; -.
DR   SMR; P51692; -.
DR   BioGrid; 112654; 57.
DR   CORUM; P51692; -.
DR   IntAct; P51692; 26.
DR   MINT; P51692; -.
DR   STRING; 9606.ENSP00000293328; -.
DR   BindingDB; P51692; -.
DR   ChEMBL; CHEMBL5817; -.
DR   DrugBank; DB01254; Dasatinib.
DR   iPTMnet; P51692; -.
DR   PhosphoSitePlus; P51692; -.
DR   BioMuta; STAT5B; -.
DR   DMDM; 41019536; -.
DR   EPD; P51692; -.
DR   MaxQB; P51692; -.
DR   PaxDb; P51692; -.
DR   PeptideAtlas; P51692; -.
DR   PRIDE; P51692; -.
DR   DNASU; 6777; -.
DR   Ensembl; ENST00000293328; ENSP00000293328; ENSG00000173757.
DR   GeneID; 6777; -.
DR   KEGG; hsa:6777; -.
DR   UCSC; uc002hzh.4; human.
DR   CTD; 6777; -.
DR   DisGeNET; 6777; -.
DR   EuPathDB; HostDB:ENSG00000173757.9; -.
DR   GeneCards; STAT5B; -.
DR   HGNC; HGNC:11367; STAT5B.
DR   HPA; CAB004298; -.
DR   HPA; HPA042128; -.
DR   HPA; HPA049883; -.
DR   HPA; HPA051156; -.
DR   MalaCards; STAT5B; -.
DR   MIM; 245590; phenotype.
DR   MIM; 604260; gene.
DR   neXtProt; NX_P51692; -.
DR   OpenTargets; ENSG00000173757; -.
DR   Orphanet; 520; Acute promyelocytic leukemia.
DR   Orphanet; 220465; Laron syndrome with immunodeficiency.
DR   PharmGKB; PA36186; -.
DR   eggNOG; KOG3667; Eukaryota.
DR   eggNOG; ENOG410XPN8; LUCA.
DR   GeneTree; ENSGT00760000119236; -.
DR   HOVERGEN; HBG107486; -.
DR   InParanoid; P51692; -.
DR   KO; K11224; -.
DR   OMA; VWNLMPY; -.
DR   OrthoDB; EOG091G03O3; -.
DR   PhylomeDB; P51692; -.
DR   TreeFam; TF318648; -.
DR   Reactome; R-HSA-1170546; Prolactin receptor signaling.
DR   Reactome; R-HSA-1266695; Interleukin-7 signaling.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-1839117; Signaling by cytosolic FGFR1 fusion mutants.
DR   Reactome; R-HSA-186763; Downstream signal transduction.
DR   Reactome; R-HSA-2586552; Signaling by Leptin.
DR   Reactome; R-HSA-512988; Interleukin-3, 5 and GM-CSF signaling.
DR   Reactome; R-HSA-8854691; Interleukin-20 family signaling.
DR   Reactome; R-HSA-8983432; Interleukin-15 signaling.
DR   Reactome; R-HSA-9020558; Interleukin-2 signaling.
DR   Reactome; R-HSA-9020958; Interleukin-21 signaling.
DR   Reactome; R-HSA-982772; Growth hormone receptor signaling.
DR   SignaLink; P51692; -.
DR   SIGNOR; P51692; -.
DR   ChiTaRS; STAT5B; human.
DR   GeneWiki; STAT5B; -.
DR   GenomeRNAi; 6777; -.
DR   PMAP-CutDB; P51692; -.
DR   PRO; PR:P51692; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000173757; -.
DR   CleanEx; HS_STAT5B; -.
DR   ExpressionAtlas; P51692; baseline and differential.
DR   Genevisible; P51692; HS.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; ISS:UniProtKB.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; TAS:ProtInc.
DR   GO; GO:0035259; F:glucocorticoid receptor binding; IPI:BHF-UCL.
DR   GO; GO:0046983; F:protein dimerization activity; ISS:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; TAS:Reactome.
DR   GO; GO:0000978; F:RNA polymerase II proximal promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0004871; F:signal transducer activity; IEA:Ensembl.
DR   GO; GO:0001077; F:transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0006103; P:2-oxoglutarate metabolic process; ISS:BHF-UCL.
DR   GO; GO:0000255; P:allantoin metabolic process; ISS:BHF-UCL.
DR   GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; ISS:UniProtKB.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; ISS:UniProtKB.
DR   GO; GO:0032870; P:cellular response to hormone stimulus; IDA:BHF-UCL.
DR   GO; GO:0006101; P:citrate metabolic process; ISS:BHF-UCL.
DR   GO; GO:0006600; P:creatine metabolic process; ISS:BHF-UCL.
DR   GO; GO:0046449; P:creatinine metabolic process; ISS:BHF-UCL.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0046543; P:development of secondary female sexual characteristics; IEA:Ensembl.
DR   GO; GO:0046544; P:development of secondary male sexual characteristics; IEA:Ensembl.
DR   GO; GO:0006631; P:fatty acid metabolic process; ISS:BHF-UCL.
DR   GO; GO:0007565; P:female pregnancy; IEA:Ensembl.
DR   GO; GO:0035723; P:interleukin-15-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0038110; P:interleukin-2-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0038111; P:interleukin-7-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0006549; P:isoleucine metabolic process; ISS:BHF-UCL.
DR   GO; GO:0007259; P:JAK-STAT cascade; TAS:ProtInc.
DR   GO; GO:0060397; P:JAK-STAT cascade involved in growth hormone signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0007595; P:lactation; IEA:Ensembl.
DR   GO; GO:0019915; P:lipid storage; IEA:Ensembl.
DR   GO; GO:0001553; P:luteinization; IEA:Ensembl.
DR   GO; GO:0097531; P:mast cell migration; IEA:Ensembl.
DR   GO; GO:0001779; P:natural killer cell differentiation; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0045647; P:negative regulation of erythrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0006107; P:oxaloacetate metabolic process; ISS:BHF-UCL.
DR   GO; GO:0048541; P:Peyer's patch development; IEA:Ensembl.
DR   GO; GO:0042104; P:positive regulation of activated T cell proliferation; IEA:Ensembl.
DR   GO; GO:0045579; P:positive regulation of B cell differentiation; IEA:Ensembl.
DR   GO; GO:0045648; P:positive regulation of erythrocyte differentiation; IDA:UniProtKB.
DR   GO; GO:0045588; P:positive regulation of gamma-delta T cell differentiation; IEA:Ensembl.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; IEA:Ensembl.
DR   GO; GO:0045086; P:positive regulation of interleukin-2 biosynthetic process; IEA:Ensembl.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0040018; P:positive regulation of multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0032825; P:positive regulation of natural killer cell differentiation; IEA:Ensembl.
DR   GO; GO:0045954; P:positive regulation of natural killer cell mediated cytotoxicity; IEA:Ensembl.
DR   GO; GO:0032819; P:positive regulation of natural killer cell proliferation; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0042448; P:progesterone metabolic process; IEA:Ensembl.
DR   GO; GO:0030856; P:regulation of epithelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0040014; P:regulation of multicellular organism growth; ISS:BHF-UCL.
DR   GO; GO:0019218; P:regulation of steroid metabolic process; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; TAS:ProtInc.
DR   GO; GO:0032355; P:response to estradiol; IDA:BHF-UCL.
DR   GO; GO:0070670; P:response to interleukin-4; IEA:Ensembl.
DR   GO; GO:0006105; P:succinate metabolic process; ISS:BHF-UCL.
DR   GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl.
DR   GO; GO:0043029; P:T cell homeostasis; IEA:Ensembl.
DR   GO; GO:0019530; P:taurine metabolic process; ISS:BHF-UCL.
DR   GO; GO:0006573; P:valine metabolic process; ISS:BHF-UCL.
DR   CDD; cd10420; SH2_STAT5b; 1.
DR   Gene3D; 1.10.532.10; -; 1.
DR   Gene3D; 2.60.40.630; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR001217; STAT.
DR   InterPro; IPR035858; STAT5a/5b.
DR   InterPro; IPR035886; STAT5b_SH2.
DR   InterPro; IPR036535; STAT_N_sf.
DR   InterPro; IPR013800; STAT_TF_alpha.
DR   InterPro; IPR015988; STAT_TF_coiled-coil.
DR   InterPro; IPR013801; STAT_TF_DNA-bd.
DR   InterPro; IPR012345; STAT_TF_DNA-bd_N.
DR   InterPro; IPR013799; STAT_TF_prot_interaction.
DR   PANTHER; PTHR11801; PTHR11801; 1.
DR   PANTHER; PTHR11801:SF39; PTHR11801:SF39; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF01017; STAT_alpha; 1.
DR   Pfam; PF02864; STAT_bind; 1.
DR   Pfam; PF02865; STAT_int; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00964; STAT_int; 1.
DR   SUPFAM; SSF47655; SSF47655; 1.
DR   SUPFAM; SSF48092; SSF48092; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   PROSITE; PS50001; SH2; 1.
PE   1: Evidence at protein level;
KW   Activator; Complete proteome; Cytoplasm; Disease mutation;
KW   DNA-binding; Dwarfism; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; SH2 domain; Transcription;
KW   Transcription regulation.
FT   CHAIN         1    787       Signal transducer and activator of
FT                                transcription 5B.
FT                                /FTId=PRO_0000182429.
FT   DOMAIN      589    686       SH2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   REGION      232    321       Required for interaction with NMI.
FT                                {ECO:0000269|PubMed:9989503}.
FT   MOD_RES      90     90       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     128    128       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     193    193       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     699    699       Phosphotyrosine; by HCK, JAK and PTK6.
FT                                {ECO:0000269|PubMed:12411494,
FT                                ECO:0000269|PubMed:17997837}.
FT   VARIANT     130    130       A -> V (in dbSNP:rs2277619).
FT                                /FTId=VAR_052074.
FT   VARIANT     630    630       A -> P (in GHII; affects activation by
FT                                growth hormone or interferon-gamma;
FT                                dbSNP:rs121908501).
FT                                {ECO:0000269|PubMed:13679528}.
FT                                /FTId=VAR_018728.
FT   VARIANT     646    646       F -> S (in GHII; transcriptionally
FT                                inactive). {ECO:0000269|PubMed:22419735}.
FT                                /FTId=VAR_067368.
FT   MUTAGEN     684    684       T->A: Abolishes interaction with INSR.
FT                                {ECO:0000269|PubMed:9428692}.
FT   MUTAGEN     699    699       Y->F: Abolishes phosphorylation by HCK.
FT                                {ECO:0000269|PubMed:12411494}.
FT   CONFLICT    230    230       A -> P (in Ref. 2; AAC50491).
FT                                {ECO:0000305}.
SQ   SEQUENCE   787 AA;  89866 MW;  AA2F1CAB20955ACA CRC64;
     MAVWIQAQQL QGEALHQMQA LYGQHFPIEV RHYLSQWIES QAWDSVDLDN PQENIKATQL
     LEGLVQELQK KAEHQVGEDG FLLKIKLGHY ATQLQNTYDR CPMELVRCIR HILYNEQRLV
     REANNGSSPA GSLADAMSQK HLQINQTFEE LRLVTQDTEN ELKKLQQTQE YFIIQYQESL
     RIQAQFGPLA QLSPQERLSR ETALQQKQVS LEAWLQREAQ TLQQYRVELA EKHQKTLQLL
     RKQQTIILDD ELIQWKRRQQ LAGNGGPPEG SLDVLQSWCE KLAEIIWQNR QQIRRAEHLC
     QQLPIPGPVE EMLAEVNATI TDIISALVTS TFIIEKQPPQ VLKTQTKFAA TVRLLVGGKL
     NVHMNPPQVK ATIISEQQAK SLLKNENTRN DYSGEILNNC CVMEYHQATG TLSAHFRNMS
     LKRIKRSDRR GAESVTEEKF TILFESQFSV GGNELVFQVK TLSLPVVVIV HGSQDNNATA
     TVLWDNAFAE PGRVPFAVPD KVLWPQLCEA LNMKFKAEVQ SNRGLTKENL VFLAQKLFNN
     SSSHLEDYSG LSVSWSQFNR ENLPGRNYTF WQWFDGVMEV LKKHLKPHWN DGAILGFVNK
     QQAHDLLINK PDGTFLLRFS DSEIGGITIA WKFDSQERMF WNLMPFTTRD FSIRSLADRL
     GDLNYLIYVF PDRPKDEVYS KYYTPVPCES ATAKAVDGYV KPQIKQVVPE FVNASADAGG
     GSATYMDQAP SPAVCPQAHY NMYPQNPDSV LDTDGDFDLE DTMDVARRVE ELLGRPMDSQ
     WIPHAQS
//
ID   J3QQW9_HUMAN            Unreviewed;       716 AA.
AC   J3QQW9;
DT   03-OCT-2012, integrated into UniProtKB/TrEMBL.
DT   03-OCT-2012, sequence version 1.
DT   28-FEB-2018, entry version 47.
DE   SubName: Full=Polycomb protein SUZ12 {ECO:0000313|Ensembl:ENSP00000463936};
GN   Name=SUZ12 {ECO:0000313|Ensembl:ENSP00000463936};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000463936, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000213|PubMed:17081983}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [2] {ECO:0000313|Ensembl:ENSP00000463936, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [3] {ECO:0000213|PubMed:18220336}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.D., Yates J.R.;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [4] {ECO:0000213|PubMed:18669648}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [5] {ECO:0000213|PubMed:19413330}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [6] {ECO:0000213|PubMed:19690332}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:ra46-RA46(2009).
RN   [7] {ECO:0000213|PubMed:20068231}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:ra3-RA3(2010).
RN   [8] {ECO:0000213|PubMed:21406692}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:rs3-RS3(2011).
RN   [9] {ECO:0000313|Ensembl:ENSP00000463936}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (AUG-2012) to UniProtKB.
RN   [10] {ECO:0000213|PubMed:23186163}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=23186163;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [11] {ECO:0000213|PubMed:24129315}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=24129315;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V.,
RA   Aguiar M., Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C.,
RA   Vemulapalli V., Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [12] {ECO:0000213|PubMed:28112733}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-
RT   modification with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   -!- CAUTION: The sequence shown here is derived from an Ensembl
CC       automatic analysis pipeline and should be considered as
CC       preliminary data. {ECO:0000313|Ensembl:ENSP00000463936}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AC090616; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC129917; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_001308136.1; NM_001321207.1.
DR   UniGene; Hs.462732; -.
DR   ProteinModelPortal; J3QQW9; -.
DR   EPD; J3QQW9; -.
DR   MaxQB; J3QQW9; -.
DR   PeptideAtlas; J3QQW9; -.
DR   PRIDE; J3QQW9; -.
DR   Ensembl; ENST00000580398; ENSP00000463936; ENSG00000178691.
DR   GeneID; 23512; -.
DR   UCSC; uc002hgt.3; human.
DR   CTD; 23512; -.
DR   EuPathDB; HostDB:ENSG00000178691.10; -.
DR   HGNC; HGNC:17101; SUZ12.
DR   OpenTargets; ENSG00000178691; -.
DR   eggNOG; KOG2350; Eukaryota.
DR   eggNOG; ENOG410YJ29; LUCA.
DR   GeneTree; ENSGT00390000012364; -.
DR   ChiTaRS; SUZ12; human.
DR   GenomeRNAi; 23512; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000178691; -.
DR   ExpressionAtlas; J3QQW9; baseline and differential.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   InterPro; IPR019135; Polycomb_protein_VEFS-Box.
DR   Pfam; PF09733; VEFS-Box; 1.
PE   1: Evidence at protein level;
KW   Coiled coil {ECO:0000256|SAM:Coils};
KW   Complete proteome {ECO:0000313|Proteomes:UP000005640};
KW   Proteomics identification {ECO:0000213|EPD:J3QQW9,
KW   ECO:0000213|MaxQB:J3QQW9, ECO:0000213|PeptideAtlas:J3QQW9};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640}.
FT   DOMAIN      524    656       VEFS-Box. {ECO:0000259|Pfam:PF09733}.
FT   COILED      651    671       {ECO:0000256|SAM:Coils}.
SQ   SEQUENCE   716 AA;  80322 MW;  7DC4178E12AEB8D7 CRC64;
     MAPQKHGGGG GGGSGPSAGS GGGGFGGSAA VAAATASGGK SGGGSCGGGG SYSASSSSSA
     AAAAGAAVLP VKKPKMEHVQ ADHELFLQAF EKPTQIYRFL RTRNLIAPIF LHRTLTYMSH
     RNSRTNIKSL SAHLQLTFTG FFHKNDKPSP NSENEQNSVT LEVLLVKVCH KKRKDVSCPI
     RQVPTGKKQV PLNPDLNQTK PGNFPSLAVS SNEFEPSNSH MVKSYSLLFR VTRPGRREFN
     GMINGETNEN IDVNEELPAR RKRNREDGEK TFVAQMTVFD KNRRLQLLDG EYEVAMQEME
     ECPISKKRAT WETILDGKRL PPFETFSQGP TLQFTLRWTG ETNDKSTAPI AKPLATRNSE
     SLHQENKPGS VKPTQTIAVK ESLTTDLQTR KEKDTPNENR QKLRIFYQFL YNNNTRQQTE
     ARDDLHCPWC TLNCRKLYSL LKHLKLCHSR FIFNYVYHPK GARIDVSINE CYDGSYAGNP
     QDIHRQPGFA FSRNGPVKRT PITHILVCRP KRTKASMSEF LESEDGEVEQ QRTYSSGHNR
     LYFHSDTCLP LRPQEMEVDS EDEKDPEWLR EKTITQIEEF SDVNEGEKEV MKLWNLHVMK
     HGFIADNQMN HACMLFVENY GQKIIKKNLC RNFMLHLVSM HDFNLISIMS IDKAVTKLRE
     MQQKLEKGES ASPANEEITE EQNGTANGFS EINSKEKALE TDSVSGVSKQ SKKQKL
//
ID   SUZ12_HUMAN             Reviewed;         739 AA.
AC   Q15022; Q96BD9;
DT   11-JUL-2003, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 3.
DT   28-FEB-2018, entry version 173.
DE   RecName: Full=Polycomb protein SUZ12;
DE   AltName: Full=Chromatin precipitated E2F target 9 protein;
DE            Short=ChET 9 protein;
DE   AltName: Full=Joined to JAZF1 protein;
DE   AltName: Full=Suppressor of zeste 12 protein homolog;
GN   Name=SUZ12; Synonyms=CHET9, JJAZ1, KIAA0160;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ILE-216.
RC   TISSUE=Bone marrow;
RX   PubMed=8590280; DOI=10.1093/dnares/2.4.167;
RA   Nagase T., Seki N., Tanaka A., Ishikawa K., Nomura N.;
RT   "Prediction of the coding sequences of unidentified human genes. IV.
RT   The coding sequences of 40 new genes (KIAA0121-KIAA0160) deduced by
RT   analysis of cDNA clones from human cell line KG-1.";
RL   DNA Res. 2:167-174(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   DISEASE, AND CHROMOSOMAL TRANSLOCATION WITH JAZF1.
RX   PubMed=11371647; DOI=10.1073/pnas.101132598;
RA   Koontz J.I., Soreng A.L., Nucci M., Kuo F.C., Pauwels P.,
RA   van Den Berghe H., Cin P.D., Fletcher J.A., Sklar J.;
RT   "Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal
RT   tumors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:6348-6353(2001).
RN   [4]
RP   INDUCTION.
RX   PubMed=11564866; DOI=10.1128/MCB.21.20.6820-6832.2001;
RA   Weinmann A.S., Bartley S.M., Zhang T., Zhang M.Q., Farnham P.J.;
RT   "Use of chromatin immunoprecipitation to clone novel E2F target
RT   promoters.";
RL   Mol. Cell. Biol. 21:6820-6832(2001).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN THE PRC2
RP   COMPLEX WITH EED; EZH2; RBBP4 AND RBBP7, AND METHYLTRANSFERASE
RP   ACTIVITY OF THE PRC2 COMPLEX.
RX   PubMed=12435631; DOI=10.1101/gad.1035902;
RA   Kuzmichev A., Nishioka K., Erdjument-Bromage H., Tempst P.,
RA   Reinberg D.;
RT   "Histone methyltransferase activity associated with a human
RT   multiprotein complex containing the Enhancer of Zeste protein.";
RL   Genes Dev. 16:2893-2905(2002).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN THE PRC2
RP   COMPLEX WITH EED; EZH2; RBBP4 AND RBBP7, AND METHYLTRANSFERASE
RP   ACTIVITY OF THE PRC2 COMPLEX.
RX   PubMed=12351676; DOI=10.1126/science.1076997;
RA   Cao R., Wang L., Wang H., Xia L., Erdjument-Bromage H., Tempst P.,
RA   Jones R.S., Zhang Y.;
RT   "Role of histone H3 lysine 27 methylation in Polycomb-group
RT   silencing.";
RL   Science 298:1039-1043(2002).
RN   [7]
RP   INDUCTION.
RX   PubMed=14532106; DOI=10.1093/emboj/cdg542;
RA   Bracken A.P., Pasini D., Capra M., Prosperini E., Colli E., Helin K.;
RT   "EZH2 is downstream of the pRB-E2F pathway, essential for
RT   proliferation and amplified in cancer.";
RL   EMBO J. 22:5323-5335(2003).
RN   [8]
RP   FUNCTION, INTERACTION WITH EZH2, METHYLTRANSFERASE ACTIVITY OF THE
RP   PRC2 COMPLEX, AND DEVELOPMENTAL STAGE.
RX   PubMed=15385962; DOI=10.1038/sj.emboj.7600402;
RA   Pasini D., Bracken A.P., Jensen M.R., Lazzerini Denchi E., Helin K.;
RT   "Suz12 is essential for mouse development and for EZH2 histone
RT   methyltransferase activity.";
RL   EMBO J. 23:4061-4071(2004).
RN   [9]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=15231737; DOI=10.1101/gad.1200204;
RA   Kirmizis A., Bartley S.M., Kuzmichev A., Margueron R., Reinberg D.,
RA   Green R., Farnham P.J.;
RT   "Silencing of human polycomb target genes is associated with
RT   methylation of histone H3 Lys 27.";
RL   Genes Dev. 18:1592-1605(2004).
RN   [10]
RP   CHARACTERIZATION OF THE PRC2 AND PRC3 COMPLEXES INCLUDING EED; EZH2;
RP   RBBP4; RBBP7 AND SUZ12, AND METHYLTRANSFERASE ACTIVITY OF THE PRC2 AND
RP   PRC3 COMPLEXES.
RX   PubMed=15099518; DOI=10.1016/S1097-2765(04)00185-6;
RA   Kuzmichev A., Jenuwein T., Tempst P., Reinberg D.;
RT   "Different EZH2-containing complexes target methylation of histone H1
RT   or nucleosomal histone H3.";
RL   Mol. Cell 14:183-193(2004).
RN   [11]
RP   FUNCTION, CHARACTERIZATION OF THE PRC2 COMPLEX INCLUDING AEBP2; EED;
RP   EZH2; RBBP4 AND SUZ12, AND METHYLTRANSFERASE ACTIVITY OF THE PRC2
RP   COMPLEX.
RX   PubMed=15225548; DOI=10.1016/j.molcel.2004.06.020;
RA   Cao R., Zhang Y.;
RT   "SUZ12 is required for both the histone methyltransferase activity and
RT   the silencing function of the EED-EZH2 complex.";
RL   Mol. Cell 15:57-67(2004).
RN   [12]
RP   CHARACTERIZATION OF THE PRC4 COMPLEX INCLUDING EED; EZH2; RBBP4;
RP   RBBP7; SUZ12 AND SIRT1, METHYLTRANSFERASE ACTIVITY OF THE PRC4
RP   COMPLEX, AND TISSUE SPECIFICITY.
RX   PubMed=15684044; DOI=10.1073/pnas.0409875102;
RA   Kuzmichev A., Margueron R., Vaquero A., Preissner T.S., Scher M.,
RA   Kirmizis A., Ouyang X., Brockdorff N., Abate-Shen C., Farnham P.J.,
RA   Reinberg D.;
RT   "Composition and histone substrates of polycomb repressive group
RT   complexes change during cellular differentiation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:1859-1864(2005).
RN   [13]
RP   INTERACTION WITH EZH2.
RX   PubMed=16224021; DOI=10.1126/science.1118947;
RA   Cha T.-L., Zhou B.P., Xia W., Wu Y., Yang C.-C., Chen C.-T., Ping B.,
RA   Otte A.P., Hung M.-C.;
RT   "Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine
RT   27 in histone H3.";
RL   Science 310:306-310(2005).
RN   [14]
RP   INTERACTION WITH WDR77.
RX   PubMed=16712789; DOI=10.1016/j.bbrc.2006.05.014;
RA   Furuno K., Masatsugu T., Sonoda M., Sasazuki T., Yamamoto K.;
RT   "Association of Polycomb group SUZ12 with WD-repeat protein MEP50 that
RT   binds to histone H2A selectively in vitro.";
RL   Biochem. Biophys. Res. Commun. 345:1051-1058(2006).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-546, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [16]
RP   FUNCTION.
RX   PubMed=16618801; DOI=10.1101/gad.381706;
RA   Bracken A.P., Dietrich N., Pasini D., Hansen K.H., Helin K.;
RT   "Genome-wide mapping of Polycomb target genes unravels their roles in
RT   cell fate transitions.";
RL   Genes Dev. 20:1123-1136(2006).
RN   [17]
RP   METHYLTRANSFERASE ACTIVITY OF THE PRC2 COMPLEX, AND INTERACTION WITH
RP   HISTONE H1.
RX   PubMed=16431907; DOI=10.1074/jbc.M513425200;
RA   Martin C., Cao R., Zhang Y.;
RT   "Substrate preferences of the EZH2 histone methyltransferase
RT   complex.";
RL   J. Biol. Chem. 281:8365-8370(2006).
RN   [18]
RP   FUNCTION.
RX   PubMed=17344414; DOI=10.1101/gad.415507;
RA   Bracken A.P., Kleine-Kohlbrecher D., Dietrich N., Pasini D.,
RA   Gargiulo G., Beekman C., Theilgaard-Moench K., Minucci S., Porse B.T.,
RA   Marine J.-C., Hansen K.H., Helin K.;
RT   "The Polycomb group proteins bind throughout the INK4A-ARF locus and
RT   are disassociated in senescent cells.";
RL   Genes Dev. 21:525-530(2007).
RN   [19]
RP   DE NOVO DNA METHYLATION OF PRC2 TARGET GENES.
RX   PubMed=17200670; DOI=10.1038/ng1950;
RA   Schlesinger Y., Straussman R., Keshet I., Farkash S., Hecht M.,
RA   Zimmerman J., Eden E., Yakhini Z., Ben-Shushan E., Reubinoff B.E.,
RA   Bergman Y., Simon I., Cedar H.;
RT   "Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes
RT   for de novo methylation in cancer.";
RL   Nat. Genet. 39:232-236(2007).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-546 AND SER-583, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [21]
RP   IDENTIFICATION IN THE PRC2/EED-EZH1 COMPLEX.
RX   PubMed=19026781; DOI=10.1016/j.molcel.2008.11.004;
RA   Margueron R., Li G., Sarma K., Blais A., Zavadil J., Woodcock C.L.,
RA   Dynlacht B.D., Reinberg D.;
RT   "Ezh1 and Ezh2 maintain repressive chromatin through different
RT   mechanisms.";
RL   Mol. Cell 32:503-518(2008).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN THE PRC2
RP   COMPLEX, AND METHYLTRANSFERASE ACTIVITY OF THE PRC2 COMPLEX.
RX   PubMed=18086877; DOI=10.1128/MCB.01589-07;
RA   Cao R., Wang H., He J., Erdjument-Bromage H., Tempst P., Zhang Y.;
RT   "Role of hPHF1 in H3K27 methylation and Hox gene silencing.";
RL   Mol. Cell. Biol. 28:1862-1872(2008).
RN   [23]
RP   FUNCTION, INTERACTION WITH EED AND EZH2, INTERACTION OF THE PRC2
RP   COMPLEX WITH PHF1, AND METHYLTRANSFERASE ACTIVITY OF THE PRC2 COMPLEX.
RX   PubMed=18285464; DOI=10.1128/MCB.02017-07;
RA   Sarma K., Margueron R., Ivanov A., Pirrotta V., Reinberg D.;
RT   "Ezh2 requires PHF1 to efficiently catalyze H3 lysine 27
RT   trimethylation in vivo.";
RL   Mol. Cell. Biol. 28:2718-2731(2008).
RN   [24]
RP   SUMOYLATION AT LYS-72; LYS-73 AND LYS-75.
RX   PubMed=18628979; DOI=10.1371/journal.pone.0002704;
RA   Riising E.M., Boggio R., Chiocca S., Helin K., Pasini D.;
RT   "The polycomb repressive complex 2 is a potential target of SUMO
RT   modifications.";
RL   PLoS ONE 3:E2704-E2704(2008).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-546, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [26]
RP   TRANS-SPLICING.
RX   PubMed=18772439; DOI=10.1126/science.1156725;
RA   Li H., Wang J., Mor G., Sklar J.;
RT   "A neoplastic gene fusion mimics trans-splicing of RNAs in normal
RT   human cells.";
RL   Science 321:1357-1361(2008).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-546, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-546, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [30]
RP   INTERACTION WITH CDYL.
RX   PubMed=22009739; DOI=10.1074/jbc.M111.271064;
RA   Zhang Y., Yang X., Gui B., Xie G., Zhang D., Shang Y., Liang J.;
RT   "Corepressor protein CDYL functions as a molecular bridge between
RT   polycomb repressor complex 2 and repressive chromatin mark
RT   trimethylated histone lysine 27.";
RL   J. Biol. Chem. 286:42414-42425(2011).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-546, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-20; SER-541; SER-546 AND
RP   SER-726, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.O113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V.,
RA   Aguiar M., Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C.,
RA   Vemulapalli V., Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [34]
RP   INVOLVEMENT IN DISEASE, VARIANT VAL-610, CHARACTERIZATION OF VARIANT
RP   VAL-610, AND FUNCTION.
RX   PubMed=28229514; DOI=10.1002/humu.23200;
RA   Imagawa E., Higashimoto K., Sakai Y., Numakura C., Okamoto N.,
RA   Matsunaga S., Ryo A., Sato Y., Sanefuji M., Ihara K., Takada Y.,
RA   Nishimura G., Saitsu H., Mizuguchi T., Miyatake S., Nakashima M.,
RA   Miyake N., Soejima H., Matsumoto N.;
RT   "Mutations in genes encoding polycomb repressive complex 2 subunits
RT   cause Weaver syndrome.";
RL   Hum. Mutat. 38:637-648(2017).
RN   [35]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-75; LYS-223 AND LYS-390, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-
RT   modification with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   -!- FUNCTION: Polycomb group (PcG) protein. Component of the PRC2/EED-
CC       EZH2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys-27'
CC       (H3K27me) of histone H3, leading to transcriptional repression of
CC       the affected target gene. The PRC2/EED-EZH2 complex may also serve
CC       as a recruiting platform for DNA methyltransferases, thereby
CC       linking two epigenetic repression systems. Genes repressed by the
CC       PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1 and CDKN2A.
CC       {ECO:0000269|PubMed:15225548, ECO:0000269|PubMed:15231737,
CC       ECO:0000269|PubMed:15385962, ECO:0000269|PubMed:16618801,
CC       ECO:0000269|PubMed:17344414, ECO:0000269|PubMed:18285464,
CC       ECO:0000269|PubMed:28229514}.
CC   -!- SUBUNIT: Component of the PRC2/EED-EZH2 complex, which includes
CC       EED, EZH2, SUZ12, RBBP4 and RBBP7 and possibly AEBP2. The minimum
CC       components required for methyltransferase activity of the
CC       PRC2/EED-EZH2 complex are EED, EZH2 and SUZ12. Component of the
CC       PRC2/EED-EZH1 complex, which includes EED, EZH1, SUZ12, RBBP4 and
CC       AEBP2. The PRC2 complex may also interact with DNMT1, DNMT3A,
CC       DNMT3B and PHF1 via the EZH2 subunit and with SIRT1 via the SUZ12
CC       subunit. Interacts with WDR77. Interacts with histone H1.
CC       Interacts with CDYL. Interacts with ARNTL/BMAL1.
CC       {ECO:0000269|PubMed:12351676, ECO:0000269|PubMed:12435631,
CC       ECO:0000269|PubMed:15385962, ECO:0000269|PubMed:16224021,
CC       ECO:0000269|PubMed:16431907, ECO:0000269|PubMed:16712789,
CC       ECO:0000269|PubMed:18086877, ECO:0000269|PubMed:18285464,
CC       ECO:0000269|PubMed:19026781, ECO:0000269|PubMed:22009739}.
CC   -!- INTERACTION:
CC       O75530:EED; NbExp=8; IntAct=EBI-1264675, EBI-923794;
CC       Q15910:EZH2; NbExp=22; IntAct=EBI-1264675, EBI-530054;
CC       O15379:HDAC3; NbExp=7; IntAct=EBI-1264675, EBI-607682;
CC       Q14774:HLX; NbExp=2; IntAct=EBI-1264675, EBI-6678255;
CC       Q92833-1:JARID2; NbExp=7; IntAct=EBI-1264675, EBI-15825247;
CC       Q15156:PML-RAR; NbExp=6; IntAct=EBI-1264675, EBI-867256;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15231737}.
CC   -!- TISSUE SPECIFICITY: Overexpressed in breast and colon cancer.
CC       {ECO:0000269|PubMed:15231737, ECO:0000269|PubMed:15684044}.
CC   -!- DEVELOPMENTAL STAGE: Expressed at low levels in quiescent cells.
CC       Expression rises at the G1/S phase transition.
CC       {ECO:0000269|PubMed:15385962}.
CC   -!- INDUCTION: Expression is induced by E2F1, E2F2 and E2F3.
CC       {ECO:0000269|PubMed:11564866, ECO:0000269|PubMed:14532106}.
CC   -!- PTM: Sumoylated, probably by PIAS2. {ECO:0000269|PubMed:18628979}.
CC   -!- DISEASE: Note=A chromosomal aberration involving SUZ12 may be a
CC       cause of endometrial stromal tumors. Translocation
CC       t(7;17)(p15;q21) with JAZF1. The translocation generates the
CC       JAZF1-SUZ12 oncogene consisting of the N-terminus part of JAZF1
CC       and the C-terminus part of SUZ12. It is frequently found in all
CC       cases of endometrial stromal tumors, except in endometrial stromal
CC       sarcomas, where it is rarer. {ECO:0000269|PubMed:11371647}.
CC   -!- DISEASE: Note=Defects in EED are associated with Weaver syndrome
CC       (WVS): A syndrome of accelerated growth and osseous maturation,
CC       unusual craniofacial appearance, hoarse and low-pitched cry, and
CC       hypertonia with camptodactyly. Distinguishing features of Weaver
CC       syndrome include broad forehead and face, ocular hypertelorism,
CC       prominent wide philtrum, micrognathia, deep horizontal chin
CC       groove, and deep-set nails. In addition, carpal bone development
CC       is advanced over the rest of the hand.
CC       {ECO:0000269|PubMed:28229514}.
CC   -!- MISCELLANEOUS: Under hypoxic conditions, the precursor SUZ12 RNA
CC       undergoes regulated trans-splicing with the JAZF1 RNA, resulting
CC       in a chimeric isoform which may be protective against apoptosis.
CC       The chimeric transcript is characterized by JAZF1 exons 1-3 joined
CC       to SUZ12 exon 2-16. The chimeric transcript is expressed primarily
CC       in the endometrium from late secretory and early proliferative
CC       phases of the menstrual cycle, but not in normal myometrium at any
CC       phase of the cycle. Its expression is slightly induced by low
CC       levels of progesterone, but suppressed by both estrogen and high
CC       levels of progesterone (PubMed:18772439).
CC       {ECO:0000305|PubMed:18772439}.
CC   -!- SIMILARITY: Belongs to the VEFS (VRN2-EMF2-FIS2-SU(Z)12) family.
CC       {ECO:0000305}.
CC   -!- CAUTION: Two variants of the PRC2 complex have been described,
CC       termed PRC3 and PRC4. Each of the three complexes may include a
CC       different complement of EED isoforms, although the precise
CC       sequences of the isoforms in each complex have not been
CC       determined. The PRC2 and PRC4 complexes may also methylate 'Lys-
CC       26' of histone H1 in addition to 'Lys-27' of histone H3
CC       (PubMed:15099518 and PubMed:15684044), although other studies have
CC       demonstrated no methylation of 'Lys-26' of histone H1 by PRC2
CC       (PubMed:16431907). {ECO:0000305|PubMed:16431907}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA09931.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/JJAZ1ID41039ch17q11.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D63881; BAA09931.2; ALT_INIT; mRNA.
DR   EMBL; BC015704; AAH15704.1; -; mRNA.
DR   CCDS; CCDS11270.1; -.
DR   RefSeq; NP_056170.2; NM_015355.3.
DR   UniGene; Hs.462732; -.
DR   PDB; 4W2R; X-ray; 2.81 A; S/T=545-725.
DR   PDB; 5HYN; X-ray; 2.95 A; C/H/M/S=558-685.
DR   PDB; 5IJ7; X-ray; 2.62 A; S/T=545-725.
DR   PDB; 5IJ8; X-ray; 2.99 A; S/T=545-725.
DR   PDB; 5LS6; X-ray; 3.47 A; C/F/I/L=558-685.
DR   PDB; 6B3W; X-ray; 3.05 A; S/T=545-725.
DR   PDBsum; 4W2R; -.
DR   PDBsum; 5HYN; -.
DR   PDBsum; 5IJ7; -.
DR   PDBsum; 5IJ8; -.
DR   PDBsum; 5LS6; -.
DR   PDBsum; 6B3W; -.
DR   ProteinModelPortal; Q15022; -.
DR   SMR; Q15022; -.
DR   BioGrid; 117059; 348.
DR   CORUM; Q15022; -.
DR   DIP; DIP-38524N; -.
DR   IntAct; Q15022; 39.
DR   MINT; Q15022; -.
DR   STRING; 9606.ENSP00000316578; -.
DR   BindingDB; Q15022; -.
DR   ChEMBL; CHEMBL3137287; -.
DR   iPTMnet; Q15022; -.
DR   PhosphoSitePlus; Q15022; -.
DR   BioMuta; SUZ12; -.
DR   DMDM; 116242808; -.
DR   EPD; Q15022; -.
DR   MaxQB; Q15022; -.
DR   PaxDb; Q15022; -.
DR   PeptideAtlas; Q15022; -.
DR   PRIDE; Q15022; -.
DR   Ensembl; ENST00000322652; ENSP00000316578; ENSG00000178691.
DR   GeneID; 23512; -.
DR   KEGG; hsa:23512; -.
DR   UCSC; uc002hgs.3; human.
DR   CTD; 23512; -.
DR   DisGeNET; 23512; -.
DR   EuPathDB; HostDB:ENSG00000178691.10; -.
DR   GeneCards; SUZ12; -.
DR   HGNC; HGNC:17101; SUZ12.
DR   HPA; HPA057436; -.
DR   MalaCards; SUZ12; -.
DR   MIM; 606245; gene.
DR   neXtProt; NX_Q15022; -.
DR   OpenTargets; ENSG00000178691; -.
DR   PharmGKB; PA134936035; -.
DR   eggNOG; KOG2350; Eukaryota.
DR   eggNOG; ENOG410YJ29; LUCA.
DR   GeneTree; ENSGT00390000012364; -.
DR   HOGENOM; HOG000047340; -.
DR   HOVERGEN; HBG039522; -.
DR   InParanoid; Q15022; -.
DR   KO; K11463; -.
DR   OMA; AMQEMEE; -.
DR   OrthoDB; EOG091G012Q; -.
DR   PhylomeDB; Q15022; -.
DR   TreeFam; TF323249; -.
DR   Reactome; R-HSA-212300; PRC2 methylates histones and DNA.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-3214841; PKMTs methylate histone lysines.
DR   Reactome; R-HSA-4551638; SUMOylation of chromatin organization proteins.
DR   Reactome; R-HSA-5617472; Activation of anterior HOX genes in hindbrain development during early embryogenesis.
DR   Reactome; R-HSA-8943724; Regulation of PTEN gene transcription.
DR   Reactome; R-HSA-8953750; Transcriptional Regulation by E2F6.
DR   SignaLink; Q15022; -.
DR   SIGNOR; Q15022; -.
DR   ChiTaRS; SUZ12; human.
DR   GeneWiki; SUZ12; -.
DR   GenomeRNAi; 23512; -.
DR   PRO; PR:Q15022; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000178691; -.
DR   CleanEx; HS_SUZ12; -.
DR   ExpressionAtlas; Q15022; baseline and differential.
DR   Genevisible; Q15022; HS.
DR   GO; GO:0035098; C:ESC/E(Z) complex; IDA:UniProtKB.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0032993; C:protein-DNA complex; IEA:Ensembl.
DR   GO; GO:0016586; C:RSC-type complex; IBA:GO_Central.
DR   GO; GO:0001739; C:sex chromatin; IEA:Ensembl.
DR   GO; GO:0031490; F:chromatin DNA binding; IBA:GO_Central.
DR   GO; GO:0042054; F:histone methyltransferase activity; IMP:MGI.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0035064; F:methylated histone binding; IDA:UniProtKB.
DR   GO; GO:1990841; F:promoter-specific chromatin binding; IEA:Ensembl.
DR   GO; GO:0003723; F:RNA binding; IEA:Ensembl.
DR   GO; GO:0000978; F:RNA polymerase II proximal promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0070734; P:histone H3-K27 methylation; IEA:GOC.
DR   GO; GO:0016574; P:histone ubiquitination; IEA:Ensembl.
DR   GO; GO:0045596; P:negative regulation of cell differentiation; IMP:UniProtKB.
DR   GO; GO:0070317; P:negative regulation of G0 to G1 transition; TAS:Reactome.
DR   GO; GO:0045814; P:negative regulation of gene expression, epigenetic; TAS:Reactome.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IBA:GO_Central.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   InterPro; IPR019135; Polycomb_protein_VEFS-Box.
DR   Pfam; PF09733; VEFS-Box; 1.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Chromatin regulator; Chromosomal rearrangement;
KW   Complete proteome; Isopeptide bond; Metal-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Proto-oncogene; Reference proteome;
KW   Repressor; Transcription; Transcription regulation; Ubl conjugation;
KW   Zinc; Zinc-finger.
FT   CHAIN         1    739       Polycomb protein SUZ12.
FT                                /FTId=PRO_0000047057.
FT   ZN_FING     448    471       C2H2-type.
FT   REGION      563    639       VEFS-box.
FT   COMPBIAS      7     50       Gly-rich.
FT   COMPBIAS     51     59       Poly-Ser.
FT   COMPBIAS     60     67       Poly-Ala.
FT   SITE         93     94       Breakpoint for translocation to form
FT                                JAZF1-SUZ12 oncogene.
FT   MOD_RES      20     20       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     541    541       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     546    546       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18220336,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     583    583       Phosphoserine.
FT                                {ECO:0000244|PubMed:18220336}.
FT   MOD_RES     726    726       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   CROSSLNK     72     72       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000269|PubMed:18628979}.
FT   CROSSLNK     73     73       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000269|PubMed:18628979}.
FT   CROSSLNK     75     75       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO);
FT                                alternate. {ECO:0000269|PubMed:18628979}.
FT   CROSSLNK     75     75       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2);
FT                                alternate. {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    223    223       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    390    390       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   VARIANT     216    216       N -> I (in dbSNP:rs17339444).
FT                                {ECO:0000269|PubMed:8590280}.
FT                                /FTId=VAR_028100.
FT   VARIANT     610    610       E -> V (found in a patient with Weaver
FT                                syndrome; decreased trimethylation of
FT                                'Lys-27' of histone H3; no effect on
FT                                interaction with EZH2).
FT                                {ECO:0000269|PubMed:28229514}.
FT                                /FTId=VAR_078318.
FT   TURN        568    570       {ECO:0000244|PDB:5IJ7}.
FT   HELIX       576    578       {ECO:0000244|PDB:5IJ7}.
FT   HELIX       590    601       {ECO:0000244|PDB:5IJ7}.
FT   STRAND      604    606       {ECO:0000244|PDB:5IJ7}.
FT   HELIX       608    624       {ECO:0000244|PDB:5IJ7}.
FT   HELIX       629    631       {ECO:0000244|PDB:5IJ7}.
FT   HELIX       632    649       {ECO:0000244|PDB:5IJ7}.
FT   HELIX       653    665       {ECO:0000244|PDB:5IJ7}.
FT   HELIX       671    686       {ECO:0000244|PDB:5IJ7}.
SQ   SEQUENCE   739 AA;  83055 MW;  A8830EBC3FD38D56 CRC64;
     MAPQKHGGGG GGGSGPSAGS GGGGFGGSAA VAAATASGGK SGGGSCGGGG SYSASSSSSA
     AAAAGAAVLP VKKPKMEHVQ ADHELFLQAF EKPTQIYRFL RTRNLIAPIF LHRTLTYMSH
     RNSRTNIKRK TFKVDDMLSK VEKMKGEQES HSLSAHLQLT FTGFFHKNDK PSPNSENEQN
     SVTLEVLLVK VCHKKRKDVS CPIRQVPTGK KQVPLNPDLN QTKPGNFPSL AVSSNEFEPS
     NSHMVKSYSL LFRVTRPGRR EFNGMINGET NENIDVNEEL PARRKRNRED GEKTFVAQMT
     VFDKNRRLQL LDGEYEVAMQ EMEECPISKK RATWETILDG KRLPPFETFS QGPTLQFTLR
     WTGETNDKST APIAKPLATR NSESLHQENK PGSVKPTQTI AVKESLTTDL QTRKEKDTPN
     ENRQKLRIFY QFLYNNNTRQ QTEARDDLHC PWCTLNCRKL YSLLKHLKLC HSRFIFNYVY
     HPKGARIDVS INECYDGSYA GNPQDIHRQP GFAFSRNGPV KRTPITHILV CRPKRTKASM
     SEFLESEDGE VEQQRTYSSG HNRLYFHSDT CLPLRPQEME VDSEDEKDPE WLREKTITQI
     EEFSDVNEGE KEVMKLWNLH VMKHGFIADN QMNHACMLFV ENYGQKIIKK NLCRNFMLHL
     VSMHDFNLIS IMSIDKAVTK LREMQQKLEK GESASPANEE ITEEQNGTAN GFSEINSKEK
     ALETDSVSGV SKQSKKQKL
//
ID   TBL1R_HUMAN             Reviewed;         514 AA.
AC   Q9BZK7; D3DNQ9; Q14DC3; Q9H2I1; Q9H9A1;
DT   19-SEP-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2001, sequence version 1.
DT   28-FEB-2018, entry version 164.
DE   RecName: Full=F-box-like/WD repeat-containing protein TBL1XR1;
DE   AltName: Full=Nuclear receptor corepressor/HDAC3 complex subunit TBLR1;
DE   AltName: Full=TBL1-related protein 1;
DE   AltName: Full=Transducin beta-like 1X-related protein 1;
GN   Name=TBL1XR1; Synonyms=IRA1, TBLR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   COMPONENT OF THE N-COR COMPLEX WITH NCOR1; NCOR2; GPS2; TBL1X AND
RP   HDAC3.
RX   PubMed=11931768; DOI=10.1016/S1097-2765(02)00468-9;
RA   Zhang J., Kalkum M., Chait B.T., Roeder R.G.;
RT   "The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK
RT   pathway through the integral subunit GPS2.";
RL   Mol. Cell 9:611-623(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=11063877; DOI=10.1016/S0301-472X(00)00539-7;
RA   Zhang X., Dormady S.P., Basch R.S.;
RT   "Identification of four human cDNAs that are differentially expressed
RT   by early hematopoietic progenitors.";
RL   Exp. Hematol. 28:1286-1296(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Adrenal cortex, and Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   COMPONENT OF THE N-COR COMPLEX WITH TBL1X; CORO2A AND HDAC3, AND
RP   HISTONE-BINDING.
RX   PubMed=12628926; DOI=10.1093/emboj/cdg120;
RA   Yoon H.-G., Chan D.W., Huang Z.-Q., Li J., Fondell J.D., Qin J.,
RA   Wong J.;
RT   "Purification and functional characterization of the human N-CoR
RT   complex: the roles of HDAC3, TBL1 and TBLR1.";
RL   EMBO J. 22:1336-1346(2003).
RN   [7]
RP   FUNCTION, AND RECRUITMENT OF 19S PROTEASOME COMPLEX.
RX   PubMed=14980219; DOI=10.1016/S0092-8674(04)00133-3;
RA   Perissi V., Aggarwal A., Glass C.K., Rose D.W., Rosenfeld M.G.;
RT   "A corepressor/coactivator exchange complex required for
RT   transcriptional activation by nuclear receptors and other regulated
RT   transcription factors.";
RL   Cell 116:511-526(2004).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-119, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [12]
RP   INVOLVEMENT IN MRD41, AND VARIANT MRD41 PRO-282.
RX   PubMed=22495309; DOI=10.1038/nature10989;
RA   O'Roak B.J., Vives L., Girirajan S., Karakoc E., Krumm N., Coe B.P.,
RA   Levy R., Ko A., Lee C., Smith J.D., Turner E.H., Stanaway I.B.,
RA   Vernot B., Malig M., Baker C., Reilly B., Akey J.M., Borenstein E.,
RA   Rieder M.J., Nickerson D.A., Bernier R., Shendure J., Eichler E.E.;
RT   "Sporadic autism exomes reveal a highly interconnected protein network
RT   of de novo mutations.";
RL   Nature 485:246-250(2012).
RN   [13]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [14]
RP   INVOLVEMENT IN MRD41.
RX   PubMed=23160955; DOI=10.1126/science.1227764;
RA   O'Roak B.J., Vives L., Fu W., Egertson J.D., Stanaway I.B.,
RA   Phelps I.G., Carvill G., Kumar A., Lee C., Ankenman K., Munson J.,
RA   Hiatt J.B., Turner E.H., Levy R., O'Day D.R., Krumm N., Coe B.P.,
RA   Martin B.K., Borenstein E., Nickerson D.A., Mefford H.C., Doherty D.,
RA   Akey J.M., Bernier R., Eichler E.E., Shendure J.;
RT   "Multiplex targeted sequencing identifies recurrently mutated genes in
RT   autism spectrum disorders.";
RL   Science 338:1619-1622(2012).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-119, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   INVOLVEMENT IN MRD41, VARIANT MRD41 ASP-70, AND VARIANTS SER-116;
RP   GLU-405 AND SER-407.
RX   PubMed=25102098; DOI=10.1038/jhg.2014.71;
RA   Saitsu H., Tohyama J., Walsh T., Kato M., Kobayashi Y., Lee M.,
RA   Tsurusaki Y., Miyake N., Goto Y., Nishino I., Ohtake A., King M.C.,
RA   Matsumoto N.;
RT   "A girl with West syndrome and autistic features harboring a de novo
RT   TBL1XR1 mutation.";
RL   J. Hum. Genet. 59:581-583(2014).
RN   [17]
RP   INVOLVEMENT IN MRD41, AND VARIANT MRD41 CYS-245.
RX   PubMed=27133561; DOI=10.1002/ajmg.a.37684;
RG   FORGE Canada Consortium;
RA   Armour C.M., Smith A., Hartley T., Chardon J.W., Sawyer S.,
RA   Schwartzentruber J., Hennekam R., Majewski J., Bulman D.E., Suri M.,
RA   Boycott K.M.;
RT   "Syndrome disintegration: Exome sequencing reveals that Fitzsimmons
RT   syndrome is a co-occurrence of multiple events.";
RL   Am. J. Med. Genet. A 170:1820-1825(2016).
RN   [18]
RP   TISSUE SPECIFICITY, INVOLVEMENT IN PRPTS, VARIANT PRPTS CYS-446, AND
RP   CHARACTERIZATION OF VARIANT PRPTS CYS-446.
RX   PubMed=26769062; DOI=10.1136/jmedgenet-2015-103233;
RA   Heinen C.A., Jongejan A., Watson P.J., Redeker B., Boelen A.,
RA   Boudzovitch-Surovtseva O., Forzano F., Hordijk R., Kelley R.,
RA   Olney A.H., Pierpont M.E., Schaefer G.B., Stewart F.,
RA   van Trotsenburg A.S., Fliers E., Schwabe J.W., Hennekam R.C.;
RT   "A specific mutation in TBL1XR1 causes Pierpont syndrome.";
RL   J. Med. Genet. 53:330-337(2016).
RN   [19]
RP   ERRATUM.
RX   PubMed=27221108; DOI=10.1136/jmedgenet-2015-103233corr1;
RA   Heinen C.A., Jongejan A., Watson P.J., Redeker B., Boelen A.,
RA   Boudzovitch-Surovtseva O., Forzano F., Hordijk R., Kelley R.,
RA   Olney A.H., Pierpont M.E., Schaefer G.B., Stewart F.,
RA   van Trotsenburg A.S., Fliers E., Schwabe J.W., Hennekam R.C.;
RL   J. Med. Genet. 53:430-430(2016).
RN   [20]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-277, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-
RT   modification with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   -!- FUNCTION: F-box-like protein involved in the recruitment of the
CC       ubiquitin/19S proteasome complex to nuclear receptor-regulated
CC       transcription units. Plays an essential role in transcription
CC       activation mediated by nuclear receptors. Probably acts as
CC       integral component of the N-Cor corepressor complex that mediates
CC       the recruitment of the 19S proteasome complex, leading to the
CC       subsequent proteasomal degradation of N-Cor complex, thereby
CC       allowing cofactor exchange, and transcription activation.
CC       {ECO:0000269|PubMed:14980219}.
CC   -!- SUBUNIT: Component of the N-Cor repressor complex, at least
CC       composed of NCOR1, NCOR2, HDAC3, TBL1X, TBL1XR1, CORO2A and GPS2
CC       (PubMed:11931768). Probable component of some E3 ubiquitin ligase
CC       complex. Interacts with histones H2B and H4 (PubMed:12628926).
CC       Interacts with MECP2; bridges interaction between MECP2 and NCOR1
CC       (By similarity). {ECO:0000250|UniProtKB:Q8BHJ5,
CC       ECO:0000269|PubMed:11931768, ECO:0000269|PubMed:12628926}.
CC   -!- INTERACTION:
CC       P36404:ARL2; NbExp=3; IntAct=EBI-765729, EBI-752365;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000305}.
CC   -!- TISSUE SPECIFICITY: Widely expressed including the pituitary,
CC       hypothalamus, white and brown adipose tissue, muscle and liver.
CC       {ECO:0000269|PubMed:26769062}.
CC   -!- DOMAIN: The F-box-like domain is related to the F-box domain, and
CC       apparently displays the same function as component of ubiquitin E3
CC       ligase complexes. {ECO:0000250}.
CC   -!- DISEASE: Pierpont syndrome (PRPTS) [MIM:602342]: An autosomal
CC       dominant syndrome characterized by multiple congenital anomalies,
CC       global developmental delay, learning disability, palmar and
CC       plantar fat pads, and distinctive facial characteristics,
CC       especially when smiling. {ECO:0000269|PubMed:26769062}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Mental retardation, autosomal dominant 41 (MRD41)
CC       [MIM:616944]: A form of mental retardation, a disorder
CC       characterized by significantly below average general intellectual
CC       functioning associated with impairments in adaptive behavior and
CC       manifested during the developmental period. MRD41 patients
CC       manifest delayed psychomotor development, variable severity of
CC       intellectual disability, and delayed language. Non-specific
CC       dysmorphic features and autistic behavior is observed in some
CC       patients. {ECO:0000269|PubMed:22495309,
CC       ECO:0000269|PubMed:23160955, ECO:0000269|PubMed:25102098,
CC       ECO:0000269|PubMed:27133561}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the WD repeat EBI family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH60320.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF314544; AAK00301.1; -; mRNA.
DR   EMBL; AF268193; AAG44736.1; -; mRNA.
DR   EMBL; AK022956; BAB14331.1; -; mRNA.
DR   EMBL; CH471052; EAW78438.1; -; Genomic_DNA.
DR   EMBL; BC060320; AAH60320.1; ALT_SEQ; mRNA.
DR   EMBL; BC113421; AAI13422.1; -; mRNA.
DR   CCDS; CCDS46961.1; -.
DR   RefSeq; NP_001308122.1; NM_001321193.1.
DR   RefSeq; NP_001308123.1; NM_001321194.1.
DR   RefSeq; NP_001308124.1; NM_001321195.1.
DR   RefSeq; NP_078941.2; NM_024665.5.
DR   RefSeq; XP_005247832.1; XM_005247775.2.
DR   RefSeq; XP_006713809.1; XM_006713746.1.
DR   RefSeq; XP_011511443.1; XM_011513141.1.
DR   RefSeq; XP_011511444.1; XM_011513142.2.
DR   RefSeq; XP_011511445.1; XM_011513143.2.
DR   RefSeq; XP_016862674.1; XM_017007185.1.
DR   UniGene; Hs.714201; -.
DR   UniGene; Hs.715026; -.
DR   PDB; 4LG9; X-ray; 2.28 A; A=134-514.
DR   PDBsum; 4LG9; -.
DR   ProteinModelPortal; Q9BZK7; -.
DR   SMR; Q9BZK7; -.
DR   BioGrid; 122834; 73.
DR   CORUM; Q9BZK7; -.
DR   DIP; DIP-34582N; -.
DR   IntAct; Q9BZK7; 32.
DR   MINT; Q9BZK7; -.
DR   STRING; 9606.ENSP00000405574; -.
DR   iPTMnet; Q9BZK7; -.
DR   PhosphoSitePlus; Q9BZK7; -.
DR   BioMuta; TBL1XR1; -.
DR   DMDM; 23396874; -.
DR   EPD; Q9BZK7; -.
DR   MaxQB; Q9BZK7; -.
DR   PaxDb; Q9BZK7; -.
DR   PeptideAtlas; Q9BZK7; -.
DR   PRIDE; Q9BZK7; -.
DR   Ensembl; ENST00000430069; ENSP00000405574; ENSG00000177565.
DR   Ensembl; ENST00000457928; ENSP00000413251; ENSG00000177565.
DR   GeneID; 79718; -.
DR   KEGG; hsa:79718; -.
DR   UCSC; uc003fiw.5; human.
DR   CTD; 79718; -.
DR   DisGeNET; 79718; -.
DR   EuPathDB; HostDB:ENSG00000177565.15; -.
DR   GeneCards; TBL1XR1; -.
DR   H-InvDB; HIX0147994; -.
DR   HGNC; HGNC:29529; TBL1XR1.
DR   HPA; HPA019182; -.
DR   MalaCards; TBL1XR1; -.
DR   MIM; 602342; phenotype.
DR   MIM; 608628; gene.
DR   MIM; 616944; phenotype.
DR   neXtProt; NX_Q9BZK7; -.
DR   OpenTargets; ENSG00000177565; -.
DR   Orphanet; 520; Acute promyelocytic leukemia.
DR   PharmGKB; PA134928556; -.
DR   eggNOG; ENOG410IQU2; Eukaryota.
DR   eggNOG; COG2319; LUCA.
DR   GeneTree; ENSGT00890000139430; -.
DR   HOGENOM; HOG000220902; -.
DR   HOVERGEN; HBG050240; -.
DR   InParanoid; Q9BZK7; -.
DR   KO; K04508; -.
DR   OMA; KWDPQGQ; -.
DR   OrthoDB; EOG091G04MW; -.
DR   PhylomeDB; Q9BZK7; -.
DR   TreeFam; TF323190; -.
DR   Reactome; R-HSA-1368082; RORA activates gene expression.
DR   Reactome; R-HSA-1368108; BMAL1:CLOCK,NPAS2 activates circadian gene expression.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-2032785; YAP1- and WWTR1 (TAZ)-stimulated gene expression.
DR   Reactome; R-HSA-2122947; NOTCH1 Intracellular Domain Regulates Transcription.
DR   Reactome; R-HSA-2151201; Transcriptional activation of mitochondrial biogenesis.
DR   Reactome; R-HSA-2426168; Activation of gene expression by SREBF (SREBP).
DR   Reactome; R-HSA-2644606; Constitutive Signaling by NOTCH1 PEST Domain Mutants.
DR   Reactome; R-HSA-2894862; Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants.
DR   Reactome; R-HSA-3214815; HDACs deacetylate histones.
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   Reactome; R-HSA-400206; Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha).
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   Reactome; R-HSA-8951671; RUNX3 regulates YAP1-mediated transcription.
DR   SignaLink; Q9BZK7; -.
DR   SIGNOR; Q9BZK7; -.
DR   ChiTaRS; TBL1XR1; human.
DR   GeneWiki; TBL1XR1; -.
DR   GenomeRNAi; 79718; -.
DR   PMAP-CutDB; Q9BZK7; -.
DR   PRO; PR:Q9BZK7; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000177565; -.
DR   CleanEx; HS_TBL1XR1; -.
DR   ExpressionAtlas; Q9BZK7; baseline and differential.
DR   Genevisible; Q9BZK7; HS.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005876; C:spindle microtubule; IDA:UniProtKB.
DR   GO; GO:0017053; C:transcriptional repressor complex; IDA:UniProtKB.
DR   GO; GO:0008013; F:beta-catenin binding; IPI:UniProtKB.
DR   GO; GO:0042393; F:histone binding; IDA:UniProtKB.
DR   GO; GO:0047485; F:protein N-terminus binding; IPI:UniProtKB.
DR   GO; GO:0003714; F:transcription corepressor activity; IDA:UniProtKB.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IDA:UniProtKB.
DR   GO; GO:0060613; P:fat pad development; IEA:Ensembl.
DR   GO; GO:0016575; P:histone deacetylation; IBA:GO_Central.
DR   GO; GO:0016042; P:lipid catabolic process; IEA:Ensembl.
DR   GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; ISS:UniProtKB.
DR   GO; GO:0030814; P:regulation of cAMP metabolic process; IEA:Ensembl.
DR   GO; GO:0019216; P:regulation of lipid metabolic process; TAS:Reactome.
DR   GO; GO:0090207; P:regulation of triglyceride metabolic process; IEA:Ensembl.
DR   GO; GO:0002021; P:response to dietary excess; IEA:Ensembl.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0050872; P:white fat cell differentiation; IEA:Ensembl.
DR   Gene3D; 2.130.10.10; -; 1.
DR   InterPro; IPR020472; G-protein_beta_WD-40_rep.
DR   InterPro; IPR006594; LisH.
DR   InterPro; IPR015943; WD40/YVTN_repeat-like_dom_sf.
DR   InterPro; IPR001680; WD40_repeat.
DR   InterPro; IPR019775; WD40_repeat_CS.
DR   InterPro; IPR017986; WD40_repeat_dom.
DR   InterPro; IPR036322; WD40_repeat_dom_sf.
DR   Pfam; PF08513; LisH; 1.
DR   Pfam; PF00400; WD40; 6.
DR   PRINTS; PR00320; GPROTEINBRPT.
DR   SMART; SM00667; LisH; 1.
DR   SMART; SM00320; WD40; 8.
DR   SUPFAM; SSF50978; SSF50978; 2.
DR   PROSITE; PS50896; LISH; 1.
DR   PROSITE; PS00678; WD_REPEATS_1; 4.
DR   PROSITE; PS50082; WD_REPEATS_2; 6.
DR   PROSITE; PS50294; WD_REPEATS_REGION; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Chromatin regulator;
KW   Complete proteome; Disease mutation; Isopeptide bond;
KW   Mental retardation; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Repressor; Transcription;
KW   Transcription regulation; Ubl conjugation; Ubl conjugation pathway;
KW   WD repeat.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378}.
FT   CHAIN         2    514       F-box-like/WD repeat-containing protein
FT                                TBL1XR1.
FT                                /FTId=PRO_0000051266.
FT   DOMAIN        4     36       LisH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00126}.
FT   DOMAIN       41     86       F-box-like.
FT   REPEAT      167    206       WD 1.
FT   REPEAT      223    262       WD 2.
FT   REPEAT      264    303       WD 3.
FT   REPEAT      306    344       WD 4.
FT   REPEAT      347    386       WD 5.
FT   REPEAT      389    437       WD 6.
FT   REPEAT      440    479       WD 7.
FT   REPEAT      481    513       WD 8.
FT   COMPBIAS    108    118       Poly-Ala.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378}.
FT   MOD_RES     102    102       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q8BHJ5}.
FT   MOD_RES     119    119       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   CROSSLNK    277    277       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   VARIANT      70     70       G -> D (in MRD41; dbSNP:rs786205859).
FT                                {ECO:0000269|PubMed:25102098}.
FT                                /FTId=VAR_076753.
FT   VARIANT     116    116       A -> S (in dbSNP:rs372813783).
FT                                {ECO:0000269|PubMed:25102098}.
FT                                /FTId=VAR_076754.
FT   VARIANT     245    245       Y -> C (in MRD41; dbSNP:rs878854401).
FT                                {ECO:0000269|PubMed:27133561}.
FT                                /FTId=VAR_076755.
FT   VARIANT     282    282       L -> P (in MRD41).
FT                                {ECO:0000269|PubMed:22495309}.
FT                                /FTId=VAR_076756.
FT   VARIANT     405    405       G -> E (found in a patient with epilepsy;
FT                                unknown pathological significance;
FT                                dbSNP:rs747932785).
FT                                {ECO:0000269|PubMed:25102098}.
FT                                /FTId=VAR_076757.
FT   VARIANT     407    407       N -> S (found in a patient with epilepsy;
FT                                unknown pathological significance;
FT                                dbSNP:rs781011308).
FT                                {ECO:0000269|PubMed:25102098}.
FT                                /FTId=VAR_076758.
FT   VARIANT     446    446       Y -> C (in PRPTS; does not affect
FT                                assembly into the N-Cor repressor
FT                                complex; dbSNP:rs878854402).
FT                                {ECO:0000269|PubMed:26769062}.
FT                                /FTId=VAR_076759.
FT   CONFLICT     31     31       E -> K (in Ref. 2; AAG44736).
FT                                {ECO:0000305}.
FT   CONFLICT     59     59       Y -> H (in Ref. 3; BAB14331).
FT                                {ECO:0000305}.
FT   CONFLICT    389    389       A -> Q (in Ref. 2; AAG44736).
FT                                {ECO:0000305}.
FT   HELIX       159    161       {ECO:0000244|PDB:4LG9}.
FT   STRAND      162    165       {ECO:0000244|PDB:4LG9}.
FT   STRAND      172    177       {ECO:0000244|PDB:4LG9}.
FT   STRAND      179    188       {ECO:0000244|PDB:4LG9}.
FT   STRAND      191    197       {ECO:0000244|PDB:4LG9}.
FT   STRAND      208    212       {ECO:0000244|PDB:4LG9}.
FT   STRAND      228    233       {ECO:0000244|PDB:4LG9}.
FT   STRAND      237    244       {ECO:0000244|PDB:4LG9}.
FT   STRAND      247    253       {ECO:0000244|PDB:4LG9}.
FT   STRAND      258    264       {ECO:0000244|PDB:4LG9}.
FT   STRAND      269    274       {ECO:0000244|PDB:4LG9}.
FT   STRAND      276    285       {ECO:0000244|PDB:4LG9}.
FT   STRAND      290    294       {ECO:0000244|PDB:4LG9}.
FT   TURN        295    298       {ECO:0000244|PDB:4LG9}.
FT   STRAND      299    304       {ECO:0000244|PDB:4LG9}.
FT   STRAND      311    326       {ECO:0000244|PDB:4LG9}.
FT   STRAND      331    335       {ECO:0000244|PDB:4LG9}.
FT   STRAND      342    345       {ECO:0000244|PDB:4LG9}.
FT   STRAND      352    357       {ECO:0000244|PDB:4LG9}.
FT   STRAND      361    368       {ECO:0000244|PDB:4LG9}.
FT   STRAND      371    377       {ECO:0000244|PDB:4LG9}.
FT   STRAND      384    388       {ECO:0000244|PDB:4LG9}.
FT   STRAND      394    399       {ECO:0000244|PDB:4LG9}.
FT   STRAND      406    408       {ECO:0000244|PDB:4LG9}.
FT   STRAND      415    419       {ECO:0000244|PDB:4LG9}.
FT   STRAND      424    428       {ECO:0000244|PDB:4LG9}.
FT   TURN        429    432       {ECO:0000244|PDB:4LG9}.
FT   STRAND      433    438       {ECO:0000244|PDB:4LG9}.
FT   STRAND      445    450       {ECO:0000244|PDB:4LG9}.
FT   STRAND      454    461       {ECO:0000244|PDB:4LG9}.
FT   STRAND      464    470       {ECO:0000244|PDB:4LG9}.
FT   TURN        471    473       {ECO:0000244|PDB:4LG9}.
FT   STRAND      476    481       {ECO:0000244|PDB:4LG9}.
FT   STRAND      486    491       {ECO:0000244|PDB:4LG9}.
FT   STRAND      495    502       {ECO:0000244|PDB:4LG9}.
FT   STRAND      507    511       {ECO:0000244|PDB:4LG9}.
SQ   SEQUENCE   514 AA;  55595 MW;  0B556D2EE4BA796D CRC64;
     MSISSDEVNF LVYRYLQESG FSHSAFTFGI ESHISQSNIN GALVPPAALI SIIQKGLQYV
     EAEVSINEDG TLFDGRPIES LSLIDAVMPD VVQTRQQAYR DKLAQQQAAA AAAAAAAASQ
     QGSAKNGENT ANGEENGAHT IANNHTDMME VDGDVEIPPN KAVVLRGHES EVFICAWNPV
     SDLLASGSGD STARIWNLSE NSTSGSTQLV LRHCIREGGQ DVPSNKDVTS LDWNSEGTLL
     ATGSYDGFAR IWTKDGNLAS TLGQHKGPIF ALKWNKKGNF ILSAGVDKTT IIWDAHTGEA
     KQQFPFHSAP ALDVDWQSNN TFASCSTDMC IHVCKLGQDR PIKTFQGHTN EVNAIKWDPT
     GNLLASCSDD MTLKIWSMKQ DNCVHDLQAH NKEIYTIKWS PTGPGTNNPN ANLMLASASF
     DSTVRLWDVD RGICIHTLTK HQEPVYSVAF SPDGRYLASG SFDKCVHIWN TQTGALVHSY
     RGTGGIFEVC WNAAGDKVGA SASDGSVCVL DLRK
//
ID   A0A0A0MRB7_HUMAN        Unreviewed;       600 AA.
AC   A0A0A0MRB7;
DT   07-JAN-2015, integrated into UniProtKB/TrEMBL.
DT   07-JAN-2015, sequence version 1.
DT   28-FEB-2018, entry version 31.
DE   SubName: Full=Transcription factor E2-alpha {ECO:0000313|Ensembl:ENSP00000344375};
GN   Name=TCF3 {ECO:0000313|Ensembl:ENSP00000344375};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000344375, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Ensembl:ENSP00000344375, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [2] {ECO:0000213|PubMed:16964243}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [3] {ECO:0000213|PubMed:18669648}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [4] {ECO:0000213|PubMed:19690332}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:ra46-RA46(2009).
RN   [5] {ECO:0000213|PubMed:20068231}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:ra3-RA3(2010).
RN   [6] {ECO:0000213|PubMed:21406692}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:rs3-RS3(2011).
RN   [7] {ECO:0000213|PubMed:23186163}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=23186163;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [8] {ECO:0000213|PubMed:25218447}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [9] {ECO:0000313|Ensembl:ENSP00000344375}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (NOV-2014) to UniProtKB.
RN   [10] {ECO:0000213|PubMed:25755297}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.O114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurethsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide Analysis of SUMOylation Dynamics in Response to
RT   Replication Stress Reveals Novel Small Ubiquitin-like Modified Target
RT   Proteins and Acceptor Lysines Relevant for Genome Stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [11] {ECO:0000213|PubMed:28112733}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-
RT   modification with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   -!- CAUTION: The sequence shown here is derived from an Ensembl
CC       automatic analysis pipeline and should be considered as
CC       preliminary data. {ECO:0000313|Ensembl:ENSP00000344375}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AC005321; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC006274; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KC877695; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; XP_011526529.1; XM_011528227.2.
DR   UniGene; Hs.371282; -.
DR   UniGene; Hs.657044; -.
DR   PeptideAtlas; A0A0A0MRB7; -.
DR   PRIDE; A0A0A0MRB7; -.
DR   Ensembl; ENST00000344749; ENSP00000344375; ENSG00000071564.
DR   GeneID; 6929; -.
DR   UCSC; uc002ltn.4; human.
DR   CTD; 6929; -.
DR   EuPathDB; HostDB:ENSG00000071564.14; -.
DR   HGNC; HGNC:11633; TCF3.
DR   OpenTargets; ENSG00000071564; -.
DR   GeneTree; ENSGT00510000046438; -.
DR   ChiTaRS; TCF3; human.
DR   GenomeRNAi; 6929; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000071564; -.
DR   ExpressionAtlas; A0A0A0MRB7; baseline and differential.
DR   GO; GO:0046983; F:protein dimerization activity; IEA:InterPro.
DR   CDD; cd00083; HLH; 1.
DR   Gene3D; 4.10.280.10; -; 1.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR036638; HLH_DNA-bd_sf.
DR   Pfam; PF00010; HLH; 1.
DR   SMART; SM00353; HLH; 1.
DR   SUPFAM; SSF47459; SSF47459; 1.
DR   PROSITE; PS50888; BHLH; 1.
PE   1: Evidence at protein level;
KW   Complete proteome {ECO:0000313|Proteomes:UP000005640};
KW   Proteomics identification {ECO:0000213|EPD:A0A0A0MRB7,
KW   ECO:0000213|MaxQB:A0A0A0MRB7, ECO:0000213|PeptideAtlas:A0A0A0MRB7};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640}.
FT   DOMAIN      495    548       BHLH. {ECO:0000259|PROSITE:PS50888}.
SQ   SEQUENCE   600 AA;  62045 MW;  FF458037E3BF2F30 CRC64;
     MNQPQRMAPV GTDKELSDLL DFSMMFPLPV TNGKGRPASL AGAQFGGSGK SGERGAYASF
     GRDAGVGGLT QAGFLSGELA LNSPGPLSPS GMKGTSQYYP SYSGSSRRRA ADGSLDTQPK
     KVRKVPPGLP SSVYPPSSGE DYGRDATAYP SAKTPSSTYP APFYVADGSL HPSAELWSPP
     GQAGFGPMLG GGSSPLPLPP GSGPVGSSGS SSTFGGLHQH ERMGYQLHGA EVNGGLPSAS
     SFSSAPGATY GGVSSHTPPV SGADSLLGSR GTTAGSSGDA LGKALASIYS PDHSSNNFSS
     SPSTPVGSPQ GLAGTSQWPR AGAPGALSPS YDGGLHGLQS KIEDHLDEAI HVLRSHAVGT
     AGDMHTLLPG HGALASGFTG PMSLGGRHAG LVGGSHPEDG LAGSTSLMHN HAALPSQPGT
     LPDLSRPPDS YSGLGRAGAT AAASEIKREE KEDEENTSAA DHSEEEKKEL KAPRARTSST
     DEVLSLEEKD LRDRERRMAN NARERVRVRD INEAFRELGR MCQMHLKSDK AQTKLLILQQ
     AVQVILGLEQ QVRERNLNPK AACLKRREEE KVSGVVGDPQ MVLSAPHPGL SEAHNPAGHM
//
ID   TFE2_HUMAN              Reviewed;         654 AA.
AC   P15923; P15883; Q14208; Q14635; Q14636; Q2TB39; Q2TB40; Q9UPI9;
DT   01-APR-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1990, sequence version 1.
DT   28-FEB-2018, entry version 210.
DE   RecName: Full=Transcription factor E2-alpha;
DE   AltName: Full=Class B basic helix-loop-helix protein 21;
DE            Short=bHLHb21;
DE   AltName: Full=Immunoglobulin enhancer-binding factor E12/E47;
DE   AltName: Full=Immunoglobulin transcription factor 1;
DE   AltName: Full=Kappa-E2-binding factor;
DE   AltName: Full=Transcription factor 3;
DE            Short=TCF-3;
DE   AltName: Full=Transcription factor ITF-1;
GN   Name=TCF3; Synonyms=BHLHB21, E2A, ITF1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM E12), AND CHROMOSOMAL
RP   TRANSLOCATION WITH PBX1.
RX   PubMed=1967983; DOI=10.1016/0092-8674(90)90658-2;
RA   Kamps M.P., Murre C., Sun X.-H., Baltimore D.;
RT   "A new homeobox gene contributes the DNA binding domain of the t(1;19)
RT   translocation protein in pre-B ALL.";
RL   Cell 60:547-555(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM E12).
RX   PubMed=1967982; DOI=10.1016/0092-8674(90)90657-Z;
RA   Nourse J., Mellentin J.D., Galili N., Wilkinson J., Stanbridge E.,
RA   Smith S.D., Cleary M.L.;
RT   "Chromosomal translocation t(1;19) results in synthesis of a homeobox
RT   fusion mRNA that codes for a potential chimeric transcription
RT   factor.";
RL   Cell 60:535-545(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS E47 AND 3).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 214-654 (ISOFORMS E12 AND E47), AND
RP   DOMAIN BHLH.
RC   TISSUE=Lymphoma;
RX   PubMed=2493990; DOI=10.1016/0092-8674(89)90682-X;
RA   Murre C., McCaw P.S., Baltimore D.;
RT   "A new DNA binding and dimerization motif in immunoglobulin enhancer
RT   binding, daughterless, MyoD, and myc proteins.";
RL   Cell 56:777-783(1989).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 69-654 (ISOFORM E47).
RX   PubMed=2308859; DOI=10.1093/nar/18.3.677;
RA   Henthorn P., McCarrick-Walmsley R., Kadesch T.;
RT   "Sequence of the cDNA encoding ITF-1, a positive-acting transcription
RT   factor.";
RL   Nucleic Acids Res. 18:677-677(1990).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 511-654 (ISOFORM E47).
RX   PubMed=1818757; DOI=10.3109/10425179109039690;
RA   Zhang Y., Bina M.;
RT   "Sequence of a HeLa cDNA provides the DNA binding domain and carboxy
RT   terminus of HE47: a human helix-loop-helix protein related to the
RT   enhancer binding factor E47.";
RL   DNA Seq. 2:197-202(1991).
RN   [8]
RP   DISCUSSION OF SEQUENCE.
RX   PubMed=2105528; DOI=10.1126/science.2105528;
RA   Henthorn P., Kiledjian M., Kadesch T.;
RT   "Two distinct transcription factors that bind the immunoglobulin
RT   enhancer microE5/kappa 2 motif.";
RL   Science 247:467-470(1990).
RN   [9]
RP   MUTAGENESIS, DNA-BINDING, AND HOMODIMERIZATION.
RX   PubMed=2112746; DOI=10.1073/pnas.87.12.4722;
RA   Voronova A., Baltimore D.;
RT   "Mutations that disrupt DNA binding and dimer formation in the E47
RT   helix-loop-helix protein map to distinct domains.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:4722-4726(1990).
RN   [10]
RP   CHROMOSOMAL TRANSLOCATION WITH PBX1.
RX   PubMed=1671560;
RA   Hunger S.P., Galili N., Carroll A.J., Crist W.M., Link M.P.,
RA   Cleary M.L.;
RT   "The t(1;19)(q23;p13) results in consistent fusion of E2A and PBX1
RT   coding sequences in acute lymphoblastic leukemias.";
RL   Blood 77:687-693(1991).
RN   [11]
RP   CHROMOSOMAL TRANSLOCATION WITH HLF.
RX   PubMed=1386162; DOI=10.1126/science.1386162;
RA   Inaba T., Roberts W.M., Shapiro L.H., Jolly K.W., Raimondi S.C.,
RA   Smith S.D., Look A.T.;
RT   "Fusion of the leucine zipper gene HLF to the E2A gene in human acute
RT   B-lineage leukemia.";
RL   Science 257:531-534(1992).
RN   [12]
RP   INTERACTION WITH UBE2I.
RX   PubMed=9409784; DOI=10.1016/S0378-1119(97)00444-7;
RA   Loveys D.A., Streiff M.B., Schaefer T.S., Kato G.J.;
RT   "The mUBC9 murine ubiquitin conjugating enzyme interacts with the E2A
RT   transcription factors.";
RL   Gene 201:169-177(1997).
RN   [13]
RP   CHROMOSOMAL TRANSLOCATION WITH TFPT.
RX   PubMed=10086727; DOI=10.1038/sj/leu/2401338;
RA   Brambillasca F., Mosna G., Colombo M., Rivolta A., Caslini C.,
RA   Minuzzo M., Giudici G., Mizzi L., Biondi A., Privitera E.;
RT   "Identification of a novel molecular partner of the E2A gene in
RT   childhood leukemia.";
RL   Leukemia 13:369-375(1999).
RN   [14]
RP   INTERACTION WITH NEUROD1 AND EP300, HOMODIMERIZATION, AND
RP   HETERODIMERIZATION.
RX   PubMed=14752053; DOI=10.1210/me.2003-0311;
RA   Kim J.Y., Chu K., Kim H.J., Seong H.A., Park K.C., Sanyal S.,
RA   Takeda J., Ha H., Shong M., Tsai M.J., Choi H.S.;
RT   "Orphan nuclear receptor small heterodimer partner, a novel
RT   corepressor for a basic helix-loop-helix transcription factor
RT   BETA2/neuroD.";
RL   Mol. Endocrinol. 18:776-790(2004).
RN   [15]
RP   INTERACTION WITH FIGLA.
RX   PubMed=15044608; DOI=10.1093/molehr/gah056;
RA   Bayne R.A.L., Martins da Silva S.J., Anderson R.A.;
RT   "Increased expression of the FIGLA transcription factor is associated
RT   with primordial follicle formation in the human fetal ovary.";
RL   Mol. Hum. Reprod. 10:373-381(2004).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-531 (ISOFORM E47), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-139 AND SER-359, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-134, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-379 AND SER-529, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [22]
RP   INTERACTION WITH BHLHA9.
RX   PubMed=25466284; DOI=10.1016/j.ajhg.2014.10.012;
RA   Malik S., Percin F.E., Bornholdt D., Albrecht B., Percesepe A.,
RA   Koch M.C., Landi A., Fritz B., Khan R., Mumtaz S., Akarsu N.A.,
RA   Grzeschik K.H.;
RT   "Mutations affecting the BHLHA9 DNA-binding domain cause MSSD,
RT   mesoaxial synostotic syndactyly with phalangeal reduction, Malik-
RT   Percin type.";
RL   Am. J. Hum. Genet. 95:649-659(2014).
RN   [23]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-498, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [24]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-498, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.O114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to
RT   replication stress reveals novel small ubiquitin-like modified target
RT   proteins and acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [25]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-498 AND LYS-625, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-
RT   modification with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [26]
RP   3D-STRUCTURE MODELING OF 549-610.
RX   PubMed=8433970; DOI=10.1093/protein/6.1.41;
RA   Gibson T.J., Thompson J.D., Abagyan R.A.;
RT   "Proposed structure for the DNA-binding domain of the helix-loop-helix
RT   family of eukaryotic gene regulatory proteins.";
RL   Protein Eng. 6:41-50(1993).
RN   [27]
RP   VARIANT [LARGE SCALE ANALYSIS] VAL-8.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [28]
RP   DOMAIN.
RX   PubMed=17467953; DOI=10.1016/j.ygeno.2007.02.003;
RA   Piskacek S., Gregor M., Nemethova M., Grabner M., Kovarik P.,
RA   Piskacek M.;
RT   "Nine-amino-acid transactivation domain: establishment and prediction
RT   utilities.";
RL   Genomics 89:756-768(2007).
RN   [29]
RP   INVOLVEMENT IN AGM8, VARIANT AGM8 LYS-555 (ISOFORM E47), AND
RP   CHARACTERIZATION OF VARIANT AGM8 (ISOFORM E47) LYS-555.
RX   PubMed=24216514; DOI=10.1172/JCI71927;
RA   Boisson B., Wang Y.D., Bosompem A., Ma C.S., Lim A., Kochetkov T.,
RA   Tangye S.G., Casanova J.L., Conley M.E.;
RT   "A recurrent dominant negative E47 mutation causes agammaglobulinemia
RT   and BCR(-) B cells.";
RL   J. Clin. Invest. 123:4781-4786(2013).
CC   -!- FUNCTION: Transcriptional regulator. Involved in the initiation of
CC       neuronal differentiation. Heterodimers between TCF3 and tissue-
CC       specific basic helix-loop-helix (bHLH) proteins play major roles
CC       in determining tissue-specific cell fate during embryogenesis,
CC       like muscle or early B-cell differentiation. Dimers bind DNA on E-
CC       box motifs: 5'-CANNTG-3'. Binds to the kappa-E2 site in the kappa
CC       immunoglobulin gene enhancer. Binds to IEB1 and IEB2, which are
CC       short DNA sequences in the insulin gene transcription control
CC       region. {ECO:0000250|UniProtKB:P15806}.
CC   -!- SUBUNIT: Forms a heterodimer with ASH1 and TWIST2. Isoform E12
CC       interacts with RALGAPA1 and FIGLA. Efficient DNA binding requires
CC       dimerization with another bHLH protein. Component of a nuclear
CC       TAL-1 complex composed at least of CBFA2T3, LDB1, TAL1 and TCF3.
CC       Interacts with NEUROD2, PTF1A and TGFB1I1. Forms a heterodimer
CC       with MYOG; heterodimerization enhances MYOG DNA-binding and
CC       transcriptional activities (By similarity). Homodimer.
CC       Heterodimer. Forms a heterodimer with NEUROD1; the heterodimer is
CC       inhibited in presence of ID2, but not NR0B2, to E-box element.
CC       Interacts with EP300 and UBE2I. Interacts with BHLHA9
CC       (PubMed:25466284). Forms a heterodimer with ATOH8; repress
CC       transcription of TCF3 and TCF3/NEUROG3 dimer-induced
CC       transactivation of E box-dependent promoters (By similarity).
CC       {ECO:0000250|UniProtKB:P15806, ECO:0000269|PubMed:14752053,
CC       ECO:0000269|PubMed:15044608, ECO:0000269|PubMed:25466284,
CC       ECO:0000269|PubMed:9409784}.
CC   -!- INTERACTION:
CC       P50553:ASCL1; NbExp=3; IntAct=EBI-769630, EBI-957042;
CC       O95273:CCNDBP1; NbExp=3; IntAct=EBI-769645, EBI-748961;
CC       O75593:FOXH1; NbExp=2; IntAct=EBI-769630, EBI-1759806;
CC       Q02363:ID2; NbExp=3; IntAct=EBI-769645, EBI-713450;
CC       Q02535:ID3; NbExp=3; IntAct=EBI-769630, EBI-1387094;
CC       P15172:MYOD1; NbExp=2; IntAct=EBI-769645, EBI-488878;
CC       O00233:PSMD9; NbExp=2; IntAct=EBI-769645, EBI-750973;
CC       P17542:TAL1; NbExp=7; IntAct=EBI-769630, EBI-1753878;
CC       Q9Y4C2:TCAF1; NbExp=3; IntAct=EBI-769630, EBI-750484;
CC       Q8WVJ9:TWIST2; NbExp=4; IntAct=EBI-12000326, EBI-1797313;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=E12; Synonyms=PAN-2;
CC         IsoId=P15923-1; Sequence=Displayed;
CC       Name=E47; Synonyms=PAN-1;
CC         IsoId=P15923-2; Sequence=VSP_002155;
CC         Note=The bHLH domain encompassing amino acids 546 to 599 is
CC         sufficient to mediate DNA-binding and homodimerization. Combined
CC         mutagenesis of Phe-566 and Leu-569 to Asp-566 and Glu-569,
CC         mutagenesis of Lys-585 to Ala-585 or combined mutagenesis of
CC         Ile-588 and Leu-589 to Asp-588 and Glu-589 prevents DNA-binding
CC         and homodimerization. Mutagenesis of Arg-548 to Lys-548,
CC         combined mutagenesis of Arg-547 and Arg-548 to Gly-547 and
CC         Gly-548, mutagenesis of Arg-556 to Lys-556, mutagenesis of
CC         Arg-558 to Lys-558, or combined mutagenesis of Arg-556 and
CC         Arg-558 to Gly-556 and Gly-558, alter DNA-binding but not
CC         dimerization. Variant in position: 555:E->K (in AGM8, localizes
CC         normally to the nucleus, does not perform proper DNA binding,
CC         acts in a dominant-negative manner when coexpressed with
CC         wild-type) (Ref.29). Contains a phosphothreonine at position
CC         531. {ECO:0000244|PubMed:18669648, ECO:0000269|PubMed:24216514};
CC       Name=3;
CC         IsoId=P15923-3; Sequence=VSP_057277, VSP_057278;
CC         Note=No experimental confirmation available.;
CC   -!- DOMAIN: the 9aaTAD motif is a transactivation domain present in a
CC       large number of yeast and animal transcription factors.
CC       {ECO:0000269|PubMed:17467953, ECO:0000269|PubMed:2493990}.
CC   -!- PTM: Phosphorylated following NGF stimulation. {ECO:0000250}.
CC   -!- DISEASE: Note=Chromosomal aberrations involving TCF3 are cause of
CC       forms of pre-B-cell acute lymphoblastic leukemia (B-ALL).
CC       Translocation t(1;19)(q23;p13.3) with PBX1. TCF3-PBX1 transforms
CC       cells by constitutively activating transcription of genes
CC       regulated by PBX1 or by other members of the PBX protein family
CC       (PubMed:1967983, PubMed:1671560). Translocation
CC       t(17;19)(q22;p13.3) with HLF (PubMed:1386162). Inversion
CC       inv(19)(p13;q13) with TFPT (PubMed:10086727).
CC       {ECO:0000269|PubMed:10086727, ECO:0000269|PubMed:1386162,
CC       ECO:0000269|PubMed:1671560, ECO:0000269|PubMed:1967983}.
CC   -!- DISEASE: Agammaglobulinemia 8, autosomal dominant (AGM8)
CC       [MIM:616941]: A form of agammaglobulinemia, a primary
CC       immunodeficiency characterized by profoundly low or absent serum
CC       antibodies and low or absent circulating B-cells due to an early
CC       block of B-cell development. Affected individuals develop severe
CC       infections in the first years of life.
CC       {ECO:0000269|PubMed:24216514}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA52331.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/E2AID50.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M31523; AAA61146.1; -; mRNA.
DR   EMBL; M31522; AAA36764.1; ALT_TERM; mRNA.
DR   EMBL; M31222; AAA52331.1; ALT_INIT; mRNA.
DR   EMBL; AC006274; AAC99797.1; -; Genomic_DNA.
DR   EMBL; AC005321; AAC27373.1; -; Genomic_DNA.
DR   EMBL; KC877695; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC110579; AAI10580.1; -; mRNA.
DR   EMBL; BC110580; AAI10581.1; -; mRNA.
DR   EMBL; M24404; AAA56829.1; -; mRNA.
DR   EMBL; M24405; AAA56830.1; -; mRNA.
DR   EMBL; X52078; CAA36297.1; -; mRNA.
DR   EMBL; M65214; AAC41693.1; -; mRNA.
DR   CCDS; CCDS12074.1; -. [P15923-1]
DR   CCDS; CCDS45899.1; -. [P15923-2]
DR   PIR; A34734; A34734.
DR   PIR; S10099; S10099.
DR   RefSeq; NP_001129611.1; NM_001136139.2. [P15923-2]
DR   RefSeq; NP_003191.1; NM_003200.3. [P15923-1]
DR   RefSeq; XP_016882669.1; XM_017027180.1. [P15923-3]
DR   RefSeq; XP_016882670.1; XM_017027181.1. [P15923-1]
DR   RefSeq; XP_016882671.1; XM_017027182.1. [P15923-2]
DR   UniGene; Hs.371282; -.
DR   UniGene; Hs.657044; -.
DR   PDB; 1HLH; Model; -; A/B=549-610.
DR   PDB; 2MH0; NMR; -; A=1-37.
DR   PDB; 2YPA; X-ray; 2.80 A; B=546-616.
DR   PDB; 2YPB; X-ray; 2.87 A; B=546-616.
DR   PDB; 3U5V; X-ray; 1.70 A; A=563-613.
DR   PDBsum; 1HLH; -.
DR   PDBsum; 2MH0; -.
DR   PDBsum; 2YPA; -.
DR   PDBsum; 2YPB; -.
DR   PDBsum; 3U5V; -.
DR   ProteinModelPortal; P15923; -.
DR   SMR; P15923; -.
DR   BioGrid; 112791; 158.
DR   CORUM; P15923; -.
DR   DIP; DIP-74N; -.
DR   IntAct; P15923; 31.
DR   MINT; P15923; -.
DR   STRING; 9606.ENSP00000262965; -.
DR   iPTMnet; P15923; -.
DR   PhosphoSitePlus; P15923; -.
DR   BioMuta; TCF3; -.
DR   DMDM; 135655; -.
DR   EPD; P15923; -.
DR   MaxQB; P15923; -.
DR   PaxDb; P15923; -.
DR   PeptideAtlas; P15923; -.
DR   PRIDE; P15923; -.
DR   Ensembl; ENST00000262965; ENSP00000262965; ENSG00000071564. [P15923-1]
DR   Ensembl; ENST00000395423; ENSP00000378813; ENSG00000071564. [P15923-3]
DR   Ensembl; ENST00000588136; ENSP00000468487; ENSG00000071564. [P15923-2]
DR   Ensembl; ENST00000611869; ENSP00000480564; ENSG00000071564. [P15923-1]
DR   GeneID; 6929; -.
DR   KEGG; hsa:6929; -.
DR   UCSC; uc002ltr.3; human. [P15923-1]
DR   CTD; 6929; -.
DR   DisGeNET; 6929; -.
DR   EuPathDB; HostDB:ENSG00000071564.14; -.
DR   GeneCards; TCF3; -.
DR   HGNC; HGNC:11633; TCF3.
DR   HPA; CAB018351; -.
DR   HPA; HPA049808; -.
DR   HPA; HPA062476; -.
DR   MalaCards; TCF3; -.
DR   MIM; 147141; gene.
DR   MIM; 616941; phenotype.
DR   neXtProt; NX_P15923; -.
DR   OpenTargets; ENSG00000071564; -.
DR   Orphanet; 33110; Autosomal agammaglobulinemia.
DR   Orphanet; 99860; Precursor B-cell acute lymphoblastic leukemia.
DR   PharmGKB; PA164742580; -.
DR   eggNOG; KOG3910; Eukaryota.
DR   eggNOG; ENOG410XYUA; LUCA.
DR   GeneTree; ENSGT00510000046438; -.
DR   HOGENOM; HOG000234180; -.
DR   HOVERGEN; HBG003854; -.
DR   InParanoid; P15923; -.
DR   KO; K09063; -.
DR   OMA; KGGSQYY; -.
DR   PhylomeDB; P15923; -.
DR   TreeFam; TF321672; -.
DR   Reactome; R-HSA-375170; CDO in myogenesis.
DR   Reactome; R-HSA-8939236; RUNX1 regulates transcription of genes involved in differentiation of HSCs.
DR   SignaLink; P15923; -.
DR   SIGNOR; P15923; -.
DR   ChiTaRS; TCF3; human.
DR   GeneWiki; TCF3; -.
DR   GenomeRNAi; 6929; -.
DR   PRO; PR:P15923; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000071564; -.
DR   CleanEx; HS_TCF3; -.
DR   ExpressionAtlas; P15923; baseline and differential.
DR   Genevisible; P15923; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:BHF-UCL.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0043234; C:protein complex; IDA:UniProtKB.
DR   GO; GO:0090575; C:RNA polymerase II transcription factor complex; IDA:BHF-UCL.
DR   GO; GO:0005667; C:transcription factor complex; IDA:UniProtKB.
DR   GO; GO:0043425; F:bHLH transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IDA:BHF-UCL.
DR   GO; GO:0070888; F:E-box binding; IDA:UniProtKB.
DR   GO; GO:0035326; F:enhancer binding; IC:BHF-UCL.
DR   GO; GO:0031435; F:mitogen-activated protein kinase kinase kinase binding; IPI:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0070491; F:repressing transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0000978; F:RNA polymerase II proximal promoter sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0001078; F:transcriptional repressor activity, RNA polymerase II proximal promoter sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0070644; F:vitamin D response element binding; IDA:BHF-UCL.
DR   GO; GO:0030183; P:B cell differentiation; NAS:UniProtKB.
DR   GO; GO:0002326; P:B cell lineage commitment; IDA:UniProtKB.
DR   GO; GO:0033152; P:immunoglobulin V(D)J recombination; IDA:MGI.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:NTNU_SB.
DR   GO; GO:0030890; P:positive regulation of B cell proliferation; IMP:UniProtKB.
DR   GO; GO:0045787; P:positive regulation of cell cycle; IDA:UniProtKB.
DR   GO; GO:0051091; P:positive regulation of DNA binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0051149; P:positive regulation of muscle cell differentiation; TAS:Reactome.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:BHF-UCL.
DR   GO; GO:2000045; P:regulation of G1/S transition of mitotic cell cycle; IDA:UniProtKB.
DR   GO; GO:1902036; P:regulation of hematopoietic stem cell differentiation; TAS:Reactome.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; NAS:UniProtKB.
DR   GO; GO:0006351; P:transcription, DNA-templated; IDA:UniProtKB.
DR   CDD; cd00083; HLH; 1.
DR   Gene3D; 4.10.280.10; -; 1.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR036638; HLH_DNA-bd_sf.
DR   Pfam; PF00010; HLH; 1.
DR   SMART; SM00353; HLH; 1.
DR   SUPFAM; SSF47459; SSF47459; 1.
DR   PROSITE; PS50888; BHLH; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Chromosomal rearrangement;
KW   Complete proteome; Differentiation; Disease mutation; DNA-binding;
KW   Isopeptide bond; Methylation; Neurogenesis; Nucleus; Phosphoprotein;
KW   Polymorphism; Proto-oncogene; Reference proteome; Transcription;
KW   Transcription regulation; Ubl conjugation.
FT   CHAIN         1    654       Transcription factor E2-alpha.
FT                                /FTId=PRO_0000127466.
FT   DOMAIN      549    602       bHLH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00981}.
FT   REGION      389    425       Leucine-zipper.
FT   MOTIF        19     27       9aaTAD.
FT   MOTIF       170    176       Nuclear localization signal.
FT                                {ECO:0000255}.
FT   SITE        483    484       Breakpoint for translocation to form
FT                                TCF3-PBX1 oncogene.
FT   MOD_RES     134    134       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES     139    139       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     355    355       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P15806}.
FT   MOD_RES     359    359       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES     371    371       Omega-N-methylarginine.
FT                                {ECO:0000250|UniProtKB:P15806}.
FT   MOD_RES     379    379       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     529    529       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   CROSSLNK    498    498       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25218447,
FT                                ECO:0000244|PubMed:25755297,
FT                                ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    625    625       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   VAR_SEQ      49     99       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_057277.
FT   VAR_SEQ     528    528       T -> TRCQPTPRHSPPSPHQDAHVHRPHAHRTHTGRPSAG
FT                                PTLFPQPHCLPLAPSRRPPH (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_057278.
FT   VAR_SEQ     530    601       PDEDEDDLLPPEQKAEREKERRVANNARERLRVRDINEAFK
FT                                ELGRMCQLHLNSEKPQTKLLILHQAVSVILN -> STDEVL
FT                                SLEEKDLRDRERRMANNARERVRVRDINEAFRELGRMCQMH
FT                                LKSDKAQTKLLILQQAVQVILG (in isoform E47).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:1818757,
FT                                ECO:0000303|PubMed:2308859,
FT                                ECO:0000303|PubMed:2493990}.
FT                                /FTId=VSP_002155.
FT   VARIANT       8      8       A -> V (in a colorectal cancer sample;
FT                                somatic mutation; dbSNP:rs376780559).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036396.
FT   VARIANT     120    120       L -> P (in dbSNP:rs35354874).
FT                                /FTId=VAR_049552.
FT   VARIANT     198    198       T -> A (in dbSNP:rs11879402).
FT                                /FTId=VAR_049553.
FT   VARIANT     431    431       G -> S (in dbSNP:rs1052692).
FT                                /FTId=VAR_049554.
FT   CONFLICT     69     99       FDPSRTFSEGTHFTESHSSLSSSTFLGPGLG -> GGGECL
FT                                AWCGPSAVHRCADVGLGMVSARTAP (in Ref. 6;
FT                                CAA36297). {ECO:0000305}.
FT   CONFLICT    214    216       FYV -> EFR (in Ref. 5; AAA56830).
FT                                {ECO:0000305}.
FT   CONFLICT    302    302       Missing (in Ref. 1; AAA36764).
FT                                {ECO:0000305}.
FT   CONFLICT    390    390       Missing (in Ref. 5; AAA56830).
FT                                {ECO:0000305}.
FT   HELIX        12     25       {ECO:0000244|PDB:2MH0}.
FT   HELIX       543    580       {ECO:0000244|PDB:2YPA}.
FT   HELIX       588    611       {ECO:0000244|PDB:2YPA}.
SQ   SEQUENCE   654 AA;  67600 MW;  52F5E3DE1890AE13 CRC64;
     MNQPQRMAPV GTDKELSDLL DFSMMFPLPV TNGKGRPASL AGAQFGGSGL EDRPSSGSWG
     SGDQSSSSFD PSRTFSEGTH FTESHSSLSS STFLGPGLGG KSGERGAYAS FGRDAGVGGL
     TQAGFLSGEL ALNSPGPLSP SGMKGTSQYY PSYSGSSRRR AADGSLDTQP KKVRKVPPGL
     PSSVYPPSSG EDYGRDATAY PSAKTPSSTY PAPFYVADGS LHPSAELWSP PGQAGFGPML
     GGGSSPLPLP PGSGPVGSSG SSSTFGGLHQ HERMGYQLHG AEVNGGLPSA SSFSSAPGAT
     YGGVSSHTPP VSGADSLLGS RGTTAGSSGD ALGKALASIY SPDHSSNNFS SSPSTPVGSP
     QGLAGTSQWP RAGAPGALSP SYDGGLHGLQ SKIEDHLDEA IHVLRSHAVG TAGDMHTLLP
     GHGALASGFT GPMSLGGRHA GLVGGSHPED GLAGSTSLMH NHAALPSQPG TLPDLSRPPD
     SYSGLGRAGA TAAASEIKRE EKEDEENTSA ADHSEEEKKE LKAPRARTSP DEDEDDLLPP
     EQKAEREKER RVANNARERL RVRDINEAFK ELGRMCQLHL NSEKPQTKLL ILHQAVSVIL
     NLEQQVRERN LNPKAACLKR REEEKVSGVV GDPQMVLSAP HPGLSEAHNP AGHM
//
ID   X6REB3_HUMAN            Unreviewed;       679 AA.
AC   X6REB3;
DT   11-JUN-2014, integrated into UniProtKB/TrEMBL.
DT   29-OCT-2014, sequence version 2.
DT   28-FEB-2018, entry version 36.
DE   SubName: Full=Transcription factor E2-alpha {ECO:0000313|Ensembl:ENSP00000396363};
GN   Name=TCF3 {ECO:0000313|Ensembl:ENSP00000396363};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000396363, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Ensembl:ENSP00000396363, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [2] {ECO:0000213|PubMed:18669648}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [3] {ECO:0000213|PubMed:19690332}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:ra46-RA46(2009).
RN   [4] {ECO:0000213|PubMed:20068231}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:ra3-RA3(2010).
RN   [5] {ECO:0000213|PubMed:21406692}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:rs3-RS3(2011).
RN   [6] {ECO:0000213|PubMed:23186163}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=23186163;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [7] {ECO:0000213|PubMed:25218447}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [8] {ECO:0000313|Ensembl:ENSP00000396363}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (APR-2014) to UniProtKB.
RN   [9] {ECO:0000213|PubMed:25755297}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.O114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurethsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide Analysis of SUMOylation Dynamics in Response to
RT   Replication Stress Reveals Novel Small Ubiquitin-like Modified Target
RT   Proteins and Acceptor Lysines Relevant for Genome Stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [10] {ECO:0000213|PubMed:28112733}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-
RT   modification with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   -!- CAUTION: The sequence shown here is derived from an Ensembl
CC       automatic analysis pipeline and should be considered as
CC       preliminary data. {ECO:0000313|Ensembl:ENSP00000396363}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AC005321; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC006274; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KC877695; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; XP_006722920.1; XM_006722857.3.
DR   RefSeq; XP_006722921.1; XM_006722858.3.
DR   RefSeq; XP_011526523.1; XM_011528221.2.
DR   UniGene; Hs.371282; -.
DR   UniGene; Hs.657044; -.
DR   ProteinModelPortal; X6REB3; -.
DR   PeptideAtlas; X6REB3; -.
DR   PRIDE; X6REB3; -.
DR   Ensembl; ENST00000453954; ENSP00000396363; ENSG00000071564.
DR   GeneID; 6929; -.
DR   UCSC; uc060ree.1; human.
DR   CTD; 6929; -.
DR   EuPathDB; HostDB:ENSG00000071564.14; -.
DR   HGNC; HGNC:11633; TCF3.
DR   OpenTargets; ENSG00000071564; -.
DR   GeneTree; ENSGT00510000046438; -.
DR   OrthoDB; EOG091G07E2; -.
DR   ChiTaRS; TCF3; human.
DR   GenomeRNAi; 6929; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000071564; -.
DR   ExpressionAtlas; X6REB3; baseline and differential.
DR   GO; GO:0046983; F:protein dimerization activity; IEA:InterPro.
DR   CDD; cd00083; HLH; 1.
DR   Gene3D; 4.10.280.10; -; 1.
DR   InterPro; IPR011598; bHLH_dom.
DR   InterPro; IPR036638; HLH_DNA-bd_sf.
DR   Pfam; PF00010; HLH; 1.
DR   SMART; SM00353; HLH; 1.
DR   SUPFAM; SSF47459; SSF47459; 1.
DR   PROSITE; PS50888; BHLH; 1.
PE   1: Evidence at protein level;
KW   Complete proteome {ECO:0000313|Proteomes:UP000005640};
KW   Proteomics identification {ECO:0000213|EPD:X6REB3,
KW   ECO:0000213|MaxQB:X6REB3, ECO:0000213|PeptideAtlas:X6REB3};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640}.
FT   DOMAIN      574    627       BHLH. {ECO:0000259|PROSITE:PS50888}.
SQ   SEQUENCE   679 AA;  70075 MW;  A64B0EF1626FA35E CRC64;
     MNQPQRMAPV GTDKELSDLL DFSMMFPLPV TNGKGRPASL AGAQFGGSGL EDRPSSGSWG
     SGDQSSSSFD PSRTFSEGTH FTESHSSLSS STFLGPGLGG ECLAWCGPSA VHRCADVGLG
     MVSARTAPGK SGERGAYASF GRDAGVGGLT QAGFLSGELA LNSPGPLSPS GMKGTSQYYP
     SYSGSSRRRA ADGSLDTQPK KVRKVPPGLP SSVYPPSSGE DYGRDATAYP SAKTPSSTYP
     APFYVADGSL HPSAELWSPP GQAGFGPMLG GGSSPLPLPP GSGPVGSSGS SSTFGGLHQH
     ERMGYQLHGA EVNGGLPSAS SFSSAPGATY GGVSSHTPPV SGADSLLGSR GTTAGSSGDA
     LGKALASIYS PDHSSNNFSS SPSTPVGSPQ GLAGTSQWPR AGAPGALSPS YDGGLHGLQS
     KIEDHLDEAI HVLRSHAVGT AGDMHTLLPG HGALASGFTG PMSLGGRHAG LVGGSHPEDG
     LAGSTSLMHN HAALPSQPGT LPDLSRPPDS YSGLGRAGAT AAASEIKREE KEDEENTSAA
     DHSEEEKKEL KAPRARTSTD EVLSLEEKDL RDRERRMANN ARERVRVRDI NEAFRELGRM
     CQMHLKSDKA QTKLLILQQA VQVILGLEQQ VRERNLNPKA ACLKRREEEK VSGVVGDPQM
     VLSAPHPGLS EAHNPAGHM
//
ID   TET1_HUMAN              Reviewed;        2136 AA.
AC   Q8NFU7; Q5VUP7; Q7Z6B6; Q8TCR1; Q9C0I7;
DT   03-OCT-2006, integrated into UniProtKB/Swiss-Prot.
DT   03-OCT-2006, sequence version 2.
DT   28-FEB-2018, entry version 122.
DE   RecName: Full=Methylcytosine dioxygenase TET1;
DE            EC=1.14.11.n2 {ECO:0000269|PubMed:19372391, ECO:0000269|PubMed:21496894};
DE   AltName: Full=CXXC-type zinc finger protein 6;
DE   AltName: Full=Leukemia-associated protein with a CXXC domain;
DE   AltName: Full=Ten-eleven translocation 1 gene protein;
GN   Name=TET1; Synonyms=CXXC6, KIAA1676, LCX;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], VARIANT MET-1123, FUNCTION, TISSUE
RP   SPECIFICITY, AND CHROMOSOMAL TRANSLOCATION WITH KMT2A/MLL1.
RC   TISSUE=Leukemia;
RX   PubMed=12124344;
RA   Ono R., Taki T., Taketani T., Taniwaki M., Kobayashi H., Hayashi Y.;
RT   "LCX, leukemia-associated protein with a CXXC domain, is fused to MLL
RT   in acute myeloid leukemia with trilineage dysplasia having
RT   t(10;11)(q22;q23).";
RL   Cancer Res. 62:4075-4080(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1402-2136.
RC   TISSUE=Brain;
RX   PubMed=11214970; DOI=10.1093/dnares/7.6.347;
RA   Nagase T., Kikuno R., Hattori A., Kondo Y., Okumura K., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XIX.
RT   The complete sequences of 100 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 7:347-355(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1665-2074.
RC   TISSUE=Brain;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1809-2136.
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   CHROMOSOMAL TRANSLOCATION WITH KMT2A/MLL1, TISSUE SPECIFICITY, AND
RP   INVOLVEMENT IN ACUTE LEUKEMIAS.
RX   PubMed=12646957; DOI=10.1038/sj.leu.2402834;
RA   Lorsbach R.B., Moore J., Mathew S., Raimondi S.C., Mukatira S.T.,
RA   Downing J.R.;
RT   "TET1, a member of a novel protein family, is fused to MLL in acute
RT   myeloid leukemia containing the t(10;11)(q22;q23).";
RL   Leukemia 17:637-641(2003).
RN   [7]
RP   FUNCTION.
RX   PubMed=19372393; DOI=10.1126/science.1169786;
RA   Kriaucionis S., Heintz N.;
RT   "The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje
RT   neurons and the brain.";
RL   Science 324:929-930(2009).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, DNA-BINDING, COFACTOR, AND MUTAGENESIS
RP   OF HIS-1672 AND ASP-1674.
RX   PubMed=19372391; DOI=10.1126/science.1170116;
RA   Tahiliani M., Koh K.P., Shen Y., Pastor W.A., Bandukwala H.,
RA   Brudno Y., Agarwal S., Iyer L.M., Liu D.R., Aravind L., Rao A.;
RT   "Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in
RT   mammalian DNA by the MLL fusion partner TET1.";
RL   Science 324:930-935(2009).
RN   [9]
RP   FUNCTION IN DNA DEMETHYLATION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF
RP   HIS-1672 AND ASP-1674.
RX   PubMed=21496894; DOI=10.1016/j.cell.2011.03.022;
RA   Guo J.U., Su Y., Zhong C., Ming G.L., Song H.;
RT   "Hydroxylation of 5-methylcytosine by TET1 promotes active DNA
RT   demethylation in the adult brain.";
RL   Cell 145:423-434(2011).
RN   [10]
RP   INTERACTION WITH SIN3A.
RX   PubMed=21490601; DOI=10.1038/nature10066;
RA   Williams K., Christensen J., Pedersen M.T., Johansen J.V., Cloos P.A.,
RA   Rappsilber J., Helin K.;
RT   "TET1 and hydroxymethylcytosine in transcription and DNA methylation
RT   fidelity.";
RL   Nature 473:343-348(2011).
RN   [11]
RP   FUNCTION.
RX   PubMed=21778364; DOI=10.1126/science.1210597;
RA   Ito S., Shen L., Dai Q., Wu S.C., Collins L.B., Swenberg J.A., He C.,
RA   Zhang Y.;
RT   "Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-
RT   carboxylcytosine.";
RL   Science 333:1300-1303(2011).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-871, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [13]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=25284789; DOI=10.1016/j.celrep.2014.08.071;
RA   Takai H., Masuda K., Sato T., Sakaguchi Y., Suzuki T., Suzuki T.,
RA   Koyama-Nasu R., Nasu-Nishimura Y., Katou Y., Ogawa H., Morishita Y.,
RA   Kozuka-Hata H., Oyama M., Todo T., Ino Y., Mukasa A., Saito N.,
RA   Toyoshima C., Shirahige K., Akiyama T.;
RT   "5-Hydroxymethylcytosine plays a critical role in glioblastomagenesis
RT   by recruiting the CHTOP-methylosome complex.";
RL   Cell Rep. 9:48-60(2014).
CC   -!- FUNCTION: Dioxygenase that catalyzes the conversion of the
CC       modified genomic base 5-methylcytosine (5mC) into 5-
CC       hydroxymethylcytosine (5hmC) and plays a key role in active DNA
CC       demethylation. Also mediates subsequent conversion of 5hmC into 5-
CC       formylcytosine (5fC), and conversion of 5fC to 5-carboxylcytosine
CC       (5caC). Conversion of 5mC into 5hmC, 5fC and 5caC probably
CC       constitutes the first step in cytosine demethylation. Methylation
CC       at the C5 position of cytosine bases is an epigenetic modification
CC       of the mammalian genome which plays an important role in
CC       transcriptional regulation. In addition to its role in DNA
CC       demethylation, plays a more general role in chromatin regulation.
CC       Preferentially binds to CpG-rich sequences at promoters of both
CC       transcriptionally active and Polycomb-repressed genes. Involved in
CC       the recruitment of the O-GlcNAc transferase OGT to CpG-rich
CC       transcription start sites of active genes, thereby promoting
CC       histone H2B GlcNAcylation by OGT. Also involved in transcription
CC       repression of a subset of genes through recruitment of
CC       transcriptional repressors to promoters. Involved in the balance
CC       between pluripotency and lineage commitment of cells it plays a
CC       role in embryonic stem cells maintenance and inner cell mass cell
CC       specification. Plays an important role in the tumorigenicity of
CC       glioblastoma cells. TET1-mediated production of 5hmC acts as a
CC       recruitment signal for the CHTOP-methylosome complex to selective
CC       sites on the chromosome, where it methylates H4R3 and activates
CC       the transcription of genes involved in glioblastomagenesis
CC       (PubMed:25284789). {ECO:0000269|PubMed:12124344,
CC       ECO:0000269|PubMed:19372391, ECO:0000269|PubMed:19372393,
CC       ECO:0000269|PubMed:21496894, ECO:0000269|PubMed:21778364,
CC       ECO:0000269|PubMed:25284789}.
CC   -!- CATALYTIC ACTIVITY: DNA 5-methylcytosine + 2-oxoglutarate + O(2) =
CC       DNA 5-hydroxymethylcytosine + succinate + CO(2).
CC       {ECO:0000269|PubMed:19372391, ECO:0000269|PubMed:21496894}.
CC   -!- CATALYTIC ACTIVITY: DNA 5-hydroxymethylcytosine + 2-oxoglutarate +
CC       O(2) = DNA 5-formylcytosine + succinate + CO(2).
CC       {ECO:0000305|PubMed:21778364}.
CC   -!- CATALYTIC ACTIVITY: DNA 5-formylcytosine + 2-oxoglutarate + O(2) =
CC       DNA 5-carboxylcytosine + succinate + CO(2).
CC       {ECO:0000305|PubMed:21778364}.
CC   -!- COFACTOR:
CC       Name=Fe(2+); Xref=ChEBI:CHEBI:29033;
CC         Evidence={ECO:0000269|PubMed:19372391};
CC       Note=Binds 1 Fe(2+) ion per subunit.
CC       {ECO:0000269|PubMed:19372391};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 3 zinc ions per subunit. The zinc ions have a
CC       structural role. {ECO:0000250};
CC   -!- SUBUNIT: Interacts with HCFC1 and OGT (By similarity). Interacts
CC       with SIN3A; recruits the transcriptional corepressor SIN3A to gene
CC       promoters (PubMed:21490601). Found in a complex composed of at
CC       least SINHCAF, SIN3A, HDAC1, SAP30, RBBP4, OGT and TET1 (By
CC       similarity). {ECO:0000250|UniProtKB:Q3URK3,
CC       ECO:0000269|PubMed:21490601}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000305}.
CC   -!- TISSUE SPECIFICITY: Expressed in fetal heart, lung and brain, and
CC       in adult skeletal muscle, thymus and ovary. Not detected in adult
CC       heart, lung or brain. Up-regulated in glioblastoma cells (at
CC       protein level) (PubMed:25284789). {ECO:0000269|PubMed:12124344,
CC       ECO:0000269|PubMed:12646957, ECO:0000269|PubMed:25284789}.
CC   -!- PTM: Glycosylated. Interaction with OGT leads to GlcNAcylation (By
CC       similarity). {ECO:0000250}.
CC   -!- DISEASE: Note=A chromosomal aberration involving TET1 may be a
CC       cause of acute leukemias (PubMed:12646957). Translocation
CC       t(10;11)(q22;q23) with KMT2A/MLL1. This is a rare chromosomal
CC       translocation 5' KMT2A/MLL1-TET1 3' (PubMed:12124344,
CC       PubMed:12646957). {ECO:0000269|PubMed:12124344,
CC       ECO:0000269|PubMed:12646957}.
CC   -!- SIMILARITY: Belongs to the TET family. {ECO:0000305}.
CC   -!- CAUTION: Subsequent steps in cytosine demethylation are subject to
CC       discussion. According to a first model cytosine demethylation
CC       occurs through deamination of 5hmC into 5-hydroxymethyluracil
CC       (5hmU) and subsequent replacement by unmethylated cytosine by the
CC       base excision repair system (PubMed:21496894). According to
CC       another model, cytosine demethylation is rather mediated via
CC       conversion of 5hmC into 5fC and 5caC, followed by excision by TDG
CC       and replacement by unmethylated cytosine.
CC       {ECO:0000305|PubMed:21496894}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAD28467.3; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF430147; AAM88301.1; -; mRNA.
DR   EMBL; AL513534; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL713888; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AB051463; BAB21767.1; -; mRNA.
DR   EMBL; AL713658; CAD28467.3; ALT_SEQ; mRNA.
DR   EMBL; BC053905; AAH53905.1; -; mRNA.
DR   CCDS; CCDS7281.1; -.
DR   RefSeq; NP_085128.2; NM_030625.2.
DR   UniGene; Hs.258855; -.
DR   UniGene; Hs.567594; -.
DR   UniGene; Hs.598166; -.
DR   UniGene; Hs.708977; -.
DR   PDB; 6ASD; X-ray; 1.85 A; C=587-632.
DR   PDBsum; 6ASD; -.
DR   ProteinModelPortal; Q8NFU7; -.
DR   SMR; Q8NFU7; -.
DR   BioGrid; 123225; 3.
DR   IntAct; Q8NFU7; 2.
DR   MINT; Q8NFU7; -.
DR   STRING; 9606.ENSP00000362748; -.
DR   iPTMnet; Q8NFU7; -.
DR   PhosphoSitePlus; Q8NFU7; -.
DR   BioMuta; TET1; -.
DR   DMDM; 115502139; -.
DR   EPD; Q8NFU7; -.
DR   PaxDb; Q8NFU7; -.
DR   PeptideAtlas; Q8NFU7; -.
DR   PRIDE; Q8NFU7; -.
DR   DNASU; 80312; -.
DR   Ensembl; ENST00000373644; ENSP00000362748; ENSG00000138336.
DR   GeneID; 80312; -.
DR   KEGG; hsa:80312; -.
DR   UCSC; uc001jok.5; human.
DR   CTD; 80312; -.
DR   DisGeNET; 80312; -.
DR   EuPathDB; HostDB:ENSG00000138336.8; -.
DR   GeneCards; TET1; -.
DR   HGNC; HGNC:29484; TET1.
DR   HPA; CAB014886; -.
DR   HPA; HPA019032; -.
DR   HPA; HPA057273; -.
DR   MIM; 607790; gene.
DR   neXtProt; NX_Q8NFU7; -.
DR   OpenTargets; ENSG00000138336; -.
DR   PharmGKB; PA162405605; -.
DR   eggNOG; ENOG410IE22; Eukaryota.
DR   eggNOG; ENOG410XPWW; LUCA.
DR   GeneTree; ENSGT00910000144072; -.
DR   HOGENOM; HOG000154549; -.
DR   InParanoid; Q8NFU7; -.
DR   KO; K13097; -.
DR   OMA; NQKAHPL; -.
DR   OrthoDB; EOG091G007O; -.
DR   PhylomeDB; Q8NFU7; -.
DR   TreeFam; TF324004; -.
DR   Reactome; R-HSA-5221030; TET1,2,3 and TDG demethylate DNA.
DR   ChiTaRS; TET1; human.
DR   GeneWiki; Tet_methylcytosine_dioxygenase_1; -.
DR   GenomeRNAi; 80312; -.
DR   PRO; PR:Q8NFU7; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000138336; -.
DR   CleanEx; HS_TET1; -.
DR   Genevisible; Q8NFU7; HS.
DR   GO; GO:0005634; C:nucleus; IC:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0005506; F:iron ion binding; IDA:UniProtKB.
DR   GO; GO:0070579; F:methylcytosine dioxygenase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0016569; P:covalent chromatin modification; IEA:UniProtKB-KW.
DR   GO; GO:0080111; P:DNA demethylation; IMP:UniProtKB.
DR   GO; GO:0001826; P:inner cell mass cell differentiation; ISS:UniProtKB.
DR   GO; GO:0090310; P:negative regulation of methylation-dependent chromatin silencing; IMP:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0031062; P:positive regulation of histone methylation; IMP:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0006493; P:protein O-linked glycosylation; ISS:UniProtKB.
DR   GO; GO:0019827; P:stem cell population maintenance; ISS:UniProtKB.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   InterPro; IPR024779; 2OGFeDO_noxygenase_dom.
DR   InterPro; IPR002857; Znf_CXXC.
DR   Pfam; PF12851; Tet_JBP; 1.
DR   Pfam; PF02008; zf-CXXC; 1.
DR   SMART; SM01333; Tet_JBP; 1.
DR   PROSITE; PS51058; ZF_CXXC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Chromatin regulator;
KW   Chromosomal rearrangement; Complete proteome; Dioxygenase;
KW   DNA-binding; Glycoprotein; Iron; Metal-binding; Nucleus;
KW   Oxidoreductase; Phosphoprotein; Polymorphism; Reference proteome;
KW   Repressor; Transcription; Transcription regulation; Zinc; Zinc-finger.
FT   CHAIN         1   2136       Methylcytosine dioxygenase TET1.
FT                                /FTId=PRO_0000251949.
FT   ZN_FING     584    625       CXXC-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00509}.
FT   REGION      528    674       Sufficient for binding to genomic CpG
FT                                islands.
FT   REGION     1580   1593       Interaction with DNA. {ECO:0000250}.
FT   REGION     2043   2045       2-oxoglutarate binding. {ECO:0000250}.
FT   REGION     2049   2051       Substrate binding. {ECO:0000250}.
FT   METAL      1422   1422       Zinc 1. {ECO:0000250}.
FT   METAL      1424   1424       Zinc 1. {ECO:0000250}.
FT   METAL      1482   1482       Zinc 2. {ECO:0000250}.
FT   METAL      1508   1508       Zinc 1; via pros nitrogen. {ECO:0000250}.
FT   METAL      1510   1510       Zinc 1. {ECO:0000250}.
FT   METAL      1561   1561       Zinc 2. {ECO:0000250}.
FT   METAL      1563   1563       Zinc 2. {ECO:0000250}.
FT   METAL      1579   1579       Zinc 3. {ECO:0000250}.
FT   METAL      1588   1588       Zinc 3. {ECO:0000250}.
FT   METAL      1648   1648       Zinc 3. {ECO:0000250}.
FT   METAL      1670   1670       Zinc 2; via tele nitrogen. {ECO:0000250}.
FT   METAL      1672   1672       Iron; catalytic.
FT   METAL      1674   1674       Iron; catalytic.
FT   METAL      2028   2028       Iron; catalytic. {ECO:0000250}.
FT   METAL      2059   2059       Zinc 3; via pros nitrogen. {ECO:0000250}.
FT   BINDING    1551   1551       2-oxoglutarate. {ECO:0000250}.
FT   BINDING    1664   1664       2-oxoglutarate. {ECO:0000250}.
FT   BINDING    1677   1677       Substrate. {ECO:0000250}.
FT   BINDING    1706   1706       2-oxoglutarate. {ECO:0000250}.
FT   SITE       1608   1609       Breakpoint for translocation to form
FT                                KMT2A/MLL1-TET1 oncogene.
FT   MOD_RES     871    871       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VARIANT     162    162       D -> G (in dbSNP:rs10823229).
FT                                /FTId=VAR_027734.
FT   VARIANT     193    193       S -> T (in dbSNP:rs12773594).
FT                                /FTId=VAR_027735.
FT   VARIANT     256    256       A -> V (in dbSNP:rs12221107).
FT                                /FTId=VAR_027736.
FT   VARIANT    1018   1018       N -> S (in dbSNP:rs16925541).
FT                                /FTId=VAR_027737.
FT   VARIANT    1123   1123       I -> M (in dbSNP:rs3998860).
FT                                {ECO:0000269|PubMed:12124344}.
FT                                /FTId=VAR_027738.
FT   MUTAGEN    1672   1672       H->Y: Loss of catalytic activity and loss
FT                                of the ability to induce DNA
FT                                demethylation.
FT                                {ECO:0000269|PubMed:19372391,
FT                                ECO:0000269|PubMed:21496894}.
FT   MUTAGEN    1674   1674       D->A: Loss of catalytic activity and loss
FT                                of the ability to induce DNA
FT                                demethylation.
FT                                {ECO:0000269|PubMed:19372391,
FT                                ECO:0000269|PubMed:21496894}.
FT   CONFLICT   2001   2001       F -> L (in Ref. 4; CAD28467).
FT                                {ECO:0000305}.
FT   HELIX       595    598       {ECO:0000244|PDB:6ASD}.
FT   STRAND      604    606       {ECO:0000244|PDB:6ASD}.
FT   HELIX       607    610       {ECO:0000244|PDB:6ASD}.
FT   TURN        611    614       {ECO:0000244|PDB:6ASD}.
FT   TURN        620    622       {ECO:0000244|PDB:6ASD}.
FT   HELIX       625    628       {ECO:0000244|PDB:6ASD}.
SQ   SEQUENCE   2136 AA;  235309 MW;  66E24EF0594A964C CRC64;
     MSRSRHARPS RLVRKEDVNK KKKNSQLRKT TKGANKNVAS VKTLSPGKLK QLIQERDVKK
     KTEPKPPVPV RSLLTRAGAA RMNLDRTEVL FQNPESLTCN GFTMALRSTS LSRRLSQPPL
     VVAKSKKVPL SKGLEKQHDC DYKILPALGV KHSENDSVPM QDTQVLPDIE TLIGVQNPSL
     LKGKSQETTQ FWSQRVEDSK INIPTHSGPA AEILPGPLEG TRCGEGLFSE ETLNDTSGSP
     KMFAQDTVCA PFPQRATPKV TSQGNPSIQL EELGSRVESL KLSDSYLDPI KSEHDCYPTS
     SLNKVIPDLN LRNCLALGGS TSPTSVIKFL LAGSKQATLG AKPDHQEAFE ATANQQEVSD
     TTSFLGQAFG AIPHQWELPG ADPVHGEALG ETPDLPEIPG AIPVQGEVFG TILDQQETLG
     MSGSVVPDLP VFLPVPPNPI ATFNAPSKWP EPQSTVSYGL AVQGAIQILP LGSGHTPQSS
     SNSEKNSLPP VMAISNVENE KQVHISFLPA NTQGFPLAPE RGLFHASLGI AQLSQAGPSK
     SDRGSSQVSV TSTVHVVNTT VVTMPVPMVS TSSSSYTTLL PTLEKKKRKR CGVCEPCQQK
     TNCGECTYCK NRKNSHQICK KRKCEELKKK PSVVVPLEVI KENKRPQREK KPKVLKADFD
     NKPVNGPKSE SMDYSRCGHG EEQKLELNPH TVENVTKNED SMTGIEVEKW TQNKKSQLTD
     HVKGDFSANV PEAEKSKNSE VDKKRTKSPK LFVQTVRNGI KHVHCLPAET NVSFKKFNIE
     EFGKTLENNS YKFLKDTANH KNAMSSVATD MSCDHLKGRS NVLVFQQPGF NCSSIPHSSH
     SIINHHASIH NEGDQPKTPE NIPSKEPKDG SPVQPSLLSL MKDRRLTLEQ VVAIEALTQL
     SEAPSENSSP SKSEKDEESE QRTASLLNSC KAILYTVRKD LQDPNLQGEP PKLNHCPSLE
     KQSSCNTVVF NGQTTTLSNS HINSATNQAS TKSHEYSKVT NSLSLFIPKS NSSKIDTNKS
     IAQGIITLDN CSNDLHQLPP RNNEVEYCNQ LLDSSKKLDS DDLSCQDATH TQIEEDVATQ
     LTQLASIIKI NYIKPEDKKV ESTPTSLVTC NVQQKYNQEK GTIQQKPPSS VHNNHGSSLT
     KQKNPTQKKT KSTPSRDRRK KKPTVVSYQE NDRQKWEKLS YMYGTICDIW IASKFQNFGQ
     FCPHDFPTVF GKISSSTKIW KPLAQTRSIM QPKTVFPPLT QIKLQRYPES AEEKVKVEPL
     DSLSLFHLKT ESNGKAFTDK AYNSQVQLTV NANQKAHPLT QPSSPPNQCA NVMAGDDQIR
     FQQVVKEQLM HQRLPTLPGI SHETPLPESA LTLRNVNVVC SGGITVVSTK SEEEVCSSSF
     GTSEFSTVDS AQKNFNDYAM NFFTNPTKNL VSITKDSELP TCSCLDRVIQ KDKGPYYTHL
     GAGPSVAAVR EIMENRYGQK GNAIRIEIVV YTGKEGKSSH GCPIAKWVLR RSSDEEKVLC
     LVRQRTGHHC PTAVMVVLIM VWDGIPLPMA DRLYTELTEN LKSYNGHPTD RRCTLNENRT
     CTCQGIDPET CGASFSFGCS WSMYFNGCKF GRSPSPRRFR IDPSSPLHEK NLEDNLQSLA
     TRLAPIYKQY APVAYQNQVE YENVARECRL GSKEGRPFSG VTACLDFCAH PHRDIHNMNN
     GSTVVCTLTR EDNRSLGVIP QDEQLHVLPL YKLSDTDEFG SKEGMEAKIK SGAIEVLAPR
     RKKRTCFTQP VPRSGKKRAA MMTEVLAHKI RAVEKKPIPR IKRKNNSTTT NNSKPSSLPT
     LGSNTETVQP EVKSETEPHF ILKSSDNTKT YSLMPSAPHP VKEASPGFSW SPKTASATPA
     PLKNDATASC GFSERSSTPH CTMPSGRLSG ANAAAADGPG ISQLGEVAPL PTLSAPVMEP
     LINSEPSTGV TEPLTPHQPN HQPSFLTSPQ DLASSPMEED EQHSEADEPP SDEPLSDDPL
     SPAEEKLPHI DEYWSDSEHI FLDANIGGVA IAPAHGSVLI ECARRELHAT TPVEHPNRNH
     PTRLSLVFYQ HKNLNKPQHG FELNKIKFEA KEAKNKKMKA SEQKDQAANE GPEQSSEVNE
     LNQIPSHKAL TLTHDNVVTV SPYALTHVAG PYNHWV
//
ID   A0A087WT22_HUMAN        Unreviewed;       187 AA.
AC   A0A087WT22;
DT   29-OCT-2014, integrated into UniProtKB/TrEMBL.
DT   29-OCT-2014, sequence version 1.
DT   28-FEB-2018, entry version 29.
DE   RecName: Full=Cellular tumor antigen p53 {ECO:0000256|RuleBase:RU003304};
GN   Name=TP53 {ECO:0000313|Ensembl:ENSP00000477531};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000477531, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Ensembl:ENSP00000477531, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [2] {ECO:0000213|PubMed:19413330}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [3] {ECO:0000213|PubMed:21269460}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Burckstummer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [4] {ECO:0000313|Ensembl:ENSP00000477531}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (SEP-2014) to UniProtKB.
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression. {ECO:0000256|RuleBase:RU003304}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000256|RuleBase:RU003304};
CC       Note=Binds 1 zinc ion per subunit.
CC       {ECO:0000256|RuleBase:RU003304};
CC   -!- SUBUNIT: Binds DNA as a homotetramer.
CC       {ECO:0000256|RuleBase:RU003304}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000256|RuleBase:RU003304}.
CC       Nucleus {ECO:0000256|RuleBase:RU003304}.
CC   -!- SIMILARITY: Belongs to the p53 family.
CC       {ECO:0000256|RuleBase:RU003401}.
CC   -!- CAUTION: The sequence shown here is derived from an Ensembl
CC       automatic analysis pipeline and should be considered as
CC       preliminary data. {ECO:0000313|Ensembl:ENSP00000477531}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AC007421; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC087388; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_001263628.1; NM_001276699.1.
DR   UniGene; Hs.437460; -.
DR   UniGene; Hs.740601; -.
DR   ProteinModelPortal; A0A087WT22; -.
DR   SMR; A0A087WT22; -.
DR   PeptideAtlas; A0A087WT22; -.
DR   PRIDE; A0A087WT22; -.
DR   Ensembl; ENST00000610623; ENSP00000477531; ENSG00000141510.
DR   GeneID; 7157; -.
DR   UCSC; uc010cnf.2; human.
DR   CTD; 7157; -.
DR   EuPathDB; HostDB:ENSG00000141510.16; -.
DR   HGNC; HGNC:11998; TP53.
DR   OpenTargets; ENSG00000141510; -.
DR   eggNOG; ENOG410IITK; Eukaryota.
DR   eggNOG; ENOG410ZSWV; LUCA.
DR   GeneTree; ENSGT00390000015092; -.
DR   ChiTaRS; TP53; human.
DR   GenomeRNAi; 7157; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000141510; -.
DR   ExpressionAtlas; A0A087WT22; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:InterPro.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   1: Evidence at protein level;
KW   Activator {ECO:0000256|RuleBase:RU003304};
KW   Apoptosis {ECO:0000256|RuleBase:RU003304};
KW   Cell cycle {ECO:0000256|RuleBase:RU003304};
KW   Complete proteome {ECO:0000313|Proteomes:UP000005640};
KW   Cytoplasm {ECO:0000256|RuleBase:RU003304};
KW   DNA-binding {ECO:0000256|RuleBase:RU003304};
KW   Metal-binding {ECO:0000256|RuleBase:RU003304};
KW   Nucleus {ECO:0000256|RuleBase:RU003304};
KW   Phosphoprotein {ECO:0000256|RuleBase:RU003304};
KW   Proteomics identification {ECO:0000213|EPD:A0A087WT22,
KW   ECO:0000213|MaxQB:A0A087WT22, ECO:0000213|PeptideAtlas:A0A087WT22};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640};
KW   Transcription {ECO:0000256|RuleBase:RU003304};
KW   Transcription regulation {ECO:0000256|RuleBase:RU003304};
KW   Zinc {ECO:0000256|RuleBase:RU003304}.
FT   DOMAIN        1    129       P53. {ECO:0000259|Pfam:PF00870}.
SQ   SEQUENCE   187 AA;  21416 MW;  C60E05EDDBC150C2 CRC64;
     MAIYKQSQHM TEVVRRCPHH ERCSDSDGLA PPQHLIRVEG NLRVEYLDDR NTFRHSVVVP
     YEPPEVGSDC TTIHYNYMCN SSCMGGMNRR PILTIITLED SSGNLLGRNS FEVRVCACPG
     RDRRTEEENL RKKGEPHHEL PPGSTKRALP NNTSSSPQPK KKPLDGEYFT LQMLLDLRWC
     YFLINSS
//
ID   A0A087WXZ1_HUMAN        Unreviewed;       182 AA.
AC   A0A087WXZ1;
DT   29-OCT-2014, integrated into UniProtKB/TrEMBL.
DT   29-OCT-2014, sequence version 1.
DT   28-FEB-2018, entry version 29.
DE   RecName: Full=Cellular tumor antigen p53 {ECO:0000256|RuleBase:RU003304};
GN   Name=TP53 {ECO:0000313|Ensembl:ENSP00000481401};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000481401, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Ensembl:ENSP00000481401, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [2] {ECO:0000213|PubMed:19413330}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [3] {ECO:0000213|PubMed:21269460}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Burckstummer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [4] {ECO:0000313|Ensembl:ENSP00000481401}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (SEP-2014) to UniProtKB.
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression. {ECO:0000256|RuleBase:RU003304}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000256|RuleBase:RU003304};
CC       Note=Binds 1 zinc ion per subunit.
CC       {ECO:0000256|RuleBase:RU003304};
CC   -!- SUBUNIT: Binds DNA as a homotetramer.
CC       {ECO:0000256|RuleBase:RU003304}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000256|RuleBase:RU003304}.
CC       Nucleus {ECO:0000256|RuleBase:RU003304}.
CC   -!- SIMILARITY: Belongs to the p53 family.
CC       {ECO:0000256|RuleBase:RU003401}.
CC   -!- CAUTION: The sequence shown here is derived from an Ensembl
CC       automatic analysis pipeline and should be considered as
CC       preliminary data. {ECO:0000313|Ensembl:ENSP00000481401}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AC007421; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC087388; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_001263627.1; NM_001276698.1.
DR   UniGene; Hs.437460; -.
DR   UniGene; Hs.740601; -.
DR   ProteinModelPortal; A0A087WXZ1; -.
DR   SMR; A0A087WXZ1; -.
DR   PeptideAtlas; A0A087WXZ1; -.
DR   PRIDE; A0A087WXZ1; -.
DR   Ensembl; ENST00000618944; ENSP00000481401; ENSG00000141510.
DR   GeneID; 7157; -.
DR   UCSC; uc010cng.2; human.
DR   CTD; 7157; -.
DR   EuPathDB; HostDB:ENSG00000141510.16; -.
DR   HGNC; HGNC:11998; TP53.
DR   OpenTargets; ENSG00000141510; -.
DR   eggNOG; ENOG410IITK; Eukaryota.
DR   eggNOG; ENOG410ZSWV; LUCA.
DR   GeneTree; ENSGT00390000015092; -.
DR   ChiTaRS; TP53; human.
DR   GenomeRNAi; 7157; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000141510; -.
DR   ExpressionAtlas; A0A087WXZ1; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:InterPro.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   1: Evidence at protein level;
KW   Activator {ECO:0000256|RuleBase:RU003304};
KW   Apoptosis {ECO:0000256|RuleBase:RU003304};
KW   Cell cycle {ECO:0000256|RuleBase:RU003304};
KW   Complete proteome {ECO:0000313|Proteomes:UP000005640};
KW   Cytoplasm {ECO:0000256|RuleBase:RU003304};
KW   DNA-binding {ECO:0000256|RuleBase:RU003304};
KW   Metal-binding {ECO:0000256|RuleBase:RU003304};
KW   Nucleus {ECO:0000256|RuleBase:RU003304};
KW   Phosphoprotein {ECO:0000256|RuleBase:RU003304};
KW   Proteomics identification {ECO:0000213|EPD:A0A087WXZ1,
KW   ECO:0000213|MaxQB:A0A087WXZ1, ECO:0000213|PeptideAtlas:A0A087WXZ1};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640};
KW   Transcription {ECO:0000256|RuleBase:RU003304};
KW   Transcription regulation {ECO:0000256|RuleBase:RU003304};
KW   Zinc {ECO:0000256|RuleBase:RU003304}.
FT   DOMAIN        1    129       P53. {ECO:0000259|Pfam:PF00870}.
SQ   SEQUENCE   182 AA;  20741 MW;  141DBA75C051D39D CRC64;
     MAIYKQSQHM TEVVRRCPHH ERCSDSDGLA PPQHLIRVEG NLRVEYLDDR NTFRHSVVVP
     YEPPEVGSDC TTIHYNYMCN SSCMGGMNRR PILTIITLED SSGNLLGRNS FEVRVCACPG
     RDRRTEEENL RKKGEPHHEL PPGSTKRALP NNTSSSPQPK KKPLDGEYFT LQDQTSFQKE
     NC
//
ID   A0A087X1Q1_HUMAN        Unreviewed;       234 AA.
AC   A0A087X1Q1;
DT   29-OCT-2014, integrated into UniProtKB/TrEMBL.
DT   29-OCT-2014, sequence version 1.
DT   28-FEB-2018, entry version 31.
DE   RecName: Full=Cellular tumor antigen p53 {ECO:0000256|RuleBase:RU003304};
GN   Name=TP53 {ECO:0000313|Ensembl:ENSP00000484375};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000484375, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Ensembl:ENSP00000484375, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [2] {ECO:0000213|PubMed:19413330}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [3] {ECO:0000213|PubMed:19608861}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [4] {ECO:0000213|PubMed:21269460}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Burckstummer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [5] {ECO:0000313|Ensembl:ENSP00000484375}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (SEP-2014) to UniProtKB.
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression. {ECO:0000256|RuleBase:RU003304}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000256|RuleBase:RU003304};
CC       Note=Binds 1 zinc ion per subunit.
CC       {ECO:0000256|RuleBase:RU003304};
CC   -!- SUBUNIT: Binds DNA as a homotetramer.
CC       {ECO:0000256|RuleBase:RU003304}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000256|RuleBase:RU003304}.
CC       Nucleus {ECO:0000256|RuleBase:RU003304}.
CC   -!- SIMILARITY: Belongs to the p53 family.
CC       {ECO:0000256|RuleBase:RU003401}.
CC   -!- CAUTION: The sequence shown here is derived from an Ensembl
CC       automatic analysis pipeline and should be considered as
CC       preliminary data. {ECO:0000313|Ensembl:ENSP00000484375}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AC007421; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC087388; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_001263626.1; NM_001276697.1.
DR   UniGene; Hs.437460; -.
DR   UniGene; Hs.740601; -.
DR   ProteinModelPortal; A0A087X1Q1; -.
DR   SMR; A0A087X1Q1; -.
DR   EPD; A0A087X1Q1; -.
DR   PeptideAtlas; A0A087X1Q1; -.
DR   PRIDE; A0A087X1Q1; -.
DR   Ensembl; ENST00000619186; ENSP00000484375; ENSG00000141510.
DR   GeneID; 7157; -.
DR   UCSC; uc002gii.2; human.
DR   CTD; 7157; -.
DR   EuPathDB; HostDB:ENSG00000141510.16; -.
DR   HGNC; HGNC:11998; TP53.
DR   OpenTargets; ENSG00000141510; -.
DR   eggNOG; ENOG410IITK; Eukaryota.
DR   eggNOG; ENOG410ZSWV; LUCA.
DR   GeneTree; ENSGT00390000015092; -.
DR   ChiTaRS; TP53; human.
DR   GenomeRNAi; 7157; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000141510; -.
DR   ExpressionAtlas; A0A087X1Q1; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:InterPro.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR036674; p53_tetramer_sf.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   1: Evidence at protein level;
KW   Activator {ECO:0000256|RuleBase:RU003304};
KW   Apoptosis {ECO:0000256|RuleBase:RU003304};
KW   Cell cycle {ECO:0000256|RuleBase:RU003304};
KW   Complete proteome {ECO:0000313|Proteomes:UP000005640};
KW   Cytoplasm {ECO:0000256|RuleBase:RU003304};
KW   DNA-binding {ECO:0000256|RuleBase:RU003304};
KW   Metal-binding {ECO:0000256|RuleBase:RU003304};
KW   Nucleus {ECO:0000256|RuleBase:RU003304};
KW   Phosphoprotein {ECO:0000256|RuleBase:RU003304};
KW   Proteomics identification {ECO:0000213|EPD:A0A087X1Q1,
KW   ECO:0000213|MaxQB:A0A087X1Q1, ECO:0000213|PeptideAtlas:A0A087X1Q1};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640};
KW   Transcription {ECO:0000256|RuleBase:RU003304};
KW   Transcription regulation {ECO:0000256|RuleBase:RU003304};
KW   Zinc {ECO:0000256|RuleBase:RU003304}.
FT   DOMAIN        1    129       P53. {ECO:0000259|Pfam:PF00870}.
FT   DOMAIN      160    198       P53_tetramer. {ECO:0000259|Pfam:PF07710}.
SQ   SEQUENCE   234 AA;  26569 MW;  AABDD005298DDF31 CRC64;
     MAIYKQSQHM TEVVRRCPHH ERCSDSDGLA PPQHLIRVEG NLRVEYLDDR NTFRHSVVVP
     YEPPEVGSDC TTIHYNYMCN SSCMGGMNRR PILTIITLED SSGNLLGRNS FEVRVCACPG
     RDRRTEEENL RKKGEPHHEL PPGSTKRALP NNTSSSPQPK KKPLDGEYFT LQIRGRERFE
     MFRELNEALE LKDAQAGKEP GGSRAHSSHL KSKKGQSTSR HKKLMFKTEG PDSD
//
ID   H2EHT1_HUMAN            Unreviewed;       354 AA.
AC   H2EHT1;
DT   21-MAR-2012, integrated into UniProtKB/TrEMBL.
DT   21-MAR-2012, sequence version 1.
DT   31-JAN-2018, entry version 47.
DE   RecName: Full=Cellular tumor antigen p53 {ECO:0000256|RuleBase:RU003304};
GN   Name=TP53 {ECO:0000313|EMBL:AEX20383.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AEX20383.1};
RN   [1] {ECO:0000313|EMBL:AEX20383.1}
RP   NUCLEOTIDE SEQUENCE.
RX   PubMed=21112961; DOI=10.1093/carcin/bgq253;
RA   Marcel V., Tran P.L., Sagne C., Martel-Planche G., Vaslin L.,
RA   Teulade-Fichou M.P., Hall J., Mergny J.L., Hainaut P., Van Dyck E.;
RT   "G-quadruplex structures in TP53 intron 3: role in alternative
RT   splicing and in production of p53 mRNA isoforms.";
RL   Carcinogenesis 32:271-278(2011).
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression. {ECO:0000256|RuleBase:RU003304}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000256|RuleBase:RU003304};
CC       Note=Binds 1 zinc ion per subunit.
CC       {ECO:0000256|RuleBase:RU003304};
CC   -!- SUBUNIT: Binds DNA as a homotetramer.
CC       {ECO:0000256|RuleBase:RU003304}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000256|RuleBase:RU003304}.
CC       Nucleus {ECO:0000256|RuleBase:RU003304}.
CC   -!- SIMILARITY: Belongs to the p53 family.
CC       {ECO:0000256|RuleBase:RU003401}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; JN900492; AEX20383.1; -; mRNA.
DR   RefSeq; NP_001119590.1; NM_001126118.1.
DR   RefSeq; NP_001263689.1; NM_001276760.1.
DR   RefSeq; NP_001263690.1; NM_001276761.1.
DR   UniGene; Hs.437460; -.
DR   UniGene; Hs.740601; -.
DR   ProteinModelPortal; H2EHT1; -.
DR   SMR; H2EHT1; -.
DR   PRIDE; H2EHT1; -.
DR   GeneID; 7157; -.
DR   CTD; 7157; -.
DR   EuPathDB; HostDB:ENSG00000141510.16; -.
DR   eggNOG; ENOG410IITK; Eukaryota.
DR   eggNOG; ENOG410ZSWV; LUCA.
DR   ChiTaRS; TP53; human.
DR   GenomeRNAi; 7157; -.
DR   Bgee; ENSG00000141510; -.
DR   ExpressionAtlas; H2EHT1; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:InterPro.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR036674; p53_tetramer_sf.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   2: Evidence at transcript level;
KW   Activator {ECO:0000256|RuleBase:RU003304};
KW   Apoptosis {ECO:0000256|RuleBase:RU003304};
KW   Cell cycle {ECO:0000256|RuleBase:RU003304};
KW   Cytoplasm {ECO:0000256|RuleBase:RU003304};
KW   DNA-binding {ECO:0000256|RuleBase:RU003304};
KW   Metal-binding {ECO:0000256|RuleBase:RU003304};
KW   Nucleus {ECO:0000256|RuleBase:RU003304};
KW   Phosphoprotein {ECO:0000256|RuleBase:RU003304};
KW   Transcription {ECO:0000256|RuleBase:RU003304};
KW   Transcription regulation {ECO:0000256|RuleBase:RU003304};
KW   Zinc {ECO:0000256|RuleBase:RU003304}.
FT   DOMAIN       56    249       P53. {ECO:0000259|Pfam:PF00870}.
FT   DOMAIN      280    318       P53_tetramer. {ECO:0000259|Pfam:PF07710}.
SQ   SEQUENCE   354 AA;  39320 MW;  6F12310423325770 CRC64;
     MDDLMLSPDD IEQWFTEDPG PDEAPRMPEA APPVAPAPAA PTPAAPAPAP SWPLSSSVPS
     QKTYQGSYGF RLGFLHSGTA KSVTCTYSPA LNKMFCQLAK TCPVQLWVDS TPPPGTRVRA
     MAIYKQSQHM TEVVRRCPHH ERCSDSDGLA PPQHLIRVEG NLRVEYLDDR NTFRHSVVVP
     YEPPEVGSDC TTIHYNYMCN SSCMGGMNRR PILTIITLED SSGNLLGRNS FEVRVCACPG
     RDRRTEEENL RKKGEPHHEL PPGSTKRALP NNTSSSPQPK KKPLDGEYFT LQIRGRERFE
     MFRELNEALE LKDAQAGKEP GGSRAHSSHL KSKKGQSTSR HKKLMFKTEG PDSD
//
ID   K7PPA8_HUMAN            Unreviewed;       393 AA.
AC   K7PPA8;
DT   06-FEB-2013, integrated into UniProtKB/TrEMBL.
DT   06-FEB-2013, sequence version 1.
DT   28-FEB-2018, entry version 52.
DE   RecName: Full=Cellular tumor antigen p53 {ECO:0000256|RuleBase:RU003304};
GN   Name=TP53 {ECO:0000313|EMBL:AFN61604.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AFN61604.1};
RN   [1] {ECO:0000313|EMBL:AFN61604.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mahalingam D., Kong C.M., Lai J.K.H., Tay L.L., Yang H., Wang X.;
RT   "Reversal of aberrant cancer methylome and transcriptome upon direct
RT   reprogramming of lung cancer cells.";
RL   Submitted (FEB-2012) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression. {ECO:0000256|RuleBase:RU003304}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000256|RuleBase:RU003304};
CC       Note=Binds 1 zinc ion per subunit.
CC       {ECO:0000256|RuleBase:RU003304};
CC   -!- SUBUNIT: Binds DNA as a homotetramer.
CC       {ECO:0000256|RuleBase:RU003304}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000256|RuleBase:RU003304}.
CC       Nucleus {ECO:0000256|RuleBase:RU003304}.
CC   -!- SIMILARITY: Belongs to the p53 family.
CC       {ECO:0000256|RuleBase:RU003401}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; JQ694049; AFN61604.1; -; mRNA.
DR   EMBL; JQ694050; AFN61605.1; -; mRNA.
DR   RefSeq; NP_000537.3; NM_000546.5.
DR   RefSeq; NP_001119584.1; NM_001126112.2.
DR   UniGene; Hs.437460; -.
DR   UniGene; Hs.740601; -.
DR   SMR; K7PPA8; -.
DR   GeneID; 7157; -.
DR   KEGG; hsa:7157; -.
DR   CTD; 7157; -.
DR   EuPathDB; HostDB:ENSG00000141510.16; -.
DR   eggNOG; ENOG410IITK; Eukaryota.
DR   eggNOG; ENOG410ZSWV; LUCA.
DR   KO; K04451; -.
DR   OMA; PATSWPL; -.
DR   OrthoDB; EOG091G0XY5; -.
DR   ChiTaRS; TP53; human.
DR   GenomeRNAi; 7157; -.
DR   Bgee; ENSG00000141510; -.
DR   GO; GO:0000785; C:chromatin; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005667; C:transcription factor complex; IEA:Ensembl.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0097371; F:MDM2/MDM4 family protein binding; IEA:Ensembl.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008022; F:protein C-terminus binding; IEA:Ensembl.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0001221; F:transcription cofactor binding; IEA:Ensembl.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:InterPro.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IEA:Ensembl.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0034605; P:cellular response to heat; IEA:Ensembl.
DR   GO; GO:0071417; P:cellular response to organonitrogen compound; IEA:Ensembl.
DR   GO; GO:0034614; P:cellular response to reactive oxygen species; IEA:Ensembl.
DR   GO; GO:2000279; P:negative regulation of DNA biosynthetic process; IEA:Ensembl.
DR   GO; GO:0048662; P:negative regulation of smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0045787; P:positive regulation of cell cycle; IEA:Ensembl.
DR   GO; GO:0002687; P:positive regulation of leukocyte migration; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:1903205; P:regulation of hydrogen peroxide-induced cell death; IEA:Ensembl.
DR   GO; GO:0051453; P:regulation of intracellular pH; IEA:Ensembl.
DR   GO; GO:0043200; P:response to amino acid; IEA:Ensembl.
DR   GO; GO:0031000; P:response to caffeine; IEA:Ensembl.
DR   GO; GO:0034097; P:response to cytokine; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0055093; P:response to hyperoxia; IEA:Ensembl.
DR   GO; GO:0010038; P:response to metal ion; IEA:Ensembl.
DR   GO; GO:0032526; P:response to retinoic acid; IEA:Ensembl.
DR   GO; GO:0010224; P:response to UV-B; IEA:Ensembl.
DR   GO; GO:0033552; P:response to vitamin B3; IEA:Ensembl.
DR   GO; GO:0010165; P:response to X-ray; IEA:Ensembl.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0042060; P:wound healing; IEA:Ensembl.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR036674; p53_tetramer_sf.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR013872; p53_transactivation_domain.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF08563; P53_TAD; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   2: Evidence at transcript level;
KW   Activator {ECO:0000256|RuleBase:RU003304};
KW   Apoptosis {ECO:0000256|RuleBase:RU003304};
KW   Cell cycle {ECO:0000256|RuleBase:RU003304};
KW   Cytoplasm {ECO:0000256|RuleBase:RU003304};
KW   DNA-binding {ECO:0000256|RuleBase:RU003304};
KW   Metal-binding {ECO:0000256|RuleBase:RU003304};
KW   Nucleus {ECO:0000256|RuleBase:RU003304};
KW   Phosphoprotein {ECO:0000256|RuleBase:RU003304};
KW   Transcription {ECO:0000256|RuleBase:RU003304};
KW   Transcription regulation {ECO:0000256|RuleBase:RU003304};
KW   Zinc {ECO:0000256|RuleBase:RU003304}.
FT   DOMAIN        5     29       P53_TAD. {ECO:0000259|Pfam:PF08563}.
FT   DOMAIN       95    288       P53. {ECO:0000259|Pfam:PF00870}.
FT   DOMAIN      319    357       P53_tetramer. {ECO:0000259|Pfam:PF07710}.
SQ   SEQUENCE   393 AA;  43653 MW;  AD5C149FD8106131 CRC64;
     MEEPQSDPSV EPPLSQETFS DLWKLLPENN VLSPLPSQAM DDLMLSPDDI EQWFTEDPGP
     DEAPRMPEAA PPVAPAPAAP TPAAPAPAPS WPLSSSVPSQ KTYQGSYGFR LGFLHSGTAK
     SVTCTYSPAL NKMFCQLAKT CPVQLWVDST PPPGTRVRAM AIYKQSQHMT EVVRRCPHHE
     RCSDSDGLAP PQHLIRVEGN LRVEYLDDRN TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS
     SCMGGMNRRP ILTIITLEDS SGNLLGRNSF EVRVCACPGR DRRTEEENLR KKGEPHHELP
     PGSTKRALPN NTSSSPQPKK KPLDGEYFTL QIRGRERFEM FRELNEALEL KDAQAGKEPG
     GSRAHSSHLK SKKGQSTSRH KKLMFKTEGP DSD
//
ID   P53_HUMAN               Reviewed;         393 AA.
AC   P04637; Q15086; Q15087; Q15088; Q16535; Q16807; Q16808; Q16809;
AC   Q16810; Q16811; Q16848; Q2XN98; Q3LRW1; Q3LRW2; Q3LRW3; Q3LRW4;
AC   Q3LRW5; Q86UG1; Q8J016; Q99659; Q9BTM4; Q9HAQ8; Q9NP68; Q9NPJ2;
AC   Q9NZD0; Q9UBI2; Q9UQ61;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   24-NOV-2009, sequence version 4.
DT   28-FEB-2018, entry version 263.
DE   RecName: Full=Cellular tumor antigen p53;
DE   AltName: Full=Antigen NY-CO-13;
DE   AltName: Full=Phosphoprotein p53;
DE   AltName: Full=Tumor suppressor p53;
GN   Name=TP53; Synonyms=P53;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=4006916;
RA   Zakut-Houri R., Bienz-Tadmor B., Givol D., Oren M.;
RT   "Human p53 cellular tumor antigen: cDNA sequence and expression in COS
RT   cells.";
RL   EMBO J. 4:1251-1255(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANT
RP   GLY-76.
RX   PubMed=2946935; DOI=10.1128/MCB.6.5.1379;
RA   Lamb P., Crawford L.;
RT   "Characterization of the human p53 gene.";
RL   Mol. Cell. Biol. 6:1379-1385(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3894933; DOI=10.1128/MCB.5.7.1601;
RA   Harlow E., Williamson N.M., Ralston R., Helfman D.M., Adams T.E.;
RT   "Molecular cloning and in vitro expression of a cDNA clone for human
RT   cellular tumor antigen p53.";
RL   Mol. Cell. Biol. 5:1601-1610(1985).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3025664; DOI=10.1128/MCB.6.12.4650;
RA   Harris N., Brill E., Shohat O., Prokocimer M., Wolf D., Arai N.,
RA   Rotter V.;
RT   "Molecular basis for heterogeneity of the human p53 protein.";
RL   Mol. Cell. Biol. 6:4650-4656(1986).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2905688; DOI=10.1016/0378-1119(88)90196-5;
RA   Buchman V.L., Chumakov P.M., Ninkina N.N., Samarina O.P.,
RA   Georgiev G.P.;
RT   "A variation in the structure of the protein-coding region of the
RT   human p53 gene.";
RL   Gene 70:245-252(1988).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS SPORADIC CANCERS.
RX   PubMed=1915267;
RA   Farrell P.J., Allan G., Shanahan F., Vousden K.H., Crook T.;
RT   "p53 is frequently mutated in Burkitt's lymphoma cell lines.";
RL   EMBO J. 10:2879-2887(1991).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-286.
RX   PubMed=8316628;
RA   Allalunis-Turner M.J., Barron G.M., Day R.S. III, Dobler K.D.,
RA   Mirzayans R.;
RT   "Isolation of two cell lines from a human malignant glioma specimen
RT   differing in sensitivity to radiation and chemotherapeutic drugs.";
RL   Radiat. Res. 134:349-354(1993).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH WWOX.
RX   PubMed=11058590; DOI=10.1074/jbc.M007140200;
RA   Chang N.-S., Pratt N., Heath J., Schultz L., Sleve D., Carey G.B.,
RA   Zevotek N.;
RT   "Hyaluronidase induction of a WW domain-containing oxidoreductase that
RT   enhances tumor necrosis factor cytotoxicity.";
RL   J. Biol. Chem. 276:3361-3370(2001).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3; 7; 8 AND 9), SUBCELLULAR
RP   LOCATION, TISSUE SPECIFICITY, ALTERNATIVE PROMOTER USAGE, ALTERNATIVE
RP   SPLICING, INDUCTION, AND VARIANT ARG-72.
RC   TISSUE=Colon;
RX   PubMed=16131611; DOI=10.1101/gad.1339905;
RA   Bourdon J.C., Fernandes K., Murray-Zmijewski F., Liu G., Diot A.,
RA   Xirodimas D.P., Saville M.K., Lane D.P.;
RT   "p53 isoforms can regulate p53 transcriptional activity.";
RL   Genes Dev. 19:2122-2137(2005).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Chumakov P.M., Almazov V.P., Jenkins J.R.;
RL   Submitted (JUN-1991) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Rozemuller E.H., Tilanus M.G.J.;
RT   "P53 genomic sequence. Corrections and polymorphism.";
RL   Submitted (MAR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-47; LYS-339 AND
RP   ALA-366.
RG   NIEHS SNPs program;
RL   Submitted (NOV-2004) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-286.
RX   PubMed=11023613; DOI=10.1667/0033-7587(2000)154[0473:HTFTMG]2.0.CO;2;
RA   Anderson C.W., Allalunis-Turner M.J.;
RT   "Human TP53 from the malignant glioma-derived cell lines M059J and
RT   M059K has a cancer-associated mutation in exon 8.";
RL   Radiat. Res. 154:473-476(2000).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS HIS-273 AND
RP   SER-309.
RA   Azuma K., Shichijo S., Itoh K.;
RT   "Identification of a tumor-rejection antigen recognized by HLA-B46
RT   restricted CTL.";
RL   Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   ARG-72.
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ARG-72.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [18]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   ALA-278.
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [19]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-379 (ISOFORM 1), AND VARIANTS ASN-139
RP   AND PRO-155.
RC   TISSUE=Lung carcinoma;
RX   PubMed=14660794; DOI=10.1073/pnas.2536558100;
RA   Kanashiro C.A., Schally A.V., Groot K., Armatis P., Bernardino A.L.,
RA   Varga J.L.;
RT   "Inhibition of mutant p53 expression and growth of DMS-153 small cell
RT   lung carcinoma by antagonists of growth hormone-releasing hormone and
RT   bombesin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:15836-15841(2003).
RN   [20]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 101-393.
RX   PubMed=6396087;
RA   Matlashewski G., Lamb P., Pim D., Peacock J., Crawford L.,
RA   Benchimol S.;
RT   "Isolation and characterization of a human p53 cDNA clone: expression
RT   of the human p53 gene.";
RL   EMBO J. 3:3257-3262(1984).
RN   [21]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 126-185.
RA   Pan X.L., Zhang A.H.;
RT   "Study on the effect of tumor suppressor gene p53 in arsenism
RT   patients.";
RL   Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
RN   [22]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 261-298, AND VARIANT GLN-282.
RC   TISSUE=Blood;
RA   Nimri L.F., Owais W., Momani E.;
RT   "Detection of P53 gene mutations and serum p53 antibodies associated
RT   with cigarette smoking.";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [23]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 262-306, AND VARIANT VAL-262.
RC   TISSUE=Ovarian adenocarcinoma;
RA   Filippini G., Soldati G.;
RL   Submitted (JUL-1996) to the EMBL/GenBank/DDBJ databases.
RN   [24]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-260.
RC   TISSUE=Glial cell, and Glial tumor;
RA   Thompson-Hehir J., Davies M.P.A., Green J.A., Halliwell N.,
RA   Joyce K.A., Salisbury J., Sibson D.R., Vergote I., Walker C.;
RT   "Mutation detection utilizing a novel PCR approach for amplification
RT   of the p53 gene from microdissected tissue: application to archival
RT   tumor samples.";
RL   Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
RN   [25]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 225-260.
RA   Yavuz A.S., Farner N.L., Yavuz S., Grammer A.C., Girschick H.J.,
RA   Lipsky P.E.;
RT   "Bcl6 and P53 gene mutations in tonsillar B cells.";
RL   Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [26]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 332-366.
RA   Pinto E.M., Mendonca B.B., Latronico A.C.;
RT   "Allelic variant in intron 9 of TP53 gene.";
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [27]
RP   NUCLEAR LOCALIZATION SIGNAL, AND MUTAGENESIS OF LYS-319; LYS-320 AND
RP   LYS-321.
RX   PubMed=2156209;
RA   Addison C., Jenkins J.R., Sturzbecher H.-W.;
RT   "The p53 nuclear localisation signal is structurally linked to a
RT   p34cdc2 kinase motif.";
RL   Oncogene 5:423-426(1990).
RN   [28]
RP   PHOSPHORYLATION BY P60/CDC2 AND CYCLIN B/CDC2.
RX   PubMed=2141171; DOI=10.1073/pnas.87.12.4766;
RA   Bischoff J.R., Friedman P.N., Marshak D.R., Prives C., Beach D.;
RT   "Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:4766-4770(1990).
RN   [29]
RP   PHOSPHORYLATION.
RX   PubMed=1705009; DOI=10.1128/MCB.11.3.1598;
RA   Samad A., Carroll R.B.;
RT   "The tumor suppressor p53 is bound to RNA by a stable covalent
RT   linkage.";
RL   Mol. Cell. Biol. 11:1598-1606(1991).
RN   [30]
RP   DEPHOSPHORYLATION BY PP2A.
RX   PubMed=1848668; DOI=10.1128/MCB.11.4.1996;
RA   Scheidtmann K.H., Mumby M.C., Rundell K., Walter G.;
RT   "Dephosphorylation of simian virus 40 large-T antigen and p53 protein
RT   by protein phosphatase 2A: inhibition by small-t antigen.";
RL   Mol. Cell. Biol. 11:1996-2003(1991).
RN   [31]
RP   ALTERNATIVE SPLICING.
RX   PubMed=8632903;
RA   Flaman J.-M., Waridel F., Estreicher A., Vannier A., Limacher J.-M.,
RA   Gilbert D., Iggo R., Frebourg T.;
RT   "The human tumour suppressor gene p53 is alternatively spliced in
RT   normal cells.";
RL   Oncogene 12:813-818(1996).
RN   [32]
RP   GLYCOSYLATION.
RX   PubMed=8632915;
RA   Shaw P., Freeman J., Bovey R., Iggo R.;
RT   "Regulation of specific DNA binding by p53: evidence for a role for O-
RT   glycosylation and charged residues at the carboxy-terminus.";
RL   Oncogene 12:921-930(1996).
RN   [33]
RP   PHOSPHORYLATION AT SER-33.
RX   PubMed=9372954; DOI=10.1128/MCB.17.12.7220;
RA   Ko L.J., Shieh S.-Y., Chen X., Jayaraman L., Tamai K., Taya Y.,
RA   Prives C., Pan Z.-Q.;
RT   "p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent
RT   manner.";
RL   Mol. Cell. Biol. 17:7220-7229(1997).
RN   [34]
RP   FUNCTION, AND IDENTIFICATION IN COMPLEX WITH CAK.
RX   PubMed=9840937; DOI=10.1038/sj.onc.1202504;
RA   Schneider E., Montenarh M., Wagner P.;
RT   "Regulation of CAK kinase activity by p53.";
RL   Oncogene 17:2733-2741(1998).
RN   [35]
RP   SUMOYLATION AT LYS-386, AND MUTAGENESIS OF LYS-386.
RA   Gostissa M., Hengstermann A., Fogal V., Sandy P., Schwarz S.E.,
RA   Scheffner M., Del Sal G.;
RT   "Activation of p53 by conjugation to the ubiquitin-like protein SUMO-
RT   1.";
RL   EMBO J. 18:6462-6471(1999).
RN   [36]
RP   PHOSPHORYLATION AT THR-18 BY CSNK1D/CK1.
RX   PubMed=10606744; DOI=10.1016/S0014-5793(99)01647-6;
RA   Dumaz N., Milne D.M., Meek D.W.;
RT   "Protein kinase CK1 is a p53-threonine 18 kinase which requires prior
RT   phosphorylation of serine 15.";
RL   FEBS Lett. 463:312-316(1999).
RN   [37]
RP   BIPARTITE NUCLEAR LOCALIZATION SIGNAL, AND CHARACTERIZATION OF VARIANT
RP   ASN-305.
RX   PubMed=10551826; DOI=10.1074/jbc.274.46.32699;
RA   Liang S.H., Clarke M.F.;
RT   "A bipartite nuclear localization signal is required for p53 nuclear
RT   import regulated by a carboxyl-terminal domain.";
RL   J. Biol. Chem. 274:32699-32703(1999).
RN   [38]
RP   PHOSPHORYLATION AT SER-15 AND SER-20, INDUCTION BY DNA DAMAGE,
RP   CHARACTERIZATION OF LFS VARIANT HIS-273, MUTAGENESIS OF THR-18; SER-20
RP   AND 22-LEU-TRP-23, SUBCELLULAR LOCATION, AND INTERACTION WITH PML AND
RP   MDM2.
RX   PubMed=10570149; DOI=10.1073/pnas.96.24.13777;
RA   Chehab N.H., Malikzay A., Stavridi E.S., Halazonetis T.D.;
RT   "Phosphorylation of Ser-20 mediates stabilization of human p53 in
RT   response to DNA damage.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:13777-13782(1999).
RN   [39]
RP   UBIQUITINATION.
RX   PubMed=10722742; DOI=10.1074/jbc.275.12.8945;
RA   Fang S., Jensen J.P., Ludwig R.L., Vousden K.H., Weissman A.M.;
RT   "Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself
RT   and p53.";
RL   J. Biol. Chem. 275:8945-8951(2000).
RN   [40]
RP   ACETYLATION AT LYS-373 AND LYS-382.
RX   PubMed=10656795; DOI=10.1006/jmbi.1999.3415;
RA   Abraham J., Kelly J., Thibault P., Benchimol S.;
RT   "Post-translational modification of p53 protein in response to
RT   ionizing radiation analyzed by mass spectrometry.";
RL   J. Mol. Biol. 295:853-864(2000).
RN   [41]
RP   PHOSPHORYLATION AT SER-315 AND SER-392 BY CDK2, AND MUTAGENESIS OF
RP   LYS-382; LEU-383 AND PHE-385.
RX   PubMed=10884347; DOI=10.1006/jmbi.2000.3830;
RA   Luciani M.G., Hutchins J.R.A., Zheleva D., Hupp T.R.;
RT   "The C-terminal regulatory domain of p53 contains a functional docking
RT   site for cyclin A.";
RL   J. Mol. Biol. 300:503-518(2000).
RN   [42]
RP   FUNCTION, INTERACTION WITH PML, AND SUBCELLULAR LOCATION.
RX   PubMed=11025664; DOI=10.1038/35036365;
RA   Guo A., Salomoni P., Luo J., Shih A., Zhong S., Gu W., Pandolfi P.P.;
RT   "The function of PML in p53-dependent apoptosis.";
RL   Nat. Cell Biol. 2:730-736(2000).
RN   [43]
RP   INTERACTION WITH E4F1.
RX   PubMed=10644996; DOI=10.1038/sj.onc.1203250;
RA   Sandy P., Gostissa M., Fogal V., Cecco L.D., Szalay K., Rooney R.J.,
RA   Schneider C., Del Sal G.;
RT   "p53 is involved in the p120E4F-mediated growth arrest.";
RL   Oncogene 19:188-199(2000).
RN   [44]
RP   PHOSPHORYLATION AT THR-18.
RX   PubMed=10951572; DOI=10.1038/sj.onc.1203709;
RA   Lopez-Borges S., Lazo P.A.;
RT   "The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-
RT   18 within the mdm-2 binding site of the p53 tumour suppressor
RT   protein.";
RL   Oncogene 19:3656-3664(2000).
RN   [45]
RP   REVIEW ON ZINC-BINDING PROPERTIES.
RX   PubMed=11554448; DOI=10.1089/15230860152542961;
RA   Hainaut P., Mann K.;
RT   "Zinc binding and redox control of p53 structure and function.";
RL   Antioxid. Redox Signal. 3:611-623(2001).
RN   [46]
RP   PHOSPHORYLATION AT SER-15.
RX   PubMed=11554766; DOI=10.1006/bbrc.2001.5627;
RA   Imamura K., Ogura T., Kishimoto A., Kaminishi M., Esumi H.;
RT   "Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated
RT   protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D-
RT   ribofuranoside, in a human hepatocellular carcinoma cell line.";
RL   Biochem. Biophys. Res. Commun. 287:562-567(2001).
RN   [47]
RP   DEACETYLATION AT LYS-382 BY SIRT1.
RX   PubMed=11672523; DOI=10.1016/S0092-8674(01)00527-X;
RA   Vaziri H., Dessain S.K., Ng Eaton E., Imai S., Frye R.A.,
RA   Pandita T.K., Guarente L., Weinberg R.A.;
RT   "hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase.";
RL   Cell 107:149-159(2001).
RN   [48]
RP   MINIMAL REPRESSION DOMAIN.
RX   PubMed=11007800; DOI=10.1074/jbc.M008231200;
RA   Hong T.M., Chen J.J., Peck K., Yang P.C., Wu C.W.;
RT   "p53 amino acids 339-346 represent the minimal p53 repression
RT   domain.";
RL   J. Biol. Chem. 276:1510-1515(2001).
RN   [49]
RP   PHOSPHORYLATION AT SER-20 BY PLK3.
RX   PubMed=11447225; DOI=10.1074/jbc.M104157200;
RA   Xie S., Wang Q., Wu H., Cogswell J., Lu L., Jhanwar-Uniyal M., Dai W.;
RT   "Reactive oxygen species-induced phosphorylation of p53 on serine 20
RT   is mediated in part by polo-like kinase-3.";
RL   J. Biol. Chem. 276:36194-36199(2001).
RN   [50]
RP   PHOSPHORYLATION AT SER-20 BY PLK3.
RX   PubMed=11551930; DOI=10.1074/jbc.M106050200;
RA   Xie S., Wu H., Wang Q., Cogswell J.P., Husain I., Conn C.,
RA   Stambrook P., Jhanwar-Uniyal M., Dai W.;
RT   "Plk3 functionally links DNA damage to cell cycle arrest and apoptosis
RT   at least in part via the p53 pathway.";
RL   J. Biol. Chem. 276:43305-43312(2001).
RN   [51]
RP   SUMOYLATION AT LYS-386, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   PHE-385; LYS-386; THR-387 AND GLU-388.
RX   PubMed=11124955; DOI=10.1074/jbc.M009476200;
RA   Rodriguez M.S., Dargemont C., Hay R.T.;
RT   "SUMO-1 conjugation in vivo requires both a consensus modification
RT   motif and nuclear targeting.";
RL   J. Biol. Chem. 276:12654-12659(2001).
RN   [52]
RP   PHOSPHORYLATION BY PRPK.
RX   PubMed=11546806; DOI=10.1074/jbc.M105669200;
RA   Abe Y., Matsumoto S., Wei S., Nezu K., Miyoshi A., Kito K., Ueda N.,
RA   Shigemoto K., Hitsumoto Y., Nikawa J., Enomoto Y.;
RT   "Cloning and characterization of a p53-related protein kinase
RT   expressed in interleukin-2-activated cytotoxic T-cells, epithelial
RT   tumor cell lines, and the testes.";
RL   J. Biol. Chem. 276:44003-44011(2001).
RN   [53]
RP   PHOSPHORYLATION AT SER-392.
RX   PubMed=11239457; DOI=10.1016/S1097-2765(01)00176-9;
RA   Keller D.M., Zeng X., Wang Y., Zhang Q.H., Kapoor M., Shu H.,
RA   Goodman R., Lozano G., Zhao Y., Lu H.;
RT   "A DNA damage-induced p53 serine 392 kinase complex contains CK2,
RT   hSpt16, and SSRP1.";
RL   Mol. Cell 7:283-292(2001).
RN   [54]
RP   INTERACTION WITH USP7.
RX   PubMed=12507430; DOI=10.1016/S0092-8674(02)01199-6;
RA   Hu M., Li P., Li M., Li W., Yao T., Wu J.-W., Gu W., Cohen R.E.,
RA   Shi Y.;
RT   "Crystal structure of a UBP-family deubiquitinating enzyme in
RT   isolation and in complex with ubiquitin aldehyde.";
RL   Cell 111:1041-1054(2002).
RN   [55]
RP   IDENTIFICATION IN A COMPLEX WITH CABLES1 AND TP73.
RX   PubMed=11706030; DOI=10.1074/jbc.M108535200;
RA   Tsuji K., Mizumoto K., Yamochi T., Nishimoto I., Matsuoka M.;
RT   "Differential effect of ik3-1/cables on p53- and p73-induced cell
RT   death.";
RL   J. Biol. Chem. 277:2951-2957(2002).
RN   [56]
RP   INTERACTION WITH HIPK2.
RX   PubMed=11925430; DOI=10.1074/jbc.M200153200;
RA   Kim E.-J., Park J.-S., Um S.-J.;
RT   "Identification and characterization of HIPK2 interacting with p73 and
RT   modulating functions of the p53 family in vivo.";
RL   J. Biol. Chem. 277:32020-32028(2002).
RN   [57]
RP   INTERACTION WITH HIPK2, PHOSPHORYLATION AT SER-46, AND MUTAGENESIS OF
RP   SER-46 AND LYS-382.
RX   PubMed=11740489; DOI=10.1038/ncb715;
RA   Hofmann T.G., Moeller A., Sirma H., Zentgraf H., Taya Y., Droege W.,
RA   Will H., Schmitz M.L.;
RT   "Regulation of p53 activity by its interaction with homeodomain-
RT   interacting protein kinase-2.";
RL   Nat. Cell Biol. 4:1-10(2002).
RN   [58]
RP   INTERACTION WITH HIPK2, AND PHOSPHORYLATION AT SER-46.
RX   PubMed=11780126; DOI=10.1038/ncb714;
RA   D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y.,
RA   Saito S., Gostissa M., Coen S., Marchetti A., Del Sal G., Piaggio G.,
RA   Fanciulli M., Appella E., Soddu S.;
RT   "Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46
RT   and mediates apoptosis.";
RL   Nat. Cell Biol. 4:11-19(2002).
RN   [59]
RP   INTERACTION WITH ING4.
RX   PubMed=12750254;
RA   Shiseki M., Nagashima M., Pedeux R.M., Kitahama-Shiseki M., Miura K.,
RA   Okamura S., Onogi H., Higashimoto Y., Appella E., Yokota J.,
RA   Harris C.C.;
RT   "p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity.";
RL   Cancer Res. 63:2373-2378(2003).
RN   [60]
RP   ACETYLATION AT LYS-305.
RX   PubMed=12724314; DOI=10.1074/jbc.M212574200;
RA   Wang Y.H., Tsay Y.G., Tan B.C., Lo W.Y., Lee S.C.;
RT   "Identification and characterization of a novel p300-mediated p53
RT   acetylation site, lysine 305.";
RL   J. Biol. Chem. 278:25568-25576(2003).
RN   [61]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH CHEK2 AND PML,
RP   UBIQUITINATION BY MDM2, AND PHOSPHORYLATION AT SER-20.
RX   PubMed=12810724; DOI=10.1074/jbc.M301264200;
RA   Louria-Hayon I., Grossman T., Sionov R.V., Alsheich O., Pandolfi P.P.,
RA   Haupt Y.;
RT   "The promyelocytic leukemia protein protects p53 from Mdm2-mediated
RT   inhibition and degradation.";
RL   J. Biol. Chem. 278:33134-33141(2003).
RN   [62]
RP   INTERACTION WITH TP53INP1.
RX   PubMed=12851404; DOI=10.1074/jbc.M301979200;
RA   Tomasini R., Samir A.A., Carrier A., Isnardon D., Cecchinelli B.,
RA   Soddu S., Malissen B., Dagorn J.-C., Iovanna J.L., Dusetti N.J.;
RT   "TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are
RT   partners in regulating p53 activity.";
RL   J. Biol. Chem. 278:37722-37729(2003).
RN   [63]
RP   NUCLEOCYTOPLASMIC SHUTTLING, AND NUCLEAR EXPORT SIGNAL.
RX   PubMed=12944468; DOI=10.1128/MCB.23.18.6396-6405.2003;
RA   O'Keefe K., Li H., Zhang Y.;
RT   "Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated
RT   cytoplasmic degradation but not ubiquitination.";
RL   Mol. Cell. Biol. 23:6396-6405(2003).
RN   [64]
RP   INTERACTION WITH HIPK1.
RX   PubMed=12702766; DOI=10.1073/pnas.0530308100;
RA   Kondo S., Lu Y., Debbas M., Lin A.W., Sarosi I., Itie A., Wakeham A.,
RA   Tuan J., Saris C., Elliott G., Ma W., Benchimol S., Lowe S.W.,
RA   Mak T.W., Thukral S.K.;
RT   "Characterization of cells and gene-targeted mice deficient for the
RT   p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1).";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:5431-5436(2003).
RN   [65]
RP   INTERACTION WITH CDKN2AIP.
RX   PubMed=15109303; DOI=10.1042/BJ20040337;
RA   Hasan M.K., Yaguchi T., Minoda Y., Hirano T., Taira K., Wadhwa R.,
RA   Kaul S.C.;
RT   "Alternative reading frame protein (ARF)-independent function of CARF
RT   (collaborator of ARF) involves its interactions with p53: evidence for
RT   a novel p53-activation pathway and its negative feedback control.";
RL   Biochem. J. 380:605-610(2004).
RN   [66]
RP   INTERACTION WITH HRMT1L2; EP300 AND CARM1, AND FUNCTION.
RX   PubMed=15186775; DOI=10.1016/j.cell.2004.05.009;
RA   An W., Kim J., Roeder R.G.;
RT   "Ordered cooperative functions of PRMT1, p300, and CARM1 in
RT   transcriptional activation by p53.";
RL   Cell 117:735-748(2004).
RN   [67]
RP   INTERACTION WITH ANKRD2.
RX   PubMed=15136035; DOI=10.1016/j.jmb.2004.03.071;
RA   Kojic S., Medeot E., Guccione E., Krmac H., Zara I., Martinelli V.,
RA   Valle G., Faulkner G.;
RT   "The Ankrd2 protein, a link between the sarcomere and the nucleus in
RT   skeletal muscle.";
RL   J. Mol. Biol. 339:313-325(2004).
RN   [68]
RP   PHOSPHORYLATION AT THR-55, MUTAGENESIS OF THR-55, AND INTERACTION WITH
RP   TAF1.
RX   PubMed=15053879; DOI=10.1016/S1097-2765(04)00123-6;
RA   Li H.-H., Li A.G., Sheppard H.M., Liu X.;
RT   "Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role
RT   for TAF1 in cell G1 progression.";
RL   Mol. Cell 13:867-878(2004).
RN   [69]
RP   DEUBIQUITINATION BY USP7.
RX   PubMed=15053880; DOI=10.1016/S1097-2765(04)00157-1;
RA   Li M., Brooks C.L., Kon N., Gu W.;
RT   "A dynamic role of HAUSP in the p53-Mdm2 pathway.";
RL   Mol. Cell 13:879-886(2004).
RN   [70]
RP   ALTERNATIVE SPLICING (ISOFORM 4), FUNCTION, SUBCELLULAR LOCATION, AND
RP   UBIQUITINATION.
RX   PubMed=15340061; DOI=10.1128/MCB.24.18.7987-7997.2004;
RA   Ghosh A., Stewart D., Matlashewski G.;
RT   "Regulation of human p53 activity and cell localization by alternative
RT   splicing.";
RL   Mol. Cell. Biol. 24:7987-7997(2004).
RN   [71]
RP   METHYLATION AT LYS-372, AND MUTAGENESIS OF LYS-372.
RX   PubMed=15525938; DOI=10.1038/nature03117;
RA   Chuikov S., Kurash J.K., Wilson J.R., Xiao B., Justin N., Ivanov G.S.,
RA   McKinney K., Tempst P., Prives C., Gamblin S.J., Barlev N.A.,
RA   Reinberg D.;
RT   "Regulation of p53 activity through lysine methylation.";
RL   Nature 432:353-360(2004).
RN   [72]
RP   INTERACTION WITH AURKA, AND PHOSPHORYLATION AT SER-315.
RX   PubMed=14702041; DOI=10.1038/ng1279;
RA   Katayama H., Sasai K., Kawai H., Yuan Z.M., Bondaruk J., Suzuki F.,
RA   Fujii S., Arlinghaus R.B., Czerniak B.A., Sen S.;
RT   "Phosphorylation by aurora kinase A induces Mdm2-mediated
RT   destabilization and inhibition of p53.";
RL   Nat. Genet. 36:55-62(2004).
RN   [73]
RP   INTERACTION WITH NOC2L.
RX   PubMed=16322561; DOI=10.1101/gad.351205;
RA   Hublitz P., Kunowska N., Mayer U.P., Muller J.M., Heyne K., Yin N.,
RA   Fritzsche C., Poli C., Miguet L., Schupp I.W., van Grunsven L.A.,
RA   Potiers N., van Dorsselaer A., Metzger E., Roemer K., Schule R.;
RT   "NIR is a novel INHAT repressor that modulates the transcriptional
RT   activity of p53.";
RL   Genes Dev. 19:2912-2924(2005).
RN   [74]
RP   INTERACTION WITH BANP, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT
RP   SER-15.
RX   PubMed=15701641; DOI=10.1074/jbc.M413200200;
RA   Jalota-Badhwar A., Singh K., Pavithra L., Kaul-Ghanekar R., Jameel S.,
RA   Chattopadhyay S.;
RT   "Tumor suppressor SMAR1 activates and stabilizes p53 through its
RT   arginine-serine-rich motif.";
RL   J. Biol. Chem. 280:16019-16029(2005).
RN   [75]
RP   INTERACTION WITH PTK2/FAK1.
RX   PubMed=15855171; DOI=10.1074/jbc.M414172200;
RA   Golubovskaya V.M., Finch R., Cance W.G.;
RT   "Direct interaction of the N-terminal domain of focal adhesion kinase
RT   with the N-terminal transactivation domain of p53.";
RL   J. Biol. Chem. 280:25008-25021(2005).
RN   [76]
RP   INTERACTION WITH WWOX, AND MUTAGENESIS OF SER-46.
RX   PubMed=16219768; DOI=10.1074/jbc.M505590200;
RA   Chang N.-S., Doherty J., Ensign A., Schultz L., Hsu L.-J., Hong Q.;
RT   "WOX1 is essential for tumor necrosis factor-, UV light-,
RT   staurosporine-, and p53-mediated cell death, and its tyrosine 33-
RT   phosphorylated form binds and stabilizes serine 46-phosphorylated
RT   p53.";
RL   J. Biol. Chem. 280:43100-43108(2005).
RN   [77]
RP   PHOSPHORYLATION AT SER-15.
RX   PubMed=15866171; DOI=10.1016/j.molcel.2005.03.027;
RA   Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y.,
RA   Birnbaum M.J., Thompson C.B.;
RT   "AMP-activated protein kinase induces a p53-dependent metabolic
RT   checkpoint.";
RL   Mol. Cell 18:283-293(2005).
RN   [78]
RP   INTERACTION WITH STK11/LKB1, AND PHOSPHORYLATION AT SER-15 AND
RP   SER-392.
RX   PubMed=17108107; DOI=10.1158/0008-5472.CAN-06-0999;
RA   Zeng P.Y., Berger S.L.;
RT   "LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate
RT   transcriptional activation.";
RL   Cancer Res. 66:10701-10708(2006).
RN   [79]
RP   PHOSPHORYLATION AT THR-18.
RX   PubMed=16704422; DOI=10.1111/j.1742-4658.2006.05256.x;
RA   Blanco S., Klimcakova L., Vega F.M., Lazo P.A.;
RT   "The subcellular localization of vaccinia-related kinase-2 (VRK2)
RT   isoforms determines their different effect on p53 stability in tumour
RT   cell lines.";
RL   FEBS J. 273:2487-2504(2006).
RN   [80]
RP   INTERACTION WITH YWHAZ.
RX   PubMed=16376338; DOI=10.1016/j.febslet.2005.12.024;
RA   Gu Y.-M., Jin Y.-H., Choi J.-K., Baek K.-H., Yeo C.-Y., Lee K.-Y.;
RT   "Protein kinase A phosphorylates and regulates dimerization of 14-3-3
RT   epsilon.";
RL   FEBS Lett. 580:305-310(2006).
RN   [81]
RP   PHOSPHORYLATION AT SER-46, AND INTERACTION WITH PRKCG.
RX   PubMed=16377624; DOI=10.1074/jbc.M512074200;
RA   Yoshida K., Liu H., Miki Y.;
RT   "Protein kinase C delta regulates Ser46 phosphorylation of p53 tumor
RT   suppressor in the apoptotic response to DNA damage.";
RL   J. Biol. Chem. 281:5734-5740(2006).
RN   [82]
RP   METHYLATION AT LYS-370, AND MUTAGENESIS OF LYS-370.
RX   PubMed=17108971; DOI=10.1038/nature05287;
RA   Huang J., Perez-Burgos L., Placek B.J., Sengupta R., Richter M.,
RA   Dorsey J.A., Kubicek S., Opravil S., Jenuwein T., Berger S.L.;
RT   "Repression of p53 activity by Smyd2-mediated methylation.";
RL   Nature 444:629-632(2006).
RN   [83]
RP   INTERACTION WITH DAXX.
RX   PubMed=16845383; DOI=10.1038/ncb1442;
RA   Tang J., Qu L.K., Zhang J., Wang W., Michaelson J.S., Degenhardt Y.Y.,
RA   El-Deiry W.S., Yang X.;
RT   "Critical role for Daxx in regulating Mdm2.";
RL   Nat. Cell Biol. 8:855-862(2006).
RN   [84]
RP   MOTIF, AND METHYLATION AT LYS-372.
RX   PubMed=16415881; DOI=10.1038/nsmb1045;
RA   Couture J.-F., Collazo E., Hauk G., Trievel R.C.;
RT   "Structural basis for the methylation site specificity of SET7/9.";
RL   Nat. Struct. Mol. Biol. 13:140-146(2006).
RN   [85]
RP   INTERACTION WITH POU4F2.
RX   PubMed=17145718; DOI=10.1093/nar/gkl878;
RA   Budhram-Mahadeo V.S., Bowen S., Lee S., Perez-Sanchez C., Ensor E.,
RA   Morris P.J., Latchman D.S.;
RT   "Brn-3b enhances the pro-apoptotic effects of p53 but not its
RT   induction of cell cycle arrest by cooperating in trans-activation of
RT   bax expression.";
RL   Nucleic Acids Res. 34:6640-6652(2006).
RN   [86]
RP   PHOSPHORYLATION AT SER-37, AND MUTAGENESIS OF SER-37.
RX   PubMed=17254968; DOI=10.1016/j.cell.2006.11.050;
RA   Sun P., Yoshizuka N., New L., Moser B.A., Li Y., Liao R., Xie C.,
RA   Chen J., Deng Q., Yamout M., Dong M.Q., Frangou C.G., Yates J.R. III,
RA   Wright P.E., Han J.;
RT   "PRAK is essential for ras-induced senescence and tumor suppression.";
RL   Cell 128:295-308(2007).
RN   [87]
RP   INTERACTION WITH ZNF385A, AND CHARACTERIZATION OF VARIANTS ALA-143;
RP   HIS-175 AND PRO-175.
RX   PubMed=17719541; DOI=10.1016/j.cell.2007.06.013;
RA   Das S., Raj L., Zhao B., Kimura Y., Bernstein A., Aaronson S.A.,
RA   Lee S.W.;
RT   "Hzf Determines cell survival upon genotoxic stress by modulating p53
RT   transactivation.";
RL   Cell 130:624-637(2007).
RN   [88]
RP   UBIQUITINATION, INTERACTION WITH SYVN1, AND SUBCELLULAR LOCATION.
RX   PubMed=17170702; DOI=10.1038/sj.emboj.7601490;
RA   Yamasaki S., Yagishita N., Sasaki T., Nakazawa M., Kato Y.,
RA   Yamadera T., Bae E., Toriyama S., Ikeda R., Zhang L., Fujitani K.,
RA   Yoo E., Tsuchimochi K., Ohta T., Araya N., Fujita H., Aratani S.,
RA   Eguchi K., Komiya S., Maruyama I., Higashi N., Sato M., Senoo H.,
RA   Ochi T., Yokoyama S., Amano T., Kim J., Gay S., Fukamizu A.,
RA   Nishioka K., Tanaka K., Nakajima T.;
RT   "Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident
RT   ubiquitin ligase 'Synoviolin'.";
RL   EMBO J. 26:113-122(2007).
RN   [89]
RP   INTERACTION WITH PPP2CA; PPP2R1A; PPP2R2A AND PPP2R5C.
RX   PubMed=17245430; DOI=10.1038/sj.emboj.7601519;
RA   Li H.H., Cai X., Shouse G.P., Piluso L.G., Liu X.;
RT   "A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-
RT   induced dephosphorylation of p53 at Thr55.";
RL   EMBO J. 26:402-411(2007).
RN   [90]
RP   INTERACTION WITH ARMC10.
RX   PubMed=17904127; DOI=10.1016/j.febslet.2007.09.025;
RA   Zhou X., Yang G., Huang R., Chen X., Hu G.;
RT   "SVH-B interacts directly with p53 and suppresses the transcriptional
RT   activity of p53.";
RL   FEBS Lett. 581:4943-4948(2007).
RN   [91]
RP   PHOSPHORYLATION AT SER-9.
RX   PubMed=18022393; DOI=10.1016/j.febslet.2007.11.022;
RA   Arai S., Matsushita A., Du K., Yagi K., Okazaki Y., Kurokawa R.;
RT   "Novel homeodomain-interacting protein kinase family member, HIPK4,
RT   phosphorylates human p53 at serine 9.";
RL   FEBS Lett. 581:5649-5657(2007).
RN   [92]
RP   DOMAIN.
RX   PubMed=17467953; DOI=10.1016/j.ygeno.2007.02.003;
RA   Piskacek S., Gregor M., Nemethova M., Grabner M., Kovarik P.,
RA   Piskacek M.;
RT   "Nine-amino-acid transactivation domain: establishment and prediction
RT   utilities.";
RL   Genomics 89:756-768(2007).
RN   [93]
RP   INTERACTION WITH RFFL AND RNF34.
RX   PubMed=17121812; DOI=10.1074/jbc.M610793200;
RA   Yang W., Rozan L.M., McDonald E.R. III, Navaraj A., Liu J.J.,
RA   Matthew E.M., Wang W., Dicker D.T., El-Deiry W.S.;
RT   "CARPs are ubiquitin ligases that promote MDM2-independent p53 and
RT   phospho-p53ser20 degradation.";
RL   J. Biol. Chem. 282:3273-3281(2007).
RN   [94]
RP   FUNCTION, AND INTERACTION WITH MAML1.
RX   PubMed=17317671; DOI=10.1074/jbc.M608974200;
RA   Zhao Y., Katzman R.B., Delmolino L.M., Bhat I., Zhang Y.,
RA   Gurumurthy C.B., Germaniuk-Kurowska A., Reddi H.V., Solomon A.,
RA   Zeng M.S., Kung A., Ma H., Gao Q., Dimri G., Stanculescu A., Miele L.,
RA   Wu L., Griffin J.D., Wazer D.E., Band H., Band V.;
RT   "The notch regulator MAML1 interacts with p53 and functions as a
RT   coactivator.";
RL   J. Biol. Chem. 282:11969-11981(2007).
RN   [95]
RP   PHOSPHORYLATION AT SER-15; SER-33 AND SER-46, INTERACTION WITH CDK5,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=17591690; DOI=10.1242/jcs.03468;
RA   Lee J.-H., Kim H.-S., Lee S.-J., Kim K.-T.;
RT   "Stabilization and activation of p53 induced by Cdk5 contributes to
RT   neuronal cell death.";
RL   J. Cell Sci. 120:2259-2271(2007).
RN   [96]
RP   INTERACTION WITH MORC3.
RX   PubMed=17332504; DOI=10.1091/mbc.E06-08-0747;
RA   Takahashi K., Yoshida N., Murakami N., Kawata K., Ishizaki H.,
RA   Tanaka-Okamoto M., Miyoshi J., Zinn A.R., Shime H., Inoue N.;
RT   "Dynamic regulation of p53 subnuclear localization and senescence by
RT   MORC3.";
RL   Mol. Biol. Cell 18:1701-1709(2007).
RN   [97]
RP   FUNCTION, PHOSPHORYLATION AT SER-46, AND MUTAGENESIS OF SER-46.
RX   PubMed=17349958; DOI=10.1016/j.molcel.2007.02.007;
RA   Taira N., Nihira K., Yamaguchi T., Miki Y., Yoshida K.;
RT   "DYRK2 is targeted to the nucleus and controls p53 via Ser46
RT   phosphorylation in the apoptotic response to DNA damage.";
RL   Mol. Cell 25:725-738(2007).
RN   [98]
RP   DEMETHYLATION BY KDM1A.
RX   PubMed=17805299; DOI=10.1038/nature06092;
RA   Huang J., Sengupta R., Espejo A.B., Lee M.G., Dorsey J.A., Richter M.,
RA   Opravil S., Shiekhattar R., Bedford M.T., Jenuwein T., Berger S.L.;
RT   "p53 is regulated by the lysine demethylase LSD1.";
RL   Nature 449:105-108(2007).
RN   [99]
RP   METHYLATION AT LYS-382, AND MUTAGENESIS OF LYS-382.
RX   PubMed=17707234; DOI=10.1016/j.molcel.2007.07.012;
RA   Shi X., Kachirskaia I., Yamaguchi H., West L.E., Wen H., Wang E.W.,
RA   Dutta S., Appella E., Gozani O.;
RT   "Modulation of p53 function by SET8-mediated methylation at lysine
RT   382.";
RL   Mol. Cell 27:636-646(2007).
RN   [100]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [101]
RP   ACETYLATION, AND DEACETYLATION BY SIRT2.
RX   PubMed=18249187; DOI=10.1016/j.bbrc.2008.01.114;
RA   Jin Y.H., Kim Y.J., Kim D.W., Baek K.H., Kang B.Y., Yeo C.Y.,
RA   Lee K.Y.;
RT   "Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the
RT   activity of p53.";
RL   Biochem. Biophys. Res. Commun. 368:690-695(2008).
RN   [102]
RP   INTERACTION WITH SETD2.
RX   PubMed=18585004; DOI=10.1016/j.cellsig.2008.05.012;
RA   Xie P., Tian C., An L., Nie J., Lu K., Xing G., Zhang L., He F.;
RT   "Histone methyltransferase protein SETD2 interacts with p53 and
RT   selectively regulates its downstream genes.";
RL   Cell. Signal. 20:1671-1678(2008).
RN   [103]
RP   UBIQUITINATION, AND SUBCELLULAR LOCATION.
RX   PubMed=18206965; DOI=10.1016/j.molcel.2007.11.031;
RA   Lim S.T., Chen X.L., Lim Y., Hanson D.A., Vo T.T., Howerton K.,
RA   Larocque N., Fisher S.J., Schlaepfer D.D., Ilic D.;
RT   "Nuclear FAK promotes cell proliferation and survival through FERM-
RT   enhanced p53 degradation.";
RL   Mol. Cell 29:9-22(2008).
RN   [104]
RP   INTERACTION WITH PPP2CA; PPP2R1A AND PPP2R5C, PHOSPHORYLATION AT
RP   SER-15 BY ATM, AND MUTAGENESIS OF SER-15.
RX   PubMed=17967874; DOI=10.1128/MCB.00983-07;
RA   Shouse G.P., Cai X., Liu X.;
RT   "Serine 15 phosphorylation of p53 directs its interaction with
RT   B56gamma and the tumor suppressor activity of B56gamma-specific
RT   protein phosphatase 2A.";
RL   Mol. Cell. Biol. 28:448-456(2008).
RN   [105]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [106]
RP   INTERACTION WITH MKRN1, MUTAGENESIS OF 291-LYS-LYS-292, AND
RP   UBIQUITINATION AT LYS-291 AND LYS-292 BY MKRN1.
RX   PubMed=19536131; DOI=10.1038/emboj.2009.164;
RA   Lee E.-W., Lee M.-S., Camus S., Ghim J., Yang M.-R., Oh W., Ha N.-C.,
RA   Lane D.P., Song J.;
RT   "Differential regulation of p53 and p21 by MKRN1 E3 ligase controls
RT   cell cycle arrest and apoptosis.";
RL   EMBO J. 28:2100-2113(2009).
RN   [107]
RP   UBIQUITINATION BY TOPORS.
RX   PubMed=19473992; DOI=10.1074/jbc.C109.001560;
RA   Yang X., Li H., Zhou Z., Wang W.H., Deng A., Andrisani O., Liu X.;
RT   "Plk1-mediated phosphorylation of Topors regulates p53 stability.";
RL   J. Biol. Chem. 284:18588-18592(2009).
RN   [108]
RP   INTERACTION WITH MTA1 AND RFWD2, AND UBIQUITINATION.
RX   PubMed=19837670; DOI=10.1074/jbc.M109.056499;
RA   Li D.Q., Divijendra Natha Reddy S., Pakala S.B., Wu X., Zhang Y.,
RA   Rayala S.K., Kumar R.;
RT   "MTA1 coregulator regulates p53 stability and function.";
RL   J. Biol. Chem. 284:34545-34552(2009).
RN   [109]
RP   INTERACTION WITH HHV-5 PROTEIN UL123.
RX   PubMed=19776115; DOI=10.1128/JVI.00304-09;
RA   Hwang E.S., Zhang Z., Cai H., Huang D.Y., Huong S.M., Cha C.Y.,
RA   Huang E.S.;
RT   "Human cytomegalovirus IE1-72 protein interacts with p53 and inhibits
RT   p53-dependent transactivation by a mechanism different from that of
RT   IE2-86 protein.";
RL   J. Virol. 83:12388-12398(2009).
RN   [110]
RP   INTERACTION WITH FBXO42.
RX   PubMed=19509332; DOI=10.1073/pnas.0901864106;
RA   Sun L., Shi L., Li W., Yu W., Liang J., Zhang H., Yang X., Wang Y.,
RA   Li R., Yao X., Yi X., Shang Y.;
RT   "JFK, a Kelch domain-containing F-box protein, links the SCF complex
RT   to p53 regulation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:10195-10200(2009).
RN   [111]
RP   FUNCTION, UBIQUITINATION, AND INTERACTION WITH TRIM24.
RX   PubMed=19556538; DOI=10.1073/pnas.0813177106;
RA   Allton K., Jain A.K., Herz H.M., Tsai W.W., Jung S.Y., Qin J.,
RA   Bergmann A., Johnson R.L., Barton M.C.;
RT   "Trim24 targets endogenous p53 for degradation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:11612-11616(2009).
RN   [112]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-381 AND LYS-382, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [113]
RP   UBIQUITINATION, AND DEUBIQUITINATION BY USP10.
RX   PubMed=20096447; DOI=10.1016/j.cell.2009.12.032;
RA   Yuan J., Luo K., Zhang L., Cheville J.C., Lou Z.;
RT   "USP10 regulates p53 localization and stability by deubiquitinating
RT   p53.";
RL   Cell 140:384-396(2010).
RN   [114]
RP   FUNCTION.
RX   PubMed=20673990; DOI=10.1016/j.cell.2010.06.040;
RA   Huarte M., Guttman M., Feldser D., Garber M., Koziol M.J.,
RA   Kenzelmann-Broz D., Khalil A.M., Zuk O., Amit I., Rabani M.,
RA   Attardi L.D., Regev A., Lander E.S., Jacks T., Rinn J.L.;
RT   "A large intergenic noncoding RNA induced by p53 mediates global gene
RT   repression in the p53 response.";
RL   Cell 142:409-419(2010).
RN   [115]
RP   PHOSPHORYLATION AT SER-20 BY CSNK1D/CK1.
RX   PubMed=20041275; DOI=10.1007/s00018-009-0236-7;
RA   Venerando A., Marin O., Cozza G., Bustos V.H., Sarno S., Pinna L.A.;
RT   "Isoform specific phosphorylation of p53 by protein kinase CK1.";
RL   Cell. Mol. Life Sci. 67:1105-1118(2010).
RN   [116]
RP   INTERACTION WITH SNAI1, CHARACTERIZATION OF VARIANTS LEU-110; PRO-155;
RP   HIS-175; SER-232; SER-249; HIS-273 AND TRP-282, AND MUTAGENESIS OF
RP   ARG-248.
RX   PubMed=20385133; DOI=10.1016/j.febslet.2010.04.006;
RA   Lim S.O., Kim H., Jung G.;
RT   "p53 inhibits tumor cell invasion via the degradation of snail protein
RT   in hepatocellular carcinoma.";
RL   FEBS Lett. 584:2231-2236(2010).
RN   [117]
RP   INTERACTION WITH PTK2B/PYK2 AND MDM2, UBIQUITINATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=19880522; DOI=10.1074/jbc.M109.064212;
RA   Lim S.T., Miller N.L., Nam J.O., Chen X.L., Lim Y., Schlaepfer D.D.;
RT   "Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism
RT   facilitating cell proliferation and survival.";
RL   J. Biol. Chem. 285:1743-1753(2010).
RN   [118]
RP   METHYLATION AT LYS-373, AND MUTAGENESIS OF LYS-373.
RX   PubMed=20118233; DOI=10.1074/jbc.M109.062588;
RA   Huang J., Dorsey J., Chuikov S., Perez-Burgos L., Zhang X.,
RA   Jenuwein T., Reinberg D., Berger S.L.;
RT   "G9a and Glp methylate lysine 373 in the tumor suppressor p53.";
RL   J. Biol. Chem. 285:9636-9641(2010).
RN   [119]
RP   ERRATUM.
RA   Huang J., Dorsey J., Chuikov S., Perez-Burgos L., Zhang X.,
RA   Jenuwein T., Reinberg D., Berger S.L.;
RL   J. Biol. Chem. 285:18122-18122(2010).
RN   [120]
RP   PHOSPHORYLATION AT THR-55, AND INTERACTION WITH GRK5.
RX   PubMed=20124405; DOI=10.1074/jbc.M109.094243;
RA   Chen X., Zhu H., Yuan M., Fu J., Zhou Y., Ma L.;
RT   "G-protein-coupled receptor kinase 5 phosphorylates p53 and inhibits
RT   DNA damage-induced apoptosis.";
RL   J. Biol. Chem. 285:12823-12830(2010).
RN   [121]
RP   INTERACTION WITH BRD7, AND ACETYLATION AT LYS-382.
RX   PubMed=20228809; DOI=10.1038/ncb2038;
RA   Drost J., Mantovani F., Tocco F., Elkon R., Comel A., Holstege H.,
RA   Kerkhoven R., Jonkers J., Voorhoeve P.M., Agami R., Del Sal G.;
RT   "BRD7 is a candidate tumour suppressor gene required for p53
RT   function.";
RL   Nat. Cell Biol. 12:380-389(2010).
RN   [122]
RP   UBIQUITINATION BY RFWD3.
RX   PubMed=20173098; DOI=10.1073/pnas.0912094107;
RA   Fu X., Yucer N., Liu S., Li M., Yi P., Mu J.J., Yang T., Chu J.,
RA   Jung S.Y., O'Malley B.W., Gu W., Qin J., Wang Y.;
RT   "RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53
RT   stability in response to DNA damage.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:4579-4584(2010).
RN   [123]
RP   INTERACTION WITH BRD7.
RX   PubMed=20660729; DOI=10.1073/pnas.1009559107;
RA   Burrows A.E., Smogorzewska A., Elledge S.J.;
RT   "Polybromo-associated BRG1-associated factor components BRD7 and
RT   BAF180 are critical regulators of p53 required for induction of
RT   replicative senescence.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:14280-14285(2010).
RN   [124]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [125]
RP   INTERACTION WITH UHRF2.
RX   PubMed=21952639; DOI=10.4161/cc.10.19.17176;
RA   Mori T., Ikeda D.D., Fukushima T., Takenoshita S., Kochi H.;
RT   "NIRF constitutes a nodal point in the cell cycle network and is a
RT   candidate tumor suppressor.";
RL   Cell Cycle 10:3284-3299(2011).
RN   [126]
RP   FUNCTION, INTERACTION WITH AURKB AND NOC2L, PHOSPHORYLATION AT
RP   SER-183; SER-269 AND THR-284, CHARACTERIZATION OF VARIANT ALA-284,
RP   MUTAGENESIS OF SER-183 AND SER-269, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=20959462; DOI=10.1074/jbc.M110.174755;
RA   Wu L., Ma C.A., Zhao Y., Jain A.;
RT   "Aurora B interacts with NIR-p53, leading to p53 phosphorylation in
RT   its DNA-binding domain and subsequent functional suppression.";
RL   J. Biol. Chem. 286:2236-2244(2011).
RN   [127]
RP   INVOLVEMENT IN BCC7.
RX   PubMed=21946351; DOI=10.1038/ng.926;
RA   Stacey S.N., Sulem P., Jonasdottir A., Masson G., Gudmundsson J.,
RA   Gudbjartsson D.F., Magnusson O.T., Gudjonsson S.A., Sigurgeirsson B.,
RA   Thorisdottir K., Ragnarsson R., Benediktsdottir K.R., Nexo B.A.,
RA   Tjonneland A., Overvad K., Rudnai P., Gurzau E., Koppova K.,
RA   Hemminki K., Corredera C., Fuentelsaz V., Grasa P., Navarrete S.,
RA   Fuertes F., Garcia-Prats M.D., Sanambrosio E., Panadero A.,
RA   De Juan A., Garcia A., Rivera F., Planelles D., Soriano V.,
RA   Requena C., Aben K.K., van Rossum M.M., Cremers R.G., van Oort I.M.,
RA   van Spronsen D.J., Schalken J.A., Peters W.H., Helfand B.T.,
RA   Donovan J.L., Hamdy F.C., Badescu D., Codreanu O., Jinga M.,
RA   Csiki I.E., Constantinescu V., Badea P., Mates I.N., Dinu D.E.,
RA   Constantin A., Mates D., Kristjansdottir S., Agnarsson B.A.,
RA   Jonsson E., Barkardottir R.B., Einarsson G.V., Sigurdsson F.,
RA   Moller P.H., Stefansson T., Valdimarsson T., Johannsson O.T.,
RA   Sigurdsson H., Jonsson T., Jonasson J.G., Tryggvadottir L., Rice T.,
RA   Hansen H.M., Xiao Y., Lachance D.H., O'Neill B.P., Kosel M.L.,
RA   Decker P.A., Thorleifsson G., Johannsdottir H., Helgadottir H.T.,
RA   Sigurdsson A., Steinthorsdottir V., Lindblom A., Sandler R.S.,
RA   Keku T.O., Banasik K., Jorgensen T., Witte D.R., Hansen T.,
RA   Pedersen O., Jinga V., Neal D.E., Catalona W.J., Wrensch M.,
RA   Wiencke J., Jenkins R.B., Nagore E., Vogel U., Kiemeney L.A.,
RA   Kumar R., Mayordomo J.I., Olafsson J.H., Kong A., Thorsteinsdottir U.,
RA   Rafnar T., Stefansson K.;
RT   "A germline variant in the TP53 polyadenylation signal confers cancer
RT   susceptibility.";
RL   Nat. Genet. 43:1098-1103(2011).
RN   [128]
RP   INTERACTION WITH NUAK1, AND PHOSPHORYLATION AT SER-15 AND SER-392.
RX   PubMed=21317932; DOI=10.1038/onc.2011.19;
RA   Hou X., Liu J.E., Liu W., Liu C.Y., Liu Z.Y., Sun Z.Y.;
RT   "A new role of NUAK1: directly phosphorylating p53 and regulating cell
RT   proliferation.";
RL   Oncogene 30:2933-2942(2011).
RN   [129]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PPIF.
RX   PubMed=22726440; DOI=10.1016/j.cell.2012.05.014;
RA   Vaseva A.V., Marchenko N.D., Ji K., Tsirka S.E., Holzmann S.,
RA   Moll U.M.;
RT   "p53 opens the mitochondrial permeability transition pore to trigger
RT   necrosis.";
RL   Cell 149:1536-1548(2012).
RN   [130]
RP   INTERACTION WITH UBC9, PHOSPHORYLATION AT SER-392, AND SUMOYLATION AT
RP   LYS-386.
RX   PubMed=22214662; DOI=10.4161/cc.11.2.18999;
RA   Bennett R.L., Pan Y., Christian J., Hui T., May W.S. Jr.;
RT   "The RAX/PACT-PKR stress response pathway promotes p53 sumoylation and
RT   activation, leading to G(1) arrest.";
RL   Cell Cycle 11:407-417(2012).
RN   [131]
RP   INTERACTION WITH NOP53.
RX   PubMed=22522597; DOI=10.1038/cdd.2012.40;
RA   Lee S., Kim J.Y., Kim Y.J., Seok K.O., Kim J.H., Chang Y.J.,
RA   Kang H.Y., Park J.H.;
RT   "Nucleolar protein GLTSCR2 stabilizes p53 in response to ribosomal
RT   stresses.";
RL   Cell Death Differ. 19:1613-1622(2012).
RN   [132]
RP   INTERACTION WITH ZNF385B.
RX   PubMed=22945289; DOI=10.1002/eji.201242530;
RA   Iijima K., Yamada H., Miharu M., Imadome K., Miyagawa Y., Akimoto S.,
RA   Kobayashi K., Okita H., Nakazawa A., Fujiwara S., Fujimoto J.,
RA   Kiyokawa N.;
RT   "ZNF385B is characteristically expressed in germinal center B cells
RT   and involved in B-cell apoptosis.";
RL   Eur. J. Immunol. 42:3405-3415(2012).
RN   [133]
RP   METHYLATION AT LYS-370 AND LYS-382.
RX   PubMed=22864287; DOI=10.1038/nsmb.2353;
RA   Cui G., Park S., Badeaux A.I., Kim D., Lee J., Thompson J.R., Yan F.,
RA   Kaneko S., Yuan Z., Botuyan M.V., Bedford M.T., Cheng J.Q., Mer G.;
RT   "PHF20 is an effector protein of p53 double lysine methylation that
RT   stabilizes and activates p53.";
RL   Nat. Struct. Mol. Biol. 19:916-924(2012).
RN   [134]
RP   FUNCTION.
RX   PubMed=24051492; DOI=10.1038/ncomms3444;
RA   Miki T., Matsumoto T., Zhao Z., Lee C.C.;
RT   "p53 regulates Period2 expression and the circadian clock.";
RL   Nat. Commun. 4:2444-2444(2013).
RN   [135]
RP   INTERACTION WITH KAT6A, AND ACETYLATION AT LYS-120 AND LYS-382.
RX   PubMed=23431171; DOI=10.1073/pnas.1300490110;
RA   Rokudai S., Laptenko O., Arnal S.M., Taya Y., Kitabayashi I.,
RA   Prives C.;
RT   "MOZ increases p53 acetylation and premature senescence through its
RT   complex formation with PML.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:3895-3900(2013).
RN   [136]
RP   INTERACTION WITH UBD.
RX   PubMed=25422469; DOI=10.1073/pnas.1403383111;
RA   Theng S.S., Wang W., Mah W.C., Chan C., Zhuo J., Gao Y., Qin H.,
RA   Lim L., Chong S.S., Song J., Lee C.G.;
RT   "Disruption of FAT10-MAD2 binding inhibits tumor progression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:E5282-E5291(2014).
RN   [137]
RP   UBIQUITINATION.
RX   PubMed=25591766; DOI=10.1159/000369691;
RA   Yang L., Zhou B., Li X., Lu Z., Li W., Huo X., Miao Z.;
RT   "RNF125 is a ubiquitin-protein ligase that promotes p53 degradation.";
RL   Cell. Physiol. Biochem. 35:237-245(2015).
RN   [138]
RP   INTERACTION WITH HADV5 E1B-55K.
RX   PubMed=25772236; DOI=10.1038/onc.2015.63;
RA   Wimmer P., Berscheminski J., Blanchette P., Groitl P., Branton P.E.,
RA   Hay R.T., Dobner T., Schreiner S.;
RT   "PML isoforms IV and V contribute to adenovirus-mediated oncogenic
RT   transformation by functionally inhibiting the tumor-suppressor p53.";
RL   Oncogene 35:69-82(2016).
RN   [139]
RP   INTERACTION WITH AFG1L, AND SUBCELLULAR LOCATION.
RX   PubMed=27323408; DOI=10.18632/oncotarget.9959;
RA   Cesnekova J., Spacilova J., Hansikova H., Houstek J., Zeman J.,
RA   Stiburek L.;
RT   "LACE1 interacts with p53 and mediates its mitochondrial translocation
RT   and apoptosis.";
RL   Oncotarget 7:47687-47698(2016).
RN   [140]
RP   STRUCTURE BY NMR OF 319-360.
RX   PubMed=8023159; DOI=10.1126/science.8023159;
RA   Clore G.M., Omichinski J.G., Sakaguchi K., Zambrano N., Sakamoto H.,
RA   Appella E., Gronenborn A.M.;
RT   "High-resolution structure of the oligomerization domain of p53 by
RT   multidimensional NMR.";
RL   Science 265:386-391(1994).
RN   [141]
RP   STRUCTURE BY NMR OF 325-355.
RX   PubMed=7773777; DOI=10.1038/nsb1294-877;
RA   Lee W., Harvey T.S., Yin Y., Yau P., Litchfield D., Arrowsmith C.H.;
RT   "Solution structure of the tetrameric minimum transforming domain of
RT   p53.";
RL   Nat. Struct. Biol. 1:877-890(1994).
RN   [142]
RP   STRUCTURE BY NMR OF 326-354.
RX   PubMed=9321402; DOI=10.1093/emboj/16.20.6230;
RA   McCoy M., Stavridi E.S., Waterman J.L., Wieczorek A.M., Opella S.J.,
RA   Halazonetis T.D.;
RT   "Hydrophobic side-chain size is a determinant of the three-dimensional
RT   structure of the p53 oligomerization domain.";
RL   EMBO J. 16:6230-6236(1997).
RN   [143]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 94-289.
RX   PubMed=8023157; DOI=10.1126/science.8023157;
RA   Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P.;
RT   "Crystal structure of a p53 tumor suppressor-DNA complex:
RT   understanding tumorigenic mutations.";
RL   Science 265:346-355(1994).
RN   [144]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 325-356.
RX   PubMed=7878469; DOI=10.1126/science.7878469;
RA   Jeffrey P.D., Gorina S., Pavletich N.P.;
RT   "Crystal structure of the tetramerization domain of the p53 tumor
RT   suppressor at 1.7 angstroms.";
RL   Science 267:1498-1502(1995).
RN   [145]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 13-29 IN COMPLEX WITH MDM2.
RX   PubMed=8875929; DOI=10.1126/science.274.5289.948;
RA   Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J.,
RA   Levine A.J., Pavletich N.P.;
RT   "Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor
RT   transactivation domain.";
RL   Science 274:948-953(1996).
RN   [146]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 97-287 IN COMPLEX WITH 53BP2.
RX   PubMed=8875926; DOI=10.1126/science.274.5289.1001;
RA   Gorina S., Pavletich N.P.;
RT   "Structure of the p53 tumor suppressor bound to the ankyrin and SH3
RT   domains of 53BP2.";
RL   Science 274:1001-1005(1996).
RN   [147]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 94-312 IN COMPLEX WITH ZINC
RP   IONS, AND SUBUNIT.
RX   PubMed=14534297; DOI=10.1074/jbc.M309732200;
RA   Joerger A.C., Allen M.D., Fersht A.R.;
RT   "Crystal structure of a superstable mutant of human p53 core domain.
RT   Insights into the mechanism of rescuing oncogenic mutations.";
RL   J. Biol. Chem. 279:1291-1296(2004).
RN   [148]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 94-293 IN COMPLEX WITH DNA
RP   AND ZINC IONS, AND SUBUNIT.
RX   PubMed=16793544; DOI=10.1016/j.molcel.2006.05.015;
RA   Kitayner M., Rozenberg H., Kessler N., Rabinovich D., Shaulov L.,
RA   Haran T.E., Shakked Z.;
RT   "Structural basis of DNA recognition by p53 tetramers.";
RL   Mol. Cell 22:741-753(2006).
RN   [149]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 358-367 IN COMPLEX WITH USP7,
RP   AND INTERACTION WITH USP7.
RX   PubMed=16474402; DOI=10.1038/nsmb1067;
RA   Sheng Y., Saridakis V., Sarkari F., Duan S., Wu T., Arrowsmith C.H.,
RA   Frappier L.;
RT   "Molecular recognition of p53 and MDM2 by USP7/HAUSP.";
RL   Nat. Struct. Mol. Biol. 13:285-291(2006).
RN   [150]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 360-368 IN COMPLEX WITH
RP   USP7, MUTAGENESIS OF PRO-359; GLY-361 AND SER-362, AND INTERACTION
RP   WITH USP7.
RX   PubMed=16402859; DOI=10.1371/journal.pbio.0040027;
RA   Hu M., Gu L., Li M., Jeffrey P.D., Gu W., Shi Y.;
RT   "Structural basis of competitive recognition of p53 and MDM2 by
RT   HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway.";
RL   PLoS Biol. 4:228-239(2006).
RN   [151]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 377-386, METHYLATION AT
RP   LYS-382, MUTAGENESIS OF LYS-382, AND INTERACTION WITH L3MBTL1.
RX   PubMed=20870725; DOI=10.1074/jbc.M110.139527;
RA   West L.E., Roy S., Lachmi-Weiner K., Hayashi R., Shi X., Appella E.,
RA   Kutateladze T.G., Gozani O.;
RT   "The MBT repeats of L3MBTL1 link SET8-mediated p53 methylation at
RT   lysine 382 to target gene repression.";
RL   J. Biol. Chem. 285:37725-37732(2010).
RN   [152]
RP   REVIEW.
RX   PubMed=8266092; DOI=10.1126/science.8266092;
RA   Harris C.C.;
RT   "p53: at the crossroads of molecular carcinogenesis and risk
RT   assessment.";
RL   Science 262:1980-1981(1993).
RN   [153]
RP   REVIEW ON VARIANTS.
RX   PubMed=1905840; DOI=10.1126/science.1905840;
RA   Hoolstein M., Sidransky D., Vogelstein B., Harris C.C.;
RT   "p53 mutations in human cancers.";
RL   Science 253:49-53(1991).
RN   [154]
RP   REVIEW ON VARIANTS.
RX   PubMed=8829653;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:3<202::AID-HUMU4>3.3.CO;2-5;
RA   de Vries E.M.G., Ricke D.O., de Vries T.N., Hartmann A., Blaszyk H.,
RA   Liao D., Soussi T., Kovach J.S., Sommer S.S.;
RT   "Database of mutations in the p53 and APC tumor suppressor genes
RT   designed to facilitate molecular epidemiological analyses.";
RL   Hum. Mutat. 7:202-213(1996).
RN   [155]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 94-312 IN COMPLEX WITH ZINC
RP   IONS.
RX   PubMed=17015838; DOI=10.1073/pnas.0607286103;
RA   Joerger A.C., Ang H.C., Fersht A.R.;
RT   "Structural basis for understanding oncogenic p53 mutations and
RT   designing rescue drugs.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:15056-15061(2006).
RN   [156]
RP   X-RAY CRYSTALLOGRAPHY (1.54 ANGSTROMS) OF 94-292 OF VARIANT GLN-282.
RX   PubMed=18453682; DOI=10.1107/S0907444908003338;
RA   Tu C., Tan Y.H., Shaw G., Zhou Z., Bai Y., Luo R., Ji X.;
RT   "Impact of low-frequency hotspot mutation R282Q on the structure of
RT   p53 DNA-binding domain as revealed by crystallography at 1.54
RT   angstroms resolution.";
RL   Acta Crystallogr. D 64:471-477(2008).
RN   [157]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 94-312 OF VARIANT CYS-202 IN
RP   COMPLEX WITH ZINC IONS AND PHIKAN083.
RX   PubMed=18650397; DOI=10.1073/pnas.0805326105;
RA   Boeckler F.M., Joerger A.C., Jaggi G., Rutherford T.J.,
RA   Veprintsev D.B., Fersht A.R.;
RT   "Targeted rescue of a destabilized mutant of p53 by an in silico
RT   screened drug.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10360-10365(2008).
RN   [158]
RP   X-RAY CRYSTALLOGRAPHY (1.2 ANGSTROMS) OF 94-293 OF VARIANT SER-249 IN
RP   COMPLEX WITH DNA.
RX   PubMed=18996393; DOI=10.1016/j.jmb.2008.10.063;
RA   Suad O., Rozenberg H., Brosh R., Diskin-Posner Y., Kessler N.,
RA   Shimon L.J., Frolow F., Liran A., Rotter V., Shakked Z.;
RT   "Structural basis of restoring sequence-specific DNA binding and
RT   transactivation to mutant p53 by suppressor mutations.";
RL   J. Mol. Biol. 385:249-265(2009).
RN   [159]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 94-310 IN COMPLEX WITH ZINC
RP   IONS.
RX   PubMed=19515728; DOI=10.1093/protein/gzp018;
RA   Khoo K.H., Joerger A.C., Freund S.M., Fersht A.R.;
RT   "Stabilising the DNA-binding domain of p53 by rational design of its
RT   hydrophobic core.";
RL   Protein Eng. Des. Sel. 22:421-430(2009).
RN   [160]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 94-312 OF VARIANT CYS-220 IN
RP   COMPLEX WITH ZINC IONS.
RX   PubMed=20142040; DOI=10.1016/j.chembiol.2009.12.011;
RA   Basse N., Kaar J.L., Settanni G., Joerger A.C., Rutherford T.J.,
RA   Fersht A.R.;
RT   "Toward the rational design of p53-stabilizing drugs: probing the
RT   surface of the oncogenic Y220C mutant.";
RL   Chem. Biol. 17:46-56(2010).
RN   [161]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 94-293 IN COMPLEX WITH DNA
RP   AND ZINC IONS, AND SUBUNIT.
RX   PubMed=20364130; DOI=10.1038/nsmb.1800;
RA   Kitayner M., Rozenberg H., Rohs R., Suad O., Rabinovich D., Honig B.,
RA   Shakked Z.;
RT   "Diversity in DNA recognition by p53 revealed by crystal structures
RT   with Hoogsteen base pairs.";
RL   Nat. Struct. Mol. Biol. 17:423-429(2010).
RN   [162]
RP   VARIANT ARG-72.
RX   PubMed=1999338; DOI=10.1007/BF00201836;
RA   Olschwang S., Laurent-Puig P., Vassal A., Salmon R.-J., Thomas G.;
RT   "Characterization of a frequent polymorphism in the coding sequence of
RT   the Tp53 gene in colonic cancer patients and a control population.";
RL   Hum. Genet. 86:369-370(1991).
RN   [163]
RP   VARIANT LFS THR-133.
RX   PubMed=1933902;
RA   Law J.C., Strong L.C., Chidambaram A., Ferrell R.E.;
RT   "A germ line mutation in exon 5 of the p53 gene in an extended cancer
RT   family.";
RL   Cancer Res. 51:6385-6387(1991).
RN   [164]
RP   VARIANTS LFS CYS-245; TRP-248; PRO-252 AND LYS-258.
RX   PubMed=1978757; DOI=10.1126/science.1978757;
RA   Malkin D., Li F.P., Strong L.C., Fraumeni J.F. Jr., Nelson C.E.,
RA   Kim D.H., Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A.,
RA   Friend S.H.;
RT   "Germ line p53 mutations in a familial syndrome of breast cancer,
RT   sarcomas, and other neoplasms.";
RL   Science 250:1233-1238(1990).
RN   [165]
RP   VARIANT LFS ASP-245.
RX   PubMed=2259385; DOI=10.1038/348747a0;
RA   Srivastava S., Zou Z., Pirollo K., Blattner W., Chang E.H.;
RT   "Germ-line transmission of a mutated p53 gene in a cancer-prone family
RT   with Li-Fraumeni syndrome.";
RL   Nature 348:747-749(1990).
RN   [166]
RP   VARIANT LFS LEU-272.
RX   PubMed=1737852; DOI=10.1172/JCI115630;
RA   Felix C.A., Nau M.M., Takahashi T., Mitsudomi T., Chiba I.,
RA   Poplack D.G., Reaman G.H., Cole D.E., Letterio J.J., Whang-Peng J.,
RA   Knutsen T., Minna J.D.;
RT   "Hereditary and acquired p53 gene mutations in childhood acute
RT   lymphoblastic leukemia.";
RL   J. Clin. Invest. 89:640-647(1992).
RN   [167]
RP   VARIANTS LFS HIS-273 AND VAL-325.
RX   PubMed=1565144; DOI=10.1056/NEJM199205143262002;
RA   Malkin D., Jolly K.W., Barbier N., Look A.T., Friend S.H.,
RA   Gebhardt M.C., Andersen T.I., Boerresen A.-L., Li F.P., Garber J.,
RA   Strong L.C.;
RT   "Germline mutations of the p53 tumor-suppressor gene in children and
RT   young adults with second malignant neoplasms.";
RL   N. Engl. J. Med. 326:1309-1315(1992).
RN   [168]
RP   VARIANTS SPORADIC CANCERS GLN-132; SER-249; LYS-280 AND LYS-285.
RX   PubMed=1694291;
RA   Bartek J., Iggo R., Gannon J., Lane D.P.;
RT   "Genetic and immunochemical analysis of mutant p53 in human breast
RT   cancer cell lines.";
RL   Oncogene 5:893-899(1990).
RN   [169]
RP   VARIANTS SPORADIC CANCERS PHE-241 AND HIS-273.
RX   PubMed=1699228; DOI=10.1073/pnas.87.19.7555;
RA   Rodrigues N.R., Rowan A., Smith M.E.F., Kerr I.B., Bodmer W.F.,
RA   Gannon J.V., Lane D.P.;
RT   "p53 mutations in colorectal cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:7555-7559(1990).
RN   [170]
RP   VARIANTS SPORADIC CANCER VAL-154; VAL-245; GLN-248; LEU-278 AND
RP   SER-278.
RX   PubMed=2263646; DOI=10.1073/pnas.87.24.9958;
RA   Hollstein M.C., Metcalf R.A., Welsh J.A., Montesano R., Harris C.C.;
RT   "Frequent mutation of the p53 gene in human esophageal cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:9958-9961(1990).
RN   [171]
RP   VARIANTS SPORADIC CANCERS.
RX   PubMed=1647768; DOI=10.1016/0006-291X(91)90623-F;
RA   Ishioka C., Sato T., Gamoh M., Suzuki T., Shibata H., Kanamaru R.,
RA   Wakui A., Yamazaki T.;
RT   "Mutations of the P53 gene, including an intronic point mutation, in
RT   colorectal tumors.";
RL   Biochem. Biophys. Res. Commun. 177:901-906(1991).
RN   [172]
RP   VARIANTS SPORADIC CANCERS LEU-152; ALA-155; HIS-175; PHE-176 AND
RP   HIS-273.
RX   PubMed=1868473;
RA   Casson A.G., Mukhopadhyay T., Cleary K.R., Ro J.Y., Levin B.,
RA   Roth J.A.;
RT   "p53 gene mutations in Barrett's epithelium and esophageal cancer.";
RL   Cancer Res. 51:4495-4499(1991).
RN   [173]
RP   VARIANTS SPORADIC CANCERS IN CHINA.
RX   PubMed=1849234; DOI=10.1038/350427a0;
RA   Hsu I.C., Metcalf R.A., Sun T., Welsh J.A., Wang N.J., Harris C.C.;
RT   "Mutational hotspot in the p53 gene in human hepatocellular
RT   carcinomas.";
RL   Nature 350:427-428(1991).
RN   [174]
RP   VARIANTS SPORADIC CANCERS IN SOUTH AFRICA.
RX   PubMed=1672732; DOI=10.1038/350429a0;
RA   Bressac B., Kew M., Wands J., Ozturk M.;
RT   "Selective G to T mutations of p53 gene in hepatocellular carcinoma
RT   from southern Africa.";
RL   Nature 350:429-431(1991).
RN   [175]
RP   VARIANTS SPORADIC CANCERS PHE-176; PHE-242; CYS-245; LEU-248 AND
RP   HIS-273.
RX   PubMed=1394225;
RA   Somers K.D., Merrick M.A., Lopez M.E., Incognito L.S., Schechter G.L.,
RA   Casey G.;
RT   "Frequent p53 mutations in head and neck cancer.";
RL   Cancer Res. 52:5997-6000(1992).
RN   [176]
RP   VARIANTS SPORADIC CANCERS.
RX   PubMed=1327751;
RA   Crook T., Vousden K.H.;
RT   "Properties of p53 mutations detected in primary and secondary
RT   cervical cancers suggest mechanisms of metastasis and involvement of
RT   environmental carcinogens.";
RL   EMBO J. 11:3935-3940(1992).
RN   [177]
RP   VARIANTS SPORADIC CANCERS CYS-205; GLU-281 AND LYS-285.
RX   PubMed=1459726; DOI=10.1002/ijc.2910520606;
RA   Sakai E., Rikimaru K., Ueda M., Matsumoto Y., Ishii N., Enomoto S.,
RA   Yamamoto H., Tsuchida N.;
RT   "The p53 tumor-suppressor gene and ras oncogene mutations in oral
RT   squamous-cell carcinoma.";
RL   Int. J. Cancer 52:867-872(1992).
RN   [178]
RP   VARIANT PRO-HIS-PRO-178 INS.
RX   PubMed=1303181; DOI=10.1093/hmg/1.3.207;
RA   Bhatia K., Guiterrez M.I., Magrath I.T.;
RT   "A novel mutation in the p53 gene in a Burkitt's lymphoma cell line.";
RL   Hum. Mol. Genet. 1:207-208(1992).
RN   [179]
RP   VARIANTS SPORADIC CANCERS.
RX   PubMed=1437144;
RA   Duthu A., Debuire B., Romano J.W., Ehrhart J.C., Fiscella M., May E.,
RA   Appella E., May P.;
RT   "p53 mutations in Raji cells: characterization and localization
RT   relative to other Burkitt's lymphomas.";
RL   Oncogene 7:2161-2167(1992).
RN   [180]
RP   VARIANT SPORADIC CANCER THR-280.
RX   PubMed=1631151; DOI=10.1073/pnas.89.14.6516;
RA   Sun Y., Hegamyer G., Heng Y.-J., Hildesheim A., Chen J.-Y.,
RA   Chen I.-H., Cao Y., Yao K.-T., Colburn N.H.;
RT   "An infrequent point mutation of the p53 gene in human nasopharyngeal
RT   carcinoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:6516-6520(1992).
RN   [181]
RP   VARIANTS SPORADIC CANCERS SER-151; PRO-156; LYS-174; ARG-194; CYS-220;
RP   GLN-248; LEU-248 AND HIS-273.
RX   PubMed=7682763;
RA   Caamano J., Zhang S.Y., Rosvold E.A., Bauer B., Klein-Szanto A.J.P.;
RT   "p53 alterations in human squamous cell carcinomas and carcinoma cell
RT   lines.";
RL   Am. J. Pathol. 142:1131-1139(1993).
RN   [182]
RP   VARIANTS SPORADIC CANCERS.
RX   PubMed=8402617;
RA   Boyle J.O., Hakim J., Koch W., van der Riet P., Hruban R.H., Roa R.A.,
RA   Correo R., Eby Y.J., Ruppert J.M., Sidransky D.;
RT   "The incidence of p53 mutations increases with progression of head and
RT   neck cancer.";
RL   Cancer Res. 53:4477-4480(1993).
RN   [183]
RP   VARIANTS SPORADIC CANCERS.
RX   PubMed=8336944;
RA   Hamelin R., Jego N., Laurent-Puig P., Vidaud M., Thomas G.;
RT   "Efficient screening of p53 mutations by denaturing gradient gel
RT   electrophoresis in colorectal tumors.";
RL   Oncogene 8:2213-2220(1993).
RN   [184]
RP   VARIANTS, AND INVOLVEMENT IN LFL.
RX   PubMed=8118819;
RA   Birch J.M., Hartley A.L., Tricker K.J., Prosser J., Condie A.,
RA   Kelsey A.M., Harris M., Jones P.H., Binchy A., Crowther D.,
RA   Craft A.W., Eden O.B., Evans D.G.R., Thompson E., Mann J.R.,
RA   Martin J., Mitchell E.L.D., Santibanez-Koref M.F.;
RT   "Prevalence and diversity of constitutional mutations in the p53 gene
RT   among 21 Li-Fraumeni families.";
RL   Cancer Res. 54:1298-1304(1994).
RN   [185]
RP   CHARACTERIZATION OF VARIANT ALA-143.
RX   PubMed=8013454;
RA   Zhang W., Guo X.-Y., Hu G.-Y., Liu W.-B., Shay J.W., Deisseroth A.B.;
RT   "A temperature-sensitive mutant of human p53.";
RL   EMBO J. 13:2535-2544(1994).
RN   [186]
RP   VARIANTS LFS HIS-175; ARG-193; GLN-248; CYS-273 AND TYR-275.
RX   PubMed=7887414;
RA   Frebourg T., Barbier N., Yan Y.-X., Garber J.E., Dreyfus M.,
RA   Fraumeni J.F. Jr., Li F.P., Friend S.H.;
RT   "Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome.";
RL   Am. J. Hum. Genet. 56:608-615(1995).
RN   [187]
RP   VARIANTS, AND INVOLVEMENT IN LFL.
RX   PubMed=8718514;
RA   Eeles R.A.;
RT   "Germline mutations in the TP53 gene.";
RL   Cancer Surv. 25:101-124(1995).
RN   [188]
RP   VARIANT LFS HIS-175.
RX   PubMed=8825920; DOI=10.1136/jmg.32.12.942;
RA   Varley J.M., McGrown G., Thorncroft M., Tricker K.J., Teare M.D.,
RA   Santibanez-Koref M.F., Houlston R.S., Martin J., Birch J.M.,
RA   Evans D.G.R.;
RT   "An extended Li-Fraumeni kindred with gastric carcinoma and a codon
RT   175 mutation in TP53.";
RL   J. Med. Genet. 32:942-945(1995).
RN   [189]
RP   VARIANTS SPORADIC CANCERS PHE-176; SER-245; TRP-248; TRP-282 AND
RP   GLN-286.
RX   PubMed=8829627;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:2<109::AID-HUMU4>3.3.CO;2-0;
RA   Audrezet M.-P., Robaszkiewicz M., Mercier B., Nousbaum J.-B.,
RA   Hardy E., Bail J.-P., Volant A., Lozac'H P., Gouerou H., Ferec C.;
RT   "Molecular analysis of the TP53 gene in Barrett's adenocarcinoma.";
RL   Hum. Mutat. 7:109-113(1996).
RN   [190]
RP   VARIANTS SPORADIC CANCERS.
RX   PubMed=9101296;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:4<348::AID-HUMU8>3.0.CO;2-1;
RA   Guldberg P., Nedergaard T., Nielsen H.J., Olsen A.C., Ahrenkiel V.,
RA   Zeuthen J.;
RT   "Single-step DGGE-based mutation scanning of the p53 gene: application
RT   to genetic diagnosis of colorectal cancer.";
RL   Hum. Mutat. 9:348-355(1997).
RN   [191]
RP   VARIANT SPORADIC CANCER ILE-157.
RX   PubMed=9419979; DOI=10.1038/sj.onc.1201668;
RA   Miyaki M., Nishio J., Konishi M., Kikuchi-Yanoshita R., Tanaka K.,
RA   Muraoka M., Nagato M., Chong J.-M., Koike M., Terada T., Kawahara Y.,
RA   Fukutome A., Tomiyama J., Chuganji Y., Momoi M., Utsunomiya J.;
RT   "Drastic genetic instability of tumors and normal tissues in Turcot
RT   syndrome.";
RL   Oncogene 15:2877-2881(1997).
RN   [192]
RP   VARIANTS SER-152; ILE-169; PHE-176; THR-195; CYS-220; ILE-230; CYS-273
RP   AND SER-278.
RX   PubMed=9450901;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:1<39::AID-HUMU6>3.0.CO;2-G;
RA   van Rensburg E.J., Engelbrecht S., van Heerden W.F.P., Kotze M.J.,
RA   Raubenheimer E.J.;
RT   "Detection of p53 gene mutations in oral squamous cell carcinomas of a
RT   black African population sample.";
RL   Hum. Mutat. 11:39-44(1998).
RN   [193]
RP   VARIANT NON-CLASSICAL LFS CYS-337.
RX   PubMed=9452042;
RA   Luca J.W., Strong L.C., Hansen M.F.;
RT   "A germline missense mutation R337C in exon 10 of the human p53
RT   gene.";
RL   Hum. Mutat. Suppl. 1:S58-S61(1998).
RN   [194]
RP   VARIANT LFS ILE-292.
RX   PubMed=10484981; DOI=10.1016/S0165-4608(98)00276-3;
RA   Gueran S., Tunca Y., Imirzalioglu N.;
RT   "Hereditary TP53 codon 292 and somatic P16INK4A codon 94 mutations in
RT   a Li-Fraumeni syndrome family.";
RL   Cancer Genet. Cytogenet. 113:145-151(1999).
RN   [195]
RP   VARIANTS.
RX   PubMed=10549356;
RA   Hainaut P., Hollstein M.;
RT   "p53 and human cancer: the first ten thousand mutations.";
RL   Adv. Cancer Res. 77:81-137(2000).
RN   [196]
RP   VARIANT ADCC HIS-337.
RX   PubMed=11481490; DOI=10.1073/pnas.161479898;
RA   Ribeiro R.C., Sandrini F., Figueiredo B., Zambetti G.P.,
RA   Michalkiewicz E., Lafferty A.R., DeLacerda L., Rabin M., Cadwell C.,
RA   Sampaio G., Cat I., Stratakis C.A., Sandrini R.;
RT   "An inherited p53 mutation that contributes in a tissue-specific
RT   manner to pediatric adrenal cortical carcinoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:9330-9335(2001).
RN   [197]
RP   INVOLVEMENT IN CPP.
RX   PubMed=12085209; DOI=10.1038/sj.bjc.6600269;
RA   Rutherford J., Chu C.E., Duddy P.M., Charlton R.S., Chumas P.,
RA   Taylor G.R., Lu X., Barnes D.M., Camplejohn R.S.;
RT   "Investigations on a clinically and functionally unusual and novel
RT   germline p53 mutation.";
RL   Br. J. Cancer 86:1592-1596(2002).
RN   [198]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-134; PHE-157; CYS-163; HIS-175;
RP   ARG-177; ARG-193; PRO-213; PHE-241; PHE-242; GLN-248; TRP-248;
RP   SER-249; TRP-267; LYS-271; CYS-273; HIS-273; LEU-273; SER-278; ILE-280
RP   AND HIS-281.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [199]
RP   VARIANTS PRO-110; VAL-113; VAL-138; CYS-163; HIS-163; THR-195;
RP   MET-216; ALA-241; MET-249; SER-251; TYR-259 AND CYS-273.
RX   PubMed=17224074; DOI=10.1186/bcr1637;
RA   Chanock S.J., Burdett L., Yeager M., Llaca V., Langeroed A.,
RA   Presswalla S., Kaaresen R., Strausberg R.L., Gerhard D.S.,
RA   Kristensen V., Perou C.M., Boerresen-Dale A.-L.;
RT   "Somatic sequence alterations in twenty-one genes selected by
RT   expression profile analysis of breast carcinomas.";
RL   Breast Cancer Res. 9:R5-R5(2007).
RN   [200]
RP   VARIANTS.
RX   PubMed=17311302; DOI=10.1002/humu.20495;
RA   Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V.,
RA   Hainaut P., Olivier M.;
RT   "Impact of mutant p53 functional properties on TP53 mutation patterns
RT   and tumor phenotype: lessons from recent developments in the IARC TP53
RT   database.";
RL   Hum. Mutat. 28:622-629(2007).
RN   [201]
RP   CHARACTERIZATION OF VARIANT SPORADIC CANCER LYS-280, UBIQUITINATION,
RP   PROTEASOMAL DEGRADATION, AND INTERACTION WITH CCAR2.
RX   PubMed=25732823; DOI=10.1016/j.celrep.2015.01.066;
RA   Qin B., Minter-Dykhouse K., Yu J., Zhang J., Liu T., Zhang H., Lee S.,
RA   Kim J., Wang L., Lou Z.;
RT   "DBC1 functions as a tumor suppressor by regulating p53 stability.";
RL   Cell Rep. 10:1324-1334(2015).
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression. In cooperation with mitochondrial PPIF is involved in
CC       activating oxidative stress-induced necrosis; the function is
CC       largely independent of transcription. Induces the transcription of
CC       long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-
CC       Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional
CC       repression leading to apoptosis and seem to have to effect on
CC       cell-cycle regulation. Implicated in Notch signaling cross-over.
CC       Prevents CDK7 kinase activity when associated to CAK complex in
CC       response to DNA damage, thus stopping cell cycle progression.
CC       Isoform 2 enhances the transactivation activity of isoform 1 from
CC       some but not all TP53-inducible promoters. Isoform 4 suppresses
CC       transactivation activity and impairs growth suppression mediated
CC       by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis.
CC       Regulates the circadian clock by repressing CLOCK-ARNTL/BMAL1-
CC       mediated transcriptional activation of PER2 (PubMed:24051492).
CC       {ECO:0000269|PubMed:11025664, ECO:0000269|PubMed:12810724,
CC       ECO:0000269|PubMed:15186775, ECO:0000269|PubMed:15340061,
CC       ECO:0000269|PubMed:17317671, ECO:0000269|PubMed:17349958,
CC       ECO:0000269|PubMed:19556538, ECO:0000269|PubMed:20673990,
CC       ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:22726440,
CC       ECO:0000269|PubMed:24051492, ECO:0000269|PubMed:9840937}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC       Note=Binds 1 zinc ion per subunit.;
CC   -!- SUBUNIT: Interacts with AXIN1. Probably part of a complex
CC       consisting of TP53, HIPK2 and AXIN1 (By similarity). Binds DNA as
CC       a homotetramer. Interacts with histone acetyltransferases EP300
CC       and methyltransferases HRMT1L2 and CARM1, and recruits them to
CC       promoters. In vitro, the interaction of TP53 with cancer-
CC       associated/HPV (E6) viral proteins leads to ubiquitination and
CC       degradation of TP53 giving a possible model for cell growth
CC       regulation. This complex formation requires an additional factor,
CC       E6-AP, which stably associates with TP53 in the presence of E6.
CC       Interacts (via C-terminus) with TAF1; when TAF1 is part of the
CC       TFIID complex. Interacts with ING4; this interaction may be
CC       indirect. Found in a complex with CABLES1 and TP73. Interacts with
CC       HIPK1, HIPK2, and TP53INP1. Interacts with WWOX. May interact with
CC       HCV core protein. Interacts with USP7 and SYVN1. Interacts with
CC       HSP90AB1. Interacts with CHD8; leading to recruit histone H1 and
CC       prevent transactivation activity (By similarity). Interacts with
CC       ARMC10, BANP, CDKN2AIP, NUAK1, STK11/LKB1, UHRF2 and E4F1.
CC       Interacts with YWHAZ; the interaction enhances TP53
CC       transcriptional activity. Phosphorylation of YWHAZ on 'Ser-58'
CC       inhibits this interaction. Interacts (via DNA-binding domain) with
CC       MAML1 (via N-terminus). Interacts with MKRN1. Interacts with PML
CC       (via C-terminus). Interacts with MDM2; leading to ubiquitination
CC       and proteasomal degradation of TP53. Directly interacts with
CC       FBXO42; leading to ubiquitination and degradation of TP53.
CC       Interacts (phosphorylated at Ser-15 by ATM) with the phosphatase
CC       PP2A-PPP2R5C holoenzyme; regulates stress-induced TP53-dependent
CC       inhibition of cell proliferation. Interacts with PPP2R2A.
CC       Interacts with AURKA, DAXX, BRD7 and TRIM24. Interacts (when
CC       monomethylated at Lys-382) with L3MBTL1. Isoform 1 interacts with
CC       isoform 2 and with isoform 4. Interacts with GRK5. Binds to the
CC       CAK complex (CDK7, cyclin H and MAT1) in response to DNA damage.
CC       Interacts with CDK5 in neurons. Interacts with AURKB, SETD2, UHRF2
CC       and NOC2L. Interacts (via N-terminus) with PTK2/FAK1; this
CC       promotes ubiquitination by MDM2. Interacts with PTK2B/PYK2; this
CC       promotes ubiquitination by MDM2. Interacts with PRKCG. Interacts
CC       with PPIF; the association implicates preferentially tetrameric
CC       TP53, is induced by oxidative stress and is impaired by
CC       cyclosporin A (CsA). Interacts with human cytomegalovirus/HHV-5
CC       protein UL123. Interacts with SNAI1; the interaction induces SNAI1
CC       degradation via MDM2-mediated ubiquitination and inhibits SNAI1-
CC       induced cell invasion. Interacts with KAT6A. Interacts with UBC9.
CC       Interacts with ZNF385B; the interaction is direct. Interacts (via
CC       DNA-binding domain) with ZNF385A; the interaction is direct and
CC       enhances p53/TP53 transactivation functions on cell-cycle arrest
CC       target genes, resulting in growth arrest. Interacts with ANKRD2.
CC       Interacts with RFFL and RNF34; involved in p53/TP53
CC       ubiquitination. Interacts with MTA1 and RFWD2. Interacts with
CC       CCAR2 (via N-terminus). Interacts (via N-terminus) with human
CC       adenovirus 5 E1B-55K protein; this interaction leads to the
CC       inhibition of TP53 function and/or its degradation
CC       (PubMed:25772236). Interacts with MORC3 (PubMed:17332504).
CC       Interacts (via C-terminus) with POU4F2 isoform 1 (via C-terminus)
CC       (PubMed:17145718). Interacts (via oligomerization region) with
CC       NOP53; the interaction is direct and may prevent the MDM2-mediated
CC       proteasomal degradation of TP53 (PubMed:22522597). Interacts with
CC       AFG1L; mediates mitochondrial translocation of TP53
CC       (PubMed:27323408). Interacts with UBD (PubMed:25422469).
CC       {ECO:0000250, ECO:0000269|PubMed:12750254,
CC       ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:12851404,
CC       ECO:0000269|PubMed:14534297, ECO:0000269|PubMed:14702041,
CC       ECO:0000269|PubMed:15053879, ECO:0000269|PubMed:15109303,
CC       ECO:0000269|PubMed:15136035, ECO:0000269|PubMed:15186775,
CC       ECO:0000269|PubMed:15701641, ECO:0000269|PubMed:15855171,
CC       ECO:0000269|PubMed:16219768, ECO:0000269|PubMed:16322561,
CC       ECO:0000269|PubMed:16376338, ECO:0000269|PubMed:16377624,
CC       ECO:0000269|PubMed:16402859, ECO:0000269|PubMed:16474402,
CC       ECO:0000269|PubMed:16793544, ECO:0000269|PubMed:16845383,
CC       ECO:0000269|PubMed:17015838, ECO:0000269|PubMed:17108107,
CC       ECO:0000269|PubMed:17121812, ECO:0000269|PubMed:17145718,
CC       ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:17245430,
CC       ECO:0000269|PubMed:17317671, ECO:0000269|PubMed:17332504,
CC       ECO:0000269|PubMed:17591690, ECO:0000269|PubMed:17719541,
CC       ECO:0000269|PubMed:17904127, ECO:0000269|PubMed:17967874,
CC       ECO:0000269|PubMed:18585004, ECO:0000269|PubMed:18650397,
CC       ECO:0000269|PubMed:18996393, ECO:0000269|PubMed:19509332,
CC       ECO:0000269|PubMed:19515728, ECO:0000269|PubMed:19536131,
CC       ECO:0000269|PubMed:19556538, ECO:0000269|PubMed:19776115,
CC       ECO:0000269|PubMed:19837670, ECO:0000269|PubMed:19880522,
CC       ECO:0000269|PubMed:20124405, ECO:0000269|PubMed:20142040,
CC       ECO:0000269|PubMed:20228809, ECO:0000269|PubMed:20364130,
CC       ECO:0000269|PubMed:20385133, ECO:0000269|PubMed:20660729,
CC       ECO:0000269|PubMed:20870725, ECO:0000269|PubMed:20959462,
CC       ECO:0000269|PubMed:21317932, ECO:0000269|PubMed:21952639,
CC       ECO:0000269|PubMed:22214662, ECO:0000269|PubMed:22522597,
CC       ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:22945289,
CC       ECO:0000269|PubMed:23431171, ECO:0000269|PubMed:25422469,
CC       ECO:0000269|PubMed:25732823, ECO:0000269|PubMed:25772236,
CC       ECO:0000269|PubMed:27323408, ECO:0000269|PubMed:8875926,
CC       ECO:0000269|PubMed:8875929, ECO:0000269|PubMed:9840937}.
CC   -!- INTERACTION:
CC       Self; NbExp=24; IntAct=EBI-366083, EBI-366083;
CC       P03070:- (xeno); NbExp=19; IntAct=EBI-366083, EBI-617698;
CC       P26663:- (xeno); NbExp=9; IntAct=EBI-366083, EBI-6838571;
CC       Q7L7W2:-; NbExp=2; IntAct=EBI-366083, EBI-7210801;
CC       Q8QW27:- (xeno); NbExp=2; IntAct=EBI-366083, EBI-6863726;
CC       Q13155:AIMP2; NbExp=6; IntAct=EBI-366083, EBI-745226;
CC       O95376:ARIH2; NbExp=5; IntAct=EBI-366083, EBI-711158;
CC       P49407:ARRB1; NbExp=5; IntAct=EBI-366083, EBI-743313;
CC       P29066:Arrb1 (xeno); NbExp=3; IntAct=EBI-366083, EBI-4303019;
CC       Q9UBL3:ASH2L; NbExp=7; IntAct=EBI-366083, EBI-540797;
CC       O95352-2:ATG7; NbExp=4; IntAct=EBI-366083, EBI-15980880;
CC       O15169:AXIN1; NbExp=4; IntAct=EBI-366083, EBI-710484;
CC       Q8N9N5:BANP; NbExp=3; IntAct=EBI-366083, EBI-744695;
CC       P10415:BCL2; NbExp=5; IntAct=EBI-366083, EBI-77694;
CC       Q07817-1:BCL2L1; NbExp=26; IntAct=EBI-366083, EBI-287195;
CC       P11274:BCR; NbExp=2; IntAct=EBI-366083, EBI-712838;
CC       O14503:BHLHE40; NbExp=11; IntAct=EBI-366083, EBI-711810;
CC       P51587:BRCA2; NbExp=7; IntAct=EBI-366083, EBI-79792;
CC       Q9NPI1:BRD7; NbExp=9; IntAct=EBI-366083, EBI-711221;
CC       Q9BX70:BTBD2; NbExp=2; IntAct=EBI-366083, EBI-710091;
CC       Q9Y297:BTRC; NbExp=2; IntAct=EBI-366083, EBI-307461;
CC       Q9ESJ1:Cables1 (xeno); NbExp=3; IntAct=EBI-366083, EBI-604411;
CC       Q9BWC9:CCDC106; NbExp=3; IntAct=EBI-366083, EBI-711501;
CC       P38936:CDKN1A; NbExp=3; IntAct=EBI-366083, EBI-375077;
CC       P17676:CEBPB; NbExp=4; IntAct=EBI-366083, EBI-969696;
CC       Q92793:CREBBP; NbExp=11; IntAct=EBI-366083, EBI-81215;
CC       P45481:Crebbp (xeno); NbExp=9; IntAct=EBI-366083, EBI-296306;
CC       P55060:CSE1L; NbExp=5; IntAct=EBI-366083, EBI-286709;
CC       P68400:CSNK2A1; NbExp=2; IntAct=EBI-366083, EBI-347804;
CC       Q14999:CUL7; NbExp=5; IntAct=EBI-366083, EBI-308606;
CC       Q8IWT3:CUL9; NbExp=4; IntAct=EBI-366083, EBI-311123;
CC       Q9P0U4:CXXC1; NbExp=7; IntAct=EBI-366083, EBI-949911;
CC       Q9UER7:DAXX; NbExp=12; IntAct=EBI-366083, EBI-77321;
CC       Q92841:DDX17; NbExp=3; IntAct=EBI-366083, EBI-746012;
CC       P17844:DDX5; NbExp=6; IntAct=EBI-366083, EBI-351962;
CC       Q9NRR4:DROSHA; NbExp=5; IntAct=EBI-366083, EBI-528367;
CC       Q9BV47:DUSP26; NbExp=9; IntAct=EBI-366083, EBI-2924519;
CC       O14641:DVL2; NbExp=4; IntAct=EBI-366083, EBI-740850;
CC       P03126:E6 (xeno); NbExp=5; IntAct=EBI-366083, EBI-1177242;
CC       P06463:E6 (xeno); NbExp=3; IntAct=EBI-366083, EBI-1186926;
CC       Q09472:EP300; NbExp=20; IntAct=EBI-366083, EBI-447295;
CC       P15036:ETS2; NbExp=4; IntAct=EBI-366083, EBI-1646991;
CC       Q86XK2:FBXO11; NbExp=4; IntAct=EBI-366083, EBI-1047804;
CC       O43524:FOXO3; NbExp=2; IntAct=EBI-366083, EBI-1644164;
CC       P49841:GSK3B; NbExp=3; IntAct=EBI-366083, EBI-373586;
CC       P32780:GTF2H1; NbExp=5; IntAct=EBI-366083, EBI-715539;
CC       Q13547:HDAC1; NbExp=7; IntAct=EBI-366083, EBI-301834;
CC       Q86Z02:HIPK1; NbExp=2; IntAct=EBI-366083, EBI-692891;
CC       P09429:HMGB1; NbExp=9; IntAct=EBI-366083, EBI-389432;
CC       P61978:HNRNPK; NbExp=2; IntAct=EBI-366083, EBI-304185;
CC       P61978-2:HNRNPK; NbExp=2; IntAct=EBI-366083, EBI-7060731;
CC       P02829:HSP82 (xeno); NbExp=8; IntAct=EBI-366083, EBI-8659;
CC       P34931:HSPA1L; NbExp=2; IntAct=EBI-366083, EBI-354912;
CC       P38646:HSPA9; NbExp=6; IntAct=EBI-366083, EBI-354932;
CC       P04792:HSPB1; NbExp=3; IntAct=EBI-366083, EBI-352682;
CC       P42858:HTT; NbExp=4; IntAct=EBI-366083, EBI-466029;
CC       Q7Z6Z7:HUWE1; NbExp=3; IntAct=EBI-366083, EBI-625934;
CC       Q16666-2:IFI16; NbExp=6; IntAct=EBI-366083, EBI-6273540;
CC       Q08619:Ifi205b (xeno); NbExp=2; IntAct=EBI-366083, EBI-8064290;
CC       O14920:IKBKB; NbExp=2; IntAct=EBI-366083, EBI-81266;
CC       Q9UHH9:IP6K2; NbExp=4; IntAct=EBI-366083, EBI-747509;
CC       Q6NYC1:JMJD6; NbExp=7; IntAct=EBI-366083, EBI-8464037;
CC       Q92993:KAT5; NbExp=3; IntAct=EBI-366083, EBI-399080;
CC       Q9H7Z6:KAT8; NbExp=2; IntAct=EBI-366083, EBI-896414;
CC       O60341-1:KDM1A; NbExp=6; IntAct=EBI-366083, EBI-15599570;
CC       Q8IZD2:KMT2E; NbExp=4; IntAct=EBI-366083, EBI-2689959;
CC       Q16363:LAMA4; NbExp=2; IntAct=EBI-366083, EBI-711505;
CC       P43356:MAGEA2B; NbExp=7; IntAct=EBI-366083, EBI-5650739;
CC       Q9UBF1:MAGEC2; NbExp=3; IntAct=EBI-366083, EBI-5651487;
CC       P46821:MAP1B; NbExp=6; IntAct=EBI-366083, EBI-764611;
CC       Q15759:MAPK11; NbExp=2; IntAct=EBI-366083, EBI-298304;
CC       Q8IW41:MAPKAPK5; NbExp=2; IntAct=EBI-366083, EBI-1201460;
CC       Q00987:MDM2; NbExp=91; IntAct=EBI-366083, EBI-389668;
CC       O15151:MDM4; NbExp=19; IntAct=EBI-366083, EBI-398437;
CC       Q9UHC7:MKRN1; NbExp=8; IntAct=EBI-366083, EBI-373524;
CC       O75970:MPDZ; NbExp=3; IntAct=EBI-366083, EBI-821405;
CC       P04731:MT1A; NbExp=3; IntAct=EBI-366083, EBI-8045030;
CC       P19338:NCL; NbExp=2; IntAct=EBI-366083, EBI-346967;
CC       Q9Y618:NCOR2; NbExp=7; IntAct=EBI-366083, EBI-80830;
CC       P23511:NFYA; NbExp=11; IntAct=EBI-366083, EBI-389739;
CC       P25208:NFYB; NbExp=6; IntAct=EBI-366083, EBI-389728;
CC       Q9Y3T9:NOC2L; NbExp=8; IntAct=EBI-366083, EBI-751547;
CC       O60936:NOL3; NbExp=3; IntAct=EBI-366083, EBI-740992;
CC       P06748:NPM1; NbExp=6; IntAct=EBI-366083, EBI-78579;
CC       P06748-1:NPM1; NbExp=3; IntAct=EBI-366083, EBI-354150;
CC       Q15466:NR0B2; NbExp=3; IntAct=EBI-366083, EBI-3910729;
CC       P22736:NR4A1; NbExp=6; IntAct=EBI-366083, EBI-721550;
CC       O43847:NRDC; NbExp=6; IntAct=EBI-366083, EBI-2371631;
CC       P89055:NSP1 (xeno); NbExp=6; IntAct=EBI-366083, EBI-9522973;
CC       O60285:NUAK1; NbExp=5; IntAct=EBI-366083, EBI-1046789;
CC       P49757:NUMB; NbExp=5; IntAct=EBI-366083, EBI-915016;
CC       Q96FW1:OTUB1; NbExp=8; IntAct=EBI-366083, EBI-1058491;
CC       Q8TEW0:PARD3; NbExp=3; IntAct=EBI-366083, EBI-81968;
CC       P09874:PARP1; NbExp=3; IntAct=EBI-366083, EBI-355676;
CC       Q96KB5:PBK; NbExp=7; IntAct=EBI-366083, EBI-536853;
CC       P35232:PHB; NbExp=6; IntAct=EBI-366083, EBI-354213;
CC       O75925:PIAS1; NbExp=4; IntAct=EBI-366083, EBI-629434;
CC       O75928:PIAS2; NbExp=2; IntAct=EBI-366083, EBI-348555;
CC       Q8N2W9:PIAS4; NbExp=2; IntAct=EBI-366083, EBI-473160;
CC       Q13526:PIN1; NbExp=12; IntAct=EBI-366083, EBI-714158;
CC       P53350:PLK1; NbExp=6; IntAct=EBI-366083, EBI-476768;
CC       P29590:PML; NbExp=4; IntAct=EBI-366083, EBI-295890;
CC       P30405:PPIF; NbExp=4; IntAct=EBI-366083, EBI-5544229;
CC       P36873-1:PPP1CC; NbExp=2; IntAct=EBI-366083, EBI-356289;
CC       Q8WUF5:PPP1R13L; NbExp=12; IntAct=EBI-366083, EBI-5550163;
CC       P30153:PPP2R1A; NbExp=3; IntAct=EBI-366083, EBI-302388;
CC       Q13362:PPP2R5C; NbExp=4; IntAct=EBI-366083, EBI-1266156;
CC       Q05655:PRKCD; NbExp=4; IntAct=EBI-366083, EBI-704279;
CC       P61289:PSME3; NbExp=7; IntAct=EBI-366083, EBI-355546;
CC       Q05397:PTK2; NbExp=13; IntAct=EBI-366083, EBI-702142;
CC       Q06609:RAD51; NbExp=2; IntAct=EBI-366083, EBI-297202;
CC       Q06330:RBPJ; NbExp=5; IntAct=EBI-366083, EBI-632552;
CC       Q96PM5:RCHY1; NbExp=11; IntAct=EBI-366083, EBI-947779;
CC       Q6PCD5:RFWD3; NbExp=5; IntAct=EBI-366083, EBI-2129159;
CC       P23396:RPS3; NbExp=4; IntAct=EBI-366083, EBI-351193;
CC       Q8N488:RYBP; NbExp=3; IntAct=EBI-366083, EBI-752324;
CC       P23297:S100A1; NbExp=2; IntAct=EBI-366083, EBI-743686;
CC       P29034:S100A2; NbExp=2; IntAct=EBI-366083, EBI-752230;
CC       P26447:S100A4; NbExp=7; IntAct=EBI-366083, EBI-717058;
CC       P04271:S100B; NbExp=2; IntAct=EBI-366083, EBI-458391;
CC       Q15424:SAFB; NbExp=5; IntAct=EBI-366083, EBI-348298;
CC       Q8WTS6:SETD7; NbExp=11; IntAct=EBI-366083, EBI-1268586;
CC       P31947:SFN; NbExp=4; IntAct=EBI-366083, EBI-476295;
CC       Q96ST3:SIN3A; NbExp=2; IntAct=EBI-366083, EBI-347218;
CC       Q96EB6:SIRT1; NbExp=18; IntAct=EBI-366083, EBI-1802965;
CC       Q923E4:Sirt1 (xeno); NbExp=4; IntAct=EBI-366083, EBI-1802585;
CC       Q15796:SMAD2; NbExp=7; IntAct=EBI-366083, EBI-1040141;
CC       Q9NRG4:SMYD2; NbExp=6; IntAct=EBI-366083, EBI-1055671;
CC       Q8R5A0:Smyd2 (xeno); NbExp=3; IntAct=EBI-366083, EBI-15612527;
CC       O95863:SNAI1; NbExp=2; IntAct=EBI-366083, EBI-1045459;
CC       Q06945:SOX4; NbExp=4; IntAct=EBI-366083, EBI-6672525;
CC       P08047:SP1; NbExp=3; IntAct=EBI-366083, EBI-298336;
CC       Q12772:SREBF2; NbExp=3; IntAct=EBI-366083, EBI-465059;
CC       Q96SB4:SRPK1; NbExp=3; IntAct=EBI-366083, EBI-539478;
CC       P63165:SUMO1; NbExp=3; IntAct=EBI-366083, EBI-80140;
CC       Q86TM6:SYVN1; NbExp=5; IntAct=EBI-366083, EBI-947849;
CC       P20226:TBP; NbExp=2; IntAct=EBI-366083, EBI-355371;
CC       P15884:TCF4; NbExp=2; IntAct=EBI-366083, EBI-533224;
CC       Q96GM8:TOE1; NbExp=3; IntAct=EBI-366083, EBI-717460;
CC       Q12888:TP53BP1; NbExp=6; IntAct=EBI-366083, EBI-396540;
CC       Q12888-1:TP53BP1; NbExp=17; IntAct=EBI-366083, EBI-8022649;
CC       Q13625:TP53BP2; NbExp=7; IntAct=EBI-366083, EBI-77642;
CC       Q9H3D4:TP63; NbExp=5; IntAct=EBI-366083, EBI-2337775;
CC       O88898:Tp63 (xeno); NbExp=2; IntAct=EBI-366083, EBI-2338025;
CC       P13693:TPT1; NbExp=7; IntAct=EBI-366083, EBI-1783169;
CC       O15164:TRIM24; NbExp=3; IntAct=EBI-366083, EBI-2130378;
CC       Q15672:TWIST1; NbExp=10; IntAct=EBI-366083, EBI-1797287;
CC       P26687:Twist1 (xeno); NbExp=4; IntAct=EBI-366083, EBI-6123119;
CC       P0CG48:UBC; NbExp=15; IntAct=EBI-366083, EBI-3390054;
CC       Q05086:UBE3A; NbExp=6; IntAct=EBI-366083, EBI-954357;
CC       Q96PU4:UHRF2; NbExp=3; IntAct=EBI-366083, EBI-625304;
CC       Q9H9J4:USP42; NbExp=2; IntAct=EBI-366083, EBI-2513638;
CC       Q9H9J4-2:USP42; NbExp=2; IntAct=EBI-366083, EBI-9118105;
CC       Q93009:USP7; NbExp=18; IntAct=EBI-366083, EBI-302474;
CC       P11473:VDR; NbExp=6; IntAct=EBI-366083, EBI-286357;
CC       Q99986:VRK1; NbExp=9; IntAct=EBI-366083, EBI-1769146;
CC       Q14191:WRN; NbExp=5; IntAct=EBI-366083, EBI-368417;
CC       O14980:XPO1; NbExp=3; IntAct=EBI-366083, EBI-355867;
CC       P12956:XRCC6; NbExp=2; IntAct=EBI-366083, EBI-353208;
CC       P61981:YWHAG; NbExp=5; IntAct=EBI-366083, EBI-359832;
CC       P63104:YWHAZ; NbExp=2; IntAct=EBI-366083, EBI-347088;
CC       Q8TAQ5:ZNF420; NbExp=4; IntAct=EBI-366083, EBI-3923307;
CC       Q9PST7:znf585b (xeno); NbExp=3; IntAct=EBI-366083, EBI-1782562;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Nucleus, PML body.
CC       Endoplasmic reticulum. Mitochondrion matrix. Note=Interaction with
CC       BANP promotes nuclear localization. Recruited into PML bodies
CC       together with CHEK2. Translocates to mitochondria upon oxidative
CC       stress. Translocates to mitochondria in response to mitomycin C
CC       treatment (PubMed:27323408). {ECO:0000269|PubMed:27323408}.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Nucleus. Cytoplasm.
CC       Note=Predominantly nuclear but localizes to the cytoplasm when
CC       expressed with isoform 4.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Nucleus. Cytoplasm.
CC       Note=Localized mainly in the nucleus with minor staining in the
CC       cytoplasm.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Nucleus. Cytoplasm.
CC       Note=Localized in the nucleus in most cells but found in the
CC       cytoplasm in some cells.
CC   -!- SUBCELLULAR LOCATION: Isoform 4: Nucleus. Cytoplasm.
CC       Note=Predominantly nuclear but translocates to the cytoplasm
CC       following cell stress.
CC   -!- SUBCELLULAR LOCATION: Isoform 7: Nucleus. Cytoplasm.
CC       Note=Localized mainly in the nucleus with minor staining in the
CC       cytoplasm.
CC   -!- SUBCELLULAR LOCATION: Isoform 8: Nucleus. Cytoplasm.
CC       Note=Localized in both nucleus and cytoplasm in most cells. In
CC       some cells, forms foci in the nucleus that are different from
CC       nucleoli.
CC   -!- SUBCELLULAR LOCATION: Isoform 9: Cytoplasm.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=9;
CC       Name=1; Synonyms=p53, p53alpha;
CC         IsoId=P04637-1; Sequence=Displayed;
CC       Name=2; Synonyms=I9RET, p53beta;
CC         IsoId=P04637-2; Sequence=VSP_006535, VSP_006536;
CC         Note=Expressed in quiescent lymphocytes. Seems to be
CC         non-functional. May be produced at very low levels due to a
CC         premature stop codon in the mRNA, leading to nonsense-mediated
CC         mRNA decay.;
CC       Name=3; Synonyms=p53gamma;
CC         IsoId=P04637-3; Sequence=VSP_040560, VSP_040561;
CC         Note=Expressed in quiescent lymphocytes. Seems to be
CC         non-functional. May be produced at very low levels due to a
CC         premature stop codon in the mRNA, leading to nonsense-mediated
CC         mRNA decay.;
CC       Name=4; Synonyms=Del40-p53, Del40-p53alpha, p47;
CC         IsoId=P04637-4; Sequence=VSP_040832;
CC       Name=5; Synonyms=Del40-p53beta;
CC         IsoId=P04637-5; Sequence=VSP_040832, VSP_006535, VSP_006536;
CC       Name=6; Synonyms=Del40-p53gamma;
CC         IsoId=P04637-6; Sequence=VSP_040832, VSP_040560, VSP_040561;
CC       Name=7; Synonyms=Del133-p53, Del133-p53alpha;
CC         IsoId=P04637-7; Sequence=VSP_040833;
CC         Note=Produced by alternative promoter usage.;
CC       Name=8; Synonyms=Del133-p53beta;
CC         IsoId=P04637-8; Sequence=VSP_040833, VSP_006535, VSP_006536;
CC         Note=Produced by alternative promoter usage and alternative
CC         splicing.;
CC       Name=9; Synonyms=Del133-p53gamma;
CC         IsoId=P04637-9; Sequence=VSP_040833, VSP_040560, VSP_040561;
CC         Note=Produced by alternative promoter usage and alternative
CC         splicing.;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Isoforms are expressed in a wide
CC       range of normal tissues but in a tissue-dependent manner. Isoform
CC       2 is expressed in most normal tissues but is not detected in
CC       brain, lung, prostate, muscle, fetal brain, spinal cord and fetal
CC       liver. Isoform 3 is expressed in most normal tissues but is not
CC       detected in lung, spleen, testis, fetal brain, spinal cord and
CC       fetal liver. Isoform 7 is expressed in most normal tissues but is
CC       not detected in prostate, uterus, skeletal muscle and breast.
CC       Isoform 8 is detected only in colon, bone marrow, testis, fetal
CC       brain and intestine. Isoform 9 is expressed in most normal tissues
CC       but is not detected in brain, heart, lung, fetal liver, salivary
CC       gland, breast or intestine. {ECO:0000269|PubMed:16131611}.
CC   -!- INDUCTION: Up-regulated in response to DNA damage. Isoform 2 is
CC       not induced in tumor cells in response to stress.
CC       {ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:16131611}.
CC   -!- DOMAIN: The nuclear export signal acts as a transcriptional
CC       repression domain. The TADI and TADII motifs (residues 17 to 25
CC       and 48 to 56) correspond both to 9aaTAD motifs which are
CC       transactivation domains present in a large number of yeast and
CC       animal transcription factors. {ECO:0000269|PubMed:17467953}.
CC   -!- PTM: Acetylated. Acetylation of Lys-382 by CREBBP enhances
CC       transcriptional activity. Deacetylation of Lys-382 by SIRT1
CC       impairs its ability to induce proapoptotic program and modulate
CC       cell senescence. Deacetylation by SIRT2 impairs its ability to
CC       induce transcription activation in a AKT-dependent manner.
CC       {ECO:0000269|PubMed:10656795, ECO:0000269|PubMed:20228809,
CC       ECO:0000269|PubMed:23431171}.
CC   -!- PTM: Phosphorylation on Ser residues mediates transcriptional
CC       activation. Phosphorylated by HIPK1 (By similarity).
CC       Phosphorylation at Ser-9 by HIPK4 increases repression activity on
CC       BIRC5 promoter. Phosphorylated on Thr-18 by VRK1. Phosphorylated
CC       on Ser-20 by CHEK2 in response to DNA damage, which prevents
CC       ubiquitination by MDM2. Phosphorylated on Ser-20 by PLK3 in
CC       response to reactive oxygen species (ROS), promoting p53/TP53-
CC       mediated apoptosis. Phosphorylated on Thr-55 by TAF1, which
CC       promotes MDM2-mediated degradation. Phosphorylated on Ser-33 by
CC       CDK7 in a CAK complex in response to DNA damage. Phosphorylated on
CC       Ser-46 by HIPK2 upon UV irradiation. Phosphorylation on Ser-46 is
CC       required for acetylation by CREBBP. Phosphorylated on Ser-392
CC       following UV but not gamma irradiation. Phosphorylated on Ser-15
CC       upon ultraviolet irradiation; which is enhanced by interaction
CC       with BANP. Phosphorylated by NUAK1 at Ser-15 and Ser-392; was
CC       initially thought to be mediated by STK11/LKB1 but it was later
CC       shown that it is indirect and that STK11/LKB1-dependent
CC       phosphorylation is probably mediated by downstream NUAK1
CC       (PubMed:21317932). It is unclear whether AMP directly mediates
CC       phosphorylation at Ser-15. Phosphorylated on Thr-18 by isoform 1
CC       and isoform 2 of VRK2. Phosphorylation on Thr-18 by isoform 2 of
CC       VRK2 results in a reduction in ubiquitination by MDM2 and an
CC       increase in acetylation by EP300. Stabilized by CDK5-mediated
CC       phosphorylation in response to genotoxic and oxidative stresses at
CC       Ser-15, Ser-33 and Ser-46, leading to accumulation of p53/TP53,
CC       particularly in the nucleus, thus inducing the transactivation of
CC       p53/TP53 target genes. Phosphorylated by DYRK2 at Ser-46 in
CC       response to genotoxic stress. Phosphorylated at Ser-315 and Ser-
CC       392 by CDK2 in response to DNA-damage. {ECO:0000250,
CC       ECO:0000269|PubMed:10570149, ECO:0000269|PubMed:10606744,
CC       ECO:0000269|PubMed:10884347, ECO:0000269|PubMed:10951572,
CC       ECO:0000269|PubMed:11239457, ECO:0000269|PubMed:11447225,
CC       ECO:0000269|PubMed:11546806, ECO:0000269|PubMed:11551930,
CC       ECO:0000269|PubMed:11554766, ECO:0000269|PubMed:11740489,
CC       ECO:0000269|PubMed:11780126, ECO:0000269|PubMed:12810724,
CC       ECO:0000269|PubMed:14702041, ECO:0000269|PubMed:15053879,
CC       ECO:0000269|PubMed:15701641, ECO:0000269|PubMed:15866171,
CC       ECO:0000269|PubMed:16377624, ECO:0000269|PubMed:16704422,
CC       ECO:0000269|PubMed:1705009, ECO:0000269|PubMed:17108107,
CC       ECO:0000269|PubMed:17254968, ECO:0000269|PubMed:17349958,
CC       ECO:0000269|PubMed:17591690, ECO:0000269|PubMed:17967874,
CC       ECO:0000269|PubMed:18022393, ECO:0000269|PubMed:20041275,
CC       ECO:0000269|PubMed:20124405, ECO:0000269|PubMed:20959462,
CC       ECO:0000269|PubMed:21317932, ECO:0000269|PubMed:2141171,
CC       ECO:0000269|PubMed:22214662, ECO:0000269|PubMed:9372954}.
CC   -!- PTM: Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40
CC       small T antigen inhibits the dephosphorylation by the AC form of
CC       PP2A.
CC   -!- PTM: May be O-glycosylated in the C-terminal basic region. Studied
CC       in EB-1 cell line. {ECO:0000269|PubMed:8632915}.
CC   -!- PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal
CC       degradation (PubMed:10722742, PubMed:12810724, PubMed:15340061,
CC       PubMed:17170702, PubMed:19880522). Ubiquitinated by RFWD3, which
CC       works in cooperation with MDM2 and may catalyze the formation of
CC       short polyubiquitin chains on p53/TP53 that are not targeted to
CC       the proteasome (PubMed:10722742, PubMed:12810724,
CC       PubMed:20173098). Ubiquitinated by MKRN1 at Lys-291 and Lys-292,
CC       which leads to proteasomal degradation (PubMed:19536131).
CC       Deubiquitinated by USP10, leading to its stabilization
CC       (PubMed:20096447). Ubiquitinated by TRIM24, RFFL, RNF34 and
CC       RNF125, which leads to proteasomal degradation (PubMed:19556538).
CC       Ubiquitination by TOPORS induces degradation (PubMed:19473992).
CC       Deubiquitination by USP7, leading to stabilization
CC       (PubMed:15053880). Isoform 4 is monoubiquitinated in an MDM2-
CC       independent manner (PubMed:15340061). Ubiquitinated by RFWD2,
CC       which leads to proteasomal degradation (PubMed:19837670).
CC       Ubiquitination and subsequent proteasomal degradation is
CC       negatively regulated by CCAR2 (PubMed:25732823).
CC       {ECO:0000269|PubMed:10722742, ECO:0000269|PubMed:12810724,
CC       ECO:0000269|PubMed:15053880, ECO:0000269|PubMed:15340061,
CC       ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:18206965,
CC       ECO:0000269|PubMed:19473992, ECO:0000269|PubMed:19536131,
CC       ECO:0000269|PubMed:19556538, ECO:0000269|PubMed:19837670,
CC       ECO:0000269|PubMed:19880522, ECO:0000269|PubMed:20096447,
CC       ECO:0000269|PubMed:20173098, ECO:0000269|PubMed:25591766,
CC       ECO:0000269|PubMed:25732823}.
CC   -!- PTM: Monomethylated at Lys-372 by SETD7, leading to stabilization
CC       and increased transcriptional activation. Monomethylated at Lys-
CC       370 by SMYD2, leading to decreased DNA-binding activity and
CC       subsequent transcriptional regulation activity. Lys-372
CC       monomethylation prevents interaction with SMYD2 and subsequent
CC       monomethylation at Lys-370. Dimethylated at Lys-373 by EHMT1 and
CC       EHMT2. Monomethylated at Lys-382 by KMT5A, promoting interaction
CC       with L3MBTL1 and leading to repress transcriptional activity.
CC       Dimethylation at Lys-370 and Lys-382 diminishes p53
CC       ubiquitination, through stabilizing association with the methyl
CC       reader PHF20. Demethylation of dimethylated Lys-370 by KDM1A
CC       prevents interaction with TP53BP1 and represses TP53-mediated
CC       transcriptional activation.
CC   -!- PTM: Sumoylated with SUMO1. Sumoylated at Lys-386 by UBC9.
CC       {ECO:0000269|PubMed:11124955, ECO:0000269|PubMed:22214662,
CC       ECO:0000269|Ref.35}.
CC   -!- DISEASE: Note=TP53 is found in increased amounts in a wide variety
CC       of transformed cells. TP53 is frequently mutated or inactivated in
CC       about 60% of cancers. TP53 defects are found in Barrett metaplasia
CC       a condition in which the normally stratified squamous epithelium
CC       of the lower esophagus is replaced by a metaplastic columnar
CC       epithelium. The condition develops as a complication in
CC       approximately 10% of patients with chronic gastroesophageal reflux
CC       disease and predisposes to the development of esophageal
CC       adenocarcinoma.
CC   -!- DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of
CC       the esophagus. The most common types are esophageal squamous cell
CC       carcinoma and adenocarcinoma. Cancer of the esophagus remains a
CC       devastating disease because it is usually not detected until it
CC       has progressed to an advanced incurable stage. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Li-Fraumeni syndrome (LFS) [MIM:151623]: Autosomal
CC       dominant familial cancer syndrome that in its classic form is
CC       defined by the existence of a proband affected by a sarcoma before
CC       45 years with a first degree relative affected by any tumor before
CC       45 years and another first degree relative with any tumor before
CC       45 years or a sarcoma at any age. Other clinical definitions for
CC       LFS have been proposed (PubMed:8118819 and PubMed:8718514) and
CC       called Li-Fraumeni like syndrome (LFL). In these families affected
CC       relatives develop a diverse set of malignancies at unusually early
CC       ages. Four types of cancers account for 80% of tumors occurring in
CC       TP53 germline mutation carriers: breast cancers, soft tissue and
CC       bone sarcomas, brain tumors (astrocytomas) and adrenocortical
CC       carcinomas. Less frequent tumors include choroid plexus carcinoma
CC       or papilloma before the age of 15, rhabdomyosarcoma before the age
CC       of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal
CC       and gastric cancers. {ECO:0000269|PubMed:10484981,
CC       ECO:0000269|PubMed:1565144, ECO:0000269|PubMed:1737852,
CC       ECO:0000269|PubMed:1933902, ECO:0000269|PubMed:1978757,
CC       ECO:0000269|PubMed:2259385, ECO:0000269|PubMed:7887414,
CC       ECO:0000269|PubMed:8825920, ECO:0000269|PubMed:9452042}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Squamous cell carcinoma of the head and neck (HNSCC)
CC       [MIM:275355]: A non-melanoma skin cancer affecting the head and
CC       neck. The hallmark of cutaneous SCC is malignant transformation of
CC       normal epidermal keratinocytes. Note=The gene represented in this
CC       entry is involved in disease pathogenesis.
CC   -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy
CC       affecting tissues of the lung. The most common form of lung cancer
CC       is non-small cell lung cancer (NSCLC) that can be divided into 3
CC       major histologic subtypes: squamous cell carcinoma,
CC       adenocarcinoma, and large cell lung cancer. NSCLC is often
CC       diagnosed at an advanced stage and has a poor prognosis. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Papilloma of choroid plexus (CPP) [MIM:260500]: A benign
CC       tumor of neuroectodermal origin that generally occurs in
CC       childhood, but has also been reported in adults. Although
CC       generally found within the ventricular system, choroid plexus
CC       papillomas can arise ectopically in the brain parenchyma or
CC       disseminate throughout the neuraxis. Patients present with signs
CC       and symptoms of increased intracranial pressure including
CC       headache, hydrocephalus, papilledema, nausea, vomiting, cranial
CC       nerve deficits, gait impairment, and seizures.
CC       {ECO:0000269|PubMed:12085209}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Adrenocortical carcinoma (ADCC) [MIM:202300]: A malignant
CC       neoplasm of the adrenal cortex and a rare childhood tumor. It
CC       occurs with increased frequency in patients with Beckwith-
CC       Wiedemann syndrome and Li-Fraumeni syndrome.
CC       {ECO:0000269|PubMed:11481490}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Basal cell carcinoma 7 (BCC7) [MIM:614740]: A common
CC       malignant skin neoplasm that typically appears on hair-bearing
CC       skin, most commonly on sun-exposed areas. It is slow growing and
CC       rarely metastasizes, but has potentialities for local invasion and
CC       destruction. It usually develops as a flat, firm, pale area that
CC       is small, raised, pink or red, translucent, shiny, and waxy, and
CC       the area may bleed following minor injury. Tumor size can vary
CC       from a few millimeters to several centimeters in diameter.
CC       {ECO:0000269|PubMed:21946351}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=IARC TP53 mutation database; Note=Somatic and
CC       germline TP53 mutations in human cancers;
CC       URL="http://p53.iarc.fr/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/P53ID88.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/tp53/";
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=TP53";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=P53 entry;
CC       URL="https://en.wikipedia.org/wiki/P53";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X02469; CAA26306.1; -; mRNA.
DR   EMBL; M13121; AAA59987.1; -; Genomic_DNA.
DR   EMBL; M13112; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13113; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13114; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13115; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13116; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13117; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13118; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13119; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; M13120; AAA59987.1; JOINED; Genomic_DNA.
DR   EMBL; K03199; AAA59989.1; -; mRNA.
DR   EMBL; M14694; AAA61211.1; -; mRNA.
DR   EMBL; M14695; AAA61212.1; -; mRNA.
DR   EMBL; M22898; AAA59988.1; -; Genomic_DNA.
DR   EMBL; M22882; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22883; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22884; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22887; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22888; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22894; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22895; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22896; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; M22897; AAA59988.1; JOINED; Genomic_DNA.
DR   EMBL; X01405; CAA25652.1; -; mRNA.
DR   EMBL; X60011; CAA42626.1; -; mRNA.
DR   EMBL; X60012; CAA42627.1; ALT_TERM; mRNA.
DR   EMBL; X60013; CAA42628.1; -; mRNA.
DR   EMBL; X60014; CAA42629.1; -; mRNA.
DR   EMBL; X60015; CAA42630.1; -; mRNA.
DR   EMBL; X60016; CAA42631.1; -; mRNA.
DR   EMBL; X60017; CAA42632.1; -; mRNA.
DR   EMBL; X60018; CAA42633.1; -; mRNA.
DR   EMBL; X60019; CAA42634.1; -; mRNA.
DR   EMBL; X60020; CAA42635.1; -; mRNA.
DR   EMBL; AF307851; AAG28785.1; -; mRNA.
DR   EMBL; DQ186648; ABA29753.1; -; mRNA.
DR   EMBL; DQ186649; ABA29754.1; -; mRNA.
DR   EMBL; DQ186650; ABA29755.1; -; mRNA.
DR   EMBL; DQ186651; ABA29756.1; -; mRNA.
DR   EMBL; DQ186652; ABA29757.1; -; mRNA.
DR   EMBL; DQ191317; ABB80262.1; -; mRNA.
DR   EMBL; DQ286964; ABB80266.1; -; mRNA.
DR   EMBL; X54156; CAA38095.1; -; Genomic_DNA.
DR   EMBL; U94788; AAC12971.1; -; Genomic_DNA.
DR   EMBL; AY838896; AAV80424.1; -; Genomic_DNA.
DR   EMBL; AF135121; AAD28535.1; -; Genomic_DNA.
DR   EMBL; AF135120; AAD28535.1; JOINED; Genomic_DNA.
DR   EMBL; AF136271; AAD28628.1; -; Genomic_DNA.
DR   EMBL; AF136270; AAD28628.1; JOINED; Genomic_DNA.
DR   EMBL; AB082923; BAC16799.1; -; mRNA.
DR   EMBL; AK312568; BAG35463.1; -; mRNA.
DR   EMBL; AC007421; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC087388; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471108; EAW90143.1; -; Genomic_DNA.
DR   EMBL; CH471108; EAW90144.1; -; Genomic_DNA.
DR   EMBL; BC003596; AAH03596.1; -; mRNA.
DR   EMBL; AY429684; AAR10356.1; -; mRNA.
DR   EMBL; AY390341; AAQ90158.1; -; Genomic_DNA.
DR   EMBL; AY359814; AAR13239.1; -; Genomic_DNA.
DR   EMBL; U63714; AAB39322.1; -; Genomic_DNA.
DR   EMBL; AF209136; AAF36362.1; -; Genomic_DNA.
DR   EMBL; AF209128; AAF36354.1; -; Genomic_DNA.
DR   EMBL; AF209129; AAF36355.1; -; Genomic_DNA.
DR   EMBL; AF209130; AAF36356.1; -; Genomic_DNA.
DR   EMBL; AF209131; AAF36357.1; -; Genomic_DNA.
DR   EMBL; AF209132; AAF36358.1; -; Genomic_DNA.
DR   EMBL; AF209133; AAF36359.1; -; Genomic_DNA.
DR   EMBL; AF209134; AAF36360.1; -; Genomic_DNA.
DR   EMBL; AF209135; AAF36361.1; -; Genomic_DNA.
DR   EMBL; AF209148; AAF36374.1; -; Genomic_DNA.
DR   EMBL; AF209149; AAF36375.1; -; Genomic_DNA.
DR   EMBL; AF209150; AAF36376.1; -; Genomic_DNA.
DR   EMBL; AF209151; AAF36377.1; -; Genomic_DNA.
DR   EMBL; AF209152; AAF36378.1; -; Genomic_DNA.
DR   EMBL; AF209153; AAF36379.1; -; Genomic_DNA.
DR   EMBL; AF209154; AAF36380.1; -; Genomic_DNA.
DR   EMBL; AF209155; AAF36381.1; -; Genomic_DNA.
DR   EMBL; AF209156; AAF36382.1; -; Genomic_DNA.
DR   EMBL; AF210309; AAF63442.1; -; Genomic_DNA.
DR   EMBL; AF210308; AAF63442.1; JOINED; Genomic_DNA.
DR   EMBL; AF210310; AAF63443.1; -; Genomic_DNA.
DR   EMBL; AF240684; AAK76358.1; -; Genomic_DNA.
DR   EMBL; AF240685; AAK76359.1; -; Genomic_DNA.
DR   EMBL; AY270155; AAP30003.1; -; Genomic_DNA.
DR   CCDS; CCDS11118.1; -. [P04637-1]
DR   CCDS; CCDS45605.1; -. [P04637-3]
DR   CCDS; CCDS45606.1; -. [P04637-2]
DR   CCDS; CCDS73966.1; -. [P04637-7]
DR   CCDS; CCDS73967.1; -. [P04637-9]
DR   CCDS; CCDS73968.1; -. [P04637-8]
DR   CCDS; CCDS73969.1; -. [P04637-4]
DR   CCDS; CCDS73970.1; -. [P04637-6]
DR   CCDS; CCDS73971.1; -. [P04637-5]
DR   PIR; A25224; DNHU53.
DR   RefSeq; NP_000537.3; NM_000546.5. [P04637-1]
DR   RefSeq; NP_001119584.1; NM_001126112.2. [P04637-1]
DR   RefSeq; NP_001119585.1; NM_001126113.2. [P04637-3]
DR   RefSeq; NP_001119586.1; NM_001126114.2. [P04637-2]
DR   RefSeq; NP_001119587.1; NM_001126115.1. [P04637-7]
DR   RefSeq; NP_001119588.1; NM_001126116.1. [P04637-8]
DR   RefSeq; NP_001119589.1; NM_001126117.1. [P04637-9]
DR   RefSeq; NP_001119590.1; NM_001126118.1. [P04637-4]
DR   RefSeq; NP_001263624.1; NM_001276695.1. [P04637-6]
DR   RefSeq; NP_001263625.1; NM_001276696.1. [P04637-5]
DR   RefSeq; NP_001263626.1; NM_001276697.1.
DR   RefSeq; NP_001263627.1; NM_001276698.1.
DR   RefSeq; NP_001263628.1; NM_001276699.1.
DR   RefSeq; NP_001263689.1; NM_001276760.1. [P04637-4]
DR   RefSeq; NP_001263690.1; NM_001276761.1. [P04637-4]
DR   UniGene; Hs.437460; -.
DR   UniGene; Hs.740601; -.
DR   PDB; 1A1U; NMR; -; A/C=324-358.
DR   PDB; 1AIE; X-ray; 1.50 A; A=326-356.
DR   PDB; 1C26; X-ray; 1.70 A; A=325-356.
DR   PDB; 1DT7; NMR; -; X/Y=367-388.
DR   PDB; 1GZH; X-ray; 2.60 A; A/C=95-292.
DR   PDB; 1H26; X-ray; 2.24 A; E=376-386.
DR   PDB; 1HS5; NMR; -; A/B=324-357.
DR   PDB; 1JSP; NMR; -; A=367-386.
DR   PDB; 1KZY; X-ray; 2.50 A; A/B=95-289.
DR   PDB; 1MA3; X-ray; 2.00 A; B=372-389.
DR   PDB; 1OLG; NMR; -; A/B/C/D=319-360.
DR   PDB; 1OLH; NMR; -; A/B/C/D=319-360.
DR   PDB; 1PES; NMR; -; A/B/C/D=325-355.
DR   PDB; 1PET; NMR; -; A/B/C/D=325-355.
DR   PDB; 1SAE; NMR; -; A/B/C/D=319-360.
DR   PDB; 1SAF; NMR; -; A/B/C/D=319-360.
DR   PDB; 1SAK; NMR; -; A/B/C/D=319-360.
DR   PDB; 1SAL; NMR; -; A/B/C/D=319-360.
DR   PDB; 1TSR; X-ray; 2.20 A; A/B/C=94-312.
DR   PDB; 1TUP; X-ray; 2.20 A; A/B/C=94-312.
DR   PDB; 1UOL; X-ray; 1.90 A; A/B=94-312.
DR   PDB; 1XQH; X-ray; 1.75 A; B/F=369-377.
DR   PDB; 1YC5; X-ray; 1.40 A; B=372-389.
DR   PDB; 1YCQ; X-ray; 2.30 A; B=13-29.
DR   PDB; 1YCR; X-ray; 2.60 A; B=15-29.
DR   PDB; 1YCS; X-ray; 2.20 A; A=94-292.
DR   PDB; 2AC0; X-ray; 1.80 A; A/B/C/D=94-293.
DR   PDB; 2ADY; X-ray; 2.50 A; A/B=94-293.
DR   PDB; 2AHI; X-ray; 1.85 A; A/B/C/D=94-293.
DR   PDB; 2ATA; X-ray; 2.20 A; A/B/C/D=94-293.
DR   PDB; 2B3G; X-ray; 1.60 A; B=33-60.
DR   PDB; 2BIM; X-ray; 1.98 A; A/B=94-312.
DR   PDB; 2BIN; X-ray; 1.90 A; A=94-312.
DR   PDB; 2BIO; X-ray; 1.90 A; A=94-312.
DR   PDB; 2BIP; X-ray; 1.80 A; A=94-312.
DR   PDB; 2BIQ; X-ray; 1.80 A; A=94-312.
DR   PDB; 2F1X; X-ray; 2.30 A; A/B=359-368.
DR   PDB; 2FEJ; NMR; -; A=94-297.
DR   PDB; 2FOJ; X-ray; 1.60 A; B=361-367.
DR   PDB; 2FOO; X-ray; 2.20 A; B=358-363.
DR   PDB; 2GS0; NMR; -; B=20-73.
DR   PDB; 2H1L; X-ray; 3.16 A; M/N/O/P/Q/R/S/T/U/V/W/X=92-292.
DR   PDB; 2H2D; X-ray; 1.70 A; B=372-389.
DR   PDB; 2H2F; X-ray; 2.20 A; B=372-389.
DR   PDB; 2H4F; X-ray; 2.00 A; D=372-389.
DR   PDB; 2H4H; X-ray; 1.99 A; B=372-389.
DR   PDB; 2H4J; X-ray; 2.10 A; D=372-389.
DR   PDB; 2H59; X-ray; 1.90 A; D/E=372-389.
DR   PDB; 2J0Z; NMR; -; A/B/C/D=326-356.
DR   PDB; 2J10; NMR; -; A/B/C/D=326-356.
DR   PDB; 2J11; NMR; -; A/B/C/D=326-356.
DR   PDB; 2J1W; X-ray; 1.80 A; A/B=94-312.
DR   PDB; 2J1X; X-ray; 1.65 A; A/B=94-312.
DR   PDB; 2J1Y; X-ray; 1.69 A; A/B/C/D=94-293.
DR   PDB; 2J1Z; X-ray; 1.80 A; A/B=94-312.
DR   PDB; 2J20; X-ray; 1.80 A; A/B=94-312.
DR   PDB; 2J21; X-ray; 1.60 A; A/B=94-312.
DR   PDB; 2K8F; NMR; -; B=1-39.
DR   PDB; 2L14; NMR; -; B=13-61.
DR   PDB; 2LY4; NMR; -; B=1-93.
DR   PDB; 2MEJ; NMR; -; B=96-312.
DR   PDB; 2MWO; NMR; -; B=363-377.
DR   PDB; 2MWP; NMR; -; B=376-387.
DR   PDB; 2MWY; NMR; -; B=15-29.
DR   PDB; 2MZD; NMR; -; B=35-59.
DR   PDB; 2OCJ; X-ray; 2.05 A; A/B/C/D=94-312.
DR   PDB; 2PCX; X-ray; 1.54 A; A=94-292.
DR   PDB; 2RUK; NMR; -; A=41-62.
DR   PDB; 2VUK; X-ray; 1.50 A; A/B=94-312.
DR   PDB; 2WGX; X-ray; 1.75 A; A/B=94-312.
DR   PDB; 2X0U; X-ray; 1.60 A; A/B=94-312.
DR   PDB; 2X0V; X-ray; 1.80 A; A/B=94-312.
DR   PDB; 2X0W; X-ray; 2.10 A; A/B=94-312.
DR   PDB; 2XWR; X-ray; 1.68 A; A/B=89-293.
DR   PDB; 2YBG; X-ray; 1.90 A; A/B/C/D=94-293.
DR   PDB; 2YDR; X-ray; 2.75 A; P=144-154.
DR   PDB; 2Z5S; X-ray; 2.30 A; P/Q/R=15-29.
DR   PDB; 2Z5T; X-ray; 2.30 A; P/Q/R=15-29.
DR   PDB; 3D05; X-ray; 1.70 A; A=94-293.
DR   PDB; 3D06; X-ray; 1.20 A; A=94-293.
DR   PDB; 3D07; X-ray; 2.20 A; A/B=94-293.
DR   PDB; 3D08; X-ray; 1.40 A; A=94-293.
DR   PDB; 3D09; X-ray; 1.90 A; A=94-293.
DR   PDB; 3D0A; X-ray; 1.80 A; A/B/C/D=94-293.
DR   PDB; 3DAB; X-ray; 1.90 A; B/D/F/H=15-29.
DR   PDB; 3DAC; X-ray; 1.80 A; B/P=17-37.
DR   PDB; 3IGK; X-ray; 1.70 A; A=94-293.
DR   PDB; 3IGL; X-ray; 1.80 A; A=94-293.
DR   PDB; 3KMD; X-ray; 2.15 A; A/B/C/D=92-291.
DR   PDB; 3KZ8; X-ray; 1.91 A; A/B=94-293.
DR   PDB; 3LW1; X-ray; 1.28 A; P=385-393.
DR   PDB; 3OQ5; X-ray; 2.50 A; D/E=377-386.
DR   PDB; 3PDH; X-ray; 1.80 A; D=372-389.
DR   PDB; 3Q01; X-ray; 2.10 A; A/B=94-356.
DR   PDB; 3Q05; X-ray; 2.40 A; A/B/C/D=94-356.
DR   PDB; 3Q06; X-ray; 3.20 A; A/B/C/D=96-354.
DR   PDB; 3SAK; NMR; -; A/B/C/D=319-360.
DR   PDB; 3TG5; X-ray; 2.30 A; B=365-375.
DR   PDB; 3TS8; X-ray; 2.80 A; A/B/C/D=94-356.
DR   PDB; 3ZME; X-ray; 1.35 A; A/B=94-312.
DR   PDB; 4AGL; X-ray; 1.70 A; A/B=94-312.
DR   PDB; 4AGM; X-ray; 1.52 A; A/B=94-312.
DR   PDB; 4AGN; X-ray; 1.60 A; A/B=94-312.
DR   PDB; 4AGO; X-ray; 1.45 A; A/B=94-312.
DR   PDB; 4AGP; X-ray; 1.50 A; A/B=94-312.
DR   PDB; 4AGQ; X-ray; 1.42 A; A/B=94-312.
DR   PDB; 4BUZ; X-ray; 1.90 A; P=379-386.
DR   PDB; 4BV2; X-ray; 3.30 A; E/H=376-388.
DR   PDB; 4HFZ; X-ray; 2.69 A; B/D=15-29.
DR   PDB; 4HJE; X-ray; 1.91 A; A/B/C/D=92-291.
DR   PDB; 4IBQ; X-ray; 1.80 A; A/B/C/D=94-293.
DR   PDB; 4IBS; X-ray; 1.78 A; A/B/C/D=94-293.
DR   PDB; 4IBT; X-ray; 1.70 A; A/B/C/D=94-293.
DR   PDB; 4IBU; X-ray; 1.70 A; A/B/C/D=94-293.
DR   PDB; 4IBV; X-ray; 2.10 A; A=94-293.
DR   PDB; 4IBW; X-ray; 1.79 A; A=94-293.
DR   PDB; 4IBY; X-ray; 1.45 A; A/B=94-293.
DR   PDB; 4IBZ; X-ray; 1.92 A; A/B/C/D=94-293.
DR   PDB; 4IJT; X-ray; 1.78 A; A=94-293.
DR   PDB; 4KVP; X-ray; 1.50 A; A/B/C/D=94-312.
DR   PDB; 4LO9; X-ray; 2.50 A; A/B/C/D=94-312.
DR   PDB; 4LOE; X-ray; 1.85 A; A/B/C/D=94-312.
DR   PDB; 4LOF; X-ray; 2.00 A; A=94-312.
DR   PDB; 4MZI; X-ray; 1.25 A; A=94-292.
DR   PDB; 4MZR; X-ray; 2.90 A; A/B/C/D=94-388.
DR   PDB; 4QO1; X-ray; 1.92 A; B=92-312.
DR   PDB; 4RP6; X-ray; 1.70 A; Z=252-258.
DR   PDB; 4RP7; X-ray; 1.58 A; Z=253-258.
DR   PDB; 4X34; X-ray; 1.80 A; C/D=377-386.
DR   PDB; 4XR8; X-ray; 2.25 A; C/D=94-292.
DR   PDB; 4ZZJ; X-ray; 2.74 A; B=379-383.
DR   PDB; 5A7B; X-ray; 1.40 A; A/B=94-312.
DR   PDB; 5AB9; X-ray; 1.36 A; A/B=94-312.
DR   PDB; 5ABA; X-ray; 1.62 A; A/B=94-312.
DR   PDB; 5AOI; X-ray; 1.78 A; A/B=94-312.
DR   PDB; 5AOJ; X-ray; 1.47 A; A/B=94-312.
DR   PDB; 5AOK; X-ray; 1.35 A; A/B=94-312.
DR   PDB; 5AOL; X-ray; 1.50 A; A/B=94-312.
DR   PDB; 5AOM; X-ray; 1.74 A; A/B=94-312.
DR   PDB; 5BUA; X-ray; 1.81 A; A=94-293.
DR   PDB; 5ECG; X-ray; 3.00 A; A/B=95-312.
DR   PDB; 5G4M; X-ray; 1.38 A; A/B=94-312.
DR   PDB; 5G4N; X-ray; 1.35 A; A/B=94-312.
DR   PDB; 5G4O; X-ray; 1.48 A; A/B=94-312.
DR   PDB; 5HOU; NMR; -; A=1-61.
DR   PDB; 5HP0; NMR; -; A=37-61.
DR   PDB; 5HPD; NMR; -; A=2-61.
DR   PDB; 5LAP; X-ray; 1.42 A; A/B=94-312.
DR   PDB; 5LGY; X-ray; 2.92 A; A/B/C/D=94-291.
DR   PDB; 5MHC; X-ray; 1.20 A; P=382-393.
DR   PDB; 5MOC; X-ray; 1.80 A; P=382-393.
DR   PDB; 5UN8; X-ray; 2.13 A; E/F/G/H=144-154.
DR   PDBsum; 1A1U; -.
DR   PDBsum; 1AIE; -.
DR   PDBsum; 1C26; -.
DR   PDBsum; 1DT7; -.
DR   PDBsum; 1GZH; -.
DR   PDBsum; 1H26; -.
DR   PDBsum; 1HS5; -.
DR   PDBsum; 1JSP; -.
DR   PDBsum; 1KZY; -.
DR   PDBsum; 1MA3; -.
DR   PDBsum; 1OLG; -.
DR   PDBsum; 1OLH; -.
DR   PDBsum; 1PES; -.
DR   PDBsum; 1PET; -.
DR   PDBsum; 1SAE; -.
DR   PDBsum; 1SAF; -.
DR   PDBsum; 1SAK; -.
DR   PDBsum; 1SAL; -.
DR   PDBsum; 1TSR; -.
DR   PDBsum; 1TUP; -.
DR   PDBsum; 1UOL; -.
DR   PDBsum; 1XQH; -.
DR   PDBsum; 1YC5; -.
DR   PDBsum; 1YCQ; -.
DR   PDBsum; 1YCR; -.
DR   PDBsum; 1YCS; -.
DR   PDBsum; 2AC0; -.
DR   PDBsum; 2ADY; -.
DR   PDBsum; 2AHI; -.
DR   PDBsum; 2ATA; -.
DR   PDBsum; 2B3G; -.
DR   PDBsum; 2BIM; -.
DR   PDBsum; 2BIN; -.
DR   PDBsum; 2BIO; -.
DR   PDBsum; 2BIP; -.
DR   PDBsum; 2BIQ; -.
DR   PDBsum; 2F1X; -.
DR   PDBsum; 2FEJ; -.
DR   PDBsum; 2FOJ; -.
DR   PDBsum; 2FOO; -.
DR   PDBsum; 2GS0; -.
DR   PDBsum; 2H1L; -.
DR   PDBsum; 2H2D; -.
DR   PDBsum; 2H2F; -.
DR   PDBsum; 2H4F; -.
DR   PDBsum; 2H4H; -.
DR   PDBsum; 2H4J; -.
DR   PDBsum; 2H59; -.
DR   PDBsum; 2J0Z; -.
DR   PDBsum; 2J10; -.
DR   PDBsum; 2J11; -.
DR   PDBsum; 2J1W; -.
DR   PDBsum; 2J1X; -.
DR   PDBsum; 2J1Y; -.
DR   PDBsum; 2J1Z; -.
DR   PDBsum; 2J20; -.
DR   PDBsum; 2J21; -.
DR   PDBsum; 2K8F; -.
DR   PDBsum; 2L14; -.
DR   PDBsum; 2LY4; -.
DR   PDBsum; 2MEJ; -.
DR   PDBsum; 2MWO; -.
DR   PDBsum; 2MWP; -.
DR   PDBsum; 2MWY; -.
DR   PDBsum; 2MZD; -.
DR   PDBsum; 2OCJ; -.
DR   PDBsum; 2PCX; -.
DR   PDBsum; 2RUK; -.
DR   PDBsum; 2VUK; -.
DR   PDBsum; 2WGX; -.
DR   PDBsum; 2X0U; -.
DR   PDBsum; 2X0V; -.
DR   PDBsum; 2X0W; -.
DR   PDBsum; 2XWR; -.
DR   PDBsum; 2YBG; -.
DR   PDBsum; 2YDR; -.
DR   PDBsum; 2Z5S; -.
DR   PDBsum; 2Z5T; -.
DR   PDBsum; 3D05; -.
DR   PDBsum; 3D06; -.
DR   PDBsum; 3D07; -.
DR   PDBsum; 3D08; -.
DR   PDBsum; 3D09; -.
DR   PDBsum; 3D0A; -.
DR   PDBsum; 3DAB; -.
DR   PDBsum; 3DAC; -.
DR   PDBsum; 3IGK; -.
DR   PDBsum; 3IGL; -.
DR   PDBsum; 3KMD; -.
DR   PDBsum; 3KZ8; -.
DR   PDBsum; 3LW1; -.
DR   PDBsum; 3OQ5; -.
DR   PDBsum; 3PDH; -.
DR   PDBsum; 3Q01; -.
DR   PDBsum; 3Q05; -.
DR   PDBsum; 3Q06; -.
DR   PDBsum; 3SAK; -.
DR   PDBsum; 3TG5; -.
DR   PDBsum; 3TS8; -.
DR   PDBsum; 3ZME; -.
DR   PDBsum; 4AGL; -.
DR   PDBsum; 4AGM; -.
DR   PDBsum; 4AGN; -.
DR   PDBsum; 4AGO; -.
DR   PDBsum; 4AGP; -.
DR   PDBsum; 4AGQ; -.
DR   PDBsum; 4BUZ; -.
DR   PDBsum; 4BV2; -.
DR   PDBsum; 4HFZ; -.
DR   PDBsum; 4HJE; -.
DR   PDBsum; 4IBQ; -.
DR   PDBsum; 4IBS; -.
DR   PDBsum; 4IBT; -.
DR   PDBsum; 4IBU; -.
DR   PDBsum; 4IBV; -.
DR   PDBsum; 4IBW; -.
DR   PDBsum; 4IBY; -.
DR   PDBsum; 4IBZ; -.
DR   PDBsum; 4IJT; -.
DR   PDBsum; 4KVP; -.
DR   PDBsum; 4LO9; -.
DR   PDBsum; 4LOE; -.
DR   PDBsum; 4LOF; -.
DR   PDBsum; 4MZI; -.
DR   PDBsum; 4MZR; -.
DR   PDBsum; 4QO1; -.
DR   PDBsum; 4RP6; -.
DR   PDBsum; 4RP7; -.
DR   PDBsum; 4X34; -.
DR   PDBsum; 4XR8; -.
DR   PDBsum; 4ZZJ; -.
DR   PDBsum; 5A7B; -.
DR   PDBsum; 5AB9; -.
DR   PDBsum; 5ABA; -.
DR   PDBsum; 5AOI; -.
DR   PDBsum; 5AOJ; -.
DR   PDBsum; 5AOK; -.
DR   PDBsum; 5AOL; -.
DR   PDBsum; 5AOM; -.
DR   PDBsum; 5BUA; -.
DR   PDBsum; 5ECG; -.
DR   PDBsum; 5G4M; -.
DR   PDBsum; 5G4N; -.
DR   PDBsum; 5G4O; -.
DR   PDBsum; 5HOU; -.
DR   PDBsum; 5HP0; -.
DR   PDBsum; 5HPD; -.
DR   PDBsum; 5LAP; -.
DR   PDBsum; 5LGY; -.
DR   PDBsum; 5MHC; -.
DR   PDBsum; 5MOC; -.
DR   PDBsum; 5UN8; -.
DR   DisProt; DP00086; -.
DR   ProteinModelPortal; P04637; -.
DR   SMR; P04637; -.
DR   BioGrid; 113010; 1038.
DR   CORUM; P04637; -.
DR   DIP; DIP-368N; -.
DR   ELM; P04637; -.
DR   IntAct; P04637; 463.
DR   MINT; P04637; -.
DR   STRING; 9606.ENSP00000269305; -.
DR   BindingDB; P04637; -.
DR   ChEMBL; CHEMBL4096; -.
DR   DrugBank; DB08363; 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine.
DR   DrugBank; DB00945; Acetylsalicylic acid.
DR   DrugBank; DB05404; AZD 3355.
DR   TCDB; 1.C.110.1.1; the pore-forming pnc-27 peptide of 32 aas from the p53 tumor suppressor protein (pnc-27) family.
DR   iPTMnet; P04637; -.
DR   PhosphoSitePlus; P04637; -.
DR   BioMuta; TP53; -.
DR   DMDM; 269849759; -.
DR   SWISS-2DPAGE; P04637; -.
DR   EPD; P04637; -.
DR   MaxQB; P04637; -.
DR   PaxDb; P04637; -.
DR   PeptideAtlas; P04637; -.
DR   PRIDE; P04637; -.
DR   DNASU; 7157; -.
DR   Ensembl; ENST00000269305; ENSP00000269305; ENSG00000141510. [P04637-1]
DR   Ensembl; ENST00000420246; ENSP00000391127; ENSG00000141510. [P04637-2]
DR   Ensembl; ENST00000445888; ENSP00000391478; ENSG00000141510. [P04637-1]
DR   Ensembl; ENST00000455263; ENSP00000398846; ENSG00000141510. [P04637-3]
DR   Ensembl; ENST00000504290; ENSP00000484409; ENSG00000141510. [P04637-9]
DR   Ensembl; ENST00000504937; ENSP00000481179; ENSG00000141510. [P04637-7]
DR   Ensembl; ENST00000510385; ENSP00000478499; ENSG00000141510. [P04637-8]
DR   Ensembl; ENST00000610292; ENSP00000478219; ENSG00000141510. [P04637-4]
DR   Ensembl; ENST00000610538; ENSP00000480868; ENSG00000141510. [P04637-6]
DR   Ensembl; ENST00000617185; ENSP00000482258; ENSG00000141510. [P04637-2]
DR   Ensembl; ENST00000619485; ENSP00000482537; ENSG00000141510. [P04637-4]
DR   Ensembl; ENST00000620739; ENSP00000481638; ENSG00000141510. [P04637-4]
DR   Ensembl; ENST00000622645; ENSP00000482222; ENSG00000141510. [P04637-5]
DR   GeneID; 7157; -.
DR   KEGG; hsa:7157; -.
DR   UCSC; uc002gij.4; human. [P04637-1]
DR   CTD; 7157; -.
DR   DisGeNET; 7157; -.
DR   EuPathDB; HostDB:ENSG00000141510.16; -.
DR   GeneCards; TP53; -.
DR   GeneReviews; TP53; -.
DR   HGNC; HGNC:11998; TP53.
DR   HPA; CAB002973; -.
DR   HPA; CAB039238; -.
DR   HPA; CAB039239; -.
DR   HPA; CAB072876; -.
DR   HPA; HPA051244; -.
DR   MalaCards; TP53; -.
DR   MIM; 133239; phenotype.
DR   MIM; 151623; phenotype.
DR   MIM; 191170; gene+phenotype.
DR   MIM; 202300; phenotype.
DR   MIM; 211980; phenotype.
DR   MIM; 260500; phenotype.
DR   MIM; 275355; phenotype.
DR   MIM; 614740; phenotype.
DR   neXtProt; NX_P04637; -.
DR   OpenTargets; ENSG00000141510; -.
DR   Orphanet; 1501; Adrenocortical carcinoma.
DR   Orphanet; 67038; B-cell chronic lymphocytic leukemia.
DR   Orphanet; 3318; Essential thrombocythemia.
DR   Orphanet; 1333; Familial pancreatic carcinoma.
DR   Orphanet; 251579; Giant cell glioblastoma.
DR   Orphanet; 251576; Gliosarcoma.
DR   Orphanet; 524; Li-Fraumeni syndrome.
DR   Orphanet; 2807; Papilloma of choroid plexus.
DR   Orphanet; 99860; Precursor B-cell acute lymphoblastic leukemia.
DR   PharmGKB; PA36679; -.
DR   eggNOG; ENOG410IITK; Eukaryota.
DR   eggNOG; ENOG410ZSWV; LUCA.
DR   GeneTree; ENSGT00390000015092; -.
DR   HOVERGEN; HBG005201; -.
DR   InParanoid; P04637; -.
DR   KO; K04451; -.
DR   OMA; PATSWPL; -.
DR   OrthoDB; EOG091G0XY5; -.
DR   PhylomeDB; P04637; -.
DR   TreeFam; TF106101; -.
DR   Reactome; R-HSA-111448; Activation of NOXA and translocation to mitochondria.
DR   Reactome; R-HSA-139915; Activation of PUMA and translocation to mitochondria.
DR   Reactome; R-HSA-1912408; Pre-NOTCH Transcription and Translation.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-2559584; Formation of Senescence-Associated Heterochromatin Foci (SAHF).
DR   Reactome; R-HSA-2559585; Oncogene Induced Senescence.
DR   Reactome; R-HSA-2559586; DNA Damage/Telomere Stress Induced Senescence.
DR   Reactome; R-HSA-3232118; SUMOylation of transcription factors.
DR   Reactome; R-HSA-349425; Autodegradation of the E3 ubiquitin ligase COP1.
DR   Reactome; R-HSA-390471; Association of TriC/CCT with target proteins during biosynthesis.
DR   Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-5689896; Ovarian tumor domain proteases.
DR   Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks.
DR   Reactome; R-HSA-6785807; Interleukin-4 and 13 signaling.
DR   Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes.
DR   Reactome; R-HSA-6803204; TP53 Regulates Transcription of Genes Involved in Cytochrome C Release.
DR   Reactome; R-HSA-6803205; TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain.
DR   Reactome; R-HSA-6803207; TP53 Regulates Transcription of Caspase Activators and Caspases.
DR   Reactome; R-HSA-6803211; TP53 Regulates Transcription of Death Receptors and Ligands.
DR   Reactome; R-HSA-6804114; TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest.
DR   Reactome; R-HSA-6804115; TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain.
DR   Reactome; R-HSA-6804116; TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest.
DR   Reactome; R-HSA-6804754; Regulation of TP53 Expression.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-HSA-6804757; Regulation of TP53 Degradation.
DR   Reactome; R-HSA-6804758; Regulation of TP53 Activity through Acetylation.
DR   Reactome; R-HSA-6804759; Regulation of TP53 Activity through Association with Co-factors.
DR   Reactome; R-HSA-6804760; Regulation of TP53 Activity through Methylation.
DR   Reactome; R-HSA-6811555; PI5P Regulates TP53 Acetylation.
DR   Reactome; R-HSA-69473; G2/M DNA damage checkpoint.
DR   Reactome; R-HSA-69481; G2/M Checkpoints.
DR   Reactome; R-HSA-69541; Stabilization of p53.
DR   Reactome; R-HSA-69895; Transcriptional activation of cell cycle inhibitor p21.
DR   Reactome; R-HSA-8852276; The role of GTSE1 in G2/M progression after G2 checkpoint.
DR   Reactome; R-HSA-8941855; RUNX3 regulates CDKN1A transcription.
DR   Reactome; R-HSA-8943724; Regulation of PTEN gene transcription.
DR   Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production.
DR   SignaLink; P04637; -.
DR   SIGNOR; P04637; -.
DR   ChiTaRS; TP53; human.
DR   EvolutionaryTrace; P04637; -.
DR   GeneWiki; P53; -.
DR   GenomeRNAi; 7157; -.
DR   PMAP-CutDB; P04637; -.
DR   PRO; PR:P04637; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000141510; -.
DR   ExpressionAtlas; P04637; baseline and differential.
DR   Genevisible; P04637; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0005622; C:intracellular; IDA:CAFA.
DR   GO; GO:0005759; C:mitochondrial matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:BHF-UCL.
DR   GO; GO:0016363; C:nuclear matrix; IDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IDA:UniProtKB.
DR   GO; GO:0043234; C:protein complex; IDA:CAFA.
DR   GO; GO:0005657; C:replication fork; IBA:GO_Central.
DR   GO; GO:0005667; C:transcription factor complex; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0051087; F:chaperone binding; IPI:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0005507; F:copper ion binding; IDA:UniProtKB.
DR   GO; GO:0001046; F:core promoter sequence-specific DNA binding; IDA:CAFA.
DR   GO; GO:0003684; F:damaged DNA binding; IBA:GO_Central.
DR   GO; GO:0097718; F:disordered domain specific binding; IPI:CAFA.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0035035; F:histone acetyltransferase binding; IPI:UniProtKB.
DR   GO; GO:0042826; F:histone deacetylase binding; IPI:CAFA.
DR   GO; GO:0042802; F:identical protein binding; IMP:CAFA.
DR   GO; GO:0097371; F:MDM2/MDM4 family protein binding; IEA:Ensembl.
DR   GO; GO:0003730; F:mRNA 3'-UTR binding; IDA:CAFA.
DR   GO; GO:0002039; F:p53 binding; IPI:CAFA.
DR   GO; GO:0002020; F:protease binding; IPI:UniProtKB.
DR   GO; GO:0008022; F:protein C-terminus binding; IEA:Ensembl.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0047485; F:protein N-terminus binding; IPI:UniProtKB.
DR   GO; GO:0051721; F:protein phosphatase 2A binding; IPI:UniProtKB.
DR   GO; GO:0019903; F:protein phosphatase binding; IPI:UniProtKB.
DR   GO; GO:0043621; F:protein self-association; IPI:AgBase.
DR   GO; GO:0030971; F:receptor tyrosine kinase binding; IPI:BHF-UCL.
DR   GO; GO:0000977; F:RNA polymerase II regulatory region sequence-specific DNA binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0000981; F:RNA polymerase II transcription factor activity, sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0001085; F:RNA polymerase II transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0001221; F:transcription cofactor binding; IEA:Ensembl.
DR   GO; GO:0000990; F:transcription factor activity, core RNA polymerase binding; IDA:CAFA.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IDA:BHF-UCL.
DR   GO; GO:0001228; F:transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding; IDA:BHF-UCL.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; TAS:UniProtKB.
DR   GO; GO:0006914; P:autophagy; IMP:CAFA.
DR   GO; GO:0006284; P:base-excision repair; TAS:UniProtKB.
DR   GO; GO:0007569; P:cell aging; IMP:UniProtKB.
DR   GO; GO:0007050; P:cell cycle arrest; IDA:BHF-UCL.
DR   GO; GO:0030154; P:cell differentiation; TAS:UniProtKB.
DR   GO; GO:0008283; P:cell proliferation; TAS:UniProtKB.
DR   GO; GO:0034613; P:cellular protein localization; IDA:UniProtKB.
DR   GO; GO:0072717; P:cellular response to actinomycin D; IDA:CAFA.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0035690; P:cellular response to drug; IEP:UniProtKB.
DR   GO; GO:0071480; P:cellular response to gamma radiation; IDA:CAFA.
DR   GO; GO:0042149; P:cellular response to glucose starvation; IDA:UniProtKB.
DR   GO; GO:0034605; P:cellular response to heat; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEP:UniProtKB.
DR   GO; GO:0071479; P:cellular response to ionizing radiation; IMP:BHF-UCL.
DR   GO; GO:0034614; P:cellular response to reactive oxygen species; IEA:Ensembl.
DR   GO; GO:0034644; P:cellular response to UV; IDA:CAFA.
DR   GO; GO:0031497; P:chromatin assembly; IDA:UniProtKB.
DR   GO; GO:0048512; P:circadian behavior; ISS:UniProtKB.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0008340; P:determination of adult lifespan; ISS:BHF-UCL.
DR   GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; IDA:BHF-UCL.
DR   GO; GO:0006977; P:DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; IMP:CAFA.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; IDA:CAFA.
DR   GO; GO:0000733; P:DNA strand renaturation; IDA:UniProtKB.
DR   GO; GO:0043153; P:entrainment of circadian clock by photoperiod; ISS:UniProtKB.
DR   GO; GO:0006983; P:ER overload response; IDA:MGI.
DR   GO; GO:0097193; P:intrinsic apoptotic signaling pathway; TAS:HGNC.
DR   GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; IMP:UniProtKB.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; IDA:UniProtKB.
DR   GO; GO:0031571; P:mitotic G1 DNA damage checkpoint; IMP:BHF-UCL.
DR   GO; GO:0009299; P:mRNA transcription; IMP:UniProtKB.
DR   GO; GO:0007275; P:multicellular organism development; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; IMP:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:CACAO.
DR   GO; GO:0048147; P:negative regulation of fibroblast proliferation; IMP:UniProtKB.
DR   GO; GO:0051097; P:negative regulation of helicase activity; TAS:UniProtKB.
DR   GO; GO:0048662; P:negative regulation of smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0051974; P:negative regulation of telomerase activity; IDA:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0006289; P:nucleotide-excision repair; IMP:UniProtKB.
DR   GO; GO:0097252; P:oligodendrocyte apoptotic process; IDA:UniProtKB.
DR   GO; GO:0090403; P:oxidative stress-induced premature senescence; IMP:BHF-UCL.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0071158; P:positive regulation of cell cycle arrest; IDA:CAFA.
DR   GO; GO:1900119; P:positive regulation of execution phase of apoptosis; IMP:AgBase.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:CAFA.
DR   GO; GO:0031065; P:positive regulation of histone deacetylation; IBA:GO_Central.
DR   GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0002687; P:positive regulation of leukocyte migration; IEA:Ensembl.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IBA:GO_Central.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; ISS:BHF-UCL.
DR   GO; GO:1902895; P:positive regulation of pri-miRNA transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0046827; P:positive regulation of protein export from nucleus; TAS:Reactome.
DR   GO; GO:1900740; P:positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0032461; P:positive regulation of protein oligomerization; IDA:UniProtKB.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IMP:BHF-UCL.
DR   GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; IDA:UniProtKB.
DR   GO; GO:0070245; P:positive regulation of thymocyte apoptotic process; ISS:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:1990440; P:positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; TAS:Reactome.
DR   GO; GO:0006461; P:protein complex assembly; IDA:UniProtKB.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0051289; P:protein homotetramerization; IMP:CAFA.
DR   GO; GO:0008104; P:protein localization; IDA:UniProtKB.
DR   GO; GO:0051262; P:protein tetramerization; TAS:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; IEP:BHF-UCL.
DR   GO; GO:0042981; P:regulation of apoptotic process; IDA:MGI.
DR   GO; GO:1902749; P:regulation of cell cycle G2/M phase transition; TAS:Reactome.
DR   GO; GO:1903205; P:regulation of hydrogen peroxide-induced cell death; IEA:Ensembl.
DR   GO; GO:0051453; P:regulation of intracellular pH; IEA:Ensembl.
DR   GO; GO:0046902; P:regulation of mitochondrial membrane permeability; TAS:UniProtKB.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0090399; P:replicative senescence; IMP:BHF-UCL.
DR   GO; GO:0043200; P:response to amino acid; IEA:Ensembl.
DR   GO; GO:0046677; P:response to antibiotic; IEP:UniProtKB.
DR   GO; GO:0031000; P:response to caffeine; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0010332; P:response to gamma radiation; IMP:BHF-UCL.
DR   GO; GO:0055093; P:response to hyperoxia; IEA:Ensembl.
DR   GO; GO:0010038; P:response to metal ion; IEA:Ensembl.
DR   GO; GO:0032526; P:response to retinoic acid; IEA:Ensembl.
DR   GO; GO:0010224; P:response to UV-B; IEA:Ensembl.
DR   GO; GO:0033552; P:response to vitamin B3; IEA:Ensembl.
DR   GO; GO:0010165; P:response to X-ray; IBA:GO_Central.
DR   GO; GO:0072331; P:signal transduction by p53 class mediator; IDA:CAFA.
DR   GO; GO:0016032; P:viral process; IMP:CACAO.
DR   GO; GO:0042060; P:wound healing; IEA:Ensembl.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR036674; p53_tetramer_sf.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR013872; p53_transactivation_domain.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF08563; P53_TAD; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
DR   PROSITE; PS00348; P53; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative promoter usage;
KW   Alternative splicing; Apoptosis; Biological rhythms; Cell cycle;
KW   Complete proteome; Cytoplasm; Disease mutation; DNA-binding;
KW   Endoplasmic reticulum; Glycoprotein; Host-virus interaction;
KW   Isopeptide bond; Li-Fraumeni syndrome; Metal-binding; Methylation;
KW   Mitochondrion; Necrosis; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repressor; Transcription;
KW   Transcription regulation; Tumor suppressor; Ubl conjugation; Zinc.
FT   CHAIN         1    393       Cellular tumor antigen p53.
FT                                /FTId=PRO_0000185703.
FT   DNA_BIND    102    292
FT   REGION        1    320       Interaction with CCAR2.
FT                                {ECO:0000269|PubMed:25732823}.
FT   REGION        1     83       Interaction with HRMT1L2.
FT                                {ECO:0000269|PubMed:15186775}.
FT   REGION        1     44       Transcription activation (acidic).
FT   REGION       66    110       Interaction with WWOX.
FT   REGION      100    370       Interaction with HIPK1. {ECO:0000250}.
FT   REGION      100    300       Required for interaction with ZNF385A.
FT                                {ECO:0000269|PubMed:17719541}.
FT   REGION      113    236       Required for interaction with FBXO42.
FT                                {ECO:0000269|PubMed:19509332}.
FT   REGION      116    292       Interaction with AXIN1. {ECO:0000250}.
FT   REGION      241    248       Interaction with the 53BP2 SH3 domain.
FT   REGION      256    294       Interaction with E4F1.
FT                                {ECO:0000269|PubMed:10644996}.
FT   REGION      273    280       Interaction with DNA.
FT   REGION      300    393       Interaction with CARM1.
FT                                {ECO:0000269|PubMed:15186775}.
FT   REGION      319    360       Interaction with HIPK2.
FT   REGION      325    356       Oligomerization.
FT   REGION      359    363       Interaction with USP7.
FT   REGION      368    387       Basic (repression of DNA-binding).
FT   MOTIF        17     25       TADI.
FT   MOTIF        48     56       TADII.
FT   MOTIF       305    321       Bipartite nuclear localization signal.
FT   MOTIF       339    350       Nuclear export signal.
FT   MOTIF       370    372       [KR]-[STA]-K motif.
FT   METAL       176    176       Zinc.
FT   METAL       179    179       Zinc.
FT   METAL       238    238       Zinc.
FT   METAL       242    242       Zinc.
FT   SITE        120    120       Interaction with DNA.
FT   MOD_RES       9      9       Phosphoserine; by HIPK4.
FT                                {ECO:0000269|PubMed:18022393}.
FT   MOD_RES      15     15       Phosphoserine; by CDK5, PRPK, AMPK, NUAK1
FT                                and ATM. {ECO:0000269|PubMed:10570149,
FT                                ECO:0000269|PubMed:11554766,
FT                                ECO:0000269|PubMed:15701641,
FT                                ECO:0000269|PubMed:15866171,
FT                                ECO:0000269|PubMed:17108107,
FT                                ECO:0000269|PubMed:17591690,
FT                                ECO:0000269|PubMed:17967874,
FT                                ECO:0000269|PubMed:21317932}.
FT   MOD_RES      18     18       Phosphothreonine; by CK1, VRK1 and VRK2.
FT                                {ECO:0000269|PubMed:10606744,
FT                                ECO:0000269|PubMed:10951572,
FT                                ECO:0000269|PubMed:16704422}.
FT   MOD_RES      20     20       Phosphoserine; by CHEK2, CK1 and PLK3.
FT                                {ECO:0000269|PubMed:10570149,
FT                                ECO:0000269|PubMed:11447225,
FT                                ECO:0000269|PubMed:11551930,
FT                                ECO:0000269|PubMed:12810724,
FT                                ECO:0000269|PubMed:20041275}.
FT   MOD_RES      33     33       Phosphoserine; by CDK5 and CDK7.
FT                                {ECO:0000269|PubMed:17591690,
FT                                ECO:0000269|PubMed:9372954}.
FT   MOD_RES      37     37       Phosphoserine; by MAPKAPK5.
FT                                {ECO:0000269|PubMed:17254968}.
FT   MOD_RES      46     46       Phosphoserine; by CDK5, DYRK2, HIPK2 and
FT                                PKC/PRKCG. {ECO:0000269|PubMed:11740489,
FT                                ECO:0000269|PubMed:11780126,
FT                                ECO:0000269|PubMed:16377624,
FT                                ECO:0000269|PubMed:17349958,
FT                                ECO:0000269|PubMed:17591690}.
FT   MOD_RES      55     55       Phosphothreonine; by TAF1 and GRK5.
FT                                {ECO:0000269|PubMed:15053879,
FT                                ECO:0000269|PubMed:20124405}.
FT   MOD_RES     120    120       N6-acetyllysine; by KAT6A.
FT                                {ECO:0000269|PubMed:23431171}.
FT   MOD_RES     183    183       Phosphoserine; by AURKB.
FT                                {ECO:0000269|PubMed:20959462}.
FT   MOD_RES     269    269       Phosphoserine; by AURKB.
FT                                {ECO:0000269|PubMed:20959462}.
FT   MOD_RES     284    284       Phosphothreonine; by AURKB.
FT                                {ECO:0000269|PubMed:20959462}.
FT   MOD_RES     305    305       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:12724314}.
FT   MOD_RES     315    315       Phosphoserine; by AURKA, CDK1 and CDK2.
FT                                {ECO:0000269|PubMed:10884347,
FT                                ECO:0000269|PubMed:14702041}.
FT   MOD_RES     321    321       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P02340}.
FT   MOD_RES     370    370       N6,N6-dimethyllysine; alternate.
FT                                {ECO:0000269|PubMed:17108971,
FT                                ECO:0000269|PubMed:22864287}.
FT   MOD_RES     370    370       N6-methyllysine; by SMYD2; alternate.
FT                                {ECO:0000269|PubMed:17108971,
FT                                ECO:0000269|PubMed:22864287}.
FT   MOD_RES     372    372       N6-methyllysine; by SETD7.
FT                                {ECO:0000269|PubMed:15525938,
FT                                ECO:0000269|PubMed:16415881}.
FT   MOD_RES     373    373       N6,N6-dimethyllysine; by EHMT1 and EHMT2;
FT                                alternate. {ECO:0000269|PubMed:20118233}.
FT   MOD_RES     373    373       N6-acetyllysine; alternate.
FT                                {ECO:0000269|PubMed:10656795}.
FT   MOD_RES     381    381       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     382    382       N6,N6-dimethyllysine; alternate.
FT                                {ECO:0000269|PubMed:17707234,
FT                                ECO:0000269|PubMed:20870725,
FT                                ECO:0000269|PubMed:22864287}.
FT   MOD_RES     382    382       N6-acetyllysine; by KAT6A; alternate.
FT                                {ECO:0000244|PubMed:19608861,
FT                                ECO:0000269|PubMed:10656795,
FT                                ECO:0000269|PubMed:20228809,
FT                                ECO:0000269|PubMed:23431171}.
FT   MOD_RES     382    382       N6-methyllysine; by KMT5A; alternate.
FT                                {ECO:0000269|PubMed:17707234,
FT                                ECO:0000269|PubMed:20870725,
FT                                ECO:0000269|PubMed:22864287}.
FT   MOD_RES     392    392       Phosphoserine; by CK2, CDK2 and NUAK1.
FT                                {ECO:0000269|PubMed:10884347,
FT                                ECO:0000269|PubMed:11239457,
FT                                ECO:0000269|PubMed:17108107,
FT                                ECO:0000269|PubMed:21317932,
FT                                ECO:0000269|PubMed:22214662}.
FT   CROSSLNK    291    291       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:19536131}.
FT   CROSSLNK    292    292       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:19536131}.
FT   CROSSLNK    386    386       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000269|PubMed:11124955,
FT                                ECO:0000269|PubMed:22214662,
FT                                ECO:0000269|Ref.35}.
FT   VAR_SEQ       1    132       Missing (in isoform 7, isoform 8 and
FT                                isoform 9).
FT                                {ECO:0000303|PubMed:16131611}.
FT                                /FTId=VSP_040833.
FT   VAR_SEQ       1     39       Missing (in isoform 4, isoform 5 and
FT                                isoform 6). {ECO:0000305}.
FT                                /FTId=VSP_040832.
FT   VAR_SEQ     332    346       IRGRERFEMFRELNE -> MLLDLRWCYFLINSS (in
FT                                isoform 3, isoform 6 and isoform 9).
FT                                {ECO:0000303|PubMed:16131611}.
FT                                /FTId=VSP_040560.
FT   VAR_SEQ     332    341       IRGRERFEMF -> DQTSFQKENC (in isoform 2,
FT                                isoform 5 and isoform 8).
FT                                {ECO:0000303|PubMed:16131611}.
FT                                /FTId=VSP_006535.
FT   VAR_SEQ     342    393       Missing (in isoform 2, isoform 5 and
FT                                isoform 8).
FT                                {ECO:0000303|PubMed:16131611}.
FT                                /FTId=VSP_006536.
FT   VAR_SEQ     347    393       Missing (in isoform 3, isoform 6 and
FT                                isoform 9).
FT                                {ECO:0000303|PubMed:16131611}.
FT                                /FTId=VSP_040561.
FT   VARIANT       5      5       Q -> H (in a sporadic cancer; somatic
FT                                mutation; abolishes strongly
FT                                phosphorylation).
FT                                /FTId=VAR_044543.
FT   VARIANT       6      6       S -> L (in a sporadic cancer; somatic
FT                                mutation; reduces interaction with
FT                                ZNF385A).
FT                                /FTId=VAR_044544.
FT   VARIANT       7      7       D -> H (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs587782646).
FT                                /FTId=VAR_005851.
FT   VARIANT       8      8       P -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044545.
FT   VARIANT      10     10       V -> I (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs535274413).
FT                                /FTId=VAR_044546.
FT   VARIANT      11     11       E -> K (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs201382018).
FT                                /FTId=VAR_044547.
FT   VARIANT      11     11       E -> Q (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs201382018).
FT                                /FTId=VAR_044548.
FT   VARIANT      15     15       S -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044549.
FT   VARIANT      16     16       Q -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044550.
FT   VARIANT      17     17       E -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044551.
FT   VARIANT      24     24       K -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044552.
FT   VARIANT      28     28       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044553.
FT   VARIANT      29     30       NN -> KD (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047158.
FT   VARIANT      31     31       V -> I (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs201753350).
FT                                /FTId=VAR_044554.
FT   VARIANT      33     33       S -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044555.
FT   VARIANT      34     34       P -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044556.
FT   VARIANT      35     35       L -> F (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs121912661).
FT                                /FTId=VAR_005852.
FT   VARIANT      36     36       P -> L (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs587781866).
FT                                /FTId=VAR_044557.
FT   VARIANT      37     37       S -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044558.
FT   VARIANT      37     37       S -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044559.
FT   VARIANT      39     39       A -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044560.
FT   VARIANT      39     39       A -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044561.
FT   VARIANT      42     42       D -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044562.
FT   VARIANT      43     43       L -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_005853.
FT   VARIANT      44     44       M -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044563.
FT   VARIANT      44     44       M -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044564.
FT   VARIANT      44     44       M -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044565.
FT   VARIANT      45     45       L -> M (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044566.
FT   VARIANT      46     46       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044567.
FT   VARIANT      46     46       S -> P (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs876659630).
FT                                /FTId=VAR_044568.
FT   VARIANT      47     47       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044569.
FT   VARIANT      47     47       P -> S (in dbSNP:rs1800371).
FT                                {ECO:0000269|Ref.12}.
FT                                /FTId=VAR_014632.
FT   VARIANT      48     48       D -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044570.
FT   VARIANT      49     49       D -> H (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587780728).
FT                                /FTId=VAR_044571.
FT   VARIANT      49     49       D -> N (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs587780728).
FT                                /FTId=VAR_044572.
FT   VARIANT      49     49       D -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044573.
FT   VARIANT      52     52       Q -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044574.
FT   VARIANT      53     53       W -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005854.
FT   VARIANT      53     53       W -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044575.
FT   VARIANT      54     54       F -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044576.
FT   VARIANT      54     54       F -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044577.
FT   VARIANT      56     56       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044578.
FT   VARIANT      56     56       E -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044579.
FT   VARIANT      58     58       P -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044580.
FT   VARIANT      58     58       P -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044581.
FT   VARIANT      59     59       G -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044582.
FT   VARIANT      59     59       G -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044583.
FT   VARIANT      59     59       G -> N (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045783.
FT   VARIANT      60     60       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044584.
FT   VARIANT      60     60       P -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044585.
FT   VARIANT      60     60       P -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_005855.
FT   VARIANT      61     61       D -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044586.
FT   VARIANT      61     61       D -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044587.
FT   VARIANT      62     62       E -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044588.
FT   VARIANT      63     63       A -> T (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs876658902).
FT                                /FTId=VAR_044589.
FT   VARIANT      63     63       A -> V (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs372201428).
FT                                /FTId=VAR_044590.
FT   VARIANT      65     65       R -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044591.
FT   VARIANT      66     66       M -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044592.
FT   VARIANT      66     66       M -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044593.
FT   VARIANT      67     67       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044594.
FT   VARIANT      67     67       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044595.
FT   VARIANT      67     67       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044596.
FT   VARIANT      68     68       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044597.
FT   VARIANT      68     68       E -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044598.
FT   VARIANT      69     69       A -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044599.
FT   VARIANT      69     69       A -> G (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs756233241).
FT                                /FTId=VAR_044600.
FT   VARIANT      69     69       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044601.
FT   VARIANT      69     69       A -> V (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs756233241).
FT                                /FTId=VAR_044602.
FT   VARIANT      70     70       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044603.
FT   VARIANT      71     71       P -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044604.
FT   VARIANT      72     72       P -> C (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions; dbSNP:rs730882014).
FT                                /FTId=VAR_045784.
FT   VARIANT      72     72       P -> G (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045785.
FT   VARIANT      72     72       P -> H (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs1042522).
FT                                /FTId=VAR_045786.
FT   VARIANT      72     72       P -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045787.
FT   VARIANT      72     72       P -> R (in dbSNP:rs1042522).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:16131611,
FT                                ECO:0000269|PubMed:1999338,
FT                                ECO:0000269|Ref.17}.
FT                                /FTId=VAR_005856.
FT   VARIANT      73     73       V -> E (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044605.
FT   VARIANT      73     73       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044606.
FT   VARIANT      73     73       V -> M (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587782423).
FT                                /FTId=VAR_044607.
FT   VARIANT      74     74       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044608.
FT   VARIANT      75     75       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044609.
FT   VARIANT      75     75       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044610.
FT   VARIANT      75     75       P -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044611.
FT   VARIANT      76     76       A -> G (in a sporadic cancer; somatic
FT                                mutation). {ECO:0000269|PubMed:2946935}.
FT                                /FTId=VAR_044612.
FT   VARIANT      76     76       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044613.
FT   VARIANT      77     77       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044614.
FT   VARIANT      78     78       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044615.
FT   VARIANT      79     79       A -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044616.
FT   VARIANT      79     79       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_005857.
FT   VARIANT      79     79       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044617.
FT   VARIANT      80     80       P -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044618.
FT   VARIANT      80     80       P -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044619.
FT   VARIANT      81     81       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044620.
FT   VARIANT      82     82       P -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs534447939).
FT                                /FTId=VAR_044621.
FT   VARIANT      82     82       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044622.
FT   VARIANT      83     83       A -> E (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs201717599).
FT                                /FTId=VAR_044623.
FT   VARIANT      83     83       A -> V (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs201717599).
FT                                /FTId=VAR_044624.
FT   VARIANT      84     84       A -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044625.
FT   VARIANT      84     84       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044626.
FT   VARIANT      85     85       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044627.
FT   VARIANT      85     85       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044628.
FT   VARIANT      86     86       A -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044629.
FT   VARIANT      87     87       P -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005858.
FT   VARIANT      88     88       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044630.
FT   VARIANT      88     88       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044631.
FT   VARIANT      89     89       P -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs730881994).
FT                                /FTId=VAR_044632.
FT   VARIANT      89     89       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044633.
FT   VARIANT      90     90       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044634.
FT   VARIANT      90     90       S -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044635.
FT   VARIANT      91     91       W -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044636.
FT   VARIANT      92     92       P -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044637.
FT   VARIANT      92     92       P -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044638.
FT   VARIANT      92     92       P -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044639.
FT   VARIANT      93     93       L -> M (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044640.
FT   VARIANT      93     93       L -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044641.
FT   VARIANT      94     94       S -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044642.
FT   VARIANT      94     94       S -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005859.
FT   VARIANT      95     95       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044643.
FT   VARIANT      95     95       S -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044644.
FT   VARIANT      96     96       S -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044645.
FT   VARIANT      96     96       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044646.
FT   VARIANT      96     96       S -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044647.
FT   VARIANT      97     97       V -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044648.
FT   VARIANT      97     97       V -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044649.
FT   VARIANT      97     97       V -> I (in familial cancer not matching
FT                                LFS; germline mutation and in a sporadic
FT                                cancer; somatic mutation).
FT                                /FTId=VAR_044650.
FT   VARIANT      98     98       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044651.
FT   VARIANT      98     98       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044652.
FT   VARIANT      99     99       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044653.
FT   VARIANT      99     99       S -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044654.
FT   VARIANT     100    100       Q -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044655.
FT   VARIANT     101    101       K -> N (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs878854069).
FT                                /FTId=VAR_044656.
FT   VARIANT     101    101       K -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044657.
FT   VARIANT     102    102       T -> I (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786202717).
FT                                /FTId=VAR_044658.
FT   VARIANT     104    104       Q -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044659.
FT   VARIANT     104    104       Q -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044660.
FT   VARIANT     105    105       G -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044661.
FT   VARIANT     105    105       G -> D (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587781504).
FT                                /FTId=VAR_044662.
FT   VARIANT     105    105       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044663.
FT   VARIANT     105    105       G -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044664.
FT   VARIANT     105    105       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044665.
FT   VARIANT     106    106       S -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044666.
FT   VARIANT     106    106       S -> R (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_044667.
FT   VARIANT     107    107       Y -> C (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs587782447).
FT                                /FTId=VAR_044668.
FT   VARIANT     107    107       Y -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044669.
FT   VARIANT     107    107       Y -> H (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs368771578).
FT                                /FTId=VAR_044670.
FT   VARIANT     108    108       G -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044671.
FT   VARIANT     108    108       G -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587782461).
FT                                /FTId=VAR_044672.
FT   VARIANT     109    109       F -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044673.
FT   VARIANT     109    109       F -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044674.
FT   VARIANT     109    109       F -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044675.
FT   VARIANT     110    110       R -> C (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587781371).
FT                                /FTId=VAR_005860.
FT   VARIANT     110    110       R -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044676.
FT   VARIANT     110    110       R -> H (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs11540654).
FT                                /FTId=VAR_044677.
FT   VARIANT     110    110       R -> L (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation; does not
FT                                induce SNAI1 degradation;
FT                                dbSNP:rs11540654).
FT                                {ECO:0000269|PubMed:20385133}.
FT                                /FTId=VAR_005861.
FT   VARIANT     110    110       R -> P (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs11540654).
FT                                {ECO:0000269|PubMed:17224074}.
FT                                /FTId=VAR_005862.
FT   VARIANT     110    110       R -> S (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs587781371).
FT                                /FTId=VAR_044678.
FT   VARIANT     111    111       L -> M (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044679.
FT   VARIANT     111    111       L -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044680.
FT   VARIANT     111    111       L -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044681.
FT   VARIANT     111    111       L -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044682.
FT   VARIANT     112    112       G -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044683.
FT   VARIANT     112    112       G -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044684.
FT   VARIANT     113    113       F -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005863.
FT   VARIANT     113    113       F -> G (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045788.
FT   VARIANT     113    113       F -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044685.
FT   VARIANT     113    113       F -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044686.
FT   VARIANT     113    113       F -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044687.
FT   VARIANT     113    113       F -> V (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587781642).
FT                                {ECO:0000269|PubMed:17224074}.
FT                                /FTId=VAR_033033.
FT   VARIANT     115    115       H -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044688.
FT   VARIANT     116    116       S -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044689.
FT   VARIANT     116    116       S -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044690.
FT   VARIANT     116    116       S -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044691.
FT   VARIANT     117    117       G -> E (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs755238756).
FT                                /FTId=VAR_044692.
FT   VARIANT     117    117       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044693.
FT   VARIANT     118    118       T -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044694.
FT   VARIANT     118    118       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044695.
FT   VARIANT     118    118       T -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044696.
FT   VARIANT     119    119       A -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044697.
FT   VARIANT     119    119       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044698.
FT   VARIANT     120    120       K -> E (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs121912658).
FT                                /FTId=VAR_044699.
FT   VARIANT     120    120       K -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044700.
FT   VARIANT     120    120       K -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044701.
FT   VARIANT     120    120       K -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044702.
FT   VARIANT     121    121       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044703.
FT   VARIANT     122    122       V -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044704.
FT   VARIANT     123    123       T -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044705.
FT   VARIANT     123    123       T -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044706.
FT   VARIANT     124    124       C -> G (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs730881997).
FT                                /FTId=VAR_044707.
FT   VARIANT     124    124       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044708.
FT   VARIANT     124    124       C -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs730881997).
FT                                /FTId=VAR_044709.
FT   VARIANT     124    124       C -> W (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044710.
FT   VARIANT     124    124       C -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044711.
FT   VARIANT     125    125       T -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044712.
FT   VARIANT     125    125       T -> K (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786201057).
FT                                /FTId=VAR_044713.
FT   VARIANT     125    125       T -> M (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786201057).
FT                                /FTId=VAR_005864.
FT   VARIANT     125    125       T -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044714.
FT   VARIANT     125    125       T -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044715.
FT   VARIANT     126    126       Y -> C (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_044716.
FT   VARIANT     126    126       Y -> D (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs886039483).
FT                                /FTId=VAR_005865.
FT   VARIANT     126    126       Y -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044717.
FT   VARIANT     126    126       Y -> G (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045789.
FT   VARIANT     126    126       Y -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044718.
FT   VARIANT     126    126       Y -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005866.
FT   VARIANT     126    126       Y -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044719.
FT   VARIANT     127    127       S -> C (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs730881999).
FT                                /FTId=VAR_044720.
FT   VARIANT     127    127       S -> F (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs730881999).
FT                                /FTId=VAR_005867.
FT   VARIANT     127    127       S -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044721.
FT   VARIANT     127    127       S -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044722.
FT   VARIANT     127    127       S -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044723.
FT   VARIANT     128    128       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044724.
FT   VARIANT     128    128       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044725.
FT   VARIANT     128    128       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044726.
FT   VARIANT     128    128       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005868.
FT   VARIANT     129    129       A -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005869.
FT   VARIANT     129    129       A -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044727.
FT   VARIANT     129    129       A -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044728.
FT   VARIANT     129    129       A -> V (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs137852792).
FT                                /FTId=VAR_044729.
FT   VARIANT     130    130       L -> F (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs863224683).
FT                                /FTId=VAR_044730.
FT   VARIANT     130    130       L -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044731.
FT   VARIANT     130    130       L -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044732.
FT   VARIANT     130    130       L -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044733.
FT   VARIANT     130    130       L -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005870.
FT   VARIANT     130    130       L -> V (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs863224683).
FT                                /FTId=VAR_044734.
FT   VARIANT     131    131       N -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044735.
FT   VARIANT     131    131       N -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044736.
FT   VARIANT     131    131       N -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044737.
FT   VARIANT     131    131       N -> K (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs769270327).
FT                                /FTId=VAR_005872.
FT   VARIANT     131    131       N -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005871.
FT   VARIANT     131    131       N -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044738.
FT   VARIANT     131    131       N -> Y (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587782160).
FT                                /FTId=VAR_044739.
FT   VARIANT     132    133       KM -> NL (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047159.
FT   VARIANT     132    132       K -> E (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs747342068).
FT                                /FTId=VAR_044740.
FT   VARIANT     132    132       K -> L (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045790.
FT   VARIANT     132    132       K -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005873.
FT   VARIANT     132    132       K -> N (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs866775781).
FT                                /FTId=VAR_044741.
FT   VARIANT     132    132       K -> Q (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:1694291}.
FT                                /FTId=VAR_005874.
FT   VARIANT     132    132       K -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044742.
FT   VARIANT     132    132       K -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044743.
FT   VARIANT     132    132       K -> W (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045791.
FT   VARIANT     133    133       M -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044744.
FT   VARIANT     133    133       M -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044745.
FT   VARIANT     133    133       M -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044746.
FT   VARIANT     133    133       M -> R (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044747.
FT   VARIANT     133    133       M -> T (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934873).
FT                                {ECO:0000269|PubMed:1933902}.
FT                                /FTId=VAR_005875.
FT   VARIANT     133    133       M -> V (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs1057280220).
FT                                /FTId=VAR_044748.
FT   VARIANT     134    134       F -> C (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs780442292).
FT                                /FTId=VAR_044749.
FT   VARIANT     134    134       F -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044750.
FT   VARIANT     134    134       F -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs267605077).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036504.
FT   VARIANT     134    134       F -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044751.
FT   VARIANT     134    134       F -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044752.
FT   VARIANT     135    135       C -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005877.
FT   VARIANT     135    135       C -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044753.
FT   VARIANT     135    135       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044754.
FT   VARIANT     135    135       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005876.
FT   VARIANT     135    135       C -> T (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045792.
FT   VARIANT     135    135       C -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044755.
FT   VARIANT     135    135       C -> Y (in sporadic cancers; somatic
FT                                mutation; decreased E6-mediated binding
FT                                to E6-AP; dbSNP:rs587781991).
FT                                /FTId=VAR_044756.
FT   VARIANT     136    136       Q -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005878.
FT   VARIANT     136    136       Q -> H (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs758781593).
FT                                /FTId=VAR_044757.
FT   VARIANT     136    136       Q -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_005879.
FT   VARIANT     136    136       Q -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044758.
FT   VARIANT     136    136       Q -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044759.
FT   VARIANT     137    137       L -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044760.
FT   VARIANT     137    137       L -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044761.
FT   VARIANT     137    137       L -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005880.
FT   VARIANT     137    137       L -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044762.
FT   VARIANT     138    138       A -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044763.
FT   VARIANT     138    138       A -> P (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934875).
FT                                /FTId=VAR_005881.
FT   VARIANT     138    138       A -> S (in LFS; germline mutation).
FT                                /FTId=VAR_044764.
FT   VARIANT     138    138       A -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044765.
FT   VARIANT     138    138       A -> V (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs750600586).
FT                                {ECO:0000269|PubMed:17224074}.
FT                                /FTId=VAR_033034.
FT   VARIANT     139    139       K -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044766.
FT   VARIANT     139    139       K -> N (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:14660794}.
FT                                /FTId=VAR_005882.
FT   VARIANT     139    139       K -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044767.
FT   VARIANT     139    139       K -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044768.
FT   VARIANT     139    139       K -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044769.
FT   VARIANT     140    140       T -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044770.
FT   VARIANT     140    140       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044771.
FT   VARIANT     140    140       T -> N (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs786202561).
FT                                /FTId=VAR_044772.
FT   VARIANT     140    140       T -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044773.
FT   VARIANT     140    140       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044774.
FT   VARIANT     141    141       C -> A (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045793.
FT   VARIANT     141    141       C -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005885.
FT   VARIANT     141    141       C -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005884.
FT   VARIANT     141    141       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044775.
FT   VARIANT     141    141       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044776.
FT   VARIANT     141    141       C -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044777.
FT   VARIANT     141    141       C -> Y (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs587781288).
FT                                /FTId=VAR_005886.
FT   VARIANT     142    142       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044778.
FT   VARIANT     142    142       P -> F (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045794.
FT   VARIANT     142    142       P -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044779.
FT   VARIANT     142    142       P -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs779196500).
FT                                /FTId=VAR_044780.
FT   VARIANT     142    142       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044781.
FT   VARIANT     142    142       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044782.
FT   VARIANT     142    142       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044783.
FT   VARIANT     143    143       V -> A (in sporadic cancers; somatic
FT                                mutation; strong DNA binding ability at
FT                                32.5 degrees Celsius; strong reduction of
FT                                transcriptional activity at 37.5 degrees
FT                                Celsius; severely represses interaction
FT                                with ZNF385A).
FT                                {ECO:0000269|PubMed:17719541,
FT                                ECO:0000269|PubMed:8013454}.
FT                                /FTId=VAR_005887.
FT   VARIANT     143    143       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044784.
FT   VARIANT     143    143       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044785.
FT   VARIANT     143    143       V -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587782620).
FT                                /FTId=VAR_044786.
FT   VARIANT     143    143       V -> M (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587782620).
FT                                /FTId=VAR_044787.
FT   VARIANT     144    144       Q -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044788.
FT   VARIANT     144    144       Q -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044789.
FT   VARIANT     144    144       Q -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044790.
FT   VARIANT     144    144       Q -> P (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786203071).
FT                                /FTId=VAR_005888.
FT   VARIANT     144    144       Q -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044791.
FT   VARIANT     145    145       L -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044792.
FT   VARIANT     145    145       L -> P (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587782197).
FT                                /FTId=VAR_005889.
FT   VARIANT     145    145       L -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005890.
FT   VARIANT     145    145       L -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044793.
FT   VARIANT     145    145       L -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044794.
FT   VARIANT     146    146       W -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044795.
FT   VARIANT     146    146       W -> G (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786203064).
FT                                /FTId=VAR_044796.
FT   VARIANT     146    146       W -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044797.
FT   VARIANT     146    146       W -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044798.
FT   VARIANT     146    146       W -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044799.
FT   VARIANT     147    147       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044800.
FT   VARIANT     147    147       V -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005891.
FT   VARIANT     147    147       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044801.
FT   VARIANT     147    147       V -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044802.
FT   VARIANT     147    147       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005892.
FT   VARIANT     147    147       V -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044803.
FT   VARIANT     148    148       D -> A (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs1046611742).
FT                                /FTId=VAR_044804.
FT   VARIANT     148    148       D -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044805.
FT   VARIANT     148    148       D -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044806.
FT   VARIANT     148    148       D -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044807.
FT   VARIANT     148    148       D -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044808.
FT   VARIANT     148    148       D -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044809.
FT   VARIANT     149    149       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044810.
FT   VARIANT     149    149       S -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005893.
FT   VARIANT     149    149       S -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044811.
FT   VARIANT     150    150       T -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044812.
FT   VARIANT     150    150       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044813.
FT   VARIANT     150    150       T -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044814.
FT   VARIANT     150    150       T -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044815.
FT   VARIANT     150    150       T -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044816.
FT   VARIANT     150    150       T -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044817.
FT   VARIANT     151    151       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005894.
FT   VARIANT     151    151       P -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044818.
FT   VARIANT     151    151       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044819.
FT   VARIANT     151    151       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044820.
FT   VARIANT     151    151       P -> S (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934874).
FT                                {ECO:0000269|PubMed:7682763}.
FT                                /FTId=VAR_005895.
FT   VARIANT     151    151       P -> T (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934874).
FT                                /FTId=VAR_005896.
FT   VARIANT     152    152       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044821.
FT   VARIANT     152    152       P -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs587782705).
FT                                {ECO:0000269|PubMed:1868473}.
FT                                /FTId=VAR_005897.
FT   VARIANT     152    152       P -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044822.
FT   VARIANT     152    152       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044823.
FT   VARIANT     152    152       P -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs767328513).
FT                                {ECO:0000269|PubMed:9450901}.
FT                                /FTId=VAR_005898.
FT   VARIANT     152    152       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044824.
FT   VARIANT     153    153       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044825.
FT   VARIANT     153    153       P -> F (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045795.
FT   VARIANT     153    153       P -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044826.
FT   VARIANT     153    153       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044827.
FT   VARIANT     153    153       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044828.
FT   VARIANT     153    153       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044829.
FT   VARIANT     153    153       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005899.
FT   VARIANT     154    154       G -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044830.
FT   VARIANT     154    154       G -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044831.
FT   VARIANT     154    154       G -> D (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs762846821).
FT                                /FTId=VAR_044832.
FT   VARIANT     154    154       G -> I (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045796.
FT   VARIANT     154    154       G -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs137852789).
FT                                /FTId=VAR_044833.
FT   VARIANT     154    154       G -> V (in a brain tumor with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                {ECO:0000269|PubMed:2263646}.
FT                                /FTId=VAR_005900.
FT   VARIANT     155    155       T -> A (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs772683278).
FT                                {ECO:0000269|PubMed:1868473}.
FT                                /FTId=VAR_005901.
FT   VARIANT     155    155       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044834.
FT   VARIANT     155    155       T -> M (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044835.
FT   VARIANT     155    155       T -> N (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044836.
FT   VARIANT     155    155       T -> P (in sporadic cancers; somatic
FT                                mutation; does not induce SNAI1
FT                                degradation).
FT                                {ECO:0000269|PubMed:14660794,
FT                                ECO:0000269|PubMed:20385133}.
FT                                /FTId=VAR_044837.
FT   VARIANT     155    155       T -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786202752).
FT                                /FTId=VAR_044838.
FT   VARIANT     156    156       R -> C (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs563378859).
FT                                /FTId=VAR_044839.
FT   VARIANT     156    156       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044840.
FT   VARIANT     156    156       R -> H (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs371524413).
FT                                /FTId=VAR_044841.
FT   VARIANT     156    156       R -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044842.
FT   VARIANT     156    156       R -> P (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:7682763}.
FT                                /FTId=VAR_005902.
FT   VARIANT     156    156       R -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044843.
FT   VARIANT     157    157       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044844.
FT   VARIANT     157    157       V -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005903.
FT   VARIANT     157    157       V -> F (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs121912654).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_005904.
FT   VARIANT     157    157       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044845.
FT   VARIANT     157    157       V -> I (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs121912654).
FT                                {ECO:0000269|PubMed:9419979}.
FT                                /FTId=VAR_012977.
FT   VARIANT     157    157       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044846.
FT   VARIANT     158    158       R -> C (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587780068).
FT                                /FTId=VAR_005905.
FT   VARIANT     158    158       R -> F (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045797.
FT   VARIANT     158    158       R -> G (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005906.
FT   VARIANT     158    158       R -> H (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs587782144).
FT                                /FTId=VAR_005907.
FT   VARIANT     158    158       R -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044847.
FT   VARIANT     158    158       R -> P (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587782144).
FT                                /FTId=VAR_044848.
FT   VARIANT     158    158       R -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044849.
FT   VARIANT     158    158       R -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044850.
FT   VARIANT     158    158       R -> Y (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045798.
FT   VARIANT     159    159       A -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044851.
FT   VARIANT     159    159       A -> F (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions; dbSNP:rs730882022).
FT                                /FTId=VAR_045799.
FT   VARIANT     159    159       A -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044852.
FT   VARIANT     159    159       A -> P (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs730882000).
FT                                /FTId=VAR_044853.
FT   VARIANT     159    159       A -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044854.
FT   VARIANT     159    159       A -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044855.
FT   VARIANT     159    159       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044856.
FT   VARIANT     160    161       MA -> IP (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047160.
FT   VARIANT     160    161       MA -> IS (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047161.
FT   VARIANT     160    161       MA -> IT (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047162.
FT   VARIANT     160    160       M -> I (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs772354334).
FT                                /FTId=VAR_005908.
FT   VARIANT     160    160       M -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044857.
FT   VARIANT     160    160       M -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044858.
FT   VARIANT     160    160       M -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044859.
FT   VARIANT     161    161       A -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044860.
FT   VARIANT     161    161       A -> F (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045800.
FT   VARIANT     161    161       A -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044861.
FT   VARIANT     161    161       A -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044862.
FT   VARIANT     161    161       A -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005909.
FT   VARIANT     161    161       A -> T (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs193920817).
FT                                /FTId=VAR_044863.
FT   VARIANT     161    161       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044864.
FT   VARIANT     162    162       I -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044865.
FT   VARIANT     162    162       I -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044866.
FT   VARIANT     162    162       I -> N (in a breast cancer with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044867.
FT   VARIANT     162    162       I -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587780069).
FT                                /FTId=VAR_005910.
FT   VARIANT     162    162       I -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044868.
FT   VARIANT     162    162       I -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005911.
FT   VARIANT     163    163       Y -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs148924904).
FT                                {ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:17224074}.
FT                                /FTId=VAR_033035.
FT   VARIANT     163    163       Y -> D (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786203436).
FT                                /FTId=VAR_044869.
FT   VARIANT     163    163       Y -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044870.
FT   VARIANT     163    163       Y -> H (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:17224074}.
FT                                /FTId=VAR_005912.
FT   VARIANT     163    163       Y -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044871.
FT   VARIANT     163    163       Y -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044872.
FT   VARIANT     164    164       K -> E (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs879254249).
FT                                /FTId=VAR_044873.
FT   VARIANT     164    164       K -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044874.
FT   VARIANT     164    164       K -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005913.
FT   VARIANT     164    164       K -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005914.
FT   VARIANT     164    164       K -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044875.
FT   VARIANT     164    164       K -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044876.
FT   VARIANT     165    165       Q -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044877.
FT   VARIANT     165    165       Q -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044878.
FT   VARIANT     165    165       Q -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005915.
FT   VARIANT     165    165       Q -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044879.
FT   VARIANT     165    165       Q -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005916.
FT   VARIANT     166    166       S -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044880.
FT   VARIANT     166    166       S -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044881.
FT   VARIANT     166    166       S -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005917.
FT   VARIANT     166    166       S -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044882.
FT   VARIANT     166    166       S -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044883.
FT   VARIANT     167    168       QH -> HD (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047163.
FT   VARIANT     167    168       QH -> YL (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047164.
FT   VARIANT     167    167       Q -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044884.
FT   VARIANT     167    167       Q -> K (in LFS; germline mutation and in
FT                                a sporadic cancer; somatic mutation).
FT                                /FTId=VAR_044885.
FT   VARIANT     167    167       Q -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044886.
FT   VARIANT     167    167       Q -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044887.
FT   VARIANT     168    169       HM -> LI (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047165.
FT   VARIANT     168    168       H -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044888.
FT   VARIANT     168    168       H -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044889.
FT   VARIANT     168    168       H -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044890.
FT   VARIANT     168    168       H -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044891.
FT   VARIANT     168    168       H -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044892.
FT   VARIANT     168    168       H -> R (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs867114783).
FT                                /FTId=VAR_005918.
FT   VARIANT     168    168       H -> V (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045801.
FT   VARIANT     168    168       H -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044893.
FT   VARIANT     169    170       MT -> IS (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047166.
FT   VARIANT     169    169       M -> I (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:9450901}.
FT                                /FTId=VAR_005919.
FT   VARIANT     169    169       M -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044894.
FT   VARIANT     169    169       M -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005920.
FT   VARIANT     169    169       M -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044895.
FT   VARIANT     170    170       T -> A (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587780729).
FT                                /FTId=VAR_044896.
FT   VARIANT     170    170       T -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044897.
FT   VARIANT     170    170       T -> M (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs779000871).
FT                                /FTId=VAR_005921.
FT   VARIANT     170    170       T -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044898.
FT   VARIANT     170    170       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005922.
FT   VARIANT     171    171       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044899.
FT   VARIANT     171    171       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044900.
FT   VARIANT     171    171       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044901.
FT   VARIANT     171    171       E -> K (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587781845).
FT                                /FTId=VAR_044902.
FT   VARIANT     171    171       E -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044903.
FT   VARIANT     171    171       E -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044904.
FT   VARIANT     172    172       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005923.
FT   VARIANT     172    172       V -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044905.
FT   VARIANT     172    172       V -> F (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_044906.
FT   VARIANT     172    172       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044907.
FT   VARIANT     172    172       V -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044908.
FT   VARIANT     173    173       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044909.
FT   VARIANT     173    173       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005924.
FT   VARIANT     173    173       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044910.
FT   VARIANT     173    173       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005925.
FT   VARIANT     173    173       V -> M (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs876660754).
FT                                /FTId=VAR_005926.
FT   VARIANT     173    173       V -> W (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045802.
FT   VARIANT     174    174       R -> G (in LFS; germline mutation and in
FT                                a sporadic cancer; somatic mutation;
FT                                dbSNP:rs864622115).
FT                                /FTId=VAR_044911.
FT   VARIANT     174    174       R -> K (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:7682763}.
FT                                /FTId=VAR_005927.
FT   VARIANT     174    174       R -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044912.
FT   VARIANT     174    174       R -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044913.
FT   VARIANT     174    174       R -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044914.
FT   VARIANT     174    174       R -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044915.
FT   VARIANT     175    175       R -> C (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs138729528).
FT                                /FTId=VAR_005928.
FT   VARIANT     175    175       R -> G (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs138729528).
FT                                /FTId=VAR_005929.
FT   VARIANT     175    175       R -> H (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation; does
FT                                not induce SNAI1 degradation; reduces
FT                                interaction with ZNF385A;
FT                                dbSNP:rs28934578).
FT                                {ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:17719541,
FT                                ECO:0000269|PubMed:1868473,
FT                                ECO:0000269|PubMed:20385133,
FT                                ECO:0000269|PubMed:7887414,
FT                                ECO:0000269|PubMed:8825920}.
FT                                /FTId=VAR_005932.
FT   VARIANT     175    175       R -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934578).
FT                                /FTId=VAR_005930.
FT   VARIANT     175    175       R -> P (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:17719541}.
FT                                /FTId=VAR_005931.
FT   VARIANT     175    175       R -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044916.
FT   VARIANT     175    175       R -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044917.
FT   VARIANT     176    177       CP -> FS (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047167.
FT   VARIANT     176    176       C -> F (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:1394225,
FT                                ECO:0000269|PubMed:1868473,
FT                                ECO:0000269|PubMed:8829627,
FT                                ECO:0000269|PubMed:9450901}.
FT                                /FTId=VAR_005933.
FT   VARIANT     176    176       C -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044918.
FT   VARIANT     176    176       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044919.
FT   VARIANT     176    176       C -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs967461896).
FT                                /FTId=VAR_044920.
FT   VARIANT     176    176       C -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005934.
FT   VARIANT     176    176       C -> Y (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786202962).
FT                                /FTId=VAR_044921.
FT   VARIANT     177    177       P -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044922.
FT   VARIANT     177    177       P -> F (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045803.
FT   VARIANT     177    177       P -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044923.
FT   VARIANT     177    177       P -> I (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045804.
FT   VARIANT     177    177       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005935.
FT   VARIANT     177    177       P -> R (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs751477326).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036505.
FT   VARIANT     177    177       P -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs147002414).
FT                                /FTId=VAR_044924.
FT   VARIANT     177    177       P -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044925.
FT   VARIANT     178    179       HH -> QS (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047168.
FT   VARIANT     178    178       H -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044926.
FT   VARIANT     178    178       H -> HPHP (in a Burkitt lymphoma).
FT                                {ECO:0000269|PubMed:1303181}.
FT                                /FTId=VAR_005936.
FT   VARIANT     178    178       H -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044927.
FT   VARIANT     178    178       H -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044928.
FT   VARIANT     178    178       H -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044929.
FT   VARIANT     178    178       H -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044930.
FT   VARIANT     178    178       H -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044931.
FT   VARIANT     178    178       H -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044932.
FT   VARIANT     179    179       H -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044933.
FT   VARIANT     179    179       H -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044934.
FT   VARIANT     179    179       H -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044935.
FT   VARIANT     179    179       H -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044936.
FT   VARIANT     179    179       H -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044937.
FT   VARIANT     179    179       H -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044938.
FT   VARIANT     179    179       H -> Y (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs587780070).
FT                                /FTId=VAR_044939.
FT   VARIANT     180    180       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044940.
FT   VARIANT     180    180       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044941.
FT   VARIANT     180    180       E -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044942.
FT   VARIANT     180    180       E -> K (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs879253911).
FT                                /FTId=VAR_044943.
FT   VARIANT     180    180       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044944.
FT   VARIANT     180    180       E -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044945.
FT   VARIANT     181    181       R -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs587782596).
FT                                /FTId=VAR_044946.
FT   VARIANT     181    181       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044947.
FT   VARIANT     181    181       R -> H (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs397514495).
FT                                /FTId=VAR_044948.
FT   VARIANT     181    181       R -> L (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation;
FT                                dbSNP:rs397514495).
FT                                /FTId=VAR_005937.
FT   VARIANT     181    181       R -> P (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_044949.
FT   VARIANT     181    181       R -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587782596).
FT                                /FTId=VAR_044950.
FT   VARIANT     182    182       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044951.
FT   VARIANT     182    182       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005938.
FT   VARIANT     182    182       C -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044952.
FT   VARIANT     183    183       S -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044953.
FT   VARIANT     183    183       S -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044954.
FT   VARIANT     184    184       D -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044955.
FT   VARIANT     184    184       D -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044956.
FT   VARIANT     184    184       D -> N (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs72661117).
FT                                /FTId=VAR_047169.
FT   VARIANT     184    184       D -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044957.
FT   VARIANT     184    184       D -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005939.
FT   VARIANT     185    185       S -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044958.
FT   VARIANT     185    185       S -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044959.
FT   VARIANT     185    185       S -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044960.
FT   VARIANT     185    185       S -> N (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs150607408).
FT                                /FTId=VAR_044961.
FT   VARIANT     185    185       S -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044962.
FT   VARIANT     185    185       S -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044963.
FT   VARIANT     186    186       D -> E (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs375275361).
FT                                /FTId=VAR_044964.
FT   VARIANT     186    186       D -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044965.
FT   VARIANT     186    186       D -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044966.
FT   VARIANT     186    186       D -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044967.
FT   VARIANT     186    186       D -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044968.
FT   VARIANT     186    186       D -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_005940.
FT   VARIANT     187    187       G -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005941.
FT   VARIANT     187    187       G -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044969.
FT   VARIANT     187    187       G -> N (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045805.
FT   VARIANT     187    187       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044970.
FT   VARIANT     187    187       G -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs776167460).
FT                                /FTId=VAR_005942.
FT   VARIANT     187    187       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044971.
FT   VARIANT     188    188       L -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044972.
FT   VARIANT     188    188       L -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044973.
FT   VARIANT     189    189       A -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044974.
FT   VARIANT     189    189       A -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044975.
FT   VARIANT     189    189       A -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005943.
FT   VARIANT     189    189       A -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044976.
FT   VARIANT     189    189       A -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044977.
FT   VARIANT     189    189       A -> V (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation;
FT                                dbSNP:rs121912665).
FT                                /FTId=VAR_044978.
FT   VARIANT     190    190       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044979.
FT   VARIANT     190    190       P -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044980.
FT   VARIANT     190    190       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005944.
FT   VARIANT     190    190       P -> R (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs876660825).
FT                                /FTId=VAR_044981.
FT   VARIANT     190    190       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044982.
FT   VARIANT     190    190       P -> T (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs876660254).
FT                                /FTId=VAR_044983.
FT   VARIANT     191    191       P -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044984.
FT   VARIANT     191    191       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044985.
FT   VARIANT     191    191       P -> R (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587778718).
FT                                /FTId=VAR_044986.
FT   VARIANT     191    191       P -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs868590738).
FT                                /FTId=VAR_044987.
FT   VARIANT     191    191       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005945.
FT   VARIANT     192    193       QH -> HN (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047170.
FT   VARIANT     192    193       QH -> HY (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047171.
FT   VARIANT     192    192       Q -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044988.
FT   VARIANT     192    192       Q -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_044989.
FT   VARIANT     192    192       Q -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044990.
FT   VARIANT     192    192       Q -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044991.
FT   VARIANT     192    192       Q -> R (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs730882002).
FT                                /FTId=VAR_005946.
FT   VARIANT     193    193       H -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005947.
FT   VARIANT     193    193       H -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786201838).
FT                                /FTId=VAR_044992.
FT   VARIANT     193    193       H -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044993.
FT   VARIANT     193    193       H -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044994.
FT   VARIANT     193    193       H -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044995.
FT   VARIANT     193    193       H -> R (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs786201838).
FT                                {ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:7887414}.
FT                                /FTId=VAR_005948.
FT   VARIANT     193    193       H -> Y (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs876658468).
FT                                /FTId=VAR_044996.
FT   VARIANT     194    194       L -> F (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587780071).
FT                                /FTId=VAR_044997.
FT   VARIANT     194    194       L -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044998.
FT   VARIANT     194    194       L -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_044999.
FT   VARIANT     194    194       L -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005949.
FT   VARIANT     194    194       L -> R (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:7682763}.
FT                                /FTId=VAR_005950.
FT   VARIANT     194    194       L -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045000.
FT   VARIANT     195    195       I -> F (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs942158624).
FT                                /FTId=VAR_045001.
FT   VARIANT     195    195       I -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047172.
FT   VARIANT     195    195       I -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045002.
FT   VARIANT     195    195       I -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045003.
FT   VARIANT     195    195       I -> T (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs760043106).
FT                                {ECO:0000269|PubMed:17224074,
FT                                ECO:0000269|PubMed:9450901}.
FT                                /FTId=VAR_005951.
FT   VARIANT     195    195       I -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045004.
FT   VARIANT     195    195       I -> Y (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045806.
FT   VARIANT     196    196       R -> G (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs397516435).
FT                                /FTId=VAR_045005.
FT   VARIANT     196    196       R -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs483352697).
FT                                /FTId=VAR_045006.
FT   VARIANT     196    196       R -> P (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs483352697).
FT                                /FTId=VAR_045007.
FT   VARIANT     196    196       R -> Q (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs483352697).
FT                                /FTId=VAR_045008.
FT   VARIANT     196    196       R -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045009.
FT   VARIANT     197    197       V -> E (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_045010.
FT   VARIANT     197    197       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045011.
FT   VARIANT     197    197       V -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786204041).
FT                                /FTId=VAR_045012.
FT   VARIANT     197    197       V -> M (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs786204041).
FT                                /FTId=VAR_045013.
FT   VARIANT     198    198       E -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045014.
FT   VARIANT     198    198       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045015.
FT   VARIANT     198    198       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005952.
FT   VARIANT     198    198       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045016.
FT   VARIANT     198    198       E -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045017.
FT   VARIANT     199    199       G -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045018.
FT   VARIANT     199    199       G -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045019.
FT   VARIANT     199    199       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045020.
FT   VARIANT     199    199       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045021.
FT   VARIANT     200    200       N -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045022.
FT   VARIANT     200    200       N -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045023.
FT   VARIANT     200    200       N -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045024.
FT   VARIANT     200    200       N -> P (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045807.
FT   VARIANT     200    200       N -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045025.
FT   VARIANT     200    200       N -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045026.
FT   VARIANT     201    202       LR -> FC (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047173.
FT   VARIANT     201    201       L -> F (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs730882024).
FT                                /FTId=VAR_045027.
FT   VARIANT     201    201       L -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045028.
FT   VARIANT     201    201       L -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045029.
FT   VARIANT     202    202       R -> C (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587780072).
FT                                /FTId=VAR_045030.
FT   VARIANT     202    202       R -> G (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587780072).
FT                                /FTId=VAR_045031.
FT   VARIANT     202    202       R -> H (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587778719).
FT                                /FTId=VAR_045032.
FT   VARIANT     202    202       R -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587778719).
FT                                /FTId=VAR_045033.
FT   VARIANT     202    202       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045034.
FT   VARIANT     202    202       R -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045035.
FT   VARIANT     203    204       VE -> LV (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047174.
FT   VARIANT     203    203       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045036.
FT   VARIANT     203    203       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045037.
FT   VARIANT     203    203       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045038.
FT   VARIANT     203    203       V -> M (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs730882003).
FT                                /FTId=VAR_045039.
FT   VARIANT     203    203       V -> W (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045808.
FT   VARIANT     204    204       E -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045040.
FT   VARIANT     204    204       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045041.
FT   VARIANT     204    204       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045042.
FT   VARIANT     204    204       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045043.
FT   VARIANT     204    204       E -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045044.
FT   VARIANT     204    204       E -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045045.
FT   VARIANT     205    205       Y -> C (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:1459726}.
FT                                /FTId=VAR_005953.
FT   VARIANT     205    205       Y -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005954.
FT   VARIANT     205    205       Y -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047175.
FT   VARIANT     205    205       Y -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045046.
FT   VARIANT     205    205       Y -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045047.
FT   VARIANT     205    205       Y -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045048.
FT   VARIANT     206    206       L -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045049.
FT   VARIANT     206    206       L -> M (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045050.
FT   VARIANT     207    208       DD -> EY (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047176.
FT   VARIANT     207    207       D -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045051.
FT   VARIANT     207    207       D -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045052.
FT   VARIANT     207    207       D -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045053.
FT   VARIANT     207    207       D -> N (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs923100890).
FT                                /FTId=VAR_045054.
FT   VARIANT     207    207       D -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045055.
FT   VARIANT     207    207       D -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045056.
FT   VARIANT     208    208       D -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045057.
FT   VARIANT     208    208       D -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045058.
FT   VARIANT     208    208       D -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045059.
FT   VARIANT     208    208       D -> I (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045809.
FT   VARIANT     208    208       D -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045060.
FT   VARIANT     208    208       D -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045061.
FT   VARIANT     208    208       D -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045062.
FT   VARIANT     209    209       R -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045063.
FT   VARIANT     209    209       R -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045064.
FT   VARIANT     209    209       R -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045065.
FT   VARIANT     209    209       R -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045066.
FT   VARIANT     210    210       N -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045067.
FT   VARIANT     210    210       N -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045068.
FT   VARIANT     210    210       N -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045069.
FT   VARIANT     210    210       N -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045070.
FT   VARIANT     210    210       N -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045071.
FT   VARIANT     210    210       N -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045072.
FT   VARIANT     210    210       N -> Y (in a familial cancer not matching
FT                                LFS; germline mutation).
FT                                /FTId=VAR_045073.
FT   VARIANT     211    211       T -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045074.
FT   VARIANT     211    211       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045075.
FT   VARIANT     211    211       T -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045076.
FT   VARIANT     211    211       T -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045077.
FT   VARIANT     211    211       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045078.
FT   VARIANT     212    212       F -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045079.
FT   VARIANT     212    212       F -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045080.
FT   VARIANT     212    212       F -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045081.
FT   VARIANT     212    212       F -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045082.
FT   VARIANT     212    212       F -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045083.
FT   VARIANT     213    213       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045084.
FT   VARIANT     213    213       R -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045085.
FT   VARIANT     213    213       R -> P (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs587778720).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036506.
FT   VARIANT     213    213       R -> Q (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs587778720).
FT                                /FTId=VAR_005955.
FT   VARIANT     213    213       R -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045086.
FT   VARIANT     214    214       H -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045087.
FT   VARIANT     214    214       H -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045088.
FT   VARIANT     214    214       H -> Q (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587781386).
FT                                /FTId=VAR_047177.
FT   VARIANT     214    214       H -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045089.
FT   VARIANT     214    214       H -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045090.
FT   VARIANT     215    215       S -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045091.
FT   VARIANT     215    215       S -> G (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs886039484).
FT                                /FTId=VAR_045092.
FT   VARIANT     215    215       S -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045093.
FT   VARIANT     215    215       S -> K (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045810.
FT   VARIANT     215    215       S -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045094.
FT   VARIANT     215    215       S -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045095.
FT   VARIANT     215    215       S -> T (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587782177).
FT                                /FTId=VAR_045096.
FT   VARIANT     216    216       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045097.
FT   VARIANT     216    216       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045098.
FT   VARIANT     216    216       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045099.
FT   VARIANT     216    216       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045100.
FT   VARIANT     216    216       V -> M (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs730882025).
FT                                {ECO:0000269|PubMed:17224074}.
FT                                /FTId=VAR_005956.
FT   VARIANT     216    216       V -> W (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045811.
FT   VARIANT     217    217       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045101.
FT   VARIANT     217    217       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045102.
FT   VARIANT     217    217       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045103.
FT   VARIANT     217    217       V -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045104.
FT   VARIANT     217    217       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045105.
FT   VARIANT     217    217       V -> M (in dbSNP:rs35163653).
FT                                /FTId=VAR_047178.
FT   VARIANT     218    218       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045106.
FT   VARIANT     218    218       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045107.
FT   VARIANT     218    218       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045108.
FT   VARIANT     218    218       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045109.
FT   VARIANT     218    218       V -> M (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs878854072).
FT                                /FTId=VAR_045110.
FT   VARIANT     219    219       P -> C (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045812.
FT   VARIANT     219    219       P -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045111.
FT   VARIANT     219    219       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045112.
FT   VARIANT     219    219       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045113.
FT   VARIANT     219    219       P -> S (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation;
FT                                dbSNP:rs879253894).
FT                                /FTId=VAR_045114.
FT   VARIANT     219    219       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045115.
FT   VARIANT     220    220       Y -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs121912666).
FT                                {ECO:0000269|PubMed:7682763,
FT                                ECO:0000269|PubMed:9450901}.
FT                                /FTId=VAR_005957.
FT   VARIANT     220    220       Y -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045116.
FT   VARIANT     220    220       Y -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045117.
FT   VARIANT     220    220       Y -> H (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs530941076).
FT                                /FTId=VAR_005958.
FT   VARIANT     220    220       Y -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045118.
FT   VARIANT     220    220       Y -> S (in a brain tumor with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs121912666).
FT                                /FTId=VAR_005959.
FT   VARIANT     221    221       E -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045119.
FT   VARIANT     221    221       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045120.
FT   VARIANT     221    221       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045121.
FT   VARIANT     221    221       E -> K (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786201592).
FT                                /FTId=VAR_045122.
FT   VARIANT     221    221       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045123.
FT   VARIANT     222    222       P -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045124.
FT   VARIANT     222    222       P -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs146340390).
FT                                /FTId=VAR_045125.
FT   VARIANT     222    222       P -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045126.
FT   VARIANT     222    222       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045127.
FT   VARIANT     222    222       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045128.
FT   VARIANT     222    222       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045129.
FT   VARIANT     223    223       P -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047179.
FT   VARIANT     223    223       P -> H (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs138983188).
FT                                /FTId=VAR_045130.
FT   VARIANT     223    223       P -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs138983188).
FT                                /FTId=VAR_045131.
FT   VARIANT     223    223       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045132.
FT   VARIANT     223    223       P -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045133.
FT   VARIANT     223    223       P -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045134.
FT   VARIANT     224    224       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045135.
FT   VARIANT     224    224       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045136.
FT   VARIANT     224    224       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045137.
FT   VARIANT     224    224       E -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045138.
FT   VARIANT     225    225       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045139.
FT   VARIANT     225    225       V -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045140.
FT   VARIANT     225    225       V -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045141.
FT   VARIANT     225    225       V -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045142.
FT   VARIANT     225    225       V -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045143.
FT   VARIANT     225    225       V -> L (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs746504075).
FT                                /FTId=VAR_045144.
FT   VARIANT     226    226       G -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045145.
FT   VARIANT     226    226       G -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047180.
FT   VARIANT     226    226       G -> N (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045844.
FT   VARIANT     226    226       G -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045146.
FT   VARIANT     226    226       G -> V (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs970212462).
FT                                /FTId=VAR_045147.
FT   VARIANT     227    227       S -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045148.
FT   VARIANT     227    227       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045149.
FT   VARIANT     227    227       S -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045150.
FT   VARIANT     227    227       S -> T (in LFS; germline mutation and in
FT                                a sporadic cancer; somatic mutation).
FT                                /FTId=VAR_045151.
FT   VARIANT     228    228       D -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045152.
FT   VARIANT     228    228       D -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005960.
FT   VARIANT     228    228       D -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045153.
FT   VARIANT     228    228       D -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045154.
FT   VARIANT     228    228       D -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045155.
FT   VARIANT     228    228       D -> P (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045845.
FT   VARIANT     228    228       D -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045156.
FT   VARIANT     228    228       D -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045157.
FT   VARIANT     229    229       C -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045158.
FT   VARIANT     229    229       C -> N (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045846.
FT   VARIANT     229    229       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045159.
FT   VARIANT     229    229       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045160.
FT   VARIANT     229    229       C -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045161.
FT   VARIANT     230    230       T -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045162.
FT   VARIANT     230    230       T -> I (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:9450901}.
FT                                /FTId=VAR_005961.
FT   VARIANT     230    230       T -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045163.
FT   VARIANT     230    230       T -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045164.
FT   VARIANT     230    230       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045165.
FT   VARIANT     231    231       T -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045166.
FT   VARIANT     231    231       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045167.
FT   VARIANT     231    231       T -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045168.
FT   VARIANT     231    231       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045169.
FT   VARIANT     232    232       I -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045170.
FT   VARIANT     232    232       I -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045171.
FT   VARIANT     232    232       I -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045172.
FT   VARIANT     232    232       I -> S (in sporadic cancers; somatic
FT                                mutation; does not induce SNAI1
FT                                degradation).
FT                                {ECO:0000269|PubMed:20385133}.
FT                                /FTId=VAR_045173.
FT   VARIANT     232    232       I -> T (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587781589).
FT                                /FTId=VAR_005962.
FT   VARIANT     232    232       I -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045174.
FT   VARIANT     233    233       H -> D (in LFS; germline mutation and in
FT                                a sporadic cancer; somatic mutation).
FT                                /FTId=VAR_045175.
FT   VARIANT     233    233       H -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045176.
FT   VARIANT     233    233       H -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045177.
FT   VARIANT     233    233       H -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045178.
FT   VARIANT     233    233       H -> R (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs879254233).
FT                                /FTId=VAR_047181.
FT   VARIANT     233    233       H -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045179.
FT   VARIANT     234    234       Y -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs587780073).
FT                                /FTId=VAR_005963.
FT   VARIANT     234    234       Y -> D (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs864622237).
FT                                /FTId=VAR_045180.
FT   VARIANT     234    234       Y -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045181.
FT   VARIANT     234    234       Y -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005964.
FT   VARIANT     234    234       Y -> K (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045847.
FT   VARIANT     234    234       Y -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045182.
FT   VARIANT     234    234       Y -> Q (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045848.
FT   VARIANT     234    234       Y -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045183.
FT   VARIANT     235    235       N -> D (in an adrenocortical carcinoma
FT                                with no family history; germline mutation
FT                                and in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047182.
FT   VARIANT     235    235       N -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045184.
FT   VARIANT     235    235       N -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045185.
FT   VARIANT     235    235       N -> M (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045849.
FT   VARIANT     235    235       N -> S (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs144340710).
FT                                /FTId=VAR_045186.
FT   VARIANT     235    235       N -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045187.
FT   VARIANT     235    235       N -> Y (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786204145).
FT                                /FTId=VAR_045188.
FT   VARIANT     236    236       Y -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045189.
FT   VARIANT     236    236       Y -> D (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587782289).
FT                                /FTId=VAR_045190.
FT   VARIANT     236    236       Y -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045191.
FT   VARIANT     236    236       Y -> H (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587782289).
FT                                /FTId=VAR_045192.
FT   VARIANT     236    236       Y -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045193.
FT   VARIANT     236    236       Y -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs730882026).
FT                                /FTId=VAR_045194.
FT   VARIANT     237    237       M -> I (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs587782664).
FT                                /FTId=VAR_005965.
FT   VARIANT     237    237       M -> K (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs765848205).
FT                                /FTId=VAR_045195.
FT   VARIANT     237    237       M -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045196.
FT   VARIANT     237    237       M -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045197.
FT   VARIANT     237    237       M -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045198.
FT   VARIANT     237    237       M -> V (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs730882004).
FT                                /FTId=VAR_045199.
FT   VARIANT     238    238       C -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005966.
FT   VARIANT     238    238       C -> G (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045200.
FT   VARIANT     238    238       C -> H (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045850.
FT   VARIANT     238    238       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045201.
FT   VARIANT     238    238       C -> S (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045202.
FT   VARIANT     238    238       C -> W (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs193920789).
FT                                /FTId=VAR_045203.
FT   VARIANT     238    238       C -> Y (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation;
FT                                dbSNP:rs730882005).
FT                                /FTId=VAR_005967.
FT   VARIANT     239    239       N -> D (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs876660807).
FT                                /FTId=VAR_045204.
FT   VARIANT     239    239       N -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045205.
FT   VARIANT     239    239       N -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045206.
FT   VARIANT     239    239       N -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045207.
FT   VARIANT     239    239       N -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045208.
FT   VARIANT     239    239       N -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045209.
FT   VARIANT     239    239       N -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045210.
FT   VARIANT     240    240       S -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045211.
FT   VARIANT     240    240       S -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045212.
FT   VARIANT     240    240       S -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005968.
FT   VARIANT     240    240       S -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045213.
FT   VARIANT     240    240       S -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045214.
FT   VARIANT     240    240       S -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045215.
FT   VARIANT     240    240       S -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045216.
FT   VARIANT     241    241       S -> A (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:17224074}.
FT                                /FTId=VAR_033036.
FT   VARIANT     241    241       S -> C (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs28934573).
FT                                /FTId=VAR_045217.
FT   VARIANT     241    241       S -> F (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934573).
FT                                {ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:1699228}.
FT                                /FTId=VAR_005969.
FT   VARIANT     241    241       S -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045218.
FT   VARIANT     241    241       S -> T (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_047183.
FT   VARIANT     241    241       S -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045219.
FT   VARIANT     242    242       C -> F (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:1394225,
FT                                ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_005970.
FT   VARIANT     242    242       C -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045220.
FT   VARIANT     242    242       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045221.
FT   VARIANT     242    242       C -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs121912655).
FT                                /FTId=VAR_045222.
FT   VARIANT     242    242       C -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045223.
FT   VARIANT     242    242       C -> Y (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation;
FT                                dbSNP:rs121912655).
FT                                /FTId=VAR_045224.
FT   VARIANT     243    244       MG -> IC (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047184.
FT   VARIANT     243    244       MG -> IS (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047185.
FT   VARIANT     243    243       M -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045225.
FT   VARIANT     243    243       M -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045226.
FT   VARIANT     243    243       M -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786203117).
FT                                /FTId=VAR_045227.
FT   VARIANT     243    243       M -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045228.
FT   VARIANT     243    243       M -> T (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs730882006).
FT                                /FTId=VAR_045229.
FT   VARIANT     243    243       M -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045230.
FT   VARIANT     244    244       G -> A (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs985033810).
FT                                /FTId=VAR_047186.
FT   VARIANT     244    244       G -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045231.
FT   VARIANT     244    244       G -> D (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs1057517983).
FT                                /FTId=VAR_045232.
FT   VARIANT     244    244       G -> E (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045233.
FT   VARIANT     244    244       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045234.
FT   VARIANT     244    244       G -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045235.
FT   VARIANT     244    244       G -> V (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045236.
FT   VARIANT     245    245       G -> A (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs121912656).
FT                                /FTId=VAR_005971.
FT   VARIANT     245    245       G -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934575).
FT                                {ECO:0000269|PubMed:1394225,
FT                                ECO:0000269|PubMed:1978757}.
FT                                /FTId=VAR_005972.
FT   VARIANT     245    245       G -> D (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs121912656).
FT                                {ECO:0000269|PubMed:2259385}.
FT                                /FTId=VAR_005973.
FT   VARIANT     245    245       G -> E (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045237.
FT   VARIANT     245    245       G -> F (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045851.
FT   VARIANT     245    245       G -> H (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045852.
FT   VARIANT     245    245       G -> L (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045853.
FT   VARIANT     245    245       G -> N (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045854.
FT   VARIANT     245    245       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045238.
FT   VARIANT     245    245       G -> S (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934575).
FT                                {ECO:0000269|PubMed:8829627}.
FT                                /FTId=VAR_005974.
FT   VARIANT     245    245       G -> V (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs121912656).
FT                                {ECO:0000269|PubMed:2263646}.
FT                                /FTId=VAR_005975.
FT   VARIANT     246    246       M -> I (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs1019340046).
FT                                /FTId=VAR_045239.
FT   VARIANT     246    246       M -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045240.
FT   VARIANT     246    246       M -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs483352695).
FT                                /FTId=VAR_044020.
FT   VARIANT     246    246       M -> R (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587780074).
FT                                /FTId=VAR_005976.
FT   VARIANT     246    246       M -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005977.
FT   VARIANT     246    246       M -> V (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs483352695).
FT                                /FTId=VAR_005978.
FT   VARIANT     247    248       NR -> IP (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047187.
FT   VARIANT     247    248       NR -> KW (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047188.
FT   VARIANT     247    247       N -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045241.
FT   VARIANT     247    247       N -> F (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045855.
FT   VARIANT     247    247       N -> I (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786201762).
FT                                /FTId=VAR_005980.
FT   VARIANT     247    247       N -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045242.
FT   VARIANT     247    247       N -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045243.
FT   VARIANT     247    247       N -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047189.
FT   VARIANT     247    247       N -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045244.
FT   VARIANT     248    248       R -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045245.
FT   VARIANT     248    248       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005981.
FT   VARIANT     248    248       R -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs11540652).
FT                                {ECO:0000269|PubMed:1394225,
FT                                ECO:0000269|PubMed:7682763}.
FT                                /FTId=VAR_005982.
FT   VARIANT     248    248       R -> P (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs11540652).
FT                                /FTId=VAR_045246.
FT   VARIANT     248    248       R -> Q (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs11540652).
FT                                {ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:2263646,
FT                                ECO:0000269|PubMed:7682763,
FT                                ECO:0000269|PubMed:7887414}.
FT                                /FTId=VAR_005983.
FT   VARIANT     248    248       R -> W (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs121912651).
FT                                {ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:1978757,
FT                                ECO:0000269|PubMed:8829627}.
FT                                /FTId=VAR_005984.
FT   VARIANT     249    250       RP -> SA (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047190.
FT   VARIANT     249    250       RP -> SS (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047191.
FT   VARIANT     249    249       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005985.
FT   VARIANT     249    249       R -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045247.
FT   VARIANT     249    249       R -> K (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587782329).
FT                                /FTId=VAR_045248.
FT   VARIANT     249    249       R -> M (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:17224074}.
FT                                /FTId=VAR_033037.
FT   VARIANT     249    249       R -> N (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045856.
FT   VARIANT     249    249       R -> S (in sporadic cancers; somatic
FT                                mutation; does not induce SNAI1
FT                                degradation; dbSNP:rs28934571).
FT                                {ECO:0000269|PubMed:1694291,
FT                                ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:20385133}.
FT                                /FTId=VAR_005986.
FT   VARIANT     249    249       R -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045249.
FT   VARIANT     249    249       R -> W (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587782082).
FT                                /FTId=VAR_045250.
FT   VARIANT     250    250       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045251.
FT   VARIANT     250    250       P -> F (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045857.
FT   VARIANT     250    250       P -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045252.
FT   VARIANT     250    250       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047192.
FT   VARIANT     250    250       P -> N (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045858.
FT   VARIANT     250    250       P -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045253.
FT   VARIANT     250    250       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045254.
FT   VARIANT     250    250       P -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045255.
FT   VARIANT     251    251       I -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045256.
FT   VARIANT     251    251       I -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs730882007).
FT                                /FTId=VAR_045257.
FT   VARIANT     251    251       I -> M (in LFS; germline mutation).
FT                                /FTId=VAR_045258.
FT   VARIANT     251    251       I -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005987.
FT   VARIANT     251    251       I -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs730882027).
FT                                {ECO:0000269|PubMed:17224074}.
FT                                /FTId=VAR_033038.
FT   VARIANT     251    251       I -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045259.
FT   VARIANT     251    251       I -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045260.
FT   VARIANT     252    252       L -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045261.
FT   VARIANT     252    252       L -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045262.
FT   VARIANT     252    252       L -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045263.
FT   VARIANT     252    252       L -> P (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs121912653).
FT                                {ECO:0000269|PubMed:1978757}.
FT                                /FTId=VAR_005988.
FT   VARIANT     252    252       L -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045264.
FT   VARIANT     253    253       T -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045265.
FT   VARIANT     253    253       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045266.
FT   VARIANT     253    253       T -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045267.
FT   VARIANT     253    253       T -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047193.
FT   VARIANT     253    253       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045268.
FT   VARIANT     254    254       I -> D (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045859.
FT   VARIANT     254    254       I -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045269.
FT   VARIANT     254    254       I -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045270.
FT   VARIANT     254    254       I -> M (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045271.
FT   VARIANT     254    254       I -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_017908.
FT   VARIANT     254    254       I -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045272.
FT   VARIANT     254    254       I -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_017909.
FT   VARIANT     254    254       I -> V (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs746601313).
FT                                /FTId=VAR_045273.
FT   VARIANT     255    255       I -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045274.
FT   VARIANT     255    255       I -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045275.
FT   VARIANT     255    255       I -> N (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs876659675).
FT                                /FTId=VAR_045276.
FT   VARIANT     255    255       I -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045277.
FT   VARIANT     255    255       I -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045278.
FT   VARIANT     255    255       I -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045279.
FT   VARIANT     256    256       T -> I (in a brain tumor with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045280.
FT   VARIANT     256    256       T -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045281.
FT   VARIANT     256    256       T -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045282.
FT   VARIANT     256    256       T -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045283.
FT   VARIANT     257    257       L -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005989.
FT   VARIANT     257    257       L -> Q (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934577).
FT                                /FTId=VAR_045284.
FT   VARIANT     257    257       L -> R (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs28934577).
FT                                /FTId=VAR_045285.
FT   VARIANT     257    257       L -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045286.
FT   VARIANT     258    258       E -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045287.
FT   VARIANT     258    258       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005990.
FT   VARIANT     258    258       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045288.
FT   VARIANT     258    258       E -> K (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs121912652).
FT                                {ECO:0000269|PubMed:1978757}.
FT                                /FTId=VAR_005991.
FT   VARIANT     258    258       E -> L (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045860.
FT   VARIANT     258    258       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045289.
FT   VARIANT     258    258       E -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045290.
FT   VARIANT     259    259       D -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047194.
FT   VARIANT     259    259       D -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045291.
FT   VARIANT     259    259       D -> G (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs745425759).
FT                                /FTId=VAR_045292.
FT   VARIANT     259    259       D -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045293.
FT   VARIANT     259    259       D -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045294.
FT   VARIANT     259    259       D -> P (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045861.
FT   VARIANT     259    259       D -> S (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045862.
FT   VARIANT     259    259       D -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045295.
FT   VARIANT     259    259       D -> Y (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:17224074}.
FT                                /FTId=VAR_033039.
FT   VARIANT     260    260       S -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045296.
FT   VARIANT     260    260       S -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045297.
FT   VARIANT     260    260       S -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045298.
FT   VARIANT     260    260       S -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045299.
FT   VARIANT     260    260       S -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045300.
FT   VARIANT     260    260       S -> Y (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs876658916).
FT                                /FTId=VAR_045301.
FT   VARIANT     261    261       S -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045302.
FT   VARIANT     261    261       S -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045303.
FT   VARIANT     261    261       S -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045304.
FT   VARIANT     261    261       S -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045305.
FT   VARIANT     261    261       S -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045306.
FT   VARIANT     262    263       GN -> PD (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047195.
FT   VARIANT     262    262       G -> C (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs200579969).
FT                                /FTId=VAR_045307.
FT   VARIANT     262    262       G -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047196.
FT   VARIANT     262    262       G -> H (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045863.
FT   VARIANT     262    262       G -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs200579969).
FT                                /FTId=VAR_045308.
FT   VARIANT     262    262       G -> V (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|Ref.23}.
FT                                /FTId=VAR_045309.
FT   VARIANT     263    263       N -> D (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs72661119).
FT                                /FTId=VAR_045310.
FT   VARIANT     263    263       N -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045311.
FT   VARIANT     263    263       N -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045312.
FT   VARIANT     263    263       N -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045313.
FT   VARIANT     263    263       N -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045314.
FT   VARIANT     264    264       L -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045315.
FT   VARIANT     264    264       L -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045316.
FT   VARIANT     264    264       L -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045317.
FT   VARIANT     264    264       L -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045318.
FT   VARIANT     264    264       L -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045319.
FT   VARIANT     265    265       L -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045320.
FT   VARIANT     265    265       L -> P (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs879253942).
FT                                /FTId=VAR_045321.
FT   VARIANT     265    265       L -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045322.
FT   VARIANT     265    265       L -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047197.
FT   VARIANT     266    266       G -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045323.
FT   VARIANT     266    266       G -> E (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs193920774).
FT                                /FTId=VAR_045324.
FT   VARIANT     266    266       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045325.
FT   VARIANT     266    266       G -> V (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs193920774).
FT                                /FTId=VAR_045326.
FT   VARIANT     267    267       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045327.
FT   VARIANT     267    267       R -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045328.
FT   VARIANT     267    267       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045329.
FT   VARIANT     267    267       R -> Q (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs587780075).
FT                                /FTId=VAR_045330.
FT   VARIANT     267    267       R -> W (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs55832599).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036507.
FT   VARIANT     268    268       N -> F (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045864.
FT   VARIANT     268    268       N -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045331.
FT   VARIANT     268    268       N -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045332.
FT   VARIANT     268    268       N -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045333.
FT   VARIANT     268    268       N -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045334.
FT   VARIANT     268    268       N -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045335.
FT   VARIANT     269    269       S -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045336.
FT   VARIANT     269    269       S -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045337.
FT   VARIANT     269    269       S -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047198.
FT   VARIANT     269    269       S -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045338.
FT   VARIANT     269    269       S -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045339.
FT   VARIANT     269    269       S -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045340.
FT   VARIANT     270    270       F -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045341.
FT   VARIANT     270    270       F -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045342.
FT   VARIANT     270    270       F -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045343.
FT   VARIANT     270    270       F -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045344.
FT   VARIANT     270    270       F -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045345.
FT   VARIANT     270    270       F -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045346.
FT   VARIANT     271    271       E -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045347.
FT   VARIANT     271    271       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045348.
FT   VARIANT     271    271       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045349.
FT   VARIANT     271    271       E -> K (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036508.
FT   VARIANT     271    271       E -> P (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045865.
FT   VARIANT     271    271       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045350.
FT   VARIANT     271    271       E -> R (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045866.
FT   VARIANT     271    271       E -> V (in an osteosarcoma with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_047199.
FT   VARIANT     272    272       V -> A (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_045351.
FT   VARIANT     272    272       V -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045352.
FT   VARIANT     272    272       V -> G (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs876660333).
FT                                /FTId=VAR_045353.
FT   VARIANT     272    272       V -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs121912657).
FT                                {ECO:0000269|PubMed:1737852}.
FT                                /FTId=VAR_005992.
FT   VARIANT     272    272       V -> M (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs121912657).
FT                                /FTId=VAR_045354.
FT   VARIANT     273    273       R -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs121913343).
FT                                {ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:17224074,
FT                                ECO:0000269|PubMed:7887414,
FT                                ECO:0000269|PubMed:9450901}.
FT                                /FTId=VAR_005993.
FT   VARIANT     273    273       R -> G (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_005994.
FT   VARIANT     273    273       R -> H (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                abolishes sequence-specific DNA binding;
FT                                does not induce SNAI1 degradation;
FT                                dbSNP:rs28934576).
FT                                {ECO:0000269|PubMed:10570149,
FT                                ECO:0000269|PubMed:1394225,
FT                                ECO:0000269|PubMed:1565144,
FT                                ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:1699228,
FT                                ECO:0000269|PubMed:1868473,
FT                                ECO:0000269|PubMed:20385133,
FT                                ECO:0000269|PubMed:7682763,
FT                                ECO:0000269|Ref.14}.
FT                                /FTId=VAR_005995.
FT   VARIANT     273    273       R -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934576).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036509.
FT   VARIANT     273    273       R -> N (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045867.
FT   VARIANT     273    273       R -> P (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs28934576).
FT                                /FTId=VAR_045355.
FT   VARIANT     273    273       R -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045356.
FT   VARIANT     273    273       R -> S (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation;
FT                                dbSNP:rs121913343).
FT                                /FTId=VAR_045357.
FT   VARIANT     273    273       R -> Y (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045868.
FT   VARIANT     274    274       V -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045358.
FT   VARIANT     274    274       V -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045359.
FT   VARIANT     274    274       V -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005997.
FT   VARIANT     274    274       V -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047200.
FT   VARIANT     274    274       V -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045360.
FT   VARIANT     274    274       V -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045361.
FT   VARIANT     275    275       C -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045362.
FT   VARIANT     275    275       C -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045363.
FT   VARIANT     275    275       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045364.
FT   VARIANT     275    275       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045365.
FT   VARIANT     275    275       C -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_005999.
FT   VARIANT     275    275       C -> Y (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs863224451).
FT                                {ECO:0000269|PubMed:7887414}.
FT                                /FTId=VAR_005998.
FT   VARIANT     276    276       A -> D (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786202082).
FT                                /FTId=VAR_045366.
FT   VARIANT     276    276       A -> G (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786202082).
FT                                /FTId=VAR_045367.
FT   VARIANT     276    276       A -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045368.
FT   VARIANT     276    276       A -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045369.
FT   VARIANT     276    276       A -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045370.
FT   VARIANT     276    276       A -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045371.
FT   VARIANT     277    277       C -> F (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs763098116).
FT                                /FTId=VAR_045372.
FT   VARIANT     277    277       C -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006000.
FT   VARIANT     277    277       C -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045373.
FT   VARIANT     277    277       C -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045374.
FT   VARIANT     277    277       C -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047201.
FT   VARIANT     277    277       C -> Y (in an osteosarcoma with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs763098116).
FT                                /FTId=VAR_045375.
FT   VARIANT     278    278       P -> A (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs17849781).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_006001.
FT   VARIANT     278    278       P -> F (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045869.
FT   VARIANT     278    278       P -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006002.
FT   VARIANT     278    278       P -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs876659802).
FT                                {ECO:0000269|PubMed:2263646}.
FT                                /FTId=VAR_006003.
FT   VARIANT     278    278       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045376.
FT   VARIANT     278    278       P -> S (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                {ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:2263646,
FT                                ECO:0000269|PubMed:9450901}.
FT                                /FTId=VAR_006004.
FT   VARIANT     278    278       P -> T (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_006005.
FT   VARIANT     279    279       G -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006006.
FT   VARIANT     279    279       G -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045377.
FT   VARIANT     279    279       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045378.
FT   VARIANT     279    279       G -> W (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045379.
FT   VARIANT     280    280       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045380.
FT   VARIANT     280    280       R -> I (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs121912660).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_006008.
FT   VARIANT     280    280       R -> K (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation; no effect on
FT                                interaction with CCAR2).
FT                                {ECO:0000269|PubMed:1694291,
FT                                ECO:0000269|PubMed:25732823}.
FT                                /FTId=VAR_006007.
FT   VARIANT     280    280       R -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045381.
FT   VARIANT     280    280       R -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045382.
FT   VARIANT     280    280       R -> T (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs121912660).
FT                                {ECO:0000269|PubMed:1631151}.
FT                                /FTId=VAR_006009.
FT   VARIANT     281    282       DR -> EW (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047203.
FT   VARIANT     281    281       D -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006010.
FT   VARIANT     281    281       D -> E (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:1459726}.
FT                                /FTId=VAR_006011.
FT   VARIANT     281    281       D -> G (in a brain tumor with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs587781525).
FT                                /FTId=VAR_006012.
FT   VARIANT     281    281       D -> H (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_006013.
FT   VARIANT     281    281       D -> N (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs764146326).
FT                                /FTId=VAR_047202.
FT   VARIANT     281    281       D -> R (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045870.
FT   VARIANT     281    281       D -> V (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation;
FT                                dbSNP:rs587781525).
FT                                /FTId=VAR_006014.
FT   VARIANT     281    281       D -> Y (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs764146326).
FT                                /FTId=VAR_045383.
FT   VARIANT     282    282       R -> G (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs28934574).
FT                                /FTId=VAR_045384.
FT   VARIANT     282    282       R -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045385.
FT   VARIANT     282    282       R -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs730882008).
FT                                /FTId=VAR_006015.
FT   VARIANT     282    282       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045386.
FT   VARIANT     282    282       R -> Q (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation;
FT                                dbSNP:rs730882008).
FT                                {ECO:0000269|PubMed:18453682,
FT                                ECO:0000269|Ref.22}.
FT                                /FTId=VAR_045387.
FT   VARIANT     282    282       R -> W (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation; does
FT                                not induce SNAI1 degradation;
FT                                dbSNP:rs28934574).
FT                                {ECO:0000269|PubMed:20385133,
FT                                ECO:0000269|PubMed:8829627}.
FT                                /FTId=VAR_006016.
FT   VARIANT     283    283       R -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs149633775).
FT                                /FTId=VAR_006017.
FT   VARIANT     283    283       R -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006018.
FT   VARIANT     283    283       R -> H (in a brain tumor with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs371409680).
FT                                /FTId=VAR_006019.
FT   VARIANT     283    283       R -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045388.
FT   VARIANT     283    283       R -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006020.
FT   VARIANT     283    283       R -> S (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs149633775).
FT                                /FTId=VAR_045389.
FT   VARIANT     284    284       T -> A (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:20959462}.
FT                                /FTId=VAR_006021.
FT   VARIANT     284    284       T -> I (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs863224685).
FT                                /FTId=VAR_045390.
FT   VARIANT     284    284       T -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045391.
FT   VARIANT     284    284       T -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006022.
FT   VARIANT     285    285       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045392.
FT   VARIANT     285    285       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045393.
FT   VARIANT     285    285       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045394.
FT   VARIANT     285    285       E -> K (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs112431538).
FT                                {ECO:0000269|PubMed:1459726,
FT                                ECO:0000269|PubMed:1694291}.
FT                                /FTId=VAR_006023.
FT   VARIANT     285    285       E -> Q (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_006024.
FT   VARIANT     285    285       E -> V (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs121912667).
FT                                /FTId=VAR_006025.
FT   VARIANT     286    286       E -> A (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_006026.
FT   VARIANT     286    286       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006027.
FT   VARIANT     286    286       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006028.
FT   VARIANT     286    286       E -> K (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs786201059).
FT                                {ECO:0000269|PubMed:11023613,
FT                                ECO:0000269|PubMed:8316628}.
FT                                /FTId=VAR_006029.
FT   VARIANT     286    286       E -> L (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045871.
FT   VARIANT     286    286       E -> Q (in sporadic cancers; somatic
FT                                mutation). {ECO:0000269|PubMed:8829627}.
FT                                /FTId=VAR_006030.
FT   VARIANT     286    286       E -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045395.
FT   VARIANT     287    287       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047204.
FT   VARIANT     287    287       E -> D (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs748891343).
FT                                /FTId=VAR_045396.
FT   VARIANT     287    287       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045397.
FT   VARIANT     287    287       E -> K (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587782006).
FT                                /FTId=VAR_045398.
FT   VARIANT     287    287       E -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045399.
FT   VARIANT     288    288       N -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045400.
FT   VARIANT     288    288       N -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045401.
FT   VARIANT     288    288       N -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045402.
FT   VARIANT     288    288       N -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045403.
FT   VARIANT     288    288       N -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045404.
FT   VARIANT     289    289       L -> F (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045405.
FT   VARIANT     289    289       L -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045406.
FT   VARIANT     289    289       L -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045407.
FT   VARIANT     289    289       L -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045408.
FT   VARIANT     289    289       L -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045409.
FT   VARIANT     290    290       R -> C (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs770374782).
FT                                /FTId=VAR_045410.
FT   VARIANT     290    290       R -> H (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs55819519).
FT                                /FTId=VAR_045411.
FT   VARIANT     290    290       R -> L (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                /FTId=VAR_045412.
FT   VARIANT     291    291       K -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045413.
FT   VARIANT     291    291       K -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045414.
FT   VARIANT     291    291       K -> N (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs372613518).
FT                                /FTId=VAR_045415.
FT   VARIANT     291    291       K -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047205.
FT   VARIANT     291    291       K -> R (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs781490101).
FT                                /FTId=VAR_045416.
FT   VARIANT     291    291       K -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045417.
FT   VARIANT     292    292       K -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045418.
FT   VARIANT     292    292       K -> G (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045872.
FT   VARIANT     292    292       K -> I (in LFS; germline mutation and in
FT                                a sporadic cancer; somatic mutation;
FT                                dbSNP:rs121912663).
FT                                {ECO:0000269|PubMed:10484981}.
FT                                /FTId=VAR_015819.
FT   VARIANT     292    292       K -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045419.
FT   VARIANT     292    292       K -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045420.
FT   VARIANT     292    292       K -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045421.
FT   VARIANT     292    292       K -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045422.
FT   VARIANT     293    293       G -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045423.
FT   VARIANT     293    293       G -> R (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587780076).
FT                                /FTId=VAR_045424.
FT   VARIANT     293    293       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045425.
FT   VARIANT     293    293       G -> W (in a brain tumor with no family
FT                                history; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs587780076).
FT                                /FTId=VAR_045426.
FT   VARIANT     294    294       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045427.
FT   VARIANT     294    294       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045428.
FT   VARIANT     294    294       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045429.
FT   VARIANT     294    294       E -> K (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047206.
FT   VARIANT     294    294       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045430.
FT   VARIANT     294    294       E -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045431.
FT   VARIANT     295    295       P -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045432.
FT   VARIANT     295    295       P -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs751713111).
FT                                /FTId=VAR_045433.
FT   VARIANT     295    295       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045434.
FT   VARIANT     295    295       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045435.
FT   VARIANT     296    296       H -> C (in sporadic cancers; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045873.
FT   VARIANT     296    296       H -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045436.
FT   VARIANT     296    296       H -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_047207.
FT   VARIANT     296    296       H -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045437.
FT   VARIANT     296    296       H -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_006031.
FT   VARIANT     296    296       H -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045438.
FT   VARIANT     296    296       H -> R (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs483352696).
FT                                /FTId=VAR_045439.
FT   VARIANT     296    296       H -> Y (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs672601296).
FT                                /FTId=VAR_045440.
FT   VARIANT     297    297       H -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045441.
FT   VARIANT     297    297       H -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045442.
FT   VARIANT     297    297       H -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045443.
FT   VARIANT     297    297       H -> R (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs876659477).
FT                                /FTId=VAR_045444.
FT   VARIANT     297    297       H -> Y (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045445.
FT   VARIANT     298    298       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045446.
FT   VARIANT     298    298       E -> D (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045447.
FT   VARIANT     298    298       E -> K (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs201744589).
FT                                /FTId=VAR_045448.
FT   VARIANT     298    298       E -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045449.
FT   VARIANT     298    298       E -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045450.
FT   VARIANT     299    299       L -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045451.
FT   VARIANT     299    299       L -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045452.
FT   VARIANT     299    299       L -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045453.
FT   VARIANT     299    299       L -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045454.
FT   VARIANT     300    300       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045455.
FT   VARIANT     300    300       P -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs909643864).
FT                                /FTId=VAR_045456.
FT   VARIANT     300    300       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_006032.
FT   VARIANT     300    300       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045457.
FT   VARIANT     301    301       P -> A (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045458.
FT   VARIANT     301    301       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006033.
FT   VARIANT     301    301       P -> Q (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045459.
FT   VARIANT     301    301       P -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045460.
FT   VARIANT     301    301       P -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047208.
FT   VARIANT     302    302       G -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045461.
FT   VARIANT     302    302       G -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006034.
FT   VARIANT     302    302       G -> R (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs863224686).
FT                                /FTId=VAR_045462.
FT   VARIANT     302    302       G -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_006035.
FT   VARIANT     303    303       S -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045463.
FT   VARIANT     303    303       S -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045464.
FT   VARIANT     303    303       S -> N (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs876658714).
FT                                /FTId=VAR_045465.
FT   VARIANT     303    303       S -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045466.
FT   VARIANT     304    304       T -> A (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs587782654).
FT                                /FTId=VAR_045467.
FT   VARIANT     304    304       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045468.
FT   VARIANT     304    304       T -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045469.
FT   VARIANT     304    304       T -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047209.
FT   VARIANT     305    305       K -> E (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045470.
FT   VARIANT     305    305       K -> M (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation).
FT                                /FTId=VAR_045471.
FT   VARIANT     305    305       K -> N (in sporadic cancers; somatic
FT                                mutation; loss of nuclear localization).
FT                                {ECO:0000269|PubMed:10551826}.
FT                                /FTId=VAR_045472.
FT   VARIANT     305    305       K -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045473.
FT   VARIANT     305    305       K -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045474.
FT   VARIANT     306    306       R -> P (in LFS; germline mutation and in
FT                                a sporadic cancer; somatic mutation).
FT                                /FTId=VAR_045475.
FT   VARIANT     306    306       R -> Q (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs1048095040).
FT                                /FTId=VAR_006036.
FT   VARIANT     307    307       A -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045476.
FT   VARIANT     307    307       A -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045477.
FT   VARIANT     307    307       A -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006037.
FT   VARIANT     308    308       L -> M (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045478.
FT   VARIANT     308    308       L -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045479.
FT   VARIANT     309    309       P -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045480.
FT   VARIANT     309    309       P -> S (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation).
FT                                {ECO:0000269|Ref.14}.
FT                                /FTId=VAR_006038.
FT   VARIANT     310    310       N -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045481.
FT   VARIANT     310    310       N -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045482.
FT   VARIANT     311    311       N -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045483.
FT   VARIANT     311    311       N -> K (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045484.
FT   VARIANT     311    311       N -> S (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs56184981).
FT                                /FTId=VAR_045485.
FT   VARIANT     311    311       N -> T (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs56184981).
FT                                /FTId=VAR_045486.
FT   VARIANT     312    312       T -> I (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045487.
FT   VARIANT     312    312       T -> S (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs145151284).
FT                                /FTId=VAR_045488.
FT   VARIANT     313    313       S -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045489.
FT   VARIANT     313    313       S -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045490.
FT   VARIANT     313    313       S -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045491.
FT   VARIANT     313    313       S -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045492.
FT   VARIANT     314    314       S -> F (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs751440465).
FT                                /FTId=VAR_045493.
FT   VARIANT     315    315       S -> C (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045494.
FT   VARIANT     315    315       S -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045495.
FT   VARIANT     315    315       S -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045496.
FT   VARIANT     316    316       P -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045497.
FT   VARIANT     316    316       P -> T (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs772773208).
FT                                /FTId=VAR_045498.
FT   VARIANT     317    317       Q -> H (in a kidney cancer with no family
FT                                history; germline mutation and in a
FT                                sporadic cancer; somatic mutation).
FT                                /FTId=VAR_045499.
FT   VARIANT     317    317       Q -> K (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs764735889).
FT                                /FTId=VAR_045500.
FT   VARIANT     317    317       Q -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047210.
FT   VARIANT     317    317       Q -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045501.
FT   VARIANT     317    317       Q -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045502.
FT   VARIANT     318    318       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045503.
FT   VARIANT     319    319       K -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045504.
FT   VARIANT     319    319       K -> N (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045505.
FT   VARIANT     319    319       K -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045506.
FT   VARIANT     320    320       K -> N (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045507.
FT   VARIANT     321    321       K -> E (in kidney cancer; germline
FT                                mutation).
FT                                /FTId=VAR_045508.
FT   VARIANT     321    321       K -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045509.
FT   VARIANT     322    322       P -> L (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045510.
FT   VARIANT     322    322       P -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045511.
FT   VARIANT     323    323       L -> G (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045874.
FT   VARIANT     323    323       L -> M (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045512.
FT   VARIANT     323    323       L -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045513.
FT   VARIANT     323    323       L -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045514.
FT   VARIANT     323    323       L -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047211.
FT   VARIANT     324    324       D -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045515.
FT   VARIANT     324    324       D -> S (in a sporadic cancer; somatic
FT                                mutation; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_045875.
FT   VARIANT     324    324       D -> Y (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045516.
FT   VARIANT     325    325       G -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045517.
FT   VARIANT     325    325       G -> E (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045518.
FT   VARIANT     325    325       G -> V (in LFS; germline mutation;
FT                                dbSNP:rs121912659).
FT                                {ECO:0000269|PubMed:1565144}.
FT                                /FTId=VAR_006039.
FT   VARIANT     326    326       E -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045519.
FT   VARIANT     327    327       Y -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045520.
FT   VARIANT     327    327       Y -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045521.
FT   VARIANT     328    328       F -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045522.
FT   VARIANT     328    328       F -> S (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045523.
FT   VARIANT     328    328       F -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045524.
FT   VARIANT     329    329       T -> I (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs969930693).
FT                                /FTId=VAR_045525.
FT   VARIANT     329    329       T -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045526.
FT   VARIANT     330    330       L -> H (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045527.
FT   VARIANT     330    330       L -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047212.
FT   VARIANT     330    330       L -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045528.
FT   VARIANT     331    331       Q -> H (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs11575996).
FT                                /FTId=VAR_045529.
FT   VARIANT     331    331       Q -> P (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045530.
FT   VARIANT     331    331       Q -> R (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045531.
FT   VARIANT     332    332       I -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045532.
FT   VARIANT     334    334       G -> V (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_006040.
FT   VARIANT     334    334       G -> W (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045533.
FT   VARIANT     335    335       R -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045534.
FT   VARIANT     335    335       R -> H (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs771939956).
FT                                /FTId=VAR_045535.
FT   VARIANT     335    335       R -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045536.
FT   VARIANT     337    337       R -> C (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs587782529).
FT                                {ECO:0000269|PubMed:9452042}.
FT                                /FTId=VAR_006041.
FT   VARIANT     337    337       R -> H (in LFS; germline mutation and in
FT                                sporadic cancers; somatic mutation;
FT                                dbSNP:rs121912664).
FT                                {ECO:0000269|PubMed:11481490}.
FT                                /FTId=VAR_035016.
FT   VARIANT     337    337       R -> L (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs121912664).
FT                                /FTId=VAR_045537.
FT   VARIANT     337    337       R -> P (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs121912664).
FT                                /FTId=VAR_045538.
FT   VARIANT     338    338       F -> I (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045539.
FT   VARIANT     338    338       F -> L (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs150293825).
FT                                /FTId=VAR_045540.
FT   VARIANT     339    339       E -> K (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs17882252).
FT                                {ECO:0000269|Ref.12}.
FT                                /FTId=VAR_022316.
FT   VARIANT     339    339       E -> Q (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs17882252).
FT                                /FTId=VAR_045541.
FT   VARIANT     341    341       F -> C (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045542.
FT   VARIANT     342    342       R -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045543.
FT   VARIANT     342    342       R -> P (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs375338359).
FT                                /FTId=VAR_045544.
FT   VARIANT     342    342       R -> Q (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs375338359).
FT                                /FTId=VAR_047213.
FT   VARIANT     343    343       E -> G (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045545.
FT   VARIANT     344    344       L -> P (in LFS; germline mutation and in
FT                                a sporadic cancer; somatic mutation;
FT                                dbSNP:rs121912662).
FT                                /FTId=VAR_045546.
FT   VARIANT     344    344       L -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045547.
FT   VARIANT     346    346       E -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045548.
FT   VARIANT     347    347       A -> G (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045549.
FT   VARIANT     347    347       A -> T (in sporadic cancers; somatic
FT                                mutation).
FT                                /FTId=VAR_045550.
FT   VARIANT     348    348       L -> F (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045551.
FT   VARIANT     348    348       L -> S (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045552.
FT   VARIANT     349    349       E -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045553.
FT   VARIANT     352    352       D -> H (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045554.
FT   VARIANT     353    353       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045555.
FT   VARIANT     354    354       Q -> E (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045556.
FT   VARIANT     354    354       Q -> K (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs755394212).
FT                                /FTId=VAR_045557.
FT   VARIANT     354    354       Q -> R (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs752142489).
FT                                /FTId=VAR_047214.
FT   VARIANT     356    356       G -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045558.
FT   VARIANT     356    356       G -> W (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045559.
FT   VARIANT     358    358       E -> D (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045560.
FT   VARIANT     358    358       E -> K (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs587782237).
FT                                /FTId=VAR_045561.
FT   VARIANT     360    360       G -> A (in dbSNP:rs35993958).
FT                                /FTId=VAR_045562.
FT   VARIANT     360    360       G -> V (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs35993958).
FT                                /FTId=VAR_045563.
FT   VARIANT     363    363       R -> K (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs876660285).
FT                                /FTId=VAR_045564.
FT   VARIANT     364    364       A -> P (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045565.
FT   VARIANT     364    364       A -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045566.
FT   VARIANT     364    364       A -> V (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045567.
FT   VARIANT     365    365       H -> R (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_047215.
FT   VARIANT     365    365       H -> Y (in a familial cancer not matching
FT                                LFS; germline mutation and in a sporadic
FT                                cancer; somatic mutation;
FT                                dbSNP:rs267605075).
FT                                /FTId=VAR_045568.
FT   VARIANT     366    366       S -> A (in a familial cancer not matching
FT                                LFS; germline mutation and in sporadic
FT                                cancers; somatic mutation;
FT                                dbSNP:rs17881470). {ECO:0000269|Ref.12}.
FT                                /FTId=VAR_022317.
FT   VARIANT     370    370       K -> Q (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045569.
FT   VARIANT     376    376       S -> A (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045570.
FT   VARIANT     376    376       S -> T (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045571.
FT   VARIANT     379    379       R -> H (in sporadic cancers; somatic
FT                                mutation; dbSNP:rs863224682).
FT                                /FTId=VAR_045572.
FT   VARIANT     385    385       F -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045573.
FT   VARIANT     389    389       G -> W (in a sporadic cancer; somatic
FT                                mutation; dbSNP:rs587783064).
FT                                /FTId=VAR_045574.
FT   VARIANT     392    392       S -> L (in a sporadic cancer; somatic
FT                                mutation).
FT                                /FTId=VAR_045575.
FT   MUTAGEN      15     15       S->A: Loss of interaction with PPP2R5C,
FT                                PPP2CA AND PPP2R1A.
FT                                {ECO:0000269|PubMed:17967874}.
FT   MUTAGEN      18     18       T->A: No effect on interaction with MDM2
FT                                and increase in protein levels after DNA
FT                                damage. {ECO:0000269|PubMed:10570149}.
FT   MUTAGEN      20     20       S->A: Abolishes phosphorylation site.
FT                                Abolishes increase in protein levels
FT                                after DNA damage.
FT                                {ECO:0000269|PubMed:10570149}.
FT   MUTAGEN      20     20       S->D: Constitutively increased TP53
FT                                protein levels.
FT                                {ECO:0000269|PubMed:10570149}.
FT   MUTAGEN      22     23       LW->QS: Loss of interaction with MDM2,
FT                                leading to constitutively increased TP53
FT                                protein levels.
FT                                {ECO:0000269|PubMed:10570149}.
FT   MUTAGEN      37     37       S->D: Abolihes phosphorylation by
FT                                MAPKAPK5. {ECO:0000269|PubMed:17254968}.
FT   MUTAGEN      46     46       S->A: Abolishes phosphorylation by DYRK2
FT                                and HIPK2 and acetylation of K-382 by
FT                                CREBBP. {ECO:0000269|PubMed:11740489,
FT                                ECO:0000269|PubMed:16219768,
FT                                ECO:0000269|PubMed:17349958}.
FT   MUTAGEN      46     46       Missing: Alters interaction with WWOX.
FT                                {ECO:0000269|PubMed:11740489,
FT                                ECO:0000269|PubMed:16219768,
FT                                ECO:0000269|PubMed:17349958}.
FT   MUTAGEN      55     55       T->A: Blocks phosphorylation by TAF1.
FT                                {ECO:0000269|PubMed:15053879}.
FT   MUTAGEN     183    183       S->A: Abolishes strongly phosphorylation.
FT                                {ECO:0000269|PubMed:20959462}.
FT   MUTAGEN     183    183       S->E: Inhibits slightly its
FT                                transcriptional activity.
FT                                {ECO:0000269|PubMed:20959462}.
FT   MUTAGEN     248    248       R->S: Does not induce SNAI1 degradation.
FT                                {ECO:0000269|PubMed:20385133}.
FT   MUTAGEN     269    269       S->A: Abolishes phosphorylation.
FT                                {ECO:0000269|PubMed:20959462}.
FT   MUTAGEN     269    269       S->E: Inhibits strongly its
FT                                transcriptional activity.
FT                                {ECO:0000269|PubMed:20959462}.
FT   MUTAGEN     284    284       T->E: Inhibits strongly its
FT                                transcriptional activity.
FT   MUTAGEN     291    292       KK->RR: Abolishes polyubiquitination by
FT                                MKRN1. {ECO:0000269|PubMed:19536131}.
FT   MUTAGEN     319    319       K->A: Loss of nuclear localization; when
FT                                associated with A-320 and A-321.
FT                                {ECO:0000269|PubMed:2156209}.
FT   MUTAGEN     320    320       K->A: Loss of nuclear localization; when
FT                                associated with A-319 and A-321.
FT                                {ECO:0000269|PubMed:2156209}.
FT   MUTAGEN     321    321       K->A: Loss of nuclear localization; when
FT                                associated with A-319 and A-320.
FT                                {ECO:0000269|PubMed:2156209}.
FT   MUTAGEN     359    359       P->D: Abolishes binding to USP7.
FT                                {ECO:0000269|PubMed:16402859}.
FT   MUTAGEN     361    361       G->E: Abolishes binding to USP7.
FT                                {ECO:0000269|PubMed:16402859}.
FT   MUTAGEN     362    362       S->A: Abolishes binding to USP7.
FT                                {ECO:0000269|PubMed:16402859}.
FT   MUTAGEN     370    370       K->R: Induces a decrease in methylation
FT                                by SMYD2. {ECO:0000269|PubMed:17108971}.
FT   MUTAGEN     372    372       K->R: Induces a decrease in protein
FT                                stabilization.
FT                                {ECO:0000269|PubMed:15525938}.
FT   MUTAGEN     373    373       K->R: Abolishes dimethylation by EHMT1
FT                                and EHMT2. {ECO:0000269|PubMed:20118233}.
FT   MUTAGEN     382    382       K->A: Abolishes acetylation by CREBBP.
FT                                {ECO:0000269|PubMed:10884347,
FT                                ECO:0000269|PubMed:11740489,
FT                                ECO:0000269|PubMed:17707234,
FT                                ECO:0000269|PubMed:20870725}.
FT   MUTAGEN     382    382       K->R: Abolishes monomethylation by KMT5A.
FT                                {ECO:0000269|PubMed:10884347,
FT                                ECO:0000269|PubMed:11740489,
FT                                ECO:0000269|PubMed:17707234,
FT                                ECO:0000269|PubMed:20870725}.
FT   MUTAGEN     383    383       L->A: Abolishes S-315 phosphorylation by
FT                                CDK2/cyclin A.
FT                                {ECO:0000269|PubMed:10884347}.
FT   MUTAGEN     385    385       F->A: Reduced SUMO1 conjugation.
FT                                {ECO:0000269|PubMed:10884347,
FT                                ECO:0000269|PubMed:11124955}.
FT   MUTAGEN     386    386       K->A: Abolishes SUMO1 conjugation, in
FT                                vitro and in vivo.
FT                                {ECO:0000269|PubMed:11124955,
FT                                ECO:0000269|Ref.35}.
FT   MUTAGEN     387    387       T->A: No effect SUMO1 conjugation.
FT                                {ECO:0000269|PubMed:11124955}.
FT   MUTAGEN     388    388       E->A: Abolishes SUMO1 conjugation.
FT                                {ECO:0000269|PubMed:11124955}.
FT   HELIX         3      6       {ECO:0000244|PDB:5HOU}.
FT   TURN          8     10       {ECO:0000244|PDB:5HOU}.
FT   HELIX        19     23       {ECO:0000244|PDB:3DAC}.
FT   STRAND       27     29       {ECO:0000244|PDB:2K8F}.
FT   HELIX        30     32       {ECO:0000244|PDB:5HPD}.
FT   STRAND       33     35       {ECO:0000244|PDB:2L14}.
FT   HELIX        36     38       {ECO:0000244|PDB:2B3G}.
FT   HELIX        41     44       {ECO:0000244|PDB:2B3G}.
FT   HELIX        47     55       {ECO:0000244|PDB:2B3G}.
FT   TURN        105    108       {ECO:0000244|PDB:3D06}.
FT   STRAND      110    112       {ECO:0000244|PDB:3D06}.
FT   STRAND      119    121       {ECO:0000244|PDB:1GZH}.
FT   STRAND      124    127       {ECO:0000244|PDB:3D06}.
FT   TURN        128    131       {ECO:0000244|PDB:3D06}.
FT   STRAND      132    135       {ECO:0000244|PDB:3D06}.
FT   STRAND      141    146       {ECO:0000244|PDB:3D06}.
FT   STRAND      148    150       {ECO:0000244|PDB:5UN8}.
FT   STRAND      156    165       {ECO:0000244|PDB:3D06}.
FT   HELIX       166    168       {ECO:0000244|PDB:3D06}.
FT   HELIX       177    180       {ECO:0000244|PDB:3D06}.
FT   STRAND      181    183       {ECO:0000244|PDB:4KVP}.
FT   STRAND      187    189       {ECO:0000244|PDB:4MZI}.
FT   STRAND      194    199       {ECO:0000244|PDB:3D06}.
FT   STRAND      204    207       {ECO:0000244|PDB:3D06}.
FT   TURN        209    211       {ECO:0000244|PDB:3D06}.
FT   STRAND      214    219       {ECO:0000244|PDB:3D06}.
FT   TURN        225    227       {ECO:0000244|PDB:2FEJ}.
FT   STRAND      228    236       {ECO:0000244|PDB:3D06}.
FT   HELIX       240    242       {ECO:0000244|PDB:3D07}.
FT   TURN        243    248       {ECO:0000244|PDB:3D06}.
FT   STRAND      251    258       {ECO:0000244|PDB:3D06}.
FT   STRAND      260    262       {ECO:0000244|PDB:2ADY}.
FT   STRAND      264    274       {ECO:0000244|PDB:3D06}.
FT   HELIX       278    287       {ECO:0000244|PDB:3D06}.
FT   HELIX       288    290       {ECO:0000244|PDB:4HJE}.
FT   STRAND      327    334       {ECO:0000244|PDB:4MZR}.
FT   HELIX       335    354       {ECO:0000244|PDB:1AIE}.
FT   HELIX       375    380       {ECO:0000244|PDB:1YC5}.
SQ   SEQUENCE   393 AA;  43653 MW;  AD5C149FD8106131 CRC64;
     MEEPQSDPSV EPPLSQETFS DLWKLLPENN VLSPLPSQAM DDLMLSPDDI EQWFTEDPGP
     DEAPRMPEAA PPVAPAPAAP TPAAPAPAPS WPLSSSVPSQ KTYQGSYGFR LGFLHSGTAK
     SVTCTYSPAL NKMFCQLAKT CPVQLWVDST PPPGTRVRAM AIYKQSQHMT EVVRRCPHHE
     RCSDSDGLAP PQHLIRVEGN LRVEYLDDRN TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS
     SCMGGMNRRP ILTIITLEDS SGNLLGRNSF EVRVCACPGR DRRTEEENLR KKGEPHHELP
     PGSTKRALPN NTSSSPQPKK KPLDGEYFTL QIRGRERFEM FRELNEALEL KDAQAGKEPG
     GSRAHSSHLK SKKGQSTSRH KKLMFKTEGP DSD
//
ID   Q53GA5_HUMAN            Unreviewed;       158 AA.
AC   Q53GA5;
DT   24-MAY-2005, integrated into UniProtKB/TrEMBL.
DT   24-MAY-2005, sequence version 1.
DT   31-JAN-2018, entry version 92.
DE   RecName: Full=Cellular tumor antigen p53 {ECO:0000256|RuleBase:RU003304};
DE   Flags: Fragment;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:BAD96746.1};
RN   [1] {ECO:0000313|EMBL:BAD96746.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Thyroid {ECO:0000313|EMBL:BAD96746.1};
RX   PubMed=8125298; DOI=10.1016/0378-1119(94)90802-8;
RA   Maruyama K., Sugano S.;
RT   "Oligo-capping: a simple method to replace the cap structure of
RT   eukaryotic mRNAs with oligoribonucleotides.";
RL   Gene 138:171-174(1994).
RN   [2] {ECO:0000313|EMBL:BAD96746.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Thyroid {ECO:0000313|EMBL:BAD96746.1};
RX   PubMed=9373149; DOI=10.1016/S0378-1119(97)00411-3;
RA   Suzuki Y., Yoshitomo K., Maruyama K., Suyama A., Sugano S.;
RT   "Construction and characterization of a full length-enriched and a 5'-
RT   end-enriched cDNA library.";
RL   Gene 200:149-156(1997).
RN   [3] {ECO:0000313|EMBL:BAD96746.1}
RP   NUCLEOTIDE SEQUENCE.
RC   TISSUE=Thyroid {ECO:0000313|EMBL:BAD96746.1};
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological
CC       circumstances and cell type. Involved in cell cycle regulation as
CC       a trans-activator that acts to negatively regulate cell division
CC       by controlling a set of genes required for this process. One of
CC       the activated genes is an inhibitor of cyclin-dependent kinases.
CC       Apoptosis induction seems to be mediated either by stimulation of
CC       BAX and FAS antigen expression, or by repression of Bcl-2
CC       expression. {ECO:0000256|RuleBase:RU003304}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000256|RuleBase:RU003304};
CC       Note=Binds 1 zinc ion per subunit.
CC       {ECO:0000256|RuleBase:RU003304};
CC   -!- SUBUNIT: Binds DNA as a homotetramer.
CC       {ECO:0000256|RuleBase:RU003304}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000256|RuleBase:RU003304}.
CC       Nucleus {ECO:0000256|RuleBase:RU003304}.
CC   -!- SIMILARITY: Belongs to the p53 family.
CC       {ECO:0000256|RuleBase:RU003401}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK223026; BAD96746.1; -; mRNA.
DR   RefSeq; NP_000537.3; NM_000546.5.
DR   RefSeq; NP_001119584.1; NM_001126112.2.
DR   RefSeq; NP_001119585.1; NM_001126113.2.
DR   RefSeq; NP_001119586.1; NM_001126114.2.
DR   RefSeq; NP_001119587.1; NM_001126115.1.
DR   RefSeq; NP_001119588.1; NM_001126116.1.
DR   RefSeq; NP_001119589.1; NM_001126117.1.
DR   RefSeq; NP_001119590.1; NM_001126118.1.
DR   RefSeq; NP_001263624.1; NM_001276695.1.
DR   RefSeq; NP_001263625.1; NM_001276696.1.
DR   RefSeq; NP_001263626.1; NM_001276697.1.
DR   RefSeq; NP_001263627.1; NM_001276698.1.
DR   RefSeq; NP_001263628.1; NM_001276699.1.
DR   RefSeq; NP_001263689.1; NM_001276760.1.
DR   RefSeq; NP_001263690.1; NM_001276761.1.
DR   UniGene; Hs.437460; -.
DR   UniGene; Hs.740601; -.
DR   PeptideAtlas; Q53GA5; -.
DR   PRIDE; Q53GA5; -.
DR   DNASU; 7157; -.
DR   GeneID; 7157; -.
DR   KEGG; hsa:7157; -.
DR   CTD; 7157; -.
DR   PharmGKB; PA36679; -.
DR   eggNOG; ENOG410IITK; Eukaryota.
DR   eggNOG; ENOG410ZSWV; LUCA.
DR   HOVERGEN; HBG005201; -.
DR   KO; K04451; -.
DR   GenomeRNAi; 7157; -.
DR   Genevisible; Q53GA5; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IEA:InterPro.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 4.10.170.10; -; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR036674; p53_tetramer_sf.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; PTHR11447; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; SSF47719; 1.
DR   SUPFAM; SSF49417; SSF49417; 1.
PE   2: Evidence at transcript level;
KW   Activator {ECO:0000256|RuleBase:RU003304};
KW   Apoptosis {ECO:0000256|RuleBase:RU003304};
KW   Cell cycle {ECO:0000256|RuleBase:RU003304};
KW   Cytoplasm {ECO:0000256|RuleBase:RU003304};
KW   DNA-binding {ECO:0000256|RuleBase:RU003304};
KW   Metal-binding {ECO:0000256|RuleBase:RU003304};
KW   Nucleus {ECO:0000256|RuleBase:RU003304};
KW   Phosphoprotein {ECO:0000256|RuleBase:RU003304};
KW   Transcription {ECO:0000256|RuleBase:RU003304};
KW   Transcription regulation {ECO:0000256|RuleBase:RU003304};
KW   Zinc {ECO:0000256|RuleBase:RU003304}.
FT   DOMAIN        1     53       P53. {ECO:0000259|Pfam:PF00870}.
FT   DOMAIN       84    122       P53_tetramer. {ECO:0000259|Pfam:PF07710}.
FT   NON_TER       1      1       {ECO:0000313|EMBL:BAD96746.1}.
SQ   SEQUENCE   158 AA;  17656 MW;  5C1AD3B95EB611D7 CRC64;
     YMCNSSCMGG MNGRPILTII TLEDSSGNLL GRNSFEVRVC ACPGRDRRTE EENLRKKGEP
     HHELPPGSTK RALPNNTSSS PQPKKKPLDG EYFTLQIRGR ERFEMFRELN EALELKDAQA
     GKEPGGSRAH SSHLKSKKGQ STSRHKKLMF KTEGPDSD
//
ID   A0A024R784_HUMAN        Unreviewed;      1016 AA.
AC   A0A024R784;
DT   09-JUL-2014, integrated into UniProtKB/TrEMBL.
DT   09-JUL-2014, sequence version 1.
DT   28-FEB-2018, entry version 35.
DE   SubName: Full=Tripartite motif-containing 24, isoform CRA_a {ECO:0000313|EMBL:EAW83886.1};
GN   Name=TRIM24 {ECO:0000313|EMBL:EAW83886.1};
GN   ORFNames=hCG_16386 {ECO:0000313|EMBL:EAW83886.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:EAW83886.1};
RN   [1] {ECO:0000313|EMBL:EAW83886.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11181995; DOI=10.1126/science.1058040;
RA   Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G.,
RA   Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D.,
RA   Amanatides P., Ballew R.M., Huson D.H., Wortman J.R., Zhang Q.,
RA   Kodira C.D., Zheng X.H., Chen L., Skupski M., Subramanian G.,
RA   Thomas P.D., Zhang J., Gabor Miklos G.L., Nelson C., Broder S.,
RA   Clark A.G., Nadeau J., McKusick V.A., Zinder N., Levine A.J.,
RA   Roberts R.J., Simon M., Slayman C., Hunkapiller M., Bolanos R.,
RA   Delcher A., Dew I., Fasulo D., Flanigan M., Florea L., Halpern A.,
RA   Hannenhalli S., Kravitz S., Levy S., Mobarry C., Reinert K.,
RA   Remington K., Abu-Threideh J., Beasley E., Biddick K., Bonazzi V.,
RA   Brandon R., Cargill M., Chandramouliswaran I., Charlab R.,
RA   Chaturvedi K., Deng Z., Di Francesco V., Dunn P., Eilbeck K.,
RA   Evangelista C., Gabrielian A.E., Gan W., Ge W., Gong F., Gu Z.,
RA   Guan P., Heiman T.J., Higgins M.E., Ji R.R., Ke Z., Ketchum K.A.,
RA   Lai Z., Lei Y., Li Z., Li J., Liang Y., Lin X., Lu F., Merkulov G.V.,
RA   Milshina N., Moore H.M., Naik A.K., Narayan V.A., Neelam B.,
RA   Nusskern D., Rusch D.B., Salzberg S., Shao W., Shue B., Sun J.,
RA   Wang Z., Wang A., Wang X., Wang J., Wei M., Wides R., Xiao C., Yan C.,
RA   Yao A., Ye J., Zhan M., Zhang W., Zhang H., Zhao Q., Zheng L.,
RA   Zhong F., Zhong W., Zhu S., Zhao S., Gilbert D., Baumhueter S.,
RA   Spier G., Carter C., Cravchik A., Woodage T., Ali F., An H., Awe A.,
RA   Baldwin D., Baden H., Barnstead M., Barrow I., Beeson K., Busam D.,
RA   Carver A., Center A., Cheng M.L., Curry L., Danaher S., Davenport L.,
RA   Desilets R., Dietz S., Dodson K., Doup L., Ferriera S., Garg N.,
RA   Gluecksmann A., Hart B., Haynes J., Haynes C., Heiner C., Hladun S.,
RA   Hostin D., Houck J., Howland T., Ibegwam C., Johnson J., Kalush F.,
RA   Kline L., Koduru S., Love A., Mann F., May D., McCawley S.,
RA   McIntosh T., McMullen I., Moy M., Moy L., Murphy B., Nelson K.,
RA   Pfannkoch C., Pratts E., Puri V., Qureshi H., Reardon M.,
RA   Rodriguez R., Rogers Y.H., Romblad D., Ruhfel B., Scott R., Sitter C.,
RA   Smallwood M., Stewart E., Strong R., Suh E., Thomas R., Tint N.N.,
RA   Tse S., Vech C., Wang G., Wetter J., Williams S., Williams M.,
RA   Windsor S., Winn-Deen E., Wolfe K., Zaveri J., Zaveri K., Abril J.F.,
RA   Guigo R., Campbell M.J., Sjolander K.V., Karlak B., Kejariwal A.,
RA   Mi H., Lazareva B., Hatton T., Narechania A., Diemer K.,
RA   Muruganujan A., Guo N., Sato S., Bafna V., Istrail S., Lippert R.,
RA   Schwartz R., Walenz B., Yooseph S., Allen D., Basu A., Baxendale J.,
RA   Blick L., Caminha M., Carnes-Stine J., Caulk P., Chiang Y.H.,
RA   Coyne M., Dahlke C., Mays A., Dombroski M., Donnelly M., Ely D.,
RA   Esparham S., Fosler C., Gire H., Glanowski S., Glasser K., Glodek A.,
RA   Gorokhov M., Graham K., Gropman B., Harris M., Heil J., Henderson S.,
RA   Hoover J., Jennings D., Jordan C., Jordan J., Kasha J., Kagan L.,
RA   Kraft C., Levitsky A., Lewis M., Liu X., Lopez J., Ma D., Majoros W.,
RA   McDaniel J., Murphy S., Newman M., Nguyen T., Nguyen N., Nodell M.,
RA   Pan S., Peck J., Peterson M., Rowe W., Sanders R., Scott J.,
RA   Simpson M., Smith T., Sprague A., Stockwell T., Turner R., Venter E.,
RA   Wang M., Wen M., Wu D., Wu M., Xia A., Zandieh A., Zhu X.;
RT   "The sequence of the human genome.";
RL   Science 291:1304-1351(2001).
RN   [2] {ECO:0000313|EMBL:EAW83886.1}
RP   NUCLEOTIDE SEQUENCE.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; CH471070; EAW83886.1; -; Genomic_DNA.
DR   RefSeq; NP_003843.3; NM_003852.3.
DR   UniGene; Hs.490287; -.
DR   ProteinModelPortal; A0A024R784; -.
DR   SMR; A0A024R784; -.
DR   PRIDE; A0A024R784; -.
DR   GeneID; 8805; -.
DR   CTD; 8805; -.
DR   EuPathDB; HostDB:ENSG00000122779.16; -.
DR   eggNOG; ENOG410KDQG; Eukaryota.
DR   eggNOG; COG5076; LUCA.
DR   ChiTaRS; TRIM24; human.
DR   GenomeRNAi; 8805; -.
DR   Bgee; ENSG00000122779; -.
DR   ExpressionAtlas; A0A024R784; baseline and differential.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   CDD; cd00021; BBOX; 1.
DR   Gene3D; 1.20.920.10; -; 1.
DR   InterPro; IPR003649; Bbox_C.
DR   InterPro; IPR001487; Bromodomain.
DR   InterPro; IPR036427; Bromodomain-like_sf.
DR   InterPro; IPR018359; Bromodomain_CS.
DR   InterPro; IPR019786; Zinc_finger_PHD-type_CS.
DR   InterPro; IPR000315; Znf_B-box.
DR   InterPro; IPR011011; Znf_FYVE_PHD.
DR   InterPro; IPR001965; Znf_PHD.
DR   InterPro; IPR019787; Znf_PHD-finger.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   Pfam; PF00439; Bromodomain; 1.
DR   Pfam; PF00628; PHD; 1.
DR   Pfam; PF00643; zf-B_box; 1.
DR   PRINTS; PR00503; BROMODOMAIN.
DR   SMART; SM00502; BBC; 1.
DR   SMART; SM00336; BBOX; 2.
DR   SMART; SM00297; BROMO; 1.
DR   SMART; SM00249; PHD; 1.
DR   SMART; SM00184; RING; 1.
DR   SUPFAM; SSF47370; SSF47370; 1.
DR   SUPFAM; SSF57903; SSF57903; 1.
DR   PROSITE; PS00633; BROMODOMAIN_1; 1.
DR   PROSITE; PS50014; BROMODOMAIN_2; 1.
DR   PROSITE; PS50119; ZF_BBOX; 2.
DR   PROSITE; PS01359; ZF_PHD_1; 1.
DR   PROSITE; PS50016; ZF_PHD_2; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   4: Predicted;
KW   Bromodomain {ECO:0000256|PROSITE-ProRule:PRU00035,
KW   ECO:0000256|SAAS:SAAS00735317}; Coiled coil {ECO:0000256|SAM:Coils};
KW   Metal-binding {ECO:0000256|PROSITE-ProRule:PRU00024,
KW   ECO:0000256|SAAS:SAAS01007077};
KW   Zinc {ECO:0000256|PROSITE-ProRule:PRU00024,
KW   ECO:0000256|SAAS:SAAS01007077};
KW   Zinc-finger {ECO:0000256|PROSITE-ProRule:PRU00024,
KW   ECO:0000256|SAAS:SAAS01007077}.
FT   DOMAIN       56    131       RING-type. {ECO:0000259|PROSITE:PS50089}.
FT   DOMAIN      158    211       B box-type.
FT                                {ECO:0000259|PROSITE:PS50119}.
FT   DOMAIN      218    259       B box-type.
FT                                {ECO:0000259|PROSITE:PS50119}.
FT   DOMAIN      792    839       PHD-type. {ECO:0000259|PROSITE:PS50016}.
FT   DOMAIN      898    953       Bromo. {ECO:0000259|PROSITE:PS50014}.
FT   COILED      328    355       {ECO:0000256|SAM:Coils}.
SQ   SEQUENCE   1016 AA;  113018 MW;  4621C94EB3A74AE2 CRC64;
     MEVAVEKAVA AAAAASAAAS GGPSAAPSGE NEAESRQGPD SERGGEAARL NLLDTCAVCH
     QNIQSRAPKL LPCLHSFCQR CLPAPQRYLM LPAPMLGSAE TPPPVPAPGS PVSGSSPFAT
     QVGVIRCPVC SQECAERHII DNFFVKDTTE VPSSTVEKSN QVCTSCEDNA EANGFCVECV
     EWLCKTCIRA HQRVKFTKDH TVRQKEEVSP EAVGVTSQRP VFCPFHKKEQ LKLYCETCDK
     LTCRDCQLLE HKEHRYQFIE EAFQNQKVII DTLITKLMEK TKYIKFTGNQ IQNRIIEVNQ
     NQKQVEQDIK VAIFTLMVEI NKKGKALLHQ LESLAKDHRM KLMQQQQEVA GLSKQLEHVM
     HFSKWAVSSG SSTALLYSKR LITYRLRHLL RARCDASPVT NNTIQFHCDP SFWAQNIINL
     GSLVIEDKES QPQMPKQNPV VEQNSQPPSG LSSNQLSKFP TQISLAQLRL QHMQQQQPPP
     RLINFQNHSP KPNGPVLPPH PQQLRYPPNQ NIPRQAIKPN PLQMAFLAQQ AIKQWQISSG
     QGTPSTTNST SSTPSSPTIT SAAGYDGKAF GSPMIDLSSP VGGSYNLPSL PDIDCSSTIM
     LDNIVRKDTN IDHGQPRPPS NRTVQSPNSS VPSPGLAGPV TMTSVHPPIR SPSASSVGSR
     GSSGSSSKPA GADSTHKVPV VMLEPIRIKQ ENSGPPENYD FPVVIVKQES DEESRPQNAN
     YPRSILTSLL LNSSQSSTSE ETVLRSDAPD STGDQPGLHQ DNSSNGKSEW LDPSQKSPLH
     VGETRKEDDP NEDWCAVCQN GGELLCCEKC PKVFHLSCHV PTLTNFPSGE WICTFCRDLS
     KPEVEYDCDA PSHNSEKKKT EGLVKLTPID KRKCERLLLF LYCHEMSLAF QDPVPLTVPD
     YYKIIKNPMD LSTIKKRLQE DYSMYSKPED FVADFRLIFQ NCAEFNEPDS EVANAGIKLE
     NYFEELLKNL YPEKRFPKPE FRNESEDNKF SDDSDDDFVQ PRKKRLKSIE ERQLLK
//
ID   TIF1A_HUMAN             Reviewed;        1050 AA.
AC   O15164; A4D1R7; A4D1R8; O95854;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   24-JAN-2001, sequence version 3.
DT   28-FEB-2018, entry version 189.
DE   RecName: Full=Transcription intermediary factor 1-alpha;
DE            Short=TIF1-alpha;
DE            EC=2.3.2.27;
DE   AltName: Full=E3 ubiquitin-protein ligase TRIM24;
DE   AltName: Full=RING finger protein 82;
DE   AltName: Full=RING-type E3 ubiquitin transferase TIF1-alpha {ECO:0000305};
DE   AltName: Full=Tripartite motif-containing protein 24;
GN   Name=TRIM24; Synonyms=RNF82, TIF1, TIF1A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT), AND SUBUNIT.
RC   TISSUE=Mammary cancer;
RX   PubMed=9115274; DOI=10.1074/jbc.272.18.12062;
RA   Thenot S., Henriquet C., Rochefort H., Cavailles V.;
RT   "Differential interaction of nuclear receptors with the putative human
RT   transcriptional coactivator hTIF1.";
RL   J. Biol. Chem. 272:12062-12068(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT).
RX   PubMed=10022127; DOI=10.1038/sj.onc.1202655;
RA   Venturini L., You J., Stadler M., Galien R., Lallemand V.,
RA   Koken M.H.M., Mattei M.-G., Ganser A., Chambon P., Losson R.,
RA   De The H.;
RT   "TIF1gamma, a novel member of the transcriptional intermediary factor
RT   1 family.";
RL   Oncogene 18:1209-1217(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG).
RC   TISSUE=Retinoblastoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S.,
RA   Kwasnicka D., Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z.,
RA   Lu F., Zeesman S., Nowaczyk M.J., Teshima I., Chitayat D., Shuman C.,
RA   Weksberg R., Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J.,
RA   Rahman N., Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F.,
RA   Belloni E., Shaffer L.G., Pober B., Morton C.C., Gusella J.F.,
RA   Bruns G.A.P., Korf B.R., Quade B.J., Ligon A.H., Ferguson H.,
RA   Higgins A.W., Leach N.T., Herrick S.R., Lemyre E., Farra C.G.,
RA   Kim H.-G., Summers A.M., Gripp K.W., Roberts W., Szatmari P.,
RA   Winsor E.J.T., Grzeschik K.-H., Teebi A., Minassian B.A., Kere J.,
RA   Armengol L., Pujana M.A., Estivill X., Wilson M.D., Koop B.F.,
RA   Tosi S., Moore G.E., Boright A.P., Zlotorynski E., Kerem B.,
RA   Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W.,
RA   Mural R.J., Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 477-510 (ISOFORM LONG).
RC   TISSUE=Mammary cancer;
RA   Cavailles V.;
RL   Submitted (JAN-1999) to UniProtKB.
RN   [8]
RP   INTERACTION WITH NR3C2.
RX   PubMed=10935545; DOI=10.1210/mend.14.8.0502;
RA   Hellal-Levy C., Fagart J., Souque A., Wurtz J.-M., Moras D.,
RA   Rafestin-Oblin M.-E.;
RT   "Crucial role of the H11-H12 loop in stabilizing the active
RT   conformation of the human mineralocorticoid receptor.";
RL   Mol. Endocrinol. 14:1210-1221(2000).
RN   [9]
RP   CHROMOSOMAL TRANSLOCATION WITH RET.
RC   TISSUE=Thyroid;
RX   PubMed=10439047; DOI=10.1038/sj.onc.1202824;
RA   Klugbauer S., Rabes H.M.;
RT   "The transcription coactivator HTIF1 and a related protein are fused
RT   to the RET receptor tyrosine kinase in childhood papillary thyroid
RT   carcinomas.";
RL   Oncogene 18:4388-4393(1999).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-811; SER-1025 AND
RP   SER-1028, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [11]
RP   FUNCTION.
RX   PubMed=16322096; DOI=10.1210/me.2005-0393;
RA   Teyssier C., Ou C.Y., Khetchoumian K., Losson R., Stallcup M.R.;
RT   "Transcriptional intermediary factor 1alpha mediates physical
RT   interaction and functional synergy between the coactivator-associated
RT   arginine methyltransferase 1 and glucocorticoid receptor-interacting
RT   protein 1 nuclear receptor coactivators.";
RL   Mol. Endocrinol. 20:1276-1286(2006).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-667; SER-768; SER-808
RP   AND SER-811, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [14]
RP   INTERACTION WITH AR.
RX   PubMed=19909775; DOI=10.1016/j.bbamcr.2009.11.001;
RA   Kikuchi M., Okumura F., Tsukiyama T., Watanabe M., Miyajima N.,
RA   Tanaka J., Imamura M., Hatakeyama S.;
RT   "TRIM24 mediates ligand-dependent activation of androgen receptor and
RT   is repressed by a bromodomain-containing protein, BRD7, in prostate
RT   cancer cells.";
RL   Biochim. Biophys. Acta 1793:1828-1836(2009).
RN   [15]
RP   FUNCTION AS E3 UBIQUITIN LIGASE, AND INTERACTION WITH TP53.
RX   PubMed=19556538; DOI=10.1073/pnas.0813177106;
RA   Allton K., Jain A.K., Herz H.M., Tsai W.W., Jung S.Y., Qin J.,
RA   Bergmann A., Johnson R.L., Barton M.C.;
RT   "Trim24 targets endogenous p53 for degradation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:11612-11616(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1025 AND SER-1028, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-101; SER-110; SER-768
RP   AND SER-811, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-744; SER-811; THR-818;
RP   SER-1019; SER-1028 AND SER-1042, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-654; SER-744; SER-811;
RP   SER-1025 AND SER-1028, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [23]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-711; LYS-723 AND LYS-949,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [24]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-723 AND LYS-741, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [25]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-702; LYS-723 AND LYS-1041,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [26]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-723, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.O114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to
RT   replication stress reveals novel small ubiquitin-like modified target
RT   proteins and acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [27]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-7; LYS-205; LYS-276;
RP   LYS-436; LYS-458; LYS-552; LYS-641; LYS-702; LYS-711; LYS-723;
RP   LYS-741; LYS-801; LYS-810; LYS-875 AND LYS-992, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-
RT   modification with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 891-1012.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Crystal structure of human bromodomain protein.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 824-1006 IN COMPLEXES WITH
RP   METHYLATED HISTONE PEPTIDES AND ZINC IONS, FUNCTION, MUTAGENESIS OF
RP   ASP-827; CYS-840 AND 979-PHE-ASN-980, SUBCELLULAR LOCATION, SUBUNIT,
RP   AND INDUCTION.
RX   PubMed=21164480; DOI=10.1038/nature09542;
RA   Tsai W.W., Wang Z., Yiu T.T., Akdemir K.C., Xia W., Winter S.,
RA   Tsai C.Y., Shi X., Schwarzer D., Plunkett W., Aronow B., Gozani O.,
RA   Fischle W., Hung M.C., Patel D.J., Barton M.C.;
RT   "TRIM24 links a non-canonical histone signature to breast cancer.";
RL   Nature 468:927-932(2010).
RN   [30]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-320; ASN-403; ASN-762 AND
RP   SER-1009.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Transcriptional coactivator that interacts with numerous
CC       nuclear receptors and coactivators and modulates the transcription
CC       of target genes. Interacts with chromatin depending on histone H3
CC       modifications, having the highest affinity for histone H3 that is
CC       both unmodified at 'Lys-4' (H3K4me0) and acetylated at 'Lys-23'
CC       (H3K23ac). Has E3 protein-ubiquitin ligase activity. Promotes
CC       ubiquitination and proteasomal degradation of p53/TP53. Plays a
CC       role in the regulation of cell proliferation and apoptosis, at
CC       least in part via its effects on p53/TP53 levels. Up-regulates
CC       ligand-dependent transcription activation by AR, GCR/NR3C1,
CC       thyroid hormone receptor (TR) and ESR1. Modulates transcription
CC       activation by retinoic acid (RA) receptors, including RARA. Plays
CC       a role in regulating retinoic acid-dependent proliferation of
CC       hepatocytes (By similarity). {ECO:0000250,
CC       ECO:0000269|PubMed:16322096, ECO:0000269|PubMed:19556538,
CC       ECO:0000269|PubMed:21164480}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts with CARM1, NCOA2/GRIP1, PML, KAT5/TIP60, BRD7,
CC       CBX1, CBX3 and CBX5. Part of a coactivator complex containing
CC       TRIM24, NCOA2 and CARM1 (By similarity). Interacts with NR3C2/MCR.
CC       Interacts with the ligand-binding domain of estrogen receptors (in
CC       vitro). Interaction with DNA-bound estrogen receptors requires the
CC       presence of estradiol. Interacts with AR and p53/TP53. Interacts
CC       (via bromo domain) with histone H3 (via N-terminus), provided that
CC       it is not methylated at 'Lys-4' (H3K4me0). Does not interact with
CC       histone H3 that is methylated at 'Lys-4' (H3K4me1, H3K4me2 or
CC       H3K4me3). Interacts (via bromo domain) with histone H3 (via N-
CC       terminus) that is acetylated at 'Lys-23' (H3K23ac). Has the
CC       highest affinity for histone H3 that is both unmodified at 'Lys-4'
CC       (H3K4me0) and acetylated at 'Lys-23' (H3K23ac). Has very low
CC       affinity for histone H3 that is methylated at 'Lys-9' (H3K9me), or
CC       acetylated at both 'Lys-9' (H3K9ac) and 'Lys-14' (H3K14ac), or
CC       acetylated at 'Lys-27' (H3K27ac) (in vitro). {ECO:0000250,
CC       ECO:0000269|PubMed:10935545, ECO:0000269|PubMed:19556538,
CC       ECO:0000269|PubMed:19909775, ECO:0000269|PubMed:21164480,
CC       ECO:0000269|PubMed:9115274}.
CC   -!- INTERACTION:
CC       P03372:ESR1; NbExp=3; IntAct=EBI-2130378, EBI-78473;
CC       P04637:TP53; NbExp=3; IntAct=EBI-2130378, EBI-366083;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:21164480}.
CC       Cytoplasm {ECO:0000269|PubMed:21164480}. Note=Colocalizes with
CC       sites of active transcription. Detected both in nucleus and
CC       cytoplasm in some breast cancer samples. Predominantly nuclear.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Long;
CC         IsoId=O15164-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=O15164-2; Sequence=VSP_005772;
CC   -!- INDUCTION: Up-regulated in some cases of breast cancer.
CC       {ECO:0000269|PubMed:21164480}.
CC   -!- PTM: Sumoylated. {ECO:0000250}.
CC   -!- DISEASE: Note=A chromosomal aberration involving TRIM24/TIF1 is
CC       found in papillary thyroid carcinomas (PTCs). Translocation
CC       t(7;10)(q32;q11) with RET. The translocation generates the
CC       TRIM24/RET (PTC6) oncogene. {ECO:0000269|PubMed:10439047}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/TRIM24ID504ch7q34.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF009353; AAB63585.1; -; mRNA.
DR   EMBL; AF119042; AAD17258.1; -; mRNA.
DR   EMBL; AK075306; BAG52105.1; -; mRNA.
DR   EMBL; AC008265; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC013429; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH236950; EAL24046.1; -; Genomic_DNA.
DR   EMBL; CH236950; EAL24047.1; -; Genomic_DNA.
DR   EMBL; CH471070; EAW83884.1; -; Genomic_DNA.
DR   EMBL; CH471070; EAW83885.1; -; Genomic_DNA.
DR   EMBL; BC028689; AAH28689.2; -; mRNA.
DR   CCDS; CCDS47720.1; -. [O15164-2]
DR   CCDS; CCDS5847.1; -. [O15164-1]
DR   RefSeq; NP_003843.3; NM_003852.3. [O15164-2]
DR   RefSeq; NP_056989.2; NM_015905.2. [O15164-1]
DR   UniGene; Hs.490287; -.
DR   PDB; 2YYN; X-ray; 2.50 A; A/B/C/D=891-1012.
DR   PDB; 3O33; X-ray; 2.00 A; A/B/C/D=824-1006.
DR   PDB; 3O34; X-ray; 1.90 A; A=824-1006.
DR   PDB; 3O35; X-ray; 1.76 A; A/B=824-1006.
DR   PDB; 3O36; X-ray; 1.70 A; A/B=824-1006.
DR   PDB; 3O37; X-ray; 2.00 A; A/B/C/D=824-1006.
DR   PDB; 4YAB; X-ray; 1.90 A; A/B=824-1006.
DR   PDB; 4YAD; X-ray; 1.73 A; A/B=824-1006.
DR   PDB; 4YAT; X-ray; 2.18 A; A/B=824-1006.
DR   PDB; 4YAX; X-ray; 2.25 A; A/B=824-1006.
DR   PDB; 4YBM; X-ray; 1.46 A; A/B=824-1006.
DR   PDB; 4YBS; X-ray; 1.83 A; A=824-1006.
DR   PDB; 4YBT; X-ray; 1.82 A; A=824-1006.
DR   PDB; 4YC9; X-ray; 1.82 A; A=824-1006.
DR   PDB; 4ZQL; X-ray; 1.79 A; A/B=825-1006.
DR   PDB; 5H1T; X-ray; 1.95 A; A/B/C/D=824-1006.
DR   PDB; 5H1U; X-ray; 1.90 A; A/B/C/D=824-1006.
DR   PDB; 5H1V; X-ray; 2.00 A; A/B=824-1006.
DR   PDBsum; 2YYN; -.
DR   PDBsum; 3O33; -.
DR   PDBsum; 3O34; -.
DR   PDBsum; 3O35; -.
DR   PDBsum; 3O36; -.
DR   PDBsum; 3O37; -.
DR   PDBsum; 4YAB; -.
DR   PDBsum; 4YAD; -.
DR   PDBsum; 4YAT; -.
DR   PDBsum; 4YAX; -.
DR   PDBsum; 4YBM; -.
DR   PDBsum; 4YBS; -.
DR   PDBsum; 4YBT; -.
DR   PDBsum; 4YC9; -.
DR   PDBsum; 4ZQL; -.
DR   PDBsum; 5H1T; -.
DR   PDBsum; 5H1U; -.
DR   PDBsum; 5H1V; -.
DR   ProteinModelPortal; O15164; -.
DR   SMR; O15164; -.
DR   BioGrid; 114333; 94.
DR   DIP; DIP-52713N; -.
DR   ELM; O15164; -.
DR   IntAct; O15164; 21.
DR   MINT; O15164; -.
DR   STRING; 9606.ENSP00000340507; -.
DR   BindingDB; O15164; -.
DR   ChEMBL; CHEMBL3108638; -.
DR   GuidetoPHARMACOLOGY; 2252; -.
DR   iPTMnet; O15164; -.
DR   PhosphoSitePlus; O15164; -.
DR   BioMuta; TRIM24; -.
DR   EPD; O15164; -.
DR   MaxQB; O15164; -.
DR   PaxDb; O15164; -.
DR   PeptideAtlas; O15164; -.
DR   PRIDE; O15164; -.
DR   DNASU; 8805; -.
DR   Ensembl; ENST00000343526; ENSP00000340507; ENSG00000122779. [O15164-1]
DR   Ensembl; ENST00000415680; ENSP00000390829; ENSG00000122779. [O15164-2]
DR   GeneID; 8805; -.
DR   KEGG; hsa:8805; -.
DR   UCSC; uc003vub.4; human. [O15164-1]
DR   CTD; 8805; -.
DR   DisGeNET; 8805; -.
DR   EuPathDB; HostDB:ENSG00000122779.16; -.
DR   GeneCards; TRIM24; -.
DR   HGNC; HGNC:11812; TRIM24.
DR   HPA; HPA043495; -.
DR   HPA; HPA061717; -.
DR   MalaCards; TRIM24; -.
DR   MIM; 603406; gene.
DR   neXtProt; NX_O15164; -.
DR   OpenTargets; ENSG00000122779; -.
DR   Orphanet; 146; Papillary or follicular thyroid carcinoma.
DR   PharmGKB; PA36519; -.
DR   eggNOG; ENOG410KDQG; Eukaryota.
DR   eggNOG; COG5076; LUCA.
DR   GeneTree; ENSGT00890000139374; -.
DR   HOGENOM; HOG000252971; -.
DR   HOVERGEN; HBG054599; -.
DR   InParanoid; O15164; -.
DR   KO; K08881; -.
DR   OMA; FWAQNIF; -.
DR   OrthoDB; EOG091G01KK; -.
DR   PhylomeDB; O15164; -.
DR   TreeFam; TF106455; -.
DR   Reactome; R-HSA-1839117; Signaling by cytosolic FGFR1 fusion mutants.
DR   Reactome; R-HSA-5655302; Signaling by FGFR1 in disease.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF fusions.
DR   SIGNOR; O15164; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; TRIM24; human.
DR   EvolutionaryTrace; O15164; -.
DR   GeneWiki; TRIM24; -.
DR   GenomeRNAi; 8805; -.
DR   PRO; PR:O15164; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; ENSG00000122779; -.
DR   CleanEx; HS_TRIM24; -.
DR   ExpressionAtlas; O15164; baseline and differential.
DR   Genevisible; O15164; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005719; C:nuclear euchromatin; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005726; C:perichromatin fibrils; IEA:Ensembl.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0034056; F:estrogen response element binding; IDA:UniProtKB.
DR   GO; GO:0016922; F:ligand-dependent nuclear receptor binding; IEA:Ensembl.
DR   GO; GO:0070577; F:lysine-acetylated histone binding; IDA:UniProtKB.
DR   GO; GO:0002039; F:p53 binding; IPI:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; TAS:Reactome.
DR   GO; GO:0005102; F:receptor binding; TAS:ProtInc.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IEA:Ensembl.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0055074; P:calcium ion homeostasis; IEA:Ensembl.
DR   GO; GO:0071391; P:cellular response to estrogen stimulus; IDA:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IEA:Ensembl.
DR   GO; GO:0030163; P:protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0031647; P:regulation of protein stability; IMP:UniProtKB.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; IEA:Ensembl.
DR   GO; GO:0070562; P:regulation of vitamin D receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0006366; P:transcription from RNA polymerase II promoter; TAS:ProtInc.
DR   CDD; cd00021; BBOX; 1.
DR   Gene3D; 1.20.920.10; -; 1.
DR   InterPro; IPR003649; Bbox_C.
DR   InterPro; IPR001487; Bromodomain.
DR   InterPro; IPR036427; Bromodomain-like_sf.
DR   InterPro; IPR018359; Bromodomain_CS.
DR   InterPro; IPR019786; Zinc_finger_PHD-type_CS.
DR   InterPro; IPR000315; Znf_B-box.
DR   InterPro; IPR011011; Znf_FYVE_PHD.
DR   InterPro; IPR001965; Znf_PHD.
DR   InterPro; IPR019787; Znf_PHD-finger.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   Pfam; PF00439; Bromodomain; 1.
DR   Pfam; PF00628; PHD; 1.
DR   Pfam; PF00643; zf-B_box; 1.
DR   PRINTS; PR00503; BROMODOMAIN.
DR   SMART; SM00502; BBC; 1.
DR   SMART; SM00336; BBOX; 2.
DR   SMART; SM00297; BROMO; 1.
DR   SMART; SM00249; PHD; 1.
DR   SMART; SM00184; RING; 1.
DR   SUPFAM; SSF47370; SSF47370; 1.
DR   SUPFAM; SSF57903; SSF57903; 1.
DR   PROSITE; PS00633; BROMODOMAIN_1; 1.
DR   PROSITE; PS50014; BROMODOMAIN_2; 1.
DR   PROSITE; PS50119; ZF_BBOX; 2.
DR   PROSITE; PS01359; ZF_PHD_1; 1.
DR   PROSITE; PS50016; ZF_PHD_2; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Bromodomain;
KW   Chromosomal rearrangement; Coiled coil; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; DNA-binding; Isopeptide bond;
KW   Metal-binding; Methylation; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Repressor; Transcription;
KW   Transcription regulation; Transferase; Tumor suppressor;
KW   Ubl conjugation; Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN         1   1050       Transcription intermediary factor 1-
FT                                alpha.
FT                                /FTId=PRO_0000056390.
FT   DOMAIN      932    987       Bromo. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00035}.
FT   ZN_FING      56     82       RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00175}.
FT   ZN_FING     158    211       B box-type 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00024}.
FT   ZN_FING     218    259       B box-type 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00024}.
FT   ZN_FING     826    873       PHD-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00146}.
FT   REGION      754    779       Nuclear receptor binding site (NRBS).
FT   REGION      834    840       Interaction with histone H3 that is not
FT                                methylated at 'Lys-4' (H3K4me0).
FT   REGION      979    980       Interaction with histone H3 that is
FT                                acetylated at 'Lys-23' (H3K23ac).
FT   COILED      289    359       {ECO:0000255}.
FT   MOTIF       891    907       Nuclear localization signal.
FT                                {ECO:0000255}.
FT   COMPBIAS      9     15       Poly-Ala.
FT   COMPBIAS    344    347       Poly-Gln.
FT   SITE        476    477       Breakpoint for translocation to form
FT                                TRIM24-RET oncogene.
FT   SITE        827    827       Interaction with histone H3 that is not
FT                                methylated at 'Lys-4' (H3K4me0).
FT   MOD_RES     101    101       Phosphothreonine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES     110    110       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES     469    469       Omega-N-methylarginine.
FT                                {ECO:0000250|UniProtKB:Q64127}.
FT   MOD_RES     654    654       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     660    660       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q64127}.
FT   MOD_RES     667    667       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     744    744       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     768    768       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231}.
FT   MOD_RES     808    808       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     811    811       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     818    818       Phosphothreonine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES    1019   1019       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES    1025   1025       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1028   1028       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1042   1042       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   CROSSLNK      7      7       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    205    205       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    276    276       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    436    436       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    458    458       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    552    552       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    641    641       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    702    702       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25772364,
FT                                ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    711    711       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25218447,
FT                                ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    723    723       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO1);
FT                                alternate. {ECO:0000244|PubMed:25114211}.
FT   CROSSLNK    723    723       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2);
FT                                alternate. {ECO:0000244|PubMed:25114211,
FT                                ECO:0000244|PubMed:25218447,
FT                                ECO:0000244|PubMed:25755297,
FT                                ECO:0000244|PubMed:25772364,
FT                                ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    741    741       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25114211,
FT                                ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    801    801       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    810    810       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    875    875       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    949    949       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25218447}.
FT   CROSSLNK    992    992       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK   1041   1041       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25772364}.
FT   VAR_SEQ     477    510       Missing (in isoform Short).
FT                                {ECO:0000303|PubMed:10022127,
FT                                ECO:0000303|PubMed:9115274}.
FT                                /FTId=VSP_005772.
FT   VARIANT     320    320       I -> T (in an ovarian serous carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042382.
FT   VARIANT     403    403       T -> N (in a lung squamous cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042383.
FT   VARIANT     762    762       S -> N. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042384.
FT   VARIANT     796    796       N -> S (in dbSNP:rs35356723).
FT                                /FTId=VAR_052148.
FT   VARIANT    1009   1009       R -> S (in dbSNP:rs34585297).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042385.
FT   MUTAGEN     827    827       D->A: Strongly reduced affinity for
FT                                histone H3 that is not methylated at
FT                                'Lys-4' (H3K4me0).
FT                                {ECO:0000269|PubMed:21164480}.
FT   MUTAGEN     840    840       C->W: Abolishes interaction with histone
FT                                H3. {ECO:0000269|PubMed:21164480}.
FT   MUTAGEN     979    980       FN->AA: Strongly reduced affinity for
FT                                histone H3 that is acetylated at 'Lys-23'
FT                                (H3K23ac). {ECO:0000269|PubMed:21164480}.
FT   CONFLICT     14     20       AASAAAS -> RLGCAP (in Ref. 1; AAB63585).
FT                                {ECO:0000305}.
FT   CONFLICT     24     28       SAAPS -> RGG (in Ref. 1; AAB63585).
FT                                {ECO:0000305}.
FT   CONFLICT    109    114       GSPVSG -> ARRSA (in Ref. 1; AAB63585).
FT                                {ECO:0000305}.
FT   CONFLICT    350    350       A -> T (in Ref. 1; AAB63585).
FT                                {ECO:0000305}.
FT   CONFLICT    600    600       D -> N (in Ref. 1; AAB63585).
FT                                {ECO:0000305}.
FT   CONFLICT    608    608       M -> I (in Ref. 1; AAB63585).
FT                                {ECO:0000305}.
FT   CONFLICT    967    967       A -> R (in Ref. 1; AAB63585).
FT                                {ECO:0000305}.
FT   STRAND      827    829       {ECO:0000244|PDB:3O33}.
FT   TURN        830    832       {ECO:0000244|PDB:4YBM}.
FT   STRAND      836    840       {ECO:0000244|PDB:3O37}.
FT   STRAND      842    845       {ECO:0000244|PDB:4YBM}.
FT   TURN        850    852       {ECO:0000244|PDB:4YBM}.
FT   STRAND      853    855       {ECO:0000244|PDB:4YBM}.
FT   TURN        868    870       {ECO:0000244|PDB:4YBM}.
FT   STRAND      873    875       {ECO:0000244|PDB:4YBM}.
FT   HELIX       881    883       {ECO:0000244|PDB:4YBM}.
FT   TURN        889    891       {ECO:0000244|PDB:3O36}.
FT   HELIX       902    917       {ECO:0000244|PDB:4YBM}.
FT   HELIX       919    921       {ECO:0000244|PDB:3O37}.
FT   HELIX       922    924       {ECO:0000244|PDB:4YBM}.
FT   HELIX       935    938       {ECO:0000244|PDB:4YBM}.
FT   HELIX       945    953       {ECO:0000244|PDB:4YBM}.
FT   TURN        954    956       {ECO:0000244|PDB:4YC9}.
FT   HELIX       962    979       {ECO:0000244|PDB:4YBM}.
FT   HELIX       985   1004       {ECO:0000244|PDB:4YBM}.
FT   STRAND     1005   1007       {ECO:0000244|PDB:2YYN}.
SQ   SEQUENCE   1050 AA;  116831 MW;  D341E8022AACC67E CRC64;
     MEVAVEKAVA AAAAASAAAS GGPSAAPSGE NEAESRQGPD SERGGEAARL NLLDTCAVCH
     QNIQSRAPKL LPCLHSFCQR CLPAPQRYLM LPAPMLGSAE TPPPVPAPGS PVSGSSPFAT
     QVGVIRCPVC SQECAERHII DNFFVKDTTE VPSSTVEKSN QVCTSCEDNA EANGFCVECV
     EWLCKTCIRA HQRVKFTKDH TVRQKEEVSP EAVGVTSQRP VFCPFHKKEQ LKLYCETCDK
     LTCRDCQLLE HKEHRYQFIE EAFQNQKVII DTLITKLMEK TKYIKFTGNQ IQNRIIEVNQ
     NQKQVEQDIK VAIFTLMVEI NKKGKALLHQ LESLAKDHRM KLMQQQQEVA GLSKQLEHVM
     HFSKWAVSSG SSTALLYSKR LITYRLRHLL RARCDASPVT NNTIQFHCDP SFWAQNIINL
     GSLVIEDKES QPQMPKQNPV VEQNSQPPSG LSSNQLSKFP TQISLAQLRL QHMQQQVMAQ
     RQQVQRRPAP VGLPNPRMQG PIQQPSISHQ QPPPRLINFQ NHSPKPNGPV LPPHPQQLRY
     PPNQNIPRQA IKPNPLQMAF LAQQAIKQWQ ISSGQGTPST TNSTSSTPSS PTITSAAGYD
     GKAFGSPMID LSSPVGGSYN LPSLPDIDCS STIMLDNIVR KDTNIDHGQP RPPSNRTVQS
     PNSSVPSPGL AGPVTMTSVH PPIRSPSASS VGSRGSSGSS SKPAGADSTH KVPVVMLEPI
     RIKQENSGPP ENYDFPVVIV KQESDEESRP QNANYPRSIL TSLLLNSSQS STSEETVLRS
     DAPDSTGDQP GLHQDNSSNG KSEWLDPSQK SPLHVGETRK EDDPNEDWCA VCQNGGELLC
     CEKCPKVFHL SCHVPTLTNF PSGEWICTFC RDLSKPEVEY DCDAPSHNSE KKKTEGLVKL
     TPIDKRKCER LLLFLYCHEM SLAFQDPVPL TVPDYYKIIK NPMDLSTIKK RLQEDYSMYS
     KPEDFVADFR LIFQNCAEFN EPDSEVANAG IKLENYFEEL LKNLYPEKRF PKPEFRNESE
     DNKFSDDSDD DFVQPRKKRL KSIEERQLLK
//
ID   A0A1W2PPP2_HUMAN        Unreviewed;       514 AA.
AC   A0A1W2PPP2;
DT   07-JUN-2017, integrated into UniProtKB/TrEMBL.
DT   07-JUN-2017, sequence version 1.
DT   28-FEB-2018, entry version 9.
DE   SubName: Full=Wilms tumor protein {ECO:0000313|Ensembl:ENSP00000491511};
GN   Name=WT1 {ECO:0000313|Ensembl:ENSP00000491511};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000491511, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Ensembl:ENSP00000491511, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [2] {ECO:0000213|PubMed:28112733}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-
RT   modification with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [3] {ECO:0000313|Ensembl:ENSP00000491511}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (APR-2017) to UniProtKB.
CC   -!- CAUTION: The sequence shown here is derived from an Ensembl
CC       automatic analysis pipeline and should be considered as
CC       preliminary data. {ECO:0000313|Ensembl:ENSP00000491511}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AL049692; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_077742.2; NM_024424.3.
DR   UniGene; Hs.591980; -.
DR   PeptideAtlas; A0A1W2PPP2; -.
DR   Ensembl; ENST00000639907; ENSP00000491511; ENSG00000184937.
DR   GeneID; 7490; -.
DR   CTD; 7490; -.
DR   HGNC; HGNC:12796; WT1.
DR   OpenTargets; ENSG00000184937; -.
DR   GeneTree; ENSGT00550000074455; -.
DR   ChiTaRS; WT1; human.
DR   Proteomes; UP000005640; Chromosome 11.
DR   ExpressionAtlas; A0A1W2PPP2; baseline and differential.
DR   GO; GO:0005634; C:nucleus; IEA:InterPro.
DR   GO; GO:0003676; F:nucleic acid binding; IEA:InterPro.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:InterPro.
DR   InterPro; IPR017987; Wilms_tumour.
DR   InterPro; IPR000976; Wilms_tumour_N.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   Pfam; PF02165; WT1; 2.
DR   PRINTS; PR00049; WILMSTUMOUR.
DR   SMART; SM00355; ZnF_C2H2; 4.
DR   SUPFAM; SSF57667; SSF57667; 2.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 4.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 4.
PE   1: Evidence at protein level;
KW   Complete proteome {ECO:0000313|Proteomes:UP000005640};
KW   Metal-binding {ECO:0000256|PROSITE-ProRule:PRU00042};
KW   Proteomics identification {ECO:0000213|EPD:A0A1W2PPP2,
KW   ECO:0000213|MaxQB:A0A1W2PPP2, ECO:0000213|PeptideAtlas:A0A1W2PPP2};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640};
KW   Zinc {ECO:0000256|PROSITE-ProRule:PRU00042};
KW   Zinc-finger {ECO:0000256|PROSITE-ProRule:PRU00042}.
FT   DOMAIN      391    420       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
FT   DOMAIN      421    450       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
FT   DOMAIN      451    478       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
FT   DOMAIN      479    508       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
SQ   SEQUENCE   514 AA;  55965 MW;  83BC92BA2B0D4A14 CRC64;
     MQDPASTCVP EPASQHTLRS GPGCLQQPEQ QGVRDPGGIW AKLGAAEASA ERLQGRRSRG
     ASGSEPQQMG SDVRDLNALL PAVPSLGGGG GCALPVSGAA QWAPVLDFAP PGASAYGSLG
     GPAPPPAPPP PPPPPPHSFI KQEPSWGGAE PHEEQCLSAF TVHFSGQFTG TAGACRYGPF
     GPPPPSQASS GQARMFPNAP YLPSCLESQP AIRNQGYSTV TFDGTPSYGH TPSHHAAQFP
     NHSFKHEDPM GQQGSLGEQQ YSVPPPVYGC HTPTDSCTGS QALLLRTPYS SDNLYQMTSQ
     LECMTWNQMN LGATLKGVAA GSSSSVKWTE GQSNHSTGYE SDNHTTPILC GAQYRIHTHG
     VFRGIQDVRR VPGVAPTLVR SASETSEKRP FMCAYPGCNK RYFKLSHLQM HSRKHTGEKP
     YQCDFKDCER RFSRSDQLKR HQRRHTGVKP FQCKTCQRKF SRSDHLKTHT RTHTGEKPFS
     CRWPSCQKKF ARSDELVRHH NMHQRNMTKL QLAL
//
ID   A0A1W2PQQ0_HUMAN        Unreviewed;       497 AA.
AC   A0A1W2PQQ0;
DT   07-JUN-2017, integrated into UniProtKB/TrEMBL.
DT   07-JUN-2017, sequence version 1.
DT   28-FEB-2018, entry version 9.
DE   SubName: Full=Wilms tumor protein {ECO:0000313|Ensembl:ENSP00000492269};
GN   Name=WT1 {ECO:0000313|Ensembl:ENSP00000492269};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000492269, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Ensembl:ENSP00000492269, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [2] {ECO:0000213|PubMed:28112733}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-
RT   modification with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [3] {ECO:0000313|Ensembl:ENSP00000492269}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (APR-2017) to UniProtKB.
CC   -!- CAUTION: The sequence shown here is derived from an Ensembl
CC       automatic analysis pipeline and should be considered as
CC       preliminary data. {ECO:0000313|Ensembl:ENSP00000492269}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AL049692; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_000369.3; NM_000378.4.
DR   UniGene; Hs.591980; -.
DR   SMR; A0A1W2PQQ0; -.
DR   Ensembl; ENST00000639563; ENSP00000492269; ENSG00000184937.
DR   GeneID; 7490; -.
DR   KEGG; hsa:7490; -.
DR   CTD; 7490; -.
DR   HGNC; HGNC:12796; WT1.
DR   OpenTargets; ENSG00000184937; -.
DR   GeneTree; ENSGT00550000074455; -.
DR   KO; K09234; -.
DR   ChiTaRS; WT1; human.
DR   Proteomes; UP000005640; Chromosome 11.
DR   ExpressionAtlas; A0A1W2PQQ0; baseline and differential.
DR   GO; GO:0005634; C:nucleus; IEA:InterPro.
DR   GO; GO:0003676; F:nucleic acid binding; IEA:InterPro.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:InterPro.
DR   InterPro; IPR017987; Wilms_tumour.
DR   InterPro; IPR000976; Wilms_tumour_N.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   Pfam; PF02165; WT1; 1.
DR   PRINTS; PR00049; WILMSTUMOUR.
DR   SMART; SM00355; ZnF_C2H2; 4.
DR   SUPFAM; SSF57667; SSF57667; 2.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 4.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 4.
PE   1: Evidence at protein level;
KW   Complete proteome {ECO:0000313|Proteomes:UP000005640};
KW   Metal-binding {ECO:0000256|PROSITE-ProRule:PRU00042};
KW   Proteomics identification {ECO:0000213|EPD:A0A1W2PQQ0,
KW   ECO:0000213|MaxQB:A0A1W2PQQ0, ECO:0000213|PeptideAtlas:A0A1W2PQQ0};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640};
KW   Zinc {ECO:0000256|PROSITE-ProRule:PRU00042};
KW   Zinc-finger {ECO:0000256|PROSITE-ProRule:PRU00042}.
FT   DOMAIN      374    403       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
FT   DOMAIN      404    433       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
FT   DOMAIN      434    461       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
FT   DOMAIN      462    491       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
SQ   SEQUENCE   497 AA;  54288 MW;  EF68A3182252372B CRC64;
     MQDPASTCVP EPASQHTLRS GPGCLQQPEQ QGVRDPGGIW AKLGAAEASA ERLQGRRSRG
     ASGSEPQQMG SDVRDLNALL PAVPSLGGGG GCALPVSGAA QWAPVLDFAP PGASAYGSLG
     GPAPPPAPPP PPPPPPHSFI KQEPSWGGAE PHEEQCLSAF TVHFSGQFTG TAGACRYGPF
     GPPPPSQASS GQARMFPNAP YLPSCLESQP AIRNQGYSTV TFDGTPSYGH TPSHHAAQFP
     NHSFKHEDPM GQQGSLGEQQ YSVPPPVYGC HTPTDSCTGS QALLLRTPYS SDNLYQMTSQ
     LECMTWNQMN LGATLKGHST GYESDNHTTP ILCGAQYRIH THGVFRGIQD VRRVPGVAPT
     LVRSASETSE KRPFMCAYPG CNKRYFKLSH LQMHSRKHTG EKPYQCDFKD CERRFSRSDQ
     LKRHQRRHTG VKPFQCKTCQ RKFSRSDHLK THTRTHTGEK PFSCRWPSCQ KKFARSDELV
     RHHNMHQRNM TKLQLAL
//
ID   A0A1W2PR07_HUMAN        Unreviewed;       517 AA.
AC   A0A1W2PR07;
DT   07-JUN-2017, integrated into UniProtKB/TrEMBL.
DT   07-JUN-2017, sequence version 1.
DT   28-FEB-2018, entry version 9.
DE   SubName: Full=Wilms tumor protein {ECO:0000313|Ensembl:ENSP00000491984};
GN   Name=WT1 {ECO:0000313|Ensembl:ENSP00000491984};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|Ensembl:ENSP00000491984, ECO:0000313|Proteomes:UP000005640};
RN   [1] {ECO:0000313|Ensembl:ENSP00000491984, ECO:0000313|Proteomes:UP000005640}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [2] {ECO:0000213|PubMed:28112733}
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-
RT   modification with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [3] {ECO:0000313|Ensembl:ENSP00000491984}
RP   IDENTIFICATION.
RG   Ensembl;
RL   Submitted (APR-2017) to UniProtKB.
CC   -!- CAUTION: The sequence shown here is derived from an Ensembl
CC       automatic analysis pipeline and should be considered as
CC       preliminary data. {ECO:0000313|Ensembl:ENSP00000491984}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AL049692; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_077744.3; NM_024426.4.
DR   UniGene; Hs.591980; -.
DR   PeptideAtlas; A0A1W2PR07; -.
DR   Ensembl; ENST00000640146; ENSP00000491984; ENSG00000184937.
DR   GeneID; 7490; -.
DR   CTD; 7490; -.
DR   HGNC; HGNC:12796; WT1.
DR   OpenTargets; ENSG00000184937; -.
DR   GeneTree; ENSGT00550000074455; -.
DR   ChiTaRS; WT1; human.
DR   Proteomes; UP000005640; Chromosome 11.
DR   ExpressionAtlas; A0A1W2PR07; baseline and differential.
DR   GO; GO:0005634; C:nucleus; IEA:InterPro.
DR   GO; GO:0003676; F:nucleic acid binding; IEA:InterPro.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:InterPro.
DR   InterPro; IPR017987; Wilms_tumour.
DR   InterPro; IPR000976; Wilms_tumour_N.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   Pfam; PF02165; WT1; 2.
DR   PRINTS; PR00049; WILMSTUMOUR.
DR   SMART; SM00355; ZnF_C2H2; 4.
DR   SUPFAM; SSF57667; SSF57667; 2.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 4.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 4.
PE   1: Evidence at protein level;
KW   Complete proteome {ECO:0000313|Proteomes:UP000005640};
KW   Metal-binding {ECO:0000256|PROSITE-ProRule:PRU00042};
KW   Proteomics identification {ECO:0000213|EPD:A0A1W2PR07,
KW   ECO:0000213|MaxQB:A0A1W2PR07, ECO:0000213|PeptideAtlas:A0A1W2PR07};
KW   Reference proteome {ECO:0000313|Proteomes:UP000005640};
KW   Zinc {ECO:0000256|PROSITE-ProRule:PRU00042};
KW   Zinc-finger {ECO:0000256|PROSITE-ProRule:PRU00042}.
FT   DOMAIN      391    420       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
FT   DOMAIN      421    450       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
FT   DOMAIN      451    478       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
FT   DOMAIN      482    511       C2H2-type. {ECO:0000259|PROSITE:PS50157}.
SQ   SEQUENCE   517 AA;  56281 MW;  7644E132133E3DF3 CRC64;
     MQDPASTCVP EPASQHTLRS GPGCLQQPEQ QGVRDPGGIW AKLGAAEASA ERLQGRRSRG
     ASGSEPQQMG SDVRDLNALL PAVPSLGGGG GCALPVSGAA QWAPVLDFAP PGASAYGSLG
     GPAPPPAPPP PPPPPPHSFI KQEPSWGGAE PHEEQCLSAF TVHFSGQFTG TAGACRYGPF
     GPPPPSQASS GQARMFPNAP YLPSCLESQP AIRNQGYSTV TFDGTPSYGH TPSHHAAQFP
     NHSFKHEDPM GQQGSLGEQQ YSVPPPVYGC HTPTDSCTGS QALLLRTPYS SDNLYQMTSQ
     LECMTWNQMN LGATLKGVAA GSSSSVKWTE GQSNHSTGYE SDNHTTPILC GAQYRIHTHG
     VFRGIQDVRR VPGVAPTLVR SASETSEKRP FMCAYPGCNK RYFKLSHLQM HSRKHTGEKP
     YQCDFKDCER RFSRSDQLKR HQRRHTGVKP FQCKTCQRKF SRSDHLKTHT RTHTGKTSEK
     PFSCRWPSCQ KKFARSDELV RHHNMHQRNM TKLQLAL
//
ID   WT1_HUMAN               Reviewed;         449 AA.
AC   P19544; A8K6S1; B3KSA5; Q15881; Q16256; Q16575; Q4VXV4; Q4VXV5;
AC   Q4VXV6; Q8IYZ5;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1991, sequence version 2.
DT   28-FEB-2018, entry version 219.
DE   RecName: Full=Wilms tumor protein;
DE   AltName: Full=WT33;
GN   Name=WT1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 7).
RC   TISSUE=Fetal kidney;
RX   PubMed=2154702; DOI=10.1038/343774a0;
RA   Gessler M., Poustka A., Cavenee W., Neve R.L., Orkin S.H.,
RA   Bruns G.A.P.;
RT   "Homozygous deletion in Wilms tumours of a zinc-finger gene identified
RT   by chromosome jumping.";
RL   Nature 343:774-778(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORMS
RP   1; 2; 3 AND 4).
RC   TISSUE=Placenta;
RX   PubMed=1658787; DOI=10.1073/pnas.88.21.9618;
RA   Haber D.A., Sohn R.L., Buckler A.J., Pelletier J., Call K.M.,
RA   Housman D.E.;
RT   "Alternative splicing and genomic structure of the Wilms tumor gene
RT   WT1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:9618-9622(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORM
RP   4).
RX   PubMed=1572653; DOI=10.1016/0888-7543(92)90313-H;
RA   Gessler M., Konig A., Bruns G.A.P.;
RT   "The genomic organization and expression of the WT1 gene.";
RL   Genomics 12:807-813(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 4 AND 9).
RC   TISSUE=Placenta, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORM
RP   1).
RG   NIEHS SNPs program;
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 6).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 85-449 (ISOFORM 2).
RX   PubMed=2154335; DOI=10.1016/0092-8674(90)90601-A;
RA   Call K.M., Glaser T., Ito C.Y., Buckler A.J., Pelletier J.,
RA   Haber D.A., Rose E.A., Kral A., Yeger H., Lewis W.H., Jones C.,
RA   Housman D.E.;
RT   "Isolation and characterization of a zinc finger polypeptide gene at
RT   the human chromosome 11 Wilms' tumor locus.";
RL   Cell 60:509-520(1990).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 301-449 (ISOFORMS 2/4/6), AND FUNCTION.
RC   TISSUE=Fetal kidney;
RX   PubMed=7862533; DOI=10.1093/nar/23.2.277;
RA   Hamilton T.B., Barilla K.C., Romaniuk P.J.;
RT   "High affinity binding sites for the Wilms' tumour suppressor protein
RT   WT1.";
RL   Nucleic Acids Res. 23:277-284(1995).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 385-405, AND VARIANTS DDS.
RX   PubMed=1655284; DOI=10.1016/0092-8674(91)90194-4;
RA   Pelletier J., Bruening W., Kashtan C.E., Mauer S.M., Manivel J.C.,
RA   Striegel J.E., Houghton D.C., Junien C., Habib R., Fouser L.,
RA   Fine R.N., Silverman B.L., Haber D.A., Housman D.E.;
RT   "Germline mutations in the Wilms' tumor suppressor gene are associated
RT   with abnormal urogenital development in Denys-Drash syndrome.";
RL   Cell 67:437-447(1991).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 385-405, AND VARIANTS DDS
RP   TYR-330; PRO-394 AND TRP-394.
RX   PubMed=1302008; DOI=10.1038/ng0592-144;
RA   Bruening W., Bardeesy N., Silverman B.L., Cohn R.A., Machin G.A.,
RA   Aronson A.J., Housman D., Pelletier J.;
RT   "Germline intronic and exonic mutations in the Wilms' tumour gene
RT   (WT1) affecting urogenital development.";
RL   Nat. Genet. 1:144-148(1992).
RN   [13]
RP   IDENTIFICATION OF START CODON, AND ALTERNATIVE SPLICING.
RX   PubMed=1671709; DOI=10.1128/MCB.11.3.1707;
RA   Buckler A.J., Pelletier J., Haber D.A., Glaser T., Housman D.E.;
RT   "Isolation, characterization, and expression of the murine Wilms'
RT   tumor gene (WT1) during kidney development.";
RL   Mol. Cell. Biol. 11:1707-1712(1991).
RN   [14]
RP   RNA EDITING OF POSITION 281.
RX   PubMed=7926762; DOI=10.1101/gad.8.6.720;
RA   Sharma P.M., Bowman M., Madden S.L., Rauscher F.J. III, Sukumar S.;
RT   "RNA editing in the Wilms' tumor susceptibility gene, WT1.";
RL   Genes Dev. 8:720-731(1994).
RN   [15]
RP   ALTERNATIVE INITIATION, AND ALTERNATIVE SPLICING (ISOFORMS 7 AND 8).
RX   PubMed=8621495; DOI=10.1074/jbc.271.15.8646;
RA   Bruening W., Pelletier J.;
RT   "A non-AUG translational initiation event generates novel WT1
RT   isoforms.";
RL   J. Biol. Chem. 271:8646-8654(1996).
RN   [16]
RP   INTERACTION WITH WTAP.
RX   PubMed=11001926; DOI=10.1093/oxfordjournals.hmg.a018914;
RA   Little N.A., Hastie N.D., Davies R.C.;
RT   "Identification of WTAP, a novel Wilms' tumour 1-associating
RT   protein.";
RL   Hum. Mol. Genet. 9:2231-2239(2000).
RN   [17]
RP   INTERACTION WITH ZNF224.
RX   PubMed=12239212; DOI=10.1074/jbc.M205667200;
RA   Lee T.H., Lwu S., Kim J., Pelletier J.;
RT   "Inhibition of Wilms tumor 1 transactivation by bone marrow zinc
RT   finger 2, a novel transcriptional repressor.";
RL   J. Biol. Chem. 277:44826-44837(2002).
RN   [18]
RP   INTERACTION WITH SRY.
RX   PubMed=12970737; DOI=10.1038/sj.onc.1206717;
RA   Matsuzawa-Watanabe Y., Inoue J., Semba K.;
RT   "Transcriptional activity of testis-determining factor SRY is
RT   modulated by the Wilms' tumor 1 gene product, WT1.";
RL   Oncogene 22:7900-7904(2003).
RN   [19]
RP   REVIEW.
RX   PubMed=1313285;
RA   Haber D.A., Buckler A.J.;
RT   "WT1: a novel tumor suppressor gene inactivated in Wilms' tumor.";
RL   New Biol. 4:97-106(1992).
RN   [20]
RP   REVIEW.
RX   PubMed=8393820;
RA   Rauscher F.J. III;
RT   "The WT1 Wilms tumor gene product: a developmentally regulated
RT   transcription factor in the kidney that functions as a tumor
RT   suppressor.";
RL   FASEB J. 7:896-903(1993).
RN   [21]
RP   INVOLVEMENT IN WILMS TUMOR.
RX   PubMed=1654525; DOI=10.1038/353431a0;
RA   Pelletier J., Bruening W., Li F.P., Haber D.A., Glaser T.,
RA   Housman D.E.;
RT   "WT1 mutations contribute to abnormal genital system development and
RT   hereditary Wilms' tumour.";
RL   Nature 353:431-434(1991).
RN   [22]
RP   REVIEW.
RX   PubMed=17361230; DOI=10.1038/sj.leu.2404624;
RA   Yang L., Han Y., Suarez Saiz F., Minden M.D.;
RT   "A tumor suppressor and oncogene: the WT1 story.";
RL   Leukemia 21:868-876(2007).
RN   [23]
RP   SUBCELLULAR LOCATION, MUTAGENESIS OF LYS-73 AND LYS-177, AND
RP   SUMOYLATION AT LYS-73 AND LYS-177.
RX   PubMed=15520190; DOI=10.1158/0008-5472.CAN-04-1502;
RA   Smolen G.A., Vassileva M.T., Wells J., Matunis M.J., Haber D.A.;
RT   "SUMO-1 modification of the Wilms' tumor suppressor WT1.";
RL   Cancer Res. 64:7846-7851(2004).
RN   [24]
RP   INTERACTION WITH RBM4, SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=16934801; DOI=10.1016/j.yexcr.2006.07.008;
RA   Markus M.A., Heinrich B., Raitskin O., Adams D.J., Mangs H., Goy C.,
RA   Ladomery M., Sperling R., Stamm S., Morris B.J.;
RT   "WT1 interacts with the splicing protein RBM4 and regulates its
RT   ability to modulate alternative splicing in vivo.";
RL   Exp. Cell Res. 312:3379-3388(2006).
RN   [25]
RP   FUNCTION, AND MUTAGENESIS OF HIS-343; ARG-366; ARG-372; ARG-394 AND
RP   HIS-434.
RX   PubMed=19123921; DOI=10.1021/bi801586a;
RA   Weiss T.C., Romaniuk P.J.;
RT   "Contribution of individual amino acids to the RNA binding activity of
RT   the Wilms' tumor suppressor protein WT1.";
RL   Biochemistry 48:148-155(2009).
RN   [26]
RP   INTERACTION WITH AMER1, AND FUNCTION.
RX   PubMed=19416806; DOI=10.1073/pnas.0811349106;
RA   Rivera M.N., Kim W.J., Wells J., Stone A., Burger A., Coffman E.J.,
RA   Zhang J., Haber D.A.;
RT   "The tumor suppressor WTX shuttles to the nucleus and modulates WT1
RT   activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:8338-8343(2009).
RN   [27]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-444, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-
RT   modification with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [28]
RP   STRUCTURE BY NMR OF 381-407 IN COMPLEX WITH ZINC IONS.
RX   PubMed=15518539; DOI=10.1021/bi0491999;
RA   Lachenmann M.J., Ladbury J.E., Dong J., Huang K., Carey P.,
RA   Weiss M.A.;
RT   "Why zinc fingers prefer zinc: ligand-field symmetry and the hidden
RT   thermodynamics of metal ion selectivity.";
RL   Biochemistry 43:13910-13925(2004).
RN   [29]
RP   STRUCTURE BY NMR OF 318-438 IN COMPLEX WITH DNA AND ZINC IONS (ISOFORM
RP   4), X-RAY CRYSTALLOGRAPHY (3.15 ANGSTROMS) OF 318-438 IN COMPLEX WITH
RP   DNA AND ZINC IONS, AND FUNCTION.
RX   PubMed=17716689; DOI=10.1016/j.jmb.2007.07.017;
RA   Stoll R., Lee B.M., Debler E.W., Laity J.H., Wilson I.A., Dyson H.J.,
RA   Wright P.E.;
RT   "Structure of the Wilms tumor suppressor protein zinc finger domain
RT   bound to DNA.";
RL   J. Mol. Biol. 372:1227-1245(2007).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (1.54 ANGSTROMS) OF 350-440 IN COMPLEX WITH ZINC
RP   AND TARGET DNA, FUNCTION, AND DOMAIN.
RX   PubMed=25258363; DOI=10.1101/gad.250746.114;
RA   Hashimoto H., Olanrewaju Y.O., Zheng Y., Wilson G.G., Zhang X.,
RA   Cheng X.;
RT   "Wilms tumor protein recognizes 5-carboxylcytosine within a specific
RT   DNA sequence.";
RL   Genes Dev. 28:2304-2313(2014).
RN   [31]
RP   VARIANT WT1 CYS-366.
RX   PubMed=1317572; DOI=10.1073/pnas.89.11.4791;
RA   Little M.H., Prosser J., Condie A., Smith P.J., van Heyningen V.,
RA   Hastie N.D.;
RT   "Zinc finger point mutations within the WT1 gene in Wilms tumor
RT   patients.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:4791-4795(1992).
RN   [32]
RP   VARIANTS DDS.
RX   PubMed=1338906; DOI=10.1093/hmg/1.5.301;
RA   Baird P.N., Santos A., Groves N., Jadresic L., Cowell J.K.;
RT   "Constitutional mutations in the WT1 gene in patients with Denys-Drash
RT   syndrome.";
RL   Hum. Mol. Genet. 1:301-305(1992).
RN   [33]
RP   VARIANTS DDS.
RX   PubMed=8388765; DOI=10.1093/hmg/2.3.259;
RA   Little M.H., Williamson K.A., Mannens M., Kelsey A., Gosden C.,
RA   Hastie N.D., van Heyningen V.;
RT   "Evidence that WT1 mutations in Denys-Drash syndrome patients may act
RT   in a dominant-negative fashion.";
RL   Hum. Mol. Genet. 2:259-264(1993).
RN   [34]
RP   VARIANT DDS TYR-401.
RX   PubMed=8111391; DOI=10.1093/hmg/2.12.2193;
RA   Baird P.N., Cowell J.K.;
RT   "A novel zinc finger mutation in a patient with Denys-Drash
RT   syndrome.";
RL   Hum. Mol. Genet. 2:2193-2194(1993).
RN   [35]
RP   VARIANTS DDS TRP-394 AND PRO-398.
RX   PubMed=8295405; DOI=10.1007/BF00714282;
RA   Tsuda M., Sakiyama T., Kitagawa T., Watanabe S., Watanabe T.,
RA   Takahashi S., Kawaguchi H., Ito K.;
RT   "Molecular analysis of two Japanese cases of Denys-Drash syndrome.";
RL   J. Inherit. Metab. Dis. 16:876-880(1993).
RN   [36]
RP   VARIANTS DDS TYR-360 AND TRP-394.
RX   PubMed=8411073; DOI=10.1136/jmg.30.9.767;
RA   Clarkson P.A., Davies H.R., Williams D.M., Chaudhary R., Hughes I.A.,
RA   Patterson M.N.;
RT   "Mutational screening of the Wilms's tumour gene, WT1, in males with
RT   genital abnormalities.";
RL   J. Med. Genet. 30:767-772(1993).
RN   [37]
RP   VARIANT GLY-273, AND INVOLVEMENT IN MESOM.
RX   PubMed=8401592; DOI=10.1038/ng0893-415;
RA   Park S., Schalling M., Bernard A., Maheswaran S., Shipley G.C.,
RA   Roberts D., Fletcher J., Shipman R., Rheinwald J., Demetri G.,
RA   Griffin J., Minden M., Housman D.E., Haber D.A.;
RT   "The Wilms tumour gene WT1 is expressed in murine mesoderm-derived
RT   tissues and mutated in a human mesothelioma.";
RL   Nat. Genet. 4:415-420(1993).
RN   [38]
RP   VARIANT DDS ARG-377.
RX   PubMed=8112732; DOI=10.1007/BF00210593;
RA   Nordenskjold A., Friedman E., Anvret M.;
RT   "WT1 mutations in patients with Denys-Drash syndrome: a novel mutation
RT   in exon 8 and paternal allele origin.";
RL   Hum. Genet. 93:115-120(1994).
RN   [39]
RP   VARIANT DDS LEU-366.
RX   PubMed=8741319;
RA   Tsuda M., Sakiyama T., Owada M., Chiba Y.;
RT   "A newly identified exonic mutation of the WT1 gene in a patient with
RT   Denys-Drash syndrome.";
RL   Acta Paediatr. Jpn. Overseas Ed. 38:265-266(1996).
RN   [40]
RP   VARIANT DDS TYR-373.
RX   PubMed=8956030; DOI=10.1159/000154374;
RA   Ghahremani M., Chan C.B., Bistritzer T., Aladjem M.M., Tieder M.,
RA   Pelletier J.;
RT   "A novel mutation H373Y in the Wilms' tumor suppressor gene, WT1,
RT   associated with Denys-Drash syndrome.";
RL   Hum. Hered. 46:336-338(1996).
RN   [41]
RP   VARIANTS WT1 SER-181 AND ALA-253.
RX   PubMed=9108089; DOI=10.1073/pnas.94.8.3972;
RA   Schumacher V., Schneider S., Figge A., Wildhardt G., Harms D.,
RA   Schmidt D., Weirich A., Ludwig R., Royer-Pokora B.;
RT   "Correlation of germ-line mutations and two-hit inactivation of the
RT   WT1 gene with Wilms tumors of stromal-predominant histology.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:3972-3977(1997).
RN   [42]
RP   VARIANTS NPHS4 TYR-377; LEU-383 AND ASN-396, VARIANTS DDS CYS-366;
RP   GLN-394; TRP-394 AND PRO-398, AND VARIANT WT1 ASN-223.
RX   PubMed=9529364; DOI=10.1086/301806;
RA   Jeanpierre C., Denamur E., Henry I., Cabanis M.-O., Luce S.,
RA   Cecille A., Elion J., Peuchmaur M., Loirat C., Niaudet P.,
RA   Gubler M.-C., Junien C.;
RT   "Identification of constitutional WT1 mutations, in patients with
RT   isolated diffuse mesangial sclerosis, and analysis of
RT   genotype/phenotype correlations by use of a computerized mutation
RT   database.";
RL   Am. J. Hum. Genet. 62:824-833(1998).
RN   [43]
RP   VARIANTS DDS TYR-355; HIS-366 AND ARG-385.
RX   PubMed=9475094; DOI=10.1136/jmg.35.1.45;
RA   Kikuchi H., Takata A., Akasaka Y., Fukuzawa R., Yoneyama H.,
RA   Kurosawa Y., Honda M., Kamiyama Y., Hata J.;
RT   "Do intronic mutations affecting splicing of WT1 exon 9 cause Frasier
RT   syndrome?";
RL   J. Med. Genet. 35:45-48(1998).
RN   [44]
RP   VARIANTS NPHS4 LEU-364; HIS-366; CYS-379; ARG-385; GLN-394; TRP-394
RP   AND ASN-396.
RX   PubMed=9607189; DOI=10.1046/j.1523-1755.1998.00948.x;
RA   Schumacher V., Schaerer K., Wuehl E., Altrogge H., Bonzel K.-E.,
RA   Guschmann M., Neuhaus T.J., Pollastro R.M., Kuwertz-Broeking E.,
RA   Bulla M., Tondera A.-M., Mundel P., Helmchen U., Waldherr R.,
RA   Weirich A., Royer-Pokora B.;
RT   "Spectrum of early onset nephrotic syndrome associated with WT1
RT   missense mutations.";
RL   Kidney Int. 53:1594-1600(1998).
RN   [45]
RP   VARIANT FS LEU-392.
RX   PubMed=10571943;
RX   DOI=10.1002/(SICI)1098-1004(199912)14:6<466::AID-HUMU4>3.0.CO;2-6;
RA   Kohsaka T., Tagawa M., Takekoshi Y., Yanagisawa H., Tadokoro K.,
RA   Yamada M.;
RT   "Exon 9 mutations in the WT1 gene, without influencing KTS splice
RT   isoforms, are also responsible for Frasier syndrome.";
RL   Hum. Mutat. 14:466-470(1999).
RN   [46]
RP   VARIANT DDS TYR-396.
RX   PubMed=10738002;
RX   DOI=10.1002/(SICI)1098-1004(200004)15:4<389::AID-HUMU29>3.3.CO;2-5;
RA   Little M., Carman G., Donaldson E.;
RT   "Novel WT1 exon 9 mutation (D396Y) in a patient with early onset Denys
RT   Drash syndrome.";
RL   Hum. Mutat. 15:389-389(2000).
RN   [47]
RP   VARIANTS DDS ARG-342; TYR-355; HIS-366; ARG-385; PHE-388; TRP-394 AND
RP   ASN-396, AND VARIANT NPHS4 GLN-312.
RX   PubMed=11182928; DOI=10.1136/jmg.37.9.698;
RA   Takata A., Kikuchi H., Fukuzawa R., Ito S., Honda M., Hata J.;
RT   "Constitutional WT1 correlate with clinical features in children with
RT   progressive nephropathy.";
RL   J. Med. Genet. 37:698-701(2000).
RN   [48]
RP   VARIANT DDS PRO-369.
RX   PubMed=10799199; DOI=10.1016/S0022-5347(05)67560-X;
RA   Ohta S., Ozawa T., Izumino K., Sakuragawa N., Fuse H.;
RT   "A novel missense mutation of the WT1 gene causing Denys-Drash
RT   syndrome with exceptionally mild renal manifestations.";
RL   J. Urol. 163:1857-1858(2000).
RN   [49]
RP   VARIANT DDS TYR-388.
RX   PubMed=11519891; DOI=10.1007/s004670100626;
RA   Swiatecka-Urban A., Mokrzycki M.H., Kaskel F., Da Silva F.,
RA   Denamur E.;
RT   "Novel WT1 mutation (C388Y) in a female child with Denys-Drash
RT   syndrome.";
RL   Pediatr. Nephrol. 16:627-630(2001).
RN   [50]
RP   VARIANTS WT1 SER-181; GLY-355; CYS-366; HIS-366; GLN-373; TRP-394 AND
RP   LEU-394.
RX   PubMed=15150775; DOI=10.1002/ajmg.a.30015;
RA   Royer-Pokora B., Beier M., Henzler M., Alam R., Schumacher V.,
RA   Weirich A., Huff V.;
RT   "Twenty-four new cases of WT1 germline mutations and review of the
RT   literature: genotype/phenotype correlations for Wilms tumor
RT   development.";
RL   Am. J. Med. Genet. A 127:249-257(2004).
RN   [51]
RP   VARIANT THR-131.
RX   PubMed=15266301; DOI=10.1038/sj.ejhg.5201232;
RA   Wang Y., Li Q., Xu J., Liu Q., Wang W., Lin Y., Ma F., Chen T., Li S.,
RA   Shen Y.;
RT   "Mutation analysis of five candidate genes in Chinese patients with
RT   hypospadias.";
RL   Eur. J. Hum. Genet. 12:706-712(2004).
RN   [52]
RP   VARIANTS NPHS4 ARG-388 AND PRO-397.
RX   PubMed=15253707; DOI=10.1111/j.1523-1755.2004.00775.x;
RG   Members of the APN study group;
RA   Ruf R.G., Schultheiss M., Lichtenberger A., Karle S.M., Zalewski I.,
RA   Mucha B., Everding A.S., Neuhaus T., Patzer L., Plank C., Haas J.P.,
RA   Ozaltin F., Imm A., Fuchshuber A., Bakkaloglu A., Hildebrandt F.;
RT   "Prevalence of WT1 mutations in a large cohort of patients with
RT   steroid-resistant and steroid-sensitive nephrotic syndrome.";
RL   Kidney Int. 66:564-570(2004).
RN   [53]
RP   VARIANT DDS ARG-405.
RX   PubMed=15349765; DOI=10.1007/s00467-004-1564-3;
RA   Hu M., Craig J., Howard N., Kan A., Chaitow J., Little D.,
RA   Alexander S.I.;
RT   "A novel mutation of WT1 exon 9 in a patient with Denys-Drash syndrome
RT   and pyloric stenosis.";
RL   Pediatr. Nephrol. 19:1160-1163(2004).
RN   [54]
RP   VARIANTS MEACHS CYS-366 AND TRP-394.
RX   PubMed=17853480; DOI=10.1002/ajmg.a.31924;
RA   Suri M., Kelehan P., O'neill D., Vadeyar S., Grant J., Ahmed S.F.,
RA   Tolmie J., McCann E., Lam W., Smith S., FitzPatrick D., Hastie N.D.,
RA   Reardon W.;
RT   "WT1 mutations in Meacham syndrome suggest a coelomic mesothelial
RT   origin of the cardiac and diaphragmatic malformations.";
RL   Am. J. Med. Genet. A 143:2312-2320(2007).
RN   [55]
RP   VARIANTS NPHS4 ARG-388; GLN-394; TRP-394 AND PRO-397.
RX   PubMed=20798252; DOI=10.2215/CJN.01190210;
RA   Buescher A.K., Kranz B., Buescher R., Hildebrandt F., Dworniczak B.,
RA   Pennekamp P., Kuwertz-Broeking E., Wingen A.M., John U., Kemper M.,
RA   Monnens L., Hoyer P.F., Weber S., Konrad M.;
RT   "Immunosuppression and renal outcome in congenital and pediatric
RT   steroid-resistant nephrotic syndrome.";
RL   Clin. J. Am. Soc. Nephrol. 5:2075-2084(2010).
CC   -!- FUNCTION: Transcription factor that plays an important role in
CC       cellular development and cell survival (PubMed:7862533).
CC       Recognizes and binds to the DNA sequence 5'-GCG(T/G)GGGCG-3'
CC       (PubMed:7862533, PubMed:17716689, PubMed:25258363). Regulates the
CC       expression of numerous target genes, including EPO. Plays an
CC       essential role for development of the urogenital system. It has a
CC       tumor suppressor as well as an oncogenic role in tumor formation.
CC       Function may be isoform-specific: isoforms lacking the KTS motif
CC       may act as transcription factors (PubMed:15520190). Isoforms
CC       containing the KTS motif may bind mRNA and play a role in mRNA
CC       metabolism or splicing (PubMed:16934801). Isoform 1 has lower
CC       affinity for DNA, and can bind RNA (PubMed:19123921).
CC       {ECO:0000269|PubMed:15520190, ECO:0000269|PubMed:16934801,
CC       ECO:0000269|PubMed:17716689, ECO:0000269|PubMed:19123921,
CC       ECO:0000269|PubMed:19416806, ECO:0000269|PubMed:25258363,
CC       ECO:0000269|PubMed:7862533}.
CC   -!- SUBUNIT: Homodimer. Interacts with WTIP. Interacts with actively
CC       translating polysomes. Detected in nuclear ribonucleoprotein
CC       (mRNP) particles. Interacts with HNRNPU via the zinc-finger
CC       region. Interacts with U2AF2. Interacts with CITED2 (By
CC       similarity). Interacts with ZNF224 via the zinc-finger region.
CC       Interacts with WTAP and SRY. Interacts with AMER1. Interacts with
CC       RBM4. {ECO:0000250, ECO:0000269|PubMed:11001926,
CC       ECO:0000269|PubMed:12239212, ECO:0000269|PubMed:12970737,
CC       ECO:0000269|PubMed:15518539, ECO:0000269|PubMed:16934801,
CC       ECO:0000269|PubMed:17716689, ECO:0000269|PubMed:19416806}.
CC   -!- INTERACTION:
CC       Q6A162:KRT40; NbExp=3; IntAct=EBI-2320534, EBI-10171697;
CC       P60410:KRTAP10-8; NbExp=3; IntAct=EBI-2320534, EBI-10171774;
CC       Q9NRD5:PICK1; NbExp=4; IntAct=EBI-11745701, EBI-79165;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15520190}.
CC       Nucleus, nucleolus. Cytoplasm {ECO:0000250}. Note=Isoforms lacking
CC       the KTS motif have a diffuse nuclear location (PubMed:15520190).
CC       Shuttles between nucleus and cytoplasm. {ECO:0000250,
CC       ECO:0000269|PubMed:15520190}.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Nucleus speckle
CC       {ECO:0000269|PubMed:15520190}.
CC   -!- SUBCELLULAR LOCATION: Isoform 4: Nucleus, nucleoplasm
CC       {ECO:0000269|PubMed:15520190}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=8;
CC       Name=1;
CC         IsoId=P19544-1; Sequence=Displayed;
CC         Note=Detected in nucleus speckle, may bind mRNA.;
CC       Name=2;
CC         IsoId=P19544-2; Sequence=VSP_006866, VSP_006867;
CC       Name=3;
CC         IsoId=P19544-3; Sequence=VSP_006866;
CC       Name=4;
CC         IsoId=P19544-4; Sequence=VSP_006867;
CC       Name=6;
CC         IsoId=P19544-6; Sequence=VSP_037582, VSP_037584, VSP_006867;
CC       Name=7;
CC         IsoId=P19544-7; Sequence=VSP_037583;
CC         Note=Produced by alternative initiation of isoform 1. Extended
CC         N-terminus.;
CC       Name=8;
CC         IsoId=P19544-8; Sequence=VSP_037583, VSP_006866;
CC         Note=Produced by alternative initiation of isoform 1. Extended
CC         N-terminus.;
CC       Name=9;
CC         IsoId=P19544-9; Sequence=VSP_037582, VSP_037584, VSP_006866;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in the kidney and a subset of
CC       hematopoietic cells.
CC   -!- DOMAIN: Binds to DNA motifs with the sequence 5'-GCG(T/G)GGGCG-3'
CC       via its C2H2-type zinc fingers. Starting from the N-terminus, the
CC       second zinc finger binds to the 3'-GCG motif, the middle zinc
CC       finger interacts with the central TGG motif, and the C-terminal
CC       zinc finger binds to the 5'-GCG motif. Binds double-stranded
CC       target DNA, irrespective of the cytosine methylation status. Has
CC       reduced affinity for target DNA where the cytosines have been
CC       oxidized to 5-hydroxymethylcytosine, 5-formylcytosine or 5-
CC       carboxylcytosine. {ECO:0000269|PubMed:25258363}.
CC   -!- RNA EDITING: Modified_positions=281 {ECO:0000269|PubMed:7926762};
CC       Note=Partially edited.;
CC   -!- DISEASE: Frasier syndrome (FS) [MIM:136680]: Characterized by a
CC       slowly progressing nephropathy leading to renal failure in
CC       adolescence or early adulthood, male pseudohermaphroditism, and no
CC       Wilms tumor. As for histological findings of the kidneys, focal
CC       glomerular sclerosis is often observed. There is phenotypic
CC       overlap with Denys-Drash syndrome. Inheritance is autosomal
CC       dominant. {ECO:0000269|PubMed:10571943}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Wilms tumor 1 (WT1) [MIM:194070]: Embryonal malignancy of
CC       the kidney that affects approximately 1 in 10'000 infants and
CC       young children. It occurs both in sporadic and hereditary forms.
CC       {ECO:0000269|PubMed:1317572, ECO:0000269|PubMed:15150775,
CC       ECO:0000269|PubMed:9108089, ECO:0000269|PubMed:9529364}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Denys-Drash syndrome (DDS) [MIM:194080]: Typical
CC       nephropathy characterized by diffuse mesangial sclerosis, genital
CC       abnormalities, and/or Wilms tumor. There is phenotypic overlap
CC       with WAGR syndrome and Frasier syndrome. Inheritance is autosomal
CC       dominant, but most cases are sporadic.
CC       {ECO:0000269|PubMed:10738002, ECO:0000269|PubMed:10799199,
CC       ECO:0000269|PubMed:11182928, ECO:0000269|PubMed:11519891,
CC       ECO:0000269|PubMed:1302008, ECO:0000269|PubMed:1338906,
CC       ECO:0000269|PubMed:15349765, ECO:0000269|PubMed:1655284,
CC       ECO:0000269|PubMed:8111391, ECO:0000269|PubMed:8112732,
CC       ECO:0000269|PubMed:8295405, ECO:0000269|PubMed:8388765,
CC       ECO:0000269|PubMed:8411073, ECO:0000269|PubMed:8741319,
CC       ECO:0000269|PubMed:8956030, ECO:0000269|PubMed:9475094,
CC       ECO:0000269|PubMed:9529364}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Nephrotic syndrome 4 (NPHS4) [MIM:256370]: A form of
CC       nephrotic syndrome, a renal disease clinically characterized by
CC       severe proteinuria, resulting in complications such as
CC       hypoalbuminemia, hyperlipidemia and edema. Kidney biopsies show
CC       non-specific histologic changes such as focal segmental
CC       glomerulosclerosis and diffuse mesangial proliferation. Some
CC       affected individuals have an inherited steroid-resistant form and
CC       progress to end-stage renal failure. Most patients with NPHS4 show
CC       diffuse mesangial sclerosis on renal biopsy, which is a pathologic
CC       entity characterized by mesangial matrix expansion with no
CC       mesangial hypercellularity, hypertrophy of the podocytes,
CC       vacuolized podocytes, thickened basement membranes, and diminished
CC       patency of the capillary lumen. {ECO:0000269|PubMed:11182928,
CC       ECO:0000269|PubMed:15253707, ECO:0000269|PubMed:20798252,
CC       ECO:0000269|PubMed:9529364, ECO:0000269|PubMed:9607189}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Meacham syndrome (MEACHS) [MIM:608978]: Rare sporadically
CC       occurring multiple malformation syndrome characterized by male
CC       pseudohermaphroditism with abnormal internal female genitalia
CC       comprising a uterus and double or septate vagina, complex
CC       congenital heart defect and diaphragmatic abnormalities.
CC       {ECO:0000269|PubMed:17853480}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Note=A chromosomal aberration involving WT1 may be a
CC       cause of desmoplastic small round cell tumor (DSRCT).
CC       Translocation t(11;22)(p13;q12) with EWSR1.
CC   -!- DISEASE: Mesothelioma, malignant (MESOM) [MIM:156240]: An
CC       aggressive neoplasm of the serosal lining of the chest. It appears
CC       as broad sheets of cells, with some regions containing spindle-
CC       shaped, sarcoma-like cells and other regions showing adenomatous
CC       patterns. Pleural mesotheliomas have been linked to exposure to
CC       asbestos. {ECO:0000269|PubMed:8401592}. Note=The disease may be
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Presence of the KTS motif hinders interactions
CC       between DNA and zinc-finger 4.
CC   -!- SIMILARITY: Belongs to the EGR C2H2-type zinc-finger protein
CC       family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB33443.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the N-terminal part.; Evidence={ECO:0000305};
CC       Sequence=CAA35956.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=CAA35956.1; Type=Miscellaneous discrepancy; Note=Unusual initiator. The initiator methionine is coded by a non-canonical CTG leucine codon.; Evidence={ECO:0000305};
CC       Sequence=CAC39220.3; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=CAI95758.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=CAI95759.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/WT1ID78.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/wt1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X51630; CAA35956.1; ALT_SEQ; mRNA.
DR   EMBL; M80232; AAA61299.1; -; Genomic_DNA.
DR   EMBL; M80217; AAA61299.1; JOINED; Genomic_DNA.
DR   EMBL; M80218; AAA61299.1; JOINED; Genomic_DNA.
DR   EMBL; M80219; AAA61299.1; JOINED; Genomic_DNA.
DR   EMBL; M80220; AAA61299.1; JOINED; Genomic_DNA.
DR   EMBL; M80221; AAA61299.1; JOINED; Genomic_DNA.
DR   EMBL; M80228; AAA61299.1; JOINED; Genomic_DNA.
DR   EMBL; M80229; AAA61299.1; JOINED; Genomic_DNA.
DR   EMBL; M80231; AAA61299.1; JOINED; Genomic_DNA.
DR   EMBL; X61631; CAA43819.1; -; Genomic_DNA.
DR   EMBL; X61632; CAA43819.1; JOINED; Genomic_DNA.
DR   EMBL; X61633; CAA43819.1; JOINED; Genomic_DNA.
DR   EMBL; X61634; CAA43819.1; JOINED; Genomic_DNA.
DR   EMBL; X61635; CAA43819.1; JOINED; Genomic_DNA.
DR   EMBL; X61636; CAA43819.1; JOINED; Genomic_DNA.
DR   EMBL; X61637; CAA43819.1; JOINED; Genomic_DNA.
DR   EMBL; X61638; CAA43819.1; JOINED; Genomic_DNA.
DR   EMBL; AK093168; BAG52667.1; -; mRNA.
DR   EMBL; AK291736; BAF84425.1; -; mRNA.
DR   EMBL; AY245105; AAO61088.1; -; Genomic_DNA.
DR   EMBL; AL049692; CAC39220.3; ALT_INIT; Genomic_DNA.
DR   EMBL; AL049692; CAI95758.2; ALT_INIT; Genomic_DNA.
DR   EMBL; AL049692; CAI95759.2; ALT_INIT; Genomic_DNA.
DR   EMBL; AL049692; CAI95760.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW68220.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW68223.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW68224.1; -; Genomic_DNA.
DR   EMBL; BC032861; AAH32861.1; -; mRNA.
DR   EMBL; M30393; AAA36810.1; -; mRNA.
DR   EMBL; S75264; AAB33443.1; ALT_SEQ; mRNA.
DR   EMBL; S61515; AAB20110.1; -; Genomic_DNA.
DR   EMBL; S61522; AAB20111.1; -; Genomic_DNA.
DR   EMBL; S61524; AAB20112.1; -; Genomic_DNA.
DR   EMBL; S60755; AAC60605.1; -; Genomic_DNA.
DR   CCDS; CCDS55750.1; -. [P19544-9]
DR   CCDS; CCDS55751.1; -. [P19544-6]
DR   PIR; A38080; A38080.
DR   RefSeq; NP_000369.3; NM_000378.4.
DR   RefSeq; NP_001185480.1; NM_001198551.1. [P19544-6]
DR   RefSeq; NP_001185481.1; NM_001198552.1. [P19544-9]
DR   RefSeq; NP_077742.2; NM_024424.3.
DR   RefSeq; NP_077744.3; NM_024426.4.
DR   UniGene; Hs.591980; -.
DR   PDB; 1LU6; Model; -; A=310-449.
DR   PDB; 1XF7; NMR; -; A=381-407.
DR   PDB; 2G7T; Model; -; A=310-449.
DR   PDB; 2G7V; Model; -; A=310-449.
DR   PDB; 2G7W; Model; -; A=310-449.
DR   PDB; 2G7X; Model; -; A=310-449.
DR   PDB; 2JP9; NMR; -; A=318-438.
DR   PDB; 2JPA; NMR; -; A=318-438.
DR   PDB; 2PRT; X-ray; 3.15 A; A=318-438.
DR   PDB; 3HPJ; X-ray; 2.00 A; C/F=126-134.
DR   PDB; 3MYJ; X-ray; 1.89 A; C/F=126-134.
DR   PDB; 4R2E; X-ray; 1.84 A; A=350-440.
DR   PDB; 4R2P; X-ray; 1.79 A; A=350-440.
DR   PDB; 4R2Q; X-ray; 1.54 A; A=350-440.
DR   PDB; 4R2R; X-ray; 2.09 A; A=350-440.
DR   PDB; 4R2S; X-ray; 2.49 A; A=350-440.
DR   PDB; 4WUU; X-ray; 3.05 A; C=126-134.
DR   PDB; 5KL2; X-ray; 1.69 A; A=350-440.
DR   PDB; 5KL3; X-ray; 1.45 A; A=350-440.
DR   PDB; 5KL4; X-ray; 1.78 A; A/D=350-440.
DR   PDB; 5KL5; X-ray; 2.29 A; A=350-440.
DR   PDB; 5KL6; X-ray; 1.64 A; A=350-440.
DR   PDB; 5KL7; X-ray; 1.58 A; A=350-440.
DR   PDB; 6B0O; X-ray; 1.55 A; A/D=321-440.
DR   PDB; 6B0P; X-ray; 2.08 A; A/D=321-440.
DR   PDB; 6B0Q; X-ray; 2.79 A; A/D=321-440.
DR   PDB; 6B0R; X-ray; 1.82 A; A/D=321-440.
DR   PDB; 6BLW; X-ray; 1.83 A; A=319-440.
DR   PDBsum; 1LU6; -.
DR   PDBsum; 1XF7; -.
DR   PDBsum; 2G7T; -.
DR   PDBsum; 2G7V; -.
DR   PDBsum; 2G7W; -.
DR   PDBsum; 2G7X; -.
DR   PDBsum; 2JP9; -.
DR   PDBsum; 2JPA; -.
DR   PDBsum; 2PRT; -.
DR   PDBsum; 3HPJ; -.
DR   PDBsum; 3MYJ; -.
DR   PDBsum; 4R2E; -.
DR   PDBsum; 4R2P; -.
DR   PDBsum; 4R2Q; -.
DR   PDBsum; 4R2R; -.
DR   PDBsum; 4R2S; -.
DR   PDBsum; 4WUU; -.
DR   PDBsum; 5KL2; -.
DR   PDBsum; 5KL3; -.
DR   PDBsum; 5KL4; -.
DR   PDBsum; 5KL5; -.
DR   PDBsum; 5KL6; -.
DR   PDBsum; 5KL7; -.
DR   PDBsum; 6B0O; -.
DR   PDBsum; 6B0P; -.
DR   PDBsum; 6B0Q; -.
DR   PDBsum; 6B0R; -.
DR   PDBsum; 6BLW; -.
DR   ProteinModelPortal; P19544; -.
DR   SMR; P19544; -.
DR   BioGrid; 113327; 28.
DR   IntAct; P19544; 24.
DR   MINT; P19544; -.
DR   STRING; 9606.ENSP00000331327; -.
DR   iPTMnet; P19544; -.
DR   PhosphoSitePlus; P19544; -.
DR   BioMuta; WT1; -.
DR   DMDM; 139778; -.
DR   MaxQB; P19544; -.
DR   PaxDb; P19544; -.
DR   PeptideAtlas; P19544; -.
DR   PRIDE; P19544; -.
DR   DNASU; 7490; -.
DR   Ensembl; ENST00000379079; ENSP00000368370; ENSG00000184937. [P19544-6]
DR   Ensembl; ENST00000530998; ENSP00000435307; ENSG00000184937. [P19544-9]
DR   GeneID; 7490; -.
DR   KEGG; hsa:7490; -.
DR   UCSC; uc001mtl.3; human. [P19544-1]
DR   CTD; 7490; -.
DR   DisGeNET; 7490; -.
DR   EuPathDB; HostDB:ENSG00000184937.12; -.
DR   GeneCards; WT1; -.
DR   GeneReviews; WT1; -.
DR   H-InvDB; HIX0009531; -.
DR   HGNC; HGNC:12796; WT1.
DR   HPA; CAB000327; -.
DR   HPA; HPA035717; -.
DR   HPA; HPA053848; -.
DR   MalaCards; WT1; -.
DR   MIM; 136680; phenotype.
DR   MIM; 156240; phenotype.
DR   MIM; 194070; phenotype.
DR   MIM; 194080; phenotype.
DR   MIM; 256370; phenotype.
DR   MIM; 607102; gene.
DR   MIM; 608978; phenotype.
DR   neXtProt; NX_P19544; -.
DR   OpenTargets; ENSG00000184937; -.
DR   Orphanet; 251510; 46,XY partial gonadal dysgenesis.
DR   Orphanet; 220; Denys-Drash syndrome.
DR   Orphanet; 83469; Desmoplastic small round cell tumor.
DR   Orphanet; 93217; Familial idiopathic steroid-resistant nephrotic syndrome with diffuse mesangial sclerosis.
DR   Orphanet; 93213; Familial idiopathic steroid-resistant nephrotic syndrome with focal segmental hyalinosis.
DR   Orphanet; 347; Frasier syndrome.
DR   Orphanet; 3097; Meacham syndrome.
DR   Orphanet; 654; Nephroblastoma.
DR   Orphanet; 93220; Sporadic idiopathic steroid-resistant nephrotic syndrome with diffuse mesangial sclerosis.
DR   Orphanet; 893; WAGR syndrome.
DR   PharmGKB; PA37395; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   eggNOG; COG5048; LUCA.
DR   GeneTree; ENSGT00550000074455; -.
DR   HOVERGEN; HBG006960; -.
DR   InParanoid; P19544; -.
DR   KO; K09234; -.
DR   PhylomeDB; P19544; -.
DR   SignaLink; P19544; -.
DR   SIGNOR; P19544; -.
DR   ChiTaRS; WT1; human.
DR   EvolutionaryTrace; P19544; -.
DR   GeneWiki; WT1; -.
DR   GenomeRNAi; 7490; -.
DR   PRO; PR:P19544; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000184937; -.
DR   CleanEx; HS_WT1; -.
DR   ExpressionAtlas; P19544; baseline and differential.
DR   Genevisible; P19544; HS.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0016607; C:nuclear speck; IDA:UniProtKB.
DR   GO; GO:0005730; C:nucleolus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0070742; F:C2H2 zinc finger domain binding; IPI:UniProtKB.
DR   GO; GO:0003700; F:DNA binding transcription factor activity; ISS:UniProtKB.
DR   GO; GO:0010385; F:double-stranded methylated DNA binding; IDA:UniProtKB.
DR   GO; GO:0044729; F:hemi-methylated DNA-binding; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IDA:UniProtKB.
DR   GO; GO:0001077; F:transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0035802; P:adrenal cortex formation; ISS:UniProtKB.
DR   GO; GO:0030325; P:adrenal gland development; IGI:UniProtKB.
DR   GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; IGI:UniProtKB.
DR   GO; GO:0043010; P:camera-type eye development; ISS:UniProtKB.
DR   GO; GO:0060923; P:cardiac muscle cell fate commitment; ISS:BHF-UCL.
DR   GO; GO:0071320; P:cellular response to cAMP; IEP:UniProtKB.
DR   GO; GO:0071371; P:cellular response to gonadotropin stimulus; IDA:UniProtKB.
DR   GO; GO:0060539; P:diaphragm development; ISS:UniProtKB.
DR   GO; GO:0030855; P:epithelial cell differentiation; ISS:UniProtKB.
DR   GO; GO:0007281; P:germ cell development; ISS:UniProtKB.
DR   GO; GO:0032836; P:glomerular basement membrane development; IMP:UniProtKB.
DR   GO; GO:0072112; P:glomerular visceral epithelial cell differentiation; ISS:UniProtKB.
DR   GO; GO:0032835; P:glomerulus development; IGI:UniProtKB.
DR   GO; GO:0008406; P:gonad development; ISS:UniProtKB.
DR   GO; GO:0007507; P:heart development; IGI:UniProtKB.
DR   GO; GO:0001822; P:kidney development; IGI:UniProtKB.
DR   GO; GO:0030539; P:male genitalia development; ISS:UniProtKB.
DR   GO; GO:0008584; P:male gonad development; IEP:UniProtKB.
DR   GO; GO:0060231; P:mesenchymal to epithelial transition; ISS:UniProtKB.
DR   GO; GO:0072207; P:metanephric epithelium development; IEP:UniProtKB.
DR   GO; GO:0072075; P:metanephric mesenchyme development; ISS:UniProtKB.
DR   GO; GO:0072284; P:metanephric S-shaped body morphogenesis; IGI:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IGI:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; IDA:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:2000195; P:negative regulation of female gonad development; ISS:UniProtKB.
DR   GO; GO:0072302; P:negative regulation of metanephric glomerular mesangial cell proliferation; ISS:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:MGI.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0017148; P:negative regulation of translation; IDA:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0060421; P:positive regulation of heart growth; ISS:UniProtKB.
DR   GO; GO:2000020; P:positive regulation of male gonad development; ISS:UniProtKB.
DR   GO; GO:2001076; P:positive regulation of metanephric ureteric bud development; ISS:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0072166; P:posterior mesonephric tubule development; ISS:UniProtKB.
DR   GO; GO:0003156; P:regulation of animal organ formation; ISS:UniProtKB.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0008380; P:RNA splicing; ISS:UniProtKB.
DR   GO; GO:0007530; P:sex determination; IDA:UniProtKB.
DR   GO; GO:0007356; P:thorax and anterior abdomen determination; ISS:UniProtKB.
DR   GO; GO:0009888; P:tissue development; ISS:UniProtKB.
DR   GO; GO:0001657; P:ureteric bud development; ISS:UniProtKB.
DR   GO; GO:0001570; P:vasculogenesis; ISS:UniProtKB.
DR   GO; GO:0061032; P:visceral serous pericardium development; IGI:UniProtKB.
DR   InterPro; IPR017987; Wilms_tumour.
DR   InterPro; IPR000976; Wilms_tumour_N.
DR   InterPro; IPR036236; Znf_C2H2_sf.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   Pfam; PF02165; WT1; 1.
DR   PRINTS; PR00049; WILMSTUMOUR.
DR   SMART; SM00355; ZnF_C2H2; 4.
DR   SUPFAM; SSF57667; SSF57667; 2.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 4.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 4.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative initiation; Alternative splicing;
KW   Chromosomal rearrangement; Complete proteome; Cytoplasm;
KW   Disease mutation; DNA-binding; Isopeptide bond; Metal-binding;
KW   Nucleus; Reference proteome; Repeat; RNA editing; RNA-binding;
KW   Transcription; Transcription regulation; Tumor suppressor;
KW   Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN         1    449       Wilms tumor protein.
FT                                /FTId=PRO_0000047131.
FT   ZN_FING     323    347       C2H2-type 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00042}.
FT   ZN_FING     353    377       C2H2-type 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00042}.
FT   ZN_FING     383    405       C2H2-type 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00042}.
FT   ZN_FING     414    438       C2H2-type 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00042}.
FT   REGION      367    381       Important for interaction with target
FT                                DNA.
FT   REGION      393    401       Important for interaction with target
FT                                DNA.
FT   MOTIF       408    410       KTS motif.
FT   COMPBIAS     27     83       Pro-rich.
FT   SITE        424    424       Important for interaction with target
FT                                DNA.
FT   SITE        430    430       Important for interaction with target
FT                                DNA.
FT   CROSSLNK     73     73       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000269|PubMed:15520190}.
FT   CROSSLNK    177    177       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000269|PubMed:15520190}.
FT   CROSSLNK    444    444       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   VAR_SEQ       1    144       Missing (in isoform 6 and isoform 9).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_037582.
FT   VAR_SEQ       1      1       M -> MDFLLLQDPASTCVPEPASQHTLRSGPGCLQQPEQQ
FT                                GVRDPGGIWAKLGAAEASAERLQGRRSRGASGSEPQQM
FT                                (in isoform 7 and isoform 8).
FT                                {ECO:0000303|PubMed:2154702}.
FT                                /FTId=VSP_037583.
FT   VAR_SEQ     145    147       RNQ -> MEK (in isoform 6 and isoform 9).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_037584.
FT   VAR_SEQ     250    266       Missing (in isoform 2, isoform 3, isoform
FT                                8 and isoform 9).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:2154335}.
FT                                /FTId=VSP_006866.
FT   VAR_SEQ     408    410       Missing (in isoform 2, isoform 4 and
FT                                isoform 6). {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:2154335}.
FT                                /FTId=VSP_006867.
FT   VARIANT     131    131       A -> T (in a patient with hypospadias).
FT                                {ECO:0000269|PubMed:15266301}.
FT                                /FTId=VAR_043798.
FT   VARIANT     181    181       P -> S (in WT1; dbSNP:rs2234584).
FT                                {ECO:0000269|PubMed:15150775,
FT                                ECO:0000269|PubMed:9108089}.
FT                                /FTId=VAR_007739.
FT   VARIANT     223    223       S -> N (in WT1).
FT                                {ECO:0000269|PubMed:9529364}.
FT                                /FTId=VAR_007740.
FT   VARIANT     253    253       G -> A (in WT1).
FT                                {ECO:0000269|PubMed:9108089}.
FT                                /FTId=VAR_007741.
FT   VARIANT     273    273       S -> G (found in a mesothelioma sample;
FT                                somatic mutation; dbSNP:rs121907908).
FT                                {ECO:0000269|PubMed:8401592}.
FT                                /FTId=VAR_007742.
FT   VARIANT     281    281       L -> P (in RNA edited version).
FT                                /FTId=VAR_058021.
FT   VARIANT     312    312       R -> Q (in NPHS4).
FT                                {ECO:0000269|PubMed:11182928}.
FT                                /FTId=VAR_015053.
FT   VARIANT     330    330       C -> Y (in DDS).
FT                                {ECO:0000269|PubMed:1302008}.
FT                                /FTId=VAR_007743.
FT   VARIANT     342    342       M -> R (in DDS).
FT                                {ECO:0000269|PubMed:11182928}.
FT                                /FTId=VAR_015054.
FT   VARIANT     355    355       C -> G (in WT1).
FT                                {ECO:0000269|PubMed:15150775}.
FT                                /FTId=VAR_043799.
FT   VARIANT     355    355       C -> Y (in DDS).
FT                                {ECO:0000269|PubMed:11182928,
FT                                ECO:0000269|PubMed:9475094}.
FT                                /FTId=VAR_015055.
FT   VARIANT     360    360       C -> G (in DDS).
FT                                /FTId=VAR_007744.
FT   VARIANT     360    360       C -> Y (in DDS).
FT                                {ECO:0000269|PubMed:8411073}.
FT                                /FTId=VAR_043800.
FT   VARIANT     364    364       F -> L (in NPHS4).
FT                                {ECO:0000269|PubMed:9607189}.
FT                                /FTId=VAR_043801.
FT   VARIANT     366    366       R -> C (in WT1, DDS and MEACHS).
FT                                {ECO:0000269|PubMed:1317572,
FT                                ECO:0000269|PubMed:15150775,
FT                                ECO:0000269|PubMed:17853480,
FT                                ECO:0000269|PubMed:9529364}.
FT                                /FTId=VAR_007745.
FT   VARIANT     366    366       R -> H (in DDS and WT1).
FT                                {ECO:0000269|PubMed:11182928,
FT                                ECO:0000269|PubMed:15150775,
FT                                ECO:0000269|PubMed:9475094,
FT                                ECO:0000269|PubMed:9607189}.
FT                                /FTId=VAR_007746.
FT   VARIANT     366    366       R -> L (in DDS).
FT                                {ECO:0000269|PubMed:8741319}.
FT                                /FTId=VAR_043802.
FT   VARIANT     369    369       Q -> P (in DDS).
FT                                {ECO:0000269|PubMed:10799199}.
FT                                /FTId=VAR_043803.
FT   VARIANT     373    373       H -> Q (in DDS and WT1).
FT                                {ECO:0000269|PubMed:15150775}.
FT                                /FTId=VAR_007747.
FT   VARIANT     373    373       H -> Y (in DDS).
FT                                {ECO:0000269|PubMed:8956030}.
FT                                /FTId=VAR_015056.
FT   VARIANT     377    377       H -> R (in DDS).
FT                                {ECO:0000269|PubMed:8112732}.
FT                                /FTId=VAR_015057.
FT   VARIANT     377    377       H -> Y (in NPHS4).
FT                                {ECO:0000269|PubMed:9529364}.
FT                                /FTId=VAR_007748.
FT   VARIANT     379    379       G -> C (in NPHS4).
FT                                {ECO:0000269|PubMed:9607189}.
FT                                /FTId=VAR_043804.
FT   VARIANT     383    383       F -> L (in NPHS4).
FT                                {ECO:0000269|PubMed:9529364}.
FT                                /FTId=VAR_007749.
FT   VARIANT     385    385       C -> R (in DDS).
FT                                {ECO:0000269|PubMed:11182928,
FT                                ECO:0000269|PubMed:9475094,
FT                                ECO:0000269|PubMed:9607189}.
FT                                /FTId=VAR_015058.
FT   VARIANT     388    388       C -> F (in DDS).
FT                                {ECO:0000269|PubMed:11182928}.
FT                                /FTId=VAR_015059.
FT   VARIANT     388    388       C -> R (in NPHS4).
FT                                {ECO:0000269|PubMed:15253707,
FT                                ECO:0000269|PubMed:20798252}.
FT                                /FTId=VAR_043805.
FT   VARIANT     388    388       C -> Y (in DDS).
FT                                {ECO:0000269|PubMed:11519891}.
FT                                /FTId=VAR_043806.
FT   VARIANT     392    392       F -> L (in FS).
FT                                {ECO:0000269|PubMed:10571943}.
FT                                /FTId=VAR_015060.
FT   VARIANT     394    394       R -> L (in WT1).
FT                                {ECO:0000269|PubMed:15150775}.
FT                                /FTId=VAR_043807.
FT   VARIANT     394    394       R -> P (in DDS).
FT                                {ECO:0000269|PubMed:1302008}.
FT                                /FTId=VAR_043808.
FT   VARIANT     394    394       R -> Q (in DDS and NPHS4).
FT                                {ECO:0000269|PubMed:20798252,
FT                                ECO:0000269|PubMed:9529364,
FT                                ECO:0000269|PubMed:9607189}.
FT                                /FTId=VAR_015061.
FT   VARIANT     394    394       R -> W (in DDS, WT1, MEACHS and NPHS4).
FT                                {ECO:0000269|PubMed:11182928,
FT                                ECO:0000269|PubMed:1302008,
FT                                ECO:0000269|PubMed:15150775,
FT                                ECO:0000269|PubMed:17853480,
FT                                ECO:0000269|PubMed:20798252,
FT                                ECO:0000269|PubMed:8295405,
FT                                ECO:0000269|PubMed:8411073,
FT                                ECO:0000269|PubMed:9529364,
FT                                ECO:0000269|PubMed:9607189}.
FT                                /FTId=VAR_007750.
FT   VARIANT     396    396       D -> G (in DDS).
FT                                /FTId=VAR_007752.
FT   VARIANT     396    396       D -> N (in DDS and NPHS4).
FT                                {ECO:0000269|PubMed:11182928,
FT                                ECO:0000269|PubMed:9529364,
FT                                ECO:0000269|PubMed:9607189}.
FT                                /FTId=VAR_007751.
FT   VARIANT     396    396       D -> Y (in DDS).
FT                                {ECO:0000269|PubMed:10738002}.
FT                                /FTId=VAR_043809.
FT   VARIANT     397    397       H -> P (in NPHS4).
FT                                {ECO:0000269|PubMed:15253707,
FT                                ECO:0000269|PubMed:20798252}.
FT                                /FTId=VAR_043810.
FT   VARIANT     398    398       L -> P (in DDS).
FT                                {ECO:0000269|PubMed:8295405,
FT                                ECO:0000269|PubMed:9529364}.
FT                                /FTId=VAR_015062.
FT   VARIANT     401    401       H -> Y (in DDS).
FT                                {ECO:0000269|PubMed:8111391}.
FT                                /FTId=VAR_043811.
FT   VARIANT     405    405       H -> R (in DDS).
FT                                {ECO:0000269|PubMed:15349765}.
FT                                /FTId=VAR_043812.
FT   MUTAGEN      73     73       K->R: Abolishes sumoylation; when
FT                                associated with R-177.
FT                                {ECO:0000269|PubMed:15520190}.
FT   MUTAGEN     177    177       K->R: Abolishes sumoylation; when
FT                                associated with R-77.
FT                                {ECO:0000269|PubMed:15520190}.
FT   MUTAGEN     343    343       H->A: Reduced RNA binding.
FT                                {ECO:0000269|PubMed:19123921}.
FT   MUTAGEN     366    366       R->A: Strongly reduced binding of DNA and
FT                                RNA. {ECO:0000269|PubMed:19123921}.
FT   MUTAGEN     372    372       R->A: Strongly reduced binding of DNA and
FT                                RNA. {ECO:0000269|PubMed:19123921}.
FT   MUTAGEN     394    394       R->A,S: Strongly reduced binding of DNA
FT                                and RNA. {ECO:0000269|PubMed:19123921}.
FT   MUTAGEN     434    434       H->A: Reduced RNA binding.
FT                                {ECO:0000269|PubMed:19123921}.
FT   CONFLICT    288    288       I -> M (in Ref. 8; AAH32861).
FT                                {ECO:0000305}.
FT   CONFLICT    365    365       S -> F (in Ref. 9; AAA36810 and 10;
FT                                AAB33443). {ECO:0000305}.
FT   CONFLICT    387    387       T -> A (in Ref. 3; CAA43819).
FT                                {ECO:0000305}.
FT   STRAND      322    324       {ECO:0000244|PDB:2JPA}.
FT   TURN        328    330       {ECO:0000244|PDB:2JPA}.
FT   STRAND      333    337       {ECO:0000244|PDB:2PRT}.
FT   HELIX       338    344       {ECO:0000244|PDB:2PRT}.
FT   HELIX       345    349       {ECO:0000244|PDB:2PRT}.
FT   STRAND      363    366       {ECO:0000244|PDB:5KL3}.
FT   HELIX       367    378       {ECO:0000244|PDB:5KL3}.
FT   TURN        386    388       {ECO:0000244|PDB:5KL3}.
FT   STRAND      391    393       {ECO:0000244|PDB:5KL3}.
FT   HELIX       395    401       {ECO:0000244|PDB:5KL3}.
FT   HELIX       403    406       {ECO:0000244|PDB:5KL3}.
FT   TURN        419    421       {ECO:0000244|PDB:5KL5}.
FT   STRAND      424    427       {ECO:0000244|PDB:5KL3}.
FT   HELIX       428    438       {ECO:0000244|PDB:5KL3}.
SQ   SEQUENCE   449 AA;  49188 MW;  11C7FA3D485096B2 CRC64;
     MGSDVRDLNA LLPAVPSLGG GGGCALPVSG AAQWAPVLDF APPGASAYGS LGGPAPPPAP
     PPPPPPPPHS FIKQEPSWGG AEPHEEQCLS AFTVHFSGQF TGTAGACRYG PFGPPPPSQA
     SSGQARMFPN APYLPSCLES QPAIRNQGYS TVTFDGTPSY GHTPSHHAAQ FPNHSFKHED
     PMGQQGSLGE QQYSVPPPVY GCHTPTDSCT GSQALLLRTP YSSDNLYQMT SQLECMTWNQ
     MNLGATLKGV AAGSSSSVKW TEGQSNHSTG YESDNHTTPI LCGAQYRIHT HGVFRGIQDV
     RRVPGVAPTL VRSASETSEK RPFMCAYPGC NKRYFKLSHL QMHSRKHTGE KPYQCDFKDC
     ERRFSRSDQL KRHQRRHTGV KPFQCKTCQR KFSRSDHLKT HTRTHTGKTS EKPFSCRWPS
     CQKKFARSDE LVRHHNMHQR NMTKLQLAL
//
ID   Q6PI38_HUMAN            Unreviewed;       331 AA.
AC   Q6PI38;
DT   05-JUL-2004, integrated into UniProtKB/TrEMBL.
DT   05-SEP-2006, sequence version 2.
DT   31-JAN-2018, entry version 73.
DE   SubName: Full=WT1 protein {ECO:0000313|EMBL:AAH46461.2};
DE   Flags: Fragment;
GN   Name=WT1 {ECO:0000313|EMBL:AAH46461.2};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000313|EMBL:AAH46461.2};
RN   [1] {ECO:0000313|EMBL:AAH46461.2}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain {ECO:0000313|EMBL:AAH46461.2};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RA   Gerhard D.S., Wagner L., Feingold E.A., Shenmen C.M., Grouse L.H.,
RA   Schuler G., Klein S.L., Old S., Rasooly R., Good P., Guyer M.,
RA   Peck A.M., Derge J.G., Lipman D., Collins F.S., Jang W., Sherry S.,
RA   Feolo M., Misquitta L., Lee E., Rotmistrovsky K., Greenhut S.F.,
RA   Schaefer C.F., Buetow K., Bonner T.I., Haussler D., Kent J.,
RA   Kiekhaus M., Furey T., Brent M., Prange C., Schreiber K., Shapiro N.,
RA   Bhat N.K., Hopkins R.F., Hsie F., Driscoll T., Soares M.B.,
RA   Casavant T.L., Scheetz T.E., Brown-stein M.J., Usdin T.B.,
RA   Toshiyuki S., Carninci P., Piao Y., Dudekula D.B., Ko M.S.,
RA   Kawakami K., Suzuki Y., Sugano S., Gruber C.E., Smith M.R.,
RA   Simmons B., Moore T., Waterman R., Johnson S.L., Ruan Y., Wei C.L.,
RA   Mathavan S., Gunaratne P.H., Wu J., Garcia A.M., Hulyk S.W., Fuh E.,
RA   Yuan Y., Sneed A., Kowis C., Hodgson A., Muzny D.M., McPherson J.,
RA   Gibbs R.A., Fahey J., Helton E., Ketteman M., Madan A., Rodrigues S.,
RA   Sanchez A., Whiting M., Madari A., Young A.C., Wetherby K.D.,
RA   Granite S.J., Kwong P.N., Brinkley C.P., Pearson R.L., Bouffard G.G.,
RA   Blakesly R.W., Green E.D., Dickson M.C., Rodriguez A.C., Grimwood J.,
RA   Schmutz J., Myers R.M., Butterfield Y.S., Griffith M., Griffith O.L.,
RA   Krzywinski M.I., Liao N., Morin R., Morrin R., Palmquist D.,
RA   Petrescu A.S., Skalska U., Smailus D.E., Stott J.M., Schnerch A.,
RA   Schein J.E., Jones S.J., Holt R.A., Baross A., Marra M.A., Clifton S.,
RA   Makowski K.A., Bosak S., Malek J.;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; BC046461; AAH46461.2; -; mRNA.
DR   RefSeq; NP_000369.3; NM_000378.4.
DR   RefSeq; NP_001185480.1; NM_001198551.1.
DR   RefSeq; NP_001185481.1; NM_001198552.1.
DR   RefSeq; NP_077742.2; NM_024424.3.
DR   RefSeq; NP_077744.3; NM_024426.4.
DR   UniGene; Hs.591980; -.
DR   PeptideAtlas; Q6PI38; -.
DR   DNASU; 7490; -.
DR   GeneID; 7490; -.
DR   KEGG; hsa:7490; -.
DR   CTD; 7490; -.
DR   eggNOG; KOG1721; Eukaryota.
DR   eggNOG; COG5048; LUCA.
DR   HOGENOM; HOG000230937; -.
DR   KO; K09234; -.
DR   ChiTaRS; WT1; human.
DR   GenomeRNAi; 7490; -.
DR   Genevisible; Q6PI38; HS.
DR   GO; GO:0005634; C:nucleus; IEA:InterPro.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:InterPro.
DR   InterPro; IPR017987; Wilms_tumour.
DR   InterPro; IPR000976; Wilms_tumour_N.
DR   Pfam; PF02165; WT1; 1.
DR   PRINTS; PR00049; WILMSTUMOUR.
PE   2: Evidence at transcript level;
KW   Signal {ECO:0000256|SAM:SignalP}.
FT   SIGNAL        1     21       {ECO:0000256|SAM:SignalP}.
FT   CHAIN        22    331       {ECO:0000256|SAM:SignalP}.
FT                                /FTId=PRO_5004279522.
FT   DOMAIN       83    331       WT1. {ECO:0000259|Pfam:PF02165}.
FT   NON_TER       1      1       {ECO:0000313|EMBL:AAH46461.2}.
SQ   SEQUENCE   331 AA;  34592 MW;  BA8AA8FA79475F68 CRC64;
     GPRRLLAAIL DFLLLQDPAS TCVPEPASQH TLRSGPGCLQ QPEQQGVRDP GGIWAKLGAA
     EASAERLQGR RSRGASGSEP QQMGSDVRDL NALLPAVPSL GGGGGCALPV SGAAQWAPVL
     DFAPPGASAY GSLGGPAPPP APPPPPPPPP HSFIKQEPSW GGAEPHEEQC LSAFTVHFSG
     QFTGTAGACR YGPFGPPPPS QASSGQARMF PNAPYLPSCL ESQPAIRNQG YSTVTFDGTP
     SYGHTPSHHA AQFPNHSFKH EDPMGQQGSL GEQQYSVPPP VYGCHTPTDS CTGSQALLLR
     TPYSSDNLYQ MTSQLECMTW NQMNLGATLK G
//
